PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Khan, JA; Brint, EK; O'Neill, LAJ; Tong, L				Khan, JA; Brint, EK; O'Neill, LAJ; Tong, L			Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED MENTAL-RETARDATION; NEURONAL CALCIUM SENSOR-1; ANOMALOUS DIFFRACTION; SIGNALING PATHWAYS; FAMILY; DENSITY; SYSTEM; MODELS	The Toll/interleukin-1 receptor (TIR) domain is conserved in the intracellular regions of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) as well as in several cytoplasmic adapter molecules. This domain has crucial roles in signal transduction by these receptors for host immune response. Here we report the crystal structure at 2.3-Angstrom resolution of the TIR domain of human IL-1RAPL, the first structure of a TIR domain of the IL-1R superfamily. There are large structural differences between this TIR domain and that of TLR1 and TLR2. Helix alphaD in IL-1RAPL is almost perpendicular to its equivalent in TLR1 or TLR2. The BB loop contains a hydrogen bond unique to IL-1RAPL between Thr residues at the 8th and 10th positions. The structural and sequence diversity among these domains may be important for specificity in the signal transduction by these receptors. A dimer of the TIR domain of IL-1RAPL is observed in the crystal, although this domain is monomeric in solution. Residues in the dimer interface are mostly unique to IL-1RAPL, which is consistent with the distinct functional roles of this receptor. Our functional studies show IL-1RAPL can activate JNK but not the ERK or the p38 MAP kinases, whereas its close homolog, TIGIRR, cannot activate JNK. Deletion mutagenesis studies show that the activation of JNK by IL-1RAPL does not depend on the integrity of its TIR domain, suggesting a distinct mechanism of signaling through this receptor.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Dublin Trinity Coll, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland	Columbia University; Trinity College Dublin	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu		O'Neill, Luke/0000-0002-4333-2748; Brint, Elizabeth/0000-0001-9214-149X; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049475] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49475] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Bahi N, 2003, HUM MOL GENET, V12, P1415, DOI 10.1093/hmg/ddg147; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; Brint EK, 2002, J BIOL CHEM, V277, P49205, DOI 10.1074/jbc.M209685200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DUNNE A, 2003, SCI STKE; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koh PO, 2003, P NATL ACAD SCI USA, V100, P313, DOI 10.1073/pnas.232693499; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sims JE, 2002, CURR OPIN IMMUNOL, V14, P117, DOI 10.1016/S0952-7915(01)00306-5; Tao X, 2002, BIOCHEM BIOPH RES CO, V299, P216, DOI 10.1016/S0006-291X(02)02581-0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600	20	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31664	31670		10.1074/jbc.M403434200	http://dx.doi.org/10.1074/jbc.M403434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123616	hybrid			2022-12-27	WOS:000222726800091
J	Gawenis, LR; Ledoussal, C; Judd, LM; Prasad, V; Alper, SL; Stuart-Tilley, A; Woo, AL; Grisham, C; Sanford, LP; Doetschman, T; Miller, ML; Shull, GE				Gawenis, LR; Ledoussal, C; Judd, LM; Prasad, V; Alper, SL; Stuart-Tilley, A; Woo, AL; Grisham, C; Sanford, LP; Doetschman, T; Miller, ML; Shull, GE			Mice with a targeted disruption of the AE2 Cl-/HCO3- exchanger are achlorhydric	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; H,K-ATPASE ALPHA-SUBUNIT; RABBIT PARIETAL; ACID-SECRETION; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; NA-K-2CL COTRANSPORTER; BASOLATERAL MEMBRANE; INTRACELLULAR PH; PLASMA-MEMBRANE	The AE2 Cl-/HCO3- exchanger is expressed in numerous cell types, including epithelial cells of the kidney, respiratory tract, and alimentary tract. In gastric epithelia, AE2 is particularly abundant in parietal cells, where it may be the predominant mechanism for HCO3- efflux and Cl- influx across the basolateral membrane that is needed for acid secretion. To investigate the hypothesis that AE2 is critical for parietal cell function and to assess its importance in other tissues, homozygous null mutant (AE2(-/-)) mice were prepared by targeted disruption of the AE2 (Slc4a2) gene. AE2(-/-) mice were emaciated, edentulous (toothless), and exhibited severe growth retardation, and most of them died around the time of weaning. AE2(-/-) mice exhibited achlorhydria, and histological studies revealed abnormalities of the gastric epithelium, including moderate dilation of the gastric gland lumens and a reduction in the number of parietal cells. There was little evidence, however, that parietal cell viability was impaired. Ultrastructural analysis of AE2(-/-) gastric mucosa revealed abnormal parietal cell structure, with severely impaired development of secretory canaliculi and few tubulovesicles but normal apical microvilli. These results demonstrate that AE2 is essential for gastric acid secretion and for normal development of secretory canalicular and tubulovesicular membranes in mouse parietal cells.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Harvard Univ, Sch Med, Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Renal Unit, Boston, MA 02215 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way,ML524, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu		Judd, Louise/0000-0003-3613-4839	NHLBI NIH HHS [HL61974, T32-HL7571] Funding Source: Medline; NIDDK NIH HHS [DK3495, DK50594, DK34854, DK67749] Funding Source: Medline; NIEHS NIH HHS [P30 ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974, T32HL007571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067749, R37DK050594, P30DK034854, R01DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agnew BJ, 1999, J CELL SCI, V112, P2639; ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; Alper SL, 2002, J NEPHROL, V15, pS41; Bachmann O, 1998, AM J PHYSIOL-GASTR L, V275, pG1085, DOI 10.1152/ajpgi.1998.275.5.G1085; Cox KH, 1996, J BIOL CHEM, V271, P8895, DOI 10.1074/jbc.271.15.8895; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FLEMSTROM G, 1994, PHYSL GASTROINTESTIN; HORIE S, 1992, EUR J PHARMACOL, V229, P15; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; JONS T, 1994, HISTOCHEMISTRY, V102, P255, DOI 10.1007/BF00269161; Jons T, 1998, EUR J CELL BIOL, V75, P232; KAKEI N, 1993, BIOCHEM BIOPH RES CO, V195, P997, DOI 10.1006/bbrc.1993.2143; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; LAMPRECHT G, 1993, AM J PHYSIOL, V265, pG903, DOI 10.1152/ajpgi.1993.265.5.G903; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAEDA M, 1995, J BIOCHEM-TOKYO, V117, P1305, DOI 10.1093/oxfordjournals.jbchem.a124859; McDaniel N, 1999, AM J PHYSIOL-GASTR L, V276, pG1273, DOI 10.1152/ajpgi.1999.276.5.G1273; Medina JF, 2003, P NATL ACAD SCI USA, V100, P15847, DOI 10.1073/pnas.2536127100; Medina JF, 1997, GENOMICS, V39, P74, DOI 10.1006/geno.1996.4467; Medina JF, 2000, BIOCHEM BIOPH RES CO, V267, P228, DOI 10.1006/bbrc.1999.1951; Milller ML, 2002, CELL TISSUE RES, V309, P369, DOI 10.1007/s00441-002-0606-z; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; PARADISO AM, 1989, AM J PHYSIOL, V257, pC554, DOI 10.1152/ajpcell.1989.257.3.C554; Parkkila S, 1996, SCAND J GASTROENTERO, V31, P305, DOI 10.3109/00365529609006403; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; PETROVIC S, 2002, AM J PHYSIOL, V283, pR1207; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Rossmann H, 2001, J PHYSIOL-LONDON, V534, P837, DOI 10.1111/j.1469-7793.2001.00837.x; Rossmann H, 2001, AM J PHYSIOL-GASTR L, V281, pG447, DOI 10.1152/ajpgi.2001.281.2.G447; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Smolka AJ, 2000, BIOCHEM BIOPH RES CO, V273, P942, DOI 10.1006/bbrc.2000.3031; Sonnentag T, 2000, AM J PHYSIOL-GASTR L, V279, pG40, DOI 10.1152/ajpgi.2000.279.1.G40; SOYBEL DI, 1995, AM J PHYSIOL-CELL PH, V269, pC242, DOI 10.1152/ajpcell.1995.269.1.C242; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; THOMAS HA, 1991, CELL REGUL, V2, P727, DOI 10.1091/mbc.2.9.727; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200	44	110	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30531	30539		10.1074/jbc.M403779200	http://dx.doi.org/10.1074/jbc.M403779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123620	hybrid			2022-12-27	WOS:000222531900082
J	Lin, H; Juang, JL; Wang, PS				Lin, H; Juang, JL; Wang, PS			Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; CARDIAC-GLYCOSIDES; GROWTH-FACTOR; DIGITALIS; P35; EXPRESSION; P25; EVENTS; LEYDIG; DEATH	Cardiac digitalis has been considered to be a treatment for breast cancer. Our previous study indicates that digoxin, one member in digitalis, decreases the proliferation of prostate cancer cells, but the mechanisms remain unclear. In the present study, Ca2+ proved to be an important factor in digoxin-triggered prostate cancer cell death. Because cyclin-dependent kinase (Cdk) 5 and p35 cleavage (p25 formation) have been reported to be targets of intracellular Ca2+, and subsequently correlated to apoptosis, we not only demonstrated first that Cdk5, p35, and p25 proteins were all expressed in prostate cancer cells (including lymph node carcinoma of the prostate (LNCaP) and DU-145 cells), but also showed where p25 formation and Cdk5 kinase activity were affected by treatment with digoxin. The inhibitor of p35 cleavage (calpeptin) was used to reduce p25 formation, and the result suggested that p25 accumulation might be the major cause of digoxin-triggered LNCaP cell death. Butyrolactone-I and roscovitine, two Cdk5 kinase inhibitors, were also found to prevent digoxin-triggered LNCaP cell death. In addition, treatment of siRNA-Cdk5 diminished digoxin-triggered cell death, as compared with the treatments of siRNA-Cdk1 or siRNA-Cdk2, which implies the specific involvement of Cdk5 in digoxin-triggered cell death. Caspase inhibitor set and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay were used to demonstrate that digoxin-triggered LNCaP cell apoptosis through Cdk5 activation. These results suggest that Cdk5/p35 and p25 are novel players in digoxin-triggered prostate cancer cell apoptosis and, therefore, become potential therapeutic targets.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Physiol, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Wang, PS (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Yen Chiu Yuan Rd,Sec 2, Taipei 115, Taiwan.	pswang@ym.edu.tw	Juang, Jyh-Lyh/E-3944-2010	Lin, Ho/0000-0001-7849-9137				Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Chen JJ, 2002, J CELL BIOCHEM, V86, P107, DOI 10.1002/jcb.10154; Chen JJ, 2001, BRIT J PHARMACOL, V132, P1761, DOI 10.1038/sj.bjp.0703974; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Demers C, 1999, CORONARY ARTERY DIS, V10, P353, DOI 10.1097/00019501-199909000-00002; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hauptman PJ, 1999, CIRCULATION, V99, P1265, DOI 10.1161/01.CIR.99.9.1265; Hsieh TC, 1997, PROSTATE, V33, P97; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lin H, 1998, BRIT J PHARMACOL, V125, P1635, DOI 10.1038/sj.bjp.0702229; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; McConkey DJ, 2000, CANCER RES, V60, P3807; Musa FRM, 1998, J ANDROL, V19, P657; Musa FRM, 2000, J ANDROL, V21, P392; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, TRENDS NEUROSCI, V25, P8, DOI 10.1016/S0166-2236(00)02000-2; Rhim JS, 1997, CRIT REV ONCOGENESIS, V8, P305, DOI 10.1615/CritRevOncog.v8.i4.20; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; Stenkvist B, 1999, ONCOL REP, V6, P493; STENKVIST B, 1982, NEW ENGL J MED, V306, P484; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Weishaupt JH, 2003, CELL TISSUE RES, V312, P1, DOI 10.1007/s00441-003-0703-7; Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172; Yeh JY, 2001, J UROLOGY, V166, P1937, DOI 10.1016/S0022-5347(05)65724-2; Zapata-Torres G, 2004, J NAT PROD, V67, P416, DOI 10.1021/np034011s; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	32	81	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29302	29307		10.1074/jbc.M403664200	http://dx.doi.org/10.1074/jbc.M403664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123618	hybrid			2022-12-27	WOS:000222445300060
J	Tempel, W; Karaveg, K; Liu, ZJ; Rose, J; Wang, BC; Moremen, KW				Tempel, W; Karaveg, K; Liu, ZJ; Rose, J; Wang, BC; Moremen, KW			Structure of mouse Golgi alpha-mannosidase IA reveals the molecular basis for substrate specificity among class 1 (family 47 glycosylhydrolase) alpha 1,2-mannosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; RETICULUM-ASSOCIATED DEGRADATION; NON-DETERGENT SULFOBETAINES; SHORT-LIVED VARIANT; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; PROCESSING ALPHA-1,2-MANNOSIDASE; NONDETERGENT SULFOBETAINES; GLYCOPROTEIN DEGRADATION; MISFOLDED GLYCOPROTEINS	Three subfamilies of mammalian Class 1 processing alpha1,2-mannosidases ( family 47 glycosidases) play critical roles in the maturation of Asn-linked glycoproteins in the endoplasmic reticulum ( ER) and Golgi complex as well as influencing the timing and recognition for disposal of terminally unfolded proteins by ER-associated degradation. In an effort to define the structural basis for substrate recognition among Class 1 mannosidases, we have crystallized murine Golgi mannosidase IA ( space group P2(1)2(1)2(1)), and the structure was solved to 1.5-Angstrom resolution by molecular replacement. The enzyme assumes an (alphaalpha)(7) barrel structure with a Ca(2+) ion coordinated at the base of the barrel similar to other Class 1 mannosidases. Critical residues within the barrel structure that coordinate the Ca(2+) ion or presumably bind and catalyze the hydrolysis of the glycone are also highly conserved. A Man(6)GlcNAc(2) oligosaccharide attached to Asn(515) in the murine enzyme was found to extend into the active site of an adjoining protein unit in the crystal lattice in a presumed enzyme-product complex. In contrast to an analogous complex previously isolated for Saccharomyces cerevisiae ER mannosidase I, the oligosaccharide in the active site of the murine Golgi enzyme assumes a different conformation to present an alternate oligosaccharide branch into the active site pocket. A comparison of the observed protein-carbohydrate interactions for the murine Golgi enzyme with the binding cleft topologies of the other family 47 glycosidases provides a framework for understanding the structural basis for substrate recognition among this class of enzymes.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	moremen@uga.edu	Moremen, Kelley/AAD-4661-2019; Liu, Zhi-Jie/A-3946-2012	Liu, Zhi-Jie/0000-0001-7279-2893	NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ermonval M, 2001, GLYCOBIOLOGY, V11, P565, DOI 10.1093/glycob/11.7.565; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Goldberg, 1995, Fold Des, V1, P21; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 2002, ROY SOC CH, P28, DOI 10.1039/9781847550323-00028; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; More TA, 2000, US FOR SERV RMRS-P, V2, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; RENKEL Z, 2003, J BIOL CHEM, V278, P34119; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; Vallee F, 1999, ACTA CRYSTALLOGR D, V55, P571, DOI 10.1107/S090744499801244X; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x; VUILLARD L, 1995, ANAL BIOCHEM, V230, P290, DOI 10.1006/abio.1995.1476; VUILLARD L, 1995, BIOCHEM J, V305, P337, DOI 10.1042/bj3050337; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; VUILLARD L, 1995, ELECTROPHORESIS, V16, P295, DOI 10.1002/elps.1150160148; Wang T, 2003, NAT STRUCT BIOL, V10, P319, DOI 10.1038/nsb0503-319; Winn MD, 2002, ACTA CRYSTALLOGR D, V58, P1929, DOI 10.1107/S0907444902016116; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	59	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29774	29786		10.1074/jbc.M403065200	http://dx.doi.org/10.1074/jbc.M403065200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102839	hybrid			2022-12-27	WOS:000222445300114
J	Hibbs, RE; Talley, TT; Taylor, P				Hibbs, RE; Talley, TT; Taylor, P			Acrylodan-conjugated cysteine side chains reveal conformational state and ligand site locations of the acetylcholine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN; NICOTINIC RECEPTOR; SUBUNIT INTERFACES; CRYSTAL-STRUCTURE; COMPLEX; NEUROTOXINS; CYS(69)-CYS(96); ANTAGONISTS; INHIBITION; RESIDUES	We undertook cysteine substitution mutagenesis and fluorophore conjugation at selected residue positions to map sites of ligand binding and changes in solvent exposure of the acetylcholine-binding protein from Lymnaea stagnalis, a nicotinic receptor surrogate. Acrylodan fluorescence emission is highly sensitive to its local environment, and when bound to protein, exhibits changes in both intensity and emission wavelength that are reflected in the degree of solvent exclusion and the effective dielectric constant of the environment of the fluorophore. Hence, cysteine mutants were generated based on the acetylcholine- binding protein crystal structure and predicted ligand binding sites, and fluorescence parameters were assayed on the acrylodan-conjugated proteins. This approach allows one to analyze the environment around the conjugated fluorophore side chain and the changes induced by bound ligand. Introduction of an acrylodan-cysteine conjugate at position 178 yields a large blue shift with alpha-bungarotoxin association, whereas the agonists and alkaloid antagonists induce red shifts reflecting solvent exposure at this position. Such residue-selective changes in fluorescence parameters suggest that certain ligands can induce distinct conformational states of the binding protein, and that mutually exclusive binding results from disparate portals of entry to and orientations of the bound alpha-toxin and smaller acetylcholine congeners at the binding pocket. Labeling at other residue positions around the predicted binding pocket also reveals distinctive spectral changes for alpha-bungarotoxin, agonists, and alkaloid antagonists.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, T32GM007752] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 18360, GM/NS 043063, T32 GM 07752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bourne Y, 2004, P NATL ACAD SCI USA, V101, P1449, DOI 10.1073/pnas.0308206100; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lozzi L, 2003, CHEM BIOL, V10, P411, DOI 10.1016/S1074-5521(03)00094-2; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; REITER MJ, 1972, P NATL ACAD SCI USA, V69, P1168, DOI 10.1073/pnas.69.5.1168; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; SILMAN I, 2000, CHOLINESTERASES CHOL, P9; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEBER M, 1974, MOL PHARMACOL, V10, P15; WEILAND G, 1977, J BIOL CHEM, V252, P7648; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200	37	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28483	28491		10.1074/jbc.M403713200	http://dx.doi.org/10.1074/jbc.M403713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117947	hybrid			2022-12-27	WOS:000222265400083
J	Pohlmann, T; Bockmann, RA; Grubmuller, H; Uchanska-Ziegler, B; Ziegler, A; Alexiev, U				Pohlmann, T; Bockmann, RA; Grubmuller, H; Uchanska-Ziegler, B; Ziegler, A; Alexiev, U			Differential peptide dynamics is linked to major histocompatibility complex polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MHC MOLECULES; CONFORMATIONAL-CHANGES; TCR BINDING; CELL; HLA-B27; RECOGNITION; AMINO; TIME; FLEXIBILITY; SUBTYPE	Peptide presentation by major histocompatibility complex (MHC) molecules is of central importance for immune responses, which are triggered through recognition of peptide-loaded MHC molecules (pMHC) by cellular ligands such as T-cell receptors (TCR). However, a unifying link between structural features of pMHC and cellular responses has not been established. Instead, pMHC/TCR binding studies suggest conformational and/or flexibility changes of the binding partners as a possible cause of differential T-cell stimulation, but information on real-time dynamics is lacking. We therefore probed the real-time dynamics of a MHC-bound nonapeptide (m9), by combining time-resolved fluorescence depolarization and molecular dynamics simulations. Here we show that the nanosecond dynamics of this peptide presented by two human MHC class I subtypes (HLA-B*2705 and HLA-B*2709) with differential autoimmune disease association varies dramatically, despite virtually identical crystal structures. The peptide dynamics is linked to the single, buried polymorphic residue 116 in the peptide binding groove. Pronounced peptide flexibility is seen only for the non-disease-associated subtype HLA-B*2709, suggesting an entropic control of peptide recognition. Thermodynamic data obtained for two additional peptides support this hypothesis.	Free Univ Berlin, Dept Phys, D-14195 Berlin, Germany; Max Planck Inst Biophys Chem, Theoret & Computat Biophys Dept, D-37077 Gottingen, Germany; Humboldt Univ, Charite Univ Med Berlin, Inst Immungenet, D-14050 Berlin, Germany	Free University of Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Alexiev, U (corresponding author), Free Univ Berlin, Dept Phys, Arnimallee 14, D-14195 Berlin, Germany.	alexiev@physik.fu-berlin.de	Böckmann, Rainer A/G-7863-2015; Alexiev, Ulrike/L-8478-2016	Böckmann, Rainer A/0000-0002-9325-5162; 				Alexiev U, 2003, J MOL BIOL, V328, P705, DOI 10.1016/S0022-2836(03)00326-7; AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Bankovich AJ, 2003, IMMUNITY, V18, P7, DOI 10.1016/S1074-7613(02)00517-4; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Haan EC, 2002, BIOORGAN MED CHEM, V10, P1939, DOI 10.1016/S0968-0896(01)00434-5; Degano M, 2000, IMMUNITY, V12, P251, DOI 10.1016/S1074-7613(00)80178-8; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Fiorillo MT, 1998, EUR J IMMUNOL, V28, P2508, DOI 10.1002/(SICI)1521-4141(199808)28:08<2508::AID-IMMU2508>3.0.CO;2-1; GAKAMSKY DM, 1995, IMMUNOL LETT, V44, P195, DOI 10.1016/0165-2478(94)00214-C; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hillig RC, 2004, J BIOL CHEM, V279, P652, DOI 10.1074/jbc.M307457200; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Nojima H, 2003, CHEM PHARM BULL, V51, P923; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Reiser JB, 2002, IMMUNITY, V16, P345, DOI 10.1016/S1074-7613(02)00288-1; Rudolph MG, 2002, ANNU REV BIOPH BIOM, V31, P121, DOI 10.1146/annurev.biophys.31.082901.134423; SCHLITTER J, 1993, CHEM PHYS LETT, V215, P617, DOI 10.1016/0009-2614(93)89366-P; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920	37	74	74	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28197	28201		10.1074/jbc.C400128200	http://dx.doi.org/10.1074/jbc.C400128200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15084610	Green Published, hybrid			2022-12-27	WOS:000222265400048
J	Ji, HL; Benos, DJ				Ji, HL; Benos, DJ			Degenerin sites mediate proton activation of delta beta gamma-epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CATION CHANNELS; SENSING ION CHANNELS; NA+ CHANNEL; XENOPUS OOCYTES; ALPHA-SUBUNIT; EXTERNAL PROTONS; FROG SKIN; ISCHEMIA; ENAC; TRANSPORT	The delta-subunit of epithelial Na+ channels (ENaC) is predominately expressed in brain, heart, and pancreas. The amiloride sensitivity, Na+ conductance, and critical domains for gating are characterized as a cross between proton-activated Na+ channels and alpha-ENaC. The hypothesis that external protons may activate human delta-ENaC was addressed by expressing deltabetagamma-hENaC in Xenopus oocytes and evaluating proton-activated current with the two-electrode voltage clamp technique. Our results showed that protons transiently evoked a Na+ current with an EC50 of pH 6 overlapped on the basal current of deltabetagamma-hENaC. Proton-activated current was not observed in uninjected oocytes. Studies on gating kinetics revealed that activation, desensitization, and recovery times of proton-activated Na+ current were 3.8 +/- 0.5 s, 253 +/- 9.5 s, and 10 +/- 3.6 s, respectively (n = 4-12). Alkali metal cation selectivity of the proton-activated current was identical to that of the basal current of deltabetagamma-hENaC. The metabolic acids, lactate, pyruvate, and formate, modified the proton-activated current, as did hypo-osmotic stress. EDTA, hypo-osmolarity, and lactate enhanced proton activation synergistically. Our results suggest that delta-hENaC subunit is essential for proton-activated current and gamma-subunit may potentially regulate the response of delta-hENaC to protons. We have concluded that deltabetagamma-hENaC is a proton-activated cation channel whose closing gate can be regulated by a proton-induced conformational change. Proton-sensitivity of deltabetagamma-hENaC may be an important mechanism for integrating external ischemic signals in inflamed and hypoxic tissues.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ji, HL (corresponding author), 1918 Univ Blvd,844 MCLM, Birmingham, AL 35294 USA.	ji@physiology.uab.edu	JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK056095, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56095, DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Bertog M, 2000, AM J PHYSIOL-CELL PH, V278, pC885, DOI 10.1152/ajpcell.2000.278.5.C885; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; CHUNG RS, 1977, SURG FORUM, V28, P435; COBBE SM, 1980, J MOL CELL CARDIOL, V12, P745, DOI 10.1016/0022-2828(80)90077-2; CUTHBERT AW, 1976, MOL PHARMACOL, V12, P945; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P65, DOI 10.1111/j.1748-1716.1967.tb03710.x; GRINSTEIN S, 1978, J MEMBRANE BIOL, V40, P261, DOI 10.1007/BF02026010; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Ji HL, 2004, J BIOL CHEM, V279, P8428, DOI 10.1074/jbc.M312012200; Ji HL, 2003, BIOPHYS J, V84, p529A; Ji HL, 2003, FASEB J, V17, pA913; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Ladilov Y, 2000, CARDIOVASC RES, V47, P394, DOI 10.1016/S0008-6363(00)00108-5; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; LEAF A, 1964, AM J PHYSIOL, V207, P547, DOI 10.1152/ajplegacy.1964.207.3.547; LI JHY, 1981, ADV PHYSL SCI, V3, P151; MANDEL LJ, 1978, AM J PHYSIOL, V235, pC35, DOI 10.1152/ajpcell.1978.235.1.C35; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mori S, 2002, BRAIN RES, V957, P1, DOI 10.1016/S0006-8993(02)03574-6; PALMER LG, 1982, J MEMBRANE BIOL, V67, P91, DOI 10.1007/BF01868651; Palmer LG, 2001, J MEMBRANE BIOL, V184, P305, DOI 10.1007/s00232-001-0092-3; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; ROUSSEAU B, 1971, BIOCHIM BIOPHYS ACTA, V233, P591, DOI 10.1016/0005-2736(71)90157-X; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; USSING HH, 1949, ACTA PHYSIOL SCAND, V17, P1, DOI 10.1111/j.1748-1716.1949.tb00550.x; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WALZ W, 1993, DEV NEUROSCI-BASEL, V15, P216, DOI 10.1159/000111337; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3; Zima AV, 2003, J PHYSIOL-LONDON, V550, P765, DOI 10.1113/jphysiol.2003.040345	51	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26939	26947		10.1074/jbc.M401143200	http://dx.doi.org/10.1074/jbc.M401143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084585	hybrid			2022-12-27	WOS:000222120400019
J	Wehner, A; Storf, S; Jahns, P; Schmid, VHR				Wehner, A; Storf, S; Jahns, P; Schmid, VHR			De-epoxidation of violaxanthin in light-harvesting complex I proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOID-BINDING-SITES; XANTHOPHYLL CYCLE PIGMENT; PHOTOSYSTEM-I; MECHANISTIC ASPECTS; CRYSTAL-STRUCTURE; HIGHER-PLANTS; DYNAMICS; BARLEY; LEAVES; PHOTOINHIBITION	The conversion of violaxanthin (Vx) to zeaxanthin (Zx) in the de-epoxidation reaction of the xanthophyll cycle plays an important role in the protection of chloroplasts against photooxidative damage. Vx is bound to the antenna proteins of both photosystems. In photosystem II, the formation of Zx is essential for the pH-dependent dissipation of excess light energy as heat. The function of Zx in photosystem I is still unclear. In this work we investigated the de-epoxidation characteristics of light-harvesting complex proteins of photosystem I (LHCI) under in vivo and in vitro conditions. Recombinant LHCI (Lhcal-4) proteins were reconstituted with Vx and lutein, and the convertibility of Vx was studied in an in vitro assay using partially purified Vx de-epoxidase isolated from spinach thylakoids. All four LHCI proteins exhibited unique de-epoxidation characteristics. An almost complete Vx conversion to Zx was observed only in Lhca3, whereas Zx formation in the other LHCI proteins decreased in the order Lhca4 > Lhca1 > Lhca2. Most likely, these differences in Vx de-epoxidation were related to the different accessibility of the respective carotenoid binding sites in the distinct antenna proteins. The results indicate that Vx bound to site V1 and N1 is easily accessible for de-epoxidation, whereas Vx bound to L2 is only partially and/or with the slower kinetics convertible to Zx. The de-epoxidation properties determined for the monomeric recombinant proteins were consistent with those obtained for isolated native LHCI-730 and LHCI-680 in the same in vitro assay and the de-epoxidation state found under in vivo conditions in native LHCIs.	Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55128 Mainz, Germany	Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz	Jahns, P (corresponding author), Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany.	pjahns@uni-duesseldorf.de						Arvidsson PO, 1997, PHOTOSYNTH RES, V52, P39, DOI 10.1023/A:1005868026374; Arvidsson PO, 1996, PHOTOSYNTH RES, V49, P119, DOI 10.1007/BF00117662; Barth C, 2001, PLANT CELL ENVIRON, V24, P163, DOI 10.1111/j.1365-3040.2001.00673.x; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bukhov NG, 2001, PLANTA, V212, P739, DOI 10.1007/s004250000485; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 2003, LIGHT HARVESTING ANT, P1; Hartel H, 1996, PLANT PHYSIOL, V110, P471, DOI 10.1104/pp.110.2.471; HAVAUX M, 1994, PHOTOSYNTH RES, V40, P75, DOI 10.1007/BF00019047; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; IKEUCHI M, 1991, PLANT CELL PHYSIOL, V32, P103; JAHNS P, 1995, PLANT PHYSIOL, V108, P149, DOI 10.1104/pp.108.1.149; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; Krause GH, 2003, LIGHT HARVESTING ANT, P373; LAM E, 1984, FEBS LETT, V168, P10, DOI 10.1016/0014-5793(84)80197-0; LEE ALC, 1995, PLANT PHYSIOL, V107, P565, DOI 10.1104/pp.107.2.565; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Macko S, 2002, PLANTA, V216, P309, DOI 10.1007/s00425-002-0848-8; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Morosinotto T, 2003, PHYSIOL PLANTARUM, V119, P347, DOI 10.1034/j.1399-3054.2003.00213.x; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Niyogi KK, 2000, CURR OPIN PLANT BIOL, V3, P455, DOI 10.1016/S1369-5266(00)00113-8; PAULSEN H, 2002, HEME CHLOROPHYLL BIL, P235; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; SCHAFER C, 1994, J PHOTOCH PHOTOBIO B, V22, P67, DOI 10.1016/1011-1344(93)06952-Y; Scheer H, 2003, LIGHT HARVESTING ANT, P29; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; SIEFERMANN D, 1974, BIOCHIM BIOPHYS ACTA, V357, P144, DOI 10.1016/0005-2728(74)90119-4; SONOIKE K, 1994, PLANTA, V194, P287, DOI 10.1007/BF01101690; THAYER SS, 1992, PHOTOSYNTH RES, V33, P213, DOI 10.1007/BF00030032; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; Tjus SE, 2001, PLANT PHYSIOL, V125, P2007, DOI 10.1104/pp.125.4.2007; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Zhu JX, 1997, PHOTOSYNTH RES, V51, P137, DOI 10.1023/A:1005810430973	54	46	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26823	26829		10.1074/jbc.M402399200	http://dx.doi.org/10.1074/jbc.M402399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15070896	hybrid			2022-12-27	WOS:000222120400005
J	Cheng, Q; Jayaraman, V				Cheng, Q; Jayaraman, V			Chemistry and conformation of the ligand-binding domain of GluR2 subtype of glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; ACTIVATION; CORE; PROTEINS; CHANNELS	In the present report, using vibrational spectroscopy we have probed the ligand-protein interactions for full agonists (glutamate and alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate ( AMPA)) and a partial agonist ( kainate) in the isolated ligand-binding domain of the GluR2 subunit of the glutamate receptor. These studies indicate differences in the strength of the interactions of the alpha-carboxylates for the various agonists, with kainate having the strongest interactions and glutamate having the weakest. Additionally, the interactions at the alpha-amine group of the agonists have also been probed by studying the environment of the non-disulfide-bonded Cys-425, which is in close proximity to the alpha-amine group. These investigations suggest that the interactions at the alpha-amine group are stronger for full agonists such as glutamate and AMPA as evidenced by the increase in the hydrogen bond strength at Cys-425. Partial agonists such as kainate do not change the environment of Cys-425 relative to the apo form, suggesting weak interactions at the alpha-amine group of kainate. In addition to probing the ligand environment, we have also investigated the changes in the secondary structure of the protein. Results clearly indicate that full agonists such as glutamate and AMPA induce similar secondary structural changes that are different from those of the partial agonist kainate; thus, a spectroscopic signature is provided for identifying the functional consequences of a specific ligand binding to this protein.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	vasanthi.jayaraman@uth.tmc.edu						Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAPMAN D, 1989, BIOCHEM SOC T, V17, P617, DOI 10.1042/bst0170617; Cheng Q, 2002, BIOCHEMISTRY-US, V41, P1602, DOI 10.1021/bi015729e; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; LI HM, 1991, J AM CHEM SOC, V113, P456, DOI 10.1021/ja00002a012; Madden DR, 2002, CURR OPIN DRUG DI DE, V5, P741; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; McFeeters RL, 2004, FASEB J, V18, P428, DOI 10.1096/fj.03-0873rev; McFeeters RL, 2002, J BIOMOL NMR, V22, P297, DOI 10.1023/A:1014954931635; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SPINNER E, 1967, J CHEM SOC B, P874, DOI 10.1039/j29670000874; Spiro T., 1987, BIOL APPL RAMAN SPEC; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a	21	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26346	26350		10.1074/jbc.M403111200	http://dx.doi.org/10.1074/jbc.M403111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15100219	hybrid			2022-12-27	WOS:000222003000054
J	Fabrick, JA; Baker, JE; Kanost, MR				Fabrick, JA; Baker, JE; Kanost, MR			Innate immunity in a pyralid moth - Functional evaluation of domains from a beta-1,3-glucan recognition protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPHENOLOXIDASE-ACTIVATING ENZYME; LIPOPOLYSACCHARIDE-BINDING PROTEIN; COMPLEMENT-LIKE PROTEIN; SILKWORM BOMBYX-MORI; PRO-PHENOL-OXIDASE; C-TYPE LECTIN; PATTERN-RECOGNITION; MANDUCA-SEXTA; PROPHENOLOXIDASE-ACTIVATION; IMMUNOGLOBULIN SUPERFAMILY	Invertebrates, like vertebrates, utilize pattern recognition proteins for detection of microbes and subsequent activation of innate immune responses. We report structural and functional properties of two domains from a beta-1,3-glucan recognition protein present in the hemolymph of a pyralid moth, Plodia interpunctella. A recombinant protein corresponding to the first 181 amino-terminal residues bound to beta-1,3-glucan, lipopolysaccharide, and lipoteichoic acid, polysaccharides found on cell surfaces of microorganisms, and also activated the prophenoloxidase-activating system, an immune response pathway in insects. The amino-terminal domain consists primarily of an alpha-helical secondary structure with a minor beta-structure. This domain was thermally stable and resisted proteolytic degradation. The 290 residue carboxyl-terminal domain, which is similar in sequence to glucanases, had less affinity for the polysaccharides, did not activate the prophenoloxidase cascade, had a more complicated CD spectrum, and was heat-labile and susceptible to proteinase digestion. The carboxyl-terminal domain bound to laminarin, a beta-1,3-glucan with beta-1,6 branches, but not to curdlan, a beta-1,3-glucan that lacks branching. These results indicate that the two domains of Plodia beta-1,3-glucan recognition protein, separated by a putative linker region, bind microbial polysaccharides with differing specificities and that the amino-terminal domain, which is unique to this class of pattern recognition receptors from invertebrates, is responsible for stimulating prophenoloxidase activation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; ARS, USDA, Grain Mkt & Prod Res Ctr, Manhattan, KS 66502 USA	Kansas State University; United States Department of Agriculture (USDA)	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu		Kanost, Michael/0000-0002-6827-0061; Fabrick, Jeffrey/0000-0002-3893-9545	NIGMS NIH HHS [R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Bilej M, 2001, J BIOL CHEM, V276, P45840, DOI 10.1074/jbc.M107220200; Chosa N, 1997, INSECT BIOCHEM MOLEC, V27, P61, DOI 10.1016/S0965-1748(96)00070-7; Dimopoulos G, 2003, CELL MICROBIOL, V5, P3, DOI 10.1046/j.1462-5822.2003.00252.x; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P203, DOI 10.1016/0003-9861(73)90406-2; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; DULARAY B, 1985, INSECT BIOCHEM, V15, P827, DOI 10.1016/0020-1790(85)90112-X; Fabrick JA, 2003, INSECT BIOCHEM MOLEC, V33, P579, DOI 10.1016/S0965-1748(03)00029-8; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gorman MJ, 2001, INSECT BIOCHEM MOLEC, V31, P257, DOI 10.1016/S0965-1748(00)00145-4; Imler JL, 2002, CURR TOP MICROBIOL, V270, P63; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; LADENDORFF NE, 1991, ARCH INSECT BIOCHEM, V18, P285, DOI 10.1002/arch.940180410; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; LEE IY, 2002, BIOPOLYMERS, V5, P135; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; LEONARD C, 1985, J INSECT PHYSIOL, V31, P789, DOI 10.1016/0022-1910(85)90072-1; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; Rowley A.F., 1986, P381; *SAS I, 1998, SAS SYST WIND VERS 7; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; Sritunyalucksana K, 2002, DEV COMP IMMUNOL, V26, P237, DOI 10.1016/S0145-305X(01)00074-X; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tsuchiya M, 1996, FEMS IMMUNOL MED MIC, V15, P129, DOI 10.1016/0928-8244(96)00053-3; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Young SH, 2000, J BIOL CHEM, V275, P11874, DOI 10.1074/jbc.275.16.11874; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3; Yu XQ, 2002, EUR J BIOCHEM, V269, P1827, DOI 10.1046/j.1432-1033.2002.02830.x; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200	59	42	49	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26605	26611		10.1074/jbc.M403382200	http://dx.doi.org/10.1074/jbc.M403382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084591	hybrid			2022-12-27	WOS:000222003000086
J	Townson, SM; Kang, KY; Lee, AV; Oesterreich, S				Townson, SM; Kang, KY; Lee, AV; Oesterreich, S			Structure-function analysis of the estrogen receptor alpha corepressor scaffold attachment factor-B1 - Identification of a potent transcriptional repression domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEIN; HNRNP-U/SAF-A; HISTONE DEACETYLASE; BINDING-PROTEIN; MULTIPLE INTERACTIONS; HET/SAF-B; SAF-B; RNA; REGIONS; MOTIF	Scaffold attachment factor-B1 (SAFB1) is a nuclear matrix protein that has been proposed to couple chromatin structure, transcription, and RNA processing. We have previously shown that SAFB1 can repress estrogen receptor (ERalpha)-mediated transactivation. Here we present a structure-function study showing that transactivation is mediated via an intrinsic and transferable C-terminal repression domain (RD). A similar C-terminal RD was found in the family member SAFB2. Removal of the RD from SAFB1 resulted in a dominant-negative SAFB1 protein that increased ligand-dependent and - independent ERalpha activity. SAFB1RD-mediated repression was partly blocked by histone deacetylase inhibitors; however, no histone deacetylase inhibitors were identified in a yeast two-hybrid screen using the RD as bait. Instead, SAFB1RD was found to interact with TAFII68, a member of the basal transcription machinery. We propose a model in which SAFB1 represses ERalpha activity via indirect association with histone deacetylation and interaction with the basal transcription machinery.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Oesterreich, S (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	steffio@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X	NATIONAL CANCER INSTITUTE [R01CA097213, K01CA077674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097213, K01 CA77674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Frisch M, 2002, GENOME RES, V12, P349, DOI 10.1101/gr.206602.ArticlepublishedonlinebeforeprintinJanuary2002; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hong W, 2002, MOL CANCER RES, V1, P48; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Jepsen K, 2002, J CELL SCI, V115, P689; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Li J, 2003, MOL CELL BIOL, V23, P7437, DOI 10.1128/MCB.23.21.7437-7447.2003; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; OESTERREICH S, 2000, EJC SUPPL, V4, P43; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Scott RE, 2003, J CELL BIOCHEM, V90, P6, DOI 10.1002/jcb.10618; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Tai HH, 2003, BIOCHEM BIOPH RES CO, V308, P170, DOI 10.1016/S0006-291X(03)01354-8; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Townson SM, 2000, CLIN CANCER RES, V6, P3788; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Trifillis P, 1999, RNA, V5, P1071, DOI 10.1017/S1355838299981803; Weighardt F, 1999, J CELL SCI, V112, P1465; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	55	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26074	26081		10.1074/jbc.M313726200	http://dx.doi.org/10.1074/jbc.M313726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066997	hybrid			2022-12-27	WOS:000222003000020
J	Satoh, Y; Matsumura, I; Tanaka, H; Ezoe, S; Sugahara, H; Mizuki, M; Shibayama, H; Ishiko, E; Ishiko, J; Nakajima, K; Kanakura, Y				Satoh, Y; Matsumura, I; Tanaka, H; Ezoe, S; Sugahara, H; Mizuki, M; Shibayama, H; Ishiko, E; Ishiko, J; Nakajima, K; Kanakura, Y			Roles for c-Myc in self-renewal of hematopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; IN-VITRO; TELOMERASE ACTIVITY; CYCLIN E/CDK2; DNA-BINDING; TRANSCRIPTION; EXPRESSION; TARGET; EXPANSION; PROTEIN	Notch and HOXB4 have been reported to expand hematopoietic stem cells (HSCs) in vitro. However, their critical effector molecules remain undetermined. We found that the expression of c-myc, cyclin D2, cyclin D3, cyclin E, and E2F1 was induced or enhanced during Notch1- or HOXB4-induced self-renewal of murine HSCs. Since c-Myc can act as a primary regulator of G(1)/S transition, we examined whether c-Myc alone can induce self-renewal of HSCs. In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-) Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days. c-Myc activated by 4-hydroxytamoxifen augmented telomerase activities and increased the number of CFU-Mix about 2-fold in colony assays. Also, in reconstitution assays, HSCs expanded by c-Myc could reconstitute hematopoiesis for more than 6 months. As for the mechanism of c-myc induction by Notch1, we found that activated forms of Notch1 (NotchIC) and its downstream effector recombination signal-binding protein-J kappa (RBP-VP16) can activate the c-myc promoter through the element between -195 bp and -161 bp by inducing the DNA-binding complex. Together, these results suggest that c-Myc can support self-renewal of HSCs as a downstream mediator of Notch and HOXB4.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Osaka City Univ, Grad Sch Med, Dept Immunol, Osaka 5458585, Japan	Osaka University; Osaka Metropolitan University	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 2001, BLOOD, V98, P3643, DOI 10.1182/blood.V98.13.3643; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dao MA, 2002, BLOOD, V99, P499, DOI 10.1182/blood.V99.2.499; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Fortunel NO, 2000, BLOOD, V96, P2022; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; RAGIONE FD, 1997, BIOCHEM BIOPH RES CO, V231, P73; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Szilvassy SJ, 2001, EXP HEMATOL, V29, P1494, DOI 10.1016/S0301-472X(01)00751-2; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272	54	112	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24986	24993		10.1074/jbc.M400407200	http://dx.doi.org/10.1074/jbc.M400407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067010	hybrid			2022-12-27	WOS:000221827900012
J	Schmelter, T; Trigatti, BL; Gerber, GE; Mangroo, D				Schmelter, T; Trigatti, BL; Gerber, GE; Mangroo, D			Biochemical demonstration of the involvement of fatty acyl-CoA synthetase in fatty acid translocation across the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ESCHERICHIA-COLI FADD; SACCHAROMYCES-CEREVISIAE; TRANSPORT PROTEIN; 3T3-L1 ADIPOCYTES; TRANSMEMBRANE MOVEMENT; BINDING PROTEIN; SIGNATURE MOTIF; FLIP-FLOP; LONG	Fatty acyl-CoA synthetase, the first enzyme of the beta-oxidation pathway, has been proposed to be involved in long chain fatty acid translocation across the plasma membrane of prokaryotic and eukaryotic cells. To test this proposal, we used an in vitro system consisting of Escherichia coli inner ( plasma) membrane vesicles containing differing amounts of trapped fatty acyl-CoA synthetase and its substrates CoA and ATP. This system allowed us to investigate the involvement of fatty acyl-CoA synthetase independently of other proteins that are involved in fatty acid translocation across the outer membrane and in downstream steps in beta-oxidation, because these proteins are not retained in the inner membrane vesicles. Fatty acid uptake in vesicles containing fatty acyl-CoA synthetase was dependent on the amount of exogenous ATP and CoASH trapped by freeze-thawing. The uptake of fatty acid in the presence of nonlimiting amounts of ATP and CoASH was dependent on the amount of endogenous fatty acyl-CoA synthetase either retained within vesicles during isolation or trapped within vesicles after isolation by freeze-thawing. Moreover, the fatty acid taken up by the vesicles was converted to fatty acyl-CoA. These data are consistent with the proposal that fatty acyl-CoA synthetase facilitates long chain fatty acid permeation of the inner membrane by a vectorial thioesterification mechanism.	Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Guelph; McMaster University	Mangroo, D (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.	dmangroo@uoguelph.ca		Trigatti, Bernardo (Dino) L./0000-0002-4556-119X				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; BLACK PN, 1987, J BIOL CHEM, V262, P1412; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Caviglia JM, 2004, J BIOL CHEM, V279, P11163, DOI 10.1074/jbc.M311392200; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Gargiulo CE, 1999, J LIPID RES, V40, P881; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1972, BIOCHIM BIOPHYS ACTA, V265, P367, DOI 10.1016/0304-4157(72)90014-7; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KONINGS WN, 1973, P NATL ACAD SCI USA, V70, P3376, DOI 10.1073/pnas.70.12.3376; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; MALAMY MH, 1964, BIOCHEMISTRY-US, V3, P1889, DOI 10.1021/bi00900a017; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1995, BIOCHEM CELL BIOL, V73, P223, DOI 10.1139/o95-027; MANGROO D, 1992, J BIOL CHEM, V267, P17095; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; MANGROO D, 1991, FASEB J, V5, P6602; MANGROO D, 1991, CAN FED BIOL SOC P, V34, P85; NUNN WD, 1979, J BIOL CHEM, V254, P9130; NUNN WD, 1986, J BIOL CHEM, V261, P167; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OSUMI T, 1979, BIOCHIM BIOPHYS ACTA, V574, P258; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; SAMUEL D, 1970, European Journal of Biochemistry, V12, P576, DOI 10.1111/j.1432-1033.1970.tb00889.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SPECTOR AA, 1969, J LIPID RES, V10, P56; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; Uberti MA, 2003, BBA-PROTEINS PROTEOM, V1645, P193, DOI 10.1016/S1570-9639(02)00540-X; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; ZHOU SL, 1992, J BIOL CHEM, V267, P14456; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	52	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24163	24170		10.1074/jbc.M313632200	http://dx.doi.org/10.1074/jbc.M313632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067008	hybrid			2022-12-27	WOS:000221702500039
J	Nandakumar, J; Ho, CK; Lima, CD; Shuman, S				Nandakumar, J; Ho, CK; Lima, CD; Shuman, S			RNA substrate specificity and structure-guided mutational analysis of bacteriophage T4 RNA ligase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(+)-DEPENDENT DNA-LIGASE; CRYSTAL-STRUCTURE; CAPPING ENZYME; FUNCTIONAL DOMAINS; MITOCHONDRIAL RNA; EDITING LIGASES; COMPLEX; GENE; PURIFICATION; MECHANISM	Here we report that bacteriophage T4 RNA ligase 2 (Rnl2) is an efficient catalyst of RNA ligation at a 3'-OH/ 5'-PO4 nick in a double-stranded RNA or an RNA . DNA hybrid. The critical role of the template strand in approximating the reactive 3'-OH and 5'-PO4 termini is underscored by the drastic reductions in the RNA-sealing activity of Rnl2 when the duplex substrates contain gaps or flaps instead of nicks. RNA nick joining requires ATP and a divalent cation cofactor ( either Mg or Mn). Neither dATP, GTP, CTP, nor UTP can substitute for ATP. We identify by alanine scanning seven functionally important amino acids (Tyr-5, Arg-33, Lys-54, Gln-106, Asp-135, Arg-155, and Ser-170) within the N-terminal nucleotidyltransferase domain of Rnl2 and impute specific roles for these residues based on the crystal structure of the AMP-bound enzyme. Mutational analysis of 14 conserved residues in the C-terminal domain of Rnl2 identifies 3 amino acids ( Arg-266, Asp-292, and Glu-296) as essential for ligase activity. Our findings consolidate the evolutionary connections between bacteriophage Rnl2 and the RNA-editing ligases of kinetoplastid protozoa.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022	Lima, Christopher/0000-0002-9163-6092; Nandakumar, Jayakrishnan/0000-0001-9146-2785	NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; Blanc V, 1999, J BIOL CHEM, V274, P24289, DOI 10.1074/jbc.274.34.24289; Blondal T, 2003, NUCLEIC ACIDS RES, V31, P7247, DOI 10.1093/nar/gkg914; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 1999, NUCLEIC ACIDS RES, V27, P3253, DOI 10.1093/nar/27.16.3253; Doherty AJ, 1999, J MOL BIOL, V285, P63, DOI 10.1006/jmbi.1998.2301; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Lim JH, 2001, ARCH BIOCHEM BIOPHYS, V388, P253, DOI 10.1006/abbi.2001.2291; MARTINS A, 2004, IN PRESS J BIOL CHEM; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Palazzo SS, 2003, MOL BIOCHEM PARASIT, V127, P161, DOI 10.1016/S0166-6851(02)00333-X; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Sawaya R, 2003, J BIOL CHEM, V278, P43928, DOI 10.1074/jbc.M307839200; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P3536, DOI 10.1093/nar/26.15.3536; SRISKANDA V, 2002, J BIOL CHEM, V277, P9685; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Yin SM, 2004, VIROLOGY, V319, P141, DOI 10.1016/j.virol.2003.10.037; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	38	67	77	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31337	31347		10.1074/jbc.M402394200	http://dx.doi.org/10.1074/jbc.M402394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15084599	hybrid			2022-12-27	WOS:000222726800054
J	Johns, TG; Adamas, TE; Cochran, JR; Hall, NE; Hoyne, PA; Olsen, MJ; Kim, YS; Rothacker, J; Nice, EC; Walker, F; Ritter, G; Jungbluth, AJ; Old, LJ; Ward, CW; Burgess, AW; Wittrup, KD; Scott, AM				Johns, TG; Adamas, TE; Cochran, JR; Hall, NE; Hoyne, PA; Olsen, MJ; Kim, YS; Rothacker, J; Nice, EC; Walker, F; Ritter, G; Jungbluth, AJ; Old, LJ; Ward, CW; Burgess, AW; Wittrup, KD; Scott, AM			Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SURFACE DISPLAY; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; EGF; MUTANT; TARGET; DOMAIN; GENE; LUNG; AMPLIFICATION	The epidermal growth factor receptor (EGFR) is over-expressed in many epithelial cancers, an observation often correlated with poor clinical outcome. Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. Monoclonal antibody (mAb) 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild type (wt) EGFR when overexpressed but does not bind the wt EGFR expressed in normal tissues. Despite only binding to a low proportion of the wt EGFR expressed in A431 tumor cells (similar to10%), mAb 806 displays robust antitumor activity against A431 xenografts grown in nude mice. To elucidate the mechanism leading to its unique specificity and mode of antitumor activity, we have determined the EGFR binding epitope of mAb 806. Analysis of mAb 806 binding to EGFR fragments expressed either on the surface of yeast or in an immunoblot format identified a disulfide-bonded loop (amino acids 287-302) that contains the mAb 806 epitope. Indeed, mAb 806 binds with apparent high affinity (similar to30 nM) to a synthetic EGFR peptide corresponding to these amino acids. Analysis of EGFR structures indicates that the epitope is fully exposed only in the transitional form of the receptor that occurs because EGFR changes from the inactive tethered conformation to a ligand-bound active form. It would seem that mAb 806 binds this small proportion of transient receptors, preventing their activation, which in turn generates a strong antitumor effect. Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity.	Austin Hosp, Oncogen Signalling Lab, Ludwig Inst Canc Res, Tumor Targeting Program, Heidelberg, Vic 3084, Australia; CSIRO Hlth Sci & Nutr, Parkville, Vic 3052, Australia; MIT, Cambridge, MA 02139 USA; Royal Melbourne Hosp, Epithelial Biochem Lab, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10021 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Johns, TG (corresponding author), Austin Hosp, Oncogen Signalling Lab, Ludwig Inst Canc Res, Tumor Targeting Program, Level 6,Harold Stokes Bldg,Studley Rd, Heidelberg, Vic 3084, Australia.	terry.johns@ludwig.edu.au	Nice, Edouard C/B-1026-2011; Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Kim, Yong-Sung/0000-0003-2673-1509; Scott, Andrew/0000-0002-6656-295X; Olsen, Mark/0000-0003-2871-1923; Rothacker, Julie/0000-0001-7560-4982; Hall, Nathan/0000-0001-8942-0498	NATIONAL CANCER INSTITUTE [R01CA096504] Funding Source: NIH RePORTER; NCI NIH HHS [CA96504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cochran JR, 2004, J IMMUNOL METHODS, V287, P147, DOI 10.1016/j.jim.2004.01.024; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Frederick L, 2000, CANCER RES, V60, P1383; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Herberman RB, 2002, SEMIN ONCOL, V29, P27, DOI 10.1053/sonc.2002.33079; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Luwor RB, 2001, CANCER RES, V61, P5355; Lynch DH, 2002, SEMIN ONCOL, V29, P47, DOI 10.1053/sonc.2002.31522; MALDEN LT, 1988, CANCER RES, V48, P2711; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mishima K, 2001, CANCER RES, V61, P5349; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Stragliotto G, 1996, EUR J CANCER, V32A, P636, DOI 10.1016/0959-8049(95)00592-7; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CK, 2000, CANCER RES, V60, P3081; Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p	44	115	216	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30375	30384		10.1074/jbc.M401218200	http://dx.doi.org/10.1074/jbc.M401218200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15075331	hybrid			2022-12-27	WOS:000222531900063
J	Hawkins, LM; Prybylowski, K; Chang, K; Moussan, C; Stephenson, FA; Wenthold, RJ				Hawkins, LM; Prybylowski, K; Chang, K; Moussan, C; Stephenson, FA; Wenthold, RJ			Export from the endoplasmic reticulum of assembled N-methyl-D-aspartic acid receptors is controlled by a motif in the C terminus of the NR2 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER RETENTION SIGNAL; CELL-SURFACE EXPRESSION; NMDA RECEPTORS; GLUTAMATE RECEPTORS; PHARMACOLOGICAL CHAPERONES; MOLECULAR CHARACTERIZATION; TRAFFICKING; NEURONS; PROTEIN; PHOSPHORYLATION	Functional N-methyl-D-aspartic acid ( NMDA) receptors are formed from the assembly of NR1 and NR2 subunits. When expressed alone, the major NR1 splice variant and the NR2 subunits are retained in the endoplasmic reticulum ( ER), reflecting a quality control mechanism found in many complex multisubunit proteins to ensure that only fully assembled and properly folded complexes reach the cell surface. Recent studies have identified an RRR motif in the C terminus of the NR1 subunit, which controls the ER retention of the unassembled subunit. Here we investigated the mechanisms controlling the ER retention of the NR2 subunit and the export of the assembled complex from the ER. We found that Tac chimeras of the C terminus of the NR2B subunit show that an ER retention signal is also present in the NR2B subunit. In assembled complexes, ER retention signals on the individual subunits must be overcome to allow the complex to leave the ER. One common mechanism involves mutual masking of the signals on the individual subunits. Our data do not support such a mechanism for regulating the release of assembled NMDA receptors from the ER. We found that the motif, HLFY, immediately following transmembrane domain 4 of the NR2 subunit, is required for the assembled complex to exit from the ER. Mutation of this motif allowed the assembly of NR1 and NR2 subunits into a complex that was functional, based on MK-801 binding, but it is retained in the ER. These results are consistent with HLFY functioning as a signal that is necessary for the release of the assembled functional NMDA receptor complex from the ER.	NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of London; University College London; University of London School of Pharmacy	Wenthold, RJ (corresponding author), NIDCD, Neurochem Lab, NIH, Bldg 50,Rm 4140,50 South Dr, Bethesda, MD 20892 USA.	wenthold@nidcd.nih.gov			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000003, ZIADC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Grunwald ME, 2003, NEUROPHARMACOLOGY, V45, P768, DOI 10.1016/S0028-3908(03)00274-0; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kew JNC, 1998, J NEUROSCI, V18, P1935; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MAH SJ, 2003, SOC NEUR ABSTR, V360, P10; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Matsuda I, 2000, BIOCHEM BIOPH RES CO, V275, P565, DOI 10.1006/bbrc.2000.3351; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONTERO VM, 1989, NEUROSCIENCE, V31, P639, DOI 10.1016/0306-4522(89)90429-6; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Okabe S, 1999, J NEUROSCI, V19, P7781; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rubio ME, 1997, NEURON, V18, P939, DOI 10.1016/S0896-6273(00)80333-5; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tovar KR, 1999, J NEUROSCI, V19, P4180; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	44	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28903	28910		10.1074/jbc.M402599200	http://dx.doi.org/10.1074/jbc.M402599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102836	hybrid			2022-12-27	WOS:000222445300011
J	Woodruff, PJ; Carlson, BL; Siridechadilok, B; Pratt, MR; Senaratne, RH; Mougous, JD; Riley, LW; Williams, SJ; Bertozzi, CR				Woodruff, PJ; Carlson, BL; Siridechadilok, B; Pratt, MR; Senaratne, RH; Mougous, JD; Riley, LW; Williams, SJ; Bertozzi, CR			Trehalose is required for growth of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING LIPOOLIGOSACCHARIDES; CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; PYRUVYLATED GLYCOLIPIDS; BIOSYNTHESIS GENES; ESCHERICHIA-COLI; SYNTHASE GENE; 3 PATHWAYS; IN-VIVO; TUBERCULOSIS	Mycobacteria contain high levels of the disaccharide trehalose in free form as well as within various immunologically relevant glycolipids such as cord factor and sulfolipid-1. By contrast, most bacteria use trehalose solely as a general osmoprotectant or thermoprotectant. Mycobacterium tuberculosis and Mycobacterium smegmatis possess three pathways for the synthesis of trehalose. Most bacteria possess only one trehalose biosynthesis pathway and do not elaborate the disaccharide into more complex metabolites, suggesting a distinct role for trehalose in mycobacteria. We disabled key enzymes required for each of the three pathways in M. smegmatis by allelic replacement. The resulting trehalose biosynthesis mutant was unable to proliferate and enter stationary phase unless supplemented with trehalose. At elevated temperatures, however, the mutant was unable to proliferate even in the presence of trehalose. Genetic complementation experiments showed that each of the three pathways was able to recover the mutant in the absence of trehalose, even at elevated temperatures. From a panel of trehalose analogs, only those with the native alpha,alpha- (1,1) anomeric stereochemistry rescued the mutant, whereas alternate stereoisomers and general osmo- and thermoprotectants were inactive. These findings suggest a dual role for trehalose as both a thermoprotectant and a precursor of critical cell wall metabolites.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Williams, SJ (corresponding author), Univ Melbourne, Sch Chem, Parkville, Vic 3054, Australia.	sjwill@unimelb.edu.au; crb@berkeley.edu	Williams, Spencer/C-3545-2009	Williams, Spencer/0000-0001-6341-4364	NIAID NIH HHS [AI51622] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; Bell W, 1998, J BIOL CHEM, V273, P33311, DOI 10.1074/jbc.273.50.33311; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P12705, DOI 10.1021/bi00210a020; BESRA GS, 1994, CARBOHYD RES, V251, P99, DOI 10.1016/0008-6215(94)84279-5; BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; DHARIWAL KR, 1987, J GEN MICROBIOL, V133, P201; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; GAUTIER N, 1992, FEMS MICROBIOL LETT, V98, P81; Gibson RP, 2002, ACTA CRYSTALLOGR D, V58, P349, DOI 10.1107/S090744490102056X; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6; Hamasaki N, 2000, INFECT IMMUN, V68, P3704, DOI 10.1128/IAI.68.6.3704-3709.2000; HUNTER SW, 1983, J BIOL CHEM, V258, P481; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; KAMISANGO K, 1985, J BIOL CHEM, V260, P4117; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; Maruta K, 1996, BBA-GEN SUBJECTS, V1291, P177, DOI 10.1016/S0304-4165(96)00082-7; Maruta K, 1996, BBA-GEN SUBJECTS, V1289, P10, DOI 10.1016/0304-4165(95)00139-5; Maruta K, 1996, BIOSCI BIOTECH BIOCH, V60, P717, DOI 10.1271/bbb.60.717; Mougous JD, 2002, P NATL ACAD SCI USA, V99, P17037, DOI 10.1073/pnas.252514899; MOUGOUS JD, IN PRESS NAT STRUCT; NARUMI K, 1967, J BIOL CHEM, V242, P2233; Ohta M, 2002, EUR J BIOCHEM, V269, P3142, DOI 10.1046/j.1432-1033.2002.02971.x; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Pan YT, 2002, EUR J BIOCHEM, V269, P6091, DOI 10.1046/j.1432-1033.2002.03327.x; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; Pratt MR, 2003, ORG LETT, V5, P3185, DOI 10.1021/ol034836t; SAADAT S, 1983, J BIOL CHEM, V258, P1813; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Smeulders MJ, 1999, J BACTERIOL, V181, P270, DOI 10.1128/JB.181.1.270-283.1999; Tsusaki K, 1996, BBA-GEN SUBJECTS, V1290, P1, DOI 10.1016/0304-4165(96)00023-2; Tsusaki K, 1997, BBA-GEN SUBJECTS, V1334, P28, DOI 10.1016/S0304-4165(96)00103-1; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	85	91	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28835	28843		10.1074/jbc.M313103200	http://dx.doi.org/10.1074/jbc.M313103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102847	hybrid			2022-12-27	WOS:000222445300003
J	Xu, H; Vavilin, D; Funk, C; Vermaas, W				Xu, H; Vavilin, D; Funk, C; Vermaas, W			Multiple deletions of small cab-like proteins in the cyanobacterium Synechocystis sp PCC 6803 - Consequences for pigment biosynthesis and accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; LIGHT-INDUCIBLE POLYPEPTIDES; STRAIN PCC 6803; PHOTOSYSTEM-II; CHLOROPHYLL-B; GENE FAMILY; TETRAPYRROLE BIOSYNTHESIS; HIGHER-PLANTS; EVOLUTION; COMPLEXES	Deletion of the genes for four or five small Cab-like proteins (SCPs) in photosystem (PS) I-less and PS I-less/ PS II-less strains of Synechocystis sp. PCC 6803 caused a large decrease in the chlorophyll and carotenoid content of the cells without accumulation of early intermediates in the chlorophyll biosynthesis pathway, suggesting limited chlorophyll availability. The PS II/PS I ratio increased upon deletion of multiple SCPs in a wild type background, similar to what is observed in the presence of subsaturating concentrations of gabaculin, an inhibitor of an early step in the tetrapyrrole biosynthesis pathway. Upon deletion of multiple SCPs, neither 77 K fluorescence emission properties of phycobilisomeless thylakoids from the PS I- less/PS II-less strain nor the energy trapping efficiency of PS II were affected, indicating that under steady-state conditions SCPs do not bind much chlorophyll and do not serve as PS II antenna. Under conditions where protochlorophyllide reduction and thus chlorophyll synthesis were inhibited, chlorophyll disappeared quickly in a mutant lacking all five SCPs. This implies a role of SCPs in stabilization of chlorophyll-binding proteins and/or in reuse of chlorophylls. Under these conditions of inhibited reduction of protochlorophyllide, the accumulation kinetics of this intermediate were greatly altered in the absence of the five SCPs. This indicates an alteration of tetrapyrrole biosynthesis kinetics by SCPs. Based on this and other evidence, we propose that SCPs bind carotenoids and transiently bind chlorophyll, aiding in the supply of chlorophyll to nascent or reassembling photosynthetic complexes, and regulate the tetrapyrrole biosynthesis pathway as a function of the demand for chlorophyll.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA; Umea Univ, Umea Plant Sci Ctr, SE-90187 Umea, Sweden; Umea Univ, Dept Biochem, SE-90187 Umea, Sweden	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Umea University; Umea University	Vermaas, W (corresponding author), Arizona State Univ, Sch Life Sci, Box 874501, Tempe, AZ 85287 USA.	wim@asu.edu	Funk, Christiane/AAO-6041-2021	Funk, Christiane/0000-0002-7897-4038				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Bhaya D, 2002, FEMS MICROBIOL LETT, V215, P209, DOI 10.1111/j.1574-6968.2002.tb11393.x; BOUSSIBA S, 1992, RES PHOTOSYNTHESIS, V3, P429; CARPENTER SD, 1990, FEBS LETT, V260, P135, DOI 10.1016/0014-5793(90)80085-W; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; ERMAKOVAGERDES S, 1995, PHOTOSYNTHESIS LIGHT, V1, P483; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; HAO L, 2001, PS2001 P 12 INT C PH; Hartel H, 1998, J EXP BOT, V49, P535, DOI 10.1093/jexbot/49.320.535; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; He QF, 1999, PLANT MOL BIOL, V39, P1175, DOI 10.1023/A:1006177103225; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Hirschberg J., 1994, MOL BIOL CYANOBACTER, DOI [10.1007/978-94-011-0227-8_18, DOI 10.1007/978-94-011-0227-8_18]; Howitt CA, 1999, J BACTERIOL, V181, P3994, DOI 10.1128/JB.181.13.3994-4003.1999; Howitt CA, 2001, PLANTA, V214, P46, DOI 10.1007/s004250100578; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; Lagarde D, 2000, APPL ENVIRON MICROB, V66, P64, DOI 10.1128/AEM.66.1.64-72.2000; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RICCHELLI F, 1995, J PHOTOCH PHOTOBIO B, V29, P109, DOI 10.1016/1011-1344(95)07155-U; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1994, J BIOL CHEM, V269, P13904; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Vavilin D, 2003, BIOCHEMISTRY-US, V42, P1731, DOI 10.1021/bi026853g; VERMAAS WFJ, 1987, PLANT MOL BIOL, V8, P317, DOI 10.1007/BF00021311; Wu QG, 1995, PLANT MOL BIOL, V29, P933, DOI 10.1007/BF00014967; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905; Xu H, 2002, J BIOL CHEM, V277, P42726, DOI 10.1074/jbc.M205237200; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298; YIN JCP, 1988, J MOL BIOL, V199, P35, DOI 10.1016/0022-2836(88)90377-4	38	82	85	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27971	27979		10.1074/jbc.M403307200	http://dx.doi.org/10.1074/jbc.M403307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107425	hybrid			2022-12-27	WOS:000222265400019
J	Bohren, KM; Nadkarni, V; Song, JH; Gabbay, KH; Owerbach, D				Bohren, KM; Nadkarni, V; Song, JH; Gabbay, KH; Owerbach, D			A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; UBIQUITIN; SENTRIN; LINKAGE; BINDING; STRESS; HSP60; CELLS	Three SUMO ( small ubiquitin-related modifier) genes have been identified in humans, which tag proteins to modulate subcellular localization and/or enhance protein stability and activity. We report the identification of a novel intronless SUMO gene, SUMO-4, that encodes a 95-amino acid protein having an 86% amino acid homology with SUMO-2. In contrast to SUMO-2, which is highly expressed in all of the tissues examined, SUMO-4 mRNA was detected mainly in the kidney. A single nucleotide polymorphism was detected in SUMO-4, substituting a highly conserved methionine with a valine residue (M55V). In HepG2 ( liver carcinoma) cells transiently transfected with SUMO-4 expression vectors, Met-55 was associated with the elevated levels of activated heat shock factor transcription factors as compared with Val-55, whereas the levels of NF-kappaB were suppressed to an identical degree. The SUMO-4M ( Met) variant is associated with type I diabetes mellitus susceptibility in families ( p = 4.0 x 10(-4)), suggesting that it may be involved in the pathogenesis of type I diabetes.	Baylor Coll Med, Mol Diabet & Metab Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Harry B & Aileen B Gordon Diabet Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Owerbach, D (corresponding author), Baylor Coll Med, Mol Diabet & Metab Sect, Houston, TX 77030 USA.	davido@bcm.tmc.edu	Owerbach, David/A-3144-2008	Bohren, Kurt/0000-0002-3183-4118				Barski OA, 1999, GENOMICS, V60, P188, DOI 10.1006/geno.1999.5915; Birk OS, 1996, J AUTOIMMUN, V9, P159, DOI 10.1006/jaut.1996.0019; Cohen IR, 2002, DIABETOLOGIA, V45, P1468, DOI 10.1007/s00125-002-0937-z; Cox NJ, 2001, AM J HUM GENET, V69, P820, DOI 10.1086/323501; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Devaney JM, 2001, ANAL CHEM, V73, P620, DOI 10.1021/ac000912j; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; JONES DB, 1993, IMMUNOL TODAY, V14, P115, DOI 10.1016/0167-5699(93)90210-C; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Martin ER, 1997, AM J HUM GENET, V61, P439, DOI 10.1086/514860; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okura T, 1996, J IMMUNOL, V157, P4277; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192	23	273	299	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27233	27238		10.1074/jbc.M402273200	http://dx.doi.org/10.1074/jbc.M402273200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123604	hybrid			2022-12-27	WOS:000222120400051
J	Camarota, LM; Chapman, JM; Hui, DY; Howles, PN				Camarota, LM; Chapman, JM; Hui, DY; Howles, PN			Carboxyl ester lipase cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SR-BI; TARGETED MUTATION; PARTICLE UPTAKE; HEART-DISEASE; SECRETION; TRANSPORT; HYDROLASE; PATHWAY	Cholesteryl esters are selectively removed from high density lipoproteins by hepatocytes and steroidogenic cells through a process mediated by scavenger receptor BI. In the liver this cholesterol is secreted into bile, primarily as free cholesterol. Previous work showed that carboxyl ester lipase enhanced selective uptake of cholesteryl ether from high density lipoprotein by an unknown mechanism. Experiments were performed to determine whether carboxyl ester lipase plays a role in scavenger receptor BI-mediated selective uptake. When added to cultures of HepG2 cells, carboxyl ester lipase cofractionated with scavenger receptor BI and [H-3]cholesteryl ether-labeled high density lipoprotein in lipid raft fractions of cell homogenates. Confocal microscopy of immunostained carboxyl ester lipase and scavenger receptor BI showed a close association of these proteins in HepG2 cells. The enzyme and receptor also cofractionated from homogenates of mouse liver using two different fractionation methods. Antibodies that block scavenger receptor BI function prevented carboxyl ester lipase stimulation of selective uptake in primary hepatocytes from carboxyl ester lipase knockout mice. Heparin blockage of cell-surface proteoglycans also prevented carboxyl ester lipase stimulation of cholesteryl ester uptake by HepG2 cells. Inhibition of carboxyl ester lipase activity in HepG2 cells reduced hydrolysis of high density lipoprotein-cholesteryl esters similar to40%. In vivo, hydrolysis was similarly reduced in lipid rafts from the livers of carboxyl ester lipase-null mice compared with control animals. Primary hepatocytes from these mice yielded similar results. The data suggest that carboxyl ester lipase plays a physiological role in hepatic selective uptake and metabolism of high density lipoprotein cholesteryl esters by direct and indirect interactions with the scavenger receptor BI pathway.	Univ Cincinnati, Coll Med, Dept Pathol N, GRI, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati	Howles, PN (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol N, GRI, ML 0507,2120 E Galbraith Rd, Cincinnati, OH 45237 USA.	philip.howles@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066246] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL66246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Connelly MA, 2003, J LIPID RES, V44, P331, DOI 10.1194/jlr.M200186-JLR200; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; Fresnedo O, 2001, HEPATOLOGY, V33, P662, DOI 10.1053/jhep.2001.22763; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; Howles PN, 1999, AM J PHYSIOL-GASTR L, V277, pG653, DOI 10.1152/ajpgi.1999.277.3.G653; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; IVERSON SJ, 1991, BIOCHIM BIOPHYS ACTA, V1083, P109, DOI 10.1016/0005-2760(91)90131-Z; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; Li F, 1996, BIOCHEMISTRY-US, V35, P6657, DOI 10.1021/bi952313q; Li H, 2002, ENDOCRINOLOGY, V143, P3333, DOI 10.1210/en.2002-220341; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MYERSPAYNE SC, 1995, BIOCHEMISTRY-US, V34, P3942, DOI 10.1021/bi00012a011; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170; Sawle A, 2002, J LIPID RES, V43, P335; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Tall AR, 1998, EUR HEART J, V19, pA31; Temel RE, 2002, J BIOL CHEM, V277, P26565, DOI 10.1074/jbc.M203014200; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151	57	24	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27599	27606		10.1074/jbc.M402946200	http://dx.doi.org/10.1074/jbc.M402946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105424	hybrid			2022-12-27	WOS:000222120400094
J	Dasgupta, A; Ramsey, KL; Smith, JS; Auble, DT				Dasgupta, A; Ramsey, KL; Smith, JS; Auble, DT			Sir antagonist 1 (San1) is a ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; TRANSCRIPTIONAL STATES; CHROMATIN-STRUCTURE; SILENCING PROTEINS; SHUTTLE VECTORS; GENE-EXPRESSION; HISTONE H2B; YEAST	Mutations in Sir Antagonist 1 (SAN1) suppress defects in SIR4 and SPT16 in Saccharomyces cerevisiae. San1 contains a RING domain, suggesting that it functions by targeting mutant sir4 and spt16 proteins for degradation by a ubiquitin-mediated pathway. Consistent with this idea, mutant sir4 and spt16 proteins are unstable in SAN1 cells but are stabilized in san1Delta cells. We demonstrate that San1 possesses ubiquitin-protein isopeptide ligase activity in vitro, and the ubiquitin-protein isopeptide ligase activity of San1 is required for its function in vivo. Wild-type Sir4 has a half-life of about 21 min, and san1Delta increased Sir4 half-life to >90 min. In contrast, san1Delta did not affect the stability of wild-type Spt16, Sir3, Sir2, or the Spt16-associated proteins Pob3 and Nhp6. Loss of SAN1 also did not affect the stability of Ste6-166, a highly unstable protein in yeast. These results support the idea that San1 controls the turnover of a specific class of unstable nuclear proteins. Sir4 nucleates the assembly of silent chromatin at telomeres and the silent mating-type loci (HM) in S. cerevisiae. Sir4 can also affect silencing in the rDNA indirectly by sequestering limiting Sir2. Increasing the stability of wild-type Sir4 by deleting SAN1 had only subtle effects on silencing, suggesting that silent chromatin in yeast is robustly buffered against changes in Sir4 stability. Consistent with the idea that San1 participates as an accessory factor to regulate silent chromatin, including the silent mating-type loci, microarray analysis defined a small but statistically significant role for San1 in transcription of several mating pheromone-responsive genes.	Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Auble, DT (corresponding author), Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave,Rm 6213, Charlottesville, VA 22908 USA.	dta4n@virginia.edu			NCI NIH HHS [P30-CA44579] Funding Source: Medline; NIGMS NIH HHS [GM55763, GM61692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA044579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763, R01GM061692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, CELL, V111, P281, DOI 10.1016/S0092-8674(02)01081-4; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Aravind L, 1998, CURR BIOL, V8, pR111, DOI 10.1016/S0960-9822(98)70982-0; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Evans DRH, 1998, GENETICS, V150, P1393; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Freiberg G, 2000, CURR GENET, V37, P221, DOI 10.1007/s002940050523; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Guarente L, 2000, GENE DEV, V14, P1021; HABER JE, 1979, GENETICS, V93, P13; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kahana A, 1999, MOL CELL BIOL, V19, P6608; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KLAR AJS, 1979, GENETICS, V93, P37; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Lau A, 2002, GENE DEV, V16, P2935, DOI 10.1101/gad.764102; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Parsons XH, 2003, P NATL ACAD SCI USA, V100, P1609, DOI 10.1073/pnas.0434064100; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; RINE J, 1979, GENETICS, V93, P877; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHNELL R, 1989, GENETICS, V122, P29; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; Stone EM, 1996, J CELL BIOL, V135, P571, DOI 10.1083/jcb.135.3.571; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; XU QL, 1995, MOL CELL BIOL, V15, P6025; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Zhang ZM, 1997, MOL CELL BIOL, V17, P5461, DOI 10.1128/MCB.17.9.5461; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	68	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26830	26838		10.1074/jbc.M400894200	http://dx.doi.org/10.1074/jbc.M400894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078868	hybrid			2022-12-27	WOS:000222120400006
J	Selvamurugan, N; Kwok, S; Partridge, NC				Selvamurugan, N; Kwok, S; Partridge, NC			Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta-stimulated collagenase-3 expression in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOARTHRITIC CHONDROCYTES; TGF-BETA; C-JUN; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST-DIFFERENTIATION; COOPERATIVE INTERACTION; ACTIVATOR PROTEIN-1; CBFA1 CONTRIBUTES; PROMOTER	We have previously shown that transforming growth factor (TGF)-beta1, a crucial molecule in metastatic bone cancer, stimulates collagenase-3 expression in the human breast cancer cell line, MDA-MB231. To understand the molecular mechanisms responsible for TGF-beta1 response on collagenase-3 promoter activity, a functional analysis of the promoter region of the collagenase-3 gene was carried out, and we identified the distal runt domain (RD) and proximal RD/activator protein-1 (AP-1) sites as necessary for full TGF-beta1-stimulated collagenase-3 promoter activity. Gel shift, real time reverse transcriptase-PCR, and Western blot analyses showed increased levels of c-Jun, JunB, and Cbfa1/Runx2 upon TGF-beta1 treatment in MDA-MB231 cells. Co-immunoprecipitation in vitro studies identified no physical interaction between JunB and Cbfa1/Runx2, whereas Smad3 interacted with both. Chromatin immunoprecipitation experiments confirmed interaction of Smad3 with JunB and Cbfa1/Runx2. Under basal conditions, Cbfa1/Runx2 bound to both the proximal RD/AP-1 and distal RD sites. In response to TGF-beta1, Cbfa1/Runx2 was seen only at the distal RD site, whereas JunB occupied the proximal RD/ AP-1 site. An assemblage of Smad3, JunB, and Cbfa1/ Runx2 at the distal RD site of the collagenase-3 promoter occurred in response to TGF-beta1 in MDA-MB231 cells. Co-transfection of Smad3, JunB, and Cbfa1/ Runx2 constructs along with a constitutively active TGF-beta type I receptor construct identified functional interaction of these proteins and transcriptional activation of the collagenase-3 gene by TGF-beta1. Taken together, our results suggest that TGF-beta1 stimulated JunB and Cbfa1/ Runx2 to bind to their respective DNA consensus sites and that Smad3 is likely to stabilize their interaction to confer functional TGF-beta1-stimulation of collagenase-3 expression in MDA-MB231 cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Selvamurugan, N (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	selvamn2@umdnj.edu	Selvamurugan, Nagarajan/P-7894-2016	Selvamurugan, Nagarajan/0000-0003-3713-1920; Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [R01 DK047420, DK47420] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047420, R56DK047420] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Attisano L, 2001, MOL CELL ENDOCRINOL, V180, P3, DOI 10.1016/S0303-7207(01)00524-X; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Barnes GL, 2003, CANCER RES, V63, P2631; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Benderdour M, 2002, J RHEUMATOL, V29, P1262; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DALONZO RC, 2002, PRINCIPLES BONE BIOL, P251; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; Selvamurugan N, 2000, J CELL BIOCHEM, V79, P182, DOI 10.1002/1097-4644(20001101)79:2<182::AID-JCB20>3.0.CO;2-0; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; SELVAMURUGAN N, 2000, MOL CELL BIOL RES CO, V4, P218; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; STEIN GS, 1998, FRONT BIOSCI, V3, pD848; Tardif G, 2001, J RHEUMATOL, V28, P1631; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	62	96	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27764	27773		10.1074/jbc.M312870200	http://dx.doi.org/10.1074/jbc.M312870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084595	hybrid			2022-12-27	WOS:000222120400111
J	De Ioannes, P; Moltedo, B; Oliva, H; Pacheco, R; Faunes, F; De Ioannes, AE; Becker, MI				De Ioannes, P; Moltedo, B; Oliva, H; Pacheco, R; Faunes, F; De Ioannes, AE; Becker, MI			Hemocyanin of the molluscan Concholepas concholepas exhibits an unusual heterodecameric array of subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEYHOLE LIMPET HEMOCYANIN; OCTOPUS-DOFLEINI HEMOCYANIN; HALIOTIS-TUBERCULATA; MONOCLONAL-ANTIBODIES; FUNCTIONAL UNITS; OLIGOMERIC STABILITY; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; POLYACRYLAMIDE-GELS; ORGANIZATION	We describe here the structure of the hemocyanin from the Chilean gastropod Concholepas concholepas (CCH), emphasizing some attributes that make it interesting among molluscan hemocyanins. CCH exhibits a predominant didecameric structure as revealed by electron microscopy and a size of 8 MDa by gel filtration, and, in contrast with other mollusc hemocyanins, its stabilization does not require additional Ca2+ and/or Mg2+ in the medium. Polyacrylamide gel electrophoresis studies, analyses by a MonoQ FPLC column, and Western blots with specific monoclonal antibodies showed that CCH is made by two subunits noncovalently linked, named CCH-A and CCH-B, with molecular masses of 405 and 350 kDa, respectively. Interestingly, one of the subunits undergoes changes within the macromolecule; we demonstrated that CCH-A has an autocleavage site that under reducing conditions is cleaved to yield two polypeptides, CCH-A1 ( 300 kDa) and CCH-A2 ( 108 kDa), whereas CCH-B remains unchanged. The CCH-A nick occurs at 4 C, increases at 37 C, and is not inhibited by the addition of protease inhibitors and/or divalent cations. Since the CCH structure is a heterodimer, we investigated whether subunits would be either intermingled, forming heterodecamers, or assembled as two homogeneous decamers. Light scattering and electron microscope studies of the in vitro reassociation of purified CCH subunits demonstrated that the sole addition of Mg2+ is needed for its reassembly into the native decameric molecule; no homodecamer reorganization was found with either CCH-A or CCH-B subunits alone. Our evidence showed that C. concholepas hemocyanin is an unusual example of heterodecameric organization.	BIOSONDA Corp, Dept Res & Dev, Santiago 7750269, Chile		Becker, MI (corresponding author), BIOSONDA Corp, Dept Res & Dev, Ave Alcalde Eduardo Castillo Velasco 2902, Santiago 7750269, Chile.	mib@biosonda.cl	Becker, María/R-8252-2019	Pacheco, Rodrigo/0000-0001-8057-9806				Becker MI, 1998, HYBRIDOMA, V17, P373, DOI 10.1089/hyb.1998.17.373; BECKER MI, 2001, SCAN J IMMUNOL S1, V54, P107; Behrens JW, 2002, J EXP BIOL, V205, P253; BONAFE CFS, 1994, BIOCHEMISTRY-US, V33, P2651, DOI 10.1021/bi00175a038; BONAVENTURA C, 1981, ARCH BIOCHEM BIOPHYS, V211, P589, DOI 10.1016/0003-9861(81)90493-8; BROUWER M, 1978, BIOCHEMISTRY-US, V17, P2810, DOI 10.1021/bi00607a017; Coligan J.E., 1994, CURRENT PROTOCOLS IM, V2; Cordova JL, 2001, J SHELLFISH RES, V20, P55; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Destoumieux-Garzon D, 2001, J BIOL CHEM, V276, P47070, DOI 10.1074/jbc.M103817200; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Dolashka-Angelova P, 2003, BBA-PROTEINS PROTEOM, V1646, P77, DOI 10.1016/S1570-9639(02)00549-6; FERNANDEZMORAN H, 1966, J MOL BIOL, V16, P191, DOI 10.1016/S0022-2836(66)80272-3; GARRIDO J, 1981, DEV COMP IMMUNOL, V5, P691, DOI 10.1016/S0145-305X(81)80044-4; Gebauer W, 1999, J STRUCT BIOL, V128, P280, DOI 10.1006/jsbi.1999.4198; Gebauer W, 2002, J STRUCT BIOL, V139, P153, DOI 10.1016/S1047-8477(02)00591-9; GEBAUER W, 1994, ZOOL-ANAL COMPLEX SY, V98, P51; Gebauer W, 1999, ARCH BIOCHEM BIOPHYS, V372, P128, DOI 10.1006/abbi.1999.1478; Harris JR, 2000, MICRON, V31, P613, DOI 10.1016/S0968-4328(99)00145-6; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; HARRIS JR, 1993, J STRUCT BIOL, V111, P96, DOI 10.1006/jsbi.1993.1040; HERSCOWITZ HB, 1972, IMMUNOLOGY, V22, P51; HERSKOVITS TT, 1986, BIOCHEMISTRY-US, V25, P3612, DOI 10.1021/bi00360a020; Idakieva K, 2002, MICRON, V33, P7, DOI 10.1016/S0968-4328(00)00099-8; Jurincic-Winkler CD, 2000, EUR UROL, V37, P45, DOI 10.1159/000052392; Keller H, 1999, EUR J BIOCHEM, V264, P27, DOI 10.1046/j.1432-1327.1999.00564.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamy J, 1998, J MOL BIOL, V284, P1051, DOI 10.1006/jmbi.1998.2235; LAMY J, 1987, BIOCHEMISTRY-US, V26, P3509, DOI 10.1021/bi00386a039; Lieb B, 1999, EUR J BIOCHEM, V265, P134, DOI 10.1046/j.1432-1327.1999.00694.x; Lieb B, 2001, P NATL ACAD SCI USA, V98, P4546, DOI 10.1073/pnas.071049998; Manosalva H, 2004, HYBRIDOMA HYBRIDOM, V23, P45, DOI 10.1089/153685904322772024; MARKL J, 1991, NATURWISSENSCHAFTEN, V78, P512, DOI 10.1007/BF01131401; Markl J, 2001, J CANCER RES CLIN, V127, pR3, DOI 10.1007/BF01470992; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meissner U, 2000, J MOL BIOL, V298, P21, DOI 10.1006/jmbi.2000.3631; MELLEMA JE, 1972, NATURE, V239, P146, DOI 10.1038/239146a0; MILLER KI, 1990, P NATL ACAD SCI USA, V87, P1496, DOI 10.1073/pnas.87.4.1496; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Mura CV, 2002, J IMMUNOL METHODS, V260, P263, DOI 10.1016/S0022-1759(01)00546-4; Musselli C, 2001, J CANCER RES CLIN, V127, pR20, DOI 10.1007/BF01470995; Oliva H, 2002, HYBRIDOMA HYBRIDOM, V21, P365, DOI 10.1089/153685902761022715; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; SALVATO B, 1979, BIOCHEMISTRY-US, V18, P2731, DOI 10.1021/bi00580a007; Sohngen SM, 1997, EUR J BIOCHEM, V248, P602, DOI 10.1111/j.1432-1033.1997.00602.x; Swerdlow RD, 1996, COMP BIOCHEM PHYS B, V113, P537, DOI 10.1016/0305-0491(95)02091-8; TAKANARI H, 1990, BIOL CELL, V70, P83, DOI 10.1016/0248-4900(90)90363-8; Tan IP, 1996, BIOL REPROD, V54, P1300, DOI 10.1095/biolreprod54.6.1300; TERWILLIGER NB, 1988, COMP BIOCHEM PHYS B, V89, P189, DOI 10.1016/0305-0491(88)90282-9; Torres M, 1999, J AGR FOOD CHEM, V47, P4231, DOI 10.1021/jf981336j; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; van Holde KE, 2000, BIOPHYS CHEM, V86, P165, DOI 10.1016/S0301-4622(00)00154-X; VANHOLDE KE, 1991, J MOL BIOL, V217, P307, DOI 10.1016/0022-2836(91)90545-H; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WALKER JM, 1996, PROTEIN PROTOCOLS HD, P127	56	41	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26134	26142		10.1074/jbc.M400903200	http://dx.doi.org/10.1074/jbc.M400903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075320	hybrid			2022-12-27	WOS:000222003000027
J	Howell, M; Borchers, C; Milgram, SL				Howell, M; Borchers, C; Milgram, SL			Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; RNA-POLYMERASE-II; KAPPA-B PROTEINS; HNRNP-U; HELA-CELLS; WW DOMAIN; SUBCELLULAR-LOCALIZATION; DEPENDENT TRANSCRIPTION; P53/P63/P73 FAMILY; BINDING-PROTEIN	Although initially described as a cytosolic scaffolding protein, YAP (Yes-associated protein of 65 kDa) is known to associate with multiple transcription factors in the nucleus. Using affinity chromatography and mass spectrometry, we show that YAP interacts with heterogeneous nuclear ribonuclear protein U (hnRNP U), an RNA- and DNA-binding protein enriched in the nuclear matrix that also plays a role in the regulation of gene expression. hnRNP U interacts specifically with the proline-rich amino terminus of YAP, a region of YAP that is not found in the related protein TAZ. Although hnRNP U and YAP localize to both the nucleus and the cytoplasm, YAP does not translocate to the nucleus in an hnRNP U-dependent manner. Furthermore, hnRNP U and YAP only interact in the nucleus, suggesting that the association between the two proteins is regulated. Co-expression of hnRNP U attenuates the ability of YAP to increase the activity of a p73-driven Bax-luciferase reporter plasmid. In contrast, hnRNP U has no effect when co-expressed with a truncated YAP protein lacking the hnRNP U-binding site. Because YAP is distinguished from the homologue TAZ by its proline-rich amino terminus, the YAP-hnRNP U interaction may uniquely regulate the nuclear function(s) of YAP. The YAP-hnRNP U interaction provides another mechanism of YAP transcriptional regulation.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.	milg@med.unc.edu	BORCHERS, Christoph/U-5964-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378-1119(03)00627-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Berezney R, 1995, INT REV CYTOL, V162A, P1; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goodman RH, 2000, GENE DEV, V14, P1553; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang KH, 2002, FEBS LETT, V522, P161, DOI 10.1016/S0014-5793(02)02921-6; Kast J, 2003, RAPID COMMUN MASS SP, V17, P1825, DOI 10.1002/rcm.1114; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mery L, 2002, J CELL SCI, V115, P3497; Mohler Peter J, 2002, Methods Mol Med, V70, P383; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Rousseau G G, 1979, Monogr Endocrinol, V12, P49; Sasaki Y, 2003, CANCER RES, V63, P8145; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Takahashi Y, 2003, NEUROCHEM RES, V28, P1265, DOI 10.1023/A:1024296932670; Taniura H, 2002, J CELL BIOCHEM, V84, P545, DOI 10.1002/jcb.10047.abs; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhu JH, 1998, CANCER RES, V58, P5061; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	66	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26300	26306		10.1074/jbc.M401070200	http://dx.doi.org/10.1074/jbc.M401070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096513	hybrid, Green Published			2022-12-27	WOS:000222003000048
J	Lively, TN; Nguyen, TN; Galasinski, SK; Goodrich, JA				Lively, TN; Nguyen, TN; Galasinski, SK; Goodrich, JA			The basic leucine zipper domain of c-Jun functions in transcriptional activation through interaction with the N terminus of human TATA-binding protein-associated factor-1 (human TAF(II)250)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA-BINDING; BOX-BINDING; TFIID COMPLEX; MINOR-GROOVE; PROMOTER SELECTIVITY; V-JUN; FOS; DROSOPHILA; VITRO	We previously reported that c-Jun binds directly to the N-terminal 163 amino acids of Homo sapiens TATA-binding protein-associated factor-1 (hsTAF1), causing a derepression of transcription factor IID (TFIID)-driven transcription (Lively, T. N., Ferguson, H. A., Galasinski, S. K., Seto, A. G., and Goodrich, J. A. (2001) J. Biol. Chem. 276, 25582-25588). This region of hsTAF1 binds TATA-binding protein to repress TFIID DNA binding and transcription. Here we show that the basic leucine zipper domain of c-Jun, which allows for DNA binding and homodimerization, is necessary and sufficient for interaction with hsTAF1. Interestingly, the isolated basic leucine zipper domain of c-Jun was able to derepress TFIID-directed basal transcription in vitro. Moreover, when the N-terminal region of hsTAF1 was added to in vitro transcription reactions and overexpressed in cells, it blocked c-Jun activation. c-Fos, another basic leucine zipper protein, did not interact with hsTAF1, but c-Fos/c-Jun heterodimers did bind the N terminus of hsTAF1. Our studies show that, in addition to dimerization and DNA binding, the well characterized basic leucine zipper domain of c-Jun functions in transcriptional activation by binding to the N terminus of hsTAF1 to derepress transcription.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JA (corresponding author), Univ Colorado, Dept Chem & Biochem, 215 UCB, Boulder, CO 80309 USA.	james.goodrich@colorado.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055235, T32GM008759, T32GM007135] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008759, T32 GM08759, T32 GM142607, GM-55235, T32 GM07135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bartusel T, 2003, ONCOGENE, V22, P2932, DOI 10.1038/sj.onc.1206494; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Ferguson HA, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.20.e98; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kim LJ, 2001, MOL CELL BIOL, V21, P3503, DOI 10.1128/MCB.21.10.3503-3513.2001; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	51	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26257	26265		10.1074/jbc.M400892200	http://dx.doi.org/10.1074/jbc.M400892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087451	hybrid			2022-12-27	WOS:000222003000043
J	Castaldo, P; Stefanoni, P; Miceli, F; Coppola, G; del Giudice, EM; Bellini, G; Pascotto, A; Trudell, JR; Harrison, NL; Annunziato, L; Taglialatela, M				Castaldo, P; Stefanoni, P; Miceli, F; Coppola, G; del Giudice, EM; Bellini, G; Pascotto, A; Trudell, JR; Harrison, NL; Annunziato, L; Taglialatela, M			A novel hyperekplexia-causing mutation in the pre-transmembrane segment 1 of the human glycine receptor alpha(1) subunit reduces membrane expression and impairs gating by agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-SUBUNIT; HEREDITARY HYPEREKPLEXIA; FRAMESHIFT MUTATION; MISSENSE MUTATION; ALPHA-1 SUBUNIT; STARTLE DISEASE; XENOPUS-OOCYTES; GENE GLRA1; DOMAIN; MOUSE	In this study, we have compared the functional consequences of three mutations (R218Q, V260M, and Q266H) in the alpha(1) subunit of the glycine receptor (GlyRA1) causing hyperekplexia, an inherited neurological channelopathy. In HEK-293 cells, the agonist EC50s for glycine-activated Cl- currents were increased from 26 muM in wtGlyRA1, to 5747, 135, and 129 muM in R218Q, V260M, and Q266H GlyRA1 channels, respectively. Cl- currents elicited by beta-alanine and taurine, which behave as agonists at wtGlyRA1, were decreased in V260M and Q266H mutant receptors and virtually abolished in GlyRA1 R218Q receptors. Gly-gated Cl- currents were similarly antagonized by low concentrations of strychnine in both wild-type (wt) and R218Q GlyRA1 channels, suggesting that the Arg-218 residue plays a crucial role in GlyRA1 channel gating, with only minor effects on the agonist/antagonist binding site, a hypothesis supported by our molecular model of the GlyRA1 subunit. The R218Q mutation, but not the V260M or the Q266H mutation, caused a marked decrease of receptor subunit expression both in total cell lysates and in isolated plasma membrane proteins. This decreased expression does not seem to explain the reduced agonist sensitivity of GlyRA1 R218Q channels since no difference in the apparent sensitivity to glycine or taurine was observed when wtGlyRA1 receptors were expressed at levels comparable with those of R218Q mutant receptors. In conclusion, multiple mechanisms may explain the dramatic decrease in GlyR function caused by the R218Q mutation, possibly providing the molecular basis for its association with a more severe clinical phenotype.	Univ Naples Federico II, Sch Med, Dept Neurosci, Div Pharmacol, I-80131 Naples, Italy; Univ Naples 2, Dept Child Neuropsychiat, I-80138 Naples, Italy; Univ Naples 2, Dept Pediat, I-80138 Naples, Italy; Stanford Univ, Beckman Program Mol & Genet Med, Dept Anesthesia, Stanford, CA 94305 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	University of Naples Federico II; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Stanford University; Cornell University; Cornell University	Taglialatela, M (corresponding author), Univ Naples Federico II, Sch Med, Dept Neurosci, Div Pharmacol, Via Pansini 5, I-80131 Naples, Italy.	mtaglial@unina.it	Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/ABH-4262-2020; del Giudice, Emanuele Muraglia/AAC-2824-2019; Taglialatela, Maurizio/A-2062-2019; Miceli, Francesco/H-3767-2013	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; Miceli, Francesco/0000-0002-5393-1402; Coppola, Giangennaro/0000-0002-9574-0081; ANNUNZIATO, LUCIO/0000-0002-8534-8270	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013378] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA013378] Funding Source: Medline; NIGMS NIH HHS [R01 GM63034, R01 GM45129] Funding Source: Medline; Telethon [GGP030209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bertaccini E, 2001, INT REV NEUROBIOL, V48, P141, DOI 10.1016/S0074-7742(01)48015-9; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brune W, 1996, AM J HUM GENET, V58, P989; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; Castaldo P, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0003.2002; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Coppola G, 2003, NEUROLOGY, V61, P131, DOI 10.1212/01.WNL.0000069465.53698.BD; del Giudice EM, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e71; del Giudice EM, 2001, EUR J HUM GENET, V9, P873, DOI 10.1038/sj.ejhg.5200729; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; Kumamoto E, 1997, PROG NEUROBIOL, V52, P197, DOI 10.1016/S0301-0082(97)00016-6; LANGOSCH D, 1993, FEBS LETT, V336, P540, DOI 10.1016/0014-5793(93)80872-R; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Milani N, 1996, AM J HUM GENET, V58, P420; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 1999, MOL PHARMACOL, V55, P386, DOI 10.1124/mol.55.2.386; RYAN SG, 1992, ANN NEUROL, V31, P663, DOI 10.1002/ana.410310615; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; Saint Jan DD, 2001, J PHYSIOL-LONDON, V535, P741; Saul B, 1999, J NEUROSCI, V19, P869; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Schmieden V, 1999, MOL PHARMACOL, V56, P464, DOI 10.1124/mol.56.3.464; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; TALEB O, 1994, EMBO J, V13, P1318, DOI 10.1002/j.1460-2075.1994.tb06384.x; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; Trudell JR, 2002, BRIT J ANAESTH, V89, P32, DOI 10.1093/bja/aef157; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Zhou L, 2002, BRAIN DEV-JPN, V24, P669, DOI 10.1016/S0387-7604(02)00095-5	43	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25598	25604		10.1074/jbc.M311021200	http://dx.doi.org/10.1074/jbc.M311021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066993	hybrid			2022-12-27	WOS:000221827900087
J	Foster, MW; Stamler, JS				Foster, MW; Stamler, JS			New insights into protein S-nitrosylation - Mitochondria as a model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER MITOCHONDRIA; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; IN-VIVO; SARCOSINE DEHYDROGENASE; NITROSATIVE STRESS; OUTER-MEMBRANE; SERUM-ALBUMIN; MECHANISM	The biological effects of nitric oxide ( NO) are in significant part mediated through S-nitrosylation of cysteine thiol. Work on model thiol substrates has raised the idea that molecular oxygen (O-2) is required for S-nitrosylation by NO; however, the relevance of this mechanism at the low physiological pO(2) of tissues is unclear. Here we have used a proteomic approach to study S-nitrosylation reactions in situ. We identify endogenously S-nitrosylated proteins in subcellular organelles, including dihydrolipoamide dehydrogenase and catalase, and show that these, as well as hydroxymethylglutaryl-CoA synthase and sarcosine dehydrogenase (SarDH), are S-nitrosylated by NO under strictly anaerobic conditions. S-Nitrosylation of SarDH by NO is best rationalized by a novel mechanism involving the covalently bound flavin of the enzyme. We also identify a set of mitochondrial proteins that can be S-nitrosylated through multiple reaction channels, including anaerobic/oxidative, NO/O-2, and GSNO-mediated transnitrosation. Finally, we demonstrate that steady state levels of S-nitrosylation are higher in mitochondrial extracts than the intact organelles, suggesting the importance of denitrosylation reactions. Collectively, our results provide new insight into the determinants of S-nitrosothiol levels in subcellular compartments.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Rm 321 MSRB,Box 2612, Durham, NC 27710 USA.	STAML001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572				BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Chan NL, 2004, BIOCHEMISTRY-US, V43, P118, DOI 10.1021/bi030172j; COOK RJ, 1984, J BIOL CHEM, V259, P2475; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Datta B, 2004, CIRCULATION, V109, P1339, DOI 10.1161/01.CIR.0000124450.07016.1D; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; DULING BR, 1970, CIRC RES, V27, P669, DOI 10.1161/01.RES.27.5.669; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Eschenbrenner M, 1999, GENOMICS, V59, P300, DOI 10.1006/geno.1999.5886; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Gnaiger E, 1998, BBA-BIOENERGETICS, V1365, P249, DOI 10.1016/S0005-2728(98)00076-0; GORCZYNSKI RJ, 1978, AM J PHYSIOL, V235, pH505, DOI 10.1152/ajpheart.1978.235.5.H505; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Greenawalt J W, 1979, Methods Enzymol, V55, P88; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Houk KN, 2003, J AM CHEM SOC, V125, P6972, DOI 10.1021/ja029655l; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; OEI J, 1985, BIOCHIM BIOPHYS ACTA, V840, P1, DOI 10.1016/0304-4165(85)90154-0; PATEL MS, 1995, METHOD ENZYMOL, V252, P186; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RADI R, 1991, J BIOL CHEM, V266, P22028; Richmond KN, 1999, AM J PHYSIOL-HEART C, V277, pH1831, DOI 10.1152/ajpheart.1999.277.5.H1831; Rizzo MA, 2003, J CELL BIOL, V161, P243, DOI 10.1083/jcb.200301063; Romeo AA, 2003, J AM CHEM SOC, V125, P14370, DOI 10.1021/ja0289752; Romeo AA, 2001, J AM CHEM SOC, V123, P1782, DOI 10.1021/ja005612y; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; Tao LM, 2003, BIOCHEMISTRY-US, V42, P3326, DOI 10.1021/bi0269963; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; WHALEN WJ, 1967, CIRC RES, V21, P251, DOI 10.1161/01.RES.21.3.251; Wiegant FAC, 1999, FEBS LETT, V455, P179, DOI 10.1016/S0014-5793(99)00806-6; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	68	145	152	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25891	25897		10.1074/jbc.M313853200	http://dx.doi.org/10.1074/jbc.M313853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069080	hybrid			2022-12-27	WOS:000221827900121
J	Green, KA; Naylor, MJ; Lowe, ET; Wang, PB; Marshman, E; Streuli, CH				Green, KA; Naylor, MJ; Lowe, ET; Wang, PB; Marshman, E; Streuli, CH			Caspase-mediated cleavage of insulin receptor substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND INVOLUTION; GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY DOMAIN; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; PROTEIN-KINASE; APOPTOTIC FUNCTION; SURVIVAL SIGNALS; BH3 DOMAIN; 1ST STAGE	Apoptosis is an important mechanism for maintaining tissue homeostasis. The efficient induction and execution of apoptosis are essential for cell clearance in specific developmental situations. Insulin-like growth factor (IGF)-I is a survival factor for epithelial cells in the mammary gland, and its withdrawal or inhibition leads to apoptosis. In this paper we describe a novel mechanism that may lead to suppression of an IGF-I-mediated signaling pathway through cleavage of insulin receptor substrate (IRS). During the process of forced weaning, when mammary epithelial cells rapidly enter apoptosis in vivo, IRS-1 and IRS-2 disappear. We have used cultured mammary epithelial cells to demonstrate that IRS removal can be mediated through the action of caspase 10. Caspase 10 activation and IRS-1 cleavage are regulated by a MKK1-signaling pathway but not by a phosphatidylinositol- 3 kinase pathway nor by the extracellular proapoptotic ligands FasL, tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL), or transforming growth factor-beta3. In addition we show that the loss of IRS-1 after MKK1 inhibition prevents IGF-mediated phosphorylation of FKHRL1.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Streuli, CH (corresponding author), Univ Manchester, Sch Biol Sci, Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cstreuli@man.ac.uk						ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Badock V, 2001, CELL DEATH DIFFER, V8, P308, DOI 10.1038/sj.cdd.4400812; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEL PL, 1997, SCIENCE, V278, P687; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Giampietri C, 2003, CELL DEATH DIFFER, V10, P175, DOI 10.1038/sj.cdd.4401137; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; GREEN KA, 2004, IN PRESS CELL MOL LI; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hadsell DL, 2001, ENDOCRINOLOGY, V142, P1479, DOI 10.1210/en.142.4.1479; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KITTRELL FS, 1992, CANCER RES, V52, P1924; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Lacher MD, 2003, CELL DEATH DIFFER, V10, P528, DOI 10.1038/sj.cdd.4401197; Lee AV, 2003, CLIN CANCER RES, V9, p516S; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leroith Derek, 1995, Progress in Growth Factor Research, V6, P433, DOI 10.1016/0955-2235(96)00009-9; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Lund LR, 1996, DEVELOPMENT, V122, P181; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Marti A, 1997, EUR J CELL BIOL, V73, P158; Marti A, 2000, ADV EXP MED BIOL, V480, P195; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nakajima K, 2000, J BIOL CHEM, V275, P10484, DOI 10.1074/jbc.275.14.10484; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Prince JM, 2002, DEV DYNAM, V223, P497, DOI 10.1002/dvdy.10070; Pullan S, 1996, J CELL SCI, V109, P631; Pullan Shirley E., 1996, P97; Runswick SK, 2001, NAT CELL BIOL, V3, P823, DOI 10.1038/ncb0901-823; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schere-Levy C, 2003, EXP CELL RES, V282, P35, DOI 10.1006/excr.2002.5666; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sohn BH, 2001, BIOCHEM J, V360, P31, DOI 10.1042/0264-6021:3600031; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; Velthuis JHL, 2002, J BIOL CHEM, V277, P24631, DOI 10.1074/jbc.M111572200; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	68	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25149	25156		10.1074/jbc.M402395200	http://dx.doi.org/10.1074/jbc.M402395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069074	hybrid			2022-12-27	WOS:000221827900030
J	Smith, SA; Tabita, FR				Smith, SA; Tabita, FR			Glycine 176 affects catalytic properties and stability of the Synechococcus sp strain PCC6301 ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; ACTIVATION; CARBAMATE; MECHANISM; RUBISCO; CO2	A previously described system for biological selection of randomly mutagenized ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) employing the phototrophic bacterium Rhodobacter capsulatus (Smith, S. A., and Tabita, F. R. (2003) J. Mol. Biol. 331, 557-569) was used to select a catalytically altered form of a cyanobacterial (Synechococcus sp. strain PCC6301) enzyme. This mutant Rubisco, in which conserved glycine 176 was replaced with an aspartate residue, was not able to support CO2-dependent growth of the host strain. Site-directed mutant proteins were also constructed, e. g. asparagine and alanine residues replaced the native glycine with the result that these mutant proteins either greatly reduced the ability of R. capsulatus to support growth or had little effect, respectively. Growth phenotypes were consistent with the Rubisco activity levels associated with these proteins, and this was also borne out with purified recombinant proteins. Despite being catalytically challenged, the G176D and G176N mutant proteins were found to exhibit a more favorable interaction with CO2 than the wild type protein but exhibited a reduced affinity for the substrate ribulose 1,5-bisphosphate. The G176A enzyme differed little from the wild type protein in these properties. None of the mutants had CO2/O-2 specificities that differed markedly from the wild type. Further studies taken from the known structure of the Synechococcus Rubisco indicated that substitutions at Gly-176 affected associations between large subunits. Supporting experimental data included an unusual protein concentration-dependent effect on in vitro activity, differences in thermal stability relative to the wild type protein, and aberrant migration on nondenaturing polyacrylamide gels. From these results, it is apparent that residues not directly located within the active site but near large subunit interfaces can affect key kinetic properties of Rubisco. These results suggest that further bioselection protocols (using these proteins as starting material) might yield novel mutant forms of Rubisco that relate to key functional properties.	Ohio State Univ, Dept Microbiol & Plant Mol Biol, Biotechnol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol & Plant Mol Biol, Biotechnol Program, 484 W 12th Ave, Columbus, OH 43210 USA.	tabita.1@osu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Cheng ZQ, 1998, PROTEIN ENG, V11, P457, DOI 10.1093/protein/11.6.457; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Horken KM, 1999, ARCH BIOCHEM BIOPHYS, V361, P183, DOI 10.1006/abbi.1998.0979; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1980, BIOCHEMISTRY-US, V19, P5321, DOI 10.1021/bi00564a027; Maniatis T., 1982, MOL CLONING; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; Paoli GC, 1998, J BACTERIOL, V180, P4258, DOI 10.1128/JB.180.16.4258-4269.1998; Smith SA, 2003, J MOL BIOL, V331, P557, DOI 10.1016/S0022-2836(03)00786-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; WEAVER KE, 1983, J BACTERIOL, V156, P507, DOI 10.1128/JB.156.2.507-515.1983; WHITMAN W, 1976, BIOCHEM BIOPH RES CO, V71, P1034, DOI 10.1016/0006-291X(76)90758-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25632	25637		10.1074/jbc.M401360200	http://dx.doi.org/10.1074/jbc.M401360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067012	hybrid			2022-12-27	WOS:000221827900091
J	Pinakoulaki, E; Ohta, T; Soulimane, T; Kitagawa, T; Varotsis, C				Pinakoulaki, E; Ohta, T; Soulimane, T; Kitagawa, T; Varotsis, C			Simultaneous resonance Raman detection of the heme a(3)-Fe-CO and Cu-B-CO species in CO-bound ba(3)-cytochrome c oxidase from Thermus thermophilus - Evidence for a charge transfer Cu-B-CO transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE ACTIVE-SITE; BINUCLEAR CENTER; INFRARED-SPECTROSCOPY; DOCKING SITE; FTIR; TEMPERATURE; COMPLEX; BINDING; A(3)	Understanding of the chemical nature of the dioxygen and nitric oxide moiety of ba(3)-cytochrome c oxidase from Thermus thermophilus is crucial for elucidation of its physiological function. In the present work, direct resonance Raman (RR) observation of the Fe-C-O stretching and bending modes and the C-O stretching mode of the Cu-B-CO complex unambiguously establishes the vibrational characteristics of the heme-copper moiety in ba(3)-oxidase. We assigned the bands at 507 and 568 cm(-1) to the Fe-CO stretching and Fe-C-O bending modes, respectively. The frequencies of these modes in conjunction with the C-O mode at 1973 cm(-1) showed, despite the extreme values of the Fe-CO and C-O stretching vibrations, the presence of the alpha-conformation in the catalytic center of the enzyme. These data, distinctly different from those observed for the caa(3)-oxidase, are discussed in terms of the proposed coupling of the alpha- and beta-conformations that occur in the binuclear center of heme-copper oxidases with enzymatic activity. The Cu-B-CO complex was identified by its nu(CO) at 2053 cm(-1) and was strongly enhanced with 413.1 nm excitation indicating the presence of a metal-to-ligand charge transfer transition state near 410 nm. These findings provide, for the first time, RR vibrational information on the EPR silent Cu-B(I) that is located at the O-2 delivery channel and has been proposed to play a crucial role in both the catalytic and proton pumping mechanisms of heme-copper oxidases.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	University of Crete; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.	varotsis@edu.uoc.gr		Pinakoulaki, Eftychia/0000-0003-3320-6112; Varotsis, Constantinos/0000-0003-2771-8891				ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Hirota S, 1999, BIOCHEMISTRY-US, V38, P14256, DOI 10.1021/bi991129s; HIROTA S, 1994, J PHYS CHEM-US, V98, P6652, DOI 10.1021/j100077a035; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; Koutsoupakis C, 2004, BIOPHYS J, V86, P2438, DOI 10.1016/S0006-3495(04)74300-3; Koutsoupakis C, 2003, J AM CHEM SOC, V125, P14728, DOI 10.1021/ja036107e; Koutsoupakis C, 2003, J BIOL CHEM, V278, P36806, DOI 10.1074/jbc.M307117200; Koutsoupakis K, 2003, J BIOL CHEM, V278, P14893, DOI 10.1074/jbc.M210293200; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, J AM CHEM SOC, V117, P9363, DOI 10.1021/ja00141a033	21	33	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22791	22794		10.1074/jbc.C400124200	http://dx.doi.org/10.1074/jbc.C400124200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15066990	Green Published, hybrid			2022-12-27	WOS:000221570900002
J	Boswell, EJ; Jeon, H; Blacklow, SC; Downing, AK				Boswell, EJ; Jeon, H; Blacklow, SC; Downing, AK			Global defects in the expression and function of the low density lipoprotein receptor (LDLR) associated with two familial hypercholesterolemia mutations resulting in misfolding of the LDLR epidermal growth factor-AB pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; CALCIUM-BINDING; MOLECULAR-GENETICS; FACTOR-IX; IN-VITRO; MODULES; GENES; 1ST	The low density lipoprotein (LDL) receptor is a modular protein involved in the endocytosis of cholesterol-rich lipoproteins from the circulation. Mutations to the receptor result in familial hypercholesterolemia, and over 60 of these occur in the calcium-binding epidermal growth factor-like domain pair. Two selected mutations in this region (G322S and R329P) were introduced into the domain pair and analyzed by in vitro refolding. Both exhibited differing levels of protein misfolding with R329P being the most pronounced. Solution NMR studies of the mutant domain pairs after purification established that a fraction of protein maintains a native-like fold and that this fraction contains two intact calcium-binding sites. An in vivo analysis of intact receptors containing these binding sites showed significantly reduced cell-surface expression compared with the native LDL receptor levels, again with R329P showing the most severe decrease. The sum of these results suggests that either local changes in structure or domain misfolding may be associated with the mutations. There is also the possibility that the misfolding of the calcium-binding epidermal growth factor-like pair region is propagated to other regions of the intact receptor, resulting in more global defects. Surprisingly, for both mutants, those full-length receptors that fold and reach the cell surface retain the ability to bind LDL and release the ligand upon exposure to low pH. This analysis provides significant insight into the protein defect resulting from each of the two mutations and allows their classification to be 2B (partially transport-defective). The results also highlight a range of misfolding defects that may be associated with familial hypercholesterolemia and may enable the prediction of the consequences of homologous disease-causing mutations to other proteins.	Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Oxford; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Downing, AK (corresponding author), Univ Oxford, Dept Biochem, Div Struct Biol, S Parks Rd, Oxford OX1 3QU, England.	kristy.downing@bioch.ox.ac.uk			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Day INM, 1997, HUM MUTAT, V10, P116; DENTON PH, 1988, BLOOD, V72, P1407; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fouchier SW, 2001, HUM GENET, V109, P602, DOI 10.1007/s00439-001-0628-8; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; GUDNASON V, 1994, ARTERIOSCLER THROMB, V14, P1717, DOI 10.1161/01.ATV.14.11.1717; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; JEENAH M, 1993, ATHEROSCLEROSIS, V98, P51, DOI 10.1016/0021-9150(93)90222-G; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; Malby S, 2001, BIOCHEMISTRY-US, V40, P2555, DOI 10.1021/bi002322l; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Rand MD, 1997, PROTEIN SCI, V6, P2059; Reshef A, 1996, HUM GENET, V98, P581, DOI 10.1007/s004390050263; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; Salazar LA, 2000, BRAZ J MED BIOL RES, V33, P1301, DOI 10.1590/S0100-879X2000001100006; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Thiart R, 2000, MOL CELL PROBE, V14, P299, DOI 10.1006/mcpr.2000.0318; Villeger L, 2002, HUM MUTAT, V20, P81, DOI 10.1002/humu.10102; Webb JC, 1996, J LIPID RES, V37, P368; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807	42	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30611	30621		10.1074/jbc.M401412200	http://dx.doi.org/10.1074/jbc.M401412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15100232	hybrid			2022-12-27	WOS:000222531900091
J	Kang, SK; Chung, TW; Lee, JY; Lee, YC; Morton, RE; Kim, CH				Kang, SK; Chung, TW; Lee, JY; Lee, YC; Morton, RE; Kim, CH			The hepatitis B virus x protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; RAT-LIVER CARCINOGENESIS; HEPG2 CELLS; HEPATOCELLULAR-CARCINOMA; APO-B; CONTAINING LIPOPROTEINS; INTRACELLULAR DEGRADATION; TRANSGENIC MICE; SUGAR CHAINS; HUMAN-SERUM	The X protein of hepatitis B virus (HBx) plays a major role on hepatocellular carcinoma (HCC). Apolipoprotein B ( apoB) in the liver is an important glycoprotein for transportation of very low density lipoproteins and low density lipoproteins. Although lipid accumulation in the liver is known as one of the factors for the HCC, the relationship between HBx and apoB during the HCC development is poorly understood. To better understand the biological significance of HBx in HCC, liver Chang cells that specifically express HBx were established and characterized. In this study we demonstrate that overexpression of HBx significantly up-regulates the expression of UDP-N-acetylglucosamine: beta-D-mannoside-1,4- N-acetylglucosaminyltransferase- III (GnT-III), an enzyme that functions as a bisecting-N-acetylglucosamine ( GlcNAc) transferase in apoB, and increases GnT-III promoter activity in a chloramphenicol acetyltransferase assay. GnT-III expression levels of HBx-transfected cells appeared to be higher than that of hepatocarcinoma cells as well as GnT-III-transfected cells, indicating that HBx may has a strong GnT-III promotor-enhancing activity. Intracellular levels of apoBs, which contained the increased bisecting GlcNAc, were accumulated in HBx-transfected liver cells. These cells as well as GnT-III-transfected liver cells revealed the inhibition of apoB secretion and the increased accumulation of intracellular triglyceride and cholesterol compared with vector-transfected cells. Moreover, overexpression of GnT-III and HBx in liver cells was shown to down-regulate the transcriptional level of microsomal triglyceride transfer protein, which regulates the assembly and secretion of apoB. Therefore, our study strongly suggested that the HBx increase in intracellular accumulation of aberrantly glycosylated apoB resulted in inhibition of secretion of apoB as well as intracellular lipid accumulation by elevating the expression of GnT-III.	Dongguk Univ, Coll Oriental Med, NRLG, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Dongguk University; Dongguk University; Dong A University; Cleveland Clinic Foundation	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, NRLG, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714; Chung, Tae-Wook/0000-0001-5243-5020				Avramoglu RK, 1995, J LIPID RES, V36, P2513; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; Bullock C, 2000, METHOD ENZYMOL, V326, P202; Caselmann WH, 1998, HEPATITIS B VIRUS, P161; Chung TW, 2003, CANCER RES, V63, P3453; Colombo M, 1998, HEPATO-GASTROENTEROL, V45, P1221; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 2001, ARTERIOSCL THROM VAS, V21, P887, DOI 10.1161/01.ATV.21.6.887; DAVIS RA, 1999, BIOCHIM BIOPHYS ACTA, V1441, P1; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kang BS, 1998, J BIOCHEM MOL BIOL, V31, P578; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim YJ, 1996, GENE, V170, P281, DOI 10.1016/0378-1119(95)00818-7; Koyama N, 1996, EUR J BIOCHEM, V238, P853, DOI 10.1111/j.1432-1033.1996.0853w.x; Lee J, 2004, ARCH BIOCHEM BIOPHYS, V426, P18, DOI 10.1016/j.abb.2003.12.039; MIYOSHI E, 1993, CANCER RES, V53, P3899; Mori S, 1998, J GASTROEN HEPATOL, V13, P610, DOI 10.1111/j.1440-1746.1998.tb00699.x; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SERAFINICESSI F, 1979, BIOCHEM J, V183, P381, DOI 10.1042/bj1830381; Song EY, 2000, BIOTECHNOL LETT, V22, P201, DOI 10.1023/A:1005641115696; Song EY, 2001, CANCER INVEST, V19, P799, DOI 10.1081/CNV-100107741; SONG EY, 2003, GLYCOCONJ J, V9, P1415; SWAMINATHAN N, 1976, BIOCHEMISTRY-US, V15, P1516, DOI 10.1021/bi00652a024; TANIGUCHI N, 1999, BIOCHIM BIOPHYS ACTA, V455, P287; TANIGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V273, P197, DOI 10.1016/0003-9861(89)90179-3; TIOLLAIS P, 1981, SCIENCE, V213, P406, DOI 10.1126/science.6264599; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; Wilcox LJ, 1999, J LIPID RES, V40, P1078; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; YAMASHITA K, 1983, CANCER RES, V43, P5059; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yao ZM, 1997, J LIPID RES, V38, P1937; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	56	57	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28106	28112		10.1074/jbc.M403176200	http://dx.doi.org/10.1074/jbc.M403176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123606	hybrid			2022-12-27	WOS:000222265400036
J	Methot, N; Vaillancourt, JP; Huang, JQ; Colucci, J; Han, YX; Menard, S; Zamboni, R; Toulmond, S; Nicholson, DW; Roy, S				Methot, N; Vaillancourt, JP; Huang, JQ; Colucci, J; Han, YX; Menard, S; Zamboni, R; Toulmond, S; Nicholson, DW; Roy, S			A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; IN-VIVO; MYOCARDIAL-ISCHEMIA; IMPROVES SURVIVAL; INDUCED APOPTOSIS; GRANZYME-B; ACTIVATION; SEPSIS; LYMPHOCYTE; PATHWAYS	Apoptotic markers consist of either caspase substrate cleavage products or phenotypic changes that manifest themselves as a consequence of caspase-mediated substrate cleavage. We have shown recently that pharmacological inhibitors of caspase activity prevent the appearance of two such apoptotic manifestations, alphaII-spectrin cleavage and DNA fragmentation, but that blockade of the latter required a significantly higher concentration of inhibitor. We investigated this phenomenon through the use of a novel radiolabeled caspase inhibitor, [I-125] M808, which acts as a caspase active site probe. [I-125] M808 bound to active caspases irreversibly and with high sensitivity in apoptotic cell extracts, in tissue extracts from several commonly used animal models of cellular injury, and in living cells. Moreover, [I-125] M808 detected active caspases in septic mice when injected intravenously. Using this caspase probe, an active site occupancy assay was developed and used to measure the fractional inhibition required to block apoptosis- induced DNA fragmentation. In thymocytes, occupancy of up to 40% of caspase active sites had no effect on DNA fragmentation, whereas inhibition of half of the DNA cleaving activity required between 65 and 75% of active site occupancy. These results suggest that a high and persistent fractional inhibition will be required for successful caspase inhibition-based therapies.	Merck Frosst Ctr Therapeut Res, Merck Res Labs, Dept Biochem & Mol Biol, Montreal, PQ H9H 3L1, Canada	Merck & Company	Methot, N (corresponding author), Merck Frosst Ctr Therapeut Res, Merck Res Labs, Dept Biochem & Mol Biol, 16711 Trans Canada Highway, Montreal, PQ H9H 3L1, Canada.	nathalie_methot@merck.com						Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Adrie C, 2001, AM J RESP CRIT CARE, V164, P389, DOI 10.1164/ajrccm.164.3.2009088; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chapman JG, 2002, EUR J PHARMACOL, V456, P59, DOI 10.1016/S0014-2999(02)02484-6; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Coopersmith CM, 2002, CRIT CARE MED, V30, P195, DOI 10.1097/00003246-200201000-00028; Cursio R, 2000, Transpl Int, V13 Suppl 1, pS568, DOI 10.1111/j.1432-2277.2000.tb02108.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gibson RE, 2000, CURR PHARM DESIGN, V6, P973, DOI 10.2174/1381612003399987; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoglen NC, 2001, J PHARMACOL EXP THER, V297, P811; Holly TA, 1999, J MOL CELL CARDIOL, V31, P1709, DOI 10.1006/jmcc.1999.1006; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; McIlroy D, 2000, GENE DEV, V14, P549; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; REVESZ L, 1994, TETRAHEDRON LETT, V35, P9693, DOI 10.1016/0040-4039(94)88361-0; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Schroeder S, 2001, LANGENBECK ARCH SURG, V386, P42; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Waarde A, 2000, CURR PHARM DESIGN, V6, P1593, DOI 10.2174/1381612003398951; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WANG SD, 1994, J IMMUNOL, V152, P5014; Wiessner C, 2000, CELL MOL BIOL, V46, P53	44	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27905	27914		10.1074/jbc.M400247200	http://dx.doi.org/10.1074/jbc.M400247200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15067000	hybrid			2022-12-27	WOS:000222265400012
J	Roy, AK; Korkaya, H; Oberoi, R; Lal, SK; Jameel, S				Roy, AK; Korkaya, H; Oberoi, R; Lal, SK; Jameel, S			The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DUAL-SPECIFICITY PHOSPHATASE; ORF3 PROTEIN; CORE PROTEIN; KINASE-C; SIGNAL-TRANSDUCTION; FULMINANT-HEPATITIS; MOLECULAR-CLONING; VIRAL-HEPATITIS; EXPRESSION	The hepatitis E virus causes acute viral hepatitis endemic in much of the developing world and is a serious public health problem. However, due to the lack of an in vitro culture system or a small animal model, its biology and pathogenesis are poorly understood. We have shown earlier that the ORF3 protein (pORF3) of hepatitis E virus activates ERK, a member of the MAPK superfamily. Here we have explored the mechanism of pORF3-mediated ERK activation and demonstrated it to be independent of the Raf/MEK pathway. Using biochemical assays, yeast two-hybrid analysis, and intracellular fluorescence resonance energy transfer we showed that pORF3 binds Pyst1, a prototypic member of the ERK-specific MAPK phosphatase. The binding regions in the two proteins were mapped to the N terminus of pORF3 and a central portion of Pyst1. Expression of pORF3 protected ERK from the inhibitory effects of ectopically expressed Pyst1. This is the first example of a viral protein regulating ERK activation by inhibition of its cognate dual specificity phosphatase.	ICGEB, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Jameel, S (corresponding author), ICGEB, Virol Grp, Aruna Asaf Marg, New Delhi 110067, India.	shahid@icgeb.res.in	Korkaya, Hasan/C-2201-2009; Korkaya, Hasan/ABD-6282-2020; Korkaya, Hasan/GRY-1016-2022	Korkaya, Hasan/0000-0002-0719-5862; 	Wellcome Trust [063171] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Agrawal S, 2001, VIROLOGY, V282, P87, DOI 10.1006/viro.2000.0819; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DAVIS RJ, 2000, SIGNALING NETWORKS C, P3219; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; Kabrane-Lazizi Y, 1999, J VIROL, V73, P8848, DOI 10.1128/JVI.73.10.8848-8850.1999; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LAU JYN, 1995, J HEPATOL, V22, P605, DOI 10.1016/0168-8278(95)80215-0; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Li TC, 2001, VACCINE, V19, P3476, DOI 10.1016/S0264-410X(01)00059-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; NANDA SK, 1994, J MED VIROL, V42, P133, DOI 10.1002/jmv.1890420207; NAYAK NC, 1989, J GASTROEN HEPATOL, V4, P345, DOI 10.1111/j.1440-1746.1989.tb00846.x; NORTHOVER BJ, 1992, BIOCHEM PHARMACOL, V44, P425, DOI 10.1016/0006-2952(92)90432-I; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Purcell R.H., 2001, FIELDS VIROLOGY, P3051; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; RAMALINGASWAMI V, 1988, LANCET, V1, P571; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSENBERG IM, 1996, PROTEIN ANAL PURIFIC, P343; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Tyagi S, 2002, J BIOL CHEM, V277, P22759, DOI 10.1074/jbc.M200185200; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; ZACHARIAS DA, 2002, SCI STKE; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997; Zafrullah M, 1999, J VIROL, V73, P4074, DOI 10.1128/JVI.73.5.4074-4082.1999; Zhang MD, 2002, VACCINE, V20, P3285, DOI 10.1016/S0264-410X(02)00314-6; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; [No title captured]	73	65	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28345	28357		10.1074/jbc.M400457200	http://dx.doi.org/10.1074/jbc.M400457200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096509	hybrid, Green Accepted			2022-12-27	WOS:000222265400067
J	Abbing, A; Blaschke, UK; Grein, S; Kretschmar, M; Stark, CMB; Thies, MJW; Walter, J; Weigand, M; Woith, DC; Hess, J; Reiser, COA				Abbing, A; Blaschke, UK; Grein, S; Kretschmar, M; Stark, CMB; Thies, MJW; Walter, J; Weigand, M; Woith, DC; Hess, J; Reiser, COA			Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CAPSID PROTEIN; VIRUS-LIKE PARTICLES; MURINE POLYOMAVIRUS; ESCHERICHIA-COLI; GENE DELIVERY; IN-VITRO; METHOTREXATE; VP1; METABOLISM; RESOLUTION	Efficient encapsulation of foreign molecules like proteins and low molecular weight drugs into polyoma virus-like particles (capsoids) was achieved by the development of an anchoring technique based upon the specific interaction of the inner core protein VP2 with VP1 pentamers. A stretch of 49 amino acids of VP2 served as an anchor molecule, either expressed as a fusion protein with green fluorescent protein (GFP) or covalently linked to methotrexate (MTX). The loaded capsoids showed regular morphology and stability for several months. GFP and MTX were internalized into cells in vitro, as was demonstrated by the detection of GFP and VP1 fluorescence in mouse fibroblasts and the cytostatic effect of intracellularly released MTX on leukemia T cells.	Responsif GmbH, D-91056 Erlangen, Germany; November AG, D-91056 Erlangen, Germany		Hess, J (corresponding author), Responsif GmbH, Schallershofer Str 84, D-91056 Erlangen, Germany.	hess@responsif.de						An K, 2000, J VIROL METHODS, V84, P153, DOI 10.1016/S0166-0934(99)00137-8; BAROUCH DH, 1994, J VIROL, V68, P3982, DOI 10.1128/JVI.68.6.3982-3989.1994; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; BRADY JN, 1978, J VIROL, V27, P193, DOI 10.1128/JVI.27.1.193-204.1978; Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31; BRINKMAN M, 2004, LETT DRUG DES DISCOV, V1, P137; Calvert H, 1999, SEMIN ONCOL, V26, P3; Chen XJS, 1998, EMBO J, V17, P3233, DOI 10.1093/emboj/17.12.3233; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Goldmann C, 2000, J VIROL METHODS, V90, P85, DOI 10.1016/S0166-0934(00)00226-3; GRIFFITH JP, 1992, NATURE, V355, P652, DOI 10.1038/355652a0; GUENTHER K, 2001, FASEB J         0509, DOI DOI 10.1096/FJ.00-0645FJE; Gunther C, 2001, FASEB J, V15, P1646, DOI 10.1096/fj.00-0645fje; Harris Jr, 1999, METH MOL B, V117, P13; Henke S, 2000, PHARMACEUT RES, V17, P1062, DOI 10.1023/A:1026497411053; Hong MS, 2002, J PHARM PHARMACOL, V54, P51, DOI 10.1211/0022357021771913; Konigsberg PJ, 1998, BBA-BIOMEMBRANES, V1370, P243, DOI 10.1016/S0005-2736(97)00269-1; Krauzewicz N, 2000, GENE THER, V7, P1094, DOI 10.1038/sj.gt.3301219; KUEFNER U, 1990, BIOCHEMISTRY-US, V29, P10540, DOI 10.1021/bi00498a017; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; MICHAEL SI, 1994, GENE THER, V1, P223; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; NG KY, 1989, BIOCHIM BIOPHYS ACTA, V981, P261; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; Richterova Z, 2001, J VIROL, V75, P10880, DOI 10.1128/JVI.75.22.10880-10891.2001; Riebeseel K, 2002, BIOCONJUGATE CHEM, V13, P773, DOI 10.1021/bc010098m; ROSOWSKY A, 1978, J MED CHEM, V21, P170, DOI 10.1021/jm00200a005; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schmidt U, 2000, J VIROL, V74, P1658, DOI 10.1128/JVI.74.4.1658-1662.2000; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Weigand M, 2001, ANTI-CANCER DRUG DES, V16, P227; WRIGHT JE, 1987, BIOCHEM PHARMACOL, V36, P2209, DOI 10.1016/0006-2952(87)90152-3; Yang YW, 2000, BIOTECHNOL APPL BIOC, V32, P73, DOI 10.1042/BA20000024	36	77	93	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27410	27421		10.1074/jbc.M313612200	http://dx.doi.org/10.1074/jbc.M313612200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102846	hybrid			2022-12-27	WOS:000222120400072
J	Fraser, ME; Fujinaga, M; Cherney, MM; Melton-Celsa, AR; Twiddy, EM; O'Brien, AD; James, MNG				Fraser, ME; Fujinaga, M; Cherney, MM; Melton-Celsa, AR; Twiddy, EM; O'Brien, AD; James, MNG			Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157 : H7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; CRYSTAL-STRUCTURE; PROGRAM; GENES; MOLSCRIPT; ELASTASE; ERRORS; MODEL; RICIN	Several serotypes of Escherichia coli produce protein toxins closely related to Shiga toxin (Stx) from Shigella dysenteriae serotype 1. These Stx-producing E. coli cause outbreaks of hemorrhagic colitis and hemolytic uremic syndrome in humans, with the latter being more likely if the E. coli produce Stx2 than if they only produce Stx1. To investigate the differences among the Stxs, which are all AB(5) toxins, the crystal structure of Stx2 from E. coli O157:H7 was determined at 1.8-Angstrom resolution and compared with the known structure of Stx. Our major finding was that, in contrast to Stx, the active site of the A-subunit of Stx2 is accessible in the holotoxin, and a molecule of formic acid and a water molecule mimic the binding of the adenine base of the substrate. Further, the A-subunit adopts a different orientation with respect to the B-subunits in Stx2 than in Stx, due to interactions between the carboxyl termini of the B-subunits and neighboring regions of the A-subunit. Of the three types of receptor-binding sites in the B-pentamer, one has a different conformation in Stx2 than in Stx, and the carboxyl terminus of the A-subunit binds at another. Any of these structural differences might result in different mechanisms of action of the two toxins and the development of hemolytic uremic syndrome upon exposure to Stx2.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Institute for Work & Health; University of Alberta; University of Calgary; Uniformed Services University of the Health Sciences - USA	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Michael.James@ualberta.ca		O'Brien, Alison/0000-0002-1315-3204; Fraser, Marie/0000-0001-8501-1494				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bast DJ, 1999, MOL MICROBIOL, V32, P953, DOI 10.1046/j.1365-2958.1999.01405.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; FRASER ME, 1996, PROTEIN TOXIN STRUCT, P173; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEAD SC, 1991, J BIOL CHEM, V266, P3617; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JACKSON MP, 1987, MICROB PATHOGENESIS, V2, P147, DOI 10.1016/0882-4010(87)90106-9; JACKSON MP, 1987, FEMS MICROBIOL LETT, V44, P109, DOI 10.1016/0378-1097(87)90210-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Kokai-Kun JF, 2000, J BIOL CHEM, V275, P3713, DOI 10.1074/jbc.275.5.3713; KOZLOV IV, 1987, DOKL AKAD NAUK SSSR+, V295, P740; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Ling H, 2000, STRUCTURE, V8, P253, DOI 10.1016/S0969-2126(00)00103-9; LING H, 1999, THESIS U ALBERTA EDM, P185; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Melton-Celsa AR, 2000, HANDB EXP PHARM, V145, P385; Melton-Celsa AR, 2002, MOL MICROBIOL, V43, P207, DOI 10.1046/j.1365-2958.2002.02733.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller DJ, 2002, J MED CHEM, V45, P90, DOI 10.1021/jm010186s; Mulvey GL, 2003, J INFECT DIS, V187, P640, DOI 10.1086/373996; O'Loughlin EV, 2001, MICROBES INFECT, V3, P493, DOI 10.1016/S1286-4579(01)01405-8; OLSNES S, 1981, J BIOL CHEM, V256, P8732; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; READY MP, 1988, PROTEINS, V3, P53, DOI 10.1002/prot.340030105; Shiga K., 1898, ZENTRALBLAT FUER BAK, V24, P913; Siegler RL, 2003, PEDIATR NEPHROL, V18, P92, DOI 10.1007/s00467-002-1035-7; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WESTON SA, 1994, J MOL BIOL, V244, P410, DOI 10.1006/jmbi.1994.1739	42	213	232	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27511	27517		10.1074/jbc.M401939200	http://dx.doi.org/10.1074/jbc.M401939200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075327	hybrid, Green Published			2022-12-27	WOS:000222120400083
J	Lee, HHC; Choi, RCY; Ting, AKL; Siow, NL; Jiang, JXS; Massoulie, J; Tsim, KWK				Lee, HHC; Choi, RCY; Ting, AKL; Siow, NL; Jiang, JXS; Massoulie, J; Tsim, KWK			Transcriptional regulation of acetylcholinesterase-associated collagen ColQ - Differential expression in fast and slow twitch muscle fibers is driven by distinct promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; CHICK MUSCLE; TAILED FORMS; SUBUNIT; STABILITY; SEQUENCES; KINASE; DOMAIN; LEVEL; RAT	The presence of a collagenous protein ( ColQ) characterizes the collagen-tailed forms of acetylcholinesterase and butyrylcholinesterase at vertebrate neuromuscular junctions which is tethered in the synaptic basal lamina. ColQ subunits, differing mostly by their signal sequences, are encoded by transcripts ColQ-1 and ColQ-1a, which are differentially expressed in slow and fast twitch muscles in mammals. Two distinct promoters, pColQ-1 and pColQ-1a, were isolated from the upstream sequences of human COLQ gene; they showed muscle-specific expression and were activated by myogenic transcriptional elements in cultured myotubes. After in vivo DNA transfection, pColQ-1 showed strong activity in slow twitch muscle ( e. g. soleus), whereas pColQ-1a was preferably expressed in fast twitch muscle ( e. g. tibialis). Mutation analysis of the ColQ promoters suggested that the muscle fiber type-specific expression pattern of ColQ transcripts were regulated by a slow upsteam regulatory element ( SURE) and a fast intronic regulatory element ( FIRE). These regulatory elements were responsive to a calcium ionophore and to calcineurin inhibition by cyclosporine A. The slow fiber type-specific expression of ColQ-1 was abolished by the mutation of an NFAT element in pColQ-1. Moreover, both the ColQ promoters contained N-box element that was responsible for the synapse-specific expression of ColQ transcripts. These results explain the specific expression patterns of collagen-tailed acetylcholinesterase in slow and fast muscle fibers.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, F-75005 Paris, France	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Kowloon, Hong Kong, Peoples R China.	botsim@ust.hk	Lee, Henry HC/S-6014-2016; Lee, Henry/GVS-2114-2022	Lee, Henry HC/0000-0003-4975-7330; Tsim, Karl/0000-0003-4808-1674				Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; Boudreau-Lariviere C, 2000, AM J PHYSIOL-REG I, V278, pR140, DOI 10.1152/ajpregu.2000.278.1.R140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; CRESNAR B, 1994, J NEUROSCI RES, V38, P294, DOI 10.1002/jnr.490380307; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; Donger C, 1998, AM J HUM GENET, V63, P967, DOI 10.1086/302059; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; FERNANDEZ HL, 1984, NEUROSCI LETT, V44, P187, DOI 10.1016/0304-3940(84)90079-X; GISIGER V, 1988, J NEUROSCI RES, V19, P62, DOI 10.1002/jnr.490190110; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jiang JXS, 2003, J BIOL CHEM, V278, P45435, DOI 10.1074/jbc.M306320200; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; LAI J, 1986, NATURE, V321, P72, DOI 10.1038/321072a0; Legay C, 1999, J NEUROSCI, V19, P8252; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Mineo C, 1997, J BIOL CHEM, V272, P10345; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; PUN S, 1995, NEUROSCI LETT, V198, P107, DOI 10.1016/0304-3940(95)11974-2; Sambrook J., 2001, MOL CLONING LAB MANU; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; SILMAN I, 1978, FEBS LETT, V94, P166, DOI 10.1016/0014-5793(78)80929-6; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; SKETELJ J, 1985, J NEUROSCI RES, V14, P95, DOI 10.1002/jnr.490140109; Sketelj J, 1998, J NEUROSCI, V18, P1944; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; TSIM KWK, 1988, P NATL ACAD SCI USA, V85, P1262, DOI 10.1073/pnas.85.4.1262; WALKE W, 1994, J BIOL CHEM, V269, P19447	50	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27098	27107		10.1074/jbc.M402596200	http://dx.doi.org/10.1074/jbc.M402596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102835	hybrid			2022-12-27	WOS:000222120400036
J	Levasseur, DN; Ryan, TM; Reilly, MP; McCune, SL; Asakura, T; Townes, TM				Levasseur, DN; Ryan, TM; Reilly, MP; McCune, SL; Asakura, T; Townes, TM			A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEATION-CONTROLLED AGGREGATION; CELL-DISEASE; DEOXYHEMOGLOBIN-S; TRANSGENIC MICE; MOUSE MODEL; CHEMICAL DIFFERENCE; CRYSTAL-STRUCTURE; BETA-THALASSEMIA; STEM-CELLS; GLOBIN	A new recombinant, human anti-sickling beta-globin polypeptide designated beta(AS3) (beta(Gly16) --> Asp/betaGlu(22) --> Ala/betaThr(87) --> Gln) was designed to increase affinity for alpha-globin. The amino acid substitutions at beta22 and beta87 are located at axial and lateral contacts of the sickle hemoglobin (HbS) polymers and strongly inhibit deoxy-HbS polymerization. The beta16 substitution confers the recombinant beta-globin subunit (beta(AS3)) with a competitive advantage over beta(S) for interaction with the alpha-globin polypeptide. Transgenic mouse lines that synthesize high levels of HbAS3 (alpha(2)beta(2)(AS3)) were established, and recombinant HbAS3 was purified from hemolysates and then characterized. HbAS3 binds oxygen cooperatively and has an oxygen affinity that is comparable with fetal hemoglobin. Delay time experiments demonstrate that HbAS3 is a potent inhibitor of HbS polymerization. Subunit competition studies confirm that beta(AS3) has a distinct advantage over beta(S) for dimerization with alpha-globin. When equal amounts of beta(S)- and beta(AS3)-globin monomers compete for limiting alpha-globin chains up to 82% of the tetramers formed is HbAS3. Knock-out transgenic mice that express exclusively human HbAS3 were produced. When these mice were bred with knock-out transgenic sickle mice the beta(AS3) polypeptides corrected all hematological parameters and organ pathology associated with the disease. Expression of beta(AS3)-globin should effectively lower the concentration of HbS in erythrocytes of patients with sickle cell disease, especially in the 30% percent of these individuals who coinherit alpha-thalassemia. Therefore, constructs expressing the beta(AS3)-globin gene may be suitable for future clinical trials for sickle cell disease.	Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Townes, TM (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, 502 Kaul Genet Bldg,720 20th St S, Birmingham, AL 35294 USA.	ttownes@uab.edu		Ryan, Thomas/0000-0002-8982-0253	NATIONAL CANCER INSTITUTE [T32CA009467] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057619, R01HL035559, P60HL038632] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09467] Funding Source: Medline; NHLBI NIH HHS [HL35559, HL 43508, HL38632, HL57619] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1987, J CHROMATOGR-BIOMED, V419, P303, DOI 10.1016/0378-4347(87)80291-8; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1980, J BIOL CHEM, V255, P7595; ALTAY C, 1977, AM J HEMATOL, V3, P1; ASAKURA T, 1986, OXYGEN TRANSPORT RED; BAGLIONI C, 1963, BIOCHIM BIOPHYS ACTA, V78, P637, DOI 10.1016/0006-3002(63)91029-1; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BRITTENHAM G, 1979, AM J HEMATOL, V6, P107, DOI 10.1002/ajh.2830060203; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1987, BLOOD, V69, P1; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CY IP, 1986, ANAL BIOCHEM, V156, P348, DOI 10.1016/0003-2697(86)90264-2; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; HIGGS DR, 1989, BLOOD, V73, P1081; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; KUTLAR A, 1990, HUM GENET, V85, P106; Levasseur DN, 2003, BLOOD, V102, P4312, DOI 10.1182/blood-2003-04-1251; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; MCCUNE SL, 1994, P NATL ACAD SCI USA, V91, P9852, DOI 10.1073/pnas.91.21.9852; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MRABET NT, 1986, J BIOL CHEM, V261, P5222; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; SAMBROOK J, 1989, MOL CLONING LAB MANU, P390; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHROEDER WA, 1985, HEMOGLOBIN, V9, P461, DOI 10.3109/03630268508997024; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	40	50	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27518	27524		10.1074/jbc.M402578200	http://dx.doi.org/10.1074/jbc.M402578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084588	hybrid			2022-12-27	WOS:000222120400084
J	Neco, P; Giner, D; Viniegra, S; Borges, R; Villarroel, A; Gutierrez, LM				Neco, P; Giner, D; Viniegra, S; Borges, R; Villarroel, A; Gutierrez, LM			New roles of myosin II during vesicle transport and fusion in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SYNAPTOSOME-ASSOCIATED PROTEIN; CATECHOLAMINE SECRETION; ACTIN-FILAMENTS; C-TERMINUS; PHOSPHORYLATION; EXOCYTOSIS; GRANULES; CORTEX; DEPHOSPHORYLATION	Modified herpes virus (amplicons) were used to express myosin regulatory light chain (RLC) chimeras with green fluorescent protein (GFP) in cultured bovine chromaffin cells to study myosin II implication in secretion. After infection, RLC-GFP constructs were clearly identified in the cytoplasm and accumulated in the cortical region, forming a complex network that co-localized with cortical F-actin. Cells expressing wild type RLC-GFP maintained normal vesicle mobility, whereas cells expressing an unphosphorylatable form (T18A/ S19A RLC-GFP) presented severe restrictions in granule movement as measured by individual tracking in dynamic confocal microscopy studies. Interestingly, the overexpression of this mutant form of RLC also affected the initial secretory burst elicited by either high K+ or BaCl2, as well as the secretion induced by fast release of calcium from caged compounds in individual cells. Moreover, T18A/ S19A RLC-GFP-infected cells presented slower fusion kinetics of individual granules compared with controls as measured by analysis of amperometric spikes. Taken together, our results demonstrate the implication of myosin II in the transport of vesicles, and, surprisingly, in the final phases of exocytosis involving transitions affecting the activity of docked granules, and therefore uncovering a new role for this cytoskeletal element.	Univ Miguel Hernandez, Inst Neurociencias, Ctr Mixto, CSIC, E-03550 Alicante, Spain; Univ La Laguna, Unidad Farmacol, Fac Med, E-38071 Tenerife, Spain; CSIC, Inst Cajal, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad de la Laguna; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Gutierrez, LM (corresponding author), Univ Miguel Hernandez, Inst Neurociencias, Ctr Mixto, CSIC, Campus San Juan, E-03550 Alicante, Spain.	luisguti@umh.es	Gutierrez, Luis/K-8633-2014; Villarroel, Alvaro/H-5580-2015; Borges, Ricardo/N-3250-2014; Viniegra, Salvador/K-5063-2014	Gutierrez, Luis/0000-0002-0512-7858; Borges, Ricardo/0000-0003-3413-4392; Viniegra, Salvador/0000-0002-3892-8563				ALMAZAN G, 1984, BRIT J PHARMACOL, V81, P599, DOI 10.1111/j.1476-5381.1984.tb16124.x; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; COTE A, 1986, NEUROSCIENCE, V19, P629, DOI 10.1016/0306-4522(86)90286-1; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Duncan RR, 2003, NATURE, V422, P176, DOI 10.1038/nature01389; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Gil A, 1998, EUR J NEUROSCI, V10, P3369, DOI 10.1046/j.1460-9568.1998.00341.x; Gil A, 2000, NEUROSCIENCE, V98, P605, DOI 10.1016/S0306-4522(00)00132-9; Gil A, 2002, J BIOL CHEM, V277, P9904, DOI 10.1074/jbc.M110182200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTIERREZ LM, 1989, BIOCHEM J, V264, P589, DOI 10.1042/bj2640589; GUTIERREZ LM, 1988, J NEUROCHEM, V51, P1023, DOI 10.1111/j.1471-4159.1988.tb03063.x; Haller T, 1999, AM J PHYSIOL-LUNG C, V277, pL893, DOI 10.1152/ajplung.1999.277.5.L893; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; KUMAKURA K, 1994, J NEUROSCI, V14, P7695; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; LAZARIDES E, 1976, J CELL BIOL, V68, P202, DOI 10.1083/jcb.68.2.202; LEE SA, 1987, BIOSCIENCE REP, V7, P323, DOI 10.1007/BF01121454; Lim F, 1996, BIOTECHNIQUES, V20, P460; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; NAKANISHI A, 1989, BIOCHEM PHARMACOL, V38, P2615, DOI 10.1016/0006-2952(89)90546-7; Neco P, 2003, EUR J NEUROSCI, V18, P733, DOI 10.1046/j.1460-9568.2003.02801.x; Neco P, 2002, BIOCHEM J, V368, P405, DOI 10.1042/BJ20021090; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; Oheim M, 2000, EUR BIOPHYS J BIOPHY, V29, P67, DOI 10.1007/s002490050253; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Rose SD, 2003, J NEUROCHEM, V85, P287, DOI 10.1046/j.1471-4159.2003.01649.x; Rudolf R, 2003, J CELL SCI, V116, P1339, DOI 10.1242/jcs.00317; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VIVEROS OH, 1974, HDB ENDOCRINOLOGY, P389	36	103	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27450	27457		10.1074/jbc.M311462200	http://dx.doi.org/10.1074/jbc.M311462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15069078	hybrid			2022-12-27	WOS:000222120400076
J	Yamashita, M; Ukai-Tadenuma, M; Miyamoto, T; Sugaya, K; Hosokawa, H; Hasegawa, A; Kimura, M; Taniguchi, M; DeGregori, J; Nakayama, T				Yamashita, M; Ukai-Tadenuma, M; Miyamoto, T; Sugaya, K; Hosokawa, H; Hasegawa, A; Kimura, M; Taniguchi, M; DeGregori, J; Nakayama, T			Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; CELL-DIFFERENTIATION; HISTONE H3; CUTTING EDGE; DNA METHYLATION; IL-4 PRODUCTION; IN-VIVO; EXPRESSION; ACTIVATION; RECEPTOR	GATA3 expression is essential for type-2 helper T (Th2) cell differentiation. GATA3-mediated chromatin remodeling at the Th2 cytokine gene loci, including Th2-specific long range histone hyperacetylation of the interleukin (IL)-13/IL-4 gene loci, occurs in developing Th2 cells. However, little is known about the role of GATA3, if any, in the maintenance of established remodeled chromatin at the Th2 cytokine gene loci. Here, we established a Cre/LoxP-based site-specific recombination system in cultured CD4 T cells using a unique adenovirus-mediated gene transfer technique. This system allowed us to investigate the effect of loss of GATA3 expression in in vitro differentiated Th2 cells. After ablation of GATA3, we detected reduced production of all Th2 cytokines, increased DNA methylation at the IL- 4 gene locus, and decreased histone hyperacetylation at the IL- 5 gene locus but not significantly so at the IL-13/IL-4 gene loci. Thus, GATA3 plays important roles in the maintenance of the Th2 phenotype and continuous chromatin remodeling of the specific Th2 cytokine gene locus through cell division.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO Project, Chuo Ku, Chiba 2608670, Japan; RIKEN Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	Chiba University; Japan Science & Technology Agency (JST); RIKEN; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007; Hosokawa, Hiroyuki/0000-0002-9592-2889; DeGregori, James/0000-0002-1287-1976; Sugaya, Kiminobu/0000-0002-2788-5457	NCI NIH HHS [R01 CA077314, R01 CA077314-06, R01 CA77314] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Farrar JD, 2001, J EXP MED, V193, P643, DOI 10.1084/jem.193.5.643; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Finkelman FD, 2000, J IMMUNOL, V164, P2303, DOI 10.4049/jimmunol.164.5.2303; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Guo LY, 2002, P NATL ACAD SCI USA, V99, P10623, DOI 10.1073/pnas.162360199; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; INAMI M, 2004, J BIOL CHEM; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kaplan MH, 1999, J IMMUNOL, V163, P6536; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Garra A, 2000, NATURE, V404, P719, DOI 10.1038/35008191; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Wan YY, 2000, P NATL ACAD SCI USA, V97, P13784, DOI 10.1073/pnas.250356297; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	47	122	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26983	26990		10.1074/jbc.M403688200	http://dx.doi.org/10.1074/jbc.M403688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087456	hybrid			2022-12-27	WOS:000222120400024
J	Imamura, Y; Katahira, T; Kitamura, D				Imamura, Y; Katahira, T; Kitamura, D			Identification and characterization of a novel BASH N terminus-associated protein, BNAS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; CELL LINKER PROTEIN; RECEPTOR-MEDIATED ACTIVATION; BRUTONS TYROSINE KINASE; JUN NH2-TERMINAL KINASE; ANTIGEN RECEPTOR; MAP KINASE; B-LYMPHOCYTES; DEVELOPMENTAL PROGRESSION; ALLELIC EXCLUSION	A B cell-specific adaptor protein, BASH ( also known as BLNK or SLP-65), is crucial for B cell receptor (BCR) signaling. BASH binds to various signaling intermediates, such as Btk, PLCgamma2, Vav, and Grb2, through its well defined motifs. Although functional significance of such interactions has been documented, BASH-mediated signal transduction mechanism is not fully understood. Using the yeast two-hybrid system, we have identified a novel protein that binds to a conserved N-terminal domain of BASH, which we named BNAS2 (BASH N terminus associated protein 2). From its deduced amino acid sequence, BNAS2 is presumed to contain four transmembrane domains, which are included in a central MARVEL domain, and to localize to endoplasmic reticulum. BNAS2 was co-precipitated with BASH as well as Btk and ERK2 from a lysate of mouse B cell line. In the transfected cells, the exogenous BNAS2 was localized in a mesh-like structure in the cytoplasm resembling that of endoplasmic reticulum ( ER) and nuclear membrane. BASH was co-localized with BNAS2 in a manner dependent on its N-terminal domain. RT-PCR analysis indicated that BNAS2 mRNA is expressed ubiquitously except for plasma cells. In chicken B cell line DT40, overexpression of BNAS2 resulted in an enhancement of BCR ligation-mediated transcriptional activation of Elk1, but not of NF-kappaB, in a manner dependent on the dose of BNAS2. Thus BNAS2 may serve as a scaffold for signaling proteins such as BASH, Btk, and ERK at the ER and nuclear membrane and may facilitate ERK activation by signaling from cell-surface receptors.	Tokyo Univ Sci, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Matsumoto Dent Univ, Dept Pharmacol, Shiojiri, Nagano 3990781, Japan	Tokyo University of Science; Matsumoto Dental University	Kitamura, D (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.	kitamura@rs.noda.tus.ac.jp						AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Breitwieser GE, 1997, AM J PHYSIOL-CELL PH, V272, pC957, DOI 10.1152/ajpcell.1997.272.3.C957; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Goitsuka R, 2000, INT IMMUNOL, V12, P573, DOI 10.1093/intimm/12.4.573; Goitsuka R, 1998, J IMMUNOL, V161, P5804; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Katsuta H, 1998, J IMMUNOL, V160, P1547; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; KITANI S, 1991, J BIOL CHEM, V266, P1903; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVY S, 1991, J BIOL CHEM, V266, P14597; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nagaoka H, 2000, J EXP MED, V192, P171, DOI 10.1084/jem.192.2.171; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SCHWARTZALBIEZ R, 1988, J IMMUNOL, V140, P905; Shaw AC, 1999, P NATL ACAD SCI USA, V96, P2239, DOI 10.1073/pnas.96.5.2239; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; YAGI T, 1993, ONCOGENE, V8, P3343; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	60	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26425	26432		10.1074/jbc.M403685200	http://dx.doi.org/10.1074/jbc.M403685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087455	hybrid			2022-12-27	WOS:000222003000064
J	Mammoto, A; Huang, S; Moore, K; Oh, P; Ingber, DE				Mammoto, A; Huang, S; Moore, K; Oh, P; Ingber, DE			Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27(kip1) pathway and the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; CYCLIN D1; RETINOBLASTOMA PROTEIN; P27(KIP1) DEGRADATION; MYOSIN PHOSPHATASE; GEOMETRIC CONTROL; CDC42 GTPASES; FORMIN MDIA1	Cell shape-dependent control of cell-cycle progression underlies the spatial differentials of growth that drive tissue morphogenesis, yet little is known about how cell distortion impacts the biochemical signaling machinery that is responsible for growth control. Here we show that the Rho family GTPase, RhoA, conveys the "cell shape signal" to the cell-cycle machinery in human capillary endothelial cells. Cells accumulating p27(kip1) and arrested in mid G(1) phase when spreading were inhibited by restricted extracellular matrix adhesion, whereas constitutively active RhoA increased expression of the F-box protein Skp2 required for ubiquitination-dependent degradation of p27(kip1) and restored G1 progression in these cells. Studies with dominant-negative and constitutively active forms of mDia1, a downstream effector of RhoA, and with a pharmacological inhibitor of ROCK, another RhoA target, revealed that RhoA promoted G1 progression by altering the balance of activities between these two downstream effectors. These data indicate that signaling proteins such as mDia1 and ROCK, which are thought to be involved primarily in cytoskeletal remodeling, also mediate cell growth regulation by coupling cell shape to the cell-cycle machinery at the level of signal transduction.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Vasc Biol Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Vasc Biol Program, Room 11-127,Karp Family Res Labs,300 Londwood Ave, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019		NATIONAL CANCER INSTITUTE [S15CA058833] Funding Source: NIH RePORTER; NCI NIH HHS [CA58833] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Galbraith CG, 1998, CURR OPIN CELL BIOL, V10, P566, DOI 10.1016/S0955-0674(98)80030-6; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Hirai A, 1997, J BIOL CHEM, V272, P13; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; IWIG M, 1995, EUR J CELL BIOL, V67, P145; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; LEE KM, 1998, AM J PHYSIOL, V274, pG76; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishi K, 2002, EXP CELL RES, V280, P233, DOI 10.1006/excr.2002.5637; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Numaguchi Yasushi, 2003, Angiogenesis, V6, P55, DOI 10.1023/A:1025821517679; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; POLTE T, 2003, AM J PHYSIOL, V286, pC518; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schwartz MA, 2001, J CELL SCI, V114, P2553; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	82	172	181	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26323	26330		10.1074/jbc.M402725200	http://dx.doi.org/10.1074/jbc.M402725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096506	hybrid			2022-12-27	WOS:000222003000051
J	Petropoulos, AD; Xaplanteri, MA; Dinos, GP; Wilson, DN; Kalpaxis, DL				Petropoulos, AD; Xaplanteri, MA; Dinos, GP; Wilson, DN; Kalpaxis, DL			Polyamines affect diversely the antibiotic potency - Insight gained from kinetic studies of the blasticidin S and spiramycin interactions with functional ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA; PHOTOAFFINITY POLYAMINES; PROTEIN-SYNTHESIS; STRUCTURAL BASIS; BOND FORMATION; PEPTIDYLTRANSFERASE; SPERMINE; BINDING	The effects of spermine on peptidyltransferase inhibition by an aminohexosylcytosine nucleoside, blasticidin S, and by a macrolide, spiramycin, were investigated in a model system derived from Escherichia coli, in which a peptide bond is formed between puromycin and AcPhe-tRNA bound at the P-site of poly(U)-programmed ribosomes. Kinetics revealed that blasticidin S, after a transient phase of interference with the A-site, is slowly accommodated near to the P-site so that peptide bond is still formed but with a lower catalytic rate constant. At high concentrations of blasticidin S (> 10 x K-i), a second drug molecule binds to a weaker binding site on ribosomes, and this may account for the onset of a subsequent mixed-noncompetitive inhibition phase. Spermine enhances the blasticidin S inhibitory effect by facilitating the drug accommodation to both sites. On the other hand, spiramycin (A) was found competing with puromycin for the A-site of AcPhe-tRNA.poly(U).70 S ribosomal complex (C) via a two-step mechanism, according to which the fast formation of the encounter complex CA is followed by a slow isomerization to a tighter complex, termed C*A. In contrast to that observed with blasticidin S, spermine reduced spiramycin potency by decreasing the formation and stability of complex C*A. Polyamine effects on drug binding were more pronounced when a mixture of spermine and spermidine was used, instead of spermine alone. Our kinetic results correlate well with cross-linking and crystallographic data and suggest that polyamines bound at the vicinity of the antibiotic binding pockets modulate diversely the interaction of these drugs with ribosomes.	Univ Patras, Sch Med, Biochem Lab, GR-26500 Patras, Greece; Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany	University of Patras; Max Planck Society	Kalpaxis, DL (corresponding author), Univ Patras, Sch Med, Biochem Lab, GR-26500 Patras, Greece.	dimkal@med.upatras.gr	Kalpaxis, Dimitrios L./A-5195-2008; Dinos, George/AAR-8444-2020; Wilson, Daniel/AAE-8504-2019	Dinos, George/0000-0003-3914-7408; Wilson, Daniel/0000-0003-3816-3828				Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Amarantos I, 2002, NUCLEIC ACIDS RES, V30, P2832, DOI 10.1093/nar/gkf404; Amarantos I, 2001, BIOCHEMISTRY-US, V40, P7641, DOI 10.1021/bi010010s; Amarantos I, 2000, NUCLEIC ACIDS RES, V28, P3733, DOI 10.1093/nar/28.19.3733; BALLESTA JPG, 1990, RIBOSOME, P502; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; Champney W. S., 2001, Current Drug Targets - Infectious Disorders, V1, P19, DOI 10.2174/1568005013343281; CLARK E, 1991, BIOCHEMISTRY-US, V30, P4009, DOI 10.1021/bi00230a028; COHEN SS, 1998, GUIDE POLYAMINES, P495; Depardieu F, 2001, ANTIMICROB AGENTS CH, V45, P319, DOI 10.1128/AAC.45.1.319-323.2001; DINOS G, 1993, BIOCHEMISTRY-US, V32, P10638, DOI 10.1021/bi00091a014; DRAINAS D, 1994, BBA-PROTEIN STRUCT M, V1208, P55, DOI 10.1016/0167-4838(94)90159-7; ERION MD, 1987, BIOCHEMISTRY-US, V26, P3417, DOI 10.1021/bi00386a025; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0022-2836(03)00668-5; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KALPAXIS DL, 1986, EUR J BIOCHEM, V154, P267, DOI 10.1111/j.1432-1033.1986.tb09392.x; KALPAXIS DL, 1993, ARCH BIOCHEM BIOPHYS, V300, P629, DOI 10.1006/abbi.1993.1087; Kirillov SV, 1999, RNA, V5, P1003, DOI 10.1017/S1355838299990568; MENNINGER JR, 1982, ANTIMICROB AGENTS CH, V21, P811, DOI 10.1128/AAC.21.5.811; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PESTKA S, 1974, ANTIMICROB AGENTS CH, V5, P255, DOI 10.1128/AAC.5.3.255; Pestka S, 1974, Methods Enzymol, V30, P261; PESTKA S, 1972, J BIOL CHEM, V247, P4669; Polacek N, 1998, RNA, V4, P1282, DOI 10.1017/S1355838298980347; Poulsen SM, 2000, J MOL BIOL, V304, P471, DOI 10.1006/jmbi.2000.4229; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SEGEL IH, 1993, ENZYME KINETICS, P39; Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; TERAOKA H, 1973, EUR J BIOCHEM, V33, P578, DOI 10.1111/j.1432-1033.1973.tb02718.x; THEOCHARIS DA, 1986, EUR J BIOCHEM, V159, P479, DOI 10.1111/j.1432-1033.1986.tb09911.x; Triman KL, 1999, ADV GENET, V41, P157, DOI 10.1016/S0065-2660(08)60153-4; Vester B, 2001, ANTIMICROB AGENTS CH, V45, P1, DOI 10.1128/AAC.45.1.1-12.2001; VOGEL Z, 1971, J MOL BIOL, V60, P339, DOI 10.1016/0022-2836(71)90298-1; Xaplanteri MA, 2003, NUCLEIC ACIDS RES, V31, P5074, DOI 10.1093/nar/gkg686	41	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26518	26525		10.1074/jbc.M313634200	http://dx.doi.org/10.1074/jbc.M313634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075341	hybrid			2022-12-27	WOS:000222003000075
J	Xiao, YC; Tang, JZ; Yang, YJ; Wang, MC; Hu, WJ; Xie, JY; Zeng, XZ; Liang, SP				Xiao, YC; Tang, JZ; Yang, YJ; Wang, MC; Hu, WJ; Xie, JY; Zeng, XZ; Liang, SP			Jingzhaotoxin-III, a novel spider toxin inhibiting activation of voltage-gated sodium channel in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTHUS-MARTENSI KARSCH; 3-DIMENSIONAL STRUCTURE; PEPTIDE TOXINS; NA+ CHANNELS; VENOM; NEUROTOXINS; EVOLUTION; INACTIVATION; CONTRACTION; CLONING	We have isolated a cardiotoxin, denoted jingzhaotoxin-III (JZTX-III), from the venom of the Chinese spider Chilobrachys jingzhao. The toxin contains 36 residues stabilized by three intracellular disulfide bridges (I-IV, II-V, and III-VI), assigned by a chemical strategy of partial reduction and sequence analysis. Cloned and sequenced using 3'-rapid amplification of cDNA ends and 5'-rapid amplification of cDNA ends, the full-length cDNA encoded a 63-residue precursor of JZTX-III. Different from other spider peptides, it contains an uncommon endoproteolytic site (-X-Ser-) anterior to mature protein and the intervening regions of 5 residues, which is the smallest in spider toxin cDNAs identified to date. Under whole cell recording, JZTX-III showed no effects on voltage-gated sodium channels (VGSCs) or calcium channels in dorsal root ganglion neurons, whereas it significantly inhibited tetrodotoxin-resistant VGSCs with an IC50 value of 0.38 muM in rat cardiac myocytes. Different from scorpion beta-toxins, it caused a 10-mV depolarizing shift in the channel activation threshold. The binding site for JZTX-III on VGSCs is further suggested to be site 4 with a simple competitive assay, which at 10 muM eliminated the slowing currents induced by Buthus martensi Karsch I (BMK-I, scorpion alpha-like toxin) completely. JZTX-III shows higher selectivity for VGSC isoforms than other spider toxins affecting VGSCs, and the toxin hopefully represents an important ligand for discriminating cardiac VGSC subtype.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China	Hunan Normal University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China.	liangsp@hunnu.edu.cn	Xiao, Yucheng/H-3600-2012					Alami M, 2003, BIOCHEM J, V375, P551, DOI 10.1042/BJ20030688; Cao CM, 2002, PFLUG ARCH EUR J PHY, V443, P635, DOI 10.1007/s00424-001-0743-3; Cardoso FC, 2003, TOXICON, V41, P755, DOI 10.1016/S0041-0101(03)00011-4; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; Corzo G, 2003, FEBS LETT, V547, P43, DOI 10.1016/S0014-5793(03)00666-5; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; Diao JB, 2003, TOXICON, V42, P715, DOI 10.1016/j.toxicon.2003.08.007; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; Goldin AL, 2002, J EXP BIOL, V205, P575; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Herzog RI, 2003, J NEUROSCI, V23, P8261; Huys I, 2003, EUR J NEUROSCI, V17, P1786, DOI 10.1046/j.1460-9568.2003.02613.x; Ji YH, 1996, TOXICON, V34, P987, DOI 10.1016/0041-0101(96)00065-7; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Lopreato GF, 2001, P NATL ACAD SCI USA, V98, P7588, DOI 10.1073/pnas.131171798; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Ogata N, 2002, JPN J PHARMACOL, V88, P365, DOI 10.1254/jjp.88.365; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Shu Q, 2002, PROTEIN SCI, V11, P245, DOI 10.1110/ps.30502; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; Wang CZ, 2003, TOXICON, V42, P613, DOI 10.1016/j.toxicon.2003.08.005; Xiao XC, 2003, EUR J PHARMACOL, V477, P1, DOI 10.1016/S0014-2999(03)02190-3; ZHU MS, 2001, J BAODING TEACHERS C, V14, P1; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	30	55	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26220	26226		10.1074/jbc.M401387200	http://dx.doi.org/10.1074/jbc.M401387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084603	hybrid			2022-12-27	WOS:000222003000038
J	Cui, XY; Hu, QD; Tekaya, M; Shimoda, Y; Ang, BT; Nie, DY; Sun, L; Hu, WP; Karsak, M; Duka, T; Takeda, Y; Ou, LY; Dawe, GS; Yu, FG; Ahmed, S; Jin, LH; Schachner, M; Watanabe, K; Arsenijevic, Y; Xiao, ZC				Cui, XY; Hu, QD; Tekaya, M; Shimoda, Y; Ang, BT; Nie, DY; Sun, L; Hu, WP; Karsak, M; Duka, T; Takeda, Y; Ou, LY; Dawe, GS; Yu, FG; Ahmed, S; Jin, LH; Schachner, M; Watanabe, K; Arsenijevic, Y; Xiao, ZC			NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION MOLECULE NB-3; CONTACTIN/F3 SUBGROUP; MULTIPLE-SCLEROSIS; NOTCH RECEPTOR; STEM-CELLS; RAT-BRAIN; NEUROGENESIS; F3/CONTACTIN; GLIOGENESIS; MATURATION	Neurons and glia in the vertebrate central nervous system arise in temporally distinct, albeit overlapping, phases. Neurons are generated first followed by astrocytes and oligodendrocytes from common progenitor cells. Increasing evidence indicates that axon-derived signals spatiotemporally modulate oligodendrocyte maturation and myelin formation. Our previous observations demonstrate that F3/contactin is a functional ligand of Notch during oligodendrocyte maturation, revealing the existence of another group of Notch ligands. Here, we establish that NB-3, a member of the F3/contactin family, acts as a novel Notch ligand to participate in oligodendrocyte generation. NB-3 triggers nuclear translocation of the Notch intracellular domain and promotes oligodendrogliogenesis from progenitor cells and differentiation of oligodendrocyte precursor cells via Deltex1. In primary oligodendrocytes, NB-3 increases myelin-associated glycoprotein transcripts. Thus, the NB-3/Notch signaling pathway may prove to be a molecular handle to treat demyelinating diseases.	Singapore Gen Hosp, Dept Clin Res, Neurobiol Lab, Singapore 169608, Singapore; Singapore Gen Hosp, Grp Stem Cell Res, Singapore 169608, Singapore; Harbin Med Coll, Dept Histol & Embryol, Harbin 150086, Peoples R China; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore; Eye Hosp Jules Gonin, Unit Oculogenet, CH-1004 Lausanne, Switzerland; Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany; Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima 8908544, Japan; Natl Univ Singapore, Dept Pharmacol, Singapore 119260, Singapore; Inst Mol & Cell Biol, Singapore 117609, Singapore	Singapore General Hospital; Singapore General Hospital; Harbin Medical University; National University of Singapore; Nagaoka University of Technology; Singapore General Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Kagoshima University; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Xiao, ZC (corresponding author), Singapore Gen Hosp, Dept Clin Res, Neurobiol Lab, Block A,7 Hosp Dr, Singapore 169608, Singapore.	gcrxzc@sgh.com.sg	xiao, zhicheng/A-1529-2011; Messier, Claude/A-2322-2008; Nie, Duyu A./AAR-6211-2020	Messier, Claude/0000-0002-4791-1763; Nie, Duyu A./0000-0002-4280-6956; Arsenijevic, Yvan/0000-0001-6960-1291; Dawe, Gavin/0000-0001-6119-701X; Karsak, Meliha/0000-0001-6612-6317				*ABI, 1997, US B ABI, V2; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Arsenijevic Y, 2001, J NEUROSCI, V21, P7194, DOI 10.1523/JNEUROSCI.21-18-07194.2001; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; BOGLER O, 1997, CURRENT PROTOCOLS NE; COLELLO RJ, 1998, CURRENT PROTOCOLS NE; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Genoud S, 2002, J CELL BIOL, V158, P709, DOI 10.1083/jcb.200202002; HARLOW E, 1998, ANTIBODIES LAB MANUA, P53; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Itoh K, 2002, BRAIN RES PROTOC, V10, P23; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Lee S, 2000, GENE, V245, P253, DOI 10.1016/S0378-1119(00)00031-7; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Morrison SJ, 2001, CURR OPIN CELL BIOL, V13, P666, DOI 10.1016/S0955-0674(00)00269-6; Ogawa J, 1996, NEUROSCI LETT, V218, P173, DOI 10.1016/S0304-3940(96)13156-6; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Rogister B, 1999, MOL CELL NEUROSCI, V14, P287, DOI 10.1006/mcne.1999.0790; Sauvageot CM, 2002, CURR OPIN NEUROBIOL, V12, P244, DOI 10.1016/S0959-4388(02)00322-7; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimazaki K, 1998, NEUROSCI LETT, V245, P117, DOI 10.1016/S0304-3940(98)00179-7; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Takeda Y, 2003, J NEUROBIOL, V56, P252, DOI 10.1002/neu.10222; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	34	102	113	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25858	25865		10.1074/jbc.M313505200	http://dx.doi.org/10.1074/jbc.M313505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082708	hybrid			2022-12-27	WOS:000221827900117
J	Ito, T; Tsukumo, S; Suzuki, N; Motohashi, H; Yamamoto, M; Fujii-Kuriyama, Y; Mimura, J; Lin, TM; Peterson, RE; Tohyama, C; Nohara, K				Ito, T; Tsukumo, S; Suzuki, N; Motohashi, H; Yamamoto, M; Fujii-Kuriyama, Y; Mimura, J; Lin, TM; Peterson, RE; Tohyama, C; Nohara, K			A constitutively active arylhydrocarbon receptor induces growth inhibition of Jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; RETINOBLASTOMA PROTEIN; CYTOKINE PRODUCTION; AH RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; CYTOCHROME P4501A1; DEFICIENT MICE; TRANSCRIPTION; SUPPRESSION; ACTIVATION	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is known to suppress T cell-dependent immune reactions through the activation of the arylhydrocarbon receptor (AhR). Our previous findings suggest that TCDD inhibits the activation and subsequent expansion of T cells following antigen stimulation in mice, leading to a decreased level of T cell-derived cytokines involved in antibody production. In the present study, we investigated the effects of activated AhR on T cells by transiently expressing a constitutively active AhR (CA-AhR) mutant in AhR-null Jurkat T cells. In agreement with our previous findings, CA-AhR markedly inhibited the growth of Jurkat T cells. The inhibited cell growth was found to be concomitant with both an increase in the annexin V-positive apoptotic cells and the accumulation of cells in the G(1) phase. The growth inhibition was also shown to be mediated by both xenobiotic response element (XRE)-dependent and -independent mechanisms, because an A78D mutant of the CA-AhR, which lacks the ability of XRE-dependent transcription, partially inhibited the growth of Jurkat T cells. Furthermore, we demonstrated that CA-AhR induces expression changes in genes related to apoptosis and cell cycle arrest. These expression changes were shown to be solely mediated in an XRE-dependent manner, because the A78D mutant of the CA-AhR did not induce them. To summarize, these results suggest that AhR activation causes apoptosis and cell cycle arrest, especially through expression changes in genes related to apoptosis and cell cycle arrest by the XRE-dependent mechanism, leading to the inhibition of T cell growth.	Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA	National Institute for Environmental Studies - Japan; University of Tsukuba; University of Wisconsin System; University of Wisconsin Madison	Nohara, K (corresponding author), Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan.	keikon@nies.go.jp	Suzuki, Norio/AAZ-9458-2021; Suzuki, Norio/F-3456-2010; Motohashi, Hozumi/AAZ-2628-2020; Tohyama, Chiharu/AAI-5598-2020; Mimura, Junsei/E-7893-2013	Suzuki, Norio/0000-0001-6100-3350; Tohyama, Chiharu/0000-0003-1061-6872; 				Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Birnbaum LS, 2000, FOOD ADDIT CONTAM A, V17, P275, DOI 10.1080/026520300283351; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Dearstyne EA, 2002, TOXICOLOGY, V170, P139, DOI 10.1016/S0300-483X(01)00542-X; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; Doi H, 2003, CHEMOSPHERE, V52, P655, DOI 10.1016/S0045-6535(03)00112-7; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fujimaki H, 2002, TOXICOL SCI, V66, P117, DOI 10.1093/toxsci/66.1.117; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; Hossain A, 1998, J BIOL CHEM, V273, P19853, DOI 10.1074/jbc.273.31.19853; Ito T, 2002, TOXICOL SCI, V70, P46, DOI 10.1093/toxsci/70.1.46; Kerkvliet NI, 2002, TOXICOL APPL PHARM, V185, P146, DOI 10.1006/taap.2002.9537; Kerkvliet NI, 1996, J IMMUNOL, V157, P2310; Kerkvliet NI, 2002, INT IMMUNOPHARMACOL, V2, P277, DOI 10.1016/S1567-5769(01)00179-5; Kohle C, 2002, ARCH BIOCHEM BIOPHYS, V402, P172, DOI 10.1016/S0003-9861(02)00076-0; Laiosa MD, 2003, J IMMUNOL, V171, P4582, DOI 10.4049/jimmunol.171.9.4582; Lawrence BP, 1996, TOXICOL APPL PHARM, V138, P275, DOI 10.1006/taap.1996.0126; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Levine SL, 2000, MOL PHARMACOL, V58, P1517, DOI 10.1124/mol.58.6.1517; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Nohara K, 2002, TOXICOLOGY, V172, P49, DOI 10.1016/S0300-483X(01)00582-0; Park JH, 2003, TOXICOL LETT, V145, P55, DOI 10.1016/S0378-4274(03)00259-5; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Staples JE, 1998, J IMMUNOL, V160, P3844; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; TOHYAMA C, 2002, ENV SCI, V9, P37; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vorderstrasse BA, 2001, TOXICOL APPL PHARM, V171, P157, DOI 10.1006/taap.2000.9122; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; Zeytun A, 2002, TOXICOLOGY, V178, P241, DOI 10.1016/S0300-483X(02)00230-5	45	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25204	25210		10.1074/jbc.M402143200	http://dx.doi.org/10.1074/jbc.M402143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069065	hybrid			2022-12-27	WOS:000221827900037
J	Hinkle, CL; Sunnarborg, SW; Loiselle, D; Parker, CE; Stevenson, M; Russell, WE; Lee, DC				Hinkle, CL; Sunnarborg, SW; Loiselle, D; Parker, CE; Stevenson, M; Russell, WE; Lee, DC			Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family - The juxtamembrane stalk determines cleavage efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CELL-SURFACE; EGF RECEPTOR; TRANSFORMING GROWTH; TGF-ALPHA; MICE LACKING; HB-EGF; EPITHELIAL-CELLS; METALLOPROTEASE-DISINTEGRIN; ECTODOMAIN CLEAVAGE	Epidermal growth factor (EGF) family ligands are derived by proteolytic cleavage of the ectodomains of integral membrane precursors. Previously, we established that tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) is a physiologic transforming growth factor-alpha (TGF-alpha) sheddase, and we also demonstrated enhanced shedding of amphiregulin (AR) and heparin-binding (HB)-EGF upon restoration of TACE activity in TACE-deficient EC-2 fibroblasts. Here we extended these results by showing that purified soluble TACE cleaved single sites in the juxtamembrane stalks of mouse pro-HB-EGF and pro-AR ectodomains in vitro. For pro-HB-EGF, this site matched the C terminus of the purified human growth factor, and we speculate that the AR cleavage site is also physiologically relevant. In contrast, ADAM9 and -10, both implicated in HB-EGF shedding, failed to cleave the ectodomain or cleaved at a nonphysiologic site, respectively. Cotransfection of TACE in EC-2 cells enhanced phorbol myristate acetate-induced but not constitutive shedding of epiregulin and had no effect on betacellulin (BTC) processing. Additionally, soluble TACE did not cleave the juxtamembrane stalks of either pro-BTC or pro-epiregulin ectodomains in vitro. Substitution of the shorter pro-BTC juxtamembrane stalk or truncation of the pro-TGF-alpha stalk to match the pro-BTC length reduced TGF-alpha shedding from transfected cells to background levels, whereas substitution of the pro-BTC P2-P2' sequence reduced TGF-alpha shedding less dramatically. Conversely, substitution of the pro-TGF-alpha stalk or lengthening of the pro-BTC stalk, especially when combined with substitution of the pro-TGF-alpha P2-P2' sequence, markedly increased BTC shedding. These results indicate that efficient TACE cleavage is determined by a combination of stalk length and scissile bond sequence.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Univ N Carolina Proteom & Mass Spectrometry Facil, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Vanderbilt University; Vanderbilt University	Lee, DC (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	dclee@med.unc.edu	Russell, William/A-7307-2009		NATIONAL CANCER INSTITUTE [T32CA071341, R01CA085410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053804, R56DK053804] Funding Source: NIH RePORTER; NCI NIH HHS [CA71341, CA85410] Funding Source: Medline; NIDDK NIH HHS [DK53804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baba I, 2000, CANCER RES, V60, P6886; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Chubb AJ, 2002, BIOCHEM BIOPH RES CO, V297, P1225, DOI 10.1016/S0006-291X(02)02324-0; Conte F, 2002, BIOCHEM BIOPH RES CO, V290, P851, DOI 10.1006/bbrc.2001.6261; Deng P, 1998, BIOCHEMISTRY-US, V37, P17898, DOI 10.1021/bi9817313; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hinkle CL, 2003, BIOCHEMISTRY-US, V42, P2127, DOI 10.1021/bi026709v; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; LEE DC, 2003, CYTOKINE HDB, P959; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; Nemzek JA, 2001, J IMMUNOL METHODS, V255, P149, DOI 10.1016/S0022-1759(01)00419-7; ONO M, 1994, J BIOL CHEM, V269, P31315; Pan BC, 2002, MOL HUM REPROD, V8, P734, DOI 10.1093/molehr/8.8.734; PAPAC DI, 1994, PROTEIN SCI, V3, P1485, DOI 10.1002/pro.5560030914; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raska CS, 2003, J AM SOC MASS SPECTR, V14, P1076, DOI 10.1016/S1044-0305(03)00405-7; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Singh AB, 2004, J CELL SCI, V117, P1365, DOI 10.1242/jcs.01037; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 2002, KIDNEY INT, V61, P1968, DOI 10.1046/j.1523-1755.2002.00358.x; Takemura T, 2001, J AM SOC NEPHROL, V12, P964, DOI 10.1681/ASN.V125964; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zhou HM, 2004, MOL CELL BIOL, V24, P96, DOI 10.1128/MCB.24.1.96-104.2004	80	119	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24179	24188		10.1074/jbc.M312141200	http://dx.doi.org/10.1074/jbc.M312141200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15066986	hybrid			2022-12-27	WOS:000221702500041
J	Milenkovic, D; Kozjak, V; Wiedemann, N; Lohaus, C; Meyer, HE; Guiard, B; Pfanner, N; Meisinger, C				Milenkovic, D; Kozjak, V; Wiedemann, N; Lohaus, C; Meyer, HE; Guiard, B; Pfanner, N; Meisinger, C			Sam35 of the mitochondrial protein sorting and assembly machinery is a peripheral outer membrane protein essential for cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT CHANNEL; TOM COMPLEX; INTERMEMBRANE SPACE; BIOGENESIS; BETA; PREPROTEINS; RECEPTORS; METAXIN; PORE; TRANSLOCASE	The mitochondrial outer membrane contains two integral proteins essential for cell viability, Tom40 of the translocase of the outer membrane ( TOM complex) and Sam50 of the sorting and assembly machinery ( SAM complex). Here we report the identification of Sam35, the first peripheral mitochondrial outer membrane protein that is essential for cell viability. Sam35 ( encoded by the Saccharomyces cerevisiae ORF YHR083w) is a novel subunit of the SAM complex and is crucial for the assembly pathway of outer membrane beta- barrel proteins, such as the precursors of Tom40 and porin. Sam35 is not required for the import of inner membrane or matrix targeted proteins. The presence of two essential proteins in the SAM complex, Sam35 and Sam50, indicates that it plays a central role in mitochondrial biogenesis.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany; Univ Paris 06, Ctr Genet Mol, Lab Propre CNRS, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Ruhr University Bochum; UDICE-French Research Universities; Sorbonne Universite	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de	Kozjak-Pavlovic, Vera/E-1494-2013; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Kozjak-Pavlovic, Vera/0000-0001-9658-7018; Meisinger, Chris/0000-0002-8326-3548; Wiedemann, Nils/0000-0001-8305-6728				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Armstrong LC, 1999, J CELL BIOCHEM, V74, P11, DOI 10.1002/(SICI)1097-4644(19990701)74:1<11::AID-JCB2>3.0.CO;2-V; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Johnson AE, 2004, NAT STRUCT MOL BIOL, V11, P113, DOI 10.1038/nsmb0204-113; KEIL P, 1993, J BIOL CHEM, V268, P19177; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Mihara K, 2003, NATURE, V424, P505, DOI 10.1038/424505a; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Niedenthal R, 1999, YEAST, V15, P1775, DOI 10.1002/(SICI)1097-0061(199912)15:16<1775::AID-YEA496>3.3.CO;2-L; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Wang XF, 2001, EMBO REP, V2, P628, DOI 10.1093/embo-reports/kve135; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200	37	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22781	22785		10.1074/jbc.C400120200	http://dx.doi.org/10.1074/jbc.C400120200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15067005	hybrid			2022-12-27	WOS:000221417100130
J	Gonzales, PE; Solomon, A; Miller, AB; Leesnitzer, MA; Sagi, I; Milla, ME				Gonzales, PE; Solomon, A; Miller, AB; Leesnitzer, MA; Sagi, I; Milla, ME			Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; PROTEIN-FOLDING REACTION; INTRACELLULAR MATURATION; MATRIX METALLOPROTEINASE-2; SUBTILISIN BPN; CELL-CELL; DISINTEGRIN; ACTIVATION; MECHANISM; LOCALIZATION	Tumor necrosis factor-alpha-converting enzyme ( TACE) is a disintegrin metalloproteinase that processes tumor necrosis factor and a host of other ectodomains. TACE is biosynthesized as a zymogen, and activation requires the removal of an inhibitory pro domain. Little is known about how the pro domain exerts inhibition for this class of enzymes. To study the inhibitory properties of the pro domain of TACE, we have expressed it in isolation from the rest of the protease. Here we show that the TACE pro domain ( TACE Pro) is a stably folded protein that is able to inhibit this enzyme. TACE Pro inhibited the catalytic domain of TACE with an IC50 of 70 nM. In contrast, this inhibitory potency decreased over 30-fold against a TACE form containing the catalytic plus disintegrin/ cysteine-rich domains (IC50 greater that 2 muM). The disintegrin/ cysteine-rich region in isolation also decreases the interaction of TACE Pro with the catalytic domain. Surprisingly, we found that the cysteine switch motif located in TACE Pro was not essential for inhibition of the enzymatic activity of TACE; the pro domain variant C184A showed the same inhibitory potency against both TACE forms as wild type TACE Pro. X-ray absorption spectroscopy experiments indicate that binding of TACE Pro to the catalytic domain does include ligation of the catalytic zinc ion via the sulfur atom of its conserved Cys(184) residue. Moreover, the binding of TACE Pro to the catalytic zinc ion partially oxidizes the catalytic zinc ion of the enzyme. Despite this, the nature of the interaction between the pro and catalytic domains of TACE is not consistent with a simple competitive model of inhibition based on cysteine switch ligation of the zinc ion within the active site of TACE.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA	University of Pennsylvania; University of Pennsylvania; Weizmann Institute of Science; GlaxoSmithKline	Milla, ME (corresponding author), 242 Anat Chem Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	mmilla@mail.med.upenn.edu			NIAMS NIH HHS [AR-45949] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045949] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; FEIMARK BD, 1994, J BIOL CHEM, V269, P26982; Galazka G, 1999, BIOCHEMISTRY-US, V38, P1316, DOI 10.1021/bi982135b; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kleifeld O, 2003, NAT STRUCT BIOL, V10, P98, DOI 10.1038/nsb889; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Solomon A, 2004, J BIOL CHEM, V279, P31646, DOI 10.1074/jbc.M401310200; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	36	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31638	31645		10.1074/jbc.M401311200	http://dx.doi.org/10.1074/jbc.M401311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15100227	hybrid			2022-12-27	WOS:000222726800088
J	Chen, H; Hewison, M; Hu, B; Sharma, M; Sun, ZJ; Adams, JS				Chen, H; Hewison, M; Hu, B; Sharma, M; Sun, ZJ; Adams, JS			An Hsp27-related, dominant-negative-acting intracellular estradiol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HUMAN ESTROGEN-RECEPTOR; WORLD PRIMATE CELLS; ALPHA-B-CRYSTALLIN; VITAMIN-D; SQUIRREL-MONKEY; BREAST-CANCER; FUNCTIONAL-CHARACTERIZATION; HEAT-SHOCK-PROTEIN-27 GENE; GLUCOCORTICOID-RECEPTOR	New World primates (NWPs) exhibit a compensated form of resistance to gonadal steroid hormones. We demonstrated recently that estrogen resistance in NWP cells was associated with the overexpression of two proteins, a nonreceptor-related, dominant-negative-acting estrogen response element (ERE)-binding protein (ERE-BP) and an intracellular estradiol-binding protein (IEBP). Based on the N-terminal sequences of tryptic fragments of IEBP isolated from a 17beta-estradiol (E-2) affinity column we cloned a full-length cDNA for IEBP from the estrogen-resistant NWP cell line, B95-8. Subsequent sequence analysis revealed 87% sequence identity between the deduced peptide for IEBP and human Hsp27. When hormone-responsive, wild-type Old World primate (OWP) cells were transiently transfected with IEBP cDNA, E-2-directed ERE reporter luciferase activity was reduced by 50% compared with vector only-transfected OWP cells (p < 0.0018). When IEBP and ERE-BP were cotransfected, ERE promoter-reporter activity was reduced by a further 60% (p < 0.0001). Electrophoresis mobility shift analyses showed that IEBP neither bound to ERE nor competed with the estrogen receptor (ER) for binding to ERE. However, there was evidence of protein-protein interaction of IEBP and ERalpha; IEBP was coimmunoprecipitated with anti-ERalpha antibody in wildtype cells stably transfected with IEBP. A specific interaction between ERalpha and IEBP was confirmed in glutathione S-transferase pull-down and yeast two-hybrid assays. Data indicate that the Hsp27-related IEBP interacts with the ligand binding domain of the ERalpha. In summary, by inhibiting the ERalpha-E-2 interaction, IEBP acts to squelch ERalpha-directed ERE-regulated transactivation and promote estrogen resistance in NWP cells.	Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pathol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Birmingham, Queen Elizabeth Med Ctr, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Birmingham City University; University of Birmingham; Stanford University	Adams, JS (corresponding author), Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Rm B-131, Los Angeles, CA 90048 USA.	adamsj@cshs.org	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NCI NIH HHS [R01 CA087767, R01 CA070297] Funding Source: Medline; NIDDK NIH HHS [R01 DK055843, R01 DK061002, R01DK55843, R01 DK055843-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JS, 1985, ENDOCRINOLOGY, V116, P2523, DOI 10.1210/endo-116-6-2523; Adams JS, 2003, J CELL BIOCHEM, V88, P308, DOI 10.1002/jcb.10333; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BONNEGARD M, 1995, TRENDS ENDOCRIN MET, V6, P160; BROWN GM, 1970, ENDOCRINOLOGY, V86, P519, DOI 10.1210/endo-86-3-519; Bullard B, 2004, J BIOL CHEM, V279, P7917, DOI 10.1074/jbc.M307473200; Chen H, 2003, J CLIN ENDOCR METAB, V88, P501, DOI 10.1210/jc.2002-021488; Chen H, 1997, J CLIN INVEST, V99, P669, DOI 10.1172/JCI119210; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; CHROUSOS GP, 1984, J CLIN ENDOCR METAB, V58, P516, DOI 10.1210/jcem-58-3-516; CHROUSOS GP, 1984, ENDOCRINOLOGY, V115, P25, DOI 10.1210/endo-115-1-25; CHROUSOS GP, 1982, P NATL ACAD SCI-BIOL, V79, P2036, DOI 10.1073/pnas.79.6.2036; CHROUSOS GP, 1982, J CLIN ENDOCR METAB, V55, P364, DOI 10.1210/jcem-55-2-364; CHROUSOS GP, 1984, ADV EXP MED BIOL, V196, P317; Chun RF, 2001, AM J PRIMATOL, V54, P107, DOI 10.1002/ajp.1016; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; deToro MMM, 1997, J STEROID BIOCHEM, V60, P277, DOI 10.1016/S0960-0760(96)00221-X; Ferro P, 2003, INT J MOL MED, V12, P355; Fu L, 2003, BIOCHEM BIOPH RES CO, V302, P710, DOI 10.1016/S0006-291X(03)00257-2; Gacad MA, 1998, J CLIN ENDOCR METAB, V83, P1264, DOI 10.1210/jc.83.4.1264; Gacad MA, 1997, J BIOL CHEM, V272, P8433, DOI 10.1074/jbc.272.13.8433; GACAD MA, 1992, AM J PRIMATOL, V28, P263, DOI 10.1002/ajp.1350280404; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUTCHISON KA, 1993, ANN NY ACAD SCI, V684, P35, DOI 10.1111/j.1749-6632.1993.tb32269.x; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Klein-Hitpass L, 1998, J MOL MED, V76, P490, DOI 10.1007/s001090050243; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Labrie F, 2000, J MOL ENDOCRINOL, V25, P1, DOI 10.1677/jme.0.0250001; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Oesterreich S, 1996, CLIN CANCER RES, V2, P1199; Pasta SY, 2003, J BIOL CHEM, V278, P51159, DOI 10.1074/jbc.M307523200; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Reynolds PD, 1997, J CLIN ENDOCR METAB, V82, P465, DOI 10.1210/jc.82.2.465; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; Siiteri P K, 1986, Adv Exp Med Biol, V196, P279; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Smith LL, 2000, CRIT REV TOXICOL, V30, P571, DOI 10.1080/10408440008951120; Stock AD, 2003, AM J MED GENET A, V120A, P320, DOI 10.1002/ajmg.a.20055; TAKAHASHI N, 1985, BIOCHEM J, V227, P555, DOI 10.1042/bj2270555; TAKAHASHI S, 1995, ONCOLOGY, V52, P371; Tamrazi A, 2002, MOL ENDOCRINOL, V16, P2706, DOI 10.1210/me.2002-0250; Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x; Witek Andrzej, 2003, Ginekol Pol, V74, P246; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wu SX, 2000, MOL ENDOCRINOL, V14, P1387, DOI 10.1210/me.14.9.1387; Wu SX, 2002, ENDOCRINOLOGY, V143, P4135, DOI 10.1210/en.2002-220568; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	64	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29944	29951		10.1074/jbc.M401317200	http://dx.doi.org/10.1074/jbc.M401317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123601	hybrid			2022-12-27	WOS:000222531900011
J	Le Gall, M; Giniger, E				Le Gall, M; Giniger, E			Identification of two binding regions for the suppressor of hairless protein within the intracellular domain of Drosophila Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN REPEATS; CELL FATES; C-ELEGANS; RBP-J; TRANSCRIPTIONAL COACTIVATOR; ACTIVATES TRANSCRIPTION; NUCLEAR-LOCALIZATION; MOUSE NOTCH1; RECEPTOR; STABILITY	Notch is a phylogenetically conserved transmembrane receptor that is required for many aspects of animal development. Upon ligand stimulation, a fragment of Notch is released proteolytically and enters the nucleus to form a complex with the DNA-binding protein CSL (CBF1/Suppressor of Hairless/Lag1) and activate transcription of Notch-CSL target genes. The physical structure of the Notch-CSL complex remains unclear, however, clouding the interpretation of previous efforts to correlate Notch structure and function. We have, therefore, characterized the binding of Drosophila CSL (called Suppressor of Hairless, or Su(H)) to the intracellular domain of Drosophila Notch both in vitro and in vivo. We report the identification of two Su(H) binding regions in Notch. The first is in the juxtamembrane region (the "RAM" domain). The second is just C-terminal to the Notch ankyrin repeats, overlapping or identical to two previously proposed nuclear localization sequences, in a domain we term PPD (potential phosphorylated domain). The ankyrin repeats themselves do not bind to Su(H); however, they substantially enhance binding of Su(H) to the more C-terminal region. Consistent with this picture, removal of either the Ram or PPD binding sites, separately, modestly reduces Notch activity in vivo, whereas removal of both renders Notch severely defective. These results clarify the relationship between Notch and CSL, help to explain the importance of the ankyrin repeats in Notch signaling, and reconcile many apparently contradictory results from previous Notch structure/function studies. Moreover, they suggest a second function for the Notch nuclear localization sequence elements.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Giniger, E (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	eginiger@fhcrc.org	Le Gall, Maude/C-3917-2017; Le Gall, Maude/W-2593-2019; Giniger, Edward/C-1764-2015	Le Gall, Maude/0000-0002-5372-4585; Le Gall, Maude/0000-0002-5372-4585; Giniger, Edward/0000-0002-8340-6158	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057830, R55GM057830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003013, Z01NS003013] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Foltz DR, 2001, BIOCHEM BIOPH RES CO, V286, P484, DOI 10.1006/bbrc.2001.5421; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lai EC, 2002, CURR BIOL, V12, pR200, DOI 10.1016/S0960-9822(02)00749-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Matsuno K, 2002, DEVELOPMENT, V129, P1049; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tani S, 2001, NUCLEIC ACIDS RES, V29, P1373, DOI 10.1093/nar/29.6.1373; Wesley CS, 2000, J CELL BIOL, V149, P683, DOI 10.1083/jcb.149.3.683; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14344, DOI 10.1021/bi011435h; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	42	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29418	29426		10.1074/jbc.M404589200	http://dx.doi.org/10.1074/jbc.M404589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123610	hybrid			2022-12-27	WOS:000222445300074
J	Lilja, L; Johansson, JU; Gromada, J; Mandic, SA; Fried, G; Berggren, PO; Bark, C				Lilja, L; Johansson, JU; Gromada, J; Mandic, SA; Fried, G; Berggren, PO; Bark, C			Cyclin-dependent kinase 5 associated with p39 promotes Munc18-1 phosphorylation and Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES NEUROTRANSMITTER RELEASE; PANCREATIC BETA-CELLS; CDK5 ACTIVATOR; PROTEIN-KINASE; INSULIN-RELEASE; NEGATIVE REGULATOR; SEC1 HOMOLOG; SYNTAXIN 1A; EXPRESSION; BRAIN	Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine protein kinase that requires association with a regulatory protein, p35 or p39, to form an active enzyme. Munc18-1 plays an essential role in membrane fusion, and its function is regulated by phosphorylation. We report here that both p35 and p39 were expressed in insulin-secreting beta-cells, where they exhibited individual subcellular distributions and associated with membranous organelles of different densities. Overexpression of Cdk5, p35, or p39 showed that Cdk5 and p39 augmented Ca2+-induced insulin exocytosis. Suppression of p39 and Cdk5, but not of p35, by antisense oligonucleotides selectively inhibited insulin exocytosis. Transient transfection of primary beta-cells with Munc18-1 templates mutated in potential Cdk5 or PKC phosphorylation sites, in combination with Cdk5 and the different Cdk5 activators, suggested that Cdk5/p39-promoted Ca2+-dependent insulin secretion from primary beta-cells by phosphorylating Munc18-1 at a biochemical step immediately prior to vesicle fusion.	Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, SE-17176 Stockholm, Sweden; Lilly Res Labs, D-22419 Hamburg, Germany; Karolinska Univ Hosp, Karolinska Inst, Dept Woman & Child Hlth, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Eli Lilly; Lilly Deutschland GmbH; Karolinska Institutet; Karolinska University Hospital	Berggren, PO (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, SE-17176 Stockholm, Sweden.	per-olof.berggren@molmed.ki.se		Bark, Christina/0000-0002-0724-6017; Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK58505] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R13DK058505] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson J, 2000, EUR J CELL BIOL, V79, P781, DOI 10.1078/0171-9335-00106; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; Chergui K, 2004, P NATL ACAD SCI USA, V101, P2191, DOI 10.1073/pnas.0308652100; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; Dresbach T, 1998, J NEUROSCI, V18, P2923; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Hanson PI, 2000, NAT STRUCT BIOL, V7, P347, DOI 10.1038/75103; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; Humbert S, 2000, J CELL SCI, V113, P975; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Ko J, 2001, J NEUROSCI, V21, P6758; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; MARTELL AE, 1971, AMINO ACIDS AMINES, V2; MARTELL AE, 1971, AMINO ACIDS AMINES, V1; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nilden F, 1998, BBA-GENE STRUCT EXPR, V1398, P371, DOI 10.1016/S0167-4781(98)00073-6; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Pigino G, 1997, J CELL SCI, V110, P257; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe J, 1999, J CELL SCI, V112, P1865; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tian JH, 2003, J BIOL CHEM, V278, P26265, DOI 10.1074/jbc.M300492200; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	65	57	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29534	29541		10.1074/jbc.M312711200	http://dx.doi.org/10.1074/jbc.M312711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123626	hybrid			2022-12-27	WOS:000222445300087
J	Mizusawa, N; Kimura, Y; Ishii, A; Yamanari, T; Nakazawa, S; Teramoto, H; Ono, T				Mizusawa, N; Kimura, Y; Ishii, A; Yamanari, T; Nakazawa, S; Teramoto, H; Ono, T			Impact of replacement of D1 C-terminal alanine with glycine on structure and function of photosynthetic oxygen-evolving complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; II REACTION-CENTER; TYROSINE Y-Z; TRANSFORM INFRARED-SPECTROSCOPY; PHOTOSYSTEM-II; MANGANESE CLUSTER; POLYPEPTIDE LIGATE; CRYSTAL-STRUCTURE; REDOX PROPERTIES; MN-CLUSTER	The C-terminal alanine 344 (Ala-344) in the D1 protein of photosystem II is conserved in all of the organisms performing oxygenic photosynthesis. A free alpha-COO- of Ala-344 has been proposed to be responsible for ligating the Mn cluster. Here, we constructed a mutant having D1 in which D1-Ala-344 was replaced with glycine (Gly) in cyanobacterium Synechocystis sp. PCC 6803. The effects of this minimal change in the side group from methyl to hydrogen on the properties of the oxygen-evolving complex were comprehensively investigated using purified core particles. The mutant grew photoautotrophically, and little change was observed in the protein composition of the oxygen-evolving core particles. The Gly-substituted oxygen-evolving complex showed small but normal S-2 multiline and enhanced g = 4.1 electron spin resonance signals and S-2-state thermoluminescence bands with slightly elevated peak temperature. The Gly substitution resulted in distinct but relatively small changes in a few bands arising from the putative carboxylate ligand for the Mn cluster in the mid-frequency ( 1800 - 1000 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum. In contrast, the low frequency (670 - 350 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum was markedly changed by the substitution. The results indicate that the internal structure of the Mn cluster and/or the interaction between the Mn cluster and its ligand are considerably altered by a simple change in the side group, from methyl to hydrogen, at the C-terminal of the D1 protein.	RIKEN, Inst Phys & Chem Res, Photodynam Res Ctr, Lab Photobiol 1,Aoba Ku, Sendai, Miyagi 9800845, Japan; Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	RIKEN; Hiroshima University	Ono, T (corresponding author), RIKEN, Inst Phys & Chem Res, Photodynam Res Ctr, Lab Photobiol 1,Aoba Ku, 519-1399 Aoba, Sendai, Miyagi 9800845, Japan.	takaaki@postman.riken.go.jp						Boussac A, 1996, BIOCHEMISTRY-US, V35, P6984, DOI 10.1021/bi960636w; Chu HA, 2000, BIOCHEMISTRY-US, V39, P14371, DOI 10.1021/bi001751g; Chu HA, 2004, BIOCHEMISTRY-US, V43, P3152, DOI 10.1021/bi035915f; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; Chu HA, 2001, BIOCHEMISTRY-US, V40, P2312, DOI 10.1021/bi0022994; Chu HA, 2001, BBA-BIOENERGETICS, V1503, P69, DOI 10.1016/S0005-2728(00)00216-4; Chu HA, 1999, BIOCHEMISTRY-US, V38, P4533, DOI 10.1021/bi982807y; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P470, DOI 10.1021/bi9917737; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P6275, DOI 10.1021/bi992749w; Debus RJ, 2003, BIOCHEMISTRY-US, V42, P10600, DOI 10.1021/bi034859f; Debus RJ, 2001, BIOCHEMISTRY-US, V40, P3690, DOI 10.1021/bi002394c; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1988, J BIOL CHEM, V263, P8972; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fromme P, 2002, PHILOS T R SOC B, V357, P1337, DOI 10.1098/rstb.2002.1143; Hasegawa K, 2000, J PHYS CHEM B, V104, P4253, DOI 10.1021/jp000157d; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kimura Y, 2003, BIOCHEMISTRY-US, V42, P13170, DOI 10.1021/bi035420q; Kimura Y, 2002, BIOCHEMISTRY-US, V41, P5844, DOI 10.1021/bi016093u; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KUSUNOKI M, 1992, RES PHOTOSYNTHESIS, V2, P297; LERS A, 1992, J BIOL CHEM, V267, P17494; MARDER JB, 1984, J BIOL CHEM, V259, P3900; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; Noguchi T, 1999, BIOCHEMISTRY-US, V38, P10187, DOI 10.1021/bi990631+; NOGUCHI T, 1995, BBA-BIOENERGETICS, V1228, P189, DOI 10.1016/0005-2728(94)00171-Z; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; Onoda K, 2000, PHOTOSYNTH RES, V63, P47, DOI 10.1023/A:1006362118267; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; Smith JC, 1997, INORG CHIM ACTA, V255, P99, DOI 10.1016/S0020-1693(96)05350-9; Socrates G., 1994, INFRARED RAMAN CHARA; Tamura N, 1997, PLANT CELL PHYSIOL, V38, P578, DOI 10.1093/oxfordjournals.pcp.a029207; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; Visser H, 2002, J AM CHEM SOC, V124, P11008, DOI 10.1021/ja020409j; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29622	29627		10.1074/jbc.M402397200	http://dx.doi.org/10.1074/jbc.M402397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123635	hybrid			2022-12-27	WOS:000222445300098
J	Saravanamuthu, A; Vickers, TJ; Bond, CS; Peterson, MR; Hunter, WN; Fairlamb, AH				Saravanamuthu, A; Vickers, TJ; Bond, CS; Peterson, MR; Hunter, WN; Fairlamb, AH			Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase - A template for drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; CRITHIDIA-FASCICULATA; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; GLUTATHIONE-REDUCTASE; LEISHMANIA-DONOVANI; OXIDATIVE STRESS; INHIBITORS; PURIFICATION; PROGRAM	Trypanothione reductase is a key enzyme in the trypanothione-based redox metabolism of pathogenic trypanosomes. Because this system is absent in humans, being replaced with glutathione and glutathione reductase, it offers a target for selective inhibition. The rational design of potent inhibitors requires accurate structures of enzyme-inhibitor complexes, but this is lacking for trypanothione reductase. We therefore used quinacrine mustard, an alkylating derivative of the competitive inhibitor quinacrine, to probe the active site of this dimeric flavoprotein. Quinacrine mustard irreversibly inactivates Trypanosoma cruzi trypanothione reductase, but not human glutathione reductase, in a time-dependent manner with a stoichiometry of two inhibitors bound per monomer. The rate of inactivation is dependent upon the oxidation state of trypanothione reductase, with the NADPH-reduced form being inactivated significantly faster than the oxidized form. Inactivation is slowed by clomipramine and a melarsen oxide-trypanothione adduct ( both are competitive inhibitors) but accelerated by quinacrine. The structure of the trypanothione reductase-quinacrine mustard adduct was determined to 2.7 Angstrom, revealing two molecules of inhibitor bound in the trypanothione-binding site. The acridine moieties interact with each other through pi-stacking effects, and one acridine interacts in a similar fashion with a tryptophan residue. These interactions provide a molecular explanation for the differing effects of clomipramine and quinacrine on inactivation by quinacrine mustard. Synergism with quinacrine occurs as a result of these planar acridines being able to stack together in the active site cleft, thereby gaining an increased number of binding interactions, whereas antagonism occurs with nonplanar molecules, such as clomipramine, where stacking is not possible.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Bond, Charles/AAF-9608-2020; Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011; Fairlamb, Alan/A-5272-2009	Bond, Charles/0000-0002-9584-6783; Bond, Charles S/0000-0002-9584-6783; Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust [079838] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; ATTWOOD D, 1995, ADV COLLOID INTERFAC, V55, P271, DOI 10.1016/0001-8686(94)00228-5; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENSON TJ, 1992, BIOCHEM J, V286, P9, DOI 10.1042/bj2860009; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; Bonse S, 1999, J MED CHEM, V42, P5448, DOI 10.1021/jm990386s; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; BROCKLEHURST K, 1979, BIOCHEM J, V181, P775, DOI 10.1042/bj1810775; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARLSON GM, 1984, BIOCHIM BIOPHYS ACTA, V789, P347, DOI 10.1016/0167-4838(84)90191-2; Chibale K, 2001, BIOORG MED CHEM LETT, V11, P2655, DOI 10.1016/S0960-894X(01)00528-5; Chitkul B, 2000, BIOORG MED CHEM LETT, V10, P2367, DOI 10.1016/S0960-894X(00)00471-6; COURSEIL.C, 1973, ACTA CRYSTALLOGR B, V29, P2349, DOI 10.1107/S0567740873006680; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; Garforth J, 1997, J ENZYM INHIB, V12, P161, DOI 10.3109/14756369709029312; HENDERSON GB, 1987, BIOCHEMISTRY-US, V26, P3023, DOI 10.1021/bi00385a011; Jacoby EM, 1996, PROTEINS, V24, P73, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;73::AID-PROT5&gt;3.0.CO;2-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNG MJ, 1975, BIOCHEM BIOPH RES CO, V67, P301, DOI 10.1016/0006-291X(75)90316-2; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauth-Siegel R.L., 1991, P493; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANSONBAHR PEC, 1987, MANSONS TROPICAL DIS, P54; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSULLIVAN MC, 1995, BIOORG MED CHEM LETT, V5, P1957, DOI 10.1016/0960-894X(95)00331-M; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; World Health Organization, 2002, WORLD REPORT VIOLENC, P169; WORTHINGTON DJ, 1974, EUR J BIOCHEM, V48, P167, DOI 10.1111/j.1432-1033.1974.tb03754.x; YIN H, 1996, CHEM COMMUN, V1, P973; Zani CL, 2003, MEM I OSWALDO CRUZ, V98, P565, DOI 10.1590/S0074-02762003000400026; Zhang YH, 1996, PROTEIN SCI, V5, P52	47	91	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29493	29500		10.1074/jbc.M403187200	http://dx.doi.org/10.1074/jbc.M403187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15102853	hybrid, Green Accepted			2022-12-27	WOS:000222445300082
J	Gazzarrini, S; Kang, M; Van Etten, JL; Tayefeh, S; Kast, SM; DiFrancesco, D; Thiel, G; Moroni, A				Gazzarrini, S; Kang, M; Van Etten, JL; Tayefeh, S; Kast, SM; DiFrancesco, D; Thiel, G; Moroni, A			Long distance interactions within the potassium channel pore are revealed by molecular diversity of viral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; CHLORELLA VIRUSES; SELECTIVITY; CONDUCTION; ACTIVATION; DESIGN; DOMAIN; BLOCK; KAT1; CS+	Kcv is a 94-amino acid protein encoded by chlorella virus PBCV-1 that corresponds to the pore module of K+ channels. Therefore, Kcv can be a model for studying the protein design of K+ channel pores. We analyzed the molecular diversity generated by similar to1 billion years of evolution on kcv genes isolated from 40 additional chlorella viruses. Because the channel is apparently required for virus replication, the Kcv variants are all functional and contain multiple and dispersed substitutions that represent a repertoire of allowed sets of amino acid substitutions ( from 4 to 12 amino acids). Correlations between amino acid substitutions and the new properties displayed by these channels guided site-directed mutations that revealed synergistic amino acid interactions within the protein as well as previously unknown interactions between distant channel domains. The effects of these multiple changes were not predictable from a priori structural knowledge of the channel pore.	Univ Milan, Dept Biol, I-20133 Milan, Italy; Univ Milan, CNR, Ist Biofis Mi, I-20133 Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; Tech Univ Darmstadt, Inst Inorgan & Phys Chem, D-64287 Darmstadt, Germany; Tech Univ Darmstadt, Dept Bot, D-64287 Darmstadt, Germany; Unita Milano Univ, Ist Nazl Fis Mat, I-20133 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Milan; University of Milan; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Technical University of Darmstadt; Technical University of Darmstadt; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan	Moroni, A (corresponding author), Univ Milan, Dept Biol, Via Celoria 26, I-20133 Milan, Italy.	anna.moroni@unimi.it	DiFrancesco, Dario/G-8408-2017; moroni, anna/H-2097-2014	DiFrancesco, Dario/0000-0002-7322-1790; moroni, anna/0000-0002-1860-406X; Thiel, Gerhard/0000-0002-2335-1351; Tayefeh, Sascha/0000-0002-3338-3488; gazzarrini, sabrina/0000-0003-3062-7536	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 15635] Funding Source: Medline; NIGMS NIH HHS [GM 32441] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; BRICKMANN J, 1995, DATA VISUALIZATION M, P83; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Garafoli S, 2003, BIOPHYS J, V84, P2814, DOI 10.1016/S0006-3495(03)70011-3; Gazzarrini S, 2003, FEBS LETT, V552, P12, DOI 10.1016/S0014-5793(03)00777-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Ichida AM, 1996, J MEMBRANE BIOL, V151, P53, DOI 10.1007/s002329900057; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kang M, 2004, P NATL ACAD SCI USA, V101, P5318, DOI 10.1073/pnas.0307824100; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MACKINNON R, 1991, J BIOENERG BIOMEMBR, V23, P647, DOI 10.1007/BF00785815; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Moroni A, 2002, FEBS LETT, V530, P65, DOI 10.1016/S0014-5793(02)03397-5; Plugge B, 2000, SCIENCE, V287, P1641, DOI 10.1126/science.287.5458.1641; Saven JG, 2002, CURR OPIN STRUC BIOL, V12, P453, DOI 10.1016/S0959-440X(02)00347-0; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Tobin MB, 2000, CURR OPIN STRUC BIOL, V10, P421, DOI 10.1016/S0959-440X(00)00109-3; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	27	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28443	28449		10.1074/jbc.M401184200	http://dx.doi.org/10.1074/jbc.M401184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105432	hybrid			2022-12-27	WOS:000222265400078
J	Sesaki, H; Jensen, RE				Sesaki, H; Jensen, RE			Ugo1p links the Fzo1p and Mgm1p GTPases for mitochondrial fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST REQUIRES; PROTEIN; DNA; DIVISION; FISSION; SHAPE	In yeast, mitochondrial fusion requires Ugo1p and two GTPases, Fzo1p and Mgm1p. Ugo1p is anchored in the mitochondrial outer membrane with its N terminus facing the cytosol and C terminus in the intermembrane space. Fzo1p is also an outer membrane protein, whereas Mgm1p is located in the intermembrane space. Recent studies suggest that these three proteins form protein complexes that mediate mitochondrial fusion. Here, we show that the cytoplasmic domain of Ugo1p directly interacts with Fzo1p, whereas its intermembrane space domain binds to Mgm1p. We identified the Ugo1p-binding site in Fzo1p and demonstrated that Ugo1p-Fzo1p interaction is essential for the formation of mitochondrial shape, maintenance of mitochondrial DNA, and fusion of mitochondria. Although the GTPase domains of Fzo1p and Mgm1p regulate mitochondrial fusion, they were not required for association with Ugo1p. Furthermore, we found that Ugo1p bridges the interaction between Fzo1p and Mgm1p in mitochondria. Our data indicate that distinct regions of Ugo1p bind directly to Fzo1p and Mgm1p and thereby link these two GTPases during mitochondrial fusion.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Sesaki, H (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	hsesaki@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054021] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54021-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P145; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2001, J CELL SCI, V114, P867; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; SIKORSKI RS, 1989, GENETICS, V122, P19; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Westermann B, 2003, BBA-MOL CELL RES, V1641, P195, DOI 10.1016/S0167-4889(03)00091-0; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 2003, NAT CELL BIOL, V5, P497, DOI 10.1038/ncb0603-497b	36	136	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28298	28303		10.1074/jbc.M401363200	http://dx.doi.org/10.1074/jbc.M401363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087460	hybrid			2022-12-27	WOS:000222265400061
J	Alexiadis, V; Lusser, A; Kadonaga, JT				Alexiadis, V; Lusser, A; Kadonaga, JT			A conserved N-terminal motif in Rad54 is important for chromatin remodeling and homologous strand pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION FACTORS RAD51; HISTONE METHYLATION; YEAST RAD51; DNA; PROTEIN; MECHANISMS; CATALYSIS; BREAKS; ACF1	The Swi2/Snf2-related protein Rad54 is a chromatin remodeling enzyme that is important for homologous strand pairing catalyzed by the eukaryotic recombinase Rad51. The chromatin remodeling and DNA-stimulated ATPase activities of Rad54 are significantly enhanced by Rad51. To investigate the functions of Rad54, we generated and analyzed a series of mutant Rad54 proteins. Notably, the deletion of an N-terminal motif ( amino acid residues 2 - 9), which is identical in Rad54 in Drosophila, mice, and humans, results in a complete loss of chromatin remodeling and strand pairing activities, and partial inhibition of the ATPase activity. In contrast, this conserved N-terminal motif has no apparent effect on the ability of DNA to stimulate the ATPase activity or of Rad51 to enhance the DNA-stimulated ATPase activity. Unexpectedly, as the N terminus of Rad54 is progressively truncated, the mutant proteins regain partial chromatin remodeling activity as well as essentially complete DNA-stimulated ATPase activity, both of which are no longer responsive to Rad51. These findings suggest that the N-terminal region of Rad54 contains an autoinhibitory activity that is relieved by Rad51.	Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Mol Biol Sect, 0347,Pacific Hall,Rm 2212B,9500 Gilman Dr, La Jolla, CA 92093 USA.	jkadonaga@ucsd.edu		Lusser, Alexandra/0000-0002-2226-9081	NIGMS NIH HHS [GM46995] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046995] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Peterson CL, 2002, CURR BIOL, V12, pR245, DOI 10.1016/S0960-9822(02)00782-0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	35	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27824	27829		10.1074/jbc.M402648200	http://dx.doi.org/10.1074/jbc.M402648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105430	hybrid			2022-12-27	WOS:000222120400118
J	Xiao, LP; Naganawa, T; Obugunde, E; Gronowicz, G; Ornitz, DM; Coffin, JD; Hurley, MM				Xiao, LP; Naganawa, T; Obugunde, E; Gronowicz, G; Ornitz, DM; Coffin, JD; Hurley, MM			Stat1 controls postnatal bone formation by regulating fibroblast growth factor signaling in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-3 FGFR3; CHONDROCYTE PROLIFERATION; TRANSDUCTION PATHWAY; TARGETED DISRUPTION; GENE; DIFFERENTIATION; ACTIVATION; MICE; OSTEOPENIA; INTERLEUKIN-6	Activation of the signal transducers and activators of transcription ( STAT) pathway is important in fibroblast growth factor (FGF) modulation of chondrocyte proliferation and endochondral bone formation during embryogenesis. However, it is not known if the FGF/STAT signaling pathway is important for postnatal bone formation. To examine this, we have characterized a novel skeletal phenotype in Stat1-/- mice in which we find a significant increase in bone mineral density, bone mineral content, and other parameters of bone growth. The data show that osteoblasts derived from Stat1-/- mice have decreased expression of cell cycle inhibitor p21WAF/CIP and FGF receptor 3, a known negative regulator of chondrocyte proliferation. Interestingly, Stat1-/- osteoblasts showed increased expression of FGF18 in vivo and increased responsiveness to FGF18 in vitro. These results suggest a mechanism for the regulation of the osteoblast in which Stat1 functions not only to directly regulate the cell cycle but also to modify the repertoire of FGF receptor expression from a potentially inhibitory receptor, FGFR3 to a stimulatory receptor such as FGFR1 or FGFR2.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Orthopaed, Farmington, CT 06030 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	University of Connecticut; University of Connecticut; Washington University (WUSTL); University of Montana System; University of Montana	Hurley, MM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.	hurley@exchange.uchc.edu		Ornitz, David/0000-0003-1592-7629; Gronowicz, Gloria/0000-0001-7158-3598	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD039952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046025, P30AR046026] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46025, P30 AR46026] Funding Source: Medline; NICHD NIH HHS [P01HD39952] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BANCROFT JD, 1990, ENZYME HISTOCHEMISTR, P387; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bellosta P, 2003, J BONE MINER RES, V18, P818, DOI 10.1359/jbmr.2003.18.5.818; Boyce BF, 2002, PRINCIPLES BONE BIOL, V1, P151; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; De Luca F, 1999, TRENDS ENDOCRIN MET, V10, P61, DOI 10.1016/S1043-2760(98)00120-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; Friedenstein A., 1990, BONE MINERAL RES, P243, DOI DOI 10.1016/B978-0-444-81371-8.50012-1; FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x; GOULET RW, 1994, J BIOMECH, V27, P375, DOI 10.1016/0021-9290(94)90014-0; Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; HURLEY MM, 2002, PRINCIPLES BONE BIOL, P825; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; KATAGIRI T, 1994, J CELL BIOCHEM, V79, P80; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lievens PMJ, 2003, J BIOL CHEM, V278, P17344, DOI 10.1074/jbc.M212710200; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Lucarelli E, 2002, INT J CANCER, V98, P344, DOI 10.1002/ijc.10203; LUKE Y, 2003, J NEUROSCI RES, V23, P883; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; NARUSAWA K, 1995, J BONE MINER RES, V10, P1853; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz David M., 2000, P197; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valverde-Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034	53	73	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27743	27752		10.1074/jbc.M314323200	http://dx.doi.org/10.1074/jbc.M314323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073186	hybrid			2022-12-27	WOS:000222120400109
J	Zijlstra, A; Aimes, RT; Zhu, D; Regazzoni, K; Kupriyanova, T; Seandel, M; Deryugina, EI; Quigley, JP				Zijlstra, A; Aimes, RT; Zhu, D; Regazzoni, K; Kupriyanova, T; Seandel, M; Deryugina, EI; Quigley, JP			Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; GROWTH-FACTOR; I COLLAGEN; MOLECULAR-CLONING; TISSUE INHIBITOR; ACTIVATION; EXPRESSION; SURFACE; MMP-13; PLASMINOGEN	We have demonstrated previously that new blood vessel formation induced by angiogenic growth factors in onplants placed on the chorioallantoic membrane (CAM) of the chick embryos is critically dependent on the cleavage of fibrillar collagen by a previously unidentified interstitial collagenase. In the present study we have used a quantitative CAM angiogenesis system to search for and functionally characterize host avian collagenases responsible for the collagen remodeling associated with angiogenesis. Among the matrix metalloproteinases ( MMPs) identified in the CAM onplant tissue, the chicken MMP-13 (chMMP-13) was the only enzyme whose induction and expression coincided with the onset of angiogenesis and blood vessel formation. The chMMP-13 cDNA has been cloned and recombinantly expressed. The chMMP-13 protein has been purified, characterized in vitro, and examined in situ in the CAM. MMP-13-positive cells appear in the CAM shortly after angiogenic stimulation and then accumulate in the collagen onplant tissue. Morphologically, the chMMP-13-containing cells appear as hematopoietic cells of monocyte/macrophage lineage. In vitro, the chMMP-13 proenzyme is rapidly and efficiently activated through the urokinase plasminogen activator/plasminogen/plasmin cascade into a collagenase capable of cleaving native but not the (r/r) mutant collagenase-resistant collagen. Surprisingly, nanogram levels of purified chMMP-13 elicit an angiogenic response in the CAM onplants comparable with that induced by the angiogenic growth factors. The chMMP-13-mediated response was efficiently blocked by select protease inhibitors indicating that plasmin-activated chMMP-13 can function as an angiogenic factor in vivo. Altogether, the results of this study extend the physiological role of MMP-13, previously associated with cartilage/bone resorption, to the collagen remodeling involved in the angiogenic cascade.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu	zijlstra, andries/G-4564-2013	zijlstra, andries/0000-0001-8460-8803	NATIONAL CANCER INSTITUTE [R01CA055852] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER; NCI NIH HHS [CA55852] Funding Source: Medline; NHLBI NIH HHS [HL31950] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Aimes RT, 1998, J CELL PHYSIOL, V174, P342, DOI 10.1002/(SICI)1097-4652(199803)174:3<342::AID-JCP8>3.3.CO;2-K; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Deryugina EI, 2002, CANCER RES, V62, P580; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hahn-Dantona EA, 2000, J BIOL CHEM, V275, P40827, DOI 10.1074/jbc.M006234200; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jeffrey JJ, 1998, BIOL EXTRAC, P15; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Lei HQ, 1999, BIOL REPROD, V60, P183, DOI 10.1095/biolreprod60.1.183; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; QUIGLEY JP, 1974, J BIOL CHEM, V249, P4306; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 2000, GENE DEV, V14, P163	39	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27633	27645		10.1074/jbc.M313617200	http://dx.doi.org/10.1074/jbc.M313617200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15066996	hybrid			2022-12-27	WOS:000222120400098
J	Li, D; Stuehr, DJ; Yeh, SR; Rousseau, DL				Li, D; Stuehr, DJ; Yeh, SR; Rousseau, DL			Heme distortion modulated by ligand-protein interactions in inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; HIGH-LEVEL EXPRESSION; STOPPED-FLOW ANALYSIS; ELECTRON-TRANSFER; OXYGENASE DOMAIN; L-ARGININE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; NO SYNTHASE; NONPLANAR PORPHYRINS	The catalytic center of nitric-oxide synthase ( NOS) consists of a thiolate-coordinated heme macrocycle, a tetrahydrobiopterin (H4B) cofactor, and an L-arginine (L-Arg)/N-hydroxyarginine substrate binding site. To determine how the interplay between the cofactor, the substrates, and the protein matrix housing the heme regulates the enzymatic activity of NOS, the CO-, NO-, and CN--bound adducts of the oxygenase domain of the inducible isoform of NOS (iNOS(oxy)) were examined with resonance Raman spectroscopy. The Raman data of the CO- bound ferrous protein demonstrated that the presence of L-Arg causes the Fe-C-O moiety to adopt a bent structure because of an H-bonding interaction whereas H4B binding exerts no effect. Similar behavior was found in the CN--bound ferric protein and in the nitric oxide (NO)-bound ferrous protein. In contrast, in the NO- bound ferric complexes, the addition of L-Arg alone does not affect the structural properties of the Fe-N-O moiety, but H4B binding forces it to adopt a bent structure, which is further enhanced by the subsequent addition of L-Arg. The differential interactions between the various heme ligands and the protein matrix in response to L-Arg and/or H4B binding is coupled to heme distortions, as reflected by the development of a variety of out-of-plane heme modes in the low frequency Raman spectra. The extent and symmetry of heme deformation modulated by ligand, substrate, and cofactor binding may provide important control over the catalytic and autoinhibitory properties of the enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM054806] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NIGMS NIH HHS [GM51491, GM54806, GM07288, GM08572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BARKIGIA KM, 1993, J AM CHEM SOC, V115, P3627, DOI 10.1021/ja00062a029; BARKIGIA KM, 1988, J AM CHEM SOC, V110, P7566, DOI 10.1021/ja00230a063; BARKIGIA KM, 1990, J AM CHEM SOC, V112, P8851, DOI 10.1021/ja00180a029; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; Blackwood ME, 1998, BIOCHEMISTRY-US, V37, P779, DOI 10.1021/bi972616f; Chen YS, 2002, BIOCHEMISTRY-US, V41, P4618, DOI 10.1021/bi011877t; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Deng TJ, 2001, J AM CHEM SOC, V123, P269, DOI 10.1021/ja001517d; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; Fukuzumi S, 1999, ANGEW CHEM INT EDIT, V38, P964, DOI 10.1002/(SICI)1521-3773(19990401)38:7<964::AID-ANIE964>3.0.CO;2-O; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HU SZ, 1993, J BIOL CHEM, V268, P6189; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; JORDAN T, 1995, PROTEIN SCI, V4, P716; Jung C, 2000, BIOCHEMISTRY-US, V39, P10163, DOI 10.1021/bi0003792; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; RENNER MW, 1994, J AM CHEM SOC, V116, P8582, DOI 10.1021/ja00098a019; Roberts SA, 2001, BIOCHEMISTRY-US, V40, P11327, DOI 10.1021/bi0109257; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sato H, 1998, FEBS LETT, V430, P377, DOI 10.1016/S0014-5793(98)00699-1; Scheele JS, 1997, J BIOL CHEM, V272, P12523, DOI 10.1074/jbc.272.19.12523; Schelvis JPM, 2002, BIOCHEMISTRY-US, V41, P5695, DOI 10.1021/bi0118456; Shelnutt J.A., 2000, PORPHYRIN HDB, V7, P168; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Tierney DL, 2000, J AM CHEM SOC, V122, P5405, DOI 10.1021/ja993685f; TSUBAKI M, 1990, BIOCHEMISTRY-US, V29, P8805, DOI 10.1021/bi00489a043; VALENZUELA JG, 1995, J EXP BIOL, V198, P1519; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Werner ER, 2003, EXP BIOL MED, V228, P1291, DOI 10.1177/153537020322801108; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; XIE QW, 1994, J BIOL CHEM, V269, P28500; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	70	63	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26489	26499		10.1074/jbc.M400968200	http://dx.doi.org/10.1074/jbc.M400968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066989	hybrid			2022-12-27	WOS:000222003000072
J	Mic, FA; Sirbu, IO; Duester, G				Mic, FA; Sirbu, IO; Duester, G			Retinoic acid synthesis controlled by Raldh2 is required early for limb bud initiation and then later as a proximodistal signal during apical ectodermal ridge formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZING ACTIVITY; VITAMIN-A; EMBRYONIC-DEVELOPMENT; LETHAL DEFECT; CHICK; MOUSE; EXPRESSION; OUTGROWTH; PATTERN; DHAND	We present evidence for the existence of two phases of retinoic acid ( RA) signaling required for vertebrate limb development. Limb RA synthesis is under the control of retinaldehyde dehydrogenase-2 (Raldh2) expressed in the lateral plate mesoderm, which generates a proximodistal RA signal during limb outgrowth. We report that Raldh2(-/-) embryos lack trunk mesodermal RA activity and fail to initiate forelimb development. This is associated with deficient expression of important limb determinants Tbx5, Meis2, and dHand needed to establish forelimb bud initiation, proximal identity, and the zone of polarizing activity (ZPA), respectively. Limb expression of these genes can be rescued by maternal RA treatment limited to embryonic day 8 (E8) during limb field establishment, but the mutant forelimbs obtained at E10 display a significant growth defect associated with a smaller apical ectodermal ridge (AER), referred to here as an apical ectodermal mound (AEM). In these RA-deficient forelimbs, a ZPA expressing Shh forms, but it is located distally adjacent to the Fgf8 expression domain in the AEM rather than posteriorly as is normal. AER formation in Raldh2(-/-) forelimbs is rescued by continuous RA treatment through E10, which restores RA to distal ectoderm fated to become the AER. Our findings indicate the existence of an early phase of RA signaling acting upstream of Tbx5, Meis2, and dHand, followed by a late phase of RA signaling needed to expand AER structure fully along the distal ectoderm. During ZPA formation, RA acts early to activate expression of dHand, but it is not required later for Shh activation.	Burnham Inst, Oncodev Biol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	duester@burnham.org	Sirbu, Ioan Ovidiu/F-1841-2010; Sirbu, Ioan Ovidiu/AAP-1290-2021	Sirbu, Ioan Ovidiu/0000-0003-1618-9656; Sirbu, Ioan Ovidiu/0000-0003-1618-9656	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62848, R01 GM062848-02, R01 GM062848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn DG, 2002, NATURE, V417, P754, DOI 10.1038/nature00814; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Begemann G, 2001, DEVELOPMENT, V128, P3081; Charite J, 2000, DEVELOPMENT, V127, P2461; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Grandel H, 2002, DEVELOPMENT, V129, P2851; Helms JA, 1996, DEVELOPMENT, V122, P1385; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; Mercader N, 2000, DEVELOPMENT, V127, P3961; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mic FA, 2003, DEV BIOL, V264, P191, DOI 10.1016/S0012-1606(03)00403-2; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Moon AM, 2000, DEVELOPMENT, V127, P989; Ng JK, 2002, DEVELOPMENT, V129, P5161; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2002, DEVELOPMENT, V129, P3563; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; Power SC, 1999, DEV DYNAM, V216, P469, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<469::AID-DVDY15>3.0.CO;2-3; Qin P, 2002, TERATOLOGY, V66, P224, DOI 10.1002/tera.10082; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SCOTT WJ, 1994, DEV BIOL, V165, P397, DOI 10.1006/dbio.1994.1262; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Stratford T, 1999, MECH DEVELOP, V81, P115, DOI 10.1016/S0925-4773(98)00231-7; Stratford T, 1996, CURR BIOL, V6, P1124, DOI 10.1016/S0960-9822(02)70679-9; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; TAMURA K, 1990, DEV BIOL, V140, P20, DOI 10.1016/0012-1606(90)90049-O; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	47	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26698	26706		10.1074/jbc.M401920200	http://dx.doi.org/10.1074/jbc.M401920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069081	hybrid			2022-12-27	WOS:000222003000096
J	Suda, T; Kamiyama, S; Suzuki, M; Kikuchi, N; Nakayama, K; Narimatsu, H; Jigami, Y; Aoki, T; Nishihara, S				Suda, T; Kamiyama, S; Suzuki, M; Kikuchi, N; Nakayama, K; Narimatsu, H; Jigami, Y; Aoki, T; Nishihara, S			Molecular cloning and characterization of a human multisubstrate specific nucleotide-sugar transporter homologous to Drosophila fringe connection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; GLYCOSYLATION; GLYCOSYLTRANSFERASE; ACETYLGALACTOSAMINE; LOCALIZATION; COMPLEX	Nucleotide-sugar transporters are crucial components in the synthesis of glycoconjugates. We identified a novel human nucleotide-sugar transporter gene, hfrc1, which is homologous to Drosophila melanogaster fringe connection, Caenorhabditis elegans sqv-7, and human UGTrel7. HFRC1 was localized within the Golgi apparatus following its transient expression in HCT116 cells. In human tissues, hfrc1 and UGTrel7 exhibited similar tissue distributions, although hfrc1 transcripts showed a 10 times greater abundance than those of UGTrel7. The heterologous expression of HFRC1 in the yeast revealed the multisubstrate specific transport activity of HFRC1 (for UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-glucose (UDP-Glc), and GDP-mannose (GDP-Man), with apparent Km values of 8.0, 2.1, and 0.14 muM, respectively). In the mammalian cells, HFRC1 transported UDP-GlcNAc and UDP-Glc, but not GDP-Man. Overexpression of the hfrc1 gene in HCT116 cells modulated the cell surface heparan sulfate expression status. These results suggest that HFRC1 takes part in the synthesis of heparan sulfate by regulating the level of UDP-GlcNAc, a donor substrate for the heparan sulfate synthases.	Soka Univ, Fac Engn, Dept Bioinformat, Cell Biol Lab, Tokyo 1928577, Japan; Tokyo Med Univ, Dept Surg, Shinjuku Ku, Tokyo 1600023, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058586, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Soka University; Tokyo Medical University; Seikagaku Corporation; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Nishihara, S (corresponding author), Soka Univ, Fac Engn, Dept Bioinformat, Cell Biol Lab, 1-236 Tangi Cho, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp	Narimatsu, Hisashi/M-4757-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Prydz K, 2000, J CELL SCI, V113, P193; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; UEMURA M, 1992, CANCER RES, V52, P6153; VERBERT A, 1987, BIOCHIMIE, V69, P91, DOI 10.1016/0300-9084(87)90240-9	36	50	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26469	26474		10.1074/jbc.M311353200	http://dx.doi.org/10.1074/jbc.M311353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082721	hybrid			2022-12-27	WOS:000222003000069
J	Vruchte, DT; Lloyd-Evans, E; Veldman, RJ; Neville, DCA; Dwek, RA; Platt, FM; van Blitterswijk, WJ; Sillence, DJ				Vruchte, DT; Lloyd-Evans, E; Veldman, RJ; Neville, DCA; Dwek, RA; Platt, FM; van Blitterswijk, WJ; Sillence, DJ			Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID-STORAGE DISEASES; MUCOLIPIDOSIS TYPE-IV; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; LIPID RAFTS; RETROGRADE TRANSPORT; CELL-SURFACE; ANNEXIN-II; LYSOSOMAL CHOLESTEROL; POLARIZED EPITHELIA	Glycosphingolipids are endocytosed and targeted to the Golgi apparatus but are mistargeted to lysosomes in sphingolipid storage disorders. Substrate reduction therapy utilizes imino sugars to inhibit glucosylceramide synthase and potentially abrogate the effects of storage. Niemann-Pick type C (NPC) disease is a disorder of intracellular transport where glycosphingolipids (GSLs) and cholesterol accumulate in endosomal compartments. The mechanisms of altered intracellular trafficking are not known but may involve the mistargeting and disrupted function of proteins associated with GSL membrane microdomains. Membrane microdomains were isolated by Triton X-100 and sucrose density gradient ultracentrifugation. High pressure liquid chromatography and mass spectrometric analysis of NPC1(-/-) mouse brain revealed large increases in GSL. Sphingosine was also found to be a component of membrane microdomains, and in NPC liver and spleen, large increases in cholesterol and sphingosine were found. GSL and cholesterol levels were increased in mutant NPC1-null Chinese hamster ovary cells as well as U18666A and progesterone induced NPC cell culture models. However, inhibition of GSL synthesis in NPC cells with N-butyldeoxygalactonojirimycin led to marked decreases in GSL but only small decreases in cholesterol levels. Both annexin 2 and 6, membrane-associated proteins that are important in endocytic trafficking, show distorted distributions in NPC cells. Altered BODIPY lactosylceramide targeting, decreased endocytic uptake of a fluid phase marker, and mistargeting of annexin 2 (phenotypes associated with NPC) are reversed by inhibition of GSL synthesis. It is suggested that accumulating GSL is part of a mislocalized membrane microdomain and is responsible for the deficit in endocytic trafficking found in NPC disease.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Oxford; Netherlands Cancer Institute	Sillence, DJ (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	dan@glycob.ox.ac.uk	Sillence, Dan J/J-9513-2019; Platt, Frances/G-1004-2010	Sillence, Dan J/0000-0003-4747-5655; Neville, David/0000-0003-2385-8993; Platt, Frances/0000-0001-7614-0403				Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; BREIMER ME, 1975, LIPIDS, V10, P17, DOI 10.1007/BF02532188; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Diakonova M, 1997, J CELL SCI, V110, P1199; DIAMOND JM, 1994, NATURE, V368, P291, DOI 10.1038/368291a0; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; FRANEY RJ, 1968, CLIN CHIM ACTA, V21, P255, DOI 10.1016/0009-8981(68)90135-6; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; George T, 2001, CELL MOL BIOL, V47, P1179; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Gu F, 2000, J BIOL CHEM, V275, P8154, DOI 10.1074/jbc.275.11.8154; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; Hunnam V, 2001, J AM SOC MASS SPECTR, V12, P1220, DOI 10.1016/S1044-0305(01)00309-9; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Khine AA, 1998, J CELL PHYSIOL, V176, P281, DOI 10.1002/(SICI)1097-4652(199808)176:2<281::AID-JCP6>3.0.CO;2-K; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Lloyd-Evans E, 2003, BIOCHEM J, V375, P561, DOI 10.1042/BJ20030613; Lusa S, 2001, J CELL SCI, V114, P1893; Malathi K, 2004, J CELL BIOL, V164, P547, DOI 10.1083/jcb.200310046; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Merrill AH, 2000, METHOD ENZYMOL, V312, P3; MILLERPODRAZA H, 1992, BIOCHIM BIOPHYS ACTA, V1124, P45, DOI 10.1016/0005-2760(92)90124-E; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NEVILLE DCA, 2004, IN PRESS ANAL BIOCH; Nix M, 2000, CELL DEATH DIFFER, V7, P413, DOI 10.1038/sj.cdd.4400666; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Pelled D, 2003, J BIOL CHEM, V278, P29496, DOI 10.1074/jbc.M302964200; Pentchev P G, 1980, Birth Defects Orig Artic Ser, V16, P225; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; PENTCHEV PG, 1980, BIOCHIM BIOPHYS ACTA, V619, P669, DOI 10.1016/0005-2760(80)90116-2; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; Romiti E, 2001, FEBS LETT, V506, P163, DOI 10.1016/S0014-5793(01)02878-2; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sillence DJ, 2003, TRENDS CELL BIOL, V13, P195, DOI 10.1016/S0962-8924(03)00033-3; Sillence DJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-24; Sillence DJ, 2000, J LIPID RES, V41, P1252; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STEINHART WL, 1984, INTERVIROLOGY, V21, P70, DOI 10.1159/000149504; Sugimoto Y, 2001, P NATL ACAD SCI USA, V98, P12391, DOI 10.1073/pnas.221181998; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANCE DE, 1967, J LIPID RES, V8, P621; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANIER MT, 1983, BIOCHIM BIOPHYS ACTA, V750, P178, DOI 10.1016/0005-2760(83)90218-7; Vanier MT, 1999, NEUROCHEM RES, V24, P481, DOI 10.1023/A:1022575511354; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; WAKI H, 1994, ANAL BIOCHEM, V222, P156, DOI 10.1006/abio.1994.1467; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898	92	138	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26167	26175		10.1074/jbc.M311591200	http://dx.doi.org/10.1074/jbc.M311591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078881	hybrid			2022-12-27	WOS:000222003000031
J	Miyazaki, M; Dobrzyn, A; Man, WC; Chu, KK; Sampath, H; Kim, HJ; Ntambi, JN				Miyazaki, M; Dobrzyn, A; Man, WC; Chu, KK; Sampath, H; Kim, HJ; Ntambi, JN			Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; TRANSGENIC MICE; PROTEIN-1 EXPRESSION; 3T3-L1 PREADIPOCYTES; INSULIN-RESISTANCE; NUCLEAR SREBP-1C; OLEOYL-COA; US ADULTS; CHOLESTEROL; LIVERS	Stearoyl-CoA desaturase (SCD) synthesizes oleate necessary for the biosynthesis of triglycerides and other lipids. Mice with a targeted disruption of the SCD1 gene are deficient in tissue oleate and have reduced expression of the sterol regulatory element-binding protein ( SREBP) and its target genes. The SREBP-1c isoform is a known mediator of insulin action on hepatic gene expression, but its transcriptional effects due to glucose or fructose are still unclear. We found that fructose compared with glucose is a stronger inducer of SREBP-1c and lipogenic gene expression, causing a dramatic increase in hepatic triglyceride levels. However, when fed to the SCD1-/- mice, fructose failed to induce SREBP-1 or lipogenic genes and the triglyceride levels were not increased. Instead fructose feeding caused a decrease in hepatic glycogen and plasma glucose levels. The induction of SREBP-1 and lipogenic gene expression as well as the levels of liver triglycerides, glycogen, and plasma glucose was partially restored when the fructose diet was supplemented with very high levels of oleate (20% by weight) but not with palmitate, stearate, or linoleate. Fructose in a long term feeding induced the expression of SCD1 and that of other lipogenic genes in the liver of SREBP-1c-/- mice, and a further increase in expression of these genes occurred when the fructose diet was supplemented with oleate. Our observations demonstrated that oleate produced by SCD is necessary for fructose-mediated induction of lipogenic gene expression through SREBP-1c-dependent and -independent mechanisms and suggested that SCD1 gene expression is important in lipid and carbohydrate homeostasis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JN (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Dobrzyn, Agnieszka/R-4073-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460	NIDDK NIH HHS [R01 DK162388] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN RC, 1966, J BIOL CHEM, V241, P5467; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Elliott SS, 2002, AM J CLIN NUTR, V76, P911, DOI 10.1093/ajcn/76.5.911; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Garbay B, 1998, J NEUROCHEM, V71, P1719; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; HARDY S, 2003, J BIOL CHEM, V12, P278; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lee Y, 2002, IMMUNOLOGY, V107, P435, DOI 10.1046/j.1365-2567.2002.01532.x; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Medina JM, 2002, J PHYSIOL-PARIS, V96, P265, DOI 10.1016/S0928-4257(02)00015-3; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2001, J BIOL CHEM, V276, P39455, DOI 10.1074/jbc.M106442200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Ntambi JM, 2001, J MOL NEUROSCI, V16, P273, DOI 10.1385/JMN:16:2-3:273; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; ROEHRIG KL, 1974, ANAL BIOCHEM, V58, P414, DOI 10.1016/0003-2697(74)90210-3; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimizu S, 2003, J BIOL CHEM, V278, P43095, DOI 10.1074/jbc.M306880200; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	65	224	240	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25164	25171		10.1074/jbc.M402781200	http://dx.doi.org/10.1074/jbc.M402781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066988	hybrid			2022-12-27	WOS:000221827900032
J	Salazar, G; Love, R; Styers, ML; Werner, E; Peden, A; Rodriguez, S; Gearing, M; Wainer, BH; Faundez, V				Salazar, G; Love, R; Styers, ML; Werner, E; Peden, A; Rodriguez, S; Gearing, M; Wainer, BH; Faundez, V			AP-3-dependent mechanisms control the targeting of a chloride channel (ClC-3) in neuronal and non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE BIOGENESIS; IN-VITRO; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; PC12 CELLS; ZINC; PROTEIN; TRANSPORTER; ENDOSOMES; GLUTAMATE	Adaptor protein (AP)-2 and AP-3-dependent mechanisms control the sorting of membrane proteins into synaptic vesicles. Mouse models deficient in AP-3, mocha, develop a neurological phenotype of which the central feature is an alteration of the luminal synaptic vesicle composition. This is caused by a severe reduction of vesicular levels of the zinc transporter 3 (ZnT3). It is presently unknown whether this mocha defect is restricted to ZnT3 or encompasses other synaptic vesicle proteins capable of modifying synaptic vesicle contents, such as transporters or channels. In this study, we identified a chloride channel, ClC-3, whose level in synaptic vesicles and hippocampal mossy fiber terminals was reduced in the context of the mocha AP-3 deficiency. In PC-12 cells, ClC-3 was present in transferrin receptor-positive endosomes, where it was targeted to synaptic-like microvesicles (SLMV) by a mechanism sensitive to brefeldin A, a signature of the AP-3-dependent route of SLMV biogenesis. ClC-3 was packed in SLMV along with the AP-3-targeted synaptic vesicle protein ZnT3. Co-segregation of ClC-3 and ZnT3 to common intracellular compartments was functionally significant as revealed by increased vesicular zinc transport with increased ClC3 expression. Our work has identified a synaptic vesicle protein in which trafficking to synaptic vesicles is regulated by AP-3. In addition, our findings indicate that ClC-3 and ZnT3 reside in a common vesicle population where they functionally interact to determine vesicle luminal composition.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Genentech Inc, San Francisco, CA 94080 USA	Emory University; Emory University; Emory University; Roche Holding; Genentech	Faundez, V (corresponding author), Whitehead Biomed Res Bldg,615 Michael St,Rm 446, Atlanta, GA 30322 USA.	faundez@cellbio.emory.edu		Love, Rachal/0000-0002-7038-8747; Werner, Erica/0000-0002-8183-1601; Peden, Andrew/0000-0003-0144-7712; Faundez, Victor/0000-0002-2114-5271	NINDS NIH HHS [R01-NS42599-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042599] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Blumstein J, 2001, J NEUROSCI, V21, P8034, DOI 10.1523/JNEUROSCI.21-20-08034.2001; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Faundez VV, 2000, MOL BIOL CELL, V11, P2591, DOI 10.1091/mbc.11.8.2591; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Lim C, 1997, J COMP NEUROL, V385, P325, DOI 10.1002/(SICI)1096-9861(19970901)385:3<325::AID-CNE1>3.0.CO;2-5; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Murakawa R, 2001, J COMP NEUROL, V429, P113, DOI 10.1002/1096-9861(20000101)429:1<113::AID-CNE9>3.0.CO;2-D; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Reimer RJ, 2001, CURR OPIN CELL BIOL, V13, P417, DOI 10.1016/S0955-0674(00)00230-1; Salazar G, 2004, MOL BIOL CELL, V15, P575, DOI 10.1091/mbc.E03-06-0401; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Seong E, 2004, TRENDS GENET, V20, P59, DOI 10.1016/j.tig.2003.12.006; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; Yang W, 2000, J CELL SCI, V113, P4077; ZALEWSKI PD, 1994, J HISTOCHEM CYTOCHEM, V42, P877, DOI 10.1177/42.7.8014471; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	52	95	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25430	25439		10.1074/jbc.M402331200	http://dx.doi.org/10.1074/jbc.M402331200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073168	hybrid			2022-12-27	WOS:000221827900066
J	Singh, SV; Herman-Antosiewicz, A; Singh, AV; Lew, KL; Srivastava, SK; Kamath, R; Brown, KD; Zhang, L; Baskaran, R				Singh, SV; Herman-Antosiewicz, A; Singh, AV; Lew, KL; Srivastava, SK; Kamath, R; Brown, KD; Zhang, L; Baskaran, R			Sulforaphane-induced G(2)/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; DNA-DAMAGE; HELICOBACTER-PYLORI; UP-REGULATION; GLUTATHIONE; APOPTOSIS; ISOTHIOCYANATES; VEGETABLES; CHK1; ATR	Previously, we showed that sulforaphane (SFN), a naturally occurring cancer chemopreventive agent, effectively inhibits proliferation of PC-3 human prostate cancer cells by causing caspase-9- and caspase-8-mediated apoptosis. Here, we demonstrate that SFN treatment causes an irreversible arrest in the G(2)/M phase of the cell cycle. Cell cycle arrest induced by SFN was associated with a significant decrease in protein levels of cyclin B1, cell division cycle (Cdc) 25B, and Cdc25C, leading to accumulation of Tyr-15-phosphorylated (inactive) cyclin-dependent kinase 1. The SFN-induced decline in Cdc25C protein level was blocked in the presence of proteasome inhibitor lactacystin, but lactacystin did not confer protection against cell cycle arrest. Interestingly, SFN treatment also resulted in a rapid and sustained phosphorylation of Cdc25C at Ser-216, leading to its translocation from the nucleus to the cytoplasm because of increased binding with 14-3-3beta. Increased Ser-216 phosphorylation of Cdc25C upon treatment with SFN was the result of activation of checkpoint kinase 2 (Chk2), which was associated with Ser-1981 phosphorylation of ataxia telangiectasia-mutated, generation of reactive oxygen species, and Ser-139 phosphorylation of histone H2A.X, a sensitive marker for the presence of DNA double-strand breaks. Transient transfection of PC-3 cells with Chk2-specific small interfering RNA duplexes significantly attenuated SFN-induced G(2)/M arrest. HCT116 human colon cancer-derived Chk2(-/-) cells were significantly more resistant to G(2)/M arrest by SFN compared with the wild type HCT116 cells. These findings indicate that Chk2-mediated phosphorylation of Cdc25C plays a major role in irreversible G(2)/M arrest by SFN. Activation of Chk2 in response to DNA damage is well documented, but the present study is the first published report to link Chk2 activation to cell cycle arrest by an isothiocyanate.	Univ Pittsburgh, Sch Med, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Hillman Canc Ctr, Res Pavil Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu	Zhang, Lin/A-7389-2009	Zhang, Lin/0000-0003-0018-3903; Herman-Antosiewicz, Anna/0000-0003-0526-2168	NATIONAL CANCER INSTITUTE [R01CA101753] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945, CA101753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; Bonnesen C, 2001, CANCER RES, V61, P6120; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chiao JW, 2002, INT J ONCOL, V20, P631; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fimognari C, 2002, CARCINOGENESIS, V23, P581, DOI 10.1093/carcin/23.4.581; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haristoy X, 2003, ANTIMICROB AGENTS CH, V47, P3982, DOI 10.1128/AAC.47.12.3982-3984.2003; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Kohlmeier L, 1997, FASEB J, V11, P2141; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Liu QH, 2000, GENE DEV, V14, P1448; Maheo K, 1997, CANCER RES, V57, P3649; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Morgan DO, 1992, CURR OPIN GENET DEV, V2, P33, DOI 10.1016/S0959-437X(05)80318-1; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shishu, 2003, PLANTA MED, V69, P184, DOI 10.1055/s-2003-37713; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Wu LY, 2001, J HYPERTENS, V19, P1819, DOI 10.1097/00004872-200110000-00016; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987; Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; ZHANG YS, 1994, CANCER RES, V54, pS1976; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	52	308	313	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25813	25822		10.1074/jbc.M313538200	http://dx.doi.org/10.1074/jbc.M313538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073169	hybrid			2022-12-27	WOS:000221827900112
J	Anuradha, S; Muniyappa, K				Anuradha, S; Muniyappa, K			Saccharomyces cerevisiae hop1 zinc finger motif is the minimal region required for its function in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; DNA-BINDING DOMAIN; MEIOTIC CHROMOSOMES; QUADRUPLEX DNA; TELOMERIC DNA; HOMOLOGOUS CHROMOSOMES; CIRCULAR-DICHROISM; YEAST ADR1; MEIOSIS; SYNAPSIS	Saccharomyces cerevisiae meiosis-specific HOP1, which encodes a core component of synaptonemal complex, plays a key role in proper pairing of homologous chromosomes and processing of meiotic DNA double strand breaks. Isolation and analysis of hop1 mutants indicated that these functions require Cys(371) of Hop1 embedded in a region ( residues 343 - 378) sharing homology to a zinc finger motif (ZnF). However, the precise biochemical function of Hop1, or its putative ZnF, in these processes is poorly understood. Our previous studies revealed that Hop1 is a DNA-binding protein, showed substantially higher binding affinity for G4 DNA, and enhances its formation. We report herein that ZnF appears to be sufficient for both zinc as well as DNA-binding activities. Molecular modeling studies suggested that Hop1 ZnF differs from the previously characterized natural ZnFs. The zinc-binding assay showed that the affinity for zinc is weaker for C371S ZnF mutant compared with the wild type (WT) ZnF. Analysis of CD spectra indicated that zinc and DNA induce substantial conformational changes in WT ZnF, but not in C371S ZnF mutant. The results from a number of different experimental approaches suggested that the DNA-binding properties of ZnF are similar to those of full-length Hop1 and that interaction with DNA rich in G residues is particularly robust. Significantly, WT ZnF by itself, but not C371S mutant, was able to bind duplex DNA and promote interstitial pairing of DNA double helices via the formation of guanine quartets. Together, these results implicate a direct role for Hop1 in pairing of homologous chromosomes during meiosis.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Anuradha S, 2004, NUCLEIC ACIDS RES, V32, P2378, DOI 10.1093/nar/gkh559; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Arthanari H, 2001, CHEM BIOL, V8, P221, DOI 10.1016/S1074-5521(01)00007-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Brown BA, 1998, BIOCHEMISTRY-US, V37, P16325, DOI 10.1021/bi981354u; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; de los Santos T, 1999, J BIOL CHEM, V274, P1783, DOI 10.1074/jbc.274.3.1783; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FRIEDMAN DB, 1994, GENETICS, V136, P449; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; Hiraoka Y, 1998, GENES CELLS, V3, P405, DOI 10.1046/j.1365-2443.1998.00205.x; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; Hollingsworth NM, 1997, GENETICS, V147, P33; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; Isalan M, 2001, BIOCHEMISTRY-US, V40, P830, DOI 10.1021/bi001728v; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kironmai KM, 1998, MOL CELL BIOL, V18, P1424, DOI 10.1128/MCB.18.3.1424; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Muniyappa K, 2000, MOL CELL BIOL, V20, P1361, DOI 10.1128/MCB.20.4.1361-1369.2000; NAG DK, 1995, GENETICS, V141, P75; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; Rockmill B, 1998, GENE DEV, V12, P2574, DOI 10.1101/gad.12.16.2574; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Salazar M, 1996, BIOCHEMISTRY-US, V35, P16110, DOI 10.1021/bi961442j; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shafer RH, 2001, BIOPOLYMERS, V56, P209, DOI 10.1002/1097-0282(2000/2001)56:3<209::AID-BIP10018>3.0.CO;2-Y; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TREICH I, 1991, J BIOL CHEM, V266, P21971; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	62	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28961	28969		10.1074/jbc.M403727200	http://dx.doi.org/10.1074/jbc.M403727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123624	hybrid			2022-12-27	WOS:000222445300018
J	Schiaretti, F; Bettati, S; Viappiani, C; Mozzarelli, A				Schiaretti, F; Bettati, S; Viappiani, C; Mozzarelli, A			pH dependence of tryptophan synthase catalytic mechanism - I. The first stage, the beta-elimination reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LIGAND COMPLEXES; MONOVALENT CATION ACTION; ALPHA(2)BETA(2) COMPLEX; ESCHERICHIA-COLI; L-SERINE; ALLOSTERIC REGULATION; BIENZYME COMPLEX; ALPHA-SUBUNIT; FREE-ENERGY; INTERSUBUNIT COMMUNICATION	The pyridoxal 5'-phosphate-dependent beta-subunit of the tryptophan synthase alpha(2)beta(2) complex catalyzes the condensation of L-serine with indole to form L-tryptophan. The first stage of the reaction is a beta-elimination that involves a very fast interconversion of the internal aldimine in a highly fluorescent L-serine external aldimine that decays, via the alpha-carbon proton removal and beta-hydroxyl group release, to the alpha-aminoacrylate Schiff base. This reaction is influenced by protons, monovalent cations, and alpha-subunit ligands that modulate the distribution between open and closed conformations. In order to identify the ionizable residues that might assist catalysis, we have investigated the pH dependence of the rate of the external aldimine decay by rapid scanning UV-visible absorption and single wavelength fluorescence stopped flow. In the pH range 6-9, the reaction was found to be biphasic with the first phase (rate constants k(1)) accounting for more than 70% of the signal change. In the absence of monovalent cations or in the presence of sodium and potassium ions, the pH dependence of k1 exhibits a bell shaped profile characterized by a pK(a1) of about 6 and a pK(a2) of about 9, whereas in the presence of cesium ions, the pH dependence exhibits a saturation profile characterized by a single pK(a) of 9. The presence of the allosteric effector indole acetylglycine increases the rate of reaction without altering the pH profile and pKa values. By combining structural information for the internal aldimine, the external aldimine, and the alpha-aminoacrylate with kinetic data on the wild type enzyme and beta-active site mutants, we have tentatively assigned pK(a1) to betaAsp-305 and pK(a2) to betaLys-87. The loss of pK(a1) in the presence of cesium ions might be due to a shift to lower values, caused by the selective stabilization of a closed form of the beta-subunit.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Dept Publ Hlth, I-43100 Parma, Italy; Univ Parma, Dept Phys, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy	University of Parma; University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Mozzarelli, A (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci 23-A, I-43100 Parma, Italy.	biochim@unipr.it	Bettati, Stefano/V-9975-2018; Mozzarelli, Andrea/C-3615-2014; Viappiani, Cristiano/AAC-7579-2019	Bettati, Stefano/0000-0001-6787-0594; Mozzarelli, Andrea/0000-0003-3762-0062; Viappiani, Cristiano/0000-0001-7470-4770				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Burnett JC, 2000, BIOCHEMISTRY-US, V39, P1622, DOI 10.1021/bi991724u; Burnett JC, 2001, PROTEINS, V42, P355, DOI 10.1002/1097-0134(20010215)42:3<355::AID-PROT60>3.0.CO;2-F; Cozzini P, 2004, CURR MED CHEM, V11, P3093, DOI 10.2174/0929867043363929; Cozzini P, 2002, J MED CHEM, V45, P2469, DOI 10.1021/jm0200299; CRAWFORD IP, 1960, BIOCHIM BIOPHYS ACTA, V45, P405, DOI 10.1016/0006-3002(60)91474-8; DIXON HBF, 1991, BIOCHEM J, V278, P279, DOI 10.1042/bj2780279; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; Ferrari D, 2003, BIOCHEMISTRY-US, V42, P7807, DOI 10.1021/bi034291a; Ferrari D, 2001, BIOCHEMISTRY-US, V40, P7421, DOI 10.1021/bi002892l; FERSHT A, 1984, ENZYME STRUCTURE MEC, P155; Fornabaio M, 2003, J MED CHEM, V46, P4487, DOI 10.1021/jm0302593; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; Hur O, 2002, BIOCHEMISTRY-US, V41, P9991, DOI 10.1021/bi025568u; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Kellogg GE, 2000, EUR J MED CHEM, V35, P651, DOI 10.1016/S0223-5234(00)00167-7; KELLOGG GE, 1991, J COMPUT AID MOL DES, V5, P545, DOI 10.1007/BF00135313; Kellogg GE, 2001, J COMPUT AID MOL DES, V15, P381, DOI 10.1023/A:1011136228678; Kulik V, 2002, J MOL BIOL, V324, P677, DOI 10.1016/S0022-2836(02)01109-9; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; Marabotti A, 2001, J BIOL CHEM, V276, P17747, DOI 10.1074/jbc.M011781200; Marabotti A, 2000, BBA-PROTEIN STRUCT M, V1476, P287, DOI 10.1016/S0167-4838(99)00242-3; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1989, J BIOL CHEM, V264, P6280; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 2000, J BIOL CHEM, V275, P6956, DOI 10.1074/jbc.275.10.6956; Osborne A, 2003, J BIOL CHEM, V278, P44083, DOI 10.1074/jbc.M308276200; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PHILLIPS RS, 1991, BIOCHEMISTRY-US, V30, P5927, DOI 10.1021/bi00238a017; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Ro HS, 1999, J BIOL CHEM, V274, P31189, DOI 10.1074/jbc.274.44.31189; Ro HS, 1999, J BIOL CHEM, V274, P36439, DOI 10.1074/jbc.274.51.36439; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Sam MD, 1999, BIOCHEMISTRY-US, V38, P6576, DOI 10.1021/bi9901580; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Vaccari S, 1996, BIOPHYS CHEM, V61, P9, DOI 10.1016/0301-4622(96)00020-8; Weyand M, 2002, J BIOL CHEM, V277, P10653, DOI 10.1074/jbc.M111031200; Weyand M, 2002, J BIOL CHEM, V277, P10647, DOI 10.1074/jbc.M111285200; Weyand M, 2000, J BIOL CHEM, V275, P41058, DOI 10.1074/jbc.C000479200; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7131, DOI 10.1021/bi982919p; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029	64	10	10	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29572	29582		10.1074/jbc.M401895200	http://dx.doi.org/10.1074/jbc.M401895200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117965	hybrid			2022-12-27	WOS:000222445300092
J	Konig, S; Hinard, V; Arnaudeau, S; Holzer, N; Potter, G; Bader, CR; Bernheim, L				Konig, S; Hinard, V; Arnaudeau, S; Holzer, N; Potter, G; Bader, CR; Bernheim, L			Membrane hyperpolarization triggers myogenin and myocyte enhancer factor-2 expression during human myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; SKELETAL-MUSCLE DIFFERENTIATION; FUSION-COMPETENT MYOBLASTS; CREATINE-KINASE ENHANCER; REGULATORY ELEMENTS; POTASSIUM CHANNELS; KIR2.1 CHANNELS; SATELLITE CELLS; K+ CURRENT; GENE	It is widely thought that myogenin is one of the earliest detectable markers of skeletal muscle differentiation. Here we show that, during human myoblast differentiation, an inward rectifier K+ channel (Kir2.1) and its associated hyperpolarization trigger expression and activity of the myogenic transcription factors, myogenin and myocyte enhancer factor-2 (MEF2). Furthermore, Kir2.1 current precedes and is required for the developmental increase in expression/activity of myogenin and MEF2. Drugs or antisense reducing Kir2.1 current diminished or suppressed fusion as well as expression/ activity of myogenin and MEF2. In contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase ( a pathway controlling initiation of the myogenic program) that inhibited both myogenin/MEF2 expression and fusion, did not affect Kir2.1 current. This non-blockade by LY294002 indicates that Kir2.1 acts upstream of myogenin and MEF2. We propose that Kir2.1 channel activation is a required key early event that initiates myogenesis by turning on myogenin and MEF2 transcription factors via a hyperpolarization-activated Ca2+-dependent pathway.	Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Hop Cantonal Univ Geneva, Dept Neurosci Clin & Dermatol, Div Rech Clin Neuromusculaire, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Konig, S (corresponding author), Ctr Med Univ Geneva, Dept Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Stephane.Konig@medecine.unige.ch		Koenig, Stephane/0000-0002-0801-279X				ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAROFFIO A, 1993, MUSCLE NERVE, V16, P498, DOI 10.1002/mus.880160511; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; Bijlenga P, 1998, J PHYSIOL-LONDON, V512, P317, DOI 10.1111/j.1469-7793.1998.317be.x; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; DallAsta V, 1997, EXP CELL RES, V231, P260, DOI 10.1006/excr.1996.3469; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Espinos E, 2001, NEUROMUSCULAR DISORD, V11, P341, DOI 10.1016/S0960-8966(00)00204-2; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Hamann M, 1995, J PHYSIOL-LONDON, V489, P791, DOI 10.1113/jphysiol.1995.sp021092; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Liu JH, 1999, BRIT J PHARMACOL, V126, P245, DOI 10.1038/sj.bjp.0702321; Liu JH, 1998, J PHYSIOL-LONDON, V510, P467, DOI 10.1111/j.1469-7793.1998.467bk.x; Liu JH, 2003, DEVELOPMENT, V130, P3437, DOI 10.1242/dev.00562; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016	34	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28187	28196		10.1074/jbc.M313932200	http://dx.doi.org/10.1074/jbc.M313932200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15084602	hybrid			2022-12-27	WOS:000222265400047
J	Milutinovic, S; Brown, SE; Zhuang, QL; Szyf, M				Milutinovic, S; Brown, SE; Zhuang, QL; Szyf, M			DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN MECP2; CPG METHYLATION; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; GROWTH-REGULATION; DOWN-REGULATION; HUMAN CANCERS; METHYLTRANSFERASE; PROMOTER; HYPOMETHYLATION	DNA methyltransferase 1 (DNMT1) catalyzes the postreplication methylation of DNA and is responsible for maintaining the DNA methylation pattern during cell division. A long list of data supports a role for DNMT1 in cellular transformation and inhibitors of DNMT1 were shown to have antitumorigenic effects. It was long believed that DNMT1 promoted tumorigenesis by maintaining the hypermethylated and silenced state of tumor suppressor genes. We have previously shown that DNMT1 knock down by either antisense oligonucleotides directed at DNMT1 or expressed antisense activates a number of genes involved in stress response and cell cycle arrest by a DNA methylation-independent mechanism. In this report we demonstrate that antisense knock down of DNMT1 in human lung carcinoma A549 and embryonal kidney HEK293 cells induces gene expression by a mechanism that does not involve either of the known epigenomic mechanisms, DNA methylation, histone acetylation, or histone methylation. The mechanism of activation of the cell cycle inhibitor p21 and apoptosis inducer BIK by DNMT1 inhibition is independent of the mechanism of activation of the same genes by histone deacetylase inhibition. We determine whether DNMT1 knock down activates one of the nodal transcription activation pathways in the cell and demonstrate that DNMT1 activates Sp1 response elements. This activation of Sp1 response does not involve an increase in either Sp1 or Sp3 protein levels in the cell or the occupancy of the Sp1 elements with these proteins. The methylation-independent regulation of Sp1 elements by DNMT1 unravels a novel function for DNMT1 in gene regulation. DNA methylation was believed to be a mechanism for suppression of CG-rich Sp1-bearing promoters. Our data suggest a fundamentally different and surprising role for DNMT1 regulation of CG-rich genes by a mechanism independent of DNA methylation and histone acetylation. The implications of our data on the biological roles of DNMT1 and the therapeutic potential of DNMT1 inhibitors as anticancer agents are discussed.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Chen T, 2002, ARCH BIOCHEM BIOPHYS, V408, P171, DOI 10.1016/S0003-9861(02)00564-7; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Gupta A, 2003, CANCER RES, V63, P664; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERMAN JG, 1995, CANCER RES, V55, P4525; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; JONES PA, 1983, RECENT RES CANCER, V84, P202; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6; Szyf M, 2002, METHODS, V27, P184, DOI 10.1016/S1046-2023(02)00073-7; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wu J C, 1985, Prog Clin Biol Res, V198, P119; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	54	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27915	27927		10.1074/jbc.M312823200	http://dx.doi.org/10.1074/jbc.M312823200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087453	hybrid			2022-12-27	WOS:000222265400013
J	Jeromin, A; Muralidhar, D; Parameswaran, MN; Roder, J; Fairwell, T; Scarlata, S; Dowal, L; Mustafi, SM; Chary, KVR; Sharma, Y				Jeromin, A; Muralidhar, D; Parameswaran, MN; Roder, J; Fairwell, T; Scarlata, S; Dowal, L; Mustafi, SM; Chary, KVR; Sharma, Y			N-terminal myristoylation regulates calcium-induced conformational changes in neuronal calcium sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ SIGNAL-TRANSDUCTION; BINDING-PROTEINS; FREQUENIN; RECOVERIN; CELLS; SWITCH; CHROMAFFIN; EXPRESSION; FAMILY; VILIP	Neuronal calcium sensor-1 (NCS-1), a Ca2+-binding protein, plays an important role in the modulation of neurotransmitter release and phosphatidylinositol signaling pathway. It is known that the physiological activity of NCS-1 is governed by its myristoylation. Here, we present the role of myristoylation of NSC-1 in governing Ca2+ binding and Ca2+-induced conformational changes in NCS-1 as compared with the role in the nonmyristoylated protein. The Ca-45 binding and isothermal titration calorimetric data show that myristoylation increases the degree of cooperativity; thus, the myristoylated NCS-1 binds Ca2+ more strongly ( with three Ca2+ binding sites) than the non-myristoylated one ( with two Ca2+ binding sites). Both forms of protein show different conformational features in far-UV CD when titrated with Ca2+. Large conformational changes were seen in the near-UV CD with more changes in the case of nonmyristoylated protein than the myristoylated one. Although the changes in the far-UV CD upon Ca2+ binding were not seen in E120Q mutant ( disabling EF-hand 3), the near-UV CD changes in conformation also were not influenced by this mutation. The difference in the binding affinity of myristoylated and non-myristoylated proteins to Ca2+ also was reflected by Trp fluorescence. Collisional quenching by iodide showed more inaccessibility of the fluorophore in the myristoylated protein. Mg2+-induced changes in near-UV CD are different from Ca2+-induced changes, indicating ion selectivity. 8-Anilino-1-naphthalene sulfonic acid binding data showed solvation of the myristoyl group in the presence of Ca2+, which could be attributed to the myristoyl-dependent conformational changes in NCS-1. These results suggest that myristoylation influences the protein conformation and Ca2+ binding, which might be crucial for its physiological functions.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Baylor Coll Med, Houston, TX 77030 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; NHLBI, NIH, Bethesda, MD 20892 USA; SUNY Stony Brook, Basic Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Baylor College of Medicine; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tata Institute of Fundamental Research (TIFR)	Sharma, Y (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	yogendra@ccmb.res.in	Roder, John/G-6468-2013					Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Bhatnagar RS, 1999, BBA-MOL CELL BIOL L, V1441, P162, DOI 10.1016/S1388-1981(99)00155-9; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; COX JA, 1994, J BIOL CHEM, V269, P32807; Ehrlich LS, 1996, BIOCHEMISTRY-US, V35, P3933, DOI 10.1021/bi952337x; Fasman G.D., 1996, CIRCULAR DICHROISM C; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; Joseph R, 1983, PRINCIPLES FLUORESCE; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; Kretsinger RH, 1975, CALCIUM TRANSPORT CO, P469; LADANT D, 1995, J BIOL CHEM, V270, P3179; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rousset M, 2003, J BIOL CHEM, V278, P7019, DOI 10.1074/jbc.M209537200; SCHELLMAN JA, 1962, J CHEM PHYS, V37, P2114, DOI 10.1063/1.1733432; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; Sippy T, 2003, NAT NEUROSCI, V6, P1031, DOI 10.1038/nn1117; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Weiergraber OH, 2003, J BIOL CHEM, V278, P22972, DOI 10.1074/jbc.M300447200; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOODY RW, 1967, J CHEM PHYS, V46, P4927, DOI 10.1063/1.1840658; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; ZOZULYA S, 1995, METHOD ENZYMOL, V250, P383; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27158	27167		10.1074/jbc.M312172200	http://dx.doi.org/10.1074/jbc.M312172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102861	hybrid			2022-12-27	WOS:000222120400042
J	Tomita, T; Noguchi, K; Mimuro, H; Ukaji, F; Ito, K; Sugawara-Tomita, N; Hashimoto, Y				Tomita, T; Noguchi, K; Mimuro, H; Ukaji, F; Ito, K; Sugawara-Tomita, N; Hashimoto, Y			Pleurotolysin, a novel sphingomyelin-specific two-component cytolysin from the edible mushroom Pleurotus ostreatus, assembles into a transmembrane pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; FLAMMULINA-VELUTIPES; ALPHA-TOXIN; PROTEIN; CHOLESTEROL; MEMBRANES; OLIGOMERIZATION; FLAMMUTOXIN; QUANTITIES; HEMOLYSINS	Self-assembling, pore-forming cytolysins are illustrative molecules for the study of the assembly and membrane insertion of transmembrane pores. Here we purified pleurotolysin, a novel sphingomyelin-specific two-component cytolysin from the basidiocarps of Pleurotus ostreatus and studied the pore-forming properties of the cytolysin. Pleurotolysin consisted of non-associated A (17 kDa) and B (59 kDa) components, which cooperatively caused leakage of potassium ions from human erythrocytes and swelling of the cells at nanomolar concentrations, leading to colloid-osmotic hemolysis. Hemolytic assays in the presence of poly( ethylene glycol) s with different hydrodynamic diameters suggested that pleurotolysin formed membrane pores with a functional diameter of 3.8-5 nm. Pleurotolysin-induced lysis of human erythrocytes was specifically inhibited by the addition of sphingomyelin-cholesterol liposomes to the extracellular space. Pleurotolysin A specifically bound to sphingomyelin-cholesterol liposomes and caused leakage of the internal carboxyfluorescein in concert with pleurotolysin B. Experiments including solubilization of pleurotolysin-treated erythrocytes with 2% (w/v) SDS at 25degreesC and SDS-polyacrylamide gel electrophoresis/Western immunoblotting showed that pleurotolysin A and B bound to human erythrocytes in this sequence and assembled into an SDS-stable, 700-kDa complex. Ring-shaped structures with outer and inner diameters of 14 and 7 nm, respectively, were isolated from the solubilized erythrocyte membranes by a sucrose gradient centrifugation. Pleurotolysin A and B formed an SDS-stable, ring-shaped complex of the same dimensions on sphingomyelin-cholesterol liposomes as well.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan; Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama 3888570, Japan	Tohoku University; Saitama University	Tomita, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan.	tomita@biochem.tohoku.ac.jp						Berne S, 2002, BBA-GEN SUBJECTS, V1570, P153, DOI 10.1016/S0304-4165(02)00190-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BERNHEIMER AW, 1979, BIOCHIM BIOPHYS ACTA, V585, P451, DOI 10.1016/0304-4165(79)90090-4; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Espinar MTF, 1997, CURR GENET, V32, P420, DOI 10.1007/s002940050297; FAULSTICH H, 1983, BIOCHEMISTRY-US, V22, P4574, DOI 10.1021/bi00288a035; FREEDMAN JC, 1979, J GEN PHYSIOL, V74, P157, DOI 10.1085/jgp.74.2.157; GERLACH E, 1963, BIOCHEM Z, V337, P477; KUSUMI A, 1986, BIOCHIM BIOPHYS ACTA, V854, P307, DOI 10.1016/0005-2736(86)90124-0; LIN JY, 1974, NATURE, V252, P235, DOI 10.1038/252235a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; OLDFIELD E, 1978, BIOCHEMISTRY-US, V17, P2727, DOI 10.1021/bi00607a006; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROUSER G, 1968, BIOLOGICAL MEMBRANES, P5; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Sepcic K, 2003, EUR J BIOCHEM, V270, P1199, DOI 10.1046/j.1432-1033.2003.03480.x; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; Tadjibaeva G, 2000, BBA-BIOMEMBRANES, V1467, P431, DOI 10.1016/S0005-2736(00)00240-6; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; Tomita T, 1997, BIOSCI BIOTECH BIOCH, V61, P565, DOI 10.1271/bbb.61.565; TOMITA T, 1992, J BIOL CHEM, V267, P13391; WADSTROM T, 1971, BIOCHIM BIOPHYS ACTA, V242, P308, DOI 10.1016/0005-2744(71)90110-0; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; WILMSEN HU, 1985, EUR BIOPHYS J BIOPHY, V12, P199; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	33	92	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26975	26982		10.1074/jbc.M402676200	http://dx.doi.org/10.1074/jbc.M402676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084605	hybrid			2022-12-27	WOS:000222120400023
J	Horke, S; Reumann, K; Schweizer, M; Will, H; Heise, T				Horke, S; Reumann, K; Schweizer, M; Will, H; Heise, T			Nuclear trafficking of La protein depends on a newly identified nucleolar localization signal and the ability to bind RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SS-B AUTOANTIGEN; LUPUS ANTIGEN-LA; RECOGNITION MOTIF; SMALL RIBONUCLEOPROTEINS; RIBOSOMAL-RNA; NASCENT RNA; VIRUS-RNA; DOMAINS; TRANSLATION; PRECURSOR	Here we provide evidence for an interaction-dependent subnuclear trafficking of the human La (hLa) protein, known as transient interaction partner of a variety of RNAs. Among these, precursor transcripts of certain RNAs are located in the nucleoplasm or nucleolus. Here we examined which functional domains of hLa are involved in its nuclear trafficking. By using green fluorescent-hLa fusion proteins, we discovered a nucleolar localization signal and demonstrated its functionality in a heterologous context. In addition, we revealed that the RRM2 motif of hLa is essential both for its RNA binding competence in vitro and in vivo and its exit from the nucleolus. Our data imply that hLa traffics between different subnuclear compartments, which depend decisively on a functional nucleolar localization signal as well as on RNA binding. Directed trafficking of hLa is fully consistent with its function in the maturation of precursor RNAs located in different subnuclear compartments.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Krankenhaus Hamburg Eppendorf, Zentrum Mol Neurobiol, Abt Elektronenmikroskopie, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52,Postfach 201652, D-20251 Hamburg, Germany.	heise@hpi.uni-hamburg.de		Horke, Sven/0000-0003-1309-3923				Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1976, ARTHRITIS RHEUM-US, V19, P216, DOI 10.1002/art.1780190214; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Annilo T, 1998, BIOCHEM BIOPH RES CO, V249, P759, DOI 10.1006/bbrc.1998.9187; ARNOLD GJ, 1986, GENE, V44, P287, DOI 10.1016/0378-1119(86)90193-9; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1987, MOL CELL BIOL, V7, P2588, DOI 10.1128/MCB.7.7.2588; CHAN EKL, 1989, NUCLEIC ACIDS RES, V17, P2233, DOI 10.1093/nar/17.6.2233; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DENG JS, 1981, J CELL BIOL, V91, P654, DOI 10.1083/jcb.91.3.654; Dundr M, 2002, MOL CELL, V9, P5, DOI 10.1016/S1097-2765(02)00433-1; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Gerbi SA, 2002, MOL BIOL CELL, V13, P3123, DOI 10.1091/mbc.01-12-0596; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; Heise T, 1999, J VIROL, V73, P474, DOI 10.1128/JVI.73.1.474-481.1999; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Horke S, 2002, J BIOL CHEM, V277, P34949, DOI 10.1074/jbc.M201911200; Houtsmuller AB, 2001, HISTOCHEM CELL BIOL, V115, P13, DOI 10.1007/s004180000234; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Intine RV, 2002, MOL CELL, V9, P1113, DOI 10.1016/S1097-2765(02)00533-6; Intine RVA, 2000, MOL CELL, V6, P339, DOI 10.1016/S1097-2765(00)00034-4; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Long KS, 2001, RNA, V7, P1589; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Meissner M, 2000, J CELL BIOCHEM, V76, P559, DOI 10.1002/(SICI)1097-4644(20000315)76:4<559::AID-JCB4>3.0.CO;2-U; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pellar GJ, 2003, CHROMOSOMA, V111, P461, DOI 10.1007/s00412-003-0231-y; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Raats JMH, 2003, EUR J CELL BIOL, V82, P131, DOI 10.1078/0171-9335-00304; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Swedlow JR, 2001, GENOME BIOL, V2; Tan DSW, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-17; TOPFER F, 1993, J IMMUNOL, V150, P3091; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Ueki N, 1998, BIOCHEM BIOPH RES CO, V252, P97, DOI 10.1006/bbrc.1998.9606; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Zirwes RF, 2000, MOL BIOL CELL, V11, P1153, DOI 10.1091/mbc.11.4.1153	79	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26563	26570		10.1074/jbc.M401017200	http://dx.doi.org/10.1074/jbc.M401017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060081	hybrid			2022-12-27	WOS:000222003000081
J	Xing, HR; Campodonico, L; Kolesnick, R				Xing, HR; Campodonico, L; Kolesnick, R			The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTESTINAL EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; MAP KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; GENE ENCODES; C-ELEGANS; PHOSPHORYLATION; SCAFFOLD	Kinase Suppressor of Ras1 (KSR1) functions as a positive modulator of Ras-dependent signaling either upstream of or parallel to Raf-1, and pharmacologic inactivation of KSR1 may serve as a treatment for Ras-driven malignancies such as pancreatic cancer (Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., and Kolesnick, R. (2003) Nat. Med. 9, 1266-1268). Although some studies demonstrated a requirement for KSR1 kinase activity for its action, others suggested KSR1 acts primarily as a scaffold facilitating assembly of the c-Raf-1/MEK module. We recently established a two-stage in vitro reconstitution assay to measure KSR1 kinase activity (Xing, H. R., Lozano, J., and Kolesnick, R. (2000) J. Biol. Chem. 275, 17276-17280). In this assay, KSR1, immunopurified to apparent homogeneity, never comes in contact with recombinant kinases other than c-Raf-1. In the first assay stage, activated KSR1 is incubated with recombinant c-Raf-1 and ATP. In the second stage, activated c-Raf-1 is separated from KSR1, and incubated with unactivated MEK1, unactivated MAPK, Elk-1, and ATP. Elk-1 phosphorylation serves as a specific readout for MAPK activation. However, because KSR1 constitutively associates with MEK1 and this interaction appears critical for KSR1 scaffolding function, it has been argued that the kinase activity detected is an artifact of KSR1-bound MEK1. To address these concerns, we depleted as much as 90% of KSR1-bound MEK1 by high salt washing without altering KSR1 kinase activity. Further, a complete inactivation of KSR1-bound MEK1 by pretreating with the MEK inhibitor PD 98059 prior to the first assay stage did not alter KSR1 kinase activity. In addition, the omission of exogenous recombinant GST-MEK1 from the reaction mixture during the second assay stage abolished Elk-1 phosphorylation confirming KSR1-bound MEK1 does not support MAPK activation in our in vitro assay. Moreover, a kinase-inactive mutant, FLAG-KiKSR1(D683A/D700A), which efficiently interacts with endogenous MEK1, lacks kinase activity. These results collectively support our contention that the kinase activity of KSR1 is an intrinsic property of this protein independent of KSR1-bound endogenous MEK.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cloan Kettering Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org			NCI NIH HHS [CA98022, CA42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385, R01CA098022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kaldis P, 1998, J CELL SCI, V111, P3585; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Tsakraklides V, 2002, J BIOL CHEM, V277, P33482, DOI 10.1074/jbc.M205537200; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Wang XN, 2004, J CELL PHYSIOL, V198, P333, DOI 10.1002/jcp.10443; Wang XN, 2001, EXP CELL RES, V268, P294, DOI 10.1006/excr.2001.5292; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xing HR, 2000, J BIOL CHEM, V275, P17276, DOI 10.1074/jbc.C900989199; Xing HR, 2003, NAT MED, V9, P1266, DOI 10.1038/nm927; Xing HR, 2001, J BIOL CHEM, V276, P9733, DOI 10.1074/jbc.M008096200; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yan F, 2001, CANCER RES, V61, P8668; Yan F, 2001, CANCER RES, V61, P963; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	31	13	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26210	26214		10.1074/jbc.M401323200	http://dx.doi.org/10.1074/jbc.M401323200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084597	hybrid			2022-12-27	WOS:000222003000036
J	Champagne, C; Landry, MC; Gingras, MC; Lavoie, JN				Champagne, C; Landry, MC; Gingras, MC; Lavoie, JN			Activation of adenovirus type 2 early region 4 ORF4 cytoplasmic death function by direct binding to Src kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; MIDDLE-T-ANTIGEN; FOCAL ADHESION KINASE; E4ORF4 PROTEIN; TYROSINE KINASE; V-SRC; C-SRC; TRANSFORMED-CELLS; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE	Adenovirus type 2 (Ad2) early region 4 ORF4 (E4orf4) triggers a major death pathway that requires its accumulation in cellular membranes and its tyrosine phosphorylation. This program is regulated by Src family kinases and triggers a potent ZVAD ( benzyloxycarbonyl-VAD)- and Bcl2-resistant cell death response in human-transformed cells. How E4orf4 deregulates Src-dependent signaling is unknown. Here we provide strong evidence that a physical interaction requiring the kinase domain of Src and the arginine-rich motif of E4orf4 is involved. The Src binding domain of E4orf4 overlaps with, but is distinct from that of the Balpha subunit of protein phosphatase 2A (PP2A-Balpha) and some E4orf4 complexes contain both PP2A and Src. Functional assays using mutant E4orf4 revealed that deregulation of Src signaling, activation of the Jun kinase pathway, and cell blebbing were all critically dependent on Src binding. In contrast, PP2A-Balpha binding per se was not required to engage the Src-dependent death pathway but was more critical for triggering a distinct death activity. Both E4orf4 death activities were manifested within a given cell population, were typified by distinct morphological features, and contributed to overall cell killing, although to different extents in various cell types. We conclude that E4orf4 binding to the Src kinase domain leads to deregulation of Src signaling and plays a crucial role in induction of the cytoplasmic death pathway. Nonetheless, both Src and PP2A enzymes are critical targets of E4orf4 that likely cooperate to trigger E4orf4-induced tumor cell killing and whose relative contributions may vary in function of the cellular background.	Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Lavoie, JN (corresponding author), Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	josee.lavoie@crhdq.ulaval.ca		Lavoie, Josee N/0000-0001-6912-1132				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Choidas A, 1998, EUR J CELL BIOL, V77, P81, DOI 10.1016/S0171-9335(98)80075-7; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; DAMUNI Z, 1994, FEBS LETT, V352, P311, DOI 10.1016/0014-5793(94)00981-3; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUPTA R, 1994, BIOCHEM BIOPH RES CO, V205, P1043, DOI 10.1006/bbrc.1994.2771; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MULLER U, 1992, J VIROL, V66, P5867; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tauber B, 2001, GENE, V278, P1, DOI 10.1016/S0378-1119(01)00722-3; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Violette SM, 2001, BONE, V28, P54, DOI 10.1016/S8756-3282(00)00427-0; Xiong WC, 1998, J CELL SCI, V111, P1981; Yokoyama N, 2001, FEBS LETT, V505, P460, DOI 10.1016/S0014-5793(01)02874-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25905	25915		10.1074/jbc.M400933200	http://dx.doi.org/10.1074/jbc.M400933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070897	hybrid			2022-12-27	WOS:000221827900123
J	Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE				Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE			Analysis of sequence determinants of F1Fo-ATP synthase in the N-terminal region of alpha subunit for binding of delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; ESCHERICHIA-COLI; F1F0-ATP SYNTHASE; QUANTITATIVE-DETERMINATION; F0F1-ATP SYNTHASE; CATALYTIC SITES; CROSS-LINKING; B-SUBUNIT; F-1-ATPASE; F-1	The stator in F1Fo-ATP synthase resists strain generated by rotor torque. In Escherichia coli, the b(2)delta subunit complex comprises the stator, bound to subunit a in F-o and to the alpha(3)beta(3) hexagon of F-1. Previous work has shown that N-terminal residues of alpha subunit are involved in binding delta. A synthetic peptide consisting of the first 22 residues of alpha(alphaN1-22) binds specifically to isolated wildtype delta subunit with 1: 1 stoichiometry and high affinity, accounting for a major portion of the binding energy between delta and F-1. Residues alpha6-18 are predicted by secondary structure algorithms and helical wheels to be alpha-helical and amphipathic, and a potential helix capping box occurs at residues alpha3-8. We introduced truncations, deletions, and mutations into alphaN1-22 and examined their effects on binding to the delta subunit. The deletions and mutations were introduced also into the N-terminal region of the uncA (alpha subunit) gene to determine effects on cell growth in vivo and membrane ATP synthase activity in vitro. Effects seen in the peptides were well correlated with those seen in the uncA gene. The results show that, with the possible exception of residues close to the initial Met, all of the alphaN1-22 sequence is required for binding of delta to alpha. Within this sequence, an amphipathic helix seems important. Hydrophobic residues on the predicted nonpolar surface are important for delta binding, namely alphaIle-8, alphaLeu-11, alphaIle-12, alphaIle-16, and alphaPhe-19. Several or all of these residues probably make direct interaction with helices 1 and 5 of delta. The potential capping box sequence per se appeared less important. Impairment of alpha/delta binding brings about functional impairment due to reduced level of assembly of ATP synthase in cells.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Diez M, 2004, BIOCHEMISTRY-US, V43, P1054, DOI 10.1021/bi0357098; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1997, NAT STRUCT BIOL, V4, P197	28	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25673	25679		10.1074/jbc.M402738200	http://dx.doi.org/10.1074/jbc.M402738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069069	hybrid			2022-12-27	WOS:000221827900096
J	Kast-Woelbern, HR; Dana, SL; Cesario, RM; Sun, L; de Grandpre, LY; Brooks, ME; Osburn, DL; Reifel-Miller, A; Klausing, K; Leibowitz, MD				Kast-Woelbern, HR; Dana, SL; Cesario, RM; Sun, L; de Grandpre, LY; Brooks, ME; Osburn, DL; Reifel-Miller, A; Klausing, K; Leibowitz, MD			Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROFILE; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL HOMEOSTASIS; INSULIN ACTION; IDENTIFICATION; TRANSCRIPTION; ADD1/SREBP1; RETENTION; AGONISTS	Insulin-induced gene 1 (INSIG-1) is a key regulator in the processing of the sterol regulatory element-binding proteins (SREBPs). We demonstrated that Insig-1 is regulated by peroxisome proliferator-activated receptor gamma (PPARgamma) providing a link between insulin sensitization/glucose homeostasis and lipid homeostasis. Insig-1 was identified as a PPARgamma target gene using microarray analysis of mRNA from the white adipose tissue of diabetic (db/db) animals treated with PPARgamma agonists. Insig1 was induced in subcutaneous (9-fold) and epididymal (4-fold) fat pads from db/db mice treated for 8 days with the PPARgamma agonist rosiglitazone (30 mg/kg/day). This in vivo response was confirmed in differentiated C3H10T1/2 adipocytes treated with rosiglitazone. To elucidate the molecular mechanisms regulating INSIG-1 expression, we cloned and characterized the human INSIG-1 promoter. Co-expression of PPARgamma and RXRalpha transactivated the INSIG-1 promoter in the presence of PPARgamma agonists. This induction was attenuated when a dominant negative PPARgamma construct was transfected into cells. Furthermore, a PPARgamma antagonist repressed the transactivation of the INSIG-1 promoter-reporter construct. Truncations of the promoter resulted in the identification of a PPAR response element that mediated the regulation of the promoter. We demonstrated with recombinant proteins that the PPARgamma/RXRalpha heterodimer binds directly to this PPAR response element. In addition to regulation by PPARgamma/RXRalpha, we demonstrated that the INSIG-1 promoter is regulated by transcriptionally active SREBP. The sterol response element was identified 380 base pairs upstream of the transcriptional start site. These findings suggest that the regulation of Insig-1 by PPARgamma agonists could in turn regulate SREBP processing and thus couple insulin sensitizers with the regulation of lipid homeostasis.	Ligand Pharmaceut Inc, Dept Mol & Cell Biol, San Diego, CA 92121 USA; Ligand Pharmaceut Inc, Dept Pharmacol, San Diego, CA 92121 USA; Ligand Pharmaceut Inc, Dept Mol Oncol, San Diego, CA 92121 USA; Eli Lilly & Co, Lilly Res Labs, Div Endocrine Res, Indianapolis, IN 46285 USA	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Eli Lilly	Kast-Woelbern, HR (corresponding author), Ligand Pharmaceut Inc, Dept Mol & Cell Biol, 10275 Sci Ctr Dr, San Diego, CA 92121 USA.	hwoelbern@ligand.com						Albrektsen T, 2002, DIABETES, V51, P1042, DOI 10.2337/diabetes.51.4.1042; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bortoff KD, 1997, ENDOCRINE, V7, P199, DOI 10.1007/BF02778142; Croston GE, 1997, ENDOCRINOLOGY, V138, P3779, DOI 10.1210/en.138.9.3779; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; Flier JS, 1999, P NATL ACAD SCI USA, V96, P14191, DOI 10.1073/pnas.96.25.14191; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Gurnell M, 2003, J CLIN ENDOCR METAB, V88, P2412, DOI 10.1210/jc.2003-030435; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Larsen TM, 2003, INT J OBESITY, V27, P147, DOI 10.1038/sj.ijo.802223; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Nesto RW, 2004, DIABETES CARE, V27, P256, DOI 10.2337/diacare.27.1.256; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	30	84	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23908	23915		10.1074/jbc.M403145200	http://dx.doi.org/10.1074/jbc.M403145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15073165	hybrid			2022-12-27	WOS:000221702500011
J	Gregory, LA; Thielens, NM; Matsushita, M; Sorensen, R; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C				Gregory, LA; Thielens, NM; Matsushita, M; Sorensen, R; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C			The X-ray structure of human mannan-binding lectin-associated protein 19 (MAp19) and its interaction site with mannan-binding lectin and L-ficolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY-OCCURRING MUTATIONS; SERINE PROTEASES-1 AND-2; COMPLEMENT PATHWAY; ACTIVATES COMPLEMENT; CLASSICAL PATHWAY; DOMAIN; COMPLEXES; SYSTEM; REGION; MBL	MAp19 is an alternative splicing product of the MASP-2 gene comprising the N-terminal CUB1-epidermal growth factor (EGF) segment of MASP-2, plus four additional residues at its C-terminal end. Like full-length MASP-2, it forms Ca2+-dependent complexes with mannan-binding lectin (MBL) and L-ficolin. The x-ray structure of human MAp19 was solved to a resolution of 2.5 Angstrom. It shows a head to tail homodimer held together by interactions between the CUB1 module of one monomer and the EGF module of its counterpart. A Ca2+ ion bound to each EGF module stabilizes the dimer interfaces. A second Ca2+ ion is bound to the distal end of each CUB1 module, through six ligands contributed by Glu(52), Asp(60), Asp(105), Ser(107), Asn(108), and a water molecule. Compared with its counterpart in human C1s, the N-terminal end of the MAp19 CUB1 module contains a 7-residue extension that forms additional inter-monomer contacts. To identify the residues involved in the interaction of MAp19 with MBL and L-ficolin, point mutants were generated and their binding ability was determined using surface plasmon resonance spectroscopy. Six mutations at Tyr(59), Asp(60), Glu(83), Asp(105), Tyr(106), and Glu(109) either strongly decreased or abolished interaction with both MBL and L-ficolin. These mutations map a common binding site for these proteins located at the distal end of each CUB1 module and stabilized by the Ca2+ ion.	Inst Biol Struct, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; Inst Biol Struct, Lab Enzymol Mol, F-38027 Grenoble 1, France; Tokai Univ, Dept Appl Biochem, Kanagawa 2591292, Japan; Tokai Univ, Inst Glycobiol, Kanagawa 2591292, Japan; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Tokai University; Tokai University; Aarhus University	Gaboriaud, C (corresponding author), Inst Biol Struct, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France.	christine.gaboriaud@ibs.fr	Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302				BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Cseh S, 2002, J IMMUNOL, V169, P5735, DOI 10.4049/jimmunol.169.10.5735; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LU J, 1990, J IMMUNOL, V144, P2287; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Rainey JK, 2002, PROTEIN SCI, V11, P2748, DOI 10.1110/ps.0218502; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; ROMERO A, 1997, NAT STRUCT BIOL, V5, P458; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836; Stover CM, 1999, J IMMUNOL, V162, P3481; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342	34	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29391	29397		10.1074/jbc.M402687200	http://dx.doi.org/10.1074/jbc.M402687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117939	hybrid			2022-12-27	WOS:000222445300071
J	Markey, M; Siddiqui, H; Knudsen, ES				Markey, M; Siddiqui, H; Knudsen, ES			Geminin is targeted for repression by the retinoblastoma tumor suppressor pathway through intragenic E2F sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PROTEIN; INHIBITION; GENE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; MITOSIS; XENOPUS; ARREST	The geminin protein is a critical regulator of DNA replication. It functions to control replication fidelity by blocking the assembly of prereplication complexes in the S and G(2) phases of the cell cycle. Geminin protein levels, which are low in G(0)/G(1) and increase at the G(1)/S transition, are controlled through coordinate transcriptional and proteolytic regulation. Here we show that geminin is regulated transcriptionally by the retinoblastoma tumor suppressor (RB)/E2F pathway. Initially, we observed that the activation of RB led to the repression of geminin transcription. Conversely, Rb-null mouse embryonic fibroblasts have enhanced the expression of geminin relative to wild type mouse embryonic fibroblasts. Similarly, an acute loss of Rb in mouse adult fibroblasts deregulated geminin RNA and protein levels. To delineate the responsible regulatory motifs, luciferase reporter constructs containing fragments of the geminin promoter were generated. An analysis of the critical regulatory cis-acting elements in the geminin promoter indicated that intragenic E2F sites downstream of the first exon were responsible for RB-mediated repression of geminin. The direct analysis of the endogenous geminin promoter revealed that these intragenic E2F sites are occupied by E2F proteins, and the mutation of these sites eliminates responsiveness to RB. Together, these data link the expression of geminin to the RB/E2F pathway and represent the first promoter analysis of this important regulator of DNA replication.	Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu		Markey, Michael/0000-0002-8593-2290				Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Broceno C, 2002, P NATL ACAD SCI USA, V99, P14200, DOI 10.1073/pnas.212519499; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jegga AG, 2002, GENOME RES, V12, P1408, DOI 10.1101/gr.255002; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Khan SH, 1998, CANCER RES, V58, P396; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kobayashi T, 2002, J CELL SCI, V115, P3159; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Markey MP, 2002, CANCER RES, V62, P6587; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	32	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29255	29262		10.1074/jbc.M313482200	http://dx.doi.org/10.1074/jbc.M313482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15084580	hybrid			2022-12-27	WOS:000222445300054
J	Agou, F; Traincard, F; Vinolo, E; Courtois, G; Yamaoka, S; Israel, A; Veron, M				Agou, F; Traincard, F; Vinolo, E; Courtois, G; Yamaoka, S; Israel, A; Veron, M			The trimerization domain of nemo is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GAMMA IKK-GAMMA; KINASE COMPLEX; ACTIVATION; PHOSPHORYLATION; OLIGOMERIZATION; PROTEINS; BETA; CLASSIFICATION; UBIQUITINATION	NEMO (NF-kappaB essential modulator) plays a key role in the canonical NF-kappaB pathway as the scaffold/regulatory component of the IkappaB kinase (IKK) complex. The self-association of NEMO involves the C-terminal halves of the polypeptide chains containing two putative coiled-coil motifs (a CC2 and a LZ leucine zipper), a proline-rich region, and a ZF zinc finger motif. Using purified truncation mutants, we showed that the minimal oligomerization domain of NEMO is the CC2-LZ segment and that both CC2 and LZ subdomains are necessary to restore the LPS-dependent activation of the NF-kappaB pathway in a NEMO-deficient cell line. We confirmed the association of the oligomerization domain in a trimer and investigated the specific role of CC2 and LZ subdomains in the building of the oligomer. Whereas a recombinant CC2-LZ polypeptide self-associated into a trimer with an association constant close to that of the wildtype protein, the isolated CC2 and LZ peptides, respectively, formed trimers and dimers with weaker association constants. Upon mixing, isolated CC2 and LZ peptides associated to form a stable hetero-hexamer as shown by gel filtration and fluorescence anisotropy experiments. We propose a structural model for the organization of the oligomerization domain of activated NEMO in which three C-terminal domains associate into a pseudo-hexamer forming a six-helix bundle. This model is discussed in relation to the mechanism of activation of the IKK complex by upstream activators.	Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 113, Japan	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tokyo Medical & Dental University (TMDU)	Agou, F (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, 25 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1999, J BIOL CHEM, V274, P19630, DOI 10.1074/jbc.274.28.19630; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan WC, 2000, FMOC SOLID PHASE PEP; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gunasekaran K, 2003, TRENDS BIOCHEM SCI, V28, P81, DOI 10.1016/S0968-0004(03)00003-3; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mousson F, 2002, BIOCHEMISTRY-US, V41, P13611, DOI 10.1021/bi026274b; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SIEGEL LM, 1965, BIOCHEM BIOPH RES CO, V19, P494, DOI 10.1016/0006-291X(65)90152-X; Smahi A, 2000, NATURE, V405, P466; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27861	27869		10.1074/jbc.M314278200	http://dx.doi.org/10.1074/jbc.M314278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107419	Green Published, hybrid			2022-12-27	WOS:000222265400007
J	Alberty, RA				Alberty, RA			A short history of the thermodynamics of enzyme-catalyzed reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							ADENOSINE-TRIPHOSPHATE; CHEMICAL THERMODYNAMICS; LEGENDRE TRANSFORMS; ION CONCENTRATION; SPECIFIED PH; EQUILIBRIUM; HYDROLYSIS; SYSTEMS; PMG; BACTERIA		MIT, Dept Chem, Cambridge, MA 02319 USA	Massachusetts Institute of Technology (MIT)	Alberty, RA (corresponding author), MIT, Dept Chem, Cambridge, MA 02319 USA.	alberty@mit.edu						Alberty R. A., 2003, THERMODYNAMICS BIOCH; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ALBERTY RA, 1992, BIOPHYS CHEM, V42, P117, DOI 10.1016/0301-4622(92)85002-L; ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; ALBERTY RA, 1994, PURE APPL CHEM, V66, P1641, DOI 10.1351/pac199466081641; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ALBERTY RA, 1968, J BIOL CHEM, V243, P1337; ALBERTY RA, 1988, J CHEM PHYS, V89, P3689, DOI 10.1063/1.454889; ALBERTY RA, 1992, BIOPHYS CHEM, V43, P239, DOI 10.1016/0301-4622(92)85024-X; Alberty RA, 2000, J PHYS CHEM B, V104, P650, DOI 10.1021/jp993460r; Alberty RA, 2001, PURE APPL CHEM, V73, P1349, DOI 10.1351/pac200173081349; ALBERTY RA, 1994, CHEM REV, V94, P1457, DOI 10.1021/cr00030a001; ALBERTY RA, 1951, J BIOL CHEM, V193, P425; ALBERTY RA, 1954, J AM CHEM SOC, V76, P2486; Beattie JA, 1979, PRINCIPLES THERMODYN; BOCK RM, 1953, J AM CHEM SOC, V75, P1921, DOI 10.1021/ja01104a043; Boerio-Goates J, 2001, J CHEM THERMODYN, V33, P929, DOI 10.1006/jcht.2001.0820; BURTON K, 1953, BIOCHEM J, V54, P94, DOI 10.1042/bj0540094; CALLEN HB, 1985, THERMODYNAMICS INTRO, P26; FRIEDEN C, 1954, J AM CHEM SOC, V76, P2482, DOI 10.1021/ja01638a052; Gibbs J., 1948, COLLECTED WORKS JW G, V1; GOLDBERG RN, 1989, J PHYS CHEM REF DATA, V18, P809, DOI 10.1063/1.555831; Goldberg RN, 1999, J PHYS CHEM REF DATA, V28, P931, DOI 10.1063/1.556041; GUYNN RW, 1973, J BIOL CHEM, V248, P6966; Krebs HA., 1957, ENERGY TRANSFORMATIO; MILLER SL, 1990, J PHYS CHEM REF DATA, V19, P1049, DOI 10.1063/1.555878; PHILLIPS RC, 1969, J BIOL CHEM, V244, P3330; Quastel JH, 1926, BIOCHEM J, V20, P545, DOI 10.1042/bj0200545; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; WADSO I, 1976, J BIOL CHEM, V251, P6879; WAGMAN DD, 1982, J PHYS CHEM REF DA S, V11, P2; Wolfram S., 2003, MATH BOOK; Wyman J., 1990, BINDING LINKAGE; [No title captured]	34	14	14	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27831	27836		10.1074/jbc.X400003200	http://dx.doi.org/10.1074/jbc.X400003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15073189	hybrid			2022-12-27	WOS:000222265400001
J	Lairson, LL; Chiu, CPC; Ly, HD; He, SM; Wakarchuk, WW; Strynadka, NCJ; Withers, SG				Lairson, LL; Chiu, CPC; Ly, HD; He, SM; Wakarchuk, WW; Strynadka, NCJ; Withers, SG			Intermediate trapping on a mutant retaining alpha-galactosyltransferase identifies an unexpected aspartate residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-MENINGITIDIS; CRYSTAL-STRUCTURE; CYCLODEXTRIN GLYCOSYLTRANSFERASE; BIOSYNTHESIS; COMPLEX; ENZYME; ROLES; ALPHA-1,3-GALACTOSYLTRANSFERASE; CLASSIFICATION; GLYCOSYLATION	Lipopolysaccharyl-alpha-1,4-galactosyltransferase C (LgtC), a glycosyltransferase family 8 alpha-1,4-galactosyltransferase from Neisseria meningitidis, catalyzes the transfer of galactose from UDP galactose to terminal lactose-containing acceptor sugars with net retention of anomeric configuration. To investigate the potential role of discrete nucleophilic catalysis suggested by the double displacement mechanism generally proposed for retaining glycosyltransferases, the side chain amide of Gln-189, which is suitably positioned to act as the catalytic nucleophile of LgtC, was substituted with the more nucleophilic carboxylate-containing side chain of glutamate in the hope of accumulating a glycosyl-enzyme intermediate. The resulting mutant was subjected to kinetic, mass spectrometric, and x-ray crystallographic analysis. Although the K-m for UDP-galactose is not significantly altered, the k(cat) was reduced to 3% that of the wild type enzyme. Electrospray mass spectrometric analysis revealed that a steady state population of the Q189E variant contains a covalently bound galactosyl moiety. Liquid chromatographic/mass spectrometric analysis of fragmented proteolytic digests identified the site of labeling not as Glu-189 but, surprisingly, as the sequentially adjacent Asp-190. However, the side chain carboxylate of Asp-190 is located 8.9 Angstrom away from the donor substrate in the available crystal structure. Kinetic analysis of a D190N mutant at this position revealed a k(cat) value 3000-fold lower than that of the wild type enzyme. A 2.6-crystal structure of the Q189E mutant with bound uridine 5'-diphospho-2-deoxy-2-fluoro-alpha-D-galactopyranose revealed no significant perturbation of the mode of donor sugar binding nor of active site configuration. This is the first trapping of an intermediate in the active site of a retaining glycosyltransferase and, although not conclusive, implicates Asp-190 as an alternative candidate catalytic nucleophile, thereby rekindling a longstanding mechanistic debate.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; University of British Columbia; National Research Council Canada	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Lairson, Luke/0000-0001-6701-996X				Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Fukuda M, 1996, CANCER RES, V56, P2237; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; GOSSELIN S, 1994, ANAL BIOCHEM, V220, P92, DOI 10.1006/abio.1994.1303; Jack DL, 1998, J IMMUNOL, V160, P1346; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEATHERBARROW RJ, 1990, GRAFIT VERSION 4 0; Ljungh A, 1996, FEMS IMMUNOL MED MIC, V16, P117, DOI 10.1016/S0928-8244(96)00073-9; Ly HD, 2002, BIOCHEMISTRY-US, V41, P6572, DOI 10.1021/bi025160x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mark BL, 2002, CAN J CHEM, V80, P1064, DOI 10.1139/V02-130; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell EP, 1996, BIOCHEMISTRY-US, V35, P7341, DOI 10.1021/bi960072w; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; Withers S.G., 1997, COMPREHENSIVE BIOL C, P119; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang YN, 2003, BIOCHEMISTRY-US, V42, P13512, DOI 10.1021/bi035430r	38	80	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28339	28344		10.1074/jbc.M400451200	http://dx.doi.org/10.1074/jbc.M400451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15075344	hybrid			2022-12-27	WOS:000222265400066
J	Schuh, K; Cartwright, EJ; Jankevics, E; Bundschu, K; Liebermann, J; Williams, JC; Armesilla, AL; Emerson, M; Oceandy, D; Knobeloch, KP; Neyses, L				Schuh, K; Cartwright, EJ; Jankevics, E; Bundschu, K; Liebermann, J; Williams, JC; Armesilla, AL; Emerson, M; Oceandy, D; Knobeloch, KP; Neyses, L			Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MOUSE SPERM; ACROSOME REACTION; CA2+-ATPASE; CHANNELS; ENTRY; MICE; EXPRESSION; ISOFORMS; MUTATION	Calcium and Ca2+-dependent signals play a crucial role in sperm motility and mammalian fertilization, but the molecules and mechanisms underlying these Ca2+-dependent pathways are incompletely understood. Here we show that homozygous male mice with a targeted gene deletion of isoform 4 of the plasma membrane calcium/ calmodulin-dependent calcium ATPase (PMCA), which is highly enriched in the sperm tail, are infertile due to severely impaired sperm motility. Furthermore, the PMCA inhibitor 5-(and-6)-carboxyeosin diacetate succinimidyl ester reduced sperm motility in wild-type animals, thus mimicking the effects of PMCA4 deficiency on sperm motility and supporting the hypothesis of a pivotal role of the PMCA4 on the regulation of sperm function and intracellular Ca2+ levels.	Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Latvia, Biochem Res & Study Ctr, LV-1067 Riga, Latvia; Univ Wurzburg, Dept Obstet & Gynecol, D-97080 Wurzburg, Germany; FMP, D-12207 Berlin, Germany; Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England	University of Wurzburg; University of Latvia; University of Wurzburg; University of Manchester	Schuh, K (corresponding author), Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	schuh_k@klinik.uni-wuerzburg.de; ludwig.neyses@man.ac.uk	Neyses, Ludwig/AGY-7446-2022; Oceandy, Delvac/G-9911-2015	Oceandy, Delvac/0000-0002-6242-6491; Armesilla, Angel/0000-0003-3546-5580; Cartwright, Elizabeth/0000-0002-6836-7795	Medical Research Council [G0200020] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Choi HS, 1999, J PHYSIOL-LONDON, V515, P109, DOI 10.1111/j.1469-7793.1999.109ad.x; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Feng HL, 2003, ARCH ANDROLOGY, V49, P19, DOI 10.1080/01485010290031556-1; Fukami K, 2003, J CELL BIOL, V161, P79, DOI 10.1083/jcb.200210057; GATTO C, 1995, BIOCHEMISTRY-US, V34, P965, DOI 10.1021/bi00003a031; GATTO C, 1993, AM J PHYSIOL, V264, pC1577, DOI 10.1152/ajpcell.1993.264.6.C1577; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Takahashi K, 1999, BIOCHEM BIOPH RES CO, V261, P773, DOI 10.1006/bbrc.1999.1102; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Wood CD, 2003, J CELL BIOL, V161, P89, DOI 10.1083/jcb.200212053; Zacharias DA, 1999, BBA-GEN SUBJECTS, V1428, P397, DOI 10.1016/S0304-4165(99)00058-6	38	188	198	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28220	28226		10.1074/jbc.M312599200	http://dx.doi.org/10.1074/jbc.M312599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15078889	Green Published, hybrid			2022-12-27	WOS:000222265400051
J	Yakovlev, AG; Di Giovanni, S; Wang, GP; Liu, WF; Stoica, B; Faden, AI				Yakovlev, AG; Di Giovanni, S; Wang, GP; Liu, WF; Stoica, B; Faden, AI			BOK and NOXA are essential mediators of p53-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PROGRAMMED CELL-DEATH; ETOPOSIDE-INDUCED APOPTOSIS; STRESS-INDUCED APOPTOSIS; MITOCHONDRIAL DYSFUNCTION; BH3-ONLY PROTEINS; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; BCL-2 PROTEIN; CANCER CELLS	Cellular stress leads to DNA damage and activation of the intrinsic apoptotic pathway in which translocation of mitochondrial cytochrome c to the cytosol plays a critical role. Previous studies have suggested alternative mechanisms responsible for this process. We examined initiation mechanisms of the intrinsic apoptotic pathway using human neuroblastoma and breast cancer cells. Results indicated that translocation of cytochrome c does not require prior activation of caspases but rather depends on activation of specific BCL-2 family members, depending upon the type of death signal. Thus, DNA damage-induced apoptosis requires new protein synthesis, accumulation of p53 tumor suppressor protein, and p53-dependent induction of BOK and NOXA genes, while a role for BAX in this pathway is not essential. In contrast, apoptosis induced by staurosporine does not require protein synthesis but is characterized by translocation of BAX. Based on these findings, we propose a model of the intrinsic apoptotic cascade induced by DNA damage where proapoptotic BOK substitutes for a function of BAX.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Georgetown University	Yakovlev, AG (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,WP-14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	ayakou01@georgetown.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038941] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 38941] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Gao CF, 2001, EXP CELL RES, V265, P145; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pearson AS, 2000, CLIN CANCER RES, V6, P887; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SUN XM, 1994, BIOCHEM PHARMACOL, V47, P187; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; WALKER PR, 1991, CANCER RES, V51, P1078; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	114	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28367	28374		10.1074/jbc.M313526200	http://dx.doi.org/10.1074/jbc.M313526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102863	hybrid			2022-12-27	WOS:000222265400069
J	Li, JY; Stevens, L; Klugbauer, N; Wray, D				Li, JY; Stevens, L; Klugbauer, N; Wray, D			Roles of molecular regions in determining differences between voltage dependence of activation of Ca(v)3.1 and Ca(v)1.2 calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; CONFORMATIONAL-CHANGES; POTASSIUM CHANNEL; BETA-SUBUNIT; GATING PROPERTIES; FAST INACTIVATION; SODIUM-CHANNELS; PROTEIN-KINASE; ION CHANNELS; S4 SEGMENT	Voltage-dependent calcium channels are classified into low voltage-activated and high voltage-activated channels. We have investigated the molecular basis for this difference in voltage dependence of activation by constructing chimeras between a low voltage-activated channel (Ca(V)3.1) and a high voltage-activated channel (Ca(V)1.2), focusing on steady-state activation properties. Wild type and chimeras were expressed in oocytes, and two-electrode voltage clamp recordings were made of calcium channel currents. Replacement of domains I, III, or IV of the Ca(V)3.1 channel with the corresponding domain of Ca(V)1.2 led to high voltage-activated channels; for these constructs the current/voltage (I/V) curves were similar to those for Ca(V)1.2 wild type. However, replacement of domain II gave only a small shift to the right of the I/V curve and modulation of the activation kinetics but did not lead to a high voltage-activating channel with an I/V curve like Ca(V)1.2. We also investigated the role of the voltage sensor S4 by replacing the S4 segment of Ca(V)3.1 with that of Ca(V)1.2. For domain I, there was no shift in the I/V curve as compared with Ca(V)3.1, and there were relatively small shifts to the right for domains III and IV. Taken together, these results suggest that domains I, III, and IV (rather than domain II) are apparently critical for channel opening and, therefore, contribute strongly to the difference in voltage dependence of activation between Ca(V)3.1 and Ca(V)1.2. However, the S4 segments in domains I, III, and IV did not account for this difference in voltage dependence.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-79104 Freiburg, Germany	University of Leeds; University of Freiburg	Wray, D (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	d.wray@leeds.ac.uk						Berjukow S, 2001, J BIOL CHEM, V276, P17076, DOI 10.1074/jbc.M010491200; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chanda B, 2002, J GEN PHYSIOL, V120, P629, DOI 10.1085/jgp.20028679; Chemin J, 2001, BIOPHYS J, V80, P1238, DOI 10.1016/S0006-3495(01)76100-0; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Geib S, 2002, J BIOL CHEM, V277, P10003, DOI 10.1074/jbc.M106231200; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Kontis KJ, 1997, J GEN PHYSIOL, V110, P391, DOI 10.1085/jgp.110.4.391; Lacinova L, 1999, J PHYSIOL-LONDON, V516, P639, DOI 10.1111/j.1469-7793.1999.0639u.x; Lee JH, 1999, J NEUROSCI, V19, P1912; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Milligan CJ, 2000, BIOPHYS J, V78, P1852, DOI 10.1016/S0006-3495(00)76734-8; Mitrovic N, 1998, J GEN PHYSIOL, V111, P451, DOI 10.1085/jgp.111.3.451; Monteil A, 2000, J BIOL CHEM, V275, P16530, DOI 10.1074/jbc.C000090200; Murbartian J, 2002, FEBS LETT, V528, P272, DOI 10.1016/S0014-5793(02)03341-0; Neale EJ, 2003, J BIOL CHEM, V278, P29079, DOI 10.1074/jbc.M301991200/6493; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Sato Y, 2003, J BIOL CHEM, V278, P13227, DOI 10.1074/jbc.M300431200; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; Staes M, 2001, J PHYSIOL-LONDON, V530, P35, DOI 10.1111/j.1469-7793.2001.0035m.x; Talavera K, 2003, J GEN PHYSIOL, V121, P529, DOI 10.1085/jgp.200308794; Talavera K, 2001, J BIOL CHEM, V276, P45628, DOI 10.1074/jbc.M103047200; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; Yamaguchi H, 1999, P NATL ACAD SCI USA, V96, P1357, DOI 10.1073/pnas.96.4.1357	43	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26858	26867		10.1074/jbc.M313981200	http://dx.doi.org/10.1074/jbc.M313981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100229	hybrid			2022-12-27	WOS:000222120400009
J	Lin, ZP; Belcourt, MF; Cory, JG; Sartorelli, AC				Lin, ZP; Belcourt, MF; Cory, JG; Sartorelli, AC			Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR-ACTIVITY; CYCLE CHECKPOINT; MAMMALIAN-CELLS; ENZYMATIC ASSAY; IN-VITRO; P53; PROTEIN; GENE; EXPRESSION; RESISTANCE	Ribonucleotide reductase catalyzes the production of deoxyribonucleoside diphosphates, the precursors of deoxyribonucleoside triphosphates for DNA synthesis. Mammalian ribonucleotide reductase (RNR) is a tetramer consisting of two non-identical homodimers, R1 and either R2 or p53R2, which are considered to be involved in DNA replication and repair, respectively. We have demonstrated that DNA damage by doxorubicin and cisplatin caused a steady elevation of the R2 protein in p53(-/-) HCT-116 human colon carcinoma cells but induced degradation of the protein in p53(+/+) cells. To evaluate the involvement of R2 in response to DNA damage, p53(-/-) HCT-116 cells were stably transfected with an expression vector transcribing short hairpin/short interference RNA directed against R2 mRNA. Stably transfected clones exhibited a pronounced reduction of the R2 protein with no change in the cellular growth rate. Furthermore, short interference RNA-mediated reduction of the R2 protein caused a marked increase in sensitivity to the DNA-damaging agent cisplatin as well as to the RNR inhibitors Triapine(R) and hydroxyurea. Ectopic expression of p53R2 partially reversed the cytotoxicity of cisplatin but not that of RNR inhibitors to R2 knockdown cells. The increase in sensitivity to cisplatin and RNR inhibitors was correlated with the suppression of dATP and dGTP levels caused by stable expression of R2-targeted short interference RNA. These results indicated that DNA damage resulted in elevated levels of the R2 protein and dNTPs and, consequently, enhanced the survival of p53(-/-) HCT-116 cells. The findings provide evidence that R2- RNR can be employed to supply dNTPs for the repair of DNA damage in cells with an impaired p53-dependent induction of p53R2.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, New Haven, CT 06520 USA; Vion Pharmaceut Inc, New Haven, CT 06511 USA; E Carolina Univ, Sch Med, Dept Biochem, Greenville, NC 27834 USA	Yale University; Yale University; Vion Pharmaceuticals, Inc.; University of North Carolina; East Carolina University	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	alan.sartorelli@yale.edu						BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; CORY JG, 1994, BIOCHEM PHARMACOL, V48, P335, DOI 10.1016/0006-2952(94)90105-8; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FAN SJ, 1995, CANCER RES, V55, P1649; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Finch RA, 1999, ADV ENZYME REGUL, V39, P3, DOI 10.1016/S0065-2571(98)00017-X; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fritzer-Szekeres M, 2002, BIOCHEM PHARMACOL, V64, P481, DOI 10.1016/S0006-2952(02)01186-3; Furuta T, 2002, CANCER RES, V62, P4899; GAO WY, 1994, ANAL BIOCHEM, V222, P116, DOI 10.1006/abio.1994.1462; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hawkins DS, 1996, CANCER RES, V56, P892; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Kuo ML, 1998, CANCER RES, V58, P2245; Lee Y, 2003, CANCER RES, V63, P2802; LIU MC, 1992, J MED CHEM, V35, P3672, DOI 10.1021/jm00098a012; MANN GJ, 1988, CANCER RES, V48, P5151; MULSANT P, 1988, SOMAT CELL MOLEC GEN, V14, P243, DOI 10.1007/BF01534585; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Shao JM, 2004, CANCER RES, V64, P1, DOI 10.1158/0008-5472.CAN-03-3048; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WEBER G, 1980, ONCOLOGY, V37, P19, DOI 10.1159/000225492; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zhou BS, 2003, CANCER RES, V63, P6583	43	66	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27030	27038		10.1074/jbc.M402056200	http://dx.doi.org/10.1074/jbc.M402056200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096505	hybrid			2022-12-27	WOS:000222120400029
J	Mishina, Y; Starbuck, MW; Gentile, MA; Fukuda, T; Kasparcova, V; Seedor, JG; Hanks, MC; Amling, M; Pinero, GJ; Harada, S; Behringer, RR				Mishina, Y; Starbuck, MW; Gentile, MA; Fukuda, T; Kasparcova, V; Seedor, JG; Hanks, MC; Amling, M; Pinero, GJ; Harada, S; Behringer, RR			Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; MOUSE OSTEOCALCIN GENE; OSTEOCLAST FORMATION; CRE RECOMBINASE; EXPRESSION; MICE; DIFFERENTIATION; CELLS; LIMB; MEMBER	Bone morphogenetic proteins (BMPs) function during various aspects of embryonic development including skeletogenesis. However, their biological functions after birth are less understood. To investigate the role of BMPs during bone remodeling, we generated a postnatal osteoblast-specific disruption of Bmpr1a that encodes the type IA receptor for BMPs in mice. Mutant mice were smaller than controls up to 6 months after birth. Irregular calcification and low bone mass were observed, but there were normal numbers of osteoblasts. The ability of the mutant osteoblasts to form mineralized nodules in culture was severely reduced. Interestingly, bone mass was increased in aged mutant mice due to reduced bone resorption evidenced by reduced bone turnover. The mutant mice lost more bone after ovariectomy likely resulting from decreased osteoblast function which could not overcome ovariectomy-induced bone resorption. In organ culture of bones from aged mice, ablation of the Bmpr1a gene by adenoviral Cre recombinase abolished the stimulatory effects of BMP4 on the expression of lysosomal enzymes essential for osteoclastic bone resorption. These results demonstrate essential and age-dependent roles for BMP signaling mediated by BMPRIA ( a type IA receptor for BMP) in osteoblasts for bone remodeling.	NIEHS, LRDT, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Merck Res Labs, Dept Mol Endocrinol Bone Biol, West Point, PA 19486 USA; Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Mason, OH USA; Univ Hamburg, Dept Trauma Surg, Hamburg, Germany; Univ Texas, Dent Branch, Dept Basic Sci, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; UTMD Anderson Cancer Center; Merck & Company; Procter & Gamble; University of Hamburg; University of Texas System	Mishina, Y (corresponding author), NIEHS, LRDT, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	mishina@niehs.nih.gov	Fukuda, Tomokazu/O-1257-2018	Fukuda, Tomokazu/0000-0001-8456-0483	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Baur ST, 2000, DEVELOPMENT, V127, P605; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; HENTUNEN TA, 1995, BIOCHEM BIOPH RES CO, V209, P433, DOI 10.1006/bbrc.1995.1521; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756-3282(00)00358-6; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Mishina Y, 2003, FRONT BIOSCI-LANDMRK, V8, pD855, DOI 10.2741/1097; Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takeda S, 2003, ANNU REV NUTR, V23, P403, DOI 10.1146/annurev.nutr.23.011702.073312; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yi SE, 2000, DEVELOPMENT, V127, P621; YOKOUCHI Y, 1996, DEVELOPMENT CAMB, V122, P3723; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	43	150	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27560	27566		10.1074/jbc.M404222200	http://dx.doi.org/10.1074/jbc.M404222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090551	hybrid			2022-12-27	WOS:000222120400089
J	Voronina, SG; Barrow, SL; Gerasimenko, OV; Petersen, OH; Tepikin, AV				Voronina, SG; Barrow, SL; Gerasimenko, OV; Petersen, OH; Tepikin, AV			Effects of secretagogues and bile acids on mitochondrial membrane potential of pancreatic acinar cells - Comparison of different modes of evaluating Delta psi(m)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA2+ SIGNALS; ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; CALCIUM SIGNALS; ADENOSINE 3'-5'-MONOPHOSPHATE; GASTROINTESTINAL HORMONES; PERMEABILITY TRANSITION; RYANODINE-RECEPTORS; EXOCRINE PANCREAS; RAT PANCREAS	In this study, we investigated the effects of secretagogues and bile acids on the mitochondrial membrane potential of pancreatic acinar cells. We measured the mitochondrial membrane potential using the tetramethylrhodamine-based probes tetramethylrhodamine ethyl ester and tetramethylrhodamine methyl ester. At low levels of loading, these indicators appeared to have a low sensitivity to the uncoupler carbonyl cyanide m-chlorophenylhydrazone, and no response was observed to even high doses of cholecystokinin. When loaded at high concentrations, tetramethylrhodamine methyl ester and tetramethylrhodamine ethyl ester undergo quenching and can be dequenched by mitochondrial depolarization. We found the dequench mode to be 2 orders of magnitude more sensitive than the low concentration mode. Using the dequench mode, we resolved mitochondrial depolarizations produced by supramaximal and by physiological concentrations of cholecystokinin. Other calcium-releasing agonists, acetylcholine, JMV-180, and bombesin, also produced mitochondrial depolarization. Secretin, which employs the cAMP pathway, had no effect on the mitochondrial potential; dibutyryl cAMP was also ineffective. The cholecystokinin-induced mitochondrial depolarizations were abolished by buffering cytosolic calcium. A non-agonist-dependent calcium elevation induced by thapsigargin depolarized the mitochondria. These experiments suggest that a cytosolic calcium concentration rise is sufficient for mitochondrial depolarization and that the depolarizing effect of cholecystokinin is mediated by a cytosolic calcium rise. Bile acids are considered possible triggers of acute pancreatitis. The bile acids taurolithocholic acid 3-sulfate, taurodeoxycholic acid, and taurochenodeoxycholic acid, at low submillimolar concentrations, induced mitochondrial depolarization, resolved by the dequench mode. Our experiments demonstrate that physiological concentrations of secretagogues and pathologically relevant concentrations of bile acids trigger mitochondrial depolarization in pancreatic acinar cells.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Tepikin, AV (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	a.tepikin@liv.ac.uk	Gerasimenko, Oleg/A-6622-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513				Ashby MC, 2003, J BIOL CHEM, V278, P20860, DOI 10.1074/jbc.M302599200; Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; Camello-Almaraz C, 2002, BIOCHEM PHARMACOL, V63, P283, DOI 10.1016/S0006-2952(01)00830-9; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; DESCHODTLANCKMAN M, 1975, GASTROENTEROLOGY, V68, P318; Duchen MR, 2003, METHOD ENZYMOL, V361, P353; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Feeney CJ, 2003, J NEUROSCI METH, V125, P13, DOI 10.1016/S0165-0270(03)00027-X; GARDNER JD, 1976, GASTROENTEROLOGY, V70, P29; Gerasimenko JV, 2002, J CELL SCI, V115, P485; Gerasimenko OV, 2002, CELL CALCIUM, V32, P261, DOI 10.1016/S0143416002001938; Gukovskaya AS, 2002, J BIOL CHEM, V277, P22595, DOI 10.1074/jbc.M202929200; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Halangk W, 1998, PANCREAS, V16, P88, DOI 10.1097/00006676-199801000-00014; Johnson PR, 2003, CELL TISSUE RES, V313, P37, DOI 10.1007/s00441-003-0741-1; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kim JY, 2002, GASTROENTEROLOGY, V122, P1941, DOI 10.1053/gast.2002.33617; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; MOODY FG, 1993, GASTROENTEROLOGY, V104, P927, DOI 10.1016/0016-5085(93)91034-F; Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Raraty M, 2000, P NATL ACAD SCI USA, V97, P13126, DOI 10.1073/pnas.97.24.13126; REBER HA, 1980, BRIT J SURG, V67, P59, DOI 10.1002/bjs.1800670119; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROBBERECHT P, 1976, J BIOL CHEM, V251, P4635; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schild L, 1999, MOL CELL BIOCHEM, V195, P191, DOI 10.1023/A:1006988625831; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1993, J BIOL CHEM, V268, P23219; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TRIMBLE ER, 1987, BIOCHEM J, V242, P289, DOI 10.1042/bj2420289; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Voronina S, 2002, J PHYSIOL-LONDON, V540, P49, DOI 10.1113/jphysiol.2002.017525; WALSH JH, 1994, PHYSL GASTROINTESTIN, P49; WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140-6736(95)91695-4; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZIMNIAK P, 1991, BIOCHEMISTRY-US, V30, P8598, DOI 10.1021/bi00099a015	63	92	95	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27327	27338		10.1074/jbc.M311698200	http://dx.doi.org/10.1074/jbc.M311698200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084611	hybrid			2022-12-27	WOS:000222120400063
J	Chiu, A; Revenkova, E; Jessberger, R				Chiu, A; Revenkova, E; Jessberger, R			DNA interaction and dimerization of eukaryotic SMC hinge domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; CHROMOSOME CONDENSATION; STRUCTURAL MAINTENANCE; RECOMBINATION COMPLEX; PROTEIN COMPLEXES; 13S CONDENSIN; IN-VITRO; MEIOSIS; REPAIR; BIND	The eukaryotic SMC1/SMC3 heterodimer is essential for sister chromatid cohesion and acts in DNA repair and recombination. Dimerization depends on the central hinge domain present in all SMC proteins, which is flanked at each side by extended coiled-coil regions that terminate in specific globular domains. Here we report on DNA interactions of the eukaryotic, heterodimeric SMC1/SMC3 hinge regions, using the two known isoforms, SMC1alpha/SMC3 and the meiotic SMC1beta/SMC3. Both dimers bind DNA with a preference for double-stranded DNA and DNA rich in potential secondary structures. Both dimers form large protein-DNA networks and promote reannealing of complementary DNA strands. DNA binding but not dimerization depends on approximately 20 amino acids of transitional sequence into the coiled-coil region. Replacement of three highly conserved glycine residues, thought to be required for dimerization, in one of the two hinge domains still allows formation of a stable dimer, but if two hinge domains are mutated dimerization fails. Single-mutant dimers bind DNA, but hinge monomers do not. Together, we show that eukaryotic hinge dimerization does not require conserved glycines in both hinge domains, that only the transition into the coiled-coil region rather than the entire coiled-coil region is necessary for DNA binding, and that dimerization is required but not sufficient for DNA binding of the eukaryotic hinge heterodimer.	Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Jessberger, R (corresponding author), Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.	rolf.jessberger@mssm.edu			NIGMS NIH HHS [GM 62517] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062517] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Fousteri MI, 2000, EMBO J, V19, P1691, DOI 10.1093/emboj/19.7.1691; GANEA D, 1987, MOL CELL BIOL, V7, P3124, DOI 10.1128/MCB.7.9.3124; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 2003, IUBMB LIFE, V55, P643, DOI 10.1080/15216540310001639661; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Lowe J, 2001, J MOL BIOL, V306, P25, DOI 10.1006/jmbi.2000.4379; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; WARBURTON PE, 1990, J MOL BIOL, V216, P3, DOI 10.1016/S0022-2836(05)80056-7; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	46	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26233	26242		10.1074/jbc.M402439200	http://dx.doi.org/10.1074/jbc.M402439200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087462	hybrid			2022-12-27	WOS:000222003000040
J	Ouko, L; Ziegler, TR; Gu, LH; Eisenberg, LM; Yang, VW				Ouko, L; Ziegler, TR; Gu, LH; Eisenberg, LM; Yang, VW			Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONVERGENT EXTENSION MOVEMENTS; COLORECTAL-CANCER; BETA-CATENIN; WNT/BETA-CATENIN; E-CADHERIN; FRIZZLED HOMOLOGS; MOLECULAR-CLONING; EXPRESSION; MUTATIONS	Wnts are morphogens with well recognized functions during embryogenesis. Aberrant Wnt signaling has been demonstrated to be important in colorectal carcinogenesis. However, the role of Wnt in regulating normal intestinal epithelial cell proliferation is not well established. Here we determine that Wnt11 is expressed throughout the mouse intestinal tract including the epithelial cells. Conditioned media from Wnt11-secreting cells stimulated proliferation and migration of IEC6 intestinal epithelial cells. Co-culture of Wnt11-secreting cells with IEC6 cells resulted in morphological transformation of the latter as evidenced by the formation of foci, a condition also accomplished by stable transfection of IEC6 with a Wnt11-expressing construct. Treatment of IEC6 cells with Wnt11 conditioned media failed to induce nuclear translocation of beta-catenin but led to increased activities of protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Inhibition of protein kinase C resulted in a decreased ability of Wnt11 to induce foci formation in IEC6 cells. Finally, E-cadherin was redistributed in Wnt11-treated IEC6 cells, resulting in diminished E-cadherin-mediated cell-cell contact. We conclude that Wnt11 stimulates proliferation, migration, cytoskeletal rearrangement, and contact-independent growth of IEC6 cells by a beta-catenin-independent mechanism. These findings may help understand the molecular mechanisms that regulate proliferation and migration of intestinal epithelial cells.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA	Emory University; Emory University; Emory University; Medical University of South Carolina	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850, R01DK052230, R24DK064399] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker N, 2000, BIOESSAYS, V22, P961; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BJERKNES M, 1981, AM J ANAT, V160, P105, DOI 10.1002/aja.1001600109; Bond J, 2003, DEV DYNAM, V227, P536, DOI 10.1002/dvdy.10333; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Buyse M, 2003, AM J PATHOL, V163, P1969, DOI 10.1016/S0002-9440(10)63555-9; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Christiansen JH, 1996, ONCOGENE, V12, P2705; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Eisenberg CA, 1999, DEV DYNAM, V216, P45, DOI 10.1002/(SICI)1097-0177(199909)216:1<45::AID-DVDY7>3.0.CO;2-L; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Kirikoshi H, 2001, INT J MOL MED, V8, P651; Kispert A, 1996, DEVELOPMENT, V122, P3627; Kitaeva MN, 1997, CANCER RES, V57, P4478; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; McBride HJ, 2003, DEV BIOL, V256, P18, DOI 10.1016/S0012-1606(02)00118-5; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Millar JBA, 2002, GENOME BIOL, V3; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miyaki M, 1999, CANCER RES, V59, P4506; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Perry I, 1999, J CLIN PATHOL-MOL PA, V52, P166, DOI 10.1136/mp.52.4.166; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; QUARONI A, 1978, P NATL ACAD SCI USA, V75, P5548, DOI 10.1073/pnas.75.11.5548; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Tada M, 2000, DEVELOPMENT, V127, P2227; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theodosiou NA, 2003, DEV BIOL, V259, P258, DOI 10.1016/S0012-1606(03)00185-4; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu LF, 2000, GENE DEV, V14, P585; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yoshida R, 2001, INT J ONCOL, V18, P513; Zschiesche W, 1997, ANTICANCER RES, V17, P561	91	80	86	2	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26707	26715		10.1074/jbc.M402877200	http://dx.doi.org/10.1074/jbc.M402877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084607	Green Accepted, hybrid			2022-12-27	WOS:000222003000097
J	Padilla, S; Jonassen, T; Jimenez-Hidalgo, MA; Fernandez-Ayala, DJM; Lopez-Lluch, G; Marbois, B; Navas, P; Clarke, CF; Santos-Ocana, C				Padilla, S; Jonassen, T; Jimenez-Hidalgo, MA; Fernandez-Ayala, DJM; Lopez-Lluch, G; Marbois, B; Navas, P; Clarke, CF; Santos-Ocana, C			Demethoxy-Q, an intermediate of coenzyme Q biosynthesis, fails to support respiration in Saccharomyces cerevisiae and lacks antioxidant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS CLK-1; MEMBRANE ELECTRON-TRANSPORT; CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; TIMING GENE CLK-1; UBIQUINONE BIOSYNTHESIS; ESCHERICHIA-COLI; POTENTIAL IMPLICATIONS; PLASMA-MEMBRANE; LONGEVITY GENE	Caenorhabditis elegans clk-1 mutants cannot produce coenzyme Q(9) and instead accumulate demethoxy-Q(9) (DMQ(9)). DMQ(9) has been proposed to be responsible for the extended lifespan of clk-1 mutants, theoretically through its enhanced antioxidant properties and its decreased function in respiratory chain electron transport. In the present study, we assess the functional roles of DMQ(6) in the yeast Saccharomyces cerevisiae. Three mutations designed to mirror the clk-1 mutations of C. elegans were introduced into COQ7, the yeast homologue of clk-1: E233K, predicted to disrupt the di-iron carboxylate site considered essential for hydroxylase activity; L237Stop, a deletion of 36 amino acid residues from the carboxyl terminus; and P175Stop, a deletion of the carboxyl-terminal half of Coq7p. Growth on glycerol, quinone content, respiratory function, and response to oxidative stress were analyzed in each of the coq7 mutant strains. Yeast strains lacking Q(6) and producing solely DMQ(6) were respiratory deficient and unable to support either NADH-cytochrome c reductase or succinate-cytochrome c reductase activities. DMQ(6) failed to protect cells against oxidative stress generated by H2O2 or linolenic acid. Thus, in the yeast model system, DMQ does not support respiratory activity and fails to act as an effective antioxidant. These results suggest that the life span extension observed in the C. elegans clk-1 mutants cannot be attributed to the presence of DMQ per se.	Univ Pablo de Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); University of California System; University of California Los Angeles	Santos-Ocana, C (corresponding author), Univ Pablo de Olavide, Ctr Andaluz Biol Desarrollo, Carretera Utrera Km 1, Seville 41013, Spain.	csantos@dex.upo.es	NAVAS, PLACIDO/R-5943-2019; Lopez-Lluch, Guillermo/N-4742-2014; Ocaña, Carlos Santos/E-8115-2011	NAVAS, PLACIDO/0000-0002-4115-7966; Lopez-Lluch, Guillermo/0000-0001-9830-8502; Ocaña, Carlos Santos/0000-0002-2379-796X; Fernandez-Ayala, Daniel Jose Moreno/0000-0001-8176-1431	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG019777, R01AG019777] Funding Source: NIH RePORTER; NIA NIH HHS [AG19777] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi A, 2003, FEBS LETT, V543, P174, DOI 10.1016/S0014-5793(03)00419-8; Asencio C, 2003, FASEB J, V17, P1135, DOI 10.1096/fj.02-1022fje; BAA SW, 2004, J BIOL CHEM, V279, P10052; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berthold DA, 2002, J BIOL CHEM, V277, P43608, DOI 10.1074/jbc.M206724200; Boumans H, 1998, BIOCHEM J, V331, P877, DOI 10.1042/bj3310877; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Burgess J, 2003, J BIOL CHEM, V278, P49555, DOI 10.1074/jbc.M308507200; Davidson JF, 2001, MOL CELL BIOL, V21, P8483, DOI 10.1128/MCB.21.24.8483-8489.2001; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; FRERMAN FE, 1988, BIOCHEM SOC T, V16, P416, DOI 10.1042/bst0160416; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Higuchi R., 1990, PCR PROTOCOLS GUIDE; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Holt SJ, 2003, MECH AGEING DEV, V124, P779, DOI 10.1016/S0047-6374(03)00132-5; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Murakami S, 1996, GENETICS, V143, P1207; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Namy O, 2001, EMBO REP, V2, P787, DOI 10.1093/embo-reports/kve176; Namy O, 2002, MOL MICROBIOL, V43, P641, DOI 10.1046/j.1365-2958.2002.02770.x; Obungu VH, 1998, J BIOL CHEM, V273, P11917, DOI 10.1074/jbc.273.19.11917; Ong WC, 1997, YEAST, V13, P1357, DOI 10.1002/(SICI)1097-0061(199711)13:14<1357::AID-YEA180>3.0.CO;2-3; POON WW, 1997, MOL ASPECTS MED, V18, P121; Prelich G, 1999, TRENDS GENET, V15, P261, DOI 10.1016/S0168-9525(99)01749-7; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Rose MD., 1990, METHODS YEAST GENETI; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Shibata Y, 2003, SCIENCE, V302, P1779, DOI 10.1126/science.1087167; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247; YOUNG IG, 1973, J BACTERIOL, V114, P42, DOI 10.1128/JB.114.1.42-52.1973; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; ZWECK A, 1989, EUR J BIOCHEM, V183, P199, DOI 10.1111/j.1432-1033.1989.tb14913.x	70	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25995	26004		10.1074/jbc.M400001200	http://dx.doi.org/10.1074/jbc.M400001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078893	hybrid, Green Published			2022-12-27	WOS:000222003000010
J	Thorey, IS; Hinz, B; Hoeflich, A; Kaesler, S; Bugnon, P; Elmlinger, M; Wanke, R; Wolf, E; Werner, S				Thorey, IS; Hinz, B; Hoeflich, A; Kaesler, S; Bugnon, P; Elmlinger, M; Wanke, R; Wolf, E; Werner, S			Transgenic mice reveal novel activities of growth hormone in wound repair, angiogenesis, and myofibroblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; FACTOR-BINDING PROTEIN-2; SKIN INCISIONAL WOUNDS; FACTOR-I; IGF-I; TRANSFORMING GROWTH-FACTOR-BETA-1; CULTURED FIBROBLASTS; COLLAGEN LATTICES; MESSENGER-RNA; TISSUE	An increasing number of patients are being treated with growth hormone (GH) for the enhancement of body growth but also as an anti-aging strategy. However, the side effects of GH have been poorly defined. In this study we determined the effect of GH on wound repair and its mechanisms of action at the wound site. For this purpose, we performed wound healing studies in transgenic mice overexpressing GH. Full thickness incisional and excisional wounds of transgenic animals developed extensive, highly vascularized granulation tissue. However, wound bursting strength was not increased. Wound closure was strongly delayed as a result of enhanced granulation tissue formation and impaired wound contraction. The latter effect is most likely due to a significantly reduced number of myofibroblasts at the wound site. By using in vitro studies with stressed collagen lattices, we identified GH as an inhibitor of transforming growth factor beta-induced myofibroblast differentiation, resulting in a reduction in fibroblast contractile activity. These results revealed novel roles of GH in angiogenesis and myofibroblast differentiation, which are most likely not mediated via insulin-like growth factors at the wound site. Furthermore, our data suggested that systemic GH treatment is detrimental for wound healing in healthy individuals.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, D-81377 Munich, Germany; Swiss Fed Inst Technol, Lab Cell Biophys, CH-1015 Lausanne, Switzerland; Univ Tubingen, Childrens Hosp, D-72076 Tubingen, Germany; Univ Munich, Inst Vet Pathol, D-80539 Munich, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Munich; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Munich	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.	Sabine.Werner@cell.biol.ethz.ch		Wanke, Rudiger/0000-0002-0153-224X; Wolf, Eckhard/0000-0002-0430-9510; Werner, Sabine/0000-0001-7397-8710; Hinz, Boris/0000-0002-0526-393X; Hoeflich, Andreas/0000-0003-2018-2836				Ashcroft GS, 2002, J CLIN INVEST, V110, P615, DOI 10.1172/JCI200215704; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BANG P, 1994, J ENDOCRINOL, V143, pC1; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Bitar MS, 1997, HORM METAB RES, V29, P383, DOI 10.1055/s-2007-979060; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; Clemmons David R., 1999, V17, P273; Cummings DE, 2003, ANNU REV MED, V54, P513, DOI 10.1146/annurev.med.54.101601.152147; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dunaiski V, 2002, GROWTH HORM IGF RES, V12, P381, DOI 10.1016/S1096-6374(02)00080-1; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; Eming SA, 1996, J INVEST DERMATOL, V107, P113, DOI 10.1111/1523-1747.ep12298351; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Ghofrani A, 1999, PLAST RECONSTR SURG, V104, P470, DOI 10.1097/00006534-199908000-00020; GIANNINI S, 1994, J CLIN ENDOCR METAB, V79, P1824, DOI 10.1210/jc.79.6.1824; GOULD J, 1995, LIFE SCI, V56, P587, DOI 10.1016/0024-3205(94)00491-A; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; Grose R, 2002, EMBO REP, V3, P575, DOI 10.1093/embo-reports/kvf119; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hoeflich A, 2001, ENDOCRINOLOGY, V142, P1889, DOI 10.1210/en.142.5.1889; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jeschke MG, 1999, GENE THER, V6, P1015, DOI 10.1038/sj.gt.3300923; JYUNG RW, 1994, SURGERY, V115, P233; Kanekar S, 2000, CELL ADHES COMMUN, V7, P513, DOI 10.3109/15419060009040308; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kuroda K, 2001, J DERMATOL SCI, V26, P156, DOI 10.1016/S0923-1811(00)00155-9; Lal SO, 2000, GROWTH HORM IGF RES, V10, P39, DOI 10.1016/S1096-6374(00)80008-8; LEE YR, 1996, ENDOCRINOLOGY, V137, P5378; LYNCH SE, 1989, J CLIN INVEST, V84, P640, DOI 10.1172/JCI114210; Martin JL, 1999, CONT ENDOCRINOL, V17, P227; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; RASMUSSEN LH, 1995, EUR J SURG, V161, P157; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Seyer-Hansen M, 1999, GROWTH HORM IGF RES, V9, P254, DOI 10.1054/ghir.1999.0116; SEYERHANSEN M, 1993, EUR SURG RES, V25, P162, DOI 10.1159/000129273; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STEENFOS HH, 1992, J ENDOCRINOL, V132, P293, DOI 10.1677/joe.0.1320293; Struman I, 1999, P NATL ACAD SCI USA, V96, P1246, DOI 10.1073/pnas.96.4.1246; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wanke R, 1999, J INVEST DERMATOL, V113, P967, DOI 10.1046/j.1523-1747.1999.00807.x; WELSH KM, 1991, J DERMATOL SURG ONC, V17, P942, DOI 10.1111/j.1524-4725.1991.tb01694.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WOLF E, 1994, ENDOCRINOLOGY, V135, P1877, DOI 10.1210/en.135.5.1877; WOLF E, 1996, WELFARE TRANSGENIC A, P26; ZAIZEN Y, 1995, EUR J PEDIATR SURG, V5, P226, DOI 10.1055/s-2008-1066211	48	40	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26674	26684		10.1074/jbc.M311467200	http://dx.doi.org/10.1074/jbc.M311467200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15070902	hybrid			2022-12-27	WOS:000222003000094
J	Zhou, WL; Zhao, Q; Sutton, R; Cumming, H; Wang, X; Cerruti, L; Hall, M; Wu, RQ; Cunningham, JM; Jane, SM				Zhou, WL; Zhao, Q; Sutton, R; Cumming, H; Wang, X; Cerruti, L; Hall, M; Wu, RQ; Cunningham, JM; Jane, SM			The role of p22 NF-E4 in human globin gene switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GAMMA-GLOBIN; LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; HUMAN FETAL; CHROMATIN-STRUCTURE; BETA-THALASSEMIA; IN-VIVO; TRANSCRIPTION	The human stage selector protein, a complex containing the ubiquitous transcription factor CP2 and the erythroid-specific factor p22 NF-E4, facilitates the interaction of the gamma-globin genes with the locus control region in fetal erythroid cells. Enforced expression of p22 NF-E4 in K562 cells and human cord blood progenitors increases fetal globin gene expression, and in progenitors, reduces beta-globin expression. To examine the role of NF-E4 in an in vivo model of hemoglobin switching, we enforced the expression of p22 NF-E4 in transgenic mice carrying the human beta-globin locus yeast artificial chromosome. Although murine erythropoiesis and globin gene expression is unaffected in these mice, the expression profile of the human globin genes is altered. All three transgenic lines displayed an increased gamma:beta-globin ratio in E12.5-14.5 fetal liver, resulting in a delay in the fetal/adult switch. At E12.5, this is primarily due to a reduction of beta-gene expression, whereas at E14.5, the increased gamma:beta ratio is due to enhanced gamma-gene expression. Despite this, the switch in globin subtype is fully completed in the adult bone marrow. These findings indicate that p22 NF-E4 is capable of influencing human globin gene expression in vivo but is incapable of overriding the intrinsic mechanisms governing gamma-gene silencing in this context.	Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38101 USA	Royal Melbourne Hospital; St Jude Children's Research Hospital	Jane, SM (corresponding author), Rotary Bone Marrow Res Lab, Royal Melbourne Hosp PO,Grattan St, Parkville, Vic 3050, Australia.	jane@wehi.edu.au	Zhao, Quan/E-9147-2011; Jane, Stephen/D-6659-2011	Zhao, Quan/0000-0002-8533-1938; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749, R01HL069232] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [R01 HL69232-01, P01 HL53749-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DIGNAM JD, METHODS ENZYMOL, V182, P194; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; METCALF D, 1984, HEAMTOPOIETIC COLONY; MORLEY BJ, 1991, BLOOD, V78, P1355; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; Ristaldi MS, 2001, EMBO J, V20, P5242, DOI 10.1093/emboj/20.18.5242; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Schubeler D, 2000, GENE DEV, V14, P940; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; STARCK J, 1994, BLOOD, V84, P1656; TARAMELLI R, 1986, NUCLEIC ACIDS RES, V14, P7017, DOI 10.1093/nar/14.17.7017; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zhou WL, 2000, MOL CELL BIOL, V20, P7662, DOI 10.1128/MCB.20.20.7662-7672.2000	40	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26227	26232		10.1074/jbc.M402191200	http://dx.doi.org/10.1074/jbc.M402191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084587	hybrid			2022-12-27	WOS:000222003000039
J	Filippova, M; Parkhurst, L; Duerkesen-Hughes, PJ				Filippova, M; Parkhurst, L; Duerkesen-Hughes, PJ			The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; NECROSIS-FACTOR RECEPTOR; HUMAN KERATINOCYTES; MEDIATED APOPTOSIS; HPV E6; E6-ENHANCED SUSCEPTIBILITY; CASPASE-8 ACTIVATION; ADENOVIRUS E4-ORF1; SIGNALING PATHWAY	High risk strains of human papillomavirus (HPV), such as HPV 16, cause human cervical carcinoma. The E6 protein of HPV 16 mediates the rapid degradation of the tumor suppressor p53, although this is not the only function of E6 and cannot completely explain its transforming potential. Previous work in our laboratory has demonstrated that E6 can protect cells from tumor necrosis factor-induced apoptosis by binding to the C-terminal end of tumor necrosis factor R1, thus blocking apoptotic signal transduction. In this study, E6 was shown to also protect cells from apoptosis induced via the Fas pathway. Furthermore, use of an inducible E6 expression system demonstrated that this protection is dose-dependent, with higher levels of E6 leading to greater protection. Although E6 suppresses activation of both caspase 3 and caspase 8, it does not affect apoptotic signaling through the mitochondrial pathway. Mammalian two-hybrid and in vitro pull-down assays were then used to demonstrate that E6 binds directly to the death effector domain of Fas-associated death domain (FADD), with deletion and site-directed mutants enabling the localization of the E6-binding site to the N-terminal end of the FADD death effector domain. E6 is produced in two forms as follows: a full-length version of similar to16 kDa and a smaller version of about half that size corresponding to the N-terminal half of the full-length protein. Pull-down and functional assays demonstrated that the full-length version, but not the small version of E6, was able to bind to FADD and to protect cells from Fas-induced apoptosis. In addition, binding to E6 leads to degradation of FADD, with the loss of cellular FADD proportional to the amount of E6 expressed. These results support a model in which E6-mediated degradation of FADD prevents transmission of apoptotic signals via the Fas pathway.	Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, Loma Linda, CA 92354 USA	Loma Linda University	Duerkesen-Hughes, PJ (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, 11085 Campus St,121 Mortensen Hall, Loma Linda, CA 92354 USA.	pdhughes@som.llu.edu	Duerksen-Hughes, Penelope/A-3488-2008	Duerksen-Hughes, Penelope/0000-0002-0998-2157	NCI NIH HHS [1R01 CA095461-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Aguilar-Lemarroy A, 2001, INT J CANCER, V93, P823, DOI 10.1002/ijc.1405; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; Be XB, 2001, BIOCHEMISTRY-US, V40, P1293, DOI 10.1021/bi0019592; Benedict CA, 2003, CYTOKINE GROWTH F R, V14, P349, DOI 10.1016/S1359-6101(03)00030-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; Degenhardt YY, 2001, J VIROL, V75, P11791, DOI 10.1128/JVI.75.23.11791-11802.2001; Du MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962, DOI 10.1016/S0006-291X(02)02041-7; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; Fogel S, 1998, VIROLOGY, V244, P97, DOI 10.1006/viro.1998.9086; Gao QS, 1999, MOL CELL BIOL, V19, P733; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hay S, 2002, J GEN VIROL, V83, P1547, DOI 10.1099/0022-1317-83-7-1547; HOWLEY PM, 1992, PRINCESS TAKAMATSU S, V22, P239; Hu SM, 1997, J BIOL CHEM, V272, P9621; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Inoue T, 1998, MOL CARCINOGEN, V21, P215; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kabsch K, 2002, ONCOGENE, V21, P947, DOI 10.1038/sj.onc.1205147; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kim PKM, 2003, BIOCHEM BIOPH RES CO, V302, P290, DOI 10.1016/S0006-291X(03)00186-4; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kobayashi T, 2001, Nihon Jibiinkoka Gakkai Kaiho, V104, P139; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Langelier Y, 2002, J GEN VIROL, V83, P2779, DOI 10.1099/0022-1317-83-11-2779; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MCNICOL P, 1995, J CLIN MICROBIOL, V33, P1169, DOI 10.1128/JCM.33.5.1169-1173.1995; Mishima K, 2003, INT J CANCER, V105, P593, DOI 10.1002/ijc.11133; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Shisler JL, 2001, VIROLOGY, V282, P14, DOI 10.1006/viro.2001.0834; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Spitkovsky D, 1996, ONCOGENE, V13, P1027; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivenugopal KS, 2002, ONCOGENE, V21, P5940, DOI 10.1038/sj.onc.1205762; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tourneur L, 2003, ONCOGENE, V22, P2795, DOI 10.1038/sj.onc.1206399; TROSSMESILATY S, 1998, P NATL ACAD SCI USA, V95, P8058; Tsukumo S, 1999, GENES CELLS, V4, P541, DOI 10.1046/j.1365-2443.1999.00280.x; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Yang J, 1998, CARCINOGENESIS, V19, P1117, DOI 10.1093/carcin/19.6.1117; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	90	123	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25729	25744		10.1074/jbc.M401172200	http://dx.doi.org/10.1074/jbc.M401172200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073179	hybrid			2022-12-27	WOS:000221827900103
J	Morenilla-Palao, C; Planells-Cases, R; Garcia-Sanz, N; Ferrer-Montiel, A				Morenilla-Palao, C; Planells-Cases, R; Garcia-Sanz, N; Ferrer-Montiel, A			Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR; SYNAPTOTAGMIN-IX; VR1; ACTIVATION; PHOSPHORYLATION; DESENSITIZATION; SENSITIZATION; DETERMINANT; NOCICEPTION; RELEASE	The vanilloid receptor-1 (TRPV1) plays a key role in the perception of peripheral thermal and inflammatory pain. TRPV1 expression and channel activity are notably up-regulated by proalgesic agents. The transduction pathways involved in TRPV1 sensitization are still elusive. We have used a yeast two-hybrid screen to identify proteins that associate with the N terminus of TRPV1. We report that two vesicular proteins, Snapin and synaptotagmin IX (Syt IX), strongly interact in vitro and in vivo with the TRPV1 N-terminal domain. In primary dorsal root ganglion neurons, TRPV1 co-distributes in vesicles with Syt IX and the vesicular protein synaptobrevin. Neither Snapin nor Syt IX affected channel function, but they notably inhibited protein kinase C (PKC)-induced potentiation of TRPV1 channel activity with a potency that rivaled the blockade evoked by botulinum neurotoxin A, a potent blocker of neuronal exocytosis. Noteworthily, we found that PKC activation induced a rapid delivery of functional TRPV1 channels to the plasma membrane. Botulinum neurotoxin A blocked the TRPV1 membrane translocation induced by PKC that was activated with a phorbol ester or the metabotropic glutamate receptor mGluR5. Therefore, our results indicate that PKC signaling promotes at least in part the SNARE-dependent exocytosis of TRPV1 to the cell surface. Taken together, these findings imply that activity-dependent delivery of channels to the neuronal surface may contribute to the buildup and maintenance of thermal inflammatory hyperalgesia in peripheral nociceptor terminals.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Elche, Alicante, Spain	Universidad Miguel Hernandez de Elche	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Ave Ferrocarril S-N, Elche, Alicante, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Morenilla-Palao, Cruz/0000-0002-8159-1206				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Blanes-Mira C, 2001, BIOCHEMISTRY-US, V40, P2234, DOI 10.1021/bi001919y; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Crandall M, 2002, PAIN, V98, P109, DOI 10.1016/S0304-3959(02)00034-9; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Eaton BA, 2000, J NEUROSCI, V20, P7334; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Haberman Y, 2003, J CELL SCI, V116, P4307, DOI 10.1242/jcs.00719; Hu HJ, 2002, J NEUROSCI, V22, P7444; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Nakahara K, 1997, J NEUROCHEM, V69, P1467; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Yang Y, 2002, P NATL ACAD SCI USA, V99, P17060, DOI 10.1073/pnas.242624699; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu HL, 2002, P NATL ACAD SCI USA, V99, P17055, DOI 10.1073/pnas.232588899	42	311	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25665	25672		10.1074/jbc.M311515200	http://dx.doi.org/10.1074/jbc.M311515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066994	hybrid			2022-12-27	WOS:000221827900095
J	Puig-Kroger, A; Serrano-Gomez, D; Caparros, E; Dominguez-Soto, A; Relloso, M; Colmenares, M; Martinez-Munoz, L; Longo, N; Sanchez-Sanchez, N; Rincon, M; Rivas, L; Sanchez-Mateos, P; Fernandez-Ruiz, E; Corbi, AL				Puig-Kroger, A; Serrano-Gomez, D; Caparros, E; Dominguez-Soto, A; Relloso, M; Colmenares, M; Martinez-Munoz, L; Longo, N; Sanchez-Sanchez, N; Rincon, M; Rivas, L; Sanchez-Mateos, P; Fernandez-Ruiz, E; Corbi, AL			Regulated expression of the pathogen receptor dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin in THP-1 human leukemic cells, monocytes, and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; DC-SIGN CD209; TGF-BETA; DIFFERENTIATION; ANTIGEN; IL-4; INTERLEUKIN-4; MATURATION; IDENTIFICATION; PROGENITORS	Dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is a type II C-type lectin that functions as an adhesion receptor and mediates binding and internalization of pathogens such as virus (human immunodeficiency virus, hepatitis C), bacteria (Mycobacterium), fungi, and parasites. DC-SIGN expression in vivo is primarily restricted to interstitial dendritic cells (DC) and certain tissue macrophages. We now report that leukemic THP-1 cells, widely used as a model for monocyte-macrophage differentiation, express very low basal levels of DC-SIGN and that DC-SIGN expression in THP-1 cells is regulated during differentiation. Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13. DC-SIGN up-regulation required a functional JAK-STAT signaling pathway, was inhibited in the presence of lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha), and conferred THP-1 cells with increased pathogen recognition and T cell stimulatory capabilities. The up-regulation of DC-SIGN on THP-1 cells resembles its inducible expression on monocytes and macrophages, where DC-SIGN expression is also induced by IL-4/IL-13 and negatively regulated by TNF-alpha, LPS, and vitamin D-3. These results point to THP-1 cells as a useful cellular system to characterize the pathogen-binding capabilities of DC-SIGN and to dissect the molecular mechanisms that control its regulated and tissue-specific expression in myeloid dendritic cells, and the results suggest that DC-SIGN constitutes a marker for both DC and alternatively activated macrophages.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Hosp Univ Gregorio Maranon, Unidad Inmunooncol, Madrid 28006, Spain; Univ Vermont, Dept Med & Immunobiol, Burlington, VT 05405 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); General University Gregorio Maranon Hospital; University of Vermont	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maetzu 9, Madrid 28040, Spain.	acorbi@cib.csic.es	Sanchez-Mateos, Paloma/E-8931-2013; Colmenares, Maria Isabel/H-2848-2017; Serrano-Gómez, Diego/W-2857-2018; Relloso, Miguel/K-2238-2014; DOMINGUEZ-SOTO, ANGELES/K-5937-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Martínez-Muñoz, Laura/C-2719-2017; Fernández-Ruiz, Elena/A-7971-2019; Rivas, Luis/O-8657-2017; Puig, Amaya/B-6164-2015; Caparrós, Esther/AHD-3233-2022	Colmenares, Maria Isabel/0000-0003-4114-277X; Serrano-Gómez, Diego/0000-0003-4965-8869; Relloso, Miguel/0000-0002-9181-2244; Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Martínez-Muñoz, Laura/0000-0003-3098-279X; Fernández-Ruiz, Elena/0000-0001-5380-1686; Rivas, Luis/0000-0002-2958-3233; Puig, Amaya/0000-0003-2943-9757; Caparrós, Esther/0000-0002-9681-0408; Dominguez Soto, Angeles/0000-0003-1299-5992				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BOMBARA C, 1992, J CELL PHYSIOL, V153, P30, DOI 10.1002/jcp.1041530106; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029; Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231; Chen Z, 2003, J IMMUNOL, V171, P3627, DOI 10.4049/jimmunol.171.7.3627; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HART PH, 1995, J LEUKOCYTE BIOL, V57, P909, DOI 10.1002/jlb.57.6.909; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; Kodelja V, 1998, J IMMUNOL, V160, P1411; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; LAUENER RP, 1990, EUR J IMMUNOL, V20, P2375, DOI 10.1002/eji.1830201103; LENT PL, 2003, ARTHRITIS RHEUM, V48, P360; Li Y, 1997, LEUKEMIA RES, V21, P391, DOI 10.1016/S0145-2126(96)00078-1; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rougier N, 1998, EUR J CELL BIOL, V75, P287, DOI 10.1016/S0171-9335(98)80124-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; St Louis DC, 1999, J IMMUNOL, V162, P3237; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VEY E, 1992, J IMMUNOL, V149, P2040; WONG HL, 1992, J IMMUNOL, V148, P2118; Zhu JF, 2000, J EXP MED, V192, P1125, DOI 10.1084/jem.192.8.1125	41	82	89	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25680	25688		10.1074/jbc.M311516200	http://dx.doi.org/10.1074/jbc.M311516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070901	hybrid, Green Published			2022-12-27	WOS:000221827900097
J	Bonnevier, J; Arner, A				Bonnevier, J; Arner, A			Actions downstream of cyclic GMP/protein kinase G can reverse protein kinase C-mediated phosphorylation of CPI-17 and Ca2+ sensitization in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN DEPHOSPHORYLATION; MYOSIN-BINDING SUBUNIT; SIGNAL-TRANSDUCTION; INHIBITORY PHOSPHOPROTEIN; RHO-KINASE; PHOSPHATASE; ACTIVATION; CONTRACTION; SENSITIVITY; MODULATION	Ca2+ sensitivity of smooth muscle contraction is modulated by several systems converging on myosin light chain phosphatase (MLCP). Rho-Rho kinase is considered to inhibit MLCP via phosphorylation, whereas protein kinase C (PKC) induced sensitization has been shown to be dependent on phosphorylation of the inhibitory protein CPI-17. We have explored the interaction of cGMP-dependent protein kinase (PKG) with Ca2+ sensitization pathways using permeabilized mouse smooth muscle. Three conditions giving similar to 50% of maximal active force were compared in small intestinal preparations: 1) Ca2+-activated unsensitized muscle (pCa 5.9 with Rho kinase inhibitor Y27632); 2) Rho-Rho kinase-sensitized muscle (pCa 6.1 with guanosine 5'-3-O-(thio) triphosphate); and 3) PKC-sensitized muscle ( pCa 6.0 with Y27632 and PKC activator phorbol 12,13-dibutyrate). 8-Br-cGMP relaxed the sensitized muscles but had marginal effects on unsensitized preparations, showing that PKG reverses both PKC and Rho-mediated Ca2+ sensitization. CPI-17 was present in permeabilized intestinal tissue. In PKC-sensitized preparations, CPI-17 phosphorylation decreased in response to 8-Br-cGMP. The rate of PKC-mediated phosphorylation in the presence of the MLCP inhibitor microcystin-LR was not influenced by 8-Br-cGMP. PKC-induced Ca2+ sensitization also was reversed in vascular smooth muscle tissues ( portal vein and femoral artery). We conclude that actions downstream of cGMP/PKG can reverse PKC-mediated phosphorylation of CPI-17 and Ca2+ sensitization in smooth muscle.	Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden	Lund University	Arner, A (corresponding author), Lund Univ, Dept Physiol Sci, BMC F11, SE-22184 Lund, Sweden.	Anders.Arner@mphy.lu.se						Arner A, 1999, Rev Physiol Biochem Pharmacol, V134, P63; Beall AC, 1997, J BIOL CHEM, V272, P11283; Bonnevier J, 2004, J BIOL CHEM, V279, P5146, DOI 10.1074/jbc.M306532200; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dubois T, 2003, BIOCHEM BIOPH RES CO, V302, P186, DOI 10.1016/S0006-291X(03)00130-X; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Eto M, 2002, NEURON, V36, P1145, DOI 10.1016/S0896-6273(02)01107-8; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; Hayashi Y, 2001, J BIOL CHEM, V276, P39858, DOI 10.1074/jbc.M107302200; Hofmann F, 2000, J CELL SCI, V113, P1671; JIANG H, 1992, J BIOL CHEM, V267, P1015; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Kitazawa T, 2003, J PHYSIOL-LONDON, V546, P879, DOI 10.1113/jphysiol.2002.029306; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; Lucius C, 1998, J PHYSIOL-LONDON, V506, P83, DOI 10.1111/j.1469-7793.1998.083bx.x; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Ohama T, 2003, J BIOL CHEM, V278, P48794, DOI 10.1074/jbc.M310166200; Ohki SY, 2003, J MOL BIOL, V326, P1539, DOI 10.1016/S0022-2836(03)00048-2; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; STULL JT, 1993, MOL CELL BIOCHEM, V128, P229, DOI 10.1007/BF01076774; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 2002, FEBS LETT, V515, P127, DOI 10.1016/S0014-5793(02)02451-1; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; Toth A, 2000, FEBS LETT, V484, P113, DOI 10.1016/S0014-5793(00)02138-4; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	53	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28998	29003		10.1074/jbc.M404259200	http://dx.doi.org/10.1074/jbc.M404259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123611	hybrid			2022-12-27	WOS:000222445300022
J	Garate, M; Cao, ZY; Bateman, E; Panjwani, N				Garate, M; Cao, ZY; Bateman, E; Panjwani, N			Cloning and characterization of a novel mannose-binding protein of Acanthamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIUM; LECTIN; CASTELLANII; KERATITIS; SEQUENCE; IDENTIFICATION; CONTAMINATION; PREDICTION; ADHERENCE; CLEAVAGE	Acanthamoebae produce a painful, blinding infection of the cornea. The mannose-binding protein (MBP) of Acanthamoeba is thought to play a key role in the pathogenesis of the infection by mediating the adhesion of parasites to the host cells. We describe here the isolation and molecular cloning of Acanthamoeba MBP. The MBP was isolated by chromatography on the mannose affinity gel. Gel filtration experiments revealed that the Acanthamoeba lectin is a similar to400-kDa protein that is constituted of multiple 130-kDa subunits. Cloning and sequencing experiments indicated that the Acanthamoeba MBP gene is composed of 6 exons and 5 introns that span 3.6 kb of the amoeba genome and that MBP cDNA codes for a precursor protein of 833 amino acids. That the cloned cDNA encodes authentic MBP was demonstrated by showing that: (i) recombinant MBP possesses mannose binding activity, and (ii) polyclonal antibodies prepared against Acanthamoeba MBP bound to the recombinant protein. Sequence analysis revealed that the MBP contains a large N-terminal extracellular domain, a transmembrane domain, and a short C-terminal cytoplasmic domain. Despite extensive BLAST searches using the MBP sequence, no significant matches were retrieved. The most striking feature of the Acanthamoeba MBP sequence is the presence of a cysteine-rich region containing 14 CXCXC motifs within the extracellular domain. In summary, we have isolated, cloned, and characterized a novel MBP from Acanthamoeba. Because the presence of antibodies to MBP in tears provides protection against infection, the availability of the MBP cDNA sequence and rMBP should help develop: ( i) a tear-based test to identify individuals who are at risk of developing the keratitis and ( ii) strategies to immunize high-risk individuals.	Tufts Univ, Sch Med, Ctr Vis Res, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol, Burlington, VT 05405 USA	Tufts University; Tufts University; Tufts University; University of Vermont	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Ctr Vis Res, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.	Noorjahan.Panjwani@tufts.edu			NATIONAL EYE INSTITUTE [R01EY008706, P30EY013078, R29EY008706, R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EYP30-13078, EY09349, EY08706] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Burge CB, 1998, N COMP BIOC, V32, P129; Cao ZY, 1998, J BIOL CHEM, V273, P15838, DOI 10.1074/jbc.273.25.15838; Case ST, 1997, J MOL EVOL, V44, P452, DOI 10.1007/PL00006165; Cohen EJ, 1996, CORNEA, V15, P566, DOI 10.1097/00003226-199611000-00005; DEJONCKHEERE JF, 1980, APPL ENVIRON MICROB, V39, P681, DOI 10.1128/AEM.39.4.681-685.1980; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; JENSEN T, 1970, J PARASITOL, V56, P904, DOI 10.2307/3277503; Joukov V, 1996, EMBO J, V15, P290; Kilvington S, 2004, INVEST OPHTH VIS SCI, V45, P165, DOI 10.1167/iovs.03-0559; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar R, 2002, CLIN INFECT DIS, V35, P434, DOI 10.1086/341487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN DFP, 1990, BRIT J OPHTHALMOL, V74, P133, DOI 10.1136/bjo.74.3.133; LARKIN DFP, 1991, EYE, V5, P70, DOI 10.1038/eye.1991.14; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; Madden TL, 1996, METHOD ENZYMOL, V266, P131; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003; Marciano-Cabral F, 2000, J EUKARYOT MICROBIOL, V47, P29, DOI 10.1111/j.1550-7408.2000.tb00007.x; McCulley James P., 2000, CLAO Journal, V26, P47; MOORE MB, 1991, CORNEA, V10, P291, DOI 10.1097/00003226-199107000-00003; MORTON LD, 1991, INFECT IMMUN, V59, P3819, DOI 10.1128/IAI.59.10.3819-3822.1991; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Panjwani N, 1997, INVEST OPHTH VIS SCI, V38, P1858; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Radford CF, 2002, BRIT J OPHTHALMOL, V86, P536, DOI 10.1136/bjo.86.5.536; Sack RA, 2002, ADV EXP MED BIOL, V506, P539; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sathe S, 1998, CURR EYE RES, V17, P348, DOI 10.1080/02713689808951215; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Srinivasan Muthaiah, 2003, Med Sci Monit, V9, pCR125; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; TANNICH E, 1991, P NATL ACAD SCI USA, V88, P1849, DOI 10.1073/pnas.88.5.1849; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; VANKLINK F, 1992, CURR EYE RES, V11, P1207, DOI 10.3109/02713689208999546; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; Yang ZT, 1997, INFECT IMMUN, V65, P439, DOI 10.1128/IAI.65.2.439-445.1997	45	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29849	29856		10.1074/jbc.M402334200	http://dx.doi.org/10.1074/jbc.M402334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117936	hybrid			2022-12-27	WOS:000222445300122
J	Perdomo, G; Commerford, SR; Richard, AMT; Adams, SH; Corkey, BE; O'Doherty, RM; Brown, NF				Perdomo, G; Commerford, SR; Richard, AMT; Adams, SH; Corkey, BE; O'Doherty, RM; Brown, NF			Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; CARNITINE PALMITOYLTRANSFERASE-I; DEPENDENT DIABETES-MELLITUS; KINASE-C; WEIGHT-LOSS; QUANTITATIVE MEASUREMENT; P38 MAPK; SENSITIVITY; TRANSPORT; RATS	Skeletal muscle insulin resistance may be aggravated by intramyocellular accumulation of fatty acid-derived metabolites that inhibit insulin signaling. We tested the hypothesis that enhanced fatty acid oxidation in myocytes should protect against fatty acid-induced insulin resistance by limiting lipid accumulation. L6 myotubes were transduced with adenoviruses encoding carnitine palmitoyltransferase I (CPT I) isoforms or beta-galactosidase (control). Two to 3-fold overexpression of L-CPT I, the endogenous isoform in L6 cells, proportionally increased oxidation of the long-chain fatty acids palmitate and oleate and increased insulin stimulation of [C-14] glucose incorporation into glycogen by 60% while enhancing insulin-stimulated phosphorylation of p38MAPK. Incubation of control cells with 0.2 mM palmitate for 18 h caused accumulation of triacylglycerol, diacylglycerol, and ceramide ( but not long-chain acyl-CoA) and decreased insulin-stimulated [C-14] glucose incorporation into glycogen ( 60%), [H-3] deoxyglucose uptake ( 60%), and protein kinase B phosphorylation (20%). In the context of L-CPT I overexpression, palmitate preincubation produced a relative decrease in insulin-stimulated incorporation of [C-14] glucose into glycogen ( 60%) and [H-3] deoxyglucose uptake (40%) but did not inhibit phosphorylation of protein kinase B. Due to the enhancement of insulin-stimulated glucose metabolism induced by L-CPT I overexpression itself, net insulin-stimulated incorporation of [C-14] glucose into glycogen and [H-3] deoxyglucose uptake in L-CPT I-transduced, palmitate-treated cells were significantly greater than in palmitate-treated control cells ( 71 and 75% greater, respectively). However, L-CPT I overexpression failed to decrease intracellular triacylglycerol, diacylglycerol, ceramide, or long-chain acyl-CoA. We propose that accelerated beta-oxidation in muscle cells exerts an insulin-sensitizing effect independently of changes in intracellular lipid content.	Univ Pittsburgh, Div Endocrinol & Metab, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Obes Res Ctr, Boston, MA 02118 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Boston University; Boston University; Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, NF (corresponding author), Univ Pittsburgh, Div Endocrinol & Metab, Dept Med, E1140 BST,200 Lothrop St, Pittsburgh, PA 15261 USA.	brownn@msx.dept-med.pitt.edu	Perdomo, German/K-6703-2014; Corkey, Barbara/E-7712-2015	Perdomo, German/0000-0002-2301-0012; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [R01 DK58855-01, DK46204, T32-DK07052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007052, R01DK058855] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balon TW, 2001, MED SCI SPORT EXER, V33, P382, DOI 10.1097/00005768-200103000-00008; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERRY MN, 1991, ISOLATED HEPATOCYTES, P172; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; Brown NF, 1997, BIOCHEM J, V327, P225, DOI 10.1042/bj3270225; Brown Nicholas F, 2003, Methods Mol Biol, V228, P281, DOI 10.1385/1-59259-400-X:281; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Cooney GJ, 2002, ANN NY ACAD SCI, V967, P196; DANNO H, 1992, J NUTR SCI VITAMINOL, V38, P517, DOI 10.3177/jnsv.38.517; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; DZCZEPANIAK LS, 1999, AM J PHYSIOL, V276, pE977; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Helge JW, 2003, DIABETES, V52, P1881, DOI 10.2337/diabetes.52.8.1881; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002; Huppertz C, 2001, J BIOL CHEM, V276, P12520, DOI 10.1074/jbc.M011708200; Ide T, 2000, METABOLISM, V49, P521, DOI 10.1016/S0026-0495(00)80019-0; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; KELLEY DE, 1990, J CLIN INVEST, V86, P1999, DOI 10.1172/JCI114935; Kern PA, 1999, J CLIN ENDOCR METAB, V84, P4185, DOI 10.1210/jc.84.11.4185; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lau R, 2001, AM J PHYSIOL-ENDOC M, V281, pE122, DOI 10.1152/ajpendo.2001.281.1.E122; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Magnan C, 1996, LIPIDS, V31, P1141, DOI 10.1007/BF02524288; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; RANDLE PJ, 1963, LANCET, V1, P785; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rubi B, 2002, BIOCHEM J, V364, P219, DOI 10.1042/bj3640219; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; SPRINGER ML, 1997, CURRENT PROTOCOLS HU; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V282, pE593, DOI 10.1152/ajpendo.00303.2001; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tremblay F, 2001, J BIOL CHEM, V276, P38052; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wasada T, 2002, INTERNAL MED, V41, P84, DOI 10.2169/internalmedicine.41.84; Webster JM, 1996, BBA-MOL BASIS DIS, V1316, P109, DOI 10.1016/0925-4439(96)00011-7; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	71	125	131	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27177	27186		10.1074/jbc.M403566200	http://dx.doi.org/10.1074/jbc.M403566200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105415	hybrid			2022-12-27	WOS:000222120400044
J	Scott, EE; White, MA; He, YA; Johnson, EF; Stout, CD; Halpert, JR				Scott, EE; White, MA; He, YA; Johnson, EF; Stout, CD; Halpert, JR			Structure of mammalian cytochrome P4502B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-angstrom resolution - Insight into the range of P450 conformations and the coordination of redox partner binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; THERMOPHILIC CYTOCHROME-P450; ANGSTROM RESOLUTION; RABBIT LIVER; SUBSTRATE; PROTEIN; IDENTIFICATION; MONOOXYGENASE; MECHANISM	A 1.9-Angstrom molecular structure of the microsomal cytochrome P450 2B4 with the specific inhibitor 4-(4-chlorophenyl) imidazole (CPI) in the active site was determined by x-ray crystallography. In contrast to the previous experimentally determined 2B4 structure, this complex adopted a closed conformation similar to that observed for the mammalian 2C enzymes. The differences between the open and closed structures of 2B4 were primarily limited to the lid domain of helices F through G, helices B' and C, the N terminus of helix I, and the beta(4) region. These large-scale conformational changes were generally due to the relocation of conserved structural elements toward each other with remarkably little remodeling at the secondary structure level. For example, the F' and G' helices were maintained with a sharp turn between them but are placed to form the exterior ceiling of the active site in the CPI complex. CPI was closely surrounded by residues from substrate recognition sites 1, 4, 5, and 6 to form a small, isolated hydrophobic cavity. The switch from open to closed conformation dramatically relocated helix C to a more proximal position. As a result, heme binding interactions were altered, and the putative NADPH-cytochrome P450 reductase binding site was reformed. This suggests a structural mechanism whereby ligand-induced conformational changes may coordinate catalytic activity. Comparison of the 2B4/CPI complex with the open 2B4 structure yields insights into the dynamics involved in substrate access, tight inhibitor binding, and coordination of substrate and redox partner binding.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Scripps Research Institute; Scripps Research Institute	Scott, EE (corresponding author), Univ Kansas, Dept Med Chem, 1251 Wescoe Hall Dr,4070 Malott Hall, Lawrence, KS 66045 USA.	eescott@ku.edu	White, Mark Andrew/B-1723-2012	White, Mark Andrew/0000-0003-1057-4203	NIEHS NIH HHS [ES03619, ES06676] Funding Source: Medline; NIGMS NIH HHS [GM31001, GM20674] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003619, P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZC, 2004, BIOCHEMISTRY-US, V43, P1798, DOI 10.1021/bi034920g; DeLano WL, 2002, PYMOL USERS MANUAL; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Domanski TL, 2001, ARCH BIOCHEM BIOPHYS, V394, P21, DOI 10.1006/abbi.2001.2504; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Harlow GR, 1996, ARCH BIOCHEM BIOPHYS, V326, P85, DOI 10.1006/abbi.1996.0050; HASLER JA, 1994, MOL PHARMACOL, V46, P338; KANAEVA IP, 1992, ARCH BIOCHEM BIOPHYS, V298, P403, DOI 10.1016/0003-9861(92)90428-Y; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehnerer M, 2000, J BIOCHEM, V127, P163, DOI 10.1093/oxfordjournals.jbchem.a022578; LESLIE AGW, 1994, MOSFILM USERS GUIDE; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Lin HL, 2003, J PHARMACOL EXP THER, V306, P744, DOI 10.1124/jpet.103.050260; Macdonald IDG, 1996, BIOCHEM BIOPH RES CO, V226, P51, DOI 10.1006/bbrc.1996.1310; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Otwinowski Z, 1993, P CCP4 STUD WEEK DAT, P55; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2004, PROTEIN SCI, V13, P255, DOI 10.1110/ps.03384804; Podust LM, 2003, J BIOL CHEM, V278, P12214, DOI 10.1074/jbc.M212210200; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Reed JR, 2003, J INORG BIOCHEM, V97, P276, DOI 10.1016/S0162-0134(03)00310-6; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; SERBE K, 2002, J BIOL CHEM, V277, P47476; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P243, DOI 10.1107/S090744499701041X; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200	42	273	278	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27294	27301		10.1074/jbc.M403349200	http://dx.doi.org/10.1074/jbc.M403349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100217	hybrid			2022-12-27	WOS:000222120400059
J	Wu, ZP; Hasan, A; Liu, TY; Teller, DC; Crabb, JW				Wu, ZP; Hasan, A; Liu, TY; Teller, DC; Crabb, JW			Identification of CRALBP ligand interactions by photoaffinity labeling, hydrogen/deuterium exchange, and structural modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINALDEHYDE-BINDING PROTEIN; VISUAL-PIGMENT REGENERATION; CRYSTAL-STRUCTURE; VITAMIN-E; HYDROGEN-EXCHANGE; MASS-SPECTROMETRY; RETINOIC ACID; BIOCHEMISTRY; PROGRAM	Cellular retinaldehyde-binding protein (CRALBP) functions in the retinal pigment epithelium (RPE) as an acceptor of 11-cis-retinol in the isomerization step of the rod visual cycle and as a substrate carrier for 11-cis-retinol dehydrogenase. Toward a better understanding of CRALBP function, the ligand binding cavity in human recombinant CRALBP (rCRALBP) was characterized by photoaffinity labeling with 3-diazo-4-keto-11-cis-retinal and by high resolution mass spectrometric topological analyses. Eight photoaffinity-modified residues were identified in rCRALBP by liquid chromatography tandem mass spectrometry, including Tyr(179), Phe(197), Cys(198), Met(208), Lys(221), Met(222), Val(223), and Met(225). Multiple different adduct masses were found on the photolabeled residues, and the molecular identity of each modification remains unknown. Supporting the specificity of photolabeling, 50% of the modified residues have been associate with retinoid interactions by independent analyses. In addition, topological analysis of apo- and holo-rCRALBP by hydrogen/deuterium exchange and mass spectrometry demonstrated residues 198 - 255 incorporate significantly less deuterium when the retinoid binding pocket is occupied with 11-cis-retinal. This hydrophobic region encompasses all but one of the photolabeled residues. A structural model of CRALBP ligand binding domain was constructed based on the crystal structures of three homologues in the CRAL-TRIO family of lipid-binding proteins. In the model, all of the photolabeled residues line the ligand binding cavity except Met208, which appears to reside in a flexible loop at the entrance/exit of the ligand cavity. Overall, the results expand to 12 the number of residues proposed to interact with ligand and provide further insight into CRALBP ligand and protein interactions.	Cleveland Clin Fdn, Cole Eye Inst I31, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; University of Washington; University of Washington Seattle	Crabb, JW (corresponding author), Cleveland Clin Fdn, Cole Eye Inst I31, 9500 Euclid Ave, Cleveland, OH 44195 USA.	crabbj@ccf.org			NATIONAL EYE INSTITUTE [R01EY014239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER; NEI NIH HHS [EY14239, EY6603] Funding Source: Medline; NIGMS NIH HHS [GM63020] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behnke CA, 1998, BIOCHEMISTRY-US, V37, P15277, DOI 10.1021/bi9812266; BERNSTEIN PS, 1995, P NATL ACAD SCI USA, V92, P654, DOI 10.1073/pnas.92.3.654; Bhattacharya SK, 2002, FASEB J, V16, pA14; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CHEM COMP GROUP I, 2003, MOE 2003 02; Chen GP, 2000, BIOCHEMISTRY-US, V39, P12568, DOI 10.1021/bi000321n; CHEN Y, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P371; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; CRABB JW, 1991, J BIOL CHEM, V266, P16674; CRABB JW, 1997, CURRENT PROTOCOLS PR, V7; Crouch RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P613, DOI 10.1111/j.1751-1097.1996.tb03114.x; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Golovleva I, 2003, J BIOL CHEM, V278, P12397, DOI 10.1074/jbc.M207300200; Hasan A, 2002, BIOCHEMISTRY-US, V41, P15876, DOI 10.1021/bi026568x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Mata NL, 1998, INVEST OPHTH VIS SCI, V39, P1312; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meier R, 2003, J MOL BIOL, V331, P725, DOI 10.1016/S0022-2836(03)00724-1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Min KC, 2003, P NATL ACAD SCI USA, V100, P14713, DOI 10.1073/pnas.2136684100; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Nawrot M, 2004, INVEST OPHTH VIS SCI, V45, P393, DOI 10.1167/iovs.03-0989; Panagabko C, 2003, BIOCHEMISTRY-US, V42, P6467, DOI 10.1021/bi034086v; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; Saari John C., 1994, P351; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Souto ML, 2000, HELV CHIM ACTA, V83, P2617, DOI 10.1002/1522-2675(20000906)83:9<2617::AID-HLCA2617>3.0.CO;2-9; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Stocker A, 2003, J MOL BIOL, V332, P759, DOI 10.1016/S0022-2836(03)00924-0; Wang LT, 2002, MOL CELL PROTEOMICS, V1, P132, DOI 10.1074/mcp.M100009-MCP200; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Wu ZP, 2003, J BIOL CHEM, V278, P12390, DOI 10.1074/jbc.M212775200; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	48	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27357	27364		10.1074/jbc.M401960200	http://dx.doi.org/10.1074/jbc.M401960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100222	hybrid			2022-12-27	WOS:000222120400066
J	Hallier, M; Ivanova, N; Rametti, A; Pavlov, M; Ehrenberg, MN; Felden, B				Hallier, M; Ivanova, N; Rametti, A; Pavlov, M; Ehrenberg, MN; Felden, B			Pre-binding of small protein B to a stalled ribosome triggers trans-translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; 10SA RNA; TAGGING SYSTEM; TMRNA; SMPB; DEGRADATION; COMPETITION; RESCUE; SITE	To rescue stalled ribosomes, eubacteria employ a molecule, transfer messenger RNA ( tmRNA), which functions both as a tRNA and as an mRNA. With the help of small protein B ( SmpB), tmRNA restarts protein synthesis and adds by the trans-translation mechanism a peptide tag to the stalled protein to target it for destruction by cellular proteases. Here, the cellular location and expression of endogenous SmpB were monitored in vivo. We report that SmpB is associated with 70S ribosomes and not in the soluble fraction, independently of the presence of tmRNA. In vitro, SmpB that is pre-bound to a stalled ribosome can trigger initiation of trans-translation. Our results demonstrate the existence of a novel pathway for the entry of tmRNA to the ribosome and for the trans-transfer of a nascent peptide chain from peptidyl-tRNA to charged tmRNA.	Univ Rennes 1, Unite Propre Rech & Enseignement Super Jeune Equi, F-35043 Rennes, France; Uppsala Univ, BMC, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Universite de Rennes; Uppsala University	Felden, B (corresponding author), Univ Rennes 1, Unite Propre Rech & Enseignement Super Jeune Equi, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.	bfelden@univ-rennes1.fr	felden, brice/L-4825-2015; Hallier, Marc/L-2031-2015					Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; Collier J, 2002, MOL MICROBIOL, V45, P745, DOI 10.1046/j.1365-2958.2002.03045.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Felden B, 1999, BBA-GENE STRUCT EXPR, V1446, P145, DOI 10.1016/S0167-4781(99)00085-8; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; JELENC PC, 1980, ANAL BIOCHEM, V105, P369, DOI 10.1016/0003-2697(80)90472-8; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Komine Y, 1996, J BIOCHEM-TOKYO, V119, P463; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; RUDINGERTHIRION J, 1999, RNA, V5, P1; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612	33	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25978	25985		10.1074/jbc.M314086200	http://dx.doi.org/10.1074/jbc.M314086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069072	hybrid			2022-12-27	WOS:000222003000008
J	Herbst, R; Marciano-Cabral, F; Leippe, M				Herbst, R; Marciano-Cabral, F; Leippe, M			Antimicrobial and pore-forming peptides of free-living and potentially highly pathogenic Naegleria fowleri are released from the same precursor molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEINS; ENTAMOEBA-HISTOLYTICA; PROTEOLYSIS; PROSAPOSIN; ANTIBACTERIAL; AMOEBAPORES; MECHANISM; INSECT; CELLS	The pore-forming polypeptides of Naegleria fowleri, naegleriapores A and B, are processed from separate multipeptide precursor structures. According to their transcripts, each precursor molecule appears to contain additional naegleriapore-like polypeptides, all of which share a structural motif of six invariant cysteine residues within their amino acid sequence. To identify the putative pronaegleriapore-derived peptides at the protein level, amoebic extracts were screened for small cysteine-rich polypeptides by fluorescently labeling their cysteine residues. Three novel naegleriapore isoforms derived from the precursor molecule of naegleriapore B were identified. Two of the isoforms were purified to homogeneity and tested for their biological activity. The pore-forming activity of the novel peptides was remarkably lower than that of the originally isolated naegleriapores, but both peptides killed bacteria by permeabilizing their cytoplasmic membranes. Collectively, these results indicate that naegleriapore isoforms with antibacterial and pore-forming activity are proteolytically released from the same precursor protein, presumably to generate a phylogenetically ancient complementary antimicrobial arsenal.	Univ Kiel, Inst Zool, D-24098 Kiel, Germany; Ruhr Univ Bochum, Dept Special Zool, D-44780 Bochum, Germany; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA	University of Kiel; Ruhr University Bochum; Virginia Commonwealth University	Leippe, M (corresponding author), Univ Kiel, Inst Zool, Olshausenstr 40, D-24098 Kiel, Germany.	mleippe@zoologie.uni-kiel.de	Leippe, Matthias/AAP-1677-2020	Herbst, Rosa/0000-0002-2379-7433				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; FULFORD DE, 1986, J PROTOZOOL, V33, P498, DOI 10.1111/j.1550-7408.1986.tb05649.x; Herbst R, 2002, J BIOL CHEM, V277, P22353, DOI 10.1074/jbc.M201475200; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; MA P, 1990, REV INFECT DIS, V12, P490; MARCIANOCABRAL F, 1988, MICROBIOL REV, V52, P114, DOI 10.1128/MMBR.52.1.114-133.1988; Nickel R, 1999, EUR J BIOCHEM, V265, P1002, DOI 10.1046/j.1432-1327.1999.00807.x; OKEEFE DO, 1994, ANAL BIOCHEM, V222, P86, DOI 10.1006/abio.1994.1458; Pena SV, 1997, J IMMUNOL, V158, P2680; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TERRY AS, 1988, J BIOL CHEM, V263, P5745; YOUNG JDE, 1989, J BIOL CHEM, V264, P1077; Zaltash S, 1998, FEBS LETT, V423, P1, DOI 10.1016/S0014-5793(97)01582-2; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	21	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25955	25958		10.1074/jbc.M401965200	http://dx.doi.org/10.1074/jbc.M401965200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075336	hybrid			2022-12-27	WOS:000222003000005
J	Hwang, SG; Ryu, JH; Kim, IC; Jho, EH; Jung, HC; Kim, K; Kim, SJ; Chun, JS				Hwang, SG; Ryu, JH; Kim, IC; Jho, EH; Jung, HC; Kim, K; Kim, SJ; Chun, JS			Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; PROTEIN-KINASE-C; CHICK LIMB BUD; BETA-CATENIN; N-CADHERIN; EXPRESSION; CHONDROGENESIS; GROWTH; DEDIFFERENTIATION; OSTEOARTHRITIS	Although regulation of chondrogenesis and cartilage development by Wnt signaling is well established, the function of Wnt in the maintenance and destruction of cartilage remains largely unknown. Here we investigated the involvement and regulatory mechanisms of Wnt signaling in cartilage destruction. We found that interleukin-1beta, the primary pro-inflammatory cytokine involved in cartilage destruction, induces expression of Wnt-5a and - 7a in primary culture articular chondrocytes. The level of beta-catenin was also increased in chondrocytes of arthritic cartilage, suggesting the association of Wnt/beta-catenin signaling with arthritic cartilage destruction. In addition, our results show that Wnt-7a induces dedifferentiation and inhibits NO-induced apoptosis of primary culture articular chondrocytes. Wnt-7a induces dedifferentiation of articular chondrocytes by stimulating transcriptional activity of beta-catenin, whereas NO-induced apoptosis is inhibited via the activation of cell survival signaling, such as phosphatidylinositol 3-kinase and Akt, which block apoptotic signaling cascade. Our results collectively suggest that Wnt-7a is associated with cartilage destruction by regulating the maintenance of differentiation status and the apoptosis of articular chondrocytes via different mechanisms.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Kongju Natl Univ, Dept Biol Sci, Chungnam 314701, South Korea	Gwangju Institute of Science & Technology (GIST); University of Seoul; Chonnam National University; Kongju National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jschun@kjist.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bergwitz C, 2001, BBA-MOL CELL RES, V1538, P129, DOI 10.1016/S0167-4889(00)00123-3; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ghosh P, 2002, BIOGERONTOLOGY, V3, P85, DOI 10.1023/A:1015219716583; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lyu J, 2003, J BIOL CHEM, V278, P13487, DOI 10.1074/jbc.M300591200; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Piepenburg O, 2000, MOL CELL, V6, P203, DOI 10.1016/S1097-2765(00)00022-8; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yang X, 2000, DEVELOPMENT, V127, P3695; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	41	98	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26597	26604		10.1074/jbc.M401401200	http://dx.doi.org/10.1074/jbc.M401401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082716	hybrid			2022-12-27	WOS:000222003000085
J	Klaavuniemi, T; Kelloniemi, A; Ylanne, J				Klaavuniemi, T; Kelloniemi, A; Ylanne, J			The ZASP-like motif in actinin-associated LIM protein is required for interaction with the alpha-actinin rod and for targeting to the muscle Z-line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN; PDZ-DOMAIN; CYTOSKELETAL PROTEINS; SKELETAL-MUSCLE; KINASE-C; Z-BAND; RIL; FILAMENTS; BINDING; CYPHER	The Z-line is a specialized structure connecting adjacent sarcomeres in muscle cells. alpha-Actinin cross-links actin filaments in the Z-line. Several PDZ-LIM domain proteins localize to the Z-line and interact with alpha-actinin. Actinin-associated LIM protein (ALP), C-terminal LIM domain protein (CLP36), and Z band alternatively spliced PDZ-containing protein ( ZASP) have a conserved region named the ZASP-like motif (ZM) between PDZ and LIM domains. To study the interactions and function of ALP we used purified recombinant proteins in surface plasmon resonance measurements. We show that ALP and alpha-actinin 2 have two interaction sites. The ZM motif was required for the interaction of ALP internal region with the alpha-actinin rod and for targeting of ALP to the Z-line. The PDZ domain of ALP bound to the C terminus of alpha-actinin. This is the first indication that the ZM motif would have a direct role in a protein-protein interaction. These results suggest that the two interaction sites of ALP would stabilize certain conformations of alpha-actinin 2 that would strengthen the Z-line integrity.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Ylanne, J (corresponding author), Univ Oulu, Dept Biochem, Linnanmaa H4, FIN-90570 Oulu, Finland.	jari.ylanne@oulu.fi		Ylanne, Jari/0000-0003-4627-021X				Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; Bashirova AA, 1998, GENE, V210, P239, DOI 10.1016/S0378-1119(98)00080-8; Bauer K, 2000, BLOOD, V96, P4236; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; GLUKHOVA MA, 1990, J BIOL CHEM, V265, P13042; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Harris BZ, 2001, J CELL SCI, V114, P3219; Henderson JR, 2003, CELL MOTIL CYTOSKEL, V54, P254, DOI 10.1002/cm.10102; Huang CQ, 2003, J BIOL CHEM, V278, P7360, DOI 10.1074/jbc.M211875200; KIESS M, 1995, ONCOGENE, V10, P61; Kotaka M, 2000, J CELL BIOCHEM, V78, P558, DOI 10.1002/1097-4644(20000915)78:4<558::AID-JCB5>3.0.CO;2-I; Kotaka M, 1999, J CELL BIOCHEM, V72, P279, DOI 10.1002/(SICI)1097-4644(19990201)72:2<279::AID-JCB12>3.0.CO;2-7; Kotaka M, 2001, J CELL BIOCHEM, V83, P463, DOI 10.1002/jcb.1244; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Luther PK, 2002, J MOL BIOL, V315, P9, DOI 10.1006/jmbi.2001.5217; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Pomies P, 1999, J BIOL CHEM, V274, P29242, DOI 10.1074/jbc.274.41.29242; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Taylor KA, 2000, J CELL BIOL, V149, P635, DOI 10.1083/jcb.149.3.635; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; Vallenius T, 2004, EXP CELL RES, V293, P117, DOI 10.1016/j.yexcr.2003.09.004; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Vatta M, 2003, J AM COLL CARDIOL, V42, P2014, DOI 10.1016/j.jacc.2003.10.021; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; Young P, 2000, EMBO J, V19, P6331, DOI 10.1093/emboj/19.23.6331; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	39	61	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26402	26410		10.1074/jbc.M401871200	http://dx.doi.org/10.1074/jbc.M401871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084604	hybrid			2022-12-27	WOS:000222003000061
J	Lei, WL; Rushton, JJ; Davis, LM; Liu, F; Ness, SA				Lei, WL; Rushton, JJ; Davis, LM; Liu, F; Ness, SA			Positive and negative determinants of target gene specificity in Myb transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC-CELLS; RECEPTOR FUSION PROTEIN; SMOOTH-MUSCLE CELLS; C-MYB; V-MYB; B-MYB; A-MYB; REGULATORY DOMAIN; PHOSPHORYLATION SITE; ACTIVATION DOMAINS	The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Ness, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, MSC08 4660,915 Camino Salud NE, Albuquerque, NM 87131 USA.	ness@unm.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL CANCER INSTITUTE [R01CA058443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; Bies J, 2001, BLOOD CELL MOL DIS, V27, P422, DOI 10.1006/bcmd.2001.0400; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DYSON PJ, 1989, DIFFERENTIATION, V42, P24, DOI 10.1111/j.1432-0436.1989.tb00603.x; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hibi K, 1998, CANCER RES, V58, P5690; Hodges LC, 2003, MOL CANCER RES, V1, P300; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KASTAN MB, 1989, BLOOD, V73, P1444; LAM EWF, 1992, ONCOGENE, V7, P1885; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; RAMSAY RG, 1995, ONCOGENE, V11, P2113; Raschella G, 1999, CANCER RES, V59, P3365; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Wang DM, 2002, ONCOGENE, V21, P1611, DOI 10.1038/sj.onc.1205236; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	46	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29519	29527		10.1074/jbc.M403133200	http://dx.doi.org/10.1074/jbc.M403133200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105423	hybrid			2022-12-27	WOS:000222445300085
J	Douglas, MW; Diefenbach, RJ; Homa, FL; Miranda-Saksena, M; Rixon, FJ; Vittone, V; Byth, K; Cunningham, AL				Douglas, MW; Diefenbach, RJ; Homa, FL; Miranda-Saksena, M; Rixon, FJ; Vittone, V; Byth, K; Cunningham, AL			Herpes simplex virus type 1 capsid protein VP26 interacts with dynein light chains RP3 and Tctex1 and plays a role in retrograde cellular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; RECOMBINANT BACULOVIRUSES; SUBUNIT HETEROGENEITY; ANTEROGRADE TRANSPORT; PRIMARY ENVELOPMENT; HEAVY-CHAIN; LOCALIZATION; COMPLEX; BINDING	Cytoplasmic dynein is the major molecular motor involved in minus-end-directed cellular transport along microtubules. There is increasing evidence that the retrograde transport of herpes simplex virus type 1 along sensory axons is mediated by cytoplasmic dynein, but the viral and cellular proteins involved are not known. Here we report that the herpes simplex virus outer capsid protein VP26 interacts with dynein light chains RP3 and Tctex1 and is sufficient to mediate retrograde transport of viral capsids in a cellular model. A library of herpes simplex virus capsid and tegument structural genes was constructed and tested for interactions with dynein subunits in a yeast two-hybrid system. A strong interaction was detected between VP26 and the homologous 14-kDa dynein light chains RP3 and Tctex1. In vitro pull-down assays confirmed binding of VP26 to RP3, Tctex1, and intact cytoplasmic dynein complexes. Recombinant herpes simplex virus capsids were constructed either with or without VP26. In pull-down assays VP26+ capsids bound to RP3; VP26- capsids did not. To investigate intracellular transport, the recombinant viral capsids were microinjected into living cells and incubated at 37degreesC. After 1 h VP26+ capsids were observed to co-localize with RP3, Tctex1, and microtubules. After 2 or 4 h VP26+ capsids had moved closer to the cell nucleus, whereas VP26- capsids remained in a random distribution. We propose that VP26 mediates binding of incoming herpes simplex virus capsids to cytoplasmic dynein during cellular infection, through interactions with dynein light chains.	Univ Sydney, Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW 2145, Australia; Westmead Hosp, Westmead, NSW 2145, Australia; Pharmacia Corp, Infect Dis Biol, Kalamazoo, MI 49001 USA; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	University of Sydney; Westmead Institute for Medical Research; University of Sydney; Pfizer; University of Glasgow	Diefenbach, RJ (corresponding author), Univ Sydney, Westmead Millennium Inst, Ctr Virus Res, POB 412, Westmead, NSW 2145, Australia.	russell_diefenbach@wmi.usyd.edu.au	Diefenbach, Russell J./E-9602-2015; Douglas, Mark/D-5513-2011	Diefenbach, Russell J./0000-0002-8433-4336; Douglas, Mark/0000-0003-4621-3485; Cunningham, Anthony/0000-0002-6744-5667; Byth Wilson, Karen/0000-0002-1253-6393				Alonso C, 2001, J VIROL, V75, P9819, DOI 10.1128/JVI.75.20.9819-9827.2001; Bearer EL, 2000, P NATL ACAD SCI USA, V97, P8146, DOI 10.1073/pnas.97.14.8146; Bowman BR, 2003, EMBO J, V22, P757, DOI 10.1093/emboj/cdg086; Cassady KA, 1998, J VIROL, V72, P7005; Chen DH, 2001, J VIROL, V75, P11863, DOI 10.1128/JVI.75.23.11863-11867.2001; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; COHEN GH, 1980, J VIROL, V34, P521, DOI 10.1128/JVI.34.2.521-531.1980; Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; CUNNINGHAM C, 1993, VIROLOGY, V197, P116, DOI 10.1006/viro.1993.1572; Desai P, 1996, VIROLOGY, V220, P516, DOI 10.1006/viro.1996.0341; Desai P, 2003, J VIROL, V77, P391, DOI 10.1128/JVI.77.1.391-404.2003; Desai P, 1998, VIROLOGY, V247, P115, DOI 10.1006/viro.1998.9230; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Diefenbach RJ, 2002, BIOCHEMISTRY-US, V41, P14906, DOI 10.1021/bi026417u; Diefenbach RJ, 2002, J VIROL, V76, P3282, DOI 10.1128/JVI.76.7.3282-3291.2002; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Elliott G, 1999, J VIROL, V73, P4110, DOI 10.1128/JVI.73.5.4110-4119.1999; Enquist LW, 2002, VET MICROBIOL, V86, P5, DOI 10.1016/S0378-1135(01)00486-2; Farnsworth A, 2003, J VIROL, V77, P8481, DOI 10.1128/JVI.77.15.8481-8494.2003; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Holland DJ, 1999, J VIROL, V73, P8503, DOI 10.1128/JVI.73.10.8503-8511.1999; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Klupp BG, 2000, J VIROL, V74, P10063, DOI 10.1128/JVI.74.21.10063-10073.2000; Kramer MF, 1998, J VIROL, V72, P1177, DOI 10.1128/JVI.72.2.1177-1185.1998; LYCKE E, 1984, J GEN VIROL, V65, P55, DOI 10.1099/0022-1317-65-1-55; MACNABBAIN SJ, 1999, THESIS U GLASGOW GLA; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; McCLelland DA, 2002, J VIROL, V76, P7407, DOI 10.1128/JVI.76.15.7407-7417.2002; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; Miranda-Saksena M, 2002, J VIROL, V76, P9934, DOI 10.1128/JVI.76.19.9934-9951.2002; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Morrison EE, 1998, J GEN VIROL, V79, P2517, DOI 10.1099/0022-1317-79-10-2517; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; NICHOLSON P, 1994, J GEN VIROL, V75, P1091, DOI 10.1099/0022-1317-75-5-1091; Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Reynolds AE, 2002, J VIROL, V76, P8939, DOI 10.1128/JVI.76.17.8939-8952.2002; Roizman B, 1996, FIELDS VIROLOGY, P2231; Roller RJ, 2000, J VIROL, V74, P117, DOI 10.1128/JVI.74.1.117-129.2000; Rozen S, 2000, Methods Mol Biol, V132, P365; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; TATMAN JD, 1994, J GEN VIROL, V75, P1101, DOI 10.1099/0022-1317-75-5-1101; THOMSEN DR, 1994, J VIROL, V68, P2442, DOI 10.1128/JVI.68.4.2442-2457.1994; Tomishima MJ, 2001, TRAFFIC, V2, P429, DOI 10.1034/j.1600-0854.2001.020701.x; TRUS BL, 1995, J VIROL, V69, P7362, DOI 10.1128/JVI.69.11.7362-7366.1995; Willard M, 2002, J VIROL, V76, P5220, DOI 10.1128/JVI.76.10.5220-5232.2002; Wingfield PT, 1997, J VIROL, V71, P8955, DOI 10.1128/JVI.71.12.8955-8961.1997; Ye GJ, 2000, J VIROL, V74, P1355, DOI 10.1128/JVI.74.3.1355-1363.2000; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999; ZHOU ZH, 1995, NAT STRUCT BIOL, V2, P1026, DOI 10.1038/nsb1195-1026	58	128	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28522	28530		10.1074/jbc.M311671200	http://dx.doi.org/10.1074/jbc.M311671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117959	hybrid			2022-12-27	WOS:000222265400088
J	Subramanian, VS; Marchant, JS; Boulware, MJ; Said, HM				Subramanian, VS; Marchant, JS; Boulware, MJ; Said, HM			A C-terminal region dictates the apical plasma membrane targeting of the human sodium-dependent vitamin C transporter-1 in polarized epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; ACID TRANSPORTER; INTRACELLULAR TRAFFICKING; SORTING SIGNALS; BETA-TURNS; CELLS; PROTEINS; FAMILY; PREDICTION; EXPRESSION	The human sodium-dependent vitamin C transporter (hSVCT1) mediates sodium-dependent cellular uptake of the essential micronutrient L-ascorbic acid ( vitamin C). However, the molecular determinants that control the cell surface expression, subcellular distribution, and dynamics of hSVCT1 remain undefined. To identify molecular determinants involved in hSVCT1 targeting in polarized epithelia, we used live cell imaging approaches to resolve the targeting and trafficking dynamics of hSVCT1 truncation mutants in renal and intestinal cells. Confocal imaging demonstrated that hSVCT1 was expressed at the apical cell surface and video rate measurements revealed hSVCT1 also resided in a heterogeneous population of intracellular organelles with discrete dynamic properties. By progressive truncation of the cytoplasmic C-terminal tail of hSVCT1, we delimited an essential role for an embedded ten amino acid sequence PICPVFKGFS ( amino acids 563 - 572) in defining the physiological targeting of hSVCT1. Intriguingly, this sequence bears significant homology to recently identified apical targeting motifs in two other sodium-dependent transporters, and we suggest this conservation is reflected topologically through the adoption of a beta-turn confirmation in the cytoplasmic C-tail of each transporter. Our results provide the first direct resolution of functional hSVCT1 expression at the apical cell surface of polarized epithelia and define an apical targeting signal of relevance to transporters of diverse substrate specificity.	Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities	Said, HM (corresponding author), Dept Vet Affairs Med Ctr, 151, Long Beach, CA 90822 USA.	hmsaid@uci.edu	Marchant, Jonathan/Q-5484-2019; MARCHANT, Jonathan/B-8051-2009	Marchant, Jonathan/0000-0001-6592-0877; MARCHANT, Jonathan/0000-0001-6592-0877	NCI NIH HHS [P30-CA77598] Funding Source: Medline; NIDDK NIH HHS [DK-58057, DK-56061, DK-63750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA077598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK063750, R37DK056061, R01DK058057, R01DK056061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boulware MJ, 2003, BIOCHEM J, V376, P43, DOI 10.1042/BJ20031220; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; Cheng CL, 2002, J NEUROSCI, V22, P10643; Chou KC, 1997, J PEPT RES, V49, P120; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Duclos S, 2003, J CELL SCI, V116, P907, DOI 10.1242/jcs.00259; Dunbar LA, 1998, ACTA PHYSIOL SCAND, V163, P289; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Kaur H, 2003, PROTEIN SCI, V12, P627, DOI 10.1110/ps.0228903; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Packer L., 1997, VITAMIN C HLTH DIS; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Said HM, 2004, AM J PHYSIOL-GASTR L, V286, pG491, DOI 10.1152/ajpgi.00361.2003; Sakai T, 1998, BIOCHEM BIOPH RES CO, V242, P151, DOI 10.1006/bbrc.1997.7577; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; Sun AQ, 2003, J BIOL CHEM, V278, P4000, DOI 10.1074/jbc.M207163200; Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1; Trinczek B, 1999, J CELL SCI, V112, P2355; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0	33	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27719	27728		10.1074/jbc.M400876200	http://dx.doi.org/10.1074/jbc.M400876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084584	hybrid			2022-12-27	WOS:000222120400106
J	Zhang, YX; Hamburger, AW				Zhang, YX; Hamburger, AW			Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; CELL-CYCLE PROGRESSION; BREAST-CANCER CELLS; TUMOR-CELLS; ANDROGEN RECEPTOR; CARCINOMA-CELLS; EXPRESSION; ACTIVATION; DNA; GROWTH	The ErbB3/4 ligand heregulin (HRG) profoundly affects cell growth and differentiation, but its mechanism of action is poorly understood. Ebp1, a protein isolated by its binding to ErbB3, inhibits cell growth and represses transcription of E2F-regulated cell cycle genes. Since Ebp1 shares 38% identity with a Schizosaccharomyces pombe DNA-binding protein, we postulated that Ebp1 could bind E2F consensus elements in an HRG-inducible manner, leading to transcriptional repression. We show here that GST-Ebp1 bound to the DNA sequence bound by the S. pombe protein. Whereas GST-Ebp1 alone failed to bind E2F1 promoter elements, Ebp1 contained in nuclear lysates associated with E2F1 consensus sequences in the E2F1 promoter. Endogenous Ebp1 was recruited to the E2F1 promoter in vivo as demonstrated by chromatin immunoprecipitation assays. Ebp1 bound E2F consensus oligonucleotides in association with E2F1, retinoblastoma protein, and HDAC2. HRG regulated the association of Ebp1 with E2F promoter sequences and enhanced the ability of Ebp1 to repress transcription. Our findings suggest that Ebp1, by linking HRG activation of membrane receptors to E2F gene activity, may be a downstream modulator of the effects of HRG on cell cycle progression.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Hamburger, AW (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, BRB 9-047,655 W Baltimore St, Baltimore, MD 21201 USA.	ahamburg@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA076047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76047] Funding Source: Medline; PHS HHS [R21 088882-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Alroy I, 1999, MOL CELL BIOL, V19, P1961; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; Barnes CJ, 2002, CANCER RES, V62, P1251; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DEGREGORI J, 1995, MOL CELL BIOL, V15, P5846; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Farhana L, 2002, CANCER RES, V62, P3842; HARA E, 1993, ONCOGENE, V8, P1023; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lewis GD, 1996, CANCER RES, V56, P1457; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nakagawa Y, 1997, ACTA MED OKAYAMA, V51, P195; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, SCIENCE, V258, P424; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Talukder AH, 2000, CANCER RES, V60, P276; Wang QB, 2001, ANAL BIOCHEM, V289, P217, DOI 10.1006/abio.2000.4960; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; YAMADA H, 1994, YEAST, V10, P883, DOI 10.1002/yea.320100704; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; Zhang YX, 2002, ONCOGENE, V21, P5609, DOI 10.1038/sj.onc.1205638	40	42	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26126	26133		10.1074/jbc.M314305200	http://dx.doi.org/10.1074/jbc.M314305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073182	hybrid			2022-12-27	WOS:000222003000026
J	Jones, CE; Green, EM; Stephens, JA; Mueser, TC; Nossal, NG				Jones, CE; Green, EM; Stephens, JA; Mueser, TC; Nossal, NG			Mutations of bacteriophage T4 59 helicase loader defective in binding fork DNA and in interactions with T4 32 single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR BRANCH MIGRATION; 4-WAY JUNCTION DNA; ASSEMBLY PROTEIN; GENE-59 PROTEIN; ARCHITECTURAL PROTEINS; REPLICATION PROTEINS; LOADING PROTEIN; RECOMBINATION; PURIFICATION; COMPLEX	Bacteriophage T4 gene 59 protein greatly stimulates the loading of the T4 gene 41 helicase in vitro and is required for recombination and recombination-dependent DNA replication in vivo. 59 protein binds preferentially to forked DNA and interacts directly with the T4 41 helicase and gene 32 single-stranded DNA-binding protein. The helicase loader is an almost completely alpha-helical, two-domain protein, whose N-terminal domain has strong structural similarity to the DNA-binding domains of high mobility group proteins. We have previously speculated that this high mobility group-like region may bind the duplex ahead of the fork, with the C-terminal domain providing separate binding sites for the fork arms and at least part of the docking area for the helicase and 32 protein. Here, we characterize several mutants of 59 protein in an initial effort to test this model. We find that the I87A mutation, at the position where the fork arms would separate in the model, is defective in binding fork DNA. As a consequence, it is defective in stimulating both unwinding by the helicase and replication by the T4 system. 59 protein with a deletion of the two C-terminal residues, Lys(216) and Tyr(217), binds fork DNA normally. In contrast to the wild type, the deletion protein fails to promote binding of 32 protein on short fork DNA. However, it binds 32 protein in the absence of DNA. The deletion is also somewhat defective in stimulating unwinding of fork DNA by the helicase and replication by the T4 system. We suggest that the absence of the two terminal residues may alter the configuration of the lagging strand fork arm on the surface of the C-terminal domain, so that it is a poorer docking site for the helicase and 32 protein.	NIDDK, NIH, Dept Mol & Cell Biol, Bethesda, MD 20892 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Toledo	Nossal, NG (corresponding author), NIDDK, NIH, Dept Mol & Cell Biol, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.	ngn@helix.nih.gov	Green, Erin/J-6098-2019; Jones, Charles/GVS-9497-2022	Green, Erin/0000-0003-3923-6726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mosig G, 1995, METHOD ENZYMOL, V262, P587; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	38	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25721	25728		10.1074/jbc.M402128200	http://dx.doi.org/10.1074/jbc.M402128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084598	hybrid			2022-12-27	WOS:000221827900102
J	Karunakaran, C; Zhang, H; Crow, JP; Antholine, WE; Kalyanaraman, B				Karunakaran, C; Zhang, H; Crow, JP; Antholine, WE; Kalyanaraman, B			Direct probing of copper active site and free radical formed during bicarbonate-dependent peroxidase activity of bovine and human copper, zinc-superoxide dismutases - Low-temperature electron paramagnetic resonance and electron nuclear double resonance studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; HIGH-FIELD EPR; CU,ZN-SUPEROXIDE DISMUTASE; RIBONUCLEOTIDE REDUCTASE; HYDROGEN-PEROXIDE; ENDOR; TRYPTOPHAN; OXIDATION; ENZYME; SPECTROSCOPY	Using X-band electron paramagnetic resonance (EPR) and electron nuclear double resonance (ENDOR) spectroscopy at liquid helium temperatures, the Cu(II) coordination geometry at the active site of bovine and human copper, zinc-superoxide dismutases (bSOD1 and hSOD1) treated with H2O2 and bicarbonate (HCO3-) was examined. The time course EPR of wild type human SOD1 (WT hSOD1), W32F hSOD1 mutant ( tryptophan 32 substituted with phenylalanine), and bSOD1 treated with H2O2 and HCO3- shows an initial reduction of active site Cu( II) to Cu(I) followed by its oxidation back to Cu(II) in the presence of H2O2. However, HCO3- induced a Trp-32-derived radical from WT hSOD1 but not from bSOD1. The mutation of Trp-32 by phenylalanine totally eliminated the Trp-32 radical signal generated from W32F hSOD1 treated with HCO3- and H2O2. Further characterization of the free radical was performed by UV irradiation of WT hSOD1 and bSOD1 that generated tryptophanyl and tyrosyl radicals. Both proton (H-1) and nitrogen (N-14) ENDOR studies of bSOD1 and hSOD1 in the presence of H2O2 revealed a change in the geometry of His-46 (or His-44) and His-48 (or His-46) coordinated to Cu( II) at the active site of WT hSOD1 and bSOD1, respectively. However, in the presence of HCO3- and H2O2, both H-1 and N-14 ENDOR spectra were almost identical to those derived from native bSOD1. We conclude that HCO3--derived oxidant does not alter significantly the Cu(II) active site geometry and histidine coordination to Cu( II) in SOD1 as does H2O2 alone; however, the oxidant derived from HCO3- (i.e. carbonate anion radical) reacts with surface-associated Trp-32 in hSOD1 to form the corresponding radical.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Arkansas, Dept Med & Pharmacol, Little Rock, AR 72205 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM34009] Funding Source: Medline; NINDS NIH HHS [NS40494] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040494] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abragam A., 1986, ELECT PARAMAGNETIC R; ATTANASIO D, 1977, J MAGN RESON, V26, P81, DOI 10.1016/0022-2364(77)90237-2; Ayala I, 2002, J AM CHEM SOC, V124, P5496, DOI 10.1021/ja0164327; BANCI L, 1990, INORG CHEM, V29, P4867, DOI 10.1021/ic00349a011; BELFORD RL, 1973, J CHEM PHYS, V59, P853, DOI 10.1063/1.1680104; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Flores M, 2000, BIOPHYS J, V78, P2107, DOI 10.1016/S0006-3495(00)76757-9; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; GREINER SP, 1992, J PHYS CHEM-US, V96, P9132, DOI 10.1021/j100202a012; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Hoffman BM, 2003, ACCOUNTS CHEM RES, V36, P522, DOI 10.1021/ar0202565; Hoffman BM, 2003, P NATL ACAD SCI USA, V100, P3575, DOI 10.1073/pnas.0636464100; HOFFMAN BM, 1993, BIOL MAGN RESON, V13, P151; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Kalyanaraman B, 2001, ADV EXP MED BIOL, V500, P175; LIEBERMAN RA, 1982, J BIOL CHEM, V257, P336; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 2003, FREE RADICAL BIO MED, V34, P1383, DOI 10.1016/S0891-5849(03)00153-9; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; REINHARD H, 1994, J PHYS CHEM-US, V98, P8806, DOI 10.1021/j100086a035; SAHLIN M, 1982, J BIOL CHEM, V257, P366; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; SATO K, 1992, J BIOL CHEM, V267, P25371; Scholl HJ, 1998, INORG CHIM ACTA, V273, P131, DOI 10.1016/S0020-1693(97)06014-3; SCHOLL HJ, 1992, J PHYS CHEM-US, V96, P9684, DOI 10.1021/j100203a023; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; SWALEN JD, 1970, J CHEM PHYS, V52, P4078, DOI 10.1063/1.1673613; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Telser J, 2000, J AM CHEM SOC, V122, P182, DOI 10.1021/ja992386n; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218; [No title captured]	41	28	28	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32534	32540		10.1074/jbc.M314272200	http://dx.doi.org/10.1074/jbc.M314272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15123612	hybrid			2022-12-27	WOS:000222849700068
J	Hama, E; Shirotani, K; Iwata, N; Saido, TC				Hama, E; Shirotani, K; Iwata, N; Saido, TC			Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PLAQUE-FORMATION; DEGRADING ENDOPEPTIDASE; EC 3.4.24.11; MOUSE MODEL; BRAIN; LOCALIZATION; IDENTIFICATION	Neprilysin (NEP) is a rate-limiting amyloid beta peptide (Abeta)-degrading enzyme in the brain. We demonstrated previously that overexpression of neprilysin in primary cortical neurons remarkably decreased not only extracellular but also intracellular Abeta levels. To investigate the subcellular compartments where neprilysin degrades Abeta most efficiently, we expressed neprilysin chimeric proteins containing various subcellular compartment-targeting domains in neurons. Sec12-NEP, beta-galactoside alpha2,6-sialyltransferase-NEP, transferrin receptor-NEP, and growth-associated protein 43-NEP were successfully sorted to the endoplasmic reticulum, trans-Golgi network, early/recycling endosomes, and lipid rafts, respectively. We found that intracellularly, wild-type neprilysin and all the chimeras showed equivalent Abeta40-degrading activities. Abeta40 was more effectively cleared than Abeta42, and this tendency was greater for intracellular Abeta than for extracellular Abeta. Wild-type and trans-Golgi network- targeted ST-NEP cleared more intracellular Abeta42 than the other chimeras. Wild-type neprilysin cleared extracellular Abeta more effectively than any of the chimeras, among which endoplasmic reticulum-targeted Sec12-NEP was the least effective. These observations indicate that different intracellular compartments may be involved in the metabolism of distinct pools of Abeta (Abeta40 and Abeta42) to be retained or recycled intracellularly and to be secreted extracellularly, and that the endogenous targeting signal in wildtype neprilysin is well optimized for the overall neuronal clearance of Abeta.	RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	RIKEN	Saido, TC (corresponding author), RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	saido@brain.riken.go.jp	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				ALMEIDA CG, 2003, 6678 SOC NEUR; Angelisova P, 1999, BLOOD, V93, P1437, DOI 10.1182/blood.V93.4.1437a; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BARNES K, 1993, NEUROSCIENCE, V53, P1073, DOI 10.1016/0306-4522(93)90490-7; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cailler F, 1998, BBA-BIOMEMBRANES, V1415, P1, DOI 10.1016/S0005-2736(98)00167-9; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; Echeverria V, 2002, MOL NEUROBIOL, V26, P299, DOI 10.1385/MN:26:2-3:299; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; MARCEL D, 1990, J NEUROSCI, V10, P2804; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; NUKINA N, 1983, P JPN ACAD B-PHYS, V59, P284, DOI 10.2183/pjab.59.284; Saido T.C., 2003, ABETA METABOLISM ALZ, P61; Saido T. C., 2000, NEUROSCI NEWS, V3, P52; SAITO T, 2003, SCI AGING KNOWLEDGE, pPE1; Saria A, 1997, NEUROSCI LETT, V234, P27, DOI 10.1016/S0304-3940(97)00660-5; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schmitz A, 2004, TRAFFIC, V5, P89, DOI 10.1111/j.1600-0854.2004.00159.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shie FS, 2003, NEUROREPORT, V14, P123, DOI 10.1097/00001756-200301200-00023; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839; West AE, 1997, J NEUROSCI, V17, P6038; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Yasojima K, 2001, BRAIN RES, V919, P115, DOI 10.1016/S0006-8993(01)03008-6	50	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30259	30264		10.1074/jbc.M401891200	http://dx.doi.org/10.1074/jbc.M401891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15100223	hybrid			2022-12-27	WOS:000222531900050
J	Chang, CJ; Freeman, DJ; Wu, H				Chang, CJ; Freeman, DJ; Wu, H			PTEN regulates Mdm2 expression through the P1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 PROTEIN; PROSTATE-CANCER; GENE; DEGRADATION; ONCOPROTEIN; CHEMOTHERAPY; TRANSACTIVATION; UBIQUITINATION; AMPLIFICATION; ACTIVATION	MDM2 is an oncoprotein that controls tumorigenesis through both p53-dependent and - independent mechanisms. Mdm2 mRNA level is transcriptionally regulated by p53 in response to stress such as DNA damage, and its protein level and subcellular localization are post-translationally modulated by the AKT serine/threonine kinase. Previous studies showed that PTEN, a dual specificity phosphatase that antagonizes phosphatidylinositol 3-kinase/ AKT signaling, is capable of blocking MDM2 nuclear translocation and destabilizing the MDM2 protein. Results from our current study demonstrate an additional role for PTEN in regulating MDM2 functions; PTEN modulates Mdm2 transcription and isoform selection by negatively regulating its P1 promoter. In Pten-null cell lines and prostate cancer tissues, Mdm2 P1 promoter activity is up-regulated, resulting in increased L-Mdm2 expression and enhanced p90(MDM2) isoform production. Furthermore, PTEN controls Mdm2 P1 promoter activity through its lipid phosphatase activity, independent of p53. Thus, our results provide a novel mechanism for PTEN in controlling MDM2 oncoprotein functions.	Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, H (corresponding author), Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, CHS 23-214,650 CE Young Dr S, Los Angeles, CA 90095 USA.	hwu@mednet.ucla.edu		Chang, Chunju/0000-0003-2887-9603	NATIONAL CANCER INSTITUTE [R01CA107166, P50CA092131, U01CA084128, P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [CA092131, CA-86306, CA84128, CA107166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou MX, 2003, CANCER RES, V63, P6357	36	76	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29841	29848		10.1074/jbc.M401488200	http://dx.doi.org/10.1074/jbc.M401488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090541	hybrid			2022-12-27	WOS:000222445300121
J	Hu, YF; Fang, XH; Dunham, SM; Prada, C; Stachowiak, EK; Stachowiak, MK				Hu, YF; Fang, XH; Dunham, SM; Prada, C; Stachowiak, EK; Stachowiak, MK			90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1) - Role in FGFR1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PATHWAY MEDIATES ACTIVATION; ADRENAL-MEDULLARY CELLS; ADAPTER PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN-II; SH2 DOMAIN; GENE; IDENTIFICATION; PHOSPHORYLATION	Fibroblast growth factor receptor 1 (FGFR1) is a transmembrane protein capable of transducing stimulation by secreted FGFs. In addition, newly synthesized FGFR1 enters the nucleus in response to cellular stimulation and during development. Nuclear FGFR1 can transactivate CRE (cAMP responsive element), activate CRE-binding protein (CREB)-binding protein (CBP) and gene activities causing cellular growth and differentiation. Here, a yeast two-hybrid assay was performed to identify FGFR1-binding proteins and the mechanism of nuclear FGFR1 action. Ten FGFR1-binding proteins were identified. Among the proteins detected with the intracellular FGFR1 domain was a 90-kDa ribosomal S6 kinase (RSK1), a regulator of CREB, CBP, and histone phosphorylation. FGFR1 bound to the N-terminal region of RSK1. The FGFR1-RSK1 interaction was confirmed by co-immunoprecipitation and colocalization in the nucleus and cytoplasm of mammalian cells. Predominantly nuclear FGFR1-RSK1 interaction was observed in the rat brain during neurogenesis and in cAMP-stimulated cultured neural cells. In TE671 cells, transfected FGFR1 colocalized and coimmunoprecipitated, almost exclusively, with nuclear RSK1. Nuclear RSK1 kinase activity and RSK1 activation of CREB were enhanced by transfected FGFR1. In contrast, kinase-deleted FGFR1 (TK-), which did not bind to RSK1 failed to stimulate nuclear RSK1 activity or RSK1 activation of CREB. Kinase inactive FGFR1 (K514A) bound effectively to nuclear RSK1, but it failed to stimulate RSK1. Thus, active FGFR1 kinase regulates the functions of nuclear RSK1. The interaction of nuclear FGFR1 with pluripotent RSK1 offers a new mechanism through which FGFR1 may control fundamental cellular processes.	SUNY Buffalo, Dept Pathol & Anat Sci, Mol & Struct Neurobiol & Gene Therapy Program, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Stachowiak, MK (corresponding author), SUNY Buffalo, Dept Pathol & Anat Sci, Mol & Struct Neurobiol & Gene Therapy Program, Buffalo, NY 14214 USA.	mks4@buffalo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS043621] Funding Source: NIH RePORTER; NINDS NIH HHS [NS43621-01HL-49376] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bell SM, 1997, GENOMICS, V44, P163, DOI 10.1006/geno.1997.4849; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BEREZNEY R, 1981, BIOCHEMISTRY-US, V20, P4995, DOI 10.1021/bi00520a028; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buzanska L, 2002, J CELL SCI, V115, P2131; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; Horbinski C, 2002, J NEUROCHEM, V80, P54, DOI 10.1046/j.0022-3042.2001.00657.x; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Meijerink PHS, 1998, EUR J BIOCHEM, V254, P297, DOI 10.1046/j.1432-1327.1998.2540297.x; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLAH Z, 1991, EXP BRAIN RES, V84, P403; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; Romisch K, 1999, J CELL SCI, V112, P4185; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Somanathan S, 2003, J CELL BIOCHEM, V90, P856, DOI 10.1002/jcb.10672; Stachowiak EK, 2003, J NEUROCHEM, V84, P1296, DOI 10.1046/j.1471-4159.2003.01624.x; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Wu M, 2000, GENE DEV, V14, P301; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	67	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29325	29335		10.1074/jbc.M311144200	http://dx.doi.org/10.1074/jbc.M311144200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117958	hybrid			2022-12-27	WOS:000222445300063
J	Kim, KY; Kim, BC; Xu, ZL; Kim, SJ				Kim, KY; Kim, BC; Xu, ZL; Kim, SJ			Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; MOLECULAR-CLONING; BINDING MOTIF; CROSS-TALK; IN-VIVO; IDENTIFICATION; PHOSPHORYLATION; PATHWAYS; FAMILY	Although transforming growth factor beta1 (TGF-beta1) acts via the Smad signaling pathway to initiate de novo gene transcription, the TGF-beta1-induced MAPK kinase activation that is involved in the regulation of apoptosis is less well understood. Even though the p38 MAP kinase and c-Jun NH2-terminal kinases (JNKs) are involved in TGF-beta1- induced cell death in hepatoma cells, the upstream mediators of these kinases remain to be defined. We show here that the members of the mixed lineage kinase (MLK) family ( including MLK1, MLK2, MLK3, and dual leucine zipper-bearing kinase (DLK)) are expressed in FaO rat hepatoma cells and are likely to act between p38 and TGF-beta receptor kinase in death signaling. TGF-beta1 treatment leads to an increase in MLK3 activity. Overexpression of MLK3 enhances TGF-beta1-induced apoptotic death in FaO cells and Hep3B human hepatoma cells, whereas expression of the dominant-negative forms of MLK3 suppresses cell death induced by TGF-beta1. The dominant-negative forms of MLK1 and -2 also suppress TGF-beta1-induced cell death. In MLK3-overexpressing cells, ERK, JNKs, and p38 MAP kinases were further activated in response to TGF-beta1 compared with the control cells. In contrast, overexpression of the dominant-negative MLK3 resulted in suppression of TGF-beta1-induced MAP kinase activation and TGF-beta1-induced caspase-3 activation. We also show that only the inhibition of the p38 pathway suppressed TGF-beta1-induced apoptosis. These observations support a role for MLKs in the TGF-beta1-induced cell death mechanism.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Kangweon Natl Univ, Coll Nat Sci, Chunchon 200701, South Korea; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kangwon National University; Columbia University; Columbia University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	kims@mail.nih.gov		Xu, Zhiheng/0000-0002-4809-2851	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Hartkamp J, 1999, CANCER RES, V59, P2195; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hsing AY, 1996, CANCER RES, V56, P5146; ING YL, 1994, ONCOGENE, V9, P1745; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yue J, 2004, J CELL PHYSIOL, V199, P284, DOI 10.1002/jcp.10469; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	38	78	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29478	29484		10.1074/jbc.M313947200	http://dx.doi.org/10.1074/jbc.M313947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15069087	hybrid			2022-12-27	WOS:000222445300080
J	Rabizadeh, S; Xavier, RJ; Ishiguro, K; Bernabeortiz, J; Lopez-Ilasaca, M; Khokhlatchev, A; Mollahan, P; Pfeifer, GP; Avruch, J; Seed, B				Rabizadeh, S; Xavier, RJ; Ishiguro, K; Bernabeortiz, J; Lopez-Ilasaca, M; Khokhlatchev, A; Mollahan, P; Pfeifer, GP; Avruch, J; Seed, B			The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC INACTIVATION; PROMOTES APOPTOSIS; FAMILY PROTEIN; CYCLE EXIT; RAS; KINASE; GENE; DROSOPHILA; PROLIFERATION; ACTIVATION	The connector enhancer of KSR (CNK) is a multidomain scaffold protein discovered in Drosophila, where it is necessary for Ras activation of the Raf kinase. Recent studies have shown that CNK1 also interacts with RalA and Rho and participates in some aspects of signaling by these GTPases. Herein we demonstrate a novel aspect of CNK1 function, i.e. reexpression of CNK1 suppresses tumor cell growth and promotes apoptosis. As shown previously for apoptosis induced by Ki-Ras(G12V), CNK1-induced apoptosis is suppressed by a dominant inhibitor of the mammalian sterile 20 kinases 1 and (MST1/MST2). Immunoprecipitates of MST1 endogenous to LoVo colon cancer cells contain endogenous CNK1; however, no association of these two polypeptides can be detected in a yeast two-hybrid assay. CNK1 does, however, bind directly to the RASSF1A and RASSF1C polypeptides, constitutive binding partners of the MST1/2 kinases. Deletion of the MST1 carboxyl-terminal segment that mediates its binding to RASSF1A/C eliminates the association of MST1 with CNK1. Coexpression of CNK1 with the tumor suppressive isoform, RASSF1A, greatly augments CNK1-induced apoptosis, whereas the nonsuppressive RASSF1C isoform is without effect on CNK1-induced apoptosis. Overexpression of CNK1-(1-282), a fragment that binds RASSF1A but is not proapoptotic, blocks the apoptosis induced by CNK1 and by Ki-Ras( G12V). Thus, in addition to its positive role in the proliferative outputs of active Ras, the CNK1 scaffold protein, through its binding of a RASSF1A.MST complex, also participates in the proapoptotic signaling initiated by active Ras.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA; Buck Inst Age Res, Discovery Translat Unit, Novato, CA 94945 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; City Hope Natl Med Ctr, Dept Biol, Duarte, CA 91010 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Buck Institute for Research on Aging; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; City of Hope	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 50 Blossom St, Boston, MA 02114 USA.	seed@molbio.mgh.harvard.edu		Ishiguro, Kazuhiro/0000-0003-1776-2805; Bernabe-Ortiz, Julio Cesar/0000-0003-0313-1033				Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; VOS MD, 2003, J BIOL CHEM, V278, P21943; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	43	78	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29247	29254		10.1074/jbc.M401699200	http://dx.doi.org/10.1074/jbc.M401699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15075335	hybrid, Green Published			2022-12-27	WOS:000222445300053
J	Yuzawa, S; Ogura, K; Horiuchi, M; Suzuki, NN; Fujioka, Y; Kataoka, M; Sumimoto, H; Inagaki, F				Yuzawa, S; Ogura, K; Horiuchi, M; Suzuki, NN; Fujioka, Y; Kataoka, M; Sumimoto, H; Inagaki, F			Solution structure of the tandem src homology 3 domains of p47(phox) in an autoinhibited form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; RESIDUAL DIPOLAR COUPLINGS; RESPIRATORY BURST OXIDASE; PHOSPHORYLATION-INDUCED ACTIVATION; PROTEIN-KINASE-C; SH3 DOMAIN; BIOLOGICAL MACROMOLECULES; CONFORMATIONAL-CHANGE; MOLECULAR-MECHANISM; INTERTWINED DIMER	The phagocyte NADPH oxidase is a multisubunit enzyme responsible for the generation of superoxide anions (O-2(radical anion)) that kill invading microorganisms. p47(phox) is a cytosolic subunit of the phagocyte NADPH oxidase, which plays a crucial role in the assembly of the activated NADPH oxidase complex. The molecular shapes of the p47(phox) tandem SH3 domains either with or without a polybasic/autoinhibitory region (PBR/AIR) at the C terminus were studied using small angle x-ray scattering. The tandem SH3 domains with PBR/AIR formed a compact globular structure, whereas the tandem SH3 domains lacking the PBR/AIR formed an elongated structure. Alignment anisotropy analysis by NMR based on the residual dipolar couplings revealed that the tandem SH3 domains with PBR/AIR were in good agreement with a globular module corresponding to the split half of the intertwisted dimer in crystalline state. The structure of the globular module was elucidated to represent a solution structure of the tandem SH3 domain in the autoinhibited form, where the PBR/AIR bundled the tandem SH3 domains and the linker forming a closed structure. Once PBR/AIR is released by phosphorylation, rearrangements of the SH3 domains may occur, forming an open structure that binds to the cytoplasmic proline-rich region of membrane-bound p22(phox).	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Nara Inst Sci & Technol, Dept Mat Sci, Nara 6300101, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Nara Institute of Science & Technology; Kyushu University	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Kataoka, Mikio/H-4402-2011; Horiuchi, Masataka/D-5491-2012; Noda, Nobuo/P-1397-2015	Fujioka, Yuko/0000-0002-6905-0669; Yuzawa, Satoru/0000-0002-1031-5781; Noda, Nobuo/0000-0002-6940-8069				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W. L., 2001, PYMOL MOL GRAPHICS S; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Guinier A., 1955, SMALL ANGLE SCATTERI; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kishan KVR, 2001, PROTEIN SCI, V10, P1046, DOI 10.1110/ps.50401; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Mal TK, 2002, BIOCHEMISTRY-US, V41, P12899, DOI 10.1021/bi0264162; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottiger M, 1998, J BIOMOL NMR, V12, P361, DOI 10.1023/A:1008366116644; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Takeya R, 2003, MOL CELLS, V16, P271; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Ulmer TS, 2002, STRUCTURE, V10, P901, DOI 10.1016/S0969-2126(02)00781-5; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x; Yuzawa S, 2003, ACTA CRYSTALLOGR D, V59, P1479, DOI 10.1107/S0907444903011636; Yuzawa S, 2001, J MOL BIOL, V306, P527, DOI 10.1006/jmbi.2000.4396; YUZAWA S, 2004, IN PRESS J BIOMOL NM	48	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29752	29760		10.1074/jbc.M401457200	http://dx.doi.org/10.1074/jbc.M401457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123602	hybrid			2022-12-27	WOS:000222445300111
J	Aoyama, T; Okamoto, T; Nagayama, S; Nishijo, K; Ishibe, T; Yasura, K; Nakayama, T; Nakamura, T; Toguchida, J				Aoyama, T; Okamoto, T; Nagayama, S; Nishijo, K; Ishibe, T; Yasura, K; Nakayama, T; Nakamura, T; Toguchida, J			Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; OSTEOCALCIN GENE; CARTILAGE; GROWTH; DIFFERENTIATION; VITRO; HETEROGENEITY; CHONDROCYTES; CLONING; MATRIX	Transcriptional regulation of cell- and stage-specific genes is a crucial process in the development of mesenchymal tissues. Here we have investigated the regulatory mechanism of the expression of the chondromodulin-I (ChM-I) gene, one of the chondrocyte-specific genes, in osteogenic cells using osteosarcoma ( OS) cells as a model. Methylation-specific sequence analyses revealed that the extent of methylation in the core-promoter region of the ChM-I gene was correlated inversely with the expression of the ChM-I gene in OS primary tumors and cell lines. 5-Aza-deoxycytidine treatment induced the expression of the ChM-I gene in ChM-I-negative OS cell lines, and the induction of expression was associated tightly with the demethylation of cytosine at -52 (C(-52)) in the middle of an Sp1/3 binding site to which the Sp3, but not Sp1, bound. The replacement of C(-52) with methyl-cytosine or thymine abrogated Sp3 binding and also the transcription activity of the genomic fragment including C(-52). The inhibition of Sp3 expression by small interfering RNA reduced the expression of the ChM-I gene in ChM-I-positive normal chondrocytes, indicating Sp3 as a physiological transcriptional activator of the ChM-I gene. These results suggest that the methylation status of the core-promoter region is one of the mechanisms to determine the cell-specific expression of the ChM-I gene through the regulation of the binding of Sp3.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Orthoped Surg, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Oncol, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	togjun@frontier.kyoto-u.ac.jp						ALI NN, 1993, BONE, V14, P847, DOI 10.1016/8756-3282(93)90314-Z; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gerstenfeld LC, 1996, LAB INVEST, V74, P895; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; HAGAN G, 1994, EMBO J, V13, P3843; Hayami T, 1999, FEBS LETT, V458, P436, DOI 10.1016/S0014-5793(99)01201-6; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; ISHII S, 1982, INT ORTHOP, V6, P215; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KalffSuske M, 1996, GENOMICS, V37, P410, DOI 10.1006/geno.1996.0582; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lock GSH, 1998, T CAN SOC MECH ENG, V22, P207; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Muraglia A, 2000, J CELL SCI, V113, P1161; Murakami H, 2002, CANCER LETT, V182, P203, DOI 10.1016/S0304-3835(02)00096-4; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; PROKOP DJ, 1997, SCIENCE, V276, P71; Ryhanen S, 1997, J CELL BIOCHEM, V66, P404, DOI 10.1002/(SICI)1097-4644(19970901)66:3<404::AID-JCB12>3.0.CO;2-E; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1998, BIOCHEM BIOPH RES CO, V249, P885, DOI 10.1006/bbrc.1998.9233; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Unni KK, 1996, DAHLINS BONE TUMORS; Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113; Yanagihara I, 2000, J BONE MINER RES, V15, P421, DOI 10.1359/jbmr.2000.15.3.421; Yusa N, 2000, J LEUKOCYTE BIOL, V68, P772	35	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28789	28797		10.1074/jbc.M401273200	http://dx.doi.org/10.1074/jbc.M401273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107420	hybrid			2022-12-27	WOS:000222265400117
J	Frirdich, E; Vinogradov, E; Whitfield, C				Frirdich, E; Vinogradov, E; Whitfield, C			Biosynthesis of a novel 3-deoxy-D-manno-oct-2-ulosonic acid-containing outer core oligosaccharide in the lipopolysaccharide of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; EXTRACELLULAR TOXIC COMPLEX; UDP-N-ACETYLGLUCOSAMINE; GENE-CLUSTER; INNER-CORE; N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE; GLUCOSAMINE-1-PHOSPHATE ACETYLTRANSFERASE; LIPOOLIGOSACCHARIDE BIOSYNTHESIS; SALMONELLA-ENTERICA; HAEMOPHILUS-DUCREYI	The core oligosaccharide region of Klebsiella pneumoniae lipopolysaccharide contains some novel features that distinguish it from the corresponding lipopolysaccharide region in other members of the Enterobacteriaceae family, such as Escherichia coli and Salmonella. The conserved Klebsiella outer core contains the unusual trisaccharide 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo)-(2,6)- GlcN-(1,4)- GalUA. In general, Kdo residues are normally found in the inner core, but in K. pneumoniae, this Kdo residue provides the ligation site for O polysaccharide. The outer core Kdo residue can also be non-stoichiometrically substituted with an L-glycero-D-manno-heptopyranose (Hep) residue, another component more frequently found in the inner core. To understand the genetics and biosynthesis of core oligosaccharide synthesis in Klebsiella, the gene products involved in the addition of the outer core GlcN (WabH), Kdo (WabI), and Hep (WabJ) residues as well as the inner core HepIII residue ( WaaQ) were identified. Non-polar mutations were created in each of the genes, and the resulting mutant lipopolysaccharide was analyzed by mass spectrometry. The in vitro glycosyltransferase activity of WabI and WabH was verified. WabI transferred a Kdo residue from CMP-Kdo onto the acceptor lipopolysaccharide. The activated precursor required for GlcN addition has not been identified. However, lysates overexpressing WabH were able to transfer a GlcNAc residue from UDP-GlcNAc onto the acceptor GalUA residue in the outer core.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; DOMENICO P, 1985, CAN J MICROBIOL, V31, P472, DOI 10.1139/m85-088; Enderle PJ, 1998, BIOTECHNIQUES, V25, P954, DOI 10.2144/98256bm05; Finan TM, 2001, P NATL ACAD SCI USA, V98, P9889, DOI 10.1073/pnas.161294698; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Frirdich E, 2003, J BACTERIOL, V185, P1659, DOI 10.1128/JB.185.5.1659-1671.2003; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; GABRIEL O, 1982, METHOD ENZYMOL, V83, P332; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; Gibson BW, 1997, J BACTERIOL, V179, P5062, DOI 10.1128/jb.179.16.5062-5071.1997; Gronow S, 2000, EUR J BIOCHEM, V267, P6602, DOI 10.1046/j.1432-1327.2000.01754.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; Holst O, 2000, METH MOL B, V145, P345; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Izquierdo L, 2003, J BACTERIOL, V185, P7213, DOI 10.1128/JB.185.24.7213-7221.2003; Izquierdo L, 2002, MICROBIOL-SGM, V148, P3485, DOI 10.1099/00221287-148-11-3485; Izquierdo L, 2002, FEMS MICROBIOL LETT, V216, P211, DOI 10.1016/S0378-1097(02)01027-3; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KAST P, 1994, GENE, V138, P109, DOI 10.1016/0378-1119(94)90790-0; KORNFELD S, 1962, J BIOL CHEM, V237, P3052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENARD R, 1993, J BACTERIOL, V175, P5899; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Noah C, 2001, J ENDOTOXIN RES, V7, P25, DOI 10.1179/096805101101532495; Olsthoorn MMA, 1999, J MASS SPECTROM, V34, P622, DOI 10.1002/(SICI)1096-9888(199906)34:6<622::AID-JMS814>3.3.CO;2-M; Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589; Pompeo F, 2001, J BIOL CHEM, V276, P3833, DOI 10.1074/jbc.M004788200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahn A, 2003, MOL MICROBIOL, V47, P1045, DOI 10.1046/j.1365-2958.2003.03354.x; RAY PH, 1982, METHOD ENZYMOL, V83, P535; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SLAUCH JM, 1995, INFECT IMMUN, V63, P437, DOI 10.1128/IAI.63.2.437-441.1995; Stevens MK, 1997, INFECT IMMUN, V65, P651, DOI 10.1128/IAI.65.2.651-660.1997; STRAUS DC, 1985, INFECT IMMUN, V50, P787, DOI 10.1128/IAI.50.3.787-795.1985; STRAUS DC, 1987, INFECT IMMUN, V55, P44, DOI 10.1128/IAI.55.1.44-48.1987; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Tullius MV, 2002, INFECT IMMUN, V70, P2853, DOI 10.1128/IAI.70.6.2853-2861.2002; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Wang L, 2001, GENE, V270, P231, DOI 10.1016/S0378-1119(01)00471-1; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310	58	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27928	27940		10.1074/jbc.M402549200	http://dx.doi.org/10.1074/jbc.M402549200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090547	hybrid			2022-12-27	WOS:000222265400014
J	Yasumoto, K; Watabe, H; Valencia, JC; Kushimoto, T; Kobayashi, T; Appella, E; Hearing, VJ				Yasumoto, K; Watabe, H; Valencia, JC; Kushimoto, T; Kobayashi, T; Appella, E; Hearing, VJ			Epitope mapping of the melanosomal matrix protein gp100 (PMEL17) - Rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; ANTIBODIES NKI-BETEB; VESICLE FORMATION; MELANOMA-CELLS; ANTIGEN GENES; TYROSINASE; TRAFFICKING; EXPRESSION; MODEL; CORTICOSTERONE	Melanosomes, specific organelles produced only by melanocytes, undergo a unique maturation process that involves their transition form amorphous rounded vesicles to fibrillar ellipsoid organelles, during which they move from the perinuclear to the distal areas of the cells. This depends upon the trafficking and processing of gp100 (also known as Pmel17 and the silver protein), a protein of great interest, because it elicits immune responses in melanoma patients but in which specific function(s) remains elusive. In this study, we have used biochemical and immunochemical approaches to more critically assess the synthesis, processing, glycosylation, and trafficking of gp100. We now report that gp100 is processed and sorted in a manner distinct from other melanosomal proteins (such as tyrosinase, Tyrp1 and Dct) and is predominantly delivered directly to immature melanosomes following its rapid processing in the endoplasmic reticulum and cis-Golgi. Following its arrival, gp100 is cleaved at the amino and at the carboxyl termini in a series of specific steps that result in the reorganization of immature melanosomes to the fibrillar mature melanosomes. Once this structural reorganization occurs, melanogenic enzymes begin to be targeted to the melanosomes, which are then competent to synthesize melanin pigment.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Nagoya, Aichi 4600012, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Japan Science & Technology Agency (JST)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Kobayashi, Takeshi/0000-0002-4372-5285; Yasumoto, Ken-ichi/0000-0002-8090-1161	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOWITZ J, 1978, ARCH DERMATOL RES, V261, P303, DOI 10.1007/BF00455300; ABRAMOWITZ J, 1979, ARCH DERMATOL RES, V264, P293, DOI 10.1007/BF00412656; ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; Dell'Angelica EC, 2003, TRENDS CELL BIOL, V13, P503, DOI 10.1016/j.tcb.2003.08.001; Forslund KO, 2001, EXP CELL RES, V265, P185, DOI 10.1006/excr.2001.5173; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1987, MOL BIOL MED, V4, P339; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; SEIJI M, 1963, ANN NY ACAD SCI, V100, P497, DOI 10.1111/j.1749-6632.1963.tb42911.x; Setaluri V, 2003, J INVEST DERMATOL, V121, P650, DOI 10.1046/j.1523-1747.2003.12500.x; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Spritz RA, 2000, PIGM CELL RES, V13, P15, DOI 10.1034/j.1600-0749.2000.130104.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Takeuchi H, 2003, CANCER RES, V63, P441; Touloukian CE, 2001, CANCER RES, V61, P8100; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; VARKI A, 2002, ESSENTIALS GLYCOBIOL; Virador V, 2001, PIGM CELL RES, V14, P289, DOI 10.1034/j.1600-0749.2001.140410.x; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200	38	53	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28330	28338		10.1074/jbc.M401269200	http://dx.doi.org/10.1074/jbc.M401269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096515	hybrid			2022-12-27	WOS:000222265400065
J	Kim, JH; Nam, JH; Kim, MH; Koh, DS; Choi, SJ; Kim, SJ; Lee, JE; Min, KM; Uhm, DY; Kim, SJ				Kim, JH; Nam, JH; Kim, MH; Koh, DS; Choi, SJ; Kim, SJ; Lee, JE; Min, KM; Uhm, DY; Kim, SJ			Purinergic receptors coupled to intracellular Ca2+ signals and exocytosis in rat prostate neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CHANNEL CURRENTS; EPITHELIAL-CELLS; VENTRAL PROSTATE; INTERNAL STORES; RELEASE; ENDOCYTOSIS; AMPEROMETRY; STIMULATION; CARCINOMA	Rat prostate neuroendocrine cells (RPNECs) display a variety of ion channels and exhibit alpha-adrenergic regulation of cytosolic Ca2+ concentration ([Ca2+](c)). In this study, purinergic regulation of [Ca2+](c) and exocytosis was investigated in freshly isolated single RPNECs showing chromogranin A immunoreactivity. The presence of P2X and P2Y receptors in RPNECs was verified by the transient activation of Ca2+-permeable cationic channels and the release of Ca2+ from intracellular stores by extracellular ATP, respectively. The transient inward cationic current was effectively activated by alpha,beta-methyleneadenosine 5'-triphosphate (alpha,beta-MeATP) and blocked by 2',3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate, suggesting the presence of a P2X(1) or P2X(3) subtype. For the release of stored Ca2+, ATP and UTP were equally potent, indicating the functional expression of the P2Y(2) or P2Y(4) subtype. The mRNAs for P2X(1) and P2Y(2) were confirmed from reverse transcription-PCR analysis of RPNECs. The application of alpha,beta-MeATP induced large and transient increases in [Ca2+](c), which were not attenuated by the blockers of voltage-activated Ca2+ channels or by depleting intracellular Ca2+ stores, but were abolished by omitting extracellular Ca2+. The application of UTP increased [Ca2+](c) to 55% of the peak Delta[Ca2+](c) induced by alpha,beta-MeATP. The application of alpha,beta-MeATP induced exocytotic responses of RPNECs as monitored by carbon fiber amperometry and capacitance measurements. To our interest, the application of UTP did not induce amperometric currents, but reduced the membrane capacitance, indicating a net endocytosis. From these results, we postulate that a sharp rise in [Ca2+](c) by the P2X-mediated Ca2+ influx is required for exocytosis, whereas the relatively slow release of stored Ca2+ induces endocytosis in RPNECs.	Sungkyunkwan Univ, Dept Physiol, Sch Med, Suwon 440746, South Korea; Sungkyunkwan Univ, Ctr Mol Med, Sch Med, Suwon 440746, South Korea; Sungkyunkwan Univ, Dept Mol & Cellular Biol, Samsung Biomed Res Inst, Sch Med, Suwon 440746, South Korea; Pohang Univ Sci & Technol, Dept Phys, Pohang 790784, South Korea	Sungkyunkwan University (SKKU); Samsung; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Pohang University of Science & Technology (POSTECH)	Kim, SJ (corresponding author), Sungkyunkwan Univ, Dept Physiol, Sch Med, Suwon 440746, South Korea.	sjoonkim@med.skku.ac.kr	Nam, Joohyun/AAD-4491-2021; Kim, Sung Joon/H-1825-2012	Nam, Joo Hyun/0000-0001-8300-6974; Kim, Sung-Joon/0000-0002-0289-121X				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Boehm S, 1999, J NEUROSCI, V19, P737; Bonkhoff H, 1998, PROSTATE, P18; CASTRO E, 1995, J BIOL CHEM, V270, P5098, DOI 10.1074/jbc.270.10.5098; Charlton SJ, 1996, BRIT J PHARMACOL, V119, P1301, DOI 10.1111/j.1476-5381.1996.tb16038.x; Di Sant'Agnese PA, 1998, UROLOGY, V51, P121, DOI 10.1016/S0090-4295(98)00064-8; Dranoff JA, 2001, AM J PHYSIOL-GASTR L, V281, pG1059, DOI 10.1152/ajpgi.2001.281.4.G1059; Fisher RJ, 1999, PFLUG ARCH EUR J PHY, V437, P754, DOI 10.1007/s004240050842; Hansson J, 2001, ANN ONCOL, V12, pS145, DOI 10.1093/annonc/12.suppl_2.S145; He ML, 2003, AM J PHYSIOL-CELL PH, V285, pC467, DOI 10.1152/ajpcell.00042.2003; HILLE B, 2000, ION CHANNELS EXCITAB; Jabs R, 2000, MOL BRAIN RES, V76, P205, DOI 10.1016/S0169-328X(99)00339-3; Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kim JH, 2003, PFLUG ARCH EUR J PHY, V446, P88, DOI 10.1007/s00424-002-0995-6; Kim JH, 2003, PROSTATE, V57, P99, DOI 10.1002/pros.10277; Kim JH, 2002, PROSTATE, V51, P201, DOI 10.1002/pros.10090; Koh DS, 2000, J GEN PHYSIOL, V116, P507, DOI 10.1085/jgp.116.4.507; Koshimizu TA, 2000, MOL PHARMACOL, V58, P936, DOI 10.1124/mol.58.5.936; Kuromi H, 2004, NEURON, V41, P101, DOI 10.1016/S0896-6273(03)00815-8; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Poberaj I, 2002, BIOPHYS J, V82, P226, DOI 10.1016/S0006-3495(02)75389-7; Polge A, 1998, PROSTATE, V34, P1, DOI 10.1002/(SICI)1097-0045(19980101)34:1<1::AID-PROS1>3.0.CO;2-P; Prinz C, 2003, ANNU REV PHYSIOL, V65, P371, DOI 10.1146/annurev.physiol.65.092101.142205; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rodriguez R, 2003, PROSTATE, V57, P176, DOI 10.1002/pros.10287; Sauer H, 2002, J CELL SCI, V115, P3265; Travis ER, 1998, ANNU REV BIOPH BIOM, V27, P77, DOI 10.1146/annurev.biophys.27.1.77; VANKUGELGEN L, 2000, N-S ARCH PHARMACOL, V362, P310; VITTORIA A, 1990, J ANAT, V171, P169; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27345	27356		10.1074/jbc.M313575200	http://dx.doi.org/10.1074/jbc.M313575200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100230	hybrid			2022-12-27	WOS:000222120400065
J	Liao, GX; Zhang, MY; Harhaj, EW; Sun, SC				Liao, GX; Zhang, MY; Harhaj, EW; Sun, SC			Regulation of the NF-kappa B-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; UBIQUITIN LIGASE; ACTIVATION; LYMPHOTOXIN; CD40; PATHWAYS; MDM2; IKK; TNF; NF-KAPPA-B2	The NF-kappaB family of transcription factors plays a pivotal role in regulation of diverse biological processes, including immune responses, cell growth, and apoptosis. Activation of NF-kappaB is mediated by both canonical and noncanonical signaling pathways. Although the canonical pathway has been extensively studied, the mechanism mediating the noncanonical pathway is still poorly understood. Recent studies have identified the NF-kappaB-inducing kinase (NIK) as a key component of the noncanonical pathway of NF-kappaB activation; however, how the signaling function of NIK is regulated remains unknown. We report here that one important mechanism of NIK regulation is through its dynamic interaction with the tumor necrosis factor receptor-associated factor 3 (TRAF3). TRAF3 physically associates with NIK via a specific sequence motif located in the N-terminal region of NIK; this molecular interaction appears to target NIK for degradation by the proteasome. Interestingly, induction of noncanonical NF-kappaB signaling by extracellular signals involves degradation of TRAF3 and the concomitant enhancement of NIK expression. These results suggest that induction of noncanonical NF-kappaB signaling may involve the rescue of NIK from TRAF3-mediated negative regulation.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NCI NIH HHS [CA94922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HAMANO T, 1982, J IMMUNOL, V129, P1403; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Iciek LA, 1997, J IMMUNOL, V158, P4769; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin SC, 1996, MOL CELL BIOL, V16, P4591; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Xu LG, 2002, J IMMUNOL, V169, P6883, DOI 10.4049/jimmunol.169.12.6883; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	48	359	376	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26243	26250		10.1074/jbc.M403286200	http://dx.doi.org/10.1074/jbc.M403286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084608	hybrid			2022-12-27	WOS:000222003000041
J	Pulfer, MK; Murphy, RC				Pulfer, MK; Murphy, RC			Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROMOTER-BINDING PROTEIN; OZONATION PRODUCTS; REVISED MECHANISM; EPITHELIAL-CELLS; MAP KINASE; CN-TPBP; OZONE; METABOLISM; INHIBITION	Exposure of the lung to concentrations of ozone found in ambient air is known to cause toxicity to the epithelial cells of the lung. Because of the chemical reactivity of ozone, it likely reacts with target molecules in pulmonary surfactant, a lipid-rich material that lines the epithelial cells in the airways. Phospholipids containing unsaturated fatty acyl groups and cholesterol would be susceptible to attack by ozone, which may lead to the formation of cytotoxic products. Whereas free radical-derived oxidized cholesterol products have been frequently studied for their cytotoxic effects, ozonized cholesterol products have not been studied, although they could reasonably play a role in the toxicity of ozone. The reaction of ozone with cholesterol yielded a complex series of products including 3beta-hydroxy-5-oxo-5,6-secocholestan-6-al, 5-hydroperoxy-B-homo-6-oxa-cholestan-3beta,7a-diol, and 5beta,6beta-epoxycholesterol. Mass spectrometry and radioactive monitoring were used to identify the major cholesterol-derived product during the reaction of 2 ppm ozone in surfactant as 5beta,6beta-epoxycholesterol, which is only a minor product during ozonolysis of cholesterol in solution. A dose-dependent formation of 5beta,6beta-epoxycholesterol was also seen during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. Studies of the metabolism of this epoxide in lung epithelial cells yielded small amounts of the expected metabolite, cholestan-3beta,5alpha,6beta-triol, and more abundant levels of an unexpected metabolite, cholestan-6-oxo-3beta,5alpha-diol. Both 5beta,6beta-epoxycholesterol and cholestan-6-oxo-3beta,5alpha-diol were shown to be cytotoxic to cultured 16-HBE cells. A possible mechanism for cytotoxicity is the ability of these oxysterols to inhibit isoprenoid-based cholesterol biosynthesis in these cells.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES012347] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline; NIEHS NIH HHS [ES012347] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonio V, 2003, BIOCHEM J, V376, P351, DOI 10.1042/BJ20030098; Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4; ARINGER L, 1974, J LIPID RES, V15, P389; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Awad AB, 2003, J NUTR BIOCHEM, V14, P111, DOI 10.1016/S0955-2863(02)00274-7; Azuma A, 1997, BIOL PHARM BULL, V20, P6; BAILEY PS, 1958, CHEM REV, V58, P925, DOI 10.1021/cr50023a005; BAILEY PS, 1985, J ORG CHEM, V50, P231, DOI 10.1021/jo00202a015; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904, DOI 10.1164/ajrccm.153.3.8630571; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUDZIKIEWICZ H, 1972, BIOCH APPLICATIONS M, P262; CAO J, 1995, P SOC EXP BIOL MED, V209, P195; CASEY PJ, 1992, J LIPID RES, V33, P1731; CONNOR LM, 2004, AM J PHYSIOL, V286, pL1109; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074/jbc.M104197200; ENDO Y, 1993, BIOCHEM BIOPH RES CO, V194, P1529, DOI 10.1006/bbrc.1993.1998; FIESER LF, 1949, J AM CHEM SOC, V71, P3938, DOI 10.1021/ja01180a016; FIESER LF, 1959, REAGENTS ORGANIC SYN, P796; Ghelli A, 2002, ARCH BIOCHEM BIOPHYS, V402, P208, DOI 10.1016/S0003-9861(02)00085-1; Goldberg MS, 2001, AM J EPIDEMIOL, V154, P817, DOI 10.1093/aje/154.9.817; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GUMULKA J, 1983, J AM CHEM SOC, V105, P1972, DOI 10.1021/ja00345a052; HASHIMOTO Y, 1990, BIOCHEM BIOPH RES CO, V166, P1126, DOI 10.1016/0006-291X(90)90983-T; JAWORSKI K, 1988, J ORG CHEM, V53, P545, DOI 10.1021/jo00238a014; Kafoury RM, 1999, AM J RESP CRIT CARE, V160, P1934, DOI 10.1164/ajrccm.160.6.9902025; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, LIPIDS, V13, P704, DOI 10.1007/BF02533749; KANOFSKY JR, 1995, ARCH BIOCHEM BIOPHYS, V316, P52, DOI 10.1006/abbi.1995.1009; Koken PJM, 2003, ENVIRON HEALTH PERSP, V111, P1312, DOI 10.1289/ehp.5957; Loscalzo J, 2004, NEW ENGL J MED, V350, P834, DOI 10.1056/NEJMcibr033352; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; O'Callaghan YC, 2001, CELL BIOL TOXICOL, V17, P127, DOI 10.1023/A:1010914306375; O'Sullivan AJ, 2003, J APPL TOXICOL, V23, P191, DOI 10.1002/jat.906; Panini SR, 2001, J LIPID RES, V42, P1678; PARYZEK Z, 1988, CAN J CHEM, V66, P2130, DOI 10.1139/v88-338; Paryzek Z, 1997, J CHEM SOC PERK T 2, P2313, DOI 10.1039/a702633a; PARYZEK Z, 1990, J CHEM SOC PERK T 1, P1222, DOI 10.1039/p19900001222; PRYOR WA, 1992, BIOCHEM BIOPH RES CO, V188, P618, DOI 10.1016/0006-291X(92)91101-U; PRYOR WA, 1994, FREE RADICAL BIO MED, V17, P451, DOI 10.1016/0891-5849(94)90172-4; PRYOR WA, 1995, FREE RADICAL BIO MED, V19, P934; Pulfer MK, 2004, J AM SOC MASS SPECTR, V15, P194, DOI 10.1016/j.jasms.2003.10.011; RAAPHORST GP, 1987, BIOCHEM PHARMACOL, V36, P2369, DOI 10.1016/0006-2952(87)90605-8; ROSCOE HG, 1971, J LIPID RES, V12, P17; SEVANIAN A, 1987, LIPIDS, V22, P627, DOI 10.1007/BF02533940; SEVANIAN A, 1979, LIPIDS, V14, P634, DOI 10.1007/BF02533449; SEVANIAN A, 1991, J LIPID RES, V32, P147; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; UPPU RM, 1995, ARCH BIOCHEM BIOPHYS, V319, P257, DOI 10.1006/abbi.1995.1290; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; WEIBEL ER, 1984, PATHWAY OXYGEN STRUC, P325; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525	53	92	95	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26331	26338		10.1074/jbc.M403581200	http://dx.doi.org/10.1074/jbc.M403581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096493	hybrid			2022-12-27	WOS:000222003000052
J	Edavettal, SC; Lee, KA; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC				Edavettal, SC; Lee, KA; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC			Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; N-DEACETYLASE/N-SULFOTRANSFERASE; HERPES-SIMPLEX-VIRUS; ANTITHROMBIN-III; ESTROGEN SULFOTRANSFERASE; HUMAN CDNAS; BINDING; BIOSYNTHESIS; EXPRESSION; CRYSTALLOGRAPHY	Heparan sulfate interacts with antithrombin, a protease inhibitor, to regulate blood coagulation. Heparan sulfate 3-O-sulfotransferase isoform 1 performs the crucial last step modification in the biosynthesis of anticoagulant heparan sulfate. This enzyme transfers the sulfuryl group (SO3) from 3'-phosphoadenosine 5'-phosphosulfate to the 3-OH position of a glucosamine residue to form the 3-O-sulfo glucosamine, a structural motif critical for binding of heparan sulfate to antithrombin. In this study, we report the crystal structure of 3-O-sulfotransferase isoform 1 at 2.5-Angstrom resolution in a binary complex with 3'-phosphoadenosine 5'-phosphate. This structure reveals residues critical for 3'-phosphoadenosine 5'-phosphosulfate binding and suggests residues required for the binding of heparan sulfate. In addition, site-directed mutagenesis analyses suggest that residues Arg-67, Lys-68, Arg-72, Glu-90, His-92, Asp-95, Lys-123, and Arg-276 are essential for enzymatic activity. Among these essential amino acid residues, we find that residues Arg-67, Arg-72, His-92, and Asp-95 are conserved in heparan sulfate 3-O-sulfotransferases but not in heparan N-deacetylase/N-sulfotransferase, suggesting a role for these residues in conferring substrate specificity. Results from this study provide information essential for understanding the biosynthesis of anticoagulant heparan sulfate and the general mechanism of action of heparan sulfate sulfotransferases.	Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Troy, NY 12180 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rensselaer Polytechnic Institute	Liu, J (corresponding author), Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Rm 309,Beard Hall, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NIAID NIH HHS [AI50050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, Z01ES080040, ZIAES080040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BOYER C, 1986, THROMB HAEMOSTASIS, V56, P18; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; Dewerchin M, 2003, CIRC RES, V93, P1120, DOI 10.1161/01.RES.0000103634.69868.4F; Duncan MB, 2004, BBA-GEN SUBJECTS, V1671, P34, DOI 10.1016/j.bbagen.2003.12.010; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gorokhov A, 2000, BIOPHYS J, V79, P2909, DOI 10.1016/S0006-3495(00)76528-3; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 2003, BIOCHEM SOC T, V31, P331, DOI 10.1042/BST0310331; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu Jian, 2002, P475; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Myette JR, 2002, BIOCHEM BIOPH RES CO, V290, P1206, DOI 10.1006/bbrc.2001.6268; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; Weitz JI, 2003, J CLIN INVEST, V111, P952, DOI 10.1172/JCI200318234; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	39	60	64	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25789	25797		10.1074/jbc.M401089200	http://dx.doi.org/10.1074/jbc.M401089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060080	Green Published, hybrid			2022-12-27	WOS:000221827900109
J	Stephan, F; Kobor, MS; Philippi, A; Greenblatt, J; Tschochner, H				Stephan, F; Kobor, MS; Philippi, A; Greenblatt, J; Tschochner, H			Dephosphorylation of RNA polymerase I by Fcp1p is required for efficient rRNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; UPSTREAM ACTIVATION FACTOR; TRANSCRIPTION FACTOR UBF; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; DEPENDENT REGULATION; TIF-IA; PREINITIATION COMPLEX; GENE-TRANSCRIPTION	Differently phosphorylated forms of RNA polymerase (Pol) II are required to guide the enzyme through the transcription cycle. Here, we show that a phosphorylation/dephosphorylation cycle is also important for RNA polymerase I-dependent synthesis of rRNA precursors. A key component of the Pol II transcription system is Fcp1p, a phosphatase that dephosphorylates the C-terminal domain of the largest Pol II subunit. Fcp1p stimulates transcription elongation and is required for Pol II recycling after transcription termination. We found that Fcp1p is also part of the RNA Pol I transcription apparatus. Fcp1p is required for efficient rDNA transcription in vivo, and also, recombinant Fcp1p stimulates rRNA synthesis both in promoter-dependent and in nonspecific transcription assays in vitro. We demonstrate that Fcp1 activity is not involved in the formation of the initiation-active form of Pol I (the Pol I-Rrn3p complex) and propose that dephosphorylation of Pol I by Fcp1p facilitates chain elongation during rRNA synthesis.	Univ Regensburg, Inst Biochem Mikrobiol & Genet, D-94034 Regensburg, Germany; Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Regensburg; Ruprecht Karls University Heidelberg; University of California System; University of California Berkeley; University of Toronto; University of Toronto	Tschochner, H (corresponding author), Univ Regensburg, Inst Biochem Mikrobiol & Genet, Univ Str 1, D-94034 Regensburg, Germany.	herbert.tschochner@vkl.uni-regensburg.de		Kobor, Michael/0000-0003-4140-1743				Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Fath S, 2000, J CELL BIOL, V149, P575, DOI 10.1083/jcb.149.3.575; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Hirschler-Laszkiewicz I, 2003, J BIOL CHEM, V278, P18953, DOI 10.1074/jbc.M301093200; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUET J, 1982, EMBO J, V1, P1193, DOI 10.1002/j.1460-2075.1982.tb00012.x; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Keener J, 1997, P NATL ACAD SCI USA, V94, P13458, DOI 10.1073/pnas.94.25.13458; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kuhn A, 1998, J MOL BIOL, V284, P1, DOI 10.1006/jmbi.1998.2164; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; Lin CW, 1996, MOL CELL BIOL, V16, P6436; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Milkereit P, 1997, BIOL CHEM, V378, P1433, DOI 10.1515/bchm.1997.378.12.1433; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; MUSTERS W, 1989, NUCLEIC ACIDS RES, V17, P9661, DOI 10.1093/nar/17.23.9661; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Siddiqi IN, 2001, EMBO J, V20, P4512, DOI 10.1093/emboj/20.16.4512; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; Steffan JS, 1998, MOL CELL BIOL, V18, P3752, DOI 10.1128/MCB.18.7.3752; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212; Zhai WG, 1999, MOL CELL BIOL, V19, P2791; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	55	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25251	25259		10.1074/jbc.M401867200	http://dx.doi.org/10.1074/jbc.M401867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073185	hybrid			2022-12-27	WOS:000221827900043
J	Samaha, FF; Rubenstein, RC; Yan, WS; Ramkumar, M; Levy, DI; Ahn, YJ; Sheng, SH; Kleyman, TR				Samaha, FF; Rubenstein, RC; Yan, WS; Ramkumar, M; Levy, DI; Ahn, YJ; Sheng, SH; Kleyman, TR			Functional polymorphism in the carboxyl terminus of the alpha-subunit of the human epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SENSITIVE NA+ CHANNEL; LIDDLE-SYNDROME; BETA-SUBUNIT; MEMBRANE TOPOLOGY; GAMMA-SUBUNIT; ESSENTIAL-HYPERTENSION; BLACK-PEOPLE; MUTATIONS; AMILORIDE	A common human epithelial sodium channel ( ENaC) polymorphism, alphaT663A, is present in the cytoplasmic C terminus of the alpha-subunit, although it is unclear whether this polymorphism segregates with blood pressure. We examined whether this polymorphism was associated with differences in functional Na+ channel expression. Whole cell amiloride-sensitive currents in Xenopus oocytes expressing wild type channels (alphaT663betagamma) were significantly similar to1.3-2.0-fold higher than currents measured in oocytes expressing channels with an Ala, Gly or Leu, or Lys at position alpha663. In contrast, differences in functional human ENaC expression were not observed with oocytes expressing channels having Thr (wild type), Ser, or Asp at this position. The surface expression of channels, measured using an epitope-tagged beta-subunit, was significantly reduced in oocytes expressing alphaT663Abetagamma when compared with oocytes expressing alphaT663betagamma. The corresponding polymorphism was generated in the mouse alpha-subunit (malphaA692T) and was not associated with differences in functional alphabetagamma-mouse ENaC expression. The polymorphism is present in a region that is not well conserved between human and mouse. We generated a mouse/human chimera by replacement of the distal C terminus of the mouse alpha-subunit with the distal C terminus of the human alpha-subunit. Co-expression of this m(1-678)/h(650-669)T663A chimera with mouse betagamma led to a significant reduction in whole cell Na+ currents and surface expression when compared with m(1-678)/h( 650-669) T663-mbetagamma. Our results suggest that h alphaT663A is a functional polymorphism that affects human ENaC surface expression.	Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rubenstein, RC (corresponding author), Childrens Hosp Philadelphia, Div Pulm Med, 34th St & Civ Ctr Blvd,Abramson 410C, Philadelphia, PA 19104 USA.	rrubenst@mail.med.upenn.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Rubenstein, Ronald/0000-0002-3138-4006; Levy, Daniel/0000-0003-0603-0297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, R37DK051391, R01DK058046, R01DK051391] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58046, DK54354, DK51391] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Ambrosius WT, 1999, HYPERTENSION, V34, P631, DOI 10.1161/01.HYP.34.4.631; AMBROSIUS WT, 2003, HYPERTENSION, V41, pE1; Baker EH, 2002, HYPERTENSION, V40, P13, DOI 10.1161/01.HYP.0000022570.02119.75; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Corvol P, 1999, HYPERTENSION, V33, P1324, DOI 10.1161/01.HYP.33.6.1324; Cui Y, 1997, P NATL ACAD SCI USA, V94, P9962, DOI 10.1073/pnas.94.18.9962; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Hummler E, 2003, CURR HYPERTENS REP, V5, P11, DOI 10.1007/s11906-003-0005-1; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Persu A, 1998, HYPERTENSION, V32, P129, DOI 10.1161/01.HYP.32.1.129; RENARD S, 1994, J BIOL CHEM, V269, P12981; Saxena A, 2002, J CLIN ENDOCR METAB, V87, P3344, DOI 10.1210/jcem.87.7.8674; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Sugiyama T, 2001, HYPERTENS RES, V24, P515, DOI 10.1291/hypres.24.515; Warnock DG, 2001, AM J MED SCI, V322, P302, DOI 10.1097/00000441-200112000-00002; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; ZAR JH, 1984, BIOSTAT ANAL, P241; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23900	23907		10.1074/jbc.M401941200	http://dx.doi.org/10.1074/jbc.M401941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069064	hybrid			2022-12-27	WOS:000221702500010
J	Smith, WA; Schurter, BT; Wong-Staal, F; David, M				Smith, WA; Schurter, BT; Wong-Staal, F; David, M			Arginine methylation of RNA helicase A determines its subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; PROTEIN; SEQUENCES; BINDING; TRANSCRIPTION; CONTAINS; PEPTIDES; SIGNALS; TYPE-1; EXPORT	RNA helicase A (RHA) undergoes nuclear translocation via a classical import mechanism utilizing karyopherin beta. The nuclear transport domain (NTD) of RHA is known to be necessary and sufficient for its bi-directional nuclear trafficking. We report here that arginine methylation is a novel requirement for NTD-mediated nuclear import. Nuclear translocation of glutathione S-transferase (GST)-NTD fusion proteins is abrogated by arginine-methylation inhibitors. However, in vitro arginine-methylation of GST-NTD prior to injection allows the fusion protein to localize to the nucleus in the presence of methylation inhibitors. Removal of the arginine-rich C-terminal region negates the effects of the methylation inhibitors on NTD import, suggesting that methylation of the NTD C terminus the relieves the cytoplasmic retention of RHA. The NTD physically interacts with PRMT1, the major protein arginine methyltransferase. These findings provide evidence for a novel arginine methylation-dependent regulatory pathway controlling the nuclear import of RHA.	Univ Calif San Diego, Dept Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Div Biol Sci, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.	midavid@ucsd.edu			NCI NIH HHS [R01CA80105] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; LEE CG, 1993, J BIOL CHEM, V268, P16822; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Zhang SS, 2002, J BIOL CHEM, V277, P843, DOI 10.1074/jbc.M109393200; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	25	100	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22795	22798		10.1074/jbc.C300512200	http://dx.doi.org/10.1074/jbc.C300512200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15084609	hybrid			2022-12-27	WOS:000221570900003
J	Choi, YG; Kim, JI; Jeon, YC; Park, SJ; Choi, EK; Rubenstein, R; Kascsak, RJ; Carp, RI; Kim, YS				Choi, YG; Kim, JI; Jeon, YC; Park, SJ; Choi, EK; Rubenstein, R; Kascsak, RJ; Carp, RI; Kim, YS			Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION END-PRODUCTS; MAILLARD REACTION; ALZHEIMER-DISEASE; OXIDATIVE STRESS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; KNOCKOUT MICE; GLYCOSYLATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; GLYCOXIDATION	Transmissible spongiform encephalopathies (TSEs) are transmissible neurodegenerative diseases characterized by the accumulation of an abnormally folded prion protein, termed PrPSc, and the development of pathological features of astrogliosis, vacuolation, neuronal cell loss, and in some cases amyloid plaques. Although considerable structural characterization of prion protein has been reported, neither the method of conversion of cellular prion protein, PrPC, into the pathogenic isoform nor the post-translational modification processes involved is known. We report that in animal and human TSEs, one or more lysines at residues 23, 24, and 27 of PrPSc are covalently modified with advanced glycosylation end products (AGEs), which may be carboxymethyllysine (CML), one of the structural varieties of AGEs. The arginine residue at position 37 may also be modified with AGE, but not the arginine residue at position 25. This result suggests that nonenzymatic glycation is one of the post-translational modifications of PrPSc. Furthermore, immunostaining studies indicate that, at least in clinically affected hamsters, astrocytes are the first site of this glycation process.	Hallym Univ, Ilsong Inst Life Sci, Coll Med, Anyang 431060, Kyeonggi Do, South Korea; Hallym Univ, Dept Microbiol, Coll Med, Anyang 431060, Kyeonggi Do, South Korea; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Hallym University; Hallym University; Institute for Basic Research in Developmental Disabilities	Kim, YS (corresponding author), Hallym Univ, Ilsong Inst Life Sci, Coll Med, 1605-4 Kwanyangdong, Anyang 431060, Kyeonggi Do, South Korea.	yskim@hallym.ac.kr						Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; BRONWLEE M, 1988, NEW ENGL J MED, V318, P1315; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; Castellani R, 1996, BRAIN RES, V737, P195, DOI 10.1016/0006-8993(96)00729-9; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; Dukic-Stefanovic S, 2002, J IMMUNOL METHODS, V266, P45, DOI 10.1016/S0022-1759(02)00097-2; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kascsak RJ, 1997, IMMUNOL INVEST, V26, P259, DOI 10.3109/08820139709048931; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mironova R, 2003, J BIOL CHEM, V278, P51068, DOI 10.1074/jbc.M307470200; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; Miyata T, 1997, KIDNEY INT, V51, P1170, DOI 10.1038/ki.1997.160; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; Montrasio F, 2001, P NATL ACAD SCI USA, V98, P4034, DOI 10.1073/pnas.051609398; Nerlich AG, 1999, ATHEROSCLEROSIS, V144, P41, DOI 10.1016/S0021-9150(99)00038-6; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Raeber AJ, 1998, BRAIN PATHOL, V8, P715, DOI 10.1111/j.1750-3639.1998.tb00197.x; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; Shibayama P, 1999, DIABETES, V48, P1842, DOI 10.2337/diabetes.48.9.1842; SMITH MA, 1994, ANN NY ACAD SCI, V738, P447; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	35	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30402	30409		10.1074/jbc.M400854200	http://dx.doi.org/10.1074/jbc.M400854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15084583	hybrid			2022-12-27	WOS:000222531900066
J	Jensen, LT; Sanchez, RJ; Srinivasan, C; Valentine, JS; Culotta, VC				Jensen, LT; Sanchez, RJ; Srinivasan, C; Valentine, JS; Culotta, VC			Mutations in Saccharomyces cerevisiae iron-sulfur cluster assembly genes and oxidative stress relevant to Cu,Zn superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; YEAST-CELLS; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PROTEINS; HOMEOSTASIS; COPPER; MITOCHONDRIA; BIOGENESIS; FRATAXIN; DAMAGE	Saccharomyces cerevisiae lacking Cu,Zn superoxide dismutase (SOD1) show several metabolic defects including aerobic blockages in methionine and lysine biosynthesis. We have previously shown that mutations in genes implicated in the formation of iron-sulfur clusters, designated seo ( suppressors of endogenous oxidation), reverse the oxygen-dependent methionine and lysine auxotrophies of a sod1Delta strain. We now report the surprising finding that seo mutants do not reduce oxidative damage as shown by the lack of reduction of EPR-detectable "free" iron, which is characteristic of sod1Delta mutants. In fact, they exhibit increased oxidative damage as evidenced by increased accumulation of protein carbonyls. The seo class of mutants overaccumulates mitochondrial iron, and this iron accumulation is critical for suppression of the sod1Delta biosynthetic defects. Blocking overaccumulation of mitochondrial iron abolished the ability of the seo mutants to suppress the sod1Delta auxotrophies. By contrast, increasing the mitochondrial iron content of sod1Delta yeast using high copy MMT1, which encodes a mitochondrial iron transporter, was sufficient to mimic the seo mutants. Our studies indicated that suppression of the sod1Delta methionine auxotrophy was dependent on the pentose phosphate pathway, which is a major source of NADPH production. By comparison, the sod1Delta lysine auxotrophy appears to be reversed in the seo mutants by increased expression of genes in the lysine biosynthetic pathway, perhaps through sensing of mitochondrial damage by the retrograde response.	Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles	Jensen, LT (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	ljensen@jhsph.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Jensen, Laran/0000-0003-3199-1743	NIDDK NIH HHS [DK 46828] Funding Source: Medline; NIGMS NIH HHS [GM 50016] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BHATTACH.JK, 1972, MOL GEN GENET, V115, P26, DOI 10.1007/BF00272214; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4; Feller A, 1997, YEAST, V13, P1337, DOI 10.1002/(SICI)1097-0061(199711)13:14<1337::AID-YEA186>3.0.CO;2-O; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Srinivasan C, 2002, METHOD ENZYMOL, V349, P173, DOI 10.1016/S0076-6879(02)49333-0; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sturtz LA, 2002, METHOD ENZYMOL, V349, P167, DOI 10.1016/S0076-6879(02)49332-9; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	49	26	28	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29938	29943		10.1074/jbc.M402795200	http://dx.doi.org/10.1074/jbc.M402795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15107423	hybrid			2022-12-27	WOS:000222531900010
J	Citovsky, V; Kapelnikov, A; Oliel, S; Zakai, N; Rojas, MR; Gilbertson, RL; Tzfira, T; Loyter, A				Citovsky, V; Kapelnikov, A; Oliel, S; Zakai, N; Rojas, MR; Gilbertson, RL; Tzfira, T; Loyter, A			Protein interactions involved in nuclear import of the Agrobacterium VirE2 protein in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMEFACIENS-MEDIATED TRANSFORMATION; T-DNA TRANSFER; LOCALIZATION SIGNAL; VIRD2 PROTEIN; PLANT-CELLS; CYTOSOLIC FACTORS; BINDING-PROTEIN; HIV-1 VPR; TRANSPORT; INTEGRATION	Agrobacterium, the only known organism capable of trans-kingdom DNA transfer, genetically transforms plants by transferring a segment of its DNA, T-DNA, into the nucleus of the host cell where it integrates into the plant genome. One of the central events in this genetic transformation process is nuclear import of the T-DNA molecule, which to a large degree is mediated by the bacterial virulence protein VirE2. VirE2 is distinguished by its nuclear targeting, which occurs only in plant but not in animal cells and is facilitated by the cellular VIP1 protein. The molecular mechanism of the VIP1 function is still unclear. Here, we used in vitro assays for nuclear import and quantification of protein-protein interactions to directly demonstrate formation of ternary complexes between VirE2, VIP1, and a component of the cellular nuclear import machinery, karyopherin alpha. Our results indicate that VIP1 functions as a molecular bridge between VirE2 and karyopherin alpha, allowing VirE2 to utilize the host cell nuclear import machinery even without being directly recognized by its components.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Hebrew University of Jerusalem; University of California System; University of California Davis; University of California System; University of California Davis	Citovsky, V (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	vitaly.citovsky@stonybrook.edu		Citovsky, Vitaly/0000-0003-2024-6844				Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; Broder YC, 1997, FEBS LETT, V412, P535, DOI 10.1016/S0014-5793(97)00855-7; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CITOVSKY V, 1991, P NATL ACAD SCI USA, V88, P2476, DOI 10.1073/pnas.88.6.2476; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; Friedler A, 1998, BIOCHEMISTRY-US, V37, P5616, DOI 10.1021/bi972878h; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guralnick B, 1996, PLANT CELL, V8, P363, DOI 10.1105/tpc.8.3.363; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; Karni O, 1998, FEBS LETT, V429, P421, DOI 10.1016/S0014-5793(98)00645-0; KOUKOLIKOVANICOLA Z, 1993, J BACTERIOL, V175, P723; Krichevsky A, 2003, VIROLOGY, V305, P77, DOI 10.1006/viro.2002.1765; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Mysore KS, 1998, MOL PLANT MICROBE IN, V11, P668, DOI 10.1094/MPMI.1998.11.7.668; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; ROSSI L, 1993, MOL GEN GENET, V239, P345, DOI 10.1007/BF00276932; STACHEL SE, 1989, NATURE, V340, P190, DOI 10.1038/340190a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; Tzfira T, 2001, EMBO J, V20, P3596, DOI 10.1093/emboj/20.13.3596; Tzfira T, 2002, P NATL ACAD SCI USA, V99, P10435, DOI 10.1073/pnas.162304099; Tzfira T, 2002, TRENDS CELL BIOL, V12, P121, DOI 10.1016/S0962-8924(01)02229-2; Tzfira T, 2001, MOL PLANT PATHOL, V2, P171, DOI 10.1046/j.1364-3703.2001.00065.x; Ward DV, 2001, P NATL ACAD SCI USA, V98, P385, DOI 10.1073/pnas.98.2.385; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Ziemienowicz A, 1999, P NATL ACAD SCI USA, V96, P3729, DOI 10.1073/pnas.96.7.3729; Ziemienowicz A, 2001, PLANT CELL, V13, P369, DOI 10.1105/tpc.13.2.369; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150; Zupan JR, 1996, P NATL ACAD SCI USA, V93, P2392, DOI 10.1073/pnas.93.6.2392	49	47	55	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29528	29533		10.1074/jbc.M403159200	http://dx.doi.org/10.1074/jbc.M403159200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123622	hybrid			2022-12-27	WOS:000222445300086
J	Fabian, MR; White, KA				Fabian, MR; White, KA			5 '-3 ' RNA-RNA interaction facilitates cap- and poly(A) tail-independent translation of tomato bushy stunt virus mRNA - A potential common mechanism for Tombusviridae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW DWARF VIRUS; SATELLITE TOBACCO; BINDING-PROTEIN; STIMULATES TRANSLATION; 3'-UNTRANSLATED REGION; UNTRANSLATED REGIONS; MOLECULAR-BIOLOGY; SEQUENCE; ELEMENT; INITIATION	Tomato bushy stunt virus (TBSV) is the prototypical member of the genus Tombusvirus in the family Tombusviridae. The (+)-strand RNA genome of TBSV lacks both a 5' cap and a 3' poly( A) tail and instead contains a 3'-terminal RNA sequence that acts as a cap-independent translational enhancer (3' CITE). In this study, we have determined the RNA secondary structure of the translation-specific central segment of the 3' CITE, termed region 3.5 (R3.5). MFOLD structural modeling combined with solution structure mapping and comparative sequence analysis indicate that R3.5 adopts a branched structure that contains three major helices. Deletion and substitution studies revealed that two of these extended stem-loop (SL) structures are essential for 3' CITE activity in vivo. In particular, the terminal loop of one of these SLs, SL-B, was found to be critical for translation. Compensatory mutational analysis showed that SL-B functions by base pairing with another SL, SL3, in the 5' untranslated region of the TBSV genome. Thus, efficient translation of TBSV mRNA in vivo requires a 5'-3' RNA-RNA interaction that effectively circularizes the message. Similar types of interactions are also predicted to occur in TBSV subgenomic mRNAs between their 5' untranslated regions and the 3' CITE, and both genomic and subgenomic 5'-3' interactions are well conserved in all members of the genus Tombusvirus. In addition, a survey of other genera in Tombusviridae revealed the potential for similar 5'-3' RNA-RNA-based interactions in their viral mRNAs, suggesting that this mechanism extends throughout this large virus family.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada	York University - Canada	White, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	kawhite@yorku.ca						Allen E, 1999, VIROLOGY, V253, P139, DOI 10.1006/viro.1998.9507; Bailey-Serres J, 1999, TRENDS PLANT SCI, V4, P142, DOI 10.1016/S1360-1385(99)01386-2; Barry JK, 2002, P NATL ACAD SCI USA, V99, P11133, DOI 10.1073/pnas.162223099; Barton DJ, 1999, J VIROL, V73, P10104, DOI 10.1128/JVI.73.12.10104-10112.1999; Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; Choi IR, 2002, J BIOL CHEM, V277, P3760, DOI 10.1074/jbc.M109067200; Choi IR, 2001, J BIOL CHEM, V276, P41761, DOI 10.1074/jbc.M106727200; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; Fabian MR, 2003, VIROLOGY, V313, P567, DOI 10.1016/S0042-6822(03)00349-0; Franch T, 2000, CURR OPIN MICROBIOL, V3, P159, DOI 10.1016/S1369-5274(00)00069-2; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gazo BM, 2004, J BIOL CHEM, V279, P13584, DOI 10.1074/jbc.M311361200; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Guo L, 2000, RNA, V6, P1808, DOI 10.1017/S1355838200001539; HEARNE PQ, 1990, VIROLOGY, V177, P141, DOI 10.1016/0042-6822(90)90468-7; HULL R, 2002, MATHEWS PLANT VIRUSE; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kawaguchi R, 2002, CURR OPIN PLANT BIOL, V5, P460, DOI 10.1016/S1369-5266(02)00290-X; Khromykh AA, 2001, J VIROL, V75, P6719, DOI 10.1128/JVI.75.14.6719-6728.2001; Kim KH, 1999, RNA, V5, P636, DOI 10.1017/S1355838299982006; Koh DCY, 2002, J VIROL, V76, P1144, DOI 10.1128/JVI.76.3.1144-1153.2002; Lindenbach BD, 2002, J VIROL, V76, P3905, DOI 10.1128/JVI.76.8.3905-3919.2002; Ling J, 2002, MOL CELL BIOL, V22, P7853, DOI 10.1128/MCB.22.22.7853-7867.2002; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mayo MA, 1996, ADV VIRUS RES, V46, P413, DOI 10.1016/S0065-3527(08)60077-9; Meulewaeter F, 2004, NUCLEIC ACIDS RES, V32, P1721, DOI 10.1093/nar/gkh338; Meulewaeter F, 1998, PLANT J, V14, P169, DOI 10.1046/j.1365-313X.1998.00104.x; Michel YM, 2001, MOL CELL BIOL, V21, P4097, DOI 10.1128/MCB.21.13.4097-4109.2001; Miller WA, 2002, MOL PLANT PATHOL, V3, P177, DOI 10.1046/j.1364-3703.2002.00112.x; Mizumoto H, 2003, J VIROL, V77, P12113, DOI 10.1128/JVI.77.22.12113-12121.2003; MOLINARO M, 1995, NUCLEIC ACIDS RES, V23, P3056, DOI 10.1093/nar/23.15.3056; Oster SK, 1998, J VIROL, V72, P5845, DOI 10.1128/JVI.72.7.5845-5851.1998; Panavas T, 2003, J VIROL, V77, P258, DOI 10.1128/JVI.77.1.258-269.2003; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Pogany J, 2003, EMBO J, V22, P5602, DOI 10.1093/emboj/cdg523; Qiu WP, 2002, MOL PLANT MICROBE IN, V15, P269, DOI 10.1094/MPMI.2002.15.3.269; Qu F, 2002, MOL PLANT MICROBE IN, V15, P193, DOI 10.1094/MPMI.2002.15.3.193; Qu F, 2000, J VIROL, V74, P1085, DOI 10.1128/JVI.74.3.1085-1093.2000; Ray D, 2003, RNA, V9, P1232, DOI 10.1261/rna.5630203; Ray D, 2003, J VIROL, V77, P245, DOI 10.1128/JVI.77.1.245-257.2003; Ray D, 1999, VIROLOGY, V256, P162, DOI 10.1006/viro.1999.9630; RUSSO M, 1994, ADV VIRUS RES, V44, P381, DOI 10.1016/S0065-3527(08)60334-6; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; SCHOLTHOF KBG, 1995, VIROLOGY, V208, P365, DOI 10.1006/viro.1995.1162; Shen RZ, 2004, J VIROL, V78, P4655, DOI 10.1128/JVI.78.9.4655-4664.2004; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; van Lipzig R, 2001, NUCLEIC ACIDS RES, V29, P1080, DOI 10.1093/nar/29.5.1080; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; WHITE KA, 1994, J VIROL, V68, P14, DOI 10.1128/JVI.68.1.14-24.1994; Wu BD, 2001, J MOL BIOL, V305, P741, DOI 10.1006/jmbi.2000.4298; Wu BD, 1999, J VIROL, V73, P8982, DOI 10.1128/JVI.73.11.8982-8988.1999; You SY, 2001, J BIOL CHEM, V276, P15581, DOI 10.1074/jbc.M010923200; Zhang GC, 1999, RNA, V5, P550, DOI 10.1017/S1355838299982080; Zuker M., 1999, V70, P11	61	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28862	28872		10.1074/jbc.M401272200	http://dx.doi.org/10.1074/jbc.M401272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123633	hybrid			2022-12-27	WOS:000222445300006
J	Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Rafter, JD; Melowic, HR; Cho, WH				Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Rafter, JD; Melowic, HR; Cho, WH			Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CYTOSOLIC PHOSPHOLIPASE A(2); PHORBOL ESTER RECEPTORS; SMOOTH-MUSCLE-CELLS; PKC-DELTA; DIFFERENTIAL ROLES; MOLECULAR-BASIS; C2-LIKE DOMAIN; MITOCHONDRIAL TRANSLOCATION; MACROMOLECULAR INTERACTIONS	The regulatory domains of novel protein kinases C (PKC) contain two C1 domains (C1A and C1B), which have been identified as the interaction site for sn-1,2-diacylglycerol (DAG) and phorbol ester, and a C2 domain that may be involved in interaction with lipids and/or proteins. Although recent reports have indicated that C1A and C1B domains of conventional PKCs play different roles in their DAG-mediated membrane binding and activation, the individual roles of C1A and C1B domains in the DAG-mediated activation of novel PKCs have not been fully understood. In this study, we determined the roles of C1A and C1B domains of PKCdelta by means of in vitro lipid binding analyses and cellular protein translocation measurements. Isothermal titration calorimetry and surface plasmon resonance measurements showed that isolated C1A and C1B domains of PKCdelta have opposite affinities for DAG and phorbol ester; i.e. the C1A domain with high affinity for DAG and the C1B domain with high affinity for phorbol ester. Furthermore, in vitro activity and membrane binding analyses of PKCdelta mutants showed that the C1A domain is critical for the DAG-induced membrane binding and activation of PKCdelta. The studies also indicated that an anionic residue, Glu(177), in the C1A domain plays a key role in controlling the DAG accessibility of the conformationally restricted C1A domain in a phosphatidylserine-dependent manner. Cell studies with enhanced green fluorescent protein-tagged PKCdelta and mutants showed that because of its phosphatidylserine specificity PKCdelta preferentially translocated to the plasma membrane under the conditions in which DAG is randomly distributed among intracellular membranes of HEK293 cells. Collectively, these results provide new insight into the differential roles of C1 domains in the DAG-induced membrane activation of PKCdelta and the origin of its specific subcellular localization in response to DAG.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WH (corresponding author), M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598, R01GM068849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598, GM53987, GM68849] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Aroca P, 2000, FEBS LETT, V483, P27, DOI 10.1016/S0014-5793(00)02075-5; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bogi K, 1998, CANCER RES, V58, P1423; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho Wonhwa, 2003, Methods Mol Biol, V233, P291; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clarke H, 2000, KIDNEY INT, V58, P1004, DOI 10.1046/j.1523-1755.2000.00258.x; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH404, DOI 10.1152/ajpheart.2001.281.1.H404; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Lorenzo PS, 1999, CANCER RES, V59, P6137; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Mozsolits H, 2003, J PEPT SCI, V9, P77, DOI 10.1002/psc.439; Mozsolits H, 2002, BIOPOLYMERS, V66, P3, DOI 10.1002/bip.10200; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; ONO Y, 1988, J BIOL CHEM, V263, P6927; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Pappa H, 1998, ACTA CRYSTALLOGR D, V54, P693, DOI 10.1107/S0907444997019732; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	84	118	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29501	29512		10.1074/jbc.M403191200	http://dx.doi.org/10.1074/jbc.M403191200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105418	hybrid			2022-12-27	WOS:000222445300083
J	Cabrera-Poch, N; Sanchez-Ruiloba, L; Rodriguez-Martinez, M; Iglesias, T				Cabrera-Poch, N; Sanchez-Ruiloba, L; Rodriguez-Martinez, M; Iglesias, T			Lipid raft disruption triggers protein kinase C and Src-dependent protein kinase D activation and Kidins220 phosphorylation in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVEOLAE-LIKE DOMAINS; PLECKSTRIN HOMOLOGY DOMAIN; D PKD ACTIVATION; DOWNSTREAM TARGET; TYROSINE KINASE; PHORBOL ESTERS; LOOP SER(744); DNA-SYNTHESIS; INTACT-CELLS; MU	Kidins220 ( kinase D-interacting substrate of 220 kDa) is a novel neurospecific protein recently cloned as the first substrate for the Ser/Thr kinase protein kinase D (PKD). Herein we report that Kidins220 is constitutively associated to lipid rafts in PC12 cells, rat primary cortical neurons, and brain synaptosomes. Immunocytochemistry and confocal microscopy together with sucrose gradient fractionation show co-localization of Kidins220 and lipid raft-associated proteins. In addition, cholesterol depletion of cell membranes with methyl-beta-cyclodextrin dramatically alters Kidins220 localization and detergent solubility. By studying the putative involvement of lipid rafts in PKD activation and signaling we have found that active PKD partitions in lipid raft fractions after sucrose gradient centrifugation and that green fluorescent protein-PKD translocates to lipid raft microdomains at the plasma membrane after phorbol ester treatment. Strikingly, lipid rafts disruption by methyl-beta-cyclodextrin delays green fluorescent protein-PKD translocation, as determined by live cell confocal microscopy, and activates PKD, increasing Kidins220 phosphorylation on Ser(919) by a mechanism involving PKCepsilon and the small soluble tyrosine kinase Src. Collectively, these results reveal the importance of lipid rafts on PKD activation, translocation, and downstream signaling to its substrate Kidins220.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Iglesias, T (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, C Arturo Duperier 4, Madrid 28029, Spain.	tiglesias@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Sanchez-Ruiloba, Lucia/0000-0001-5418-2290				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Colman DR, 1999, NEURON, V23, P649, DOI 10.1016/S0896-6273(01)80024-6; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GRAY EG, 1962, J ANAT, V96, P79; Guha S, 2002, CANCER RES, V62, P1632; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Lang ML, 2002, BIOCHEM J, V364, P517, DOI 10.1042/BJ20011696; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Paolucci L, 1999, CANCER RES, V59, P572; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schultz J, 1997, PROTEIN SCI, V6, P249; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	80	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28592	28602		10.1074/jbc.M312242200	http://dx.doi.org/10.1074/jbc.M312242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096499	hybrid			2022-12-27	WOS:000222265400095
J	Feng, ZH; Kachnic, L; Zhang, JR; Powell, SN; Xia, F				Feng, ZH; Kachnic, L; Zhang, JR; Powell, SN; Xia, F			DNA damage induces p53-dependent BRCA1 nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE REGULATION; OVARIAN-CANCER CELLS; SUBCELLULAR-LOCALIZATION; INDUCED PHOSPHORYLATION; IONIZING IRRADIATION; GENOTOXIC STRESS; EPITHELIAL-CELLS; GROWTH ARREST; MEIOTIC CELLS	The tumor suppressor gene BRCA1 plays an important role in the response to DNA damage. BRCA1 function is regulated by a variety of mechanisms including transcriptional control, phosphorylation, and protein-protein interactions. Recent studies have shown that BRCA1 is a nuclear-cytoplasmic shuttle protein. Its subcellular localization is controlled by a nuclear localization signal-mediated nuclear import via the importin receptor pathway and a nuclear export signal-facilitated nuclear export through a CRM1-dependent pathway. Using the human breast cancer cell line, MCF7, the subcellular distribution of BRCA1 was assessed by immunohistochemical staining and Western blotting analyses of fractionated subcellullar extracts. Ionizing radiation stimulated BRCA1 nuclear export in a dose-dependent manner. This DNA damage-induced BRCA1 nuclear export utilized a CRM1-dependent mechanism and also required wild-type p53, whose function was abrogated by the E6 protein in MCF7 cells. In addition, the dependence on p53 was confirmed using a second cell type operating a tetracycline-inducible system. The effect of ionizing radiation on BRCA1 export was observed in every phase of the cell cycle, although BRCA1 localization did vary between the G(1), S, and G(2)/M phases. These results imply that, in addition to ATM-, ATR-, and Chk2-dependent phosphorylations, cytoplasmic relocalization of BRCA1 protein is a mechanism whereby BRCA1 function is regulated in response to DNA damage.	Massachusetts Gen Hosp, Dept Radiat Oncol, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University	Xia, F (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 1301 22nd Ave, Nashville, TN 37232 USA.	fen.xia@vanderbilt.edu	Xia, Fen/G-3708-2013					Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Bellamy COC, 1997, BRIT MED BULL, V53, P522; Bertwistle D, 1997, CANCER RES, V57, P5485; BHATIA U, Z CLIN CANC RES, V1, P873; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 2000, CANCER RES, V60, P5037; Chen YM, 1996, CANCER RES, V56, P3168; Chodosh LA, 1998, J MAMMARY GLAND BIOL, V3, P389, DOI 10.1023/A:1018784031651; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Gatei M, 2000, CANCER RES, V60, P3299; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Gurley KE, 1998, CANCER RES, V58, P3111; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Miura M, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.1; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rosen EM, 2001, CANCER INVEST, V19, P396, DOI 10.1081/CNV-100103134; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	65	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28574	28584		10.1074/jbc.M404137200	http://dx.doi.org/10.1074/jbc.M404137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087457	hybrid			2022-12-27	WOS:000222265400093
J	Ogawa, H; Qiu, Y; Ogata, CM; Misono, KS				Ogawa, H; Qiu, Y; Ogata, CM; Misono, KS			Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain - Rotation mechanism for transmembrane signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL-CYCLASE; ERYTHROPOIETIN RECEPTOR; VASORELAXANT ACTIVITY; MOLECULAR-BIOLOGY; BINDING DOMAIN; ANP RECEPTOR; ACTIVATION; SYSTEM; EXPRESSION; HYPERTENSION	A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in blood pressure and volume regulation. ANP activities are mediated by a single span transmembrane receptor carrying intrinsic guanylate cyclase activity. ANP binding to its extracellular domain stimulates guanylate cyclase activity by an as yet unknown mechanism. Here we report the crystal structure of dimerized extracellular hormone-binding domain in complex with ANP. The structural comparison with the unliganded receptor reveals that hormone binding causes the two receptor monomers to undergo an intermolecular twist with little intramolecular conformational change. This motion produces a Ferris wheel-like translocation of two juxtamembrane domains in the dimer with essentially no change in the interdomain distance. This movement alters the relative orientation of the two domains by a shift equivalent to counterclock-wise rotation of each by 24degrees. These results suggest that transmembrane signaling by the ANP receptor is initiated via a hormone-induced rotation mechanism.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA	Cleveland Clinic Foundation; United States Department of Energy (DOE); Argonne National Laboratory	Misono, KS (corresponding author), Univ Nevada, Sch Med, Dept Biochem, Reno, NV 89557 USA.	kmisono@unr.edu			NHLBI NIH HHS [HL 54329] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; FULLER F, 1988, J BIOL CHEM, V263, P9395; GRAMMER RT, 1983, BIOCHEM BIOPH RES CO, V116, P696, DOI 10.1016/0006-291X(83)90581-8; HE XL, 1995, BIOCONJUGATE CHEM, V6, P541, DOI 10.1021/bc00035a007; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misono KS, 2000, CIRC RES, V86, P1135; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; MISONO KS, 1984, BIOCHEM BIOPH RES CO, V123, P444, DOI 10.1016/0006-291X(84)90250-X; Miyagi M, 2000, EUR J BIOCHEM, V267, P5758, DOI 10.1046/j.1432-1327.2000.01647.x; Miyagi M, 2000, BBA-PROTEIN STRUCT M, V1478, P30, DOI 10.1016/S0167-4838(00)00002-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakane M, 1994, Adv Pharmacol, V26, P7, DOI 10.1016/S1054-3589(08)60048-4; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1992, J HYPERTENS, V10, P1111, DOI 10.1097/00004872-199210000-00002; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogawa H, 2003, ACTA CRYSTALLOGR D, V59, P1831, DOI 10.1107/S0907444903016445; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu Y, 2004, J BIOL CHEM, V279, P6115, DOI 10.1074/jbc.M310225200; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	43	113	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28625	28631		10.1074/jbc.M313222200	http://dx.doi.org/10.1074/jbc.M313222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117952	hybrid			2022-12-27	WOS:000222265400098
J	Rossner, S; Fuchsbrunner, K; Lange-Dohna, C; Hartlage-Rubsamen, M; Bigl, V; Betz, A; Reim, K; Brose, N				Rossner, S; Fuchsbrunner, K; Lange-Dohna, C; Hartlage-Rubsamen, M; Bigl, V; Betz, A; Reim, K; Brose, N			Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; BETA-SECRETASE; PHORBOL ESTERS; MUNC13-1; ALPHA; PHOSPHORYLATION; CLEAVAGE; RELEASE; DIACYLGLYCEROL; PEPTIDE	The amyloid precursor protein (APP) gives rise to beta-amyloid peptides, which are the main constituents of senile plaques in brains of Alzheimer's disease patients. Non-amyloidogenic processing of the APP can be stimulated by phorbol esters (PEs) and by intracellular diacylglycerol (DAG) generation. This led to the hypothesis that classical and novel protein kinase Cs (PKCs), which are activated by DAG/PEs, regulate APP processing. However, in addition to PKCs, there are other DAG/PE receptors present in neurons that may participate in the modulation of APP processing. Munc13-1, a presynaptic protein with an essential role in synaptic vesicle priming, represents such an alternative target of the DAG second messenger pathway. Using Munc13-1 knock- out mice and knock- in mice expressing a Munc13-1(H567K) variant deficient in DAG/PE binding, we determined the relative contributions of PKCs and Munc13-1 to PE-stimulated secretory APP processing. We establish that, in addition to PKC, Munc13-1 significantly contributes to the regulation of secretory APP metabolism.	Paul Flechsig Inst Brain Res, Dept Neurochem, D-04109 Leipzig, Germany; Max Planck Inst Expt Med, Abt Mol Neurobiol, D-37075 Gottingen, Germany	Max Planck Society	Rossner, S (corresponding author), Paul Flechsig Inst Brain Res, Dept Neurochem, Jahnallee 59, D-04109 Leipzig, Germany.	rossn@medizin.uni-leipzig.de	Hartlage-Rübsamen, Maike/A-5056-2017; Rossner, Steffen/A-5184-2017					Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Bruckner G, 2001, EXP BRAIN RES, V137, P83; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	22	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27841	27844		10.1074/jbc.C400122200	http://dx.doi.org/10.1074/jbc.C400122200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123597	hybrid			2022-12-27	WOS:000222265400003
J	Thomas, SK; Messam, CA; Spengler, BA; Biedler, JL; Ross, RA				Thomas, SK; Messam, CA; Spengler, BA; Biedler, JL; Ross, RA			Nestin is a potential mediator of malignancy in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT NESTIN; N-MYC; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROTEIN; VIMENTIN; DNA; LINES; DIFFERENTIATION; IDENTIFICATION	Amplification of the N-myc proto-oncogene signifies aggressive behavior in human neuroblastoma. Likewise, overexpression of the intermediate filament nestin, a neuroectodermal stem cell marker, is linked to increased aggressiveness in several nervous system tumors. We investigated the interaction of these two proteins in human neuroblastoma cells. Neuroblastic cell variants with high levels of N-Myc protein have significantly higher nestin protein levels than non-amplified cell lines, suggesting that the transcription factor N-Myc may regulate nestin expression. Stable transfection of a nestin antisense sequence into neuroblastic, N-myc-amplified, LA1-55n cells results in a 2-fold reduction in nestin protein without altering N-Myc expression. However, cell functions attributed to N-Myc ( growth rate, anchorage-independent growth, and motility) all decrease significantly. Transfection studies that modulate N-Myc levels also result in commensurate changes in nestin mRNA and protein amounts as well as in cell proliferation and motility. Thus, nestin appears to be downstream of and regulated by N-Myc. Gel mobility shift assays show that N-Myc binds specifically to E-box sequences in the regulatory second intron of the nestin gene and nuclear run-off studies show that increases in N-Myc protein up-regulate nestin transcription rate. Subcellular fractionation and immunoblot studies indicate that nestin is present in the nucleus as well as in the cytoplasm of neuroblastoma cell lines. Finally, DNA cross-linking experiments show that nestin binds DNA in N-myc-amplified N-type cell lines. Thus, nestin may be one mediator of N-myc-associated tumor aggressiveness of human neuroblastoma.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Fordham University; University of Pennsylvania	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Rd, Bronx, NY 10458 USA.	rross@fordham.edu			NATIONAL CANCER INSTITUTE [R01CA077593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; Aubry S, 2000, DNA CELL BIOL, V19, P353, DOI 10.1089/10445490050043326; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; COHN SL, 1990, ONCOGENE, V5, P1821; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FERRARO A, 1991, BIOCHEM BIOPH RES CO, V178, P1365, DOI 10.1016/0006-291X(91)91044-D; FLORENES VA, 1994, CANCER RES, V54, P354; FOLEY J, 1991, CANCER RES, V51, P6338; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P282; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hartig R, 1998, J CELL SCI, V111, P3573; Hendrix MJC, 1996, CANCER METAST REV, V15, P413, DOI 10.1007/BF00054009; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Lutz W, 1996, ONCOGENE, V13, P803; Messam CA, 2000, EXP NEUROL, V161, P585, DOI 10.1006/exnr.1999.7319; Norris MD, 2000, MED PEDIATR ONCOL, V35, P585, DOI 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.3.CO;2-G; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Rutka JT, 1999, INT J DEV NEUROSCI, V17, P503, DOI 10.1016/S0736-5748(99)00049-0; Shohet JM, 2002, CANCER RES, V62, P1123; Spencer VA, 1998, J BIOL CHEM, V273, P29093, DOI 10.1074/jbc.273.44.29093; Spencer VA, 2000, CANCER RES, V60, P288; Spengler BA, 1997, ONCOL RES, V9, P467; Sugiura Y, 1999, CANCER RES, V59, P1327; THOMAS SK, 2003, THESIS FORDHAM U NEW; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOHYAMA T, 1992, LAB INVEST, V66, P303; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	44	79	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27994	27999		10.1074/jbc.M312663200	http://dx.doi.org/10.1074/jbc.M312663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117961	hybrid			2022-12-27	WOS:000222265400022
J	Umland, TC; Wolff, EC; Park, MH; Davies, DR				Umland, TC; Wolff, EC; Park, MH; Davies, DR			A new crystal structure of deoxyhypusine synthase reveals the configuration of the active enzyme and of an enzyme center dot NAD center dot inhibitor ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; HYPUSINE-CONTAINING PROTEIN; SUBSTRATE INTERMEDIATE; CELL-CYCLE; SPERMIDINE; HOMOSPERMIDINE; FEATURES; BINDING; IDENTIFICATION; EXPRESSION	Deoxyhypusine synthase catalyzes the first step in the two-step post-translational synthesis of hypusine, which is uniquely present in eukaryotic initiation factor 5A (eIF5A). Deoxyhypusine synthase and eIF5A are conserved throughout the eukaryotic kingdom, and both are essential for cell proliferation and survival. A previous study (Liao, D. I., Wolff, E. C., Park, M. H., and Davies, D. R. ( 1998) Structure 6, 23-32) of human deoxyhypusine synthase revealed four active sites of the homotetrameric enzyme located within deep tunnels. These Form I crystals were obtained under conditions of acidic pH and high ionic strength and likely contain an inactive enzyme. Each active-site entrance is blocked by a ball-and-chain motif composed of a region of extended structure capped by a two-turn alpha-helix. We report here at 2.2 Angstrom a new Form II crystal of the deoxyhypusine synthase: NAD holoenzyme grown at low ionic strength and pH 8.0, near the optimal pH for enzymatic activity. The ball-and-chain motif could not be detected in the electron density, suggesting that it swings freely and thus it no longer obstructs the active-site entrance. The deoxyhypusine synthase competitive inhibitor N-1-guanyl-1,7-diaminoheptane (GC(7)) is observed bound within the putative active site of the enzyme in the new crystal form ( Form II) after exposure to the inhibitor. This first structure of a deoxyhypusine synthase.NAD.inhibitor ternary complex under physiological conditions now provides a structural context to discuss the results of previous biochemical investigations of the deoxyhypusine synthase reaction mechanism. This structure also provides a basis for the development of improved inhibitors and antiproliferative agents.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Davies, DR (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	david.davies@nih.gov		Umland, Timothy/0000-0002-0772-9510	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036109] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen KY, 1997, BIOL SIGNAL, V6, P105; Chen ZP, 1996, CANCER LETT, V105, P233, DOI 10.1016/0304-3835(96)04287-5; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; JAKUS J, 1993, J BIOL CHEM, V268, P13151; Jansson BPM, 2000, J BACTERIOL, V182, P1158, DOI 10.1128/JB.182.4.1158-1161.2000; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Joe YA, 1997, J BIOL CHEM, V272, P32679, DOI 10.1074/jbc.272.51.32679; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang KR, 1999, EXP MOL MED, V31, P210, DOI 10.1038/emm.1999.34; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CH, 2000, BIOCHEM J, V352, P851, DOI 10.1042/0264-6021:3520851; Lee GH, 2001, BIOCHEM J, V355, P841, DOI 10.1042/bj3550841; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lee YB, 1998, BIOORGAN MED CHEM, V6, P253, DOI 10.1016/S0968-0896(97)10030-X; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura K, 2002, BIOCHEM J, V363, P761, DOI 10.1042/0264-6021:3630761; Ober D, 2003, J BIOL CHEM, V278, P12805, DOI 10.1074/jbc.M207112200; Ober D, 2003, PHYTOCHEMISTRY, V62, P339, DOI 10.1016/S0031-9422(02)00553-8; Ober D, 1999, J BIOL CHEM, V274, P32040, DOI 10.1074/jbc.274.45.32040; Ober D, 1999, P NATL ACAD SCI USA, V96, P14777, DOI 10.1073/pnas.96.26.14777; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; PARK MH, 1994, J BIOL CHEM, V269, P27827; Park MH, 1997, BIOL SIGNAL, V6, P115; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Wolff EC, 2000, J BIOL CHEM, V275, P9170, DOI 10.1074/jbc.275.13.9170; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yao M, 2003, J BIOCHEM, V133, P75, DOI 10.1093/jb/mvg011	43	63	66	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28697	28705		10.1074/jbc.M404095200	http://dx.doi.org/10.1074/jbc.M404095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100216	hybrid			2022-12-27	WOS:000222265400107
J	Chen, F; Arseven, OK; Cryns, VL				Chen, F; Arseven, OK; Cryns, VL			Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; CYTOCHROME-C RELEASE; MEDIATED CLEAVAGE; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; CELL-DEATH; ACTIVATION; MUTATION; HMLH1; IDENTIFICATION	Caspases are critical proapoptotic proteases that execute cell death signals by selectively cleaving proteins at Asp residues to alter their function. Caspases trigger apoptotic chromatin degradation by activating caspase-activated DNase and by inactivating a number of enzymes that sense or repair DNA damage. We have identified the mismatch repair protein MLH1 as a novel caspase-3 substrate by screening small pools of a human prostate adenocarcinoma cDNA library for cDNAs encoding caspase substrates. In this report, we demonstrate that human MLH1 is specifically cleaved by caspase-3 at Asp(418) in vitro. Furthermore, MLH1 is rapidly proteolyzed by caspase-3 in cancer cells induced to undergo apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA. Importantly, proteolysis of MLH1 by caspase-3 triggers its partial redistribution from the nucleus to the cytoplasm and generates a proapoptotic carboxyl-terminal product. In addition, we demonstrate that a caspase-3 cleavage-resistant D418E MLH1 mutant inhibits etoposide-induced apoptosis but has little effect on TRAIL-induced apoptosis. These results indicate that the proteolysis of MLH1 by caspase-3 plays a functionally important and previously unrecognized role in the execution of DNA damage-induced apoptosis.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Cell Death Regulat Lab, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA097198] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA097198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1997, CLIN CANCER RES, V3, P1763; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Bischof O, 2001, J BIOL CHEM, V276, P12068, DOI 10.1074/jbc.M006462200; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brieger A, 2002, GUT, V51, P677, DOI 10.1136/gut.51.5.677; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gong JG, 1999, NATURE, V399, P806; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 2000, NATURE, V407, P687, DOI 10.1038/35037701; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lin XJ, 2001, CANCER RES, V61, P1508; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Partlin MM, 2003, ONCOGENE, V22, P819, DOI DOI 10.1038/SJ.0NC.1206252; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang Y, 2000, GENE DEV, V14, P927; Yan T, 2001, CANCER RES, V61, P8290; Zhan QM, 2002, ONCOGENE, V21, P5335, DOI 10.1038/sj.onc.1205665; Zhang H, 1999, CANCER RES, V59, P3021; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	27	29	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27542	27548		10.1074/jbc.M400971200	http://dx.doi.org/10.1074/jbc.M400971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087450	hybrid			2022-12-27	WOS:000222120400087
J	Kageyama, A; Oka, M; Okada, T; Nakamura, S; Ueyama, T; Saito, N; Hearing, VJ; Ichihashi, M; Nishigori, C				Kageyama, A; Oka, M; Okada, T; Nakamura, S; Ueyama, T; Saito, N; Hearing, VJ; Ichihashi, M; Nishigori, C			Down-regulation of melanogenesis by phospholipase D2 through ubiquitin proteasome-mediated degradation of tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; MESSENGER-RNA LEVELS; GTP-BINDING PROTEIN; B16 MELANOMA-CELLS; MAMMALIAN-CELLS; D ACTIVATION; D1; PIGMENTATION; MELANOCYTES	The involvement of phospholipase D (PLD) in the regulation of melanogenesis was examined. Treatment of B16 mouse melanoma cells with 12-O-tetradecanoylphorbol-13- acetate (TPA) resulted in the activation of PLD and a decrease in melanin content. 1-Butanol, but not 2-butanol, completely blocked the TPA-induced inhibition of melanogenesis, suggesting the involvement of PLD in this event. Reverse transcription-PCR and immunoblot analyses revealed the existence of both PLD isozymes, PLD1 and PLD2, in B16 cells. When PLD1 or PLD2 was introduced into those cells by an adenoviral gene-transfer technique, both PLD1 and PLD2 were activated by TPA. When PLD1 and PLD2 were overexpressed, PLD2 potently caused a decrease in melanin content, whereas the effect of PLD1 expression on melanin content was minimal. Over-expression of PLD2 itself did not affect protein kinase C activity, as assessed by the intracellular distribution and levels of expression of each isoform expressed in B16 cells. The effects of TPA on the down-regulation of basal or alpha-melanocyte-stimulating hormone-enhanced melanogenesis were almost completely blocked by expressing a lipase activity-negative mutant, LN-PLD2, but not by LN-PLD1. Further, the PLD2-induced decrease in melanin content was accompanied by a decrease in the amount and activity of tyrosinase, a key enzyme in melanogenesis, whereas the mRNA level of tyrosinase was unchanged by the over-expression of PLD2. Moreover, treatment with proteasome inhibitors completely blocked the PLD2-induced down-regulation of melanogenesis. Taken together, the present results indicate that the TPA-induced down-regulation of melanogenesis is mediated by PLD2 but not by PLD1 through the ubiquitin proteasome-mediated degradation of tyrosinase. This suggests that PLD2 may play an important role in regulating pigmentation in vivo.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Dermatol, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Clin Mol Med, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan; Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Kobe University; Kobe University; Kobe University; Kobe University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Oka, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Dermatol, Kobe, Hyogo 6500017, Japan.	oka@med.kobe-u.ac.jp			DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO H, 1995, J CELL PHYSIOL, V163, P608, DOI 10.1002/jcp.1041630322; Ando H, 2004, J BIOL CHEM, V279, P15427, DOI 10.1074/jbc.M313701200; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; FULLER BB, 1990, MOL CELL ENDOCRINOL, V72, P81, DOI 10.1016/0303-7207(90)90097-R; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mahalingam H, 1996, J CELL PHYSIOL, V168, P549, DOI 10.1002/(SICI)1097-4652(199609)168:3<549::AID-JCP7>3.0.CO;2-P; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Mosher DB, 1987, DERMATOLOGY GENERAL, P794; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Nakamura S, 1998, P NATL ACAD SCI USA, V95, P12249, DOI 10.1073/pnas.95.21.12249; Nakamura S, 1995, P NATL ACAD SCI USA, V92, P12319, DOI 10.1073/pnas.92.26.12319; Ohguchi K, 2004, J BIOL CHEM, V279, P3408, DOI 10.1074/jbc.M308054200; Oka M, 2002, BIOCHEM BIOPH RES CO, V294, P1109, DOI 10.1016/S0006-291X(02)00614-9; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; OKA M, 1993, J INVEST DERMATOL, V100, pS204, DOI 10.1111/1523-1747.ep12465200; POMERANTZ SH, 1969, SCIENCE, V164, P838, DOI 10.1126/science.164.3881.838; QUEVEDO WC, 1987, BIOL MELANOCYTES DER, P224; Sarkar S, 2001, BIOCHEM J, V359, P599, DOI 10.1042/0264-6021:3590599; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Singer WD, 1996, J BIOL CHEM, V271, P4504; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; WAKELAM MJO, 1995, SIGNAL TRANSDUCTION, P271; Xie Z, 2002, BBA-MOL CELL BIOL L, V1580, P9, DOI 10.1016/S1388-1981(01)00168-8; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121	49	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27774	27780		10.1074/jbc.M401786200	http://dx.doi.org/10.1074/jbc.M401786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15067002	hybrid			2022-12-27	WOS:000222120400112
J	Wickremasinghe, MI; Thomas, LH; O'Kane, CM; Uddin, J; Friedland, JS				Wickremasinghe, MI; Thomas, LH; O'Kane, CM; Uddin, J; Friedland, JS			Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RANTES GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; COOPERATIVE INTERACTION; INDUCIBLE EXPRESSION; ACTIVATOR PROTEIN-1; ENDOTHELIAL-CELLS; PROMOTER ACTIVITY	CCL5 ( or RANTES ( regulated upon activation, normal T cell expressed and secreted)) recruits T lymphocytes and monocytes. The source and regulation of CCL5 in pulmonary tuberculosis are unclear. Infection of the human alveolar epithelial cell line (A549) by Mycobacterium tuberculosis caused no CCL5 secretion and little monocyte secretion. Conditioned medium from tuberculosis-infected human monocytes (CoMTB) stimulated significant CCL5 secretion from A549 cells and from primary alveolar, but not upper airway, epithelial cells. Differential responsiveness of small airway and normal human bronchial epithelial cells to CoMTB but not to conditioned medium from unstimulated human monocytes was specific to CCL5 and not to CXCL8. CoMTB induced CCL5 mRNA accumulation in A549 cells and induced nuclear translocation of nuclear factor kappaB (NFkappaB) subunits p50, p65, and c-rel at 1 h; nuclear binding of activator protein (AP)-1 (c-Fos, FosB, and c-Jun) at 4 - 8 h; and binding of NF-interleukin (IL)-6 at 24 h. CCL5 promoter-reporter analysis using deletion and site-specific mutagenesis constructs demonstrated a key role for AP-1, NF-IL-6, and NFkappaB in driving CoMTB-induced promoter activity. The IL-1 receptor antagonist inhibited A549 and small airway epithelial cell CCL5 secretion, gene expression, and promoter activity. CoMTB contained IL-1beta, and recombinant IL-1beta reproduced CoMTB effects. Monocyte alveolar, but not upper airway, epithelial cell networks in pulmonary tuberculosis cause AP-1-, NF-IL-6-, and NFkappaB-dependent CCL5 secretion. IL-1beta is the critical regulator of tuberculosis-stimulated CCL5 secretion in the lung.	Hammersmith Hosp, Imperial Coll, Dept Infect Dis, London W12 0NN, England	Imperial College London	Friedland, JS (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Infect Dis, Du Cane Rd, London W12 0NN, England.	j.friedland@ic.ac.uk		Friedland, Jonathan S/0000-0001-7789-9649; O'Kane, Cecilia/0000-0002-7138-5396				Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; Ayad O, 1998, J IMMUNOL, V161, P2594; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bergeron A, 1997, J IMMUNOL, V159, P3034; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; Bermudez LE, 1996, INFECT IMMUN, V64, P1400, DOI 10.1128/IAI.64.4.1400-1406.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Casola A, 2002, AM J PHYSIOL-LUNG C, V283, pL1280, DOI 10.1152/ajplung.00162.2002; Casola A, 2001, J VIROL, V75, P6428, DOI 10.1128/JVI.75.14.6428-6439.2001; Chensue SW, 1999, J IMMUNOL, V163, P165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FRIEDLAND JS, 1992, EUR J IMMUNOL, V22, P1373, DOI 10.1002/eji.1830220607; Hashimoto S, 2000, AM J RESP CRIT CARE, V162, P1075, DOI 10.1164/ajrccm.162.3.9911099; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Jamaluddin M, 1996, J VIROL, V70, P1554, DOI 10.1128/JVI.70.3.1554-1563.1996; Koga T, 1999, P NATL ACAD SCI USA, V96, P5680, DOI 10.1073/pnas.96.10.5680; Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1474, DOI 10.1164/ajrccm.155.4.9105097; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Law K, 1996, AM J RESP CRIT CARE, V153, P799, DOI 10.1164/ajrccm.153.2.8564135; Levine SJ, 1997, J IMMUNOL, V158, P5949; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Lin YG, 1998, INFECT IMMUN, V66, P1121, DOI 10.1128/IAI.66.3.1121-1126.1998; Manni A, 1996, BIOCHEM BIOPH RES CO, V220, P120, DOI 10.1006/bbrc.1996.0367; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MCDONOUGH KA, 1995, INFECT IMMUN, V63, P4802, DOI 10.1128/IAI.63.12.4802-4811.1995; Miyamoto NG, 2000, J NEUROIMMUNOL, V105, P78, DOI 10.1016/S0165-5728(00)00195-8; Moriuchi H, 1997, J IMMUNOL, V158, P3483; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; Pazdrak K, 2002, AM J PHYSIOL-LUNG C, V283, pL364, DOI 10.1152/ajplung.00331.2001; Propst SM, 2002, J BIOL CHEM, V277, P37054, DOI 10.1074/jbc.M205778200; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; ROSSI GA, 1990, AM J RESP CELL MOL, V3, P431, DOI 10.1165/ajrcmb/3.5.431; Sadek MI, 1998, AM J RESP CELL MOL, V19, P513, DOI 10.1165/ajrcmb.19.3.2815; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STELLATO C, 1995, J IMMUNOL, V155, P410; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Thomas LH, 1998, J IMMUNOL, V161, P1007; THURLBEC.WM, 1967, THORAX, V22, P483, DOI 10.1136/thx.22.6.483; TOOSSI Z, 1995, J IMMUNOL, V154, P465; Wickremasinghe MI, 1999, J IMMUNOL, V163, P3936; Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863; ZHANG YH, 1993, J CLIN INVEST, V91, P2076, DOI 10.1172/JCI116430	66	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27199	27210		10.1074/jbc.M403107200	http://dx.doi.org/10.1074/jbc.M403107200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15117956	hybrid			2022-12-27	WOS:000222120400047
J	Leikina, E; Mittal, A; Cho, MS; Melikov, K; Kozlov, MM; Chernomordik, LV				Leikina, E; Mittal, A; Cho, MS; Melikov, K; Kozlov, MM; Chernomordik, LV			Influenza hemagglutinins outside of the contact zone are necessary for fusion pore expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; BIOLOGICAL-MEMBRANES; LATERAL MOBILITY; HEMIFUSION; CELL; FISSION; PATHWAY; PH; CONFORMATION	Current models for membrane fusion in diverse biological processes are focused on the local action of fusion proteins present in the contact zone where the proteins anchored in one membrane might interact directly with the other membrane. Are the fusion proteins outside of the contact zone just bystanders? Here we assess the role of these "outsider" proteins in influenza virus hemagglutinin-mediated fusion between red blood cells and either hemagglutinin-expressing cells or viral particles. To selectively inhibit or enhance the actions of hemagglutinin outsiders, the antibodies that bind to hemagglutinin and proteases that cleave it were conjugated to polystyrene microspheres too large to enter the contact zone. We also involved hemagglutinin outsiders into interactions with additional red blood cells. We find the hemagglutinin outsiders to be necessary and sufficient for fusion. Interfering with the activity of the hemagglutinin outsiders inhibited fusion. Selective conversion of hemagglutinin outsiders alone into fusion-competent conformation was sufficient to achieve fusion. The discovered functional role of fusion proteins located outside of the contact zone suggests a tempting analogy to mechanisms by which proteins mediate membrane fission from outside of the fission site.	NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Chernomordik, LV (corresponding author), NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bldg 10,Rm 10D04,10 Ctr Dr, Bethesda, MD 20892 USA.	lchern@helix.nih.gov	Mittal, Aditya/E-3087-2010; Melikov, Kamran/A-6604-2009	Mittal, Aditya/0000-0002-4030-0951; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001501] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001501] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DOXSEY SJ, 1985, J CELL BIOL, V101, P19, DOI 10.1083/jcb.101.1.19; Edwards MJ, 2001, J VIROL, V75, P10208, DOI 10.1128/JVI.75.21.10208-10218.2001; Frolov VA, 2000, TRAFFIC, V1, P622, DOI 10.1034/j.1600-0854.2000.010806.x; GUTMAN O, 1993, BIOCHEMISTRY-US, V32, P101, DOI 10.1021/bi00052a014; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Jacobson KA, 1997, BBA-BIOMEMBRANES, V1330, P138, DOI 10.1016/S0005-2736(97)00128-4; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kozlov MM, 2002, TRAFFIC, V3, P256, DOI 10.1034/j.1600-0854.2002.030403.x; Leikina E, 2000, MOL BIOL CELL, V11, P2359, DOI 10.1091/mbc.11.7.2359; Leikina E, 2001, BIOCHEMISTRY-US, V40, P8378, DOI 10.1021/bi010466+; Leikina E, 2000, BIOPHYS J, V79, P1415, DOI 10.1016/S0006-3495(00)76393-4; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; Melikyan GB, 1997, VIROLOGY, V235, P118, DOI 10.1006/viro.1997.8686; MELIKYAN GB, 1995, J CELL BIOL, V131, P679, DOI 10.1083/jcb.131.3.679; Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995; Mittal A, 2001, BIOPHYS J, V81, P1521, DOI 10.1016/S0006-3495(01)75806-7; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; TAYLOR HP, 1987, VIROLOGY, V159, P288, DOI 10.1016/0042-6822(87)90466-1; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; WHALLEY T, 1994, BIOCHEM J, V302, P391, DOI 10.1042/bj3020391; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; White JM, 1995, COLD SPRING HARB SYM, V60, P581, DOI 10.1101/SQB.1995.060.01.062; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	33	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26526	26532		10.1074/jbc.M401883200	http://dx.doi.org/10.1074/jbc.M401883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078874	hybrid			2022-12-27	WOS:000222003000076
J	Ajroud, K; Sugimori, T; Goldmann, WH; Fathallah, DM; Xiong, JP; Arnaout, MA				Ajroud, K; Sugimori, T; Goldmann, WH; Fathallah, DM; Xiong, JP; Arnaout, MA			Binding affinity of metal ions to the CD11b A-domain is regulated by integrin activation and ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION REGULATION; I-DOMAIN; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; STRUCTURAL BASIS; CR3 CD11B/CD18; CA2+; ADHESION; COLLAGEN; SITE	The divalent cations Mg2+ and Ca2+ regulate the interaction of integrins with their cognate ligands, with Mg2+ uniformly facilitating and Ca2+ generally inhibiting such interactions in vitro. Because both cations are present in mM concentrations in vivo, the physiologic relevance of the in vitro observations is unclear. We measured the affinity of both cations to the inactive and active states of the ligand- and cation-binding A-domain (CD11bA) from integrin CD11b/CD18 in the absence and presence of the single-chain 107 antibody (scFv107), an activation-insensitive ligand- mimetic antibody. Using titration calorimetry, we found that Mg2+ and Ca2+ display equivalent (mM) affinities to inactive CD11bA. Activation induced a similar to10-fold increase in the binding affinity of Mg2+ to CD11bA with no change in that of Ca2+ (106 muM +/- 16 and 2.1 mM +/- 0.19, respectively, n = 4). This increase is largely driven by favorable enthalpy. scFv107 induced a 50-80-fold increase in the binding affinity of Ca2+ (but not Mg2+ or Mn2+) to either form of CD11bA. Thus the affinity of metal ions to integrins is itself regulated by the activation state of these receptors and by certain ligands. These findings, which we expect will be applicable in vivo, elucidate a new level of regulation of the integrin-metal-ligand ternary complex and help explain some of the discrepant effects of Ca2+ on integrin-ligand interactions.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Inst Pasteur, Immunol Lab, Mol Biotechnol Grp, Tunis 1002, Tunisia	Harvard University; Massachusetts General Hospital; Harvard University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, 149 13th St, Charlestown, MA 02129 USA.	arnaout@receptor.mgh.harvard.edu	Goldmann, Wolfgang H/H-5572-2013					Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Brady GP, 1997, CURR OPIN STRUC BIOL, V7, P215, DOI 10.1016/S0959-440X(97)80028-0; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Doolittle RF, 1998, CURR OPIN STRUC BIOL, V8, P792, DOI 10.1016/S0959-440X(98)80100-0; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Griggs DW, 1998, J BIOL CHEM, V273, P22113, DOI 10.1074/jbc.273.34.22113; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; Habermann SM, 1996, PROTEIN SCI, V5, P1229, DOI 10.1002/pro.5560050702; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Li R, 1999, METH MOL B, V129, P105; Li R, 2002, J IMMUNOL, V168, P1219, DOI 10.4049/jimmunol.168.3.1219; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Pepinsky RB, 2002, BIOCHEMISTRY-US, V41, P7125, DOI 10.1021/bi020024d; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SMITH JW, 1994, J BIOL CHEM, V269, P960; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; Vorup-Jensen T, 2003, P NATL ACAD SCI USA, V100, P1873, DOI 10.1073/pnas.0237387100; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	41	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25483	25488		10.1074/jbc.M402901200	http://dx.doi.org/10.1074/jbc.M402901200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070893	hybrid			2022-12-27	WOS:000221827900072
J	Al-Khalili, L; Kotova, O; Tsuchida, H; Ehren, I; Feraille, E; Krook, A; Chibalin, AV				Al-Khalili, L; Kotova, O; Tsuchida, H; Ehren, I; Feraille, E; Krook, A; Chibalin, AV			ERK1/2 mediates insulin stimulation of Na,K-ATPase by phosphorylation of the alpha-subunit in human skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EXERCISE-INDUCED TRANSLOCATION; K+ PUMP SUBUNITS; PLASMA-MEMBRANE; NA+/K+-ATPASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; WIDE PREDICTION; XENOPUS OOCYTES; NA+,K+-ATPASE	Insulin stimulates Na+,K+-ATPase activity and induces translocation of Na+,K+-ATPase molecules to the plasma membrane in skeletal muscle. We determined the molecular mechanism by which insulin regulates Na+,K+-ATPase in differentiated primary human skeletal muscle cells (HSMCs). Insulin action on Na+,K+-ATPase was dependent on ERK1/2 in HSMCs. Sequence analysis of Na+,K+-ATPase alpha-subunits revealed several potential ERK phosphorylation sites. Insulin increased ouabain-sensitive Rb-86(+) uptake and [H-3]ouabain binding in intact cells. Insulin also increased phosphorylation and plasma membrane content of the Na+,K+-ATPase alpha(1)- and alpha(2)-subunits. Insulin-stimulated Na+,K+-ATPase activation, phosphorylation, and translocation of alpha-subunits to the plasma membrane were abolished by 20 muM PD98059, which is an inhibitor of MEK1/2, an upstream kinase of ERK1/2. Furthermore, inhibitors of phosphatidylinositol 3-kinase (100 nM wortmannin) and protein kinase C (10 muM GF109203X) had similar effects. Notably, insulin-stimulated ERK1/2 phosphorylation was abolished by wortmannin and GF109203X in HSMCs. Insulin also stimulated phosphorylation of alpha(1)- and alpha(2)-subunits on Thr-Pro amino acid motifs, which form specific ERK substrates. Furthermore, recombinant ERK1 and -2 kinases were able to phosphorylate alpha-subunit of purified human Na+,K+-ATPase in vitro. In conclusion, insulin stimulates Na+,K+-ATPase activity and translocation to plasma membrane in HSMCs via phosphorylation of the alpha-subunits by ERK1/2 mitogen-activated protein kinase.	Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Surg Sci, Urol Sect, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Hop Cantonal Univ Geneva, Div Nephrol, CH-1211 Geneva, Switzerland	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Geneva	Chibalin, AV (corresponding author), Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, Eulers Vag 4,4 Tr, SE-17177 Stockholm, Sweden.	Alexander.Chibalin@kirurgi.ki.se	Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Feraille, Eric/0000-0003-1656-8365; Chibalin, Alexander/0000-0002-6339-6271; Ehren, Ingrid/0000-0001-7995-1252				Al-Khalili L, 2004, ACTA PHYSIOL SCAND, V180, P395, DOI 10.1111/j.1365-201X.2004.01259.x; Al-Khalili L, 2003, FEBS LETT, V536, P198, DOI 10.1016/S0014-5793(03)00047-4; ALKHALILI L, 2004, IN PRESS AM J PHYSL; Aydemir-Koksoy A, 2001, AM J PHYSIOL-HEART C, V280, pH1869, DOI 10.1152/ajpheart.2001.280.4.H1869; Beguin P, 1996, BIOCHEMISTRY-US, V35, P14098, DOI 10.1021/bi960516o; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 2001, ENDOCRINOLOGY, V142, P3474, DOI 10.1210/en.142.8.3474; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; Clausen T, 1996, ACTA PHYSIOL SCAND, V156, P227, DOI 10.1046/j.1365-201X.1996.209000.x; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feraille E, 1999, MOL BIOL CELL, V10, P2847, DOI 10.1091/mbc.10.9.2847; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gonin S, 2001, MOL BIOL CELL, V12, P255, DOI 10.1091/mbc.12.2.255; Gronborg M, 2002, MOL CELL PROTEOMICS, V1, P517, DOI 10.1074/mcp.M200010-MCP200; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; HUNDAL HS, 1993, FEBS LETT, V328, P253, DOI 10.1016/0014-5793(93)80938-Q; Isenovic ER, 2004, ENDOCRINOLOGY, V145, P1151, DOI 10.1210/en.2003-0100; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Juel C, 2001, PFLUG ARCH EUR J PHY, V443, P212, DOI 10.1007/s004240100674; Juel C, 2000, AM J PHYSIOL-REG I, V278, pR1107, DOI 10.1152/ajpregu.2000.278.4.R1107; Khundmiri SJ, 2004, J BIOL CHEM, V279, P17418, DOI 10.1074/jbc.M311715200; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu HZ, 2000, BIOCHEM BIOPH RES CO, V274, P845, DOI 10.1006/bbrc.2000.3208; Lucking K, 1996, AM J PHYSIOL-RENAL, V271, pF253, DOI 10.1152/ajprenal.1996.271.2.F253; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonough AA, 2002, AM J PHYSIOL-RENAL, V282, pF967, DOI 10.1152/ajprenal.00360.2001; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; SWEADNER KJ, 1992, J BIOL CHEM, V267, P769; Sweeney G, 1998, DIABETOLOGIA, V41, P1199, DOI 10.1007/s001250051052; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Upadhyay D, 2003, FEBS LETT, V545, P173, DOI 10.1016/S0014-5793(03)00527-1; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; Widegren U, 2001, ACTA PHYSIOL SCAND, V172, P227, DOI 10.1046/j.1365-201x.2001.00855.x; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe Michael B, 2004, Methods Mol Biol, V250, P237; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	55	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25211	25218		10.1074/jbc.M402152200	http://dx.doi.org/10.1074/jbc.M402152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069082	hybrid			2022-12-27	WOS:000221827900038
J	Chen, CM; Gong, YS; Zhang, M; Chen, JJ				Chen, CM; Gong, YS; Zhang, M; Chen, JJ			Reciprocal cross-talk between Nod2 and TAK1 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; KINASE KINASE KINASE; CROHNS-DISEASE; IMMUNE-RESPONSES; ACTIVATION; RECEPTOR; GENE; PROTEIN	Mutations in the leucine-rich repeat (LRR) domain of Nod2 have been implicated in the pathogenesis of Crohn's disease, yet the function of Nod2 and regulation of the Nod2 pathway remain unclear. In this study, we determined that mitogen-activated protein kinase kinase transforming growth factor (TGF)-beta-activated kinase 1 (TAK1) interacts with Nod2 and is required for Nod2-mediated NF-kappaB activation. The dominant negative form of TAK1 abolished muramyl dipeptide-induced NF-kappaB activation in Nod2-expressing cells. Nod2, acting in a reciprocal manner, inhibited TAK1-induced NF-kappaB activation in RICK-deficient embryonic fibroblasts. Nod2 appears to interact with TAK1 through its LRR region to exert its inhibitory effect on TAK1-induced NF-kappaB activation. Further, wild-type LRR more effectively suppressed NF-kappaB activation induced by TAK1 than LRR with a 3020insC mutation. Considered together, these findings demonstrate a critical role for TAK1 in Nod2-mediated innate immune responses and reveal a novel function for Nod2 in the regulation of the TAK1 signaling pathway.	Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chen, JJ (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol, 1150 W Med Ctr Dr,4500 MSRB I, Ann Arbor, MI 48109 USA.	jjjchen@umich.edu			NATIONAL CANCER INSTITUTE [K08CA087943] Funding Source: NIH RePORTER; NCI NIH HHS [CA87943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Elson CO, 2002, NEW ENGL J MED, V346, P614, DOI 10.1056/NEJM200202213460812; FERGUSON A, 1994, BRIT MED J, V309, P355, DOI 10.1136/bmj.309.6951.355; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Judge Thomas, 2002, Gastroenterology, V122, P826, DOI 10.1016/S0016-5085(02)80138-X; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; McGovern DPB, 2001, GUT, V49, P752, DOI 10.1136/gut.49.6.752; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Neurath MF, 1998, ANN NY ACAD SCI, V859, P149, DOI 10.1111/j.1749-6632.1998.tb11119.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	33	67	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25876	25882		10.1074/jbc.M400682200	http://dx.doi.org/10.1074/jbc.M400682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075345	hybrid			2022-12-27	WOS:000221827900119
J	Fukuchi, J; Hiipakka, RA; Kokontis, JM; Nishimura, K; Igarashi, K; Liao, S				Fukuchi, J; Hiipakka, RA; Kokontis, JM; Nishimura, K; Igarashi, K; Liao, S			TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER; C-JUN; ESCHERICHIA-COLI; EXPRESSION; CELLS; GENE; ACTIVATION; GROWTH; MUTANTS; BIS(GUANYLHYDRAZONE)	Identification of the polyamine transporter gene will be useful for modulating polyamine accumulation in cells and should be a good target for controlling cell proliferation. Polyamine transport activity in mammalian cells is critical for accumulation of the polyamine analog methylglyoxal bis(guanylhydrazone) (MGBG) that induces apoptosis, although a gene responsible for transport activity has not been identified. Using a retroviral gene trap screen, we generated MGBG-resistant Chinese hamster ovary (CHO) cells to identify genes involved in polyamine transport activity. One gene identified by the method encodes TATA-binding protein-associated factor 7 (TAF7), which functions not only as one of the TAFs, but also a coactivator for c-Jun. TAF7-deficient cells had decreased capacity for polyamine uptake (20% of CHO cells), decreased AP-1 activation, as well as resistance to MGBG-induced apoptosis. Stable expression of TAF7 in TAF7-deficient cells restored transport activity (55% of CHO cells), AP-1 gene transactivation (100% of CHO cells), and sensitivity to MGBG-induced apoptosis. Overexpression of TAF7 in CHO cells did not increase transport activity, suggesting that TAF7 may be involved in the maintenance of basal activity. c-Jun NH2-terminal kinase inhibitors blocked MGBG-induced apoptosis without alteration of polyamine transport. Decreased TAF7 expression, by RNA interference, in androgen-independent human prostate cancer LN-CaP104-R1 cells resulted in lower polyamine transport activity (25% of control) and resistance to MGBG-induced growth arrest. Taken together, these results reveal a physiological function of TAF7 as a basal regulator for mammalian polyamine transport activity and MGBG-induced apoptosis.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	University of Chicago; University of Chicago; Chiba University	Liao, S (corresponding author), Univ Chicago, Ben May Inst Canc Res, MC6027,5841 S Maryland Ave, Chicago, IL 60637 USA.	sliao@huggins.bsd.uchicago.edu		Igarashi, Kazuei/0000-0003-3751-3187; Nishimura, Kazuhiro/0000-0002-6209-5522	NCCIH NIH HHS [AT00850] Funding Source: Medline; NCI NIH HHS [CA58073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058073] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000850] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ADAIR GM, 1985, MOL CELL BIOL, V5, P109, DOI 10.1128/MCB.5.1.109; ADAIR GM, 1984, SOMAT CELL MOLEC GEN, V10, P283, DOI 10.1007/BF01535250; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Bhattacharya S, 2003, AM J PHYSIOL-GASTR L, V285, pG980, DOI 10.1152/ajpgi.00206.2003; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BYERS TL, 1989, BIOCHEM J, V263, P745, DOI 10.1042/bj2630745; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Cullis PM, 1999, CHEM BIOL, V6, P717, DOI 10.1016/S1074-5521(00)80019-8; Davidson K, 1998, ANTI-CANCER DRUG, V9, P635, DOI 10.1097/00001813-199808000-00009; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; Gegonne A, 2001, P NATL ACAD SCI USA, V98, P12432, DOI 10.1073/pnas.211444798; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; HEATON MA, 1988, J CELL PHYSIOL, V136, P133, DOI 10.1002/jcp.1041360117; HESTON WDW, 1991, CANCER SURV, V11, P217; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAKINUMA Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P171, DOI 10.1016/0003-9861(87)90483-8; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kuroiwa A, 2001, CHROMOSOME RES, V9, P641, DOI 10.1023/A:1012952223509; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; MATSUI I, 1980, BIOCHIM BIOPHYS ACTA, V633, P87, DOI 10.1016/0304-4165(80)90040-9; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Paasinen-Sohns A, 2000, J CELL BIOL, V151, P801, DOI 10.1083/jcb.151.4.801; Patel AR, 1997, AM J PHYSIOL-CELL PH, V273, pC1020, DOI 10.1152/ajpcell.1997.273.3.C1020; PEGG AE, 1988, CANCER RES, V48, P759; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RAGO R, 1990, ANAL BIOCHEM, V191, P31; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEPPANEN P, 1980, FEBS LETT, V111, P99, DOI 10.1016/0014-5793(80)80770-8; Shao D, 1996, J CELL PHYSIOL, V166, P43; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; WILLIAMSASHMAN HG, 1972, BIOCHEM BIOPH RES CO, V46, P288, DOI 10.1016/0006-291X(72)90661-4; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301	53	17	18	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29921	29929		10.1074/jbc.M401078200	http://dx.doi.org/10.1074/jbc.M401078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15078871	hybrid			2022-12-27	WOS:000222531900008
J	Gunawardena, RW; Siddiqui, H; Solomon, DA; Mayhew, CN; Held, J; Angus, SP; Knudsen, ES				Gunawardena, RW; Siddiqui, H; Solomon, DA; Mayhew, CN; Held, J; Angus, SP; Knudsen, ES			Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE-KINASE; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; PROGNOSTIC-SIGNIFICANCE; DOWN-REGULATION; RB/E2F PATHWAY; RB; E2F; EXPRESSION; COMPLEXES	Plk1 (Polo-like kinase 1) is a critical regulator of cell cycle progression that harbors oncogenic activity and exhibits aberrant expression in multiple tumors. However, the mechanism through which Plk1 expression is regulated has not been extensively studied. Here we demonstrate that Plk1 is a target of the retinoblastoma tumor suppressor (RB) pathway. Activation of RB and related pocket proteins p107/p130 mediate attenuation of Plk1. Conversely, RB loss deregulates the control of Plk1 expression. RB pathway activation resulted in the repression of Plk1 promoter activity, and this action was dependent on the SWI/SNF chromatin remodeling complex. Although SWI/SNF subunits are lost during tumorigenesis and cooperate with RB for transcriptional repression, the mechanism through which SWI/SNF impinges on RB action is unresolved. Therefore, we delineated the requirement of SWI/SNF for three critical facets of Plk1 promoter regulation: transcription factor binding, corepressor binding, and histone modification. We find that E2F4 and pocket protein association with the Plk1 promoter is independent of SWI/SNF. However, these analyses revealed that SWI/SNF is required for histone deacetylation of the Plk1 promoter. The importance of SWI/SNF-dependent histone deacetylation of the Plk1 promoter was evident, because blockade of this event restored Plk1 expression in the presence of active RB. In summary, these data demonstrate that Plk1 is a target of the RB pathway. Moreover, these findings demonstrate a hierarchical role for SWI/SNF in the control of promoter activity through histone modification.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell Biol, Cincinnati, OH 45267 USA.	Erik.Knudsen@UC.edu	Mayhew, Christopher N/AGB-4929-2022	Angus, Steven/0000-0002-7655-657X	NATIONAL CANCER INSTITUTE [R01CA106471, T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA59268, CA106471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leung GC, 2003, CELL, V115, P3, DOI 10.1016/S0092-8674(03)00761-X; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Markey MP, 2002, CANCER RES, V62, P6587; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sherr C J, 2000, Harvey Lect, V96, P73; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takahashi Y, 2000, GENE DEV, V14, P804; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vooijs M, 2002, CANCER RES, V62, P1862; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	55	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29278	29285		10.1074/jbc.M400395200	http://dx.doi.org/10.1074/jbc.M400395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105433	hybrid			2022-12-27	WOS:000222445300057
J	Schmidt, AE; Ogawa, T; Gailani, D; Bajaj, SP				Schmidt, AE; Ogawa, T; Gailani, D; Bajaj, SP			Structural role of Gly(193) in serine proteases - Investigations of a G555E (Gly(193) in chymotrypsin) mutant of blood coagulation factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; BETA-PROTEIN PRECURSOR; RAY CRYSTAL-STRUCTURE; FACTOR-IX; HEMOPHILIA-B; BINDING-SITE; INHIBITOR DOMAIN; CHRISTMAS-FACTOR; TISSUE FACTOR; ACTIVE-SITE	In serine proteases, Gly(193) is highly conserved with few exceptions. A patient with inherited deficiency of the coagulation serine protease factor XI (FXI) was reported to be homozygous for a Gly(555)-->Glu substitution. Gly(555) in FXI corresponds to Gly(193) in chymotrypsin, which is the numbering system used subsequently. To investigate the abnormality in FXIG193E, we expressed and purified recombinant FXIa(G193E), activated it to FXIa(G193E), and compared its activity to wild type-activated FXI ( FXIa(WT)). FXIa(G193E) activated FIX with similar to300-fold reduced k(cat) and similar K-m, and hydrolyzed synthetic substrate with similar to10-fold reduced K-m and modestly reduced kcat. Binding of antithrombin and the amyloid beta-precursor protein Kunitz domain inhibitor (APPI) to FXIa(G193E) was impaired similar to 8,000- and similar to 100,000-fold, respectively. FXIaG193E inhibition by diisopropyl fluorophosphate was similar to 30-fold slower and affinity for p-aminobenzamidine (S1 site probe) was 6-fold weaker than for FXIa(WT). The rate of carbamylation of NH2-Ile(16), which forms a salt bridge with Asp(194) in active serine proteases, was 4-fold faster for FXIa(G193E). These data indicate that the unoccupied active site of FXIa(G193E) is incompletely formed, and the amide N of Glu(193) may not point toward the oxyanion hole. Inclusion of saturating amounts of p-aminobenzamidine resulted in comparable rates of carbamylation for FXIaWT and FXIa(G193E), suggesting that the occupied active site has near normal conformation. Thus, binding of small synthetic substrates or inhibitors provides sufficient energy to allow the amide N of Glu(193) to point correctly toward the oxyanion hole. Homology modeling also indicates that the inability of FXIa(G193E) to bind antithrombin/APPI or activate FIX is caused, in part, by impaired accessibility of the S2' site because of a steric clash with Glu(193). Such arguments will apply to other serine proteases with substitutions of Gly(193) with a non-glycine residue.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Orthopaed Hosp, Los Angeles, CA 90095 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Saint Louis University; Vanderbilt University	Bajaj, SP (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Orthopaed Hosp, 1000 Vet Ave,Rehab Bldg,Rm 21-31, Los Angeles, CA 90095 USA.	pbajaj@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036365, R56HL036365, R01HL036365, K08HL002917, R01HL058837, R01HL070369] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70369, HL58837, HL36365, HL02917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1990, J BIOL CHEM, V265, P2956; Bernardi F, 1996, HUM MUTAT, V8, P108; BERNARDI F, 1994, BRIT J HAEMATOL, V86, P610, DOI 10.1111/j.1365-2141.1994.tb04793.x; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Gunasekaran K, 1998, J MOL BIOL, V284, P1505, DOI 10.1006/jmbi.1998.2154; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; Halfon S., 1998, HDB PROTEOLYTIC ENZY, P12; Helland R, 1999, J MOL BIOL, V287, P923, DOI 10.1006/jmbi.1999.2654; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAITO K, 1991, J BIOL CHEM, V266, P7353; Navaneetham D, 2003, BLOOD, V102, p127A; Papageorgiou AC, 2000, PROTEIN SCI, V9, P610; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; Pjura PE, 2000, J MOL BIOL, V300, P235, DOI 10.1006/jmbi.2000.3851; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; SAAD S, 1994, THROMB HAEMOSTASIS, V71, P563; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; Schmidt AE, 2003, BLOOD, V102, p303A; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; STRYER L, 1995, BIOCHEMISTRY-US, P224; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THOMPSON AR, 1992, THROMB RES, V65, P289, DOI 10.1016/0049-3848(92)90249-A; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; TULINSKY A, 1987, J BIOL CHEM, V262, P7737; vandeWater NS, 1996, HAEMOPHILIA, V2, P24, DOI 10.1111/j.1365-2516.1996.tb00005.x; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; ZIVELIN A, 2001, THROMB HAEMOSTASIS S, pP1111	56	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29485	29492		10.1074/jbc.M402971200	http://dx.doi.org/10.1074/jbc.M402971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090552	hybrid			2022-12-27	WOS:000222445300081
J	Pierchala, BA; Ahrens, RC; Paden, AJ; Johnson, EM				Pierchala, BA; Ahrens, RC; Paden, AJ; Johnson, EM			Nerve growth factor promotes the survival of sympathetic neurons through the cooperative function of the protein kinase C and phosphatidylinositol 3-kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; DOWN-REGULATION; FACTOR RECEPTOR; NGF; PHOSPHORYLATION; ACTIVATION; JUN	The signaling pathways activated by nerve growth factor (NGF) that account for its ability to promote the survival of neurons are not completely understood. Phosphatidylinositol 3-kinase (PI3K) is critical for the survival of several cell types, including neurons. To determine whether additional signaling pathways cooperate with PI3K to promote survival, we examined other pathways known to be activated by NGF. NGF activated protein kinases C (PKCs) in sympathetic neurons, and pharmacologic PKC activation rescued neurons from apoptosis induced by the withdrawal of NGF. Inhibition of PKCs did not inhibit the survival of NGF-maintained neurons. Similarly, inhibition of PI3K caused only a modest attrition of neurons in the presence of NGF. In contrast, the simultaneous inhibition of both PKCs and PI3K induced the apoptotic death of NGF-maintained sympathetic neurons. Inhibition of both PI3K and PKCs promoted the expression and phosphorylation of the proapoptotic transcription factor c-Jun, indicating that these pathways inhibit programmed cell death at the stage of proapoptotic gene expression. In culture conditions under which PI3K inhibition alone kills NGF-maintained neurons, PKC inhibition also led to a significant loss of viability, indicating that both pathways are required. Therefore, PKC and PI3K, regardless of the culture conditions, cooperate to promote the NGF-dependent survival of sympathetic neurons.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Pierchala, BA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 4566 Scott Ave,Box 8103, St Louis, MO 63110 USA.	btp@msnotes.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K01NS045221, R01NS038651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER; NIA NIH HHS [R38 AG 12947] Funding Source: Medline; NINDS NIH HHS [R01 NS 38651, K01 NS 045221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Battaini F, 2001, PHARMACOL RES, V44, P353, DOI 10.1006/phrs.2001.0893; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; LOEB DM, 1994, J BIOL CHEM, V269, P8901; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Musashi M, 2000, INT J HEMATOL, V72, P12; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tanaka S, 2001, NEUROSCI LETT, V313, P9, DOI 10.1016/S0304-3940(01)02193-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Tsui-Pierchala BA, 2000, J NEUROSCI, V20, P7228; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; VIRDEE K, 1999, BRAIN RES; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M	47	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27986	27993		10.1074/jbc.M312237200	http://dx.doi.org/10.1074/jbc.M312237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117960	hybrid			2022-12-27	WOS:000222265400021
J	Schaap, FG; Rensen, PCN; Voshol, PJ; Vrins, C; van der Vliet, HN; Chamuleau, RAFM; Havekes, LM; Groen, AK; van Dijk, KW				Schaap, FG; Rensen, PCN; Voshol, PJ; Vrins, C; van der Vliet, HN; Chamuleau, RAFM; Havekes, LM; Groen, AK; van Dijk, KW			ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN A-V; ACTIVATED RECEPTOR-ALPHA; TRANSGENIC MICE; IN-VIVO; GENE; CHOLESTEROL; LIVER; HOMEOSTASIS; DETERMINANT; SECRETION	ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but the pathways involved are currently unknown. To gain insight into the function of apoAV, adenovirus-mediated gene transfer of murine apoa5 to C57Bl/6 mice was employed. The injection of low doses of Ad-apoa5 (1 - 5 x 10(8) plaque-forming units/mouse) dose-dependently reduced plasma very low density lipoprotein ( VLDL)- TG levels. First, we evaluated whether a reduced hepatic VLDL production contributed to the TG-lowering effect. Ad-apoa5 treatment dose-dependently diminished ( 29 - 37%) the VLDL-TG production rate without affecting VLDL particle production, suggesting that apoAV impairs the lipidation of apoB. Second, Ad-apoa5 treatment dose-dependently reduced ( 68 - 88%) the postprandial hypertriglyceridemia following an intragastric fat load, suggesting that apoAV also stimulates the lipoprotein lipase (LPL)-dependent clearance of TG-rich lipoproteins. Indeed, recombinant apoAV was found to dose-dependently stimulate LPL activity up to 2.3-fold in vitro. Accordingly, intravenously injected VLDL-like TG-rich emulsions were cleared at an accelerated rate concomitant with the increased uptake of emulsion TG-derived fatty acids by skeletal muscle and white adipose tissue in Ad-apoa5-treated mice. From these data, we conclude that apoAV is a potent stimulator of LPL activity. Thus, apoAV lowers plasma TG by both reducing the hepatic VLDL-TG production rate and by enhancing the lipolytic conversion of TG-rich lipoproteins.	AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; TNO Prevent & Hlth, Gaubius Lab, NL-2333 CK Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2333 ZA Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schaap, FG (corresponding author), AMC Liver Ctr, Meibergdreef 69-71, NL-1105 BK Amsterdam, Netherlands.	f.g.schaap@amc.uva.nl	Rensen, Patrick C.N./D-7176-2018; van Dijk, Ko Willems/A-1798-2008; van Dijk, Ko Willems/AAT-4681-2021	Rensen, Patrick C.N./0000-0002-8455-4988; van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; Schaap, Frank/0000-0002-1597-572X				Aouizerat BE, 2003, J LIPID RES, V44, P1167, DOI 10.1194/jlr.M200480-JLR200; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Endo K, 2002, HUM GENET, V111, P570, DOI 10.1007/s00439-002-0825-0; Gerritsen G, 2003, J LIPID RES, V44, P408, DOI 10.1194/jlr.M200313-JLR200; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Kao JT, 2003, HUM MOL GENET, V12, P2533, DOI 10.1093/hmg/ddg255; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LIU MS, 1994, J BIOL CHEM, V269, P11417; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; YAMADA N, 1986, J LIPID RES, V27, P910; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	28	249	275	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27941	27947		10.1074/jbc.M403240200	http://dx.doi.org/10.1074/jbc.M403240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090553	hybrid			2022-12-27	WOS:000222265400015
J	Sone, T; Saeki, Y; Toh-e, A; Yokosawa, H				Sone, T; Saeki, Y; Toh-e, A; Yokosawa, H			Sem1p is a novel subunit of the 26 S proteasome from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME CORE PARTICLE; YEAST 26S PROTEASOME; DNA-REPAIR; REGULATORY PARTICLE; USTILAGO-MAYDIS; CANCER SUSCEPTIBILITY; GENOME STABILITY; CANDIDATE GENE; BRCA2; RECOMBINATION	The 26 S proteasome, which catalyzes degradation of polyubiquitinated proteins, is composed of the 20 S proteasome and the 19 S regulatory particle ( RP). The RP is composed of the lid and base subcomplexes and regulates the catalytic activity of the 20 S proteasome. In this study, we carried out affinity purification of the lid and base subcomplexes from the tagged strains of Saccharomyces cerevisiae, and we found that the lid contains a small molecular mass protein, Sem1. The Sem1 protein binds with the 26 S proteasome isolated from a mutant with deletion of SEM1 but not with the 26 S proteasome from the wild type. The lid lacking Sem1 is unstable at a high salt concentration. The 19 S RP was immunoprecipitated together with Sem1 by immunoprecipitation using hemagglutinin epitope-tagged Sem1 as bait. Degradation of polyubiquitinated proteins in vivo or in vitro is impaired in the Sem1-deficient 26 S proteasome. In addition, genetic interaction between SEM1 and RPN10 was detected. The human Sem1 homologue hDSS1 was found to be a functional homologue of Sem1 and capable of interacting with the human 26 S proteasome. The results suggest that Sem1, possibly hDSS1, is a novel subunit of the 26 S proteasome and plays a role in ubiquitin-dependent proteolysis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	Hokkaido University; University of Tokyo	Yokosawa, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan.	yoko@pharm.hokudai.ac.jp						Bailly E, 1999, MOL CELL BIOL, V19, P6872; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferguson DO, 1997, GENETICS, V145, P243; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2000, BIOCHEM BIOPH RES CO, V273, P509, DOI 10.1006/bbrc.2000.2980; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	42	104	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28807	28816		10.1074/jbc.M403165200	http://dx.doi.org/10.1074/jbc.M403165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117943	hybrid			2022-12-27	WOS:000222265400119
J	Xie, J; Guo, Q				Xie, J; Guo, Q			Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation on the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; BASAL FOREBRAIN; CELL-LINE; NEUROTROPHIC FACTORS; HIPPOCAMPAL-NEURONS; TRANSPORTER CHT1; SPATIAL MEMORY; UPTAKE CARRIER	CHT1 is a Na+- and Cl--dependent, hemicholinium-3 (HC-3)-sensitive, high affinity choline transporter. Par-4 (prostate apoptosis response-4) is a leucine zipper protein involved in neuronal degeneration and cholinergic signaling in Alzheimer's disease. We now report that Par-4 is a negative regulator of CHT1 choline uptake activity. Transfection of neural IMR-32 cells with human CHT1 conferred Na+-dependent, HC-3-sensitive choline uptake that was effectively inhibited by cotransfection of Par-4. Mapping studies indicated that the C-terminal half of Par-4 was physically involved in interacting with CHT1, and the absence of Par-4.CHT1 complex formation precluded the loss of CHT1-mediated choline uptake induced by Par-4, indicating that Par-4.CHT1 complex formation is essential. Kinetic and cell-surface biotinylation assays showed that Par-4 inhibited CHT1-mediated choline uptake by reducing CHT1 expression in the plasma membrane without significantly altering the affinity of CHT1 for choline or HC-3. These results suggest that Par-4 is directly involved in regulating choline uptake by interacting with CHT1 and by reducing its incorporation on the cell surface.	Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Guo, Q (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	qing-guo@ouhsc.edu			NINDS NIH HHS [R01 NS 043296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apparsundaram S, 2000, BIOCHEM BIOPH RES CO, V276, P862, DOI 10.1006/bbrc.2000.3561; Apparsundaram S, 2001, BIOCHEM SOC T, V29, P711, DOI 10.1042/0300-5127:0290711; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Bissette G, 1996, ANN NY ACAD SCI, V777, P197, DOI 10.1111/j.1749-6632.1996.tb34419.x; BREER H, 1990, J NEUROBIOL, V21, P269, DOI 10.1002/neu.480210202; Chan SL, 1999, J NEUROCHEM, V73, P502, DOI 10.1046/j.1471-4159.1999.0730502.x; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dickinson-Anson H, 2003, MOL THER, V8, P51, DOI 10.1016/S1525-0016(03)00145-X; FINE A, 1985, P NATL ACAD SCI USA, V82, P5227, DOI 10.1073/pnas.82.15.5227; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; Friedrich A, 2001, BBA-BIOMEMBRANES, V1512, P299, DOI 10.1016/S0005-2736(01)00333-9; Fujii T, 2003, LIFE SCI, V72, P2131, DOI 10.1016/S0024-3205(03)00073-0; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; GOTTFRIES CG, 1983, NEUROBIOL AGING, V4, P261, DOI 10.1016/0197-4580(83)90002-7; Guermonprez L, 2002, J NEUROCHEM, V82, P874, DOI 10.1046/j.1471-4159.2002.01044.x; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 2001, BRAIN RES, V903, P13, DOI 10.1016/S0006-8993(01)02304-6; Guo Q, 2001, J BIOL CHEM, V276, P16040, DOI 10.1074/jbc.M010996200; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Guo Q, 2000, BRAIN RES, V874, P221, DOI 10.1016/S0006-8993(00)02559-2; Haberberger RV, 2002, J INVEST DERMATOL, V119, P943, DOI 10.1046/j.1523-1747.2002.00182.x; Kobayashi Y, 2002, NEUROSCI LETT, V317, P25, DOI 10.1016/S0304-3940(01)02413-2; Lips KS, 2002, CELL TISSUE RES, V307, P275, DOI 10.1007/s00441-002-0520-4; Lyness SA, 2003, NEUROBIOL AGING, V24, P1, DOI 10.1016/S0197-4580(02)00057-X; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Okuda T, 2003, NEUROCHEM RES, V28, P483, DOI 10.1023/A:1022809003997; Okuda T, 2002, J BIOL CHEM, V277, P45315, DOI 10.1074/jbc.M207742200; PASCUAL J, 1991, BRAIN RES, V552, P170, DOI 10.1016/0006-8993(91)90676-M; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pedersen WA, 2000, FASEB J, V14, P913, DOI 10.1096/fasebj.14.7.913; Pfeil U, 2003, LIFE SCI, V72, P2087, DOI 10.1016/S0024-3205(03)00088-2; Pfeil U, 2003, AM J RESP CELL MOL, V28, P473, DOI 10.1165/rcmb.2002-0190OC; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; PRICE DL, 1985, ANN NY ACAD SCI, V457, P35, DOI 10.1111/j.1749-6632.1985.tb20798.x; PRICE DL, 1993, PROG BRAIN RES, V98, P51; RABINOVSKY ED, 1992, J NEUROSCI, V12, P171; Ribeiro FM, 2003, J NEUROCHEM, V87, P136, DOI 10.1046/j.1471-4159.2003.01974.x; RODRIGUEZPUERTAS R, 1994, J NEURAL TRANSM-PARK, V8, P161, DOI 10.1007/BF02260937; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sirvio J, 1999, GERONTOLOGY, V45, P3, DOI 10.1159/000052759; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; Wang YL, 2001, GENE, V268, P123, DOI 10.1016/S0378-1119(01)00421-8; Warburton EC, 2003, NEURON, V38, P987, DOI 10.1016/S0896-6273(03)00358-1; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Xie J, 2001, BRAIN RES, V915, P1, DOI 10.1016/S0006-8993(01)02803-7; Zapata A, 2000, SYNAPSE, V35, P272, DOI 10.1002/(SICI)1098-2396(20000315)35:4<272::AID-SYN5>3.0.CO;2-B	50	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28266	28275		10.1074/jbc.M401495200	http://dx.doi.org/10.1074/jbc.M401495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090548	hybrid			2022-12-27	WOS:000222265400057
J	Choudhury, GG				Choudhury, GG			A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C epsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1 alpha transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT1 SERINE PHOSPHORYLATION; IFN-GAMMA; PKC-EPSILON; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; ACTIVE STAT1; BMP-2 GENE; ALPHA; REQUIRES	Interferon-gamma (IFN-gamma) exerts an pleiotropic effect in mesangial cells in inflammatory glomerular diseases. The biologic effect of IFN-gamma is mediated by STAT1alpha. The precise mechanism by which IFN-gamma stimulates the transcriptional activity of STAT1alpha is poorly understood. I investigated the role of protein kinase C (PKC) epsilon in regulating the transcriptional activation of STAT1alpha in mesangial cells. IFN-gamma increased PKCepsilon activity in a time-dependent manner with a concomitant increase in STAT1alpha transcriptional activity. Expression of constitutively active PKCepsilon mimicked the effect of IFN-gamma on STAT1alpha-dependent transcription. Expression of dominant negative PKCepsilon inhibited IFN-gamma-induced STAT1alpha-dependent transcription. Ly294002, a pharmacological inhibitor of phosphatidylinositol ( PI) 3-kinase, blocked IFN-gamma-induced PKCepsilon activity and resulted in inhibition of STAT1alpha transcriptional activity but had no effect on STAT1alpha tyrosine phosphorylation and STAT1alpha-DNA complex formation. A PKC inhibitor, H7, also had no effect on STAT1alpha tyrosine phosphorylation and DNA binding. However, Ly294002 and H7 blocked IFN-gamma-induced serine phosphorylation of STAT1alpha. These data indicate that PI 3 kinase-dependent PKCepsilon regulates STAT1alpha transcriptional activity in the absence of any effect on its DNA binding capability. In addition to activating PKCepsilon, IFN-gamma increased MAPK activity, resulting in transcriptional activation of Elk-1, a nuclear target of MAPK. Ly294002 or a dominant negative PI 3-kinase significantly blocked IFN-gamma-induced MAPK activity. On the other hand, ectopic expression of constitutively active PKCepsilon significantly increased MAPK activity. IFN-gamma-stimulated MAPK phosphorylated STAT1alpha in vitro. Inhibition of MAPK activity blocked IFN-gamma-induced serine phosphorylation of STAT1alpha; but its tyrosine phosphorylation and DNA binding were partially inhibited. Finally, expression of dominant negative MAPK significantly inhibited IFN-gamma-induced STAT1alpha-dependent transcription. These data provide the first evidence that IFN-gamma stimulates PKCepsilon in a PI 3-kinase-sensitive manner to activate MAPK, which regulates STAT1alpha transcriptional activity.	Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815, P50DK061597] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK061597, R01 DK55815] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BALKWILL FR, 1977, INT J CANCER, V20, P500, DOI 10.1002/ijc.2910200405; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Carvalho-Pinto CE, 2002, J IMMUNOL, V169, P1058, DOI 10.4049/jimmunol.169.2.1058; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; CELADA A, 1986, J IMMUNOL, V137, P2373; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; CHOUDHURY GG, 1993, AM J PHYSIOL, V265, pF634, DOI 10.1152/ajprenal.1993.265.5.F634; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choudhury GG, 2003, CELL SIGNAL, V15, P161, DOI 10.1016/S0898-6568(02)00057-8; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choudhury GG, 2000, BIOCHEM BIOPH RES CO, V273, P1069, DOI 10.1006/bbrc.2000.3081; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GRANDALIANO G, 1994, J LAB CLIN MED, V123, P282; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; HUWILER A, 1993, EXP NEPHROL, V1, P19; Ikezumi Y, 2003, J AM SOC NEPHROL, V14, P888, DOI 10.1097/01.ASN.0000056604.13964.62; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; JOHNSON RJ, 1995, KIDNEY INT, V47, P62, DOI 10.1038/ki.1995.7; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kitching AR, 1999, J AM SOC NEPHROL, V10, P752; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; MATTILA P, 1993, SCAND J IMMUNOL, V38, P197, DOI 10.1111/j.1365-3083.1993.tb01713.x; MATTILA P, 1992, BIOCHEM BIOPH RES CO, V189, P1732, DOI 10.1016/0006-291X(92)90278-S; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MENE P, 1989, PHYSIOL REV, V69, P1372; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Nakashima O, 2000, KIDNEY INT, V57, P2249, DOI 10.1046/j.1523-1755.2000.00085.x; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; PONZONI M, 1993, FEBS LETT, V322, P120, DOI 10.1016/0014-5793(93)81550-J; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; Ring GH, 1999, J IMMUNOL, V163, P2243; SCHENA FP, 1992, J AM SOC NEPHROL, V2, pS167; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schwarting A, 1998, J IMMUNOL, V161, P494; Senthil D, 2002, AM J PHYSIOL-RENAL, V283, pF1226, DOI 10.1152/ajprenal.00109.2002; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Valente AJ, 1998, J IMMUNOL, V161, P3719; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Whiteside CI, 2002, AM J PHYSIOL-RENAL, V282, pF975, DOI 10.1152/ajprenal.00014.2002; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	78	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27399	27409		10.1074/jbc.M403530200	http://dx.doi.org/10.1074/jbc.M403530200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082710	hybrid			2022-12-27	WOS:000222120400071
J	Goux, WJ; Kopplin, L; Nguyen, AD; Leak, K; Rutkofsky, M; Shanmuganandam, VD; Sharma, D; Inouye, H; Kirschner, DA				Goux, WJ; Kopplin, L; Nguyen, AD; Leak, K; Rutkofsky, M; Shanmuganandam, VD; Sharma, D; Inouye, H; Kirschner, DA			The formation of straight and twisted filaments from short tau peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; AMYLOID FIBRIL FORMATION; PROTEIN SECONDARY STRUCTURE; IN-VITRO; CIRCULAR-DICHROISM; ALZHEIMER-DISEASE; ABNORMAL PHOSPHORYLATION; MICROTUBULE INTERACTIONS; POLYPEPTIDE IAPP; AGGREGATION	We studied fibril formation in a family of peptides based on PHF6 (VQIVYK), a short peptide segment found in the microtubule binding region of tau protein. N-Acetylated peptides AcVYK-amide (AcVYK), AcIVYK-amide (AcPHF4), AcQIVYK-amide (AcPHF5), and AcV-QIVYK-amide (AcPHF6) rapidly formed straight filaments in the presence of 0.15 M NaCl, each composed of two laterally aligned protofilaments similar to5 nm in width. X-ray fiber diffraction showed the omnipresent sharp 4.7-Angstrom reflection indicating that the scattering objects are likely elongated along the hydrogen-bonding direction in a cross-beta conformation, and Fourier transform IR suggested the peptide chains were in a parallel (AcVYK, AcPHF6) or antiparallel (AcPHF4, AcPHF5) beta-sheet configuration. The dipeptide N-acetyl-YK-amide (AcYK) formed globular structures similar to200 nm to 1 mum in diameter. The polymerization rate, as measured by thioflavin S binding, increased with the length of the peptide going from AcYK 3 AcPHF6, and peptides that aggregated most rapidly displayed CD spectra consistent with beta-sheet structure. There was a 3-fold decrease in rate when Val was substituted for Ile or Gln, nearly a 10-fold decrease when Ala was substituted for Tyr, and an increase in polymerization rate when Glu was substituted for Lys. Twisted filaments, composed of four laterally aligned protofilaments (9-19 nm width, similar to90 nm half-periodicity), were formed by mixing AcPHF6 with AcVYK. Taken together these results suggest that the core of PHF6 is localized at VYK, and the interaction between small amphiphilic segments of tau may initiate nucleation and lead to filaments displaying paired helical filament morphology.	Univ Texas, Dept Chem, Richardson, TX 75083 USA; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	University of Texas System; University of Texas Dallas; Boston College	Goux, WJ (corresponding author), Univ Texas, Dept Chem, POB 830688, Richardson, TX 75083 USA.	wgoux@utdallas.edu		Sharma, Deepak/0000-0001-8436-1759; Kirschner, Daniel/0000-0003-3498-1452	NIA NIH HHS [1R03AG16042-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG016042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraha A, 2000, J CELL SCI, V113, P3737; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caplan MR, 2000, BIOMACROMOLECULES, V1, P627, DOI 10.1021/bm005586w; Caplan MR, 2002, BIOMATERIALS, V23, P219, DOI 10.1016/S0142-9612(01)00099-0; CHOMA CT, 1994, J AM CHEM SOC, V116, P856, DOI 10.1021/ja00082a005; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Feany MB, 1996, J NEUROPATH EXP NEUR, V55, P53, DOI 10.1097/00005072-199601000-00006; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giannetti AM, 2000, PROTEIN SCI, V9, P2427, DOI 10.1110/ps.9.12.2427; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOUX WJ, 1980, J AM CHEM SOC, V102, P7080, DOI 10.1021/ja00543a033; Goux WJ, 2002, BIOCHEMISTRY-US, V41, P13798, DOI 10.1021/bi016079h; Goux WJ, 1996, J NEUROCHEM, V67, P723; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Kosik Kenneth S., 1994, P335; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2000, J AM CHEM SOC, V122, P5262, DOI 10.1021/ja9937831; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; MAKOWSKI L, 1989, BROOKH S SYNCHR RAD, P341; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Mazor Y, 2002, J MOL BIOL, V322, P1013, DOI 10.1016/S0022-2836(02)00887-2; Nilsson MR, 2003, BIOCHEMISTRY-US, V42, P375, DOI 10.1021/bi0204746; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; OLDENBOURG R, 1986, REV SCI INSTRUM, V57, P2362, DOI 10.1063/1.1138680; Pace CN, 1995, METHOD ENZYMOL, V259, P538; POLLANEN MS, 1994, AM J PATHOL, V144, P869; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Sreerama N, 2003, PROTEIN SCI, V12, P384, DOI 10.1110/ps.0235003; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1985, J CELL BIOL, V100, P1905, DOI 10.1083/jcb.100.6.1905; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q; Yanagawa H, 1998, BIOCHEMISTRY-US, V37, P1979, DOI 10.1021/bi9724265; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	83	183	184	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26868	26875		10.1074/jbc.M402379200	http://dx.doi.org/10.1074/jbc.M402379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100221	hybrid			2022-12-27	WOS:000222120400010
J	Ondr, JK; Pham, CTN				Ondr, JK; Pham, CTN			Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL CYSTEINE PROTEASES; DIPEPTIDYL PEPTIDASE-I; ENDOPLASMIC-RETICULUM; T-LYMPHOCYTES; GRANZYME-A; CHROMOSOMAL LOCALIZATION; ESTABLISHED TUMORS; TARGET-CELLS; EXPRESSION; APOPTOSIS	Cathepsin W is a member of the papain-like family of cysteine proteases. In this report, we have isolated the cDNA for murine CtsW (mCtsW) from a splenocyte library. The deduced 371-amino-acid sequence shares 68% identity with human CtsW and includes the conserved catalytic triad cysteine, histidine, and asparagine found in all members of this family. In addition to the full-length form of mCtsW, we have isolated an alternatively spliced form of the mRNA that lacks a complete catalytic triad. An S1 nuclease protection assay and a Western blot analysis showed that mCtsW is mainly restricted to the CD8(+) T cell and natural killer cell compartments. In addition, we confirmed that, like its human homologue, mCtsW is localized mainly to the endoplasmic reticulum and its expression is up-regulated upon activation. We also characterized the mCtsW locus using bacterial artificial chromosome clones. The gene consists of 10 coding exons and 9 introns spanning 3.2 kb. To elucidate the physiologic role of this protease, we generated mice deficient in mCtsW. Our data establish that mCtsW is not required for cytotoxic lymphocyte-induced target cell death in vitro. In addition, mCtsW deficiency does not alter the susceptibility of cytotoxic lymphocytes to suicide or fratricide after degranulation. Thus, mCtsW does not have a unique role in target cell apoptosis or cytotoxic cell survival in vitro.	Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Pham, CTN (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.	cpham@im.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049261, R01AI049261, T32AI007163] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07163, R01 AI049261, AI49261] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Brinkworth RI, 2000, INT J BIOCHEM CELL B, V32, P373, DOI 10.1016/S1357-2725(99)00129-6; Brown J, 1998, LEUKEMIA, V12, P1771, DOI 10.1038/sj.leu.2401164; Buhling F, 2002, BIOL CHEM, V383, P1285, DOI 10.1515/BC.2002.144; Buhling F, 2000, ADV EXP MED BIOL, V477, P241; Cygler M, 1997, BIOCHIMIE, V79, P645, DOI 10.1016/S0300-9084(97)83497-9; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; Matsui K, 2003, INT IMMUNOL, V15, P797, DOI 10.1093/intimm/dxg078; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Shresta S, 1997, J BIOL CHEM, V272, P20236, DOI 10.1074/jbc.272.32.20236; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wex T, 2003, FEBS LETT, V552, P115, DOI 10.1016/S0014-5793(03)00895-0; Wex T, 1998, BIOCHEM BIOPH RES CO, V248, P255, DOI 10.1006/bbrc.1998.8954; Wex T, 1999, BIOCHEM BIOPH RES CO, V259, P401, DOI 10.1006/bbrc.1999.0700; Wex T, 2001, J IMMUNOL, V167, P2172, DOI 10.4049/jimmunol.167.4.2172; Wex T, 2000, ADV EXP MED BIOL, V477, P271	38	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27525	27533		10.1074/jbc.M400304200	http://dx.doi.org/10.1074/jbc.M400304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087452	hybrid			2022-12-27	WOS:000222120400085
J	Zou, YL; Ewton, DZ; Deng, XB; Mercer, SE; Friedman, E				Zou, YL; Ewton, DZ; Deng, XB; Mercer, SE; Friedman, E			Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE; MIRK PROTEIN-KINASE; DEPENDENT KINASE; BINDING PROTEIN; D1; CELLS; DIFFERENTIATION; INHIBITOR; PREVENTS; DEGRADATION	The phosphorylation of cyclin D1 at threonine 286 by glycogen synthase kinase 3beta (GSK3beta) has been shown to be required for the ubiquitination and nuclear export of cyclin D1 and its subsequent degradation in the proteasome. The mutation of the nearby residue, threonine 288, to nonphosphorylatable alanine has also been shown to reduce the ubiquitination of cyclin D1, suggesting that phosphorylation at threonine 288 may also lead to degradation of cyclin D1. We now demonstrate that the G(0)/G(1)-active arginine-directed protein kinase Mirk/dyrk1B binds to cyclin D1 and phosphorylates cyclin D1 at threonine 288 in vivo and that the cyclin D1-T288A construct is more stable than wild-type cyclin D1. Transient overexpression of Mirk in nontransformed Mv1Lu lung epithelial cells blocked cells in G(0)/ G(1). Depletion of endogenous Mirk by RNA interference increased cyclin D1 protein levels but not mRNA levels, indicating that Mirk destabilizes cyclin D1 protein. Destabilization was confirmed by induction of a stable Mirk transfectant of Mv1Lu cells, which blocked cell migration (Zou, Y., Lim, S., Lee, K., Deng, X., and Friedman, E. ( 2003) J. Biol. Chem. 278, 49573 - 49581), and caused a decrease in the half-life of endogenous cyclin D1, concomitant with an increase in Mirk expression. In vitro cyclin D1 was phosphorylated in an additive fashion by Mirk and GSK3beta. Mirk-phosphorylated cyclin D1 mutated at the GSK3beta phosphorylation site and was capable of phosphorylating cyclin D1 in the presence of the GSK3beta inhibitor LiCl. Mirk may function together with GSK3beta to assist cell arrest in G(0)/G(1) by destabilizing cyclin D1.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu			NCI NIH HHS [R01 CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BORJA PF, 2001, EMBO J, V20, P5737; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ewton DZ, 2003, INT J CANCER, V103, P21, DOI 10.1002/ijc.10743; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LEE H, 1993, J BIOL CHEM, V268, P8181; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Lu FM, 2003, CANCER RES, V63, P7056; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Pellettieri J, 2003, DEV CELL, V5, P451, DOI 10.1016/S1534-5807(03)00231-4; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Skurat AV, 2004, J BIOL CHEM, V279, P2490, DOI 10.1074/jbc.M301769200; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	28	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27790	27798		10.1074/jbc.M403042200	http://dx.doi.org/10.1074/jbc.M403042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075324	hybrid			2022-12-27	WOS:000222120400114
J	Hashigasako, A; Machide, M; Nakamura, T; Matsumoto, K; Nakamura, T				Hashigasako, A; Machide, M; Nakamura, T; Matsumoto, K; Nakamura, T			Bi-directional regulation of Ser-985 phosphorylation of c-Met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; JUXTAMEMBRANE DOMAIN; MOLECULAR-CLONING; IDENTIFICATION; CANCER; KERATINOCYTES; MUTATION; PATHWAY; STRESS; HGF/SF	Previous studies indicated that treatment of cells with 12-O-tetradecanoylphorbol-13-acetate induced phosphorylation of Ser-985 at the juxtamembrane of c-Met, the receptor tyrosine kinase for hepatocyte growth factor (HGF), and this was associated with decreased tyrosine phosphorylation of c-Met. However, the regulatory mechanisms and the biological significance of the Ser-985 phosphorylation in c-Met remain unknown. When A549 human lung cancer cells were exposed to oxidative stress with H2O2, H2O2 treatment induced phosphorylation of Ser-985, but this was abrogated by an inhibitor for protein kinase C (PKC). Likewise, treatment of cells with NaF (an inhibitor of protein phosphatases) allowed for phosphorylation of Ser-985, and a protein phosphatase responsible for dephosphorylation of Ser-985 was identified to be protein phosphatase 2A (PP2A). The effects of PKC inhibitors revealed that PKCdelta and -epsilon were responsible for the Ser-985 phosphorylation of c-Met, and pull-down analysis indicated that associations of PKCdelta and -epsilon with c-Met may be involved in the regulation of Ser-985 phosphorylation of c-Met. Instead, PP2A was constitutively associated with c-Met, whereas its activity to dephosphorylate Ser-985 of c-Met was decreased when cells were exposed to H2O2. Addition of HGF to A549 cells in culture induced c-Met tyrosine phosphorylation, the result being mitogenic response and cell scattering. In contrast, in the presence of H2O2 stress, HGF-dependent tyrosine phosphorylation of c-Met was largely suppressed with a reciprocal relationship to Ser-985 phosphorylation, and this event was associated with abrogation of cellular responsiveness to HGF. These results indicate that Ser-985 phosphorylation of c-Met is bi-directionally regulated through PKC and PP2A, and the Ser-985 phosphorylation status may provide a unique mechanism that confers cellular responsiveness/unresponsivenss to HGF, depending on extracellular conditions.	Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka 5650871, Japan; Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448787, Japan	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, 2-2-B7 Yamada Oka, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COCHET C, 1984, J BIOL CHEM, V259, P2553; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; LEE CC, 1994, J BIOL CHEM, V269, P19457; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Ma PC, 2003, CANCER RES, V63, P6272; Matsumoto K, 2003, CANCER SCI, V94, P321, DOI 10.1111/j.1349-7006.2003.tb01440.x; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Meier M, 2000, VASC MED, V5, P173, DOI 10.1177/1358836X0000500307; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAKEHARA T, 1992, J BIOCHEM-TOKYO, V112, P330, DOI 10.1093/oxfordjournals.jbchem.a123900; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	79	80	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26445	26452		10.1074/jbc.M314254200	http://dx.doi.org/10.1074/jbc.M314254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075332	hybrid			2022-12-27	WOS:000222003000066
J	Magdinier, F; Yusufzai, TM; Felsenfeld, G				Magdinier, F; Yusufzai, TM; Felsenfeld, G			Both CTCF-dependent and -independent insulators are found between the mouse T cell receptor alpha and Dad1 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; ENHANCER-BLOCKING ACTIVITY; MATRIX-ATTACHMENT REGIONS; BETA-GLOBIN DOMAIN; ALPHA/DELTA LOCUS; BINDING-PROTEIN; TRANSGENE EXPRESSION; NUCLEAR-MATRIX; TCR-ALPHA; CHROMATIN	The T cell rearrangement of the T cell receptor (TCR) genes TCRalpha and delta is specifically regulated by a complex interplay between enhancer elements and chromatin structure. The alpha enhancer is active in T cells and drives TCRalpha recombination in collaboration with a locus control region-like element located downstream of the Calpha gene on mouse chromosome 14. Twelve kb further downstream lies another gene, Dad1, with a program of expression different from that of TCRalpha. The similar to6-kb locus control region element lying between them contains multiple regulatory sites with a variety of roles in regulating the two genes. Previous evidence has indicated that among these there are widely distributed regions with enhancer blocking (insulating) activity. We have shown in this report that one of these sites, not previously examined, strongly binds the insulator protein CCTC-binding factor (CTCF) in vitro and in vivo and can function in an enhancer blocking assay. However, other regions within the 6-kb element that also can block enhancers clearly do not harbor CTCF sites and thus must reflect the presence of a previously undetected and distinct vertebrate insulator activity.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Felsenfeld, G (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	gary.felsenfeld@nih.gov	Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK034001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Byrd K, 2003, J CELL BIOL, V162, P565, DOI 10.1083/jcb.200305013; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; Dunn KL, 2003, EXP CELL RES, V288, P218, DOI 10.1016/S0014-4827(03)00185-X; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Forrester WC, 1999, GENE DEV, V13, P3003, DOI 10.1101/gad.13.22.3003; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Glusman G, 2001, IMMUNITY, V15, P337, DOI 10.1016/S1074-7613(01)00200-X; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hong NA, 1999, J IMMUNOL, V163, P1888; Hong NA, 1997, MOL CELL BIOL, V17, P2151, DOI 10.1128/MCB.17.4.2151; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; Krangel MS, 2000, IMMUNOL RES, V22, P127, DOI 10.1385/IR:22:2-3:127; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Makishima T, 1997, GENES CELLS, V2, P129, DOI 10.1046/j.1365-2443.1997.1070303.x; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Ortiz BD, 1999, MOL CELL BIOL, V19, P1901; Ortiz BD, 2001, J IMMUNOL, V167, P3836, DOI 10.4049/jimmunol.167.7.3836; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; Robinett CC, 1997, MOL CELL BIOL, V17, P2866, DOI 10.1128/MCB.17.5.2866; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Santoso B, 2000, J BIOL CHEM, V275, P1952, DOI 10.1074/jbc.275.3.1952; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; Villemure JF, 2001, J MOL BIOL, V312, P963, DOI 10.1006/jmbi.2001.5015; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172; Zhong XP, 1999, J IMMUNOL, V163, P295	51	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25381	25389		10.1074/jbc.M403121200	http://dx.doi.org/10.1074/jbc.M403121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082712	hybrid			2022-12-27	WOS:000221827900061
J	Wollenberg, MS; Simon, SM				Wollenberg, MS; Simon, SM			Signal sequence cleavage of peptidyl-tRNA prior to release from the ribosome and translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; ER MEMBRANE; GTP; MITOCHONDRIA; PEROXISOMES; PROTEOLYSIS; PRECURSOR; PUROMYCIN	Many secretory polypeptides undergo cleavage of their signal sequence. In this study, we observed and quantitated the presence of a tRNA-bound, ribosome-associated polypeptide subpopulation present in vitro. This subpopulation was accessible to signal peptidase on ribosome-associated polypeptides longer than 114 amino acids. This demonstrates that it is possible for a peptidyl-tRNA species, in the midst of translation, to be processed by the endoplasmic reticulum signal peptidase implying that the peptidase is closely associated with the mammalian translocon.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA	Rockefeller University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave,Box 304, New York, NY 10021 USA.	simon@rockefeller.edu		Simon, Sanford/0000-0002-8615-4224				BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; DOBBERSTEIN B, 1977, P NATL ACAD SCI USA, V74, P1082, DOI 10.1073/pnas.74.3.1082; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kanner EM, 2003, J BIOL CHEM, V278, P7920, DOI 10.1074/jbc.M207462200; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NATHANS D, 1964, P NATL ACAD SCI USA, V51, P585, DOI 10.1073/pnas.51.4.585; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Promega Corp, 2000, CAN PANCR MICR MEMBR; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TALMADGE K, 1980, P NATL ACAD SCI-BIOL, V77, P3988, DOI 10.1073/pnas.77.7.3988; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679	37	3	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24919	24922		10.1074/jbc.C400018200	http://dx.doi.org/10.1074/jbc.C400018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082722	hybrid			2022-12-27	WOS:000221827900004
J	Nicholls, CD; Shields, MA; Lee, PWK; Robbins, SM; Beattie, TL				Nicholls, CD; Shields, MA; Lee, PWK; Robbins, SM; Beattie, TL			UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TUMOR-SUPPRESSOR PROTEIN; NAD(P)H-QUINONE OXIDOREDUCTASE-1; HUMAN CANCER; SR PROTEINS; DNA-DAMAGE; APOPTOSIS; KINASE; PROMOTER; STRESS	The p53-inducible gene 3 (PIG3) is a transcriptional target of the tumor suppressor protein p53 and is thought to play a role in apoptosis. In this report, we identify a novel alternatively spliced product from the PIG3 gene that we call PIG3AS ( PIG3 alternative splice). PIG3AS results from alternative pre-mRNA splicing that skips exon 4 of the five exons included in the PIG3 transcript. The resulting protein product shares its first 206 amino acids with PIG3 but has a unique 42-amino acid C terminus. In unstressed cells and after most DNA damage conditions that induce transcription from the PIG3 gene, production of the PIG3 transcript dominates. However, in response to UV light, pre-mRNA splicing shifts dramatically in favor of PIG3AS. Unlike the PIG3 protein, the PIG3AS protein is rapidly degraded with a short half-life and is stabilized by proteasome inhibition. Our results illustrate the first example of an endogenous, UV-inducible, alternative splicing event and that control of the splicing machinery is involved in the cellular DNA damage response. They also suggest that rapid proteolytic degradation represents a cellular mechanism for uncoupling p53 activity from PIG3 gene activation that is independent of promoter selectivity.	Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Beattie, TL (corresponding author), Heritage Med Res Bldg, Calgary, AB T2N 4N1, Canada.	tbeattie@ucalgary.ca						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Anwar A, 2002, J BIOL CHEM, V277, P14060, DOI 10.1074/jbc.M111576200; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Caballero OL, 2001, DIS MARKERS, V17, P67, DOI 10.1155/2001/184856; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Contente A, 2003, CANCER RES, V63, P1756; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang ZN, 2003, CANCER RES, V63, P655; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	48	24	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24171	24178		10.1074/jbc.M401049200	http://dx.doi.org/10.1074/jbc.M401049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067011	hybrid			2022-12-27	WOS:000221702500040
J	Fujioka, S; Schmidt, C; Sclabas, GM; Li, ZK; Pelicano, H; Peng, B; Yao, A; Niu, JG; Zhang, W; Evans, DB; Abbruzzese, JL; Huang, P; Chiao, PJ				Fujioka, S; Schmidt, C; Sclabas, GM; Li, ZK; Pelicano, H; Peng, B; Yao, A; Niu, JG; Zhang, W; Evans, DB; Abbruzzese, JL; Huang, P; Chiao, PJ			Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; MICE LACKING; FAS-LIGAND; CELL-DEATH; NUCLEAR TRANSLOCATION; LIVER DEGENERATION; OXIDATIVE STRESS; T-LYMPHOCYTES	Both pro- and antiapoptotic activities of NF-kappaB transcription factor have been observed; however, less is known about the mechanism by which NF-kappaB induces apoptosis. To elucidate how NF-kappaB regulates proapoptotic signaling, we performed functional analyses using wild-type, ikk1(-/-), ikk2(-/-), rela(-/-) murine fibroblasts, MDAPanc-28/Puro, MDAPanc-28/IkappaBalphaM, and HCT116/p53(+/+) and HCT116/p53(-/-) cells with investigational anticancer agent doxycycline as a superoxide inducer for generating apoptotic stimulus. In this report, we show that doxycycline increased superoxide generation and subsequently activated NF-kappaB, which in turn up-regulated p53 expression and increased the stability and DNA binding activity of p53. Consequently, NF-kappaB-dependent p53 activity induced the expression of p53-regulated genes PUMA and p21(waf1) as well as apoptosis. Importantly, lack of RelA, IKK, and p53 as well as expression of a dominant negative IkappaBalpha(IkappaBalphaM) inhibited NF-kappaB-dependent p53 activation and apoptosis. The doxycycline-induced NF-kappaB activation was not inhibited in HCT116/p53(+/+) cells. Our results demonstrate that NF-kappaB plays an essential role in activation of wild-type p53 tumor suppressor to initiate proapoptotic signaling in response to overgeneration of superoxide. Thus, these findings reveal a mechanism of NF-kappaB-regulated proapoptotic signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Bern, Inselspital, CH-3010 Bern, Switzerland; Univ Texas, Hlth Sci Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Summer Student Program, Houston, TX 77030 USA; Univ Texas, Program Canc Biol, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bern; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mail.mdanderson.org		Schmidt, Christian/0000-0002-1260-9732	NCI NIH HHS [CA78778-01] Funding Source: Medline; PHS HHS [PA-98-029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMATSU H, 1992, ACTA DERM-VENEREOL, V72, P178; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Annunziata CM, 2000, BLOOD, V96, P2841; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Cusack JC, 2001, CANCER RES, V61, P3535; de Erausquin GA, 2003, MOL PHARMACOL, V63, P784, DOI 10.1124/mol.63.4.784; Del Rio MJ, 2002, BIOCHEM PHARMACOL, V63, P677, DOI 10.1016/S0006-2952(01)00907-8; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2; Frazier ML, 1996, INT J PANCREATOL, V19, P31, DOI 10.1007/BF02788373; FRITSCHE M, 1993, ONCOGENE, V8, P307; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILBERTSONBEADLING S, 1995, CANCER CHEMOTH PHARM, V36, P418, DOI 10.1007/BF00686191; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; HARPER JW, 1993, CELL, V75, P805; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; KROON AM, 1985, BIOCHEM BIOPH RES CO, V128, P1190, DOI 10.1016/0006-291X(85)91066-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Lokeshwar BL, 2002, INT J CANCER, V98, P297, DOI 10.1002/ijc.10168; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsui K, 1998, J IMMUNOL, V161, P3469; McInnis J, 2002, J PHARMACOL EXP THER, V301, P478, DOI 10.1124/jpet.301.2.478; Mitani K, 2001, Nihon Rinsho, V59, P2316; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Prives C, 1999, J PATHOL, V187, P112; Qin ZH, 1999, J NEUROSCI, V19, P4023; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; VANDENBOGERT C, 1981, CANCER RES, V41, P1943; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	80	111	117	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27549	27559		10.1074/jbc.M313435200	http://dx.doi.org/10.1074/jbc.M313435200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102862	hybrid			2022-12-27	WOS:000222120400088
J	Ahvazi, B; Boeshans, KM; Steinert, PM				Ahvazi, B; Boeshans, KM; Steinert, PM			Crystal structure of transglutaminase 3 in complex with GMP - Structural basis for nucleotide specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CALCIUM-IONS; BINDING; PROTEIN; ACTIVATION; EXPRESSION; TRANSFECTION; TRICHOHYALIN	Epidermal-type Transglutaminase 3(TGase3) is a Ca2+-dependent enzyme involved in the cross-linking of structural proteins required in the assembly of the cell envelope. We have recently shown that calcium-activated TGase 3, like TGase 2, can bind, hydrolyze, and is inhibited by GTP despite lacking structural homology with other GTP-binding proteins. Here we report the crystal structure determined at 2.0 Angstrom resolution of TGase 3 in complex with GMP to elucidate the structural features required for nucleotide recognition. Binding affinities for various nucleotides were found by fluorescence displacement to be as follows: guanosine 5'-3-O-( thio) triphosphate (GTPgammaS) (0.4 muM), GTP (0.6 muM), GDP (1.0 muM), GMP (0.4 muM), and ATP (28.0 muM). Furthermore, we found that GMP binds as a reversible, noncompetitive inhibitor of TGase 3 transamidation activity, similar to GTPgammaS and GDP. A genetic algorithm similarity program ( GASP) approach ( virtual ligand screening) identified three compounds from the Lead Quest(TM) data base (Tripos Inc.) based on superimposition of GTPgammaS, GDP, and GMP guanine nucleotides from our crystal structures to generate the minimum align flexible fragment. These three were nucleotide analogs without a phosphate group containing the minimal binding motif for TGase 3 that includes a nucleoside recognition groove. Binding affinities were measured as follows: TP349915 (K-d = 4.1 muM), TP395289 (K-d = 38.5 muM), TP394305 (K-d = 1.0 mM). Remarkably, these compounds do not inhibit but instead activate TGase 3 transamidation by about 10-fold. These results suggest that the nucleotide binding pocket in TGase 3 may be exploited to either enhance or inhibit the enzymatic activity as required for different therapeutic approaches.	NIAMS, Xray Crystallog Facil, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ahvazi, B (corresponding author), NIAMS, Xray Crystallog Facil, Off Sci & Technol, NIH, 50 S Dr,Bldg 1345, Bethesda, MD 20892 USA.	ahvazib@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041087, Z01AR041142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Ahvazi B, 2004, J BIOL CHEM, V279, P7180, DOI 10.1074/jbc.M312310200; Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; AHVAZI B, 2004, J STRUCT BIOL; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; JOHNSON TS, 1994, ONCOGENE, V9, P2935; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HC, 2001, J STRUCT BIOL, V135, P73, DOI 10.1006/jsbi.2001.4384; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 1996, J BIOL CHEM, V271, P4561; LEE SC, 1993, J BIOL CHEM, V268, P12164; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Melino G, 1998, Results Probl Cell Differ, V24, P175; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Niki I, 1996, J BIOCHEM, V120, P685; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; *TRIP ASS INC, SYBYL VERS 6 9	46	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26716	26725		10.1074/jbc.M403481200	http://dx.doi.org/10.1074/jbc.M403481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084592	hybrid			2022-12-27	WOS:000222003000098
J	Bartrand, AJ; Iyasu, D; Brush, GS				Bartrand, AJ; Iyasu, D; Brush, GS			DNA stimulates Mec1-mediated phosphorylation of replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT GENES; MEC1-DEPENDENT PHOSPHORYLATION; MEIOTIC RECOMBINATION; RPA PHOSPHORYLATION; IONIZING-RADIATION; BINDING PROTEIN; BUDDING YEAST; CELL-GROWTH	The cellular single-stranded DNA (ssDNA)-binding protein replication protein A (RPA) becomes phosphorylated periodically during the normal cell cycle and also in response to DNA damage. In Saccharomyces cerevisiae, RPA phosphorylation requires the checkpoint protein Mec1, a protein kinase homologous in structure and function to human ATR. We confirm here that immunocomplexes containing a tagged version of Mec1 catalyze phosphorylation of purified RPA, likely reflecting an RPA kinase activity intrinsic to Mec1. A significant stimulation of this activity is observed upon the addition of covalently closed ssDNA derived from the bacteriophage M13. This stimulation is not observed with mutant RPA deficient for DNA binding, indicating that DNA-bound RPA is a preferred substrate. Stimulation is also observed upon the addition of linear ssDNA homopolymers or hydrolyzed M13 ssDNA. In contrast to circular ssDNA, these DNA cofactors stimulate both wild type and mutant RPA phosphorylation. This finding suggests that linear ssDNA can also stimulate Mec1-mediated RPA phosphorylation by activating Mec1 or an associated protein. Although the Mec1-interacting protein Ddc2 is required for RPA phosphorylation in vivo, it is required for neither basal nor ssDNA-stimulated RPA phosphorylation in vitro. Therefore, activation of Mec1-mediated RPA phosphorylation by either circular or linear ssDNA does not operate through Ddc2. Our results provide insight into the mechanisms that function in vivo to specifically induce RPA phosphorylation upon initiation of DNA replication, repair, or recombination.	Wayne State Univ, Program Mol Biol & Human Genet, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Brush, GS (corresponding author), Wayne State Univ, Program Mol Biol & Human Genet, Karmanos Canc Inst, Detroit, MI 48201 USA.	brushg@karmanos.org			NIGMS NIH HHS [GM61860] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061860] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1998, METHODS YEAST GENETI, P145; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brush GS, 2001, NUCLEIC ACIDS RES, V29, P4808, DOI 10.1093/nar/29.23.4808; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Clifford DM, 2004, J BIOL CHEM, V279, P6163, DOI 10.1074/jbc.M306943200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Grushcow JM, 1999, GENETICS, V153, P607; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Kim HS, 2003, DNA REPAIR, V2, P1321, DOI 10.1016/j.dnarep.2003.07.004; KORNBERG A, 1992, DNA REPLICATION, P275; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Mallory JC, 2003, DNA REPAIR, V2, P1041, DOI 10.1016/S1568-7864(03)00115-0; Melo JA, 2001, GENE DEV, V15, P2809; Morgan SE, 1997, CANCER RES, V57, P3386; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Paciotti V, 2000, GENE DEV, V14, P2046; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26762	26767		10.1074/jbc.M312353200	http://dx.doi.org/10.1074/jbc.M312353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078888	hybrid			2022-12-27	WOS:000222003000103
J	Gkika, D; Mahieu, F; Nilius, B; Hoenderop, JGJ; Bindels, RJM				Gkika, D; Mahieu, F; Nilius, B; Hoenderop, JGJ; Bindels, RJM			80K-H as a new Ca2+ sensor regulating the activity of the epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-3-1-ALPHA-HYDROXYLASE KNOCKOUT MICE; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; GLUCOSIDASE-II; CALCIUM-ABSORPTION; DIETARY CA2+; IDENTIFICATION; EXPRESSION; CELLS; INACTIVATION	The epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5) constitutes the apical Ca2+ entry pathway in the process of active Ca2+ reabsorption. Ca2+ influx through TRPV5 is tightly controlled by modulators of Ca2+ homeostasis, including 1,25-dihydroxyvitamin D-3 and dietary Ca2+. However, little is known about intracellular proteins that interact with TRPV5 and directly regulate the activation of this channel. By the use of cDNA microarrays, the present study identified 80K-H as the first protein involved in the Ca2+-dependent control of the epithelial Ca2+ channel TRPV5. 80K-H was initially identified as a protein kinase C substrate, but its biological function remains to be established. We demonstrated a specific interaction between 80K-H and TRPV5, co-localization of both proteins in the kidney, and similar transcriptional regulation by 1,25-dihydroxyvitamin D3 and dietary Ca2+. Furthermore, 80K-H directly bound Ca2+, and inactivation of its two EF-hand structures totally abolished Ca2+ binding. Electrophysiological studies using 80K-H mutants showed that three domains of 80K-H (the two EF-hand structures, the highly acidic glutamic stretch, and the His-Asp-Glu-Leu sequence) are critical determinants for TRPV5 activity. Importantly, inactivation of the EF-hand pair reduced the TRPV5-mediated Ca2+ current and increased the TRPV5 sensitivity to intracellular Ca2+, accelerating the feedback inhibition of the channel. None of the 80K-H mutants altered the TRPV5 plasma membrane localization nor the association of 80K-H with TRPV5, suggesting that 80K-H has a direct effect on TRPV5 activity. In conclusion, we report a novel function for 80K-H as a Ca2+ sensor controlling TRPV5 channel activity.	Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; KU Leuven	Bindels, RJM (corresponding author), Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Gkika, Dimitra/S-3054-2019; Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Gkika, Dimitra/0000-0001-8612-0836; Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Brule S, 2000, BIOL REPROD, V62, P642, DOI 10.1095/biolreprod62.3.642; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; HIRAI M, 1990, BIOCHEM J, V270, P583, DOI 10.1042/bj2700583; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2004, KIDNEY INT, V65, P531, DOI 10.1111/j.1523-1755.2004.00402.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; Madsen O, 2002, MOL BIOL EVOL, V19, P2150, DOI 10.1093/oxfordjournals.molbev.a004040; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Pagny S, 2000, PLANT CELL, V12, P739, DOI 10.1105/tpc.12.5.739; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Poirier O, 2001, DIABETES, V50, P1214, DOI 10.2337/diabetes.50.5.1214; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963	40	58	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26351	26357		10.1074/jbc.M403801200	http://dx.doi.org/10.1074/jbc.M403801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15100231	hybrid, Green Published			2022-12-27	WOS:000222003000055
J	Hodzic, DM; Yeater, DB; Bengtsson, L; Otto, H; Stahl, PD				Hodzic, DM; Yeater, DB; Bengtsson, L; Otto, H; Stahl, PD			Sun2 is a novel mammalian inner nuclear membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; LAMIN-B-RECEPTOR; CAENORHABDITIS-ELEGANS; LEM DOMAIN; CELL-LESS; IN-VITRO; ENVELOPE; EMERIN; BINDING; MIGRATION	Sun protein (Sun1 and Sun2) cDNAs were previously cloned based on the homology of their C-terminal regions (SUN (Sad1 and UNC) domain) with the Caenorhabditis elegans protein UNC-84 whose mutation disrupts nuclear migration/positioning. In this study, we raised an anti-Sun2 serum and identified Sun2 in mammalian cells. In HeLa cells, Sun2 displays a nuclear rim-like pattern typical for a nuclear envelope protein. The Sun2 antibody signal co-localizes with nuclear pore and INM markers signals. The rim-like pattern was also observed with the recombinant full-length Sun2 protein fused to either EGFP or V5 epitopes. In addition, we found that a recombinant truncated form of Sun2, extending from amino acids 26 to 339, is sufficient to specify the nuclear envelope localization. Biochemical analyses show that Sun2 is an 85-kDa protein that is partially insoluble in detergent with high salt concentration and in chaotropic agents. Furthermore, Sun2 is enriched in purified HeLa cell nuclei. Electron microscopy analysis shows that Sun2 localizes in the nuclear envelope with a sub-population present in small clusters. Additionally, we show that the SUN domain of Sun2 is localized to the periplasmic space between the inner and the outer nuclear membranes. From our data, we conclude that Sun2 is a new mammalian inner nuclear membrane protein. Because the SUN domain is conserved from fission yeast to mammals, we suggest that Sun2 belongs to a new class of nuclear envelope proteins with potential relevance to nuclear membrane function in the context of the involvement of its components in an increasing spectrum of human diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Free Univ Berlin, Inst Chem Biochem, D-141195 Berlin, Germany	Washington University (WUSTL); Johns Hopkins University; Free University of Berlin	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid, St Louis, MO 63110 USA.	pstahl@cellbiology.wustl.edu	Stahl, Philip/D-6315-2012	Bengtsson, Luiza/0000-0001-6048-3743	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI200015, AI35884] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellis JA, 1998, J CELL SCI, V111, P781; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1999, J CELL SCI, V112, P2485; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Haraguchi T, 2000, J CELL SCI, V113, P779; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/mbc.01-06-0294; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nili E, 2001, J CELL SCI, V114, P3297; Ostlund C, 2003, MUSCLE NERVE, V27, P393, DOI 10.1002/mus.10302; Raff JW, 1999, CURR BIOL, V9, pR708, DOI 10.1016/S0960-9822(99)80446-1; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Starr DA, 2001, DEVELOPMENT, V128, P5039; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sun GF, 2002, BBA-MOL BASIS DIS, V1588, P241, DOI 10.1016/S0925-4439(02)00171-0; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; Wilkinson FL, 2003, EUR J BIOCHEM, V270, P2459, DOI 10.1046/j.1432-1033.2003.03617.x; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Worman HJ, 2000, J MEMBRANE BIOL, V177, P1, DOI 10.1007/s002320001096; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859; Zhang QP, 2001, J CELL SCI, V114, P4485; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	51	159	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25805	25812		10.1074/jbc.M313157200	http://dx.doi.org/10.1074/jbc.M313157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082709	hybrid			2022-12-27	WOS:000221827900111
J	Mohler, PJ; Hoffman, JA; Davis, JQ; Abdi, KM; Kim, CR; Jones, SK; Davis, LH; Roberts, KF; Bennett, V				Mohler, PJ; Hoffman, JA; Davis, JQ; Abdi, KM; Kim, CR; Jones, SK; Davis, LH; Roberts, KF; Bennett, V			Isoform specificity among ankyrins - An amphipathic alpha-helix in the divergent regulatory domain of ankyrin-B interacts with the molecular co-chaperone Hdj1/Hsp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE; NEONATAL CARDIOMYOCYTES; SARCOPLASMIC-RETICULUM; INITIAL SEGMENTS; SKELETAL-MUSCLE; PROTEIN; SPECTRIN; MEMBRANE; BINDING	Ankyrins-R, -B, and -G are a family of membrane-associated adaptors required for localization of structurally diverse proteins to specialized membrane domains, including axon initial segments, cardiomyocyte T-tubules, and epithelial cell lateral membranes. Ankyrins are often co-expressed in the same cells and, although structurally similar, have non-overlapping functions. We previously determined that the regulatory domain of ankyrin-B defines specificity between ankyrins B and G in cardiomyocytes. Here, we identify key residues on the surface of an amphipathic alpha-helix unique to the regulatory domain of ankyrin-B that are essential for the function of ankyrin-B in cardiomyocytes. Using circular dichroism, we determined that a peptide representing the predicted helix folds as a helix in solution. Alanine-scanning mutagenesis revealed that residues 1773, 1777, 1780, 1784, and 1788 located in a patch on one surface the helix are critical for ankyrin-B function in cardiomyocytes. In a parallel set of experiments we determined that the molecular co-chaperone human DnaJ homologue 1 (Hdj1)/Hsp40 interacts with the ankyrin-B regulatory domain. Moreover, interaction of Hdj1/Hsp40 with the regulatory domain was mapped by random mutagenesis to same surface of the alpha-helix that is required for ankyrin-B function. These results provide new insight into the molecular basis for specificity between ankyrin-based pathways by defining a key alpha-helix structure in the divergent regulatory domain of ankyrin-B as well as interaction of the helix with Hdj1/Hsp40, the first downstream target for ankyrin-B-specific function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	pmohler@cellbio.duke.edu; v.bennett@cellbio.duke.edu						Abdul KM, 2002, CELL STRESS CHAPERON, V7, P156, DOI 10.1379/1466-1268(2002)007<0156:CAFAOA>2.0.CO;2; Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Farinha CM, 2002, BIOCHEM J, V366, P797, DOI 10.1042/BJ20011717; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kordeli E, 1998, J CELL SCI, V111, P2197; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAMBERT S, 1993, J NEUROSCI, V13, P3725; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25798	25804		10.1074/jbc.M401296200	http://dx.doi.org/10.1074/jbc.M401296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075330	hybrid			2022-12-27	WOS:000221827900110
J	Vulin, AI; Stanley, FM				Vulin, AI; Stanley, FM			Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; PROLACTIN GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; PROTEIN-KINASE; REACTIVE OXYGEN; C-JUN; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE	Oxidative stress is one of the characteristics of diabetes and is thought to be responsible for many of the pathophysiological changes caused by the disease. We previously identified an insulin response element in the promoter of plasminogen activator inhibitor 1 (PAI-1) that was activated by an unidentified member of the forkhead/winged helix (Fox) family of transcription factors. This element mediated a 5-7-fold increase in PAI-1 transcription because of insulin. Here we report that oxidative stress also caused a 3-fold increase in PAI-1 transcription and that the effect was additive with that of insulin. Antioxidants prevent this response. Mutational analysis of the PAI-1 promoter revealed that oxidative stress acted at an AP-1 site at -60/52 of the promoter. Gel mobility shift analysis demonstrated that binding to an AP-1 oligonucleotide was increased 4-fold by oxidative stress. Jun levels were increased by oxidants as assessed by reverse transcriptase-PCR. Western blotting demonstrated that a rapid and prolonged nuclear accumulation of phospho-c-Jun followed oxidant stimulation. The nuclear c-Jun phosphorylation was not observed in cells treated with reduced glutathione. Finally, JNK/SAPK activity was found to increase in response to oxidants, and inhibition of JNK/SAP blocked TBHQ-increased PAI-1-luciferase expression. Thus, oxidative stress stimulated AP-1 and activated the PAI-1 promoter.	NYU, Med Ctr, Sch Med, Dept Pharmacol,TH 450, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Stanley, FM (corresponding author), NYU, Med Ctr, Sch Med, Dept Pharmacol,TH 450, 550 1st Ave, New York, NY 10016 USA.	Stanlf01@med.nyu.edu		Stanley, Frederick/0000-0002-3684-2168				Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Ahn JD, 2001, DIABETOLOGIA, V44, P713, DOI 10.1007/s001250051680; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Bonfigli AR, 2001, DIABETES NUTR METAB, V14, P71; Brown NJ, 2000, J CLIN ENDOCR METAB, V85, P336, DOI 10.1210/jc.85.1.336; Carmassi F, 1999, AM J MED, V107, P344, DOI 10.1016/S0002-9343(99)00240-5; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; COCKELL KA, 1995, THROMB RES, V77, P119, DOI 10.1016/0049-3848(95)91618-U; Cummings BS, 2002, AM J PHYSIOL-RENAL, V283, pF492, DOI 10.1152/ajprenal.00022.2002; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dichtl W, 1999, ARTERIOSCL THROM VAS, V19, P3025, DOI 10.1161/01.ATV.19.12.3025; Dong WM, 1998, J INTERF CYTOK RES, V18, P629, DOI 10.1089/jir.1998.18.629; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Gallicchio M, 1996, J IMMUNOL, V157, P2610; GOMEZ DA, 1996, J BIOL CHEM, V271, P26335; Greene EL, 2000, HYPERTENSION, V35, P942, DOI 10.1161/01.HYP.35.4.942; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Madesh M, 1998, BBA-LIPID LIPID MET, V1389, P206, DOI 10.1016/S0005-2760(97)00155-0; Marutsuka K, 1998, CORONARY ARTERY DIS, V9, P177, DOI 10.1097/00019501-199809040-00002; McHowat J, 2001, Cardiovasc Toxicol, V1, P309, DOI 10.1385/CT:1:4:309; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Park SM, 1999, J IMMUNOL, V163, P631; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; Schacke W, 2002, INVEST OPHTH VIS SCI, V43, P2799; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; Siconolfi LB, 2001, J NEUROSCI, V21, P4336, DOI 10.1523/JNEUROSCI.21-12-04336.2001; Soriano FG, 2001, J MOL MED, V79, P437, DOI 10.1007/s001090100236; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Suzuki M, 2002, LIFE SCI, V72, P59, DOI 10.1016/S0024-3205(02)02182-3; Thavasu P, 1999, CANCER RES, V59, P3980; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Vulin AI, 2002, J BIOL CHEM, V277, P20169, DOI 10.1074/jbc.M112073200; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WOLFF SP, 1993, BRIT MED BULL, V49, P642, DOI 10.1093/oxfordjournals.bmb.a072637; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	63	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25172	25178		10.1074/jbc.M403184200	http://dx.doi.org/10.1074/jbc.M403184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069077	hybrid			2022-12-27	WOS:000221827900033
J	Wang, YL; Malabarba, MG; Nagy, ZS; Kirken, RA				Wang, YL; Malabarba, MG; Nagy, ZS; Kirken, RA			Interleukin 4 regulates phosphorylation of serine 756 in the transactivation domain of Stat6 - Roles for multiple phosphorylation sites and Stat6 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; SIGNAL-TRANSDUCTION; MAXIMAL ACTIVATION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; IL-4; KINASE	Lymphokines interleukin-4 (IL4) and IL13 exert overlapping biological activities via the shared use of the IL4 receptor alpha-chain and signal transducer and activator of transcription 6 (Stat6). Stat6 is critical for T-helper 2 cell differentiation, B-cell Ig class switch, and allergic diseases; thus, understanding its regulation is of central importance. Phosphorylation is crucial for Stat activity. Whereas Stat6 is phosphorylated on Tyr(641), less is known about serine or threonine. We demonstrate in primary human T-cells (>95% CD3+) that IL4 and for the first time IL13 induce Stat6 serine but not threonine phosphorylation that closely paralleled early IL4 receptor alpha-chain activation (10 min). Stat6 uniquely fails to share a positionally conserved Stat serine phosphorylation sequence; however, known phosphoacceptor sites are proline-flanked. Alanine substitutions of these conserved residues revealed that the transactivation domain, which localized Ser(756) but not Ser(827) or Ser(176), is the IL4-regulated site based on phosphoamino acid analysis. Tyr(641) was dispensable for IL4-mediated serine phosphorylation, suggesting that dimerization is not preconditional. Only Stat6 Y641F variant showed a significant effect on IL4-inducible Cepsilon DNA-binding and reporter gene expression. Lastly, recent work has shown that protein phosphatase 2A negatively regulates Stat6 (Woetmann, A., Brockdorff, J., Lovato, P., Nielsen, M., Leick, V., Rieneck, K., Svejgaard, A., Geisler, C., and Odum, N. (2003) J. Biol. Chem. 278, 2787-2791). We propose this target residue(s) is distinct from Ser(756) and may be proximal to Tyr(641) at Thr(645), a residue conserved only among Stat6 members. The phosphomimic variants T645E or T645D ablated Stat6 activation, whereas polar uncharged substitutions (Gln or Asn) and additional mutants (Ala, Val, or Phe) showed no effect. These findings suggest that Stat6 has mechanisms of regulation distinct from other Stats.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	University of Texas System; IRCCS European Institute of Oncology (IEO)	Kirken, RA (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Med Sci Bldg,Rm 4-218, Houston, TX 77030 USA.	robert.a.kirken@uth.tmc.edu	Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047	NIAID NIH HHS [AI053566] Funding Source: Medline; NIDDK NIH HHS [DK38016-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038016] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Behbod F, 2001, J IMMUNOL, V166, P3724, DOI 10.4049/jimmunol.166.6.3724; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carter LL, 1996, CURR OPIN IMMUNOL, V8, P336, DOI 10.1016/S0952-7915(96)80122-1; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEUTSCH HHJ, 1995, J IMMUNOL, V154, P3696; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Dimberg A, 2003, BLOOD, V102, P254, DOI 10.1182/blood-2002-10-3149; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Gamero AM, 2000, J BIOL CHEM, V275, P16574, DOI 10.1074/jbc.M910149199; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Hanson EM, 2003, J BIOL CHEM, V278, P3903, DOI 10.1074/jbc.M211747200; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kirken RA, 1999, J LEUKOCYTE BIOL, V65, P891, DOI 10.1002/jlb.65.6.891; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Lu BF, 1997, J IMMUNOL, V159, P1255; Malabarba MG, 1996, BIOCHEM J, V319, P865, DOI 10.1042/bj3190865; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Nelson G, 2003, J CELL SCI, V116, P2495, DOI 10.1242/jcs.00461; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Uddin S, 2000, J BIOL CHEM, V275, P27634; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	59	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25196	25203		10.1074/jbc.M313668200	http://dx.doi.org/10.1074/jbc.M313668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069079	hybrid			2022-12-27	WOS:000221827900036
J	Inari, A; Gallo, R; Palma, M; Alesse, E; Gulino, A				Inari, A; Gallo, R; Palma, M; Alesse, E; Gulino, A			Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; TRANSCRIPTION FACTOR E2F-1; APOPTOTIC TARGET GENES; KINASE C-ABL; HISTONE DEACETYLASE; REPRESS TRANSCRIPTION; ACETYLATION; DEGRADATION; PATHWAY; P53	E2F1, a member of the E2F family of transcription factors, plays a pivotal role in controlling both physiological cell-cycle progression and apoptotic cell death in response to DNA damage and oncogene activation. In response to genotoxic stresses, E2F1 is stabilized by signals that include ATM-dependent phosphorylation. We recently demonstrated that DNA damage induces also E2F1 acetylation, which is required for its recruitment onto apoptotic gene promoters. Here we show that E2F1 is stabilized in response to doxorubicin and cisplatin treatments even in the absence of either ATM-dependent phosphorylation or p53 and cAbl, two major transducers of DNA damage signaling. We found that acetylation of E2F1 is, instead, required to stabilize the protein in response to doxorubicin. Finally, we report that the formation of E2F1-p300/CREB-binding protein-associated factor (P/CAF) complexes is preferentially induced in doxorubicin-treated cells, and that P/CAF acetyltransferase (HAT), but not p300 HAT activity, is required for a significant E2F1 stabilization and accumulation. Our results unveil a differential role of P/CAF and p300 in acetylation-induced stabilization of E2F1, thus supporting a specific role for P/CAF HAT activity in E2F1-dependent apoptosis in response to DNA damage.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Sapienza University Rome; IRCCS Neuromed; University of L'Aquila	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Piazzale Aldo Moro 5, I-00161 Rome, Italy.	Alberto.gulino@uniroma1.it	Palma, Marzia/AGN-7362-2022					Agami R, 1999, NATURE, V399, P809; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gong JG, 1999, NATURE, V399, P806; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lin WC, 2001, GENE DEV, V15, P1833; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	38	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30830	30835		10.1074/jbc.M402403200	http://dx.doi.org/10.1074/jbc.M402403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123636	hybrid			2022-12-27	WOS:000222531900115
J	Ohshima, T; Koga, H; Shimotohno, K				Ohshima, T; Koga, H; Shimotohno, K			Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; COX-2 INHIBITION; E3 LIGASE; APOPTOSIS; NUCLEAR; CONJUGATION; GENE; PHOSPHORYLATION; PROTEINS; ADIPOGENESIS	Covalent modification of many transcription factors with SUMO-1 is emerging as a key role of trans-activational regulation. Here, we demonstrate that peroxisome proliferator-activated receptor (PPAR) gamma, which is a ligand-activated nuclear receptor, is modified by SUMO-1. Sumoylation of PPARgamma mainly occurs at a lysine residue within the activation function 1 domain. Furthermore, we show that the PIAS family proteins, PIAS1 and PIASxbeta, function as E3 ligases (ubiquitin-protein isopeptide ligase) for PPARgamma. PPARgamma interacts directly with PIASxbeta in a ligand-independent manner. Analysis using a PPARgamma mutant with a disrupted sumoylation site shows that modification of PPARgamma by SUMO-1 represses its transcriptional activity. Interestingly, PIASxbeta and Ubc9 enhance the transcriptional activity of PPARgamma independent of PPARgamma sumoylation. Furthermore, PPARgamma ligand-induced apoptosis in a human hepatoblastoma cell line, HepG2, is significantly enhanced by ectopic production of the sumoylation-mutant PPARgamma. These results suggest that the PPARgamma-dependent transactivation pathway seems to be modulated by SUMO-1 modification and may serve as a novel target for apoptosis-induction therapy in cancer cells.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ohshima, T (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	tohshima@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li MY, 2003, WORLD J GASTROENTERO, V9, P1220, DOI 10.3748/wjg.v9.i6.1220; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Michael MS, 2003, INT J MOL MED, V11, P733; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nagamine M, 2003, CANCER SCI, V94, P338, DOI 10.1111/j.1349-7006.2003.tb01443.x; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Ohshima T, 1999, BIOCHEM BIOPH RES CO, V264, P144, DOI 10.1006/bbrc.1999.1478; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pinsky BA, 2002, DEV CELL, V3, P4, DOI 10.1016/S1534-5807(02)00214-9; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	153	158	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29551	29557		10.1074/jbc.M403866200	http://dx.doi.org/10.1074/jbc.M403866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123625	hybrid			2022-12-27	WOS:000222445300089
J	Simmen, RCM; Eason, RR; McQuown, JR; Linz, AL; Kang, TJ; Chatman, L; Till, SR; Fujii-Kuriyama, Y; Simmen, FA; Oh, SP				Simmen, RCM; Eason, RR; McQuown, JR; Linz, AL; Kang, TJ; Chatman, L; Till, SR; Fujii-Kuriyama, Y; Simmen, FA; Oh, SP			Subfertility, uterine hypoplasia, and partial progesterone resistance in mice lacking the Kruppel-like factor 9/basic transcription element-binding protein-1 (Bteb1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR COACTIVATOR-1 SRC-1; ENDOMETRIAL EPITHELIAL-CELLS; LEUKOCYTE PROTEASE INHIBITOR; ARREST-SPECIFIC GENE-6; TYROSINE KINASES; MOUSE UTERUS; CANCER-CELLS; B ISOFORMS; CYCLIN D3; IN-VIVO	Progesterone receptor ( PR), a ligand-activated transcription factor, is a key regulator of cellular proliferation and differentiation in reproductive tissues. The transcriptional activity of PR is influenced by co-regulatory proteins typically expressed in a tissue- and cell-specific fashion. We previously demonstrated that basic transcription element-binding protein-1 (BTEB1), a member of the Sp/Kruppel-like family of transcription factors, functionally interacts with the two PR isoforms, PR-A and PR-B, to mediate progestin sensitivity of target genes in endometrial epithelial cells in vitro. Here we report that ablation of the Bteb1 gene in female mice results in uterine hypoplasia, reduced litter size, and increased incidence of neonatal deaths in offspring. The reduced litter size is solely a maternal genotype effect and results from fewer numbers of implantation sites, rather than defects in ovulation. In the early pregnant uterus, Bteb1 expression in stromal cells temporally coincides with PR-A isoform-dependent decidual formation at the time of implantation. Expression of two implantation-specific genes, Hoxa10 and cyclin D3, was decreased in uteri of early pregnant Bteb1-null mutants, whereas that of Bteb3, a related family member, was increased, the latter possibly compensating for the loss of Bteb1. Progesterone responsiveness of several uterine genes was altered with Bteb1-null mutation. These results identify Bteb1 as a functionally relevant PR-interacting protein and suggest its selective modulation of cellular processes that are regulated by PR-A in the uterine stroma.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Tsukuba, Tara Ctr, Tsukuba, Ibaraki 3058577, Japan; Univ Florida, Dept Anim Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Tsukuba; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Simmen, RCM (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA.	simmenrosalia@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754	NICHD NIH HHS [R01 HD021961, HD21961] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021961, R29HD021961] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897; Bagot CN, 2000, GENE THER, V7, P1378, DOI 10.1038/sj.gt.3301245; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; Daftary GS, 2004, MOL REPROD DEV, V67, P8, DOI 10.1002/mrd.20013; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DING YQ, 1994, ENDOCRINOLOGY, V135, P2265, DOI 10.1210/en.135.5.2265; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Hewitt SC, 2002, BIOL REPROD, V67, P1268, DOI [10.1095/biolreprod67.4.1268, 10.1095/biolreprod.102.002436]; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; King AE, 2003, BIOCHEM BIOPH RES CO, V310, P594, DOI 10.1016/j.bbrc.2003.08.151; King AE, 2003, J CLIN ENDOCR METAB, V88, P4426, DOI 10.1210/jc.2003-030239; Leonhardt SA, 1998, MOL ENDOCRINOL, V12, P1914, DOI 10.1210/me.12.12.1914; Leslie KK, 1997, ANN NY ACAD SCI, V828, P17, DOI 10.1111/j.1749-6632.1997.tb48520.x; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Liu SF, 1997, BRIT J PHARMACOL, V121, P1241; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Morita M, 2003, MOL CELL BIOL, V23, P2489, DOI 10.1128/MCB.23.7.2489-2500.2003; Mote PA, 2000, HUM REPROD, V15, P48, DOI 10.1093/humrep/15.suppl_3.48; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; MULHOLLAND J, 1994, REPROD BIOL, P33; Okulicz WC, 2003, BIOL REPROD, V69, P1593, DOI 10.1095/biolreprod.103.017525; Parandoosh Z, 1995, J REPROD FERTIL, V105, P215, DOI 10.1530/jrf.0.1050215; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Shiozawa T, 2003, J CLIN ENDOCR METAB, V88, P871, DOI 10.1210/jc.2002-020946; Simmen RCM, 2002, DNA CELL BIOL, V21, P115, DOI 10.1089/104454902753604998; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Sun WS, 2003, ANN ONCOL, V14, P898, DOI 10.1093/annonc/mdg257; Sun WS, 2002, MOL HUM REPROD, V8, P552, DOI 10.1093/molehr/8.6.552; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; Tan J, 2002, MECH DEVELOP, V111, P99, DOI 10.1016/S0925-4773(01)00614-1; Tang MY, 2002, MOL CELL ENDOCRINOL, V192, P45, DOI 10.1016/S0303-7207(02)00111-9; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Wong KHH, 2004, MOL ENDOCRINOL, V18, P184, DOI 10.1210/me.2003-0222; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; ZHANG D, 2002, ENDOCRINOLOGY, V140, P2517; Zhang DY, 2002, J BIOL CHEM, V277, P29999, DOI 10.1074/jbc.M203503200; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200; Zhang XL, 2001, MOL CELL ENDOCRINOL, V181, P81, DOI 10.1016/S0303-7207(01)00536-6	67	75	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29286	29294		10.1074/jbc.M403139200	http://dx.doi.org/10.1074/jbc.M403139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15117941	hybrid			2022-12-27	WOS:000222445300058
J	Basu, NK; Kubota, S; Meselhy, MR; Ciotti, M; Chowdhury, B; Hartori, M; Owens, IS				Basu, NK; Kubota, S; Meselhy, MR; Ciotti, M; Chowdhury, B; Hartori, M; Owens, IS			Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOESTROGEN GENISTEIN; BILIRUBIN; GLUCURONIDATION; EXPRESSION; CLONING; ALPHA; CELLS; CDNAS	Among gastrointestinal distributed isozymes encoded at the UGT1 locus, UDP-glucuronosyltransferase 1A10 (UGT1A10) metabolizes a number of important chemicals. Similar to broad conversion of phytoestrogens (Basu, N. K., Ciotti, M., Hwang, M. S., Kole, L., Mitra, P. S., Cho, J. W., and Owens, I. S. ( 2004) J. Biol. Chem. 279, 1429-1441), UGT1A10 metabolized estrogens and their derivatives, whereas UGT1A1, -1A3, -1A7, and -1A8 differentially exhibited reduced activity toward the same. UGT1A10 compared with UGT1A7, -1A8, and -1A3 generally exhibited high activity toward acidic nonsteroidal anti-inflammatory drugs and natural benzaldehyde derivatives, while UGT1A3 metabolized most efficiently aromatic transcinnamic acids known to be generated from flavonoid glycosides by microflora in the lower gastrointestinal tract. Finally UGT1A10, -1A7, -1A8, and -1A3 converted plant-based salicylic acids; methylsalicylic acid was transformed at high levels, and acetylsalicylic (aspirin) and salicylic acid were transformed at moderate to low levels. Atypically UGT1A10 transformed estrogens between pH 6 and 8 but acidic structures preferentially at pH 6.4. Furthermore evidence indicates UGT1A10 expressed in COS-1 cells depends upon phosphorylation; UGT1A10 versus its single, double, and triple mutants at three predicted protein kinase C phosphorylation sites incorporated [P-33]-orthophosphate and showed a progressive decrease with no detectable label or activity for the triple T73A/T202A/S432G-1A10 mutant. Single and double mutants revealed either null/full activity or null/additive activity, respectively. Additionally UGT1A10-expressing cultures glucuronidated 17beta-[C-14]estradiol, whereas cultures containing null mutants at protein kinase C sites showed no estrogen conversion. Importantly UGT1A10 in cells supported 10-fold higher glucuronidation of 17beta-estradiol than UGT1A1. In summary, our results suggest gastrointestinally distributed UGT1A10 is important for detoxifying estrogens/phytoestrogens and aromatic acids with complementary activity by UGT1A7, -1A8, -1A3, and/or -1A1 evidently dependent upon phosphorylation.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Toyama Med & Pharmaceut Univ, Res Inst Wakan Yaku, Toyama 93001, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toyama	Owens, IS (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S-241, Bethesda, MD 20892 USA.	owensi@mail.nih.gov		M.R., Meselhy/0000-0002-3488-7522	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008751] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008751] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADEBE W, 2002, J CLIN PHARM THER, V27, P391; Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Basu NK, 2004, J BIOL CHEM, V279, P1429, DOI 10.1074/jbc.M306439200; Basu NK, 2003, BIOCHEM BIOPH RES CO, V303, P98, DOI 10.1016/S0006-291X(03)00241-9; Bock KW, 2002, BIOCHEM PHARMACOL, V63, P1683, DOI 10.1016/S0006-2952(02)00921-8; BROWN JP, 1980, MUTAT RES, V75, P243, DOI 10.1016/0165-1110(80)90029-9; Cheng ZQ, 1998, TOXICOL SCI, V45, P52, DOI 10.1006/toxs.1998.2494; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453; Ciotti M, 1996, BIOCHEMISTRY-US, V35, P10119, DOI 10.1021/bi960584a; CIOTTI M, 1995, J BIOL CHEM, V270, P3284, DOI 10.1074/jbc.270.7.3284; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; Fitzpatrick LA, 1999, MAYO CLIN PROC, V74, P601, DOI 10.4065/74.6.601; Frigo DE, 2002, J NUTR, V132, P1848, DOI 10.1093/jn/132.7.1848; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Jinno H, 2003, DRUG METAB DISPOS, V31, P528, DOI 10.1124/dmd.31.5.528; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Liew R, 2003, FASEB J, V17, P1307, DOI 10.1096/fj.02-0760fje; Liew R, 2003, J PHARMACOL EXP THER, V304, P985, DOI 10.1124/jpet.102.042986; Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Seawright Alan A., 1995, Natural Toxins, V3, P227, DOI 10.1002/nt.2620030411; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Williams JA, 2002, DRUG METAB DISPOS, V30, P1266, DOI 10.1124/dmd.30.11.1266	30	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28320	28329		10.1074/jbc.M401396200	http://dx.doi.org/10.1074/jbc.M401396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117964	hybrid			2022-12-27	WOS:000222265400064
J	Babu, P; Deschenes, RJ; Robinson, LC				Babu, P; Deschenes, RJ; Robinson, LC			Akr1p-dependent palmitoylation of Yck2p yeast casein kinase 1 is necessary and sufficient for plasma membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; CONTAINING PROTEIN AKR1P; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; ANKYRIN REPEAT; BUDDING YEAST; GENE-PRODUCT; LOCALIZATION; MOTIF; COMPLEX	The Yck2 protein is a plasma membrane-associated casein kinase 1 isoform that attaches to membranes via palmitoylation of its C terminus. We have demonstrated that Yck2p traffics to the plasma membrane on secretory vesicles. Because Akr1p, the palmitoyl transferase for Yck2p, is located on Golgi membranes, it is likely that Yck2p first associates with Golgi membranes, and then is somehow recruited to budding plasma membrane-destined vesicles. We show here that residues 499 - 546 are sufficient for minimal Yck2p palmitoylation and plasma membrane localization. We previously described normal plasma membrane targeting of a Yck2p construct with the final five amino acids of Ras2p substituting for the final two Cys residues of Yck2p. This Yck2p variant no longer requires Akr1p for membrane association, but targets normally. We have generated the C-terminal deletions previously shown to affect Yck2p membrane association in this variant to determine which residues are important for targeting and/or modification. We find that all of the sequences previously identified as important for plasma membrane association are required only for Akr1p-dependent modification. Furthermore, palmitoylation is sufficient for specific association of Yck2p with secretory vesicles destined for the plasma membrane. Finally, both C-terminal Cys residues are palmitoylated, and dual acylation is required for efficient membrane association.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Genet Program, Iowa City, IA 52242 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Iowa; University of Iowa	Robinson, LC (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	lrobin@lsuhsc.edu	Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257; Robinson, Lucy/0000-0001-6454-040X				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Babu P, 2002, J CELL SCI, V115, P4957, DOI 10.1242/jcs.00203; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; Dong XW, 2003, MOL CELL BIOL, V23, P6574, DOI 10.1128/MCB.23.18.6574-6584.2003; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kao LR, 1996, MOL CELL BIOL, V16, P168; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loranger SS, 2002, J BIOL CHEM, V277, P34303, DOI 10.1074/jbc.M202125200; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moriya H, 2004, P NATL ACAD SCI USA, V101, P1572, DOI 10.1073/pnas.0305901101; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Sherman F., 1986, METHODS YEAST GENETI; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; Sun BM, 2004, MOL BIOL CELL, V15, P1397, DOI 10.1091/mbc.E03-09-0682; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; VANCURA A, 1994, J BIOL CHEM, V269, P19271; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	57	53	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27138	27147		10.1074/jbc.M403071200	http://dx.doi.org/10.1074/jbc.M403071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105419	hybrid			2022-12-27	WOS:000222120400040
J	Borysik, AJH; Radford, SE; Ashcroft, AE				Borysik, AJH; Radford, SE; Ashcroft, AE			Co-populated conformational ensembles of beta(2)-microglobulin uncovered quantitatively by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE-STATE DISTRIBUTIONS; HISTOCOMPATIBILITY ANTIGEN; AMYLOIDOGENIC PROTEIN; BETA-2-MICROGLOBULIN; HEMODIALYSIS; FORM; PATHOGENESIS; AGGREGATION; PRECURSOR; FIBRILS	Ordered assembly of monomeric human beta(2)-microglobulin (beta(2)m) into amyloid fibrils is associated with the disorder hemodialysis-related amyloidosis. Previously, we have shown that under acidic conditions ( pH < 5.0 at 37 degrees C), wild-type beta(2)m assembles spontaneously into fibrils with different morphologies. Under these conditions, beta(2)m populates a number of different conformational states in vitro. However, this equilibrium mixture of conformationally different species is difficult to resolve using ensemble techniques such as nuclear magnetic resonance or circular dichroism. Here we use electrospray ionization mass spectrometry to resolve different species of beta(2)m populated between pH 6.0 and 2.0. We show that by linear deconvolution of the charge state distributions, the extent to which each conformational ensemble is populated throughout the pH range can be determined and quantified. Thus, at pH 3.6, conditions under which short fibrils are produced, the conformational ensemble is dominated by a charge state distribution centered on the 9+ ions. By contrast, under more acidic conditions ( pH 2.6), where long straight fibrils are formed, the charge state distribution is dominated by the 10+ and 11+ ions. The data are reinforced by investigations on two variants of beta(2)m (V9A and F30A) that have reduced stability to pH denaturation and show changes in the pH dependence of the charge state distribution that correlate with the decrease in stability measured by tryptophan fluorescence. The data highlight the potential of electrospray ionization mass spectrometry to resolve and quantify complex mixtures of different conformational species, one or more of which may be important in the formation of amyloid.	Univ Leeds, Sch Biochem & Microbiol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Ashcroft, AE (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	a.e.ashcroft@leeds.ac.uk		Radford, Sheena/0000-0002-3079-8039	Biotechnology and Biological Sciences Research Council [SF16972] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Cech NB, 2001, MASS SPECTROM REV, V20, P362, DOI 10.1002/mas.10008; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Felitsyn N, 2002, J AM SOC MASS SPECTR, V13, P1432, DOI 10.1016/S1044-0305(02)00647-5; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FENN JB, 1993, J AM SOC MASS SPECTR, V4, P524, DOI 10.1016/1044-0305(93)85014-O; FLOEGE J, 1991, J LAB CLIN MED, V118, P153; GANEM B, 1991, J AM CHEM SOC, V113, P7818, DOI 10.1021/ja00020a085; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, NEW ENGL J MED, V314, P585; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Grandori R, 2002, J MASS SPECTROM, V37, P191, DOI 10.1002/jms.272; Grandori R, 2003, J MASS SPECTROM, V38, P11, DOI 10.1002/jms.390; Hill DM, 2003, J BIOL CHEM, V278, P5630, DOI 10.1074/jbc.M208381200; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Kaltashov IA, 2002, MASS SPECTROM REV, V21, P37, DOI 10.1002/mas.10017; KARLSSON FA, 1980, EUR J CLIN INVEST, V10, P293, DOI 10.1111/j.1365-2362.1980.tb00036.x; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Konermann L, 1998, RAPID COMMUN MASS SP, V12, P435, DOI 10.1002/(SICI)1097-0231(19980430)12:8<435::AID-RCM181>3.0.CO;2-F; Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAYER G, 1988, AM J NEPHROL, V8, P280, DOI 10.1159/000167601; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MIRZA UA, 1993, ANAL CHEM, V65, P1, DOI 10.1021/ac00049a003; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Ohashi K, 2001, PATHOL INT, V51, P1, DOI 10.1046/j.1440-1827.2001.01156.x; PITKANEN P, 1984, AM J PATHOL, V117, P391; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Samalikova M, 2003, J AM CHEM SOC, V125, P13352, DOI 10.1021/ja037000u; Samalikova M, 2003, J MASS SPECTROM, V38, P941, DOI 10.1002/jms.507; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Siuzdak G, 1996, CHEM BIOL, V3, P45, DOI 10.1016/S1074-5521(96)90083-6; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128	47	58	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27069	27077		10.1074/jbc.M401472200	http://dx.doi.org/10.1074/jbc.M401472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100226	Green Accepted, hybrid			2022-12-27	WOS:000222120400033
J	Creagh, EM; Murphy, BM; Duriez, PJ; Duckett, CS; Martin, SJ				Creagh, EM; Murphy, BM; Duriez, PJ; Duckett, CS; Martin, SJ			Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED INHIBITOR; PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; DEGRADATION; IAP; XIAP; ACTIVATION; REAPER; DIAP1; GRIM	Inhibitor of apoptosis proteins (IAPs) can block apoptosis through binding to active caspases and antagonizing their function. IAP function can be neutralized by Smac/Diablo, an IAP-binding protein that is released from mitochondria during apoptosis. In addition to their ability to interact with caspases, certain IAPs also display ubiquitin-protein isopeptide ligase activity because of the presence of a RING domain. However, it is not known whether the ubiquitin-protein isopeptide ligase activities of human IAPs contribute to their apoptosis inhibitory activity or whether this IAP property can be modulated through association with Smac/Diablo. Here we demonstrate that the ubiquitin ligase activities of XIAP, and to a lesser extent c-IAP-1 and c-IAP2, are potently repressed through binding to Smac/Diablo. We also show that mutation of the XIAP RING domain rendered this IAP a less effective inhibitor of apoptosis, suggesting that the ubiquitin ligase activity of XIAP contributes to its anti-apoptotic function. These data suggest that Smac/Diablo potentiates apoptosis by simultaneously antagonizing caspase-IAP interactions and repressing IAP ubiquitin ligase activities.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Trinity College Dublin; University of Michigan System; University of Michigan	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Murphy, Brona/D-4873-2012; Murphy, Brona/P-2544-2019; Creagh, Emma/AAX-1064-2021	Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Creagh, Emma/0000-0001-7631-4370; Martin, Seamus/0000-0002-8539-3143; Duckett, Colin/0000-0001-9413-2263				Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 2002, CELL, V9, P1031; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Shin H, 2003, BIOCHEM J, V373, P965, DOI 10.1042/BJ20030583; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	45	55	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26906	26914		10.1074/jbc.M313859200	http://dx.doi.org/10.1074/jbc.M313859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078891	hybrid, Green Published			2022-12-27	WOS:000222120400015
J	Hardy, MP; O'Neill, LAJ				Hardy, MP; O'Neill, LAJ			The murine Irak2 gene encodes four alternatively spliced isoforms, two of which are inhibitory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-ASSOCIATED KINASE; DNA-BINDING; INTERLEUKIN-1 RECEPTOR; EXPRESSION; ACTIVATION; FAMILY; MEMBER; MYD88; IDENTIFICATION	The interleukin-1 receptor-associated kinases (IRAKs) are important downstream signaling components of Toll-like receptors (TLRs). To date, four mammalian IRAKs have been found, namely IRAK-1, IRAK-2, IRAK-4, and IRAK-M. Herein, we show a detailed analysis of the genomic region encompassing the murine Irak2 gene and the molecular cloning of four isoforms of Irak2 ( designated Irak2a, Irak2b, Irak2c, and Irak2d) generated by alternative splicing at the 5'-end of the gene. This alternative splicing has direct effects on the expression of the N-terminal death domain and/or interdomain. No evidence of similar alternative splicing was found for the human IRAK2 gene. When overexpressed, Irak2a and Irak2b potentiated NF-kappaB activation by lipopolysaccharide. Importantly, Irak2c and Irak2d were inhibitory. The promoter for Irak2c differed from that of the other Irak2 isoforms in that it contained putative NF-kappaB binding sites. Lipopolysaccharide induced the expression of Irak2c, indicating a possible negative feedback effect on the signaling pathway. Alternative splicing of the Irak2 gene in mice will therefore generate agonistic or antagonistic Irak2 isoforms, which is likely to have consequences for the regulation of TLR signaling. These observations identify another distinguishing feature between mice and humans in the TLR system that is likely to be due to differences in the selective pressure imposed by pathogens on each species during evolution.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Coll Green, Dublin 2, Ireland.	laoneill@tcd.ie		O'Neill, Luke/0000-0002-4333-2748				Bray N, 2003, GENOME RES, V13, P97, DOI 10.1101/gr.789803; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; DUNNE A, 2003, SCI STKE; GRILLI M, 1993, INT REV CYTOL, V143, P1; Hardy MP, 2002, BIOCHEM J, V365, P355, DOI 10.1042/BJ20020105; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Janssens S, 2003, FEBS LETT, V548, P103, DOI 10.1016/S0014-5793(03)00747-6; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rosati O, 2002, BIOCHEM BIOPH RES CO, V297, P52, DOI 10.1016/S0006-291X(02)02130-7; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	27	85	96	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27699	27708		10.1074/jbc.M403068200	http://dx.doi.org/10.1074/jbc.M403068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082713	Green Published, hybrid			2022-12-27	WOS:000222120400104
J	Malinen, AM; Belogurov, GA; Salminen, M; Baykov, AA; Lahti, R				Malinen, AM; Belogurov, GA; Salminen, M; Baykov, AA; Lahti, R			Elucidating the role of conserved glutamates in H+-pyrophosphatase of Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; TRANSLOCATING PYROPHOSPHATASE; YEAST PYROPHOSPHATASE; DIRECTED MUTAGENESIS; INHIBITION; BINDING; CATALYSIS; SITE; RECONSTITUTION; APPARATUS	H+-pyrophosphatase (H+-PPase) catalyzes pyrophosphate-driven proton transport against the electrochemical potential gradient in various biological membranes. All 50 of the known H+-PPase amino acid sequences contain four invariant glutamate residues. In this study, we use site-directed mutagenesis in conjunction with functional studies to determine the roles of the glutamate residues Glu(197), Glu(202), Glu(550), and Glu(649) in the H+-PPase of Rhodospirillum rubrum (R-PPase). All residues were replaced with Asp and Ala. The resulting eight variant R-PPases were expressed in Escherichia coli and isolated as inner membrane vesicles. All substitutions, except E202A, generated enzymes capable of PPi hydrolysis and PPi-energized proton translocation, indicating that the negative charge of Glu(202) is essential for R-PPase function. The hydrolytic activities of all other PPase variants were impaired at low Mg2+ concentrations but were only slightly affected at high Mg2+ concentrations, signifying that catalysis proceeds through a three-metal pathway in contrast to wild-type R-PPase, which employs both two- and three-metal pathways. Substitution of Glu(197), Glu(202), and Glu(649) resulted in decreased binding affinity for the substrate analogues aminomethylenediphosphonate and methylenediphosphonate, indicating that these residues are involved in substrate binding as ligands for bridging metal ions. Following the substitutions of Glu(550) and Glu(649), R-PPase was more susceptible to inactivation by the sulfhydryl reagent mersalyl, highlighting a role of these residues in maintaining enzyme tertiary structure. None of the substitutions affected the coupling of PPi hydrolysis to proton transport.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Lomonosov Moscow State University; University of Turku	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.	baykov@genebee.msu.su; reijo.lahti@utu.fi	Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021	Malinen, Anssi/0000-0003-2987-2649; Belogurov, Georgiy/0000-0002-3070-6843; Baykov, Alexander/0000-0002-2495-8200				BALTSCHEFFSKY M, 1986, METHOD ENZYMOL, V126, P538; Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; BELOGUROV GA, 2002, J BIOL CHEM, V15, P15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Hyytia T, 2001, BIOCHEMISTRY-US, V40, P4645, DOI 10.1021/bi010049x; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Nakanishi Y, 2003, J BIOCHEM, V134, P615, DOI 10.1093/jb/mvg184; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; Pohjanjoki P, 2001, J BIOL CHEM, V276, P434, DOI 10.1074/jbc.M007360200; RAO PV, 1978, BIOCHEM BIOPH RES CO, V84, P465, DOI 10.1016/0006-291X(78)90192-4; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1986, PLANT PHYSIOL, V81, P126, DOI 10.1104/pp.81.1.126; SATO MH, 1994, J BIOL CHEM, V269, P6725; SATO MH, 1991, FEBS LETT, V290, P177, DOI 10.1016/0014-5793(91)81254-6; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; WU JJ, 1991, FEBS LETT, V283, P57, DOI 10.1016/0014-5793(91)80552-E; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26811	26816		10.1074/jbc.M404154200	http://dx.doi.org/10.1074/jbc.M404154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107429	hybrid			2022-12-27	WOS:000222120400003
J	Patenaude, A; Ven Murthy, MR; Mirault, ME				Patenaude, A; Ven Murthy, MR; Mirault, ME			Mitochondrial thioredoxin system - Effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCATOR; RAT-LIVER MITOCHONDRIA; DEPENDENT PEROXIDE REDUCTASE; 2 SEPARATE SITES; HYDROGEN-PEROXIDE; HYDROPEROXIDE METABOLISM; MAMMALIAN PEROXIREDOXIN; MEMBRANE-PERMEABILITY; PYRIDINE-NUCLEOTIDES	Thioredoxin-2 (Trx2) is a mitochondrial protein-disulfide oxidoreductase essential for control of cell survival during mammalian embryonic development. This suggests that mitochondrial thioredoxin reductase-2 (TrxR2), responsible for reducing oxidized Trx2, may also be a key player in the regulation of mitochondria-dependent apoptosis. With this in mind, we investigated the effects of overexpression of TrxR2, Trx2, or both on mammalian cell responses to various apoptotic inducers. Stable transfectants of mouse Neuro2A cells were generated that overexpressed TrxR2 or an EGFP-TrxR2 fusion protein. EGFP-TrxR2 was enzymatically active and was localized in mitochondria. TrxR2 protein level and TrxR activity could be increased up to 6-fold in mitochondria. TrxR2 and EGFP-TrxR2 transfectants showed reduced growth rates as compared with control cells. This growth alteration was not due to cytotoxic effects nor related to changes in basal mitochondrial transmembrane potential (DeltaPsi(m)), reactive oxygen species production, or to other mitochondrial antioxidant components such as Trx2, peroxyredoxin-3, MnSOD, GPx1, and glutathione whose levels were not affected by increased TrxR2 activity. In response to various apoptotic inducers, the extent of DeltaPsi(m) dissipation, reactive oxygen species induction, caspase activation, and loss of viability were remarkably similar in TrxR2 and control transfectants. Excess TrxR2 did not prevent trichostatin A-mediated neuronal differentiation of Neuro2A cells nor did it protect them against beta-amyloid neurotoxicity. Neither massive glutathione depletion nor co-transfection of Trx2 and TrxR2 in Neuro2A ( mouse), COS-7 ( monkey), or HeLa ( human) cells revealed any differential cellular resistance to prooxidant or non-oxidant apoptotic stimuli. Our results suggest that neither Trx2 nor TrxR2 gain of function modified the redox regulation of mitochondria-dependent apoptosis in these mammalian cells.	Univ Laval, Dept Med, Fac Med, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Med Biol, Fac Med, Quebec City, PQ G1V 4G2, Canada; CHUL CHUQ, Med Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Mirault, ME (corresponding author), Univ Laval, Dept Med, Entre Hosp, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	memirault@crchul.ulaval.ca			NINDS NIH HHS [R01NS37718] Funding Source: Medline; PHS HHS [NMRI98001] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037718] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; Bilodeau JF, 2002, FREE RADICAL BIO MED, V33, P1279, DOI 10.1016/S0891-5849(02)01013-4; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Boveris A, 1977, Adv Exp Med Biol, V78, P67; Bravard A, 1999, FREE RADICAL BIO MED, V26, P1027, DOI 10.1016/S0891-5849(98)00299-8; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; Calderon FH, 1999, J NEUROSCI RES, V56, P620; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Erlejman AG, 2002, NEUROCHEM RES, V27, P1499, DOI 10.1023/A:1021600522299; Franco AA, 1999, FREE RADICAL BIO MED, V27, P1122, DOI 10.1016/S0891-5849(99)00166-5; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Inokoshi J, 1999, BIOCHEM BIOPH RES CO, V256, P372, DOI 10.1006/bbrc.1999.0316; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Macho A, 1997, J IMMUNOL, V158, P4612; MANIATIS T, 1989, MOL CLONING LAB MANU, V3, P33; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; MOORE GA, 1986, XENOBIOTICA, V16, P873, DOI 10.3109/00498258609038969; MUSSER DA, 1994, PHOTOCHEM PHOTOBIOL, V59, P621; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nonn L, 2003, MOL CANCER RES, V1, P682; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Plaisant F, 2003, FREE RADICAL BIO MED, V34, P862, DOI 10.1016/S0891-5849(02)01440-5; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823; SAXENA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P79, DOI 10.1006/abbi.1995.1138; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; STOYANOVSKY D, 1993, FREE RADICAL RES COM, V19, P371, DOI 10.3109/10715769309056527; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANMAANEN JMS, 1988, FREE RADICAL RES COM, V4, P371, DOI 10.3109/10715768809066905; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wudarczyk J, 1996, ARCH BIOCHEM BIOPHYS, V327, P215, DOI 10.1006/abbi.1996.0112; YAMAMOTO T, 1989, GENE, V80, P337; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2002, METHOD ENZYMOL, V347, P236; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	84	92	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27302	27314		10.1074/jbc.M402496200	http://dx.doi.org/10.1074/jbc.M402496200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082714	hybrid			2022-12-27	WOS:000222120400060
J	Morgan, MR; Thomas, GJ; Russell, A; Hart, IR; Marshall, JF				Morgan, MR; Thomas, GJ; Russell, A; Hart, IR; Marshall, JF			The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE B SECRETION; ALPHA(V)BETA(3) INTEGRIN; ALPHA-V-BETA-6 INTEGRIN; TERMINAL DIFFERENTIATION; IN-VIVO; EXPRESSION; CARCINOMA; ANGIOGENESIS; ACTIVATION; RECEPTORS	Integrins promote cellular invasion through a combination of activities, including adhesion to an extracellular matrix ligand, which result in the generation of intracellular signals that lead to changes in cell behavior. Until now, there have been no data that identify a particular region of the cytoplasmic tail of integrin subunits as being responsible specifically for promoting the invasive activity of tumor cells. In this report, we show that amino acids with the sequence EKQKVDLSTDC, which are the C-terminal residues of the integrin beta6 subunit, promote alphavbeta6-dependent invasion in a matrix metalloproteinase (MMP)-9-dependent fashion. This same peptide sequence, when expressed at the cytoplasmic end of the beta3 integrin subunit, was able to enhance alphavbeta3-mediated invasive and enzymatic activity of tumor cells in an MMP-2-dependent fashion. Our results show that these 11 amino acids, when expressed at the C terminus of the beta subunit, are responsible for regulating the activity of invasion-promoting degradative enzymes, whereas the specific MMP involved in this cellular behavior is dependent on the context of the remainder of the beta integrin subunit.	John Vane Sci Ctr, Barts & London Sch Med & Dent, Canc Res UK Clin Ctr, Tumour Biol Lab, London EC1M 6BQ, England; UCL Eastman Dent Inst, London WC1X 8LD, England; Stanford Univ, Med Ctr, Dept Dermatol, Stanford, CA 94305 USA	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Stanford University	Marshall, JF (corresponding author), John Vane Sci Ctr, Barts & London Sch Med & Dent, Canc Res UK Clin Ctr, Tumour Biol Lab, Charterhouse Sq, London EC1M 6BQ, England.	john.marshall@cancer.org.uk		Russell, Alan/0000-0001-7545-5008; Morgan, Mark/0000-0001-7728-9883; Marshall, John/0000-0002-0494-2295				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Ahmed N, 2002, J HISTOCHEM CYTOCHEM, V50, P1371, DOI 10.1177/002215540205001010; Ahmed N, 2002, CARCINOGENESIS, V23, P237, DOI 10.1093/carcin/23.2.237; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; BREUSS JM, 1995, J CELL SCI, V108, P2241; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cass DL, 1998, J PEDIATR SURG, V33, P312, DOI 10.1016/S0022-3468(98)90453-5; Chatterjee N, 2001, J Environ Pathol Toxicol Oncol, V20, P211; Chattopadhyay N, 2001, J EXP CLIN CANC RES, V20, P269; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Di Nezza LA, 2002, CANCER, V94, P1466, DOI 10.1002/cncr.10355; Eliceiri BP, 2000, CANCER J, V6, pS245; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Furukawa A, 1998, UROLOGY, V51, P849, DOI 10.1016/S0090-4295(98)00010-7; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Jones J, 1996, ONCOGENE, V12, P119; Kerr JS, 2001, DRUG NEWS PERSPECT, V14, P143; Kumar CC, 2003, CURR DRUG TARGETS, V4, P123, DOI 10.2174/1389450033346830; LEONE D, 2003, P AM ASSOC CANC RES, V44, P4069; Li XW, 2001, J CELL SCI, V114, P2665; Liabakk NB, 1996, CANCER RES, V56, P190; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Niu J, 1998, BIOCHEM BIOPH RES CO, V249, P287, DOI 10.1006/bbrc.1998.9128; Park DW, 2001, GYNECOL ONCOL, V82, P442, DOI 10.1006/gyno.2001.6294; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Ria T, 2002, HAEMATOLOGICA, V87, P836; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; Varner Judith A., 1996, P69; Xue H, 2001, BIOCHEM BIOPH RES CO, V288, P610, DOI 10.1006/bbrc.2001.5813; Yang XQ, 2001, J SURG RES, V98, P33, DOI 10.1006/jsre.2001.6150; Zhang HY, 2002, INVEST OPHTH VIS SCI, V43, P955	54	43	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26533	26539		10.1074/jbc.M401736200	http://dx.doi.org/10.1074/jbc.M401736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067014	hybrid			2022-12-27	WOS:000222003000077
J	Nguyen, N; Zhang, XH; Olashaw, N; Seto, E				Nguyen, N; Zhang, XH; Olashaw, N; Seto, E			Molecular cloning and functional characterization of the transcription factor YY2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YIN-YANG 1; LIPOPROTEIN RECEPTOR GENE; ELEMENT-BINDING PROTEIN; ZINC-FINGER PROTEIN; C-FOS PROMOTER; ADENOVIRUS E1A; REGULATORY ELEMENTS; MAMMALIAN-CELLS; XENOPUS OOCYTES; LEUCINE ZIPPER	YY1 is a ubiquitous zinc finger transcription factor that binds to and regulates promoters and enhancers of many cellular and viral genes. Here we report the isolation of a human cDNA encoding a DNA sequence-specific binding protein with significant homology to the transcription factor YY1. A sequence analysis of this novel protein, YY2, revealed an overall 65% identity in the DNA sequence and a 56% identity in protein sequence compared with human YY1. The most pronounced similarity between YY1 and YY2 exists within the zinc finger regions of the two proteins, and consistent with this observation, YY2 can bind to and regulate some promoters known to be controlled by YY1. Similar to YY1, YY2 contains both transcriptional activation and repression functions. The finding of a protein with structure and function similar to YY1 provides a new opportunity to explore additional mechanisms by which YY1-responsive genes can be regulated and suggests that gene regulation by YY1 is far more complicated than previously assumed.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Seto, E (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	setoe@moffitt.usf.edu			NIGMS NIH HHS [GM64850] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064850] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Ficzycz A, 2001, J BIOL CHEM, V276, P22819, DOI 10.1074/jbc.M011188200; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hasegawa A, 2001, J IMMUNOL, V166, P1125, DOI 10.4049/jimmunol.166.2.1125; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; Last TJ, 1999, J CELL BIOCHEM, V72, P507, DOI 10.1002/(SICI)1097-4644(19990315)72:4<507::AID-JCB6>3.0.CO;2-5; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Moriuchi M, 1999, J IMMUNOL, V162, P5986; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Roy B, 1996, ONCOGENE, V13, P2359; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Sucharov CC, 2003, J BIOL CHEM, V278, P31233, DOI 10.1074/jbc.M301917200; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; *WA U GEN SEQ CTR, 1998, GENOME RES, V8, P1097; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1996, MOL CELL BIOL, V16, P4744; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	64	49	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25927	25934		10.1074/jbc.M402525200	http://dx.doi.org/10.1074/jbc.M402525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087442	hybrid			2022-12-27	WOS:000221827900125
J	Sanaa, N; Hmama, Z; Reiner, NE				Sanaa, N; Hmama, Z; Reiner, NE			Dual receptors and distinct pathways mediate interleukin-1 receptor-associated kinase degradation in response to lipopolysaccharide - Involvement of CD14/TLR4, CR3, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PERMEABILITY-INCREASING PROTEIN; ENDOTOXIN-TOLERANT CELLS; TOLL SIGNALING PATHWAY; LPS-BINDING-PROTEIN; HUMAN-MONOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; ENDOTHELIAL-CELLS; BORRELIA-BURGDORFERI; TYROSINE KINASE	Lipopolysaccharide (LPS) signaling leading to nuclear factor-kappaB activation in mononuclear phagocytes involves interleukin-1 receptor-associated kinase ( IRAK), which is rapidly activated after exposure to agonist. Although it is known that IRAK also undergoes rapid inactivation/degradation in response to LPS, providing negative feedback leading to LPS tolerance, mechanisms governing IRAK degradation are not fully understood. In the present study, examination of LPS signaling showed that IRAK degradation was bimodal and involved dual receptors and distinct pathways. Rapid degradation of IRAK, occurring within 30 min of exposure to agonist, was shown to signal through CD14/TLR4 and was regulated by phosphatidylinositol 3-kinase. A second delayed wave of IRAK degradation occurred 2 h after exposure to LPS and was mediated by CR3 independently of phosphatidylinositol 3-kinase. Thus, multiple independent mechanisms have evolved to regulate IRAK degradation, likely reflecting the importance of limiting cellular responses to LPS. Recognition of a CR3-dependent, CD14/TLR4-independent pathway leading to IRAK degradation has implications for understanding modulation of LPS responses by cells with important immunoregulatory function such as dendritic cells that are CD14(-).	Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 3J5, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Reiner, NE (corresponding author), Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	ethan@interchange.ubc.ca						Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; CAMUSSI G, 1995, J IMMUNOL, V155, P316; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; HAZIOT A, 1988, J IMMUNOL, V141, P547; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JIN HK, 1995, J CLIN INVEST, V95, P1947, DOI 10.1172/JCI117877; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; KOHN FR, 1993, J INFECT DIS, V168, P1307, DOI 10.1093/infdis/168.5.1307; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; LIU MK, 1994, J IMMUNOL, V153, P2642; Mayeux PR, 1997, J TOXICOL ENV HEALTH, V51, P415, DOI 10.1080/00984109708984034; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Means TK, 1999, J IMMUNOL, V163, P6748; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456; Salh B, 1998, J IMMUNOL, V161, P6947; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Sellati TJ, 1998, J IMMUNOL, V160, P5455; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; Shi C, 2001, CIRC RES, V89, P859, DOI 10.1161/hh2201.099166; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TODD RF, 1981, J IMMUNOL, V126, P1435; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wooten RM, 1998, J IMMUNOL, V160, P5485; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	60	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25189	25195		10.1074/jbc.M312431200	http://dx.doi.org/10.1074/jbc.M312431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069085	hybrid			2022-12-27	WOS:000221827900035
J	Shie, JL; Wu, GF; Wu, JP; Liu, FF; Laham, RJ; Oettgen, P; Li, J				Shie, JL; Wu, GF; Wu, JP; Liu, FF; Laham, RJ; Oettgen, P; Li, J			RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEAVY-CHAIN GENE; CAT BINDING-FACTOR; ENHANCER FACTOR-I; SMOOTH-MUSCLE-CELLS; TROPONIN-T-GENE; CARDIAC MYOCYTES; FACTOR-BETA; FACTOR EXPRESSION; SKELETAL-MUSCLE	Vascular endothelial growth factor (VEGF) is an angiogenic growth factor known to be up-regulated in ischemic heart and hypoxic endothelial cells. However, the transcriptional regulation of VEGF in hypoxia-induced angiogenesis is not fully understood. Transcriptional enhancer factor-1 (TEF-1) is a transcriptional factor family that can regulate many genes expressed in cardiac and skeletal muscle cells by binding to myocyte-specific chloramphenicol acetyltransferase heptamer elements in the promoters of these genes. In this study, we demonstrated that related TEF-1 (RTEF-1), a member of the TEF-1 family, is up-regulated in hypoxic endothelial cells. Overexpression of RTEF-1 increases VEGF promoter activity and VEGF expression. Sequential deletion and site-directed mutation analyses of the VEGF promoter demonstrated that a GC-rich region containing four Sp1 response elements, located between -114 and -50, was essential for RTEF-1 function. This region is beyond the hypoxia-inducible factor-1alpha binding site and does not consist of M-CAT-related elements. By electrophoretic mobility shift assay, RTEF-1 was found to interact with the first Sp1 residue (-97 to -87) of the four consecutive Sp1 elements. Binding activity of RTEF-1 to VEGF promoter is also confirmed by chromatin immunoprecipitation. In addition, induction of VEGF promoter activity by RTEF-1 results in an increase of angiogenic processes including endothelial cells proliferation and vascular structure formation. These results indicate that RTEF-1 acts as a transcriptional stimulator of VEGF by regulating VEGF promoter activity through binding to Sp1 site. In addition, RTEF-1-induced VEGF promoter activity was enhanced in a hypoxic condition, indicating that RTEF-1 may play an important role in the regulation of VEGF under hypoxia.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Li, J (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, 330 Brookline Ave, Boston, MA 02215 USA.	jli@caregroup.harvard.edu	Oettgen, Peter/AAF-5026-2021	Wu, Guifu/0000-0002-2823-6643	NHLBI NIH HHS [R01 HL082837, HL07374-22] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082837, T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Benckert C, 2003, CANCER RES, V63, P1083; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brenneisen P, 2003, BIOCHEM J, V369, P341, DOI 10.1042/BJ20021032; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Li J, 2002, J CELL SCI, V115, P1951; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Li J, 1997, J CLIN INVEST, V100, P18, DOI 10.1172/JCI119510; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Sen CK, 2002, AM J PHYSIOL-HEART C, V282, pH1821, DOI 10.1152/ajpheart.01015.2001; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001	59	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25010	25016		10.1074/jbc.M403103200	http://dx.doi.org/10.1074/jbc.M403103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073166	hybrid			2022-12-27	WOS:000221827900015
J	Evans, DR; Guy, HI				Evans, DR; Guy, HI			Mammalian pyrimidine biosynthesis: Fresh insights into an ancient pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CARBAMOYL-PHOSPHATE SYNTHETASE; MULTIFUNCTIONAL PROTEIN CAD; ASPARTATE-TRANSCARBAMYLASE DOMAIN; SITE-DIRECTED MUTAGENESIS; BREAST-CANCER CELLS; DE-NOVO SYNTHESIS; ESCHERICHIA-COLI; DIHYDROOROTASE DOMAIN; GENE-EXPRESSION; CTP SYNTHETASE		Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu			NIGMS NIH HHS [R01 GM060371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1995, NITROGEN METABOLISM, P33; Angeletti PC, 1998, J VIROL, V72, P2896, DOI 10.1128/JVI.72.4.2896-2904.1998; BOFILL M, 1995, J BIOL CHEM, V270, P29690, DOI 10.1074/jbc.270.50.29682; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; Carrey EA, 2002, REPRODUCTION, V123, P757, DOI 10.1530/rep.0.1230757; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CHAPARIAN MG, 1988, FASEB J, V2, P2982, DOI 10.1096/fasebj.2.14.2903106; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P3358; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; EVANS D, 2002, WILEY ENCY MOL MED, V5, P449; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; Fields C., 1999, PATHS PYRIMIDINES, V7, P49; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Huang M, 2003, CELL MOL LIFE SCI, V60, P321, DOI 10.1007/s000180300027; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLY RE, 1986, J BIOL CHEM, V261, P6073; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; KIM HS, 1992, J BIOL CHEM, V267, P7177; KUNJARA S, 1991, BIOCHEM MED METAB B, V46, P215, DOI 10.1016/0885-4505(91)90069-W; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MALEY JA, 1988, MOL GEN GENET, V213, P278, DOI 10.1007/BF00339592; Mascia L, 2001, Biochim Biophys Acta, V1524, P45; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MUSMANNO LA, 1991, GENE, V99, P211, DOI 10.1016/0378-1119(91)90129-Y; NAGY M, 1989, J BIOL CHEM, V264, P8366; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; POST LE, 1990, J BIOL CHEM, V265, P7742; Qiu Y, 2000, P NATL ACAD SCI USA, V97, P97, DOI 10.1073/pnas.97.1.97; RAO GN, 1988, FEBS LETT, V232, P238, DOI 10.1016/0014-5793(88)80424-1; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; Rawls J, 2000, EUR J BIOCHEM, V267, P2079, DOI 10.1046/j.1432-1327.2000.01213.x; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; Sanders S, 2002, AM J MED SCI, V323, P190, DOI 10.1097/00000441-200204000-00004; SCULLY JL, 1991, PROTEINS, V9, P191, DOI 10.1002/prot.340090305; Sigoillot FD, 2004, INT J CANCER, V109, P491, DOI 10.1002/ijc.11717; Sigoillot FD, 2003, J BIOL CHEM, V278, P3403, DOI 10.1074/jbc.M211078200; Sigoillot FD, 2002, J BIOL CHEM, V277, P15745, DOI 10.1074/jbc.M201112200; Sigoillot FD, 2002, J BIOL CHEM, V277, P24809, DOI 10.1074/jbc.M203512200; Simmons AJ, 1999, J MOL BIOL, V287, P277, DOI 10.1006/jmbi.1999.2618; SUTTLE DP, 1988, P NATL ACAD SCI USA, V85, P1754, DOI 10.1073/pnas.85.6.1754; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6068, DOI 10.1021/bi00567a019; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Kuilenburg ABP, 1998, ADV EXP MED BIOL, V431, P255; Weber G, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1164, DOI 10.1023/A:1012493232344; WILLIAMS NK, 1993, PROTEIN ENG, V6, P333, DOI 10.1093/protein/6.3.333; ZALKIN H, 1985, METHOD ENZYMOL, V113, P282; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016	63	280	294	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33035	33038		10.1074/jbc.R400007200	http://dx.doi.org/10.1074/jbc.R400007200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15096496	hybrid			2022-12-27	WOS:000223039700001
J	Jeang, KT; Giam, CZ; Majone, F; Aboud, M				Jeang, KT; Giam, CZ; Majone, F; Aboud, M			Life, death, and tax: Role of HTLV-I oncoprotein in genetic instability and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							VIRUS TYPE-I; NF-KAPPA-B; ONCOGENE PRODUCT TAX; DEPENDENT KINASE INHIBITORS; LONG TERMINAL REPEAT; CYCLIN D2 GENE; LEUKEMIA-VIRUS; TYPE-1 TAX; T-CELLS; RETINOBLASTOMA PROTEIN		NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol, Bethesda, MD 20814 USA; Univ Padua, Dept Biol, Padua, Italy; Ben Gurion Univ Negev, Dept Microbiol, IL-84105 Beer Sheva, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA; University of Padua; Ben Gurion University	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1996, ONCOGENE, V12, P1645; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carman JA, 2004, BIOCHEM BIOPH RES CO, V315, P445, DOI 10.1016/j.bbrc.2004.01.080; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Chowdhury IH, 2003, INT J CANCER, V107, P603, DOI 10.1002/ijc.11316; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Duensing S, 2003, CRIT REV EUKAR GENE, V13, P9, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.20; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLINT J, 1994, AM J HUM GENET, V55, P505; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; GRANA X, 1995, ONCOGENE, V11, P211; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kasai Takefumi, 2004, Retrovirology, V1, P7, DOI 10.1186/1742-4690-1-7; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; OKOCHI K, 1984, TAKAMATSU S, V15, P129; PERUCHO M, 1996, J BIOL CHEM, V377, P677; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rasnick D, 2002, CANCER GENET CYTOGEN, V136, P66, DOI 10.1016/S0165-4608(01)00665-3; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schavinsky-Khrapunsky Y, 2003, ONCOGENE, V22, P5315, DOI 10.1038/sj.onc.1206782; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Twizere JC, 2003, J NATL CANCER I, V95, P1846, DOI 10.1093/jnci/djg118; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	113	142	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					31991	31994		10.1074/jbc.R400009200	http://dx.doi.org/10.1074/jbc.R400009200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15090550	hybrid			2022-12-27	WOS:000222849700001
J	Popova, JS; Rasenick, MM				Popova, JS; Rasenick, MM			Clathrin-mediated endocytosis of m(3) muscarinic receptors - Roles for G beta gamma and tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-INDEPENDENT INTERNALIZATION; SH-SY5Y NEUROBLASTOMA-CELLS; ACETYLCHOLINE-RECEPTORS; HORMONE RECEPTOR; PLASMA-MEMBRANE; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC-RECEPTORS; COATED VESICLES; G-PROTEINS; DYNAMIN	Receptors as well as some G protein subunits internalize after agonist stimulation. It is not clear whether Galpha(q) or Gbetagamma undergo such regulated translocation. Recent studies demonstrate that m(3) muscarinic receptor activation in SK-N-SH neuroblastoma cells causes recruitment of tubulin to the plasma membrane. This subsequently transactivates Galpha(q) and activates phospholipase Cbeta(1). Interaction of tubulin-GDP with Gbetagamma at the offset of phospholipase Cbeta(1) signaling appears involved in translocation of tubulin and Gbetagamma to vesicle-like structures in the cytosol (Popova, J. S., and Rasenick, M. M. ( 2003) J. Biol. Chem. 278, 34299-34308). The relationship of this internalization to the clathrin-mediated endocytosis of the activated m(3) muscarinic receptors or Galpha(q) involvement in this process has not been clarified. To test this, SK-N-SH cells were treated with carbachol, and localization of Galpha(q), Gbetagamma, tubulin, clathrin, and m(3) receptors were analyzed by both cellular imaging and biochemical techniques. Upon agonist stimulation both tubulin and clathrin translocated to the plasma membrane and colocalized with receptors, Galpha(q) and Gbetagamma. Fifteen minutes later receptors, Gbetagamma and tubulin, but not Galpha(q), internalized with the clathrin-coated vesicles. Coimmunoprecipitation of m(3) receptors with Gbetagamma, tubulin, and clathrin from the cytosol of carbachol-treated cells was readily observed. These data suggested that Gbetagamma subunits might organize the formation of a multiprotein complex linking m3 receptors to tubulin since they interacted with both proteins. Such protein assemblies might explain the dynamin-dependent but beta-arrestin-independent endocytosis of m3 muscarinic receptors since tubulin interaction with dynamin might guide or insert the complex into clathrin-coated pits. This novel mechanism of internalization might prove important for other beta-arrestin-independent endocytic pathways. It also suggests cross-regulation between G protein-mediated signaling and the dynamics of the microtubule cytoskeleton.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Popova, JS (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.	jsp@uic.edu			NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beattie EC, 2000, J NEUROSCI, V20, P7325; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Edwardson JM, 1999, LIFE SCI, V64, P487, DOI 10.1016/S0024-3205(98)00592-X; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; MORO O, 1993, J BIOL CHEM, V268, P6862; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2003, J BIOL CHEM, V278, P34299, DOI 10.1074/jbc.M301748200; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SILVA WI, 1986, J BIOL CHEM, V261, P4788; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Sorensen SD, 1999, EUR J PHARMACOL, V372, P325, DOI 10.1016/S0014-2999(99)00234-4; Sorensen SD, 1999, J PHARMACOL EXP THER, V290, P603; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; WANG N, 1990, J BIOL CHEM, V265, P1239; Willets JM, 2002, J BIOL CHEM, V277, P15523, DOI 10.1074/jbc.M111217200; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026	56	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30410	30418		10.1074/jbc.M402871200	http://dx.doi.org/10.1074/jbc.M402871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15117940	hybrid			2022-12-27	WOS:000222531900067
J	Peschard, P; Ishiyama, N; Lin, T; Lipkowitz, S; Park, M				Peschard, P; Ishiyama, N; Lin, T; Lipkowitz, S; Park, M			A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBL; PROTEIN; PHOSPHORYLATION; ZAP-70; REGION; CELLS; AUTOINHIBITION; TRANSMEMBRANE; DEGRADATION; HOMOLOGY	The activation and phosphorylation of Met, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, initiates the recruitment of multiple signaling proteins, one of which is c-Cbl, a ubiquitin-protein ligase. c-Cbl promotes ubiquitination and enhances the down-modulation of the Met receptor and other RTKs, targeting them for lysosomal sorting and subsequent degradation. The ubiquitination of Met by c-Cbl requires the direct interaction of the c-Cbl tyrosine kinase binding (TKB) domain with tyrosine 1003 in the Met juxtamembrane domain. Although a consensus for c-Cbl TKB domain binding has been established ((D/N)XpYXX(D/E0Phi), this motif is not present in Met, suggesting that other c-Cbl TKB domain binding motifs may exist. By alanine-scanning mutagenesis, we have identified a DpYR motif including Tyr(1003) as being important for the direct recruitment of the c-Cbl TKB domain and for ubiquitination of the Met receptor. The substitution of Tyr(1003) with phenylalanine or substitution of either aspartate or arginine residues with alanine impairs c-Cbl-recruitment and ubiquitination of Met and results in the oncogenic activation of the Met receptor. We demonstrate that the TKB domain of Cbl-b, but not Cbl-3, binds to the Met receptor and requires an intact DpYR motif. Modeling studies suggest the presence of a salt bridge between the aspartate and arginine residues that would position pTyr(1003) for binding to the c-Cbl TKB domain. The DpYR motif is conserved in other members of the Met RTK family but is not present in previously identified c-Cbl-binding proteins, identifying DpYR as a new binding motif for c-Cbl and Cbl-b.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	43	91	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29565	29571		10.1074/jbc.M403954200	http://dx.doi.org/10.1074/jbc.M403954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123609	Green Submitted, hybrid			2022-12-27	WOS:000222445300091
J	Chen, XL; Lin, K; Ricciardi, RP				Chen, XL; Lin, K; Ricciardi, RP			Human Kaposi's sarcoma herpesvirus processivity factor-8 functions as a dimer in DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE PROCESSIVITY; CRYSTAL-STRUCTURE; BINDING PROTEIN; SEQUENCES; SUBUNIT; IDENTIFICATION; PHOSPHORYLATES; ASSOCIATION; COMPLEXES	In the absence of other proteins, the DNA polymerase (Pol-8) of Kaposi's sarcoma herpesvirus incorporates only several nucleotides from a primer template. However, association with the Kaposi's sarcoma herpesvirus processivity factor (PF-8) enables Pol-8 to incorporate thousands of nucleotides. Unlike the well described sliding clamp processivity factors, eukaryotic proliferating cell nuclear antigen and Escherichia coli beta-subunit, PF-8 and other herpesvirus processivity factors do not require a clamp loader or ATP to bind to template DNA. To begin to understand the mechanism used by PF-8 to achieve processivity, we have now purified PF-8 and demonstrated that it is a dimer both in solution and on the DNA. Mutational analysis of the PF-8 protein (396R) indicates that residues between 277 and 304 as well as the N-terminal 21 amino acids are required for dimerization. The results further correlate PF-8 dimerization with binding to Pol-8 and stabilizing Pol-8 on primer template. Notably, although removal of only 26 residues from the C terminus of PF-8 does not affect its ability to form dimers on DNA or to bind Pol-8, only short DNA chains (<100 nucleotides) are synthesized. This indicates that full-length PF-8 is necessary to enable Pol-8 to incorporate thousands of nucleotides. Interestingly, cross-linking of the processivity factor UL44 of cytomegalovirus reveals that it is a dimer in solution also.	Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ricciardi, RP (corresponding author), Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.	ricciardi@biochem.dental.upenn.edu			NCI NIH HHS [CA 80602] Funding Source: Medline; NIAID NIH HHS [P30 AI 45008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Advani SJ, 2001, J VIROL, V75, P10326, DOI 10.1128/JVI.75.21.10326-10333.2001; AGULNICK AD, 1993, J GEN VIROL, V74, P1003, DOI 10.1099/0022-1317-74-6-1003; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan SR, 2000, J VIROL, V74, P10920, DOI 10.1128/JVI.74.23.10920-10929.2000; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; CHOW CS, 1995, J VIROL, V69, P6965, DOI 10.1128/JVI.69.11.6965-6971.1995; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; ERTL PF, 1992, J VIROL, V66, P4126, DOI 10.1128/JVI.66.7.4126-4133.1992; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KIEHL A, 1991, VIROLOGY, V184, P330, DOI 10.1016/0042-6822(91)90849-7; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lin K, 1998, J VIROL, V72, P6228, DOI 10.1128/JVI.72.7.6228-6232.1998; Lin K, 1998, VIROLOGY, V250, P210, DOI 10.1006/viro.1998.9348; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Marschall M, 2003, VIROLOGY, V311, P60, DOI 10.1016/S0042-6822(03)00147-8; Matsumiya S, 2001, PROTEIN SCI, V10, P17, DOI 10.1110/ps.36401; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICCIARDI RP, 2004, IN PRESS METHODS MOL; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; WEILAND KL, 1994, VIRUS RES, V34, P191, DOI 10.1016/0168-1702(94)90124-4; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	36	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28375	28386		10.1074/jbc.M400032200	http://dx.doi.org/10.1074/jbc.M400032200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15075322	hybrid			2022-12-27	WOS:000222265400070
J	Francois, M; Richette, P; Tsagris, L; Raymondjean, M; Fulchignoni-Lataud, MC; Forest, C; Savouret, JF; Corvol, MT				Francois, M; Richette, P; Tsagris, L; Raymondjean, M; Fulchignoni-Lataud, MC; Forest, C; Savouret, JF; Corvol, MT			Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; COLLAGENASE GENE-EXPRESSION; TUMOR-NECROSIS-FACTOR; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); 2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OIC ACID; SYNOVIAL FIBROBLASTS; SIGNALING PATHWAY; INDUCED ARTHRITIS	Interleukin-1beta (IL-1beta) induces degradation via hyper-expression of an array of genes, including metalloproteinases (MMP), in cartilage cells during articular degenerative diseases. In contrast, natural ligands for peroxisome proliferator-activated receptors (PPARs) display protective anti-cytokine effects in these cells. We used the PPAR agonist rosiglitazone (Rtz) to investigate PPAR-gamma isotype on IL-1beta-target genes. Immunocytochemistry, electrophoretic mobility shift, and transient transfection assays revealed a functional PPAR-gamma in chondrocytes in vitro. Rtz displayed significant inhibition of IL-1beta effects in chondrocytes. Low Rtz concentrations (close to K-d values for PPAR-gamma, 0.1 to 1 muM) inhibited the effects of IL-1beta on S-35-sulfated proteoglycan production and gelatinolytic activities and downregulated MMP1 expression at mRNA and protein levels. We have investigated the mechanism of action of Rtz against IL-1beta-mediated MMP1 gene hyperexpression. Rtz effect occurs at the transcriptional level of the MMP1 promoter, as observed in transiently transfected cells with pMMP1-luciferase vector. Transient expression of wild type PPAR-gamma enhanced Rtz inhibitory effect in chondrocytes, whereas a mutated dominant negative PPAR-gamma abolished it, supporting the role of PPAR-gamma in this effect. MMP1 gene promoter analysis revealed the involvement of a cis-acting element located at -83 to -77, shown to be a composite PPRE/AP1 site. Gel mobility and supershift assays demonstrated that PPAR-gamma and c-Fos/c-Jun proteins bind this cis-acting element in a mutually exclusive way. Our data highlight a new PPAR-gamma-dependent inhibitory mechanism on IL-1beta-mediated cartilage degradation occurring through DNA binding competition on the composite PPRE/AP1 site in the MMP1 promoter.	Univ Paris 05, UFR Biomed, INSERM, UMRS 530, F-75006 Paris, France; CNRS, UMR 7079, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Corvol, MT (corresponding author), Univ Paris 05, UFR Biomed, INSERM, UMRS 530, 45 Rue St Peres, F-75006 Paris, France.	maite.corvol@univ-paris5.fr	francois, mathias/A-9604-2014	francois, mathias/0000-0002-9846-6882; Forest, Claude/0000-0003-3401-8148				Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244; CORVOL MT, 1975, BIOMED EXPRESS, V23, P103; CORVOL MT, 1987, ENDOCRINOLOGY, V120, P1422, DOI 10.1210/endo-120-4-1422; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Hamid QA, 2000, CYTOKINE, V12, P1609, DOI 10.1006/cyto.2000.0676; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Lapillonne H, 2003, CANCER RES, V63, P5926; LARSSON SE, 1974, CALC TISS RES, V14, P49, DOI 10.1007/BF02060282; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Mix KS, 2004, MOL PHARMACOL, V65, P309, DOI 10.1124/mol.65.2.309; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Pritts EA, 2003, FERTIL STERIL, V80, P415, DOI 10.1016/S0015-0282(03)00600-9; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sabatini M, 2002, OSTEOARTHR CARTILAGE, V10, P673, DOI 10.1053/joca.2002.0827; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yamasaki S, 2002, CLIN EXP IMMUNOL, V129, P379, DOI 10.1046/j.1365-2249.2002.01876.x; Yee J, 1997, KIDNEY INT, V52, P120, DOI 10.1038/ki.1997.311	48	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28411	28418		10.1074/jbc.M312708200	http://dx.doi.org/10.1074/jbc.M312708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090544	hybrid			2022-12-27	WOS:000222265400074
J	Conley, BA; Koleva, R; Smith, JD; Kacer, D; Zhang, DW; Bernabeu, C; Vary, CPH				Conley, BA; Koleva, R; Smith, JD; Kacer, D; Zhang, DW; Bernabeu, C; Vary, CPH			Endoglin controls cell migration and composition of focal adhesions - Function of the cytosolic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; HUMAN-ENDOTHELIAL-CELLS; BETA-BINDING-PROTEIN; RGD-CONTAINING GLYCOPROTEIN; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; RECEPTOR SYSTEM; EXPRESSION; ZYXIN; PHOSPHORYLATION	Mutations in the human endoglin gene result in hereditary hemorrhagic telangiectasia type 1, a vascular disorder characterized by multisystemic vascular dysplasia, arteriovenous malformations, and focal dilatation of postcapillary venules. Previous studies have implicated endoglin in the inhibition of cell migration in vivo and in vitro. In the course of studies to address the relationship of the conserved cytosolic domain to endoglin function, we identified zyxin, a LIM domain protein that is concentrated at focal adhesions, as an interactor with endoglin in human umbilical vein vascular endothelial cells. This interaction is localized within the 47-amino acid carboxyl-terminal cytosolic domain of endoglin, and maps within zyxin residues 326 - 572. The endoglin-zyxin interaction was found to be largely mediated by the third LIM domain of zyxin, and is specific for endoglin because the homologous cytosolic domain of the transforming growth factor-beta type III receptor, betaglycan, fails to interact with zyxin. Expression of endoglin is associated with reduction of zyxin, as well as its interacting proteins p130(cas) and CrkII, from a focal adhesion protein fraction, and this reduction is correlated with inhibition of cell migration. We also show that endoglin-dependent: (i) inhibition of cell migration, (ii) reduction of focal adhesion-associated p130(cas)/CrkII protein levels, (iii) tyrosine phosphorylation of p130(cas), and (iv) focal adhesion-associated endoglin levels are mediated by the cytosolic domain of endoglin. These results suggest a novel mechanism of endoglin function involving its interaction with LIM domain-containing proteins, and associated adapter proteins, affecting sites of focal adhesion.	Maine Med Ctr, Ctr Mol Med, Res Inst, Scarborough, ME 04074 USA; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Maine Medical Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Vary, CPH (corresponding author), Maine Med Ctr, Ctr Mol Med, Res Inst, Scarborough, ME 04074 USA.	varyc@mmc.org	Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162	PHS HHS [P20 15555] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; BRAVERMAN IM, 1990, J INVEST DERMATOL, V95, P422, DOI 10.1111/1523-1747.ep12555569; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chung YD, 2001, NEURON, V29, P415, DOI 10.1016/S0896-6273(01)00215-X; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Haitjema T, 1996, ARCH INTERN MED, V156, P714, DOI 10.1001/archinte.156.7.714; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hoffman LM, 2003, MOL CELL BIOL, V23, P70, DOI 10.1128/MCB.23.1.70-79.2003; Jacobson BS, 2000, AM J PATHOL, V156, P737, DOI 10.1016/S0002-9440(10)64939-5; Jazwinska A, 2003, NAT CELL BIOL, V5, P895, DOI 10.1038/ncb1049; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Leccia MT, 1999, J INVEST DERMATOL, V113, P651, DOI 10.1046/j.1523-1747.1999.00726.x; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pece N, 1997, J CLIN INVEST, V100, P2568, DOI 10.1172/JCI119800; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Prout M, 1997, GENETICS, V146, P275; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Smith JD, 1999, CIRC RES, V84, P1212, DOI 10.1161/01.RES.84.10.1212; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; TURNER CE, 1989, J BIOL CHEM, V264, P11938; WOOD CK, 1994, J CELL SCI, V107, P709; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200	48	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27440	27449		10.1074/jbc.M312561200	http://dx.doi.org/10.1074/jbc.M312561200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084601	Green Published, hybrid			2022-12-27	WOS:000222120400075
J	Gregan, B; Jurgensen, J; Papsdorf, G; Furkert, J; Schaefer, M; Beyermann, M; Rosenthal, W; Oksche, A				Gregan, B; Jurgensen, J; Papsdorf, G; Furkert, J; Schaefer, M; Beyermann, M; Rosenthal, W; Oksche, A			Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT PHARMACOLOGICAL-PROPERTIES; ASTROGLIAL GAP-JUNCTIONS; ETB-RECEPTOR; G-PROTEIN; TRAFFICKING; ACTIVATION; ROLES; IDENTIFICATION; SUBTYPE; CLONING	Endothelin-1 (ET-1) is a potent vasoactive peptide that acts on endothelin A (ETA) and endothelin B (ETB) receptors. Although both receptor subtypes are co-expressed in numerous cells, little is known about their ability to form heterodimers. Here we show that both receptors were co-immunoprecipitated with an ETB-specific antibody using extracts from HEK293 cells stably co-expressing a fusion protein consisting of a myc-tagged ETA receptor and CFP (ET(A)myc.CFP) and a fusion protein consisting of an ETB receptor and YFP (ETB . YFP). Co-immunoprecipitation was also observed with extracts from HEK293 cells transiently co-expressing FLAG-tagged ETB and myc-tagged ETA receptors, thereby excluding that heterodimerization is mediated by the CFP/YFP moieties. Heterodimerization was further confirmed in fluorescence resonance energy transfer ( FRET) analysis of HEK293 cells transiently co-expressing ET(A)myc.CFP and ETB.YFP receptors. FRET efficiencies were between 12 and 18% in untreated and antagonist- or ET-1-treated cells, indicating constitutive heterodimerization. Prolonged stimulation (30 min) with the ETB receptor-selective agonist BQ3020 decreased FRET efficiency by 50%. This decrease was not observed when internalization was inhibited by co-expression of dominant-negative K44A.dynamin I or incubation with 450 mM sucrose. Enzyme-linked immunosorbent assay and laser scanning microscopy of cell clones stably co-expressing ET(A)myc.CFP/ET(B)flag.YFP receptors revealed a slower sequestration of the ET(B)flag.YFP receptors upon stimulation with ET-1 than with BQ3020. No difference in ET-1 or BQ3020-mediated sequestration was observed with cell clones expressing ET(B)flag.YFP receptors alone. The data suggest that ETA and ETB receptors form constitutive heterodimers, which show a slower sequestration upon stimulation with ET-1 than with BQ3020. Heterodimer dissociation along the endocytic pathway only occurs upon ETB-selective stimulation.	Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Oksche, A (corresponding author), Charite Univ Med Berlin, Inst Pharmakol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	alexander.oksche@medizin.fu-berlin.de	Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770				Angelova K, 1997, ENDOCRINE, V7, P287, DOI 10.1007/BF02801321; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Blomstrand F, 1999, AM J PHYSIOL-CELL PH, V277, pC616, DOI 10.1152/ajpcell.1999.277.4.C616; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P2334; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; EGUCHI S, 1993, J CARDIOVASC PHARM, V22, pS161, DOI 10.1097/00005344-199322008-00043; Ehrenreich H, 1999, AM J PHYSIOL-CELL PH, V277, pC614, DOI 10.1152/ajpcell.1999.277.4.C614; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; Harada N, 2002, CELL MOL NEUROBIOL, V22, P207, DOI 10.1023/A:1019822107048; Hasselblatt M, 1998, BRAIN RES, V785, P253, DOI 10.1016/S0006-8993(97)01368-1; Iwasa S, 1999, ATHEROSCLEROSIS, V146, P93, DOI 10.1016/S0021-9150(99)00134-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG713, DOI 10.1152/ajpgi.1994.266.4.G713; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Oksche A, 2000, J CARDIOVASC PHARM, V36, pS44; Pagano A, 2001, J NEUROSCI, V21, P1189; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sasaki Y, 1998, EUR J NEUROSCI, V10, P2984, DOI 10.1111/j.1460-9568.1998.00305.x; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	40	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27679	27687		10.1074/jbc.M403601200	http://dx.doi.org/10.1074/jbc.M403601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075338	hybrid			2022-12-27	WOS:000222120400102
J	Jirakulaporn, T; Muslin, AJ				Jirakulaporn, T; Muslin, AJ			Cation diffusion facilitator proteins modulate Raf-1activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE-KINASE; RAF-1 KINASE; RAS; ACTIVATION; ZINC; PHOSPHORYLATION; 14-3-3-PROTEINS; BINDING; MEMBRANE	The Ras-extracellular signal-regulated kinase (ERK) cascade is a critical intracellular signaling pathway that regulates growth, survival, and differentiation. Previous work established that Ras-GTP binds to, and facilitates the activation of, the protein kinase Raf-1. Recently, it was demonstrated that the cation diffusion facilitator (CDF) proteins are involved in Ras-ERK signaling by use of a Caenorhabditis elegans genetic screen that identified suppressors of activated Ras. In the current work, we demonstrate that CDF proteins may function downstream of Ras, but upstream of Raf-1 in Xenopus oocytes. We also show that the C. elegans protein CDF-1 and its mammalian homologue ZnT-1 bind to the amino-terminal regulatory portion of Raf-1 and promote the biological and enzymatic activity of Raf-1. Furthermore, we show that Zn2+ inhibits Raf-1 binding to ZnT-1. We propose a model in which CDF protein binding facilitates Raf-1 activation.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	amuslin@imgate.wustl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054670] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM54670] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Bruinsma JJ, 2002, DEV CELL, V2, P567, DOI 10.1016/S1534-5807(02)00151-X; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NOMIZU T, 1993, MOL REPROD DEV, V36, P419, DOI 10.1002/mrd.1080360403; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Rommel C, 1996, ONCOGENE, V12, P609; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Wu CL, 2002, MECH DEVELOP, V119, P45, DOI 10.1016/S0925-4773(02)00287-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27807	27815		10.1074/jbc.M401210200	http://dx.doi.org/10.1074/jbc.M401210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096503	hybrid			2022-12-27	WOS:000222120400116
J	Kee, K; Vujcic, S; Merali, S; Diegelman, P; Kisiel, N; Powell, CT; Kramer, DL; Porter, CW				Kee, K; Vujcic, S; Merali, S; Diegelman, P; Kisiel, N; Powell, CT; Kramer, DL; Porter, CW			Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; S-ADENOSYLMETHIONINE DECARBOXYLASE; ELEMENT-BINDING PROTEINS; ANALOG-INDUCED INCREASES; HUMAN-MELANOMA CELLS; HAMSTER OVARY CELLS; GENE-EXPRESSION; ALPHA-DIFLUOROMETHYLORNITHINE; BIS(ETHYL)POLYAMINE ANALOGS; IRREVERSIBLE INHIBITION	Depletion of intracellular polyamine pools invariably inhibits cell growth. Although this is usually accomplished by inhibiting polyamine biosynthesis, we reasoned that this might be more effectively achieved by activation of polyamine catabolism at the level of spermidine/ spermine N6(1)-acetyltransferase (SSAT); a strategy first validated in MCF-7 breast carcinoma cells. We now examine the possibility that, due to unique aspects of polyamine homeostasis in the prostate gland, tumor cells derived from it may be particularly sensitive to activated polyamine catabolism. Thus, SSAT was conditionally overexpressed in LNCaP prostate carcinoma cells via a tetracycline-regulatable (Tet-off) system. Tetracycline removal resulted in a rapid similar to10-fold increase in SSAT mRNA and an increase of similar to20-fold in enzyme activity. SSAT products N-1-acetylspermidine, N-1-acetylspermine, and N-1, N-12-diacetylspermine accumulated intracellularly and extracellularly. SSAT induction also led to a growth inhibition that was not accompanied by polyamine pool depletion as it was in MCF-7 cells. Rather, intracellular spermidine and spermine pools were maintained at or above control levels by a robust compensatory increase in ornithine decarboxylase and S-adenosylmethionine decarboxylase activities. This, in turn, gave rise to a high rate of metabolic flux through both the biosynthetic and catabolic arms of polyamine metabolism. Treatment with the biosynthesis inhibitor alpha-difluoromethylornithine during tetracycline removal interrupted flux and prevented growth inhibition. Thus, flux-induced growth inhibition appears to derive from overaccumulation of metabolic products and/or from depletion of metabolic precursors. Metabolic effects that were not excluded as possible contributing factors include high levels of putrescine and acetylated polyamines, a 50% reduction in S-adenosylmethionine, and a 45% decline in the SSAT cofactor acetyl-CoA. Overall, the study demonstrates that activation of polyamine catabolism in LNCaP cells elicits a compensatory increase in polyamine biosynthesis and downstream metabolic events that culminate in growth inhibition.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Roswell Park Cancer Institute; New York University; Cleveland Clinic Foundation	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org	Deeb, Kristin K/H-5619-2016		NATIONAL CANCER INSTITUTE [R29CA072648, R01CA022153, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09072-30, CA-16056, CA-72648, CA-22153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Bettuzzi S, 2000, CANCER RES, V60, P1472; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1989, CANCER RES, V49, P3829; Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153; Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; Devens BH, 2000, PROSTATE CANCER P D, V3, P275, DOI 10.1038/sj.pcan.4500420; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gschwend JE, 1997, PROSTATE, V33, P166; Gupta S, 2000, CANCER RES, V60, P5125; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Harrison GA, 1931, BIOCHEM J, V25, P1885, DOI 10.1042/bj0251885; HECTOR S, 2004, IN PRESS MOL CANC TH; HESTON WDW, 1987, BIOCHEM PHARMACOL, V36, P1849, DOI 10.1016/0006-2952(87)90250-4; HESTON WDW, 1991, CANCER SURV, V11, P217; KEE K, 2003, P AM ASSOC CANC RES, V44, P1277; KRAMER D, 1995, BIOCHEM PHARMACOL, V50, P1433, DOI 10.1016/0006-2952(95)02037-3; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KRAMER DL, 1996, CRITICAL ROLES POLYA, P151; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; Liu GS, 2003, ANAL CHEM, V75, P78, DOI 10.1021/ac0261505; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MANN T, 1964, BIOCH SEMEN MALE REP, P193; Maxwell PJ, 2003, CANCER RES, V63, P4602; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Mi Z, 1998, PROSTATE, V34, P51, DOI 10.1002/(SICI)1097-0045(19980101)34:1<51::AID-PROS7>3.0.CO;2-N; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PEGG AE, 1968, BIOCHEM J, V108, P533, DOI 10.1042/bj1080533; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1984, BIOCHEM J, V224, P29, DOI 10.1042/bj2240029; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Porter C. W., 1992, V62, P301; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1987, CANCER, V60, P1275, DOI 10.1002/1097-0142(19870915)60:6<1275::AID-CNCR2820600619>3.0.CO;2-I; REGENASS U, 1994, CANCER RES, V54, P3210; Rhodes DR, 2002, CANCER RES, V62, P4427; SEILER N, 1981, MED BIOL, V59, P334; SEILER N, 1980, BIOCHIM BIOPHYS ACTA, V633, P181, DOI 10.1016/0304-4165(80)90404-3; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1997, CANCER RES, V57, P1086; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P; YAMANAKA H, 1987, CANCER RES, V47, P1771; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	61	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27050	27058		10.1074/jbc.M403323200	http://dx.doi.org/10.1074/jbc.M403323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096507	hybrid			2022-12-27	WOS:000222120400031
J	Pacheco, TR; Gomes, AQ; Barbosa-Morais, NL; Benes, V; Ansorge, W; Wollerton, M; Smith, CW; Valcarcel, J; Carmo-Fonseca, M				Pacheco, TR; Gomes, AQ; Barbosa-Morais, NL; Benes, V; Ansorge, W; Wollerton, M; Smith, CW; Valcarcel, J; Carmo-Fonseca, M			Diversity of vertebrate splicing factor U2AF(35) - Identification of alternatively spliced U2AF1 mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLICATE MITF GENES; GENOME DUPLICATION; SMALL-SUBUNIT; PROTEIN; EXPRESSION; SITE; RECOGNITION; U2AF(65); CLONING; SUBFUNCTIONALIZATION	U2 small nuclear ribonucleoprotein auxiliary factor small subunit (U2AF(35)) is encoded by a conserved gene designated U2AF1. Here we provide evidence for the existence of alternative vertebrate transcripts encoding different U2AF35 isoforms. Three mRNA isoforms ( termed U2AF(35)a-c) were produced by alternative splicing of the human U2AF1 gene. U2AF(35)c contains a premature stop codon that targets the resulting mRNA to nonsense-mediated mRNA decay. U2AF(35)b differs from the previously described U2AF(35)a isoform in 7 amino acids located at the atypical RNA Recognition Motif involved in dimerization with U2AF(65). Biochemical experiments indicate that isoform U2AF(35)b, which has been highly conserved from fish to man, maintains the ability to interact with U2AF(65), stimulates U2AF(65) binding to a pre-mRNA, and promotes U2AF splicing activity in vitro. Real time, quantitative PCR analysis indicates that U2AF(35)a is the most abundant isoform expressed in murine tissues, although the ratio between U2AF(35)a and U2AF(35)b varies from 10-fold in the brain to 20-fold in skeletal muscle. We propose that post-transcriptional regulation of U2AF1 gene expression may provide a mechanism by which the relative cellular concentration and availability of U2AF(35) protein isoforms are modulated, thus contributing to the finely tuned control of splicing events in different tissues.	Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal; EMBL, D-69112 Heidelberg, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Universidade de Lisboa; European Molecular Biology Laboratory (EMBL); University of Cambridge	Carmo-Fonseca, M (corresponding author), Univ Lisbon, Fac Med, Inst Mol Med, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	carmo.fonseca@fm.ul.pt	Ansorge, Wilhelm/AAN-8780-2020; Valcarcel, Juan/O-9814-2014; Gomes, Anita Q./C-3580-2014; Barbosa-Morais, Nuno L/I-2743-2013	Valcarcel, Juan/0000-0001-5398-3571; Gomes, Anita Q./0000-0002-3348-0448; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Benes, Vladimir/0000-0002-0352-2547; Carmo-Fonseca, Maria/0000-0002-3402-7143; Pacheco, Teresa/0000-0002-5506-0233	Fundação para a Ciência e a Tecnologia [POCTI/MGI/36547/2000, SFRH/BD/84517/2012] Funding Source: FCT	Fundação para a Ciência e a Tecnologia		Altschmied J, 2002, GENETICS, V161, P259; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Birney E, 1996, NUCLEIC ACIDS RES, V24, P2730, DOI 10.1093/nar/24.14.2730; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Burge CB, 1999, RNA WORLD, P525; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Erfle H, 1997, NUCLEIC ACIDS RES, V25, P2229, DOI 10.1093/nar/25.11.2229; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Force A, 1999, GENETICS, V151, P1531; Gama-Carvalho M, 2001, J BIOL CHEM, V276, P13104, DOI 10.1074/jbc.M008759200; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guth S, 1999, MOL CELL BIOL, V19, P8263; Guth S, 2001, MOL CELL BIOL, V21, P7673, DOI 10.1128/MCB.21.22.7673-7681.2001; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kaiser K, 1995, DNA CLONING, V1, P37; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; LEGUINER C, 2001, J BIOL CHEM, V76, P40638; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Lister JA, 2001, DEV BIOL, V237, P333, DOI 10.1006/dbio.2001.0379; Lynch M, 2000, GENETICS, V154, P459; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schell T, 2002, GENOME BIOL, V3; Schmittgen TD, 2003, INT J CANCER, V107, P323, DOI 10.1002/ijc.11402; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stoilov P, 2004, HUM MOL GENET, V13, P509, DOI 10.1093/hmg/ddh051; SUREAU A, 1994, P NATL ACAD SCI USA, V91, P932, DOI 10.1073/pnas.91.3.932; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; Tassone F, 1999, GENE, V226, P211, DOI 10.1016/S0378-1119(98)00559-9; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALCARCEL J, 1997, MRNA FORMATION FUNCT, P31; Van de Peer Y, 2001, J MOL EVOL, V53, P436, DOI 10.1007/s002390010233; VOSS H, 1993, BIOTECHNIQUES, V15, P714; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Wittbrodt J, 1998, BIOESSAYS, V20, P511, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;511::AID-BIES10&gt;3.0.CO;2-3; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Yu WP, 2003, TRENDS GENET, V19, P180, DOI 10.1016/S0168-9525(03)00048-9; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	74	41	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27039	27049		10.1074/jbc.M402136200	http://dx.doi.org/10.1074/jbc.M402136200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096518	Green Published, hybrid			2022-12-27	WOS:000222120400030
J	Qu, QM; Sawa, H; Suzuki, T; Semba, S; Henmi, C; Okada, Y; Tsuda, M; Tanaka, S; Atwood, WJ; Nagashima, K				Qu, QM; Sawa, H; Suzuki, T; Semba, S; Henmi, C; Okada, Y; Tsuda, M; Tanaka, S; Atwood, WJ; Nagashima, K			Nuclear entry mechanism of the human polyomavirus JC virus-like particle - Role of importins and the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CAPSID PROTEIN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LOCALIZATION SEQUENCE; TARGETING COMPLEX; SIMIAN VIRUS-40; GLIAL-CELLS; SIMIAN-VIRUS-40; EXPRESSION; VP1; IDENTIFICATION	JC virus (JCV) belongs to the polyomavirus family of double-stranded DNA viruses and causes progressive multifocal leukoencephalopathy in humans. Although transport of virions to the nucleus is an important step in JCV infection, the mechanism of this process has remained unclear. The outer shell of the JCV virion comprises the major capsid protein VP1, which possesses a putative nuclear localization signal (NLS), and virus-like particles (VLPs) consisting of recombinant VP1 exhibit a virion-like structure and physiological functions ( cellular attachment and intracytoplasmic trafficking) similar to those of JCV virions. We have now investigated the mechanism of nuclear transport of JCV with the use of VLPs. Wild-type VLPs (wtVLPs) entered the nucleus of most HeLa or SVG cells. The virion structure of VLPs was preserved during transport to the nucleus as revealed by confocal microscopy of cells inoculated with fluorescein isothiocyanate-labeled wtVLPs containing packaged Cy3. The nuclear transport of wtVLPs in digitonin-permeabilized cells was dependent on the addition of importins alpha and beta and was prevented by wheat germ agglutinin or by antibodies to the nuclear pore complex. The nuclear entry of VLPs composed of VP1 with a mutated NLS was greatly inhibited, compared with that of wtVLPs, in both intact and permeabilized cells. Unlike wtVLPs, the mutant VLPs did not bind to importins alpha or beta. Limited proteolysis analysis revealed that the NLS of VP1 was exposed on the surface of wtVLPs. These results suggest that JCV VLPs bind to cellular importins via the NLS of VP1 and are transported into the nucleus through the nuclear pore complex.	Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, 21st Century COE Program Zoonosis Control, Sapporo, Hokkaido 0608638, Japan; JST, CREST, Sapporo, Hokkaido 0608638, Japan; Brown Univ, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST); Brown University	Sawa, H (corresponding author), Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	h-sawa@patho2.med.hokudai.ac.jp	Sawa, Hirofumi/AAW-8816-2021; Sawa, Hirofumi/F-6954-2012; Suzuki, Tadaki/ABH-2661-2020; Tanaka, Shinya/D-3586-2011	Sawa, Hirofumi/0000-0003-2569-2755; Obara, Chizuka/0000-0002-7605-1029				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ashok A, 2003, J VIROL, V77, P1347, DOI 10.1128/JVI.77.2.1347-1356.2003; Chang DC, 1997, J GEN VIROL, V78, P1435, DOI 10.1099/0022-1317-78-6-1435; CHANG DC, 1992, VIROLOGY, V191, P978, DOI 10.1016/0042-6822(92)90276-U; CHANG DC, 1992, VIROLOGY, V189, P821, DOI 10.1016/0042-6822(92)90615-V; Chen PL, 2001, FEBS LETT, V500, P109, DOI 10.1016/S0014-5793(01)02598-4; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; Dworkin MS, 2002, CURR CLIN TOPICS INF, V22, P181; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Goldmann C, 1999, J VIROL, V73, P4465, DOI 10.1128/JVI.73.5.4465-4469.1999; Goldmann C, 2000, J VIROL METHODS, V90, P85, DOI 10.1016/S0166-0934(00)00226-3; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; ISHII N, 1994, J VIROL, V68, P8209, DOI 10.1128/JVI.68.12.8209-8216.1994; Ishii N, 1996, J VIROL, V70, P1317, DOI 10.1128/JVI.70.2.1317-1322.1996; Komagome R, 2002, J VIROL, V76, P12992, DOI 10.1128/JVI.76.24.12992-13000.2002; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Liu CK, 1998, J VIROL, V72, P4643, DOI 10.1128/JVI.72.6.4643-4649.1998; Nakanishi A, 2002, J VIROL, V76, P9368, DOI 10.1128/JVI.76.18.9368-9377.2002; Okada Y, 2002, ACTA NEUROPATHOL, V104, P130, DOI 10.1007/s00401-002-0526-8; Okada Y, 2001, J NEUROVIROL, V7, P302; Okada Y, 2000, J BIOL CHEM, V275, P17016, DOI 10.1074/jbc.275.22.17016; PADGETT BL, 1971, LANCET, V1, P1257; Shishido-Hara Y, 2000, J VIROL, V74, P1840, DOI 10.1128/JVI.74.4.1840-1853.2000; Suzuki S, 2001, VIROLOGY, V286, P100, DOI 10.1006/viro.2001.0972; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5	31	46	53	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27735	27742		10.1074/jbc.M310827200	http://dx.doi.org/10.1074/jbc.M310827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15069063	hybrid			2022-12-27	WOS:000222120400108
J	Alonso, MBD; Zoidl, G; Taveggia, C; Bosse, F; Zoidl, C; Rahman, M; Parmantier, E; Dean, CH; Harris, BS; Wrabetz, L; Muller, HW; Jessen, KR; Mirsky, R				Alonso, MBD; Zoidl, G; Taveggia, C; Bosse, F; Zoidl, C; Rahman, M; Parmantier, E; Dean, CH; Harris, BS; Wrabetz, L; Muller, HW; Jessen, KR; Mirsky, R			Identification and characterization of ZFP-57, a novel zinc finger transcription factor in the mammalian peripheral nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DEVELOPMENT; GROWTH-FACTOR; FACTOR SOX10; REPRESSION DOMAIN; NUCLEAR RECEPTORS; GENE-EXPRESSION; PROTEINS; KRUPPEL; DIFFERENTIATION; MYELINATION	To isolate new zinc finger genes expressed at early stages of peripheral nerve development, we have used PCR to amplify conserved zinc finger sequences. RNA from rat embryonic day 12 and 13 sciatic nerves, a stage when nerves contain Schwann cell precursors, was used to identify several genes not previously described in Schwann cells. One of them, zinc finger protein (ZFP)-57, proved to be the homologue of a mouse gene found in F9 teratocarcinoma cells. Its mRNA expression profile within embryonic and adult normal and transected peripheral nerves, and its distribution in the rest of the nervous system is described. High levels of expression are seen in embryonic nerves and spinal cord. These drop rapidly during the first few weeks after birth, a pattern mirrored in other parts of the nervous system. ZFP-57 localizes to the nucleus of Schwann and other cells. The sequence contains an N-terminal Kruppel-associated box ( KRAB) domain and ZFP-57 constructs containing green fluorescent protein reveal that the protein colocalizes with heterochromatin protein 1alpha to centromeric heterochromatin in a characteristic speckled pattern in NIH3T3 cells. The KRAB domain is required for this localization, because constructs lacking it target the protein to the nucleus but not to the centromeric heterochromatin. When fused to a heterologous DNA binding domain, the KRAB domain of ZFP-57 represses transcription, and full-length ZFP-57 represses Schwann cell transcription from myelin basic protein and P-0 promoters in co-transfection assays. Zfp-57 mRNA is up-regulated in Schwann cells in response to leukemia inhibitory factor and fibroblast growth factor 2.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44780 Bochum, Germany; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Dusseldorf, Dept Neurol, Mol Neurobiol Lab, D-40225 Dusseldorf, Germany; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	University of London; University College London; Ruhr University Bochum; Vita-Salute San Raffaele University; Heinrich Heine University Dusseldorf; Medical University of South Carolina	Mirsky, R (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	r.mirsky@ucl.ac.uk	Taveggia, Carla/AAN-4784-2020; Alonso, M. Beatriz Durán/L-5858-2017	Alonso, M. Beatriz Durán/0000-0001-7784-0591; Bosse, Frank/0000-0002-8825-2071				Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; BROCKES JP, 1980, J BIOL CHEM, V255, P8374; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CONSTANTINOUDELTAS CD, 1992, GENOMICS, V12, P581, DOI 10.1016/0888-7543(92)90451-W; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dong ZP, 1999, J NEUROSCI RES, V56, P334, DOI 10.1002/(SICI)1097-4547(19990515)56:4<334::AID-JNR2>3.0.CO;2-#; Dovat S, 1998, BBA-GENE STRUCT EXPR, V1442, P380, DOI 10.1016/S0167-4781(98)00167-5; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERDEGEN T, 1993, NEUROSCIENCE, V57, P41, DOI 10.1016/0306-4522(93)90110-2; Jaegle M, 2003, GENE DEV, V17, P1380, DOI 10.1101/gad.258203; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Jessen KR, 1999, TRENDS NEUROSCI, V22, P402, DOI 10.1016/S0166-2236(98)01391-5; Kendall G, 1996, EUR J BIOCHEM, V236, P360, DOI 10.1111/j.1432-1033.1996.00360.x; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Kury P, 2002, J NEUROSCI, V22, P7586; Labatut-Cazabat I, 1999, NEUROREPORT, V10, P3037, DOI 10.1097/00001756-199909290-00030; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Mirsky R, 1999, BRAIN PATHOL, V9, P293; MIRSKY R, 2001, GLIAL CELL DEV BASIC, P1; MULLER HW, 1986, J CELL BIOL, V102, P393, DOI 10.1083/jcb.102.2.393; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; OKAZAKI S, 1994, J BIOL CHEM, V269, P6900; OWENS GC, 1991, DEVELOPMENT, V112, P639; Parkinson DB, 2002, MOL CELL NEUROSCI, V20, P154, DOI 10.1006/mcne.2002.1109; Parkinson DB, 2004, J CELL BIOL, V164, P385, DOI 10.1083/jcb.200307132; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PORTER S, 1986, J NEUROSCI, V6, P3070; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Remboutsika E, 1999, J CELL SCI, V112, P1671; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; Tofaris GK, 2002, J NEUROSCI, V22, P6696; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; TOPILKO P, 2001, GLIAL CELL DEV, P223; VONSTRANDMANN EP, 1995, PROTEIN ENG, V8, P733; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284; ZOIDL G, 1995, EMBO J, V14, P1122, DOI 10.1002/j.1460-2075.1995.tb07095.x	71	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25653	25664		10.1074/jbc.M400415200	http://dx.doi.org/10.1074/jbc.M400415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070898	hybrid			2022-12-27	WOS:000221827900094
J	Andrin, C; Hendzel, MJ				Andrin, C; Hendzel, MJ			F-actin-dependent insolubility of chromatin-modifying components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR-MATRIX; HISTONE DEACETYLASE; SWI/SNF COMPLEX; N-COR; PROTEIN COMPLEXES; MESSENGER-RNA; L5178Y CELLS; IN-VIVO; ASSOCIATION	Many complexes involved in chromatin modification are difficult to isolate and commonly found associated with nuclear matrix preparations. In this study, we examine the elution properties of chromatin-modifying components under different extraction conditions. We find that most, but not all, histone acetyltransferases and histone deacetylases predominantly partition with the nuclear pellet during intermediate salt extraction. In attempts to identify a biological basis for the observed insolubility, we demonstrate that depolymerizing cellular actin, but not cellular tubulin, mobilizes a significant proportion of the insoluble pool into the intermediate salt-soluble nuclear extract. The disruption of cellular F-actin releases a specific subset of high molecular weight, active, nuclear histone deacetylase complexes that are not found under normal conditions. This study demonstrates that actin polymerization, a physiologically relevant process, is responsible for the observed insolubility of these components during nuclear extract preparation and establishes a simple strategy for isolating subsets of chromatin-modifying complexes that are otherwise depleted or absent under the same extraction conditions.	Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Hendzel, MJ (corresponding author), Rm 3332,11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	michaelh@cancerboard.ab.ca	Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Boyer LA, 2000, BIOESSAYS, V22, P666, DOI 10.1002/1521-1878(200007)22:7<666::AID-BIES9>3.0.CO;2-Y; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; De La Espina SMD, 2003, CELL BIOL INT, V27, P233, DOI 10.1016/S1065-6995(02)00340-2; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grzanka A, 2004, ONCOL REP, V11, P765; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Herrmann H, 2003, CELL MOL LIFE SCI, V60, P1607, DOI 10.1007/s00018-003-3004-0; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito T, 2003, CURR TOP MICROBIOL, V274, P1; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; NAKAYASU H, 1983, EXP CELL RES, V143, P55, DOI 10.1016/0014-4827(83)90108-8; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; NAKAYASU H, 1986, EXP CELL RES, V163, P327, DOI 10.1016/0014-4827(86)90064-9; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Oma Y, 2003, BIOCHEM BIOPH RES CO, V301, P521, DOI 10.1016/S0006-291X(02)03073-5; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Sun JM, 2003, METHODS, V31, P12, DOI 10.1016/S1046-2023(03)00083-5; Szerlong H, 2003, EMBO J, V22, P3175, DOI 10.1093/emboj/cdg296; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Walss-Bass C, 2002, CELL TISSUE RES, V308, P215, DOI 10.1007/s00441-002-0539-6; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Widlak P, 2002, J BIOL CHEM, V277, P21683, DOI 10.1074/jbc.M201027200; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25017	25023		10.1074/jbc.M401805200	http://dx.doi.org/10.1074/jbc.M401805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082715	hybrid			2022-12-27	WOS:000221827900016
J	Shirai, C; Takai, T; Nariai, M; Horigome, C; Mizuta, K				Shirai, C; Takai, T; Nariai, M; Horigome, C; Mizuta, K			Ebp2p, the yeast homolog of Epstein-Barr virus nuclear antigen 1-binding protein 2, interacts with factors of both the 60 S and the 40 S ribosomal subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PRE-RIBOSOMES; SECRETORY DEFECT; RNA SYNTHESIS; BIOGENESIS; IDENTIFICATION; NUCLEOLUS; CYTOPLASM; PARTICLE; SYSTEM	Ebp2p, the yeast homolog of human Epstein-Barr virus nuclear antigen 1-binding protein 2, is essential for biogenesis of the 60 S ribosomal subunit. Two-hybrid screening exhibited that, in addition to factors necessary for assembly of the 60 S subunit, Ebp2p interacts with Rps16p, ribosomal protein S16, and the 40 S ribosomal subunit assembly factor, Utp11p, as well as Yil019w, the function of which was previously uncharacterized. Depletion of Yil019w resulted in reduction in levels of both of 18 S rRNA and 40 S ribosomal subunit without affecting levels of 25 S rRNA and 60 S ribosomal subunits. 35 S pre-rRNA and aberrant 23 S RNA accumulated, indicating that pre-rRNA processing at sites A(0)-A(2) is inhibited when Yil019w is depleted. Each combination from Yil019w, Utp11p, and Rps16p showed two-hybrid interaction.	Hiroshima Univ, Grad Sch Biosphere Sci, Dept Bioresource Sci & Technol, Higashihiroshima, Japan	Hiroshima University	Mizuta, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Bioresource Sci & Technol, Kagamiyama 1-4-4, Higashihiroshima, Japan.	kmizuta@hiroshima-u.ac.jp	Horigome, Chihiro/AAH-5989-2021					Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Daugeron MC, 2001, RNA, V7, P1317, DOI 10.1017/S1355838201010640; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kaser A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Miyoshi K, 2002, J BIOL CHEM, V277, P18334, DOI 10.1074/jbc.M201667200; Miyoshi K, 2001, NUCLEIC ACIDS RES, V29, P3297, DOI 10.1093/nar/29.16.3297; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Morita D, 2002, J BIOL CHEM, V277, P28780, DOI 10.1074/jbc.M203399200; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; Wu K, 2001, NUCLEIC ACIDS RES, V29, P2938, DOI 10.1093/nar/29.14.2938	34	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25353	25358		10.1074/jbc.M403338200	http://dx.doi.org/10.1074/jbc.M403338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078877	hybrid			2022-12-27	WOS:000221827900057
J	Valeva, A; Walev, I; Weis, S; Boukhallouk, F; Wassenaar, TM; Endres, K; Fahrenholz, F; Bhakdi, S; Zitzer, A				Valeva, A; Walev, I; Weis, S; Boukhallouk, F; Wassenaar, TM; Endres, K; Fahrenholz, F; Bhakdi, S; Zitzer, A			A cellular metalloproteinase activates Vibrio cholerae pro-cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXIN; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; HEPTAMERIC TRANSMEMBRANE PORE; STRUCTURAL GENE HLYA; EL-TOR CYTOLYSIN; NUCLEOTIDE-SEQUENCE; PROTECTIVE ANTIGEN; IN-VITRO; FURIN; AEROLYSIN	Many strains of Vibrio cholerae produce a cytolysin (VCC) that forms oligomeric transmembrane pores in animal cells. The molecule is secreted as a procytolysin (pro-VCC) of 79 kDa that must be cleaved at the N terminus to generate the active 65-kDa toxin. Processing can occur in solution, and previous studies have described the action of mature VCC thus generated. However, little is known about the properties of pro-VCC itself. In this study, it is shown that pro-VCC exist as a monomer in solution and binds as a monomer to eukaryotic cells. Bound pro-VCC can then be activated either by exogenous, extracellular, or by endogenous, cell-bound proteases. In both cases, cleavage generates the 65-kDa VCC that oligomerizes to form transmembrane pores. A wide variety of exogenous proteinases can mediate activation. In contrast, the activating cellular protease is selectively inhibited by the hydroxamate inhibitor TAPI, and thus probable candidates are members of the ADAM-metalloproteinase family. Furin, MMP-2, MMP-9, and serine proteinases were excluded. Cells over-expressing ADAM-17, also known as tumor necrosis factor alpha converting enzyme, displayed increased activation of VCC, and knockout cells lacking ADAM-17 had a markedly decreased capacity to cleave the protoxin. The possibility is raised that pro-VCC is targeted to membrane sites that selectively contain or are accessible to cellular ADAM-metalloproteinases. Although many microbial toxins are activated by furin, this is the first evidence for processing by a cellular metalloproteinase. We identified ADAM-17 as a potent activator of pro-VCC.	Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Mol Microbiol & Genom Consultants, D-55576 Zotzenheim, Germany; Johannes Gutenberg Univ Mainz, Inst Biochem, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Valeva, A (corresponding author), Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, Augustuspl, D-55101 Mainz, Germany.	avaleva@uni-mainz.de	Endres, Kristina/K-4960-2015	Wassenaar, Trudy/0000-0002-7024-1139				Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; ALM RA, 1988, MOL MICROBIOL, V2, P481; Barry R, 2001, J BIOL CHEM, V276, P551, DOI 10.1074/jbc.M008097200; Fivaz M, 1999, J BIOL CHEM, V274, P37705, DOI 10.1074/jbc.274.53.37705; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; Harris JR, 2002, J STRUCT BIOL, V139, P122; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; ICHINOSE Y, 1987, INFECT IMMUN, V55, P1090, DOI 10.1128/IAI.55.5.1090-1093.1987; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KRASILNIKOV OV, 1992, BIOCHIM BIOPHYS ACTA, V1111, P7, DOI 10.1016/0005-2736(92)90268-Q; Miles G, 2001, BIOCHEMISTRY-US, V40, P8514, DOI 10.1021/bi010454o; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moschioni M, 2002, CELL MICROBIOL, V4, P397, DOI 10.1046/j.1462-5822.2002.00199.x; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; Ninin E, 2000, EUR J CLIN MICROBIOL, V19, P489, DOI 10.1007/s100960000296; Olson R, 2003, PROTEIN SCI, V12, P379, DOI 10.1110/ps.0231703; Pichel M, 2003, J CLIN MICROBIOL, V41, P124, DOI 10.1128/JCM.41.1.124-134.2003; RADER AE, 1988, INFECT IMMUN, V56, P1414, DOI 10.1128/IAI.56.6.1414-1419.1988; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAFRIN S, 1988, REV INFECT DIS, V10, P1012; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAMAMOTO K, 1986, INFECT IMMUN, V51, P927, DOI 10.1128/IAI.51.3.927-931.1986; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x; ZITZER AO, 1993, ZBL BAKT-INT J MED M, V279, P494, DOI 10.1016/S0934-8840(11)80421-4	41	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25143	25148		10.1074/jbc.M313913200	http://dx.doi.org/10.1074/jbc.M313913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066987	hybrid			2022-12-27	WOS:000221827900029
J	Gelamo, EL; Itri, R; Tabak, M				Gelamo, EL; Itri, R; Tabak, M			Small angle X-ray scattering (SAXS) study of the extracellular hemoglobin of Glossoscolex paulistus - Effect of pH, iron oxidation state, and interaction with anionic SDS surfactant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; LUMBRICUS-TERRESTRIS HEMOGLOBIN; BOVINE SERUM-ALBUMIN; DODECAMER SUBUNIT; IONIC SURFACTANTS; FLUORESCENCE; BSA; DENATURATION; COMPLEXES; NEUTRON	pH effects on the oligomeric structure of giant Glossoscolex paulistus extracellular hemoglobin in the oxy- and met-forms have been studied as well as effects of the addition of anionic sodium dodecyl sulfate surfactant. A radius of gyration of 110 Angstrom is observed for a macromolecule. At 2 mM surfactant, the radius of gyration diminishes slightly for the oxy- form. However, the extrapolated initial scattering intensity (I(0)) decreases a factor of 2.5, indicating protein dissociation. At 20 mM surfactant, further I( 0) decrease is observed, with a reduction of radius of gyration to approximately 30 Angstrom consistent with dissociation into smaller subunits. At pH 9.0, the scattering curves are similar to that obtained for the protein in the presence of 20 mM surfactant at pH 7.0. A radius of gyration of approximately 35 Angstrom shows that the giant hemoglobin dissociation into small subunits also occurs at alkaline pH. From the I( 0) value, one can suggest that the tetramer is the main scatter at pH 9.0. At pH 7.0, the met-form dissociates to a larger extent at 2 mM surfactant as compared with the oxy- form, and the main scatters seem to be the 1/12 subunit. At pH 9.0, for the oxy- form, the addition of surfactant does not modify the scattering curve and a radius of gyration approximately 30 Angstrom is obtained, while for the met-form some kind of aggregation is observed. Our results give support to conclude that the iron oxidation state is an important factor modulating the oligomeric dissociation.	Univ Sao Paulo, Dept Quim Fis Mol, Inst Quim Sao Carlos, BR-13560970 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis, Dept Fis Aplicada, BR-05515970 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Tabak, M (corresponding author), Univ Sao Paulo, Dept Quim Fis Mol, Inst Quim Sao Carlos, CP 780, BR-13560970 Sao Paulo, Brazil.	marcel@sc.usp.br	Tabak, Marcel/I-3173-2014; Itri, Rosangela/B-4312-2014	Itri, Rosangela/0000-0001-9311-0804				Agustinho SCM, 1996, BBA-PROTEIN STRUCT M, V1298, P148, DOI 10.1016/S0167-4838(96)00127-6; AJLOO D, 2002, J COLLOID INTERF SCI, V26, P185; Cabral CB, 2002, BIOPHYS CHEM, V97, P139, DOI 10.1016/S0301-4622(02)00046-7; Caetano W, 2002, J COLLOID INTERF SCI, V248, P149, DOI 10.1006/jcis.2001.8164; CHEN SH, 1986, PHYS REV LETT, V57, P2583, DOI 10.1103/PhysRevLett.57.2583; Cinelli S, 2001, BIOPHYS J, V81, P3522, DOI 10.1016/S0006-3495(01)75983-8; COSTA MCP, 1988, BRAZ J MED BIOL RES, V21, P115; deHaas F, 1997, BIOCHEMISTRY-US, V36, P7330, DOI 10.1021/bi970131l; Durchschlag H, 2001, J MOL STRUCT, V563, P449, DOI 10.1016/S0022-2860(00)00890-5; Gelamo EL, 2002, BBA-PROTEIN STRUCT M, V1594, P84, DOI 10.1016/S0167-4838(01)00287-4; Gelamo EL, 2000, SPECTROCHIM ACTA A, V56, P2255, DOI 10.1016/S1386-1425(00)00313-9; Ghosh S, 2002, BIOMACROMOLECULES, V3, P9, DOI 10.1021/bm005644d; Glatter O., 1982, SMALL ANGLE XRAYS SC; Guinier A., 1955, SMALL ANGLE SCATTERI; GUO XH, 1990, BIOPOLYMERS, V29, P335, DOI 10.1002/bip.360290206; HAYASHI T, 1995, BIOL PHARM BULL, V18, P540; IMASATO H, 1995, COMP BIOCHEM PHYS B, V112, P217, DOI 10.1016/0305-0491(95)00061-5; Inouye H, 1999, BIOPHYS J, V76, P423, DOI 10.1016/S0006-3495(99)77209-7; Jones M.N., 1995, MICELLES MONOLAYERS; JONES MN, 1992, CHEM SOC REV, V21, P127, DOI 10.1039/cs9922100127; Kelley D, 2003, FOOD HYDROCOLLOID, V17, P73, DOI 10.1016/S0268-005X(02)00040-1; Krebs A, 1996, BBA-PROTEIN STRUCT M, V1297, P115, DOI 10.1016/S0167-4838(96)00141-0; Krebs A, 1998, BIOPOLYMERS, V45, P289, DOI 10.1002/(SICI)1097-0282(19980405)45:4<289::AID-BIP3>3.0.CO;2-H; Krebs A, 1996, J BIOL CHEM, V271, P18695, DOI 10.1074/jbc.271.31.18695; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; Li GX, 1996, J ELECTROCHEM SOC, V143, pL24, DOI 10.1149/1.1836444; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; Nielsen AD, 2000, BBA-PROTEIN STRUCT M, V1479, P321, DOI 10.1016/S0167-4838(00)00012-1; Orthaber D, 2000, J APPL CRYSTALLOGR, V33, P218, DOI 10.1107/S0021889899015216; PERUSSI JR, 1990, PHYSIOL CHEM PHYS M, V22, P159; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; Santos SF, 2003, J COLLOID INTERF SCI, V262, P400, DOI 10.1016/S0021-9797(03)00109-7; Segel DJ, 1998, BIOCHEMISTRY-US, V37, P12443, DOI 10.1021/bi980535t; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; SHINAGAWA S, 1994, LANGMUIR, V10, P1690, DOI 10.1021/la00018a015; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P792, DOI 10.1107/S0021889897001039; Svergun DI, 2000, J APPL CRYSTALLOGR, V33, P530, DOI 10.1107/S0021889800001370; Tanford Ch., 1973, HYDROPHOBIC EFFECT F; TANNER RE, 1982, J CHEM PHYS, V76, P3866, DOI 10.1063/1.443528; TURRO NJ, 1995, LANGMUIR, V11, P2525, DOI 10.1021/la00007a035; WU CF, 1988, BIOPOLYMERS, V27, P1065, DOI 10.1002/bip.360270703; Zipper P, 2002, PROG COLL POL SCI S, V119, P141	46	25	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33298	33305		10.1074/jbc.M401982200	http://dx.doi.org/10.1074/jbc.M401982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15100214	hybrid			2022-12-27	WOS:000223039700036
J	Ling, L; Lobie, PE				Ling, L; Lobie, PE			RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; SERINE PHOSPHORYLATION; PROTEIN-KINASE; RHO-GTPASES; IN-VIVO; SIGNAL TRANSDUCER; PHOSPHOLIPASE-D; MAP KINASE; BINDING; STAT5	We demonstrate here that growth hormone (GH) stimulates the activation of RhoA and its substrate Rho kinase ( ROCK) in NIH-3T3 cells. GH-stimulated formation of GTP-bound RhoA requires JAK2-dependent dissociation of RhoA from its negative regulator p190 RhoGAP. Inactivation of RhoA does not affect GH-stimulated JAK2 tyrosine phosphorylation nor p44/42 MAPK activity. However, RhoA and ROCK activities are required for GH-stimulated, Stat5-mediated transcription. RhoA-dependent enhancement of GH-stimulated, Stat5-mediated transcription is due to repression of histone deacetylase 6 activity recruited by transcription cofactor p300 that negatively regulates GH-stimulated, Stat5-mediated transcription. We also demonstrate that RhoA is the pivot for cAMP-dependent protein kinase inhibition of GH-stimulated, Stat5-mediated transcription as a consequence of cAMP-dependent protein kinase inactivation of RhoA through serine residue 188 of RhoA. We have therefore provided a novel mechanism by which a Ras-like small GTPase, RhoA, can regulate Stat5-mediated transcription.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz						Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; AZNAR BS, 2003, MOL BIOL CELL, V14, P3041; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Boer AK, 2003, EXP HEMATOL, V31, P512, DOI 10.1016/S0301-472X(03)00075-4; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chan HM, 2001, J CELL SCI, V114, P2363; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GAUR S, 1996, AM J PHYSL, V270; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Goodman RH, 2000, GENE DEV, V14, P1553; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853, DOI 10.1681/ASN.V1291853; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jin SH, 2000, BIOCHEM BIOPH RES CO, V277, P718, DOI 10.1006/bbrc.2000.3744; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Krepinsky JC, 2003, J AM SOC NEPHROL, V14, P2790, DOI 10.1097/01.ASN.0000094085.04161.A7; Leemhuis J, 2002, J PHARMACOL EXP THER, V300, P1000, DOI 10.1124/jpet.300.3.1000; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; Lucas L, 2002, INT J ONCOL, V21, P477; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Mitsiou DJ, 2003, EMBO J, V22, P4501, DOI 10.1093/emboj/cdg419; Nam S Y, 2000, Obes Rev, V1, P73, DOI 10.1046/j.1467-789x.2000.00015.x; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Simar-Blanchet AE, 1998, MOL ENDOCRINOL, V12, P391, DOI 10.1210/me.12.3.391; Sirotkin AV, 2002, ANIM REPROD SCI, V70, P111, DOI 10.1016/S0378-4320(01)00196-8; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Su LF, 2002, J BIOL CHEM, V277, P37037, DOI 10.1074/jbc.M111607200; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; VAN AL, 1997, GENE DEV, V11, P2295; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yarwood SJ, 1998, MOL CELL ENDOCRINOL, V138, P41; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	66	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32737	32750		10.1074/jbc.M400601200	http://dx.doi.org/10.1074/jbc.M400601200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15102857	hybrid			2022-12-27	WOS:000222849700093
J	Li, AM; Dong, JX; Harris, DA				Li, AM; Dong, JX; Harris, DA			Cell surface expression of the prion protein in yeast does not alter copper utilization phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; SIGNAL SEQUENCES; ALPHA-SYNUCLEIN; PLASMA-MEMBRANE; CULTURED-CELLS; METAL-IONS; IN-VIVO; PRP	Prion diseases are fatal neurodegenerative disorders that result from conversion of a normal, cell surface glycoprotein (PrPC) into a conformationally altered isoform (PrPSc) that is thought to be infectious. Although a great deal is known about the role of PrPSc in the disease process, the physiological function of PrPC has remained enigmatic. In this report, we have used the yeast Saccharomyces cerevisiae to test one hypothesized function of PrPC, as a receptor for the uptake or efflux of copper ions. We first modified the PrP signal peptide by replacing its hydrophobic core with the signal sequence from the yeast protein dipeptidyl aminopeptidase B, so that the resulting protein was targeted cotranslationally to the secretory pathway when synthesized in yeast. PrP molecules with the modified signal peptide were efficiently glycosylated, glycolipid-anchored, and localized to the plasma membrane. We then tested whether PrP expression altered the growth deficiency phenotypes of yeast strains harboring deletions in genes that encode key components of copper utilization pathways, including transporters, chaperones, pumps, reductases, and cuproenzymes. We found that PrP did not rescue any of these mutant phenotypes, arguing against a direct role for the protein in copper utilization. Our results provide further clarification of the physiological function of PrPC, and lay the groundwork for using PrP-expressing yeast to study other aspects of prion biology.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbio.wustl.edu		Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS40061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 2004, CURRENT PROTOCOLS MO; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Brown Lesley R., 2002, P103; Brown LR, 2003, J NEUROCHEM, V87, P353, DOI 10.1046/j.1471-4159.2003.01996.x; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Doering TL, 1997, BIOCHEM J, V328, P669; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glick BS, 1996, CURR BIOL, V6, P1570, DOI 10.1016/S0960-9822(02)70774-4; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; Hutter G, 2003, BIOL CHEM, V384, P1279, DOI 10.1515/BC.2003.142; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Oidtmann B, 2003, FEBS LETT, V538, P96, DOI 10.1016/S0014-5793(03)00149-2; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2004, PRION BIOL DIS; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Riley ML, 2002, PROTEIN ENG, V15, P529, DOI 10.1093/protein/15.6.529; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; Simonic T, 2000, FEBS LETT, V469, P33, DOI 10.1016/S0014-5793(00)01232-1; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Strumbo B, 2001, FEBS LETT, V508, P170, DOI 10.1016/S0014-5793(01)03027-7; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2	75	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29469	29477		10.1074/jbc.M402517200	http://dx.doi.org/10.1074/jbc.M402517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15090539	hybrid			2022-12-27	WOS:000222445300079
J	Osborne, AR; Zhang, HQ; Fejer, G; Palubin, KM; Niesen, MI; Blanck, G				Osborne, AR; Zhang, HQ; Fejer, G; Palubin, KM; Niesen, MI; Blanck, G			Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells - An Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-II; BARE LYMPHOCYTE SYNDROME; DEFICIENT COMBINED IMMUNODEFICIENCY; RETINOBLASTOMA PROTEIN EXPRESSION; CD4(+) T-CELLS; IN-VIVO; COOPERATIVE BINDING; GAMMA-INDUCTION; CARCINOMA CELLS; GENE-EXPRESSION	The cell surface HLA-DR molecule binds foreign peptide antigen and forms an intercellular complex with the T cell receptor in the course of the development of an immune response against or immune tolerance to the antigen represented by the bound peptide. The HLA-DR molecule also functions as a receptor that mediates cell signaling pathways, including as yet poorly characterized pathway(s) leading to apoptosis. Expression of HLA-DR mRNA and protein is ordinarily inducible by interferon-gamma but is not inducible in tumor cells defective for the retinoblastoma tumor suppressor protein (Rb). In the case of the HLA-DRA gene, which encodes the HLA-DR heavy chain, previous work has indicated that this loss of inducibility is attributable to Oct-1 binding to the HLA-DRA promoter. In this report, we used Oct-1 antisense transformants to determine that Oct-1 represses the interferon-gamma response of the endogenous HLA-DRA gene. This determination is consistent with results from a chromatin immunoprecipitation assay, indicating that Oct-1 occupies the endogenous HLA-DRA promoter when the HLA-DRA promoter is inactive in Rb-defective cells but not when the promoter is converted to a previously defined, transcriptionally competent state, induced by treatment of the Rb-defective cells with the HDAC inhibitor, trichostatin A. In vitro DNA-protein binding analyses indicated that Oct-1 prevents HLA-DRA promoter activation by mediating the formation of a complex of proteins, termed DRAN (DRA negative), that blocks NF-Y access to the promoter.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol & Lab Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, MDC Box 7,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gblanck@hsc.usf.edu	Fejer, Gyorgy/D-5080-2011; Blanck, George/A-5365-2012; Niesen, Melissa I/J-5453-2013; Fejer, Gyorgy/F-8515-2019	Niesen, Melissa I/0000-0001-8020-0958; Fejer, Gyorgy/0000-0001-6761-0506	NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong TD, 1998, J IMMUNOTHER, V21, P218, DOI 10.1097/00002371-199805000-00008; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Eason DD, 2001, J IMMUNOL, V166, P1041, DOI 10.4049/jimmunol.166.2.1041; Fontes JD, 1999, MOL CELL BIOL, V19, P941; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Huang X, 1999, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V21, P252; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KARA CJ, 1993, J IMMUNOL, V150, P4934; KARA CJ, 1993, EMBO J, V12, P187, DOI 10.1002/j.1460-2075.1993.tb05644.x; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; Masternak K, 2000, GENE DEV, V14, P1156; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; MUNCASTER MM, 1992, CANCER RES, V52, P654; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; Pulaski BA, 1998, CANCER RES, V58, P1486; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Villard J, 1999, INT IMMUNOL, V11, P461, DOI 10.1093/intimm/11.3.461; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Wu GD, 1997, J BIOL CHEM, V272, P2396; Xu XXS, 2000, GENE, V242, P219, DOI 10.1016/S0378-1119(99)00522-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	43	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28911	28919		10.1074/jbc.M403118200	http://dx.doi.org/10.1074/jbc.M403118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105429	hybrid			2022-12-27	WOS:000222445300012
J	Kasiviswanathan, R; Shin, JH; Melamud, E; Kelman, Z				Kasiviswanathan, R; Shin, JH; Melamud, E; Kelman, Z			Biochemical characterization of the Methanothermobacter thermautotrophicus minichromosome maintenance (MCM) helicase N-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRENARCHAEON SULFOLOBUS-SOLFATARICUS; DNA-BINDING-PROTEIN; 3RD DOMAIN; REPLICATION; COMPLEX; THERMOAUTOTROPHICUM; DUPLEX; EUKARYAL; LIFE	Minichromosome maintenance helicases are ring-shaped complexes that play an essential role in archaeal and eukaryal DNA replication by separating the two strands of chromosomal DNA to provide the single-stranded substrate for the replicative polymerases. For the archaeal protein it was shown that the N-terminal portion of the protein, which is composed of domains A, B, and C, is involved in multimer formation and single-stranded DNA binding and may also play a role in regulating the helicase activity. Here, a detailed biochemical characterization of the N-terminal region of the Methanothermobacter thermautotrophicus minichromosome maintenance helicase is described. Using biochemical and biophysical analyses it is shown that domain C of the N-terminal portion, located adjacent to the helicase catalytic domains, is required for protein multimerization and that domain B is the main contact region with single-stranded DNA. It is also shown that although oligomerization is not essential for single-stranded DNA binding and ATPase activity, the presence of domain C is essential for helicase activity.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA		Kelman, Z (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Kasiviswanathan, Rajesh/D-2744-2012					Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; De Felice M, 2003, J BIOL CHEM, V278, P46424, DOI 10.1074/jbc.M306075200; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	34	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28358	28366		10.1074/jbc.M403202200	http://dx.doi.org/10.1074/jbc.M403202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100218	hybrid			2022-12-27	WOS:000222265400068
J	Kim, BC; van Gelder, H; Kim, TA; Lee, HJ; Baik, KG; Chun, HH; Lee, DA; Choi, KS; Kim, SJ				Kim, BC; van Gelder, H; Kim, TA; Lee, HJ; Baik, KG; Chun, HH; Lee, DA; Choi, KS; Kim, SJ			Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE/THREONINE KINASE; ALK7; PROTEIN; PHOSPHORYLATION; PROTEASES; CLEAVAGE; CLONING	Activin receptor-like kinase (ALK)7 is a type I serine/threonine kinase receptor of the transforming growth factor (TGF)-beta family of proteins that has similar properties to other type I receptors when activated. To see whether ALK7 can induce apoptosis as can some of the other ALK proteins, we infected the FaO rat hepatoma cell line with adenovirus expressing a constitutively active form of the ALK7. Cells infected with active ALK7 adenovirus showed an apoptotic-positive phenotype, as opposed to those that were infected with a control protein. DNA fragmentation assays and fluorescence-activated cell sorter analysis also indicated that ALK7 infection induced apoptosis in FaO cells. We also confirmed this finding in Hep3B human hepatoma cells by transiently transfecting the constitutively active form of ALK7, ALK7(T194D). Investigation into the downstream targets and mechanisms involved in ALK7-induced apoptosis revealed that the TGF-beta signaling intermediates, Smad2 and -3, were activated, as well as the MAPKs JNK and p38. In addition, caspase-3 and -9 were also activated, and cytochrome c release from the mitochondria was observed. Short interfering RNA-mediated inhibition of Smad3 markedly suppressed ALK7-induced caspase-3 activation. Treatment with protein synthesis inhibitors or the expression of the dominant-negative form of the stress-activated protein/extracellular signal-regulated kinase 1 abolished not only JNK activation but apoptosis as well. Taken together, these results suggest that ALK7 induces apoptosis through activation of the traditional TGF-beta pathway components, thus resulting in new gene transcription and JNK and p38 activation that initiates cross-talk with the cellular stress death pathway and ultimately leads to apoptosis.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Kangwon Natl Univ, Coll Nat Sci, Chunchon 200701, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol, Suwon 441749, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kangwon National University; Ajou University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov		Choi, Kyeong Sook/0000-0003-2331-0856	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hsing AY, 1996, CANCER RES, V56, P5146; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jornvall H, 2001, J BIOL CHEM, V276, P5140, DOI 10.1074/jbc.M005200200; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Watanabe R, 1999, BIOCHEM BIOPH RES CO, V254, P707, DOI 10.1006/bbrc.1998.0118	22	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28458	28465		10.1074/jbc.M313277200	http://dx.doi.org/10.1074/jbc.M313277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107418	Green Published, hybrid			2022-12-27	WOS:000222265400080
J	Werner, AB; Tait, SWG; de Vries, E; Eldering, E; Borst, J				Werner, AB; Tait, SWG; de Vries, E; Eldering, E; Borst, J			Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GRANZYME-B; THYMOCYTE APOPTOSIS; BH3-ONLY PROTEINS; DEATH RECEPTORS; FLOW-CYTOMETRY; LEUKEMIC-CELLS; P53; GENE; MITOCHONDRIA	Lymphoid malignancies can escape from DNA-damaging anti-cancer drugs and gamma-radiation by blocking apoptosis-signaling pathways. How these regimens induce apoptosis is incompletely defined, especially in cells with nonfunctional p53. We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells. Bid is not transcriptionally up-regulated in response to these stimuli but is activated by cleavage on aspartate residues 60 and/or 75, which are the targets of caspase-8 and granzyme B. Bid activity is not inhibitable by c-Flip(L), CrmA, or dominant negative caspase-9 and therefore is independent of inducer caspase activation by death receptors or the mitochondria. Caspase-2, which has been implicated as inducer caspase in DNA damage pathways, appeared to be processed in response to etoposide and gamma-radiation but downstream of caspase-9. Knock down of caspase-2 by short interfering RNA further excluded its role in Bid activation by DNA damage. Caspase-2 was implicated in the death receptor pathway however, where it contributed to effector caspase processing downstream of inducer caspases. Granzyme B-specific serpins could not block DNA damage-induced apoptosis, excluding a role for granzyme B in the generation of active Bid. We conclude that Bid, cleaved by an undefined aspartate-specific protease, can be a key mediator of the apoptotic response to DNA-damaging anticancer regimens.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1100 DD Amsterdam, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl		Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; BORST J, 1987, J IMMUNOL, V139, P1952; Brown JM, 1999, CANCER RES, V59, P1391; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bruno AP, 2000, BLOOD, V96, P1914, DOI 10.1182/blood.V96.5.1914.h8001914_1914_1920; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kataoka T, 1998, J IMMUNOL, V161, P3936; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAUMANN R, 1992, LEUKEMIA, V6, P227; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2000, COLD SPRING HARB SYM, V65, P499, DOI 10.1101/sqb.2000.65.499; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	63	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28771	28780		10.1074/jbc.M400268200	http://dx.doi.org/10.1074/jbc.M400268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117953	hybrid			2022-12-27	WOS:000222265400115
J	Banhegyi, G; Benedetti, A; Fulceri, R; Senesi, S				Banhegyi, G; Benedetti, A; Fulceri, R; Senesi, S			Cooperativity between 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CORTISONE REDUCTASE DEFICIENCY; PENTOSE-PHOSPHATE PATHWAY; FUNCTIONAL-RELATIONSHIP; GLUCOCORTICOID ACTION; VESICLES; MICE; 6-PHOSPHOGLUCONOLACTONASE; GLUCOSE-6-PHOSPHATE; METYRAPONE	The functional coupling of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase was investigated in rat liver microsomal vesicles. The activity of both enzymes was latent in intact vesicles, indicating the intraluminal localization of their active sites. Glucose-6-phosphate, a substrate for hexose-6-phosphate dehydrogenase, stimulated the cortisone reductase activity of 11B-hydroxysteroid dehydrogenase type 1. Inhibition of glucose-6-phosphate uptake by S3483, a specific inhibitor of the microsomal glucose-6-phosphate transporter, decreased this effect. Similarly, cortisone increased the intravesicular accumulation of radioactivity upon the addition of radiolabeled glucose-6-phosphate, indicating the stimulation of hexose-6-phosphate dehydrogenase activity. A correlation was shown between glucose-6-phosphate-dependent cortisone reduction and cortisone-dependent glucose-6-phosphate oxidation. The results demonstrate a close cooperation of the enzymes based on co-localization and the mutual generation of cofactors for each other.	Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, I-53100 Siena, Italy; Hungarian Acad Sci, Endoplasm Reticulum Res Grp, H-1444 Budapest, Hungary; Semmelweis Univ, H-1444 Budapest, Hungary	University of Siena; Hungarian Academy of Sciences; Semmelweis University	Benedetti, A (corresponding author), Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, Viale Aldo Moro, I-53100 Siena, Italy.	benedetti@unisi.it	Bánhegyi, Gábor/A-1476-2014					Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; BUBLITZ C, 1988, J BIOL CHEM, V263, P12849; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BUBLITZ C, 1987, BIOCHEM J, V245, P263, DOI 10.1042/bj2450263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; HINO Y, 1983, J BIOL CHEM, V258, P1415; HORI SH, 1977, BIOCHIM BIOPHYS ACTA, V496, P1, DOI 10.1016/0304-4165(77)90109-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jamieson A, 1999, J CLIN ENDOCR METAB, V84, P3570, DOI 10.1210/jc.84.10.3570; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KULKARNI AP, 1982, BIOCHEM PHARMACOL, V31, P1131, DOI 10.1016/0006-2952(82)90353-7; MASER E, 1994, BIOCHEM PHARMACOL, V47, P1805, DOI 10.1016/0006-2952(94)90309-3; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; SampathKumar R, 1997, J STEROID BIOCHEM, V62, P195, DOI 10.1016/S0960-0760(97)00027-7; SAWADA H, 1981, J BIOCHEM-TOKYO, V90, P1077, DOI 10.1093/oxfordjournals.jbchem.a133559; SAWADA H, 1980, J BIOCHEM-TOKYO, V87, P985, DOI 10.1093/oxfordjournals.jbchem.a132829; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; TAKAHASHI T, 1981, BIOCHIM BIOPHYS ACTA, V672, P165, DOI 10.1016/0304-4165(81)90390-1; TAKAHASHI T, 1978, BIOCHIM BIOPHYS ACTA, V524, P262, DOI 10.1016/0005-2744(78)90163-8; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200	31	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27017	27021		10.1074/jbc.M404159200	http://dx.doi.org/10.1074/jbc.M404159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090536	hybrid			2022-12-27	WOS:000222120400027
J	Brown, GE; Stewart, MQ; Bissonnette, SA; Elia, AEH; Wilker, E; Yaffe, MB				Brown, GE; Stewart, MQ; Bissonnette, SA; Elia, AEH; Wilker, E; Yaffe, MB			Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TUMOR-NECROSIS-FACTOR; RESPIRATORY-DISTRESS SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; ADHERENT HUMAN-NEUTROPHILS; SRC HOMOLOGY-3 DOMAINS; MULTIPLE ORGAN FAILURE; ACUTE LUNG INJURY	In response to certain cytokines and inflammatory mediators, the activity of the neutrophil NADPH oxidase enzyme is primed for enhanced superoxide production when the cells receive a subsequent oxidase-activating stimulus. The relative role of p38 MAPK in the priming and activation processes is incompletely understood. We have developed a 2-step assay that allows the relative contributions of p38 MAPK activity in priming to be distinguished from those involved in oxidase activation. Using this assay, together with in vitro kinase assays and immunochemical studies, we report that p38 MAPK plays a critical role in TNFalpha priming of the human and porcine NADPH oxidase for superoxide production in response to complement-opsonized zymosan (OpZ), but little, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent responses. The OpZ-mediated activation process per se is independent of p38 MAPK activity, in contrast to oxidase activation by fMLP, where 70% of the response is eliminated by p38 MAPK inhibitors regardless of the priming agent. We further report that incubation of neutrophils with TNFalpha results in the p38 MAPK-dependent phosphorylation of a subpopulation of p47(phox) and p67(phox) molecules, whereas PAF priming results in phosphorylation only of p67(phox). Despite these phosphorylations, TNFalpha priming does not result in significant association of either of these oxidase subunits with neutrophil membranes, demonstrating that the molecular basis for priming does not appear to involve preassembly of the NADPH oxidase holoenzyme/cytochrome complex prior to oxidase activation.	Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02120 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Div Biol Engn, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02120 USA.	myaffe@mit.edu		Stewart, Mary Q/0000-0001-6924-0123	NIGMS NIH HHS [GM98059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; AMARI T, 1993, J APPL PHYSIOL, V74, P2641, DOI 10.1152/jappl.1993.74.6.2641; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; BASS DA, 1986, J IMMUNOL, V136, P860; BENDER JG, 1983, J IMMUNOL, V130, P2316; Botha AJ, 1996, BRIT J SURG, V83, P1407, DOI 10.1002/bjs.1800831027; BROWN GE, 1991, J IMMUNOL, V147, P965; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cadwallader KA, 2002, J IMMUNOL, V169, P3336, DOI 10.4049/jimmunol.169.6.3336; Camhi S L, 1995, New Horiz, V3, P170; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CHOLLETMARTIN S, 1992, AM REV RESPIR DIS, V146, P990, DOI 10.1164/ajrccm/146.4.990; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; Duilio C, 2001, AM J PHYSIOL-HEART C, V280, pH2649, DOI 10.1152/ajpheart.2001.280.6.H2649; Dusi S, 1996, J IMMUNOL, V157, P4615; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ELAWAR FY, 1990, AM J VET RES, V51, P1561; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; EXLEY AR, 1992, GUT, V33, P1126, DOI 10.1136/gut.33.8.1126; Fink Mitchell P, 2002, Curr Opin Crit Care, V8, P6, DOI 10.1097/00075198-200202000-00002; FLETCHER MP, 1990, J LEUKOCYTE BIOL, V47, P355, DOI 10.1002/jlb.47.4.355; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Forsberg M, 2001, IMMUNOLOGY, V103, P465, DOI 10.1046/j.1365-2567.2001.01270.x; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; GONZALEZ PK, 1995, J PHARMACOL EXP THER, V275, P798; GUICE KS, 1991, J SURG RES, V51, P495, DOI 10.1016/0022-4804(91)90171-H; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HILL ME, 1994, J IMMUNOL, V153, P3673; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Kobayashi T, 1998, J CELL SCI, V111, P81; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Lian JP, 1999, J IMMUNOL, V163, P4527; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; Livingston D H, 1995, New Horiz, V3, P257; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Lundqvist H, 1996, J LEUKOCYTE BIOL, V59, P270, DOI 10.1002/jlb.59.2.270; Lundqvist H, 1996, FREE RADICAL BIO MED, V20, P785, DOI 10.1016/0891-5849(95)02189-2; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MEAKINS JL, 1990, J TRAUMA, V30, pS165; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; PARK JW, 1995, BIOCHEM BIOPH RES CO, V211, P410, DOI 10.1006/bbrc.1995.1829; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; Partrick D A, 1996, New Horiz, V4, P194; Partrick DA, 2000, ARCH SURG-CHICAGO, V135, P219, DOI 10.1001/archsurg.135.2.219; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1995, METHOD ENZYMOL, V256, P256; RAFIEE P, 1995, J IMMUNOL, V154, P4785; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; RIVKIND AI, 1991, CIRC SHOCK, V33, P48; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SHAKED G, 1994, J TRAUMA, V37, P22, DOI 10.1097/00005373-199407000-00006; SULLIVAN R, 1987, J IMMUNOL, V139, P3422; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA H, 1991, ANN SURG, V214, P187, DOI 10.1097/00000658-199108000-00014; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WEISBART RH, 1987, BLOOD, V69, P18; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEWERS MD, 1990, AM J PHYSIOL, V259, pL276, DOI 10.1152/ajplung.1990.259.4.L276; WOLLERT PS, 1994, SHOCK, V2, P362, DOI 10.1097/00024382-199411000-00011; WORTHEN GS, 1987, AM REV RESPIR DIS, V136, P19, DOI 10.1164/ajrccm/136.1.19; Yaffe MB, 1999, SURGERY, V126, P248, DOI 10.1016/S0039-6060(99)70162-5; Yan SR, 2002, INFECT IMMUN, V70, P4068, DOI 10.1128/IAI.70.8.4068-4074.2002; ZIMMERMAN GA, 1983, AM REV RESPIR DIS, V127, P290; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; Zu YL, 1998, J IMMUNOL, V160, P1982	102	70	75	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27059	27068		10.1074/jbc.M314258200	http://dx.doi.org/10.1074/jbc.M314258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102856	hybrid			2022-12-27	WOS:000222120400032
J	Hirche, TO; Crouch, EC; Espinola, M; Brokelman, TJ; Mecham, RP; DeSilva, N; Cooley, J; Remold-O'Donnell, E; Belaaouaj, A				Hirche, TO; Crouch, EC; Espinola, M; Brokelman, TJ; Mecham, RP; DeSilva, N; Cooley, J; Remold-O'Donnell, E; Belaaouaj, A			Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ENHANCES PHAGOCYTOSIS; LEUKOCYTE ELASTASE; HOST-DEFENSE; SP-A; LUNG; BINDING; PROTEASES; DEGRADATION; CALCIUM	Surfactant protein D (SP-D) plays important roles in innate immunity including the defense against bacteria, fungi, and respiratory viruses. Because SP-D specifically interacts with neutrophils that infiltrate the lung in response to acute inflammation and infection, we examined the hypothesis that the neutrophil-derived serine proteinases (NSPs): neutrophil elastase, proteinase-3, and cathepsin G degrade SP-D. All three human NSPs specifically cleaved recombinant rat and natural human SP-D dodecamers in a time- and dose-dependent manner, which was reciprocally dependent on calcium concentration. The NSPs generated similar, relatively stable, disulfide cross-linked immunoreactive fragments of similar to35 kDa ( reduced), and sequencing of a major catheptic fragment definitively localized the major sites of cleavage to a highly conserved subregion of the carbohydrate recognition domain. Cleavage markedly reduced the ability of SP-D to promote bacterial aggregation and to bind to yeast mannan in vitro. Incubation of SP-D with isolated murine neutrophils led to the generation of similar fragments, and cleavage was inhibited with synthetic and natural serine proteinase inhibitors. In addition, neutrophils genetically deficient in neutrophil elastase and/or cathepsin G were impaired in their ability to degrade SP-D. Using a mouse model of acute bacterial pneumonia, we observed the accumulation of SP-D at sites of neutrophil infiltration coinciding with the appearance of similar to35-kDa SP-D fragments in bronchoalveolar lavage fluids. Together, our data suggest that neutrophil-derived serine proteinases cleave SP-D at sites of inflammation with potential deleterious effects on its biological functions.	Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Ctr Blood Res, Inst Biomed Res, Boston, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Belaaouaj, A (corresponding author), Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA.	azzaq@im.wustl.edu	Bentaher, Abderrazzaq/M-4424-2017; A, Bentaher/F-6531-2018	A, Bentaher/0000-0001-6001-5456	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066548, P01HL029594, R01HL066415, R01HL044015] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66415, HL-66548, HL-29594, R01 HL066548, HL-44015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj A, 2002, MICROBES INFECT, V4, P1259, DOI 10.1016/S1286-4579(02)01654-4; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; BIRRER P, 1995, RESPIRATION, V62, P25; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Bufler P, 2003, AM J RESP CELL MOL, V28, P249, DOI 10.1165/rcmb.4896; CAI GZ, 1999, AM J PHYSIOL, V276, P131; Carlstedt F, 2001, CRIT CARE CLIN, V17, P139, DOI 10.1016/S0749-0704(05)70156-1; Cheng IW, 2003, CRIT CARE MED, V31, P20, DOI 10.1097/00003246-200301000-00003; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DeSilva NS, 2003, AM J RESP CELL MOL, V29, P757, DOI 10.1165/rcmb.2003-0186OC; DONG Q, 1998, AM J PHYSIOL, V274, P97; Ganz T, 1999, P ASSOC AM PHYSICIAN, V111, P390, DOI 10.1111/paa.1999.111.5.390; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; Griese M, 2003, BBA-MOL BASIS DIS, V1638, P157, DOI 10.1016/S0925-4439(03)00063-2; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hartshorn KL, 2002, BIOCHEM J, V366, P87, DOI 10.1042/BJ20011868; Hartshorn KL, 2002, INFECT IMMUN, V70, P6129, DOI 10.1128/IAI.70.11.6129-6139.2002; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HASLETT C, 1985, AM J PATHOL, V119, P101; Herbein JF, 2000, AM J PHYSIOL-LUNG C, V278, pL830, DOI 10.1152/ajplung.2000.278.4.L830; Herbein JF, 2001, AM J PHYSIOL-LUNG C, V281, pL268, DOI 10.1152/ajplung.2001.281.1.L268; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; Honda Y, 1996, CHEST, V109, P1006, DOI 10.1378/chest.109.4.1006; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kishore U, 2001, Results Probl Cell Differ, V33, P225; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Leth-Larsen R, 2003, CLIN IMMUNOL, V108, P29, DOI 10.1016/S1521-6616(03)00042-1; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; Liau DF, 1996, BBA-LIPID LIPID MET, V1302, P117, DOI 10.1016/0005-2760(96)00042-2; Lopez-boado YS, 2004, J IMMUNOL, V172, P509, DOI 10.4049/jimmunol.172.1.509; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Mariencheck WI, 2003, AM J RESP CELL MOL, V28, P528, DOI 10.1165/rcmb.2002-0141OC; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Moraes TJ, 2003, CRIT CARE MED, V31, pS189, DOI 10.1097/01.CCM.0000057842.90746.1E; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; Owen CA, 1997, AM J PHYSIOL-LUNG C, V272, pL385, DOI 10.1152/ajplung.1997.272.3.L385; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PISON U, 1989, BIOCHIM BIOPHYS ACTA, V992, P251, DOI 10.1016/0304-4165(89)90082-2; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; RAO NV, 1993, AM J RESP CELL MOL, V8, P612, DOI 10.1165/ajrcmb/8.6.612; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Rubio F, 2004, THORAX, V59, P318, DOI 10.1136/thx.2003.014902; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schochett P, 1999, EXP LUNG RES, V25, P595; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; TAMURA Y, 1992, MICROB PATHOGENESIS, V12, P237, DOI 10.1016/0882-4010(92)90058-V; Taneva S, 1997, BIOCHEMISTRY-US, V36, P8173, DOI 10.1021/bi963040h; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zivin JR, 2001, AM J KIDNEY DIS, V37, P689, DOI 10.1016/S0272-6386(01)80116-5	69	80	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27688	27698		10.1074/jbc.M402936200	http://dx.doi.org/10.1074/jbc.M402936200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078883	hybrid			2022-12-27	WOS:000222120400103
J	Li, RH; Gorelik, R; Nanda, V; Law, PB; Lear, JD; DeGrado, WF; Bennett, JS				Li, RH; Gorelik, R; Nanda, V; Law, PB; Lear, JD; DeGrado, WF; Bennett, JS			Dimerization of the transmembrane domain of integrin alpha(IIb) subunit in cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; GXXXG MOTIF; SIGNAL-TRANSDUCTION; BIOLOGICAL MEMBRANE; CYTOPLASMIC DOMAINS; HELIX ASSOCIATION; ALPHA-HELICES; INTEGRIN; PROPENSITY; PROTEINS	Homo- and hetero-oligomeric interactions between the transmembrane (TM) helices of integrin alpha and beta subunits may play an important role in integrin activation and clustering. As a first step to understanding these interactions, we used the TOXCAT assay to measure oligomerization of the wild-type alpha(IIb) TM helix and single-site TM domain mutants. TOXCAT measures the oligomerization of a chimeric protein containing a TM helix in the Escherichia coli inner membrane via the transcriptional activation of the gene for chloramphenicol acetyltransferase. We found the amount of chloramphenicol acetyltransferase induced by the wild-type alpha(IIb) TM helix was approximately half that induced by the strongly dimerizing TM helix of glycophorin A, confirming that the alpha(IIb) TM domain oligomerizes in biological membranes. Mutating each of the alpha(IIb) TM domain residues to either Ala, Leu, Ile, or Val revealed that a GXXXG motif mediates oligomerization. Further, we found that the residue preceding each glycine contributed to the oligomerization interface, as did the residue at position i + 4 after the second Gly of GXXXG. Thus, the sequence XXVGXXGGXXXLXX is critical for oligomerization of alpha(IIb) TM helix. These data were used to generate an atomic model of the alpha(IIb) homodimer, revealing a family of structures with right-handed crossing angles of 40degrees to 60degrees, consistent with a 4.0-residue periodicity, and with an interface rotated by 50degrees relative to glycophorin A. Thus, although the alpha(IIb) TM helix makes use of the GXXXG framework, neighboring residues have evolved to engineer its dimerization interface, enabling it to subserve specific and specialized functions.	Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 1009, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 1009, 422 Curie Blvd, Philadelphia, PA 19104 USA.	bennetts@mail.med.upenn.edu	Li, Renhao/B-1257-2012	Li, Renhao/0000-0002-5806-5080; Nanda, Vikas/0000-0003-2786-8347	NCI NIH HHS [K01 CA096706] Funding Source: Medline; NHLBI NIH HHS [HL54500, HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096706] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pilpel Y, 1999, J MOL BIOL, V294, P921, DOI 10.1006/jmbi.1999.3257; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2004, J BIOL CHEM, V279, P9840, DOI 10.1074/jbc.M312749200; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6	26	131	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26666	26673		10.1074/jbc.M314168200	http://dx.doi.org/10.1074/jbc.M314168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067009	hybrid			2022-12-27	WOS:000222003000093
J	Lowe, J; Vieyra, A; Catty, P; Guillain, F; Mintz, E; Cuille, M				Lowe, J; Vieyra, A; Catty, P; Guillain, F; Mintz, E; Cuille, M			A mutational study in the transmembrane domain of Ccc2p, the yeast Cu(I)-ATPase, shows different roles for each Cys-Pro-Cys cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; COPB COPPER ATPASE; TOXIC MILK MOUSE; SARCOPLASMIC-RETICULUM; ENTEROCOCCUS-HIRAE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; BIOCHEMICAL-CHARACTERIZATION	Ccc2p is homologous to the human Menkes and Wilson copper ATPases and is herein studied as a model for human copper transport. Most studies to date have sought to understand how mutations in the human Menkes or Wilson genes impair copper homeostasis and induce disease. Here we analyze whether eight conserved amino acids of the transmembrane domain are important for copper transport. Wild-type Ccc2p and variants were expressed in a ccc2-Delta yeast strain to check whether they were able to restore copper transport by complementation. Wild-type Ccc2p and variants were also expressed in Sf9 cells using baculovirus to study their enzymatic properties on membrane preparations. The latter system allowed us to measure a copper-activated ATPase activity of about 20 nmol/mg/min for the wildtype Ccc2p at 37degreesC. None of the variants was as efficient as the wild type in restoring copper homeostasis. The mutation of each cysteine of the (CPC585)-C-583 motif into a serine resulted in nonfunctional proteins that could not restore copper homeostasis in yeast and had no ATPase activity. Phosphorylation by ATP was still possible with the C583S variant, although it was not possible with the C585S variant, suggesting that the cysteines of the CPC motif have a different role in copper transport. Cys(583) would be necessary for copper dissociation and/or enzyme dephosphorylation and Cys(585) would be necessary for ATP phosphorylation, suggesting a role in copper binding.	Univ Grenoble 1, Lab Biophys Mol & Cellulaire, UMR CEA CNRS 5090, CEA,DRDC,BMC, F-38054 Grenoble 9, France; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Fisicoquim Biol Aida Hasson Voloch, BR-21941902 Rio De Janeiro, Brazil	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universidade Federal do Rio de Janeiro	Cuille, M (corresponding author), Univ Grenoble 1, Lab Biophys Mol & Cellulaire, UMR CEA CNRS 5090, CEA,DRDC,BMC, 17 Rue Martyrs, F-38054 Grenoble 9, France.	cuillel@cea.fr	Lowe, Jennifer/F-1148-2013	Lowe, Jennifer/0000-0001-7378-4561				Abe K, 2003, BIOCHEMISTRY-US, V42, P15132, DOI 10.1021/bi035686x; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Bissig KD, 2001, FEBS LETT, V507, P367, DOI 10.1016/S0014-5793(01)03009-5; Caruso-Neves C, 2000, BBA-BIOMEMBRANES, V1468, P107, DOI 10.1016/S0005-2736(00)00248-0; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; FIGUS A, 1995, AM J HUM GENET, V57, P1318; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Ge ZM, 1996, FEMS MICROBIOL LETT, V145, P181, DOI 10.1016/S0378-1097(96)00405-3; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Haas R, 1999, Hum Mutat, V14, P88, DOI 10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU15>3.0.CO;2-H; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, GASTROENTEROLOGY, V124, P335, DOI 10.1053/gast.2003.50066; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Lemos AD, 2002, Z NATURFORSCH C, V57, P500; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Muller-Ehmsen J, 2001, AM J PHYSIOL-CELL PH, V281, pC1355, DOI 10.1152/ajpcell.2001.281.4.C1355; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Takeda K, 1999, J MEMBRANE BIOL, V170, P13, DOI 10.1007/s002329900533; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; WEBER K, 1969, J BIOL CHEM, V244, P4406; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	54	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25986	25994		10.1074/jbc.M308736200	http://dx.doi.org/10.1074/jbc.M308736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078884	hybrid			2022-12-27	WOS:000222003000009
J	Oury, C; Sticker, E; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF				Oury, C; Sticker, E; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF			ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; P2X(1) ION-CHANNEL; PROTEIN-KINASE; SHAPE CHANGE; GP-IB; INTEGRIN ALPHA(IIB)BETA(3); ADENOSINE-DIPHOSPHATE; ENDOTHELIAL-CELLS; GRANULE SECRETION; RHO-KINASE	Shear stress triggers von Willebrand factor (VWF) binding to platelet glycoprotein Ibalpha and subsequent integrin alpha(IIb)beta(3)-dependent platelet aggregation. Concomitantly, nucleotides are released from platelet-dense granules, and ADP is known to contribute to shear-induced platelet aggregation (SIPA). We found that the impaired SIPA of platelets from a Hermansky-Pudlak patient lacking dense granules was restored by exogenous L-beta,gamma-methylene ATP, a stable P2X(1) agonist, as well as by ADP, confirming that in addition to ADP (via P2Y(1) and P2Y(12)), ATP (via P2X(1)) also contributes to SIPA. Likewise, SIPA of apyrase-treated platelets was restored upon P2X(1) activation with L-beta,gamma-methylene ATP, which promoted granule centralization within platelets and stimulated P-selectin expression, which is a marker of alpha-granule release. In addition, during SIPA, platelet degranulation required both extracellular Ca2+ and VWF-glycoprotein Ibalpha interactions without involving alpha(IIb)beta(3). Neither platelet release nor SIPA was affected by protein kinase C inactivation, even though protein kinase C blockade inhibits platelet responses to collagen and thrombin in stirring conditions. In contrast, inhibiting myosin light chain (MLC) kinase with ML-7 reduced platelet release and SIPA by 30%. Accordingly, the potentiating effect of P2X(1) stimulation on the aggregation of apyrase-reated platelets coincided with intensified phosphorylation of MLC and was abrogated by ML-7. SIPA-nduced MLC phosphorylation occurred exclusively through released nucleotides and selective antagonism of P2X(1) with MRS2159-reduced SIPA, ATP release, and potently inhibited MLC phosphorylation. We conclude that the P2X(1) ion channel induces MLC-mediated cytoskeletal rearrangements, thus contributing to SIPA and degranulation during VWF-triggered platelet activation.	Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Univ Louvain, Lab Morphol & Mol Pathol, B-3000 Louvain, Belgium		Hoylaerts, MF (corresponding author), Univ Louvain, Ctr Mol & Vasc Biol, Herestr 49, B-3000 Louvain, Belgium.	marc.hoylaerts@med.kuleuven.ac.be		Hoylaerts, Marc/0000-0002-6474-3933; Oury, Cecile/0000-0002-7561-0132				Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CHOW TW, 1992, BLOOD, V80, P113; Christodoulides N, 2001, THROMB RES, V102, P133, DOI 10.1016/S0049-3848(01)00243-2; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; Flaumenhaft R, 2003, ARTERIOSCL THROM VAS, V23, P1152, DOI 10.1161/01.ATV.0000075965.88456.48; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; Goto S, 2002, CIRCULATION, V105, P2531, DOI 10.1161/01.CIR.0000016703.93845.AF; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; Ikeda Y, 1997, ANN NY ACAD SCI, V811, P325, DOI 10.1111/j.1749-6632.1997.tb52012.x; Kageyama S, 1997, BRIT J PHARMACOL, V122, P165, DOI 10.1038/sj.bjp.0701354; Kasirer-Friede A, 2004, BLOOD, V103, P3403, DOI 10.1182/blood-2003-10-3664; KONSTANTOPOULOS K, 1995, THROMB HAEMOSTASIS, V74, P1329; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Kroll MH, 1996, BLOOD, V88, P1525; Kunapuli SP, 2003, CURR OPIN PHARMACOL, V3, P175, DOI 10.1016/S1471-4892(03)00007-9; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; MOAKE JL, 1988, BLOOD, V71, P1366; MORITZ MW, 1983, J LAB CLIN MED, V101, P537; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Nakai K., 1997, Life Sciences, V60, P181; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; Oury C, 2002, BLOOD, V100, P2499, DOI 10.1182/blood-2002-03-0812; Oury C, 2001, THROMB HAEMOSTASIS, V86, P1264; PAINTER RG, 1984, EXP CELL RES, V155, P198, DOI 10.1016/0014-4827(84)90781-X; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Resendiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639; Rolf MG, 2001, THROMB HAEMOSTASIS, V85, P303, DOI 10.1055/s-0037-1615684; Ruggeri ZM, 2003, CURR OPIN HEMATOL, V10, P142, DOI 10.1097/00062752-200303000-00008; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Turner NA, 2001, BLOOD, V98, P3340, DOI 10.1182/blood.V98.12.3340; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	44	38	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26266	26273		10.1074/jbc.M402032200	http://dx.doi.org/10.1074/jbc.M402032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087444	hybrid, Green Published			2022-12-27	WOS:000222003000044
J	Liu, JQ; Zelko, IN; Folz, RJ				Liu, JQ; Zelko, IN; Folz, RJ			Reoxygenation-induced constriction in murine coronary arteries - The role of endothelial NADPH oxidase (gp91(phox)) and intracellular superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; FREE-RADICAL GENERATION; REPERFUSION INJURY; NAD(P)H OXIDASE; NITRIC-OXIDE; DISMUTASE; HYPOXIA; CELLS; OVEREXPRESSION; MICE	Previous work suggests that superoxide mediates hypoxia/reoxygenation (H/R)-induced constriction of isolated mouse coronary arteries ( CA). To determine the source of superoxide overproduction during H/R we studied CA obtained from transgenic (Tg) mice overexpressing human CuZn-superoxide dismutase ( SOD) and mice lacking gp91(phox) using an in vitro vascular ring bioassay. We found that under normoxic conditions CA isolated from wild type (wt) mice, CuZn-SOD Tg mice and gp91(phox) knock-out mice had similar contractile responses to U46619 and hypoxia and similar dilation responses to acetylcholine. In wt CA, 30 min of hypoxia (1% O-2) followed by reoxygenation (16% O-2) resulted in further coronary vasoconstriction (internal diameter from 105 +/- 11 to 84.5 +/- 17.9 mum), whereas this response was completely blocked in both CuZn-SOD Tg and gp91(phox) knock-out CA (104.3 +/- 10.5 to 120.7 +/- 14 mum and 143.3 +/- 15.3 to 172.7 +/- 12.5 mum, respectively, p < 0.01). Furthermore, we show that H/R enhances the generation of superoxide radicals in wt CA (25.8 +/- 0.7 relative light units per second (RLU/s)), whereas CuZn-SOD Tg CA (12.2 +/- 0.8 RLU/s, p < 0.01) and gp91(phox) CA (12.5 +/- 0.9 RLU/s, p < 0.01) show reduced levels. These results demonstrate that H/R-induced vasoconstriction is mediated by intracellular superoxide overproduction via endothelial NADPH oxidase gp91(phox). Therefore, increasing endogenous levels of CuZn-SOD in CA may provide a novel cardioprotective strategy for maintaining coronary perfusion under conditions of H/R.	Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Liu, JQ (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Box 2620,Rm 341 MSRB, Durham, NC 27710 USA.	john.liu@duke.edu	Zelko, Igor N/L-2673-2013	Zelko, Igor N/0000-0003-3976-3884	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064894] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-64894] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbe C., 2001, Archives of Physiology and Biochemistry, V109, P24, DOI 10.1076/apab.109.1.24.4277; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BJORKMAN JA, 1991, BASIC RES CARDIOL, V86, P236, DOI 10.1007/BF02190603; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; Brandes RP, 1997, J PHYSIOL-LONDON, V500, P331, DOI 10.1113/jphysiol.1997.sp022024; BROWN IP, 1993, AM J PHYSIOL, V264, pH821, DOI 10.1152/ajpheart.1993.264.3.H821; Chen EP, 1998, J THORAC CARDIOV SUR, V115, P450, DOI 10.1016/S0022-5223(98)70289-2; Chen EP, 1996, CIRCULATION, V94, P412; Chen ZY, 2000, FREE RADICAL BIO MED, V29, P589, DOI 10.1016/S0891-5849(00)00363-4; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DIGNAN RJ, 1995, J THORAC CARDIOV SUR, V109, P892, DOI 10.1016/S0022-5223(95)70313-6; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Ghio AJ, 2003, AM J RESP CELL MOL, V29, P653, DOI 10.1165/rcmb.2003-0070OC; GRASER T, 1992, J CARDIOVASC PHARM, V20, pS117; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; JIANG C, 1994, BRIT J PHARMACOL, V111, P711, DOI 10.1111/j.1476-5381.1994.tb14795.x; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KWAN YW, 1989, BRIT J PHARMACOL, V96, P857, DOI 10.1111/j.1476-5381.1989.tb11895.x; Lee YH, 1998, YONSEI MED J, V39, P252, DOI 10.3349/ymj.1998.39.3.252; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; LIN Q, 1999, J APPL PHYSIOL, V87, P1392; Liu Q, 1997, BRIT J PHARMACOL, V120, P728, DOI 10.1038/sj.bjp.0700939; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MELLEMKJAER S, 1994, EUR J PHARM-ENVIRON, V270, P307, DOI 10.1016/0926-6917(94)90006-X; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; Nozik-Grayck E, 2003, AM J PHYSIOL-HEART C, V285, pH2327, DOI 10.1152/ajpheart.00507.2003; OTANI H, 1986, J SURG RES, V41, P126, DOI 10.1016/0022-4804(86)90017-X; PEARSON PJ, 1990, CIRC RES, V67, P385, DOI 10.1161/01.RES.67.2.385; Pearson PJ, 1996, CLIN EXP PHARMACOL P, V23, P634, DOI 10.1111/j.1440-1681.1996.tb01749.x; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; RUBANYI GM, 1985, J PHYSIOL-LONDON, V364, P45, DOI 10.1113/jphysiol.1985.sp015728; SELLKE FW, 1992, J THORAC CARDIOV SUR, V104, P357; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Terada LS, 1996, AM J PHYSIOL-HEART C, V270, pH945, DOI 10.1152/ajpheart.1996.270.3.H945; TODA N, 1992, AM J PHYSIOL, V262, pH678, DOI 10.1152/ajpheart.1992.262.3.H678; VANHAECKE J, 1991, J AM COLL CARDIOL, V18, P224, DOI 10.1016/S0735-1097(10)80243-8; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	45	136	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24493	24497		10.1074/jbc.M402920200	http://dx.doi.org/10.1074/jbc.M402920200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15070892	hybrid			2022-12-27	WOS:000221702500077
J	Miles, EW; Kraus, JP				Miles, EW; Kraus, JP			Cystathionine beta-synthase: Structure, function, regulation, and location of homocystinuria-causing mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HEME PROTEIN; SACCHAROMYCES-CEREVISIAE; PYRIDOXAL 5'-PHOSPHATE; TRANSCRIPTION FACTORS; REACTION-MECHANISM; ACTIVE CORE; NF-Y; YEAST; DOMAIN; TRANSSULFURATION		Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; NIDDK, NIH, Bethesda, MD 20892 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kraus, JP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, C233,4200 E 9th Ave, Denver, CO 80262 USA.	Jan.Kraus@uchsc.edu						Aitken SM, 2004, BIOCHEMISTRY-US, V43, P1963, DOI 10.1021/bi035496m; Banerjee R, 2003, BBA-PROTEINS PROTEOM, V1647, P30, DOI 10.1016/S1570-9639(03)00044-X; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BRAUNSTEIN AE, 1984, ADV ENZYMOL RAMB, V56, P1; Bruno S, 2001, J BIOL CHEM, V276, P16, DOI 10.1074/jbc.C000588200; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COOK PF, 1976, J BIOL CHEM, V251, P2023; Evande R, 2002, BIOCHEMISTRY-US, V41, P11832, DOI 10.1021/bi026248d; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; Jhee KH, 2002, BIOCHEMISTRY-US, V41, P1828, DOI 10.1021/bi011756t; Jhee KH, 2001, BIOCHEMISTRY-US, V40, P10873, DOI 10.1021/bi011087j; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kabil O, 1999, J BIOL CHEM, V274, P31256, DOI 10.1074/jbc.274.44.31256; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; KERY V, 1994, J BIOL CHEM, V269, P25283; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; Kraus JP, 1999, HUM MUTAT, V13, P362; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; LIPSON MH, 1980, J CLIN INVEST, V66, P188, DOI 10.1172/JCI109843; Maclean KN, 2004, J BIOL CHEM, V279, P8558, DOI 10.1074/jbc.M310211200; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Maclean KN, 2000, J INORG BIOCHEM, V81, P161, DOI 10.1016/S0162-0134(00)00100-8; MACLEAN KN, 2004, IN PRESS SIGNAL TRAN; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Meier M, 2003, BBA-PROTEINS PROTEOM, V1647, P206, DOI 10.1016/S1570-9639(03)00048-7; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Nozaki T, 2001, J BIOL CHEM, V276, P6516, DOI 10.1074/jbc.M009774200; Ojha S, 2000, BIOCHEMISTRY-US, V39, P10542, DOI 10.1021/bi000831h; Oliveriusova J, 2002, J BIOL CHEM, V277, P48386, DOI 10.1074/jbc.M207087200; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Shan XY, 2001, HUM MOL GENET, V10, P635, DOI 10.1093/hmg/10.6.635; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 2002, J BIOL CHEM, V277, P22421, DOI 10.1074/jbc.M202513200; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2002, BIOCHEMISTRY-US, V41, P10454, DOI 10.1021/bi026052d; WILLHARDT I, 1975, ANAL BIOCHEM, V63, P263, DOI 10.1016/0003-2697(75)90213-4; Zou CG, 2003, J BIOL CHEM, V278, P16802, DOI 10.1074/jbc.M212376200	50	168	185	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29871	29874		10.1074/jbc.R400005200	http://dx.doi.org/10.1074/jbc.R400005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15087459	hybrid			2022-12-27	WOS:000222531900001
J	Fischer, AM; Mercer, JC; Iyer, A; Ragin, MJ; August, A				Fischer, AM; Mercer, JC; Iyer, A; Ragin, MJ; August, A			Regulation of CXC chemokine receptor 4-mediated migration by the tec family tyrosine kinase ITK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTE CHEMOATTRACTANT; HOMOLOGY DOMAIN; CUTTING EDGE; MICE LACKING; HIV-1 ENTRY; ACTIVATION; SDF-1; CHEMOTAXIS	Chemokines are critical in controlling lymphocyte traffic and migration. The CXC chemokine CXCL12/ SDF-1alpha interacts with its receptor CXCR4 to induce the migration of a number of different cell types. Although an understanding of the physiological functions of this chemokine is emerging, the mechanism by which it regulates T cell migration is still unclear. We show here that the Tec family kinase ITK is activated rapidly following CXCL12/SDF-1alpha stimulation, and this requires Src and phosphatidylinositol 3-kinase activities. ITK regulates the ability of CXCL12/SDF-1alpha to induce T cell migration as overexpression of wild-type ITK-enhanced migration, and T cells lacking ITK exhibit reduced migration as well as adhesion in response to CXCL12/SDF-1alpha. Further analysis suggests that ITK may regulate CXCR4-mediated migration and adhesion by altering the actin cytoskeleton, as ITK null T cells were significantly defective in CXCL12/SDF-1a-mediated actin polymerization. Our data suggest that ITK may regulate the ability of CXCR4 to induce T cell migration.	Penn State Univ, Dept Vet Sci, Immunol Res Labs, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, Pathobiol Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Immunobiol Opt Integrated Biosci Grad Program, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	August, A (corresponding author), Penn State Univ, Dept Vet Sci, Immunol Res Labs, 115 Henning Bldg, University Pk, PA 16802 USA.	axa45@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI51626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Dutt P, 1998, J IMMUNOL, V161, P3652; Gibson S, 1996, J IMMUNOL, V156, P2716; GIBSON S, 1993, BLOOD, V82, P1561; Grasis JA, 2003, J IMMUNOL, V170, P3971, DOI 10.4049/jimmunol.170.8.3971; Hao SL, 2002, FEBS LETT, V525, P53, DOI 10.1016/S0014-5793(02)03066-1; Hunter AJ, 2000, J IMMUNOL, V164, P1143, DOI 10.4049/jimmunol.164.3.1143; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; LANO CM, 2003, CURR BIOL, V13, P1619; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu YL, 1998, J IMMUNOL, V161, P5404; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232	27	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29816	29820		10.1074/jbc.M312848200	http://dx.doi.org/10.1074/jbc.M312848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123627	hybrid			2022-12-27	WOS:000222445300118
J	Huang, YP; Wange, RL				Huang, YP; Wange, RL			T cell receptor signaling: Beyond complex complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; KINASE-C-THETA; IMMUNOLOGICAL SYNAPSE; ANTIGEN RECEPTOR; TRANSCRIPTIONAL REGULATION; LYMPHOCYTE-ACTIVATION; IMMUNE-RESPONSES; TYROSINE KINASES; ROADS LEAD; PKC-THETA		NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572	NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; Cannon JL, 2002, IMMUNOL REV, V186, P90, DOI 10.1034/j.1600-065X.2002.18609.x; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Clements JL, 2003, IMMUNOL REV, V191, P211, DOI 10.1034/j.1600-065X.2003.00002.x; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dienz O, 2003, J IMMUNOL, V170, P365, DOI 10.4049/jimmunol.170.1.365; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Fuller CL, 2003, IMMUNOL REV, V191, P220, DOI 10.1034/j.1600-065X.2003.00004.x; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grasis JA, 2003, J IMMUNOL, V170, P3971, DOI 10.4049/jimmunol.170.8.3971; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Herndon TM, 2001, J IMMUNOL, V166, P5654, DOI 10.4049/jimmunol.166.9.5654; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x; Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Labno CM, 2003, CURR BIOL, V13, P1619, DOI 10.1016/j.cub.2003.08.005; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Malissen B, 2003, IMMUNOL REV, V191, P7, DOI 10.1034/j.1600-065X.2003.00016.x; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Schmitz ML, 2003, FASEB J, V17, P2187, DOI 10.1096/fj.02-1100rev; Seminario MC, 2003, IMMUNOL REV, V192, P80, DOI 10.1034/j.1600-065X.2003.00013.x; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Takesono A, 2002, J CELL SCI, V115, P3039; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WANGE RL, 2000, SCI STKE; WANGE RL, 2004, MECH SIGNAL TRANSDUC, P21; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Zeng R, 2003, J IMMUNOL, V171, P1360, DOI 10.4049/jimmunol.171.3.1360; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	59	114	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28827	28830		10.1074/jbc.R400012200	http://dx.doi.org/10.1074/jbc.R400012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15084594	hybrid			2022-12-27	WOS:000222445300001
J	Marlowe, JL; Knudsen, ES; Schwemberger, S; Puga, A				Marlowe, JL; Knudsen, ES; Schwemberger, S; Puga, A			The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; RAT HEPATOMA-CELLS; AH DIOXIN RECEPTOR; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; LACTATIONAL EXPOSURE; FUNCTIONAL DOMAINS; CANCER MORTALITY; CYCLE ARREST; E2F FAMILY	The environmental contaminant 2,3,7,8-tetrachlorodibenzop- dioxin ( TCDD) causes a wide range of toxic, teratogenic, and carcinogenic effects. TCDD is a ligand for the aromatic hydrocarbon receptor (AHR), a ligand-activated transcription factor believed to be the primary mediator of these effects. Activation of the AHR by TCDD also elicits a variety of effects on cell cycle progression, ranging from proliferation to arrest. In this report, we have characterized further the role of the activated AHR in cell cycle regulation. In human mammary carcinoma MCF-7 and mouse hepatoma Hepa-1 cells, TCDD treatment decreased the number of cells in S phase and caused the accumulation of cells in G(1). In Hepa-1 cells, this effect correlated with the transcriptional repression of several E2F-regulated genes required for S phase progression. AHR-mediated gene repression was dependent on its interaction with retinoblastoma protein but was independent of its transactivation function because AHR mutants lacking DNA binding or transactivation domains repressed E2F-dependent expression as effectively as wild type AHR. Overexpression of p300 suppressed retinoblastoma protein-dependent gene repression, and this effect was reversed by TCDD. Chromatin immunoprecipitation assays showed that TCDD treatment caused the recruitment of AHR to E2F-dependent promoters and the concurrent displacement of p300. These results delineate a novel mechanism whereby the AHR, a known transcriptional activator, also mediates gene repression by pathways involving combinatorial interactions at E2F-responsive promoters, leading to the repression of E2F-dependent, S phase-specific genes. The AHR seems to act as an environmental checkpoint that senses exposure to environmental toxicants and responds by signaling cell cycle inhibition.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Puga, A (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	Alvaro.Puga@UC.edu	Puga, Alvaro/B-7676-2008		NIEHS NIH HHS [ES06273, P30 ES06096] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006273, P30ES006096, R56ES006273] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BIRNBAUM LS, 1995, ENVIRON HEALTH PERSP, V103, P89, DOI 10.2307/3432515; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; CHOI EJ, 1991, J BIOL CHEM, V266, P9591; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Dragan YP, 2000, FOOD ADDIT CONTAM A, V17, P289, DOI 10.1080/026520300283360; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GAIDO KW, 1992, J BIOL CHEM, V267, P24591; GAIDO KW, 1994, TOXICOL APPL PHARM, V127, P199, DOI 10.1006/taap.1994.1154; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GOTTLICHER M, 1990, CARCINOGENESIS, V11, P2205, DOI 10.1093/carcin/11.12.2205; GOTTLICHER M, 1991, TOXICOL APPL PHARM, V111, P496, DOI 10.1016/0041-008X(91)90253-B; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hestermann EV, 2002, AQUAT TOXICOL, V58, P201, DOI 10.1016/S0166-445X(01)00229-6; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Kamath AB, 1997, TOXICOL APPL PHARM, V142, P367, DOI 10.1006/taap.1996.8049; Kerkvliet NI, 1995, ENVIRON HEALTH PERSP, V103, P47, DOI 10.2307/3432722; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kobayashi A, 1997, J BIOCHEM, V122, P703; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Levine-Fridman A, 2004, MOL PHARMACOL, V65, P461, DOI 10.1124/mol.65.2.461; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; Mann PC, 1997, TOXICOL PATHOL, V25, P72, DOI 10.1177/019262339702500114; MANZ A, 1991, LANCET, V338, P959, DOI 10.1016/0140-6736(91)91835-I; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MCCONKEY DJ, 1989, BIOCHEM BIOPH RES CO, V160, P1003, DOI 10.1016/S0006-291X(89)80101-9; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moolgavkar SH, 1996, TOXICOL APPL PHARM, V138, P31, DOI 10.1006/taap.1996.0094; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; OUGHTON JA, 1995, FUND APPL TOXICOL, V25, P60, DOI 10.1006/faat.1995.1040; PIRKLE JL, 1989, J TOXICOL ENV HEALTH, V27, P165, DOI 10.1080/15287398909531288; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Safe S, 1998, TOXICOL LETT, V103, P343; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Steenland K, 1999, J NATL CANCER I, V91, P779, DOI 10.1093/jnci/91.9.779; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1992, CHEMOSPHERE, V25, P223, DOI 10.1016/0045-6535(92)90519-W; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Wang WL, 1998, ARCH BIOCHEM BIOPHYS, V356, P239, DOI 10.1006/abbi.1998.0782; Wang XH, 1996, BIOCHEM BIOPH RES CO, V220, P784, DOI 10.1006/bbrc.1996.0481; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WIEBEL FJ, 1991, TOXICOL LETT, V55, P161, DOI 10.1016/0378-4274(91)90130-X; WOLFLE D, 1988, CARCINOGENESIS, V9, P919, DOI 10.1093/carcin/9.6.919; Worner W, 1996, CANCER RES, V56, P1272; 1997, IARC MONOGRAPH EVALU	78	114	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29013	29022		10.1074/jbc.M404315200	http://dx.doi.org/10.1074/jbc.M404315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123621	hybrid			2022-12-27	WOS:000222445300024
J	Mortl, M; Diederichs, K; Welte, W; Molla, G; Motteran, L; Andriolo, G; Pilone, MS; Pollegioni, L				Mortl, M; Diederichs, K; Welte, W; Molla, G; Motteran, L; Andriolo, G; Pilone, MS; Pollegioni, L			Structure-function correlation in glycine oxidase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; MONOMERIC SARCOSINE OXIDASE; PARA-HYDROXYBENZOATE HYDROXYLASE; CATABOLITE REPRESSION; CRYSTAL-STRUCTURE; DIFFRACTION DATA; PROTEIN; SUBSTRATE; MECHANISM; RESOLUTION	Structure-function relationships of the flavoprotein glycine oxidase ( GO), which was recently proposed as the first enzyme in the biosynthesis of thiamine in Bacillus subtilis, has been investigated by a combination of structural and functional studies. The structure of the GO-glycolate complex was determined at 1.8 Angstrom, a resolution at which a sketch of the residues involved in FAD binding and in substrate interaction can be depicted. GO can be considered a member of the "amine oxidase" class of flavoproteins, such as D-amino acid oxidase and monomeric sarcosine oxidase. With the obtained model of GO the monomer-monomer interactions can be analyzed in detail, thus explaining the structural basis of the stable tetrameric oligomerization state of GO, which is unique for the GR(2) subfamily of flavooxidases. On the other hand, the three-dimensional structure of GO and the functional experiments do not provide the functional significance of such an oligomerization state; GO does not show an allosteric behavior. The results do not clarify the metabolic role of this enzyme in B. subtilis; the broad substrate specificity of GO cannot be correlated with the inferred function in thiamine biosynthesis, and the structure does not show how GO could interact with ThiS, the following enzyme in thiamine biosynthesis. However, they do let a general catabolic role of this enzyme on primary or secondary amines to be excluded because the expression of GO is not inducible by glycine, sarcosine, or D-alanine as carbon or nitrogen sources.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Konstanz, Biol Sect, D-7750 Constance, Germany	University of Insubria; University of Konstanz	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it		Molla, Gianluca/0000-0003-3688-3397; POLLEGIONI, LOREDANO/0000-0003-1733-7243				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Fisher Susan H., 1993, P221; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Job V, 2002, J BIOL CHEM, V277, P6985, DOI 10.1074/jbc.M111095200; Job V, 2002, EUR J BIOCHEM, V269, P1456, DOI 10.1046/j.1432-1033.2002.02790.x; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MirandaRios J, 1997, J BACTERIOL, V179, P6887, DOI 10.1128/jb.179.22.6887-6893.1997; Molla G, 2003, EUR J BIOCHEM, V270, P1474, DOI 10.1046/j.1432-1033.2003.03513.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204; PHILIPPSEN A, 2003, DINO VISUALIZING STR; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; POLLEGIONI L, 1995, BIOCHEM J, V310, P577, DOI 10.1042/bj3100577; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sacchi S, 2002, J BIOL CHEM, V277, P27510, DOI 10.1074/jbc.M203946200; Saier MH, 1996, J BACTERIOL, V178, P3411, DOI 10.1128/jb.178.12.3411-3417.1996; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHREIER HJ, 1983, BACILLUS SUBTILIS OT, P281; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8825, DOI 10.1021/bi000350y; Wagner MA, 1997, ARCH BIOCHEM BIOPHYS, V342, P176, DOI 10.1006/abbi.1997.0106; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; Zhao GH, 2002, BIOCHEMISTRY-US, V41, P9747, DOI 10.1021/bi020285n	48	55	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29718	29727		10.1074/jbc.M401224200	http://dx.doi.org/10.1074/jbc.M401224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105420	hybrid, Green Published			2022-12-27	WOS:000222445300108
J	Phan, J; Peterfy, M; Reue, K				Phan, J; Peterfy, M; Reue, K			Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL GENERALIZED LIPODYSTROPHY; FAMILIAL PARTIAL LIPODYSTROPHY; ADIPOCYTE DIFFERENTIATION; ADIPOSE-TISSUE; MICE LACKING; INSULIN-RESISTANCE; METABOLIC SYNDROME; LAMIN A/C; WHITE FAT; OBESITY	We recently identified mutations in the lipin gene, Lpin1, as the cause of lipodystrophy in the fatty liver dystrophy (fld) mouse. Here we identify impaired adipocyte differentiation as the basis for lipodystrophy in lipin-deficient mice and demonstrate that lipin is required for normal induction of the adipogenic gene transcription program. We found that the reduced adiposity in chow fed fld mice and resistance to obesity in fld mice fed a high-fat diet is associated with reduced adipogenic gene expression. Using primary mouse embryonic fibroblasts isolated from fld mice, we confirmed that lipin deficiency prevents normal lipid accumulation and induction of key adipogenic genes, including peroxisome proliferator-activated receptor (PPAR)gamma and CCAAT enhancer-binding protein (C/EBP)alpha. However, our previous studies of daily gene expression in differentiating 3T3-L1 preadipocytes indicated that lipin expression is undetectable until about day 3 of differentiation, at a point after PPARgamma and C/EBPalpha gene expression is established. This paradox was resolved by examining gene expression at 10-h intervals during 3T3-L1 cell differentiation, leading to detection of transient lipin expression at 10 h into the differentiation program, prior to the induction of PPARgamma and C/EBPalpha. Consistent with a requirement for lipin expression upstream of PPARgamma, differentiation of lipin-deficient mouse embryonic fibroblasts could be rescued by ectopic expression of PPARgamma. Thus, we conclude that lipin expression is required prior to PPARgamma during adipocyte differentiation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA; Vet Afffairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reue, K (corresponding author), 11301 Wilshire Blvd,Bldg 113,Room 312, Los Angeles, CA 90073 USA.	reuek@ucla.edu		Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL28481] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; Alexander DL, 1998, J CELL SCI, V111, P3311; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Bhayana S, 2002, CLIN BIOCHEM, V35, P171, DOI 10.1016/S0009-9120(02)00297-7; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Garg A, 2004, NEW ENGL J MED, V350, P1220, DOI 10.1056/NEJMra025261; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; Hegele RA, 2003, TRENDS ENDOCRIN MET, V14, P371, DOI 10.1016/S1043-2760(03)00142-5; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Oral EA, 2003, REV ENDOCR METAB DIS, V4, P61, DOI 10.1023/A:1021827520301; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Reue K, 2000, Curr Atheroscler Rep, V2, P390, DOI 10.1007/s11883-000-0077-1; Reue K, 2000, J LIPID RES, V41, P1067; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Scott CL, 2003, AM J CARDIOL, V92, p35I, DOI 10.1016/S0002-9149(03)00507-1; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valet P, 2002, J LIPID RES, V43, P835; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7	49	176	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29558	29564		10.1074/jbc.M403506200	http://dx.doi.org/10.1074/jbc.M403506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123608	hybrid			2022-12-27	WOS:000222445300090
J	Ding, ZH; Gillespie, LL; Mercer, FC; Paterno, GD				Ding, ZH; Gillespie, LL; Mercer, FC; Paterno, GD			The SANT domain of human MI-ER1 interacts with Sp1 to interfere with GC box recognition and repress transcription from its own promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; FUNCTIONAL INTERACTION; INDEPENDENT MECHANISMS; NUCLEAR RECEPTOR; GROWTH-FACTOR; N-COR; PROTEIN; COMPLEX; GENE; ELEMENT	ld;&. 2qTo gain insight into the regulation of hmi-er1 expression, we cloned a human genomic DNA fragment containing one of the two hmi-er1 promoters and consisting of 1460 bp upstream of the translation initiation codon of hMI-ER1. Computer-assisted sequence analysis revealed that the hmi-er1 promoter region contains a CpG island but lacks an identifiable TATA element, initiator sequence and downstream promoter element. This genomic DNA was able to direct transcription of a luciferase reporter gene in a variety of human cell lines, and the minimal promoter was shown to be located within - 68/+144 bp. Several putative Sp1 binding sites were identified, and we show that Sp1 can bind to the hmi-er1 minimal promoter and increase transcription, suggesting that the level of hmi-er1 expression may depend on the availability of Sp1 protein. Functional analysis revealed that hMI-ER1 represses Sp1-activated transcription from the minimal promoter by a histone deacetylase-independent mechanism. Chromatin immunoprecipitation analysis demonstrated that both Sp1 and hMI-ER1 are associated with the chromatin of the hmi-er1 promoter and that overexpression of hMI-ER1 in cell lines that allow Tet-On-inducible expression resulted in loss of detectable Sp1 from the endogenous hmi-er1 promoter. The mechanism by which this occurs does not involve binding of hMI-ER1 to cis-acting elements. Instead, we show that hMI-ER1 physically associates with Sp1 and that endogenous complexes containing the two proteins could be detected in vivo. Furthermore, hMI-ER1 specifically interferes with binding of Sp1 to the hmi-er1 minimal promoter as well as to an Sp1 consensus oligonucleotide. Deletion analysis revealed that this interaction occurs through a region containing the SANT domain of hMI-ER1. Together, these data reveal a functional role for the SANT domain in the action of co-repressor regulatory factors and suggest that the association of hMI-ER1 with Sp1 represents a novel mechanism for the negative regulation of Sp1 target promoters.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Labs, St John, NF A1B 3V6, Canada	Memorial University Newfoundland	Paterno, GD (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Labs, 300 Prince Phillip Dr, St John, NF A1B 3V6, Canada.	gpaterno@mun.ca						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Ding ZH, 2003, MOL CELL BIOL, V23, P250, DOI 10.1128/MCB.23.1.250-258.2003; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Paterno GD, 1998, GENE, V222, P77, DOI 10.1016/S0378-1119(98)00473-9; Paterno GD, 2002, GENE, V295, P79, DOI 10.1016/S0378-1119(02)00823-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Post JN, 2001, FEBS LETT, V502, P41, DOI 10.1016/S0014-5793(01)02653-9; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Solari F, 1999, DEVELOPMENT, V126, P2483; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	38	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28009	28016		10.1074/jbc.M403793200	http://dx.doi.org/10.1074/jbc.M403793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117948	hybrid			2022-12-27	WOS:000222265400024
J	Miranda, E; Romisch, K; Lomas, DA				Miranda, E; Romisch, K; Lomas, DA			Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; PLASMINOGEN-ACTIVATOR; INCLUSION-BODIES; ALPHA(1)-ANTITRYPSIN DEFICIENCY; CONFORMATIONAL DISEASE; PROTEINASE-INHIBITOR; REACTIVE LOOP; LIVER-INJURY; IN-VITRO; DEGRADATION	The dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) is caused by the accumulation of mutant neuroserpin within neurons (Davis, R. L., Shrimpton, A. E., Holohan, P. D., Bradshaw, C., Feiglin, D., Sonderegger, P., Kinter, J., Becker, L. M., Lacbawan, F., Krasnewich, D., Muenke, M., Lawrence, D. A., Yerby, M. S., Shaw, C.-M., Gooptu, B., Elliott, P. R., Finch, J. T., Carrell, R. W., and Lomas, D. A. ( 1999) Nature 401, 376-379), but little is known about the trafficking of wild type and mutant neuroserpins. We have established a cell model to study the processing of wild type neuroserpin and the Syracuse (S49P) and Portland (S52R) mutants that cause FENIB. Here we show that Syracuse and Portland neuroserpin are retained soon after their synthesis in the endoplasmic reticulum and that the limiting step in their processing is the transport to the Golgi complex. This is in contrast to the wild type protein, which is secreted into the culture medium. Mutant neuroserpin is retained within the endoplasmic reticulum as polymers, similar to those isolated from the intraneuronal inclusions in the brains of individuals with FENIB. Remarkably, the Portland mutant showed faster accumulation and slower secretion compared with the Syracuse mutant, in keeping with the more severe clinical phenotype found in patients with the Portland variant of neuroserpin. Both mutant and wild type neuroserpin were partially degraded by proteasomes. Taken together, our results provide further understanding of how cells handle defective but ordered mutant proteins and provide strong support for a common mechanism of disease caused by mutants of the serine protease inhibitor superfamily.	Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Miranda, E (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	em285@cam.ac.uk	Miranda, Elena/J-4999-2012; Römisch, Karin/AAO-1210-2021	Miranda, Elena/0000-0002-0586-8795; Römisch, Karin/0000-0003-0415-6558				Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200; Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Hill RM, 2002, ANN NY ACAD SCI, V971, P406, DOI 10.1111/j.1749-6632.2002.tb04503.x; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LIBBY P, 1978, SCIENCE, V199, P534, DOI 10.1126/science.622552; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Parfrey H, 2003, J BIOL CHEM, V278, P33060, DOI 10.1074/jbc.M302646200; Parmar PK, 2002, J NEUROCHEM, V82, P1406, DOI 10.1046/j.1471-4159.2002.01100.x; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Tanaka Y, 2002, J BIOL CHEM, V277, P51058, DOI 10.1074/jbc.M210231200; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhou AW, 2003, J BIOL CHEM, V278, P15116, DOI 10.1074/jbc.M211663200	50	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28283	28291		10.1074/jbc.M313166200	http://dx.doi.org/10.1074/jbc.M313166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090543	Green Published, hybrid			2022-12-27	WOS:000222265400059
J	Uccelletti, D; O'Callaghan, C; Berninsone, P; Zemtseva, I; Abeijon, C; Hirschberg, CB				Uccelletti, D; O'Callaghan, C; Berninsone, P; Zemtseva, I; Abeijon, C; Hirschberg, CB			ire-1-dependent transcriptional up-regulation of a lumenal uridine diphosphatase from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE SUGAR TRANSPORTERS; VACUOLAR H+-ATPASE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE DIPHOSPHATASE; MESSENGER-RNA; ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I; SCHIZOSACCHAROMYCES-POMBE; GUANOSINE DIPHOSPHATASE; EPITHELIAL INVAGINATION	Lumenal ecto-nucleoside tri- and di-phosphohydrolases (ENTPDases) of the secretory pathway of eukaryotes hydrolyze nucleoside diphosphates resulting from glycosyltransferase-mediated reactions, yielding nucleoside monophosphates. The latter are weaker inhibitors of glycosyltransferases than the former and are also antiporters for the transport of nucleotide sugars from the cytosol to the endoplasmic reticulum ( ER) and Golgi apparatus (GA) lumen. Here we describe the presence of two cation-dependent nucleotide phosphohydrolase activities in membranes of Caenorhabditis elegans: one, UDA-1, is a UDP/GDPase encoded by the gene uda-1, whereas the other is an apyrase encoded by the gene ntp-1. UDA-1 shares significant amino acid sequence similarity to yeast GA Gda1p and mammalian UDP/GDPases and has a lumenal active site in vesicles displaying an intermediate density between those of the ER and GA when expressed in S. cerevisiae. NTP-1 expressed in COS-7 cells appeared to localize to the GA. The transcript of uda-1 but not those of two other C. elegans ENTPDase mRNAs (ntp-1 and mig-23) was induced up to 3.5-fold by high temperature, tunicamycin, and ethanol. The same effectors triggered the unfolded protein response as shown by the induction of expression of green fluorescent protein under the control of the BiP chaperone promoter and the UDP-glucose: glycoprotein glucosyltransferase. Up-regulation of uda-1 did not occur in ire-1-deficient mutants, demonstrating the role of this ER stress sensor in this event. We hypothesize that up-regulation of uda-1 favors hydrolysis of the glucosyltransferase inhibitory product UDP to UMP, and that the latter product then exits the lumen of the ER or pre-GA compartment in a coupled exchange with the entry of UDP-glucose, thereby further relieving ER stress by favoring protein re-glycosylation.	Boston Univ, Dept Mol & Cell Biol, Goldman Sch Dent Med, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Dept Mol & Cell Biol, Goldman Sch Dent Med, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Uccelletti, Daniela/0000-0001-6841-8129	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Biederbick A, 1999, J CELL SCI, V112, P2473; BRENNER S, 1974, GENETICS, V77, P71; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CAREY DJ, 1980, J BIOL CHEM, V255, P4348; Chen SH, 2003, BIOCHIMIE, V85, P391, DOI 10.1016/S0300-9084(03)00009-9; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; Coppi MV, 1997, FEBS LETT, V405, P281, DOI 10.1016/S0014-5793(97)00182-8; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; Dejgaard S, 2004, CURR ISSUES MOL BIOL, V6, P29; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herrero AB, 2002, EUKARYOT CELL, V1, P420, DOI 10.1128/EC.1.3.420-431.2002; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Krause M, 1995, METHOD CELL BIOL, V48, P483; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lopez-Avalos MD, 2001, GLYCOBIOLOGY, V11, P413, DOI 10.1093/glycob/11.5.413; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; Nishiwaki K, 2004, NAT CELL BIOL, V6, P31, DOI 10.1038/ncb1079; Park BJ, 2001, MOL BIOL CELL, V12, P2835, DOI 10.1091/mbc.12.9.2835; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PEREZ M, 1986, J BIOL CHEM, V261, P6822; SHERMAN F, 1986, METHODS YEAST GENETI, P121; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; Zheng QL, 2002, J BIOL CHEM, V277, P39823, DOI 10.1074/jbc.M207487200; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 2003, J BIOL CHEM, V278, P33436, DOI 10.1074/jbc.M305785200; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	50	13	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27390	27398		10.1074/jbc.M402624200	http://dx.doi.org/10.1074/jbc.M402624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102851	hybrid			2022-12-27	WOS:000222120400070
J	Wang, JF; Zhang, XF; Groopman, JE				Wang, JF; Zhang, XF; Groopman, JE			Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; VEGF-C; MEDIATED ACTIVATION; BREAST-CANCER; EGF RECEPTORS; KAPPA-B; SRC; GENE	Reactive oxygen species (ROS) mediate cell damage and have been implicated in the pathogenesis of diseases that involve endothelial injury. Cells possess antioxidant systems, including intracellular antioxidants and ROS scavenging enzymes, that control the redox state and prevent cell damage. In addition to intracellular antioxidants, certain growth factor receptors can be activated under oxidative stress and trigger downstream cell survival signaling cascades. Vascular endothelial growth factor receptor-3 (VEGFR-3) is a primary modulator of lymphatic endothelial proliferation and survival. Here, we provide evidence that activation of VEGFR-3 signaling in response to hydrogen peroxide (H2O2) promotes endothelial cell survival. Treatment with H2O2 induced the tyrosine phosphorylation of VEGFR-3 and its association with the signaling adaptor proteins Shc, growth factor receptor binding protein 2, Sos, p85, SHP-2, and phospholipase C-gamma. Of note, a hereditary lymphoedema-linked mutant of VEGFR-3 was not phosphorylated by H2O2 treatment. Isoforms of protein kinase C (PKC), alpha and delta, were also tyrosine-phosphorylated after H2O2 stimulation. However, only the delta isoform of PKC was required for H2O2-induced phosphorylation of VEGFR-3. The tyrosine phosphorylation of VEGFR-3 or isoforms of PKC was completely inhibited by treatment with 4-amino-5-(4-chlorophenyl)-7-(t- butyl) pyrazolo[ 3,4-d] pyrimidine, a specific inhibitor for Src family kinases, indicating that Src family kinases are upstream of PKC and VEGFR-3. Furthermore, expression of the wild-type but not the lymphoedema-linked mutant form of VEGFR-3 in porcine artery endothelial cells significantly enhanced the activation of Akt after H2O2 stimulation. Consistent with these biochemical changes, we observed that expression and activation of the wild-type but not the mutant form of VEGFR-3 inhibited H2O2-induced apoptosis. These studies suggest that VEGFR-3 protects against oxidative damage in endothelial cells, and that patients with hereditary lymphoedema may be susceptible to ROS-induced cell damage.	Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061940] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; GALLAND F, 1993, ONCOGENE, V8, P1233; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kirkin V, 2001, EUR J BIOCHEM, V268, P5530, DOI 10.1046/j.1432-1033.2001.02476.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; LU D, 1993, AM J PHYSIOL, V264, pC715, DOI 10.1152/ajpcell.1993.264.3.C715; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Ng CKD, 2002, AM J PHYSIOL-CELL PH, V283, pC93, DOI 10.1152/ajpcell.00301.2001; Niwa K, 2001, FREE RADICAL RES, V35, P519, DOI 10.1080/10715760100301531; OHKUMA M, 1993, LYMPHOLOGY, V26, P38; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Saaristo A, 2002, ANN NY ACAD SCI, V979, P94, DOI 10.1111/j.1749-6632.2002.tb04871.x; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Shono T, 1996, MOL CELL BIOL, V16, P4231; Siems WG, 2002, QJM-INT J MED, V95, P803, DOI 10.1093/qjmed/95.12.803; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Wan YS, 2001, INT J ONCOL, V18, P461; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	65	63	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27088	27097		10.1074/jbc.M314015200	http://dx.doi.org/10.1074/jbc.M314015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102829	hybrid			2022-12-27	WOS:000222120400035
J	Li, FW; Templeton, TJ; Popov, V; Comer, JE; Tsuboi, T; Torii, M; Vinetz, JM				Li, FW; Templeton, TJ; Popov, V; Comer, JE; Tsuboi, T; Torii, M; Vinetz, JM			Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSQUITO MIDGUT STAGES; SPOROGONIC DEVELOPMENT; A-DOMAIN; FALCIPARUM; GALLINACEUM; ANTIBODIES; CTRP; IDENTIFICATION; CHITINASES; INFECTION	The mosquito midgut ookinete stage of the malaria parasite, Plasmodium, possesses microneme secretory organelles that mediate locomotion and midgut wall egress to establish sporogonic stages and subsequent transmission. The purpose of this study was 2-fold: 1) to determine whether there exists a single micronemal population with respect to soluble and membrane-associated secreted proteins; and 2) to evaluate the ookinete micronemal proteins chitinase (PgCHT1), circumsporozoite and TRAP-related protein (CTRP), and von Willebrand factor A domain-related protein ( WARP) as immunological targets eliciting sera-blocking malaria parasite infectivity to mosquitoes. Indirect immunofluorescence localization studies in Plasmodium gallinaceum using specific antisera showed that all three proteins are distributed intracellularly with a similar granular cytoplasmic appearance and with focal concentration of PgCHT1 and PgCTRP, but not PgWARP, at the ookinete apical end. Immunogold double-labeling electron microscopy, using antisera against the membrane-associated protein CTRP and the soluble WARP, showed that these two proteins co-localized to the same micronemal population. Within the microneme CTRP was associated peripherally at the microneme membrane, whereas PgCHT1 and WARP were diffuse within the micronemal lumen. Sera produced against Plasmodium falciparum WARP significantly reduced the infectivity of P. gallinaceum to Aedes aegypti and P. falciparum to Anopheles mosquitoes. Antisera against PgCTRP and PgCHT1 also significantly reduced the infectivity of P. gallinaceum for A. aegypti. These results support the concept that ookinete micronemal proteins may constitute a general class of malaria transmission-blocking vaccine candidates.	Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92093 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Ehime Univ, Sch Med, Dept Mol Parasitol, Shigenobu, Ehime 7910295, Japan	University of California System; University of California San Diego; Cornell University; University of Texas System; University of Texas Medical Branch Galveston; Ehime University	Vinetz, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Infect Dis, Rm 2052,9500 Gilman Dr 0640, La Jolla, CA 92093 USA.	jvinetz@ucsd.edu	Tsuboi, Takafumi/AAK-6145-2021	Tsuboi, Takafumi/0000-0002-7415-1325; Vinetz, Joseph/0000-0001-8344-2004	NIAID NIH HHS [K02AI50049, R01AI45999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI050049, R01AI045999] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; BERNER R, 1983, J ULTRA MOL STRUCT R, V83, P195, DOI 10.1016/S0022-5320(83)90077-1; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; CARTER R, 1984, MOL BIOCHEM PARASIT, V13, P235, DOI 10.1016/0166-6851(84)90116-6; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Gozar MMG, 1998, INFECT IMMUN, V66, P59, DOI 10.1128/IAI.66.1.59-64.1998; Hisaeda H, 2000, INFECT IMMUN, V68, P6618, DOI 10.1128/IAI.68.12.6618-6623.2000; Kaslow DC, 1997, INT J PARASITOL, V27, P183, DOI 10.1016/S0020-7519(96)00148-8; KAUSHAL DC, 1984, MOL BIOCHEM PARASIT, V11, P145, DOI 10.1016/0166-6851(84)90061-6; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; Langer RC, 2000, INFECT IMMUN, V68, P6461, DOI 10.1128/IAI.68.11.6461-6465.2000; Langer RC, 2002, INFECT IMMUN, V70, P1581, DOI 10.1128/IAI.70.3.1581-1590.2002; Langer RC, 2002, INFECT IMMUN, V70, P102, DOI 10.1128/IAI.70.1.102-106.2002; Limviroj W, 2002, J PARASITOL, V88, P664, DOI 10.1645/0022-3395(2002)088[0664:IEMOOP]2.0.CO;2; McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3; MUNDERLOH UG, 1987, J PARASITOL, V73, P919, DOI 10.2307/3282511; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; ROSENBERG R, 1982, J PARASITOL, V68, P653, DOI 10.2307/3280924; Stowers A, 2001, EXPERT OPIN BIOL TH, V1, P619, DOI 10.1517/14712598.1.4.619; Stowers AW, 2000, INFECT IMMUN, V68, P5530, DOI 10.1128/IAI.68.10.5530-5538.2000; Templeton TJ, 2000, MOL MICROBIOL, V36, P1, DOI 10.1046/j.1365-2958.2000.01821.x; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; VAUGHAN JA, 1991, J PARASITOL, V77, P758, DOI 10.2307/3282712; VAUGHAN JA, 1994, AM J TROP MED HYG, V51, P233, DOI 10.4269/ajtmh.1994.51.233; VAUGHAN JA, 1994, J PARASITOL, V80, P674, DOI 10.2307/3283245; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; Yuda M, 1999, J EXP MED, V189, P1947, DOI 10.1084/jem.189.12.1947; Yuda M, 2001, MOL BIOCHEM PARASIT, V116, P65, DOI 10.1016/S0166-6851(01)00304-8	31	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26635	26644		10.1074/jbc.M401385200	http://dx.doi.org/10.1074/jbc.M401385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069061	hybrid			2022-12-27	WOS:000222003000090
J	Kim, M; Yang, HL; Kim, SK; Reche, PA; Tirabassi, RS; Hussey, RE; Chishti, Y; Rheinwald, JG; Morehead, TJ; Zech, T; Damon, IK; Welsh, RM; Reinherz, EL				Kim, M; Yang, HL; Kim, SK; Reche, PA; Tirabassi, RS; Hussey, RE; Chishti, Y; Rheinwald, JG; Morehead, TJ; Zech, T; Damon, IK; Welsh, RM; Reinherz, EL			Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS ANTIVIRAL IMMUNITY; ERBB SIGNALING NETWORK; GENOME DNA-SEQUENCES; VACCINIA VIRUS; FACTOR-ALPHA; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; CELLS; EPIREGULIN; SPECIFICITY	Variola, the causative agent of smallpox, is a highly infectious double-stranded DNA virus of the orthopox genus that replicates within the cytoplasm of infected cells. For unknown reasons prominent skin manifestations, including "pox," mark the course of this systemic human disease. Here we characterized smallpox growth factor (SPGF), a protein containing an epidermal growth factor (EGF)-like domain that is conserved among orthopox viral genomes, and investigated its possible mechanistic link. We show that after recombinant expression, refolding, and purification, the EGF domain of SPGF binds exclusively to the broadly expressed cellular receptor, erb-B1 (EGF receptor), with subnanomolar affinity, stimulating the growth of primary human keratinocytes and fibroblasts. High affinity monoclonal antibodies specific for SPGF reveal in vivo immunoprotection in a murine vaccinia pneumonia model by a mechanism distinct from viral neutralization. These findings suggest that blockade of pathogenic factor actions, in general, may be advantageous to the infected host.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Lab Immunobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Poxvirus Sect, Atlanta, GA 30333 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Centers for Disease Control & Prevention - USA	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Lab Immunobiol, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu	Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Zech, Tobias/0000-0001-8394-088X	NIAID NIH HHS [AI19807, AI50900] Funding Source: Medline; NIAMS NIH HHS [P30 AR042689, AR35506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019807, R37AI019807, R01AI050900, R56AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035506, P30AR042689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APELLA E, 1988, FEBS LETT, V231, P1; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BULLER RML, 1988, VIROLOGY, V164, P182, DOI 10.1016/0042-6822(88)90635-6; Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Fenner Frank, 1988, SMALLPOX ITS ERADICA; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; KEMPE CH, 1960, PEDIATRICS, V26, P176; Kim M, 2001, J BIOL CHEM, V276, P42667, DOI 10.1074/jbc.M104166200; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NANNEY LB, 1990, J INVEST DERMATOL, V94, P742, DOI 10.1111/1523-1747.ep12874601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OHMURA E, 1990, CANCER RES, V50, P4915; OPGENORTH A, 1993, VIROLOGY, V192, P701, DOI 10.1006/viro.1993.1092; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schluns KS, 1997, J IMMUNOL, V158, P2704; Schon M, 1996, J INVEST DERMATOL, V107, P428, DOI 10.1111/1523-1747.ep12363411; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; Shchelkunov SN, 2000, VIROLOGY, V266, P361, DOI 10.1006/viro.1999.0086; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SONNHAMMER ELL, 1998, 6 INT C INT SYST MOL, P175; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; Tanaka T, 2001, J MOL CELL CARDIOL, V33, P1627, DOI 10.1006/jmcc.2001.1428; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; TUBO RA, 1987, ONCOGENE RES, V1, P407; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoo JY, 2003, P NATL ACAD SCI USA, V100, P1157, DOI 10.1073/pnas.0336385100	53	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25838	25848		10.1074/jbc.M400343200	http://dx.doi.org/10.1074/jbc.M400343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070899	Green Accepted, hybrid			2022-12-27	WOS:000221827900115
J	Nur-E-Kamal, A; Gross, SR; Pan, Z; Balklava, Z; Ma, JJ; Liu, LF				Nur-E-Kamal, A; Gross, SR; Pan, Z; Balklava, Z; Ma, JJ; Liu, LF			Nuclear translocation of cytochrome c during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN CONDENSATION; CELL-DEATH; CASPASE 9; DNA; PATHWAYS; NUCLEOSOMES; ACTIVATION; RECEPTORS; BRAIN; MICE	Release of cytochrome c from mitochondria is a major event during apoptosis. Released cytochrome c has been shown to activate caspase-dependent apoptotic signals. In this report, we provide evidence for a novel role of cytochrome c in caspase-independent nuclear apoptosis. We showed that cytochrome c, released from mitochondria upon apoptosis induction, gradually accumulates in the nucleus as evidenced by both immunofluorescence and subcellular fractionation. Parallel to nuclear accumulation of cytochrome c, acetylated histone H2A, but not unmodified H2A, was released from the nucleus to the cytoplasm. Addition of purified cytochrome c to isolated nuclei recapitulated the preferential release of acetylated, but not deacetylated, histone H2A. Cytochrome c was also found to induce chromatin condensation. These results suggest that the nuclear accumulation of cytochrome c may be directly involved in the remodeling of chromatin. Our results provide evidence of a novel role for cytochrome c in inducing nuclear apoptosis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Nur-E-Kamal, A (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	nurekasa@umdnj.edu	Balklava, Zita/AAU-6146-2021	Balklava, Zita/0000-0001-9039-9710; gross, stephane/0000-0002-0867-8866; Liu, Leroy/0000-0001-9396-763X; Pan, Zui/0000-0003-4105-901X	NATIONAL CANCER INSTITUTE [R01CA039662, R01CA095739] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662, CA95739] Funding Source: Medline; NHLBI NIH HHS [HL69000] Funding Source: Medline; NIA NIH HHS [AG15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Baxter BK, 1998, J BIOL CHEM, V273, P17517, DOI 10.1074/jbc.273.28.17517; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.3.CO;2-#; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Sanchez-Gomez MV, 2003, J NEUROSCI, V23, P9519; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	25	97	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24911	24914		10.1074/jbc.C400051200	http://dx.doi.org/10.1074/jbc.C400051200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073175	Green Accepted, hybrid			2022-12-27	WOS:000221827900002
J	Kask, L; Trouw, LA; Dahlback, B; Blom, AM				Kask, L; Trouw, LA; Dahlback, B; Blom, AM			The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; BINDING LECTIN ENGAGEMENT; SHBG-LIKE REGION; STRUCTURAL REQUIREMENTS; CLASSICAL PATHWAY; PLASMA-PROTEINS; ALPHA-CHAIN; C1Q; SURFACE; PURIFICATION	The phagocytosis of apoptotic cells is a complex process involving numerous interactions between the target cell and the macrophage. We have examined a role of the major soluble inhibitor of the classic and lectin complement pathways, C4b-binding protein (C4BP), in the clearance of apoptotic cells. The major form of C4BP present in blood is composed of seven alpha-chains and one beta-chain, which binds protein S ( PS). Approximately 70% of all PS in human plasma is trapped in such a complex and is able to localize C4BP to the surface of apoptotic cells due to the high affinity to phosphatidylserine. Free PS has recently been shown to enhance phagocytosis of apoptotic cells by macrophages. We observed a stimulatory effect of free PS on the engulfment of apoptotic cells (BL-41 and Jurkat) by primary human macrophages or THP-1 cells and a decrease of activity in serum depleted of PS in agreement with previous results. However, we also show that the process is strongly inhibited in the presence of the C4BP-PS complex. Addition of the C4BP-PS complex to serum deficient in both molecules abolished the enhancing effect of serum on phagocytosis. The effect of both free PS and the C4BP-PS complex could be inhibited with monoclonal antibody directed against the Gla domain of PS. Although the presence of the C4BP-PS complex on apoptotic cells may lead to decreased phagocytosis, it may still be beneficial to the host, since it could prevent secondary necrosis because it inhibits further complement attack.	Lund Univ, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Blom, AM (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden.	Anna.Blom@klkemi.mas.lu.se	Trouw, Leendert/AGK-5202-2022; Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022	Trouw, Leendert/0000-0001-5186-2290; Blom, Anna/0000-0002-1348-1734; Kask, Lena/0000-0002-4380-4354; Dahlback, Bjorn/0000-0003-1546-0328				Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DE FRUTOS PG, 1994, BLOOD, V84, P815; Evenas P, 2000, BIOL CHEM, V381, P199, DOI 10.1515/BC.2000.027; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; MALM J, 1990, EUR J BIOCHEM, V187, P737, DOI 10.1111/j.1432-1033.1990.tb15361.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; Nyberg P, 1998, FEBS LETT, V433, P28, DOI 10.1016/S0014-5793(98)00877-1; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TENNER AJ, 1981, J IMMUNOL, V127, P648; Webb JH, 2003, BLOOD COAGUL FIBRIN, V14, P355, DOI 10.1097/00001721-200306000-00006; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580	29	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23869	23873		10.1074/jbc.C400159200	http://dx.doi.org/10.1074/jbc.C400159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15096498	hybrid			2022-12-27	WOS:000221702500006
J	Johansson, E; Olsson, O; Nystrom, T				Johansson, E; Olsson, O; Nystrom, T			Progression and specificity of protein oxidation in the life cycle of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBISCO; STRESS; DAMAGE; SENESCENCE; EXPRESSION; INDUCTION; MECHANISM; SPAN	Protein carbonylation is an irreversible oxidative process leading to a loss of function of the modified proteins, and in a variety of model systems, including worms, flies, and mammals, carbonyl levels gradually increase with age. In contrast, we report here that in Arabidopsis thaliana an initial increase in protein oxidation during the first 20 days of the life cycle of the plant is followed by a drastic reduction in protein carbonyls prior to bolting and flower development. Protein carbonylation prior to the transition to flowering targets specific proteins such as Hsp70, ATP synthases, the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco), and proteins involved in light harvesting/energy transfer and the C2 oxidative photosynthetic carbon cycle. The precipitous fall in protein carbonyl levels is due to the specific reduction in the levels of oxidized proteins rather than an overall loss of chlorophyll and Rubisco associated with the senescence syndrome. The results are discussed in light of contemporary theories of aging in animals.	Univ Gothenburg, Dept Cell & Mol Biol, S-40530 Gothenburg, Sweden	University of Gothenburg	Nystrom, T (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	Nystrom@gmm.gu.se		Olsson, Olof/0000-0003-3962-9183				Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bleecker AB, 1997, PLANT CELL, V9, P1169, DOI 10.1105/tpc.9.7.1169; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Clark SE, 1997, PLANT CELL, V9, P1067, DOI 10.1105/tpc.9.7.1067; Das N, 2001, BIOCHEM J, V360, P209, DOI 10.1042/0264-6021:3600209; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Jing HC, 2002, PLANT J, V32, P51, DOI 10.1046/j.1365-313X.2002.01400.x; Kerstetter RA, 1997, PLANT CELL, V9, P1001, DOI 10.1105/tpc.9.7.1001; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; Nakamura A, 1996, J BIOCHEM, V119, P768; Neuwald AF, 1999, GENOME RES, V9, P27; Nood?n L.D., 1988, SENESCENCE AGING PLA, P329, DOI DOI 10.1016/B978-0-12-520920-5.50007-9.; NOODEN LD, 1993, AUST J PLANT PHYSIOL, V20, P639, DOI 10.1071/PP9930639; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pantke U, 1999, FREE RADICAL BIO MED, V27, P1080, DOI 10.1016/S0891-5849(99)00144-6; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; SALVUCCI ME, 1987, PLANT PHYSIOL, V84, P930, DOI 10.1104/pp.84.3.930; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Sun JT, 1999, MOL CELL BIOL, V19, P216; Sung DY, 2001, PLANT PHYSIOL, V126, P789, DOI 10.1104/pp.126.2.789; Taylor NL, 2002, J BIOL CHEM, V277, P42663, DOI 10.1074/jbc.M204761200; Thomas H, 2002, MECH AGEING DEV, V123, P747, DOI 10.1016/S0047-6374(01)00420-1; Thomson W. W., 1987, Plant senescence: its biochemistry and physiology. Proceedings of the Tenth Annual Symposium in Plant Physiology, 8-10 January, 1987, University of California, Riverside, California, USA., P20; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wilson JB, 1997, PHYSIOL PLANTARUM, V99, P511, DOI 10.1034/j.1399-3054.1997.990321.x; Yamamoto Y, 1998, BIOCHEMISTRY-US, V37, P1565, DOI 10.1021/bi9707640; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438	38	188	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22204	22208		10.1074/jbc.M402652200	http://dx.doi.org/10.1074/jbc.M402652200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15070894	hybrid			2022-12-27	WOS:000221417100066
J	Tasiemski, A; Vandenbulcke, F; Mitta, G; Lemoine, J; Lefebvre, C; Sautiere, PE; Salzet, M				Tasiemski, A; Vandenbulcke, F; Mitta, G; Lemoine, J; Lefebvre, C; Sautiere, PE; Salzet, M			Molecular characterization of two novel antibacterial peptides inducible upon bacterial challenge in an annelid, the leech Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH ANTIMICROBIAL PEPTIDE; NEMATODE ASCARIS-SUUM; INNATE IMMUNITY; INSECT IMMUNITY; HOST-DEFENSE; FROG-SKIN; DROSOPHILA; EXPRESSION; INDUCTION; MUSSEL	Two novel antimicrobial peptides named theromacin and theromyzin were isolated and characterized from the coelomic liquid of the leech Theromyzon tessulatum. Theromacin is a 75-amino acid cationic peptide containing 10 cysteine residues arranged in a disulfide array showing no similarities with other known antimicrobial peptides. Theromyzin is an 86-amino acid linear peptide and constitutes the first anionic antimicrobial peptide observed in invertebrates. Both peptides exhibit activity directed against Gram-positive bacteria. Theromacin and theromyzin cDNAs code precursor molecules containing a putative signal sequence directly followed by the mature peptide. The enhancement of theromacin and theromyzin mRNA levels has been observed after blood meal ingestion and upon bacterial challenge. In situ hybridization revealed that both genes are expressed in large fat cells in contact with coelomic cavities. Gene products were immunodetected in large fat cells, in intestinal epithelia, and at the epidermis level. In addition, a rapid release of the peptides into the coelomic liquid was observed after bacterial challenge. The presence of antimicrobial peptide genes in leeches and their expression in a specific tissue functionally resembling the insect fat body provide evidence for the first time of an antibacterial response in a lophotrochozoan comparable to that of holometabola insects.	Univ Sci & Technol Lille, CNRS, UMR 8017, Lab Neuroimmunol, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Lab Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Salzet, M (corresponding author), Univ Sci & Technol Lille, CNRS, UMR 8017, Lab Neuroimmunol, SN3, F-59655 Villeneuve Dascq, France.	michel.salzet@univ-lille1.fr	Lefebvre, christophe/J-7396-2013; MITTA, Guillaume/A-6489-2010; lemoine, jerome/C-4272-2014; Salzet, Michel/A-7675-2011; Tasiemski, Aurelie/S-2537-2016	Lefebvre, christophe/0000-0002-2690-373X; lemoine, jerome/0000-0002-5497-6880; Salzet, Michel/0000-0003-4318-0817; SAUTIERE, Pierre-Eric/0000-0003-4974-7116; mitta, guillaume/0000-0003-1188-1467; Tasiemski, Aurelie/0000-0003-3559-5115; Vandenbulcke, Franck/0000-0002-9735-1784				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brewer D, 2000, RAPID COMMUN MASS SP, V14, P1736, DOI 10.1002/1097-0231(20001015)14:19<1736::AID-RCM86>3.0.CO;2-2; Brewer D, 2002, BIOCHEMISTRY-US, V41, P5526, DOI 10.1021/bi015926d; Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; BULET P, 1991, J BIOL CHEM, V266, P24520; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Cho JH, 1998, BBA-MOL BASIS DIS, V1408, P67, DOI 10.1016/S0925-4439(98)00058-1; Engstrom Y, 1999, DEV COMP IMMUNOL, V23, P345, DOI 10.1016/S0145-305X(99)00016-6; Faure-Virelizier C, 1998, ENDOCRINOLOGY, V139, P4127, DOI 10.1210/en.139.10.4127; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Kato Y, 1996, J BIOL CHEM, V271, P30493, DOI 10.1074/jbc.271.48.30493; Kato Y, 2002, BIOCHEM J, V361, P221, DOI 10.1042/0264-6021:3610221; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; LEFEBVRE C, 2004, IN PRESS BIOCH J; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; Meister M, 1996, INSECT BIOCHEM MOLEC, V26, P155, DOI 10.1016/0965-1748(95)00076-3; Mitta G, 2000, J CELL SCI, V113, P2759; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Mitta G, 2000, FEBS LETT, V486, P185, DOI 10.1016/S0014-5793(00)02192-X; Pillai A, 2003, BIOCHEM J, V371, P663, DOI 10.1042/BJ20021948; Salzet M, 2001, TRENDS IMMUNOL, V22, P285, DOI 10.1016/S1471-4906(01)01895-6; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Vizioli J, 2001, INSECT BIOCHEM MOLEC, V31, P241, DOI 10.1016/S0965-1748(00)00143-0; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	33	77	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30973	30982		10.1074/jbc.M312156200	http://dx.doi.org/10.1074/jbc.M312156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15102860	hybrid			2022-12-27	WOS:000222726800010
J	Wang, XH; Su, Y; Deb, K; Raposo, M; Morrow, JD; Reese, J; Paria, BC				Wang, XH; Su, Y; Deb, K; Raposo, M; Morrow, JD; Reese, J; Paria, BC			Prostaglandin E-2 is a product of induced prostaglandin-endoperoxide synthase 2 and microsomal-type prostaglandin E synthase at the implantation site of the hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MOUSE UTERUS; DELAYED IMPLANTATION; EMBRYO IMPLANTATION; E-2 SYNTHASE; PREGNANCY; INDOMETHACIN; PROGESTERONE; ESTROGEN; CYCLOOXYGENASE	Certain uterine prostaglandins (PGs) are elevated at implantation sites and are needed to trigger the events of blastocyst implantation that include blastocyst-uterine attachment and stromal decidualization with vascular permeability changes. Several decades of investigations showed that treatment with PG synthesis inhibitors, prior to or during the time of implantation, resulted in either complete inhibition or a delay in implantation or reduction in the number of implantation sites with diminished decidual tissue. Consistent with these findings, we observed that whereas a selective PG endoperoxide synthase (Ptgs) 1 inhibitor SC-560 failed to inhibit implantation, a selective Ptgs2 inhibitor SC-236 showed significantly reduced number and size of implantation sites in progesterone-treated ovariectomized pregnant hamsters. It is known that Ptgs2 expression and Ptgs2-derived prostacyclin (PGI(2)) synthesis at implantation sites are needed for implantation in the mouse (a rodent that needs ovarian estrogen for implantation). However, it is unknown which Ptgs and PG synthases produce which PGs at implantation sites of the hamster (a rodent that does not need ovarian estrogen for implantation). Here we demonstrate that as blastocyst implantation proceeds, a reduction in Ptgs1 expression from uterine luminal epithelial cells and a gradual induction in Ptgs2 expression exclusively in luminal epithelial and adjacent decidual cells occurred at implantation sites of hamsters. Results also reveal that PGE(2), but not PGI(2), is the major PG at implantation sites where Ptgs2 and microsomal type PGE synthases but not PGI synthases are co-expressed. This elevated uterine PGE(2) at implantation sites may serve to initiate or amplify physiological signals required for specific aspects of the implantation process in hamsters.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med & Pharmacol, Nashville, TN 37232 USA; Univ Kansas, Med Ctr, Kansas City, KS 66160 USA	Vanderbilt University; Vanderbilt University; University of Kansas; University of Kansas Medical Center	Paria, BC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, 1161 21st Ave S, Nashville, TN 37232 USA.	bc.paria@vanderbilt.edu		Reese, Jeff/0000-0001-8751-6146	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD044741] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD042636, R03HD040193, R01HD037394, R01HD042636, K08HD040221] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77839] Funding Source: Medline; NCRR NIH HHS [RR 00095] Funding Source: Medline; NICHD NIH HHS [HD 40193, HD 37394, HD 40221, HD 42636, HD 44741] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 15431] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238; BEHRMAN HR, 1979, ANNU REV PHYSIOL, V41, P685, DOI 10.1146/annurev.ph.41.030179.003345; BIGGERS JD, 1978, BIOL REPROD, V19, P519, DOI 10.1095/biolreprod19.3.519; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; CHIDA S, 1986, PROSTAGLANDINS, V3, P337; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEY SK, 1980, PROSTAGLANDINS, V19, P449, DOI 10.1016/0090-6980(80)90078-7; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DEZIEGLER D, 1995, HUM REPROD, V10, P4, DOI 10.1093/humrep/10.1.4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FEINBERG BB, 1993, J REPROD IMMUNOL, V23, P109, DOI 10.1016/0165-0378(93)90001-X; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; GEORGE FW, 1978, SCIENCE, V199, P200, DOI 10.1126/science.579477; GHOSH D, 1994, HUM REPROD, V9, P629, DOI 10.1093/oxfordjournals.humrep.a138561; GIANNINA T, 1971, CONTRACEPTION, V3, P347, DOI 10.1016/0010-7824(71)90073-4; Harper M. J. K., 1969, Biology of Reproduction, V1, P253, DOI 10.1095/biolreprod1.3.253; HARPER MJK, 1983, BIOL REPROD, V28, P350, DOI 10.1095/biolreprod28.2.350; HOFFMAN LH, 1978, PROSTAGLANDINS, V15, P823, DOI 10.1016/0090-6980(78)90148-X; HOFFMAN LH, 1978, BIOL REPROD, V18, P148, DOI 10.1095/biolreprod18.1.148; HOVERSLAND RC, 1982, J REPROD FERTIL, V66, P259, DOI 10.1530/jrf.0.0660259; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JONES MA, 1984, ENDOCRINOLOGY, V115, P817, DOI 10.1210/endo-115-2-817; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; KENNEDY TG, 1979, BIOL REPROD, V20, P560, DOI 10.1095/biolreprod20.3.560; KHURANA NK, 1987, J REPROD FERTIL, V79, P275, DOI 10.1530/jrf.0.0790275; KWUN JK, 1974, AUST J BIOL SCI, V27, P275, DOI 10.1071/BI9740275; LALA PK, 1989, AM J REPROD IMMUNOL, V20, P147, DOI 10.1111/j.1600-0897.1989.tb00987.x; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAU IF, 1973, PROSTAGLANDINS, V4, P795, DOI 10.1016/0090-6980(73)90115-9; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu GZ, 2003, J BIOL CHEM, V278, P14956, DOI 10.1074/jbc.M212229200; Loftin CD, 2002, J CLIN INVEST, V110, P549, DOI 10.1172/JCI200214924; Marions L, 1999, MOL HUM REPROD, V5, P961, DOI 10.1093/molehr/5.10.961; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; MEYER RK, 1969, P 2 INT C PRIM, V2, P30; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Ni H, 2002, BIOL REPROD, V67, P351, DOI 10.1095/biolreprod67.1.351; ORSINI MW, 1962, P SOC EXP BIOL MED, V110, P713; Paria BC, 1999, DEV BIOL, V208, P488, DOI 10.1006/dbio.1999.9206; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PERRY JS, 1973, NATURE, V245, P45, DOI 10.1038/245045a0; PHILLIPS CA, 1981, J REPROD FERTIL, V62, P73, DOI 10.1530/jrf.0.0620073; PRASAD MRN, 1960, P SOC EXP BIOL MED, V104, P48; PSYCHOYOS A, 1973, HDB PHYSL, P187; Reese J, 1999, MOL CELL ENDOCRINOL, V150, P23, DOI 10.1016/S0303-7207(99)00033-7; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Ricchi P, 2003, J CLIN GASTROENTEROL, V37, P281, DOI 10.1097/00004836-200310000-00004; SAKSENA SK, 1976, ACTA ENDOCRINOL-COP, V81, P801, DOI 10.1530/acta.0.0810801; SANANES N, 1981, J ENDOCRINOL, V89, P25, DOI 10.1677/joe.0.0890025; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Song H, 2002, DEVELOPMENT, V129, P2879; Sookvanichsilp N, 2002, CONTRACEPTION, V65, P373, DOI 10.1016/S0010-7824(01)00322-5; Takeeda M, 2003, J PHARMACOL EXP THER, V307, P713, DOI 10.1124/jpet.103.054973; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; TERRANOVA PF, 1982, PROSTAGLANDINS, V24, P165, DOI 10.1016/0090-6980(82)90142-3; Uotila PJ, 2002, ANN MED, V34, P428, DOI 10.1080/078538902321012379; Vane JR, 1998, INFLAMM RES, V47, pS78; Wang XH, 2004, J CELL SCI, V117, P53, DOI 10.1242/jcs.00826; Wang XH, 2002, DEVELOPMENT, V129, P4125; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; ZEGERSHOCHSCHILD F, 1995, J ASSIST REPROD GEN, V12, P224, DOI 10.1007/BF02211803	65	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30579	30587		10.1074/jbc.M400573200	http://dx.doi.org/10.1074/jbc.M400573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15078866	hybrid			2022-12-27	WOS:000222531900088
J	Saitoh, F; Tian, QB; Okano, A; Sakagami, H; Kondo, H; Suzuki, T				Saitoh, F; Tian, QB; Okano, A; Sakagami, H; Kondo, H; Suzuki, T			NIDD, a novel DHHC-containing protein, targets neuronal nitric-oxide synthase (nNOS) to the synaptic membrane through a PDZ-dependent interaction and regulates nNOS activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; POSTSYNAPTIC DENSITY; MESSENGER-RNAS; SELECTIVE IMPAIRMENT; HIPPOCAMPAL-NEURONS; TERNARY COMPLEX; RAT-BRAIN; LOCALIZATION; DOMAIN	Targeting of neuronal nitric-oxide synthase (nNOS) to appropriate sites in a cell is mediated by interactions with its PDZ domain and plays an important role in specifying the sites of reaction of nitric oxide (NO) in the central nervous system. Here we report the identification and characterization of a novel nNOS-interacting DHHC domain-containing protein with dendritic mRNA (NIDD) (GenBank(TM) accession number AB098078), which increases nNOS enzyme activity by targeting the nNOS to the synaptic plasma membrane in a PDZ domain-dependent manner. The deduced NIDD protein consisted of 392 amino acid residues and possessed five transmembrane segments, a zinc finger DHHC domain, and a PDZ-binding motif (-EDIV) at its C-terminal tail. In vitro pull-down assays suggested that the C-terminal tail region of NIDD specifically interacted with the PDZ domain of nNOS. The PDZ dependence was confirmed by an experiment using a deletion mutant, and the interaction was further confirmed by co-sedimentation assays using COS-7 cells transfected with NIDD and nNOS. Both NIDD and nNOS were enriched in synaptosome and synaptic plasma membrane fractions and were present in the lipid raft and postsynaptic density fractions in the rat brain. Co-localization of these proteins was also observed by double staining of the proteins in cultured cortical neurons. Thus, NIDD and nNOS were co-localized in the brain, although the co-localizing regions were restricted, as indicated by the distribution of their mRNA expression. Most important, co-transfection of NIDD and nNOS increased NO-producing nNOS activity. These results suggested that NIDD plays an important role in the regulation of the NO signaling pathway at postsynaptic sites through targeting of nNOS to the postsynaptic membrane.	Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Neuroplast, Matsumoto, Nagano 3908621, Japan; Tohoku Univ, Grad Sch Med, Dept Cell Biol, Div Histol, Sendai, Miyagi 9808575, Japan	Shinshu University; Tohoku University	Suzuki, T (corresponding author), Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Neuroplast, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	suzukit@sch.md.shinshu-u.ac.jp						Arancio O, 1996, J PHYSIOLOGY-PARIS, V90, P321, DOI 10.1016/S0928-4257(97)87907-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Das UN, 2003, BRAIN DEV-JPN, V25, P251, DOI 10.1016/S0387-7604(02)00221-8; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HECKER M, 1994, J NEUROCHEM, V62, P1524; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Li WD, 2001, J BIOL CHEM, V276, P21417, DOI 10.1074/jbc.M010744200; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Murata S, 2000, MOL BRAIN RES, V78, P80, DOI 10.1016/S0169-328X(00)00077-2; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Sakagami H, 1998, MOL BRAIN RES, V54, P311, DOI 10.1016/S0169-328X(97)00362-8; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sun JX, 2002, P NATL ACAD SCI USA, V99, P13108, DOI 10.1073/pnas.202260999; Suzuki T, 2002, NEUROSCI RES, V44, P1, DOI 10.1016/S0168-0102(02)00080-9; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Tian QB, 2003, J NEUROCHEM, V87, P665, DOI 10.1046/j.1471-4159.2003.02024.x; Tian QB, 1999, MOL BRAIN RES, V72, P147, DOI 10.1016/S0169-328X(99)00214-4; Yun HY, 1999, DIABETES RES CLIN PR, V45, P113, DOI 10.1016/S0168-8227(99)00039-X	41	35	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29461	29468		10.1074/jbc.M401471200	http://dx.doi.org/10.1074/jbc.M401471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105416	hybrid			2022-12-27	WOS:000222445300078
J	O'Connor, MS; Safari, A; Liu, D; Qin, J; Zhou, SY				O'Connor, MS; Safari, A; Liu, D; Qin, J; Zhou, SY			The human Rap1 protein complex and modulation of telomere length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT-BINDING FACTOR-1; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE; RNA INTERFERENCE; YEAST RAP1; TRF1; END; TANKYRASE-1; DEREGULATION; MAINTENANCE	Proper maintenance of telomere length and structure is necessary for normal proliferation of mammalian cells. Mammalian telomere length is regulated by a number of proteins including human repressor activator protein (hRap1), a known association factor of TRF2. To further delineate hRap1 function and its associated proteins, we affinity-purified and identified the hRap1 protein complex through mass spectrometry analysis. In addition to TRF2, we found DNA repair proteins Rad50, Mre11, PARP1 (poly(ADP-ribose) polymerase), and Ku86/Ku70 to be in this telomeric complex. We demonstrated by deletional analysis that Rad-50/Mre-11 and Ku86 were recruited to hRap1 independent of TRF2. PARP1, however, most likely interacted with hRap1 through TRF2. Interestingly, knockdown of endogenous hRap1 expression by small hairpin interference RNA resulted in longer telomeres. In addition, overexpression of full-length and mutant hRap1 that lacked the BRCA1 C-terminal domain functioned as dominant negatives and extended telomeres. Deletion of a novel linker domain of hRap1 (residues 199-223), however, abolished the dominant negative effect of hRap1 overexpression. These results indicate that hRap1 negatively regulates telomere length in vivo and suggest that the linker region of hRap1 may modulate the recruitment of negative regulators of telomere length.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bundock P, 2002, NUCLEIC ACIDS RES, V30, P3395, DOI 10.1093/nar/gkf445; Chai WH, 2002, J BIOL CHEM, V277, P47242, DOI 10.1074/jbc.M208542200; Connelly JC, 2002, TRENDS BIOCHEM SCI, V27, P410, DOI 10.1016/S0968-0004(02)02144-8; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; Driller L, 2000, J BIOL CHEM, V275, P24921, DOI 10.1074/jbc.M002588200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gallego ME, 2003, PLANT CELL, V15, P782, DOI 10.1105/tpc.008623; Gotta M, 1997, BIOESSAYS, V19, P367, DOI 10.1002/bies.950190503; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Park MJ, 2002, MOL CELLS, V13, P327; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Riha K, 2002, EMBO J, V21, P2819, DOI 10.1093/emboj/21.11.2819; Rippmann JF, 2002, J MOL BIOL, V323, P217, DOI 10.1016/S0022-2836(02)00946-4; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Shore D, 1997, BIOL CHEM, V378, P591; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	56	136	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28585	28591		10.1074/jbc.M312913200	http://dx.doi.org/10.1074/jbc.M312913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100233	hybrid			2022-12-27	WOS:000222265400094
J	Song, BL; DeBose-Boyd, RA				Song, BL; DeBose-Boyd, RA			Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG COA REDUCTASE; STEROL-REGULATED DEGRADATION; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; IN-VIVO; PROTEIN; DOMAIN; PROTEOLYSIS; RECEPTOR	The endoplasmic reticulum ( ER) enzyme, 3-hydroxy-3-methylglutaryl-CoA reductase, catalyzes the production of mevalonate, a rate-controlling step in cholesterol biosynthesis. Excess sterols promote ubiquitination and subsequent degradation of reductase as part of a negative feedback regulatory mechanism. To characterize the process in more detail, we here report the development of a permeabilized cell system that supports reductase ubiquitination stimulated by the addition of sterols in vitro. Sterol-dependent ubiquitination of reductase in permeabilized cells is dependent upon exogenous cytosol, ATP, and either Insig-1 or Insig-2, two membrane-bound ER proteins shown previously to mediate sterol regulation of reductase degradation in intact cells. Oxysterols, but not cholesterol, promote reductase ubiquitination under our conditions. Finally, we show that ubiquitin-activating enzyme (E1) can efficiently replace cytosol to ubiquitinate reductase in response to sterol treatment, suggesting that other molecules required for ubiquitination of reductase, such as the ubiquitin-conjugating and -ligating enzymes (E2 and E3), are localized to ER membranes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu		Song, Bao-Liang/0000-0002-6397-5935	NHLBI NIH HHS [HL 20948, HL 70441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1980, J LIPID RES, V21, P505; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; INOUE S, 1991, J BIOL CHEM, V266, P13311; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	36	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28798	28806		10.1074/jbc.M402442200	http://dx.doi.org/10.1074/jbc.M402442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090540	hybrid			2022-12-27	WOS:000222265400118
J	Thomas, X; Destoumieux-Garzon, D; Peduzzi, J; Afonso, C; Blond, A; Birlirakis, N; Goulard, C; Dubost, L; Thai, R; Tabet, JC; Rebuffat, S				Thomas, X; Destoumieux-Garzon, D; Peduzzi, J; Afonso, C; Blond, A; Birlirakis, N; Goulard, C; Dubost, L; Thai, R; Tabet, JC; Rebuffat, S			Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MICROCIN E492; KLEBSIELLA-PNEUMONIAE; OUTER-MEMBRANE; CATECHOLATE SIDEROPHORE; STRUCTURAL ELUCIDATION; MASS-SPECTROMETRY; IRON; ENTEROBACTIN; PROTEIN	Microcin E492 (MccE492, 7886 Da), the 84-amino acid antimicrobial peptide from Klebsiella pneumoniae, was purified in a post-translationally modified form, MccE492m ( 8717 Da), from culture supernatants of either the recombinant Escherichia coli VCS257 strain harboring the pJAM229 plasmid or the K. pneumoniae RYC492 strain. Chymotrypsin digestion of MccE492m led to the MccE492m-( 74 - 84) C-terminal fragment that carries the modification and that was analyzed by mass spectrometry and nuclear magnetic resonance at natural abundance. The 831-Da post-translational modification consists of a trimer of N-(2,3- dihydroxybenzoyl)-L-serine linked via a C-glycosidic linkage to a beta-D-glucose moiety, itself linked to the MccE492m Ser-84-carboxyl through an O-glycosidic bond. This modification, which mimics a catechol-type siderophore, was shown to bind ferric ions by analysis of the collision-induced dissociation pattern obtained for MccE492m-( 74 - 84) by electrospray ion trap mass spectrometry experiments in the presence of FeCl3. By using a series of wild-type and mutant isogenic strains, the three catechol-type siderophore receptors Fiu, Cir, and FepA were shown to be responsible for the recognition of MccE492m at the outer membrane of sensitive bacteria. Because MccE492m shows a broader spectrum of antibacterial activity and is more potent than MccE492, we propose that by increasing the microcin/receptor affinity, the modification leads to a better recognition and subsequently to a higher antimicrobial activity of the microcin. Therefore, MccE492m is the first member of a new class of antimicrobial peptides carrying a siderophore-like post-translational modification and showing potent activity, which we term siderophore-peptides.	Museum Natl Hist Nat, Lab Chim & Biochim Subst Nat, CNRS,UMR 5154,USM 502, Dept REgulat Dev & Divers Mol, F-75005 Paris, France; Univ Paris 06, CNRS, UMR 7613, Lab Chim Struct Organ & Biol, F-75252 Paris 5, France; CNRS, Inst Chim Subst Nat, Lab RMN Haut Champ, F-91190 Gif Sur Yvette, France; CEA Saclay, Dept Etud & Ingn Prot, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Rebuffat, S (corresponding author), Museum Natl Hist Nat, Lab Chim & Biochim Subst Nat, CNRS,UMR 5154,USM 502, Dept REgulat Dev & Divers Mol, 63 Rue Buffon, F-75005 Paris, France.	rebuffat@mnhn.fr	Rebuffat, Sylvie/AAE-4194-2021; Rebuffat, Sylvie/AAO-2072-2020; Afonso, Carlos/E-9736-2011; Destoumieux-Garzón, Delphine/O-3328-2014	Afonso, Carlos/0000-0002-2406-5664; Destoumieux-Garzón, Delphine/0000-0002-8793-9138; Thai, Robert/0000-0001-9438-4225; Rebuffat, Sylvie/0000-0002-5257-5039				Afonso C, 2002, J MASS SPECTROM, V37, P755, DOI 10.1002/jms.341; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BAQUERO F, 1984, FEMS MICROBIOL LETT, V23, P117; BERNER I, 1991, BIOL MET, V4, P113, DOI 10.1007/BF01135388; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; BRICKMAN TJ, 1992, J BIOL CHEM, V267, P12350; Carlesso V, 2002, INT J MASS SPECTROM, V219, P559, DOI 10.1016/S1387-3806(02)00742-X; Corsini G, 2002, BIOCHIMIE, V84, P539, DOI 10.1016/S0300-9084(02)01415-3; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; DELORENZO V, 1984, ARCH MICROBIOL, V139, P72, DOI 10.1007/BF00692715; Destoumieux-Garzon D, 2003, MOL MICROBIOL, V49, P1031, DOI 10.1046/j.1365-2958.2003.03610.x; Destoumieux-Garzon D, 2002, BIOCHIMIE, V84, P511, DOI 10.1016/S0300-9084(02)01411-6; DRAUTZ H, 1986, J ANTIBIOT, V39, P1657, DOI 10.7164/antibiotics.39.1657; Fiedler HP, 2001, FEMS MICROBIOL LETT, V196, P147, DOI 10.1016/S0378-1097(01)00053-2; Guy PA, 1999, J AM SOC MASS SPECTR, V10, P969, DOI 10.1016/S1044-0305(99)00069-0; Hantke K, 2003, P NATL ACAD SCI USA, V100, P3677, DOI 10.1073/pnas.0737682100; HANTKE K, 1990, FEMS MICROBIOL LETT, V67, P5, DOI 10.1111/j.1574-6968.1990.tb13826.x; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Kunzel E, 1999, J AM CHEM SOC, V121, P11058, DOI 10.1021/ja9915347; Lagos R, 1999, J BACTERIOL, V181, P212, DOI 10.1128/JB.181.1.212-217.1999; Lagos R, 2001, MOL MICROBIOL, V42, P229, DOI 10.1046/j.1365-2958.2001.02630.x; LAGOS R, 1993, FEBS LETT, V321, P145, DOI 10.1016/0014-5793(93)80096-D; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Leo PM, 2002, ORG LETT, V4, P2711, DOI 10.1021/ol026222e; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Nemirovskiy OV, 1998, J AM SOC MASS SPECTR, V9, P1020, DOI 10.1016/S1044-0305(98)00071-3; NIKAIDO H, 1990, J BACTERIOL, V172, P1361, DOI 10.1128/jb.172.3.1361-1367.1990; OBRIEN IG, 1971, BIOCHIM BIOPHYS ACTA, V237, P537, DOI 10.1016/0304-4165(71)90274-1; OBRIEN IG, 1970, BIOCHIM BIOPHYS ACTA, V215, P393, DOI 10.1016/0304-4165(70)90038-3; Orellana C, 1996, FEMS MICROBIOL LETT, V136, P297; Patzer SI, 2003, MICROBIOL-SGM, V149, P2557, DOI 10.1099/mic.0.26396-0; PAYNE SM, 1988, CRC CR REV MICROBIOL, V16, P81, DOI 10.3109/10408418809104468; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLLACK JR, 1970, BIOCHEM BIOPH RES CO, V38, P989, DOI 10.1016/0006-291X(70)90819-3; Pons AM, 2002, BIOCHIMIE, V84, P531, DOI 10.1016/S0300-9084(02)01416-5; Pons AM, 2002, ANTIMICROB AGENTS CH, V46, P229, DOI 10.1128/AAC.46.1.229-230.2002; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCARROW RC, 1991, INORG CHEM, V30, P900, DOI 10.1021/ic00005a007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAKAHASHI K, 1981, J ANTIBIOT, V34, P271, DOI 10.7164/antibiotics.34.271; Wilkens M, 1997, J BACTERIOL, V179, P4789, DOI 10.1128/jb.179.15.4789-4794.1997; Wuthrich K, 1986, NMR PROTEINS NUCL AC	43	122	127	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28233	28242		10.1074/jbc.M400228200	http://dx.doi.org/10.1074/jbc.M400228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102848	hybrid			2022-12-27	WOS:000222265400053
J	Kondo, T; Kobayashi, M; Tanaka, J; Yokoyama, A; Suzuki, S; Kato, N; Onozawa, M; Chiba, K; Hashino, S; Imamura, M; Minami, Y; Minamino, N; Asaka, M				Kondo, T; Kobayashi, M; Tanaka, J; Yokoyama, A; Suzuki, S; Kato, N; Onozawa, M; Chiba, K; Hashino, S; Imamura, M; Minami, Y; Minamino, N; Asaka, M			Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; RADIOSENSITIZING AGENT; S-PHASE; LICENSING FACTOR; PROTEIN-KINASE; CYCLIN-E; REPLICATION; GEMININ; INHIBITION; LIGASE	Cdt1 is a licensing factor for DNA replication, the function of which is tightly controlled to maintain genome integrity. Previous studies have indicated that the cell cycle-dependent degradation of Cdt1 is triggered at S phase to prevent re-replication. In this study, we found that Cdt1 is degraded upon DNA damage induced by either UV treatment or gamma-irradiation (IR). Although the IR-triggered degradation of Cdt1 was caffeine-insensitive, the UV-triggered degradation of Cdt1 was caffeine-sensitive. This indicates that the cells treated with UV utilize the checkpoint pathway, which differs from that triggered by IR. A recent study has suggested that Cdt1 is phosphorylated, ubiquitylated, and degraded at the G(1)/S boundary in the normal cell cycle. Treatment with MG132, a proteasome inhibitor, inhibited the degradation of Cdt1 and resulted in the accumulation of the phosphorylated form of Cdt1 after UV treatment. In the case of UV treatment, phosphorylation of Cdt1 induced the recruitment of Cdt1 to a SCFSkp2 complex. Moreover, ectopic overexpression of Cdt1 after UV treatment interfered the inhibition of DNA synthesis. These results indicate that Cdt1 is a target molecule of the cell cycle checkpoint in UV-induced DNA damage.	Hokkaido Univ, Dept Gastroenterol & Hematol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Div Canc Pathobiol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Hokkaido Univ, Dept Hematol & Oncol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Kobe Univ, Dept Genome Sci, Grad Sch Med, Chuo Ku, Kobe, Hyogo 6500017, Japan	Hokkaido University; Hokkaido University; National Cerebral & Cardiovascular Center - Japan; Hokkaido University; Kobe University	Kondo, T (corresponding author), Hokkaido Univ, Dept Gastroenterol & Hematol, Grad Sch Med, Kita Ku, Nishi 7, Sapporo, Hokkaido 0608638, Japan.	t-kondoh@med.hokudai.ac.jp	Hashino, Satoshi/A-4815-2012; Asaka, Masahiro/A-5948-2012; Kondo, Takeshi/G-2103-2012; Onozawa, Masahiro/A-4136-2012	Kondo, Takeshi/0000-0001-7455-5824; Kobayashi, Masanobu/0000-0002-7445-9741				Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Busby EC, 2000, CANCER RES, V60, P2108; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	36	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27315	27319		10.1074/jbc.M314023200	http://dx.doi.org/10.1074/jbc.M314023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102855	hybrid			2022-12-27	WOS:000222120400061
J	Rabeh, WM; Cook, PF				Rabeh, WM; Cook, PF			Structure and mechanism of O-acetylserine sulfhydrylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ALPHA-AMINOACRYLATE INTERMEDIATE; SALMONELLA-TYPHIMURIUM LT-2; ANION-BINDING SITE; PYRIDOXAL 5'-PHOSPHATE; CONFORMATIONAL-CHANGE; COFACTOR ANALOGS; L-SERINE; FLUORESCENCE; PROBE; SPECTROSCOPY	The O-acetylserine sulfhydrylase (OASS) from Salmonella typhimurium catalyzes a beta-replacement reaction in which the beta-acetoxy group of O-acetyl-L-serine (OAS) is replaced by bisulfide to give L-cysteine and acetate. The kinetic mechanism of OASS is ping-pong with a stable alpha-aminoacrylate intermediate. The enzyme is a homodimer with one pyridoxal 5'-phosphate (PLP) bound per subunit deep within the protein in a cleft between the N- and C-terminal domains of each of the monomers. All of the active site residues are contributed by a single subunit. The enzyme cycles through open and closed conformations as it catalyzes its reaction with structural changes largely limited to a subdomain of the N- terminal domain. The elimination of acetic acid from OAS is thought to proceed via an anti-E2 mechanism, and the only catalytic group identified to date is lysine 41, which originally participates in Schiff base linkage to PLP. The transition state for the elimination of acetic acid is thought to be asynchronous and earlier for C beta-O bond cleavage than for Calpha-H bond cleavage.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu	Rabeh, Wael/AAO-4647-2020	Rabeh, Wael/0000-0001-6071-8581				Benci S, 1997, BIOCHEMISTRY-US, V36, P15419, DOI 10.1021/bi970464i; Benci S, 1999, J PHOTOCH PHOTOBIO B, V48, P17, DOI 10.1016/S1011-1344(99)00003-2; BENCI S, 1997, BIOCHIM BIOPHYS ACTA, V1429, P317; Burkhard P, 2000, J MOL BIOL, V303, P279, DOI 10.1006/jmbi.2000.4109; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; Cook PF, 1996, J BIOL CHEM, V271, P25842, DOI 10.1074/jbc.271.42.25842; Daum S, 2003, BIOCHEMISTRY-US, V42, P106, DOI 10.1021/bi0268044; Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472; Karsten WE, 2002, METHOD ENZYMOL, V354, P223; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; Mino K, 2003, J BACTERIOL, V185, P2277, DOI 10.1128/JB.185.7.2277-2284.2003; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; STREITWIESER A, 1958, J AM CHEM SOC, V80, P2326, DOI 10.1021/ja01542a075; Tai CH, 2000, PROTEIN PEPTIDE LETT, V7, P207; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l; Tai CH, 2000, ADV ENZYMOL RAMB, V74, P185; Tai CH, 2001, BIOCHEMISTRY-US, V40, P7446, DOI 10.1021/bi015511s; WESTHEIMER FH, 1961, CHEM REV, V61, P265, DOI 10.1021/cr60211a004; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o	27	73	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26803	26806		10.1074/jbc.R400001200	http://dx.doi.org/10.1074/jbc.R400001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073190	hybrid			2022-12-27	WOS:000222120400001
J	Sevilla, A; Santos, CR; Vega, FM; Lazo, PA				Sevilla, A; Santos, CR; Vega, FM; Lazo, PA			Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; C-JUN PROMOTER; RESPONSE ELEMENT; BINDING PROTEIN; MDM-2 BINDING; CREB-BINDING; FACTOR-2; EXPRESSION; FAMILY; IDENTIFICATION	In the human kinome, vaccinia-related kinase-1 (VRK1) is a new Ser-Thr kinase associated with proliferating tissues. VRK1 colocalizes with ATF2 in the nucleus and can form a stable complex. We have studied the phosphorylation of the transcription factor ATF2, which regulates gene expression by forming dimers with proteins with basic region-leucine zipper domains and recognizing cAMP-response element or AP1 sequences implicated in cellular responses to stress. VRK1 phosphorylates ATF2 mainly on Thr-73, stabilizing the ATF2 protein and increasing its intracellular level. Mutagenesis studies showed that Thr-73 and Ser-62 are implicated in ATF2 transcriptional activation by VRK1 detected in a functional assay based on ATF2 dimerization. VRK1 can activate the collagenase gene promoter that is regulated by ATF2 in a dose-dependent manner. Loss of kinase activity (K179E mutant) or the T73A substitution in ATF2 prevents both its accumulation and activation of transcription. VRK1 and JNK, which phosphorylates ATF2 in Thr-69 and Thr-71, have an additive effect on ATF2-dependent transcription at suboptimal doses. Therefore, two groups of amino acids in the ATF2 aminoterminal region can integrate different cellular signals mediated by at least five different kinases. VRK1 is an element of a novel signaling pathway that regulates gene transcription.	Univ Salamanca, Ctr Invest Canc, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Vega, Francisco M./C-4678-2008; Sevilla, Ana/N-8579-2017; Lazo, Pedro A./M-6435-2014	Vega, Francisco M./0000-0002-9015-864X; Sevilla, Ana/0000-0002-9251-4759; Lazo, Pedro A./0000-0001-8997-3025				Ban N, 2000, DIABETES, V49, P1142, DOI 10.2337/diabetes.49.7.1142; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIN SQ, 1992, J VIROL, V66, P2717, DOI 10.1128/JVI.66.5.2717-2723.1992; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Steinmuller L, 2001, BIOCHEM J, V360, P599, DOI 10.1042/0264-6021:3600599; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Xu X, 1996, VIROLOGY, V218, P362, DOI 10.1006/viro.1996.0205; ZU YL, 1992, J BIOL CHEM, V267, P20181	48	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27458	27465		10.1074/jbc.M401009200	http://dx.doi.org/10.1074/jbc.M401009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105425	hybrid			2022-12-27	WOS:000222120400077
J	Waldron, RT; Rey, O; Zhukova, E; Rozengurt, E				Waldron, RT; Rey, O; Zhukova, E; Rozengurt, E			Oxidative stress induces protein kinase C-mediated activation loop phosphorylation and nuclear redistribution of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIATES DNA-SYNTHESIS; PHORBOL ESTERS; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; FREE-RADICALS; INTACT-CELLS; D PKD; MU; GROWTH; DIACYLGLYCEROL	Oxidative stress induced by cell treatments with H2O2 activates protein kinase D (PKD) via a protein kinase C (PKC)-dependent signal transduction pathway (Waldron, R. T., and Rozengurt, E. (2000) J. Biol. Chem. 275, 17114-17121). Here we show that oxidative stress induces PKC-dependent activation loop Ser(744) and Ser(748) phosphorylation to mediate dose- and time-dependent activation of PKD, both endogenously expressed in Swiss 3T3 cells and stably overexpressed in Swiss 3T3-GFP. PKD cells. Although oxidative stress induced PKD activation loop phosphorylation and activation with identical kinetics, both were dose- dependently blocked by preincubation of cells with selective inhibitors of PKC (GF109203X and Go6983) or c-Src (PP2). Inhibition of Src tyrosine kinase activity eliminated oxidative stress-induced direct PKD tyrosine phosphorylation, but only partially attenuated activation loop phosphorylation and activation. Mutation of a putative tyrosine phosphorylation site on PKD, Tyr(469) to phenylalanine, had no effect on its activation by oxidative stress in transfected COS-7 cells. Similarly, a mutant with Tyr(469) replaced by aspartic acid had increased basal activity but was also further activated by oxidative stress. Thus, PKD tyrosine phosphorylation at this site neither produced full activation by itself nor was required for oxidative stress-induced activation mediated by activation loop phosphorylation. In addition to PKD activation, activation loop phosphorylation in response to oxidative stress also redistributed activated PKD to cell nuclei, as revealed by PKD indirect immunofluorescence, imaging of a PKD-green fluorescent protein fusion construct (GFP-PKD), and analysis of nuclear pellets. Cell preincubation with Go6983 strongly diminished H2O2-induced nuclear relocalization of GFP-PKD. Taken together, these results indicate that PKC-mediated PKD Ser(744) and Ser(748) phosphorylation induced by oxidative stress integrates PKD activation with redistribution to the nucleus.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Waldron, RT (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall Room 11-115, Los Angeles, CA 90095 USA.	rwaldron@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002; Rey, Osvaldo/0000-0003-1575-9864	NATIONAL CANCER INSTITUTE [P50CA090388, K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, K01DK002834] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA097956-01, P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [K01 DK02834-04, DK55003, DK56930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hanna IR, 2002, ANTIOXID REDOX SIGN, V4, P899, DOI 10.1089/152308602762197443; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Klein IK, 2000, CANCER RES, V60, P2077; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rhee S.G., 2000, SCI STKE; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	49	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27482	27493		10.1074/jbc.M402875200	http://dx.doi.org/10.1074/jbc.M402875200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084589	hybrid			2022-12-27	WOS:000222120400080
J	Levin, MK; Wang, YH; Patel, SS				Levin, MK; Wang, YH; Patel, SS			The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-UVRD; SINGLE-STRANDED-DNA; NS3 PROTEIN; HEXAMERIC HELICASES; CRYSTAL-STRUCTURE; STEADY-STATE; STEP-SIZE; IN-VITRO; RNA; DOMAIN	Although helicases participate in virtually every cellular process involving nucleic acids, the details of their mechanism including the role of interaction between the subunits remains unclear. Here we study the unwinding kinetics of the helicase from hepatitis C virus using DNA substrates with a range of tail and duplex lengths. The binding of the helicase to the substrates was characterized by electron microscopy and fluorimetric titrations. Depending on the length of the ssDNA tail, one or more helicase molecules can be loaded on the DNA. Unwinding was measured under single-turnover conditions, and the results show that a monomer is active on short duplexes yet multiple molecules are needed to unwind long duplexes. Thus, increasing the ssDNA tail length increases the unwinding efficiency. The unwinding kinetics was modeled as a stepwise process performed by single or multiple helicase molecules. The model programmed in MATLAB was used for global fitting of the kinetics, yielding values for the rate of unwinding, processivity, cooperativity, step size, and occlusion site. The results indicate that a single hepatitis C virus helicase molecule unwinds DNA with a low processivity. The multiple helicase molecules present on the DNA substrate show functional cooperativity and unwind with greater efficiency, although they bind and release the substrate non-cooperatively, and the ATPase cycle of the helicase molecules is not coordinated. The functional interaction model explains the efficient unwinding by multiple helicases and is generally applicable.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HAN DS, 1995, J GEN VIROL, V76, P985, DOI 10.1099/0022-1317-76-4-985; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOLYKHALOV AA, 1994, J VIROL, V68, P7525, DOI 10.1128/JVI.68.11.7525-7533.1994; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; Levin M.K., 2003, MOL MOTORS, P179; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	40	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26005	26012		10.1074/jbc.M403257200	http://dx.doi.org/10.1074/jbc.M403257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087464	hybrid			2022-12-27	WOS:000222003000011
J	Galliera, E; Jala, VR; Trent, JO; Bonecchi, R; Signorelli, P; Lefkowitz, RJ; Mantovani, A; Locati, M; Haribabu, B				Galliera, E; Jala, VR; Trent, JO; Bonecchi, R; Signorelli, P; Lefkowitz, RJ; Mantovani, A; Locati, M; Haribabu, B			beta-arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; DUFFY ANTIGEN; PROTEIN; ENDOCYTOSIS; AGONIST; DESENSITIZATION; PHOSPHORYLATION; US28; TRANSDUCTION; RECOGNITION	Seven transmembrane receptors mediate diverse physiological responses including hormone action, olfaction, neurotransmission, and chemotaxis. Human D6 is a non-signaling seven-transmembrane receptor expressed on lymphatic endothelium interacting with most inflammatory CC-chemokines resulting in their rapid internalization. Here, we demonstrate that this scavenging activity is mediated by continuous internalization and constant surface expression of the receptor, a process involving the clathrin-coated pit-dependent pathway. D6 constitutively associates with the cytoplasmic adaptor beta-arrestin, and this interaction is essential for D6 internalization. An acidic region, but not the putative phosphorylation sites in the cytoplasmic tail of D6, is critical for receptor interaction with beta-arrestin and subsequent internalization. Neither the native D6 nor mutants uncoupled from beta-arrestin activate any G-protein-mediated signaling pathways. Therefore, D6 may be considered a decoy receptor structurally adapted to perform chemokine scavenging.	Univ Louisville Hlth Sci, James Fraham Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville Hlth Sci, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Louisville Hlth Sci, Dept Med, Louisville, KY 40202 USA; Univ Milan, Inst Gen Pathol, Ctr Eccellenza Innovaz Diagnost & Terapeut, I-20133 Milan, Italy; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Louisville; University of Louisville; University of Louisville; University of Milan; Duke University; Howard Hughes Medical Institute; Duke University	Haribabu, B (corresponding author), Univ Louisville Hlth Sci, James Fraham Brown Canc Ctr, Delia Baxter Bldg 119 B,580 Preston St, Louisville, KY 40202 USA.	H0bodd01@gwise.louisville.edu	Bonecchi, Raffaella/ABI-2390-2020; Locati, Massimo/ABF-6807-2021; Locati, Massimo/H-8404-2015; Jala, Venkatakrishna R/K-7255-2018; Mantovani, Alberto/HCI-7449-2022; Bonecchi, Raffaella/A-3140-2009; Lefkowitz, Robert/AAW-2649-2021; Bodduluri, Haribabu/A-2584-2010	Locati, Massimo/0000-0003-3077-590X; Jala, Venkatakrishna R/0000-0002-4206-7305; Mantovani, Alberto/0000-0001-5578-236X; Bodduluri, Haribabu/0000-0002-8261-3294; trent, John/0000-0002-7346-4231; Bonecchi, Raffaella/0000-0003-3346-5333; signorelli, paola/0000-0003-2368-2393	FIC NIH HHS [TW-01198] Funding Source: Medline; NIAID NIH HHS [AI-43184, AI-52381] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043184, R01AI052381] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Akalin E, 2003, TRANSPLANTATION, V75, P1496, DOI 10.1097/01.TP.0000061228.38243.26; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Bonecchi R, 2004, J IMMUNOL, V172, P4972, DOI 10.4049/jimmunol.172.8.4972; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fra AM, 2003, J IMMUNOL, V170, P2279, DOI 10.4049/jimmunol.170.5.2279; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee JS, 2003, J IMMUNOL, V170, P5244, DOI 10.4049/jimmunol.170.10.5244; Luttrell LM, 2002, J CELL SCI, V115, P455; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEOTE K, 1994, BLOOD, V84, P44; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RENT JO, 2003, J BIOL CHEM, V278, P47136; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VISHNIVETSKIY SA, 2003, J BIOL CHEM; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	42	131	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25590	25597		10.1074/jbc.M400363200	http://dx.doi.org/10.1074/jbc.M400363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084596	hybrid			2022-12-27	WOS:000221827900086
J	Maye, P; Zheng, J; Li, L; Wu, DQ				Maye, P; Zheng, J; Li, L; Wu, DQ			Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERGENT EXTENSION MOVEMENTS; WNT/BETA-CATENIN; BETA-CATENIN; FRIZZLED HOMOLOGS; WINGLESS SIGNAL; XENOPUS EMBRYOS; CELL FATE; DROSOPHILA; PROTEINS; FAMILY	The effect of a noncanonical Wnt, Wnt11, on canonical Wnt signaling stimulated by Wnt1 and activated forms of LRP5 (low density lipoprotein receptor-related protein-5), Dishevelled1 (Dvl1), and beta-catenin was examined in NIH3T3 cells and P19 embryonic carcinoma cells. Wnt11 repressed Wnt1-mediated activation of LEF-1 reporter activity in both cell lines. However, Wnt11 was unable to inhibit canonical signaling activated by LRP5, Dvl1, or beta-catenin in NIH3T3 cells, although it could in P19 cells. In addition, Wnt11-mediated inhibition of canonical signaling in NIH3T3 cells is ligand-specific; Wnt11 could effectively repress canonical signaling activated by Wnt1, Wnt3, or Wnt3a but not by Wnt7a or Wnt7b. Co-culture experiments with NIH3T3 cells showed that the co-expression of Wnt11 with Wnt1 was not an essential requirement for the inhibition, suggesting receptor competition as a possible mechanism. Moreover, in both cell types, elevation of intracellular Ca2+ levels, which can result from Wnt11 treatment, led to the inhibition of canonical signaling. This result suggests that Wnt11 might not be able to signal in NIH3T3. Furthermore, P19 cells were found to express both endogenous canonical Wnts and Wnt11. Knockdown of Wnt11 expression using siRNA resulted in increased LEF-1 reporter activity, thus indicating that Wnt11-mediated suppression of canonical signaling exists in vivo.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China	University of Connecticut; St Jude Children's Research Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, MC3301,263 Farmington Ave, Farmington, CT 06030 USA.	dwu@neuron.uchc.edu		Maye, Peter/0000-0003-0098-4399; Zheng, Jie/0000-0001-6524-6800	NCI NIH HHS [CA85420] Funding Source: Medline; NIGMS NIH HHS [GM54167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Gieseler K, 1999, MECH DEVELOP, V85, P123, DOI 10.1016/S0925-4773(99)00097-0; Gieseler K, 1995, CR ACAD SCI III-VIE, V318, P1101; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PRIEVE MG, 2003, BMC DEV BIOL; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rauch GJ, 1997, COLD SPRING HARB SYM, V62, P227, DOI 10.1101/SQB.1997.062.01.028; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Strapps WR, 2001, DEVELOPMENT, V128, P4829; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200	48	109	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24659	24665		10.1074/jbc.M311724200	http://dx.doi.org/10.1074/jbc.M311724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067007	hybrid			2022-12-27	WOS:000221702500096
J	Xia, FZ; Gao, XD; Kwan, E; Lam, PPL; Chan, LL; Sy, KY; Sheu, L; Wheeler, MB; Gaisano, HY; Tsushima, RG				Xia, FZ; Gao, XD; Kwan, E; Lam, PPL; Chan, LL; Sy, KY; Sheu, L; Wheeler, MB; Gaisano, HY; Tsushima, RG			Disruption of pancreatic beta-cell lipid rafts modifies K(v)2.1 channel gating and insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNELS; CA2+ CHANNELS; POTASSIUM CHANNELS; DOWN-REGULATION; MESSENGER-RNAS; PC12 CELLS; B-CELLS; SECRETION; EXPRESSION; ISLETS	In pancreatic beta-cells, the predominant voltage-gated Ca2+ channel (Ca(V)1.2) and K+ channel (K(V)2.1) are directly coupled to SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein ( SNAP) receptor) proteins. These SNARE proteins modulate channel expression and gating and closely associate these channels with the insulin secretory vesicles. We show that K(V)2.1 and Ca(V)1.2, but not K(V)1.4, SUR1, or Kir6.2, target to specialized cholesterol-rich lipid raft domains on beta-cell plasma membranes. Similarly, the SNARE proteins syntaxin 1A, SNAP-25, and VAMP-2, but not Munc-13-1 or n-Sec1, are associated with lipid rafts. Disruption of the lipid rafts by depleting membrane cholesterol with methyl-beta-cyclodextrin shunts K(V)2.1, Ca(V)1.2, and SNARE proteins out of lipid rafts. Furthermore, methyl-beta-cyclodextrin inhibits K(V)2.1 but not Ca(V)1.2 channel activity and enhances single-cell exocytic events and insulin secretion. Membrane compartmentalization of ion channels and SNARE proteins in lipid rafts may be critical for the temporal and spatial coordination of insulin release, forming what has been described as the excitosome complex.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Tsushima, RG (corresponding author), Univ Toronto, Dept Med, 1 Kings Coll Circle,Rm 7308, Toronto, ON M5S 1A8, Canada.	r.tsushima@utoronto.ca		Wheeler, Michael B./0000-0002-7480-7267				Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; IWASHIMA Y, 1993, DIABETES, V42, P948, DOI 10.2337/diabetes.42.7.948; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MALAISSELAGAE F, 1984, BIOCHEM BIOPH RES CO, V123, P1062, DOI 10.1016/S0006-291X(84)80241-7; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MORGAN NG, 1985, BIOCHEM J, V231, P629, DOI 10.1042/bj2310629; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; ORCI L, 1981, PHILOS T ROY SOC B, V296, P47, DOI 10.1098/rstb.1981.0170; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Roe MW, 1996, AM J PHYSIOL-ENDOC M, V270, pE133, DOI 10.1152/ajpendo.1996.270.1.E133; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Yan LZ, 2004, DIABETES, V53, P597, DOI 10.2337/diabetes.53.3.597	39	146	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24685	24691		10.1074/jbc.M314314200	http://dx.doi.org/10.1074/jbc.M314314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15073181	hybrid			2022-12-27	WOS:000221702500099
J	Solomon, A; Rosenblum, G; Gonzales, PE; Leonard, JD; Mobashery, S; Milla, ME; Sagi, I				Solomon, A; Rosenblum, G; Gonzales, PE; Leonard, JD; Mobashery, S; Milla, ME; Sagi, I			Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOANAEROBACTER-BROCKII; ALCOHOL-DEHYDROGENASE; ACTIVE-SITE; TACE; GELATINASES; DISINTEGRIN; SPECTRA; DENSITY; ENERGY; CANCER	The metalloproteinase tumor necrosis factor-alpha-converting enzyme ( TACE) is involved in the regulation of several key physiological and pathological processes. Therefore, potent and selective synthetic inhibitors are highly sought for the study of the physiological roles of TACE as well as for therapeutic purposes. Because of the high structural similarities between the active site of TACE and those of other related zinc endopeptidases such as disintegrin (ADAMs) and matrix metalloproteinases ( MMPs), the design of such tailor-made inhibitors is not trivial. To obtain new insights into this problem, we have used a selective MMP inhibitor as a probe to examine the structural and kinetic effects occurring at the active site of TACE upon inhibition. Specifically, we used the selective MMP mechanism-based inhibitor SB-3CT to characterize the fine structural and electronic differences between the catalytic zinc ions within the active sites of TACE and MMP-2. We show that SB-3CT directly binds the metal ion of TACE as observed before with MMP-2. However, in contrast to MMP-2, the binding mode of SB-3CT to the catalytic zinc ion of TACE is different in the length of the Zn-S(SB-3CT) bond distance and the total effective charge of the catalytic zinc ion. In addition, SB-3CT inhibits TACE in a non-competitive fashion by inducing significant conformational changes in the structure. For MMP-2, SB-3CT behaved as a competitive inhibitor and no significant conformational changes were observed. An examination of the second shell amino acids surrounding the catalytic zinc ion of these enzymes indicated that the active site of TACE is more polar than that of MMP-2 and of other MMPs. On the basis of these results, we propose that although there is a seemingly high structural similarity between TACE and MMP-2, these enzymes are significantly diverse in the electronic and chemical properties within their active sites.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Weizmann Institute of Science; University of Pennsylvania; University of Notre Dame	Sagi, I (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	irit.sagi@weizmann.ac.il		Galli, Jennifer/0000-0001-8577-4790	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045949] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45949] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cross JB, 2002, J AM CHEM SOC, V124, P11004, DOI 10.1021/ja0201810; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Fasciglione GF, 2000, BIOPHYS J, V79, P2138, DOI 10.1016/S0006-3495(00)76461-7; Frenkel AI, 2002, J CHEM PHYS, V116, P9449, DOI 10.1063/1.1473193; FRISCH MJ, 2001, GAUSSIAN 98; Goldberg D.E., 1989, GENETIC ALGORITHMS S; HEHRE W, 1994, SPARTAN; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; KITANO K, 1993, BLOOD, V82, P2742; Kleifeld O, 2000, BIOCHEMISTRY-US, V39, P7702, DOI 10.1021/bi0002030; Kleifeld O, 2003, NAT STRUCT BIOL, V10, P98, DOI 10.1038/nsb889; Kleifeld O, 2001, J SYNCHROTRON RADIAT, V8, P978, DOI 10.1107/S0909049500017684; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Martin JML, 1998, J CHEM PHYS, V108, P2791, DOI 10.1063/1.475670; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAJMANOVICH R, 2003, THESIS WEIZMANN I SC; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; ROSEN O, 2001, THESIS WEIZMANN I SC; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SEGEL IH, 1993, ENZYME KINETICS BEHA, P21; Sobolev V, 1996, PROTEINS, V25, P120, DOI 10.1002/(SICI)1097-0134(199605)25:1<120::AID-PROT10>3.3.CO;2-1; STERN EA, 1995, PHYSICA B, V209, P117; Szatmary Z, 1999, NEOPLASMA, V46, P257; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	39	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31646	31654		10.1074/jbc.M401310200	http://dx.doi.org/10.1074/jbc.M401310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15102849	hybrid			2022-12-27	WOS:000222726800089
J	Fiermonte, G; De Leonardis, F; Todisco, S; Palmieri, L; Lasorsa, FM; Palmieri, F				Fiermonte, G; De Leonardis, F; Todisco, S; Palmieri, L; Lasorsa, FM; Palmieri, F			Identification of the mitochondrial ATP-Mg/P-i transporter - Bacterial expression, reconstitution, functional characterization, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ADENINE-NUCLEOTIDE TRANSPORT; ADP/ATP CARRIER; BOVINE MITOCHONDRIA; GLUCAGON TREATMENT; MOLECULAR-CLONING; PHOSPHATE CARRIER; YEAST; PROTEIN; ACCUMULATION	The mitochondrial carriers are a family of transport proteins that, with a few exceptions, are found in the inner membranes of mitochondria. They shuttle metabolites, nucleotides, and cofactors through this membrane and thereby connect and/or regulate cytoplasm and matrix functions. ATP-Mg is transported in exchange for phosphate, but no protein has ever been associated with this activity. We have isolated three human cDNAs that encode proteins of 458, 468, and 489 amino acids with 66-75% similarity and with the characteristic features of the mitochondrial carrier family in their C-terminal domains and three EF-hand Ca2+-binding motifs in their N-terminal domains. These proteins have been overexpressed in Escherichia coli and reconstituted into phospholipid vesicles. Their transport properties and their targeting to mitochondria demonstrate that they are isoforms of the ATP-Mg/P-i carrier described in the past in whole mitochondria. The tissue specificity of the three isoforms shows that at least one isoform was present in all of the tissues investigated. Because phosphate recycles via the phosphate carrier in mitochondria, the three isoforms of the ATP-Mg/P-i carrier are most likely responsible for the net uptake or efflux of adenine nucleotides into or from the mitochondria and hence for the variation in the matrix adenine nucleotide content, which has been found to change in many physiopathological situations.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	Fiermonte, Giuseppe/D-3680-2018; lasorsa, francesco massimo m/B-7931-2008; Todisco, Simona/AAU-2091-2021	Fiermonte, Giuseppe/0000-0002-6764-9395; lasorsa, francesco massimo m/0000-0001-8418-5222; 				APRILLE JR, 1982, BIOCHEM BIOPH RES CO, V108, P834, DOI 10.1016/0006-291X(82)90905-6; APRILLE JR, 1981, ARCH BIOCHEM BIOPHYS, V207, P157, DOI 10.1016/0003-9861(81)90021-7; APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9; APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; APRILLE JR, 1993, J BIOENERG BIOMEMBR, V25, P473, DOI 10.1007/BF01108404; APRILLE JR, 1988, INTEGRATION MITOCHON, P393; AUSTIN J, 1983, ARCH BIOCHEM BIOPHYS, V222, P321, DOI 10.1016/0003-9861(83)90529-5; AUSTIN J, 1984, J BIOL CHEM, V259, P154; BARBOUR RL, 1983, CANCER RES, V43, P1511; BATTINI R, 1987, J BIOL CHEM, V262, P4355; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; DAVIES NT, 1986, BIOCHIM BIOPHYS ACTA, V848, P294, DOI 10.1016/0005-2728(86)90203-3; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Dyall SD, 2000, MOL CELL BIOL, V20, P2488, DOI 10.1128/MCB.20.7.2488-2497.2000; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; GEHNRICH SC, 1988, COMP BIOCHEM PHYS B, V91, P11, DOI 10.1016/0305-0491(88)90107-1; Gonzalez-Barroso MM, 1999, J MOL BIOL, V292, P137, DOI 10.1006/jmbi.1999.3049; HAGEN T, 1993, ARCH BIOCHEM BIOPHYS, V303, P195, DOI 10.1006/abbi.1993.1273; Hagen T, 2003, AM J PHYSIOL-GASTR L, V285, pG274, DOI 10.1152/ajpgi.00052.2003; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; JOYAL JL, 1992, J BIOL CHEM, V267, P19198; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; LANOUE KF, 1984, BIOENERGETICS, P221; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Mashima H, 2003, J BIOL CHEM, V278, P9520, DOI 10.1074/jbc.M208398200; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; NAKAZAWA T, 1977, J BIOCHEM-TOKYO, V82, P1575, DOI 10.1093/oxfordjournals.jbchem.a131852; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; NOSEK MT, 1992, ARCH BIOCHEM BIOPHYS, V296, P691, DOI 10.1016/0003-9861(92)90628-A; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri L, 2000, BBA-BIOENERGETICS, V1459, P363, DOI 10.1016/S0005-2728(00)00173-0; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Picault N, 2004, TRENDS PLANT SCI, V9, P138, DOI 10.1016/j.tplants.2004.01.007; POLLAK JK, 1980, BIOCHEM J, V192, P75, DOI 10.1042/bj1920075; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SEITZ HJ, 1985, BIOCHEM J, V227, P149, DOI 10.1042/bj2270149; SOBOLL S, 1986, FEBS LETT, V205, P109, DOI 10.1016/0014-5793(86)80875-4; SULLIVAN TD, 1995, PLANTA, V196, P477, DOI 10.1007/BF00203647; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97; WATANABE F, 1983, J BIOCHEM-TOKYO, V94, P493, DOI 10.1093/oxfordjournals.jbchem.a134380; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; WOJTCZAK AB, 1987, INT J BIOCHEM, V19, P479, DOI 10.1016/0020-711X(87)90072-3; ZARA V, 1992, J BIOL CHEM, V267, P12077; [No title captured]	58	158	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30722	30730		10.1074/jbc.M400445200	http://dx.doi.org/10.1074/jbc.M400445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123600	hybrid			2022-12-27	WOS:000222531900103
J	Doering, CJ; Kisilevsky, AE; Feng, ZP; Arnot, MI; Peloquin, J; Hamid, J; Barr, W; Nirdosh, A; Simms, B; Winkfein, RJ; Zamponi, GW				Doering, CJ; Kisilevsky, AE; Feng, ZP; Arnot, MI; Peloquin, J; Hamid, J; Barr, W; Nirdosh, A; Simms, B; Winkfein, RJ; Zamponi, GW			A single G beta subunit locus controls cross-talk between protein kinase C and G protein regulation of N-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; GAMMA-SUBUNITS; SYNAPTIC-TRANSMISSION; DEPENDENT MODULATION; CRYSTAL-STRUCTURE; BINDING DOMAIN; INHIBITION; DETERMINANTS; NEURONS; SITES	The modulation of N-type calcium channels is a key factor in the control of neurotransmitter release. Whereas N-type channels are inhibited by Gbetagamma subunits in a G protein beta-isoform-dependent manner, channel activity is typically stimulated by activation of protein kinase C (PKC). In addition, there is cross-talk among these pathways, such that PKC-dependent phosphorylation of the Gbetagamma target site on the N-type channel antagonizes subsequent G protein inhibition, albeit only for Gbeta(1)-mediated responses. The molecular mechanisms that control this G protein beta subunit subtype-specific regulation have not been described. Here, we show that G protein inhibition of N-type calcium channels is critically dependent on two separate but adjacent similar to20-amino acid regions of the Gbeta subunit, plus a highly conserved Asn-Tyr-Val motif. These regions are distinct from those implicated previously in Gbetagamma signaling to other effectors such as G protein-coupled inward rectifier potassium channels, phospholipase beta(2), and adenylyl cyclase, thus raising the possibility that the specificity for G protein signaling to calcium channels might rely on unique G protein structural determinants. In addition, we identify a highly specific locus on the Gbeta(1) subunit that serves as a molecular detector of PKC-dependent phosphorylation of the G protein target site on the N-type channel alpha(1) subunit, thus providing for a molecular basis for G protein-PKC cross-talk. Overall, our results significantly advance our understanding of the molecular details underlying the integration of G protein and PKC signaling pathways at the level of the N-type calcium channel alpha(1) subunit.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Agler HL, 2003, J GEN PHYSIOL, V121, P495, DOI 10.1085/jgp.200208770; Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; Cooper CB, 2000, J BIOL CHEM, V275, P40777, DOI 10.1074/jbc.C000673200; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Feng ZP, 2001, J BIOL CHEM, V276, P45051, DOI 10.1074/jbc.M107784200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Page KM, 1997, J NEUROSCI, V17, P1330; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; ZAMPONI GW, 1997, NATURE, V385, P242	32	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29709	29717		10.1074/jbc.M308693200	http://dx.doi.org/10.1074/jbc.M308693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15105422	hybrid			2022-12-27	WOS:000222445300107
J	Chan, SL; Fu, WM; Zhang, PS; Cheng, AW; Lee, JW; Kokame, K; Mattson, MP				Chan, SL; Fu, WM; Zhang, PS; Cheng, AW; Lee, JW; Kokame, K; Mattson, MP			Herp stabilizes neuronal Ca2+ homeostasis and mitochondrial function during endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AMYLOID PRECURSOR PROTEIN; N-TERMINAL KINASE; INDUCED APOPTOSIS; CELL-DEATH; CALCIUM; ACTIVATION; CASPASE-12; ER; MODULATION	In response to endoplasmic reticulum ( ER) stress, cells launch homeostatic and protective responses, but can also activate cell death cascades. A 54 kDa integral ER membrane protein called Herp was identified as a stress-responsive protein in non-neuronal cells. We report that Herp is present in neurons in the developing and adult brain, and that it is regulated in neurons by ER stress; sublethal levels of ER stress increase Herp levels, whereas higher doses decrease Herp levels and induce apoptosis. The decrease in Herp protein levels following a lethal ER stress occurs prior to mitochondrial dysfunction and cell death, and is mediated by caspases which generate a 30-kDa proteolytic Herp fragment. Mutagenesis of the caspase cleavage site in Herp enhances its neuroprotective function during ER stress. While suppression of Herp induction by RNA interference sensitizes neural cells to apoptosis induced by ER stress, overexpression of Herp promotes survival by a mechanism involving stabilization of ER Ca2+ levels, preservation of mitochondrial function and suppression of caspase 3 activation. ER stress-induced activation of JNK/c-Jun and caspase 12 are reduced by Herp, whereas induction of major ER chaperones is unaffected. Herp prevents ER Ca2+ overload under conditions of ER stress and agonist-induced ER Ca2+ release is attenuated by Herp suggesting a role for Herp in regulating neuronal Ca2+ signaling. By stabilizing ER Ca2+ homeostasis and mitochondrial functions, Herp serves a neuroprotective function under conditions of ER stress.	NIA, Neurosci Lab, Gerontol Res Ctr, Intramural Res Program, Baltimore, MD 21224 USA; Natl Cardiovasc Res Inst, Osaka 5658565, Japan; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Cerebral & Cardiovascular Center - Japan; Johns Hopkins University	Chan, SL (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	chanst@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012; Lee, Jaewon/N-9064-2013	Lee, Jaewon/0000-0003-3203-2130; Kokame, Koichi/0000-0002-9654-6299	NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000313, ZIAAG000314, Z01AG000313, Z01AG000314, ZIAAG000312] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Guo Q, 1997, J NEUROSCI, V17, P4212; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P501, DOI 10.1089/ars.1999.1.4-501; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kitao Y, 2004, J NEUROSCI, V24, P1486, DOI 10.1523/JNEUROSCI.4029-03.2004; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Larsen AH, 2001, BMC BIOCHEM, V2; Lee B, 2001, ENDOCRINOLOGY, V142, P1744, DOI 10.1210/en.142.5.1744; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Mackrill JJ, 1998, BIOCHEM BIOPH RES CO, V245, P428, DOI 10.1006/bbrc.1998.8450; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Putney JW, 2001, J CELL SCI, V114, P2223; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Roth W, 2003, CELL DEATH DIFFER, V10, P1178, DOI 10.1038/sj.cdd.4401287; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Savage MJ, 2002, J NEUROSCI, V22, P3376; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Upadhya SC, 2003, TRENDS BIOCHEM SCI, V28, P280, DOI 10.1016/S0968-0004(03)00092-6; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	59	102	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28733	28743		10.1074/jbc.M404272200	http://dx.doi.org/10.1074/jbc.M404272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102845	hybrid			2022-12-27	WOS:000222265400111
J	Dhar, SK; Lynn, BC; Daosukho, C; St Clair, DK				Dhar, SK; Lynn, BC; Daosukho, C; St Clair, DK			Identification of nucleophosmin as an NF-kappa B co-activator for the induction of the human SOD2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; TUMOR-NECROSIS-FACTOR; ISCHEMIC BRAIN-INJURY; TRANSCRIPTION FACTOR; MALIGNANT PHENOTYPE; TRANSGENIC MICE; FACTOR-ALPHA; DNA-BINDING; MNSOD GENE; CELLS	Manganese superoxide dismutase (MnSOD) is an antioxidant enzyme essential for the survival of life. We have reported that NF-kappaB is essential but not sufficient for the synergistic induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines. To further identify transcription factors and co-activators that participate in the induction of MnSOD, we used NF-kappaB affinity chromatography to isolate potential NF-kappaB interacting proteins. Proteins eluted from the NF-kappaB affinity column were subjected to proteomic analysis and verified by Western analysis. Nucleophosmin (NPM), a nucleolar phosphoprotein, is the most abundant single protein identified. Co-immunoprecipitation studies suggest a physical interaction between NPM and NF-kappaB proteins. To verify the role of NPM on MnSOD gene transcription, cells were transfected with constructs expressing NPM in sense or antisense orientation as well as interference RNA. The results indicate that an increase NPM expression leads to increased MnSOD gene transcription in a dose-dependent manner. Consistent with this, expression of small interfering RNA for NPM leads to inhibition of MnSOD gene transcription but does not have any effect on the expression of interleukin-8, suggesting that the effect of NPM is selective. These results identify NPM as a partner of the NF-kappaB transcription complex in the induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Chem, Mass Spectrometry Facil, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	DSTCL00@pop.uky.edu		Lynn, Bert/0000-0001-8426-3024	NCI NIH HHS [R01 CA049797, CA 49797, R01 CA049797-13, CA 59835] Funding Source: Medline; NHLBI NIH HHS [HL 03544] Funding Source: Medline; NIA NIH HHS [AG 05119, P01 AG005119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG005119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; CARRIER F, 1994, P NATL ACAD SCI USA, V91, P1554, DOI 10.1073/pnas.91.4.1554; Chan EC, 2002, J CLIN ENDOCR METAB, V87, P2435, DOI 10.1210/jc.87.6.2435; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DELMAESTRO R, 1989, MECH AGEING DEV, V48, P15, DOI 10.1016/0047-6374(89)90022-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; EASTGATE J, 1993, BLOOD, V81, P639; FUJII J, 1991, J BIOL CHEM, V266, P23142; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1997, CANCER RES, V57, P5265; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; MANGANARO F, 1995, FREE RADICAL BIO MED, V19, P823, DOI 10.1016/0891-5849(95)02008-X; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109; SAFFORD SE, 1994, CANCER RES, V54, P4261; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893; St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7; SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; URANO M, 1995, CANCER RES, V55, P2490; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; ZABEL U, 1991, J BIOL CHEM, V266, P252; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; Zhu CH, 2001, ANTIOXID REDOX SIGN, V3, P387, DOI 10.1089/15230860152409031; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200	52	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28209	28219		10.1074/jbc.M403553200	http://dx.doi.org/10.1074/jbc.M403553200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087454	hybrid, Green Accepted			2022-12-27	WOS:000222265400050
J	Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R				Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R			Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; DUST-MITE ALLERGEN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; GM2-ACTIVATOR PROTEIN; TERTIARY STRUCTURE; INNATE IMMUNITY; DISULFIDE BONDS; RESPONSIVENESS; COMPLEX	The receptor complex resulting from association of MD-2 and the ectodomain of Toll-like receptor 4 (TLR4) mediates lipopolysaccharide (LPS) signal transduction across the cell membrane. We prepared a tertiary structure model of MD-2, based on the known structures of homologous lipid-binding proteins. Analysis of circular dichroic spectra of purified bacterially expressed MD-2 indicates high content of beta-type secondary structure, in agreement with the structural model. Bacterially expressed MD-2 was able to confer LPS responsiveness to cells expressing TLR4 despite lacking glycosylation. We identified several clusters of basic residues on the surface of MD-2. Mutation of each of two clusters encompassing the residues Lys(89)-Arg(90)-Lys(91) and Lys(125)-Lys(125) significantly decreased the signal transduction of the respective MD-2 mutants either upon co-expression with TLR4 or upon addition as soluble protein into the supernatant of cells overexpressing TLR4. These basic clusters lie at the edge of the beta-sheet sandwich, which in cholesterol-binding protein connected to Niemann-Pick disease C2 (NPC2), dust mite allergen Der p2, and ganglioside GM2-activator protein form a hydrophobic pocket. In contrast, mutation of another basic cluster composed of Arg(69)-Lys(72), which according to the model lies further apart from the hydrophobic pocket only weakly decreased MD-2 activity. Furthermore, addition of the peptide, comprising the surface loop between Cys(95) and Cys(105), predicted by model, particularly in oxidized form, decreased LPS-induced production of tumor necrosis factor alpha and interleukin-8 upon application to monocytic cells and fibroblasts, respectively, supporting its involvement in LPS signaling. Our structural model of MD-2 is corroborated by biochemical analysis and contributes to the unraveling of molecular interactions in LPS recognition.	Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	National Institute of Chemistry - Slovenia; Technical University of Munich	Jerala, R (corresponding author), Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; DASILVA CJ, 2002, J BIOL CHEM, V277, P1845, DOI [DOI 10.1074/JBC.M109910200, 10.1074/jbc.M109910200]; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Ginalski K, 2003, PROTEINS, V53, P410, DOI 10.1002/prot.10548; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Guyard-Dangremont V, 1999, PROTEIN SCI, V8, P2392; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Ohnishi T, 2001, J IMMUNOL, V167, P3354, DOI 10.4049/jimmunol.167.6.3354; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schubert WD, 2001, J MOL BIOL, V312, P783, DOI 10.1006/jmbi.2001.4989; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	47	108	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28475	28482		10.1074/jbc.M400993200	http://dx.doi.org/10.1074/jbc.M400993200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15111623	hybrid			2022-12-27	WOS:000222265400082
J	Laliberte, J; Whitson, LJ; Beaudoin, J; Holloway, SP; Hart, PJ; Labbe, S				Laliberte, J; Whitson, LJ; Beaudoin, J; Holloway, SP; Hart, PJ; Labbe, S			The Schizosaccharomyces pombe Pccs protein functions in both copper trafficking and metal detoxification pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; IRON UPTAKE; FISSION YEAST; TRANSCRIPTION FACTOR; MUTATIONAL ANALYSIS; PHYSIOLOGICAL-ROLE; HETEROLOGOUS PROTEINS; METALLOTHIONEIN GENE	Because copper is both an essential cofactor and a toxic metal, different strategies have evolved to appropriately regulate its homeostasis as a function of changing environmental copper levels. In this report, we describe a metallochaperone-like protein from Schizosaccharomyces pombe that maintains the delicate balance between essentiality and toxicity. This protein, designated Pccs, has four distinct domains. SOD activity assays reveal that the first three domains of Pccs are necessary and sufficient to deliver copper to its target, copper-zinc superoxide dismutase (SOD1). Pccs domain IV, which is absent in Saccharomyces cerevisiae CCS1, contains seventeen cysteine residues, eight pairs of which are in a potential metal coordination arrangement, Cys-Cys. We show that S. cerevisiae ace1Delta mutant cells expressing the full-length Pccs molecule are resistant to copper toxicity. Furthermore, we demonstrate that the Pccs domain IV enhances copper resistance of the ace1Delta cells by an order of magnitude compared with that observed in the same strain expressing a pccs(+)I-II-III allele encoding Pccs domains I-III. We consistently found that S. pombe cells disrupted in the pccs(+) gene exhibit an increased sensitivity to copper and cadmium. Furthermore, we demonstrate that overexpression of pccs(+) is associated with increased copper resistance in fission yeast cells. Taken together, our findings suggest that Pccs activates apo-SOD1 under copper-limiting conditions through the use of its first three domains and protects cells against metal ion toxicity via its fourth domain.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78229 USA	University of Sherbrooke; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca		Labbe, Simon/0000-0002-4947-523X	NINDS NIH HHS [R01 NS039112] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFA C, 1993, EXPT FISSION YEASTS; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; Bellemare DR, 2001, GENE, V273, P191, DOI 10.1016/S0378-1119(01)00591-1; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Borrelly GPM, 2002, J BIOL CHEM, V277, P30394, DOI 10.1074/jbc.M203145200; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CHANG EC, 1991, J BIOL CHEM, V266, P4417; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Crapo J D, 1978, Methods Enzymol, V53, P382; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; Cyrne L, 2003, FREE RADICAL BIO MED, V34, P385, DOI 10.1016/S0891-5849(02)01300-X; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Forsburg SL, 1997, GENETICS, V147, P1025; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kim J, 1998, GENETICS, V149, P795; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe Simon, 2002, P571; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lee J, 2002, BIOCHEM BIOPH RES CO, V297, P854, DOI 10.1016/S0006-291X(02)02290-8; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Mutoh N, 2002, CURR GENET, V41, P82, DOI 10.1007/s00294-002-0288-9; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SAINTJACQUES E, 1993, DNA CELL BIOL, V12, P329, DOI 10.1089/dna.1993.12.329; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; SIKORSKI RS, 1989, GENETICS, V122, P19; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sturtz LA, 2002, METHOD ENZYMOL, V349, P167, DOI 10.1016/S0076-6879(02)49332-9; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	89	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28744	28755		10.1074/jbc.M403426200	http://dx.doi.org/10.1074/jbc.M403426200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107426	hybrid			2022-12-27	WOS:000222265400112
J	Lewitzky, M; Harkiolaki, M; Domart, MC; Jones, EY; Feller, SM				Lewitzky, M; Harkiolaki, M; Domart, MC; Jones, EY; Feller, SM			Mona/Gads SH3C binding to hematopoietic progenitor kinase 1 (HPK1) combines an atypical SH3 binding motif, R/KXXK, with a classical PXXP motif embedded in a polyproline type II (PPII) helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR KINASE-1; N-TERMINAL KINASE; CASPASE-MEDIATED CLEAVAGE; SRC HOMOLOGY 3; ADAPTER PROTEINS; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; KAPPA-B; DOMAIN; ACTIVATION	Hematopoietic progenitor kinase 1 (HPK1) is implicated in signaling downstream of the T cell receptor. Its non-catalytic, C-terminal half contains several proline-rich motifs, which have been shown to interact with different SH3 domain-containing adaptor proteins in vitro. One of these, Mona/Gads, was also shown to bind HPK1 in mouse T cells in vivo. The region of HPK1 that binds to the Mona/Gads C-terminal SH3 domain has been mapped and shows only very limited similarity to a recently identified high affinity binding motif in SLP-76, another T-cell adaptor. Using isothermal titration calorimetry and x-ray crystallography, the binding of the HPK1 motif to Mona/Gads SH3C has now been characterized in molecular detail. The results indicate that although charge interactions through an RXXK motif are essential for complex formation, a PXXP motif in HPK1 strongly complements binding. This unexpected binding mode therefore differs considerably from the previously described interaction of Mona/Gads SH3C with SLP-76. The crystal structure of the complex highlights the great versatility of SH3 domains, which allows interactions with very different proteins. This currently limits our ability to categorize SH3 binding properties by simple rules.	Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Lab, Canc Res UK Cell Signalling Grp, Oxford OX3 9DS, England; Univ Burgundy, UFR Sci Vie, F-21000 Dijon, France; Canc Res UK Receptor Struct Grp, Oxford OX3 7BN, England	Cancer Research UK; University of Oxford; Universite de Bourgogne; Cancer Research UK	Feller, SM (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	stephan.feller@cancer.org.uk	Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Domart, Marie-Charlotte/0000-0002-5703-2922				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arnold R, 2001, J BIOL CHEM, V276, P14675, DOI 10.1074/jbc.M008343200; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Han J, 2003, J BIOL CHEM, V278, P52195, DOI 10.1074/jbc.M305026200; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kiefer F, 2002, TRANSPL IMMUNOL, V9, P69, DOI 10.1016/S0966-3274(02)00009-6; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Sawasdikosol S, 2003, BLOOD, V101, P3687, DOI 10.1182/blood-2002-07-2316; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	35	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28724	28732		10.1074/jbc.M402745200	http://dx.doi.org/10.1074/jbc.M402745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100220	hybrid			2022-12-27	WOS:000222265400110
J	Vindis, C; Teli, T; Cerretti, DP; Turner, CE; Huynh-Do, U				Vindis, C; Teli, T; Cerretti, DP; Turner, CE; Huynh-Do, U			EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPH RECEPTORS; LD4 MOTIF; ADHESION; KINASE; ACTIVATION; CRK	Interactions between Eph receptors and their membrane-bound ligands (ephrins) are of critical importance for key developmental processes such as boundary formation or vascular development. Their downstream signaling pathways are intricate and heterogeneous at several levels, the combined effect being a highly complex and flexible system. Here we demonstrate that activated EphB1 induces tyrosine phosphorylation of the focal adhesion protein paxillin at Tyr-31 and Tyr-118 and is recruited to paxillin-focal adhesion kinase (FAK) complexes. Pretreatment with the specific Src inhibitor PP2, or expression of dominant-negative, kinase-dead c-Src abrogates EphB1-induced tyrosine phosphorylation of paxillin. Cells transfected with the paxillin mutant Y31F/Y118F displayed a reduced migration in response to ephrin B2 stimulation. Furthermore, expression of an LD4 deletion mutant ( paxillin DeltaLD4) significantly reduces EphB1-paxillin association, paxillin tyrosine phosphorylation, as well as EphB1-dependent cell migration. Finally, mutation of the Nck-binding site of EphB1 (Y594F) interrupts the interaction between Nck, paxillin, and EphB1. These data suggest a model in which ligand-activated EphB1 forms a signaling complex with Nck, paxillin, and focal adhesion kinase and induces tyrosine phosphorylation of paxillin in a c-Src-dependent manner to promote cell migration.	Univ Bern, Dept Clin Res, Div Nephrol, CH-3010 Bern, Switzerland; Amgen Corp, Seattle, WA 98101 USA; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	University of Bern; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huynh-Do, U (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol, CH-3010 Bern, Switzerland.	uyen.huynh-do@insel.ch	Vindis, Cécile/AAH-2708-2019	Vindis, Cécile/0000-0003-2421-1155	NIGMS NIH HHS [GM 47607, R01 GM047607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076	18	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27965	27970		10.1074/jbc.M401295200	http://dx.doi.org/10.1074/jbc.M401295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107421	hybrid			2022-12-27	WOS:000222265400018
J	Ray, SS; Swanson, HI				Ray, SS; Swanson, HI			Dioxin-induced immortalization of normal human keratinocytes and silencing of p53 and p16(INK4a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; AH RECEPTOR; CELLULAR SENESCENCE; DNA METHYLATION; GENE-REGULATION; CANCER; DEGRADATION; PROMOTER; CELLS; DIFFERENTIATION	Dioxin, a potent tumor promoter, activates the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor belonging to the basic helix-loop-helix-PAS family, to enhance tumorigenesis via unknown mechanisms. We undertook this study to determine the mechanisms underlying the impact of dioxin on cell fate, in particular senescence that occurs in normal human cells and is considered to play important tumor suppressive function. We have previously shown that in primary human keratinocytes, dioxin attenuates senescence while retaining the proliferative capacity and represses expression of the tumor suppressors, p16(INK4a) and p53. Here, we show that repression of p16(INK4a) and p53 transcriptional activity by dioxin absolutely requires the AHR and is accompanied by promoter methylation. Furthermore, dioxin alone is sufficient to immortalize normal human keratinocytes. Our data introduce a previously unrecognized regulatory pathway, that of the AHR, that impacts senescence. More importantly, this is the first report of a tumor promoter capable of inhibiting senescence in a receptor mediated manner and introduces a novel mechanism by which this carcinogen may contribute to human malignancies.	Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Swanson, HI (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, 800 Rose St,MS 305, Lexington, KY 40536 USA.	hswan@uky.edu		Swanson, Hollie/0000-0002-3725-5504	NIEHS NIH HHS [R01 ES011295, ES11295-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011295] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Edelman P, 2003, ENVIRON HEALTH PERSP, V111, P1906, DOI 10.1289/ehp.6315; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henry EC, 1999, MOL PHARMACOL, V55, P716; HERMAN JG, 1995, CANCER RES, V55, P4525; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kaiser J, 2000, SCIENCE, V290, P1071; Kaiser J, 2000, SCIENCE, V288, P1941; Kubota T, 1997, NAT GENET, V16, P16, DOI 10.1038/ng0597-16; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Pelicci PG, 2004, J CLIN INVEST, V113, P4, DOI 10.1172/JCI200420750; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Ray SS, 2003, TOXICOL APPL PHARM, V192, P131, DOI 10.1016/S0041-008X(03)00277-1; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; Schmidt CW, 2004, ENVIRON HEALTH PERSP, V112, pA40, DOI 10.1289/ehp.112-a40; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Song ZJ, 2003, MOL PHARMACOL, V63, P597, DOI 10.1124/mol.63.3.597; Song ZJ, 2002, MOL PHARMACOL, V62, P806, DOI 10.1124/mol.62.4.806; Starr TB, 2003, ENVIRON HEALTH PERSP, V111, P1443, DOI 10.1289/ehp.6219; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; SWANSON HI, 2004, IN PRESS MOL METHODS	38	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27187	27193		10.1074/jbc.M402771200	http://dx.doi.org/10.1074/jbc.M402771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15111621	hybrid			2022-12-27	WOS:000222120400045
J	Alisio, A; Mueckler, M				Alisio, A; Mueckler, M			Relative proximity and orientation of helices 4 and 8 of the GLUT1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; EXOFACIAL LIGAND-BINDING; ESCHERICHIA-COLI; XENOPUS-OOCYTES; LACTOSE PERMEASE; ACCESSIBILITY; MECHANISM; PROTEINS; MEMBRANE	A structure has been proposed for glucose transporter-1 ( GLUT1) based upon homology modeling that is consistent with the results of numerous mutagenesis studies (Mueckler, M., and Makepeace, C. (2004) J. Biol. Chem. 279, 10494-10499). To further test and refine this model, the relative orientation and proximity of transmembrane helices 4 and 8 were analyzed by chemical crosslinking of di-cysteine mutants created in a reporter GLUT1 construct. All six native cysteine residues of GLUT1 were changed to either glycine or serine residues by site-directed mutagenesis, resulting in a functional Glut1 construct with Cys mutated to Gly/Ser (Cless). The GLUT1 reporter molecule was engineered from C-less GLUT1 by creating a unique cleavage site for factor Xa protease within the central cytoplasmic loop and by eliminating the site of N-linked glycosylation. Fourteen functional di-cysteine mutants were then created from the C-less reporter construct, each mutant containing a single cysteine residue in helix 4 and one cysteine residue in helix 8. These mutants were expressed in Xenopus oocytes, and the sensitivity of each mutant to intramolecular crosslinking by two homo-bifunctional, thiol-specific crosslinking reagents, bismale-imidehexane and 1,4-phenylenedimaleimide, was ascertained by protease cleavage followed by immunoblot analysis. Four pairs of cysteine residues, Cys(148)/Cys(328), Cys(145)/Cys(328), Cys(148)/Cys(325), and Cys(145)/Cys(325), were observed to be in close enough proximity to be susceptible to crosslinking by one or both reagents. All five of the cysteine residues susceptible to crosslinking are predicted to lie on the same face of helix 4 or 8 and to reside close to the cytoplasmic face of the membrane. These data indicate that the cytoplasmic ends of helices 4 and 8 lie within 6-16 Angstromof one another and that the two helices twist or tilt such that they are further than 16 Angstrom apart toward the center and the exoplasmic side of the membrane. An updated model for the clustering of the transmembrane helices of GLUT1 is presented based on these data.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER MM, 1989, RED BLOOD CELL MEMBR, V11, P31; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26540	26545		10.1074/jbc.M402303200	http://dx.doi.org/10.1074/jbc.M402303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073187	hybrid			2022-12-27	WOS:000222003000078
J	Mueller, M; Lindner, B; Kusumoto, S; Fukase, K; Schromm, AB; Seydel, U				Mueller, M; Lindner, B; Kusumoto, S; Fukase, K; Schromm, AB; Seydel, U			Aggregates are the biologically active units of endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; FREE LIPID-A; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE-BINDING; RE LIPOPOLYSACCHARIDE; CHEMICAL-STRUCTURE; CD14; PRINCIPLE; ACTIVATION; COMPLEXES	For the elucidation of the very early steps of immune cell activation by endotoxins (lipopolysaccharide, LPS) leading to the production and release of proinflammatory cytokines the question concerning the biologically active unit of endotoxins has to be addressed: are monomeric endotoxin molecules able to activate cells or is the active unit represented by larger endotoxin aggregates? This question has been answered controversially in the past. Inspired by the observation that natural isolates of lipid A, the lipid moiety of LPS harboring its endotoxic principle, from Escherichia coli express a higher endotoxic activity than the same amounts of the synthetic E. coli-like hexaacylated lipid A (compound 506), we looked closer at the chemical composition of natural isolates. We found in these isolates that the largest fraction was hexaacylated, but also significant amounts of penta- and tetraacylated molecules were present that, when administered to human mononuclear cells, may antagonize the induction of cytokines by biologically active hexaacylated endotoxins. We prepared separate aggregates of either compound 506 or 406 (tetraacylated precursor IVa), mixed at different molar ratios, and mixed aggregates containing both compounds in the same ratios. Surprisingly, the latter mixtures showed higher endotoxic activity than that of the pure compound 506 up to an admixture of 20% of compound 406. Similar results were obtained when using various phospholipids instead of compound 406. These observations can only be understood by assuming that the active unit of endotoxins is the aggregate. We further confirmed this result by preparing monomeric lipid A and LPS by a dialysis procedure and found that, at the same concentrations, only the aggregates were biologically active, whereas the monomers showed no activity.	Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, Div Biophys, D-23845 Borstel, Germany; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan	Forschungszentrum Borstel; Osaka University	Seydel, U (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, Div Biophys, Parkallee 10, D-23845 Borstel, Germany.	useydel@fz-borstel.de	Schromm, Andra/O-3936-2018; Lindner, Buko/G-9731-2014					Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; BUSCHNER S, 1999, THESIS CHRISTIAN ALB; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Friberger P, 1987, DETECTION BACTERIAL, P49; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALLATI H, 1982, J CLIN CHEM CLIN BIO, V20, P907; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; IMOTO M, 1984, P JPN ACAD B-PHYS, V60, P285, DOI 10.2183/pjab.60.285; IMOTO M, 1987, B CHEM SOC JPN, V60, P2205, DOI 10.1246/bcsj.60.2205; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P341, DOI 10.1016/B978-0-12-375182-9.10015-6; Janusch H, 2002, J ENDOTOXIN RES, V8, P343, DOI 10.1179/096805102125000678; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; Lindner B, 2000, METH MOL B, V145, P311; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LUDERITZ O, 1978, NATURWISSENSCHAFTEN, V65, P578, DOI 10.1007/BF00364907; NOWOTNY A, 1987, REV INFECT DIS, V9, pS503; Oikawa M, 1997, B CHEM SOC JPN, V70, P1435, DOI 10.1246/bcsj.70.1435; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; SHNYRA A, 1993, INFECT IMMUN, V61, P5351, DOI 10.1128/IAI.61.12.5351-5360.1993; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; TOBIAS PS, 1994, CHEST, V105, pS48, DOI 10.1378/chest.105.3.48S; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; WOLLENWEBER HW, 1982, EUR J BIOCHEM, V124, P191, DOI 10.1111/j.1432-1033.1982.tb05924.x; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3; Zahringer U, 2001, J ENDOTOXIN RES, V7, P133, DOI 10.1177/09680519010070020801	31	172	195	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26307	26313		10.1074/jbc.M401231200	http://dx.doi.org/10.1074/jbc.M401231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096514	hybrid			2022-12-27	WOS:000222003000049
J	Nishihara, H; Hwang, M; Kizaka-Kondoh, S; Eckmann, L; Insel, PA				Nishihara, H; Hwang, M; Kizaka-Kondoh, S; Eckmann, L; Insel, PA			Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PHOSPHORYLATION; GENE; CREB; PATHWAYS; ACTIVATION; BAD; TRANSCRIPTION; EXPRESSION; SURVIVAL	We recently reported that cAMP suppresses apoptosis in colon cancer cells and induces cellular inhibitor of apoptosis protein-2 (c-IAP2) via a cAMP-responsive element (CRE), suggesting a mechanism for chemoprevention of colon cancer by non-steroidal anti-inflammatory drugs. In this study, we used T84 human colon cancer cells to define the pathway by which increases in cAMP induce c-IAP2 expression. Treatment with several different cAMP agonists stimulated phosphorylation of CRE-binding protein (CREB) and activated expression of c-IAP2 in a CREB-dependent manner. Studies with pharmacological inhibitors revealed that cAMP-dependent phosphorylation of CREB required activation of ERK1/2 and p38 MAPK but was largely independent of protein kinase A. Immunoblots and transcriptional reporter assays using specific inhibitors, as well as expression of constitutively active forms of MEK1 and MKK3, showed that c-IAP2 induction by cAMP is regulated predominantly through ERK1/2 and p38 MAPK and suggested involvement of p90 ribosomal protein S6 kinase and mitogen and stress response kinase-1 as well. Consistent with those results, we found that cAMP-dependent suppression of apoptosis was blocked by treatment with inhibitors of ERK1/2 and p38 MAPK. We conclude that cAMP can induce c-IAP2 expression in colon cancer cells through CREB phosphorylation and CRE-dependent transcription in a manner that involves activation of ERK1/2 and p38 MAPK. These results emphasize that activation of kinases other than protein kinase A can mediate the actions of agents that increase cAMP, particularly in the regulation of CREB-dependent events.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kyoto University	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Kondoh, Shinae/C-6937-2015; Kondoh, Shinae/AAF-8745-2020	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782				BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Baumann CA, 1997, MECH AGEING DEV, V94, P85, DOI 10.1016/S0047-6374(96)01860-X; Belley A, 1999, GASTROENTEROLOGY, V117, P1352, DOI 10.1016/S0016-5085(99)70285-4; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Cho YS, 2002, P NATL ACAD SCI USA, V99, P15626, DOI 10.1073/pnas.242617799; Cho YS, 2002, CLIN CANCER RES, V8, P607; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garcia-Bermejo L, 1998, J CELL SCI, V111, P637; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Leahy KM, 2002, CANCER RES, V62, P625; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Tortora G, 2002, CLIN CANCER RES, V8, P303; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	57	90	96	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26176	26183		10.1074/jbc.M313346200	http://dx.doi.org/10.1074/jbc.M313346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078890	hybrid			2022-12-27	WOS:000222003000032
J	Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY				Shieh, JJ; Pan, CJ; Mansfield, BC; Chou, JY			A potential new role for muscle in blood glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PHOSPHOHISTIDINE-ENZYME INTERMEDIATE; GLUCOSE-6-PHOSPHATE TRANSPORTER; MURINE GLUCOSE-6-PHOSPHATASE; SKELETAL-MUSCLE; GENE; TYPE-1A; IDENTIFICATION; CATALYSIS; PROTEIN	The breakdown of tissue glycogen into glucose is critical for blood glucose homeostasis between meals. In the final steps of glycogenolysis, intracellular glucose 6-phosphate (Glc-6-P) is transported into the endoplasmic reticulum where it is hydrolyzed to glucose by glucose-6-phosphatase (Glc-6-Pase). Although the majority of body glycogen is stored in the muscle, the current dogma holds that Glc-6-Pase (now named Glc-6-Pase-alpha) is expressed only in the liver, kidney, and intestine, implying that muscle glycogen cannot contribute to interprandial blood glucose homeostasis. Recently we reported a second Glc-6-P hydrolase, Glc-6-Pase-beta. Glc-6-Pase-alpha shares kinetic and structural similarities to Glc-6-Pase-alpha and couples with the Glc-6-P transporter to form an active Glc-6-Pase complex (Shieh, J.-J., Pan, C.-J., Mansfield, B. C., and Chou, J. Y. (2003) J. Biol. Chem. 278, 47098-47103). Here we demonstrate that muscle expresses both Glc-6-Pase-beta and Glc-6-P transporter and that they can couple to form an active Glc-6-Pase complex. Our data suggest that muscle may have a previously unrecognized role in interprandial glucose homeostasis.	NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603; Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYNES J, 1999, MED BIOCH, P139; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; COLLINS JE, 1990, J INHERIT METAB DIS, V13, P195, DOI 10.1007/BF01799686; Gallagher D., 1999, The role of protein and amino acids in sustaining and enhancing performance., P255; Gamberucci A, 1996, MOL MEMBR BIOL, V13, P103, DOI 10.3109/09687689609160583; Gerin I, 1999, GENE, V227, P189, DOI 10.1016/S0378-1119(98)00614-3; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Ghosh A, 2004, J BIOL CHEM, V279, P12479, DOI 10.1074/jbc.M313271200; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 2000, HUM GENET, V107, P526, DOI 10.1007/s004390000404; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Mitanchez D, 1997, ENDOCR REV, V18, P520, DOI 10.1210/er.18.4.520; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; POWELL RC, 1981, METABOLISM, V30, P443, DOI 10.1016/0026-0495(81)90178-5; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Snyder WS, 1975, REPORT TASK GROUP RE; TSALIKIAN E, 1984, AM J PHYSIOL, V247, pE513, DOI 10.1152/ajpendo.1984.247.4.E513	31	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26215	26219		10.1074/jbc.M402036200	http://dx.doi.org/10.1074/jbc.M402036200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087461	hybrid			2022-12-27	WOS:000222003000037
J	Takada, Y; Khuri, FR; Aggarwal, BB				Takada, Y; Khuri, FR; Aggarwal, BB			Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappa B activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappa B-regulated gene expression and up-regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FARNESYL TRANSFERASE INHIBITOR; SIGNAL-TRANSDUCTION PATHWAYS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; KINASE C-ZETA; TRANSCRIPTIONAL ACTIVITY; P65 PHOSPHORYLATION; ENDOTHELIAL-CELLS; TNF-ALPHA	Ras farnesyltransferase inhibitor (FTI) exhibit antiproliferative and antiangiogenic effects through a mechanism that is poorly understood. Because of the known role of Ras in the activation of transcription factor NF-kappaB and because NF-kappaB-regulated genes can control cell survival and angiogenesis, we postulated that FTI mediates its effects in part by modulating NF-kappaB activation. Therefore, in the present study we investigated the effect of FTI, SCH 66336, on NF-kappaB and NF-kappaB-regulated gene expression activated by a variety of inflammatory and carcinogenic agents. We demonstrate by DNA-binding assay that NF-kappaB activation induced by tumor necrosis factor (TNF), phorbol 12-myristate 13-acetate, cigarette smoke, okadaic acid, and H2O2 was completely suppressed by SCH 66336; the suppression was not cell type-specific. This FTI suppressed the activation of IkappaBalpha kinase (IKK), thus abrogating the phosphorylation and degradation of IkappaBalpha. Additionally, TNF-activated Ras and SCH 66336 inhibited the activation. Also, overexpression of Ras (V12) enhanced TNF-induced NF-kappaB activation, and adenoviral dominant-negative Ras (N17) suppressed the activation, thus suggesting the critical role of Ras in TNF signaling. SCH 66336 also inhibited the NF-kappaB-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappaB. The TNF-induced NF-kappaB-regulated gene products cyclin D1, COX-2, MMP-9, survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP were all down-regulated by SCH 66336, which potentiated apoptosis induced by TNF and doxorubicin. Overall, our results indicate that SCH 66336 inhibited activation of NF-kappaB and NF-kappaB-regulated gene expressions induced by carcinogens and inflammatory stimuli, which may provide a molecular basis for the ability of SCH 66336 to suppress proliferation and angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; Emory University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Khuri, Fadlo R./AAU-4942-2020; Aggarwal, Bharat B/G-3388-2013	Khuri, Fadlo R./0000-0002-8638-7618; 	NCI NIH HHS [P01-CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2000, CANCER RES, V60, P1871; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chun KH, 2003, CANCER RES, V63, P4796; Cohen LH, 2000, BIOCHEM PHARMACOL, V60, P1061, DOI 10.1016/S0006-2952(00)00386-5; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Feldkamp MM, 2001, CANCER RES, V61, P4425; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOONG AC, 1994, CANCER RES, V54, P5273; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Liu M, 1998, CANCER RES, V58, P4947; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; Nakajima A, 2003, MOL CANCER THER, V2, P219; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Njoroge FG, 1998, J MED CHEM, V41, P4890, DOI 10.1021/jm980462b; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shi B, 2000, CANCER CHEMOTH PHARM, V46, P387, DOI 10.1007/s002800000170; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Smalley KSM, 2003, INT J CANCER, V105, P165, DOI 10.1002/ijc.11064; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRAVIS J, 1993, SCIENCE, V260, P1877, DOI 10.1126/science.8316828; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VAN AD, 1996, SCIENCE, V274, P787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang B, 2002, CANCER RES, V62, P450; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	73	97	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26287	26299		10.1074/jbc.M400963200	http://dx.doi.org/10.1074/jbc.M400963200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15090542	hybrid			2022-12-27	WOS:000222003000047
J	Zhu, XS; Zamudio, FZ; Olbinski, BA; Possani, LD; Valdivia, CH				Zhu, XS; Zamudio, FZ; Olbinski, BA; Possani, LD; Valdivia, CH			Activation of skeletal ryanodine receptors by two novel scorpion toxins from Buthotus judaicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; MUSCLE DIHYDROPYRIDINE RECEPTOR; CA2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; CA2+-RELEASE CHANNEL; PANDINUS-IMPERATOR; POTASSIUM CHANNEL; PEPTIDE; VENOM	Buthotus judaicus toxin 1 (BjTx-1) and toxin 2 (BjTx-2), two novel peptide activators of ryanodine receptors (RyR), were purified from the venom of the scorpion B. judaicus. Their amino acid sequences differ only in 1 residue out of 28 ( residue 16 corresponds to Lys in BjTx-1 and Ile in BjTx-2). Despite a slight difference in EC50, both toxins increased binding of [H-3] ryanodine to skeletal sarcoplasmic reticulum at micromolar concentrations but had no effect on cardiac or liver microsomes. Their activating effect was Ca2+-dependent and was synergized by caffeine. B. judaicus toxins also increased binding of [ 3H] ryanodine to the purified RyR1, suggesting that a direct protein-protein interaction mediates the effect of the peptides. BjTx-1 and BjTx-2 induced Ca2+ release from Ca2+-loaded sarcoplasmic reticulum vesicles in a dose-dependent manner and induced the appearance of long lived subconductance states in skeletal RyRs reconstituted into lipid bilayers. Three-dimensional structural modeling reveals that a cluster of positively charged residues (Lys(11) to Lys(16)) is a prominent structural motif of both toxins. A similar structural motif is believed to be important for activation of RyRs by imperatoxin A (IpTx(a)), another RyR-activating peptide (Gurrola, G. B., Arevalo, C., Sreekumar, R., Lokuta, A. J., Walker, J. W., and Valdivia, H. H. (1999) J. Biol. Chem. 274, 7879 - 7886). Thus, it is likely that B. judaicus toxins and imperatoxin A bind to RyRs by means of electrostatic interactions that lead to massive conformational changes in the channel protein. The different affinity and structural diversity of this family of scorpion peptides makes them excellent peptide probes to identify RyR domains that trigger the channel to open.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Natl Autonomous Univ Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca 62271, Morelos, Mexico	University of Wisconsin System; University of Wisconsin Madison; Universidad Nacional Autonoma de Mexico	Zhu, XS (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 149 13th St,CYN-4,CVRC 4201, Charlestown, MA 02129 USA.	xzhu2@bics.bwh.harvard.edu	Possani, Lourival D/J-2397-2013		NHLBI NIH HHS [R01HL55438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becerril B, 1996, BIOCHEM J, V313, P753, DOI 10.1042/bj3130753; Blanc E, 1996, PROTEINS, V24, P359, DOI 10.1002/(SICI)1097-0134(199603)24:3&lt;359::AID-PROT9&gt;3.0.CO;2-B; Buisine E, 1997, J PEPT RES, V49, P545; CHU A, 1993, J MEMBRANE BIOL, V135, P49; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FAZAL A, 1989, FEBS LETT, V257, P260, DOI 10.1016/0014-5793(89)81548-0; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FURUKAWA KI, 1994, BRIT J PHARMACOL, V113, P233, DOI 10.1111/j.1476-5381.1994.tb16199.x; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lee CW, 2004, BIOCHEM J, V377, P385, DOI 10.1042/BJ20031192; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; Morrissette J, 1996, BIOPHYS J, V71, P707, DOI 10.1016/S0006-3495(96)79270-6; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	33	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26588	26596		10.1074/jbc.M403284200	http://dx.doi.org/10.1074/jbc.M403284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067003	hybrid			2022-12-27	WOS:000222003000084
J	Ito, T; Williams, JD; Fraser, DJ; Phillips, AO				Ito, T; Williams, JD; Fraser, DJ; Phillips, AO			Hyaluronan regulates transforming growth factor-beta 1 receptor compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; EXPERIMENTAL GLOMERULONEPHRITIS; INDEPENDENT REGULATION; INTERSTITIAL FIBROSIS; DIABETIC-NEPHROPATHY; TUMOR-SUPPRESSOR; KIDNEY FIBROSIS	Transforming growth factor-beta1 (TGF-beta1) is a key cytokine involved in the pathogenesis of fibrosis in many organs. We previously demonstrated in renal proximal tubular cells that the engagement of the extracellular polysaccharide hyaluronan with its receptor CD44 attenuated TGF-beta1 signaling. In the current study we examined the potential mechanism by which the interaction between hyaluronan ( HA) and CD44 regulates TGF-beta receptor function. Affinity labeling of TGF-beta receptors demonstrated that in the unstimulated cells the majority of the receptor partitioned into EEA-1-associated non-lipid raft-associated membrane pools. In the presence of exogenous HA, the majority of the receptors partitioned into caveolin-1 lipid raft-associated pools. TGF-beta1 increased the association of activated/phosphorylated Smad proteins with EEA-1, consistent with activation of TGF-beta1 signaling following endosomal internalization. Following addition of HA, caveolin-1 associated with the inhibitory Smad protein Smad7, consistent with the raft pools mediating receptor turnover, which was facilitated by HA. Antagonism of TGF-beta1-dependent Smad signaling and the effect of HA on TGF-beta receptor associations were inhibited by depletion of membrane cholesterol using nystatin and augmented by inhibition of endocytosis. The effect of HA on TGF-beta receptor trafficking was inhibited by inhibition of HA-CD44 interactions, using blocking antibody to CD44 or inhibition of MAP kinase activation. In conclusion, we have proposed a model by which HA engagement of CD44 leads to MAP kinase-dependent increased trafficking of TGF-beta receptors to lipid raft-associated pools, which facilitates increased receptor turnover and attenuation of TGF-beta1-dependent alteration in proximal tubular cell function.	Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Phillips, AO (corresponding author), Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales.	PhillipsAO@cf.ac.uk		Fraser, Donald/0000-0003-0102-9342				Akagi Y, 1996, KIDNEY INT, V50, P148, DOI 10.1038/ki.1996.297; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BOHLE A, 1987, AM J NEPHROL, V7, P421, DOI 10.1159/000167514; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORDER WA, 1992, KIDNEY INT, V41, P566, DOI 10.1038/ki.1992.83; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ehrlich M, 2001, J CELL SCI, V114, P1777; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Fraser D, 2002, AM J PATHOL, V161, P1039, DOI 10.1016/S0002-9440(10)64265-4; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUMES HD, 1993, KIDNEY INT, V43, P575, DOI 10.1038/ki.1993.85; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Isaka Y, 2000, KIDNEY INT, V58, P1885, DOI 10.1046/j.1523-1755.2000.00360.x; ITO T, 2004, IN PRESS AM J PATHOL; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Jones SG, 2003, INT J BIOCHEM CELL B, V35, P1361, DOI 10.1016/S1357-2725(03)00040-2; KAGAMI S, 1993, LAB INVEST, V69, P68; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KULKARNI AB, 1993, AM J PATHOL, V143, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewington AJP, 2000, AM J PHYSIOL-REG I, V278, pR247, DOI 10.1152/ajpregu.2000.278.1.R247; MACKENSENHAEN S, 1981, CLIN NEPHROL, V15, P167; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Piek E, 1999, J CELL SCI, V112, P4557; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sibalic V, 1997, NEPHROL DIAL TRANSPL, V12, P1344, DOI 10.1093/ndt/12.7.1344; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian YC, 2003, J AM SOC NEPHROL, V14, P631, DOI 10.1097/01.ASN.0000053418.56286.5E; WELLS A, 1993, TRANSPLANTATION, V55, P1346, DOI 10.1097/00007890-199306000-00025; WELLS AF, 1990, TRANSPLANTATION, V50, P240, DOI 10.1097/00007890-199008000-00014; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yu L, 2003, KIDNEY INT, V64, P844, DOI 10.1046/j.1523-1755.2003.00162.x	54	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25326	25332		10.1074/jbc.M403135200	http://dx.doi.org/10.1074/jbc.M403135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084590	hybrid			2022-12-27	WOS:000221827900053
J	Lova, P; Campus, F; Lombardi, R; Cattaneo, M; Sinigaglia, F; Balduini, C; Torti, M				Lova, P; Campus, F; Lombardi, R; Cattaneo, M; Sinigaglia, F; Balduini, C; Torti, M			Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE; INTEGRIN ALPHA(IIB)BETA(3); ADENOSINE-DIPHOSPHATE; SIGNAL-TRANSDUCTION; AGGREGATION; ADP; IDENTIFICATION; PATHWAYS; BINDING; CELLS	Thrombin activates human platelets through three different membrane receptors, the protease-activated receptors PAR-1 and PAR-4 and the glycoprotein Ib (GPIb)-IX-V complex. We investigated the contribution of these three receptors to thrombin-induced activation of the small GTPase Rap1B. We found that, similarly to thrombin, selective stimulation of either PAR-1 or PAR-4 by specific activating peptides caused accumulation of GTP-bound Rap1B in a dose-dependent manner. By contrast, in PAR-1- and PAR-4-desensitized platelets, thrombin failed to activate Rap1B. Thrombin, PAR-1-, or PAR-4-activating peptides also induced the increase of intracellular Ca2+ concentration and the release of serotonin in a dose-dependent manner. We found that activation of Rap1B by selected doses of agonists able to elicit comparable intracellular Ca2+ increase and serotonin release was differently dependent on secreted ADP. In the presence of the ADP scavengers apyrase or phosphocreatine-phosphocreatine kinase, activation of Rap1B induced by stimulation of either PAR-1 or PAR-4 was totally inhibited. By contrast, thrombin-induced activation of Rap1B was only minimally affected by neutralization of secreted ADP. Concomitant stimulation of both PAR-1 and PAR-4 in the presence of ADP scavengers still resulted in a strongly reduced activation of Rap1B. A similar effect was also observed upon blockade of the P2Y12 receptor for ADP, as well as in P2Y12 receptor-deficient human platelets, but not after blockade of the P2Y1 receptor. Activation of Rap1B induced by thrombin was not affected by preincubation of platelets with the anti-GPIbalpha monoclonal antibody AK2 in the absence of ADP scavengers or a P2Y12 antagonist but was totally abolished when secreted ADP was neutralized or after blockade of the P2Y12 receptor. Similarly, cleavage of the extracellular portion of GPIbalpha by the cobra venom mocarhagin totally prevented Rap1B activation induced by thrombin in the presence of apyrase and in P2Y12 receptor-deficient platelets. By contrast, inhibition of MAP kinases or p160ROCK, which have been shown to be activated upon thrombin binding to GPIb-IX-V, did not affect agonist-induced activation of Rap1B in the presence of ADP scavengers. These results indicate that although both PAR-1 and PAR-4 signal Rap1B activation, the ability of thrombin to activate this GTPase independently of secreted ADP involves co-stimulation of both receptors as well as binding to GPIb-IX-V.	Univ Pavia, Dept Biochem, Ctr Excellence Appl Biol, I-27100 Pavia, Italy; Univ Milan, Osped San Paolo, Dept Surg Med & Dent, Unit Hematol & Thrombosis, I-20142 Milan, Italy; Univ Milan, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, A Bianchi Bonomi Hemophilia & Thrombosis Ctr, I-20122 Milan, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy	University of Pavia; San Paolo-Polo Universitaria Hospital; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Eastern Piedmont Amedeo Avogadro	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Ctr Excellence Appl Biol, Via Bassi 21, I-27100 Pavia, Italy.	mtorti@unipv.it	Cattaneo, Marco/AAT-4080-2020	Cattaneo, Marco/0000-0002-7343-4534				Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CATTANEO M, 1992, BLOOD, V80, P2787; Cattaneo M, 2003, P NATL ACAD SCI USA, V100, P1978, DOI 10.1073/pnas.0437879100; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, THROMB HAEMOSTASIS, V87, P722, DOI 10.1055/s-0037-1613071; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Dubois C, 2003, THROMB HAEMOSTASIS, V89, P853, DOI 10.1055/s-0037-1613473; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Kunapuli SP, 1998, PLATELETS, V9, P343, DOI 10.1080/09537109876401; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; YAMAMOTO N, 1991, BLOOD, V77, P1740	44	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25299	25306		10.1074/jbc.M313199200	http://dx.doi.org/10.1074/jbc.M313199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078882	hybrid			2022-12-27	WOS:000221827900049
J	Arif, A; Vasanthi, P; Hansen, IA; Scheller, K; Dutta-Gupta, A				Arif, A; Vasanthi, P; Hansen, IA; Scheller, K; Dutta-Gupta, A			The insect hemolymph protein HP19 mediates the nongenomic effect of ecdysteroids on acid phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LARVAL FAT-BODY; MOTH CORCYRA-CEPHALONICA; STEROID-HORMONES; RICE MOTH; 3-DIMENSIONAL STRUCTURE; POLYACRYLAMIDE GELS; HEXAMERIN RECEPTOR; PIERIS-BRASSICAE; STORAGE PROTEIN	The activity of acid phosphatase (ACP) in insect fat bodies is stimulated by the steroid hormone 20-hydoxyecdysone (20E) in vivo. However, in fat bodies kept in culture, a factor from the hemolymph is required to enhance the ACP activity. We identified the factor as a protein with a molecular mass of 19 kDa (HP19) from the hemolymph of a lepidopteran insect, the rice moth, Corcyra cephalonica. Western analysis of hemolymph proteins with denaturing and non-denaturing PAGE using antibodies raised against HP19 suggest that this protein exists as a monomer. It is synthesized by the hind gut-associated lobular fat body of the larvae and is released into the hemolymph. The stimulatory effect of HP19 on the ACP activity is developmentally regulated and exhibits its maximal effect shortly before the onset of metamorphosis. We cloned the HP19 cDNA by immunoscreening a hind gut-associated lobular fat body cDNA expression library. Analysis of the amino acid sequence shows that HP19 belongs to the family of glutathione S-transferase (GST) like proteins. However, affinity-purified GST from Corcyra failed to show any mediation effect on 20E-stimulated ACP activity, and HP19 lacks GST enzymatic activity. Notably, HP19 mediates the hormone-stimulated ACP activity in intact fat body tissue and homogenates even in the presence of inhibitors of transcription and translation, suggesting a nongenomic mode of action. In addition, we show that HP19 inhibits the 20E-induced phosphorylation of the hexamerin receptor protein.	Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500046, Andhra Pradesh, India; Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	University of Hyderabad; University of Wurzburg; University of California System; University of California Riverside	Dutta-Gupta, A (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500046, Andhra Pradesh, India.	apdgsl@uohyd.ernet.in						Arif A, 2003, INSECT BIOCHEM MOLEC, V33, P921, DOI 10.1016/S0965-1748(03)00098-5; ASHOK M, 1991, INVERTEBR REPROD DEV, V20, P159, DOI 10.1080/07924259.1991.9672193; ASHOK M, 1988, BIOCHEM INT, V17, P1087; BEAUFAY H, 1954, B SOC CHIM BIOL, V36, P1539; BIRREN B, 1997, GENOME ANAL LAB MANU, P6; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1999, NATURWISSENSCHAFTEN, V86, P468, DOI 10.1007/s001140050656; Burmester T, 1997, EUR J BIOCHEM, V247, P695, DOI 10.1111/j.1432-1033.1997.00695.x; Burmester T, 1999, EUR J BIOCHEM, V262, P49, DOI 10.1046/j.1432-1327.1999.00315.x; CAGLAYAN SH, 1990, BIOCHEM INT, V20, P511; Csikos G, 1997, ARCH INSECT BIOCHEM, V34, P369, DOI 10.1002/(SICI)1520-6327(1997)34:3<369::AID-ARCH10>3.3.CO;2-U; Dutta-Gupta Aparna, 1998, Entomon, V23, P245; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Farkas R, 1998, IN VITRO CELL DEV-AN, V34, P813; Feng QL, 1999, INSECT BIOCHEM MOLEC, V29, P779, DOI 10.1016/S0965-1748(99)00048-X; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; GRAY R, 1987, J INSECT PHYSIOL, V33, P325, DOI 10.1016/0022-1910(87)90120-X; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hansen IA, 2002, EUR J BIOCHEM, V269, P954, DOI 10.1046/j.0014-2956.2001.02736.x; HATAYAMA I, 1986, BIOCHEM BIOPH RES CO, V140, P581, DOI 10.1016/0006-291X(86)90771-0; Haunerland NH, 1996, INSECT BIOCHEM MOLEC, V26, P755, DOI 10.1016/S0965-1748(96)00035-5; Henrich VC, 1999, VITAM HORM, V55, P73; HENRIKSON PA, 1972, J INSECT PHYSIOL, V18, P1981, DOI 10.1016/0022-1910(72)90167-9; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kirankumar N, 1997, INSECT BIOCHEM MOLEC, V27, P671, DOI 10.1016/S0965-1748(97)00047-7; KUTUZOVA N M, 1991, Ukrainskii Biokhimicheskii Zhurnal, V63, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI M, 1990, BIOCHEM INT, V22, P269; Lee CY, 2001, DEVELOPMENT, V128, P1443; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARUYAMA H, 1984, J BIOL CHEM, V259, P2449; Meltzer JC, 1997, J HISTOCHEM CYTOCHEM, V45, P599, DOI 10.1177/002215549704500412; Nijhout HF, 2002, P NATL ACAD SCI USA, V99, P15446, DOI 10.1073/pnas.242548399; PRIESTER DW, 1979, CELL TISSUE RES, V200, P435; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Riddiford LM, 2001, VITAM HORM, V60, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASS M, 1989, COMP BIOCHEM PHYS A, V92, P285, DOI 10.1016/0300-9629(89)90565-3; SASS M, 1980, J INSECT PHYSIOL, V26, P569, DOI 10.1016/0022-1910(80)90132-8; Scheller K, 2003, EXP PHYSIOL, V88, P129, DOI 10.1113/eph8802507; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SHIRAISHI A, 1989, INSECT BIOCHEM, V19, P261, DOI 10.1016/0020-1790(89)90071-1; Smagghe GJ, 2003, IN VITRO CELL DEV-AN, V39, P8, DOI 10.1290/1543-706X(2003)039<0008:EOAFBE>2.0.CO;2; Staffas L, 1998, BIOCHEM J, V332, P763, DOI 10.1042/bj3320763; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; Thummel CS, 2001, BIOESSAYS, V23, P677, DOI 10.1002/bies.1096; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Truman JW, 2002, ANNU REV ENTOMOL, V47, P467, DOI 10.1146/annurev.ento.47.091201.145230; Verkuil E.V.P., 1979, J INSECT PHYSL, V25, P965; VERKUIL EVP, 1980, J INSECT PHYSL, V26, P91; VERKUIL EVP, 1979, CELL TISSUE RES, V203, P443; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATSON RD, 1987, J EXP BIOL, V128, P159; Webster SG, 1998, BIOL BULL-US, V195, P282, DOI 10.2307/1543140; White R, 1998, ENDOCR-RELAT CANCER, V5, P1, DOI 10.1677/erc.0.0050001	58	8	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28000	28008		10.1074/jbc.M402311200	http://dx.doi.org/10.1074/jbc.M402311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117951	hybrid			2022-12-27	WOS:000222265400023
J	Chen, RX; Le Rouzic, E; Kearney, JA; Mansky, LM; Benichou, S				Chen, RX; Le Rouzic, E; Kearney, JA; Mansky, LM; Benichou, S			Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; URACIL-DNA GLYCOSYLASE; VIRAL-PROTEIN-R; NUCLEAR-PORE COMPLEX; TYPE-1 VPR; CELL-CYCLE; IN-VIVO; REVERSE-TRANSCRIPTASE; REGULATORY PROTEIN; REPAIR ENZYME	Human immunodeficiency virus type 1 is able to infect nondividing cells, such as macrophages, and the viral Vpr protein has been shown to participate in this process. Here, we investigated the impact of the recruitment into virus particles of the nuclear form of uracil DNA glycosylase (UNG2), a cellular DNA repair enzyme, on the virus mutation rate and on replication in macrophages. We demonstrate that the interaction of Vpr with UNG2 led to virion incorporation of a catalytically active enzyme that is directly involved with Vpr in modulating the virus mutation rate. The lack of UNG in virions during virus replication in primary monocyte-derived macrophages further exacerbated virus mutant frequencies to an 18-fold increase compared with the 4-fold increase measured in actively dividing cells. Because the presence of UNG is also critical for efficient infection of macrophages, these observations extend the role of Vpr to another early step of the virus life cycle, e. g. viral DNA synthesis, that is essential for replication of human immunodeficiency virus type 1 in nondividing cells.	Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA; Ohio State Univ, Biochem Grad Program, Columbus, OH 43210 USA; Inst Cochin, Dept Infect Dis, INSERM,U567, CNRS,UMR 8104, Paris, France	University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benichou, S (corresponding author), Univ Minnesota, Inst Mol Virol, 18-242 Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.	benichou@cochin.inserm.fr		Benichou, Serge/0000-0003-3602-3530	NIGMS NIH HHS [GM 56615] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056615, R29GM056615] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agostini I, 1999, FEBS LETT, V450, P235, DOI 10.1016/S0014-5793(99)00501-3; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Chen RX, 2002, J GEN VIROL, V83, P2339, DOI 10.1099/0022-1317-83-10-2339; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Cohen O J, 2001, Adv Intern Med, V46, P207; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; KUMAR NV, 1994, NUCLEIC ACIDS RES, V22, P3737, DOI 10.1093/nar/22.18.3737; Le Rouzic E, 2002, J BIOL CHEM, V277, P45091, DOI 10.1074/jbc.M207439200; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; MANSKY LM, 1994, J VIROL, V68, P494, DOI 10.1128/JVI.68.1.494-499.1994; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; Mansky LM, 2003, J VIROL, V77, P2071, DOI 10.1128/JVI.77.3.2071-2080.2003; Mansky LM, 2003, VIROLOGY, V307, P116, DOI 10.1016/S0042-6822(02)00069-7; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Miller RJ, 2000, J VIROL, V74, P7187, DOI 10.1128/JVI.74.16.7187-7195.2000; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Priet S, 2003, J BIOL CHEM, V278, P4566, DOI 10.1074/jbc.M209311200; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; Yao XJ, 2002, J BIOL CHEM, V277, P48816, DOI 10.1074/jbc.M207982200; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	49	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28419	28425		10.1074/jbc.M403875200	http://dx.doi.org/10.1074/jbc.M403875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15096517	hybrid			2022-12-27	WOS:000222265400075
J	Corbett, MC; Hu, YL; Naderi, F; Ribbe, MW; Hedman, B; Hodgson, KO				Corbett, MC; Hu, YL; Naderi, F; Ribbe, MW; Hedman, B; Hodgson, KO			Comparison of iron-molybdenum cofactor-deficient nitrogenase MoFe proteins by X-ray absorption spectroscopy - Implications for P-cluster biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; FEMO-COFACTOR; KLEBSIELLA-PNEUMONIAE; CRYSTAL-STRUCTURE; 4FE-4S CLUSTERS; DINITROGENASE REDUCTASE; ANGSTROM RESOLUTION; PHOSPHINE CLUSTERS; NIFB COFACTOR; SULFUR	Nitrogenase, the enzyme system responsible for biological nitrogen fixation, is believed to utilize two unique metalloclusters in catalysis. There is considerable interest in understanding how these metalloclusters are assembled in vivo. It has been presumed that immature iron-molybdenum cofactor-deficient nitrogenase MoFe proteins contain the P-cluster, although no biosynthetic pathway for the assembly of this complex cluster has been identified as yet. Through the comparison by iron K-edge x-ray absorption edge and extended fine structure analyses of cofactor-deficient MoFe proteins resulting from nifH and nifB deletion strains of Azotobacter vinelandii, a novel [Fe-S] cluster is identified in the DeltanifH MoFe protein. The iron-iron scattering displayed by the DeltanifH MoFe protein is more similar to that of a standard [Fe4S4]-containing protein than that of the DeltanifB MoFe protein, which is shown to contain a "normal" P-cluster. The iron-sulfur scattering of the DeltanifH MoFe protein, however, indicates differences in its cluster from an [Fe4S4](Cys)(4) site that may be consistent with the presence of either oxygenic or nitrogenic ligation. Based on these results, models for the [Fe-S] center in the DeltanifH MoFe protein are constructed, the most likely of which consist of two separate [ Fe4S4] sites, each with some non-cysteinyl coordination. This type of model suggests that the P-cluster is formed by the condensation of two [ Fe4S4] fragments, possibly concomitant with Fe protein (NifH)-induced conformational change.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford Linear Accelerator Ctr, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Irvine; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Hedman, B (corresponding author), Stanford Univ, Stanford Synchrotron Radiat Lab, 2575 Sand Hill Rd,MS 69, Menlo Pk, CA 94025 USA.	hedman@ssrl.slac.stanford.edu; hodgson@ssrl.slac.stanford.edu			NCRR NIH HHS [RR 01209] Funding Source: Medline; NIGMS NIH HHS [GM 67626] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; ELLIS PJ, 1995, J SYNCHROTRON RADIAT, V2, P190, DOI 10.1107/S0909049595006789; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; Gailer J, 2001, J AM CHEM SOC, V123, P10121, DOI 10.1021/ja0158915; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; Goh C, 1998, INORG CHIM ACTA, V270, P46, DOI 10.1016/S0020-1693(97)05822-2; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; HAGEN KS, 1981, J AM CHEM SOC, V103, P4054, DOI 10.1021/ja00404a013; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KENNEDY MC, 1984, J BIOL CHEM, V259, P3145; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; Lee SC, 2004, CHEM REV, V104, P1135, DOI 10.1021/cr0206216; LIU HBI, 1994, J AM CHEM SOC, V116, P2418, DOI 10.1021/ja00085a022; LUDDEN PW, 1998, BIOL NITROGEN FIXATI, P33; Magnuson JK, 1997, TETRAHEDRON, V53, P11971, DOI 10.1016/S0040-4020(97)00710-2; Mansy SS, 2002, BIOCHEMISTRY-US, V41, P1195, DOI 10.1021/bi011811y; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Messick TE, 2002, BIOCHEMISTRY-US, V41, P3931, DOI 10.1021/bi012035x; MUCHMORE SW, 1996, MECH METALLOCLUSTER, V11, P111; Musgrave KB, 1998, J AM CHEM SOC, V120, P5325, DOI 10.1021/ja980598z; Musgrave KB, 1998, J BIOL INORG CHEM, V3, P344, DOI 10.1007/s007750050243; Ohki Y, 2003, J AM CHEM SOC, V125, P4052, DOI 10.1021/ja029383m; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rao PV, 2004, CHEM REV, V104, P527, DOI 10.1021/cr020615+; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; Ribbe MW, 2002, J BIOL CHEM, V277, P23469, DOI 10.1074/jbc.M202061200; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Rubio L. M., 2002, Nitrogen fixation at the millennium, P101, DOI 10.1016/B978-044450965-9/50004-5; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SHAH VK, 1994, J BIOL CHEM, V269, P1154; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; Strop P, 2001, BIOCHEMISTRY-US, V40, P651, DOI 10.1021/bi0016467; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; WHITE TC, 1992, J BIOL CHEM, V267, P24007; Zhang HH, 1999, INORGANIC ELECTRONIC STRUCTURE AND SPECTROSCOPY, VOL I, P513; Zhang Y, 2004, INORG CHEM, V43, P674, DOI 10.1021/ic030259t; Zhang YG, 2002, J AM CHEM SOC, V124, P14292, DOI 10.1021/ja0279702; Zhou HC, 2003, INORG CHEM, V42, P11, DOI 10.1021/ic020464t; [No title captured]	68	49	49	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28276	28282		10.1074/jbc.M403156200	http://dx.doi.org/10.1074/jbc.M403156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102840	hybrid			2022-12-27	WOS:000222265400058
J	Matsunaga, T; Kotamraju, S; Kalivendi, SV; Dhanasekaran, A; Joseph, J; Kalyanaraman, B				Matsunaga, T; Kotamraju, S; Kalivendi, SV; Dhanasekaran, A; Joseph, J; Kalyanaraman, B			Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells - Protective role of endogenous nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; OXIDATIVE STRESS; REACTIVE OXYGEN; DEPENDENT APOPTOSIS; ACTIVATION; MITOCHONDRIA; TRANSLOCATION; SUPEROXIDE; DEATH	Sphingolipid ceramide (N-acetylsphingosine), a bioactive second messenger lipid, was shown to activate reactive oxygen species (ROS), mitochondrial oxidative damage, and apoptosis in neuronal and vascular cells. The proapoptotic effects of tumor necrosis factor-alpha, hypoxia, and chemotherapeutic drugs were attributed to increased ceramide formation. Here we investigated the protective role of nitric oxide ((NO)-N-.) during hydrogen peroxide (H2O2)-mediated transferrin receptor (TfR)-dependent iron signaling and apoptosis in C-2-ceramide (C-2-cer)-treated bovine aortic endothelial cells (BAECs). Addition of C-2-cer (5-20 muM) to BAECs enhanced (NO)-N-. generation. However, at higher concentrations of C-2-cer (greater than or equal to20 muM), (NO)-N-. generation did not increase proportionately. C-2-cer (20-50 muM) also resulted in H2O2-mediated dichlorodihydrofluorescein oxidation, reduced glutathione depletion, aconitase inactivation, TfR overexpression, TfR-dependent uptake of Fe-55, release of cytochrome c from mitochondria into cytosol, caspase-3 activation, and DNA fragmentation. Nw-Nitro-L-arginine methyl ester (L-NAME), a nonspecific inhibitor of nitric-oxide synthases, augmented these effects in BAECs at much lower (i.e. nonapoptotic) concentrations of C-2-cer. The 26 S proteasomal activity in BAECs was slightly elevated at lower concentrations of C-2-cer (less than or equal to10 muM) but was greatly suppressed at higher concentrations (> 10 muM). Intracellular scavengers of H2O2, cell-permeable iron chelators, anti-TfR receptor antibody, or mitochondria-targeted antioxidant greatly abrogated C-2-cer- and/or L-NAME-induced oxidative damage, iron signaling, and apoptosis. We conclude that C-2-cer-induced H2O2 and TfR-dependent iron signaling are responsible for its prooxidant and proapoptotic effects and that (NO)-N-. exerts an antioxidative and cytoprotective role.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Dhanasekaran, Anuradha/AAF-3160-2022; Dhanasekaran, Anuradha/AFH-8265-2022	Dhanasekaran, Anuradha/0000-0002-0195-9681	NHLBI NIH HHS [HL 073056-01, 1P01 HL 68769-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073056, P01HL068769] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ariga T, 1998, J LIPID RES, V39, P1; BALLA G, 1992, J BIOL CHEM, V267, P18148; Barsacchi R, 2002, CELL DEATH DIFFER, V9, P1248, DOI 10.1038/sj.cdd.4401095; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Deshpande SS, 2003, ARTERIOSCL THROM VAS, V23, pE1, DOI 10.1161/01.ATV.0000047869.13737.53; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Irizarry MC, 2003, ANN NEUROL, V54, P7, DOI 10.1002/ana.10642; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kotamraju S, 2004, ARCH BIOCHEM BIOPHYS, V423, P74, DOI 10.1016/j.abb.2003.12.037; Kotamraju S, 2003, P NATL ACAD SCI USA, V100, P10653, DOI 10.1073/pnas.1933581100; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; Li HG, 2002, CIRCULATION, V106, P2250, DOI 10.1161/01.CIR.0000035650.05921.50; McCarty MF, 1998, MED HYPOTHESES, V51, P465, DOI 10.1016/S0306-9877(98)90066-4; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Phillips DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15, DOI 10.1016/S0003-9861(02)00496-4; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Ribeiro ACM, 2001, CARDIOVASC RES, V49, P697, DOI 10.1016/S0008-6363(00)00267-4; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schuler F, 2001, BBA-BIOENERGETICS, V1506, P79, DOI 10.1016/S0005-2728(01)00183-9; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; Tampo Y, 2003, CIRC RES, V92, P56, DOI 10.1161/01.RES.0000048195.15637.AC; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	51	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28614	28624		10.1074/jbc.M400977200	http://dx.doi.org/10.1074/jbc.M400977200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102832	hybrid			2022-12-27	WOS:000222265400097
J	Taille, C; El-Benna, J; Lanone, S; Dang, MC; Ogier-Denis, E; Aubier, M; Boczkowski, J				Taille, C; El-Benna, J; Lanone, S; Dang, MC; Ogier-Denis, E; Aubier, M; Boczkowski, J			Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b(558) expression via the reduction of heme availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; GENERATING NADPH OXIDASE; KAPPA-B ACTIVATION; FLAVOCYTOCHROME B(558); ENDOTHELIAL-CELLS; BILIRUBIN; ANTIOXIDANT; SYSTEM; GP91(PHOX); PHOSPHORYLATION	Heme-oxygenase- 1 (HO-1), the rate-limiting enzyme of heme degradation, has powerful anti-oxidant properties related to the production of the reactive oxygen species scavenger bilirubin. However, some data suggest that HO-1 could also inhibit the cellular production of reactive oxygen species. Therefore, we investigated whether the anti-oxidant properties of HO-1 could be mediated by modulation of the activity and/or expression of the heme-containing NAD(P)H oxidase, the main source of the superoxide anion (O-2((sic)) in phagocytic cells. Increasing HO-1 expression in RAW 264.7 macrophages effectively decreased NAD( P) H oxidase activity and expression of gp91(phox), its heme-containing catalytic component, because of deficient protein maturation and increased degradation. Loading cells with heme reversed the decrease in O2((sic)). production and gp91(phox) expression induced by HO-1 overexpression. Similar results were obtained in vivo in rat alveolar macrophages after pharmacological modulation of HO-1 expression or activity. These results show that a decrease in heme content due to HO-1 activation limits heme availability for maturation of the gp91(phox) subunit and assembly of the functional NAD(P)H oxidase. This study provides a new mechanism to explain HO-1 anti-oxidant properties.	Univ Paris 07, Inst Federat Rech 02, INSERM, U408, F-75018 Paris, France; Univ Paris 07, Inst Federat Rech 02, INSERM, U479, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Boczkowski, J (corresponding author), Fac Xavier Bichat, INSERM, U408, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Taille, Camille/J-3751-2017; Boczkowski, Jorge/S-7474-2018; Ogier-Denis, Eric/E-5030-2016; Lanone, Sophie/I-4042-2016	Boczkowski, Jorge/0000-0001-6619-5785; Lanone, Sophie/0000-0003-2509-8799; Ogier-Denis, Eric/0000-0002-0057-7593				Babior B M, 1995, Curr Opin Hematol, V2, P55; BALLA G, 1992, J BIOL CHEM, V267, P18148; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Foresti R, 2001, AM J PHYSIOL-HEART C, V281, pH1976, DOI 10.1152/ajpheart.2001.281.5.H1976; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Haider A, 2002, J PHARMACOL EXP THER, V300, P188, DOI 10.1124/jpet.300.1.188; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KAPPAS A, 1986, J CLIN INVEST, V77, P335, DOI 10.1172/JCI112309; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Li Volti G, 2003, HYPERTENSION, V41, P715, DOI 10.1161/01.HYP.0000049163.23426.66; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Nemeth ZH, 2004, MOL PHARMACOL, V65, P342, DOI 10.1124/mol.65.2.342; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Samb A, 2002, AM J PHYSIOL-LUNG C, V283, pL596, DOI 10.1152/ajplung.00446.2001; Schillinger M, 2002, THROMB RES, V106, P131, DOI 10.1016/S0049-3848(02)00100-7; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; Thabut G, 2002, J BIOL CHEM, V277, P22814, DOI 10.1074/jbc.M200315200; Tulis DA, 2001, ATHEROSCLEROSIS, V155, P113, DOI 10.1016/S0021-9150(00)00552-9; Turcanu V, 1998, RES IMMUNOL, V149, P741, DOI 10.1016/S0923-2494(99)80050-9; Turcanu V, 1998, TRANSPL P, V30, P4184, DOI 10.1016/S0041-1345(98)01385-2; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	43	162	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28681	28688		10.1074/jbc.M310661200	http://dx.doi.org/10.1074/jbc.M310661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123630	hybrid			2022-12-27	WOS:000222265400105
J	Dubin, MJ; Stokes, PH; Sum, EYM; Williams, RS; Valova, VA; Robinson, PJ; Lindeman, GJ; Glover, JNM; Visvader, JE; Matthews, JM				Dubin, MJ; Stokes, PH; Sum, EYM; Williams, RS; Valova, VA; Robinson, PJ; Lindeman, GJ; Glover, JNM; Visvader, JE; Matthews, JM			Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; LARGE T-ANTIGEN; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; BINDING-PROTEIN; GENE-PRODUCT; DNA-DAMAGE; BRCA1; DOMAIN; REPRESSION	CtIP is a transcriptional co-regulator that binds a number of proteins involved in cell cycle control and cell development, such as CtBP (C terminus-binding protein), BRCA1 (breast cancer-associated protein-1), and LMO4 (LIM-only protein-4). The only recognizable structural motifs within CtIP are two putative coiled-coil domains located near the N and C termini of the protein. We now show that the N-terminal coiled coil (residues 45-160), but not the C-terminal coiled coil, mediates homodimerization of CtIP in mammalian 293T cells. The N-terminal coiled coil did not facilitate binding to LMO4 and BRCA1 proteins in these cells. A protease-resistant domain (residues 27-168) that minimally encompasses the putative N-terminal coiled coil was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. This region is predicted to contain two smaller coiled-coil regions. The CtIP-(45-160) dimerization domain is helical and dimeric, indicating that the domain does form a coiled coil. The two smaller domains, CtIP( 45-92) and CtIP-(93-160), also formed dimers of lower binding affinity, but with less helical content than the longer peptide. The hydrodynamic radius of CtIP-(45-160) is the same as those of CtIP-(45-92) and CtIP-(93-160), implying that CtIP-(45-160) does not form a single long coiled coil, but a more compact structure involving homodimerization of the two smaller coiled coils, which fold back as a four-helix bundle or other compact structure. These results suggest a specific model for CtIP homodimerization via its N terminus and contribute to an improved understanding of how this protein might assemble other factors required for its role as a transcriptional corepressor.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Childrens Med Res Inst, Westmead, NSW 2145, Australia; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Sydney; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Children's Medical Research Institute - Australia; University of Alberta	Matthews, JM (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Bldg G08, Sydney, NSW 2006, Australia.	j.matthews@mmb.usyd.edu.au	Matthews, Jacqueline/A-7322-2013; Robinson, Phillip J/G-4008-2011; Williams, R Scott/A-6059-2015	Robinson, Phillip J/0000-0002-7878-0313; Matthews, Jacqueline/0000-0001-8518-3472; Lindeman, Geoffrey/0000-0001-9386-2416; Dubin, Manu/0000-0003-2374-2456; Williams, R Scott/0000-0002-4610-8397				Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beckett D, 2001, J MOL BIOL, V314, P335, DOI 10.1006/jmbi.2001.5134; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hayes D., 1995, SEDIMENTATION INTERP; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shih HA, 2002, J CLIN ONCOL, V20, P994, DOI 10.1200/JCO.20.4.994; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Whitby FG, 2000, PROTEINS, V38, P49; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	40	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26932	26938		10.1074/jbc.M313974200	http://dx.doi.org/10.1074/jbc.M313974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084581	hybrid			2022-12-27	WOS:000222120400018
J	Staruschenko, A; Medina, JL; Patel, P; Shapiro, MS; Booth, RE; Stockand, JD				Staruschenko, A; Medina, JL; Patel, P; Shapiro, MS; Booth, RE; Stockand, JD			Fluorescence resonance energy transfer analysis of subunit stoichiometry of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; ENAC; ACTIVATION; CELLS	Activity of the epithelial Na+ channel (ENaC) is rate-limiting for Na+ ( re) absorption across electrically tight epithelia. ENaC is a heteromeric channel comprised of three subunits, alpha, beta, and gamma, with each subunit contributing to the functional channel pore. The subunit stoichiometry of ENaC remains uncertain with electrophysiology and biochemical experiments supporting both a tetramer with a 2alpha: 1beta: 1gamma stoichiometry and a higher ordered channel with a 3alpha: 3beta: 3gamma stoichiometry. Here we used an independent biophysical approach based upon fluorescence resonance energy transfer ( FRET) between differentially fluorophore-tagged ENaC subunits to determine the subunit composition of mouse ENaC functionally reconstituted in Chinese hamster ovary and COS-7 cells. We found that when all three subunits were co-expressed, ENaC contained at least two of each type of subunit. Findings showing that ENaC subunits interact with similar subunits in immunoprecipitation studies are consistent with these FRET results. Upon native polyacrylamide gel electrophoresis, moreover, oligomerized ENaC runs predominantly as a single species with a molecular mass of > 600 kDa. Because single ENaC subunits have a molecular mass of similar to 90 kDa, these results also agree with the FRET results. The current results as a whole, thus, are most consistent with a higher ordered channel possibly with a 3alpha: 3beta: 3gamma stoichiometry.	SW Texas State Univ, Dept Chem & Biochem, San Marcos, TX 78666 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Texas State University System; Texas State University San Marcos; University of Texas System; University of Texas Health San Antonio	Booth, RE (corresponding author), SW Texas State Univ, Dept Chem & Biochem, 601 Univ Dr,CHEM 216, San Marcos, TX 78666 USA.	rbooth@txstate.edu		Stockand, James/0000-0002-3817-4319; Staruschenko, Alexander/0000-0002-5190-8356	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; Centonze VE, 2003, METHOD ENZYMOL, V360, P542; Dijkink L, 2002, PFLUG ARCH EUR J PHY, V444, P549, DOI 10.1007/s00424-002-0855-4; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FRINDT G, 1990, AM J PHYSIOL, V258, pF562, DOI 10.1152/ajprenal.1990.258.3.F562; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1	31	55	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27729	27734		10.1074/jbc.M404169200	http://dx.doi.org/10.1074/jbc.M404169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096495	hybrid			2022-12-27	WOS:000222120400107
J	Weser, S; Gruber, C; Hafner, HM; Teichmann, M; Roeder, RG; Seifart, KH; Meissner, W				Weser, S; Gruber, C; Hafner, HM; Teichmann, M; Roeder, RG; Seifart, KH; Meissner, W			Transcription factor (TF)-like nuclear regulator, the 250-kDa form of Homo sapiens TFIIIB '', is an essential component of human TFIIIC1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; 2 FUNCTIONAL COMPONENTS; TATA-BINDING PROTEIN; IN-VITRO; GENES; PROMOTERS; COMPLEX; CELLS; DIFFERENTIATION; SEPARATION	The general human RNA polymerase III transcription factor (TF) IIIC1 has hitherto been ill defined with respect to the polypeptides required for reconstitution of its activity. Here we identify Homo sapiens TFIIIB" (HsBdp1) as an essential component of hTFIIIC1 and hT-FIIIC1-like activities. Several forms of HsBdp1 are described. The 250-kDa form of HsBdp1, also designated the "transcription factor-like nuclear regulator," strictly co-eluted with TFIIIC1 activity over multiple chromatographic purification steps as revealed by Western blot with anti-HsBdp1 antibodies and by MALDI-TOF analysis. In addition, TFIIIC1 activity could be depleted from partially purified fractions with anti-HsBdp1 antibodies but not with control antibodies. Moreover, highly purified recombinant HsBdp1 could replace TFIIIC1 activity in reconstituted transcription of the VAI gene in vitro. Furthermore, smaller proteins of similar to 90 - 150 kDa that were recognized by anti-HsBdp1 antibodies co-eluted with TFIIIC1-like activity. Finally, cytoplasmic extracts from differentiated mouse F9 fibroblast cells that lacked TFIIIC1 activity could be made competent for transcription of the VA1 gene by the addition of TFIIIC1, TFIIIC1-like, or recombinant HsBdp1. These results suggest that HsBdp1 proteins represent essential components of TFIIIC1 and TFIIIC1-like activities.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Bordeaux 2, Inst Europeaen Chim & Biol, F-33607 Pessac, France; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Philipps University Marburg; UDICE-French Research Universities; Universite de Bordeaux; Rockefeller University	Meissner, W (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Lahnstr 3, D-35037 Marburg, Germany.	meissner@imt.uni-marburg.de	Teichmann, Martin/M-7407-2014	Teichmann, Martin/0000-0002-5257-0510				Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Cabart P, 2002, J BIOL CHEM, V277, P26831, DOI 10.1074/jbc.M203119200; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; Kelter AR, 2000, GENOMICS, V70, P315, DOI 10.1006/geno.2000.6396; Kober I, 1998, J MOL BIOL, V284, P7, DOI 10.1006/jmbi.1998.2165; Meissner W, 2002, J BIOL CHEM, V277, P7148, DOI 10.1074/jbc.M108721200; Oettel S, 1997, NUCLEIC ACIDS RES, V25, P2440, DOI 10.1093/nar/25.12.2440; Oettel S, 1998, NUCLEIC ACIDS RES, V26, P4324, DOI 10.1093/nar/26.19.4324; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 1997, EMBO J, V16, P4708, DOI 10.1093/emboj/16.15.4708; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; WEIL PA, 1979, J BIOL CHEM, V254, P6163; Weser S, 2000, NUCLEIC ACIDS RES, V28, P3935, DOI 10.1093/nar/28.20.3935; Weser S, 2003, NUCLEIC ACIDS RES, V31, P2408, DOI 10.1093/nar/gkg345; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; YOON JB, 1995, MOL CELL BIOL, V15, P2019; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	30	16	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27022	27029		10.1074/jbc.M312790200	http://dx.doi.org/10.1074/jbc.M312790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096501	hybrid			2022-12-27	WOS:000222120400028
J	Yuan, ZF; Agarwal-Mawal, A; Paudel, HK				Yuan, ZF; Agarwal-Mawal, A; Paudel, HK			14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser(9)-phosphorylated glycogen synthase kinase 3 beta in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; KINASE 3-BETA; FACTOR-I; SERINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; INSULIN; INACTIVATION; BINDING; PHOSPHATASE; ACTIVATION	In mammalian brain, tau, glycogen synthase kinase 3beta (GSK3beta), and 14-3-3, a phosphoserine-binding protein, are parts of a multiprotein tau phosphorylation complex. Within the complex, 14-3-3 simultaneously binds to tau and GSK3beta (Agarwal-Mawal, A., Qureshi, H. Y., Cafferty, P. W., Yuan, Z., Han, D., Lin, R., and Paudel, H. K. (2003) J. Biol. Chem. 278, 12722 - 12728). The molecular mechanism by which 14-3-3 connects GSK3beta to tau within the complex is not clear. In this study, we find that GSK3beta within the tau phosphorylation complex is phosphorylated on Ser(9). From extracts of rat brain and rat primary cultured neurons, Ser(9)-phosphorylated GSK3beta precipitates with glutathione-agarose beads coated with glutathione S-transferase-14-3-3. Similarly, from rat brain extract, Ser(9)-phosphorylated GSK3beta coimmunoprecipitates with tau. In vitro, 14-3-3 binds to GSK3beta only when the kinase is phosphorylated on Ser(9). In transfected HEK-293 cells, 14-3-3 binds to Ser(9)-phosphorylated GSK3beta and does not bind to GSK3beta (S9A). Tau, on the other hand, binds to both GSK3beta (WT) and GSK3beta (S9A). Moreover, 14-3-3 enhances the binding of tau with Ser9- phosphorylated GSK3beta by similar to3-fold but not with GSK3beta (S9A). Similarly, 14-3-3 stimulates phosphorylation of tau by Ser(9)- phosphorylated GSK3beta but not by GSK3beta (S9A). In transfected HEK-293 cells, Ser9 phosphorylation suppresses GSK3beta-catalyzed tau phosphorylation in the absence of 14-3-3. In the presence of 14-3-3, however, Ser(9)- phosphorylated GSK3beta remains active and phosphorylates tau. Our data indicate that within the tau phosphorylation complex, 14-3-3 connects Ser(9)- phosphorylated GSK3beta to tau and Ser9- phosphorylated GSK3beta phosphorylates tau.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca						Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dohadwala M, 1998, METH MOL B, V93, P191; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; Hutton M, 2001, TRENDS MOL MED, V7, P467, DOI 10.1016/S1471-4914(01)02123-2; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lesort M, 2000, NEUROSCIENCE, V99, P305, DOI 10.1016/S0306-4522(00)00200-1; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mattson MP, 2001, TRENDS NEUROSCI, V24, P255, DOI 10.1016/S0166-2236(00)01838-5; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wagner U, 1996, J CELL SCI, V109, P1537; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YANG SD, 1989, J BIOL CHEM, V264, P5407; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	47	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26105	26114		10.1074/jbc.M308298200	http://dx.doi.org/10.1074/jbc.M308298200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073173	hybrid			2022-12-27	WOS:000222003000024
J	Nabetani, A; Yokoyama, O; Ishikawa, F				Nabetani, A; Yokoyama, O; Ishikawa, F			Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NUCLEAR-DYNAMICS; IMMORTAL HUMAN-CELLS; DOUBLE-STRAND BREAKS; CHECKPOINT PROTEIN; SCHIZOSACCHAROMYCES-POMBE; MRE11 COMPLEX; DAMAGE; PML; BODIES; ATR	Telomere maintenance is essential for continued cell proliferation. Although most cells accomplish this by activating telomerase, a subset of immortalized tumors and cell lines do so in a telomerase-independent manner, a process called alternative lengthening of telomeres (ALT). DNA recombination has been shown to be involved in ALT, but the precise mechanisms remain unknown. A fraction of cells in a given ALT population contain a unique nuclear structure called APB (ALT-associated promyelocytic leukemia (PML) body), which is characterized by the presence of telomeric DNA in the PML body. Here we describe that hRad9, hHus1, and hRad1, which form a DNA clamp complex that is associated with DNA damage, as well as its clamp loader, hRad17, are constitutive components of APB. Phosphorylated histone H2AX (gamma-H2AX), a molecular marker of double-strand breaks (DSBs), also colocalizes with some APBs. The results suggest that telomeric DNAs at APBs are recognized as DSBs. PML staining and fluorescence in situ hybridization analyses of mitotic ALT cells revealed that telomeric DNAs present at APBs are of both extrachromosomal and native telomere origins. Furthermore, we demonstrated that DNA synthesis occurs at APBs and is significantly inhibited by caffeine, an inhibitor of phosphatidylinositol 3-kinase-related kinases. Taken together, we suggest that telomeric DNAs at APBs are recognized and processed as DSBs, leading to telomeric DNA synthesis and thereby contributing to telomere maintenance in ALT cells.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat, Kyoto 6068502, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Lab Mol & Cellular Assembly,Midori Ku, Yokohama, Kanagawa 2268501, Japan	Kyoto University; Tokyo Institute of Technology	Ishikawa, F (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat, Kyoto 6068502, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Grobelny JV, 2000, J CELL SCI, V113, P4577; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lombard DB, 2000, CANCER RES, V60, P2331; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nabetani A, 2001, CHROMOSOMA, V110, P322, DOI 10.1007/s004120100153; Naka K, 2002, BIOCHEM BIOPH RES CO, V299, P863, DOI 10.1016/S0006-291X(02)02755-9; Nakamura TM, 2002, GENETICS, V161, P1437; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ogino H, 1998, BIOCHEM BIOPH RES CO, V248, P223, DOI 10.1006/bbrc.1998.8875; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sarkaria JN, 1999, CANCER RES, V59, P4375; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Yeager TR, 1999, CANCER RES, V59, P4175; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	54	90	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25849	25857		10.1074/jbc.M312652200	http://dx.doi.org/10.1074/jbc.M312652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075340	hybrid			2022-12-27	WOS:000221827900116
J	Sazinsky, MH; Bard, J; Di Donato, A; Lippard, SJ				Sazinsky, MH; Bard, J; Di Donato, A; Lippard, SJ			Crystal structure of the toluene/o-xylene monooxygenase hydroxylase from Pseudomonas stutzeri OX1 - Insight into the substrate specificity, substrate channeling, and active site tuning of multicomponent monooxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE METHANE MONOOXYGENASE; METHYLOSINUS-TRICHOSPORIUM OB3B; ACYL CARRIER PROTEIN; COLI RIBONUCLEOTIDE REDUCTASE; RAPID ELECTRON-TRANSFER; OXYGEN ACTIVATION; R2 SUBUNIT; DIOXYGEN ACTIVATION; PHENOL HYDROXYLASE; DIIRON	The four-component toluene/o-xylene monooxygenase (ToMO) from Pseudomonas stutzeri OX1 is capable of oxidizing arenes, alkenes, and haloalkanes at a carboxylate-bridged diiron center similar to that of soluble methane monooxygenase (sMMO). The remarkable variety of substrates accommodated by ToMO invites applications ranging from bioremediation to the regio- and enantiospecific oxidation of hydrocarbons on an industrial scale. We report here the crystal structures of the ToMO hydroxylase (ToMOH), azido ToMOH, and ToMOH containing the product analogue 4-bromophenol to 2.3 or greater resolution. The catalytic diiron( III) core resembles that of the sMMO hydroxylase, but aspects of the alpha(2)beta(2)gamma(2) tertiary structure are notably different. Of particular interest is a 6-10 Angstrom-wide channel of similar to35 Angstrom in length extending from the active site to the protein surface. The presence of three bromophenol molecules in this space confirms this route as a pathway for substrate entrance and product egress. An analysis of the ToMOH active site cavity offers insights into the different substrate specificities of multicomponent monooxygenases and explains the behavior of mutant forms of homologous enzymes described in the literature.	MIT, Dept Chem, Cambridge, MA 02139 USA; Wyeth Pharmaceut, Div Struct Biol, Cambridge, MA 02140 USA; Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy	Massachusetts Institute of Technology (MIT); Pfizer; University of Naples Federico II	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Di Donato, Alberto/G-5494-2012	DI DONATO, Alberto/0000-0001-9129-9850	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032134, R01GM032134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai JY, 1997, J BIOL INORG CHEM, V2, P37, DOI 10.1007/s007750050104; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; Archelas A, 1997, ANNU REV MICROBIOL, V51, P491, DOI 10.1146/annurev.micro.51.1.491; ATTA M, 1993, EUR J BIOCHEM, V217, P217, DOI 10.1111/j.1432-1033.1993.tb18236.x; Baldwin J, 2000, J AM CHEM SOC, V122, P12195, DOI 10.1021/ja001278u; Bertoni G, 1996, APPL ENVIRON MICROB, V62, P3704, DOI 10.1128/AEM.62.10.3704-3711.1996; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadieux E, 2002, BIOCHEMISTRY-US, V41, P10680, DOI 10.1021/bi025901u; Cafaro V, 2002, EUR J BIOCHEM, V269, P5689, DOI 10.1046/j.1432-1033.2002.03281.x; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Chauhan S, 1998, APPL ENVIRON MICROB, V64, P3023; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Divari S, 2003, EUR J BIOCHEM, V270, P2244, DOI 10.1046/j.1432-1033.2003.03592.x; Elango N, 1997, PROTEIN SCI, V6, P556; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; Gherman BF, 2004, J AM CHEM SOC, V126, P2978, DOI 10.1021/ja036506+; GIBBS CR, 1976, ANAL CHEM, V48, P1197, DOI 10.1021/ac50002a034; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUPTA N, 1995, BIOCHEMISTRY-US, V34, P3310, DOI 10.1021/bi00010a021; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Krebs C, 2000, J AM CHEM SOC, V122, P12207, DOI 10.1021/ja001279m; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Lloyd JS, 1999, MICROBIOL-SGM, V145, P461, DOI 10.1099/13500872-145-2-461; MacArthur R, 2002, J AM CHEM SOC, V124, P13392, DOI 10.1021/ja0279904; McClay K, 2000, APPL ENVIRON MICROB, V66, P1877, DOI 10.1128/AEM.66.5.1877-1882.2000; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Mitchell KH, 2002, BIOCHEMISTRY-US, V41, P3176, DOI 10.1021/bi012036p; MITCHELL KH, 2002, THESIS U WISCONSIN M; MIURA A, 1995, BIOSCI BIOTECH BIOCH, V59, P853, DOI 10.1271/bbb.59.853; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Notomista E, 2003, J MOL EVOL, V56, P435, DOI 10.1007/s00239-002-2414-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Scognamiglio R, 2001, PROTEIN SCI, V10, P482, DOI 10.1110/ps.35701; STEFFAN RJ, 2000, Patent No. 2000073425; Studts JM, 2000, PROTEIN EXPRES PURIF, V20, P58, DOI 10.1006/prep.2000.1281; Sullivan JP, 1998, CRIT REV MICROBIOL, V24, P335, DOI 10.1080/10408419891294217; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487	48	157	157	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30600	30610		10.1074/jbc.M400710200	http://dx.doi.org/10.1074/jbc.M400710200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15096510	hybrid			2022-12-27	WOS:000222531900090
J	Hayashi, A; Ohnishi, H; Okazawa, H; Nakazawa, S; Ikeda, H; Motegi, S; Aoki, N; Kimura, S; Mikuni, M; Matozaki, T				Hayashi, A; Ohnishi, H; Okazawa, H; Nakazawa, S; Ikeda, H; Motegi, S; Aoki, N; Kimura, S; Mikuni, M; Matozaki, T			Positive regulation of phagocytosis by SIRP beta and its signaling mechanism in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR-MEDIATED PHAGOCYTOSIS; INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; LIGHT-CHAIN KINASE; FC-GAMMA; TYROSINE-PHOSPHATASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSMEMBRANE GLYCOPROTEIN; PHOSPHOINOSITIDE 3-KINASE	SIRPbeta (signal-regulatory protein beta) is a transmembrane protein that is expressed in hematopoietic cells but whose functions are unknown. We have now cloned mouse SIRPbeta cDNA and have shown that the gene is expressed in various tissues in addition to cells of the macrophage lineage. Engagement of SIRPbeta by specific monoclonal antibodies promoted Fcgamma receptor-dependent or -independent phagocytosis in mouse peritoneal macrophages. It also induced marked activation of MAPK and the upstream kinase MEK but weak activation of Akt. MEK inhibitors markedly blocked the promotion of phagocytosis by SIRPbeta, whereas an inhibitor of phosphoinositide 3-kinase partly blocked such response. In addition, inhibitors of myosin light chain kinase or of myosin ATPase blocked the promotion of phagocytosis by SIRPbeta. Furthermore, SIRPbeta induced the formation of filopodia and lamellipodia in macrophages as well as the translocation of activated MAPK to these structures. It also elicited tyrosine phosphorylation of DAP12, Syk, and SLP-76, and a Syk inhibitor blocked the promotion of phagocytosis and activation of MAPK by SIRPbeta. Our results suggest that engagement of SIRPbeta promotes phagocytosis in macrophages by inducing the tyrosine phosphorylation of DAP12, Syk, and SLP-76 and the subsequent activation of a MEK-MAPK-myosin light chain kinase cascade.	Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Gunma 3718512, Japan; Gunma Univ, Grad Sch Med, Dept Psychiat & Human Behav, Gunma 3718511, Japan; Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Sch Nursing, Asahikawa, Hokkaido 0788510, Japan	Gunma University; Gunma University; Asahikawa Medical College; Asahikawa Medical College	Matozaki, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, 3-39-15 Showa Machi, Gunma 3718512, Japan.	matozaki@showa.gunma-u.ac.jp	Okazawa, Hideki/C-3836-2011; Okazawa, Hideki/E-3055-2010					Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Aoki N, 2000, J IMMUNOL, V165, P3790, DOI 10.4049/jimmunol.165.7.3790; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Comu S, 1997, J NEUROSCI, V17, P8702; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Karimi K, 1998, INFLAMMATION, V22, P67, DOI 10.1023/A:1022347808042; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Paine R, 2002, AM J PHYSIOL-LUNG C, V283, pL180, DOI 10.1152/ajplung.00430.2001; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Sada K, 1997, EUR J BIOCHEM, V248, P827, DOI 10.1111/j.1432-1033.1997.00827.x; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sano S, 1999, BIOCHEM J, V344, P667, DOI 10.1042/0264-6021:3440667; Sato R, 2003, BIOCHEM BIOPH RES CO, V309, P584, DOI 10.1016/j.bbrc.2003.08.031; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Somlyo AV, 2002, CIRC RES, V91, P83, DOI 10.1161/01.RES.0000028341.63905.91; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Strzelecka A, 1997, FEBS LETT, V400, P11, DOI 10.1016/S0014-5793(96)01359-2; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; YANO H, 1993, J BIOL CHEM, V268, P25846	60	51	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29450	29460		10.1074/jbc.M400950200	http://dx.doi.org/10.1074/jbc.M400950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123631	hybrid			2022-12-27	WOS:000222445300077
J	Stok, JE; Huang, HZ; Jones, PD; Wheelock, CE; Morisseau, C; Hammock, BD				Stok, JE; Huang, HZ; Jones, PD; Wheelock, CE; Morisseau, C; Hammock, BD			Identification, expression, and purification of a pyrethroid-hydrolyzing carboxylesterase from mouse liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; RAT; ESTERASES; TOXICITY; SEQUENCE; CLONING; CDNA; METABOLISM; ENZYMES; ORGANOPHOSPHORUS	Carboxylesterases are enzymes that catalyze the hydrolysis of a wide range of ester-containing endogenous and xenobiotic compounds. Although the use of pyrethroids is increasing, the specific enzymes involved in the hydrolysis of these insecticides have yet to be identified. A pyrethroid-hydrolyzing enzyme was partially purified from mouse liver microsomes using a fluorescent reporter similar in structure to cypermethrin (Shan, G., and Hammock, B. D. ( 2001) Anal. Biochem. 299, 54 - 62 and Wheelock, C. E., Wheelock, A. M., Zhang, R., Stok, J. E., Morisseau, C., Le Valley, S. E., Green, C. E., and Hammock, B. D. ( 2003) Anal. Biochem. 315, 208 - 222) and subsequently identified as a carboxylesterase (NCBI accession number BAC36707). The expressed sequence tag was then cloned, expressed in baculovirus, and purified to homogeneity. Kinetic constants for a large number of both type I and type II pyrethroid or pyrethroid-like substrates were determined. This esterase possesses similar kinetic constants for cypermethrin and its fluorescent-surrogate (k(cat) = 0.12 +/- 0.03 versus 0.11 +/- 0.01 s(-1)). Compared with their cis-counterparts, trans-permethrin and cypermethrin were hydrolyzed 22- and 4-fold faster, respectively. Of the four fenvalerate isomers the (2R)(alphaR)-isomer was hydrolyzed at least 1 order of magnitude faster than any other isomer. However, it is unlikely that this enzyme accounts for the total pyrethroid hydrolysis in the microsomes because both isoelectrofocusing and native PAGE indicate the presence of a second region of cypermethrin-metabolizing enzymes. A second carboxylesterase gene ( NCBI accession number NM_ 133960), isolated during a cDNA mouse liver library screening, was also found to hydrolyze pyrethroids. Both these enzymes could be used as preliminary tools in establishing the relative toxicity of new pyrethroids.	Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Hammock, BD (corresponding author), Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.	bdhammock@ucdavis.edu		Stok, Jeanette/0000-0002-8759-3931	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI058267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R37ES002710, P30ES005707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI58267] Funding Source: Medline; NIDDK NIH HHS [T32 DK07355-22] Funding Source: Medline; NIEHS NIH HHS [R37 ES02710, P30 ES 05707, P42 ES04699] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABERNATHY CO, 1973, PESTIC BIOCHEM PHYS, V3, P300, DOI 10.1016/0048-3575(73)90028-X; CANTALAMESSA F, 1993, ARCH TOXICOL, V67, P510, DOI 10.1007/BF01969923; CASIDA JE, 1983, ANNU REV PHARMACOL, V23, P413, DOI 10.1146/annurev.pa.23.040183.002213; Choi J, 2002, PESTIC BIOCHEM PHYS, V74, P117, DOI 10.1016/S0048-3575(02)00154-2; El-Tawil OS, 2001, PHARMACOL RES, V44, P33, DOI 10.1006/phrs.2001.0826; Hodgson E, 2003, J BIOCHEM MOL TOXIC, V17, P201, DOI 10.1002/jbt.10080; HUANG TL, 1993, J PHARM PHARMACOL, V45, P458, DOI 10.1111/j.2042-7158.1993.tb05576.x; Huang TL, 1996, PHARMACEUT RES, V13, P1495, DOI 10.1023/A:1016071311190; Kakko I, 2004, ENVIRON TOXICOL PHAR, V15, P95, DOI 10.1016/j.etap.2003.11.005; KANEKO H, 1988, J PESTIC SCI, V13, P535; KAO LR, 1985, PESTIC BIOCHEM PHYS, V23, P66, DOI 10.1016/0048-3575(85)90079-3; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; Landrigan PJ, 1999, ENVIRON HEALTH PERSP, V107, P431, DOI 10.1289/ehp.99107s3431; LAWRENCE LJ, 1982, PESTIC BIOCHEM PHYS, V18, P9, DOI 10.1016/0048-3575(82)90082-7; LJUNGQUIST A, 1971, EUR J BIOCHEM, V23, P303, DOI 10.1111/j.1432-1033.1971.tb01622.x; Miyamoto J, 1995, TOXICOL LETT, V82-3, P933, DOI 10.1016/0378-4274(95)03604-0; MIYAMOTO J, 1976, ENVIRON HEALTH PERSP, V14, P15, DOI 10.2307/3428358; Miyata M, 2003, YAKUGAKU ZASSHI, V123, P569, DOI 10.1248/yakushi.123.569; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OZOLS J, 1989, J BIOL CHEM, V264, P12533; Pindel EV, 1997, J BIOL CHEM, V272, P14769, DOI 10.1074/jbc.272.23.14769; ROBBI M, 1991, J BIOL CHEM, V266, P20498; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Shan GM, 2001, ANAL BIOCHEM, V299, P54, DOI 10.1006/abio.2001.5388; Shan GM, 1999, J AGR FOOD CHEM, V47, P2145, DOI 10.1021/jf981210m; SODERLUND DM, 1992, XENOBIOTICA, V22, P1185, DOI 10.3109/00498259209051872; SODERLUND DM, 1982, PESTIC BIOCHEM PHYS, V17, P162, DOI 10.1016/0048-3575(82)90021-9; Soderlund DM, 2002, TOXICOLOGY, V171, P3, DOI 10.1016/S0300-483X(01)00569-8; Sogorb MA, 2002, TOXICOL LETT, V128, P215, DOI 10.1016/S0378-4274(01)00543-4; SONE T, 1994, BBA-PROTEIN STRUCT M, V1207, P138, DOI 10.1016/0167-4838(94)90063-9; SUZUKI T, 1978, PESTIC BIOCHEM PHYS, V8, P186, DOI 10.1016/0048-3575(78)90038-X; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TAKAMATSU Y, 1987, J PESTIC SCI, V12, P397; TALCOTT RE, 1979, TOXICOL APPL PHARM, V47, P145, DOI 10.1016/0041-008X(79)90081-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wheelock CE, 2003, ANAL BIOCHEM, V315, P208, DOI 10.1016/S0003-2697(03)00002-2; Wheelock CE, 2001, CHEM RES TOXICOL, V14, P1563, DOI 10.1021/tx015508+; Whyatt RM, 2002, ENVIRON HEALTH PERSP, V110, P507, DOI 10.1289/ehp.02110507	39	55	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29863	29869		10.1074/jbc.M403673200	http://dx.doi.org/10.1074/jbc.M403673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123619	hybrid			2022-12-27	WOS:000222445300124
J	Samson, T; Smyth, N; Janetzky, S; Wendler, O; Muller, JM; Schule, R; von der Mark, H; von der Mark, K; Wixler, V				Samson, T; Smyth, N; Janetzky, S; Wendler, O; Muller, JM; Schule, R; von der Mark, H; von der Mark, K; Wixler, V			The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha(7)beta(1) integrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CYTOPLASMIC DOMAINS; TRANSCRIPTIONAL COACTIVATOR; ALPHA-7-BETA-1 INTEGRIN; AFFINITY-CHROMATOGRAPHY; EXPRESSION PATTERNS; MOUSE DEVELOPMENT; BINDING PROTEIN; HUMAN-PLASMA; ACTIVATION	FHL1, FHL2, and FHL3 are members of the four and one-half LIM domain protein subclass that are expressed in striated muscles. Here we show that FHL2 and FHL3 are novel alpha(7)beta(1) integrin-interacting proteins. They bind both the alpha- and the beta-subunit as well as different splice isoforms. The minimal binding sites for FHL2 and FHL3 on beta(1A)-chain overlap, whereas on alpha(7A) and alpha(7B) subunits they are situated adjacent. Determining the binding sites for integrins on FHL2 or FHL3 revealed that the suprastructure of the whole molecule is important for these associations, rather than any single LIM domain. Immunofluorescence studies with cells expressing full-length FHL proteins or their deletion mutants showed that FHL2 and FHL3 but not FHL1 colocalize with integrins at cell adhesion sites. Further, their recruitment to the membrane results from binding to either the alpha- or the beta-chain of the integrin receptor. The association of FHL2 or FHL3 with integrin receptors neither influences attachment of cells to different substrates nor changes their migration capacity. However, in cardiac and skeletal muscles, FHL2 and FHL3, respectively, are colocalized with alpha(7)beta(1) integrin receptor at the periphery of Z-discs, suggesting a role in mechanical stabilization of muscle cells.	Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, Lehrstuhl Expt Med 1, D-91054 Erlangen, Germany; Univ Cologne, Fak Med, Inst Biochem, D-50931 Cologne, Germany; Univ Freiburg, Frauenklin, D-79106 Freiburg, Germany; Univ Freiburg Klinikum, Zentrum Klin Forsch, D-79106 Freiburg, Germany	University of Erlangen Nuremberg; University of Cologne; University of Freiburg; University of Freiburg	Wixler, V (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, Lehrstuhl Expt Med 1, Gluckstr 6, D-91054 Erlangen, Germany.	vwixler@molmed.uni-erlangen.de		Smyth, Neil/0000-0002-3734-2149; Wendler, Olaf/0000-0002-5443-4889				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kaariainen M, 2002, AM J PATHOL, V161, P1023, DOI 10.1016/S0002-9440(10)64263-0; Kong YF, 2001, CIRCULATION, V103, P2731; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; LAYROVSKII VA, 1976, TSITOLOGIYA, V18, P113; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu SC, 2000, J CELL SCI, V113, P3563; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McGrath MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1513, DOI 10.1152/ajpcell.00207.2003; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nawrotzki R, 2003, HUM MOL GENET, V12, P483, DOI 10.1093/hmg/ddg047; Paul AC, 2002, CELL TISSUE RES, V308, P255, DOI 10.1007/s00441-002-0526-y; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Robinson PA, 2003, AM J PHYSIOL-CELL PH, V284, pC681, DOI 10.1152/ajpcell.00370.2002; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; SONG WK, 1993, J CELL SCI, V106, P1139; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Vignier N, 1999, BIOCHEM BIOPH RES CO, V260, P357, DOI 10.1006/bbrc.1999.0916; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	53	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28641	28652		10.1074/jbc.M312894200	http://dx.doi.org/10.1074/jbc.M312894200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117962	hybrid			2022-12-27	WOS:000222265400100
J	Diaz, BG; Moldoveanu, T; Kuiper, MJ; Campbell, RL; Davies, PL				Diaz, BG; Moldoveanu, T; Kuiper, MJ; Campbell, RL; Davies, PL			Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; TERMINAL PRO-SEQUENCE; EXTRACELLULAR SECRETION; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; MESSENGER-RNA; LP82 CALPAIN; AQUALYSIN-I; RAT LENS; PROTEIN	The physiological role of the skeletal muscle-specific calpain 3, p94, is presently unknown, but defects in its gene cause limb girdle muscular dystrophy type 2A. This calcium-dependent cysteine protease resembles the large subunit of m-calpain but with three unique additional sequences: an N-terminal region (NS), and two insertions (IS1 and IS2). The latter two insertions have been linked to the chronic instability of the whole enzyme both in vivo and in vitro. We have shown previously that the core of p94 comprising NS, domains I and II, and IS1 is stable as a recombinant protein in the absence of Ca2+ and undergoes autolysis in its presence. Here we show that p94I-II cannot hydrolyze an exogenous substrate before autolysis but is increasingly able to do so when autolysis proceeds for several hours. This gain in activity is caused by cleavage of IS1 during autolysis because a deletion mutant lacking the NS region (p94I-II DeltaNS) shows the same activation profile. Similarly, the calpain inhibitors E-64 and leupeptin have almost no inhibitory effect on substrate hydrolysis by p94I-II soon after calcium addition but cause complete inhibition when autolysis progresses for several hours. As autolysis proceeds, there is release of the internal IS1 peptide, but the two portions of the core remain tightly associated. Modeling of p94I-II suggests that IS1 contains an amphipathic alpha-helix flanked by extended loops. The latter are the targets of autolysis and limited digestion by exogenous proteases. The presence and location of the alpha-helix in recombinant IS1 were confirmed by circular dichroism and by the introduction of a L286P helix-disrupting mutation. Within p94I-II, L286P caused premature autoproteolysis of the enzyme. IS1 is an elaboration of a loop in domain II near the active site, and it acts as an internal autoinhibitory propeptide, blocking the active site of p94 from substrates and inhibitors.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Engn Network Centres Excellence, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X; Campbell, Robert/0000-0002-5473-5876				Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Branca D, 1999, EUR J BIOCHEM, V265, P839, DOI 10.1046/j.1432-1327.1999.00817.x; De Tullio R, 2003, BIOCHEM J, V375, P689, DOI 10.1042/BJ20030706; Farkas A, 2003, BIOL CHEM, V384, P945, DOI 10.1515/BC.2003.106; Federici C, 1999, ARCH BIOCHEM BIOPHYS, V363, P237, DOI 10.1006/abbi.1998.1091; Fukiage C, 2002, J BIOL CHEM, V277, P20678, DOI 10.1074/jbc.M200697200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Jia ZC, 2001, BIOPHYS J, V80, P2590, DOI 10.1016/S0006-3495(01)76229-7; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khan AR, 1998, PROTEIN SCI, V7, P815; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; LEE YC, 1994, FEMS MICROBIOL LETT, V120, P69; Lee YC, 1996, ADV EXP MED BIOL, V379, P155; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; Mikolajczyk J, 2003, J BIOL CHEM, V278, P10458, DOI 10.1074/jbc.M210564200; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Rey MA, 2002, FEBS LETT, V532, P401, DOI 10.1016/S0014-5793(02)03722-5; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Rost B, 1997, PROTEINS, P192; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Todd B, 2003, J MOL BIOL, V328, P131, DOI 10.1016/S0022-2836(03)00274-2; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279	43	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27656	27666		10.1074/jbc.M313290200	http://dx.doi.org/10.1074/jbc.M313290200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073171	hybrid			2022-12-27	WOS:000222120400100
J	Oyama, F; Kotliarova, S; Harada, A; Ito, M; Miyazaki, H; Ueyama, Y; Hirokawa, N; Nukina, N; Ihara, Y				Oyama, F; Kotliarova, S; Harada, A; Ito, M; Miyazaki, H; Ueyama, Y; Hirokawa, N; Nukina, N; Ihara, Y			Gem GTPase and Tau - Morphological changes induced by Gem GTPase in Cho cells are antagonized by tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; FRONTOTEMPORAL DEMENTIA; RAS-FAMILY; EXPRESSION; BINDING; GENE; ISOFORMS; MICE; REORGANIZATION; ORGANIZATION	A series of observations have indicated that tau, one of the major microtubule-associated proteins, is involved in neuronal cell morphogenesis and axonal maintenance. Tau is also the major component of paired helical filaments found in brains affected by Alzheimer's disease. To explore an as yet unidentified role of tau in vivo, similar to 11,000 mRNAs were profiled from tau-deficient mouse brains and compared with those from control brains at the same ages. The expression of Gem GTPase, a small GTP-binding protein of the ras superfamily, was significantly increased in the brains of tau-deficient mice at 8 weeks of age. Because Gem GTPase is a negative regulator of the Rho-Rho kinase pathway for cytoskeletal organization, this protein was transiently overexpressed in Chinese hamster ovary cells that do not express tau. Overexpression of Gem GTPase induced a marked elongation of Chinese hamster ovary cells, and simultaneous expression of tau eliminated this effect, although tau did not bind directly to Gem GTPase. This anti-elongation activity of tau was attributed to its microtubule-binding domain, and homologous domains of microtubule-associated proteins 2 and 4 exhibited similar antagonistic activities. Taken together, the present results indicate that the level of Gem GTPase and its cell elongation activity are modulated by tau and suggest that tau may be involved in a Gem GTPase-mediated signal transduction pathway.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Cell Biol & Anat, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Lab Struct Neuropathol, Brain Sci Inst, Wako, Saitama 3510198, Japan; Gunma Univ, Lab Cellular & Mol Morphol, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan; Cent Inst Expt Anim, Kanagawa 2160001, Japan; Tokai Univ, Dept Pathol, Sch Med, Kanagawa 2591193, Japan	University of Tokyo; University of Tokyo; RIKEN; Gunma University; Tokai University	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yihara@m.u-tokyo.ac.jp	Nukina, Nobuyuki/GPP-6265-2022; Oyama, Fumitaka/Q-4268-2019	Oyama, Fumitaka/0000-0002-1095-8306				Aresta S, 2002, BIOCHEM J, V367, P57, DOI 10.1042/BJ20020829; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Dorin D, 1995, ONCOGENE, V11, P2267; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gu YJ, 1996, J NEUROCHEM, V67, P1235; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikegami S, 2000, NEUROSCI LETT, V279, P129, DOI 10.1016/S0304-3940(99)00964-7; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KINDLER S, 1994, MOL BRAIN RES, V26, P218, DOI 10.1016/0169-328X(94)90093-0; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lendon CL, 1998, NEUROLOGY, V50, P1546, DOI 10.1212/WNL.50.6.1546; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Zhukareva V, 2001, ANN NEUROL, V49, P165, DOI 10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3	36	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27272	27277		10.1074/jbc.M401634200	http://dx.doi.org/10.1074/jbc.M401634200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087445	hybrid			2022-12-27	WOS:000222120400056
J	Kockx, M; Rye, KA; Gaus, K; Quinn, CM; Wright, J; Sloane, T; Sviridov, D; Fu, Y; Sullivan, D; Burnett, JR; Rust, S; Assmann, G; Anantharamaiah, GM; Palgunachari, MN; Katz, SL; Phillips, MC; Dean, RT; Jessup, W; Kritharides, L				Kockx, M; Rye, KA; Gaus, K; Quinn, CM; Wright, J; Sloane, T; Sviridov, D; Fu, Y; Sullivan, D; Burnett, JR; Rust, S; Assmann, G; Anantharamaiah, GM; Palgunachari, MN; Katz, SL; Phillips, MC; Dean, RT; Jessup, W; Kritharides, L			Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; TANGIER-DISEASE; ACYLTRANSFERASE ACTIVATION; CELLULAR CHOLESTEROL; LIPID INTERACTION; BINDING; APOE; ATHEROSCLEROSIS; DEGRADATION	Apolipoprotein A-I (apoA-I)-mediated cholesterol efflux involves the binding of apoA-I to the plasma membrane via its C terminus and requires cellular ATP-binding cassette transporter (ABCA1) activity. ApoA-I also stimulates secretion of apolipoprotein E ( apoE) from macrophage foam cells, although the mechanism of this process is not understood. In this study, we demonstrate that apoA-I stimulates secretion of apoE independently of both ABCA1-mediated cholesterol efflux and of lipid binding by its C terminus. Pulse-chase experiments using S-35-labeled cellular apoE demonstrate that macrophage apoE exists in both relatively mobile ( Em) and stable (E-s) pools, that apoA-I diverts apoE from degradation to secretion, and that only a small proportion of apoA-I-mobilized apoE is derived from the cell surface. The structural requirements for induction of apoE secretion and cholesterol efflux are clearly dissociated, as C-terminal deletions in recombinant apoA-I reduce cholesterol efflux but increase apoE secretion, and deletion of central helices 5 and 6 decreases apoE secretion without perturbing cholesterol efflux. Moreover, a range of 11- and 22-mer alpha-helical peptides representing amphipathic alpha-helical segments of apoA-I stimulate apoE secretion whereas only the C-terminal alpha-helix ( domains 220 - 241) stimulates cholesterol efflux. Other alpha-helix-containing apolipoproteins (apoA-II, apoA-IV, apoE2, apoE3, apoE4) also stimulate apoE secretion, implying a positive feedback autocrine loop for apoE secretion, although apoE4 is less effective. Finally, apoA-I stimulates apoE secretion normally from macrophages of two unrelated subjects with genetically confirmed Tangier Disease ( mutations C733R and c. 5220 - 5222delTCT; and mutations A1046D and c. 4629 - 4630insA), despite severely inhibited cholesterol efflux. We conclude that apoA-I stimulates secretion of apoE independently of cholesterol efflux, and that this represents a novel, ABCA-1-independent, positive feedback pathway for stimulation of potentially anti-atherogenic apoE secretion by alpha-helix-containing molecules including apoA-I and apoE.	Univ New S Wales, Ctr Vasc Res, Macrophage Biol Grp, Sydney, NSW 2052, Australia; Heart Res Inst, Sydney, NSW 2050, Australia; Baker Heart Res Inst, Melbourne, Vic 8008, Australia; Univ Sydney, Royal Prince Alfred Hosp, Dept Clin Biochem, Sydney, NSW 2050, Australia; Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Canberra, Canberra, ACT 2601, Australia; Univ Sydney, Concord Hosp, Dept Cardiol, Sydney, NSW 2139, Australia	University of New South Wales Sydney; University of Sydney; Heart Research Institute; Baker Heart and Diabetes Institute; University of Sydney; Royal Perth Hospital; University of Western Australia; University of Munster; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Canberra; Concord Repatriation General Hospital; University of Sydney	Kritharides, L (corresponding author), Univ New S Wales, Ctr Vasc Res, Macrophage Biol Grp, 4th Floor Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	l.kritharides@unsw.edu.au	Sviridov, Dmitri/E-7943-2010; Kritharides, Leonard/AAQ-2720-2020	Dean, Roger Thornton/0000-0002-8859-8902; Phillips, Michael/0000-0002-7147-8007; Gaus, Katharina/0000-0002-8009-9658; fu, ying/0000-0002-1261-3336	NHLBI NIH HHS [HL22633, HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; Arakawa R, 2000, J LIPID RES, V41, P1952; ASZTALOS BF, 1995, ARTERIOSCL THROM VAS, V15, P1419, DOI 10.1161/01.ATV.15.9.1419; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bielicki JK, 1999, J LIPID RES, V40, P85; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOYUM A, 1984, METHOD ENZYMOL, V108, P88; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; Burgess JW, 2001, J LIPID RES, V42, P1413; Burgess JW, 1998, J BIOL CHEM, V273, P5645, DOI 10.1074/jbc.273.10.5645; BURNETT JR, 1994, AM J CARDIOL, V73, P923, DOI 10.1016/0002-9149(94)90831-1; DEAN RT, 1979, EXP CELL BIOL, V47, P454; DENG JT, 1995, J LIPID RES, V36, P2129; DONG LM, 1994, J BIOL CHEM, V269, P22358; DORY L, 1991, J LIPID RES, V32, P783; DORY L, 1989, J LIPID RES, V30, P809; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; FIELDING CJ, 1995, J LIPID RES, V36, P211; Garner B, 1997, ATHEROSCLEROSIS, V128, P47, DOI 10.1016/S0021-9150(96)05979-5; Gaus K, 2001, BIOCHEMISTRY-US, V40, P9363, DOI 10.1021/bi010323n; Gelissen IC, 1999, J LIPID RES, V40, P1636; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P1977, DOI 10.1161/hq1201.100221; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1992, STRUCTURE FUNCTION A, P218; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LIANG HQ, 1994, J LIPID RES, V35, P1187; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OBRIEN KD, 1994, AM J PATHOL, V144, P538; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PYLE LE, 1995, J LIPID RES, V36, P2355; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; RYE KA, 1994, J BIOL CHEM, V269, P10298; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SEGREST JP, 1992, J LIPID RES, V33, P141; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; STEINMETZ A, 1989, J CHROMATOGR-BIOMED, V487, P154, DOI 10.1016/S0378-4347(00)83018-2; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TRINDER P., 1969, Journal of Clinical Pathology, V22, P158, DOI 10.1136/jcp.22.2.158; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Weinberg RB, 1996, METHOD ENZYMOL, V263, P282; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	69	39	45	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25966	25977		10.1074/jbc.M401177200	http://dx.doi.org/10.1074/jbc.M401177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066991	hybrid			2022-12-27	WOS:000222003000007
J	Mo, E; Amin, H; Bianco, IH; Garthwaite, J				Mo, E; Amin, H; Bianco, IH; Garthwaite, J			Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE GUANYLYL CYCLASE; DEPENDENT PROTEIN-KINASES; CYCLIC-NUCLEOTIDES; OXIDE RECEPTOR; GUANOSINE 3',5'-MONOPHOSPHATE; CEREBELLAR CELLS; CGMP RESPONSE; INTACT-CELLS; ION CHANNELS; PHOSPHORYLATION	Rat platelets served as a model to evaluate quantitatively how guanylate cyclase (GC)-coupled nitric oxide (NO) receptors and phosphodiesterases (here phosphodiesterase-5) interact to transduce NO signals in cells. The platelets expressed mRNA only for the alpha(1) and beta(1) GC-coupled receptor subunits. In intact platelets, the potency of NO for elevating cGMP (EC(50) = 10 nM) was lower than in lysed platelets (EC(50) = 1.7 nM). The limiting activities of GC and phosphodiesterase in intact platelets were both very high, being equivalent to about 100 muM/s. With low phosphodiesterase activity (imposed by 100 muM sildenafil), the cGMP response over time was hyperbolic in shape for a range of NO concentrations or GC activities due to GC desensitization. Without a phosphodiesterase inhibitor, NO generated only brief cGMP transients, peaking after 2-5 s but amounting maximally to about 150 muM cGMP. The transients were caused partly by GC desensitization, which varied in rate (half-time up to 3 s) and extent (up to 80%) depending on the NO concentration, and partly by an enhancement of the phosphodiesterase catalytic activity with time, which was deduced to be up to 30-fold and to occur with a half-time of up to 5 s. The results were simulated by a quantitative model, which also explains the varied shapes of cGMP responses to NO found in other cells. Downstream phosphorylation in platelets was detectable within 2 s, and, with continuous exposure (1 min), this pathway could be engaged by subnanomolar NO concentrations (EC(50) = 0.5 nM).	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Garthwaite, J (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	john.garthwaite@ucl.ac.uk		Bianco, Isaac/0000-0002-3149-4862				Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BIDRI M, 1995, BIOCHEM BIOPH RES CO, V210, P507, DOI 10.1006/bbrc.1995.1689; Colquhoun D, 1998, NEURON, V20, P381, DOI 10.1016/S0896-6273(00)80982-4; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Griffiths C, 2003, MOL PHARMACOL, V64, P1349, DOI 10.1124/mol.64.6.1349; GUTHMANN F, 1992, N-S ARCH PHARMACOL, V346, P537; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KEELY SL, 1978, BIOCHIM BIOPHYS ACTA, V543, P251, DOI 10.1016/0304-4165(78)90070-3; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; MELLION BT, 1981, BLOOD, V57, P946; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; Moreland RB, 1999, TRENDS ENDOCRIN MET, V10, P97, DOI 10.1016/S1043-2760(98)00127-1; Mullershausen F, 2003, VASC PHARMACOL, V40, P161, DOI 10.1016/S1537-1891(03)00049-1; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Mullershausen F, 2001, J CELL BIOL, V155, P271, DOI 10.1083/jcb.200107001; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SAITO M, 1979, BIOCHIM BIOPHYS ACTA, V586, P473, DOI 10.1016/0304-4165(79)90037-0; Schmidt P, 2003, EUR J PHARMACOL, V468, P167, DOI 10.1016/S0014-2999(03)01674-1; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; WOOD KS, 1987, J BIOL CHEM, V262, P5020; Wykes V, 2002, J NEUROCHEM, V83, P37, DOI 10.1046/j.1471-4159.2002.01106.x; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; ZHOU HL, 1991, J PHARMACOL EXP THER, V258, P972	39	54	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26149	26158		10.1074/jbc.M400916200	http://dx.doi.org/10.1074/jbc.M400916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075333	hybrid			2022-12-27	WOS:000222003000029
J	Parsons, SA; Millay, DP; Wilkins, BJ; Bueno, OF; Tsika, GL; Neilson, JR; Liberatore, CM; Yutzey, KE; Crabtree, GR; Tsika, RW; Molkentin, JD				Parsons, SA; Millay, DP; Wilkins, BJ; Bueno, OF; Tsika, GL; Neilson, JR; Liberatore, CM; Yutzey, KE; Crabtree, GR; Tsika, RW; Molkentin, JD			Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; WEIGHT-LIFTING EXERCISE; DIGITORUM LONGUS MUSCLE; HEAVY-CHAIN EXPRESSION; BETA-DEFICIENT MICE; CYCLOSPORINE-A; COMPENSATORY HYPERTROPHY; CARDIAC-HYPERTROPHY; GAMMA-IRRADIATION; PAX-3 EXPRESSION	The serine/threonine phosphatase calcineurin is an important regulator of calcium-activated intracellular responses in eukaryotic cells. In higher eukaryotes, calcium/calmodulin-mediated activation of calcineurin facilitates direct dephosphorylation and nuclear translocation of the transcription factor nuclear factor of activated T-cells ( NFAT). Recently, controversy has surrounded the role of calcineurin in mediating skeletal muscle cell hypertrophy. Here we examined the ability of calcineurin-deficient mice to undergo skeletal muscle hypertrophic growth following mechanical overload (MOV) stimulation or insulin-like growth factor-1 (IGF-1) stimulation. Two distinct models of calcineurin deficiency were employed: calcineurin Abeta gene-targeted mice, which show a approximate to50% reduction in total calcineurin, and calcineurin B1-LoxP-targeted mice crossed with a myosin light chain 1f cre knock-in allele, which show a greater than 80% loss of total calcineurin only in skeletal muscle. Calcineurin Abeta-/- and calcineurin B1-LoxP(fl/fl)-MLC-cre mice show essentially no defects in muscle growth in response to IGF-1 treatment or MOV stimulation, although calcineurin Abeta-/- mice show a basal defect in total fiber number in the plantaris and a mild secondary reduction in growth, consistent with a developmental defect in myogenesis. Both groups of gene-targeted mice show normal increases in Akt activation following MOV or IGF-1 stimulation. However, overload-mediated fiber-type switching was dramatically impaired in calcineurin B1-LoxP(fl/fl)-MLC-cre mice. NFAT-luciferase reporter transgenic mice failed to show a correlation between IGF-1- or MOV-induced hypertrophy and calcineurin-NFAT-dependent signaling in vivo. We conclude that calcineurin expression is important during myogenesis and fiber-type switching, but not for muscle growth in response to hypertrophic stimuli.	Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Molkentin, JD (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Tuluc, Petronel/C-2527-2011	Yutzey, Katherine/0000-0002-1444-7124; Neilson, Joel R./0000-0002-3408-608X; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; BOBER E, 1994, DEVELOPMENT, V120, P603; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Brand-Saberi B, 1999, CELL TISSUE RES, V296, P199, DOI 10.1007/s004410051281; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; Dunn SE, 2000, J CELL BIOL, V151, P663, DOI 10.1083/jcb.151.3.663; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Dupont-Versteegden EE, 2002, AM J PHYSIOL-CELL PH, V282, pC1387, DOI 10.1152/ajpcell.00424.2001; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Friday BB, 2001, J CELL SCI, V114, P303; GONYEA W, 1977, ACTA PHYSIOL SCAND, V99, P105, DOI 10.1111/j.1748-1716.1977.tb10358.x; GOULDING M, 1994, DEVELOPMENT, V120, P957; HENNIG R, 1985, NATURE, V314, P164, DOI 10.1038/314164a0; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; HUBBARD RW, 1975, GROWTH, V39, P85; Irintchev A, 2002, CELL TISSUE RES, V308, P143, DOI 10.1007/s00441-002-0519-x; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; KRENN V, 1988, ANAT EMBRYOL, V179, P49, DOI 10.1007/BF00305099; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Mitchell PO, 2002, AM J PHYSIOL-CELL PH, V282, pC984, DOI 10.1152/ajpcell.00483.2001; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; ROSENBLATT JD, 1993, PFLUG ARCH EUR J PHY, V423, P255, DOI 10.1007/BF00374404; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; ROSS JJ, 1987, DEVELOPMENT, V100, P383; ROY RR, 1982, J APPL PHYSIOL, V52, P473, DOI 10.1152/jappl.1982.52.2.473; RUBINSTEIN NA, 1981, J CELL BIOL, V90, P128, DOI 10.1083/jcb.90.1.128; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sakuma K, 2003, HISTOCHEM CELL BIOL, V119, P149, DOI 10.1007/s00418-003-0499-2; SALLEO A, 1983, J SUBMICR CYTOL PATH, V15, P929; Sanchez H, 2003, MUSCLE NERVE, V28, P324, DOI 10.1002/mus.10423; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Tamaki T, 1997, AM J PHYSIOL-CELL PH, V273, pC246, DOI 10.1152/ajpcell.1997.273.1.C246; Tanaka N, 1998, AM J PHYSIOL-HEART C, V275, pH393, DOI 10.1152/ajpheart.1998.275.2.H393; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2111, DOI 10.1152/jappl.1987.63.5.2111; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413	69	139	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26192	26200		10.1074/jbc.M313800200	http://dx.doi.org/10.1074/jbc.M313800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082723	hybrid			2022-12-27	WOS:000222003000034
J	Thomashevski, A; High, AA; Drozd, M; Shabanowitz, J; Hunt, DF; Grant, PA; Kupfer, GM				Thomashevski, A; High, AA; Drozd, M; Shabanowitz, J; Hunt, DF; Grant, PA; Kupfer, GM			The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-C PROTEIN; GROUP-D GENE; NUCLEAR-COMPLEX; HEMATOPOIETIC-CELLS; POSITIONAL CLONING; GAMMA-INTERFERON; DNA-DAMAGE; GROUP-A; COMPLEMENTATION; APOPTOSIS	Fanconi anemia (FA) is an autosomal recessive disease marked by congenital defects, bone marrow failure, and cancer susceptibility. FA cells exhibit a characteristic hypersensitivity to DNA crosslinking agents such as mitomycin C. The molecular mechanism for the disease remains elusive, but at least 6 FA proteins are known to be part of what is termed the FA core complex. We used affinity pulldown of FLAG-FANCA to pull down the FA complex from whole-cell extracts. Mass spectroscopy detected previously reported FA-binding proteins, including FANCA, FANCC, FANCG, cdc2, and GRP94, thus validating the approach. We further describe a method of purification of the FA core complex in an effort to find novel complex components and biochemical activity to define the function of the complex. By using conventional chromatographic fractionation of subcellular preparations, we report: (i) the FA core complex exists in a cytoplasmic form at 500-600 kDa; (ii) a larger, 750-kDa cytoplasmic form is seen only at mitosis; (iii) a nuclear form achieves a size of 2 megaDaltons; and (iv) a distinct 1-megaDalton FA core complex exists bound to chromatin that contains phosphorylated FANCA after undergoing DNA damage. We are continuing our analysis using mass spectroscopy in an effort to characterize novel binding proteins. These data will help define the biochemical role of the FA core complex in normal cell physiology as well as in the development of the FA disease state.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Kupfer, GM (corresponding author), Univ Virginia, Dept Chem, Box 441,Jordan Hall, Charlottesville, VA 22908 USA.	gk9e@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368				Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1997, GENETIC BASIS HUMAN, P317; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUTRILLAUX B, 1982, HUM GENET, V62, P327, DOI 10.1007/BF00304549; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; KAISER TN, 1982, CYTOMETRY, V2, P291; Kupfer G, 1999, EXP HEMATOL, V27, P587, DOI 10.1016/S0301-472X(99)00022-3; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LO TF, 1996, NAT GENET, V14, P320; Marathi UK, 1996, BLOOD, V88, P2298, DOI 10.1182/blood.V88.6.2298.bloodjournal8862298; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Naf D, 1998, MOL CELL BIOL, V18, P5952; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Ridet A, 1997, CANCER RES, V57, P1722; STONESIFER KJ, 1987, ACTA CYTOL, V31, P125; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49; Yagasaki H, 2001, BLOOD, V98, P3650, DOI 10.1182/blood.V98.13.3650; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635	51	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26201	26209		10.1074/jbc.M400091200	http://dx.doi.org/10.1074/jbc.M400091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082718	hybrid			2022-12-27	WOS:000222003000035
J	Vites, O; Rhee, JS; Schwarz, M; Rosenmund, C; Jahn, R				Vites, O; Rhee, JS; Schwarz, M; Rosenmund, C; Jahn, R			Reinvestigation of the role of snapin in neurotransmitter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; SYNAPTIC VESICLES; PROTEIN; BINDING; EXOCYTOSIS; SNAP-25; FUSION; MECHANISM; INTERACTS; SYNAPSES	Snapin, a 15-kDa protein, has been identified recently as a binding partner of SNAP-25. Moreover, snapin is regulated by phosphorylation and enhances synaptotagmin binding to SNAREs. Furthermore, snapin and C-terminal snapin fragments have been effective in changing the release properties of neurons and chromaffin cells. Here we have reinvestigated the role of snapin using both biochemical and electrophysiological approaches. Snapin is ubiquitously expressed at low levels with no detectable enrichment in the brain or in synaptic vesicles. Using non-equilibrium and equilibrium assays including pulldown experiments, co-immunoprecipitations, and CD and fluorescence anisotropy spectroscopy, we were unable to detect any specific interaction between snapin and SNAP-25. Similarly, overexpression of a C-terminal snapin fragment in hippocampal neurons failed to influence any of the analyzed parameters of neurotransmitter release. Initial biochemical characterization of recombinant snapin revealed that the protein is a stable dimer with a predominantly alpha-helical secondary structure. We conclude that the postulated role of snapin as a SNARE regulator in neurotransmitter release needs reconsideration, leaving the true function of this evolutionarily conserved protein to be discovered.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany; Max Planck Inst Med Res, Dept Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444; Jahn, Reinhard/0000-0003-1542-3498				Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1994, J BIOL CHEM, V269, P16780; Bruns D, 1997, J NEUROSCI, V17, P1898; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637	33	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26251	26256		10.1074/jbc.M404079200	http://dx.doi.org/10.1074/jbc.M404079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084593	hybrid, Green Published			2022-12-27	WOS:000222003000042
J	Zhang, KZ; Kaufman, RJ				Zhang, KZ; Kaufman, RJ			Signaling the unfolded protein response from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PLASMA-CELL DIFFERENTIATION; GLUCOSE-REGULATED PROTEINS; TRANSCRIPTION FACTOR; STRESS-RESPONSE; ER STRESS; TRANSMEMBRANE PROTEIN; TRANSLATIONAL CONTROL; MESSENGER-RNA; MISFOLDED GLYCOPROTEINS; NF-Y		Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu		Zhang, Kezhong/0000-0002-6062-235X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394, R37DK042394] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KAUFMAN RJ, 2001, TRENDS BIOCHEM SCI, V29, P152; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; MORI K, 1993, CELL, V74, P743; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	60	454	478	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25935	25938		10.1074/jbc.R400008200	http://dx.doi.org/10.1074/jbc.R400008200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15070890	hybrid			2022-12-27	WOS:000222003000001
J	Ryu, JY; Song, JY; Lee, JM; Jeong, SW; Chow, WS; Choi, SB; Pogson, BJ; Park, YI				Ryu, JY; Song, JY; Lee, JM; Jeong, SW; Chow, WS; Choi, SB; Pogson, BJ; Park, YI			Glucose-induced expression of carotenoid biosynthesis genes in the dark is mediated by cytosolic pH in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOENE SYNTHASE; LIGHT; PHOTOSYNTHESIS; DEHYDROGENASE; FRUCTOSE; SEQUENCE	The expression of carotenoid biosynthesis genes coding for phytoene synthase (crtB), phytoene desaturase (crtP), zeta-carotene desaturase (crtQ), and beta-carotene hydroxylase (crtR) is dependent upon light in the cyanobacterium Synechocystis sp. PCC 6803 ( Synechocystis). We have demonstrated that the expression of the above four genes was also elevated in the dark-adapted Synechocystis cells upon glucose treatment as a consequence of transcriptional activation. Treatment with glucose analogs such as L-glucose, 3-O-methylglucose, 2-deoxyglucose, and mannose, or inactivation of glucose uptake and phosphorylation by deletion mutation of glucose transporter (glcP) and glucokinase (gk), respectively, did not induce up-regulation of carotenoid genes. When respiratory electron transport or coupling to oxidative phosphorylation was inhibited, glucose induction was not observed, indicating that respiratory electron transport per se is not critical for the expression of these genes. In agreement with this view, the extent of gene expression showed a saturation curve with increasing acridine yellow fluorescence yield, without having a close correlation with the ATP contents or ATP/ADP ratio. The results indicate that glucose induction of carotenoid gene expressions is mediated by an increase in cytosolic pH rather than either redox or glucose sensing.	Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Australian Natl Univ, Res Sch Biol Sci, Photobioenerget Grp, Canberra, ACT 2601, Australia; Myongji Univ, Dept Biol Sci, Yongin 449728, South Korea; Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Chungnam National University; Australian National University; Myongji University; Australian National University	Park, YI (corresponding author), Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea.	yipark@cnu.ac.kr	Pogson, Barry J/C-9953-2009; Chow, Wah Soon/D-2010-2009; Park, Youn-Il/S-2997-2019	Pogson, Barry J/0000-0003-1869-2423; Park, Youn-Il/0000-0003-2912-2821; Song, Ji-Young/0000-0003-3964-1094				Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; Bohne F, 2002, BBA-GENE STRUCT EXPR, V1579, P26, DOI 10.1016/S0167-4781(02)00500-6; Cooley JW, 2001, J BACTERIOL, V183, P4251, DOI 10.1128/JB.183.14.4251-4258.2001; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Felle HH., 1989, 2ND MESSENGERS PLANT, V6, P145; Fernandez-Gonzalez B, 1998, BBA-GENE STRUCT EXPR, V1443, P343, DOI 10.1016/S0167-4781(98)00239-5; FLORES E, 1986, J BACTERIOL, V166, P693, DOI 10.1128/jb.166.2.693-696.1986; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; GIRAUDAT J, 1995, CURR OPIN CELL BIOL, V7, P232, DOI 10.1016/0955-0674(95)80033-6; GOGARTEN JP, 1989, PLANTA, V178, P52, DOI 10.1007/BF00392526; Isfort RJ, 1996, EXP CELL RES, V226, P363, DOI 10.1006/excr.1996.0237; JOSET F, 1988, ARCH MICROBIOL, V149, P417, DOI 10.1007/BF00425581; Klein D, 1998, PLANTA, V205, P223, DOI 10.1007/s004250050315; Kujat SL, 2000, PLANT PHYSIOL, V124, P703, DOI 10.1104/pp.124.2.703; LARGADE D, 2000, APPL ENVIRON MICROB, V66, P64; Li H, 2000, J BACTERIOL, V182, P4268, DOI 10.1128/JB.182.15.4268-4277.2000; MCCARTY RE, 1980, METHOD ENZYMOL, V69, P719; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1233; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Muhlbauer SK, 1998, J BIOL CHEM, V273, P20935, DOI 10.1074/jbc.273.33.20935; Mullineaux CW, 2001, MOL MICROBIOL, V41, P965, DOI 10.1046/j.1365-2958.2001.02569.x; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; Pfannschmidt T, 2003, TRENDS PLANT SCI, V8, P33, DOI 10.1016/S1360-1385(02)00005-5; PORTER RD, 1988, METHOD ENZYMOL, V167, P703; REDDY KJ, 1989, J BACTERIOL, V171, P3486, DOI 10.1128/jb.171.6.3486-3493.1989; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Ryu JY, 2003, MOL CELLS, V15, P240; Ryu JY, 2003, MOL CELLS, V16, P74; Salgado AP, 1999, MOL CELL ENDOCRINOL, V154, P79, DOI 10.1016/S0303-7207(99)00085-4; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; SCHMETTERER GR, 1990, PLANT MOL BIOL, V14, P697, DOI 10.1007/BF00016502; Schmitz O, 1999, PHOTOSYNTH RES, V62, P261, DOI 10.1023/A:1006340423948; Steinbrenner J, 2001, PLANT PHYSIOL, V125, P810, DOI 10.1104/pp.125.2.810; Teuber M, 2001, BBA-BIOENERGETICS, V1506, P31, DOI 10.1016/S0005-2728(01)00178-5; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Welsch R, 2000, PLANTA, V211, P846, DOI 10.1007/s004250000352	37	46	52	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25320	25325		10.1074/jbc.M402541200	http://dx.doi.org/10.1074/jbc.M402541200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078876	hybrid			2022-12-27	WOS:000221827900052
J	Varga, K; Jurkuvenaite, A; Wakefield, J; Hong, JS; Guimbellot, JS; Venglarik, CJ; Niraj, A; Mazur, M; Sorscher, EJ; Collawn, JF; Bebok, Z				Varga, K; Jurkuvenaite, A; Wakefield, J; Hong, JS; Guimbellot, JS; Venglarik, CJ; Niraj, A; Mazur, M; Sorscher, EJ; Collawn, JF; Bebok, Z			Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; TRANS-LENTIVIRAL VECTOR; PROTEIN-KINASE-A; ENDOPLASMIC-RETICULUM; CL-SECRETION; SURFACE EXPRESSION; PREDICTABLE SAFETY; DELTA-F508 CFTR; APICAL MEMBRANE; AIRWAY CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent protein kinase A-activated chloride channel that resides on the apical surface of epithelial cells. One unusual feature of this protein is that during biogenesis, similar to75% of wild type CFTR is degraded by the endoplasmic reticulum ( ER)associated degradative (ERAD) pathway. Examining the biogenesis and structural instability of the molecule has been technically challenging due to the limited amount of CFTR expressed in epithelia. Consequently, investigators have employed heterologous overexpression systems. Based on recent results that epithelial specific factors regulate both CFTR biogenesis and function, we hypothesized that CFTR biogenesis in endogenous CFTR expressing epithelial cells may be more efficient. To test this, we compared CFTR biogenesis in two epithelial cell lines endogenously expressing CFTR (Calu-3 and T84) with two heterologous expression systems (COS-7 and HeLa). Consistent with previous reports, 20 and 35% of the newly synthesized CFTR were converted to maturely glycosylated CFTR in COS-7 and HeLa cells, respectively. In contrast, CFTR maturation was virtually 100% efficient in Calu-3 and T84 cells. Furthermore, inhibition of the proteasome had no effect on CFTR biogenesis in Calu-3 cells, whereas it stabilized the immature form of CFTR in HeLa cells. Quantitative reverse transcriptase-PCR indicated that CFTR message levels are similar to4-fold lower in Calu-3 than HeLa cells, yet steady-state protein levels are comparable. Our results question the structural instability model of wild type CFTR and indicate that epithelial cells endogenously expressing CFTR efficiently process this protein to post-Golgi compartments.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Tranzyme Corp, Birmingham, AL 35209 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bebok, Z (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 760,1918 Univ Blvd, Birmingham, AL 35294 USA.	bebok@uab.edu		Collawn, James/0000-0002-2528-2759; Sorscher, Eric J./0000-0001-9341-3354; Guimbellot, Jennifer/0000-0002-0514-8536; Jurkuvenaite, Asta/0000-0002-9193-5797	NIDDK NIH HHS [DK60065] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen NA, 2000, HISTOCHEM CELL BIOL, V114, P219; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Bebok Z, 2001, AM J PHYSIOL-CELL PH, V280, pC135, DOI 10.1152/ajpcell.2001.280.1.C135; BEBOK Z, 1998, AM J PHYSIOL, V44, pC599; BEBOK Z, 1999, PED PULM S, V19, P218; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Kappes John C, 2003, Methods Mol Med, V76, P449; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Krumins AM, 2004, J BIOL CHEM, V279, P2593, DOI 10.1074/jbc.M311600200; Li GM, 2003, J BIOL CHEM, V278, P19791, DOI 10.1074/jbc.M212250200; Li J, 1999, J BIOL CHEM, V274, P10790, DOI 10.1074/jbc.274.16.10790; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; Liu TI, 2001, J NEUROPHYSIOL, V85, P61, DOI 10.1152/jn.2001.85.1.61; Loffing J, 1999, AM J PHYSIOL-LUNG C, V277, pL700, DOI 10.1152/ajplung.1999.277.4.L700; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; Naren AP, 2000, NEWS PHYSIOL SCI, V15, P57; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	66	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22578	22584		10.1074/jbc.M401522200	http://dx.doi.org/10.1074/jbc.M401522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15066992	hybrid			2022-12-27	WOS:000221417100109
J	Beis, K; Collins, RF; Ford, RC; Kamis, AB; Whitfield, C; Naismith, JH				Beis, K; Collins, RF; Ford, RC; Kamis, AB; Whitfield, C; Naismith, JH			Three-dimensional structure of Wza, the protein required for translocation of group 1 capsular polysaccharide across the outer membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AUTOKINASE; ELECTRON-MICROSCOPY; MULTIDRUG EFFLUX; SECRETIN PULD; CHANNEL; EXPORT; EXPRESSION; PHOSPHORYLATION; RECONSTRUCTION; TRANSPORT	Wza is a highly conserved multimeric outer membrane protein complex required for the surface expression of the serotype K30 group 1 capsular polysaccharide in Escherichia coli. Here we present the first three-dimensional structure of this type of polysaccharide exporter at a 15.5-Angstrom resolution obtained using single particle averaging on a dataset of cryo-negatively stained protein. Previous structural studies on purified Wza have revealed a homo-oligomeric ring structure that is most probably composed of eight subunits. Symmetry analysis of the three-dimensional structure combined with biochemical two-and three-dimensional crystallographic data strongly suggest that Wza is an octameric complex with a C4 quasi-rotational symmetry and is organized as a tetramer of dimeric subunits. Wza is best described as a stack of two 4-Angstrom high rings with differing diameters providing a mushroom-like aspect from the side. The larger ring has a distinctive square shape with a diameter of 115 Angstrom, whereas the smaller is almost circular with a diameter of 90 Angstrom. In the center of the complex and enclosed by the four symmetrical arms is a small elliptical cagelike cavity of similar to 40 Angstrom in diameter. The central cavity is effectively sealed at the top and bottom of the complex but has small inter-arm holes when viewed from the side. We discuss the structure of this complex and implications in the surface translocation of cell-surface polysaccharide.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of St Andrews; University of Manchester; University of Guelph	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-andrews.ac.uk	Naismith, James Henderson/H-3408-2012; Naismith, James Henderson/AAB-8614-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Beis, Konstantinos/0000-0001-5727-4721; Ford, Robert/0000-0002-0958-1505	Biotechnology and Biological Sciences Research Council [B19490] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adrian M, 1998, MICRON, V29, P145, DOI 10.1016/S0968-4328(97)00068-1; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; Andersen C, 2001, CURR OPIN CELL BIOL, V13, P412, DOI 10.1016/S0955-0674(00)00229-5; BAILEY AE, 1994, PHYS REV E, V50, P4853, DOI 10.1103/PhysRevE.50.4853; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beis K, 2004, ACTA CRYSTALLOGR D, V60, P558, DOI 10.1107/S0907444903029494; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bliss JM, 1997, J BACTERIOL, V179, P1400, DOI 10.1128/jb.179.4.1400-1403.1997; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; FINKE A, 1991, J BACTERIOL, V173, P4088, DOI 10.1128/jb.173.13.4088-4094.1991; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; Hankamer BD, 2004, J BIOL CHEM, V279, P8862, DOI 10.1074/jbc.M307889200; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; JANN K, 1987, REV INFECT DIS, V9, pS517; JANN K, 1992, CAN J MICROBIOL, V38, P705, DOI 10.1139/m92-116; Jann K., 1997, P113; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 2003, FEBS LETT, V555, P66, DOI 10.1016/S0014-5793(03)01125-6; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MACLACHLAN PR, 1993, J BACTERIOL, V175, P7515, DOI 10.1128/JB.175.23.7515-7522.1993; Nesper J, 2003, J BIOL CHEM, V278, P49763, DOI 10.1074/jbc.M308775200; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; SAXTON WO, 1984, ULTRAMICROSCOPY, V13, P57, DOI 10.1016/0304-3991(84)90057-3; SCHMIDT MA, 1982, FEMS MICROBIOL LETT, V14, P69, DOI 10.1016/0378-1097(82)90045-3; Silver RP, 2001, RES MICROBIOL, V152, P357, DOI 10.1016/S0923-2508(01)01207-4; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	50	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28227	28232		10.1074/jbc.M402913200	http://dx.doi.org/10.1074/jbc.M402913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15090537	hybrid			2022-12-27	WOS:000222265400052
J	Fortin, A; MacLaurin, JG; Arbour, N; Cregan, SP; Kushwaha, N; Callaghan, SM; Park, DS; Albert, PR; Slack, RS				Fortin, A; MacLaurin, JG; Arbour, N; Cregan, SP; Kushwaha, N; Callaghan, SM; Park, DS; Albert, PR; Slack, RS			The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NEURONAL CELL-DEATH; FACTOR RECEPTOR FAMILY; INDUCED APOPTOSIS; DNA-DAMAGE; P53-INDUCED APOPTOSIS; CORTICAL-NEURONS; PROTECTS NEURONS; GLOBAL-ISCHEMIA; MICE LACKING	The p53 tumor suppressor gene is believed to play an important role in neuronal cell death in acute neurological disease and in neurodegeneration. The p53 signaling cascade is complex, and the mechanism by which p53 induces apoptosis is cell type-dependent. Using DNA microarray analysis, we have found a striking induction of the proapoptotic gene, SIVA. SIVA is a proapoptotic protein containing a death domain and interacts with members of the tumor necrosis factor receptor family as well as anti-apoptotic Bcl-2 family proteins. SIVA is induced following direct p53 gene delivery, treatment with a DNA-damaging agent camptothecin, and stroke injury in vivo. SIVA up-regulation is sufficient to initiate the apoptotic cascade in neurons. Through isolation and analysis of the SIVA promoter, we have identified response elements for both p53 and E2F1. Like p53, E2F1 is another tumor suppressor gene involved in the regulation of apoptosis, including neuronal injury models. We have identified E2F consensus sites in the promoter region, whereas p53 recognition sequences were found in intron1. Sequence analysis has shown that these consensus sites are also conserved between mouse and human SIVA genes. Electrophoretic mobility shift assays reveal that both transcription factors are capable of binding to putative consensus sites, and luciferase reporter assays reveal that E2F1 and p53 can activate transcription from the SIVA promoter. Here, we report that the proapoptotic gene, SIVA, which functions in a broad spectrum of cell types, is a direct transcriptional target for both tumor suppressors, p53 and E2F1.	Univ Ottawa, Ottawa Hlth Res Inst, Ctr Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Slack, RS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Ctr Neurosci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	rslack@uottawa.ca	Albert, Paul/E-4804-2010; Cregan, Sean/M-3205-2013	Albert, Paul/0000-0002-1809-3554; Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835				AGEMATSU K, 1994, J IMMUNOL, V153, P1421; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; Cregan SP, 1999, J NEUROSCI, V19, P7860; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Daoud SS, 2003, CANCER RES, V63, P2782; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jacquot S, 1997, J IMMUNOL, V159, P2652; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; KOBATA T, 1994, J IMMUNOL, V153, P5422; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morrison RS, 1996, J NEUROSCI, V16, P1337; NEVINS JR, 1992, SCIENCE, V258, P424; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Okuno K, 2001, DIS COLON RECTUM, V44, P295, DOI 10.1007/BF02234309; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Prives C, 1999, J PATHOL, V187, P112; Py B, 2004, J IMMUNOL, V172, P4008, DOI 10.4049/jimmunol.172.7.4008; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	72	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28706	28714		10.1074/jbc.M400376200	http://dx.doi.org/10.1074/jbc.M400376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105421	hybrid			2022-12-27	WOS:000222265400108
J	Marson, A; Lawn, RM; Mikita, T				Marson, A; Lawn, RM; Mikita, T			Oxidized low density lipoprotein blocks lipopolysaccharide-induced interferon beta synthesis in human macrophages by interfering with IRF3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN/P300; TOLL-LIKE RECEPTOR-4; GENE-EXPRESSION; IFN-BETA; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; ALPHA; GAMMA; ATHEROSCLEROSIS; INDUCTION	In response to lipopolysaccharide (LPS) exposure, macrophages activate the transcription of a large number of pro-inflammatory genes by way of signaling pathways downstream of the LPS receptor, Toll-Like Receptor 4. Many of these genes are expressed sequentially in time, with early synthesis events resulting in the secretion of soluble factors that drive the transcription of genes expressed later in the activation cycle. In this study we show that human blood-derived macrophages pretreated with oxidized low density lipoprotein ( OxLDL) fail to transcribe and secrete interferon beta (IFNbeta) immediately following LPS stimulation. As such, the normal downstream activation of Stat1 is blocked, and numerous IFNbeta/Stat1-activated genes, including the chemokines IP10 and ITAC, are weakly expressed or not expressed at all in these cells. Inspection of the LPS-induced activation state of several transcription factors known to play a prominent role in IFNbeta transcription reveals that, although NFkappaB, c-Jun, and ATF-2 activation appears normal, the LPS-induced activation of IFNbeta regulatory factor 3 (IRF3), as measured by DNA-binding activity and association with the coactivator CBP, is inhibited in the OxLDL pre-treated cells. These IRF3 activities have been shown to be essential for the initiation of transcription of the IFNbeta gene, and the loss of these activities presumably accounts for the lack of LPS-induced IFNbeta transcription seen in the OxLDL pre-treated cells.	CV Therapeut Inc, Palo Alto, CA 94304 USA	CV Therapeutics, Inc.	Mikita, T (corresponding author), CV Therapeut Inc, 3172 Porter Dr, Palo Alto, CA 94304 USA.	tom.mikita@cvt.com						Abbas A. K., 2000, CELLULAR MOL IMMUNOL, P270; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; BARTHOLOME EJ, 2000, J INTERFERON CYTOKIN, V21, P495; Blake GJ, 2002, J INTERN MED, V252, P283, DOI 10.1046/j.1365-2796.2002.01019.x; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cascieri MA, 2002, NAT REV DRUG DISCOV, V1, P122, DOI 10.1038/nrd723; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Cremer I, 2002, FEBS LETT, V511, P41, DOI 10.1016/S0014-5793(01)03276-8; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Espinola-Klein C, 2002, CIRCULATION, V105, P15, DOI 10.1161/hc0102.101362; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Ito Takayuki, 2003, Current Drug Targets - Inflammation and Allergy, V2, P257, DOI 10.2174/1568010033484106; Jungo F, 2001, CYTOKINE, V14, P272, DOI 10.1006/cyto.2001.0884; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mackman N, 2003, ARTERIOSCL THROM VAS, V23, P1133, DOI 10.1161/01.ATV.0000080641.10662.4C; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Mikita T, 2001, J BIOL CHEM, V276, P45729, DOI 10.1074/jbc.M106114200; Mintzer RJ, 1998, J INTERF CYTOK RES, V18, P939, DOI 10.1089/jir.1998.18.939; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Robinson CM, 2003, J INTERF CYTOK RES, V23, P413, DOI 10.1089/107999003322277829; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sgarbanti M, 2002, J EXP MED, V195, P1359, DOI 10.1084/jem.20010753; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; SOUTAR AK, 1982, BIOCHEM J, V204, P549, DOI 10.1042/bj2040549; Struyf S, 1998, J LEUKOCYTE BIOL, V63, P364; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Suzuki T, 2000, BLOOD, V96, P2584; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Widney DP, 2000, J IMMUNOL, V164, P6322, DOI 10.4049/jimmunol.164.12.6322; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x	66	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28781	28788		10.1074/jbc.M313207200	http://dx.doi.org/10.1074/jbc.M313207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15107417	hybrid			2022-12-27	WOS:000222265400116
J	Banci, L; Bertini, I; Ciofi-Baffoni, S; Su, XC; Borrelly, GPM; Robinson, NJ				Banci, L; Bertini, I; Ciofi-Baffoni, S; Su, XC; Borrelly, GPM; Robinson, NJ			Solution structures of a cyanobacterial metallochaperone - Insight into an atypical copper-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTATIONAL DIFFUSION ANISOTROPY; TORSION ANGLE DYNAMICS; P-TYPE ATPASE; HETERONUCLEAR NMR; BACKBONE DYNAMICS; BACILLUS-SUBTILIS; SUPEROXIDE-DISMUTASE; COUPLING-CONSTANTS; ESCHERICHIA-COLI; ACTIVE-SITE	The Atx1 copper metallochaperone from Synechocystis PCC 6803, ScAtx1, interacts with two P-1-type copper ATPases to supply copper proteins within intracellular compartments, avoiding ATPases for other metals en route. Here we report NMR-derived solution structures for ScAtx1. The monomeric apo form has a betaalphabetabetaalpha fold with backbone motions largely restricted to loop 1 containing Cys-12 and Cys-15. The tumbling rate of Cu(I)ScAtx1 (0.1-0.8 mM) implies dimers. Experimental restraints are satisfied by symmetrical dimers with Cys-12 or His-61, but not Cys-15, invading the copper site of the opposing subunit. A full sequence of copper ligands from the cell surface to thylakoid compartments is proposed, considering in vitro homodimer liganding to mimic in vivo liganding in ScAtx1-ATPase heterodimers. A monomeric high resolution structure for Cu( I) ScAtx1, with Cys-12, Cys-15, and His-61 as ligands, is calculated without violations despite the rotational correlation time. (2)J(NH) couplings in the imidazole ring of His-61 establish coordination of N-epsilon2 to copper. His-61 is analogous to Lys-65 in eukaryotic metallochaperones, stabilizing Cu(I)S-2 complexes but by binding Cu(I) rather than compensating charge. Cys-Cys-His ligand sets are an emergent theme in some copper metallochaperones, although not in related Atx1, CopZ, or Hah1. Surface charge (Glu-13) close to the metal-binding site of ScAtx1 is likely to support interaction with complementary surfaces of copper-transporting ATPases (PacS-Arg11 and CtaA-Lys-14) but to discourage interaction with zinc ATPase ZiaA and so inhibit aberrant formation of copper-ZiaA complexes.	Univ Florence, CERM, Magnet Resonance Ctr, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Florence; University of Florence; Newcastle University - UK	Bertini, I (corresponding author), Univ Florence, CERM, Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Florence, Italy.	bertini@cerm.unifi.it	Robinson, Nigel J/J-6363-2012; Ciofi-Baffoni, Simone/AAH-9778-2021; Su, Xun-Cheng/A-3182-2014	Robinson, Nigel J/0000-0001-5586-1092; , Xun-Cheng/0000-0003-3051-0047; Ciofi Baffoni, Simone/0000-0002-2376-3321; BANCI, LUCIA/0000-0003-0562-5774				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 2003, BIOCHEMISTRY-US, V42, P13422, DOI 10.1021/bi0353326; Banci L, 2003, J MOL BIOL, V331, P473, DOI 10.1016/S0022-2836(03)00769-1; Banci L, 2003, BIOCHEMISTRY-US, V42, P1939, DOI 10.1021/bi027096p; Banci L, 2003, BIOCHEMISTRY-US, V42, P2467, DOI 10.1021/bi0205810; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Borrelly GPM, 2004, BIOCHEM J, V378, P293, DOI 10.1042/BJ20031669; BORRELLY GPM, 2004, IN PRESS MOL MICROBI; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Cavet JS, 2003, FEMS MICROBIOL REV, V27, P165, DOI 10.1016/S0168-6445(03)00050-0; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; CHEN YL, 1995, BIOCHEMISTRY-US, V34, P12265, DOI 10.1021/bi00038a022; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FOLKERS PJM, 1993, J AM CHEM SOC, V115, P3798, DOI 10.1021/ja00062a065; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1982, J MAGN RESON, V47, P351, DOI 10.1016/0022-2364(82)90128-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mulder FAA, 1999, J BIOMOL NMR, V13, P275, DOI 10.1023/A:1008354232281; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARLMAN DA, 1997, AMBER VERSION 5 0; PELTON JG, 1993, PROTEIN SCI, V2, P543; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; Preisig O, 1996, ARCH MICROBIOL, V165, P297, DOI 10.1007/s002030050330; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Radford DS, 2003, FEMS MICROBIOL LETT, V220, P105, DOI 10.1016/S0378-1097(03)00095-8; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Tottey S, 2001, J BIOL CHEM, V276, P19999, DOI 10.1074/jbc.M011243200; Tsan P, 2000, J AM CHEM SOC, V122, P5603, DOI 10.1021/ja993654k; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Xiao ZG, 2002, CHEM COMMUN, P588, DOI 10.1039/b111180a; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	62	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27502	27510		10.1074/jbc.M402005200	http://dx.doi.org/10.1074/jbc.M402005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075318	hybrid			2022-12-27	WOS:000222120400082
J	Derouet, M; Thomas, L; Cross, A; Moots, RJ; Edwards, SW				Derouet, M; Thomas, L; Cross, A; Moots, RJ; Edwards, SW			Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; SODIUM-BUTYRATE; SURVIVAL-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BAD PHOSPHORYLATION; MULTIPLE-MYELOMA; CELL LEUKEMIA-1; BCL-2; EXPRESSION; FAMILY	Human neutrophils normally have a very short half-life and die by apoptosis. Cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) can delay this apoptosis via increases in the cellular levels of Mcl-1, an anti-apoptotic protein of the Bcl-2 family with a rapid turnover rate. Here we have shown that inhibition of the proteasome (a) decreases the rate of Mcl-1 turnover within neutrophils and (b) significantly delays apoptosis. This led us to determine whether GM-CSF could enhance neutrophil survival by altering the rate of Mcl-1 turnover. Addition of GM-CSF to neutrophils enhanced Mcl-1 stability and delayed apoptosis by signaling pathways requiring PI3K/Akt and p44/42 Erk/Mek, because inhibitors of these pathways completely abrogated the GM-CSF-mediated effect on both Mcl-1 stability and apoptosis delay. Conversely, induction of Mcl-1 hyperphosphorylation by the phosphatase inhibitor, okadaic acid, significantly accelerated both Mcl-1 turnover and apoptosis. Neither the calpain inhibitor, carbobenzoxy-valinyl-phenylalaninal, nor the pan caspase inhibitor, benzyloxycarbonyl-VAD-fluoromethylketone, had any effect on Mcl-1 stability under these conditions. These observations indicate that profound changes in the rate of neutrophil apoptosis following cytokine signaling occur via dynamic changes in the rate of Mcl-1 turnover via the proteasome.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Dept Med, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	Edwards, SW (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg, Liverpool L69 7ZB, Merseyside, England.	S.W.Edwards@liv.ac.uk	Moots, Robert/AAM-8091-2020	Edwards, Steven/0000-0002-7074-0552				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Basu A, 2002, INT J ONCOL, V21, P597; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEL PL, 1997, SCIENCE, V278, P687; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Edwards SW, 2003, CHEM IMMUNOL, V83, P204; EDWARDS SW, 1994, BIOCH PHYSL NEUTROP; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Gasmi L, 1996, BLOOD, V87, P3442, DOI 10.1182/blood.V87.8.3442.bloodjournal8783442; Gojo I, 2002, CLIN CANCER RES, V8, P3527; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Johnson AL, 1999, ENDOCRINOLOGY, V140, P5465, DOI 10.1210/en.140.12.5465; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; Leuenroth SJ, 2000, J LEUKOCYTE BIOL, V68, P158; Makishima T, 2000, J BIOCHEM-TOKYO, V128, P399, DOI 10.1093/oxfordjournals.jbchem.a022767; MARTIN MC, 2001, J BIOL CHEM, V17, P17; Moulding D, 1996, BIOLOGICALS, V24, P301, DOI 10.1006/biol.1996.0041; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 1999, J LEUKOCYTE BIOL, V65, P875, DOI 10.1002/jlb.65.6.875; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; MURRAY EJB, 1995, METABOLISM, V44, P141, DOI 10.1016/0026-0495(95)90254-6; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1; SAVILL J, 1992, CLIN SCI, V83, P649, DOI 10.1042/cs0830649; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stringer RE, 1996, BRIT J HAEMATOL, V92, P169, DOI 10.1046/j.1365-2141.1996.00307.x; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Whyte MKB, 1997, J LEUKOCYTE BIOL, V62, P195, DOI 10.1002/jlb.62.2.195; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yoon JH, 2002, CANCER RES, V62, P6500; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	59	195	198	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26915	26921		10.1074/jbc.M313875200	http://dx.doi.org/10.1074/jbc.M313875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078892	hybrid			2022-12-27	WOS:000222120400016
J	Kent, NA; Eibert, SM; Mellor, J				Kent, NA; Eibert, SM; Mellor, J			Cbf1p is required for chromatin remodeling at promoter-proximal CACGTG motifs in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROMERE-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; LEFT ARM; GENE; REGION; MET4; PURIFICATION; KINETOCHORE	Cbf1p is a basic-helix-loop-helix-zipper protein of Saccharomyces cerevisiae required for the function of centromeres and MET gene promoters, where it binds DNA via the consensus core motif CACRTG ( R = A or G). At MET genes Cbf1p appears to function in both activator recruitment and chromatin-remodeling. Cbf1p has been implicated in the regulation of other genes, and CACRTG motifs are common in potential gene regulatory DNA. A recent genome-wide location analysis showed that the majority of intergenic CACGTG palindromes are bound by Cbf1p. Here we tested whether all potential Cbf1p binding motifs in the yeast genome are likely to be bound by Cbf1p using chromatin immunoprecipitation. We also tested which of the motifs are actually functional by assaying for Cbf1p-dependent chromatin remodeling. We show that Cbf1p binding and activity is restricted to palindromic CACGTG motifs in promoter-proximal regions. Cbf1p does not function through CACGTG motifs that occur in promoter-distal locations within coding regions nor where CACATG motifs occur alone except at centromeres. Cbf1p can be made to function at promoter-distal CACGTG motifs by overexpression, suggesting that the concentration of Cbf1p is normally limiting for binding and is biased to gene regulatory DNA by interactions with other factors. We conclude that Cbf1p is required for normal nucleosome positioning wherever the CACGTG motif occurs in gene regulatory DNA. Cbf1p has been shown to interact with the chromatin-remodeling ATPase Isw1p. Here we show that recruitment of Isw1p by Cbf1p is likely to be general but that Isw1p is only partially required for Cbf1p-dependent chromatin structures.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Kent, NA (corresponding author), Univ Oxford, Dept Biochem, Genet Unit, S Parks Rd, Oxford OX1 3QU, England.	nicholas.kent@bioch.ox.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307				AVEDANO A, 1997, J BACTERIOL, V179, P5594; BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; Baker RE, 1998, GENETICS, V149, P73; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CLARK MW, 1993, YEAST, V9, P543, DOI 10.1002/yea.320090511; DEWINDE JH, 1993, YEAST, V9, P847, DOI 10.1002/yea.320090805; DEWINDE JH, 1995, EUR J BIOCHEM, V233, P200; Dormer UH, 2000, J BIOL CHEM, V275, P32611, DOI 10.1074/jbc.M004167200; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hemmerich P, 2000, P NATL ACAD SCI USA, V97, P12583, DOI 10.1073/pnas.97.23.12583; JIANG WD, 1989, MOL CELL BIOL, V9, P5585, DOI 10.1128/MCB.9.12.5585; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; KENT NA, 1994, MOL CELL BIOL, V14, P5229, DOI 10.1128/MCB.14.8.5229; KENT NA, 1993, NUCLEIC ACIDS RES, V21, P4653, DOI 10.1093/nar/21.19.4653; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KRAAKMAN LS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P204, DOI 10.1016/0167-4781(91)90102-R; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; KURAS L, 1995, FEBS LETT, V367, P15, DOI 10.1016/0014-5793(95)00528-H; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MASISON DC, 1992, GENETICS, V131, P43; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; MELLOR J, 1991, NUCLEIC ACIDS RES, V19, P2961, DOI 10.1093/nar/19.11.2961; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; NIEDENTHAL R, 1991, MOL CELL BIOL, V11, P3545, DOI 10.1128/MCB.11.7.3545; NUTTEN PR, 2000, THESIS U OXFORD; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; Oechsner U, 1996, NUCLEIC ACIDS RES, V24, P2395, DOI 10.1093/nar/24.12.2395; Oechsner U, 1998, MOL GEN GENET, V260, P417, DOI 10.1007/s004380050912; Ortiz J, 2000, PROTOPLASMA, V211, P12, DOI 10.1007/BF01279895; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Packham EA, 1996, MOL GEN GENET, V250, P348; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SINCLAIR DA, 1994, MOL CELL BIOL, V14, P214, DOI 10.1128/MCB.14.1.214; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; Wieland G, 2001, NUCLEIC ACIDS RES, V29, P1054, DOI 10.1093/nar/29.5.1054; WILMEN A, 1994, NUCLEIC ACIDS RES, V22, P2791, DOI 10.1093/nar/22.14.2791; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721	60	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27116	27123		10.1074/jbc.M403818200	http://dx.doi.org/10.1074/jbc.M403818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15111622	hybrid			2022-12-27	WOS:000222120400038
J	Mizuno, K; Whittaker, MM; Bachinger, HP; Whittaker, JW				Mizuno, K; Whittaker, MM; Bachinger, HP; Whittaker, JW			Calorimetric studies on the tight binding metal interactions of Escherichia coli manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION POTENTIALS; POTENTIOMETRIC TITRATIONS; THERMUS-THERMOPHILUS; SCANNING CALORIMETRY; IRON; SITE; DENATURATION; RESOLUTION; PATHWAY; ENZYME	Escherichia coli apomanganese superoxide dismutase, prepared by removing the native metal ion under denaturing conditions, exhibits thermally triggered metal uptake behavior previously observed for thermophilic and hyperthermophilic superoxide dismutases but over a lower temperature range. Differential scanning calorimetry of aposuperoxide dismutase and metalated superoxide dismutase unfolding transitions has provided quantitative estimates of the metal binding affinities for manganese superoxide dismutase. The binding constant for Mn(II) (K-Mn( II) = 3.2 x 10(8) M-1) is surprisingly low in light of the essentially irreversible metal binding characteristic of this family of proteins and indicates that metal binding and release processes are dominated by kinetic, rather than thermodynamic, constraints. The kinetic stability of the metalloprotein complex can be traced to stabilization by elements of the protein that are independent of the presence or absence of the metal ion reflected in the thermally triggered metalation characteristic of these proteins. Binding constants for Mn(III), Fe( II), and Fe( III) complexes were estimated using quasireversible values for the unfolding enthalpy and DeltaC(p) for apo-Mn superoxide dismutase and the observed T-m values for unfolding the metalated species in the absence of denaturants. For manganese and iron complexes, an oxidation state-dependent binding affinity reflects the protein perturbation of the metal redox potential.	Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Res, Shriners Hosp Children, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Whittaker, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	jim@ebs.ogi.edu	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042680] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42680] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETTE WC, 1983, BIOCHEMISTRY-US, V22, P624, DOI 10.1021/bi00272a015; BEYER WF, 1991, J BIOL CHEM, V266, P303; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Brewer JM, 2001, INT J BIOL MACROMOL, V28, P213, DOI 10.1016/S0141-8130(00)00168-9; Edwards RA, 1998, J BIOL INORG CHEM, V3, P161, DOI 10.1007/s007750050217; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; KEELE BB, 1970, J BIOL CHEM, V245, P6176; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; Leveque VJP, 2001, BIOCHEMISTRY-US, V40, P10586, DOI 10.1021/bi010792p; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Martell A.E., 1974, CRITICAL STABILITY C, V1, P204; McCord J M, 1993, New Horiz, V1, P70; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; Quijano C, 2001, J BIOL CHEM, V276, P11631, DOI 10.1074/jbc.M009429200; Vance CK, 2001, BIOCHEMISTRY-US, V40, P13079, DOI 10.1021/bi0113317; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker JW, 2000, MET IONS BIOL SYST, V37, P587; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Whittaker MM, 1998, J BIOL CHEM, V273, P22188, DOI 10.1074/jbc.273.35.22188; Whittaker MM, 1999, J BIOL CHEM, V274, P34751, DOI 10.1074/jbc.274.49.34751; Whittaker MM, 2000, J BIOL INORG CHEM, V5, P402; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889	33	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27339	27344		10.1074/jbc.M400813200	http://dx.doi.org/10.1074/jbc.M400813200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082717	hybrid			2022-12-27	WOS:000222120400064
J	Noti, JD; Johnson, AK; Dillon, JD				Noti, JD; Johnson, AK; Dillon, JD			The zinc finger transcription factor transforming growth factor beta-inducible early gene-1 confers myeloid-specific activation of the leukocyte integrin CD11d promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CELL-DIFFERENTIATION; RB PROTEIN; ALPHA-D; EXPRESSION; SP1; IDENTIFICATION; BINDS; LEUKOINTEGRIN; ADHESION	CD11d encodes the alpha(D) subunit for a leukocyte integrin that is expressed on myeloid cells. In this study we show that the -100 to -20 region of the CD11d promoter confers myeloid-specific activation of the CD11d promoter. Transforming growth factor beta-inducible early gene-1 (TIEG1) was isolated in a yeast one-hybrid screen using the -100 to -20 region of the CD11d promoter as bait. Purified GST.TIEG1 protein was able to bind within the -61 to -45 region that overlaps a shorter binding site for Sp1. Transient overexpression of TIEG1 activated the CD11d promoter specifically in myeloid cells, whereas, down-regulation of TIEG1 with small interfering TIEG1 RNA also down-regulated expression of CD11d. In vivo, TIEG1 does not physically interact with Sp1. Cotransfection and electrophoretic mobility shift analyses of TIEG1, Sp1, and Sp3 revealed that TIEG1 competes with these Sp proteins for binding to overlapping sites in the CD11d promoter. Although TIEG1 and Sp1 are ubiquitously expressed in myeloid and non-myeloid cells, chromatin immunoprecipitation assays revealed differential occupancy of the CD11d promoter by these factors. In undifferentiated myeloid and non-myeloid cells, occupancy of the CD11d promoter by TIEG1 is similar. Upon differentiation of myeloid cells and subsequent up-regulation of CD11d expression, TIEG1 occupancy increases. In contrast, occupancy by TIEG1 remains low in non-myeloid cells exposed to phorbol ester. We propose that up-regulation of CD11d expression following differentiation of myeloid cells is mediated through increased binding of TIEG1 binding to the CD11d promoter.	Guthrie Res Inst, Sayre, PA 18840 USA		Noti, JD (corresponding author), Guthrie Res Inst, 1 Guthrie Sq, Sayre, PA 18840 USA.	noti_john@guthrie.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063891] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL63891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chrisman HR, 2003, DNA CELL BIOL, V22, P187, DOI 10.1089/104454903321655819; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; DANILENKO DM, 1995, J IMMUNOL, V155, P35; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ElGabalawy H, 1996, ARTHRITIS RHEUM-US, V39, P1913, DOI 10.1002/art.1780391119; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J CELL BIOCHEM, V87, P233, DOI 10.1002/jcb.10299; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KURZINGER K, 1981, J IMMUNOL, V127, P596; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Noti JD, 2002, INT J MOL MED, V10, P721; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Noti John D., 2003, Current Genomics, V4, P527, DOI 10.2174/1389202033490240; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Sanchez-Madrid F, 1992, Semin Cell Biol, V3, P199; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Shanley TP, 1998, J IMMUNOL, V160, P1014; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1986, J IMMUNOL, V136, P240; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanabe A, 2002, BIOL PHARM BULL, V25, P970, DOI 10.1248/bpb.25.970; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wei Z, 1999, MOL CELL BIOL, V19, P1271; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	46	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26948	26958		10.1074/jbc.M310634200	http://dx.doi.org/10.1074/jbc.M310634200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087465	hybrid			2022-12-27	WOS:000222120400020
J	Suetake, I; Shinozaki, F; Miyagawa, J; Takeshima, H; Tajima, S				Suetake, I; Shinozaki, F; Miyagawa, J; Takeshima, H; Tajima, S			DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; CYTOSINE-5 METHYLTRANSFERASES; TRANSCRIPTIONAL REPRESSOR; ENZYMATIC-PROPERTIES; HISTONE DEACETYLASE; CONTROL REGION; FAMILY; GENE; RESTRICTION; LYSINE-9	In mammals, the resetting of DNA methylation patterns in early embryos and germ cells is crucial for development. Two DNA methyltransferases, Dnmt3a and Dnmt3b, are responsible for the creation of DNA methylation patterns. Dnmt3L, a member of the Dnmt3 family, has been reported to be necessary for maternal methylation imprinting, possibly by interacting with Dnmt3a and/or Dnmt3b (Hata, K., Okano, M., Lei, H., and Li, E. ( 2002) Development 129, 1983 - 1993). In the present study, the effect of DNMT3L, a human homologue of Dnmt3L, on the DNA methylation activity of mouse Dnmt3a and Dnmt3b was examined in vitro. DNMT3L enhanced the DNA methylation activity of Dnmt3a and Dnmt3b about 1.5-3-fold in a dose-dependent manner but did not enhance the DNA methylation activity of Dnmt1. Although the extents of stimulation were different, a stimulatory effect on the DNA methylation activity was observed for all of the substrate DNA sequences examined, such as those of the maternally methylated SNRPN and Lit-1 imprinting genes, the paternally methylated H19 imprinting gene, the CpG island of the myoD gene, the 5 S ribosomal RNA gene, an artificial 28-bp DNA, poly(dG-dC)- poly(dG-dC), and poly(dI-dC)- poly(dI-dC). DNMT3L could not bind to DNA but could bind to Dnmt3a and Dnmt3b, indicating that the stimulatory effect of DNMT3L on the DNA methylation activity may not be due to the guiding of Dnmt3a and Dnmt3b to the targeting DNA sequence but may comprise a direct effect on their catalytic activity. The carboxyl-terminal half of DNMT3L was found to be responsible for the enhancement of the enzyme activity.	Osaka Univ, Inst Prot Res, Div Physiol, Suita, Osaka 5650871, Japan	Osaka University	Tajima, S (corresponding author), Osaka Univ, Inst Prot Res, Div Physiol, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tajima@protein.osaka-u.ac.jp	Suetake, Isao/G-3144-2013; Suetake, Isao/D-4326-2009	Suetake, Isao/0000-0002-1246-8474; Takeshima, Hideyuki/0000-0002-8552-2427				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Hata K, 2002, DEVELOPMENT, V129, P1983; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Margot JB, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-7; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Riggs A.D., 1996, EPIGENETIC MECH GENE, P231; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi LH, 2001, J BIOCHEM, V130, P359, DOI 10.1093/oxfordjournals.jbchem.a002994; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; Tajima S, 1998, J BIOCHEM-TOKYO, V123, P993, DOI 10.1093/oxfordjournals.jbchem.a022066; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Watanabe D, 2002, MECH DEVELOP, V118, P187, DOI 10.1016/S0925-4773(02)00242-3; Yatsuki H, 2002, GENOME RES, V12, P1860, DOI 10.1101/gr.110702	34	320	336	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27816	27823		10.1074/jbc.M400181200	http://dx.doi.org/10.1074/jbc.M400181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105426	hybrid			2022-12-27	WOS:000222120400117
J	Brown, JM; Boysen, MS; Chung, S; Fabiyi, O; Morrison, RF; Mandrup, S; McIntosh, MK				Brown, JM; Boysen, MS; Chung, S; Fabiyi, O; Morrison, RF; Mandrup, S; McIntosh, MK			Conjugated linoleic acid induces human adipocyte delipidation - Autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KINASE-MEDIATED PHOSPHORYLATION; INDUCED INSULIN-RESISTANCE; ACTIVATED RECEPTOR-GAMMA; C-REACTIVE PROTEIN; HUMAN FAT-CELLS; FACTOR-ALPHA; GENE-EXPRESSION; TNF-ALPHA; INTERLEUKIN-6 IL-6	Dietary conjugated linoleic acid (CLA) reduces body fat in animals and some humans. Here we show that trans-10, cis-12 CLA, but not cis-9, trans-11 CLA, when added to cultures of stromal vascular cells containing newly differentiated human adipocytes, caused a time-dependent decrease in triglyceride content, insulin-stimulated glucose and fatty acid uptake, incorporation into lipid, and oxidation compared with controls. In parallel, gene expression of peroxisome proliferator-activated receptor-gamma and many of its downstream targets were diminished by trans-10, cis-12 CLA, whereas leptin gene expression was increased. Prior to changes in gene expression and metabolism, trans-10, cis-12 CLA caused a robust and sustained activation of mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) signaling. Furthermore, the trans-10, cis-12 CLA-mediated activation of MEK/ERK could be attenuated by pretreatment with U0126 and pertussis toxin. In parallel, pretreatment with U0126 blocked the ability of trans-10, cis-12 CLA to alter gene expression and attenuate glucose and fatty acid uptake of the cultures. Intriguingly, the induction by CLA of MEK/ERK signaling was linked to hypersecretion of adipocytokines interleukin-6 and interleukin-8. Collectively, these data demonstrate for the first time that trans-10, cis-12 CLA decreases the triglyceride content of newly differentiated human adipocytes by inducing MEK/ERK signaling through the autocrine/paracrine actions of interleukins-6 and 8.	Univ N Carolina, Dept Nutr, Greensboro, NC 27402 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	University of North Carolina; University of North Carolina Greensboro; University of Southern Denmark	McIntosh, MK (corresponding author), Univ N Carolina, Dept Nutr, 318 Stone Bldg, Greensboro, NC 27402 USA.	mkmcinto@uncg.edu	Mandrup, Susanne/B-6693-2008	Mandrup, Susanne/0000-0002-0961-5787; Chung, Soonkyu/0000-0001-6279-7017	NHLBI NIH HHS [R00 HL096166] Funding Source: Medline; NIDDK NIH HHS [R01DK-63070, R01 DK063070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL096166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Atta-ur-Rahman, 1999, CURR PHARM DESIGN, V5, P241; Belury MA, 2002, J NUTR, V132, P2995, DOI 10.1093/jn/131.10.2995; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200; Brown JM, 2001, J NUTR, V131, P2316, DOI 10.1093/jn/131.9.2316; Brown JM, 2003, J NUTR, V133, P3041, DOI 10.1093/jn/133.10.3041; Browning DD, 2000, AM J PHYSIOL-LUNG C, V279, pL1129, DOI 10.1152/ajplung.2000.279.6.L1129; Bruun JM, 2001, J CLIN ENDOCR METAB, V86, P1267, DOI 10.1210/jc.86.3.1267; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; COOK M, 1999, AD BIOL HORM SIGN S, pP26; Delany JP, 1999, AM J PHYSIOL-REG I, V276, pR1172, DOI 10.1152/ajpregu.1999.276.4.R1172; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Evans ME, 2002, J NUTR BIOCHEM, V13, P508, DOI 10.1016/S0955-2863(02)00211-5; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood-2002-08-2383; Lihn AS, 2003, AM J PHYSIOL-ENDOC M, V285, pE1072, DOI 10.1152/ajpendo.00206.2003; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Ostrowska E, 1999, J NUTR, V129, P2037, DOI 10.1093/jn/129.11.2037; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; Park Y, 1999, LIPIDS, V34, P243, DOI 10.1007/s11745-999-0359-7; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516; Riserus U, 2002, CIRCULATION, V106, P1925, DOI 10.1161/01.CIR.0000033589.15413.48; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ryden M, 2002, J BIOL CHEM, V277, P1085, DOI 10.1074/jbc.M109498200; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shimba S, 2001, J CELL SCI, V114, P2809; Souza SC, 2003, J CELL BIOCHEM, V89, P1077, DOI 10.1002/jcb.10565; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; WEINER FR, 1991, J BIOL CHEM, V266, P23525; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Werle M, 2002, CARDIOVASC RES, V56, P284, DOI 10.1016/S0008-6363(02)00600-4; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929	65	130	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26735	26747		10.1074/jbc.M401766200	http://dx.doi.org/10.1074/jbc.M401766200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067015	Green Accepted, hybrid			2022-12-27	WOS:000222003000100
J	Li, PF; Li, CR; Zhao, XH; Zhang, XH; Nicosia, SV; Bai, WL				Li, PF; Li, CR; Zhao, XH; Zhang, XH; Nicosia, SV; Bai, WL			P27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D-3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box Protein/Skp2 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D ANALOG; INHIBITOR P27; PROSTATE-CANCER; ANDROGEN RECEPTOR; GROWTH; D-3; APOPTOSIS; OVEREXPRESSION; ACCUMULATION; EXPRESSION	p27(Kip1) (p27) is a tumor suppressor whose stability is controlled by proteasome-mediated degradation, a process directed in part by cyclin-dependent kinase 2 (CDK2)-mediated phosphorylation of p27 at Thr(187) and its subsequent interaction with the Skp1-Cullin-F-box protein/Skp2 (Skp2) ubiquitin ligase. The present study shows that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) arrests ovarian cancer cells in G(1) by stabilizing the p27 protein. 1,25( OH) 2D3 initiates a chain of events by decreasing the amounts of cyclin E and cyclin E-associated CDK2 activity. As a result, p27 phosphorylation at Thr187 and consequently the interaction with Skp2 are decreased. 1,25( OH) 2D3 also increases p27 stability by decreasing the abundance of Skp2. It is the combined effect of 1,25(OH)(2)D-3 on both the CDK2-dependent phosphorylation of p27, and thus its affinity for Skp2, and Skp2 expression that dramatically increases the stability of the p27 protein. Similar to its effects in ovarian cancer cells, 1,25( OH) 2D3 induces p27 accumulation in wild type mouse embryo fibroblasts and arrests wild type but not p27-null mouse embryo fibroblasts in G(1). Stable expression of Skp2 in OVCAR3 cells diminishes the G(1) arrest and decreases the growth response to 1,25( OH) 2D3. Taken together, the results of this study identify p27 as the key mediator of 1,25(OH)(2)D-3-induced growth suppression in G(1) and show that the hormone achieves this by decreasing the activity of CDK2 and reducing the abundance of Skp2, which act together to degrade p27.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Ahonen MH, 2000, INT J CANCER, V86, P40, DOI 10.1002/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO;2-E; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHIDA K, 1985, CANCER RES, V45, P5426; Courjal F, 1996, INT J CANCER, V69, P247; DELUCA HF, 1990, METABOLISM, V39, P3, DOI 10.1016/0026-0495(90)90263-C; DEVASA SS, 1999, ATLAS CANC MORTALITY, P226; Diaz GD, 2000, CANCER RES, V60, P2304; DODD RC, 1983, P NATL ACAD SCI-BIOL, V80, P7538, DOI 10.1073/pnas.80.24.7538; DOKOH S, 1983, ENDOCRINOLOGY, V112, P200, DOI 10.1210/endo-112-1-200; EISMAN JA, 1989, P SOC EXP BIOL MED, V191, P221; EISMAN JA, 1987, CANCER RES, V47, P21; Feldman D, 1995, Adv Exp Med Biol, V375, P53; Guzey M, 2002, MOL CANCER THER, V1, P667; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Johnson JA, 1996, HISTOCHEM CELL BIOL, V105, P7, DOI 10.1007/BF01450873; Kim KK, 2003, PATHOL INT, V53, P291, DOI 10.1046/j.1440-1827.2003.01477.x; LEFKOWITZ ES, 1994, INT J EPIDEMIOL, V23, P1133, DOI 10.1093/ije/23.6.1133; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Liu W, 2002, BRAIN PATHOL, V12, P412; Masciullo V, 1999, CANCER RES, V59, P3790; Miettinen S, 2004, INT J CANCER, V108, P367, DOI 10.1002/ijc.11520; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; SATO T, 1982, TOHOKU J EXP MED, V138, P445, DOI 10.1620/tjem.138.445; SAUNDERS DE, 1992, GYNECOL ONCOL, V44, P131, DOI 10.1016/0090-8258(92)90028-H; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2000, CANCER RES, V60, P3689; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shigemasa K, 2001, INT J ONCOL, V18, P953; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Sung V, 2000, MOL CELL ENDOCRINOL, V164, P133, DOI 10.1016/S0303-7207(00)00226-4; Wade WN, 2002, J BIOL CHEM, V277, P37301, DOI 10.1074/jbc.M204162200; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; WATERHOUSE J, 1976, CANC INCIDENCE 5 CON, V2; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373	45	99	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25260	25267		10.1074/jbc.M311052200	http://dx.doi.org/10.1074/jbc.M311052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075339	hybrid			2022-12-27	WOS:000221827900044
J	Rim, JS; Xue, BZ; Gawronska-Kozak, B; Kozak, LP				Rim, JS; Xue, BZ; Gawronska-Kozak, B; Kozak, LP			Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; DIET-INDUCED OBESITY; RETINOID-X-RECEPTOR; PPAR-GAMMA; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; NUCLEAR-LOCALIZATION; BINDING PROTEIN	Transcription factors that regulate gene expression during adipogenesis also control the expression of genes of thermogenesis in brown adipose tissue, in particular, the mitochondrial uncoupling protein gene (Ucp1). There is evidence that a plasticity exists among adipocytes in which activation of the Ucp1 gene together with mitochondrial biogenesis can increase the brown adipocyte character of white fat. To understand this process, we have characterized the changes in transcription that occur in interscapular brown adipocytes during development. We have found dramatic reductions in both DNA-binding activity to probes and immunoreactive protein for peroxisome proliferator-activated receptor, retinoid X receptor, CCAAT/enhancer binding protein, and cAMP-response element-binding protein regulatory motifs in nuclear extracts when mice reach adulthood. Exposure of adult mice to the cold, which reactivates Ucp1 expression, leads to a re-accumulation of factors in the nucleus. We propose that transcription factors are sequestered in the cytoplasm as mice age under conditions of reduced thermogenesis. Changes in isoform subtypes for peroxisome proliferator-activated receptor-gamma and cAMP-response element-binding proteins indicate an additional level of control on gene expression during thermogenesis. The increased movement of the RIIbeta protein kinase A regulatory subunit into the nucleus with age suggests a mechanism for regulating the phosphorylation of transcription factors in the nucleus in response to the thermogenic requirements of the animal. Nuclear factor-kappaB has been used as a model to demonstrate that the nuclear localization of transcription factors in brown fat are reduced during post-natal development. Furthermore, it was found by immunofluorescence that adrenergic stimulation of primary adipocyte cultures causes an increase of both the protein kinase A catalytic alpha-subunit and nuclear factor-kappaB into the nucleus.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozaklp@pbrc.edu	Gawronska-Kozak, Barbara/A-2980-2017	Gawronska-Kozak, Barbara/0000-0002-2006-8534	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058152] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58152] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Coulter AA, 2003, PHYSIOL GENOMICS, V14, P139, DOI 10.1152/physiolgenomics.00057.2003; COUSIN B, 1992, J CELL SCI, V103, P931; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Fredriksson JM, 2001, BBA-MOL CELL RES, V1538, P206, DOI 10.1016/S0167-4889(01)00070-2; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRANNEMAN JG, 1990, J PHARMACOL EXP THER, V254, P508; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MILLER CA, 1991, CARCINOGENESIS, V12, P269, DOI 10.1093/carcin/12.2.269; NEDERGAARD J, 1986, BROWN ADIPOSE TISSUE, P153; Nicholls DG, 1986, BROWN ADIPOSE TISSUE, P1; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REHNMARK S, 1990, J BIOL CHEM, V265, P22204; Rim JS, 2002, J BIOL CHEM, V277, P34589, DOI 10.1074/jbc.M108866200; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; SIDMAN RL, 1956, ANAT REC, V124, P581, DOI 10.1002/ar.1091240306; SIDMAN RL, 1954, ANAT RECORD, V118, P487, DOI 10.1002/ar.1091180303; Silva JE, 2001, J CLIN INVEST, V108, P35, DOI 10.1172/JCI13397; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VANCUROVA I, 1995, J CELL SCI, V108, P779; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; Williams SC, 1997, GENE EXPRESSION, V6, P371; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yang LM, 1997, J IMMUNOL, V158, P2522; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	71	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25916	25926		10.1074/jbc.M402102200	http://dx.doi.org/10.1074/jbc.M402102200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073176	hybrid			2022-12-27	WOS:000221827900124
J	Mishra, S; Murphy, LJ				Mishra, S; Murphy, LJ			Tissue transglutaminase has intrinsic kinase activity - Identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; PHOSPHORYLATION; FIBRONECTIN; ACTIVATION; APOPTOSIS; DOMAIN; SITES; G(H); RHOA; GTP	Tissue transglutaminase (TG2) is a ubiquitous enzyme that cross-links glutamine residues with lysine residues, resulting in protein polymerization, cross-linking of dissimilar proteins, and incorporation of diamines and polyamines into proteins. It has not previously been known to have kinase activity. Recently, insulin-like growth factor-binding protein-3 (IGFBP-3) has been reported to be phosphorylated by breast cancer cell membranes. We purified the IGFBP-3 kinase activity from solubilized T47D breast cancer cell membranes using gel filtration, ion-exchange chromatography, and IGFBP-3 affinity chromatography. The fractions containing kinase activity were further purified by high pressure liquid chromatography and analyzed by tandem mass spectroscopy. TG2 was detected in fractions containing kinase activity. Antisera to TG2 and protein A-Sepharose were used to immunoprecipitate TG2 from membrane fractions. The immunoprecipitates retained IGFBP3 kinase, whereas immunoprecipitation deleted kinase activity in the membrane supernatant. The inhibitors of TG2, cystamine and monodansyl cadaverine, abolished the ability of the T47D cell membrane preparation to phosphorylate IGFBP-3. Both TG2 purified from guinea pig liver and recombinant human TG2 expressed in insect cells were able to phosphorylate IGFBP-3. TG2 kinase activity was inhibited in a concentration-dependent fashion by calcium, which has previously been shown to be important for the cross-linking activity of TG2. These data provide compelling evidence that TG2 has intrinsic kinase activity, a function that has not previously been ascribed to TG2. Furthermore, we provide evidence that TG2 is a major component of the IGFBP-3 kinase activity present on breast cancer cell membranes.	Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Murphy, LJ (corresponding author), Univ Manitoba, John Buhler Res Ctr, Rm 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	ljmurph@cc.umanitoba.ca	Mishra, Suresh/W-1633-2019	Mishra, Suresh/0000-0002-0364-1538				Akimov SS, 2001, J CELL SCI, V114, P2989; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GRIFFIN M, 2000, TISSUE TRANSGLUTAMIN, P223; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; HOECK WG, 1994, J CELL BIOCHEM, V56, P262, DOI 10.1002/jcb.240560220; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; KOCHHAR DM, 1993, PROG CLIN BIOL RES, V383, P815; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; Longobardi L, 2003, ENDOCRINOLOGY, V144, P1695, DOI 10.1210/en.2002-220959; Mishra S, 2003, ENDOCRINOLOGY, V144, P4042, DOI 10.1210/en.2003-0089; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, PROG GROWTH FACTOR R, V6, P205; Sakai K, 2001, J BIOL CHEM, V276, P8740, DOI 10.1074/jbc.M008359200; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Thomazy VA, 1999, CELL DEATH DIFFER, V6, P146, DOI 10.1038/sj.cdd.4400464; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Yamanaka Y, 1999, ENDOCRINOLOGY, V140, P1319, DOI 10.1210/en.140.3.1319	26	157	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23863	23868		10.1074/jbc.M311919200	http://dx.doi.org/10.1074/jbc.M311919200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069073	hybrid			2022-12-27	WOS:000221702500005
J	Belouzard, S; Delcroix, D; Rouille, Y				Belouzard, S; Delcroix, D; Rouille, Y			Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; LONG; TRAFFICKING; ACTIVATION; GENERATION; INTERNALIZATION; LOCALIZATION; PROTEINS; CLEAVAGE; ISOFORMS	The leptin receptor is mainly localized in intracellular compartments in target tissues. To study the mechanisms leading to this intracellular localization, two main isoforms of leptin receptors, OB-Ra and OB-Rb, were expressed in HeLa cells. Both isoforms were localized at steady state in the trans-Golgi network, in endosomes, and to a lesser extent, at the cell surface. They turned over with a half-life of less than 2 h. Both isoforms of leptin receptors were constitutively endocytosed in a ligand-independent manner and degraded in lysosomes with no evidence of recycling to the cell surface or to the trans-Golgi network. The endocytosis was inhibited by the deletion of the cytoplasmic domain. Newly synthesized leptin receptors were partially retained in the Golgi complex or in a post-Golgi intracellular compartment. The transmembrane domain was found to be important for this intracellular retention in the biosynthetic pathway, whereas the cytoplasmic domain was not involved. The data suggest that the low levels of expression of leptin receptors at the cell surface results from partial retention in the biosynthetic pathway, coupled to constitutive removal from the plasma membrane via ligand-independent, constitutive endocytosis.	Inst Biol Lille, CNRS, Unite Propre Rech 2511, F-59021 Lille, France; Inst Biol Lille, CNRS, Equipe Postulante 525, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Rouille, Y (corresponding author), Inst Biol Lille, CNRS, Unite Propre Rech 2511, F-59021 Lille, France.	yves.rouille@ibl.fr	Belouzard, Sandrine/AAX-1584-2021; Rouillé, Yves/P-2405-2016; Belouzard, Sandrine/O-8527-2016	Belouzard, Sandrine/0000-0002-9972-4054; Belouzard, Sandrine/0000-0002-9972-4054; Rouille, Yves/0000-0003-0788-9271				Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353, DOI 10.1177/002215549904700309; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; De Matteis R, 1998, NEUROENDOCRINOLOGY, V68, P412, DOI 10.1159/000054391; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Diano S, 1998, J NEUROENDOCRINOL, V10, P647, DOI 10.1046/j.1365-2826.1998.00261.x; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fayadat L, 2003, MOL BIOL CELL, V14, P1268, DOI 10.1091/mbc.E02-06-0363; Fourgeaud L, 2003, J BIOL CHEM, V278, P12222, DOI 10.1074/jbc.M205663200; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lundin A, 2000, BBA-MOL CELL RES, V1499, P130, DOI 10.1016/S0167-4889(00)00114-2; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Uotani S, 1999, DIABETES, V48, P279, DOI 10.2337/diabetes.48.2.279; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Kerkhof P, 2003, MOL CELL ENDOCRINOL, V201, P57, DOI 10.1016/S0303-7207(02)00434-3; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28499	28508		10.1074/jbc.M400508200	http://dx.doi.org/10.1074/jbc.M400508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123629	hybrid			2022-12-27	WOS:000222265400085
J	Brewer, BY; Malicka, J; Blackshear, PJ; Wilson, GM				Brewer, BY; Malicka, J; Blackshear, PJ; Wilson, GM			RNA sequence elements required for high affinity binding by the zinc finger domain of tristetraprolin - Conformational changes coupled to the bipartite nature of AU-rich mRNA-destabilizing motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA; FLUORESCENCE ANISOTROPY; STABILITY; ALPHA; THERMODYNAMICS; DISTINCT; HUR	Tristetraprolin (TTP) binds AU-rich elements (AREs) encoded within selected labile mRNAs and targets these transcripts for rapid cytoplasmic decay. RNA binding by TTP is mediated by an similar to70-amino acid domain containing two tandemly arrayed CCCH zinc fingers. Here we show that a 73-amino acid peptide spanning the TTP zinc finger domain, denoted TTP73, forms a dynamic, equimolar RNA . peptide complex with a 13-nucleotide fragment of the ARE from tumor necrosis factor alpha mRNA, which includes small but significant contributions from ionic interactions. Association of TTP73 with high affinity RNA substrates is accompanied by a large negative change in heat capacity without substantial modification of RNA structure, consistent with conformational changes in the peptide moiety during RNA binding. Analyses using mutant ARE substrates indicate that two adenylate residues located 3 - 6 bases apart within a uridylate-rich sequence are sufficient for high affinity recognition by TTP73 (K-d < 20 nM), with optimal affinity observed for RNA substrates containing AUUUA or AUUUUA. Linkage of conformational changes and binding affinity to the presence and spacing of these adenylate residues provides a thermodynamic basis for the RNA substrate specificity of TTP.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; NIEHS, Lab Signal Transduct, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, GM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, 108 N Greene St, Baltimore, MD 21201 USA.	gwils001@umaryland.edu	Wilson, Gerald/AAF-3874-2019; Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA 10242 8] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090080] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Bergqvist S, 2004, J MOL BIOL, V336, P829, DOI 10.1016/j.jmb.2003.12.061; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; Gryczynski Ignacy, 1997, J Fluoresc, V7, P167, DOI 10.1007/bf02758217; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hall KB, 1995, METHOD ENZYMOL, V259, P261; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Katsamba PS, 2001, J BIOL CHEM, V276, P21476, DOI 10.1074/jbc.M101624200; Klostermeier D, 2001, METHODS, V23, P240, DOI 10.1006/meth.2000.1135; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Michel SLJ, 2003, BIOCHEMISTRY-US, V42, P4626, DOI 10.1021/bi034073h; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200	43	115	117	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27870	27877		10.1074/jbc.M402551200	http://dx.doi.org/10.1074/jbc.M402551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117938	hybrid			2022-12-27	WOS:000222265400008
J	Kassenbrock, CK; Anderson, SM				Kassenbrock, CK; Anderson, SM			Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; V-CBL; PROTOONCOGENE; RING; DOMAIN; ONCOGENE; COMPLEX	c-Cbl down-regulates receptor tyrosine kinases by conjugating ubiquitin to them, leading to receptor internalization and degradation. The ubiquitin protein ligase activity of c-Cbl ( abbreviated as E3 activity) is mediated by its RING finger domain. We show here that the E3 activity of c-Cbl is negatively regulated by other domains present in the amino-terminal half of the protein ( the TKB and linker helix domains) and that this negative regulation is removed when the protein is phosphorylated on tyrosine residues. Protease digestion studies indicate that tyrosine phosphorylation alters the conformation of c-Cbl. We also show that mutation of certain conserved tyrosine residues to glutamate can constitutively activate the E3 activity of c-Cbl. In particular, a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor ( EGFR). The Y371E mutant also has altered protease sensitivity from wild type, instead resembling the proteolytic pattern seen with tyrosine-phosphorylated c-Cbl. Mutation of the homologous tyrosine residue in Cbl-b to glutamate also leads to E3 activation while retaining EGFR-binding ability. These studies argue that Tyr-371 plays a key role in activating the E3 activity of c-Cbl and that the Y371E mutant may partially mimic phosphorylation at that site. However, Tyr-371 point mutants of c-Cbl are still able to undergo phosphorylation-induced E3 activation, and we show that Tyr-368 can also be phosphorylated in addition to Tyr-371, and contributes to activation.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Box B-216,4200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055754] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53858] Funding Source: Medline; NIGMS NIH HHS [GM 55754] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bisson SA, 2002, ONCOGENE, V21, P3677, DOI 10.1038/sj.onc.1205510; BLAKE TJ, 1991, ONCOGENE, V6, P653; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tongaonkar P, 1998, ANAL BIOCHEM, V260, P135, DOI 10.1006/abio.1998.2697; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	29	106	106	5	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28017	28027		10.1074/jbc.M404114200	http://dx.doi.org/10.1074/jbc.M404114200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117950	hybrid			2022-12-27	WOS:000222265400025
J	Bourguignon, LYW; Singleton, PA; Diedrich, F; Stern, R; Gilad, E				Bourguignon, LYW; Singleton, PA; Diedrich, F; Stern, R; Gilad, E			CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ANKYRIN-BINDING DOMAIN; INTRACELLULAR PH; TRANSMEMBRANE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CHROMOSOME 3P21.3; GENE-EXPRESSION; HYALURONAN; CANCER; RECEPTOR	We have explored CD44 (a hyaluronan (HA) receptor) interaction with a Na+-H+ exchanger (NHE1) and hyaluronidase-2 (Hyal-2) during HA-induced cellular signaling in human breast tumor cells (MDA-MB-231 cell line). Immunological analyses demonstrate that CD44s (standard form) and two signaling molecules (NHE1 and Hyal-2) are closely associated in a complex in MDA-MB-231 cells. These three proteins are also significantly enriched in cholesterol and ganglioside-containing lipid rafts, characterized as caveolin and flotillin-rich plasma membrane microdomains. The binding of HA to CD44 activates Na+-H+ exchange activity which, in turn, promotes intracellular acidification and creates an acidic extracellular matrix environment. This leads to Hyal-2-mediated HA catabolism, HA modification, and cysteine proteinase (cathepsin B) activation resulting in breast tumor cell invasion. In addition, we have observed the following: (i) HA/CD44-activated Rho kinase (ROK) mediates NHE1 phosphorylation and activity, and (ii) inhibition of ROK or NHE1 activity (by treating cells with a ROK inhibitor, Y27632, or NHE1 blocker, S-(N-ethyl-N- isopropyl) amiloride, respectively) blocks NHE1 phosphorylation/Na+-H+ exchange activity, reduces intracellular acidification, eliminates the acidic environment in the extracellular matrix, and suppresses breast tumor-specific behaviors (e.g. Hyal-2-mediated HA modification, cathepsin B activation, and tumor cell invasion). Finally, down-regulation of CD44 or Hyal-2 expression (by treating cells with CD44 or Hyal-2-specific small interfering RNAs) not only inhibits HA-mediated CD44 signaling (e.g. ROK-mediated Na+-H+ exchanger reaction and cellular pH changes) but also impairs oncogenic events (e.g. Hyal-2 activity, hyaluronan modification, cathepsin B activation, and tumor cell invasion). Taken together, our results suggest that CD44 interaction with a ROK-activated NHE1 (a Na+-H+ exchanger) in cholesterol/ganglioside-containing lipid rafts plays a pivotal role in promoting intracellular/extracellular acidification required for Hyal-2 and cysteine proteinase-mediated matrix degradation and breast cancer progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78633, R01 CA66163] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Beech DJ, 2002, J SURG RES, V103, P203, DOI 10.1006/jsre.2002.6351; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BOYER MJ, 1992, CANCER RES, V52, P4441; Bullis BL, 2002, EUR J BIOCHEM, V269, P4887, DOI 10.1046/j.1432-1033.2002.03202.x; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DANILKOVITCHMIA.A, P NATL ACAD SCI US, V100, P4580; DEFIGUEIREDO CEP, 1991, AM J PHYSIOL, V261, pC1138, DOI 10.1152/ajpcell.1991.261.6.C1138; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Diwu ZJ, 1999, CHEM BIOL, V6, P411, DOI 10.1016/S1074-5521(99)80059-3; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Ge LS, 1995, J NEURO-ONCOL, V26, P251, DOI 10.1007/BF01052628; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GOTTESMAN MM, 1990, SEMIN CANCER BIOL, V1, P127; GUNTHERT U, 1999, J CELL BIOL, V146, P843; HOPKINS DM, 1992, J PATHOL, V166, P317, DOI 10.1002/path.1711660316; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; Ilangumaran S, 1998, BLOOD, V91, P3901; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; KALISH ED, 1999, FRONT BIOSCI, V4, P1; KALLINOWSKI F, 1988, CANCER RES, V48, P7264; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Kasahara K, 2000, GLYCOCONJUGATE J, V17, P153, DOI 10.1023/A:1026576804247; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lerman MI, 2000, CANCER RES, V60, P6116; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; LIAO HX, 1995, J IMMUNOL, V155, P3938; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LIOTTA LA, 1993, CANC PRINCIPLES PRAC, P134; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MARTIN GR, 1994, CANCER RES, V54, P5670; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Nicoll SB, 2002, BIOCHEM BIOPH RES CO, V292, P819, DOI 10.1006/bbrc.2002.6697; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Novak U, 1999, CANCER RES, V59, P6246; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Scott JE, 2002, BIOMACROMOLECULES, V3, P547, DOI 10.1021/bm010170j; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Strobl B, 1998, GENOMICS, V53, P214, DOI 10.1006/geno.1998.5472; STUBBS M, 1995, ADV ENZYME REGUL, V35, P101, DOI 10.1016/0065-2571(94)00016-V; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; VanNoorden CJF, 1997, ANAL BIOCHEM, V252, P71, DOI 10.1006/abio.1997.2312; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	103	340	349	3	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26991	27007		10.1074/jbc.M311838200	http://dx.doi.org/10.1074/jbc.M311838200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090545	hybrid			2022-12-27	WOS:000222120400025
J	Cismasiu, VB; Denes, SA; Reilander, H; Michel, H; Szedlacsek, SE				Cismasiu, VB; Denes, SA; Reilander, H; Michel, H; Szedlacsek, SE			The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-MU; IN-VIVO; RPTP-MU; INTERMOLECULAR INTERACTIONS; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; CELL-SURFACE; EXPRESSION; IDENTIFICATION; ADHESION	The MAM (meprin/A5-protein/PTPmu) domain is present in numerous proteins with diverse functions. PTPmu belongs to the MAM-containing subclass of protein-tyrosine phosphatases (PTP) able to promote cell-to-cell adhesion. Here we provide experimental evidence that the MAM domain is a homophilic binding site of PTPmu. We demonstrate that the MAM domain forms oligomers in solution and binds to the PTPmu ectodomain at the cell surface. The presence of two disulfide bridges in the MAM molecule was evidenced and their integrity was found to be essential for MAM homophilic interaction. Our data also indicate that PTPmu ectodomain forms oligomers and mediates the cellular adhesion, even in the absence of MAM domain homophilic binding. Reciprocally, MAM is able to interact homophilically in the absence of ectodomain trans binding. The MAM domain therefore contains independent cis and trans interaction sites and we predict that its main role is to promote lateral dimerization of PTPmu at the cell surface. This finding contributes to the understanding of the signal transduction mechanism in MAM-containing PTPs.	Inst Biochem, Dept Enzymol, Bucharest 060031, Romania; Max Planck Inst Biophys, Dept Membrane Biol, D-60528 Frankfurt, Germany	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; Max Planck Society	Szedlacsek, SE (corresponding author), Inst Biochem, Dept Enzymol, Spl Independentei 296, Bucharest 060031, Romania.	szedlacsek@biochim.ro	Szedlacsek, Stefan Eugen/F-1830-2010; Cismasiu, Valeriu Bogdan/F-1512-2011	Szedlacsek, Stefan Eugen/0000-0002-3416-5036; 				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aricescu AR, 2001, BIOCHEM BIOPH RES CO, V280, P319, DOI 10.1006/bbrc.2000.4094; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Bianchi C, 1999, EXP CELL RES, V248, P329, DOI 10.1006/excr.1999.4428; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; Brandenberger R, 2001, J CELL BIOL, V154, P447, DOI 10.1083/jcb.200103069; Buchner G, 2000, GENOMICS, V65, P16, DOI 10.1006/geno.2000.6146; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Fuchs M, 1998, MECH DEVELOP, V70, P91, DOI 10.1016/S0925-4773(97)00179-2; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Lenhard T, 1996, GENE, V169, P187, DOI 10.1016/0378-1119(95)00831-4; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Rosdahl JA, 2003, J NEUROBIOL, V56, P199, DOI 10.1002/neu.10231; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; SAP J, 1994, MOL CELL BIOL, V14, P1; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	45	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26922	26931		10.1074/jbc.M313115200	http://dx.doi.org/10.1074/jbc.M313115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084579	hybrid			2022-12-27	WOS:000222120400017
J	Gandlur, SM; Wei, L; Levine, J; Russell, J; Kaur, P				Gandlur, SM; Wei, L; Levine, J; Russell, J; Kaur, P			Membrane topology of the DrrB protein of the doxorubicin transporter of Streptomyces peucetius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABC TRANSPORTERS; P-GLYCOPROTEIN; LACZ FUSIONS; GENE; RESISTANCE; IDENTIFICATION; EXPRESSION; COMPONENT; BACTERIA	Daunorubicin and doxorubicin, two commonly used anticancer agents, are produced by the soil bacterium Streptomyces peucetius. Self-resistance to these antibiotics in S. peucetius is conferred by the drrAB locus that codes for two proteins, DrrA and DrrB. DrrA is an ATP-binding protein. It belongs to the ABC family of transporters and shares sequence and functional similarities with P-glycoprotein of cancer cells. DrrB is an integral membrane protein that might function as a transporter for the efflux of daunorubicin and doxorubicin. Together, DrrA and DrrB are believed to form an ATP-driven pump for the efflux of these drugs. The drrAB locus has been cloned, and the two proteins have been expressed in a functional form in Escherichia coli. A topological analysis of the DrrB protein was performed using gene fusion methodology. Random and site-directed fusions of the drrB gene to lacZ, phoA, or gfp reporter genes were created. Based on the fusion data, a topological model of the DrrB protein is proposed in which the protein has eight membrane-spanning domains with both the N terminus and the C terminus in the cytoplasm.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.	pkaur@gsu.edu						BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; DiGiuseppe PA, 2004, ASM NEWS, V70, P71; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FROSCH M, 1991, MOL MICROBIOL, V5, P1251, DOI 10.1111/j.1365-2958.1991.tb01899.x; Fulkerson JF, 2000, J BACTERIOL, V182, P1722, DOI 10.1128/JB.182.6.1722-1730.2000; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; Gileadi U, 1997, J BIOL CHEM, V272, P11103; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; Kaur P, 1998, J BIOL CHEM, V273, P17933, DOI 10.1074/jbc.273.28.17933; KROLL JS, 1990, J BACTERIOL, V172, P1374, DOI 10.1128/jb.172.3.1374-1379.1990; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MARULLO S, 1988, P NATL ACAD SCI USA, V85, P7551, DOI 10.1073/pnas.85.20.7551; MILLER RL, 1972, ANAL BIOCHEM, V45, P202, DOI 10.1016/0003-2697(72)90020-6; Olano C, 1996, FEMS MICROBIOL LETT, V143, P133; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PEARCE SR, 1992, MOL MICROBIOL, V6, P47, DOI 10.1111/j.1365-2958.1992.tb00836.x; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SMITH AN, 1990, MOL MICROBIOL, V4, P1863, DOI 10.1111/j.1365-2958.1990.tb02035.x; SNYDER WB, 1995, J BACTERIOL, V177, P953, DOI 10.1128/jb.177.4.953-963.1995; SOLOMON KA, 1989, J BACTERIOL, V171, P3039, DOI 10.1128/jb.171.6.3039-3045.1989; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	33	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27799	27806		10.1074/jbc.M402898200	http://dx.doi.org/10.1074/jbc.M402898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090538	hybrid			2022-12-27	WOS:000222120400115
J	Li, Z; Chan, C				Li, Z; Chan, C			Integrating gene expression and metabolic profiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REGRESSION; FATTY-ACID SYNTHASE; CULTURED-HEPATOCYTES; FLUX ANALYSIS; PLASMA; PROMOTER; ENZYMES; INSULIN; CYCLE; UREA	Recent advances in high throughput technologies have generated an abundance of biological information, such as gene expression, protein-protein interaction, and metabolic data. These various types of data capture different aspects of the cellular response to environmental factors. Integrating data from different measurements enhances the ability of modeling frameworks to predict cellular function more accurately and can lead to a more coherent reconstruction of the underlying regulatory network structure. Different techniques, newly developed and borrowed, have been applied for the purpose of extracting this information from experimental data. In this study, we developed a framework to integrate metabolic and gene expression profiles for a hepatocellular system. Specifically, we applied genetic algorithm and partial least square analysis to identify important genes relevant to a specific cellular function. We identified genes 1) whose expression levels quantitatively predict a metabolic function and 2) that play a part in regulating a hepatocellular function and reconstructed their role in the metabolic network. The framework 1) preprocesses the gene expression data using statistical techniques, 2) selects genes using a genetic algorithm and couples them to a partial least squares analysis to predict cellular function, and 3) reconstructs, with the assistance of a literature search, the pathways that regulate cellular function, namely intracellular triglyceride and urea synthesis. This provides a framework for identifying cellular pathways that are active as a function of the environment and in turn helps to uncover the interplay between gene and metabolic networks.	Michigan State Univ, Dept Clin Engn & Mat Sci, E Lansing, MI 48824 USA	Michigan State University	Chan, C (corresponding author), Michigan State Univ, Dept Clin Engn & Mat Sci, 1257 EB, E Lansing, MI 48824 USA.	krischan@egr.msu.edu						Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Bangalore AS, 1996, ANAL CHEM, V68, P4200, DOI 10.1021/ac9607121; Chan C, 2003, BIOTECHNOL BIOENG, V81, P33, DOI 10.1002/bit.10453; Chan C, 2003, METAB ENG, V5, P1, DOI 10.1016/S1096-7176(02)00011-3; Chan C, 2003, BIOTECHNOL PROGR, V19, P580, DOI 10.1021/bp025660h; Chan C, 2002, BIOTECHNOL BIOENG, V78, P753, DOI 10.1002/bit.10275; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; GELADI P, 1986, ANAL CHIM ACTA, V185, P1, DOI 10.1016/0003-2670(86)80028-9; Goldberg D.E., 1989, GENETIC ALGORITHMS S; Holland J.H., 1975, ADAPTATION NATURAL A, DOI DOI 10.7551/MITPRESS/1090.001.0001; HOUCK C, 1995, 9509 N CAR STAT U; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; IZPISUA JC, 1989, INT J OBESITY, V13, P531; Leardi R, 2000, J CHEMOMETR, V14, P643, DOI 10.1002/1099-128X(200009/12)14:5/6<643::AID-CEM621>3.0.CO;2-E; Li Z, 2004, FASEB J, V18, P746, DOI 10.1096/fj.03-0475fje; LI Z, 2004, IN PRESS TRENDS BIOT; Liang S, 1998, Pac Symp Biocomput, P18; Loew LM, 2001, TRENDS BIOTECHNOL, V19, P401, DOI 10.1016/S0167-7799(01)01740-1; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MARTINREQUERO A, 1992, AM J PHYSIOL, V263, pE493, DOI 10.1152/ajpendo.1992.263.3.E493; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Nakao, 1999, Genome Inform Ser Workshop Genome Inform, V10, P94; Roder K, 1999, EUR J BIOCHEM, V260, P743, DOI 10.1046/j.1432-1327.1999.00216.x; Smith SA, 2002, BIOCHEM SOC T, V30, P1086, DOI 10.1042/BST0301086; van Helden J, 2000, BIOL CHEM, V381, P921; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x	29	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27124	27137		10.1074/jbc.M403494200	http://dx.doi.org/10.1074/jbc.M403494200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107427	hybrid			2022-12-27	WOS:000222120400039
J	Rudberg, PC; Tholander, F; Andberg, M; Thunnissen, MMGM; Haeggstrom, JZ				Rudberg, PC; Tholander, F; Andberg, M; Thunnissen, MMGM; Haeggstrom, JZ			Leukotriene A(4) hydrolase - Identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(4) HYDROLASE; B-4 RECEPTOR; BIFUNCTIONAL ENZYME; ALLOWS CONVERSION; CRYSTAL-STRUCTURE; ARGINYL RESIDUES; BINDING; MUTATION; ACID; 5-LIPOXYGENASE	Leukotriene ( LT) A(4) hydrolase is a bifunctional zinc metalloenzyme, which converts LTA(4) into the neutrophil chemoattractant LTB4 and also exhibits an anion-dependent aminopeptidase activity. In the x-ray crystal structure of LTA(4) hydrolase, Arg(563) and Lys(565) are found at the entrance of the active center. Here we report that replacement of Arg(563), but not Lys(565), leads to complete abrogation of the epoxide hydrolase activity. However, mutations of Arg(563) do not seem to affect substrate binding strength, because values of K-i for LTA(4) are almost identical for wild type and ( R563K) LTA(4) hydrolase. These results are supported by the 2.3-Angstrom crystal structure of (R563A) LTA(4) hydrolase, which does not reveal structural changes that can explain the complete loss of enzyme function. For the aminopeptidase reaction, mutations of Arg(563) reduce the catalytic activity (V-max = 0.3 - 20%), whereas mutations of Lys(565) have limited effect on catalysis (V-max = 58 - 108%). However, in (K565A)- and (K565M) LTA(4) hydrolase, i.e. mutants lacking a positive charge, values of the Michaelis constant for alanine-p-nitroanilide increase significantly (K-m = 480 - 640%). Together, our data indicate that Arg(563) plays an unexpected, critical role in the epoxide hydrolase reaction, presumably in the positioning of the carboxylate tail to ensure perfect substrate alignment along the catalytic elements of the active site. In the aminopeptidase reaction, Arg(563) and Lys(565) seem to cooperate to provide sufficient binding strength and productive alignment of the substrate. In conclusion, Arg(563) and Lys(565) possess distinct roles as carboxylate recognition sites for two chemically different substrates, each of which is turned over in separate enzymatic reactions catalyzed by LTA(4) hydrolase.	Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden; Lund Univ, Dept Mol Biophys, Kemicentrum, S-22100 Lund, Sweden	Karolinska Institutet; Lund University	Haeggstrom, JZ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden.	jesper.haeggstrom@mbb.ki.se	Thunnissen, Marjolein MGM/B-9366-2011	Blomster Andberg, Martina/0000-0002-8021-9947				Andberg MB, 1997, J BIOL CHEM, V272, P23057, DOI 10.1074/jbc.272.37.23057; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailie MB, 1996, J IMMUNOL, V157, P5221; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P992; Baset HA, 1998, J BIOL CHEM, V273, P27978, DOI 10.1074/jbc.273.43.27978; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byrum RS, 1999, J IMMUNOL, V163, P6810; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; FORDHUTCHINSON AW, 1981, PROSTAGLANDINS, V21, P143, DOI 10.1016/0090-6980(81)90204-5; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hogg JH, 1998, CHEM-EUR J, V4, P1698, DOI 10.1002/(SICI)1521-3765(19980904)4:9<1698::AID-CHEM1698>3.3.CO;2-A; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull F, 1999, J BIOL CHEM, V274, P34683, DOI 10.1074/jbc.274.49.34683; Kull F, 2001, BIOCHEMISTRY-US, V40, P12695, DOI 10.1021/bi011348p; LEBLANC Y, 1987, PROSTAGLANDINS, V33, P617, DOI 10.1016/0090-6980(87)90029-3; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; MAYCOCK AL, 1982, J BIOL CHEM, V257, P3911; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; Mueller MJ, 1996, J BIOL CHEM, V271, P24345, DOI 10.1074/jbc.271.40.24345; MUELLER MJ, 1995, BIOCHEMISTRY-US, V34, P3536, DOI 10.1021/bi00011a007; OLLMANN IR, 1995, BIOORGAN MED CHEM, V3, P969, DOI 10.1016/0968-0896(95)00078-U; ORNING L, 1994, J BIOL CHEM, V269, P11269; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; Rudberg PC, 2002, P NATL ACAD SCI USA, V99, P4215, DOI 10.1073/pnas.072090099; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P1, DOI 10.1016/0003-9861(83)90380-6; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Thunnissen MMGM, 2002, FASEB J, V16, P1648, DOI 10.1096/fj.01-1017fje; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETTERHOLM A, 1995, J PHARMACOL EXP THER, V275, P31; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Witt S, 2000, BIOCHEM J, V347, P553, DOI 10.1042/0264-6021:3470553; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200	61	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27376	27382		10.1074/jbc.M401031200	http://dx.doi.org/10.1074/jbc.M401031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078870	hybrid			2022-12-27	WOS:000222120400068
J	Brar, SS; Watson, M; Diaz, M				Brar, SS; Watson, M; Diaz, M			Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-SWITCH RECOMBINATION; DOUBLE-STRAND BREAKS; IMMUNOGLOBULIN VARIABLE GENES; B MESSENGER-RNA; SOMATIC HYPERMUTATION; POLYMERASE-ETA; ANTIBODY DIVERSIFICATION; CYTIDINE; REPAIR; MICE	Activation-induced cytosine deaminase (AID) is a cytosine deaminase that is critical to immunoglobulin hypermutation, class switch recombination, and gene conversion. In the context of hypermutating B cells, AID deaminates cytosine in the DNA of immunoglobulin genes, leading to the accumulation of mutations in the variable regions. However, when AID is expressed ectopically, it is a generalized mutator of G: C base pairs. Therefore, we asked whether AID may be partially regulated by an active system of nuclear export. We found that removal of a highly conserved nuclear export signal in the C terminus of AID causes accumulation of AID in the nucleus. However, a putative nuclear localization signal in the N terminus does not appear to be functional. Finally, we found that agents that induce DNA breaks caused retention of AID in the nucleus, suggesting that DNA breaks or the repair patches initiated as a result are a substrate for AID binding.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Diaz, M (corresponding author), NIEHS, Genet Mol Lab, NIH, 111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	diaz@niehs.nih.gov		Diaz, Marilyn/0000-0002-3046-2746	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101603, ZIAES101603] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Barreto V, 2003, MOL CELL, V12, P501, DOI 10.1016/S1097-2765(03)00309-5; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bross L, 2002, J EXP MED, V195, P1187, DOI 10.1084/jem.20011749; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Bross Linda, 2003, Clin Dev Immunol, V10, P83, DOI 10.1080/10446670310001626571; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; CLARKE SH, 1985, J EXP MED, V161, P687, DOI 10.1084/jem.161.4.687; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fugmann SD, 2003, NAT IMMUNOL, V4, P429, DOI 10.1038/ni0503-429; Gabelova A, 1997, NEOPLASMA, V44, P380; Hardianti MS, 2004, LEUKEMIA, V18, P826, DOI 10.1038/sj.leu.2403323; Honjo T, 2002, NAT IMMUNOL, V3, P800, DOI 10.1038/ni0902-800; HONJO T, 2000, CELL, V102, P565; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Kong QZ, 2001, GENETICS, V158, P369; Larson ED, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-211; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Martin A, 2003, J EXP MED, V198, P1171, DOI 10.1084/jem.20030880; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Miller R. G., 1981, SIMULTANEOUS STAT IN, P6; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Nazarov OB, 2003, RADIAT RES, V160, P309, DOI 10.1667/RR3043; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papavasiliou FN, 2002, J EXP MED, V195, P1193, DOI 10.1084/jem.20011858; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2004, J IMMUNOL, V172, P3382, DOI 10.4049/jimmunol.172.6.3382; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Tomilin NV, 2001, RADIAT RES, V156, P347, DOI 10.1667/0033-7587(2001)156[0347:VOFNSO]2.0.CO;2; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Whisnant-Hurst N, 1999, RADIAT RES, V151, P257, DOI 10.2307/3579936; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2004, J BIOL CHEM, V279, P6496, DOI 10.1074/jbc.M311616200; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zan H, 2003, IMMUNITY, V18, P727, DOI 10.1016/S1074-7613(03)00151-1; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	60	114	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26395	26401		10.1074/jbc.M403503200	http://dx.doi.org/10.1074/jbc.M403503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087440	hybrid			2022-12-27	WOS:000222003000060
J	Broustas, CG; Gokhale, PC; Rahman, A; Dritschilo, A; Ahmad, I; Kasid, U				Broustas, CG; Gokhale, PC; Rahman, A; Dritschilo, A; Ahmad, I; Kasid, U			BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; BH3-ONLY PROTEINS; CYTOCHROME-C; CELL-DEATH; MITOCHONDRIA; DOXORUBICIN; COMPLEX; BINDING; CANCER; IDENTIFICATION	We report here the structure-functional characterization of a novel intronless gene, BRCC2, located on human chromosome 11q24.1. BRCC2 open reading frame (327 bp) codes for an similar to12-kDa protein (108 amino acids (aa)) localized predominantly in the cytosol and to a lesser extent in the mitochondria. Ectopic expression of BRCC2 cDNA also was found in both the cytosol and mitochondria. Exogenous expression of BRCC2 caused apoptotic cell death in three different cell lines as evidenced by enhanced chromatin condensation, DNA fragmentation, or an enhanced number of cells in the sub-G(1) phase. In human prostate cancer cells (PC-3), BRCC2-induced DNA fragmentation was blocked efficiently by coexpression of the anti-apoptotic molecule, Bcl-X-L. Transient transfection of BRCC2 cDNA into PC-3 cells in the presence of a broad-range caspase inhibitor, Z-VAD-fmk (100 muM, 24 h), abrogated DNA fragmentation. Consistently, BRCC2 expression correlated with the activation of caspase-3 and caspase-9. An N-terminal deletion mutant of BRCC2 (10.2 kDa, Delta1-16 aa) lacking a BH3-like domain (5 - 12 aa, LPIEGQEI) or BRCC2 containing a mutant BH3-like domain ( leucine 5 -->glutamate) failed to induce apoptosis, whereas a C-terminal deletion mutant (6.8 kDa, Delta62-108 aa) retained the apoptotic activity comparable to the full-length BRCC2. Finally, the treatment of HeLa cells with doxorubicin or hydrogen peroxide (H2O2) led to an increase in the mitochondrial ( heavy membrane) level of endogenous BRCC2 ( doxorubicin ( 100 ng/ml), 5 h, similar to2-fold; H2O2 (200 muM), 2 h, similar to2-fold). These findings demonstrate that BRCC2 functions as a proapoptotic molecule and suggest that BRCC2 induces a caspase-dependent mitochondrial pathway of cell death.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, Washington, DC 20057 USA; NeoPharm Inc, Lake Forest, IL 60045 USA	Georgetown University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, E208 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	kasidu@georgetown.edu		Broustas, Constantinos/0000-0001-7169-807X	NCI NIH HHS [CA74175, CA68322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175, R55CA068322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bottero V, 2001, CANCER RES, V61, P7785; Bouillet P, 2002, J CELL SCI, V115, P1567; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Futami Takashi, 2002, Nucleic Acids Res Suppl, P251; Gabra H, 1996, CANCER RES, V56, P950; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gentile M, 1999, BRIT J CANCER, V80, P843, DOI 10.1038/sj.bjc.6690430; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GOKHALE PC, 2000, P AM ASSOC CANC RES, V1551, P244; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	34	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26780	26788		10.1074/jbc.M400159200	http://dx.doi.org/10.1074/jbc.M400159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069058	hybrid			2022-12-27	WOS:000222003000105
J	Eneqvist, T; Lundberg, E; Karlsson, A; Huang, SH; Santos, CRA; Power, DM; Sauer-Eriksson, AE				Eneqvist, T; Lundberg, E; Karlsson, A; Huang, SH; Santos, CRA; Power, DM; Sauer-Eriksson, AE			High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-BINDING; 2.5 ANGSTROM RESOLUTION; ALTERNATIVE CONFORMATIONS; AMYLOIDOGENIC PROTEINS; RAT TRANSTHYRETIN; SPARUS-AURATA; EVOLUTION; COMPLEX; SERUM; IDENTIFICATION	Transthyretin (TTR) is an extracellular transport protein involved in the distribution of thyroid hormones and vitamin A. So far, TTR has only been found in vertebrates, of which piscine TTR displays the lowest sequence identity with human TTR (47%). Human and piscine TTR bind both thyroid hormones 3,5,3'-triiodo-L-thyronine (T-3) and 3,5,3', 5'-tetraiodo-L-thyronine (thyroxine, T-4). Human TTR has higher affinity for T-4 than T-3, whereas the reverse holds for piscine TTR. X-ray structures of Sparus aurata (sea bream) TTR have been determined as the apo-protein at 1.75 Angstrom resolution and bound to ligands T-3 and T-4, both at 1.9 Angstrom resolution. The apo structure is similar to human TTR with structural changes only at beta-strand D. This strand forms an extended loop conformation similar to the one in chicken TTR. The piscine TTR.T-4 complex shows the T-4-binding site to be similar but not identical to human TTR, whereas the TTR.T-3 complex shows the I3' halogen situated at the site normally occupied by the hydroxyl group of T-4. The significantly wider entrance of the hormone-binding channel in sea bream TTR, in combination with its narrower cavity, provides a structural explanation for the different binding affinities of human and piscine TTR to T-3 and T-4.	Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden; Univ Algarve, Ctr Ciencias MAR, P-8005139 Faro, Portugal	Umea University; Universidade do Algarve	Sauer-Eriksson, AE (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden.	liz@ucmp.umu.se	Santos, Cecilia Reis Alves/C-9032-2016; Power, Deborah M/D-3333-2011	Santos, Cecilia Reis Alves/0000-0001-6074-7825; Power, Deborah M/0000-0003-1366-0246; Sauer-Eriksson, Elisabeth/0000-0003-0124-0199				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTALENA L, 1993, CLIN LAB MED, V13, P583, DOI 10.1016/S0272-2712(18)30427-X; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang L, 1999, EUR J BIOCHEM, V259, P534, DOI 10.1046/j.1432-1327.1999.00076.x; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Connors LH, 2000, AMYLOID, V7, P54, DOI 10.3109/13506120009146826; Eneqvist T, 2003, EUR J BIOCHEM, V270, P518, DOI 10.1046/j.1432-1033.2003.03408.x; Eneqvist T, 2001, AMYLOID, V8, P149, DOI 10.3109/13506120109007359; Folli C, 2003, FEBS LETT, V555, P279, DOI 10.1016/S0014-5793(03)01248-1; Funkenstein B, 1999, MOL CELL ENDOCRINOL, V157, P67, DOI 10.1016/S0303-7207(99)00160-4; Ghosh M, 2000, ACTA CRYSTALLOGR D, V56, P1085, DOI 10.1107/S0907444900008568; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; McPherson A, 1982, PREPARATION ANAL PRO; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Plante-Bordeneuve V, 2000, CURR OPIN NEUROL, V13, P569, DOI 10.1097/00019052-200010000-00011; Power DM, 2000, GEN COMP ENDOCR, V119, P241, DOI 10.1006/gcen.2000.7520; Prapunpoj P, 2002, AM J PHYSIOL-REG I, V283, pR885, DOI 10.1152/ajpregu.00042.2002; Santos CRA, 1999, ENDOCRINOLOGY, V140, P2430, DOI 10.1210/en.140.5.2430; Santos CRA, 2002, CLIN CHEM LAB MED, V40, P1244, DOI 10.1515/CCLM.2002.215; SANTOS CRA, 1996, ANN ENDOCRINOL, V57, P58; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; Sauer UH, 1997, J APPL CRYSTALLOGR, V30, P71, DOI 10.1107/S0021889896008047; Schreiber G, 1997, COMP BIOCHEM PHYS B, V116, P137, DOI 10.1016/S0305-0491(96)00212-X; Schreiber G, 2002, J ENDOCRINOL, V175, P61, DOI 10.1677/joe.0.1750061; Sunde M, 1996, EUR J BIOCHEM, V236, P491, DOI 10.1111/j.1432-1033.1996.00491.x; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; Wojtczak A, 1997, ACTA BIOCHIM POL, V44, P505, DOI 10.18388/abp.1997_4400; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P1061, DOI 10.1107/S0907444901007235; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P957, DOI 10.1107/S0907444901006047; YAMAUCHI K, 1993, ENDOCRINOLOGY, V132, P2254, DOI 10.1210/en.132.5.2254; Yamauchi K, 1999, EUR J BIOCHEM, V265, P944, DOI 10.1046/j.1432-1327.1999.00825.x	53	67	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26411	26416		10.1074/jbc.M313553200	http://dx.doi.org/10.1074/jbc.M313553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082720	hybrid, Green Published			2022-12-27	WOS:000222003000062
J	Hira, T; Elliott, AC; Thompson, DG; Case, RM; McLaughlin, JT				Hira, T; Elliott, AC; Thompson, DG; Case, RM; McLaughlin, JT			Multiple fatty acid sensing mechanisms operate in enteroendocrine cells - Novel evidence for direct mobilization of stored calcium by cytosolic fatty acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE STORES; CHOLECYSTOKININ SECRETION; SIGNALING MECHANISMS; RELEASE; STC-1; LINE; CA2+; RESPONSES; ENDOCRINE; GLUTAG	Fatty acids ( FA) with at least 12 carbon atoms increase intracellular Ca2+ ([Ca2+](i)) to stimulate cholecystokinin release from enteroendocrine cells. Using the murine enteroendocrine cell line STC-1, we investigated whether candidate intracellular pathways transduce the FA signal, or whether FA themselves act within the cell to release Ca2+ directly from the intracellular store. STC-1 cells loaded with fura-2 were briefly ( 3 min) exposed to saturated FA above and below the threshold length (C-8, C-10, and C-12). C-12, but not C-8 or C-10, induced a dose-dependent increase in [Ca2+](i), in the presence or absence of extracellular Ca2+. Various signaling inhibitors, including D-myo-inositol 1,4,5-triphosphate receptor antagonists, all failed to block FA-induced Ca2+ responses. To identify direct effects of cytosolic FA on the intracellular Ca2+ store, [Ca2+](i) was measured in STC-1 cells loaded with the lower affinity Ca2+ dye magfura-2, permeabilized by streptolysin O. In permeabilized cells, again C-12 but not C-8 or C-10, induced release of stored Ca2+. Although C-12 released Ca2+ in other permeabilized cell lines, only intact STC-1 cells responded to C-12 in the presence of extracellular Ca2+. In addition, 30 min exposure to C-12 induced a sustained elevation of [Ca2+](i) in the presence of extracellular Ca2+, but only a transient response in the absence of extracellular Ca2+. These results suggest that at least two FA sensing mechanisms operate in enteroendocrine cells: intracellularly, FA (greater than or equal to C-12) transiently induce Ca2+ release from intracellular Ca2+ stores. However, they also induce sustained Ca2+ entry from the extracellular medium to maintain an elevated [Ca2+](i).	Hope Hosp, Salford M6 8HD, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Kita Ku, Sapporo, Hokkaido 0608589, Japan	University of Manchester; Hokkaido University	McLaughlin, JT (corresponding author), Hope Hosp, Clin Sci Bldg,Stott Lane, Salford M6 8HD, Lancs, England.	john.mclaughlin@man.ac.uk	Hira, Tohru/A-4286-2012	Hira, Tohru/0000-0002-0354-1617; Elliott, Austin/0000-0003-3569-9002; McLaughlin, John/0000-0001-6158-5135				Benson RSP, 2002, J PHYSIOL-LONDON, V538, P121, DOI 10.1113/jphysiol.2001.012969; Buchan AMJ, 1999, AM J PHYSIOL-GASTR L, V277, pG1103, DOI 10.1152/ajpgi.1999.277.6.G1103; Chang CH, 1998, AM J PHYSIOL-GASTR L, V275, pG192, DOI 10.1152/ajpgi.1998.275.2.G192; CHANG CH, 1994, BBA-MOL CELL RES, V1221, P339, DOI 10.1016/0167-4889(94)90259-3; Furness JB, 1999, AM J PHYSIOL-GASTR L, V277, pG922, DOI 10.1152/ajpgi.1999.277.5.G922; Gribble FM, 2003, DIABETES, V52, P1147, DOI 10.2337/diabetes.52.5.1147; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERTELENDY F, 1992, MOL CELL ENDOCRINOL, V83, P173, DOI 10.1016/0303-7207(92)90157-2; Hira T, 1999, BIOSCI BIOTECH BIOCH, V63, P1192, DOI 10.1271/bbb.63.1192; HOENIG M, 1986, ENDOCRINOLOGY, V119, P2502, DOI 10.1210/endo-119-6-2502; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Karlsson S, 2001, BIOCHEM BIOPH RES CO, V280, P610, DOI 10.1006/bbrc.2000.4165; Kazmi S, 2003, J PHYSIOL-LONDON, V553, P759, DOI 10.1113/jphysiol.2003.051680; McLaughlin J, 1999, GASTROENTEROLOGY, V116, P46, DOI 10.1016/S0016-5085(99)70227-1; McLaughlin JT, 1998, J PHYSIOL-LONDON, V513, P11, DOI 10.1111/j.1469-7793.1998.011by.x; Menezes A, 1996, J NEUROCHEM, V67, P2316; Nishi T, 2001, EXP BIOL MED, V226, P1031, DOI 10.1177/153537020122601110; Padfield PJ, 1996, BIOCHEM J, V314, P123, DOI 10.1042/bj3140123; PADFIELD PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG647, DOI 10.1152/ajpgi.1995.269.5.G647; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; PRPIC V, 1994, BIOCHEM BIOPH RES CO, V201, P1483, DOI 10.1006/bbrc.1994.1871; Raybould HE, 1999, AM J PHYSIOL-GASTR L, V277, pG751, DOI 10.1152/ajpgi.1999.277.4.G751; Reimann F, 2002, DIABETES, V51, P2757, DOI 10.2337/diabetes.51.9.2757; Sanders KM, 2001, J APPL PHYSIOL, V91, P1438, DOI 10.1152/jappl.2001.91.3.1438; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999	28	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26082	26089		10.1074/jbc.M400098200	http://dx.doi.org/10.1074/jbc.M400098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066999	hybrid, Green Published			2022-12-27	WOS:000222003000021
J	Birchenall-Roberts, MC; Fu, T; Bang, OS; Dambach, M; Resau, JH; Sadowski, CL; Bertolette, DC; Lee, HJ; Kim, SJ; Ruscetti, FW				Birchenall-Roberts, MC; Fu, T; Bang, OS; Dambach, M; Resau, JH; Sadowski, CL; Bertolette, DC; Lee, HJ; Kim, SJ; Ruscetti, FW			Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins - A molecular link of two tumor suppressor pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; P70 S6 KINASE; TGF-BETA; DEVELOPMENTAL EXPRESSION; TSC2 GENE; INHIBITOR; CELLS; DIFFERENTIATION; DOMAIN; ACID	Tuberin (TSC2) is a tumor suppressor gene. At the cellular level, tuberin is required as a critical regulator of cell growth, neuronal differentiation (Soucek, T., Holzl, G., Bernaschek, G., and Hengstschlager, M. (1998) Oncogene 16, 2197-2204), and tumor suppression (Crino, P. B., and Henske, E. P. (1999) Neurology 53, 1384-1390). Here we report a critical role for tuberin in late stage myeloid cell differentiation. Tuberin strongly augments transforming growth factor (TGF)-beta1 signal transduction pathways, including SMAD activation. We also demonstrate that the amino-terminal region of tuberin interacts specifically with the MH2 domain of SMAD2 and SMAD3 proteins to regulate TGF-beta1-responsive genes such as p21(CIP). Inhibition of tuberin expression by Tsc2 antisense greatly reduces the ability of TGF-beta to transcriptionally regulate p21(CIP), p27(KIP), and cyclin A leading to an abrogation of the antiproliferative effects of TGF-beta1. Also, inhibition of tuberin expression during stimulation of monocytic differentiation with vitamin D-3 and TGF-beta1 significantly impaired myeloid cell growth inhibition and differentiation. Together, the data demonstrate the presence of a novel activation process following TGF-beta1 stimulation that requires tuberin-dependent activity.	NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; Van Andel Inst, Grand Rapids, MI 49506 USA; NCI Frederick, Expt Immunol Lab, Frederick, MD 21702 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birchenall-Roberts, MC (corresponding author), NCI, SAIC Frederick, Basic Res Program, POB B,Bldg 567-259, Frederick, MD 21702 USA.	birchena@mail.ncifcrf.gov			NATIONAL CANCER INSTITUTE [Z01BC009264, Z01BC005617] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Djaborkhel R, 2000, EXP CELL RES, V261, P250, DOI 10.1006/excr.2000.5047; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; HENGSTSCHLAGER M, 2002, MUTAT RES, V488, P233; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HU X, 2004, ONCOGENE, V20, P6840; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jobert S, 1997, EUR J HUM GENET, V5, P280, DOI 10.1159/000484778; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Kim KK, 1995, CELL MOL BIOL RES, V41, P515; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; TUSCHIYA H, 1996, CANCER RES, V56, P429; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; ZAWEL L, 2002, CELL, V1, P611	41	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25605	25613		10.1074/jbc.M402790200	http://dx.doi.org/10.1074/jbc.M402790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066998	hybrid			2022-12-27	WOS:000221827900088
J	Donny, W; Demple, B				Donny, W; Demple, B			Modulation of the 5 '-deoxyribose-5-phosphate lyase and DNA synthesis activities of mammalian DNA polymerase beta by apurinic/apyrimidinic endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; DEOXYRIBOSE PHOSPHATE EXCISION; NEGATIVE GENE-REGULATION; CELL NUCLEAR ANTIGEN; ABASIC SITES; IN-VITRO; EXTRACELLULAR CALCIUM; CATALYTIC MECHANISM; FLAP ENDONUCLEASE-1	The Ape1 protein initiates the repair of apurinic/apyrimidinic sites during mammalian base excision repair (BER) of DNA. Ape1 catalyzes hydrolysis of the 5'-phosphodiester bond of abasic DNA to create nicks flanked by 3'-hydroxyl and 5'-deoxyribose 5-phosphate (dRP) termini. DNA polymerase (pol) beta catalyzes both DNA synthesis at the 3'-hydroxyl terminus and excision of the 5'-dRP moiety prior to completion of BER by DNA ligase. During BER, Ape1 recruits pol beta to the incised apurinic/apyrimidinic site and stimulates 5'-dRP excision by pol beta. The activities of these two enzymes are thus coordinated during BER. To examine further the coordination of BER, we investigated the ability of Ape1 to modulate the deoxynucleotidyltransferase and 5'-dRP lyase activities of pol beta. We report here that Ape1 stimulates 5'-dRP excision by a mechanism independent of its apurinic/apyrimidinic endonuclease activity. We also demonstrate a second mechanism, independent of Ape1, in which conditions that support DNA synthesis by pol beta also enhance 5'-dRP excision. Ape1 modulates the gap-filling activity of pol beta by specifically inhibiting synthesis on an incised abasic substrate but not on single-nucleotide gapped DNA. In contrast to the wild-type Ape1 protein, a catalytically impaired mutant form of Ape1 did not affect DNA synthesis by pol beta. However, this mutant protein retained the ability to stimulate 5'-dRP excision by pol beta. Simultaneous monitoring of 5'-dRP excision and DNA synthesis by pol beta demonstrated that the 5'-dRP lyase activity lags behind the polymerase activity despite the coordination of these two steps by Ape1 during BER.The Ape1 protein initiates the repair of apurinic/apyrimidinic sites during mammalian base excision repair (BER) of DNA. Ape1 catalyzes hydrolysis of the 5'-phosphodiester bond of abasic DNA to create nicks flanked by 3'-hydroxyl and 5'-deoxyribose 5-phosphate (dRP) termini. DNA polymerase (pol) beta catalyzes both DNA synthesis at the 3'-hydroxyl terminus and excision of the 5'-dRP moiety prior to completion of BER by DNA ligase. During BER, Ape1 recruits pol beta to the incised apurinic/apyrimidinic site and stimulates 5'-dRP excision by pol beta. The activities of these two enzymes are thus coordinated during BER. To examine further the coordination of BER, we investigated the ability of Ape1 to modulate the deoxynucleotidyltransferase and 5'-dRP lyase activities of pol beta. We report here that Ape1 stimulates 5'-dRP excision by a mechanism independent of its apurinic/apyrimidinic endonuclease activity. We also demonstrate a second mechanism, independent of Ape1, in which conditions that support DNA synthesis by pol beta also enhance 5'-dRP excision. Ape1 modulates the gap-filling activity of pol beta by specifically inhibiting synthesis on an incised abasic substrate but not on single-nucleotide gapped DNA. In contrast to the wild-type Ape1 protein, a catalytically impaired mutant form of Ape1 did not affect DNA synthesis by pol beta. However, this mutant protein retained the ability to stimulate 5'-dRP excision by pol beta. Simultaneous monitoring of 5'-dRP excision and DNA synthesis by pol beta demonstrated that the 5'-dRP lyase activity lags behind the polymerase activity despite the coordination of these two steps by Ape1 during BER.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993] Funding Source: Medline; NIEHS NIH HHS [T32ES007155] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Meira LB, 2001, CANCER RES, V61, P5552; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Mitra S, 2001, ENVIRON MOL MUTAGEN, V38, P180, DOI 10.1002/em.1070; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Piersen CE, 2000, MUTAT RES-DNA REPAIR, V459, P43, DOI 10.1016/S0921-8777(99)00054-3; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wong D, 2003, J BIOL CHEM, V278, P36242, DOI 10.1074/jbc.M306065200; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	67	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25268	25275		10.1074/jbc.M400804200	http://dx.doi.org/10.1074/jbc.M400804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078879				2022-12-27	WOS:000221827900045
J	Jang, JH; Hwang, JH; Chung, CP; Choung, PH				Jang, JH; Hwang, JH; Chung, CP; Choung, PH			Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC TOOTH MESENCHYME; HUMAN FIBRONECTIN; CELL ATTACHMENT; STRUCTURAL REQUIREMENTS; SULFATE PROTEOGLYCANS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; GROWTH-FACTOR; III MODULES; CYTOTACTIN	The interaction between tenascin-C (TN-C), a multi-subunit extracellular matrix protein, and heparin was examined using a surface plasmon resonance-based technique on a Biacore system. The aims of the present study were to examine the affinity of fibronectin type III repeats of TN-C fragments (TNIII) for heparin, to investigate the role of the TNIII4 domains in the binding of TN-C to heparin, and to delineate a sequence of amino acids within the TNIII4 domain, which mediates cooperative heparin binding. At a physiological salt concentration, and pH 7.4, TNIII3-5 binds to heparin with high affinity (K-D = 30 nM). However, a major heparin-binding site in TNIII5 produces a modest affinity binding at a KD near 4 muM, and a second site in TNIII4 enhances the binding by several orders of magnitude, although it was far too weak to produce an observable binding of TNIII4 by itself. Moreover, mutagenesis of the KEDK sequence in the TNIII4 domain resulted in the significant reduction of heparin-binding affinity. In addition, residues in the KEDK sequences are conserved in TN-C throughout mammalian evolution. Thus the structure-based sequence alignment, mutagenesis, and sequence conservation data together reveal a KEDK sequence in TNIII4 suggestive of a minor heparin-binding site. Finally, we demonstrate that TNIII4 contains binding sites for heparin sulfate proteoglycan and enhances the heparin sulfate proteoglycan-dependent human gingival fibroblast adhesion to TNIII5, thus providing the biological significance of heparin-binding site of TNIII4. These results suggest that the heparin-binding sites may traverse TNIII4-5 and thus require KEDK in TNIII4 for optimal heparin-binding.	Seoul Natl Univ, Coll Dent, IBEC, Seoul 110749, South Korea	Seoul National University (SNU)	Jang, JH (corresponding author), Seoul Natl Univ, Coll Dent, IBEC, 28 Yongon Dong, Seoul 110749, South Korea.	juhjang@snu.ac.kr						AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORK P, 1993, PROTEIN SCI, V2, P1185, DOI 10.1002/pro.5560020714; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Dorries U, 1996, J NEUROSCI RES, V43, P420; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JOSHI P, 1993, J CELL SCI, V106, P389; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lethias C, 2001, J BIOL CHEM, V276, P16432, DOI 10.1074/jbc.M010210200; MARTON LS, 1989, J BIOL CHEM, V264, P13145; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; THESLEFF I, 1987, DEVELOPMENT, V101, P289; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691	34	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25562	25566		10.1074/jbc.M403170200	http://dx.doi.org/10.1074/jbc.M403170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069070	hybrid			2022-12-27	WOS:000221827900082
J	Kim, J; Lee, J; Yadav, N; Wu, Q; Carter, C; Richard, S; Richie, E; Bedford, MT				Kim, J; Lee, J; Yadav, N; Wu, Q; Carter, C; Richard, S; Richie, E; Bedford, MT			Loss of CARM1 results in hypomethylation of thymocyte cyclic AMP-regulated phosphoprotein and deregulated early T cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE N-METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; IN-VIVO; METHYLATION; EXPRESSION; BINDING; GENE; RNA; SELECTION	The coactivator-associated arginine methyltransferase, CARM1, is a positive regulator of transcription. Using high density protein arrays, we have previously identified in vitro substrates for CARM1. One of these substrates, TARPP (thymocyte cyclic AMP-regulated phosphoprotein), is expressed specifically in immature thymocytes. Here, we have demonstrated that TARPP is arginine-methylated at a single residue, Arg(650), both in vitro and in vivo. In addition, recombinant TARPP is not methylated by extracts from Carm1(-/-) cells, indicating that there is no redundancy in this pathway. We show that thymi from Carm1(-/-) embryos (E18.5) have a 5-10-fold reduction in cellularity compared with wild type littermates. Flow cytometric analysis of thymocytes revealed a decrease in the relative proportion of double negative thymocytes in Carm1(-/-) embryos because of a partial developmental arrest in the earliest thymocyte progenitor subset. These results demonstrate that CARM1 plays a significant role in promoting the differentiation of early thymocyte progenitors, possibly through its direct action on TARPP.	Univ Texas, MD Anderson Hosp & Tumor Inst, Ctr Canc, Sci Pk Res Div, Smithville, TX 78957 USA; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Texas System; UTMD Anderson Cancer Center; Lady Davis Institute; McGill University	Bedford, MT (corresponding author), Univ Texas, MD Anderson Hosp & Tumor Inst, Ctr Canc, Sci Pk Res Div, Smithville, TX 78957 USA.	mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011	Richie, Ellen/0000-0003-0786-973X	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062248, R01DK062248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIDDK NIH HHS [DK62248-01] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Grishin NV, 1998, TRENDS BIOCHEM SCI, V23, P329, DOI 10.1016/S0968-0004(98)01258-4; Henry MF, 1996, MOL CELL BIOL, V16, P3668; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kisielow J, 2001, EUR J IMMUNOL, V31, P1141, DOI 10.1002/1521-4141(200104)31:4<1141::AID-IMMU1141>3.0.CO;2-R; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; PENIT C, 1995, J IMMUNOL, V154, P5103; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	37	84	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25339	25344		10.1074/jbc.M402544200	http://dx.doi.org/10.1074/jbc.M402544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15096520	hybrid			2022-12-27	WOS:000221827900055
J	Ma, YG; Cho, MY; Zhao, MY; Park, JW; Matsushita, M; Fujita, T; Lee, BL				Ma, YG; Cho, MY; Zhao, MY; Park, JW; Matsushita, M; Fujita, T; Lee, BL			Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; L-ALANINE AMIDASE; SERINE-PROTEASE; PROPHENOLOXIDASE ACTIVATION; BACTERIAL PEPTIDOGLYCAN; STAPHYLOCOCCUS-AUREUS; SUGAR SPECIFICITY; LIPOTEICHOIC ACID; CUTTING EDGE; BOMBYX-MORI	The innate immune response in vertebrates and invertebrates requires the presence of pattern recognition receptors or proteins that recognize microbial cell components including lipopolysaccharide, bacterial peptidoglycan (PGN), and fungal 1,3-beta-D-glucan. We reported previously that PGN and 1,3-beta-D-glucan recognition proteins from insect hemolymph were able to induce the activation of the prophenoloxidase-activating system, one of the major invertebrate innate immune reactions. The goal of this study was to characterize the biochemical properties and effects of the human counterparts of these molecules. Soluble pattern recognition proteins were purified from human serum and identified as human mannose-binding lectin (MBL) and L-ficolin. The use of specific microbial cell component-coupled columns demonstrated that MBL and L-ficolin bind to PGN and 1,3-beta-D-glucan, respectively. Purified MBL and L-ficolin were associated with MBL-associated serine proteases-1 and -2 (MASPs) and small MBL-associated protein as determined by Western blot analysis. Finally, the binding of purified MBL/MASP and L-ficolin/MASP complexes to PGN and 1,3-beta-D-glucan, respectively, resulted in the activation of the lectin-complement pathway. These results indicate that human PGN and 1,3-beta-D-glucan recognition proteins function as complement-activating lectins.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Tokai Univ, Inst Glycotechnol, Hiratsuka, Kanagawa 2591292, Japan; Tokai Univ, Dept Appl Biochem, Hiratsuka, Kanagawa 2591292, Japan; Fukushima Med Univ Sch Med, Dept Biochem, Fukushima 9601295, Japan; Japan Sci & Technol Agcy, CREST, Fukushima 9601295, Japan	Pusan National University; Tokai University; Tokai University; Fukushima Medical University; Japan Science & Technology Agency (JST)	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Jangjeon Dong, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Jie, Ying/AAJ-4697-2021	Jie, Ying/0000-0003-4003-2579				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; Ashida Masaaki, 1998, P135; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KONOPSKI Z, 1994, BBA-MOL CELL RES, V1221, P61, DOI 10.1016/0167-4889(94)90216-X; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Le Y, 1997, J IMMUNOL METHODS, V204, P43, DOI 10.1016/S0022-1759(97)00029-X; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2000, J IMMUNOL, V165, P2637, DOI 10.4049/jimmunol.165.5.2637; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; MULLER CD, 1994, RES IMMUNOL, V145, P267, DOI 10.1016/S0923-2494(94)80015-4; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; Neth O, 2002, J IMMUNOL, V169, P4430, DOI 10.4049/jimmunol.169.8.4430; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OHTA M, 1990, J BIOL CHEM, V265, P1980; Petersen SV, 2001, J IMMUNOL METHODS, V257, P107, DOI 10.1016/S0022-1759(01)00453-7; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Rice PJ, 2002, J LEUKOCYTE BIOL, V72, P140; Rogers H.J., 1980, MICROBIAL CELL WALK, P190; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SAKURAI T, 1994, BIOL PHARM BULL, V17, P617; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SZABO T, 1995, J BIOL CHEM, V270, P2145, DOI 10.1074/jbc.270.5.2145; TERAI I, 1993, BIOCHEM MED METAB B, V50, P111, DOI 10.1006/bmmb.1993.1052; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thornton BP, 1996, J IMMUNOL, V156, P1235; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Williams DL, 1996, CLIN IMMUNOTHER, V5, P392, DOI 10.1007/BF03259335; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200; Zhao LJ, 2002, BLOOD, V100, P3233, DOI 10.1182/blood-2002-01-0252	52	123	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25307	25312		10.1074/jbc.M400701200	http://dx.doi.org/10.1074/jbc.M400701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078867	hybrid			2022-12-27	WOS:000221827900050
J	Ryu, KS; Kim, C; Kim, I; Yoo, S; Choi, BS; Park, C				Ryu, KS; Kim, C; Kim, I; Yoo, S; Choi, BS; Park, C			NMR application probes a novel and ubiquitous family of enzymes that alter monosaccharide configuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SUGAR-BINDING; GALACTOSE MUTAROTASE; RIBOSE TRANSPORT; L-FUCOSE; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION; ISOMERASE	By exploiting nuclear magnetic resonance (NMR) techniques along with novel applications of saturation difference analysis, we deciphered the functions of the previously uncharacterized products of three bacterial genes, rbsD, fucU, and yiiL, which are part of the ribose, fucose, and rhamnose operons of Escherichia coli, respectively. We show that RbsD catalyzes the pyran to furan conversion of ribose, whereas FucU and YiiL are involved in the catalysis of the anomeric conversion of their respective sugars. It was observed that the anomeric exchange of only ribofuranose, not ribopyranose, occurs spontaneously in solution rationalizing its evolutionary incorporation into the nucleic acid. The RbsD and FucU proteins share sequence homology and belong to the same protein family that is found from eubacteria to human, whereas the YiiL homologues exist in archae-bacteria and lower eukaryotes. These enzymes, including the galactose mutarotase, exhibit a certain degree of cross-specificity to structurally analogous sugars thereby encompassing all existing monosaccharides in terms of their reactivities. The ubiquitous presence of enzymes involved in the anomeric changes of monosaccharides highlights an importance of these activities in various cellular processes requiring efficient monosaccharide utilization.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Choi, BS (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Gusong Dong 373-1, Taejon 305701, South Korea.	byongseok.choi@kaist.ac.kr; ckpark@kaist.ac.kr	Choi, Byong-Seok/C-1937-2011; Park, Chankyu/C-1936-2011					Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Eschenmoser A, 1999, SCIENCE, V284, P2118, DOI 10.1126/science.284.5423.2118; FOKER JE, 1988, Patent No. 4719201; FOKER JE, 1986, Patent No. 4605644; HORECKER BL, 1960, J BIOL CHEM, V235, P1580; IIDA A, 1984, J BACTERIOL, V158, P674, DOI 10.1128/JB.158.2.674-682.1984; IZUMORI K, 1975, J BIOL CHEM, V250, P8085; Kim CH, 1997, J BACTERIOL, V179, P7631, DOI 10.1128/jb.179.24.7631-7637.1997; Kim MS, 2003, J BIOL CHEM, V278, P28173, DOI 10.1074/jbc.M304523200; Korndorfer IP, 2000, J MOL BIOL, V300, P917, DOI 10.1006/jmbi.2000.3896; LIVINGSTONE G, 1977, J SOLUTION CHEM, V6, P203, DOI 10.1007/BF00646739; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Noda K, 2003, CANCER RES, V63, P6282; OCONNELL TM, 1994, BIOCHEMISTRY-US, V33, P10985, DOI 10.1021/bi00202a018; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; Park Y, 1999, EMBO J, V18, P4149, DOI 10.1093/emboj/18.15.4149; Poulsen TS, 1999, J BACTERIOL, V181, P7126, DOI 10.1128/JB.181.22.7126-7130.1999; REEZE HH, 2001, GLYCOBIOLOGY, V11, pR129; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Timson DJ, 2003, FEBS LETT, V543, P21, DOI 10.1016/S0014-5793(03)00364-8; WILLIS RC, 1974, J BIOL CHEM, V249, P6926; ZHU Y, 1986, J MOL EVOL, V23, P259, DOI 10.1007/BF02115582	25	29	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25544	25548		10.1074/jbc.M402016200	http://dx.doi.org/10.1074/jbc.M402016200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060078	hybrid			2022-12-27	WOS:000221827900080
J	Pal, S; Nemeth, MJ; Bodine, D; Miller, JL; Svaren, J; Thein, SL; Lowry, PJ; Bresnick, EH				Pal, S; Nemeth, MJ; Bodine, D; Miller, JL; Svaren, J; Thein, SL; Lowry, PJ; Bresnick, EH			Neurokinin-B transcription in erythroid cells - Direct activation by the hematopoietic transcription factor GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; DNA-BINDING; EXPRESSION; GENE; DIFFERENTIATION; IDENTIFICATION; SPECIFICITY; PROMOTER; DOMAIN; FETAL	The GATA family of transcription factors establishes genetic networks that control developmental processes including hematopoiesis, vasculogenesis, and cardiogenesis. We found that GATA-1 strongly activates transcription of the Tac-2 gene, which encodes proneurokinin-B, a precursor of neurokinin-B (NK-B). Neurokinins function through G protein-coupled transmembrane receptors to mediate diverse physiological responses including pain perception and the control of vascular tone. Whereas an elevated level of NK-B was implicated in pregnancy-associated pre-eclampsia ( Page, N. M., Woods, R. J., Gardiner, S. M., Lomthaisong, K., Gladwell, R. T., Butlin, D. J., Manyonda, I. T., and Lowry, P. J. ( 2000) Nature 405, 797 - 800), the regulation of NK-B synthesis and function are poorly understood. Tac-2 was expressed in normal murine erythroid cells and was induced upon ex vivo erythropoiesis. An estrogen receptor fusion to GATA-1 (ER-GATA-1) and endogenous GATA-1 both occupied a region of Tac-2 intron-7, which contains two conserved GATA motifs. Genetic complementation analysis in GATA-1-null G1E cells revealed that endogenous GATA-2 occupied the same region of intron-7, and expression of ER-GATA-1 displaced GATA-2 and activated Tac-2 transcription. Erythroid cells did not express neurokinin receptors, whereas aortic and yolk sac endothelial cells differentially expressed neurokinin receptor subtypes. Since NK-B induced cAMP accumulation in yolk sac endothelial cells, these results suggest a new mode of vascular regulation in which GATA-1 controls NK-B synthesis in erythroid cells.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; NHGI, NIH, Bethesda, MD 20892 USA; NIDDK, NIH, Bethesda, MD 20892 USA; Hematol Med, London SE5 9PJ, England; Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London; University of Wisconsin System; University of Wisconsin Madison; University of Reading	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.	ehbresni@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000197, Z01HG000083, ZIAHG000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025089, R01DK055700, R01DK050107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55700, DK50107] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Brownbill P, 2003, J CLIN ENDOCR METAB, V88, P2164, DOI 10.1210/jc.2002-021727; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Cintado CG, 2001, J PHARMACOL EXP THER, V299, P934; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; DORLEANSJUSTE P, 1991, EUR J PHARMACOL, V204, P329, DOI 10.1016/0014-2999(91)90860-S; Eszterhas SK, 2002, MOL CELL BIOL, V22, P469, DOI 10.1128/MCB.22.2.469-479.2002; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; GERARD NP, 1990, J BIOL CHEM, V265, P20455; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; GREENO EW, 1993, J EXP MED, V177, P1269, DOI 10.1084/jem.177.5.1269; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; Hirasawa R, 2002, J EXP MED, V195, P1379, DOI 10.1084/jem.20020170; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; Im Hogune, 2004, Methods Mol Biol, V284, P129; INGI T, 2001, J PHARMACOL EXP THER, V259, P968; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Joshi DD, 2001, BLOOD, V98, P2697, DOI 10.1182/blood.V98.9.2697; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; Letting DL, 2004, P NATL ACAD SCI USA, V101, P476, DOI 10.1073/pnas.0306315101; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Lu LS, 1996, P NATL ACAD SCI USA, V93, P14782, DOI 10.1073/pnas.93.25.14782; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minegishi N, 2003, BLOOD, V102, P896, DOI 10.1182/blood-2002-12-3809; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Page NM, 2001, REGUL PEPTIDES, V98, P97, DOI 10.1016/S0167-0115(00)00239-1; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedersen KE, 2000, J PHARMACOL EXP THER, V292, P319; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Shirahase H, 2000, BRIT J PHARMACOL, V129, P937, DOI 10.1038/sj.bjp.0703140; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Surinya KH, 1998, J BIOL CHEM, V273, P16798, DOI 10.1074/jbc.273.27.16798; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Svaren J, 1997, GENOMICS, V41, P33, DOI 10.1006/geno.1997.4609; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Vyas P, 1999, DEVELOPMENT, V126, P2799; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Wojda U, 2002, BLOOD, V99, P3005, DOI 10.1182/blood.V99.8.3005.h8003005_3005_3013; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	68	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31348	31356		10.1074/jbc.M403475200	http://dx.doi.org/10.1074/jbc.M403475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123623	hybrid			2022-12-27	WOS:000222726800055
J	Stauffer, ME; Chazin, WJ				Stauffer, ME; Chazin, WJ			Structural mechanisms of DNA replication, repair, and recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SINGLE-STRANDED-DNA; NUCLEOTIDE EXCISION-REPAIR; PROTEIN-A; OB-FOLD; FLAP ENDONUCLEASE-1; BREAK REPAIR; BINDING; RPA; DOMAINS; RECOGNITION		Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Chazin, WJ (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.	walter.chazin@vanderbilt.edu			NCI NIH HHS [T32 CA009582] Funding Source: Medline; NIGMS NIH HHS [R01 GM065484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; Arunkumar AI, 2003, J BIOL CHEM, V278, P41077, DOI 10.1074/jbc.M305871200; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Brosh RM, 2001, EMBO J, V20, P5791; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Daughdrill GW, 2003, NUCLEIC ACIDS RES, V31, P4176, DOI 10.1093/nar/gkg451; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Giraldo R, 2003, FEMS MICROBIOL REV, V26, P533, DOI 10.1111/j.1574-6976.2003.tb00629.x; Grabowski B, 2001, J BACTERIOL, V183, P5459, DOI 10.1128/JB.183.18.5459-5464.2001; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jackson D, 2002, J MOL BIOL, V321, P133, DOI 10.1016/S0022-2836(02)00541-7; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kowalczykowski SC, 2000, NAT STRUCT BIOL, V7, P1087, DOI 10.1038/81923; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Saijo M, 1996, NUCLEIC ACIDS RES, V24, P4719, DOI 10.1093/nar/24.23.4719; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Stauffer ME, 2004, J BIOL CHEM, V279, P25638, DOI 10.1074/jbc.M400029200; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Zhou HX, 2001, BIOCHEMISTRY-US, V40, P15069, DOI 10.1021/bi015795g	44	65	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30915	30918		10.1074/jbc.R400015200	http://dx.doi.org/10.1074/jbc.R400015200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15090549	hybrid			2022-12-27	WOS:000222726800001
J	Liu, W; Rogge, CE; Bambai, B; Palmer, G; Tsai, AL; Kulmacz, RJ				Liu, W; Rogge, CE; Bambai, B; Palmer, G; Tsai, AL; Kulmacz, RJ			Characterization of the heme environment in Arabidopsis thaliana fatty acid alpha-dioxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; SHEEP VESICULAR GLAND; RAY CRYSTAL-STRUCTURE; ENDOPEROXIDE SYNTHETASE; CANINE MYELOPEROXIDASE; SELECTIVE-INHIBITION; ANGSTROM RESOLUTION; CYANIDE BINDING; NSAID BINDING; H-2 SYNTHASE	Plant alpha-dioxygenases (PADOX) are hemoproteins in the myeloperoxidase family. We have used a variety of spectroscopic, mutagenic, and kinetic approaches to characterize the heme environment in Arabidopsis thaliana PADOX-1. Recombinant PADOX-1 purified to homogeneity contained 1 mol of heme bound tightly but noncovalently per protein monomer. Electronic absorbance, electron paramagnetic resonance, and magnetic circular dichroism spectra showed a high spin ferric heme that could be reduced to the ferrous state by dithionite. Cyanide bound relatively weakly in the ferric PADOX-1 heme vicinity (K-d similar to 10 mM) but did not shift the heme to the low spin state. Cyanide was a very strong inhibitor of the fatty acid oxygenase activity (K-i similar to5 muM) and increased the K-m value for oxygen but not that for fatty acid. Spectroscopic analyses indicated that carbon monoxide, azide, imidazole, and a variety of substituted imidazoles did not bind appreciably in the ferric PADOX-1 heme vicinity. Substitution of His-163 and His-389 with cysteine, glutamine, tyrosine, or methionine resulted in variable degrees of perturbation of the heme absorbance spectrum and oxygenase activity, consistent with His-389 serving as the proximal heme ligand and indicating that the heme has a functional role in catalysis. Overall, A. thaliana PADOX-1 resembles a b-type cytochrome, although with much more restricted access to the distal face of the heme than seen in most other myeloperoxidase family members, explaining the previously puzzling lack of peroxidase activity in the plant protein. PADOX-1 is unusual in that it has a high affinity, inhibitory cyanide-binding site distinct from the distal heme face and the fatty acid site.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, MSB 5-284,6431 Fannin St, Houston, TX 77030 USA.	richard.j.kulmacz@uth.tmc.edu		Bambai, Bijan/0000-0002-9947-1691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044911, R01GM052170] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK061929, DK61929] Funding Source: Medline; NIGMS NIH HHS [R01 GM052170, R01 GM044911, R01 GM044911-15, GM44911, GM52170] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Daiyasu H, 2000, J MOL EVOL, V51, P433, DOI 10.1007/s002390010106; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fei MJ, 2000, ACTA CRYSTALLOGR D, V56, P529, DOI 10.1107/S0907444900002213; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; Grossmann K, 1996, PHYSIOL PLANTARUM, V97, P772, DOI 10.1111/j.1399-3054.1996.tb00543.x; HAINING JL, 1958, J BIOL CHEM, V232, P193; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Hamberg M, 2002, PROSTAG OTH LIPID M, V68-9, P363, DOI 10.1016/S0090-6980(02)00040-0; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Koeduka T, 2002, J BIOL CHEM, V277, P22648, DOI 10.1074/jbc.M110420200; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MACDONALD ID, 1989, BIOCHEM CELL BIOL, V67, P301; MARQUEZ LA, 1989, BIOCHEM CELL BIOL, V67, P187, DOI 10.1139/o89-029; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NIMURA N, 1988, ANAL CHEM, V60, P2067, DOI 10.1021/ac00170a017; OHTAKI S, 1985, J BIOL CHEM, V260, P441; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROTH GJ, 1981, J BIOL CHEM, V256, P18; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1972, J BIOL CHEM, V247, P1038; SOMERS CE, 1989, J BIOL CHEM, V264, P17231; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; Tang MS, 1997, BIOCHEMISTRY-US, V36, P7527, DOI 10.1021/bi962750k; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TITUS BG, 1982, ARCH BIOCHEM BIOPHYS, V214, P824, DOI 10.1016/0003-9861(82)90089-3; TSAI AL, 1993, J BIOL CHEM, V268, P8554; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8; Vickery L E, 1978, Methods Enzymol, V54, P284; Williams C H Jr, 1979, Methods Enzymol, V62, P185; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	60	19	21	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29805	29815		10.1074/jbc.M401779200	http://dx.doi.org/10.1074/jbc.M401779200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15100225	hybrid, Green Accepted			2022-12-27	WOS:000222445300117
J	Brehmer, D; Gassler, C; Rist, W; Mayer, MP; Bukau, B				Brehmer, D; Gassler, C; Rist, W; Mayer, MP; Bukau, B			Influence of GrpE on DnaK-substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HSP70 MOLECULAR CHAPERONE; ESCHERICHIA-COLI; PEPTIDE BINDING; ATPASE DOMAIN; PROTEIN; SIGMA(32); RELEASE; PURIFICATION; THERMOSENSOR	The DnaK chaperone of Escherichia coli assists protein folding by an ATP-dependent interaction with short peptide stretches within substrate polypeptides. This interaction is regulated by the DnaJ and GrpE co-chaperones, which stimulate ATP hydrolysis and nucleotide exchange by DnaK, respectively. Furthermore, GrpE has been claimed to trigger substrate release independent of its role as a nucleotide exchange factor. However, we show here that GrpE can accelerate substrate release from DnaK exclusively in the presence of ATP. In addition, GrpE prevented the association of peptide substrates with DnaK through an activity of its N-terminal 33 amino acids. A ternary complex of GrpE, DnaK, and a peptide substrate could be observed only when the peptide binding to DnaK precedes GrpE binding. Furthermore, we demonstrate that GrpE slows down the release of a protein substrate, sigma(32), from DnaK in the absence of ATP. These findings suggest that the ATP-triggered dissociation of GrpE and substrates from DnaK occurs in a concerted fashion.	Heidelberg Univ, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bukau, B (corresponding author), Heidelberg Univ, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	Bukau@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Rist, Wolfgang/0000-0002-0626-3544; Bukau, Bernd/0000-0003-0521-7199				Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURKHOLDER WF, 1999, MOL CHAPERONES FOLDI, P105; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chesnokova LS, 2003, BIOCHEMISTRY-US, V42, P9028, DOI 10.1021/bi0346493; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Gelinas AD, 2003, BIOCHEMISTRY-US, V42, P9050, DOI 10.1021/bi034416b; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Laufen T., 1998, MOL CHAPERONES PROTE, P241; Mally A, 2001, NAT STRUCT BIOL, V8, P254, DOI 10.1038/85002; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tomoyasu T, 2001, J BACTERIOL, V183, P5911, DOI 10.1128/JB.183.20.5911-5917.2001; Wittung-Stafshede P, 2003, BIOCHEMISTRY-US, V42, P4937, DOI 10.1021/bi027333o; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	47	51	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27957	27964		10.1074/jbc.M403558200	http://dx.doi.org/10.1074/jbc.M403558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102842	hybrid			2022-12-27	WOS:000222265400017
J	Farhan, H; Korkhov, VM; Paulitschke, V; Dorostkar, MM; Scholze, P; Kudlacek, O; Freissmuth, M; Sitte, HH				Farhan, H; Korkhov, VM; Paulitschke, V; Dorostkar, MM; Scholze, P; Kudlacek, O; Freissmuth, M; Sitte, HH			Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ENDOPLASMIC-RETICULUM; GABA TRANSPORTER; SEROTONIN TRANSPORTER; EXOCYST COMPLEX; PDZ DOMAINS; PROTEIN; TRAFFICKING; ER; VESICLE	Like all members of the Na+/Cl--dependent neurotransmitter transporter family, the rat gamma-aminobutyric acid transporter-1 (GAT1) is sorted and targeted to specialized domains of the cell surface. Here we identify two discontinuous signals in the carboxyl terminus of GAT1 that cooperate to drive surface expression. This conclusion is based on the following observations. Upon deletion of the last 37 amino acids, the resulting GAT1-Delta37 remained trapped in the endoplasmic reticulum. The presence of 10 additional residues (GAT1-Delta27) sufficed to support the interaction with the coat protein complex II component Sec24D; surface expression of GAT1-Delta27 reached 50% of the wild type level. Additional extensions up to the position -3 (GAT1-Delta3) did not further enhance surface expression. Thus the last three amino acids (AYI) comprise a second distal signal. The sequence AYI is reminiscent of a type II PDZ-binding motif; accordingly substituting Glu for Ile abrogated the effect of this motif. Neither the AYI motif nor the last 10 residues rescued the protein from intracellular retention when grafted onto GAT1-Delta37 and GAT1-Delta32; the AYI motif was dispensable for targeting of GAT1 to the growth cone of differentiating PC12 cells. We therefore conclude that the two segments act in a hierarchical manner such that the proximal motif ((VMI571)-V-569) supports endoplasmic reticulum export of the protein and the distal AYI motif places GAT1 under the control of the exocyst.	Med Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Med Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Farhan, Hesso/C-7997-2012; Sitte, Harald/O-7025-2019; Dorostkar, Mario/AAF-6399-2020; Sitte, Harald/N-2681-2013	Farhan, Hesso/0000-0002-0889-8463; Sitte, Harald/0000-0002-1339-7444; Dorostkar, Mario/0000-0001-8037-4907; Sitte, Harald/0000-0002-1339-7444; Kudlacek, Oliver/0000-0002-3086-8551; Scholze, Petra/0000-0003-4984-6034; Freissmuth, Michael/0000-0001-9398-1765; Korkhov, Volodymyr/0000-0002-0962-9433				Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Beckman ML, 1998, J NEUROSCI, V18, P6103; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Boehm S, 1997, J NEUROSCI, V17, P4066; Chiu CS, 2002, J NEUROSCI, V22, P10251; Gu HH, 1996, J BIOL CHEM, V271, P18100, DOI 10.1074/jbc.271.30.18100; Harris BZ, 2001, J CELL SCI, V114, P3219; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MCHUGH EM, 2001, SOC NEUR ABSTR, V27, P242; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Quick MW, 1997, J NEUROSCI, V17, P2967; RADIAN R, 1990, J NEUROSCI, V10, P1319; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Wozniak M, 1998, BRAIN RES, V780, P311, DOI 10.1016/S0006-8993(97)01216-X; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1	37	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28553	28563		10.1074/jbc.M307325200	http://dx.doi.org/10.1074/jbc.M307325200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15073174	hybrid			2022-12-27	WOS:000222265400091
J	Giannone, G; Ronde, P; Gaire, M; Beaudouin, J; Haiech, J; Ellenberg, J; Takeda, K				Giannone, G; Ronde, P; Gaire, M; Beaudouin, J; Haiech, J; Ellenberg, J; Takeda, K			Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE-CELLS; C-TERMINAL DOMAIN; DIFFERENTIAL REGULATION; MIGRATING NEUTROPHILS; INTRACELLULAR CALCIUM; ASTROCYTOMA-CELLS; GENE-EXPRESSION; STRESS FIBERS; NULL CELLS	Focal adhesion kinase (FAK) activity and Ca2+ signaling led to a turnover of focal adhesions (FAs) required for cell spreading and migration. We used yellow Cameleon-2 (Ycam), a fluorescent protein-based Ca2+ sensor fused to FAK or to a FAK-related non-kinase domain, to measure simultaneously local Ca2+ variations at FA sites and FA dynamics. Discrete subcellular Ca2+ oscillators initiate both propagating and abortive Ca2+ waves in migrating U87 astrocytoma cells. Ca2+-dependent FA disassembly occurs when the Ca2+ wave reaches individual FAs, indicating that local but not global Ca2+ increases trigger FA disassembly. An unexpectedly rapid flux of FAK between cytosolic and FA compartments was revealed by fluorescence recovery after photobleaching studies. The FAK-Ycam recovery half-time (17 s) at FAs was slowed (to 29 s) by Ca2+ elevation. FAK-related non-kinase domain-Ycam had a faster, Ca2+-insensitive recovery half-time (11 s), which is consistent with the effect of Ca2+ on FAK-Ycam dynamics not being due to a general modification of the dynamics of FA components. Because FAK association at FAs was prolonged by Ca2+ and FAK autophosphorylation was correlated to intracellular Ca2+ levels, we propose that local Ca2+ elevations increase the residency of FAK at FAs, possibly by means of tyrosine phosphorylation of FAK, thereby leading to increased activation of its effectors involved in FA disassembly.	Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France; European Mol Biol Lab, Gene Express & Cell Biol Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Biophys Programme, D-69117 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Takeda, K (corresponding author), Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, CNRS, UMR 7034, BP 60024, F-67401 Illkirch Graffenstaden, France.	kt@pharma.u-strasbg.fr	Ellenberg, Jan/I-4688-2014; haiech, jacques J/F-2890-2010	Ellenberg, Jan/0000-0001-5909-701X; Giannone, Gregory/0000-0002-0932-1690; haiech, jacques/0000-0003-2908-8053				Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Alessandro R, 1998, BIOCHEM BIOPH RES CO, V248, P635, DOI 10.1006/bbrc.1998.8705; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eddy RJ, 2000, J CELL SCI, V113, P1287; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Giannone G, 2002, J BIOL CHEM, V277, P26364, DOI 10.1074/jbc.M203952200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; MANDEVILLE JTH, 1995, BIOPHYS J, V68, P1207, DOI 10.1016/S0006-3495(95)80336-X; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ronde P, 2000, BBA-MOL CELL RES, V1498, P273, DOI 10.1016/S0167-4889(00)00102-6; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Scherberich A, 2000, J CELL SCI, V113, P653; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Simpson PB, 1998, J NEUROSCI RES, V52, P672; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	70	108	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28715	28723		10.1074/jbc.M404054200	http://dx.doi.org/10.1074/jbc.M404054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102844	hybrid			2022-12-27	WOS:000222265400109
J	Tsushima, S; Kai, M; Yamada, K; Imai, S; Houkin, K; Kanoh, H; Sakane, F				Tsushima, S; Kai, M; Yamada, K; Imai, S; Houkin, K; Kanoh, H; Sakane, F			Diacylglycerol kinase gamma serves as an upstream suppressor of Rac1 and lamellipodium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; EF-HAND MOTIFS; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; REGULATORY ROLE; CELL MOTILITY; ACTIVATION	Nine diacylglycerol kinase (DGK) isozymes have been identified. However, our knowledge of their individual functions is still limited. Here, we demonstrate the role of DGKgamma in regulating Rac1-governed cell morphology. We found that the expression of kinase-dead DGKgamma, which acts as a dominant-negative mutant, and inhibition of endogenous DGKgamma activity with R59949 induced lamellipodium and membrane ruffle formation in NIH3T3 fibroblasts in the absence of growth factor stimulation. Reciprocally, lamellipodium formation induced by platelet-derived growth factor was significantly inhibited upon expression of constitutively active DGKgamma. Moreover, the constitutively active DGKgamma mutant suppressed integrin-mediated cell spreading. These effects are isoform-specific because, in the same experiments, none of the corresponding mutants of DGKalpha and DGKbeta, closely related isoforms, affected cell morphology. These results suggest that DGKgamma specifically participates in the Rac1-mediated signaling pathway leading to cytoskeletal reorganization. In support of this, DGKgamma co-localized with dominant-active Rac1 especially in lamellipodia. Moreover, we found that endogenous DGKgamma was physically associated with cellular Rac1. Dominant-negative Rac1 expression blocked the lamellipodium formation induced by kinase-dead DGKgamma, indicating that DGKgamma acts upstream of Rac1. This model is supported by studies demonstrating that kinase-dead DGKgamma selectively activated Rac1, but not Cdc42. Taken together, these results strongly suggest that DGKgamma functions through its catalytic action as an upstream suppressor of Rac1 and, consequently, lamellipodium/ruffle formation.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Neurosurg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Liberal Arts & Sci, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017; Houkin, Kiyohiro/G-5364-2012	Sakane, Fumio/0000-0003-0857-0377; 				Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; AHMED S, 1993, J BIOL CHEM, V268, P10709; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Caloca MJ, 2003, BIOCHEM J, V375, P313, DOI 10.1042/BJ20030727; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HASS R, 1989, EUR J CELL BIOL, V48, P282; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rosner H, 1999, EUR J CELL BIOL, V78, P698; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; VAN AL, 1997, GENE DEV, V11, P2295; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; Yamada K, 2003, BIOCHEM BIOPH RES CO, V305, P101, DOI 10.1016/S0006-291X(03)00713-7	58	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28603	28613		10.1074/jbc.M314031200	http://dx.doi.org/10.1074/jbc.M314031200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102830	hybrid			2022-12-27	WOS:000222265400096
J	Krauss, SW; Lee, G; Chasis, JA; Mohandas, N; Heald, R				Krauss, SW; Lee, G; Chasis, JA; Mohandas, N; Heald, R			Two protein 4.1 domains essential for mitotic spindle and aster microtubule dynamics and organization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; BINDING DOMAIN; 4.1 FAMILY; ACTIN; NUMA; DYNACTIN; ISOFORMS; IDENTIFICATION; INTERACTS; COMPONENT	Multifunctional structural proteins belonging to the 4.1 family are components of nuclei, spindles, and centrosomes in vertebrate cells. Here we report that 4.1 is critical for spindle assembly and the formation of centrosome-nucleated and motor-dependent self-organized microtubule asters in metaphase-arrested Xenopus egg extracts. Immunodepletion of 4.1 disrupted microtubule arrays and mislocalized the spindle pole protein NuMA. Remarkably, assembly was completely rescued by supplementation with a recombinant 4.1R isoform. We identified two 4.1 domains critical for its function in microtubule polymerization and organization utilizing dominant negative peptides. The 4.1 spectrin-actin binding domain or NuMA binding C-terminal domain peptides caused morphologically disorganized structures. Control peptides with low homology or variant spectrin-actin binding domain peptides that were incapable of binding actin had no deleterious effects. Unexpectedly, the addition of C-terminal domain peptides with reduced NuMA binding caused severe microtubule destabilization in extracts, dramatically inhibiting aster and spindle assembly and also depolymerizing preformed structures. However, the mutant C-terminal peptides did not directly inhibit or destabilize microtubule polymerization from pure tubulin in a microtubule pelleting assay. Our data showing that 4.1 is a crucial factor for assembly and maintenance of mitotic spindles and self-organized and centrosome-nucleated microtubule asters indicates that 4.1 is involved in regulating both microtubule dynamics and organization. These investigations underscore an important functional context for protein 4.1 in microtubule morphogenesis and highlight a previously unappreciated role for 4.1 in cell division.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; New York Blood Ctr, New York, NY 10021 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; New York Blood Center; University of California System; University of California Berkeley	Krauss, SW (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 74-157, Berkeley, CA 94720 USA.	sakrauss@lbl.gov		Heald, Rebecca/0000-0001-6671-6528	NIDDK NIH HHS [DK59079, DK32094] Funding Source: Medline; NIGMS NIH HHS [GM057839] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK059079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057839] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFORD A, 1998, CELL BIOL LAB HDB, V2, P206; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; Clark IB, 1999, J CELL SCI, V112, P3507; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Delhommeau F, 2002, BLOOD, V100, P2629, DOI 10.1182/blood.V100.7.2629; Du QS, 2002, CURR BIOL, V12, P1928, DOI 10.1016/S0960-9822(02)01298-8; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Haren L, 2002, J CELL SCI, V115, P1815; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HUANG JP, 1993, J BIOL CHEM, V268, P3758; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; KISELEVA E, 2004, IN PRESS J CELL SCI; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 2002, J BIOL CHEM, V277, P44339, DOI 10.1074/jbc.M204135200; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Moudjou M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P111; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; PARRA M, 1998, CELL, V9, pA265; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Perez-Ferreiro CM, 2001, J BIOL CHEM, V276, P44785, DOI 10.1074/jbc.M107369200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1994, MOL BIOL CELL, V5, P217, DOI 10.1091/mbc.5.2.217; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; Sun DM, 2001, J CELL SCI, V114, P161; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; Wignall SM, 2004, CHEM BIOL, V11, P135, DOI 10.1016/j.chembiol.2003.12.019; WINARDI R, 1995, BLOOD, V86, P4315, DOI 10.1182/blood.V86.11.4315.bloodjournal86114315; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	50	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27591	27598		10.1074/jbc.M402813200	http://dx.doi.org/10.1074/jbc.M402813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102852	Green Submitted, hybrid			2022-12-27	WOS:000222120400093
J	Moore, JMR; Galicia, SJ; McReynolds, AC; Nguyen, NH; Scanlan, TS; Guy, RK				Moore, JMR; Galicia, SJ; McReynolds, AC; Nguyen, NH; Scanlan, TS; Guy, RK			Quantitative proteomics of the thyroid hormone receptor-coregulator interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LXXLL-RELATED MOTIFS; GENES IN-VIVO; NUCLEAR RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATORS; POSTNATAL-DEVELOPMENT; PEPTIDE LIBRARIES; PROTEIN RIP140; LIGAND; SPECIFICITY	The thyroid hormone receptor regulates a diverse set of genes that control processes from embryonic development to adult homeostasis. Upon binding of thyroid hormone, the thyroid receptor releases corepressor proteins and undergoes a conformational change that allows for the interaction of coactivating proteins necessary for gene transcription. This interaction is mediated by a conserved motif, termed the NR box, found in many coregulators. Recent work has demonstrated that differentially assembled coregulator complexes can elicit specific biological responses. However, the mechanism for the selective assembly of these coregulator complexes has yet to be elucidated. To further understand the principles underlying thyroid receptor-coregulator selectivity, we designed a high-throughput in vitro binding assay to measure the equilibrium affinity of thyroid receptor to a library of potential coregulators in the presence of different ligands including the endogenous thyroid hormone T3, synthetic thyroid receptor beta-selective agonist GC-1, and antagonist NH-3. Using this homogenous method several coregulator NR boxes capable of associating with thyroid receptor at physiologically relevant concentrations were identified including ones found in traditional coactivating proteins such as SRC1, SRC2, TRAP220, TRBP, p300, and ARA70; and those in coregulators known to repress gene activation including RIP140 and DAX-1. In addition, it was discovered that the thyroid receptor-coregulator binding patterns vary with ligand and that this differential binding can be used to predict biological responses. Finally, it is demonstrated that this is a general method that can be applied to other nuclear receptors and can be used to establish rules for nuclear receptor-coregulator selectivity.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Guy, RK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	rguy@cgl.ucsf.edu	Guy, Rodney/J-7107-2013	Guy, Rodney/0000-0002-9638-2060	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, P01DK058390, R01DK052798] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52798, DK-58390] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Braverman L.E., 1991, THYROID FUNDAMENTAL; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Cheskis BJ, 2003, J BIOL CHEM, V278, P13271, DOI 10.1074/jbc.M211031200; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Forrest D, 1996, RECENT PROG HORM RES, V51, P1; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Geistlinger TR, 2004, CHEM BIOL, V11, P273, DOI 10.1016/j.chembiol.2004.01.016; Greenspan FS., 1997, THYROID GLAND BASIC; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; Northrop JP, 2000, MOL ENDOCRINOL, V14, P605, DOI 10.1210/me.14.5.605; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Sadow PM, 2003, MOL CELL ENDOCRINOL, V203, P65, DOI 10.1016/S0303-7207(03)00122-9; Sadow PM, 2003, MOL ENDOCRINOL, V17, P882, DOI 10.1210/me.2002-0174; Sadow PM, 2003, AM J PHYSIOL-ENDOC M, V284, pE36, DOI 10.1152/ajpendo.00226.2002; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Suzuki T, 2003, MOL CELL BIOL, V23, P238, DOI 10.1128/MCB.23.1.238-249.2003; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Takeuchi Y, 2002, ENDOCRINOLOGY, V143, P1346, DOI 10.1210/en.143.4.1346; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Weiss RE, 2002, ENDOCRINOLOGY, V143, P1554, DOI 10.1210/en.143.4.1554; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yeh S, 2000, J FORMOS MED ASSOC, V99, P885; Yoshihara HAI, 2003, J MED CHEM, V46, P3152, DOI 10.1021/jm0301181; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	60	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27584	27590		10.1074/jbc.M403453200	http://dx.doi.org/10.1074/jbc.M403453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15100213	Green Published, hybrid			2022-12-27	WOS:000222120400092
J	Zhu, M; Rajamani, S; Kaylor, J; Han, S; Zhou, FM; Fink, AL				Zhu, M; Rajamani, S; Kaylor, J; Han, S; Zhou, FM; Fink, AL			The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; OXIDATIVE STRESS; MAJOR COMPONENT; CELL-DEATH; IN-VITRO; L-DOPA; MECHANISM; PATHOGENESIS; MODEL; NEUROTOXICITY	The aggregation of alpha-synuclein has been implicated as a critical step in the development of Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopaminergic neurons from the substantia nigra; currently, no cure exists. Baicalein is a flavonoid with antioxidant properties; upon oxidation, it forms several products including quinones. We show here that low micromolar concentrations of baicalein, and especially its oxidized forms, inhibit the formation of alpha-synuclein fibrils. In addition, existing fibrils of alpha-synuclein are disaggregated by baicalein. The product of the inhibition reaction is predominantly a soluble oligomer of alpha-synuclein, in which the protein molecules have been covalently modified by baicalein quinone to form a Schiff base with a lysine side chain in alpha-synuclein. The binding of baicalein was abolished by conversion of the Tyr residues into Phe, demonstrating that Tyr is involved in the interaction of alpha-synuclein with baicalein. In disaggregation baicalein causes fragmentation throughout the length of the fibril. These observations suggest that baicalein and similar compounds may have potential as therapeutic leads in combating Parkinson's disease and that diets rich in flavonoids may be effective in preventing the disorder.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Calif State Univ Los Angeles, Los Angeles, CA 90032 USA	University of California System; University of California Santa Cruz; California State University System; California State University Los Angeles	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Kaylor, Joanna/Y-5184-2019		NINDS NIH HHS [NS43778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS043778] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT RA, 1992, EUR J CLIN NUTR, V46, P879; Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; Braak H, 2000, J NEUROL, V247, P3; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; Datla KP, 2001, NEUROREPORT, V12, P3871, DOI 10.1097/00001756-200112040-00053; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; GOEDERT M, 2001, PARKINSONS DIS METHO; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Ikezoe T, 2001, PROSTATE, V49, P285, DOI 10.1002/pros.10024; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; LANGE KW, 1994, J NEURAL TRANSM-SUPP, P183; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lebeau A, 2001, NEUROREPORT, V12, P2199, DOI 10.1097/00001756-200107200-00031; Li BQ, 2000, IMMUNOPHARMACOLOGY, V49, P295, DOI 10.1016/S0162-3109(00)00244-7; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nie GJ, 2002, REDOX REP, V7, P171, DOI 10.1179/135100002125000424; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Perry EK, 1999, J PHARM PHARMACOL, V51, P527, DOI 10.1211/0022357991772808; Prasad KN, 1999, J AM COLL NUTR, V18, P413, DOI 10.1080/07315724.1999.10718878; Schroeter H, 2000, FREE RADICAL BIO MED, V29, P1222, DOI 10.1016/S0891-5849(00)00415-9; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Spencer JPE, 1996, FREE RADICAL RES, V24, P95, DOI 10.3109/10715769609088005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Wu JA, 2001, AM J CHINESE MED, V29, P69, DOI 10.1142/S0192415X01000083; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	41	360	371	7	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26846	26857		10.1074/jbc.M403129200	http://dx.doi.org/10.1074/jbc.M403129200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096521	hybrid			2022-12-27	WOS:000222120400008
J	Akama, H; Matsuura, T; Kashiwagi, S; Yoneyama, H; Narita, SI; Tsukihara, T; Nakagawa, A; Nakae, T				Akama, H; Matsuura, T; Kashiwagi, S; Yoneyama, H; Narita, SI; Tsukihara, T; Nakagawa, A; Nakae, T			Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPRM EFFLUX PUMP; ANTIBIOTIC EXTRUSION; RESISTANCE; EXPRESSION; FAMILY; ACRA; INVOLVEMENT; REFINEMENT; SUBUNIT; GENE	The MexAB-OprM efflux pump of Pseudomonas aeruginosa is central to multidrug resistance of this organism, which infects immunocompromised hospital patients. The MexA, MexB, and OprM subunits were assumed to function as the membrane fusion protein, the body of the transporter, and the outer membrane channel protein, respectively. For better understanding of this important xenobiotic transporter, we show the x-ray crystallographic structure of MexA at a resolution of 2.40 Angstrom. The global MexA structure showed unforeseen new features with a spiral assembly of six and seven protomers that were joined together at one end by a pseudo 2-fold image. The protomer showed a new protein structure with a tandem arrangement consisting of at least three domains and presumably one more. The rod domain had a long hairpin of twisted coiled-coil that extended to one end. The second domain adjacent to the rod alpha-helical domain was globular and constructed by a cluster of eight short beta-sheets. The third domain located distal to the alpha-helical rod was globular and composed of seven short beta-sheets and one short alpha-helix. The 13-mer was shaped like a woven rattan cylinder with a large internal tubular space and widely opened flared ends. The 6-mer and 7-mer had a funnel-like structure consisting of a tubular rod at one side and a widely opened flared funnel top at the other side. Based on these results, we constructed a model of the MexAB-OprM pump assembly. The three pairs of MexA dimers interacted with the periplasmic alpha-barrel domain of OprM via the alpha-helical hairpin, the second domain interacted with both MexB and OprM at their contact site, and the third and disordered domains probably interacted with the distal domain of MexB. In this fashion, the MexA subunit connected MexB and OprM, indicating that MexA is the membrane bridge protein.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Osaka University; Tokai University	Nakagawa, A (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atsushi@protein.osaka-u.ac.jp	Nakagawa, Atsushi/M-5731-2019; Nakagawa, Atsushi/D-4329-2009; Matsuura, Takanori/J-1413-2012	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861; Matsuura, Takanori/0000-0003-2001-9537; Narita, Shin-ichiro/0000-0001-9425-2943				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P41; BRUNGER AT, 1998, ACTA CRYSTALLGOR D, V54, P240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DONG QH, 1994, MOL MICROBIOL, V14, P185, DOI 10.1111/j.1365-2958.1994.tb01278.x; Eda S, 2003, J BIOL CHEM, V278, P2085, DOI 10.1074/jbc.C200661200; Elkins CA, 2003, J BACTERIOL, V185, P5349, DOI 10.1128/JB.185.18.5349-5356.2003; GRAHAM LL, 1991, TRENDS BIOCHEM SCI, V16, P328, DOI 10.1016/0968-0004(91)90135-I; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakajima A, 2000, J BIOL CHEM, V275, P30064, DOI 10.1074/jbc.M005742200; Narita S, 2003, BIOCHEM BIOPH RES CO, V308, P922, DOI 10.1016/S0006-291X(03)01512-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; Saito K, 2001, FEMS MICROBIOL LETT, V195, P23, DOI 10.1016/S0378-1097(00)00539-5; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000	42	213	225	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25939	25942		10.1074/jbc.C400164200	http://dx.doi.org/10.1074/jbc.C400164200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15117957	Green Published, hybrid			2022-12-27	WOS:000222003000002
J	Bohuslav, J; Chen, LF; Kwon, H; Mu, YJ; Greene, WC				Bohuslav, J; Chen, LF; Kwon, H; Mu, YJ; Greene, WC			p53 induces NF-kappa B activation by an I kappa B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; LIVER DEGENERATION; GENE-EXPRESSION; PROTEIN-KINASE; EMBRYONIC LETHALITY; INDUCED APOPTOSIS; MICE LACKING; GROWTH	Apoptosis induced by p53 has been proposed to involve activation of the transcription factor NF-kappaB. Here we describe the novel molecular mechanism through which p53 and DNA-damaging agents activate NF-kappaB. NF-kappaB induction by p53 does not occur through classical activation of the IkappaB kinases and degradation of IkappaBalpha. Rather, p53 expression stimulates the serine/threonine kinase ribosomal S6 kinase 1 (RSK1), which in turn phosphorylates the p65 subunit of NF-kappaB. The lower affinity of RSK1-phosphorylated p65 for its negative regulator, IkappaBalpha, decreases IkappaBalpha-mediated nuclear export of shuttling forms of NF-kappaB, thereby promoting the binding and action of NF-kappaB on cognate kappaB enhancers. These findings highlight a rather unusual pathway of NF-kappaB activation, which is utilized by the p53 tumor suppressor.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	wgreene@gladstone.ucsf.edu			NCI NIH HHS [R01CA089001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doerre S, 1999, J IMMUNOL, V163, P269; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kang JL, 2000, TOXICOL APPL PHARM, V169, P59, DOI 10.1006/taap.2000.9039; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Teixeiro E, 1999, EUR J IMMUNOL, V29, P745, DOI 10.1002/(SICI)1521-4141(199903)29:03<745::AID-IMMU745>3.0.CO;2-0; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	80	207	217	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26115	26125		10.1074/jbc.M313509200	http://dx.doi.org/10.1074/jbc.M313509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073170	hybrid			2022-12-27	WOS:000222003000025
J	Qin, JZ; Jiang, ZF; Qian, YC; Casanova, JL; Li, XX				Qin, JZ; Jiang, ZF; Qian, YC; Casanova, JL; Li, XX			IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; BACTERIAL-INFECTIONS; DROSOPHILA TOLL; ACTIVATION; FAMILY; COMPLEX; MEMBER; MECHANISMS; PATHWAY; CASCADE	Interleukin-1 (IL-1) stimulation leads to the recruitment of interleukin-1 receptor-associated kinase ( IRAK) to the IL-1 receptor, where IRAK is phosphorylated, ubiquitinated, and eventually degraded. Kinase-inactive mutant IRAK is still phosphorylated in response to IL-1 stimulation when it is transfected into IRAK-deficient cells, suggesting that there must be an IRAK kinase in the pathway. The fact that IRAK4, another IRAK family member necessary for the IL-1 pathway, is able to phosphorylate IRAK in vitro suggests that IRAK4 might be the IRAK kinase. However, we now found that the IRAK4 kinase-inactive mutant had the same ability as the wild-type IRAK4 in restoring IL-1-mediated signaling in human IRAK4-deficient cells, including NFkappaB-dependent reporter gene expression, the activation of NFkappaB and JNK, and endogenous IL-8 gene expression. These results strongly indicate that the kinase activity of human IRAK4 is not necessary for IL-1 signaling. Furthermore, we showed that the kinase activity of IRAK4 was not necessary for IL-1-induced IRAK phosphorylation, suggesting that IRAK phosphorylation can probably be achieved either by autophosphorylation or by trans-phosphorylation through IRAK4. In support of this, only the impairment of the kinase activity of both IRAK and IRAK4 efficiently abolished the IL-1 pathway, demonstrating that the kinase activity of IRAK and IRAK4 is redundant for IL-1-mediated signaling. Moreover, consistent with the fact that IRAK4 is a necessary component of the IL-1 pathway, we found that IRAK4 was required for the efficient recruitment of IRAK to the IL-1 receptor complex.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Univ Paris 05, INSERM,U550, Unite Immunol & Hematol Pediat, Lab Genet Humaine Malad Infect Unite Mixte Rech, F-75270 Paris 06, France; Cleveland State Univ, Dept Biol, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University System of Ohio; Cleveland State University	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	lix@ccf.org	Casanova, Jean-Laurent/I-3418-2017	Casanova, Jean-Laurent/0000-0002-7782-4169	NIGMS NIH HHS [GM 60020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; JIANG Z, 2002, J BIOL CHEM; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	84	92	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26748	26753		10.1074/jbc.M400785200	http://dx.doi.org/10.1074/jbc.M400785200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084582	hybrid			2022-12-27	WOS:000222003000101
J	Sayed, AA; Williams, DL				Sayed, AA; Williams, DL			Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; CYSTEINE-SULFINIC ACID; NECROSIS-FACTOR-ALPHA; THIOREDOXIN PEROXIDASE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; ENZYMATIC CHARACTERIZATION; PLASMODIUM-FALCIPARUM; ANTIOXIDANT ENZYMES; MOLECULAR-CLONING	Peroxiredoxins are a large family of peroxidases that have important antioxidant and cell signaling functions. Genes encoding two novel 2-cysteine peroxiredoxin proteins were identified in the expressed sequence tag data base of the helminth parasite Schistosoma mansoni, a causative agent of schistosomiasis. The recombinant proteins showed peroxidase activity in vitro with a variety of hydroperoxides and used both the thioredoxin and the glutathione systems as electron donors. Steady-state kinetic analysis indicated that the new peroxiredoxins had saturable kinetics, whereas a previously identified schistosome peroxiredoxin was found to function with more typical unsaturable (ping-pong) kinetics. The catalytic efficiencies S. mansoni peroxiredoxins were similar to those for other peroxiredoxins studied (10(4)-10(5) M-1 s(-1)). Mutagenesis of S. mansoni peroxiredoxins indicated that glutathione dependence and kinetic differences were conferred by the C-terminal alpha-helix forming 22 amino acids. This is the first report of 2-cysteine peroxiredoxins efficiently utilizing reducing equivalents from both the thioredoxin and glutathione systems. Studies to determine the resistance to oxidative inactivation, important in regulating cell signaling pathways, showed that S. mansoni possess both bacterial-like resistant and mammalian-like sensitive peroxiredoxins. The susceptibility to oxidative inactivation was conferred by the C-terminal tail containing a tyrosine-phenylalanine motif. S. mansoni is the first organism shown to possess both robust and sensitive peroxiredoxins. The ability of schistosome peroxiredoxins to use alternative electron donors, and their variable resistance to overoxidation may reflect their presence in different cellular sites and emphasizes the significant differences in overall redox balance mechanisms between the parasite and its mammalian host.	Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA	Illinois State University	Williams, DL (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA.	dlwilli@ilstu.edu						Alger HM, 2002, INT J PARASITOL, V32, P1285, DOI 10.1016/S0020-7519(02)00108-X; Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Bauer H, 2003, EUR J BIOCHEM, V270, P4272, DOI 10.1046/j.1432-1033.2003.03812.x; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P27670; DAMIAN RT, 1987, J PARASITOL, V73, P3, DOI 10.2307/3282338; DOENHOFF MJ, 1985, IMMUNOL TODAY, V6, P203, DOI 10.1016/0167-5699(85)90034-9; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Foulk BW, 2002, INT J PARASITOL, V32, P1487, DOI 10.1016/S0020-7519(02)00161-3; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515; Kawazu S, 2000, MOL BIOCHEM PARASIT, V109, P165, DOI 10.1016/S0166-6851(00)00243-7; KAZURA JW, 1985, J CLIN INVEST, V75, P1297, DOI 10.1172/JCI111830; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Kwatia MA, 2000, J PARASITOL, V86, P908, DOI 10.1645/0022-3395(2000)086[0908:MAECOS]2.0.CO;2; Le Paslier MC, 2000, GENOMICS, V65, P87, DOI 10.1006/geno.2000.6147; LoVerde PT, 1998, PARASITOL TODAY, V14, P284, DOI 10.1016/S0169-4758(98)01261-7; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; MKOJI GM, 1988, INT J PARASITOL, V18, P661, DOI 10.1016/0020-7519(88)90101-4; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I; Williams DL, 2001, INFECT IMMUN, V69, P1134, DOI 10.1128/IAI.69.2.1134-1141.2001; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	48	100	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26159	26166		10.1074/jbc.M401748200	http://dx.doi.org/10.1074/jbc.M401748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075328	hybrid			2022-12-27	WOS:000222003000030
J	Tian, MY; Huitema, E; da Cunha, L; Torto-Alalibo, T; Kamoun, S				Tian, MY; Huitema, E; da Cunha, L; Torto-Alalibo, T; Kamoun, S			A Kazal-like extracellular serine protease inhibitor from Phytophthora infestans targets the tomato pathogenesis-related protease P69B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; CLADOSPORIUM-FULVUM; PROTEINASE-INHIBITOR; MOLECULAR-CLONING; RESISTANCE; DATABASE; SEQUENCE; FAMILIES; ELICITORS; PLANTS	The oomycetes form one of several lineages within the eukaryotes that independently evolved a parasitic lifestyle and consequently are thought to have developed alternative mechanisms of pathogenicity. The oomycete Phytophthora infestans causes late blight, a ravaging disease of potato and tomato. Little is known about processes associated with P. infestans pathogenesis, particularly the suppression of host defense responses. We describe and functionally characterize an extracellular protease inhibitor, EPI1, from P. infestans. EPI1 contains two domains with significant similarity to the Kazal family of serine protease inhibitors. Database searches suggested that Kazal-like proteins are mainly restricted to animals and apicomplexan parasites but appear to be widespread and diverse in the oomycetes. Recombinant EPI1 specifically inhibited subtilisin A among major serine proteases and inhibited and interacted with the pathogenesis-related P69B subtilisin-like serine protease of tomato in intercellular fluids. The epi1 and P69B genes were coordinately expressed and up-regulated during infection of tomato by P. infestans. Inhibition of tomato proteases by EPI1 could form a novel type of defense-counterdefense mechanism between plants and microbial pathogens. In addition, this study points to a common virulence strategy between the oomycete plant pathogen P. infestans and several mammalian parasites, such as the apicomplexan Toxoplasma gondii.	Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Plant Pathol, Wooster, OH 44691 USA	University System of Ohio; Ohio State University	Kamoun, S (corresponding author), Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Plant Pathol, 1680 Madison Ave, Wooster, OH 44691 USA.	kamoun.1@osu.edu	Kamoun, Sophien/B-3529-2009; Huitema, Edgar/G-3760-2011	Kamoun, Sophien/0000-0002-0290-0315; Huitema, Edgar/0000-0002-5766-0830; Tian, Miaoying/0000-0001-8900-6414				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreu A, 1998, EUR J PLANT PATHOL, V104, P777, DOI 10.1023/A:1008602910733; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Birch PRJ, 2001, MOL PLANT PATHOL, V2, P257, DOI 10.1046/j.1464-6722.2001.00073.x; Bouarab K, 2002, NATURE, V418, P889, DOI 10.1038/nature00950; CATEN CE, 1968, CAN J BOTANY, V46, P329, DOI 10.1139/b68-055; Chain P, 2003, J BACTERIOL, V185, P2759, DOI 10.1128/JB.185.9.2759-2773.2003; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Dubey JP, 1998, PARASITOLOGY, V116, P43, DOI 10.1017/S0031182097001935; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; HEATH MC, 1995, CAN J BOT, V73, pS616, DOI 10.1139/b95-303; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; HUITEMA E, 2003, FUNCTIONAL GENOMICS, P79; Joosten MHAJ, 1997, PLANT CELL, V9, P367; Jorda L, 1999, J BIOL CHEM, V274, P2360, DOI 10.1074/jbc.274.4.2360; Kamoun S, 1998, PLANT CELL, V10, P1413, DOI 10.1105/tpc.10.9.1413; KAMOUN S, 1993, MOL PLANT MICROBE IN, V6, P15, DOI 10.1094/MPMI-6-015; Kamoun S, 2003, EUKARYOT CELL, V2, P191, DOI 10.1128/EC.2.2.191-199.2003; Kamoun S, 1997, MOL PLANT MICROBE IN, V10, P13, DOI 10.1094/MPMI.1997.10.1.13; Karsch-Mizrachi I, 2001, Methods Biochem Anal, V43, P45; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lindh JG, 2001, MOL BIOCHEM PARASIT, V116, P137, DOI 10.1016/S0166-6851(01)00314-0; Lu SM, 2001, P NATL ACAD SCI USA, V98, P1410, DOI 10.1073/pnas.031581398; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MARGULIS L, 2000, 5 KINGDOMS ILLUSTRAT, P168; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; Morris MT, 2003, MOL BIOCHEM PARASIT, V128, P119, DOI 10.1016/S0166-6851(03)00051-3; Morris MT, 2002, J BIOL CHEM, V277, P45259, DOI 10.1074/jbc.M205517200; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; NIELSEN H, 1998, P 6 INT C INT SYST M, P122; Pszenny V, 2000, MOL BIOCHEM PARASIT, V107, P241, DOI 10.1016/S0166-6851(00)00202-4; Pszenny V, 2002, MOL BIOCHEM PARASIT, V121, P283, DOI 10.1016/S0166-6851(02)00045-2; Ristaino JB, 2002, MICROBES INFECT, V4, P1369, DOI 10.1016/S1286-4579(02)00010-2; Rose JKC, 2002, PLANT CELL, V14, P1329, DOI 10.1105/tpc.002253; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanchez Leandro M., 1992, Annals of the Phytopathological Society of Japan, V58, P664, DOI 10.3186/jjphytopath.58.664; Shattock RC, 2002, PEST MANAG SCI, V58, P944, DOI 10.1002/ps.527; SHEWMAKER CK, 1990, NUCLEIC ACIDS RES, V18, P4276, DOI 10.1093/nar/18.14.4276; Smart C. D., 2001, Biological Invasions, V3, P235, DOI 10.1023/A:1015200920772; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tornero P, 1997, J BIOL CHEM, V272, P14412, DOI 10.1074/jbc.272.22.14412; Torto TA, 2002, CURR GENET, V40, P385, DOI 10.1007/s00294-002-0272-4; Torto TA, 2003, GENOME RES, V13, P1675, DOI 10.1101/gr.910003; UNKLES SE, 1991, GENE, V100, P105, DOI 10.1016/0378-1119(91)90355-F; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; Waugh M, 2000, NUCLEIC ACIDS RES, V28, P87, DOI 10.1093/nar/28.1.87; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Yoshioka Hirofumi, 1995, Annals of the Phytopathological Society of Japan, V61, P7, DOI 10.3186/jjphytopath.61.7	56	216	234	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26370	26377		10.1074/jbc.M400941200	http://dx.doi.org/10.1074/jbc.M400941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096512	hybrid			2022-12-27	WOS:000222003000057
J	Wu, KL; Khan, S; Lakhe-Reddy, S; Jarad, G; Mukherjee, A; Obejero-Paz, CA; Konieczkowski, M; Sedor, JR; Schelling, JR				Wu, KL; Khan, S; Lakhe-Reddy, S; Jarad, G; Mukherjee, A; Obejero-Paz, CA; Konieczkowski, M; Sedor, JR; Schelling, JR			The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC VOLUME DECREASE; INTRACELLULAR PH; ERM PROTEINS; CASPASE ACTIVATION; OSMOTIC-STRESS; PATHWAY; MECHANISMS; GROWTH; EXPRESSION; TRANSLOCATION	Apoptosis results in cell shrinkage and intracellular acidification, processes opposed by the ubiquitously expressed NHE1 Na+/H+ exchanger. In addition to mediating Na+/H+ transport, NHE1 interacts with ezrin/radixin/moesin (ERM), which tethers NHE1 to cortical actin cytoskeleton to regulate cell shape, adhesion, motility, and resistance to apoptosis. We hypothesize that apoptotic stress activates NHE1-dependent Na+/H+ exchange, and NHE1-ERM interaction is required for cell survival signaling. Apoptotic stimuli induced NHE1-regulated Na+/H+ transport, as demonstrated by ethyl-N-isopropyl-amiloride-inhibitable, intracellular alkalinization. Ectopic NHE1, but not NHE3, expression rescued NHE1-null cells from apoptosis induced by staurosporine or N-ethylmaleimide-stimulated KCl efflux. When cells were subjected to apoptotic stress, NHE1 and phosphorylated ERM physically associated within the cytoskeleton-enriched fraction, resulting in activation of the pro-survival kinase, Akt. NHE1-associated Akt activity and cell survival were inhibited in cells expressing ERM binding-deficient NHE1, dominant negative ezrin constructs, or ezrin mutants with defective binding to phosphoinositide 3-kinase, an upstream regulator of Akt. We conclude that NHE1 promotes cell survival by dual mechanisms: by defending cell volume and pH(i) through Na+/H+ exchange and by functioning as a scaffold for recruitment of a signalplex that includes ERM, phosphoinositide 3-kinase, and Akt.	Case Western Reserve Univ, Rammelkamp Ctr Res, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Dept Physiol & Biophys, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System	Schelling, JR (corresponding author), 2500 MetroHlth Dr,G531, Cleveland, OH 44109 USA.	jeffrey.schelling@case.edu	Mukherjee, Amitava/AAK-4002-2020	Mukherjee, Amitava/0000-0001-5603-5147	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178, R01DK064719, R01DK038558] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK054178, DK64719, DK38558] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bortner CD, 2003, J BIOL CHEM, V278, P39176, DOI 10.1074/jbc.M303516200; Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Jarad G, 2002, J BIOL CHEM, V277, P47826, DOI 10.1074/jbc.M204901200; Khan S, 2001, KIDNEY INT, V60, P65, DOI 10.1046/j.1523-1755.2001.00771.x; Khan S, 1999, LAB INVEST, V79, P1089; KITAMURA K, 1995, AM J PHYSIOL, V268, P101; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Orlov SN, 1996, BIOCHEM BIOPH RES CO, V221, P708, DOI 10.1006/bbrc.1996.0661; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Segal MS, 2001, AM J PHYSIOL-CELL PH, V281, pC1196, DOI 10.1152/ajpcell.2001.281.4.C1196; Soleimani M, 1998, KIDNEY INT, V53, P423, DOI 10.1046/j.1523-1755.1998.00771.x; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wu KL, 2003, AM J PHYSIOL-RENAL, V284, pF829, DOI 10.1152/ajprenal.00314.2002	47	138	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26280	26286		10.1074/jbc.M400814200	http://dx.doi.org/10.1074/jbc.M400814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096511	hybrid			2022-12-27	WOS:000222003000046
J	Karla, N; Kumar, V				Karla, N; Kumar, V			c-Fos is a mediator of the c-Myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; TRANSGENIC MICE; CYCLE ARREST; EXPRESSION; GENE; TARGET; GROWTH; DEATH; JUN; PROTOONCOGENES	The proto-oncogene c-myc encodes a transcription factor that plays a pivotal role in cell proliferation, differentiation, and apoptosis. The signaling mechanism of c-Myc-induced apoptosis was investigated on the human hepatoma Huh7 cells under growth factor-deprived conditions. The apoptotic process did not involve p53. Rather it was dependent on the expression of c-Fos. Activation of caspases 3 and 9 and down-regulation of Bcl2 were observed in the apoptotic process, indicating it to be a mitochondria-dependent event. An increase in the p38 mitogen-activated protein kinase that was mediated by a Rac1-dependent and cdc42-independent pathway eventually leading to up-regulation of c-Fos activity was also observed. Deletion analysis of the promoter region of the c-fos gene indicated that the ATF2-responsive element conferred the Myc-induced expression of c-Fos. Co-expression of the dominant-negative mutants of c-Fos, p38, and Rac1 blocked the Myc-mediated apoptosis. SB20358, a chemical inhibitor of p38 pathway, also specifically blocked the apoptotic signaling by c-Myc. Furthermore, co-expression of the hepatitis B virus X protein (HBx) along with Myc abrogated the apoptotic signals. The HBx expression was associated with an increase in the levels of phosphorylated AKT and down-regulation of c-Fos by Myc. Thus, c-Fos seems be a new mediator of c-Myc-induced apoptosis.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Kumar, V (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, India.	vijay@icgeb.res.in		Kumar, Vijay/0000-0001-6477-8274				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIDOFF AN, 1993, ANTICANCER RES, V13, P2257; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Inada K, 1998, J IMMUNOL, V161, P3853; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Kumari SR, 2000, CANCER INVEST, V18, P715, DOI 10.3109/07357900009012203; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Poon HK, 2000, INVEST OPHTH VIS SCI, V41, P2755; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J., 2001, MOL CLONING LAB MANU; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shih WL, 2003, J BIOL CHEM, V278, P31807, DOI 10.1074/jbc.M302580200; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shirasuna K, 1999, GENES CELLS, V4, P277, DOI 10.1046/j.1365-2443.1999.00258.x; Shiu YT, 2003, BIOCHEM BIOPH RES CO, V303, P548, DOI 10.1016/S0006-291X(03)00388-7; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Teng CS, 1998, CONTRACEPTION, V57, P281, DOI 10.1016/S0010-7824(98)00023-7; Teng CS, 2000, INT REV CYTOL, V197, P137, DOI 10.1016/S0074-7696(00)97004-9; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG XW, 1995, CANCER RES, V55, P6012; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	68	67	78	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25313	25319		10.1074/jbc.M400932200	http://dx.doi.org/10.1074/jbc.M400932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078869	hybrid			2022-12-27	WOS:000221827900051
J	Murphy, KA; Villano, CM; Dorn, R; White, LA				Murphy, KA; Villano, CM; Dorn, R; White, LA			Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL REGULATION; CLEFT-PALATE; ALL-TRANS; PROTEIN; DIOXIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; BINDING; TRANSCRIPTION	Exposure to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) results in a variety of pathological lesions in humans via activation of the aryl hydrocarbon receptor (AhR) pathway. It has become apparent that this pathway interacts with a variety of signaling pathways that are believed to be involved in mediating TCDD/AhR biological effects. Our hypothesis is that TCDD mediates these pathological lesions by directly altering the expression of genes involved in matrix deposition and remodeling and that the retinoic acid signaling pathway is involved in modulating TCDD-induced effects. Therefore, we examined the effect of TCDD and all-trans retinoic acid (atRA) on the expression of matrix metalloproteinase-1 (MMP-1, interstitial collagenase), one of the proteolytic enzymes that degrade type I collagen, in normal human keratinocytes. The data show that TCDD exposure results in increased MMP-1 expression in keratinocytes that is further enhanced by co-treatment with all-trans retinoic acid. TCDD-induced expression of MMP-1 appears to be mediated through two AP-1 elements in the proximal promoter of the MMP-1 gene. However, retinoic acid-mediated induction of keratinocyte MMP-1 is a result of both promoter activation and increased mRNA stability. These findings are the first to demonstrate TCDD-induced expression of MMP-1 and to demonstrate interactions between the TCDD/AhR and retinoic acid pathways on MMP-1 expression.	Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	White, LA (corresponding author), Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA.	lawhite@aesop.rutgers.edu			NIEHS NIH HHS [K22 ES 00334-01 ZES1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES000334] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1990, TOXICOL APPL PHARM, V106, P418, DOI 10.1016/0041-008X(90)90337-T; Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Benbow U, 1999, BRIT J CANCER, V79, P221, DOI 10.1038/sj.bjc.6690037; Benbrook DM, 1997, GYNECOL ONCOL, V66, P114, DOI 10.1006/gyno.1997.4736; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; FitzGerald CT, 1996, ARCH BIOCHEM BIOPHYS, V333, P170, DOI 10.1006/abbi.1996.0378; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; Guenther MG, 2000, GENE DEV, V14, P1048; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; Huang EY, 2000, GENE DEV, V14, P45; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Khasigov PZ, 2001, BIOCHEMISTRY-MOSCOW+, V66, P130, DOI 10.1023/A:1002879128392; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kobayashi T, 1998, DERMATOLOGY, V197, P1, DOI 10.1159/000017967; Krig SR, 2000, TOXICOL SCI, V56, P357, DOI 10.1093/toxsci/56.2.357; Lorick KL, 1998, BIOCHEM BIOPH RES CO, V243, P749, DOI 10.1006/bbrc.1998.8173; Luca M, 1997, AM J PATHOL, V151, P1105; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martinez JM, 2002, TOXICOL SCI, V69, P409, DOI 10.1093/toxsci/69.2.409; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; Mueller BM, 1996, CURR TOP MICROBIOL, V213, P65; Mukerjee D, 1998, J AIR WASTE MANAGE, V48, P157, DOI 10.1080/10473289.1998.10463655; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Roman BL, 1998, TOXICOL APPL PHARM, V150, P254, DOI 10.1006/taap.1998.8395; ROSAS VE, 1996, INT J DERMATOL, V35, P643; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SADEK CM, 1994, J BIOL CHEM, V269, P16067; Sambrook J., 2001, MOL CLONING LAB MANU; Schoenermark MP, 1999, ANN NY ACAD SCI, V878, P466, DOI 10.1111/j.1749-6632.1999.tb07703.x; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takagi TN, 2000, TERATOGEN CARCIN MUT, V20, P73, DOI 10.1002/(SICI)1520-6866(2000)20:2<73::AID-TCM3>3.0.CO;2-M; VINCENTI MP, 1996, CRIT REV EUKARYOT GE; von Marschall Z, 1999, BRIT J CANCER, V80, P935, DOI 10.1038/sj.bjc.6690446; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WESTON WM, 1995, BIOCHEM BIOPH RES CO, V207, P690, DOI 10.1006/bbrc.1995.1242; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; YIN H, 1994, EXP CLIN IMMUNOGENET, V11, P128	55	67	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25284	25293		10.1074/jbc.M402168200	http://dx.doi.org/10.1074/jbc.M402168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075337	hybrid			2022-12-27	WOS:000221827900047
J	Sazonova, IY; Robinson, BR; Gladysheva, IP; Castellino, FJ; Reed, GL				Sazonova, IY; Robinson, BR; Gladysheva, IP; Castellino, FJ; Reed, GL			alpha domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; FACTOR-XIII; BINDING; COMPLEX; CONFORMATION; SUBSTRATE; KINETICS; PLASMA; SITE; UROKINASE	The mechanism of action of plasminogen (Pg) activators may affect their therapeutic properties in humans. Streptokinase (SK) is a robust Pg activator in physiologic fluids in the absence of fibrin. Deletion of a "catalytic switch" (SK residues 1-59), alters the conformation of the SK alpha domain and converts SKDelta59 into a fibrin-dependent Pg activator through unknown mechanisms. We show that the SK alpha domain binds avidly to the Pg kringle domains that maintain Glu-Pg in a tightly folded conformation. By virtue of deletion of SK residues 1-59, SKDelta59 loses the ability to unfold Glu-Pg during complex formation and becomes incapable of nonproteolytic active site formation. In this manner, SKDelta59 behaves more like staphylokinase than like SK; it requires plasmin to form a functional activator complex, and in this complex SKDelta59 does not protect plasmin from inhibition by alpha(2)-antiplasmin. At the same time, SKDelta59 is unlike staphylokinase or SK and is more like tissue Pg activator, because it is a poor activator of the tightly folded form of Glu-Pg in physiologic solutions. SKDelta59 can only activate Glu-Pg when it was unfolded by fibrin interactions or by Cl--deficient buffers. Taken together, these studies indicate that an intact alpha domain confers on SK the ability to nonproteolytically activate Glu-Pg, to unfold and process Glu-Pg substrate in physiologic solutions, and to alter the substrate-inhibitor interactions of plasmin in the activator complex. The loss of an intact alpha domain makes SKDelta59 activate Pg through classical "fibrin-dependent mechanisms" (akin to both staphylokinase and tissue Pg activator) that include: 1) a marked preference for a fibrin-bound or unfolded Glu-Pg substrate, 2) a requirement for plasmin in the activator complex, and 3) the creation of an activator complex with plasmin that is readily inhibited by alpha(2)-antiplasmin.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; University of Notre Dame	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	guyreed@hsph.harvard.edu	Gladysheva, Inna/AAU-9465-2020	Gladysheva, Inna/0000-0002-2501-9029	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R01HL058496, R37HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13423, HL58496, R01 HL058496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P275; BANYAI L, 1984, J BIOL CHEM, V259, P6466; BARLOW GH, 1984, BIOCHEMISTRY-US, V23, P2384, DOI 10.1021/bi00306a010; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; BRINGMANN P, 1995, J BIOL CHEM, V270, P25596, DOI 10.1074/jbc.270.43.25596; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gladysheva IP, 2002, J BIOL CHEM, V277, P26846, DOI 10.1074/jbc.M202999200; HOLVOET P, 1991, J BIOL CHEM, V266, P19717; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LIJNEN HR, 1989, BLOOD, V73, P1864; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; LUKACOVA D, 1991, BIOCHEMISTRY-US, V30, P10164, DOI 10.1021/bi00106a013; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MOTULSKY HG, 1994, GRAPHPAD; Mundada LV, 2003, J BIOL CHEM, V278, P24421, DOI 10.1074/jbc.M301825200; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; Reed GL, 1999, CIRCULATION, V99, P299, DOI 10.1161/01.CIR.99.2.299; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; Sazonova IY, 2001, J BIOL CHEM, V276, P12609, DOI 10.1074/jbc.M009265200; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; Stewart RJ, 1998, J BIOL CHEM, V273, P18292, DOI 10.1074/jbc.273.29.18292; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; WIMAN B, 1986, THROMB HAEMOSTASIS, V55, P189; WOHL RC, 1980, J BIOL CHEM, V255, P2005; Wu DH, 2001, J BIOL CHEM, V276, P15025, DOI 10.1074/jbc.M005935200; Yakovlev S, 2000, BIOCHEMISTRY-US, V39, P15730, DOI 10.1021/bi001847a; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	55	18	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24994	25001		10.1074/jbc.M400253200	http://dx.doi.org/10.1074/jbc.M400253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069059	hybrid			2022-12-27	WOS:000221827900013
J	Selvapandiyan, A; Debrabant, A; Duncan, R; Muller, J; Salotra, P; Sreenivas, G; Salisbury, JL; Nakhasi, HL				Selvapandiyan, A; Debrabant, A; Duncan, R; Muller, J; Salotra, P; Sreenivas, G; Salisbury, JL; Nakhasi, HL			Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; MITOTIC SPINDLE POLES; VIRULENCE FACTOR; DONOVANI; CENTROSOMES; LIPOPHOSPHOGLYCAN; SEGREGATION; DELETION; DEATH; REPLACEMENT	Centrin is a calcium-binding cytoskeletal protein involved in the duplication of centrosomes in higher eukaryotes. To explore the role of centrin in the protozoan parasite Leishmania, we created Leishmania deficient in the centrin gene (LdCEN). Remarkably, centrin null mutants (LdCEN(-/-)) showed selective growth arrest as axenic amastigotes but not as promastigotes. Flow cytometry analysis confirmed that the mutant axenic amastigotes have a cell cycle arrest at the G(2)/M stage. The axenic amastigotes also showed failure of basal body duplication and failure of cytokinesis resulting in multinucleated "large" cells. Increased terminal deoxy uridine triphosphate nick end labeling positivity was observed in centrin mutant axenic amastigotes compared with wild type cells, suggesting the activation of a programmed cell death pathway. Growth of LdCEN(-/-) amastigotes in infected macrophages in vitro was inhibited and also resulted in large multinucleated parasites. Normal basal body duplication and cell division in the LdCEN knockout promastigote is unique and surprising. Further, this is the first report where disruption of a centrin gene displays stage-specific/celltype-specific failure in cell division in a eukaryote. The centrin null mutant defective in amastigote growth could be useful as a vaccine candidate against leishmaniasis.	US FDA, Ctr Biol Evaluat & Res, Off Blood Res & Review, Div Emerging & Transfus Transmitted Dis,Lab Bacter, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Off Vaccines Res & Review, Div Viral Prod,Lab Vector Borne Dis, Bethesda, MD 20892 USA; Safdarjang Hosp, Indian Council Med Res, Inst Pathol, New Delhi 110029, India; Mayo Clin, Coll Med, Tumor Biol Program, Rochester, MN 55905 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Indian Council of Medical Research (ICMR); ICMR - National Institute of Pathology (IOP); Vardhman Mahavir Medical College & Safdarjung Hospital; Mayo Clinic	Nakhasi, HL (corresponding author), US FDA, Ctr Biol Evaluat & Res, Off Blood Res & Review, Div Emerging & Transfus Transmitted Dis,Lab Bacter, Bldg 29,Rm 222,8800 Rockville Pike, Bethesda, MD 20892 USA.	nakhasi@cber.fda.gov	Selvapandiyan, Angamuthu/AAY-2556-2021; Selvapandiyan, Angamuthu/AAA-8602-2021; Duncan, Robert/I-8168-2015	Duncan, Robert/0000-0001-8409-2501; Salisbury, Jeffrey/0000-0001-9257-4578; Gannavaram, Sreenivas/0000-0002-6557-8220; Selvapandiyan, Angamuthu/0000-0002-2194-1534; Salotra, Poonam/0000-0002-4057-4872				BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Debrabant A, 2003, INT J PARASITOL, V33, P257, DOI 10.1016/S0020-7519(03)00008-0; Debrabant A, 2002, INT J PARASITOL, V32, P1423, DOI 10.1016/S0020-7519(02)00134-0; ERRABOLU R, 1994, J CELL SCI, V107, P9; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; Gavet O, 2003, MOL BIOL CELL, V14, P1818, DOI 10.1091/mbc.E02-11-0709; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Klink VP, 2001, MOL BIOL CELL, V12, P761, DOI 10.1091/mbc.12.3.761; Koblenz B, 2003, J CELL SCI, V116, P2635, DOI 10.1242/jcs.00497; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; Salisbury JL, 2004, CURR BIOL, V14, pR27, DOI 10.1016/j.cub.2003.12.019; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; Salisbury JL, 2003, CURR BIOL, V13, pR88, DOI 10.1016/S0960-9822(03)00033-2; Selvapandiyan A, 2001, J BIOL CHEM, V276, P43253, DOI 10.1074/jbc.M106806200; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; VALLEN EA, 1994, GENETICS, V137, P407; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6	39	89	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25703	25710		10.1074/jbc.M402794200	http://dx.doi.org/10.1074/jbc.M402794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084606	hybrid			2022-12-27	WOS:000221827900100
J	Wu, JJP; Guidotti, G				Wu, JJP; Guidotti, G			Proreceptor dimerization is required for insulin receptor post-translational processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I DISULFIDES; SUBUNITS; BONDS; CYSTEINE-524; ECTODOMAIN; MONOMERS	The insulin receptor is a transmembrane protein dimer composed of two alphabeta monomers held together by inter-alpha-chain disulfide bonds. In a previous report we described a monomeric insulin receptor obtained by replacing Cys-524, -682, -683, and -685 with serine (Wu, J. J., and Guidotti, G. (2002) J. Biol. Chem. 277, 27809-27817). The membrane-bound monomeric insulin receptors could be cross-linked to dimers in the presence of insulin, indicating that although covalent interactions had been abolished, noncovalent dimerization could still occur in the membrane. To eliminate noncovalent dimerization, we replaced all or some of Cys-524, -682, -683, and -685 with arginine or aspartic acid with the expectation that the electrostatic repulsion at these contact sites would prevent noncovalent dimerization. The results indicate that mutant insulin receptors that are able to form covalent dimers are expressed at the wild type level; mutants that can form noncovalent dimers are expressed at half the level of the wild type receptor, whereas insulin receptor mutants that cannot dimerize are expressed at less than 10% of the wild type level. To elucidate the mechanism of the decrease in expression of the mutant insulin receptors, we examined their subcellular localization and biosynthesis. The results suggest that the extent of expression of these mutant receptors is related to their ability to form covalent or noncovalent dimers at the proreceptor stage.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	guidotti@fas.harvard.edu			NIDDK NIH HHS [DK27626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; BILAN PJ, 1994, BIOCHEM BIOPH RES CO, V205, P1891, DOI 10.1006/bbrc.1994.2891; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHIACCHIA KB, 1991, BIOCHEM BIOPH RES CO, V176, P1178, DOI 10.1016/0006-291X(91)90409-Z; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; HEDO JA, 1983, J BIOL CHEM, V258, P20; KASUGA M, 1982, J BIOL CHEM, V257, P392; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; OLSON TS, 1988, J BIOL CHEM, V263, P7342; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; Wu JJP, 2002, J BIOL CHEM, V277, P27809, DOI 10.1074/jbc.M200367200	19	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25765	25773		10.1074/jbc.M314281200	http://dx.doi.org/10.1074/jbc.M314281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075343	Green Published, hybrid			2022-12-27	WOS:000221827900106
J	Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Grewal, JS; Ullian, ME; Tholanikunnel, BG; Raymond, JR				Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Grewal, JS; Ullian, ME; Tholanikunnel, BG; Raymond, JR			Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; ABL TYROSINE KINASE; BREAST-CANCER CELLS; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; DIFFERENTIAL REGULATION; NUCLEAR-LOCALIZATION	We examined the relationship between mitogen-activated MEK (mitogen and extracellular signal-regulated protein kinase kinase) and phosphorylation of the gene product encoded by retinoblastoma ( hereafter referred to as Rb) in vascular smooth muscle cells. Brief treatment of the cells with 100 nM angiotensin II or 1 muM serotonin resulted in serine phosphorylation of Rb that was equal in magnitude to that induced by treating cells for 20 h with 10% fetal bovine serum (approximate to3 x basal). There was no detectable rapid phosphorylation of two close cousins of Rb, p107 and p130. Phosphorylation state-specific antisera demonstrated that the rapid phosphorylation occurred on Ser(795), but not on Ser(249), Thr(252), Thr(373), Ser(780), Ser(807), or Ser(811). Phosphorylation of Rb Ser(795) peaked at 10 min, lagging behind phosphorylation of MEK and ERK (extracellular signal-regulated protein kinase). Rb Ser(795) phosphorylation could be blocked by PD98059, a MEK inhibitor, and greatly attenuated by apigenin, an inhibitor of the Ras --> Raf --> MEK --> ERK pathway. The effect also appears to be mediated by CDK4. Immunoprecipitation/immunoblot studies revealed that serotonin and angiotensin II induced complex formation between CDK4, cyclin D1, and phosphorylated ERK. These studies show a rapid, novel, and selective phosphorylation of Rb Ser(795) by mitogens and demonstrate an unexpected rapid linkage between the actions of the Ras --> Raf --> MEK --> ERK pathway and the phosphorylation state of Rb.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Garnovskaya, MN (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.	garnovsk@musc.edu		Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002694, R01DK052448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063909] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01-DK02694, R01-DK52448] Funding Source: Medline; NIGMS NIH HHS [R01-GM63909] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Allen KE, 1997, J CELL SCI, V110, P2819; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; delaLuna S, 1996, J CELL SCI, V109, P2443; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Felzien LK, 1997, MOL IMMUNOL, V34, P507, DOI 10.1016/S0161-5890(97)00063-1; Florian JA, 1998, J PHARMACOL EXP THER, V284, P346; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; GOLINO P, 1994, NEW ENGL J MED, V331, P131; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KUO ML, 1994, CANCER LETT, V87, P91, DOI 10.1016/0304-3835(94)90414-6; KUO ML, 1994, BIOCHEM BIOPH RES CO, V212, P91767; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee SL, 1997, AM J PHYSIOL-CELL PH, V272, pC223, DOI 10.1152/ajpcell.1997.272.1.C223; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Magae J, 1996, J CELL SCI, V109, P1717; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Mukhin YV, 2003, J PHARMACOL EXP THER, V304, P968, DOI 10.1124/jpet.102.043943; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Taieb F, 1998, FEBS LETT, V425, P465, DOI 10.1016/S0014-5793(98)00291-9; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Ullian ME, 1997, AM J PHYSIOL-CELL PH, V273, pC1241, DOI 10.1152/ajpcell.1997.273.4.C1241; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; WILLERSON JT, 1991, J AM COLL CARDIOL, V17, pB101; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	66	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24899	24905		10.1074/jbc.M311622200	http://dx.doi.org/10.1074/jbc.M311622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069084	hybrid			2022-12-27	WOS:000221702500122
J	Massa, A; Barbieri, F; Aiello, C; Arena, S; Pattarozzi, A; Pirani, P; Corsaro, A; Iuliano, R; Fusco, A; Zona, G; Spaziante, R; Florio, T; Schettini, G				Massa, A; Barbieri, F; Aiello, C; Arena, S; Pattarozzi, A; Pirani, P; Corsaro, A; Iuliano, R; Fusco, A; Zona, G; Spaziante, R; Florio, T; Schettini, G			The expression of the phosphotyrosine phosphatase DEP-1/PTP eta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL-GROWTH-FACTOR; HORMONE-RELEASING HORMONE; IN-VITRO; RECEPTOR SUBTYPES; ETA SUPPRESSES; THYROID-CELLS; COLON-CANCER; TUMOR-CELLS; ACTIVATION	Here we characterize the intracellular effectors of the antiproliferative activity of somatostatin in glioma cell lines and post-surgical specimens. The responsiveness to somatostatin correlated with the expression of the phosphotyrosine phosphatase DEP-1/PTPeta, identified in C6 and U87MG cells, in which somatostatin inhibited cell growth. The expression of a dominant negative mutant of DEP-1/PTPeta in C6 cells abolished somatostatin effects, confirming the involvement of this phosphotyrosine phosphatase in such effects. Somatostatin treatment increased the activity of DEP-1/PTPeta and inhibited ERK1/2 activation. Conversely, basic fibroblast growth factor-dependent MEK phosphorylation was not affected, suggesting a direct effect on ERK1/2. In vitro experiments showed that PTPeta was able to interact and dephosphorylate ERK1/2 activated by basic fibroblast growth factor. Furthermore, by transfecting PTPeta in the somatostatin-unresponsive, DEP-1/PTPeta-deficient U373MG cells, the somatostatin-dependent control of cell proliferation was recovered. Finally we evaluated the requirement for DEP-1/PTPeta in somatostatin inhibition of cell proliferation in post-surgical specimens derived from different grade human gliomas. Although all of the glioma analyzed expressed somatostatin receptor mRNA, DEP-1/PTPeta expression was limited to 8 of 22 of the tumors. Culturing seven gliomas, a correlation between the expression of DEP-1/PTPeta and the somatostatin antiproliferative effects was identified. In conclusion we propose that the expression and activation of DEP-1/PTPeta is required for somatostatin inhibition of glioma proliferation.	Univ Genoa, Dept Oncol Biol & Genet, Pharmacol Sect, I-16132 Genoa, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Catanzaro, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Naples Federico II, Natl Res Council, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy; Univ Naples Federico II, Dept Mol & Cellular Pathol, I-80131 Naples, Italy; Univ Genoa, Dept Neurosci Ophthalmol & Genet, Div Neurosurg, I-16132 Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II; University of Genoa	Florio, T (corresponding author), Univ Genoa, Dept Oncol Biol & Genet, Pharmacol Sect, Largo R Benzi 10, I-16132 Genoa, Italy.	florio@cba.unige.it	Barbieri, Federica/L-8753-2015; zona, gianluigi/AAF-8235-2021; FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012	Barbieri, Federica/0000-0001-8988-6896; Florio, Tullio/0000-0002-2394-996X; Fusco, Alfredo/0000-0003-3332-5197; ZONA, GIANLUIGI/0000-0002-3577-7894; Corsaro, Alessandro/0000-0003-4565-7914				Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEUNG NW, 1995, ENDOCRINOLOGY, V136, P4174, DOI 10.1210/en.136.10.4174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corsaro A, 2002, NEUROCHEM INT, V41, P55, DOI 10.1016/S0197-0186(01)00137-1; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dutour A, 1998, INT J CANCER, V76, P620, DOI 10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.3.CO;2-X; DY DY, 1992, CANCER RES, V52, P917; FEINDT J, 1995, J NEUROCHEM, V65, P1997; Florio T, 1999, EUR J ENDOCRINOL, V141, P396, DOI 10.1530/eje.0.1410396; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2003, ENDOCRINOLOGY, V144, P1574, DOI 10.1210/en.2002-220949; Florio T, 1997, ENDOCRINOLOGY, V138, P3756, DOI 10.1210/en.138.9.3756; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Florio T, 1996, J MOL ENDOCRINOL, V17, P89, DOI 10.1677/jme.0.0170089; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; Iuliano R, 2003, CANCER RES, V63, P882; Keane MM, 1996, CANCER RES, V56, P4236; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lamszus K, 1997, J NEURO-ONCOL, V35, P353, DOI 10.1023/A:1005893223090; LEE MT, 1991, P NATL ACAD SCI USA, V88, P1656, DOI 10.1073/pnas.88.5.1656; Lopez F, 1996, METABOLISM, V45, P14, DOI 10.1016/S0026-0495(96)90071-2; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PINSKI J, 1994, CANCER RES, V54, P5895; Plonowski A, 2002, PROSTATE, V52, P173, DOI 10.1002/pros.10105; Porcile C, 2003, NEUROCHEM INT, V43, P31, DOI 10.1016/S0197-0186(02)00197-3; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Reardon DB, 1997, MOL ENDOCRINOL, V11, P1062, DOI 10.1210/me.11.8.1062; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; REUBI JC, 1987, CANCER RES, V47, P551; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SCHETTINI G, 1989, BRAIN RES, V492, P65, DOI 10.1016/0006-8993(89)90889-5; Srikant CB, 1996, ENDOCRINOLOGY, V137, P3461, DOI 10.1210/en.137.8.3461; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	54	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29004	29012		10.1074/jbc.M403573200	http://dx.doi.org/10.1074/jbc.M403573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123617	hybrid			2022-12-27	WOS:000222445300023
J	Akagi, T; Inoue, T; Miyoshi, G; Bessho, Y; Takahashi, M; Lee, JE; Guillemot, F; Kageyama, R				Akagi, T; Inoue, T; Miyoshi, G; Bessho, Y; Takahashi, M; Lee, JE; Guillemot, F; Kageyama, R			Requirement of multiple basic helix-loop-helix genes for retinal neuronal subtype specification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FATE DETERMINATION; DEVELOPING NERVOUS-SYSTEM; MAMMALIAN ACHAETE-SCUTE; DEVELOPING RAT RETINA; HOMEOBOX GENE; VERTEBRATE RETINA; GANGLION-CELL; BHLH PROTEIN; DIFFERENTIATION; PHOTORECEPTOR	Retinal precursor cells give rise to six types of neurons and one type of glial cell during development, and this process is controlled by multiple basic helix-loop-helix ( bHLH) genes. However, the precise mechanism for specification of retinal neuronal subtypes, particularly horizontal neurons and photoreceptors, remains to be determined. Here, we examined retinas with three different combinations of triple bHLH gene mutations. In retinas lacking the bHLH genes Ngn2, Math3, and NeuroD, horizontal neurons as well as other neurons such as bipolar cells were severely decreased in number. In the retina lacking the bHLH genes Mash1, Ngn2, and Math3, horizontal and other neurons were severely decreased, whereas ganglion cells were increased. In the retina lacking the bHLH genes Mash1, Math3, and NeuroD, photoreceptors were severely decreased, whereas ganglion cells were increased. In all cases, glial cells were increased. The increase and decrease of these cells were the result of cell fate changes and cell death and seem to be partly attributable to the remaining bHLH gene expression, which also changes because of triple bHLH gene mutations. These results indicate that multiple bHLH genes cross-regulate each other, cooperatively specify neuronal subtypes, and regulate neuronal survival in the developing retina.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan; Kyoto Univ Hosp, Translat Res Ctr, Dept Expt Therapeut, Kyoto 6068507, Japan; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Natl Inst Med Res, London NW7 1AA, England	Kyoto University; Kyoto University; Kyoto University; University of Colorado System; University of Colorado Boulder; MRC National Institute for Medical Research	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	rkageyam@virus.kyoto-u.ac.jp	Miyoshi, Goichi/H-4759-2012; Miyoshi, Goichi/O-2029-2019; Guillemot, Francois/AAV-1482-2021					AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Brown NL, 1998, DEVELOPMENT, V125, P4821; Brown NL, 2001, DEVELOPMENT, V128, P2497; Cayouette M, 2003, NEURON, V40, P897, DOI 10.1016/S0896-6273(03)00756-6; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gradwohl G, 1996, DEV BIOL, V180, P227, DOI 10.1006/dbio.1996.0297; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; Haruta M, 2001, NAT NEUROSCI, V4, P1163, DOI 10.1038/nn762; Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005; Hatakeyama J, 2002, METHODS, V28, P387, DOI 10.1016/S1046-2023(02)00257-8; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hojo M, 2000, DEVELOPMENT, V127, P2515; Inoue T, 2002, DEVELOPMENT, V129, P831; Jasoni CL, 1996, J COMP NEUROL, V369, P319; Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9; Kill IR, 1996, J CELL SCI, V109, P1253; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; McGinnis JF, 1999, J NEUROSCI RES, V55, P252, DOI 10.1002/(SICI)1097-4547(19990115)55:2<252::AID-JNR13>3.0.CO;2-N; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; Wang SW, 2001, GENE DEV, V15, P24, DOI 10.1101/gad.855301; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	44	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28492	28498		10.1074/jbc.M400871200	http://dx.doi.org/10.1074/jbc.M400871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105417	hybrid			2022-12-27	WOS:000222265400084
J	Austermuhle, MI; Hall, JA; Klug, CS; Davidson, AL				Austermuhle, MI; Hall, JA; Klug, CS; Davidson, AL			Maltose-binding protein is open in the catalytic transition state for ATP hydrolysis during maltose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE ABC TRANSPORTER; INDUCED CONFORMATIONAL-CHANGES; RECONSTITUTED P-GLYCOPROTEIN; TERTIARY STRUCTURE CHANGES; ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; ACTIVE-TRANSPORT; LIGAND-BINDING; PERIPLASMIC PERMEASES; 2 MODES	The maltose transport complex of Escherichia coli, a member of the ATP-binding cassette superfamily, mediates the high affinity uptake of maltose at the expense of ATP. The membrane-associated transporter consists of two transmembrane subunits, MalF and MalG, and two copies of the cytoplasmic ATP-binding cassette subunit, MalK. Maltose-binding protein (MBP), a soluble periplasmic protein, delivers maltose to the MalFGK(2) transporter and stimulates hydrolysis by the transporter. Site-directed spin labeling electron paramagnetic resonance spectroscopy is used to monitor binding of MBP to MalFGK(2) and conformational changes in MBP as it interacts with MalFGK(2). Cysteine residues and spin labels have been introduced into the two lobes of MBP so that spin-spin interaction will report on ligand-induced closure of the protein (Hall, J.A., Thorgeirsson, T. E., Liu, J., Shin, Y. K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17610-17614). At least two different modes of interaction between MBP and MalFGK(2) were detected. Binding of MBP to MalFGK(2) in the absence of ATP resulted in a decrease in motion of spin label at position 41 in the C-terminal domain of MBP. In a vanadate-trapped transition state intermediate, all free MBP became tightly bound to MalFGK(2), spin label in both lobes became completely immobilized, and spin-spin interactions were lost, suggesting that MBP was in an open conformation. Binding of non-hydrolyzable MgATP analogs or ATP in the absence of Mg is sufficient to stabilize a complex of open MBP and MalFGK(2). Taken together, these data suggest that closure of the MalK dimer interface coincides with opening of MBP and maltose release to the transporter.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin	Davidson, AL (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, MS BCM 280,1 Baylor Plaza, Houston, TX 77030 USA.	davidson@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049261, R29GM049261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DUPLAY P, 1987, J MOL BIOL, V194, P675, DOI 10.1016/0022-2836(87)90244-0; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; Klug Candice S., 2004, V24, P269; Klug CS, 1997, BIOCHEMISTRY-US, V36, P13027, DOI 10.1021/bi971232m; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Liu RH, 2000, BIOCHEMISTRY-US, V39, P14927, DOI 10.1021/bi0018786; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; MANSON MD, 1985, J BIOL CHEM, V260, P9727; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; MARTINEAU P, 1990, BIOCHIMIE, V72, P397, DOI 10.1016/0300-9084(90)90063-M; MERINO G, 1995, J THEOR BIOL, V177, P171, DOI 10.1006/jtbi.1995.0236; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	63	65	70	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28243	28250		10.1074/jbc.M403508200	http://dx.doi.org/10.1074/jbc.M403508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117946	hybrid			2022-12-27	WOS:000222265400054
J	Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Piubelli, L; Ferranti, P; Picariello, G; Pilone, MS; Pollegioni, L				Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Piubelli, L; Ferranti, P; Picariello, G; Pilone, MS; Pollegioni, L			Unfolding intermediate in the peroxisomal flavoprotein D-amino acid oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOTORULA-GRACILIS; BETA-LACTOGLOBULIN; PROTEIN; IMPORT; PROTEOLYSIS; STABILITY; HEAT; FORM	The flavoenzyme D-amino acid oxidase ( DAAO) from Rhodotorula gracilis is a peroxisomal enzyme and a prototypical member of the glutathione reductase family of flavoproteins. DAAO is a stable homodimer with a FAD molecule tightly bound to each 40-kDa subunit. In this work, the urea-induced unfolding of dimeric DAAO was compared with that of a monomeric form of the same protein, a deleted dimerization loop mutant. By using circular dichroism spectroscopy, protein and flavin fluorescence, 1,8-anilinonaphtalene sulfonic acid binding and activity assays, we demonstrated that the urea-induced unfolding of DAAO is a three-state process, yielding an intermediate, and that this process is reversible. The intermediate species lacks the catalytic activity and the characteristic tertiary structure of native DAAO but has significant secondary structure and retains flavin binding. Unfolding of DAAO proceeds through formation of an expanded, partially unfolded inactive intermediate, characterized by low solubility, by increased exposure of hydrophobic surfaces, and by increased sensitivity to trypsin of the beta-strand F5 belonging to the FAD binding domain. The oligomeric state does not modify the inferred folding process. The strand F5 is in contact with the C-terminal alpha-helix containing the Ser-Lys-Leu sequence corresponding to the type 1 peroxisomal targeting signal, and this structural element interacts with the N-terminal betaalphabeta flavin binding motif (Rossmann fold). The expanded conformation of the folding intermediate (and in particular the higher disorder of the mentioned secondary structure elements) could match the structure of the inactive holoenzyme required for in vivo trafficking of DAAO through the peroxisomal membrane.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Milan, Dipartimento Sci Mol Agroaliment, I-20133 Milan, Italy; Univ Naples Federico II, Dipartimento Sci Alimenti, I-80055 Portici, Italy; CNR, Inst Food Sci, I-83100 Avellino, Italy	University of Insubria; University of Milan; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR)	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it	Iametti, Stefania/AGY-9694-2022; Ferranti, Pasquale/ABF-8111-2021	POLLEGIONI, LOREDANO/0000-0003-1733-7243; PIUBELLI, LUCIANO/0000-0003-0805-5121; Iametti, Stefania/0000-0002-4159-3768; Bonomi, Francesco/0000-0003-4556-2640; PICARIELLO, Gianluca/0000-0003-1290-1239; BARBIROLI, ALBERTO GIUSEPPE/0000-0003-1678-5431; FERRANTI, Pasquale/0000-0002-6250-6512				Ayed A, 1999, PROTEIN SCI, V8, P1116, DOI 10.1110/ps.8.5.1116; Brocard CB, 2003, TRAFFIC, V4, P74, DOI 10.1034/j.1600-0854.2003.40203.x; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAIROLI S, 1994, J PROTEIN CHEM, V13, P347, DOI 10.1007/BF01901568; Campaner S, 1998, BIOCHEM J, V330, P615, DOI 10.1042/bj3300615; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; Iametti S, 2002, EUR J BIOCHEM, V269, P1362, DOI 10.1046/j.1432-1033.2002.02769.x; Iametti S, 1996, EUR J BIOCHEM, V237, P106, DOI 10.1111/j.1432-1033.1996.0106n.x; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; Molla G, 1998, PROTEIN EXPRES PURIF, V14, P289, DOI 10.1006/prep.1998.0956; Neuberger G, 2003, J MOL BIOL, V328, P567, DOI 10.1016/S0022-2836(03)00318-8; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; Piubelli L, 2003, PROTEIN ENG, V16, P1063, DOI 10.1093/protein/gzg125; Piubelli L, 2002, FEBS LETT, V526, P43, DOI 10.1016/S0014-5793(02)03111-3; Pollegioni L, 2002, J MOL BIOL, V324, P535, DOI 10.1016/S0022-2836(02)01062-8; Pollegioni L, 2003, PROTEIN SCI, V12, P1018, DOI 10.1110/ps.0234603; POLLEGIONI L, 1995, BIOCHEM J, V310, P577, DOI 10.1042/bj3100577; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; PTISTYN OB, 1992, PROTEIN FOLDING, P243; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675	31	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28426	28434		10.1074/jbc.M403489200	http://dx.doi.org/10.1074/jbc.M403489200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102841	hybrid			2022-12-27	WOS:000222265400076
J	Cordell, PA; Futers, TS; Grant, PJ; Pease, RJ				Cordell, PA; Futers, TS; Grant, PJ; Pease, RJ			The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; PROTEIN; TRANSLATION; PATHWAY; CLONING; SYSTEM; IDENTIFICATION; METHYLGLYOXAL; PURIFICATION	In yeast and higher plants, separate genes encode the cytosolic and mitochondrial forms of glyoxalase II. In contrast, although glyoxalase II activity has been detected both in the cytosol and mitochondria of mammals, only a single gene encoding glyoxalase II has been identified. Previously it was thought that this gene ( the hydroxyacylglutathione hydrolase gene), comprised 8 exons that are transcribed into mRNA and that the resulting mRNA species encoded a single cytosolic form of glyoxalase II. Here we show that this gene gives rise to two distinct mRNA species transcribed from 9 and 10 exons, respectively. The 9-exon-derived transcript encodes two protein species: mitochondrially targeted glyoxylase II, which is initiated from an AUG codon in a previously uncharacterized part of the mRNA sequence, and cytosolic glyoxalase II, which is initiated by internal ribosome entry at a downstream AUG codon. The transcript deriving from 10 exons has an in-frame termination codon between the two initiating AUG codons and hence only encodes the cytosolic form of the protein. Confocal fluorescence microscopy indicates that the mitochondrially targeted form of glyoxalase II is directed to the mitochondrial matrix. Analysis of glyoxalase II mRNA sequences from a number of species indicates that dual initiation from alternative AUG codons is conserved throughout vertebrates.	Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England	University of Leeds	Grant, PJ (corresponding author), Gen Infirm, Martin Wing, Leeds LS1 3EX, W Yorkshire, England.	p.j.grant@leeds.ac.uk	Grant, Peter/HIR-3733-2022					Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Broadway NM, 2003, BIOCHEM J, V370, P223, DOI 10.1042/BJ20021269; Cho MY, 1998, EXP MOL MED, V30, P53, DOI 10.1038/emm.1998.8; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; Ji XH, 1997, BIOCHEM BIOPH RES CO, V241, P714, DOI 10.1006/bbrc.1997.7880; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; MacLean MJ, 1998, MOL MICROBIOL, V27, P563, DOI 10.1046/j.1365-2958.1998.00701.x; Maiti MK, 1997, PLANT MOL BIOL, V35, P471, DOI 10.1023/A:1005891123344; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scire A, 2000, PROTEINS, V41, P33, DOI 10.1002/1097-0134(20001001)41:1<33::AID-PROT60>3.0.CO;2-N; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Singla-Pareek SL, 2003, P NATL ACAD SCI USA, V100, P14672, DOI 10.1073/pnas.2034667100; TALESA V, 1988, BIOCHIM BIOPHYS ACTA, V955, P103, DOI 10.1016/0167-4838(88)90183-5; TALESA V, 1989, BIOCHIM BIOPHYS ACTA, V993, P7, DOI 10.1016/0304-4165(89)90135-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; UOTILA L, 1989, COENZYMES COFACTORS, V3, P767; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; Zang TM, 2001, J BIOL CHEM, V276, P4788, DOI 10.1074/jbc.M005090200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	36	44	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28653	28661		10.1074/jbc.M403470200	http://dx.doi.org/10.1074/jbc.M403470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117945	hybrid			2022-12-27	WOS:000222265400101
J	Murakami, A; Shen, HQ; Ishida, S; Dickson, C				Murakami, A; Shen, HQ; Ishida, S; Dickson, C			SOX7 and GATA-4 are competitive activators of Fgf-3 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; PROTO-ONCOGENE INT-2; RETINOIC ACID; MESSENGER-RNA; REGULATORY ELEMENTS; HEPARAN-SULFATE; MULTIPLE ROLES; EXPRESSION; GENE; DIFFERENTIATION	Fgf-3 is expressed in a dynamic and complex spatio-temporal pattern during mouse development. Previous studies identified GATA-4 as a transcription factor that binds the key regulatory element PS4A of the Fgf-3 promoter and stimulates transcription. Here we show that members of the SOX family of transcription factors also bind PS4A and differentially modulate transcription. At least five SOX genes, Sox2, Sox6, Sox7, Sox13, and Sox17, were expressed in F9 cells, and of these, Sox7 and Sox17 were dramatically induced in parallel with Fgf-3 following differentiation into parietal endoderm-like cells with retinoic acid and dibutyryl cAMP. Complexes could be detected on PS4A with SOX2, SOX7, and SOX17 by using nuclear extracts from differentiated F9 cells. However, only Sox7 expression markedly activated the Fgf-3 promoter in these cells. By contrast, SOX2 was a poor activator of Fgf-3 transcription, and when Sox2 was co-expressed with Gata4, it negatively modulated the strong activation mediated by GATA-4. More detailed analyses showed that SOX7 competes with GATA-4 for PS4A occupancy and to activate the Fgf-3 promoter. In situ hybridization analysis showed that Sox7 is co-expressed with Fgf-3 and Gata4 in the parietal endoderm of E7.5 mouse embryos. In culture, GATA-4-deficient embryonal stem cells were shown to express Fgf-3 upon differentiation into embryoid bodies, although at lower levels than were found in wild type embryonal stem cells. This Fgf-3 expression was virtually abolished when Sox7 expression was suppressed by RNA interference. These results show that SOX7 is a potent activator of Fgf-3 transcription.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; London Res Inst, Canc Res UK, London WC2A 3PX, England	Kyoto University; Cancer Research UK	Murakami, A (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	amurakam@virus.kyoto-u.ac.jp						ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DZIADEK MA, 1983, EMBO J, V2, P549, DOI 10.1002/j.1460-2075.1983.tb01461.x; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKay IJ, 1996, DEV BIOL, V174, P370, DOI 10.1006/dbio.1996.0081; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1977, GENE DEV, V111, P1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; Murakami A, 2002, NUCLEIC ACIDS RES, V30, P1056, DOI 10.1093/nar/30.4.1056; Murakami A, 2001, NUCLEIC ACIDS RES, V29, P3347, DOI 10.1093/nar/29.16.3347; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; NISWANDER L, 1992, DEVELOPMENT, V114, P755; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Roose J, 1998, NUCLEIC ACIDS RES, V26, P469, DOI 10.1093/nar/26.2.469; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Taniguchi K, 1999, BBA-GENE STRUCT EXPR, V1445, P225, DOI 10.1016/S0167-4781(99)00047-0; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J	50	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28564	28573		10.1074/jbc.M313814200	http://dx.doi.org/10.1074/jbc.M313814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15082719	hybrid			2022-12-27	WOS:000222265400092
J	Terui, Y; Saad, N; Jia, S; McKeon, F; Yuan, JY				Terui, Y; Saad, N; Jia, S; McKeon, F; Yuan, JY			Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; KAPPA-B-ALPHA; NF-AT; SUMO-1 MODIFICATION; COVALENT MODIFICATION; PORE COMPLEX; FAMILY; CALCINEURIN; RANGAP1; ENZYME	The nuclear import of nuclear factor of activated T cells ( NFAT) transcription factors is critical for regulating NFAT activity. Here we demonstrate that the sumoylation of NFAT1 defines a novel mechanism of the nuclear anchorage and transcriptional activation downstream from the known mechanism of calcineurin-mediated dephosphorylation and nuclear import. We show that Lys(684) and Lys(897) of NFAT1 can be sumoylated. The sumoylation at Lys(684) is required for NFAT1 transcriptional activity and subsequent sumoylation of Lys(897), whereas the sumoylation of Lys(897) is only required for nuclear anchorage. Because Lys(897) of NFAT1 is not conserved among other members of the NFAT family, we propose that sumoylation of Lys(897) may provide a mechanism for NFAT1 isotype-specific regulation of nuclear anchorage and transcriptional activation. Furthermore, we found that treatment with both ionomycin and phorbol 12-myristate 13-acetate ensured efficient nuclear anchorage with the recruitment of NFAT1 into the SUMO-1 bodies, whereas treatment with ionomycin alone induced nuclear translocation of NFAT1 but not recruitment into the SUMO-1 bodies. Our results suggest that the recruitment of NFAT1 into SUMO-1 bodies may be required for the progressive transcriptional activity of NFAT1 upon co-stimulation with ionomycin and phorbol 12-myristate 13-acetate, whereas anergic transcription stimulated by ionomycin alone may occur without recruitment into the SUMO-1 bodies.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Div Clin Chemotherapy, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	Harvard University; Harvard Medical School; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Terui, Yasuhito/GWC-4824-2022					Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Matsui K, 1998, J IMMUNOL, V161, P3469; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	37	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28257	28265		10.1074/jbc.M403153200	http://dx.doi.org/10.1074/jbc.M403153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117942	hybrid			2022-12-27	WOS:000222265400056
J	Kadas, J; Weber, IT; Bagossi, P; Miklossy, G; Boross, P; Oroszlan, S; Tozser, J				Kadas, J; Weber, IT; Bagossi, P; Miklossy, G; Boross, P; Oroszlan, S; Tozser, J			Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell leukemia virus type 1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANT MUTANTS; ROUS-SARCOMA-VIRUS; HIV-1 PROTEASE; KINETIC CHARACTERIZATION; INHIBITOR COMPLEX; ESCHERICHIA-COLI; PROTEINASE; GAG; EXPRESSION; ANALOG	Human T-cell leukemia virus type 1 (HTLV-1) is associated with a number of human diseases; therefore, its protease is a potential target for chemotherapy. To compare the specificity of HTLV-1 protease with that of human immunodeficiency virus type 1 (HIV-1) protease, oligopeptides representing naturally occurring cleavage sites in various retroviruses were tested. The number of hydrolyzed peptides as well as the specificity constants suggested a substantially broader specificity of the HIV protease. Amino acid residues of HTLV-1 protease substrate-binding sites were replaced by equivalent ones of HIV-1 protease. Most of the single and multiple mutants had altered specificity and a dramatically reduced folding and catalytic capability, suggesting that mutations are not well tolerated in HTLV-1 protease. The catalytically most efficient mutant was that with the flap residues of HIV-1 protease. The inhibition profile of the mutants was also determined for five inhibitors used in clinical practice and inhibitor analogs of HTLV-1 cleavage sites. Except for indinavir, the HIV-1 protease inhibitors did not inhibit wild type and most of the mutant HTLV-1 proteases. The wild type HTLV-1 protease was inhibited by the reduced peptide bond-containing substrate analogs, whereas the mutants showed various degrees of weakened binding capability. Most interesting, the enzyme with HIV-1-like residues in the flap region was the most sensitive to the HIV-1 protease inhibitors and least sensitive to the HTLV-1 protease inhibitors, indicating that the flap plays an important role in defining the specificity differences of retroviral proteases.	Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, Res Ctr Mol Med, H-4012 Debrecen, Hungary; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	University of Debrecen; University System of Georgia; Georgia State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tozser, J (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, Res Ctr Mol Med, POB 6, H-4012 Debrecen, Hungary.	tozser@indi.biochem.dote.hu	Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729	FIC NIH HHS [TW01001] Funding Source: Medline; NIGMS NIH HHS [R01 GM062920, GM62920] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062920] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagossi P, 2004, J VIROL METHODS, V119, P87, DOI 10.1016/j.jviromet.2004.03.001; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; Burmeister T, 2001, REV MED VIROL, V11, P369, DOI 10.1002/rmv.331; CAMERON CE, 1994, J BIOL CHEM, V269, P11170; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4&lt;255::AID-RMV282&gt;3.0.CO;2-6; Ding YS, 1998, BIOCHEMISTRY-US, V37, P17514, DOI 10.1021/bi982004a; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; Ermolieff J, 1997, BIOCHEMISTRY-US, V36, P12364, DOI 10.1021/bi971072e; Feher A, 2002, EUR J BIOCHEM, V269, P4114, DOI 10.1046/j.1432-1033.2002.03105.x; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Gustchina A, 1996, PROTEIN SCI, V5, P1453, DOI 10.1002/pro.5560050802; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; Hong L, 1997, FEBS LETT, V420, P11, DOI 10.1016/S0014-5793(97)01477-4; Hruskova-Heidingsfeldova Olga Vvo Blaha, 1997, Leukemia (Basingstoke), V11, P45; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Korber B.T., 1998, HUMAN RETROVIRUSES A; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; Lin YC, 2000, J VIROL, V74, P4710, DOI 10.1128/JVI.74.10.4710-4720.2000; Louis JM, 1999, J BIOL CHEM, V274, P6660, DOI 10.1074/jbc.274.10.6660; Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x; Mahalingam B, 2001, PROTEINS, V43, P455, DOI 10.1002/prot.1057; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P24134; MENENDEZARIAS L, 1995, J BIOL CHEM, V270, P29162, DOI 10.1074/jbc.270.49.29162; MENENDEZARIAS L, 1993, VIROLOGY, V196, P557, DOI 10.1006/viro.1993.1511; Merkulov GV, 1996, J VIROL, V70, P5548, DOI 10.1128/JVI.70.8.5548-5556.1996; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Pettit SC, 1998, AIDS RES HUM RETROV, V14, P1007, DOI 10.1089/aid.1998.14.1007; Powell DJ, 1996, EUR J BIOCHEM, V241, P664, DOI 10.1111/j.1432-1033.1996.00664.x; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sambrook J., 2001, MOL CLONING LAB MANU; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shao W, 1997, P NATL ACAD SCI USA, V94, P2243, DOI 10.1073/pnas.94.6.2243; Shuker SB, 2003, CHEM BIOL, V10, P373, DOI 10.1016/S1074-5521(03)00104-2; Stebbins J, 1997, J MOL BIOL, V267, P467, DOI 10.1006/jmbi.1997.0891; Swanstrom R, 2000, PHARMACOL THERAPEUT, V86, P145, DOI 10.1016/S0163-7258(00)00037-1; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; Tozser J, 1996, J BIOL CHEM, V271, P6781, DOI 10.1074/jbc.271.12.6781; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; Tozser J, 2000, EUR J BIOCHEM, V267, P6287, DOI 10.1046/j.1432-1327.2000.01714.x; Tozser Jozsef, 1997, Pathol Oncol Res, V3, P142; Wallqvist A, 1998, PROTEIN ENG, V11, P999, DOI 10.1093/protein/11.11.999; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; Weber IT, 1997, EUR J BIOCHEM, V249, P523, DOI 10.1111/j.1432-1033.1997.00523.x; Williams J W, 1979, Methods Enzymol, V63, P437; WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480; Zahuczky G, 2000, BBA-PROTEIN STRUCT M, V1478, P1, DOI 10.1016/S0167-4838(99)00240-X; ZHAO BG, 1993, BIOCHEMISTRY-US, V32, P13054, DOI 10.1021/bi00211a015	58	42	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27148	27157		10.1074/jbc.M401868200	http://dx.doi.org/10.1074/jbc.M401868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102858	hybrid			2022-12-27	WOS:000222120400041
J	MacDonald, MJ; Husain, RD; Hoffmann-Benning, S; Baker, TR				MacDonald, MJ; Husain, RD; Hoffmann-Benning, S; Baker, TR			Immunochemical identification of coenzyme Q(0)-dihydrolipoamide adducts in the E2 components of the alpha-ketoglutarate and pyruvate dehydrogenase complexes partially explains the cellular toxicity of coenzyme Q(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CA-2&-INDUCED MEMBRANE TRANSITION; PRIMARY BILIARY-CIRRHOSIS; 2 SEPARATE SITES; PANCREATIC-ISLETS; INSULIN-SECRETION; PYRIDINE-NUCLEOTIDES; LIPOIC ACID; PORE; INHIBITION	Coenzyme Q(0) (Q(0)), a strong electrophile, is toxic to insulin-producing cells. Q(0) was incubated with rat and human pancreatic islets and INS-1 insulinoma cells, and its attachment to cellular proteins was studied with Western analysis using antiserum raised against the benzoquinone ring structure of ubiquinone (anti-Q). Q(0) covalently bonded to two proteins, one of 50 kDa and another of 70 kDa. Both proteins were found to be mitochondrial in human and rat islet cells and in many rat organs. Mitochondria were incubated with Q(0), and affinity-purified anti-Q was used to immunoprecipitate the 50-kDa protein. Amino acid sequencing identified it as dihydrolipoamide succinyltransferase, the E2 component of the alpha-ketoglutarate dehydrogenase complex (KDC). Western analysis also showed that Q(0) bonds to the E2 components of the purified KDC and the pyruvate dehydrogenase complex (PDC). Dihydrolipoamide acetyltransferase, the E2 of the PDC, has a molecular mass of 70 kDa, and the 70-kDa protein was inferred to be this enzyme. Q(0) was found to bond only to proteins containing dihydrolipoate, and in preparations of mitochondria, thiol reducing agents facilitated the attachment of Q(0), but oxidizing agents prevented it, suggesting that Q(0) bonds to thiols of dihydrolipoamide. Incubation of human or pig PDC with Q(0) followed by matrix-assisted laser desorption ionization time-of-flight and liquid chromatography/electrospray ionization mass spectrometry analyses of chymotrypsin-digested peptides of PDC E2 confirmed that Q(0) bonds to the dihydrolipoamide in these proteins. In mitochondria, coenzymes Q(1) and Q(2) did not bond to the 50-kDa protein but competed with the bonding of Q(0) to this protein. The prevention by Q(1) of the bonding of Q(0) to KDC E2, as well as other characteristics of the Q(0) effect, are reminiscent of the action of Q(0) on the mitochondrial permeability transition pore described previously (Fontaine, E., Ichas, F., and Bernardi, P. ( 1998) J. Biol. Chem. 273, 25734 - 25740).	Univ Wisconsin, Childrens Diabet Ctr, Sch Med, Madison, WI 53706 USA; Michigan State Univ, Mass Spectrometry Facil, E Lansing, MI 48824 USA	University of Wisconsin System; University of Wisconsin Madison; Michigan State University	MacDonald, MJ (corresponding author), Med Sci Ctr, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.	mjmacdon@wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28348] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hisatomi M, 1997, JPN J PHARMACOL, V74, P203, DOI 10.1254/jjp.74.203; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Irwin WA, 2002, BIOCHEM BIOPH RES CO, V291, P215, DOI 10.1006/bbrc.2002.6457; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; Kar S, 2002, J CELL PHYSIOL, V190, P356, DOI 10.1002/jcp.10063; Koike K, 1998, HEPATOLOGY, V27, P1467, DOI 10.1002/hep.510270602; Korotchkina LG, 2001, FREE RADICAL BIO MED, V30, P992, DOI 10.1016/S0891-5849(01)00491-9; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1991, BIOSCIENCE REP, V11, P165, DOI 10.1007/BF01182485; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1991, ENDOCRINOLOGY, V129, P1370, DOI 10.1210/endo-129-3-1370; MACDONALD MJ, 1980, BIOCHIM BIOPHYS ACTA, V615, P223, DOI 10.1016/0005-2744(80)90025-X; Miwa I, 2000, ENDOCRINOLOGY, V141, P2767, DOI 10.1210/en.141.8.2767; Moteki S, 1996, HEPATOLOGY, V23, P436; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Sasaki M, 2000, J AUTOIMMUN, V15, P51, DOI 10.1006/jaut.2000.0390; SORENSON RL, 1994, ENDOCRINOLOGY, V134, P1975, DOI 10.1210/en.134.4.1975; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200	32	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27278	27285		10.1074/jbc.M314148200	http://dx.doi.org/10.1074/jbc.M314148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075342	hybrid			2022-12-27	WOS:000222120400057
J	Ishida, J; Hashimoto, T; Hashimoto, Y; Nishiwaki, S; Iguchi, T; Harada, S; Sugaya, T; Matsuzaki, H; Yamamoto, R; Shiota, N; Okunishi, H; Kihara, M; Umemura, S; Sugiyama, F; Yagami, K; Kasuya, Y; Mochizuki, N; Fukamizu, A				Ishida, J; Hashimoto, T; Hashimoto, Y; Nishiwaki, S; Iguchi, T; Harada, S; Sugaya, T; Matsuzaki, H; Yamamoto, R; Shiota, N; Okunishi, H; Kihara, M; Umemura, S; Sugiyama, F; Yagami, K; Kasuya, Y; Mochizuki, N; Fukamizu, A			Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS PEPTIDE LIGAND; NITRIC-OXIDE SYNTHASE; II TYPE-2 RECEPTOR; ORPHAN RECEPTOR; TISSUE DISTRIBUTION; APELIN; MICE; GENE; AKT; PROTEIN	APJ is a G-protein-coupled receptor with seven transmembrane domains, and its endogenous ligand, apelin, was identified recently. They are highly expressed in the cardiovascular system, suggesting that APJ is important in the regulation of blood pressure. To investigate the physiological functions of APJ, we have generated mice lacking the gene encoding APJ. The base-line blood pressure of APJ-deficient mice is equivalent to that of wild-type mice in the steady state. The administration of apelin transiently decreased the blood pressure of wild-type mice and a hypertensive model animal, a spontaneously hypertensive rat. On the other hand, this hypotensive response to apelin was abolished in APJ-deficient mice. This apelin-induced response was inhibited by pretreatment with a nitric-oxide synthase inhibitor, and apelin-induced phosphorylation of endothelial nitric-oxide synthase in lung endothelial cells from APJ-deficient mice disappeared. In addition, APJ-deficient mice showed an increased vasopressor response to the most potent vasoconstrictor angiotensin II, and the base-line blood pressure of double mutant mice homozygous for both APJ and angiotensin-type 1a receptor was significantly elevated compared with that of angiotensin-type 1a receptor-deficient mice. These results demonstrate that APJ exerts the hypotensive effect in vivo and plays a counterregulatory role against the pressor action of angiotensin II.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058577, Japan; Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanagawa 2360004, Japan; Shimane Univ, Sch Med, Dept Pharmacol, Izumo, Shimane 6938501, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pharmacol & Biochem, Chuo Ku, Chiba 2608670, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Yokohama City University; Shimane University; Chiba University; National Cerebral & Cardiovascular Center - Japan	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Kasuya, Yoshitoshi/0000-0003-0614-5836; Matsuzaki, Hitomi/0000-0002-8890-5933				Chen MM, 2003, CIRCULATION, V108, P1432, DOI 10.1161/01.CIR.0000091235.94914.75; Cheng X, 2003, EUR J PHARMACOL, V470, P171, DOI 10.1016/S0014-2999(03)01821-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GOTO Y, 1995, LAB ANIM SCI, V45, P601; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miyagishi M, 2000, INT J MOL MED, V5, P27; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	27	324	371	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26274	26279		10.1074/jbc.M404149200	http://dx.doi.org/10.1074/jbc.M404149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087458	hybrid			2022-12-27	WOS:000222003000045
J	Matsuo, K; Galson, DL; Zhao, C; Peng, L; Laplace, C; Wang, KZQ; Bachler, MA; Amano, H; Aburatani, H; Ishikawa, H; Wagner, EF				Matsuo, K; Galson, DL; Zhao, C; Peng, L; Laplace, C; Wang, KZQ; Bachler, MA; Amano, H; Aburatani, H; Ishikawa, H; Wagner, EF			Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BONE; BINDING; DNA; DIFFERENTIATION; CALCINEURIN; INDUCTION; PATHWAY; TARGET	Osteoclasts are specialized macrophages that resorb bone. Mice lacking the AP-1 component c-Fos are osteopetrotic because of a lack of osteoclast differentiation and show an increased number of macrophages. The nature of the critical function of c-Fos in osteoclast differentiation is not known. Microarray analysis revealed that Nfatc1, another key regulator of osteoclastogenesis, was down-regulated in Fos(-/-) osteoclast precursors. Chromatin immunoprecipitation assay showed that c-Fos bound to the Nfatc1 and Acp5 promoters in osteoclasts. In vitro promoter analyses identified nuclear factor of activated T-cells (NFAT)/AP-1 sites in the osteoclast-specific Acp5 and Calcr promoters. Moreover, in Fos(-/-) precursors gene transfer of an active form of NFAT restored transcription of osteoclast-specific genes in the presence of receptor activator of the NF-kappaB ligand (RANKL), rescuing bone resorption. In the absence of RANKL, however, Fos(-/-) precursors were insensitive to NFAT-induced osteoclastogenesis unlike wild-type precursors. These data indicate that lack of Nfatc1 expression is the cause of the differentiation block in Fos(-/-) osteoclast precursors and that transcriptional induction of Nfatc1 is a major function of c-Fos in osteoclast differentiation.	Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan; Res Inst Mol Pathol, A-1030 Vienna, Austria; Beth Israel Deaconess Med Ctr, Dept Med, Joint Inst, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Ctr Bone Biol, Pittsburgh, PA 15213 USA; Showa Univ, Sch Dent, Dept Pharmacol, Tokyo 1428555, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan	Keio University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Showa University; University of Tokyo	Matsuo, K (corresponding author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan.	matsuo@sc.itc.keio.ac.jp	Galson, Deborah L./E-9370-2010; Matsuo, Koichi/K-5695-2012	Galson, Deborah L./0000-0002-2045-8807; Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196	NIAMS NIH HHS [R01 AR045421, AR45421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Diebold RJ, 1998, P NATL ACAD SCI USA, V95, P7915, DOI 10.1073/pnas.95.14.7915; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lean JM, 2000, BONE, V27, P29, DOI 10.1016/S8756-3282(00)00306-9; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Onishi M, 1996, EXP HEMATOL, V24, P324; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherman MA, 1999, J IMMUNOL, V162, P2820; Stroud JC, 2003, J MOL BIOL, V334, P1009, DOI 10.1016/j.jmb.2003.09.065; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	34	443	456	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26475	26480		10.1074/jbc.M313973200	http://dx.doi.org/10.1074/jbc.M313973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073183	hybrid			2022-12-27	WOS:000222003000070
J	Lin, SY; Raval, S; Zhang, ZY; Deverill, M; Siminovitch, KA; Branch, DR; Haimovich, B				Lin, SY; Raval, S; Zhang, ZY; Deverill, M; Siminovitch, KA; Branch, DR; Haimovich, B			The protein-tyrosine phosphatase SHP-1 regulates the phosphorylation of alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PLATELET INTEGRIN ALPHA(IIB)BETA(3); CELL ANTIGEN RECEPTOR; MOTH-EATEN MICE; CYTOSKELETAL REORGANIZATION; CRYSTAL-STRUCTURE; MIGRATING CELLS; BINDING DOMAIN; PTP1C; SRC	Platelet activation triggers integrin alpha(IIb)beta(3)-dependent signals and the induction of tyrosine phosphorylation of the cytoskeletal protein alpha-actinin. We have previously reported that alpha-actinin is phosphorylated by the focal adhesion kinase (FAK) (Izaguirre, G., Aguirre, L., Hu, Y.-P., Lee, H. Y., Schlaepfer, D. D., Aneskievich, B. J., and Haimovich, B. (2001) J. Biol. Chem. 276, 28676-28685). In this study, a phosphatase of 68 kDa that dephosphorylated alpha-actinin in vitro was isolated from platelet lysates by three sequential chromatography steps. The phosphatase was identified as SHP-1 by electrospray tandem mass spectrometry. alpha-Actinin was dephosphorylated in vitro by recombinant SHP-1 and by SHP-1 immunoprecipitated from unstimulated or thrombin-stimulated platelet lysates. SHP-1 immunoprecipitated from lysates of platelets adherent to fibrinogen, however, failed to dephosphorylate alpha-actinin. In contrast, the activity of SHP-1 against a synthetic substrate was not affected by the mode of platelet activation. The robust and sustained phosphorylation of alpha-actinin detected in platelets adherent to fibrinogen thus correlates with a decrease in the activity of SHP-1 toward it. Tyrosine phosphorylation of alpha-actinin is seen in vanadate-treated COS-7 cells that are co-transfected with alpha-actinin and wild type FAK. Triple transfection of the cells with cDNAs encoding for alpha-actinin, FAK, and wild type SHP-1 abolished the phosphorylation of alpha-actinin. The phosphorylation of FAK, however, was barely affected by the expression of wild type SHP-1. Both alpha-actinin and FAK were phosphorylated in cells co-expressing alpha-actinin, FAK, and a catalytic domain mutant (C453S) of SHP-1. These findings establish that SHP-1 can dephosphorylate alpha-actinin in vitro and in vivo and suggest that SHP-1 may regulate the tethering of receptors to the cytoskeleton and/or the extent of cross-linking of actin filaments in cells such as platelets.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Canc Inst New jersey, New Brunswick, NJ 08903 USA; Univ Toronto, Dept Med Immunol & Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Canadian Blood Serv, Res & Dev, Toronto, ON MG5 2M1, Canada; Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON MG5 2M1, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Haimovich, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.	haimovic@umdnj.edu	Siminovitch, Katherine/K-1475-2013	ZHANG, ZHIYONG/0000-0001-8576-1607; zhang, zhiyong/0000-0003-4061-7374	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054104, R01HL054104] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Greer SF, 1999, J IMMUNOL, V162, P5278; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; Lyons BL, 2003, EXP HEMATOL, V31, P234, DOI 10.1016/S0301-472X(02)01031-7; Ma XZ, 2003, EXP HEMATOL, V31, P131, DOI 10.1016/S0301-472X(02)01025-1; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nieset JE, 1997, J CELL SCI, V110, P1013; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pasquet JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/jbc.M001531200; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Wang LL, 1999, J IMMUNOL, V162, P1318; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	60	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25755	25764		10.1074/jbc.M314175200	http://dx.doi.org/10.1074/jbc.M314175200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070900	hybrid			2022-12-27	WOS:000221827900105
J	Zong, YN; Bice, TW; Ton-That, H; Schneewind, O; Narayana, SVL				Zong, YN; Bice, TW; Ton-That, H; Schneewind, O; Narayana, SVL			Crystal structures of Staphylococcus aureus sortase A and its substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; IMIDAZOLIUM ION-PAIR; SURFACE-PROTEINS; CELL-WALL; ANCHOR STRUCTURE; SRTA GENE; IN-VITRO; STREPTOCOCCUS-PNEUMONIAE; LISTERIA-MONOCYTOGENES; CATALYTIC MECHANISM	The cell wall envelope of staphylococci and other Gram-positive pathogens is coated with surface proteins that interact with human host tissues. Surface proteins of Staphylococcus aureus are covalently linked to the cell wall envelope by a mechanism requiring C-terminal sorting signals with an LPXTG motif. Sortase (SrtA) cleaves surface proteins between the threonine ( T) and the glycine ( G) of the LPXTG motif and catalyzes the formation of an amide bond between threonine at the C-terminal end of polypeptides and cell wall crossbridges. The active site architecture and catalytic mechanism of sortase A has hitherto not been revealed. Here we present the crystal structures of native SrtA, of an active site mutant of SrtA, and of the mutant SrtA complexed with its substrate LPETG peptide and describe the substrate binding pocket of the enzyme. Highly conserved proline ( P) and threonine ( T) residues of the LPXTG motif are held in position by hydrophobic contacts, whereas the glutamic acid residue ( E) at the X position points out into the solvent. The scissile T-G peptide bond is positioned between the active site Cys(184) and Arg(197) residues and at a greater distance from the imidazolium side chain of His(120). All three residues, His(120), Cys(184), and Arg(197), are conserved in sortase enzymes from Gram-positive bacteria. Comparison of the active sites of S. aureus sortase A and sortase B provides insight into substrate specificity and suggests a universal sortase-catalyzed mechanism of bacterial surface protein anchoring in Gram-positive bacteria.	Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA	University of Alabama System; University of Alabama Birmingham; University of Chicago	Narayana, SVL (corresponding author), Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.	narayana@uab.edu	Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI38897, AI52765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897, R01AI052765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antosiewicz J, 1996, J COMPUT CHEM, V17, P1633, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1633::AID-JCC5>3.0.CO;2-M; Barnett TC, 2002, J BACTERIOL, V184, P2181, DOI 10.1128/JB.184.8.2181-2191.2002; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton NA, 1998, FARADAY DISCUSS, V110, P463, DOI 10.1039/a801719k; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Connolly KM, 2003, J BIOL CHEM, V278, P34061, DOI 10.1074/jbc.M305245200; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; Dardenne LE, 2003, PROTEINS, V52, P236, DOI 10.1002/prot.10368; Dessen A, 2004, STRUCTURE, V12, P6, DOI 10.1016/j.str.2003.12.009; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Hava DL, 2003, J BACTERIOL, V185, P413, DOI 10.1128/JB.185.2.413-421.2003; Huang XY, 2003, BIOCHEMISTRY-US, V42, P11307, DOI 10.1021/bi034391g; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Jonsson IM, 2003, MICROBES INFECT, V5, P775, DOI 10.1016/S1286-4579(03)00143-6; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; Lee SF, 2003, INFECT IMMUN, V71, P676, DOI 10.1128/IAI.71.2.676-681.2003; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Pinitglang S, 1997, BIOCHEMISTRY-US, V36, P9968, DOI 10.1021/bi9705974; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Silvaggi NR, 2003, BIOCHEMISTRY-US, V42, P1199, DOI 10.1021/bi0268955; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Ton-That H, 2003, MOL MICROBIOL, V50, P1429, DOI 10.1046/j.1365-2958.2003.03782.x; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	52	187	207	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31383	31389		10.1074/jbc.M401374200	http://dx.doi.org/10.1074/jbc.M401374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15117963	hybrid			2022-12-27	WOS:000222726800059
J	Osawa, M; Itoh, S; Ohta, S; Huang, QH; Berk, BC; Marmarosh, NL; Che, WY; Ding, B; Yan, C; Abe, J				Osawa, M; Itoh, S; Ohta, S; Huang, QH; Berk, BC; Marmarosh, NL; Che, WY; Ding, B; Yan, C; Abe, J			ERK1/2 associates with the c-met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1) - Role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN PROMOTER; MAP-KINASE; ENDOTHELIAL-CELLS; ACTIVE-TRANSPORT; GENE-EXPRESSION; SHEAR-STRESS; ACTIVATION; SIGNAL; TRANSCRIPTION; ELEMENT	Endothelial cell (EC) migration contributes to reendothelialization after angioplasty or rupture of atherosclerotic plaques. Extracellular signal-regulated kinase (ERK) 1/2 translocates to the nucleus and activates transcription factors such as Ets-like transcription factor-1 and early growth response factor-1 (Egr-1) during reendothelialization. Because ERK1/2 does not possess a nuclear localization signal (NLS), its mechanism of translocation and accumulation in the nucleus remains unclear. Because Gab1 has a putative NLS in its N-terminal region, and Gab1 associates with phosphorylated ERK1/2, we hypothesized that Gab1 participates in ERK1/2 and Egr-1 nuclear accumulation. Using regenerating EC as a model system, we found that endogenous growth factor receptor-bound protein 2-associated binder-1 ( Gab1) translocates into the nucleus in migrating EC. Wild-type red fluorescent protein-tagged Gab1 could be observed in both nucleus and cytoplasm, whereas the putative NLS deletion mutant (DeltaNLS-Gab1) specifically localized in the cytoplasm. In addition, reduction of Gab1 expression by antisense Gab1 oligos or overexpression of DeltaNLS-Gab1 inhibited serum-induced ERK1/2 and Egr-1 nuclear accumulation, suggesting a functional role for the NLS of Gab1 and a role for Gab1-ERK1/2 interactions in ERK1/2-Egr-1 nuclear accumulation. To investigate whether Gab1-ERK1/2 interaction is critical for ERK1/2 and Egr-1 nuclear accumulation, we created a dominant-negative Gab1 construct that consisted of the c-Met binding domain ( amino acids 442 536) of Gab1. We found that overexpression of the c-Met binding domain of Gab1 disrupted serum-induced Gab1-ERK1 interaction and inhibited ERK1 and Egr-1 nuclear accumulation. These data suggest that Gab1-ERK1/2 binding and their nuclear translocation play a crucial role in Egr-1 nuclear accumulation.	Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Cardiol Unit, Rochester, NY 14642 USA	University of Rochester	Abe, J (corresponding author), Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Cardiol Unit, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	jun-ichi_abe@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919, R01HL065262, R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66919, HL-49192, HL-44721, HL-65262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Huang QH, 2002, J BIOL CHEM, V277, P29330, DOI 10.1074/jbc.M112450200; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Osawa M, 2002, J CELL BIOL, V158, P773, DOI 10.1083/jcb.200205049; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wung BS, 1999, CIRC RES, V84, P804; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	34	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29691	29699		10.1074/jbc.M309371200	http://dx.doi.org/10.1074/jbc.M309371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15078886	hybrid			2022-12-27	WOS:000222445300105
J	Connors, NC; Adams, ME; Froehner, SC; Kofuji, P				Connors, NC; Adams, ME; Froehner, SC; Kofuji, P			The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; RECTIFYING K+ CHANNEL; PHENOTYPIC IMPACT; BRAIN ASTROCYTES; WATER TRANSPORT; MULLER CELL; RAT-BRAIN; PROTEIN; AQUAPORIN-4; DYSTROGLYCAN	One of the major physiological roles of potassium channels in glial cells is to promote "potassium spatial buffering" in the central nervous system, a process necessary to maintain an optimal potassium concentration in the extracellular environment. This process requires the precise distribution of potassium channels accumulated at high density in discrete subdomains of glial cell membranes. To obtain a better understanding of how glial cells selectively target potassium channels to discrete membrane subdomains, we addressed the question of whether the glial inwardly rectifying potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex (DGC). Immunoprecipitation experiments revealed that Kir4.1 is associated with the DGC in mouse brain and cultured cortical astrocytes. In vitro immunoprecipitation and pull-down assays demonstrated that Kir4.1 can bind directly to alpha-syntrophin, requiring the presence of the last three amino acids of the channel (SNV), a consensus PDZ domain-binding motif. Furthermore, Kir4.1 failed to associate with the DGC in brains from alpha-syntrophin knockout mice. These results suggest that Kir4.1 is localized in glial cells by its association with the DGC through a PDZ domain-mediated interaction with alpha-syntrophin and suggest an important role for the DGC in central nervous system physiology.	Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	Kofuji, P (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	kofuj001@tc.umn.edu	Kofuji, Paulo/AAR-7835-2021	Kofuji, Paulo/0000-0002-4840-9986	NEI NIH HHS [EY 07133, EY 12949-01] Funding Source: Medline; NINDS NIH HHS [NS 33145] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Aleman V, 2001, HISTOCHEM CELL BIOL, V115, P243; Amedee T, 1997, GLIA, V21, P46, DOI 10.1002/(SICI)1098-1136(199709)21:1<46::AID-GLIA5>3.0.CO;2-#; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Anderson JL, 2002, BRAIN, V125, P4, DOI 10.1093/brain/awf012; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Claudepierre T, 2000, J CELL SCI, V113, P3409; Connors NC, 2002, J NEUROSCI, V22, P4321, DOI 10.1523/JNEUROSCI.22-11-04321.2002; Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Gee SH, 1998, J NEUROSCI, V18, P128; Grewal PK, 2003, HUM MOL GENET, V12, pR259, DOI 10.1093/hmg/ddg272; Gu F, 2003, J NEUROSCI RES, V72, P709, DOI 10.1002/jnr.10603; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; Hashida-Okumura A, 1999, J BIOL CHEM, V274, P11736, DOI 10.1074/jbc.274.17.11736; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Higashi K, 2001, AM J PHYSIOL-CELL PH, V281, pC922, DOI 10.1152/ajpcell.2001.281.3.C922; HILGEMANN DW, 2001, SCI STKE; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Holthoff K, 2000, GLIA, V29, P288, DOI 10.1002/(SICI)1098-1136(20000201)29:3<288::AID-GLIA10>3.0.CO;2-8; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Imamura M, 1998, P NATL ACAD SCI USA, V95, P6139, DOI 10.1073/pnas.95.11.6139; Inoue M, 2002, TOHOKU J EXP MED, V197, P87, DOI 10.1620/tjem.197.87; Ishii M, 1997, J NEUROSCI, V17, P7725; Kofuji P, 2003, MOL NEUROBIOL, V28, P195, DOI 10.1385/MN:28:2:195; Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; Leonoudakis D, 2001, J CELL SCI, V114, P987; Martin-Rendon E, 2003, TRENDS PHARMACOL SCI, V24, P178, DOI 10.1016/S0165-6147(03)00050-6; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; ODETTE LL, 1988, GLIA, V1, P198, DOI 10.1002/glia.440010305; Poopalasundaram S, 2000, GLIA, V30, P362, DOI 10.1002/(SICI)1098-1136(200006)30:4<362::AID-GLIA50>3.0.CO;2-4; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	52	150	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28387	28392		10.1074/jbc.M402604200	http://dx.doi.org/10.1074/jbc.M402604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102837	hybrid, Green Submitted			2022-12-27	WOS:000222265400071
J	Meyer, AN; Gastwirt, RF; Schlaepfer, DD; Donoghue, DJ				Meyer, AN; Gastwirt, RF; Schlaepfer, DD; Donoghue, DJ			The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MULTIPLE-MYELOMA CELLS; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT ACTIVATION; PROTEIN; MUTATIONS; EXPRESSION; APOPTOSIS; TRANSFORMATION	Activating mutations within fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase, are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II. Several of these same FGFR3 mutations have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma, and cervical cancer. The molecular pathways exploited by FGFR3 to stimulate abnormal proliferation during neoplasia are unclear. The nonreceptor protein-tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2) has been shown previously to regulate apoptosis in multiple myeloma cells. Here we describe a novel interaction between FGFR3 and Pyk2, mediated by the juxtamembrane domain of FGFR3 and the kinase domain of Pyk2. Within the FGFR family, Pyk2 also interacted significantly with FGFR2. Overexpression of Pyk2 alone led to its spontaneous activation and tyrosine phosphorylation, resulting in activation of Stat5B, indicated by the reporter GFP-Stat5B. These effects were completely dependent upon Tyr(402), the autophosphorylation site of Pyk2, which allows recruitment of Src family members for further activating phosphorylations at other sites on Pyk2. In the presence of activated FGFR3, the activation of Pyk2 itself became independent of Tyr(402), indicating that FGFR3 activation circumvents the requirement for c-Src recruitment at Tyr(402) of Pyk2. We also examined the role of the tyrosine phosphatase Shp2 in antagonizing Pyk2 activation. Taken together, these results suggest that signaling pathways regulated by FGFR3 may converge with Pyk2-dependent pathways to provide maximal activation of Stat5B.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA090900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065490] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 90900] Funding Source: Medline; NIGMS NIH HHS [R01 GM 65490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2000, J BIOL CHEM, V275, P27845; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 2000, ANN ONCOL, V11, P131, DOI 10.1023/A:1008300325610; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Jang JH, 2001, CANCER RES, V61, P3541; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Nagy ZS, 2002, J LEUKOCYTE BIOL, V72, P819; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; OZAKI S, 1994, LEUKEMIA, V8, P2207; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Thompson LM, 1997, MOL CELL BIOL, V17, P4169, DOI 10.1128/MCB.17.7.4169; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	60	24	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28450	28457		10.1074/jbc.M403335200	http://dx.doi.org/10.1074/jbc.M403335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105428	hybrid			2022-12-27	WOS:000222265400079
J	Tapley, TL; Vickery, LE				Tapley, TL; Vickery, LE			Preferential substrate binding orientation by the molecular chaperone HscA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR CLUSTER BIOSYNTHESIS; THERMOTOGA-MARITIMA ISCU; ASSEMBLY PROTEIN ISCU; ESCHERICHIA-COLI; DNAK CHAPERONE; EXTINCTION COEFFICIENTS; BIMANE FLUORESCENCE; PEPTIDE BINDING; GENE-CLUSTER; SYSTEM	HscA, a specialized bacterial hsp70-class chaperone, interacts with the iron-sulfur cluster assembly protein IscU by recognizing a conserved LPPVK sequence motif at positions 99-103. We have used a site-directed fluorescence labeling and quenching strategy to determine whether HscA binds to IscU in a preferred orientation. HscA was selectively labeled on opposite sides of the substrate binding domain with the fluorescent probe bimane, and the ability of LPPVK-containing peptides having tryptophan at the N or C terminus to quench bimane fluorescence was measured. Quenching was highly dependent on the position of tryptophan in the peptide and the location of bimane on HscA implying a strong directional preference for peptide binding. Similar experiments showed that full-length IscU binds in the same orientation as IscU-derived peptides and that binding orientation is unaffected by the co-chaperone HscB. The preferred orientation of the HscA-IscU complex is the reverse of that previously described for peptide complexes of Escherichia coli DnaK and rat Hsc70 substrate binding domain fragments establishing that hsp70 isoforms can bind peptide/polypeptide substrates in different orientations.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lvickery@uci.edu			NCI NIH HHS [5T32 CA 09054] Funding Source: Medline; NIGMS NIH HHS [GM 54264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kasper P, 2000, PROTEINS, V40, P185, DOI 10.1002/(SICI)1097-0134(20000801)40:2<185::AID-PROT20>3.0.CO;2-X; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Liu W, 2003, J PHYS CHEM B, V107, P11563, DOI 10.1021/jp035872c; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Mansy SS, 2004, J BIOL CHEM, V279, P10469, DOI 10.1074/jbc.M312051200; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SATO E, 1988, BIOORG CHEM, V16, P298, DOI 10.1016/0045-2068(88)90017-X; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	47	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28435	28442		10.1074/jbc.M400803200	http://dx.doi.org/10.1074/jbc.M400803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100228	hybrid			2022-12-27	WOS:000222265400077
J	Li, T; Lu, ZY; Lu, L				Li, T; Lu, ZY; Lu, L			Regulation of eye development by transcription control of CCCTC binding factor (CTCF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BLOCKING ACTIVITY; HUMAN PAX6 GENE; PROTEIN CTCF; XENOPUS-LAEVIS; DNA-SEQUENCE; METHYLATION; PROMOTER; EXPRESSION; ACTIVATION; MUTATIONS	CCCTC binding factor ( CTCF), a transcriptional regulator, plays important roles in epigenetics and development. In the present study, we report that overexpression of CTCF in transgenic mice during embryonic development suppresses Pax6 gene expression. This effect causes defects in ocular development that result in microophthalmia. In eye-derived cells transfected with a tetracycline turn-on CTCF system, up-regulation of CTCF expression significantly suppressed Pax6 expression. In contrast, the knockdown of CTCF mRNA resulted in the down-regulation of CTCF protein expression, which in turn enhanced the Pax6 expression. CTCF controls Pax6 transcription by interacting with a repressor element located in the 5'-flanking region upstream of the Pax6 P0 promoter. This interaction suppressed Pax6 gene transcription by blocking the effect of an ectoderm enhancer located 3.5 kb upstream from the P0 promoter. We also found an 80-bp sequence in a region -1.2 kbp upstream from the P0 promoter that contained multiple CTCF binding sites and interacted with nuclear proteins obtained from eye-derived cells forming electrophoretic mobility shift assay complexes with CTCF. We conclude that a novel function of CTCF is to regulate Pax6 transcription by binding to the repressor element, which in turn blocks the effect of the ectoderm enhancer resulting in the inhibition of P0 promoter activity.	Univ Calif Los Angeles, Harbor UCLA Med Ctr, David Geffen Sch Med, Div Mol Med, Torrance, CA 90502 USA; Shanghai Med Univ 2, Dept Med Genet, Shanghai 200025, Peoples R China	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Shanghai Jiao Tong University	Lu, L (corresponding author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, David Geffen Sch Med, Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu			NEI NIH HHS [R01 EY015281, EY12953, EY15281] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Burke LJ, 2002, MECH DEVELOP, V113, P95, DOI 10.1016/S0925-4773(02)00005-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davis JA, 1996, J NEUROSCI, V16, P5082; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kang SS, 2001, CURR EYE RES, V23, P397, DOI 10.1076/ceyr.23.6.397.6965; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; MARTIN P, 1992, ONCOGENE, V7, P1721; MCFALL RC, 1977, CANCER RES, V37, P1003; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Percec I, 2002, SCIENCE, V295, P287, DOI 10.1126/science.1068663; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P3344; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; Shiraishi A, 1998, INVEST OPHTH VIS SCI, V39, P2554; Song SY, 1999, GASTROENTEROLOGY, V117, P1416, DOI 10.1016/S0016-5085(99)70292-1; Underhill DA, 2000, BIOCHEM CELL BIOL, V78, P629, DOI 10.1139/bcb-78-5-629; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Williams SC, 1998, MECH DEVELOP, V73, P225, DOI 10.1016/S0925-4773(98)00057-4; Xu PX, 1999, DEVELOPMENT, V126, P383; Zieske JD, 2001, INVEST OPHTH VIS SCI, V42, P1465	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27575	27583		10.1074/jbc.M313942200	http://dx.doi.org/10.1074/jbc.M313942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096508	hybrid			2022-12-27	WOS:000222120400091
J	Nair, VD; Yuen, T; Olanow, CW; Sealfon, SC				Nair, VD; Yuen, T; Olanow, CW; Sealfon, SC			Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; N-TERMINAL KINASE; DNA-DAMAGE; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; PHOSPHOINOSITIDE 3-KINASE; NEURONAL DIFFERENTIATION	In a population of cells undergoing oxidative stress, an individual cell either succumbs to apoptotic cell death or maintains homeostasis and survives. Exposure of PC-12-D2R cells to 200 muM hydrogen peroxide (H2O2) induces apoptosis in about half of cells after 24 h. After 1-h exposure to 200 muM H2O2, both antiapoptotic extracellular regulated kinase (ERK) phosphorylation and pro-apoptotic Ser-15-p53 phosphorylation are observed. Microarray and real-time PCR assays of gene expression after H2O2 exposure identified several transcripts, including egr1, that are rapidly induced downstream of ERK. Single cell analysis of egr1 induction and of phospho-ERK and phospho-p53 formation revealed the presence of two distinct cellular programs. Whereas the proportion of cells activating ERK versus p53 at 1 h depended on H2O2 concentration, individual cells showed exclusively either phospho-p53 formation or activation of ERK and egr1 induction. Exposure to H2O2 for 1 h also elicited these two non-overlapping cellular responses in both dopaminergic SN4741 cells and differentiated postmitotic PC-12-D2R cells. Repressing p53 with pifithrin-alpha or small interfering RNA increased ERK phosphorylation by H2O2, indicating that p53- dependent suppression of ERK activity may contribute to the bi-stable single cell responses observed. By 24 h, the subset of cells in which ERK activity was suppressed exhibit caspase 3 activation and the nuclear condensation characteristic of apoptosis. These studies suggest that the individual cell rapidly and stochastically processes the oxidative stress stimulus, leading to an all-or-none cytoprotective or pro-apoptotic signaling response.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), Mt Sinai Sch Med, Dept Neurol, Neurol Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.sealfon@mssm.edu		Nair, Venugopalan/0000-0002-8231-6230; Nair, Venugopalan/0000-0002-0299-0998; SEALFON, Stuart/0000-0001-5791-1217				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Anderson CNG, 1999, J NEUROSCI, V19, P664; *APPL BIOS, 1997, US B APPL BIOS, V2, P1; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cregan SP, 1999, J NEUROSCI, V19, P7860; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Harris CA, 2001, J BIOL CHEM, V276, P37754; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Nair VD, 2003, J BIOL CHEM, V278, P47053, DOI 10.1074/jbc.M303364200; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nollen EAA, 2002, J CELL SCI, V115, P2809; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Park SA, 2001, MOL BRAIN RES, V93, P18, DOI 10.1016/S0169-328X(01)00176-0; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan CYI, 1998, J NEUROSCI, V18, P4042; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Yuen T, 2002, METHOD ENZYMOL, V345, P556	70	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27494	27501		10.1074/jbc.M312135200	http://dx.doi.org/10.1074/jbc.M312135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078887	hybrid			2022-12-27	WOS:000222120400081
J	Blanco, MG; Boan, F; Gomez-Marquez, J				Blanco, MG; Boan, F; Gomez-Marquez, J			A paradox in the in vitro end-joining assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-FREE-EXTRACTS; HUMAN MINISATELLITE; PROTHYMOSIN-ALPHA; GENOMIC INTEGRITY; HISTONE H1; DNA; REPAIR; RECOMBINATION; PATHWAYS	Much work has been focused on the pathways that restore the integrity of the genome after different kinds of lesions, especially double-strand breaks. A classical method to investigate double-strand break repair is the incubation of a DNA substrate with cell-free extracts. In these end-joining assays, the DNA is efficiently ligated by the proteins present in the extract, generating circular molecules and/or multimers. In contrast, using a similar in vitro system, we detected DNA cleavage rather than end ligation. When comparing our results with previous works, a paradox emerges: lower amounts of DNA become multimerized instead of degraded and higher amounts of DNA are degraded rather than multimerized. Here, we have demonstrated that when the DNA/ protein ratio is low enough, the DNA-binding proteins of the nuclear extract protect the DNA substrate, avoiding DNA degradation and vice versa. Therefore, the variation of the DNA/ protein ratio is enough to switch the outcome of the experiment from a DNA cleavage assay to a typical end-joining assay.	Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, A Coruna, Spain	Universidade de Santiago de Compostela	Gomez-Marquez, J (corresponding author), Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, A Coruna, Spain.	bnjgm@usc.es	Blanco, Miguel González/R-5754-2017; Blanco, Miguel González/J-6424-2012	Blanco, Miguel González/0000-0002-2883-7326; Blanco, Miguel González/0000-0002-2883-7326				ABMAYR SB, 1987, CURRENT PROTOCOLS MO; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Boan F, 1997, FEBS LETT, V418, P251, DOI 10.1016/S0014-5793(97)01389-6; Boan F, 2002, BIOCHEMISTRY-US, V41, P2166, DOI 10.1021/bi015780i; Boan F, 1998, J MOL BIOL, V278, P499, DOI 10.1006/jmbi.1998.1714; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; CHU G, 1997, J BIOL CHEM, V275, P26196; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589; NICOLAS AL, 1994, MOL CELL BIOL, V14, P170, DOI 10.1128/MCB.14.1.170; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Odersky A, 2002, J BIOL CHEM, V277, P11756, DOI 10.1074/jbc.M111304200; OGAWA Y, 1995, J BIOL CHEM, V270, P9272, DOI 10.1074/jbc.270.16.9272; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pospiech H, 2001, NUCLEIC ACIDS RES, V29, P3277, DOI 10.1093/nar/29.15.3277; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Sathees CR, 1999, MUTAT RES-DNA REPAIR, V433, P1, DOI 10.1016/S0921-8777(98)00055-X; Segade F, 1999, INT J BIOCHEM CELL B, V31, P1243, DOI 10.1016/S1357-2725(99)00094-1; Singleton BK, 1999, FR MOLEC B, V22, P16; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Vega FV, 1998, J BIOL CHEM, V273, P10147, DOI 10.1074/jbc.273.17.10147; Yamanaka S, 2002, BIOCHEM BIOPH RES CO, V292, P268, DOI 10.1006/bbrc.2002.6647; Zhong Q, 2002, CANCER RES, V62, P3966	28	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26797	26801		10.1074/jbc.M402832200	http://dx.doi.org/10.1074/jbc.M402832200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087441	hybrid			2022-12-27	WOS:000222003000107
J	Kaneko, S; Ichinose, H; Fujimoto, Z; Kuno, A; Yura, K; Go, M; Mizuno, H; Kusakabe, I; Kobayashi, H				Kaneko, S; Ichinose, H; Fujimoto, Z; Kuno, A; Yura, K; Go, M; Mizuno, H; Kusakabe, I; Kobayashi, H			Structure and function of a family 10 beta-xylanase chimera of Streptomyces olivaceoviridis E-86 FXYN and Cellulomonas fimi Cex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; F/10 XYLANASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; PSEUDOMONAS-FLUORESCENS; BETA-1,4-GLYCANASE CEX; XYLOPENTAOSE-BINDING; CATALYTIC DOMAIN; SPECIFICITY; XYLOOLIGOSACCHARIDES	The catalytic domain of xylanases belonging to glycoside hydrolase family 10 ( GH10) can be divided into 22 modules (M1 to M22; Sato, Y., Niimura, Y., Yura, K., and Go, M. ( 1999) Gene (Amst.) 238, 93 - 101). Inspection of the crystal structure of a GH10 xylanase from Streptomyces olivaceoviridis E-86 (SoXyn10A) revealed that the catalytic domain of GH10 xylanases can be dissected into two parts, an N-terminal larger region and C-terminal smaller region, by the substrate binding cleft, corresponding to the module border between M14 and M15. It has been suggested that the topology of the substrate binding clefts of GH10 xylanases are not conserved (Charnock, S. J., Spurway, T. D., Xie, H., Beylot, M. H., Virden, R., Warren, R. A. J., Hazlewood, G. P., and Gilbert, H. J. ( 1998) J. Biol. Chem. 273, 32187 - 32199). To facilitate a greater understanding of the structure-function relationship of the substrate binding cleft of GH10 xylanases, a chimeric xylanase between SoXyn10A and Xyn10A from Cellulomonas fimi (CfXyn10A) was constructed, and the topology of the hybrid substrate binding cleft established. At the three-dimensional level, SoXyn10A and CfXyn10A appear to possess 5 subsites, with the amino acid residues comprising subsites -3 to +1 being well conserved, although the +2 subsites are quite different. Biochemical analyses of the chimeric enzyme along with SoXyn10A and CfXyn10A indicated that differences in the structure of subsite +2 influence bond cleavage frequencies and the catalytic efficiency of xylooligosaccharide hydrolysis. The hybrid enzyme constructed in this study displays fascinating biochemistry, with an interesting combination of properties from the parent enzymes, resulting in a low production of xylose.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan; Yamagata Univ, Fac Sci, Dept Mat & Biol Chem, Yamagata 9908560, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; National Institute of Agrobiological Sciences - Japan; Yamagata University; Nagoya University; University of Tsukuba	Kaneko, S (corresponding author), Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	sakaneko@nfri.affrc.go.jp	Kuno, Atsushi/M-2151-2018; Yura, Kei/S-1030-2018	Kuno, Atsushi/0000-0002-6147-6171; Yura, Kei/0000-0003-0197-5478; Fujimoto, Zui/0000-0002-3551-6854				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEDARKAR S, 1992, J MOL BIOL, V228, P693, DOI 10.1016/0022-2836(92)90852-B; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; Fujimoto Z, 1997, J BIOCHEM-TOKYO, V121, P826; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HRMOVA M, 1995, J BIOL CHEM, V270, P14556, DOI 10.1074/jbc.270.24.14556; Kaneko S, 1999, FEBS LETT, V460, P61, DOI 10.1016/S0014-5793(99)01318-6; Kaneko S, 2000, BIOSCI BIOTECH BIOCH, V64, P741, DOI 10.1271/bbb.64.741; Kaneko S, 2000, PROTEIN ENG, V13, P873, DOI 10.1093/protein/13.12.873; Kuno A, 2000, FEBS LETT, V482, P231, DOI 10.1016/S0014-5793(00)02067-6; Kuno A, 1999, FEBS LETT, V450, P299, DOI 10.1016/S0014-5793(99)00498-6; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; KUSAKABE I, 1983, AGR BIOL CHEM TOKYO, V47, P2713, DOI 10.1080/00021369.1983.10866038; KUSAKABE I, 1977, NIPPON NOGEIKAGAKU K, V51, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Leggio L, 2000, PROTEINS, V41, P362, DOI 10.1002/1097-0134(20001115)41:3<362::AID-PROT80>3.0.CO;2-N; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUO N, 1991, AGR BIOL CHEM TOKYO, V55, P2905, DOI 10.1080/00021369.1991.10857129; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P71; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sato Y, 1999, GENE, V238, P93, DOI 10.1016/S0378-1119(99)00321-2; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; Timell T. E., 1965, ADV CARBOHYD CHEM, V20, P409, DOI DOI 10.1016/S0096-5332(08)60304-5; TULL D, 1991, J BIOL CHEM, V266, P15621; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; YOSHIDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P2068, DOI 10.1271/bbb.58.2068; YOSHIDA S, 1990, AGR BIOL CHEM TOKYO, V54, P449, DOI 10.1080/00021369.1990.10869948	53	27	28	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26619	26626		10.1074/jbc.M308899200	http://dx.doi.org/10.1074/jbc.M308899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078885	hybrid			2022-12-27	WOS:000222003000088
J	Smith, AP; DeRidder, BP; Guo, WJ; Seeley, EH; Regnier, FE; Goldsbrough, PB				Smith, AP; DeRidder, BP; Guo, WJ; Seeley, EH; Regnier, FE; Goldsbrough, PB			Proteomic analysis of Arabidopsis glutathione S-transferases from benoxacor- and copper-treated seedlings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO SEEDLINGS; SIGNATURE-PEPTIDE APPROACH; WHEAT TRITICUM-AESTIVUM; HERBICIDE SAFENERS; SALICYLIC-ACID; ETHYLENE; PROTEIN; PLANTS; GENE; DETOXIFICATION	Glutathione S-transferases (GSTs) are involved in many stress responses in plants, for example, participating in the detoxification of xenobiotics and limiting oxidative damage. Studies examining the regulation of this gene family in diverse plant species have focused primarily on RNA expression. A proteomics method was developed to identify GSTs expressed in Arabidopsis seedlings and to determine how the abundance of these proteins changed in response to copper, a promoter of oxidative stress, and benoxacor, a herbicide safener. Eight GSTs were identified in seedlings grown under control conditions, and only one, AtGSTU19, was induced by benoxacor. In contrast, four GSTs, AtGSTF2, AtGSTF6, AtGSTF7, and AtGSTU19, were significantly more abundant in copper-treated seedlings. The different responses to these treatments may reflect the potential for copper to affect many more aspects of plant growth and physiology compared with a herbicide safener. Differences between RNA and protein expression of GSTs indicate that both transcriptional and translational mechanisms are involved in regulation of GSTs under these conditions.	Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Goldsbrough, PB (corresponding author), Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA.	goldsbrough@purdue.edu	Smith, Aaron P/E-9043-2011; GUO, WOEI-JIUN/F-8487-2012	Seeley, Erin/0000-0002-8000-5754; Smith, Aaron/0000-0003-4422-6012				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; CONKLIN PL, 1995, PLANT PHYSIOL, V109, P203, DOI 10.1104/pp.109.1.203; Cummins I, 1999, PLANT J, V18, P285, DOI 10.1046/j.1365-313X.1999.00452.x; Cummins I, 1997, PESTIC BIOCHEM PHYS, V59, P35, DOI 10.1006/pest.1997.2308; Davies J, 1999, PESTIC SCI, V55, P1043, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt;1043::AID-PS60&gt;3.0.CO;2-L; DeRidder BP, 2002, PLANT PHYSIOL, V130, P1497, DOI 10.1104/pp.010066; DEVOS CHR, 1993, PLANT PHYSIOL BIOCH, V31, P151; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dixon DP, 2000, ARCH BIOCHEM BIOPHYS, V384, P407, DOI 10.1006/abbi.2000.2125; Geng MH, 2000, J CHROMATOGR A, V870, P295, DOI 10.1016/S0021-9673(99)00951-6; Gonneau J, 1998, PHYSIOL PLANTARUM, V103, P114, DOI 10.1034/j.1399-3054.1998.1030114.x; Gronwald JW, 1998, PLANT PHYSIOL, V117, P877, DOI 10.1104/pp.117.3.877; IRZYK GP, 1993, PLANT PHYSIOL, V102, P803, DOI 10.1104/pp.102.3.803; Ji JY, 2000, J CHROMATOGR B, V745, P197, DOI 10.1016/S0378-4347(00)00192-4; Lieberherr D, 2003, PLANT CELL PHYSIOL, V44, P750, DOI 10.1093/pcp/pcg093; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Mira H, 2002, PLANTA, V214, P939, DOI 10.1007/s00425-001-0706-0; Mueller LA, 2000, PLANT PHYSIOL, V123, P1561, DOI 10.1104/pp.123.4.1561; Pascal S, 1999, PHYSIOL PLANTARUM, V106, P17, DOI 10.1034/j.1399-3054.1999.106103.x; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Regnier F, 2001, LC GC N AM, V19, P200; Roxas VP, 2000, PLANT CELL PHYSIOL, V41, P1229, DOI 10.1093/pcp/pcd051; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; SCHELLER HV, 1987, PLANT PHYSIOL, V85, P1031, DOI 10.1104/pp.85.4.1031; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Smith AP, 2003, PLANT J, V36, P433, DOI 10.1046/j.1365-313X.2003.01890.x; Tabb DL, 2003, ANAL CHEM, V75, P1155, DOI 10.1021/ac026122m; Tonge R, 2001, PROTEOMICS, V1, P377; van Rossum AJ, 2001, PROTEOMICS, V1, P1463; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; YU YB, 1980, PLANT PHYSIOL, V66, P281, DOI 10.1104/pp.66.2.281; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2; ZHOU JM, 1993, PLANT MOL BIOL, V22, P517, DOI 10.1007/BF00015980	36	81	95	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26098	26104		10.1074/jbc.M402807200	http://dx.doi.org/10.1074/jbc.M402807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069083	hybrid, Green Published			2022-12-27	WOS:000222003000023
J	Wines, BD; Trist, HM; Monteiro, RC; van Kooten, C; Hogarth, PM				Wines, BD; Trist, HM; Monteiro, RC; van Kooten, C; Hogarth, PM			Fc receptor gamma chain residues at the interface of the cytoplasmic and transmembrane domains affect association with Fc alpha RI, surface expression, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; EPSILON-RI; ZETA-CHAIN; IMMUNOGLOBULIN; IGA; SUBUNIT; BETA; CD89; IDENTIFICATION	The assembly of multiple subunit immunoreceptors is dependent on transmembrane interactions. The Fc receptor gamma (FcR-gamma) chain is a ubiquitous immune receptor tyrosine-based activation motif-containing dimeric subunit, gamma(2), which in humans associates with both the activating members of the leukocyte receptor cluster, including the IgA receptor FcalphaRI, and the classical Fc receptors, including the IgE receptor FcepsilonRI. This study identifies a new site in the transmembrane region of FcR-gamma that affects receptor assembly and surface expression with FcalphaRI but not with FcepsilonRI. The wild type complex, FcalphaRI-gamma(2) WT, remains robustly associated in both Brij-96 and Thesit detergent conditions. However, mutation of either Tyr(25) or Cys(26) of FcR-gamma, near the interface of the transmembrane and cytoplasmic regions, resulted in impaired FcR-gamma association with FcalphaRI. This association was disrupted in the presence of the detergent Brij-96 but was preserved in milder conditions using the detergent Thesit. Ligand-mediated cross-linking of the FcalphaRI-gamma(2)Y25F mutant receptor resulted in diminished signal transduction, including an abnormal calcium response, compared with the FcalphaRI-gamma(2)WT receptor. Furthermore, the FcalphaRI-gamma(2)Y25F mutant receptor was expressed at the cell surface at similar to10% of that of the wild type, whereas the surface expression of FcepsilonRI-gamma(2)Y25F was not significantly different from the wild type. In contrast, although the FcalphaRI-gamma(2)C26S mutant was also less stably associated, it was not reduced in surface expression or function. Thus, these TM residues of FcR-gamma are important for association with FcalphaRI and probably other activating LRC members but not with the classical FcR, FcepsilonRI.	Austin Repatriat Med Ctr, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Heidelberg, Vic 3084, Australia; Bichat Med Sch, INSERM, E0225, F-75870 Paris, France; Leiden Univ, Med Ctr, Dept Nephrol, NL-2333 ZA Leiden, Netherlands	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Wines, BD (corresponding author), Austin Repatriat Med Ctr, Austin Res Inst, Helen Macpherson Smith Trust Inflammatory Dis Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	b.wines@ari.unimelb.edu.au	Monteiro, Renato C/U-8633-2017; van Kooten, Cees/E-5694-2018	Monteiro, Renato C/0000-0001-5202-5646; van Kooten, Cees/0000-0002-6257-0899; Hogarth, Mark/0000-0002-0360-7890				Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bolliger L, 1999, J IMMUNOL, V163, P3867; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Borges L, 2000, CYTOKINE GROWTH F R, V11, P209, DOI 10.1016/S1359-6101(00)00007-1; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Colonna M, 2000, SEMIN IMMUNOL, V12, P121, DOI 10.1006/smim.2000.0214; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Cronin FE, 1998, J IMMUNOL, V161, P252; Daeron M, 1997, Int Rev Immunol, V16, P1, DOI 10.3109/08830189709045701; Dietrich J, 1999, EUR J IMMUNOL, V29, P1719, DOI 10.1002/(SICI)1521-4141(199905)29:05<1719::AID-IMMU1719>3.3.CO;2-D; Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B; EVANS MJ, 1995, J IMMUNOL METHODS, V184, P123, DOI 10.1016/0022-1759(95)00093-P; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; GEISLER C, 1989, J IMMUNOL, V143, P4069; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; Honorio-Fransa AC, 2001, J LEUKOCYTE BIOL, V69, P289; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; JONES B, 1986, J IMMUNOL, V136, P348; Kim MK, 2003, BLOOD, V101, P4479, DOI 10.1182/blood.V101.11.4479; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; Launay P, 1999, J BIOL CHEM, V274, P7216, DOI 10.1074/jbc.274.11.7216; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Moonga BS, 2002, AM J PHYSIOL-RENAL, V282, pF921, DOI 10.1152/ajprenal.00045.2000; Morton HC, 2001, ARCH IMMUNOL THER EX, V49, P217; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nakajima H, 1999, J IMMUNOL, V162, P5; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Sahuquillo AG, 1998, J EXP MED, V187, P1179, DOI 10.1084/jem.187.8.1179; Schamel WWA, 2000, MOL IMMUNOL, V37, P253, DOI 10.1016/S0161-5890(00)00025-0; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; Shen L, 2001, BLOOD, V97, P205, DOI 10.1182/blood.V97.1.205; Spain LM, 2002, J IMMUNOL, V168, P127, DOI 10.4049/jimmunol.168.1.127; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; van der Boog PJM, 2002, J IMMUNOL, V168, P1252, DOI 10.4049/jimmunol.168.3.1252; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; van Zandbergen G, 1999, J IMMUNOL, V163, P5806; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VIVIER E, 1991, J IMMUNOL, V147, P4263; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	59	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26339	26345		10.1074/jbc.M403684200	http://dx.doi.org/10.1074/jbc.M403684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096494	hybrid			2022-12-27	WOS:000222003000053
J	Kogo, H; Aiba, T; Fujimoto, T				Kogo, H; Aiba, T; Fujimoto, T			Cell type-specific occurrence of caveolin-1 alpha and -1 beta in the lung caused by expression of distinct mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLOIDAL SILICA; ALPHA-ISOFORM; SHOW EVIDENCE; CAVEOLAE; PROTEIN; IDENTIFICATION; PHOSPHORYLATION; TRANSCRIPTION; TRAFFICKING; DYSFUNCTION	Two isoforms of caveolin-1, alpha and beta, had been thought to be generated by alternative translation initiation of an mRNA (FL mRNA), but we showed previously that a variant mRNA (5'V mRNA) encodes the beta isoform specifically (Kogo, H., and Fujimoto, T. (2000) FEBS Lett. 465, 119-123). In the present study, we demonstrated strong correlation between the expression of the caveolin-1 protein isoforms and mRNA variants in culture cells and the developing mouse lung. The alpha isoform protein and FL mRNA were expressed constantly during the lung development, whereas expression of the alpha isoform protein and 5'V mRNA was negligible in the fetal lung before 17.5 days post-coitum, and markedly increased simultaneously at 18.5 days post coitum, when the alveolar type I cells started to differentiate. Immunohistochemical analysis revealed the cell type-specific expression of the two isoforms; the alveolar type I cell expresses the beta isoform predominantly, while the endothelium harbors the alpha isoform chiefly. The mutually exclusive expression of caveolin-1 isoforms was verified by Western blotting of the selective plasma membrane preparation obtained from the endothelial and alveolar epithelial cells. The present result indicates that the two caveolin-1 isoforms are generated from distinct mRNAs in vivo and that their production is regulated independently at the transcriptional level. The result also suggests that the alpha and beta isoforms of caveolin-1 may have unique physiological functions.	Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Kogo, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Canc Sci, Div Mol Genet, Dengakugakubo 1-98, Toyoake, Aichi 4701192, Japan.	hkogo@fujita-hu.ac.jp	Fujimoto, Toyoshi/ABH-9058-2020; Kogo, Hiroshi/AAB-8467-2019	Fujimoto, Toyoshi/0000-0002-3601-7977; Kogo, Hiroshi/0000-0003-0584-7158				Aldred MA, 2003, CANCER RES, V63, P2864; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CHANEY LK, 1983, J BIOL CHEM, V258, P62; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; FARR A, 1992, J HISTOCHEM CYTOCHEM, V40, P651, DOI 10.1177/40.5.1374092; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; Fujimoto T, 2000, J CELL SCI, V113, P3509; Gumbleton M, 2001, ADV DRUG DELIVER REV, V49, P281, DOI 10.1016/S0169-409X(01)00142-9; HIRAGUN A, 1980, IN VITRO CELL DEV B, V16, P685; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ramirez MI, 2002, J HISTOCHEM CYTOCHEM, V50, P33, DOI 10.1177/002215540205000104; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schnitzer JE, 2001, ADV DRUG DELIVER REV, V49, P265, DOI 10.1016/S0169-409X(01)00141-7; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; Stolz DB, 1999, AM J PATHOL, V155, P1487, DOI 10.1016/S0002-9440(10)65464-8; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; YUSPA SH, 1980, CANCER RES, V40, P4694; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	43	45	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25574	25581		10.1074/jbc.M310807200	http://dx.doi.org/10.1074/jbc.M310807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067006	hybrid			2022-12-27	WOS:000221827900084
J	Kumar, N; Khurana, S				Kumar, N; Khurana, S			Identification of a functional switch for actin severing by cytoskeletal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GELSOLIN; VILLIN; CALCIUM; DOMAIN; CELLS; ASSOCIATION; DISRUPTION; ACTIVATION; COMPLEX	Actin severing is vital for the organization of the actin cytoskeleton during cell motility. Severing of F-actin by the homologous proteins villin and gelsolin requires unphysiologically high calcium concentrations (20-200 muM). Here we demonstrate that high calcium releases an autoinhibited conformation in villin that is maintained by two low affinity calcium binding sites (aspartic acids 467 and 715) that interact with a cluster of basic residues in the S2 domain of villin. Mutation of either of these sites as well as tyrosine phosphorylation alters the conformation of villin resulting in a protein that can sever actin in nanomolar calcium. These results suggest that tyrosine phosphorylation rather than high calcium may be the mechanism by which villin and other related proteins sever actin in vivo.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 402, Memphis, TN 38163 USA.	khurana@utmem.edu		Khurana, Seema/0000-0002-6884-810X; Kumar, Narendra/0000-0002-1193-0954	NIDDK NIH HHS [DK-65006, DK-54755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065006, R01DK054755] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; Constantin B, 1998, J CELL SCI, V111, P1695; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; De Corte V, 1999, PROTEIN SCI, V8, P234; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DITSCH A, 1995, EUR J BIOCHEM, V229, P512, DOI 10.1111/j.1432-1033.1995.tb20492.x; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lin KM, 2000, J BIOL CHEM, V275, P27746; Lu M, 1997, J CELL BIOL, V138, P1279, DOI 10.1083/jcb.138.6.1279; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Sklyarova T, 2002, J BIOL CHEM, V277, P39840, DOI 10.1074/jbc.M207052200; VILLEREAL ML, 1989, ANNU REV NUTR, V9, P347, DOI 10.1146/annurev.nu.09.070189.002023; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Yuan XL, 2003, J PROTEOME RES, V2, P476, DOI 10.1021/pr025589a; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200	25	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24915	24918		10.1074/jbc.C400110200	http://dx.doi.org/10.1074/jbc.C400110200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084600	hybrid			2022-12-27	WOS:000221827900003
J	Orsini, F; Migliaccio, E; Moroni, M; Contursi, C; Raker, VA; Piccini, D; Martin-Padura, I; Pelliccia, G; Trinei, M; Bono, M; Puri, C; Tacchetti, C; Ferrini, M; Mannucci, R; Nicoletti, I; Lanfrancone, L; Giorgio, M; Pelicci, PG				Orsini, F; Migliaccio, E; Moroni, M; Contursi, C; Raker, VA; Piccini, D; Martin-Padura, I; Pelliccia, G; Trinei, M; Bono, M; Puri, C; Tacchetti, C; Ferrini, M; Mannucci, R; Nicoletti, I; Lanfrancone, L; Giorgio, M; Pelicci, PG			The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; OXIDATIVE STRESS; SIGNALING PATHWAY; CYTOCHROME-C; PERMEABILITY TRANSITION; HSP70 FAMILY; PROTEIN; DOMAIN; TRANSDUCTION; LONGEVITY	P66Shc regulates life span in mammals and is a critical component of the apoptotic response to oxidative stress. It functions as a downstream target of the tumor suppressor p53 and is indispensable for the ability of oxidative stress-activated p53 to induce apoptosis. The molecular mechanisms underlying the apoptogenic effect of p66Shc are unknown. Here we report the following three findings. (i) The apoptosome can be properly activated in vitro in the absence of p66Shc only if purified cytochrome c is supplied. (ii) Cytochrome c release after oxidative signals is impaired in the absence of p66Shc. (iii) p66Shc induces the collapse of the mitochondrial trans-membrane potential after oxidative stress. Furthermore, we showed that a fraction of cytosolic p66Shc localizes within mitochondria where it forms a complex with mitochondrial Hsp70. Treatment of cells with ultraviolet radiation induced the dissociation of this complex and the release of monomeric p66Shc. We propose that p66Shc regulates the mitochondrial pathway of apoptosis by inducing mitochondrial damage after dissociation from an inhibitory protein complex. Genetic and biochemical evidence suggests that mitochondria regulate life span through their effects on the energetic metabolism (mitochondrial theory of aging). Our data suggest that mitochondrial regulation of apoptosis might also contribute to life span determination.	Federaz Italiana Ric Canc, Inst Mol Oncol, I-20139 Milan, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Univ Perugia, Dept Clin Expt Med, I-06122 Perugia, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Genoa; University of Perugia	Giorgio, M (corresponding author), Federaz Italiana Ric Canc, Inst Mol Oncol, Via Adamello 16, I-20139 Milan, Italy.	giorgio@ifom-firct.it; pgpelicci@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Migliaccio, Enrica/AAQ-8880-2020; mannucci, roberta/AAE-6662-2020; Giorgio, Marco/I-9425-2012; Franzeck, Fabian C/B-5055-2011	Lanfrancone, Luisa/0000-0002-4523-3815; Giorgio, Marco/0000-0002-5842-6042; TACCHETTI, CARLO/0000-0003-4602-000X				Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brown GC, 1995, BIOENERGETICS PRACTI; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Harlow E., 1988, ANTIBODIES LAB MANUA; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mitsumoto A, 2002, FREE RADICAL BIO MED, V32, P22, DOI 10.1016/S0891-5849(01)00755-9; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; NICOLLI A, 1996, J BIOL CHEM, V271, P185; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PON LA, 2001, METHODS CELL BIOL, V65; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Sadekova S, 1997, INT J RADIAT BIOL, V72, P653, DOI 10.1080/095530097142807; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Schiaffino MV, 1999, NAT GENET, V23, P108, DOI 10.1038/12715; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Wang XD, 2001, GENE DEV, V15, P2922; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	227	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25689	25695		10.1074/jbc.M401844200	http://dx.doi.org/10.1074/jbc.M401844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078873	hybrid			2022-12-27	WOS:000221827900098
J	Rhee, SH; Keates, AC; Moyer, MP; Pothoulakis, C				Rhee, SH; Keates, AC; Moyer, MP; Pothoulakis, C			MEK is a key modulator for TLR5-induced interleukin-8 and MIP3 alpha gene expression in non-transformed human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSE; NF-KAPPA-B; ELK-1 PHOSPHORYLATION; BACTERIAL FLAGELLIN; RECEPTOR; ACTIVATION; PROTEIN; TRANSCRIPTION; MECHANISM; PATHWAY	Flagellin, a specific ligand for Toll-like receptor 5 (TLR5), is a molecular pattern associated with several bacterial species. Recently, TLR signaling has been intensively studied. However, TLR5-associated signaling in non-transformed colonocytes has not been investigated. Here we studied the expression of cytokines induced by flagellin in non-transformed human colonic NCM460 cells and the signaling mechanisms mediating these responses. Cytokine expression array experiments showed that exposure of the cells to flagellin (100 ng/ml) for 12 h increased the expression of interleukin (IL)-8 and macrophage-inflammatory protein 3alpha (MIP3alpha) in a TLR5-specific manner. Flagellin also activated MAP kinases (ERK1/2, JNK, and p38) and degraded IkappaBalpha. Dominant negative MEK1 (a kinase that activates ERK1/2) blocked flagellin-stimulated IL-8 and MIP3alpha transcriptional activity, while the MEK-specific inhibitors PD98059 and U0126 reduced protein production of these cytokines. Conversely, transfection with a constitutively active MEK1 increased IL-8 and MIP3alpha transcriptional activity in a NFkappaB-independent manner. Furthermore, overexpression of the constitutively active MEK1 induced IL-8 and MIP3alpha protein production. We also demonstrated that C-terminal coiled-coil and TRAF-C domains of TRAF6, unable to mediate NFkappaB activation, are involved in MEK-mediated IL-8 and MIP3alpha expression. Thus, in non-transformed human colonocytes, MEK activation following flagellin/TLR5 engagement is a key modulator for NFkappaB-independent, IL-8 and MIP3alpha expression.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Gastrointestinal Neuropeptide C, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 79249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Gastrointestinal Neuropeptide C, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.	cpothoul@caregroup.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047343, R01DK060729, P01DK033506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33506, DK 47343, DK 60729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245; Cummings J H, 2003, Curr Issues Intest Microbiol, V4, P9; Elewaut D, 1999, J IMMUNOL, V163, P1457; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hart AL, 2003, J CLIN GASTROENTEROL, V36, P111, DOI 10.1097/00004836-200302000-00005; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Huang RC, 2002, CANCER RES, V62, P2806; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200; Kwon JH, 2002, GUT, V51, P818, DOI 10.1136/gut.51.6.818; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Madrazo DR, 2003, INFECT IMMUN, V71, P5418, DOI 10.1128/IAI.71.9.5418-5421.2003; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Natarajan R, 2001, EXP CELL RES, V266, P203, DOI 10.1006/excr.2001.5218; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Sahi Jasminder, 1998, American Journal of Physiology, V275, pC1048; Salmenpera P, 2003, AM J PHYSIOL-CELL PH, V284, pC1133, DOI 10.1152/ajpcell.00293.2002; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Stagg AJ, 2003, GUT, V52, P1522, DOI 10.1136/gut.52.10.1522; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zhou X, 2003, INFECT IMMUN, V71, P2120, DOI 10.1128/IAI.71.4.2120-2129.2003	43	73	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25179	25188		10.1074/jbc.M400967200	http://dx.doi.org/10.1074/jbc.M400967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069060	hybrid			2022-12-27	WOS:000221827900034
J	Gu, YJ; Sanjo, N; Chen, FS; Hasegawa, H; Petit, A; Ruan, XY; Li, WP; Shier, C; Kawarai, T; Schmitt-Ulms, G; Westaway, D; St George-Hyslop, P; Fraser, PE				Gu, YJ; Sanjo, N; Chen, FS; Hasegawa, H; Petit, A; Ruan, XY; Li, WP; Shier, C; Kawarai, T; Schmitt-Ulms, G; Westaway, D; St George-Hyslop, P; Fraser, PE			The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE ACTIVITY; MISSENSE MUTATIONS; BETA-CATENIN; NICASTRIN; NOTCH; APH-1; PATHWAY; APP	Several lines of evidence have indicated that the presenilin proteins function within macromolecular complexes and are necessary for the regulated intramembranous proteolysis of certain type 1 transmembrane proteins, including the amyloid precursor protein, Notch, and p75. Data from multiple complementary experiments now suggest that there may be several distinct presenilin complexes. We show here that presenilin mutations and certain detergents affect the abundance and componentry of the presenilin complexes, and these structural effects correlate with their effects on gamma-secretase activity. Our data suggest that there are at least three complexes, including a similar to150-kDa nicastrin-aph-1 complex ( which is likely to be a precursor complex). There is a stable and abundant intermediate complex of similar to 440 kDa, which contains aph-1, pen-2, nicastrin, and PS1. However, it is the very low abundance, high mass (greater than or equal to 670 kDa) heteromeric complexes that are associated with the highest gamma-secretase-specific activity.	Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Toronto Western Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Sanjo, Nobuo/0000-0002-1226-2425; Petit-Paitel, Agnes/0000-0003-1138-9966; St George-Hyslop, Peter/0000-0003-0796-7209				Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Culvenor JG, 2004, EUR J BIOCHEM, V271, P375, DOI 10.1046/j.1432-1033.2003.03936.x; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hayashi H, 2000, BBA-MOL CELL BIOL L, V1483, P81, DOI 10.1016/S1388-1981(99)00174-2; KOO EH, 1994, J BIOL CHEM, V269, P17386; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	29	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31329	31336		10.1074/jbc.M401548200	http://dx.doi.org/10.1074/jbc.M401548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123598	hybrid			2022-12-27	WOS:000222726800053
J	Azpiazu, I; Gautam, N				Azpiazu, I; Gautam, N			A fluorescence resonance energy transfer-based sensor indicates that receptor access to a G protein is unrestricted in a living mammalian cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; SIGNAL-TRANSDUCTION; MEMBRANE MICRODOMAINS; MUSCARINIC RECEPTOR; ACTIVATION; MECHANISMS; COMPLEXES; CAVEOLAE; DYNAMICS	Fluorescence recovery after photobleaching of muscarinic receptors and G protein subunits tagged with cyan or yellow fluorescent protein showed that receptors and G proteins were mobile and not immobilized on the cell membrane. The cyan fluorescent protein-tagged Galpha and yellow fluorescent protein-tagged Gbeta subunits were used to develop sensors that coupled selectively with the M2 and M3 muscarinic receptors. In living Chinese hamster ovary cells, imaging showed that sensors emitted a fluorescence resonance energy transfer signal that was abrogated on receptor activation. When sequentially activated with highly expressed muscarinic receptors and endogenous receptors expressed at low levels, sensor molecules were sensitive to the sequence of activation and the receptor numbers. The results distinguish between models proposing that receptor and G protein types interact freely with each other on the cell membrane or that they function as mutually exclusive multimolecular complexes by providing direct support for the former model in these cells.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.	gautam@morpheus.wustl.edu			NIGMS NIH HHS [GM46963, R01 GM046963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Azpiazu I, 2002, METHOD ENZYMOL, V344, P112; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; George SE, 1997, J NEUROCHEM, V69, P1278; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	29	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27709	27718		10.1074/jbc.M403712200	http://dx.doi.org/10.1074/jbc.M403712200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078878	hybrid			2022-12-27	WOS:000222120400105
J	Cao, XQ; Cismowski, MJ; Sato, M; Blumer, JB; Lanier, SM				Cao, XQ; Cismowski, MJ; Sato, M; Blumer, JB; Lanier, SM			Identification and characterization of AGS4 - A protein containing three G-protein regulatory motifs that regulate the activation state of G(i)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; GOLGI MEMBRANES; ALPHA-SUBUNITS; CELL POLARITY; GOLOCO MOTIF; BETA-GAMMA; LOCALIZATION; PHOSPHORYLATION; DISSOCIATION; TRAFFICKING	Activators of G-protein signaling 1-3 (AGS1-3) were identified in a functional screen of mammalian cDNAs that activated G-protein signaling in the absence of a receptor. We report the isolation and characterization of an additional AGS protein (AGS4) from a human prostate leiomyosarcoma cDNA library. AGS4 is identical to G18.1b, which is encoded by a gene within the major histocompatibility class III region of chromosome 6. The activity of AGS4 in the yeast-based functional screen was selective for G(i2)/G(i3) and independent of guanine-nucleotide exchange by G(i)alpha. RNA blots indicated enrichment of AGS4/G18.1b mRNA in heart, placenta, lung, and liver. Immunocytochemistry with AGS4/G18.1b-specific antisera indicated a predominant nonhomogeneous, extranuclear distribution within the cell following expression in COS7 or Chinese hamster ovary cells. AGS4/G18.1b contains three G-protein regulatory motifs downstream of an amino terminus domain with multiple prolines. Glutathione S-transferase (GST)-AGS4/G18.1b fusion proteins interacted with purified G(i)alpha, and peptides derived from each of the G-protein regulatory motifs inhibited guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding to purified G(i)alpha(1). AGS4/G18.1b was also complexed with G(i)alpha(3) in COS7 cell lysates following cell transfection. However, AGS4/G18.1b did not alter the generation of inositol phosphates in COS7 cells cotransfected with the Gbetagamma-regulated effector phospholipase C-beta2. These data suggest either that an additional signal is required to position AGS4/G18.1b in the proper cellular location where it can access heterotrimer and promote subunit dissociation or that AGS4 serves as an alternative binding partner for G(i)alpha independent of Gbetagamma participating in G-protein signaling events that are independent of classical G-protein-coupled receptors at the cell surface.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Guthrie Res Inst, Sayre, PA 18840 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607; Blumer, Joe/0000-0002-0020-3815	NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH90531, F32MH65092, F32 MH065092] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; Ahringer J, 2003, CURR OPIN CELL BIOL, V15, P73, DOI 10.1016/S0955-0674(02)00018-2; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30272, DOI 10.1074/jbc.M212688200; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kaushik R, 2003, MOL BIOL CELL, V14, P3144, DOI 10.1091/mbc.E03-04-0212; Kimple RJ, 2004, BIOCHEM J, V378, P801, DOI 10.1042/BJ20031686; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Yu FW, 2002, MOL CELL BIOL, V22, P4230, DOI 10.1128/MCB.22.12.4230-4240.2002; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755	33	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27567	27574		10.1074/jbc.M312786200	http://dx.doi.org/10.1074/jbc.M312786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096500	hybrid			2022-12-27	WOS:000222120400090
J	Maggiolini, M; Vivacqua, A; Fasanella, G; Recchia, AG; Sisci, D; Pezzi, V; Montanaro, D; Musti, AM; Picard, D; Ando, S				Maggiolini, M; Vivacqua, A; Fasanella, G; Recchia, AG; Sisci, D; Pezzi, V; Montanaro, D; Musti, AM; Picard, D; Ando, S			The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17 beta-estradiol and phytoestrogens in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; EPIDERMAL-GROWTH-FACTOR; TERNARY COMPLEX FACTORS; MEMBRANE ESTROGEN-RECEPTORS; TRANSCRIPTIONAL ACTIVATION; PROTOONCOGENE EXPRESSION; SIGNAL-TRANSDUCTION; STEROID-HORMONES; PROSTATE-CANCER; GENE-EXPRESSION	A growing body of evidence concerning estrogen effects cannot be explained by the classic model of hormone action, which involves the binding to estrogen receptors (ERs) alpha and ERbeta and the interaction of the steroid-receptor complex with specific DNA sequences associated with target genes. Using c-fos proto-oncogene expression as an early molecular sensor of estrogen action in ERalpha-positive MCF7 and ER-negative SKBR3 breast cancer cells, we have discovered that 17beta-estradiol (E2), and the two major phytoestrogens, genistein and quercetin, stimulate c-fos expression through ERalpha as well as through an ER-independent manner via the G protein-coupled receptor homologue GPR30. The c-fos response is repressed in GPR30-expressing SKBR3 cells transfected with an antisense oligonucleotide against GPR30 and reconstituted in GPR30-deficient MDA-MB 231 and BT-20 breast cancer cells transfected with a GPR30 expression vector. GPR30-dependent activation of ERK1/2 by E2 and phytoestrogens occurs via a Gbetagamma-associated pertussis toxin-sensitive pathway that requires both Src-related and EGF receptor tyrosine kinase activities. The ability of E2 and phytoestrogens to regulate the expression of growth-related genes such as c-fos even in the absence of ER has interesting implications for understanding breast cancer progression.	Univ Calabria, Dipartimento Biol Cellulare, I-87030 Arcavacata Di Rende, CS, Italy; Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy; Univ Geneva, Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland	University of Calabria; University of Calabria; University of Geneva	Ando, S (corresponding author), Univ Calabria, Dipartimento Biol Cellulare, I-87030 Arcavacata Di Rende, CS, Italy.	sebastiano.ando@unical.it	Musti, Anna Maria/M-2520-2019; Pezzi, Vincenzo/AAL-4017-2020; Maggiolini, Marcello/Z-4729-2019; Recchia, Anna Grazia/ABA-5228-2020; /AAD-9701-2019; vivacqua, adele/I-2771-2015	/0000-0001-6577-1541; vivacqua, adele/0000-0001-5333-8396; Recchia, Anna Grazia/0000-0001-5748-2002; Maggiolini, Marcello/0000-0002-7485-854X; MUSTI, Anna Maria/0000-0003-1443-2739; pezzi, Vincenzo/0000-0003-2311-2286				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bonapace IM, 1996, ONCOGENE, V12, P753; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HERBER B, 1994, ONCOGENE, V9, P1295; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; JENSEN EV, 1995, ANN NY ACAD SCI, V761, P1, DOI 10.1111/j.1749-6632.1995.tb31364.x; Kanda N, 2003, J INVEST DERMATOL, V121, P771, DOI 10.1046/j.1523-1747.2003.12487.x; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kim-Kaneyama J, 2002, BIOCHEM BIOPH RES CO, V299, P360, DOI 10.1016/S0006-291X(02)02644-X; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Lau KM, 2000, CANCER RES, V60, P3175; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Maggiolini M, 1999, BIOL CHEM, V380, P695, DOI 10.1515/BC.1999.086; Maggiolini M, 2002, J STEROID BIOCHEM, V82, P315, DOI 10.1016/S0960-0760(02)00230-3; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Recchia AG, 2004, FOOD ADDIT CONTAM A, V21, P134, DOI [10.1080/02646830020032300, 10.1080/02652030310001641177]; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Singer CA, 1999, J NEUROSCI, V19, P2455; Singh M, 1999, J NEUROSCI, V19, P1179; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Taylor AH, 2001, ANTISENSE NUCLEIC A, V11, P219, DOI 10.1089/108729001317022223; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDERBURG B, 1991, J STEROID BIOCHEM, V40, P215, DOI 10.1016/0960-0760(91)90185-8; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WILDING G, 1988, CANCER RES, V48, P802; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	86	371	392	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27008	27016		10.1074/jbc.M403588200	http://dx.doi.org/10.1074/jbc.M403588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15090535	hybrid			2022-12-27	WOS:000222120400026
J	Subramaniam, K; Chen, K; Joseph, K; Raymond, JR; Tholanikunnel, BG				Subramaniam, K; Chen, K; Joseph, K; Raymond, JR; Tholanikunnel, BG			The 3 '-untranslated region of the beta(2)-adrenergic receptor mRNA regulates receptor synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; BETA-ADRENERGIC-RECEPTOR; TRANSLATIONAL CONTROL; BETA-2-ADRENERGIC RECEPTOR; POLY(A)-BINDING PROTEIN; 3-UNTRANSLATED REGION; GAMMA-INTERFERON; CREATINE-KINASE; LEADER CISTRON	beta(2)-Adrenergic receptors (beta(2)-ARs) are low abundance integral membrane proteins that mediate the effects of catecholamines at the cell surface. Post-transcriptional regulation of beta(2)-AR is dependent, in part, on sequences within the 5'- and 3'-untranslated regions ( UTRs) of the receptor mRNA. In this work, we demonstrate that 3'-UTR sequences regulate the translation of the receptor mRNA. Deletion of the 3'-UTR sequences resulted in 2-2.5-fold increases in receptor expression. The steadystate levels of beta(2)-AR mRNA did not change significantly in the presence or absence of the 3'-UTR, suggesting that the translation of the receptor mRNA is suppressed by 3'-UTR sequences. Introduction of the receptor 3'-UTR sequences into the 3'-UTR of a heterologous reporter gene ( luciferase) resulted in a 70% decrease in reporter gene expression without significant changes in luciferase mRNA levels. Sucrose density gradient fractionation of cytoplasmic extracts from Chinese hamster ovary cells transfected with full-length receptor cDNA demonstrated that the receptor transcripts were distributed between polysomal and non-polysomal fractions. Deletion of 3'-UTR sequences from the receptor cDNA resulted in a clear shift in the distribution of receptor mRNA toward the polysomal fractions, favoring increased translation. The 3'-UTR sequences of the receptor mRNA were sufficient to shift the distribution of luciferase mRNA from predominantly polysomal fractions toward non-polysomal fractions in cells transfected with the chimeric luciferase construct. Taken together, our results provide the first evidence for translational control of beta(2\)-AR expression by 3'-UTR sequences. Presumably, this occurs by affecting the receptor mRNA localization.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Pulm Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tholanikunnel, BG (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,829 CSB, Charleston, SC 29425 USA.	tholanik@musc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058740, R01GM063909] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM63909, 1R01 GM58740] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Dalgleish G, 2001, J BIOL CHEM, V276, P13593, DOI 10.1074/jbc.M001141200; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; GRENS A, 1990, J BIOL CHEM, V265, P11810; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobs GH, 2002, NUCLEIC ACIDS RES, V30, P310, DOI 10.1093/nar/30.1.310; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LECUYER TJ, 1995, P NATL ACAD SCI USA, V92, P7520, DOI 10.1073/pnas.92.16.7520; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mbella EGM, 2000, MOL CELL BIOL, V20, P4572, DOI 10.1128/MCB.20.13.4572-4579.2000; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Reimann I, 2002, J MOL BIOL, V315, P965, DOI 10.1006/jmbi.2001.5315; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Seydoux G, 1996, CURR OPIN GENET DEV, V6, P555, DOI 10.1016/S0959-437X(96)80083-9; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; THOLANIKUNNEL BG, 2000, REGULATION G PROTEIN, P273; Wiklund L, 2002, J BIOL CHEM, V277, P40462, DOI 10.1074/jbc.M205929200; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27108	27115		10.1074/jbc.M401352200	http://dx.doi.org/10.1074/jbc.M401352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107422	hybrid			2022-12-27	WOS:000222120400037
J	van Amerongen, R; van der Gulden, H; Bleeker, F; Jonkers, J; Berns, A				van Amerongen, R; van der Gulden, H; Bleeker, F; Jonkers, J; Berns, A			Characterization and functional analysis of the murine Frat2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; GLYCOGEN-SYNTHASE KINASE-3; CATENIN DEGRADATION COMPLEX; WNT SIGNALING PATHWAY; WILLI-SYNDROME REGION; BETA-CATENIN; SUBSTRATE-SPECIFICITY; STRUCTURAL BASIS; PHOSPHORYLATION; AXIN	The Frat1 proto-oncogene was first identified as a gene contributing to tumor progression in T-cell lymphomas induced by retroviral insertional mutagenesis with the Moloney murine leukemia virus. The biological function of Frat remained elusive until its Xenopus homologue GBP was isolated as a glycogen synthase kinase 3 (GSK3)-binding protein and was shown to be an essential component of the maternal Wnt-signaling pathway. To date two Frat homologues have been described in the mouse, Frat1 and Frat3. The proteins encoded by these two genes are 84% identical. Here we describe the cloning and characterization of a third murine Frat homologue, Frat2, which is the mouse ortholog of human FRAT2. Frat1 and Frat2 are juxtaposed on chromosome 19 in a chromosomal organization conserved between man and mouse. We show that Frat1 and Frat2 are phosphorylated, which is the first evidence that these proteins are subject to posttranslational modification. Like Frat1, Frat2 is able to bind to GSK3beta. However, a side-by-side comparison of the murine Frat proteins for their capacity to induce signaling through beta-catenin/T-cell factor reveals that Frat2 is a less potent activator of the canonical Wnt pathway. Frat2 protein accumulates to higher levels upon transfection into 293T cells than either Frat1 or Frat3. Thus, whereas Frat1 may be a core component of canonical Wnt-signaling, Frat2 might very well be part of a divergent intracellular GSK3beta pathway.	Netherlands Canc Inst, Dept Mol Genet, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Dept Mol Genet, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl	van Amerongen, Renee/N-6645-2019; Jonkers, Jos/AAG-3246-2019; van Amerongen, Renee/G-2945-2017	van Amerongen, Renee/0000-0002-8808-2092; Jonkers, Jos/0000-0002-9264-9792; van Amerongen, Renee/0000-0002-8808-2092				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Chai JH, 2001, MAMM GENOME, V12, P813, DOI 10.1007/s00335-001-2083-1; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; KLEIN PS, 1996, P NATL ACAD SCI USA, V93, P455; Kobayashi S, 2002, BIOCHEM BIOPH RES CO, V290, P403, DOI 10.1006/bbrc.2001.6160; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; Saitoh T, 2001, INT J ONCOL, V19, P311; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200	35	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26967	26974		10.1074/jbc.M400439200	http://dx.doi.org/10.1074/jbc.M400439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073180	hybrid			2022-12-27	WOS:000222120400022
J	Boyd, AE; Dunlop, CS; Wong, L; Radic, Z; Taylor, P; Johnson, DA				Boyd, AE; Dunlop, CS; Wong, L; Radic, Z; Taylor, P; Johnson, DA			Nanosecond dynamics of acetylcholinesterase near the active center gorge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ACETYLCHOLINESTERASE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; OMEGA-LOOP; BACK-DOOR; LIGAND-BINDING; SNAKE-VENOM; FASCICULIN; SITE; COMPLEX	To delineate the role of peptide backbone flexibility and rapid molecular motion in acetylcholinesterase catalysis and inhibitor association, we investigated the decay of fluorescence anisotropy at three sites of fluorescein conjugation to cysteine-substitution mutants of the enzyme. One cysteine was placed in a loop at the peripheral site near the rim of the active center gorge (H287C); a second was in a helical region outside of the active center gorge (T249C); a third was at the tip of a small, flexible Omega loop well separated from the gorge (A262C). Mutation and fluorophore conjugation did not appreciably alter catalytic or inhibitor binding parameters of the enzyme. The results show that each site examined was associated with a high degree of segmental motion; however, the A262C and H287C sites were significantly more flexible than the T249C site. Association of the active center inhibitor, tacrine, and the peripheral site peptide inhibitor, fasciculin, had no effect on the anisotropy decay of fluorophores at positions 249 and 262. Fasciculin, but not tacrine, on the other hand, dramatically altered the decay profile of the fluorophore at the 287 position, in a manner consistent with fasciculin reducing the segmental motion of the peptide chain in this local region. The results suggest that the motions of residues near the active center gorge and across from the Cys(69) - Cys(96) Omega loop are uncoupled and that ligand binding at the active center or the peripheral site does not influence acetylcholinesterase conformational dynamics globally, but induces primarily domain localized decreases in flexibility proximal to the bound ligand.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; University of California System; University of California Riverside	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM18360, GM07752] Funding Source: Medline; PHS HHS [P42-E10337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERMAN JD, 1971, P NATL ACAD SCI USA, V68, P395, DOI 10.1073/pnas.68.2.395; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; Glusker Jenny P., 1985, CRYSTAL STRUCTURE AN; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; Marchot P, 1996, PROTEIN SCI, V5, P672; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Shen TY, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.041902; Shi JX, 2002, J BIOL CHEM, V277, P43301, DOI 10.1074/jbc.M204391200; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Steiner RF, 1991, TOPICS FLUORESCENCE, V2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Tara S, 1999, BIOPOLYMERS, V50, P35, DOI 10.1002/(SICI)1097-0282(199907)50:1<35::AID-BIP4>3.0.CO;2-6; Tara S, 1999, BIOPOLYMERS, V50, P347, DOI 10.1002/(SICI)1097-0282(19991005)50:4<347::AID-BIP1>3.0.CO;2-R; TAYLOR P, 1974, MOL PHARMACOL, V10, P78; Wlodek ST, 1997, J AM CHEM SOC, V119, P9513, DOI 10.1021/ja971226d; Wlodek ST, 2000, BIOPOLYMERS, V53, P265, DOI 10.1002/(SICI)1097-0282(200003)53:3<265::AID-BIP6>3.3.CO;2-E; Yguerabide J, 1972, Methods Enzymol, V26, P498; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	38	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26612	26618		10.1074/jbc.M401482200	http://dx.doi.org/10.1074/jbc.M401482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078872	hybrid			2022-12-27	WOS:000222003000087
J	Datta, G; Epand, RF; Epand, RM; Chaddha, M; Kirksey, MA; Garber, DW; Lund-Katz, S; Phillips, MC; Hama, S; Navab, M; Fogelman, AM; Palgunachari, MN; Segrest, JP; Anantharamaiah, GM				Datta, G; Epand, RF; Epand, RM; Chaddha, M; Kirksey, MA; Garber, DW; Lund-Katz, S; Phillips, MC; Hama, S; Navab, M; Fogelman, AM; Palgunachari, MN; Segrest, JP; Anantharamaiah, GM			Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; I MIMETIC PEPTIDE; CORONARY ATHEROSCLEROSIS; PLASMA-CHOLESTEROL; WATER-INTERFACE; ALPHA-HELICES; INHIBITS 3; APOLIPOPROTEIN; MICE; ANALOGS	The apolipoprotein A-I mimetic peptide 4F (Ac-DW-FKAFYDKVAEKFKEAF-NH2), with four Phe residues on the nonpolar face of the amphipathic alpha-helix, is strongly anti-inflammatory, whereas two 3F analogs (3F(3) and 3F(14)) are not. To understand how changes in helix nonpolar face structure affect function, two additional 3F analogs, Ac-DKLKAFYDKVFEWAKEAF-NH2 (3F-1) and Ac-DKWKAVYDKFAEAFKEFL-NH2 (3F-2), were designed using the same amino acid composition as 3F(3) and 3F(14). The aromatic residues in 3F-1 and 3F-2 are near the polar-nonpolar interface and at the center of the nonpolar face of the helix, respectively. Like 4F, but in contrast to 3F(3) and 3F(14), these peptides effectively inhibited lytic peptide-induced hemolysis, oxidized phospholipid-induced monocyte chemotaxis, and scavenged lipid hydroperoxides from low density lipoprotein. High pressure liquid chromatography retention times and monolayer exclusion pressures indicated that there is no direct correlation of peptide function with lipid affinity. Fluorescence studies suggested that, although the peptides bind phospholipids similarly, the Trp residue in 4F, 3F-1, and 3F-2 is less motionally restricted than in 3F(3) and 3F(14). Based on these results and molecular modeling studies, we propose that the arrangement of aromatic residues in class A amphipathic helical molecules regulates entry of reactive oxygen species into peptide-phospholipid complexes, thereby reducing the extent of monocyte chemotaxis, an important step in atherosclerosis.	Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Anantharamaiah, GM (corresponding author), Univ Alabama, Med Ctr, Dept Med, 1808 7th Ave S,DREB 640, Birmingham, AL 35294 USA.	Ananth@uab.edu	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL34343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; Anantharamaiah GM, 2001, CURR SCI INDIA, V81, P53; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Burger Danielle, 2002, Autoimmunity Reviews, V1, P111, DOI 10.1016/S1568-9972(01)00018-0; Cantor RS, 2003, BIOCHEMISTRY-US, V42, P11891, DOI 10.1021/bi034534z; Cantor RS, 1997, BIOCHEMISTRY-US, V36, P2339, DOI 10.1021/bi9627323; Chattopadhyay A, 2003, CHEM PHYS LIPIDS, V122, P3, DOI 10.1016/S0009-3084(02)00174-3; Datta G, 2001, J LIPID RES, V42, P1096; Demchenko AP, 2002, LUMINESCENCE, V17, P19, DOI 10.1002/bio.671; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Filipe P, 2002, BIOCHEMISTRY-US, V41, P11057, DOI 10.1021/bi026133+; Garber DW, 2003, ATHEROSCLEROSIS, V168, P229, DOI 10.1016/S0021-9150(03)00101-1; Garber DW, 2001, J LIPID RES, V42, P545; GARBER DW, 1992, ARTERIOSCLER THROMB, V12, P886, DOI 10.1161/01.ATV.12.8.886; GLOMSET JA, 1968, J LIPID RES, V9, P155; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HO C, 1992, BIOPHYS J, V63, P897, DOI 10.1016/S0006-3495(92)81671-5; Holvoet P, 1997, ARTERIOSCL THROM VAS, V17, P2376, DOI 10.1161/01.ATV.17.11.2376; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KARLE IL, 1988, P NATL ACAD SCI USA, V85, P299, DOI 10.1073/pnas.85.2.299; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Moosmann B, 2000, EUR J BIOCHEM, V267, P5687, DOI 10.1046/j.1432-1327.2000.01658.x; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Navab M, 2003, CIRCULATION, V108, P232; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PLUMP A, 1994, P NATL ACAD SCI USA, V94, P899; Reddy ST, 2002, ARTERIOSCL THROM VAS, V22, P1877, DOI 10.1161/01.ATV.0000035700.82829.2A; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Shah PK, 2001, CIRCULATION, V103, P3047, DOI 10.1161/hc2501.092494; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; Van Lenten BJ, 2002, CIRCULATION, V106, P1127, DOI 10.1161/01.CIR.0000030182.35880.3E; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Yamaguchi Y, 1998, ATHEROSCLEROSIS, V139, P323, DOI 10.1016/S0021-9150(98)00091-4	43	68	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26509	26517		10.1074/jbc.M314276200	http://dx.doi.org/10.1074/jbc.M314276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075321	hybrid			2022-12-27	WOS:000222003000074
J	Sedelies, KA; Sayers, TJ; Edwards, KM; Chen, WS; Pellicci, DG; Godfrey, DI; Trapani, JA				Sedelies, KA; Sayers, TJ; Edwards, KM; Chen, WS; Pellicci, DG; Godfrey, DI; Trapani, JA			Discordant regulation of granzyme H and granzyme B expression in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE ESTERASE GENE; CATHEPSIN-G GENE; CYTOTOXIC LYMPHOCYTES; CELL-DEATH; CASPASE ACTIVATION; CYTOSOLIC DELIVERY; TARGET-CELLS; T-CELLS; APOPTOSIS; PERFORIN	We analyzed the expression of granzyme H in human blood leukocytes, using a novel monoclonal antibody raised against recombinant granzyme H. 33-kDa granzyme H was easily detected in unfractionated peripheral blood mononuclear cells, due to its high constitutive expression in CD3(-)CD56(+) natural killer (NK) cells, whereas granzyme B was less abundant. The NK lymphoma cell lines, YT and Lopez, also expressed high granzyme H levels. Unstimulated CD4(+) and particularly CD8(+) T cells expressed far lower levels of granzyme H than NK cells, and various agents that classically induce T cell activation, proliferation, and enhanced granzyme B expression failed to induce granzyme H expression in T cells. Also, granzyme H was not detected in NK T cells, monocytes, or neutrophils. There was a good correlation between mRNA and protein expression in cells that synthesize both granzymes B and H, suggesting that gzmH gene transcription is regulated similarly to gzmB. Overall, our data indicate that although the gzmB and gzmH genes are tightly linked, expression of the proteins is quite discordant in T and NK cells. The finding that granzyme H is frequently more abundant than granzyme B in NK cells is consistent with a role for granzyme H in complementing the pro-apoptotic function of granzyme B in human NK cells.	Peter MacCallum Canc Ctr, Canc Immunol Lab, Melbourne 8006, Australia; NCI, Basic Res Program, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA; Austin & Repatriat Med Ctr, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia	Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Monash University	Trapani, JA (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Lab, Locked Bag 1,ABeckett St, Melbourne 8006, Australia.	joe.trapani@petermac.org	Sayers, Thomas J/G-4859-2015; Chen, Weisan/E-7828-2012; Pellicci, Daniel/AAX-8539-2020	Chen, Weisan/0000-0002-5221-9771; Pellicci, Daniel/0000-0001-5305-2398; Trapani, Joseph/0000-0003-0983-1532; Godfrey, Dale/0000-0002-3009-5472	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010012] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APOSTOLIDIS VA, 1995, MOL IMMUNOL, V32, P909, DOI 10.1016/0161-5890(95)00042-D; BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Browne KA, 1999, MOL CELL BIOL, V19, P8604; DAVIS JE, 2003, J IMMUNOL METHODS; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GEISBERG M, 1990, TISSUE ANTIGENS, V35, P229, DOI 10.1111/j.1399-0039.1990.tb01788.x; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; HOHN PA, 1989, J BIOL CHEM, V264, P13412; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; Kothapalli R, 2003, INT J ONCOL, V22, P33; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Netto MVP, 2002, TRANSPLANT P, V34, P476, DOI 10.1016/S0041-1345(02)02601-5; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; SMYTH MJ, 1990, J EXP MED, V171, P1269, DOI 10.1084/jem.171.4.1269; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; Smyth MJ, 1995, BIOCHEM BIOPH RES CO, V217, P675, DOI 10.1006/bbrc.1995.2827; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Sutton VR, 1997, J IMMUNOL, V158, P5783; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, INT REV CYTOL, V182, P111, DOI 10.1016/S0074-7696(08)62169-5; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911	38	63	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26581	26587		10.1074/jbc.M312481200	http://dx.doi.org/10.1074/jbc.M312481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069086	hybrid			2022-12-27	WOS:000222003000083
J	Huang, P; Steplock, D; Weinman, EJ; Hall, RA; Ding, Z; Li, JG; Wang, YL; Liu-Chen, LY				Huang, P; Steplock, D; Weinman, EJ; Hall, RA; Ding, Z; Li, JG; Wang, YL; Liu-Chen, LY			kappa opioid receptor interacts with Na+/H+-exchanger regulatory factor-1/ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na+/H+ exchange independent of G(i)/G(o) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; ISOLATED RAT-HEART; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; PDZ DOMAINS; BETA(2)-ADRENERGIC RECEPTOR; PARATHYROID-HORMONE; PERTUSSIS TOXIN; SIGNAL COMPLEX; H+ EXCHANGER	We previously showed that Na+/H+-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) co-immunoprecipitated with the human kappa opioid receptor (hKOR) and that its overexpression blocked the kappa agonist U50,488H-induced hKOR down-regulation by enhancing recycling. Here, we show that glutathione S-transferase (GST)-hKOR C-tail interacted with purified NHERF-1/EBP50, whereas GST or GST-C-tails of mu or delta opioid receptors did not. GST-hKOR C-tail, but not GST, bound HA-NHERF-1/EBP50 transfected into Chinese hamster ovary cells and endogenous NHERF-1/EBP50 in opossum kidney proximal tubule epithelial cells (OK cells). The PDZ domain I, but not II, of NHERF-1/EBP50 was involved in the interaction. Association of NHERF-1/EBP50 with hKOR C-tail enhanced oligomerization of NHERF-1/EBP50. NHERF-1/EBP50 was previously shown to regulate Na+/H+-exchanger 3 (NHE3) activities in OK cells. We found stimulation of OK cells with U50,488H significantly enhanced Na+/H+ exchange, which was blocked by naloxone but not by pertussis toxin pretreatment, indicating it is mediated by KORs but independent of G(i)/G(o) proteins. In OKH cells, a subclone of OK cells expressing a much lower level of NHERF-1/EBP50, U50,488H had no effect on Na+/H+ exchange, although it enhanced p44/42 mitogen-activated protein kinase phosphorylation via G(i)/G(o) proteins similar to that in OK cells. Stable transfection of NHERF-1/EBP50 into OKH cells restored the stimulatory effect of U50,488H upon Na+/H+ exchange. Thus, NHERF-1/EBP50 binds directly to KOR, and this association plays an important role in accelerating Na+/H+ exchange. We hypothesize that binding of the KOR to NHERF-1/EBP50 facilitates oligomerization of NHERF-1/EBP50, leading to stimulation of NHE3. This study provides the first direct evidence that a G protein-coupled receptor through association with NHERF-1/EBP-50 stimulates NHE3.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Med Serv, Baltimore, MD 21201 USA; Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Emory University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@astro.temple.edu		Hall, Randy/0000-0002-8318-8728	NIDA NIH HHS [P30 DA13429, DA11263, DA17302, DA04745] Funding Source: Medline; NIDDK NIH HHS [DK55881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA013429, R29DA004745, R01DA004745, R01DA011263] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bian JS, 2000, J MOL CELL CARDIOL, V32, P1415, DOI 10.1006/jmcc.2000.1175; Bian JS, 1998, J MOL CELL CARDIOL, V30, P2103, DOI 10.1006/jmcc.1998.0774; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; EINARSON MB, 2002, PROTEIN PROTEIN INTE, P37; FLIEGEL L, 1991, FEBS LETT, V279, P25, DOI 10.1016/0014-5793(91)80241-T; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356, DOI 10.1152/jn.2000.84.5.2356; Hatzoglou A, 1996, J CELL BIOCHEM, V63, P410; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee JWM, 1998, J NEUROCHEM, V70, P2203; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Mahon MJ, 2003, MOL ENDOCRINOL, V17, P2355, DOI 10.1210/me.2003-0043; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schwartz T.W., 2002, TXB RECEPTOR PHARM, P81; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	53	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25002	25009		10.1074/jbc.M313366200	http://dx.doi.org/10.1074/jbc.M313366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070904	hybrid			2022-12-27	WOS:000221827900014
J	Mann, HH; Ozbek, S; Engel, J; Paulsson, M; Wagener, R				Mann, HH; Ozbek, S; Engel, J; Paulsson, M; Wagener, R			Interactions between the cartilage oligomeric matrix protein and matrilins - Implications for matrix assembly and the pathogenesis of chondrodysplasias	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; HUMAN ARTICULAR-CARTILAGE; TISSUE DISTRIBUTION; MOLECULAR-STRUCTURE; COLLAGEN-II; PSEUDOACHONDROPLASIA; MUTATION; DOMAIN; BINDING; CALCIUM	The cartilage oligomeric matrix protein (COMP) and matrilins are abundant non-collagenous proteins in the cartilage extracellular matrix. In the presence of calcium, COMP and matrilin-1 elute together in the gel filtration of cartilage extracts and can be co-immunoprecipitated. In a screen for ligands of matrilin-1, -3, and -4 using an ELISA-style binding assay, COMP was identified as a prominent binding partner for all three, indicating a conservation of the COMP interaction among matrilins. The interaction of COMP and matrilin-4 is saturable, and an apparent K-D of 1 nM was determined. However, only the full-length COMP and the full-length matrilin-4 proteins showed a strong interaction, indicating that the oligomeric structures markedly increase the affinity. Mutations in COMP or matrilin-3 cause related forms of human chondrodysplasia, and the COMP mutation D469Delta, which is found in patients with pseudoachondroplasia, has been shown to cause a reduced calcium binding. Despite this, the mutation causes only a slight decrease in matrilin-4 binding. This indicates that impaired binding of COMP to matrilins does not cause the pseudoachondroplasia phenotype but rather that matrilins may be co-retained in the rough endoplasmatic reticulum where COMP accumulates in the chondrocytes of patients.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Basel, Bioctr, Div Biophys Chem, CH-4056 Basel, Switzerland	University of Cologne; University of Cologne; University of Basel	Wagener, R (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Özbek, Suat/D-3701-2014	Ozbek, Suat/0000-0003-2569-3942				Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Pullig O, 2002, OSTEOARTHR CARTILAGE, V10, P253, DOI 10.1053/joca.2001.0508; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; THUR J, 2000, THESIS U COLOGNE COL; Vilim V, 2003, CLIN CHIM ACTA, V328, P59, DOI 10.1016/S0009-8981(02)00375-3; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	28	130	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25294	25298		10.1074/jbc.M403778200	http://dx.doi.org/10.1074/jbc.M403778200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075323	hybrid			2022-12-27	WOS:000221827900048
J	Wajih, N; Sane, DC; Hutson, SM; Wallin, R				Wajih, N; Sane, DC; Hutson, SM; Wallin, R			The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system - Characterization of the system in normal and warfarin-resistant rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; 2,3-EPOXIDE REDUCTASE; SECRETORY PATHWAY; CALCIUM-BINDING; MOLECULAR-BASIS; EF-HAND; CALCIFICATION; LIVER; REQUIREMENT; METABOLISM	The vitamin K-dependent gamma-carboxylation system is responsible for post-translational modification of vitamin K-dependent proteins, converting them to Gla-containing proteins. The system consists of integral membrane proteins located in the endoplasmic reticulum membrane and includes the gamma-carboxylase and the warfarin-sensitive enzyme vitamin K-1 2,3-epoxide reductase (VKOR), which provides gamma-carboxylase with reduced vitamin K-1 cofactor. In this work, an in vitro gamma-carboxylation system was designed and used to understand how VKOR and gamma-carboxylase work together as a system and to identify factors that can regulate the activity of the system. Results are presented that demonstrate that the endoplasmic reticulum chaperone protein calumenin is associated with gamma-carboxylase and inhibits its activity. Silencing of the calumenin gene with siRNA resulted in a 5-fold increase in gamma-carboxylase activity. The results provide the first identification of a protein that can regulate the activity of the gamma-carboxylation system. The propeptides of vitamin K-dependent proteins stimulate gamma-carboxylase activity. Here we show that the factor X and prothrombin propeptides do not increase reduced vitamin K-1 cofactor production by VKOR in the system where VKOR is the rate-limiting step for gamma-carboxylation (Wallin, R., Sane, D. C., and Hutson, S. M. (2002) Thromb. Res. 108, 221-226). These findings put calumenin in a central position concerning regulation of gamma-carboxylation of vitamin K-dependent proteins. Reduced vitamin K-1 cofactor transfer between VKOR and gamma-carboxylase is shown to be significantly impaired in the in vitro gamma-carboxylation system prepared from warfarin-resistant rats. Furthermore, the sequence of the 18-kDa subunit 1 of the VKOR enzyme complex ( Rost, S., Fregin, A., Ivaskeviclus, V., Conzelmann, E., Hortnagel, K., Pelz, H-J., Lappegard K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., Muller, C. R., Storm, T. M., and Oldennburg, J. (2004) Nature 427, 537-541) was found to be identical in the two rat strains. This finding supports the notion that different forms of genetic warfarin resistance exist.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu			NHLBI NIH HHS [HL 069331, HL 60082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069331, R01HL060082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cain D, 1998, THROMB HAEMOSTASIS, V80, P128, DOI 10.1055/s-0037-1615151; CAIN D, 1998, J BIOL CHEM, V273, P4982; Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F; Funakoshi H, 2002, J NEUROSCI RES, V68, P150, DOI 10.1002/jnr.10211; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1990, BLOOD, V75, P1753; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HERMODSON MA, 1969, AM J PHYSIOL, V217, P1316, DOI 10.1152/ajplegacy.1969.217.5.1316; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Markussen MDK, 2003, PEST MANAG SCI, V59, P913, DOI 10.1002/ps.703; MISENHEIMER TM, 1990, BIOCHEM PHARMACOL, V40, P2079, DOI 10.1016/0006-2952(90)90238-G; Mousallem M, 2001, THROMB HAEMOSTASIS, V86, P1334, DOI 10.1055/s-0037-1616072; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SADOWSKI JA, 1976, J BIOL CHEM, V251, P2770; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538-7836.2003.00023.x; THJISSEN HH, 1989, BIOCHEM PHARMACOL, V38, P1115; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Tishler M, 1940, J AM CHEM SOC, V62, P2866, DOI 10.1021/ja01867a066; Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343; VERMEER C, 1986, HAEMOSTASIS, V16, P239; VERMEER C, 1988, BIOCHEM PHARMACOL, V37, P2872; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; WALLIN R, 1990, BIOCHEM J, V272, P473, DOI 10.1042/bj2720473; Wallin R, 1997, METHOD ENZYMOL, V282, P395; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs; WALLIN R, 1987, BIOCHEM J, V241, P389, DOI 10.1042/bj2410389; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	42	108	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25276	25283		10.1074/jbc.M401645200	http://dx.doi.org/10.1074/jbc.M401645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075329	Green Submitted, hybrid			2022-12-27	WOS:000221827900046
J	Unno, M; Kumauchi, M; Hamada, N; Tokunaga, F; Yamauchi, S				Unno, M; Kumauchi, M; Hamada, N; Tokunaga, F; Yamauchi, S			Resonance Raman evidence for two conformations involved in the L intermediate of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; ACTIVE-SITE; PHOTOCYCLE; SPECTROSCOPY; CHROMOPHORE; PHOTORECEPTOR; MUTANTS; COLOR; FOLD	The blue light receptor photoactive yellow protein (PYP) displays a photocycle that involves several intermediate states. Here we report resonance Raman spectroscopic investigations of the short-lived red-shifted intermediate denoted PYPL. We have found that the Raman bands of the carbonyl C = O stretching mode nu(11) as well as the C = C stretching mode nu(13) for the chromophore can be resolved into two peaks, and the ratio of the two components varies as a function of pH with pK(a) similar to6. The isotope effects on the resonance Raman spectra have confirmed a deprotonated cis-chromophore for the two components. The results indicate the presence of two conformations in the active site of PYPL. The normal coordinate calculations based on the density functional theory provide a structural model for the two conformations, where the low pH form is possibly an active structure for the protonation reaction generating a following intermediate in the photocycle.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan; Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Osaka 5600043, Japan; Osaka Univ, JST, CREST, Suita, Osaka 5650871, Japan	Tohoku University; Osaka University; Japan Science & Technology Agency (JST); Osaka University	Unno, M (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan.	unno@tagen.tohoku.ac.jp		Unno, Masashi/0000-0002-5016-6274				BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Chosrowjan H, 2004, J PHYS CHEM B, V108, P2686, DOI 10.1021/jp031126w; Devanathan S, 1999, BIOCHEMISTRY-US, V38, P13766, DOI 10.1021/bi991634p; El-Mashtoly SF, 2004, BIOCHEMISTRY-US, V43, P2279, DOI 10.1021/bi035638c; Frisch M.J., 2016, GAUSSIAN 16 REVISION; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Hendriks J, 2003, BIOPHYS J, V84, P1180, DOI 10.1016/S0006-3495(03)74932-7; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Mihara K, 1997, J BIOCHEM, V121, P876; Onsager L, 1936, J AM CHEM SOC, V58, P1486, DOI 10.1021/ja01299a050; Pan DH, 2004, BIOPHYS J, V86, P2374, DOI 10.1016/S0006-3495(04)74294-0; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Takeuchi H., 1981, SPECTROSCOPY BIOL SY, V13, P113; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Unno M, 2000, J AM CHEM SOC, V122, P4233, DOI 10.1021/ja000032m; Unno M, 2003, J PHYS CHEM B, V107, P2837, DOI 10.1021/jp026448z; Unno M, 2002, BIOCHEMISTRY-US, V41, P5668, DOI 10.1021/bi025508o; Voet D VJ, 1990, BIOCHEMISTRY; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	26	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23855	23858		10.1074/jbc.C400137200	http://dx.doi.org/10.1074/jbc.C400137200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15096497	hybrid			2022-12-27	WOS:000221702500003
J	Sugiura, H; Iwata, K; Matsuoka, M; Hayashi, H; Takemiya, T; Yasuda, S; Ichikawa, M; Yamauchi, T; Mehlen, P; Haga, T; Yamagata, K				Sugiura, H; Iwata, K; Matsuoka, M; Hayashi, H; Takemiya, T; Yasuda, S; Ichikawa, M; Yamauchi, T; Mehlen, P; Haga, T; Yamagata, K			Inhibitory role of endophilin 3 in receptor-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; DOPAMINE D2 RECEPTORS; HOMOLOGY 3 DOMAIN; SH3 DOMAIN; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; CULTURED-CELLS; PROTEIN; SYNAPTOJANIN	Endophilin 1 (Endo1) participates in synaptic vesicle biogenesis through interactions of its Src homology 3 domain with the polyphosphoinositide phosphatase Synaptojanin and the GTPase Dynamin. Endo1 has also been reported to affect endocytosis by converting membrane curvature via its lysophosphatidic acid acyltransferase activity. Here we report that a closely related isoform of Endo1, Endo3, inhibits clathrin-mediated endocytosis. Mutational analyses showed that the variable region of Endo3 is important in regulating transferrin endocytosis. In the brain, Endo3 is co-localized with dopamine D2 receptor in olfactory nerve terminals and inhibits its clathrin-mediated endocytosis in COS-7 cells. Furthermore, overexpression of Endo3 in an olfactory epithelium-derived cell line suppressed dopamine D2 receptor-mediated endocytosis and therefore accelerated its dopamine-induced differentiation. These results indicate that Endo3 may act as a negative regulator of clathrin-mediated endocytosis in brain neurons.	Tokyo Metropolitan Inst Neurosci, Dept Neuropharmacol, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Basictech & Facil, Tokyo 1838526, Japan; Tokyo Metropolitan Hiroo Gen Hosp, Dept Neuropsychiat, Shibuya Ku, Tokyo 1500012, Japan; Niigata Univ, Sch Med, Dept Neurobiol & Anat, Niigata 9518510, Japan; Univ Tokushima, Fac Pharmaceut Sci, Dept Biochem, Tokushima 7708505, Japan; Univ Lyon 1, CNRS, UMR 5534,Mol & Cellular Genet Ctr, Apoptosis Differentiat Lab Label La Ligue, F-69622 Villeurbanne, France; Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, Tokyo 1718588, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Niigata University; Tokushima University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Gakushuin University	Yamagata, K (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Neuropharmacol, Tokyo 1838526, Japan.	kyamagat@min.ac.jp						Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Coronas V, 1997, J NEUROCHEM, V69, P1870; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Ennis M, 2001, J NEUROPHYSIOL, V86, P2986, DOI 10.1152/jn.2001.86.6.2986; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Irie Y, 2000, J BIOL CHEM, V275, P2647, DOI 10.1074/jbc.275.4.2647; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Itokawa M, 1996, MOL PHARMACOL, V49, P560; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Koster NL, 1999, J COMP NEUROL, V411, P666, DOI 10.1002/(SICI)1096-9861(19990906)411:4<666::AID-CNE10>3.0.CO;2-S; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; PINCHING AJ, 1971, J CELL SCI, V9, P347; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schuske KR, 2003, NEURON, V40, P749, DOI 10.1016/S0896-6273(03)00667-6; Shipley MT, 1996, J NEUROBIOL, V30, P123; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUGIURA H, 1992, BRAIN RES, V593, P97, DOI 10.1016/0006-8993(92)91269-K; Torrey T, 1998, MAMM GENOME, V9, P74, DOI 10.1007/s003359900683; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	38	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23343	23348		10.1074/jbc.M312607200	http://dx.doi.org/10.1074/jbc.M312607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15066995	hybrid			2022-12-27	WOS:000221570900069
J	Schwarzenbacher, R; Stenner-Liewen, F; Liewen, H; Robinson, H; Hua, YA; Bossy-Wetzel, E; Reed, JC; Liddington, RC				Schwarzenbacher, R; Stenner-Liewen, F; Liewen, H; Robinson, H; Hua, YA; Bossy-Wetzel, E; Reed, JC; Liddington, RC			Structure of the Chlamydia protein CADD reveals a redox enzyme that modulates host cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; PNEUMONIAE; DEATH	The Chlamydia protein CADD (Chlamydia protein associating with death domains) has been implicated in the modulation of host cell apoptosis via binding to the death domains of tumor necrosis factor family receptors. Transfection of CADD into mammalian cells induces apoptosis. Here we present the CADD crystal structure, which reveals a dimer of seven-helix bundles. Each bundle contains a di-iron center adjacent to an internal cavity, forming an active site similar to that of methane mono-oxygenase hydrolase. We further show that CADD mutants lacking critical metal-coordinating residues are substantially less effective in inducing apoptosis but retain their ability to bind to death domains. We conclude that CADD is a novel redox protein toxin unique to Chlamydia species and propose that both its redox activity and death domain binding ability are required for its biological activity.	Burnham Inst, La Jolla, CA 92037 USA; Univ Saarland, Dept Med 1, D-66421 Homburg, Germany; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Sanford Burnham Prebys Medical Discovery Institute; Saarland University; United States Department of Energy (DOE); Brookhaven National Laboratory	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org		Stenner, Frank/0000-0003-4541-8817; Liewen, Heike/0000-0002-6161-4749	NCI NIH HHS [CA69381] Funding Source: Medline; NEI NIH HHS [R01 EY016164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTILLA T, 2001, J AM MED ASS, V285; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698; CHRISTOPHER JA, 1998, SPOCK; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Geng YM, 2000, J IMMUNOL, V164, P5522, DOI 10.4049/jimmunol.164.10.5522; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jaroszewski L, 2002, PROTEIN SCI, V11, P1702, DOI 10.1110/ps.4820102; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Magnusson OT, 2004, P NATL ACAD SCI USA, V101, P7913, DOI 10.1073/pnas.0402640101; MEULENBERG JJM, 1990, FEMS MICROBIOL LETT, V71, P337, DOI 10.1016/0378-1097(90)90244-K; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANG ASH, 1991, J BACTERIOL, V173, P46, DOI 10.1128/jb.173.1.46-54.1991; Perfettini JL, 2003, BIOCHIMIE, V85, P763, DOI 10.1016/j.biochi.2003.08.006; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; SCHACHTER J, 1988, CURR TOP MICROBIOL, V138, P109; Schoier J, 2001, MICROB PATHOGENESIS, V31, P173, DOI 10.1006/mpat.2001.0460; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Stenner-Liewen F, 2002, J BIOL CHEM, V277, P9633, DOI 10.1074/jbc.C100693200; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	26	37	39	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29320	29324		10.1074/jbc.M401268200	http://dx.doi.org/10.1074/jbc.M401268200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15087448	hybrid			2022-12-27	WOS:000222445300062
J	Wang, JC; Walker, A; Blackwell, TK; Yamamoto, KR				Wang, JC; Walker, A; Blackwell, TK; Yamamoto, KR			The Caenorhabditis elegans ortholog of TRAP240, CeTRAP240/let-19, selectively modulates gene expression and is essential for embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; C-ELEGANS; MEDIATOR COMPLEXES; DEPENDENT TRANSCRIPTION; EMBRYONIC-DEVELOPMENT; COACTIVATOR COMPLEX; NUCLEAR RECEPTORS; PROTEIN; YEAST	Mediator complexes are large multiprotein assemblies that function in the regulation of eukaryotic gene transcription. In yeast, certain mediator subunits appear to comprise a subcomplex that acts in the regulation of a specific subset of genes. We investigated in a metazoan, Caenorhabditis elegans, the roles and interactions of two of those subunits, CeTRAP240/let-19 and CeTRAP230/dpy-22. We found that CeTRAP240/let-19 contains four domains that are conserved in the human TRAP240 protein and that one of those domains displays intrinsic transcriptional repression activity. Using RNA interference, we found that reduced expression of CeTRAP240/let-19 displayed a high penetrance of embryonic lethality in F1 progeny; animals that escaped embryonic arrest showed mutant phenotypes such as burst vulva and molting defects. CeTRAP240/let-19 appeared to affect specific genes, as CeTRAP240/let-19(RNAi) led to selectively reduced expression of a subset of reporter genes examined. Genetic experiments supported the view that CeTRAP240/let-19 and CeTRAP230/dpy-22, like their Drosophila and yeast counterparts, can operate on common pathways. Thus, a male tail phenotype caused by the pal-1(e2091) mutation was suppressed not only by CeTRAP230/dpy-22 mutants, as reported previously, but also by reduced expression of CeTRAP240/let-19. Additionally, CeTRAP240/let-19(RNAi) in a CeTRAP230/dpy-22 mutant background produced a strong synthetic lethal phenotype. Overall, our results establish specific roles of CeTRAP240/let-19 in C. elegans embryonic development and a functional interaction between CeTRAP240/let-19 and CeTRAP230/dpy-22. Interestingly, whereas this interaction has been conserved from yeast to mammals, the subcomplex modulates metazoan-specific genetic pathways, likely in addition to those also controlled in yeast.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA	University of California System; University of California San Francisco; Harvard University; Joslin Diabetes Center, Inc.	Yamamoto, KR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, S572D,Genentech Hall,600 16th St, San Francisco, CA 94107 USA.	yamamoto@cmp.ucsf.edu	Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; DELONG L, 1987, GENETICS, V117, P657; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh K, 2001, DEVELOPMENT, V128, P2867; KRAUSE M, 1995, BIOESSAYS, V17, P219, DOI 10.1002/bies.950170308; Kwon JY, 1999, P NATL ACAD SCI USA, V96, P14990, DOI 10.1073/pnas.96.26.14990; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Sluder AE, 1997, DEV BIOL, V184, P303, DOI 10.1006/dbio.1997.8544; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Treisman JE, 2001, DEVELOPMENT, V128, P603; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Zhang H, 2000, GENE DEV, V14, P2161, DOI 10.1101/gad.814700; Zhang H, 2001, DEVELOPMENT, V128, P767; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	52	27	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29270	29277		10.1074/jbc.M401242200	http://dx.doi.org/10.1074/jbc.M401242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15073178	hybrid			2022-12-27	WOS:000222445300056
J	Bae, E; Phillips, GN				Bae, E; Phillips, GN			Structures and analysis of highly homologous psychrophilic, mesophilic, and thermophilic adenylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD ADAPTATION; EXTREME ENVIRONMENTS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; STABILITY; ENZYMES; PROTEIN; ZINC; THERMOSTABILITY; DEHYDROGENASE	The crystal structures of adenylate kinases from the psychrophile Bacillus globisporus and the mesophile Bacillus subtilis have been solved and compared with that from the thermophile Bacillus stearothermophilus. This is the first example we know of where a trio of protein structures has been solved that have the same number of amino acids and a high level of identity (66 - 74%) and yet come from organisms with different operating temperatures. The enzymes were characterized for their own thermal denaturation and inactivation, and they exhibited the same temperature preferences as their source organisms. The structures of the three highly homologous, dynamic proteins with different temperature-activity profiles provide an opportunity to explore a molecular mechanism of cold and heat adaptation. Their analysis suggests that the maintenance of the balance between stability and flexibility is crucial for proteins to function at their environmental temperatures, and it is achieved by the modification of intramolecular interactions in the process of temperature adaptation.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	phillips@biochem.wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR 13790, RR 07707] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Berry MB, 1998, PROTEIN-STRUCT FUNCT, V32, P275; Boyer P.D, 1973, ENZYMES, P279; Bruins ME, 2001, APPL BIOCHEM BIOTECH, V90, P155, DOI 10.1385/ABAB:90:2:155; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Claus D., 1986, BERGEYS MANUAL SYSTE, P1105, DOI DOI 10.1016/0922-338X(92)90270-5; Criswell AR, 2003, J MOL BIOL, V330, P1087, DOI 10.1016/S0022-2836(03)00655-7; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; Deming JW, 2002, CURR OPIN MICROBIOL, V5, P301, DOI 10.1016/S1369-5274(02)00329-6; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Gianese G, 2002, PROTEINS, V47, P236, DOI 10.1002/prot.10084; GILLES AM, 1994, J BACTERIOL, V176, P520, DOI 10.1128/JB.176.2.520-523.1994; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jamrog DC, 2003, ACTA CRYSTALLOGR D, V59, P304, DOI 10.1107/S0907444902021935; Kim SY, 1999, J BIOL CHEM, V274, P11761, DOI 10.1074/jbc.274.17.11761; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Martins LO, 1996, J BACTERIOL, V178, P5644, DOI 10.1128/jb.178.19.5644-5651.1996; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perl D, 2000, NAT STRUCT BIOL, V7, P380; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; Rayment I, 2002, STRUCTURE, V10, P147, DOI 10.1016/S0969-2126(02)00711-6; Rothschild LJ, 2001, NATURE, V409, P1092, DOI 10.1038/35059215; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Sheridan PP, 2000, BBA-PROTEIN STRUCT M, V1543, P417, DOI 10.1016/S0167-4838(00)00237-5; Shi ZS, 2002, BIOCHEMISTRY-US, V41, P2120, DOI 10.1021/bi011307t; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Thomas T, 2000, J BACTERIOL, V182, P1328, DOI 10.1128/JB.182.5.1328-1332.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai CJ, 2002, CRIT REV BIOCHEM MOL, V37, P55, DOI 10.1080/10409230290771456; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	50	166	169	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28202	28208		10.1074/jbc.M401865200	http://dx.doi.org/10.1074/jbc.M401865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15100224	hybrid			2022-12-27	WOS:000222265400049
J	Betz, C; Schlenstedt, G; Bailer, SM				Betz, C; Schlenstedt, G; Bailer, SM			Asr1p, a novel yeast ring/PHD finger protein, signals alcohol stress to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; TRANSCRIPTION FACTORS; ETHANOL STRESS; BUDDING YEAST; ENVIRONMENTAL-CHANGES; OXIDATIVE STRESS; LOCALIZATION; KINASE	During fermentation, yeast cells are exposed to increasing amounts of alcohol, which is stressful and affects both growth and viability. On the molecular level, numerous aspects of alcohol stress signaling remain unresolved. We have identified a novel yeast Ring/PHD finger protein that constitutively shuttles between nucleus and cytoplasm but accumulates in the nucleus upon exposure to ethanol, 2-propanol, or 1-butanol. Subcellular localization of this protein is not altered by osmotic, oxidative, or heat stress or during nitrogen or glucose starvation. Because of its exclusive sensitivity to environmental alcohol, the protein was called Asr1p for Alcohol Sensitive Ring/PHD finger 1 protein. Nuclear accumulation of Asr1p is rapid, reversible, and requires a functional Ran/Gsp1p gradient. Asr1p contains two N terminally located leucine-rich nuclear export sequences (NES) required for nuclear export. Consistently, it accumulates in the nucleus of xpo1-1 cells at restrictive temperature and forms a trimeric complex with the exportin Xpo1p and Ran-GTP. Deletion of ASR1 leads to sensitivity in growth on medium containing alcohol or detergent, consistent with a function of Asr1p in alcohol-related signaling. Asr1p is the first reported protein that changes its subcellular localization specifically upon exposure to alcohol and therefore represents a key element in the analysis of alcohol-responsive signaling.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Bailer, SM (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	dr.susanne.bailer@med-rz.uni-saarland.de						Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; ALEXANDRE H, 1994, FEMS MICROBIOL LETT, V124, P17, DOI 10.1016/0378-1097(94)90326-3; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; Aranda A, 2002, ARCH MICROBIOL, V177, P304, DOI 10.1007/s00203-001-0391-1; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bailer SM, 2001, MOL CELL BIOL, V21, P7944, DOI 10.1128/MCB.21.23.7944-7955.2001; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Damelin M, 2002, METHOD ENZYMOL, V351, P587; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Elion EA, 2001, J CELL SCI, V114, P3967; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorner M, 1999, BIOL CHEM, V380, P147; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; James TC, 2003, J APPL MICROBIOL, V94, P432, DOI 10.1046/j.1365-2672.2003.01849.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Lorenz MC, 2000, MOL BIOL CELL, V11, P183, DOI 10.1091/mbc.11.1.183; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; ROSE AH, 1993, J APPL BACTERIOL, V74, pS110, DOI 10.1111/j.1365-2672.1993.tb04347.x; Schuller Christoph, 2002, Results Probl Cell Differ, V35, P169; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Takahashi T, 2001, MOL GENET GENOMICS, V265, P1112, DOI 10.1007/s004380100510; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537	49	24	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28174	28181		10.1074/jbc.M401595200	http://dx.doi.org/10.1074/jbc.M401595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117954	hybrid			2022-12-27	WOS:000222265400045
J	Guzman, M; Lo Verme, J; Fu, J; Oveisi, F; Blazquez, C; Piomelli, D				Guzman, M; Lo Verme, J; Fu, J; Oveisi, F; Blazquez, C; Piomelli, D			Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; CARNITINE PALMITOYLTRANSFERASE; MESSENGER-RNA; RAT; LIPOGENESIS; HEPATOCYTES; MODULATION; METABOLISM; MECHANISMS; ASTROCYTES	Amides of fatty acids with ethanolamine (FAE) are biologically active lipids that participate in a variety of biological functions, including the regulation of feeding. The polyunsaturated FAE anandamide ( arachidonoylethanolamide) increases food intake by activating G protein-coupled cannabinoid receptors. On the other hand, the monounsaturated FAE oleoylethanolamide (OEA) reduces feeding and body weight gain by activating the nuclear receptor PPAR-alpha ( peroxisome proliferator-activated receptor alpha). In the present report, we examined whether OEA can also influence energy utilization. OEA ( 1 - 20 muM) stimulated glycerol and fatty acid release from freshly dissociated rat adipocytes in a concentration-dependent and structurally selective manner. Under the same conditions, OEA had no effect on glucose uptake or oxidation. OEA enhanced fatty acid oxidation in skeletal muscle strips, dissociated hepatocytes, and primary cardiomyocyte cultures. Administration of OEA in vivo ( 5 mg kg(-1), intraperitoneally) produced lipolysis in both rats and wild-type mice, but not in mice in which PPAR-alpha had been deleted by homologous recombination (PPAR-alpha(-/-)). Likewise, OEA was unable to enhance lipolysis in adipocytes or stimulate fatty acid oxidation in skeletal muscle strips isolated from PPAR-alpha mice. The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, which also were dependent on the presence of PPAR-alpha. Subchronic treatment with OEA reduced body weight gain and triacylglycerol content in liver and adipose tissue of diet-induced obese rats and wild-type mice, but not in obese PPAR-alpha(-/-) mice. The results suggest that OEA stimulates fat utilization through activation of PPAR-alpha and that this effect may contribute to its anti-obesity actions.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Complutense, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	University of California System; University of California Irvine; Complutense University of Madrid	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	piomelli@uci.edu	Fu, Jin/A-3510-2012	Guzman, Manuel/0000-0001-7475-118X				Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berry EM, 2002, PHARMACOL THERAPEUT, V95, P185, DOI 10.1016/S0163-7258(02)00257-7; BEYNEN AC, 1979, DIABETES, V28, P828, DOI 10.2337/diabetes.28.9.828; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; Bocher Virginie, 2002, Journal de la Societe de Biologie, V196, P47; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; COLODZIN M, 1963, BIOCHEM BIOPH RES CO, V10, P165, DOI 10.1016/0006-291X(63)90044-5; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; RODBELL M, 1964, J BIOL CHEM, V239, P375; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; STRALFORS P, 1987, J BIOL CHEM, V262, P11486; Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2; SUN YX, 2004, IN PRESS BIOCH J; Ueda Hiroshi, 2002, Nihon Yakurigaku Zasshi, V119, P79; Unger RH, 2003, ANNU REV PHYSIOL, V65, P333, DOI 10.1146/annurev.physiol.65.092101.142622; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Winegar DA, 2001, J LIPID RES, V42, P1543	37	259	273	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27849	27854		10.1074/jbc.M404087200	http://dx.doi.org/10.1074/jbc.M404087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123613	hybrid			2022-12-27	WOS:000222265400005
J	Prommeenate, P; Lennon, AM; Markert, C; Hippler, M; Nixon, PJ				Prommeenate, P; Lennon, AM; Markert, C; Hippler, M; Nixon, PJ			Subunit composition of NDH-1 complexes of Synechocystis sp PCC 6803 - Identification of two new ndh gene products with nuclear-encoded homologues in the chloroplast Ndh complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; PYRIDINE-NUCLEOTIDE DEHYDROGENASE; INORGANIC CARBON TRANSPORT; MEMBRANE-PROTEIN COMPLEXES; CYCLIC ELECTRON-TRANSPORT; SP STRAIN PCC-6803; NAD(P)H DEHYDROGENASE; RESPIRATORY COMPLEX; CO2 UPTAKE; POLYACRYLAMIDE GELS	Cyanobacteria contain several genes, annotated ndh, whose products show sequence similarities to subunits found in complex I ( NADH: ubiquinone oxidoreductase) of eubacteria and mitochondria. However, it is still unclear whether the cyanobacterial ndh gene products actually form a single large protein complex or exist as smaller independent complexes. To address this, we have constructed a strain of Synechocystis sp. PCC 6803 in which the C terminus of the NdhJ subunit was fused to an His(6) tag to aid isolation. Three major NdhJ-containing complexes were resolved by blue native polyacrylamide gel electrophoresis, with approximate apparent molecular masses of 460, 330, and 110 kDa. N-terminal sequencing and mass spectrometry revealed that the 460-kDa complex contained ten annotated ndh gene products. Detergent-induced fragmentation experiments indicated that the 460-kDa complex was composed of hydrophobic ( 150 kDa) and hydrophilic ( 110 130 kDa) modules similar to that found in the minimal form of complex I found in Escherichia coli, except that the electron input module was not conserved. The difference in size between the 460- and 330-kDa complexes is attributed to differences in the stoichiometry of the hydrophilic and hydrophobic modules in the complex, either 2: 1 or 1: 1, respectively. We have also detected the presence of two new Ndh subunits (slr1623 and sll1262) that are unrelated to subunits in the eubacterial complex I but which have homologues in the closely related chloroplast Ndh complex of maize ( Funk, E., Schafer, E., and Steinmuller, K. ( 1999) J. Plant Physiol. 154, 16 - 23). The presence of these additional subunits might reflect the use by the NDH-1 and Ndh complexes of a different, so far unidentified, electron input module.	Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, London SW7 2AZ, England; Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany	Imperial College London; Friedrich Schiller University of Jena	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, S Kensington Campus, London SW7 2AZ, England.	p.nixon@imperial.ac.uk		Michael, Hippler/0000-0001-9670-6101; Nixon, Peter/0000-0003-1952-6937				Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Appel J, 1996, BBA-PROTEIN STRUCT M, V1298, P141, DOI 10.1016/S0167-4838(96)00176-8; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Baumer S, 2000, J BIOL CHEM, V275, P17968, DOI 10.1074/jbc.M000650200; BERGER S, 1991, FEBS LETT, V286, P129, DOI 10.1016/0014-5793(91)80957-5; BERGER S, 1993, FEBS LETT, V326, P246, DOI 10.1016/0014-5793(93)81800-F; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Bruggemann H, 2000, EUR J BIOCHEM, V267, P5810, DOI 10.1046/j.1432-1327.2000.01657.x; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Cooley JW, 2001, J BACTERIOL, V183, P4251, DOI 10.1128/JB.183.14.4251-4258.2001; Deng Y, 2003, PLANT CELL PHYSIOL, V44, P534, DOI 10.1093/pcp/pcg067; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Funk E, 1999, J PLANT PHYSIOL, V154, P16, DOI 10.1016/S0176-1617(99)80312-5; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Guedeney G, 1996, FEBS LETT, V378, P277, DOI 10.1016/0014-5793(95)01473-X; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holt PJ, 2003, J BIOL CHEM, V278, P43114, DOI 10.1074/jbc.M308247200; Ito M, 1999, J BACTERIOL, V181, P2394, DOI 10.1128/JB.181.8.2394-2402.1999; Kaneko T, 1996, DNA Res, V3, P109; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Matsuo M, 1998, PLANT CELL PHYSIOL, V39, P263, DOI 10.1093/oxfordjournals.pcp.a029366; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1233; MI HL, 1995, PLANT CELL PHYSIOL, V36, P661; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nixon PJ, 2000, PHILOS T R SOC B, V355, P1541, DOI 10.1098/rstb.2000.0714; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Ohkawa H, 2001, J BACTERIOL, V183, P4938, DOI 10.1128/JB.183.16.4938-4939.2001; Pieulle L, 2000, FEBS LETT, V487, P272, DOI 10.1016/S0014-5793(00)02369-3; Quiles MJ, 2003, PLANT SCI, V164, P541, DOI 10.1016/S0168-9452(03)00003-7; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmitz O, 1996, NATURWISSENSCHAFTEN, V83, P525; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; Wellburn A. R., 1984, Advances in photosynthesis research. Vol.II., P9; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	54	98	112	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28165	28173		10.1074/jbc.M401107200	http://dx.doi.org/10.1074/jbc.M401107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102833	hybrid			2022-12-27	WOS:000222265400044
J	Bierl, C; Voetsch, B; Jin, RC; Handy, DE; Loscalzo, J				Bierl, C; Voetsch, B; Jin, RC; Handy, DE; Loscalzo, J			Determinants of human plasma glutathione peroxidase (GPx-3) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL LINING FLUID; MESSENGER-RNA; NITRIC-OXIDE; SELENIUM DEFICIENCY; OXIDATIVE STRESS; HUMAN LUNG; GENE; HYDROPEROXIDE; SEQUENCE; CELLS	Plasma glutathione peroxidase (GPx-3) is a selenocysteine-containing protein with antioxidant properties. GPx-3 deficiency has been associated with cardiovascular disease and stroke. The regulation of GPx-3 expression remains largely uncharacterized, however, and we studied its transcriptional and translational determinants in a cultured cell system. In transient transfections of a renal cell line (Caki-2), the published sequence cloned upstream of a luciferase reporter gene produced minimal activity (relative luminescence (RL) = 0.6 +/- 0.4). Rapid amplification of cDNA ends was used to identify a novel transcription start site that is located 233 bp downstream (3') of the published site and that produced a >25-fold increase in transcriptional activity (RL = 16.8 +/- 1.9; p < 0.0001). Analysis of the novel GPx-3 promoter identified Sp-1- and hypoxia-inducible factor-1-binding sites, as well as the redox-sensitive metal response element and antioxidant response element. Hypoxia was identified as a strong transcriptional regulator of GPx-3 expression, in part through the presence of the hypoxia-inducible factor-1-binding site, leading to an almost 3-fold increase in expression levels after 24 h compared with normoxic conditions (normalized RL = 3.5 +/- 0.3 versus 1.2 +/- 0.1; p < 0.001). We also investigated the role of the translational cofactors tRNA(Sec), SECIS-binding protein-2, and SelD (selenophosphate synthetase D) in GPx-3 protein expression. tRNA(Sec) and SelD significantly enhanced GPx-3 expression, whereas SECIS-binding protein-2 showed a trend toward increased expression. These results demonstrate the presence of a novel functional transcription start site for the human GPx-3 gene with a promoter regulated by hypoxia, and identify unique translational determinants of GPx-3 expression.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W507, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021	Handy, Diane/0000-0002-4310-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058976, P50HL055993, R37HL061795, R01HL061795] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58976, HL55993, HL61795] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173, DOI 10.1152/ajplung.1996.270.2.L173; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; AVISSAR N, 1994, ARCH BIOCHEM BIOPHYS, V309, P239, DOI 10.1006/abbi.1994.1108; Avissar NE, 2000, AM J RESP CRIT CARE, V162, P1342, DOI 10.1164/ajrccm.162.4.9912041; Barkats M, 2000, J NEUROCHEM, V75, P1438, DOI 10.1046/j.1471-4159.2000.0751438.x; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BrigeliusFlohe R, 1997, BIOMED ENVIRON SCI, V10, P163; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; CHU FF, 1992, BLOOD, V79, P3233; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350, DOI 10.1165/ajrcmb.23.3.4076; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Dogru-Abbasoglu S, 1999, CLIN BIOCHEM, V32, P671, DOI 10.1016/S0009-9120(99)00076-4; Flohe L, 2000, IUBMB LIFE, V49, P411; Flohe Leopold, 1997, P415; Freedman JE, 1996, J CLIN INVEST, V97, P979, DOI 10.1172/JCI118522; Holtzman Jordan L, 2002, Clin Lab, V48, P129; Kenet G, 1999, ARTERIOSCL THROM VAS, V19, P2017, DOI 10.1161/01.ATV.19.8.2017; Kim KK, 1999, PEDIATR RES, V46, P715, DOI 10.1203/00006450-199912000-00013; Kingsley PD, 1998, MOL REPROD DEV, V49, P343, DOI 10.1002/(SICI)1098-2795(199804)49:4<343::AID-MRD1>3.3.CO;2-T; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; Maiorino M, 2003, J BIOL CHEM, V278, P34286, DOI 10.1074/jbc.M305327200; Merante F, 2002, MOL CELL BIOCHEM, V229, P73, DOI 10.1023/A:1017921110363; Moreno SG, 2003, BIOL CHEM, V384, P635, DOI 10.1515/BC.2003.070; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muzakova V, 2000, PHYSIOL RES, V49, P315; Nakane T, 1998, FREE RADICAL BIO MED, V25, P504, DOI 10.1016/S0891-5849(98)00078-1; PORTER M, 1992, CLIN SCI, V83, P343, DOI 10.1042/cs0830343; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIEDER MJ, 2003, ES15478 NIEHSSNPS DE; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; Whitin JC, 2002, AM J PHYSIOL-RENAL, V283, pF20, DOI 10.1152/ajprenal.00014.2001; YOSHIMURA S, 1994, GENE, V145, P293; Yoshimura S, 1996, NEPHRON, V73, P207	49	108	116	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26839	26845		10.1074/jbc.M401907200	http://dx.doi.org/10.1074/jbc.M401907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096516	hybrid			2022-12-27	WOS:000222120400007
J	Hughes, WE; Elgundi, Z; Huang, P; Frohman, MA; Biden, TJ				Hughes, WE; Elgundi, Z; Huang, P; Frohman, MA; Biden, TJ			Phospholipase D1 regulates secretagogue-stimulated insulin release in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C ACTIVATION; LYSOPHOSPHATIDIC ACID; SECRETORY GRANULES; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; ISLET CELLS; BREFELDIN-A; MAST-CELLS; D1	Phospholipase D (PLD) has been strongly implicated in the regulation of Golgi trafficking as well as endocytosis and exocytosis. Our aim was to investigate the role of PLD in regulating the biphasic exocytosis of insulin from pancreatic beta-cells that is essential for mammalian glucose homeostasis. We observed that PLD activity in MIN6 pancreatic beta-cells is closely coupled to secretion. Cellular PLD activity was increased in response to a variety of secretagogues including the nutrient glucose and the cholinergic receptor agonist carbamoylcholine. Conversely, pharmacological or hormonal inhibition of stimulated secretion reduced PLD activity. Most importantly, blockade of PLD-catalyzed phosphatidic acid formation using butan-1-ol inhibited insulin secretion in both MIN6 cells and isolated pancreatic islets. It was further established that PLD activity was required for both the first and the second phase of glucose-stimulated insulin release, suggesting a role in the very distal steps of exocytosis, beyond granule recruitment into a readily releasable pool. Visualization of granules using green fluorescent protein-phogrin confirmed a requirement for PLD prior to granule fusion with the plasma membrane. PLD1 was shown to be the predominant isoform in MIN6 cells, and it was located at least partially on insulin granules. Overexpression of wild-type or a dominant negative catalytically inactive mutant of PLD1 augmented or inhibited secretagogue-stimulated secretion, respectively. The results suggest that phosphatidic acid formation on the granule membrane by PLD1 is essential for the regulated secretion of insulin from pancreatic beta-cells.	Garvan Inst Med Res, Cell Signalling Grp, Sydney, NSW 2010, Australia; SUNY Stony Brook, Med Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Ctr Dev Genet, Stony Brook, NY 11794 USA	Garvan Institute of Medical Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hughes, WE (corresponding author), Garvan Inst Med Res, Cell Signalling Grp, 384 Victoria St, Sydney, NSW 2010, Australia.	w.hughes@garvan.org.au	Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234; Hughes, William/0000-0002-7149-3987				Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Biden TJ, 2004, DIABETES, V53, pS159, DOI 10.2337/diabetes.53.2007.S159; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Capito K, 1996, J MOL ENDOCRINOL, V17, P101, DOI 10.1677/jme.0.0170101; Chen MC, 2000, ENDOCRINOLOGY, V141, P2822, DOI 10.1210/en.141.8.2822; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; Cockcroft S, 2002, MOL IMMUNOL, V38, P1277, DOI 10.1016/S0161-5890(02)00075-5; Dohke Y, 2002, BIOCHEM BIOPH RES CO, V299, P663, DOI 10.1016/S0006-291X(02)02713-4; DU G, 2004, MOL BIOL CELL; DUNLOP M, 1989, BIOCHEM BIOPH RES CO, V163, P922, DOI 10.1016/0006-291X(89)92310-3; DUNLOP M, 1992, ENDOCRINOLOGY, V130, P93, DOI 10.1210/en.130.1.93; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GERICH JE, 1976, ANNU REV PHYSIOL, V38, P353, DOI 10.1146/annurev.ph.38.030176.002033; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hughes WE, 2002, J BIOL CHEM, V277, P22974, DOI 10.1074/jbc.M201391200; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Kaldi K, 2002, J LEUKOCYTE BIOL, V71, P695; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Vitale N, 2002, ANN NY ACAD SCI, V971, P193, DOI 10.1111/j.1749-6632.2002.tb04463.x; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317	54	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27534	27541		10.1074/jbc.M403012200	http://dx.doi.org/10.1074/jbc.M403012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087463	hybrid			2022-12-27	WOS:000222120400086
J	Le, NH; van der Bent, P; Huls, G; van de Wetering, M; Loghman-Adham, M; Ong, ACM; Calvet, JP; Clevers, H; Breuning, MH; van Dam, H; Peters, DJM				Le, NH; van der Bent, P; Huls, G; van de Wetering, M; Loghman-Adham, M; Ong, ACM; Calvet, JP; Clevers, H; Breuning, MH; van Dam, H; Peters, DJM			Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KIDNEY-DISEASE; C-JUN; BETA-CATENIN; GENE-PRODUCT; FUNCTIONAL POLYCYSTIN-1; E-CADHERIN; 2ND GENE; LOCALIZATION; MUTATIONS	Polycystin-1, the polycystic kidney disease 1 gene product, has been implicated in several signaling complexes that are known to regulate essential cellular functions. We investigated the role of polycystin-1 in Wnt signaling and activator protein-1 (AP-1) activation. To this aim, a membrane-targeted construct encoding the conserved C-terminal region of mouse polycystin-1 reported to mediate signal transduction activity was expressed in human embryonic and renal epithelial cells. To ensure specificity and minimal co-transfection effects, we focused our study on the endogenous proteins that actually transduce the signals, beta-catenin and T-cell factor/lymphoid-enhancing factor for Wnt signaling and (phosphorylated) c-Jun, ATF2, and c-Fos for AP-1. Our data indicate that the C-terminal region of polycystin-1 activates AP-1 by inducing phosphorylation and expression of at least c-Jun and ATF2, whereas c-Fos was not affected. Under our experimental conditions, polycystin-1 did not modulate Wnt signaling. AP-1 activity was aberrant in human autosomal dominant polycystic kidney disease (ADPKD) renal cystic epithelial cells and in renal epithelial cells expressing transgenic full-length polycystin-1, resulting in decreased Jun-ATF and increased Jun-Fos activity, whereas Wnt signaling remained unaffected. Since our data indicate that aberrant polycystin-1 expression results in altered AP-1 activity, polycystin-1 may be required for adequate AP-1 activity.	Leiden Univ, Med Ctr, Dept Human Genet, Sylvius Labs, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 AB Utrecht, Netherlands; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Sheffield, Sheffield Kidney Inst, Sheffield S5 7AU, S Yorkshire, England; St Louis Univ, Dept Pediat, St Louis, MO 63104 USA; St Louis Univ, Pediat Res Inst, St Louis, MO 63104 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; University of Kansas; University of Kansas Medical Center; University of Sheffield; Saint Louis University; Saint Louis University	Peters, DJM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, Sylvius Labs, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	D.J.M.Peters@lumc.nl	Peters, Dorien/AFH-8507-2022; Ong, Albert/AAN-9430-2021; Huls, G.A./L-4398-2015; Breuning, Martijn H/E-3429-2010	Peters, Dorien/0000-0001-6974-7143; Ong, Albert/0000-0002-7211-5400; van Dam, Hans/0000-0002-8307-4325				Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Kugoh H, 2002, MOL CARCINOGEN, V33, P131, DOI 10.1002/mc.10034; Loghman-Adham M, 2003, AM J PHYSIOL-RENAL, V285, pF397, DOI 10.1152/ajprenal.00310.2002; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50; Muto S, 2002, HUM MOL GENET, V11, P1731, DOI 10.1093/hmg/11.15.1731; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodova M, 2002, J BIOL CHEM, V277, P29577, DOI 10.1074/jbc.M203570200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; TRUDEL M, 1992, CONTRIB NEPHROL, V97, P47; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; van Adelsberg J, 2000, NEPHROL DIAL TRANSPL, V15, P1, DOI 10.1093/ndt/15.1.1; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WARD CJ, 1994, CELL, V77, P881	40	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27472	27481		10.1074/jbc.M312183200	http://dx.doi.org/10.1074/jbc.M312183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087466	Green Accepted, hybrid			2022-12-27	WOS:000222120400079
J	Mao, H; Zhao, QS; Daigle, M; Ghahremani, MH; Chidiac, P; Albert, PR				Mao, H; Zhao, QS; Daigle, M; Ghahremani, MH; Chidiac, P; Albert, PR			RGS17/RGSZ2, a novel regulator of G(i/o), G(z), and G(q) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; RGS PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; RECEPTOR; INHIBITION; FAMILY; INTERACTS; DOMAIN; GAIP	To identify novel regulators of Galpha(o), the most abundant G-protein in brain, we used yeast two-hybrid screening with constitutively active Galpha(o) as bait and identified a new regulator of G-protein signaling (RGS) protein, RGS17 (RGSZ2), as a novel human member of the RZ (or A) subfamily of RGS proteins. RGS17 contains an amino-terminal cysteine-rich motif and a carboxyl-terminal RGS domain with highest homology to hRGSZ1- and hRGS-Galpha-interacting protein. RGS17 RNA was strongly expressed as multiple species in cerebellum and other brain regions. The interactions between hRGS17 and active forms of Galpha(i1-3), Galpha(o), Galpha(z), or Galpha(q) but not Galpha(s) were detected by yeast two-hybrid assay, in vitro pull-down assay, and co-immunoprecipitation studies. Recombinant RGS17 acted as a GTPase-activating protein (GAP) on free Galpha(i2) and Galpha(o) under pre-steady-state conditions, and on M2-muscarinic receptor-activated Galpha(i1), Galpha(i2), Galpha(i3), Galpha(z), and Galpha(o) in steady-state GTPase assays in vitro. Unlike RGSZ1, which is highly selective for G(z), RGS17 exhibited limited selectivity for G(o) among G(i)/G(o) proteins. All RZ family members reduced dopamine-D2/Galpha(i)-mediated inhibition of cAMP formation and abolished thyrotropin-releasing hormone receptor/Galpha(q)-mediated calcium mobilization. RGS17 is a new RZ member that preferentially inhibits receptor signaling via G(i/o), G(z), and G(q) over G(s) to enhance cAMP-dependent signaling and inhibit calcium signaling. Differences observed between in vitro GAP assays and whole-cell signaling suggest additional determinants of the G-protein specificity of RGS GAP effects that could include receptors and effectors.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario)	Chidiac, P (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Neurosci, Ottawa, ON K1H 8M5, Canada.	peter.chidiac@fmd.uwo.ca; palbert@uottawa.ca	Albert, Paul/E-4804-2010; Chidiac, Peter/L-5906-2015; Zhao, Qingshi/H-9839-2013; Ghahremani, Mohammad H/F-1615-2013	Albert, Paul/0000-0002-1809-3554; Chidiac, Peter/0000-0001-8365-6109; Ghahremani, Mohammad H/0000-0001-5051-6214				Albert PR, 1999, J BIOL CHEM, V274, P35469, DOI 10.1074/jbc.274.50.35469; ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; Albert PR, 2002, ENDOCRINOLOGY, V143, P744, DOI 10.1210/en.143.3.744; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Barker SA, 2001, GENOMICS, V78, P223, DOI 10.1006/geno.2001.6659; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Burchett SA, 2003, J NEUROCHEM, V87, P551, DOI 10.1046/j.1471-4159.2003.02047.x; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Cladman W, 2002, MOL PHARMACOL, V62, P654, DOI 10.1124/mol.62.3.654; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fischer T, 2003, P NATL ACAD SCI USA, V100, P8270, DOI 10.1073/pnas.1432965100; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; ITO M, 1993, FEBS LETT, V320, P125, DOI 10.1016/0014-5793(93)80076-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Liu YT, 2002, INT J ELEC POWER, V24, P271, DOI 10.1016/S0142-0615(01)00032-1; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nixon AB, 2002, J BIOL CHEM, V277, P18127, DOI 10.1074/jbc.M201065200; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Poyry TAA, 2004, GENE DEV, V18, P62, DOI 10.1101/gad.276504; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2003, J BIOL CHEM, V278, P52273, DOI 10.1074/jbc.M309626200; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang YR, 2002, J BIOL CHEM, V277, P48325, DOI 10.1074/jbc.M206116200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zaworski PG, 1999, BRIT J PHARMACOL, V128, P1181, DOI 10.1038/sj.bjp.0702905; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; ZHAO D, 1993, ENDOCRINOLOGY, V130, P3529; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	44	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26314	26322		10.1074/jbc.M401800200	http://dx.doi.org/10.1074/jbc.M401800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15096504	hybrid			2022-12-27	WOS:000222003000050
J	Yeh, PY; Yeh, KH; Chuang, SE; Song, YC; Cheng, AL				Yeh, PY; Yeh, KH; Chuang, SE; Song, YC; Cheng, AL			Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappa B activation by protein phosphatase 4-mediated NF-kappa B p65 Thr dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELA TRANSCRIPTION FACTOR; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; KINASE; CANCER; PHOSPHORYLATION; CELLS; SPECIFICITY; APOPTOSIS; SUBUNIT	87We previously reported that suppression of the MEK/ERK pathway increases drug resistance of SiHa cells. In this study, we further characterized the underlying mechanism of this phenomenon. Pretreatment of SiHa cells with MEK/ERK inhibitor enhanced cisplatin-induced NF-kappaB activation. However, results of immunoblotting analysis showed that neither cisplatin nor MEK/ERK inhibitors induced marked IkappaBalpha degradation, suggesting that suppression of the MEK/ERK signaling pathway may enhance cisplatin-induced NF-kappaB activation via mechanisms other than the conventional pathway. Previous findings that protein phosphatase 4 (PP4), a nuclear serine/threonine phosphatase, directly interacts with and activates NF-kappaB led us to examine the phosphorylation status of NF-kappaB p65. Coincident with activation of NF-kappaB, cisplatin induced Ser phosphorylation but decreased Thr phosphorylation of NF-kappaB p65. Suppression of the MEK/ERK pathway further enhanced cisplatin-induced Thr dephosphorylation but did not affect cisplatin-induced Ser phosphorylation of NF-kappaB p65. Further, in parallel with Thr dephosphorylation, the protein level of nuclear PP4 was increased in cisplatin-treated cells and was further increased by suppression of the MEK/ERK pathway. SiHa cells were then transfected by a sense or an antisense PP4 gene. PP4-overexpressing cells showed a decrease in Thr phosphorylation of NF-kappaB p65 to nearly undetectable levels, and both basal and cisplatin-induced NF-kappaB activities were higher than those in parental cells. By contrast, cisplatin, either alone or with MEK/ERK inhibitors, induced little NF-kappaB activation in antisense PP4-transfected cells. Coprecipitated complex kinase assay revealed a fragment of NF-kappaB p65 (amino acids 279-444) to contain potential phosphorylation sites that directly interact with PP4. Further studies by site-directed mutagenesis suggested that Thr(435) was the major phosphorylation site.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10016, Taiwan; Natl Taiwan Univ, Ctr Canc Res, Taipei 10016, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei 10016, Taiwan; Far Eastern Mem Hosp, Dept Med Res, Taipei 10016, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Chuang, Shuang-En/D-2080-2010; Yeh, Kun-Huei/HGD-3316-2022	Cheng, Ann-Lii/0000-0002-9152-6512; YEH, Kun-Huei/0000-0002-7306-174X; Song, Ying-Chyi/0000-0003-0279-4652				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; XIA Z, 1995, SCIENCE, V24, P1326; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; ZONG H, 1997, CELL, V89, P413	36	88	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26143	26148		10.1074/jbc.M402362200	http://dx.doi.org/10.1074/jbc.M402362200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073167	hybrid			2022-12-27	WOS:000222003000028
J	Angata, K; Chan, D; Thibault, J; Fukuda, M				Angata, K; Chan, D; Thibault, J; Fukuda, M			Molecular dissection of the ST8Sia IV polysialyltransferase - Distinct domains are required for neural cell adhesion molecule recognition and polysialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; POLYSIALIC ACID SYNTHESIS; NERVOUS-SYSTEM; COOPERATIVE POLYSIALYLATION; CATALYTIC DOMAIN; OLFACTORY-BULB; DISULFIDE BOND; AMINO-ACIDS; IN-VITRO; EXPRESSION	Polysialic acid, a homopolymer of alpha2,8-linked sialic acid expressed on the neural cell adhesion molecule ( NCAM), is thought to play critical roles in neural development. Two highly homologous polysialyltransferases, ST8Sia II and ST8Sia IV, which belong to the sialyltransferase gene family, synthesize polysialic acid on NCAM. By contrast, ST8Sia III, which is moderately homologous to ST8Sia II and ST8Sia IV, adds oligosialic acid to itself but very inefficiently to NCAM. Here, we report domains of polysialyltransferases required for NCAM recognition and polysialylation by generating chimeric enzymes between ST8Sia IV and ST8Sia III or ST8Sia II. We first determined the catalytic domain of ST8Sia IV by deletion mutants. To identify domains responsible for NCAM polysialylation, different segments of the ST8Sia IV catalytic domain, identified by the deletion experiments, were replaced with corresponding segments of ST8Sia II and ST8Sia III. We found that larger polysialic acid was formed on the enzymes themselves (autopolysialylation) when chimeric enzymes contained the carboxyl-terminal region of ST8Sia IV. However, chimeric enzymes that contain only the carboxyl-terminal segment of ST8Sia IV and the amino-terminal segment of ST8Sia III showed very weak activity toward NCAM, even though they had strong activity in polysialylating themselves. In fact, chimeric enzymes containing the amino-terminal portion of ST8Sia IV fused to downstream sequences of ST8Sia III inhibited NCAM polysialylation in vitro, although they did not polysialylate NCAM. These results suggest that in polysialyltransferases the NCAM recognition domain is distinct from the polysialylation domain and that some chimeric enzymes may act as a dominant negative enzyme for NCAM polysialylation.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NCI NIH HHS [R01 CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDELMAN GM, 1984, ANNU REV NEUROSCI, V7, P339; FINNE J, 1982, J BIOL CHEM, V257, P1966; FUKUDA M, 2000, MOL CELLULAR GLYCOBI, P1; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gregoriadis G, 2000, CELL MOL LIFE SCI, V57, P1964, DOI 10.1007/PL00000676; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Jimbo T, 2001, INT J CANCER, V94, P192, DOI 10.1002/ijc.1458; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Korczak B, 2000, GLYCOBIOLOGY, V10, P595, DOI 10.1093/glycob/10.6.595; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Muhlenhoff M, 2001, J BIOL CHEM, V276, P34066, DOI 10.1074/jbc.M101022200; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Sarkar M, 1998, GLYCOCONJUGATE J, V15, P193, DOI 10.1023/A:1006928624913; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1998, J NEUROSCI, V18, P3757; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Tanaka F, 2000, CANCER RES, V60, P3072; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257	56	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25883	25890		10.1074/jbc.M401562200	http://dx.doi.org/10.1074/jbc.M401562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067013	hybrid			2022-12-27	WOS:000221827900120
J	Posewitz, MC; King, PW; Smolinski, SL; Zhang, LP; Seibert, M; Ghirardi, ML				Posewitz, MC; King, PW; Smolinski, SL; Zhang, LP; Seibert, M; Ghirardi, ML			Discovery of two novel radical S-adenosylmethionine proteins required for the assembly of an active [Fe] hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGA CHLAMYDOMONAS-REINHARDTII; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BIOTIN SYNTHASE; IRON-HYDROGENASE; DESULFOVIBRIO-DESULFURICANS; THERMOTOGA-MARITIMA; ONLY HYDROGENASE; 4FE-4S CLUSTERS; SITE	To identify genes necessary for the photoproduction of H-2 in Chlamydomonas reinhardtii, random insertional mutants were screened for clones unable to produce H-2. One of the identified mutants, denoted hydEF-1, is incapable of assembling an active [Fe] hydrogenase. Although the hydEF-1 mutant transcribes both hydrogenase genes and accumulates full-length hydrogenase protein, H-2 production activity is not observed. The HydEF protein contains two unique domains that are homologous to two distinct prokaryotic proteins, HydE and HydF, which are found exclusively in organisms containing [Fe] hydrogenase. In the C. reinhardtii genome, the HydEF gene is adjacent to another hydrogenase-related gene, HydG. All organisms with [Fe] hydrogenase and sequenced genomes contain homologues of HydE, HydF, and HydG, which, prior to this study, were of unknown function. Within several prokaryotic genomes HydE, HydF, and HydG are found in putative operons with [Fe] hydrogenase structural genes. Both HydE and HydG belong to the emerging radical S-adenosylmethionine (commonly designated "Radical SAM") superfamily of proteins. We demonstrate here that HydEF and HydG function in the assembly of [Fe] hydrogenase. Northern blot analysis indicates that mRNA transcripts for both the HydEF gene and the HydG gene are anaerobically induced concomitantly with the two C. reinhardtii [Fe] hydrogenase genes, HydA1 and HydA2. Complementation of the bx;1C. reinhardtii hydEF-1 mutant with genomic DNA corresponding to a functional copy of the HydEF gene restores hydrogenase activity. Moreover, co-expression of the C. reinhardtii HydEF, HydG, and HydA1 genes in Escherichia coli results in the formation of an active HydA1 enzyme. This represents the first report on the nature of the accessory genes required for the maturation of an active [Fe] hydrogenase.	Colorado Sch Mines, Natl Renewable Energy Lab, Golden, CO 80401 USA; Colorado Sch Mines, Dept Environm Sci & Engn, Golden, CO 80401 USA	Colorado School of Mines; United States Department of Energy (DOE); National Renewable Energy Laboratory - USA; Colorado School of Mines	Ghirardi, ML (corresponding author), Colorado Sch Mines, Natl Renewable Energy Lab, Golden, CO 80401 USA.	maria_ghirardi@nrel.gov	King, Paul W./D-9979-2011	King, Paul W./0000-0001-5039-654X				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Asada Y, 2000, BBA-GENE STRUCT EXPR, V1490, P269, DOI 10.1016/S0167-4781(00)00010-5; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; BOICHENKO VA, 2004, MOL GLOBAL PHOTOSYNT, P397; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Casalot L, 2001, TRENDS MICROBIOL, V9, P228, DOI 10.1016/S0966-842X(01)02009-1; Cosper NJ, 2000, BIOCHEMISTRY-US, V39, P15668, DOI 10.1021/bi0022184; Davies JP, 1999, PLANT CELL, V11, P1179, DOI 10.1105/tpc.11.6.1179; Flynn T, 2002, INT J HYDROGEN ENERG, V27, P1421, DOI 10.1016/S0360-3199(02)00117-9; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; Frey M, 2002, CHEMBIOCHEM, V3, P153, DOI 10.1002/1439-7633(20020301)3:2/3<153::AID-CBIC153>3.0.CO;2-B; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Gaffron Hans, 1942, JOUR GEN PHYSIOL, V26, P219, DOI 10.1085/jgp.26.2.219; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; GFELLER RP, 1984, PLANT PHYSIOL, V75, P212, DOI 10.1104/pp.75.1.212; Ghirardi ML, 1997, APPL BIOCHEM BIOTECH, V63-5, P141, DOI 10.1007/BF02920420; Ghirardi ML, 2000, TRENDS BIOTECHNOL, V18, P506, DOI 10.1016/S0167-7799(00)01511-0; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x; Higuchi Y, 1997, STRUCTURE, V5, P1671, DOI 10.1016/S0969-2126(97)00313-4; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; Lumbreras V, 1998, PLANT J, V14, P441, DOI 10.1046/j.1365-313X.1998.00145.x; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; MENON NK, 1991, J BACTERIOL, V173, P4851, DOI 10.1128/jb.173.15.4851-4861.1991; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Nicolet Y, 2001, J AM CHEM SOC, V123, P1596, DOI 10.1021/ja0020963; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Pan GL, 2003, J BIOL INORG CHEM, V8, P469, DOI 10.1007/s00775-002-0439-y; Paschos A, 2001, FEBS LETT, V488, P9, DOI 10.1016/S0014-5793(00)02408-X; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Pierik AJ, 1998, EUR J BIOCHEM, V258, P572, DOI 10.1046/j.1432-1327.1998.2580572.x; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; Siebert M., 2001, . U.S. patent, Patent No. [6,277,589, 6277589, 6,277,589 B1]; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamagnini P, 2002, MICROBIOL MOL BIOL R, V66, P1, DOI 10.1128/MMBR.66.1.1-20.2002; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; VOORDOUW G, 1987, EUR J BIOCHEM, V162, P31, DOI 10.1111/j.1432-1033.1987.tb10537.x; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243; Wykoff DD, 1998, PLANT PHYSIOL, V117, P129, DOI 10.1104/pp.117.1.129	47	316	332	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25711	25720		10.1074/jbc.M403206200	http://dx.doi.org/10.1074/jbc.M403206200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082711	hybrid			2022-12-27	WOS:000221827900101
J	Wang, H; Fang, RH; Cho, JY; Libermann, TA; Oettgen, P				Wang, H; Fang, RH; Cho, JY; Libermann, TA; Oettgen, P			Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KERATINOCYTE TERMINAL DIFFERENTIATION; DNA-BINDING; KU AUTOANTIGEN; GENE-EXPRESSION; CELLS; COACTIVATOR; PROMOTER; EPITHELIUM; RECEPTOR	Epithelium-specific ETS (ESE)-1 is a prototypic member of a novel subset of the ETS transcription factor family that is predominantly expressed in cells of epithelial origin but can also be induced in other cell types including vascular endothelial and smooth muscle cells in response to inflammatory stimuli. To further define the molecular mechanisms by which the transcriptional activity of ESE-1 is regulated, we have focused our attention on identifying proteins that interact with ESE-1. We have determined that Ku70, Ku86, p300, and CREB-binding protein (CBP) are ESE-1 interacting proteins. The Ku proteins have previously been shown to bind to breaks in DNA where they function to recruit additional proteins that promote DNA repair. Interestingly, Ku70 and Ku 86 negatively regulate the transcriptional activity of ESE-1. Using a series of deletion constructs, we have determined that the Ku proteins bind to the DNA-binding domain of ESE-1. The Ku proteins inhibit the ability of ESE-1 to bind to oligonucleotide probes in gel mobility shift assays. The finding that Ku proteins can interact with other transcription factors and block their function has not been previously demonstrated. In contrast, co-transfection of p300 and CBP with ESE-1 enhances the transcriptional activity of ESE-1. Moreover, the induction of ESE-1 in response to inflammatory cytokine interleukin-1 is associated with a parallel increase of the expression of p300 in vascular endothelial cells, suggesting that in the setting of inflammation, the transcriptional activity of ESE-1 is positively modulated by interaction with the transcriptional co-activator p300. In summary, our results demonstrated that the activity of ESE-1 is positively and negatively modulated by other interacting proteins including Ku70, Ku86, p300, and CBP.	Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School	Oettgen, P (corresponding author), Harvard Univ, Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@bicmc.harvard.edu	Wang, Hong/H-6298-2012; Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067219, T32HL007374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67219, T32 HL07374-24] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aird SD, 2002, TOXICON, V40, P335, DOI 10.1016/S0041-0101(01)00232-X; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Bryntesson F, 2001, RADIAT RES, V156, P167, DOI 10.1667/0033-7587(2001)156[0167:AOGTIC]2.0.CO;2; Bush TS, 2003, BLOOD, V101, P311, DOI 10.1182/blood.V101.1.311; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Camara-Clayette V, 1999, BIOCHEM BIOPH RES CO, V265, P170, DOI 10.1006/bbrc.1999.1634; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Dube A, 2001, CIRC RES, V88, P237; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pedley J, 1998, MELANOMA RES, V8, P471, DOI 10.1097/00008390-199812000-00001; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schaffer A, 2003, J BIOL CHEM, V278, P23141, DOI 10.1074/jbc.M212952200; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman ES, 2002, AM J RESP CELL MOL, V27, P697, DOI 10.1165/rcmb.2002-0011OC; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	56	36	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25241	25250		10.1074/jbc.M401356200	http://dx.doi.org/10.1074/jbc.M401356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075319	hybrid			2022-12-27	WOS:000221827900042
J	Hansen, SB; Talley, TT; Radic, Z; Taylor, P				Hansen, SB; Talley, TT; Radic, Z; Taylor, P			Structural and ligand recognition characteristics of an acetylcholine-binding protein from Aplysia californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTORS; DOMAIN; PEPTIDES; REVEALS	We generated an acetylcholine-binding protein from Aplysia californica by synthesis of a cDNA found in existing data bases and its expression in mammalian cell culture. Its subunit assembly and ligand recognition behavior were compared with the binding protein previously derived from Lymnaea stagnalis. The secreted proteins were purified by elution from columns of attached antibodies directed to the FLAG epitope encoded in the expression construct. Although the sequences of the two proteins from marine and fresh water mollusks exhibit the characteristic features of the extracellular domain of the nicotinic receptor, they only possess 33% amino acid identity. Both assemble as stable pentamers with five binding sites per pentamer, yet they show distinguishing features of stability and sensitivity to epitope tag placement. Both proteins exhibit changes in tryptophan fluorescence upon ligand binding; however, the magnitude of the changes differs greatly. Moreover, certain ligands show marked differences in dissociation constants for the two proteins and can be regarded as distinguishing or signature ligands. Hence, the two soluble proteins from mollusks, which can be studied by a variety of physical methods, become discrete surrogate proteins for the extracellular domains of distinct sub-types of nicotinic acetylcholine receptors.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM NS043063, GM 07752, R37-GM18360, R37 GM018360, T32 GM007752] Funding Source: Medline; NINDS NIH HHS [F32 NS043063-01, F32 NS043063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; LEE C Y, 1963, Showa Igakkai Zasshi, V23, P221; LEE CY, 1972, ANNU REV PHARMACOLOG, V12, P265, DOI 10.1146/annurev.pa.12.040172.001405; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SMIT AB, 2001, Patent No. 0158951; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEILAND G, 1977, J BIOL CHEM, V252, P7648; ZOLI M, 2000, HANDB EXP PHARM, V144, P213	22	132	137	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24197	24202		10.1074/jbc.M402452200	http://dx.doi.org/10.1074/jbc.M402452200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069068	hybrid, Green Accepted			2022-12-27	WOS:000221702500043
J	Cameron, A; Read, J; Tranter, R; Winter, VJ; Sessions, RB; Brady, RL; Vivas, L; Easton, A; Kendrick, H; Croft, SL; Barros, D; Lavandera, JL; Martin, JJ; Risco, F; Garcia-Ochoa, S; Gamo, FJ; Sanz, L; Leon, L; Ruiz, JR; Gabarro, R; Mallo, A; de las Heras, FG				Cameron, A; Read, J; Tranter, R; Winter, VJ; Sessions, RB; Brady, RL; Vivas, L; Easton, A; Kendrick, H; Croft, SL; Barros, D; Lavandera, JL; Martin, JJ; Risco, F; Garcia-Ochoa, S; Gamo, FJ; Sanz, L; Leon, L; Ruiz, JR; Gabarro, R; Mallo, A; de las Heras, FG			Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; SUBSTRATE-INHIBITION; MALATE-DEHYDROGENASE; STRUCTURAL BASIS; DRUG; SPECIFICITY; INVITRO; CHLOROQUINE; ASSAY	Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermentation during its blood-borne stages for energy production. Selective inhibitors of the parasite lactate dehydrogenase (LDH), central to NAD(+) regeneration, therefore potentially provide a route to new antimalarial drugs directed against a novel molecular target. A series of heterocyclic, azole-based compounds are described that preferentially inhibit P. falciparum LDH at sub-micromolar concentrations, typically at concentrations about 100-fold lower than required for human lactate dehydrogenase inhibition. Crystal structures show these competitive inhibitors form a network of interactions with amino acids within the active site of the enzyme, stacking alongside the nicotinamide ring of the NAD(+) cofactor. These compounds display modest activity against parasitized erythrocytes, including parasite strains with known resistance to existing anti-malarials and against Plasmodium berghei in BALB/c mice. Initial toxicity data suggest the azole derivatives have generally low cytotoxicity, and preliminary pharmocokinetic data show favorable bioavailability and circulation times. These encouraging results suggest that further enhancement of these structures may yield candidates suitable for consideration as new therapeutics for the treatment of malaria. In combination these studies also provide strong support for the validity of targeting the Plasmodium glycolytic pathway and, in particular, LDH in the search for novel anti-malarials.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Mol Recognit Ctr, Bristol BS8 1TD, Avon, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; GlaxoSmithKline, Madrid 28760, Spain	University of Bristol; University of Bristol; University of London; London School of Hygiene & Tropical Medicine; GlaxoSmithKline	Brady, RL (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	L.Brady@bris.ac.uk	Mallo, Araceli/P-3345-2014; Lavandera, Jose Luis L/K-3690-2014; Lavandera, José Luis/J-6913-2019; Conners, Rebecca/C-2608-2013	Mallo, Araceli/0000-0002-5411-0382; Lavandera, Jose Luis L/0000-0003-0730-6865; Lavandera, José Luis/0000-0003-0730-6865; Sessions, Richard/0000-0003-0320-0895; Conners, Rebecca/0000-0002-8653-1771				ALLAIN CC, 1973, CLIN CHEM, V19, P223; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSTOW DA, 1990, BIOCHIM BIOPHYS ACTA, V1087, P73, DOI 10.1016/0167-4781(90)90123-J; Chapman ADM, 1999, J MOL BIOL, V285, P703, DOI 10.1006/jmbi.1998.2357; Dando C, 2001, MOL BIOCHEM PARASIT, V118, P23, DOI 10.1016/S0166-6851(01)00360-7; Deck LM, 1998, J MED CHEM, V41, P3879, DOI 10.1021/jm980334n; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Dunn CR, 1996, NAT STRUCT BIOL, V3, P912, DOI 10.1038/nsb1196-912; Eszes CM, 1996, FEBS LETT, V399, P193, DOI 10.1016/S0014-5793(96)01317-8; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gomez MS, 1997, MOL BIOCHEM PARASIT, V90, P235, DOI 10.1016/S0166-6851(97)00140-0; Hewitt CO, 1999, PROTEIN ENG, V12, P491, DOI 10.1093/protein/12.6.491; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lang-Unnasch N, 1998, ANNU REV MICROBIOL, V52, P561, DOI 10.1146/annurev.micro.52.1.561; MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739; Menting JG, 1997, MOL BIOCHEM PARASIT, V88, P215, DOI 10.1016/S0166-6851(97)00095-9; NOVOA WB, 1959, J BIOL CHEM, V234, P1143; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palomino JC, 1999, EUR J CLIN MICROBIOL, V18, P380, DOI 10.1007/PL00015025; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; PETERS W, 1975, ANN TROP MED PARASIT, V69, P155, DOI 10.1080/00034983.1975.11686997; PONNUDURAI T, 1981, TROP GEOGR MED, V33, P50; Read JA, 2001, PROTEINS, V43, P175, DOI 10.1002/1097-0134(20010501)43:2<175::AID-PROT1029>3.0.CO;2-#; Ridley RG, 1997, EXP PARASITOL, V87, P293, DOI 10.1006/expr.1997.4230; ROTH EF, 1982, BIOCHEM BIOPH RES CO, V109, P355, DOI 10.1016/0006-291X(82)91728-4; ROYER RE, 1986, J MED CHEM, V29, P1799, DOI 10.1021/jm00159a043; SCHEIBEL LW, 1979, P NATL ACAD SCI USA, V76, P5303, DOI 10.1073/pnas.76.10.5303; Sessions RB, 1997, PROTEIN ENG, V10, P301, DOI 10.1093/protein/10.4.301; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vander Jagt D.L., 1989, Progress in Clinical and Biological Research, V313, P105; Wieland H, 1930, LIEBIGS ANN CHEM, V478, P43; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Winter VJ, 2003, MOL BIOCHEM PARASIT, V131, P1, DOI 10.1016/S0166-6851(03)00170-1; Yu Y, 2001, BIOCHEM PHARMACOL, V62, P81, DOI 10.1016/S0006-2952(01)00636-0; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921	35	110	118	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31429	31439		10.1074/jbc.M402433200	http://dx.doi.org/10.1074/jbc.M402433200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15117937	hybrid, Green Published			2022-12-27	WOS:000222726800064
J	Mishra, RK; Jatiani, SS; Kumar, A; Simhadri, VR; Hosur, RV; Mittal, R				Mishra, RK; Jatiani, SS; Kumar, A; Simhadri, VR; Hosur, RV; Mittal, R			Dynamin interacts with members of the sumoylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOCAPSID PROTEIN; LARGER PROTEINS; UBIQUITIN; NUCLEAR; SUMO-1; BINDING; ASSIGNMENT; MODIFIER-1; GTPASE	Dynamin is a GTP-binding protein whose oligomerization-dependent assembly around the necks of lipid vesicles mediates their scission from parent membranes. Dynamin is thus directly involved in the regulation of endocytosis. Sumoylation is a post-translational protein modification whereby the ubiquitin-like modifier Sumo is covalently attached to lysine residues on target proteins by a process requiring the concerted action of an activating enzyme (ubiquitin-activating enzyme), a conjugating enzyme ( ubiquitin carrier protein), and a ligating enzyme (ubiquitin-protein isopeptide ligase). Here, we show that dynamin interacts with Sumo-1, Ubc9, and PIAS-1, all of which are members of the sumoylation machinery. Ubc9 and PIAS-1 are known ubiquitin carrier protein and ubiquitin-protein isopeptide ligase enzymes, respectively, for the process of sumoylation. We have identified the coiled-coil GTPase effector domain (GED) of dynamin as the site on dynamin that interacts with Sumo-1, Ubc9, and PIAS-1. Although we saw no evidence of covalent Sumo-1 attachment to dynamin, Sumo-1 and Ubc9 are shown here to inhibit the lipid-dependent oligomerization of dynamin. Expression of Sumo-1 and Ubc9 in mammalian cells down-regulated the dynamin-mediated endocytosis of transferrin, whereas dynamin-independent fluid-phase uptake was not affected. Furthermore, using high resolution NMR spectroscopy, we have identified amino acid residues on Sumo-1 that directly interact with the GED of dynamin. The results suggest that the GED of dynamin may serve as a scaffold that concentrates the sumoylation machinery in the vicinity of potential acceptor proteins.	Tata Inst Fundamental Res, Dept Biol Sci, Bombay 400005, Maharashtra, India; Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR); Tata Institute of Fundamental Research (TIFR)	Mittal, R (corresponding author), Tata Inst Fundamental Res, Dept Biol Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	mittal@tifr.res.in	Mishra, Ram/AAJ-1538-2020; Mishra, Ram/ABA-6071-2020	Mishra, Ram/0000-0002-9528-0476				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bhavesh NS, 2001, BIOCHEMISTRY-US, V40, P14727, DOI 10.1021/bi015683p; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kaukinen P, 2003, VIRUS RES, V92, P37, DOI 10.1016/S0168-1702(02)00312-X; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Maeda A, 2003, VIROLOGY, V305, P288, DOI 10.1006/viro.2002.1767; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534-5807(03)00157-6; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vorobjev I A, 2000, Membr Cell Biol, V14, P219; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008	67	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31445	31454		10.1074/jbc.M402911200	http://dx.doi.org/10.1074/jbc.M402911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123615	hybrid			2022-12-27	WOS:000222726800066
J	Klampfer, L; Huang, J; Swaby, LA; Augenlicht, L				Klampfer, L; Huang, J; Swaby, LA; Augenlicht, L			Requirement of histone deacetylase activity for signaling by STAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; INTERFERON-GAMMA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; ULCERATIVE-COLITIS; COLON-CANCER; PPAR-GAMMA; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; INDUCED APOPTOSIS	STAT1 is a transcription factor that plays a crucial role in signaling by interferons (IFNs). In this study we demonstrated that inhibitors of histone deacetylase ( HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation. Furthermore, we showed that silencing of HDAC1, HDAC2, and HDAC3 through RNA interference markedly decreased IFNgamma-driven gene activation and that overexpression of HDAC1, HDAC2, and HDAC3 enhanced STAT1-dependent transcriptional activity. Our data therefore established the essential role of deacetylase activity in STAT1 signaling. Induction of IRF-1 by IFNgamma requires functional STAT1 signaling and was abrogated by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and STAT1 small interfering RNA. In contrast, silencing of STAT1 did not interfere with IFNgamma-induced expression of STAT2 and caspase-7, and HDAC inhibitors did not preclude IFNgamma-induced expression of STAT1, STAT2, and caspase-7, suggesting that HDAC inhibitors impede the expression of IFNgamma target genes whose expression depends on STAT1 but do not interfere with STAT1-independent signaling by IFNgamma. Finally, we showed that inhibitors of deacetylase activity sensitized colon cancer cells to IFNgamma-induced apoptosis through cooperative negative regulation of Bcl-x expression, demonstrating that interruption of the balance between STAT1-dependent and STAT1-independent signaling significantly alters the biological activity of IFNgamma.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI NIH HHS [UO1 CA88104] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Biasco G, 2002, DIGEST LIVER DIS, V34, P339, DOI 10.1016/S1590-8658(02)80127-X; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BREESE E, 1993, IMMUNOLOGY, V78, P127; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen GX, 2001, J BIOL CHEM, V276, P766, DOI 10.1074/jbc.M008330200; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FAIS S, 1991, GUT, V32, P403, DOI 10.1136/gut.32.4.403; Frank DA, 1996, LEUKEMIA, V10, P1724; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kuhbacher T, 2001, CLIN EXP IMMUNOL, V123, P395, DOI 10.1046/j.1365-2249.2001.01455.x; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; LEE TH, 1993, J BIOL CHEM, V268, P6154; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Mariadason JM, 2000, CANCER RES, V60, P4561; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MARX JL, 1979, SCIENCE, V204, P1183, DOI 10.1126/science.451564; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Navarro A, 2003, J LEUKOCYTE BIOL, V73, P540, DOI 10.1189/jlb.1002508; Nikitakis NG, 2002, CANCER RES, V62, P1004; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Schreiber S, 2002, GUT, V51, P379, DOI 10.1136/gut.51.3.379; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Shao JY, 2002, CANCER RES, V62, P3282; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Stallmach A, 1998, GUT, V43, P499, DOI 10.1136/gut.43.4.499; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; SUN M, 1981, SCIENCE, V212, P141, DOI 10.1126/science.6163213; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Ullman Thomas A., 2002, Curr Treat Options Gastroenterol, V5, P163, DOI 10.1007/s11938-002-0038-6; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VILCEK J, 1970, SCIENCE, V168, P398, DOI 10.1126/science.168.3929.398; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zamai L, 1996, CYTOMETRY, V23, P303, DOI 10.1002/(SICI)1097-0320(19960401)23:4<303::AID-CYTO6>3.3.CO;2-B	83	144	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30358	30368		10.1074/jbc.M401359200	http://dx.doi.org/10.1074/jbc.M401359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123634	hybrid			2022-12-27	WOS:000222531900061
J	Janz, JM; Farrens, DL				Janz, JM; Farrens, DL			Rhodopsin activation exposes a key hydrophobic binding site for the transducin alpha-subunit C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SUBSTITUTION MUTANTS; PROTEIN-COUPLED RECEPTORS; COVALENT CROSS-LINKING; F LOOP REGION; CONFORMATIONAL-CHANGES; CYTOPLASMIC LOOPS; METARHODOPSIN-II; BOVINE RHODOPSIN; SULFHYDRYL REACTIVITY; TRANSMEMBRANE HELICES	Conformational changes enable the photoreceptor rhodopsin to couple with and activate the G-protein transducin. Here we demonstrate a key interaction between these proteins occurs between the C terminus of the transducin alpha-subunit (G(Talpha)) and a hydrophobic cleft in the rhodopsin cytoplasmic face exposed during receptor activation. We mapped this interaction by labeling rhodopsin mutants with the fluorescent probe bimane and then assessed how binding of a peptide analogue of the G(Talpha) C terminus ( containing a tryptophan quenching group) affected their fluorescence. From these and other assays, we conclude that the G(Talpha) C-terminal tail binds to the inner face of helix 6 in a retinal-linked manner. Further, we find that a "hydrophobic patch" comprising key residues in the exposed cleft is required for transducin binding/activation because it enhances the binding affinity for the G(Talpha) C-terminal tail, contributing up to 3 kcal/mol for this interaction. We speculate the hydrophobic interactions identified here may be important in other GPCR signaling systems, and our Trp/ bimane fluorescence methodology may be generally useful for mapping sites of protein-protein interaction.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	farrensd@ohsu.edu			NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER; NEI NIH HHS [T32-EY07123-09, EY12095] Funding Source: Medline; NIDA NIH HHS [DA14896] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Alexiev U, 2003, J MOL BIOL, V328, P705, DOI 10.1016/S0022-2836(03)00326-7; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bourne HR, 2000, SCIENCE, V289, P733, DOI 10.1126/science.289.5480.733; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fahmy K, 1996, BIOCHEMISTRY-US, V35, P15065, DOI 10.1021/bi961486s; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FONG TM, 1999, REC BIOCH M, P1; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; Klein-Seetharaman J, 1999, P NATL ACAD SCI USA, V96, P13744, DOI 10.1073/pnas.96.24.13744; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; MANSOOR SE, 2004, IN PRESS BIOCHEMISTR; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mielke T, 2002, BIOCHEMISTRY-US, V41, P7875, DOI 10.1021/bi011862v; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terakita A, 2002, J BIOL CHEM, V277, P40, DOI 10.1074/jbc.M104960200; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; Yamashita T, 2000, J BIOL CHEM, V275, P34272, DOI 10.1074/jbc.M002954200; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539	59	95	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29767	29773		10.1074/jbc.M402567200	http://dx.doi.org/10.1074/jbc.M402567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15070895	hybrid			2022-12-27	WOS:000222445300113
J	Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV				Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV			Phosphorylation of alpha B-crystallin alters chaperone function through loss of dimeric substructure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN LENS CRYSTALLINS; AGE-RELATED-CHANGES; MASS-SPECTROMETRY; COMPLEXES; ELECTROSPRAY; SUBUNIT; DISEASE	Phosphorylation is the most common posttranslational modification of the alpha-crystallins in the human lens. These phosphorylated forms are not only important because of their abundance in aging lenses and the implications for cataract but also because they have been identified in patients with degenerative brain disease. By using mimics corresponding to the reported in vivo phosphorylation sites in the human lens, we have examined the effects of phosphorylation upon the chaperone-like properties and structure of alphaB-crystallin. Here we show that phosphorylation of alphaB-crystallin at Ser-45 results in uncontrolled aggregation. By using an innovative tandem mass spectrometry approach, we demonstrate how this alteration in behavior stems from disruption of dimeric substructure within the polydisperse alphaB-crystallin assembly. This structural perturbation appears to disturb the housekeeping role of alphaB-crystallin and consequently has important implications for the disease states caused by protein aggregation in the lens and deposition in non-lenticular tissue.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Cambridge; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Aquilina, John Andrew/AGF-4013-2022; Aquilina, J. Andrew/A-5366-2013; Benesch, Justin/A-4250-2008	Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NEI NIH HHS [EY 3897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Benesch JLP, 2003, ANAL CHEM, V75, P2208, DOI 10.1021/ac034132x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kamei A, 2001, BIOL PHARM BULL, V24, P96, DOI 10.1248/bpb.24.96; Kantorow M, 1998, INT J BIOL MACROMOL, V22, P307, DOI 10.1016/S0141-8130(98)00028-2; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MANN E, 1991, FEBS LETT, V294, P133, DOI 10.1016/0014-5793(91)81359-G; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; Moroni M, 2001, BBA-PROTEIN STRUCT M, V1546, P282, DOI 10.1016/S0167-4838(01)00154-6; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432-1327.2001.02082.x; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	33	140	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28675	28680		10.1074/jbc.M403348200	http://dx.doi.org/10.1074/jbc.M403348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117944	hybrid			2022-12-27	WOS:000222265400104
J	Beom, SR; Cheong, D; Torres, G; Caron, MG; Kim, KM				Beom, SR; Cheong, D; Torres, G; Caron, MG; Kim, KM			Comparative studies of molecular mechanisms of dopamine D-2 and D-3 receptors for the activation of extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR RECEPTOR; G-BETA-GAMMA; C-DEPENDENT MECHANISM; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; DIFFERENTIAL REGULATION; INOSITOL TRISPHOSPHATE; MEDIATED ENDOCYTOSIS; DISTINCT PATHWAYS	Dopamine D-2 and D-3 receptors (D2R/D3R), which have similar structural architecture as well as functional similarities, are expressed in the same brain dopaminergic neurons. It is intriguing that two receptor proteins with virtually the same functional roles are expressed in the same neuron. Recently we have shown that D2R and D3R possess different regulatory processes including intracellular trafficking properties, which implies that they might employ different signaling mechanisms for regulation of the same cellular processes. Here we studied the signaling pathways of ERK activation mediated by D2R and D3R in HEK-293 cells and corroborated them with concomitant studies in COS-7 cells and C6 cells. Our results show that Src, phosphatidylinositol 3-kinase, and atypical protein kinase C were commonly involved in D2R-/D3R-mediated ERK activation. However, beta-arrestin and sequestration of D2R/D3R were found not to be involved. ERK activations mediated by D3R, but not D2R, were blocked by betaARK-CT, AG1478 epidermal growth factor receptor ( EGFR) inhibitor, and by dominant negative mutants of Ras and Raf, suggesting the involvement of the Gbeta(gammai) pathway. The alpha-subunit of G(o) (Galpha(o)) was able to couple with D3R to mediate ERK activation. We conclude that D3R mainly utilizes the betagamma pathway of G(i) protein, which involves the transactivation of EGFR in HEK-293 cells. In contrast, the alpha-subunit of the G(i) protein plays a main role in D2R-mediated ERK activation. Our study suggests one example of intricate cellular regulations in the brain, that is, dopaminergic neurons could regulate ERK activity more flexibly through alternative usage of either the D2R or D3R pathway depending on the cellular situation.	Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Chonnam National University; Duke University	Kim, KM (corresponding author), Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea.	kmkim@chonnam.ac.kr	Kim, Kyeong-Man/AAA-9847-2020					AHN S, 2004, J BIOL CHEM; Banihashemi B, 2002, MOL ENDOCRINOL, V16, P2393, DOI 10.1210/me.2001-0220; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Casabona G, 1997, PROG NEURO-PSYCHOPH, V21, P407, DOI 10.1016/S0278-5846(97)00011-0; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Choi EY, 1999, BIOCHEM BIOPH RES CO, V256, P33, DOI 10.1006/bbrc.1999.0286; Cussac D, 1999, MOL PHARMACOL, V56, P1025, DOI 10.1124/mol.56.5.1025; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Diaz J, 2000, J NEUROSCI, V20, P8677; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Downward J, 1996, CANCER SURV, V27, P87; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KAWAGOE KT, 1992, NEUROSCIENCE, V51, P55, DOI 10.1016/0306-4522(92)90470-M; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; KIM SJ, 2003, MOL ENDOCRINOL; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Liu JC, 2002, J BIOL CHEM, V277, P35819, DOI 10.1074/jbc.M202920200; Luo YQ, 1998, J NEUROCHEM, V71, P980; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIZZI M, 1987, EUR J PHARMACOL, V136, P263, DOI 10.1016/0014-2999(87)90724-2; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rasolonjanahary R, 2002, ENDOCRINOLOGY, V143, P747, DOI 10.1210/en.143.3.747; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Welsh GI, 1998, J NEUROCHEM, V70, P2139; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	65	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28304	28314		10.1074/jbc.M403899200	http://dx.doi.org/10.1074/jbc.M403899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102843	hybrid			2022-12-27	WOS:000222265400062
J	Chen, C; Dudenhausen, EE; Pan, YX; Zhong, C; Kilberg, MS				Chen, C; Dudenhausen, EE; Pan, YX; Zhong, C; Kilberg, MS			Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE GENE; TRANSCRIPTION FACTORS; MESSENGER-RNA; C/EBP FAMILY; ER STRESS; NF-Y; ATF6; CELLS; PROMOTER; PATHWAYS	CCAAT/enhancer-binding protein beta (C/EBPbeta) is a member of the bZIP family of transcription factors that contribute to the regulation of a wide range of important cellular processes. The data in the present study document that transcription from the human C/EBPbeta gene is induced in response to endoplasmic reticulum stress, such as glucose deprivation, or treatment of cells with tunicamycin or thapsigargin. Transient transfection of C/EBPbeta genomic fragments linked to a luciferase reporter gene demonstrated that the C/EBPbeta promoter plays no major regulatory role. Instead, by deletion analysis it was discovered that a 46-bp region, located at a genomic site that corresponds to the 3'-untranslated region of the C/EBPbeta mRNA, harbored an element that was required for the stress response. Mutagenesis demonstrated that a cis-regulatory element located at nt + 1614 - 1621 (5'-TGACGCAA-3') is responsible for activation of the C/EBPbeta gene. Electrophoresis mobility shift analysis revealed that proteins are bound to this element and that the amount of binding is increased following glucose deprivation. This element is homologous to a previously reported mammalian unfolded protein response element that binds XBP-1. Consistent with those data, overexpression of XBP-1 caused an increase in transcription that was mediated by the C/EBPbeta mammalian unfolded protein response element.	Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059315, R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 59315, DK 52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	39	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27948	27956		10.1074/jbc.M313920200	http://dx.doi.org/10.1074/jbc.M313920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102854	hybrid			2022-12-27	WOS:000222265400016
J	Kofler, M; Heuer, K; Zech, T; Freund, C				Kofler, M; Heuer, K; Zech, T; Freund, C			Recognition sequences for the GYF domain reveal a possible spliceosomal function of CD2BP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDE; PHOSPHOLIPASE-C; SPOT-SYNTHESIS; SH3 DOMAIN; WW DOMAIN; PROTEIN; MOTIF; IDENTIFICATION; SIMILARITY; ACTIVATION	Protein-protein interactions are often mediated by small domains that recognize solvent-exposed peptide sequences. Deciphering the recognition code for these adapter domains is an important step in the understanding of multi-protein assemblies. Here, we investigate the sequence requirements for the CD2BP2-GYF domain, a proline-rich sequence binding module previously shown to be involved in T cell signaling. We show that the signature (R/K/G)XXPPGX(R/K) defines a preferred peptide-binding motif that is present in several proteins of the splicing machinery. Specifically, the core small nuclear ribonucleoprotein, SmB/B', contains several PPP-PGMR motifs that interact with the CD2BP2-GYF domain in vitro and in vivo. The colocalization of CD2BP2 and SmB proteins in the nucleus of Jurkat T cells and HeLa cells suggests a function of the GYF domain of CD2BP2 in mediating protein-protein interactions within the spliceosome.	Forschungsinst Mol Pharmakol, Prot Engn Grp, D-13125 Berlin, Germany; Free Univ Berlin, D-13125 Berlin, Germany	Free University of Berlin	Freund, C (corresponding author), Forschungsinst Mol Pharmakol, Prot Engn Grp, Robert Rossle Str 10, D-13125 Berlin, Germany.	freund@fmp-berlin.de		Zech, Tobias/0000-0001-8394-088X				Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Espejo A, 2002, BIOCHEM J, V367, P697, DOI 10.1042/BJ20020860; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Freund C, 2003, J BIOMOL NMR, V27, P143, DOI 10.1023/A:1024983029700; Freund C, 2002, EMBO J, V21, P5985, DOI 10.1093/emboj/cdf602; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; Goddard T.D., 2004, SPARKY 3; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Kramer A, 1998, METH MOL B, V87, P25; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0	23	30	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28292	28297		10.1074/jbc.M402008200	http://dx.doi.org/10.1074/jbc.M402008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105431	hybrid			2022-12-27	WOS:000222265400060
J	Yokoyama, T; Chong, KT; Miyazaki, G; Morimoto, H; Shih, DTB; Unzai, S; Tame, JRH; Park, SY				Yokoyama, T; Chong, KT; Miyazaki, G; Morimoto, H; Shih, DTB; Unzai, S; Tame, JRH; Park, SY			Novel mechanisms of pH sensitivity in tuna hemoglobin - A structural explanation of the root effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL ADULT HEMOGLOBIN; FISH PAGOTHENIA-BERNACCHII; BETA-146 HISTIDYL RESIDUE; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; T-STATE; ALLOSTERIC MECHANISM; THUNNUS-THYNNUS; MOLECULAR-BASIS; BLUEFIN TUNA	The crystal structure of hemoglobin has been known for several decades, yet various features of the molecule remain unexplained or controversial. Several animal hemoglobins have properties that cannot be readily explained in terms of their amino acid sequence and known atomic models of hemoglobin. Among these, fish hemoglobins are well known for their widely varying interactions with heterotropic effector molecules and pH sensitivity. Some fish hemoglobins are almost completely insensitive to pH (within physiological limits), whereas others show extremely low oxygen affinity under acid conditions, a phenomenon called the Root effect. X-ray crystal structures of Root effect hemoglobins have not, to date, provided convincing explanations of this effect. Sequence alignments have signally failed to pinpoint the residues involved, and site-directed mutagenesis has not yielded a human hemoglobin variant with this property. We have solved the crystal structure of tuna hemoglobin in the deoxy form at low and moderate pH and in the presence of carbon monoxide at high pH. A comparison of these models shows clear evidence for novel mechanisms of pH-dependent control of ligand affinity.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Engn Sci, Dept Bioengn, Osaka 5608531, Japan; Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 100, Taiwan; Taipei Med Univ, Ctr Stem Cell Res, Taipei 100, Taiwan	Yokohama City University; Osaka University; Taipei Medical University; Taipei Medical University	Tame, JRH (corresponding author), Yokohama City Univ, Prot Design Lab, Suehiro Cho 1-7-29, Yokohama, Kanagawa 2300045, Japan.	jtame@tsurumi.yokohama-cu.ac.jp; park@tsurumi.yokohama-cu.ac.jp		Yokoyama, Takeshi/0000-0002-5362-8606				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Bettati S, 1996, PROTEINS, V25, P425, DOI 10.1002/(SICI)1097-0134(199608)25:4<425::AID-PROT3>3.3.CO;2-A; Bohr C, 1904, SKAND ARCH PHYSIOL, V16, P402, DOI 10.1111/j.1748-1716.1904.tb01382.x; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNGER AT, 1996, X PLOR SYSTEM CRYSTA; BRUNORI M, 1966, ARCH BIOCHEM BIOPHYS, V114, P195, DOI 10.1016/0003-9861(66)90321-3; BUSCH MR, 1991, BIOCHEMISTRY-US, V30, P1865, DOI 10.1021/bi00221a020; BUSCH MR, 1990, BIOPHYS CHEM, V37, P313, DOI 10.1016/0301-4622(90)88031-M; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; CAREY FG, 1973, COMP BIOCHEM PHYSIOL, V44, P375, DOI 10.1016/0300-9629(73)90490-8; FERMI G, 1984, HAEMOGLOBIN MYOGLOBI; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; IKEDASAITO M, 1983, J MOL BIOL, V168, P673, DOI 10.1016/S0022-2836(83)80308-8; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1989, Protein Sequences and Data Analysis, V2, P81; Imai K, 1981, Methods Enzymol, V76, P438; Imai K., 1982, ALLOSTERIC EFFECTS H; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; JESSEN TH, 1991, P NATL ACAD SCI USA, V88, P6519, DOI 10.1073/pnas.88.15.6519; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; Kimura M., 1983, NEUTRAL THEORY MOL E; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; Mazzarella L, 1999, J MOL BIOL, V287, P897, DOI 10.1006/jmbi.1999.2632; MORRIS RJ, 1981, J BIOL CHEM, V256, P4598; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PARKHURST LJ, 1983, BIOCHEMISTRY-US, V22, P5401, DOI 10.1021/bi00292a023; PERUTZ MF, 1972, NATURE, V237, P495, DOI 10.1038/237495a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1984, P NATL ACAD SCI-BIOL, V81, P4781, DOI 10.1073/pnas.81.15.4781; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; RUSSU IM, 1989, BIOCHEMISTRY-US, V28, P5298, DOI 10.1021/bi00438a057; RUSSU IM, 1982, BIOCHEMISTRY-US, V21, P5031, DOI 10.1021/bi00263a029; RUSSU IM, 1980, BIOCHEMISTRY-US, V19, P1043, DOI 10.1021/bi00546a033; RUSSU IM, 1986, BIOCHEMISTRY-US, V25, P1706, DOI 10.1021/bi00355a040; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Shibayama N, 2002, J BIOL CHEM, V277, P38791, DOI 10.1074/jbc.M205461200; SHIH DTB, 1993, J MOL BIOL, V230, P1291; SHIH DTB, 1987, J MOL BIOL, V195, P419, DOI 10.1016/0022-2836(87)90660-7; Sorensen SPL, 1909, BIOCHEM Z, V21, P131; Suzuki T, 1996, J PROTEIN CHEM, V15, P389, DOI 10.1007/BF01886865; Tame JRH, 2000, ACTA CRYSTALLOGR D, V56, P805, DOI 10.1107/S0907444900006387; Tame JRH, 1996, J MOL BIOL, V259, P749, DOI 10.1006/jmbi.1996.0355; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; WEBER RE, 1993, J APPL PHYSIOL, V75, P2646, DOI 10.1152/jappl.1993.75.6.2646; Weber RE, 2002, AM J PHYSIOL-REG I, V283, pR1052, DOI 10.1152/ajpregu.00292.2002; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200; Zhang J, 1996, J MOL BIOL, V255, P484, DOI 10.1006/jmbi.1996.0040	62	61	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28632	28640		10.1074/jbc.M401740200	http://dx.doi.org/10.1074/jbc.M401740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15117955	hybrid			2022-12-27	WOS:000222265400099
J	Boucher, A; Lu, DH; Burgess, SC; Telemaque-Potts, S; Jensen, MV; Mulder, H; Wang, MY; Unger, RH; Sherry, AD; Newgard, CB				Boucher, A; Lu, DH; Burgess, SC; Telemaque-Potts, S; Jensen, MV; Mulder, H; Wang, MY; Unger, RH; Sherry, AD; Newgard, CB			Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; FATTY-ACID OXIDATION; LONG-TERM EXPOSURE; ACETYL-COA CARBOXYLASE-2; MALONYL-COA; PHOSPHOFRUCTOKINASE ACTIVITY; REGULATED ANAPLEROSIS; ISOTOPOMER ANALYSIS; GENE-EXPRESSION; ISLETS	Hyperlipidemia appears to play an integral role in loss of glucose-stimulated insulin secretion (GSIS) in type 2 diabetes. This impairment can be simulated in vitro by chronic culture of 832/13 insulinoma cells with high concentrations of free fatty acids, or by study of lipid-laden islets from Zucker diabetic fatty rats. Here we show that impaired GSIS is not a simple result of saturation of lipid storage pathways, as adenovirus-mediated overexpression of a cytosolically localized variant of malonyl-CoA decarboxylase in either cellular model results in dramatic lowering of cellular triglyceride stores but no improvement in GSIS. Instead, the glucose-induced increment in "pyruvate cycling" activity ( pyruvate exchange with tricarboxylic acid cycle intermediates measured by C-13 NMR), previously shown to play an important role in GSIS, is completely ablated in concert with profound suppression of GSIS in lipid-cultured 832/13 cells, whereas glucose oxidation is unaffected. Moreover, GSIS is partially restored in both lipid-cultured 832/13 cells and islets from Zucker diabetic fatty rats by addition of a membrane permeant ester of a pyruvate cycling intermediate ( dimethyl malate). We conclude that chronic exposure of islet beta-cells to fatty acids grossly alters a mitochondrial pathway of pyruvate metabolism that is important for normal GSIS.	Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Durham, NC 27704 USA; Univ Texas, SW Med Ctr, Mary Nell & Ralph Rogers Magnet Resonance Ctr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabat Res, Dallas, TX 75390 USA; Wayne State Univ, Dept Internal Med, Detroit, MI 48201 USA; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden; Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27704 USA; Duke Univ, Dept Med, Med Ctr, Durham, NC 27704 USA; Duke Univ, Dept Biochem, Med Ctr, Durham, NC 27704 USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Wayne State University; Lund University; Duke University; Duke University; Duke University	Newgard, CB (corresponding author), Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Independence Pk Facil,4321 Med Pk Dr,Ste 200, Durham, NC 27704 USA.	Newga002@mc.duke.edu	Mulder, Hindrik/E-1045-2012; Sherry, Dean/P-2348-2018	Sherry, Dean/0000-0001-7150-8301; Mulder, Hindrik/0000-0002-6593-8417	NHLBI NIH HHS [HL-34557] Funding Source: Medline; NIDDK NIH HHS [P01-DK-58398, R01-DK-42582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034557, R01HL034557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Gao JM, 1999, J LIPID RES, V40, P178; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; Jacqueminet S, 2000, METABOLISM, V49, P532, DOI 10.1016/S0026-0495(00)80021-9; Jeffrey FMH, 1996, AM J PHYSIOL-ENDOC M, V271, pE788, DOI 10.1152/ajpendo.1996.271.4.E788; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; Kelpe CL, 2002, ENDOCRINOLOGY, V143, P3326, DOI 10.1210/en.2002-220402; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Malloy CR, 1996, MAGN RESON MATER PHY, V4, P35, DOI 10.1007/BF01759778; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Porterfield DM, 2000, DIABETES, V49, P1511, DOI 10.2337/diabetes.49.9.1511; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sweet Ian R, 2002, Diabetes Technol Ther, V4, P661, DOI 10.1089/152091502320798303; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YP, 1996, METABOLISM, V45, P981, DOI 10.1016/S0026-0495(96)90267-X; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; [No title captured]	48	100	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27263	27271		10.1074/jbc.M401167200	http://dx.doi.org/10.1074/jbc.M401167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073188	hybrid			2022-12-27	WOS:000222120400055
J	Isono, E; Saeki, Y; Yokosawa, H; Toh-e, A				Isono, E; Saeki, Y; Yokosawa, H; Toh-e, A			Rpn7 is required for the structural integrity of the 26 S proteasome of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; YEAST 26S PROTEASOME; COP9 SIGNALOSOME; REGULATORY PARTICLE; FUNCTIONAL-CHARACTERIZATION; DEGRADATION SIGNAL; PCI DOMAIN; SUBUNIT; PROTEINS; COMPLEX	Rpn7 is one of the lid subunits of the 26 S proteasome regulatory particle. The RPN7 gene is known to be essential, but its function remains to be elucidated. To explore the function of Rpn7, we isolated and characterized temperature-sensitive rpn7 mutants. All of the rpn7 mutants obtained accumulated poly-ubiquitinated proteins when grown at the restrictive temperature. The N-end rule substrate (Ub-Arg-beta-galactosidase), the UFD pathway substrate ( Ub-Pro-beta-galactosidase), and cell cycle regulators (Pds1 and Clb2) were found to be stabilized in experiments using one of the rpn7 mutants termed rpn7-3 at the restrictive temperature, indicating its defect in the ubiquitin-proteasome pathway. Subsequent analysis of the structure of the 26 S proteasome in rpn7-3 cells suggested that the defect was in the assembly of the 26 S holoenzyme. The most striking characteristic of the proteasome of the rpn7-3 mutant was that a lid subcomplex affinity-purified from the rpn7-3 cells grown at the restrictive temperature contained only 5 of the 8 lid components, a phenomenon that has not been reported in the previously isolated lid mutants. From these results, we concluded that Rpn7 is required for the integrity of the 26 S complex by establishing a correct lid structure.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan	University of Tokyo; Hokkaido University	Toh-e, A (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan.	toh-e@biol.s.u-tokyo.ac.jp						Asakawa K, 2001, GENETICS, V157, P1437; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bailly E, 1999, MOL CELL BIOL, V19, P6872; BURK D, 2000, METHODS YEAST GENETI; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gorbea C, 1999, MOL BIOL REP, V26, P15, DOI 10.1023/A:1006957802028; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; James P, 1996, GENETICS, V144, P1425; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; NISOGI H, 1992, EXP CELL RES, V200, P48, DOI 10.1016/S0014-4827(05)80070-9; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Schwartz AL, 1999, ANNU REV MED, V50, P57; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Smalle J, 2003, PLANT CELL, V15, P965, DOI 10.1105/tpc.009217; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Toh-e A, 2000, GENES GENET SYST, V75, P33, DOI 10.1266/ggs.75.33; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yen HCS, 2003, J BIOL CHEM, V278, P30669, DOI 10.1074/jbc.M302093200	49	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27168	27176		10.1074/jbc.M314231200	http://dx.doi.org/10.1074/jbc.M314231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102831	hybrid			2022-12-27	WOS:000222120400043
J	Kumar, MB; Potter, DW; Hormann, RE; Edwards, A; Tice, CM; Smith, HC; Dipietro, MA; Polley, M; Lawless, M; Wolohan, PRN; Kethidi, DR; Palli, SR				Kumar, MB; Potter, DW; Hormann, RE; Edwards, A; Tice, CM; Smith, HC; Dipietro, MA; Polley, M; Lawless, M; Wolohan, PRN; Kethidi, DR; Palli, SR			Highly flexible ligand binding pocket of ecdysone receptor - Nonsteroidal ecdysone agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; GENE-EXPRESSION; ECDYSTEROID RECEPTOR; MAMMALIAN-CELLS; DEVELOPMENTAL EXPRESSION; SELECTIVE REGULATION; MESSENGER-RNA; CLONING; ULTRASPIRACLE; HOMOLOG	The insect steroid hormone 20-hydroxyecdysone works through a ligand-activated nuclear receptor, the ecdysone receptor (EcR), which plays critical roles in insect development and reproduction. The EcR has been exploited to develop insecticides to control pests and gene switches for gene regulation. Recently reported crystal structures of the EcR protein show different but partially overlapping binding cavities for ecdysteroid (ECD) and diacylhydrazine (DAH) ligands, providing an explanation for the differential activity of DAH ligands in insects. 1-Aroyl-4- (arylamino)-1,2,3,4-tetrahydroquinoline (THQ) ligands were recently discovered as ecdysone agonists. Mutagenesis of the EcR ( from Choristoneura fumiferana, CfEcR) ligand binding domain followed by screening in a reporter assay led to the identification of CfEcR mutants, which responded well to THQ ligands but poorly to both ECD and DAH ligands. These mutants were further improved by introducing a second mutation, A110P, which was previously reported to cause ECD insensitivity. Testing of these V128F/ A110P and V128Y/A110P mutants in a C57BL/6 mouse model coactivator interaction assay and in insect cells showed that this mutant EcR is activated by THQ ligands but not by ECD or DAH ligands. The CfEcR and its V128F/ A110P mutant were used to demonstrate simultaneous regulation of two reporter genes using THQ and DAH ligands.	Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA; Tripos Inc, St Louis, MO 63144 USA; RheoGene Inc, Norristown, PA 19403 USA	University of Kentucky	Palli, SR (corresponding author), Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA.	rpalli@uky.edu	Winkler, David/A-3774-2008; PALLI, SUBBA REDDY/AAU-8289-2020	Winkler, David/0000-0002-7301-6076; PALLI, SUBBA REDDY/0000-0002-0873-3247; Tice, Colin/0000-0002-9918-7383				Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Billas IML, 2003, NATURE, V426, P91, DOI 10.1038/nature02112; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Carlson GR, 2001, PEST MANAG SCI, V57, P115, DOI 10.1002/1526-4998(200102)57:2<115::AID-PS245>3.0.CO;2-A; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Cherbas L, 1997, GENETICS, V145, P349; CHO WL, 1995, INSECT BIOCHEM MOLEC, V25, P19, DOI 10.1016/0965-1748(94)00045-J; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; Chung ACK, 1998, MOL CELL ENDOCRINOL, V139, P209, DOI 10.1016/S0303-7207(98)00056-2; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; DIXSON JA, 2000, AM CHEM SOC MID REG; FUJIWARA H, 1995, INSECT BIOCHEM MOLEC, V25, P845, DOI 10.1016/0965-1748(95)00023-O; Fussenegger M, 2001, BIOTECHNOL PROGR, V17, P1, DOI 10.1021/bp000129c; Guo XP, 1997, INSECT BIOCHEM MOLEC, V27, P945, DOI 10.1016/S0965-1748(97)00075-1; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; IMHOF MO, 1993, INSECT BIOCHEM MOLEC, V23, P115, DOI 10.1016/0965-1748(93)90089-B; Kasuya A, 2003, J MOL MODEL, V9, P58, DOI 10.1007/s00894-002-0113-x; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; Kothapalli R, 1995, DEV GENET, V17, P319, DOI 10.1002/dvg.1020170405; Kramer BP, 2003, BIOTECHNOL BIOENG, V83, P810, DOI 10.1002/bit.10731; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kumar MB, 2002, P NATL ACAD SCI USA, V99, P14710, DOI 10.1073/pnas.222278999; Martinez A, 1999, INSECT BIOCHEM MOLEC, V29, P915, DOI 10.1016/S0965-1748(99)00067-3; Mouillet JF, 1997, EUR J BIOCHEM, V248, P856, DOI 10.1111/j.1432-1033.1997.00856.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Palli SR, 2003, EUR J BIOCHEM, V270, P1308, DOI 10.1046/j.1432-1033.2003.03501.x; Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; Shi YH, 2002, J AM CHEM SOC, V124, P6921, DOI 10.1021/ja016897x; Shi YH, 2001, CHEM BIOL, V8, P501, DOI 10.1016/S1074-5521(01)00028-X; Smith HC, 2003, BIOORG MED CHEM LETT, V13, P1943, DOI 10.1016/S0960-894X(03)00317-2; Suhr ST, 1998, P NATL ACAD SCI USA, V95, P7999, DOI 10.1073/pnas.95.14.7999; Sundaram M, 1998, INSECT BIOCHEM MOLEC, V28, P693, DOI 10.1016/S0965-1748(98)00035-6; SWEVERS L, 1995, INSECT BIOCHEM MOLEC, V25, P857, DOI 10.1016/0965-1748(95)00024-P; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Tice CM, 2003, BIOORG MED CHEM LETT, V13, P1883, DOI 10.1016/S0960-894X(03)00315-9; Tice CM, 2003, BIOORG MED CHEM LETT, V13, P475, DOI 10.1016/S0960-894X(02)00980-0; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Wang SF, 2000, MOL CELL BIOL, V20, P3870, DOI 10.1128/MCB.20.11.3870-3879.2000; Wurtz JM, 2000, PROTEIN SCI, V9, P1073, DOI 10.1110/ps.9.6.1073; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	47	41	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27211	27218		10.1074/jbc.M403839200	http://dx.doi.org/10.1074/jbc.M403839200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15107428	hybrid			2022-12-27	WOS:000222120400048
J	Li, XJ; Fan, HZ				Li, XJ; Fan, HZ			Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Matrix Metalloproteinase Gordon Research Conference	AUG, 2003	Big Sky, MT	UMDNJ Fdn, Amer Heart Assoc, Natl Ctr, New Jersey Commiss Canc Res			GROWTH-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; TNF-ALPHA; TGF-ALPHA; L-SELECTIN; TISSUE INHIBITOR; FACTOR-RECEPTOR; CELL-ADHESION; CLEAVAGE; ACTIVATION	Tumor necrosis factor-alpha converting enzyme ( TACE), a multidomain protease essential for development and disease, releases the ectodomains from many transmembrane proteins in a regulated fashion. To understand the mechanism underlying the regulation of TACE activity, we sought to identify the cause of ectodomain shedding deficiencies in two mutated CHO sublines designated M1 and M2. Transfection of expression vectors for human and mouse TACE restored ectodomain shedding of TNF-alpha and TGF-alpha, suggesting that defects in the TACE gene contribute to the phenotype of M1 and M2 cells. The overall levels of endogenous TACE forms in M1 cells were significantly lower than those found in their parental cells, whereas only TACE zymogen, but not its mature form, was detectable in M2 cells. Molecular analyses suggested that M1 cells contained only one expressible TACE allele encoding an M435I point mutation in the catalytic center of the protease, and M2 cells produced two TACE variants with distinct point mutations in the catalytic domain (C225Y) and the cysteine-rich/ disintegrin domain (C600Y). Overexpression of the C225Y and C600Y TACE by transient transfection largely compensated for maturation defects in the variants but failed to restore TNF-alpha and TGF-alpha release in the shedding-defective CHO cell lines and fibroblasts derived from TACE-null mouse embryo. Further mutagenesis and functional analyses demonstrated that Cys(600) was absolutely essential for ectodomain shedding, suggesting that Cys(600), similar to Cys(225), participates in disulfide bonding, which is critical for both the processing and catalysis of TACE.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Fan, HZ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	fanhu@umdnj.edu	Fan, Huizhou/E-5835-2012	FAN, HUIZHOU/0000-0002-4903-926X				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Beer S, 1999, J CELL SCI, V112, P2667; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brynskov J, 2002, GUT, V51, P37, DOI 10.1136/gut.51.1.37; Butler GS, 2004, J BIOL CHEM, V279, P15615, DOI 10.1074/jbc.M312727200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Codony-Servat J, 1999, CANCER RES, V59, P1196; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; de la Torre TV, 2004, BIOCHEM BIOPH RES CO, V314, P1028, DOI 10.1016/j.bbrc.2003.12.186; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fan HZ, 2003, J BIOL CHEM, V278, P18617, DOI 10.1074/jbc.M300331200; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fujisawa T, 2002, BIOORGAN MED CHEM, V10, P2569, DOI 10.1016/S0968-0896(02)00109-8; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hahn D, 2003, J BIOL CHEM, V278, P42829, DOI 10.1074/jbc.M211169200; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jasuja RR, 2000, INT J IMMUNOPATH PH, V13, P1; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Marin V, 2002, EUR J IMMUNOL, V32, P2965, DOI 10.1002/1521-4141(2002010)32:10<2965::AID-IMMU2965>3.0.CO;2-V; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Ohta S, 2001, J RHEUMATOL, V28, P1756; Patel IR, 1998, J IMMUNOL, V160, P4570; PAXTON CJ, 1998, P NATL ACAD SCI USA, V95, P3408; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shi W, 2003, DEV BIOL, V261, P371, DOI 10.1016/S0012-1606(03)00315-4; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; STOCKER W, 1995, PROTEIN SCI, V4, P823; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao JS, 2001, INT J DEV BIOL, V45, P623; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	78	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27365	27375		10.1074/jbc.M401690200	http://dx.doi.org/10.1074/jbc.M401690200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	830KH	15075334	hybrid			2022-12-27	WOS:000222120400067
J	Vickers, TJ; Fairlamb, AH				Vickers, TJ; Fairlamb, AH			Trypanothione S-transferase activity in a trypanosomatid ribosomal elongation factor 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RESISTANT LEISHMANIA-TARENTOLAE; HUMAN GLUTATHIONE TRANSFERASES; TRANSPORTER GENE PGPA; PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING PROTEINS; FACTOR 1-GAMMA; CRUZI	Trypanothione is a thiol unique to the Kinetoplastida and has been shown to be a vital component of their antioxidant defenses. However, little is known as to the role of trypanothione in xenobiotic metabolism. A trypanothione S- transferase activity was detected in extracts of Leishmania major, L. infantum, L. tarentolae, Trypanosoma brucei, and Crithidia fasciculata, but not Trypanosoma cruzi. No glutathione S- transferase activity was detected in any of these parasites. Trypanothione S- transferase was purified from C. fasciculata and shown to be a hexadecameric complex of three subunits with a relative molecular weight of 650,000. This enzyme complex was specific for the thiols trypanothione and glutathionylspermidine and only used 1-chloro-2,4-dinitrobenzene from a range of glutathione S- transferase substrates. Peptide sequencing revealed that the three components were the alpha, beta, and gamma subunits of ribosomal eukaryotic elongation factor 1B (eEF1B). Partial dissociation of the complex suggested that the S- transferase activity was associated with the gamma subunit. Moreover, Cibacron blue was found to be a tight binding inhibitor and reactive blue 4 an irreversible time-dependent inhibitor that covalently modified only the gamma subunit. The rate of inactivation by reactive blue 4 was increased more than 600-fold in the presence of trypanothione, and Cibacron blue protected the enzyme from inactivation by 1-chloro-2,4-dinitrobenzene, confirming that these dyes interact with the active site region. Two eEF1Bgamma genes were cloned from C. fasciculata, but recombinant C. fasciculata eEF1Bgamma had no S-transferase activity, suggesting that eEF1Bgamma is unstable in the absence of the other subunits.	Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust [079838] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; ASHTON AR, 1978, BIOCHEM J, V175, P501, DOI 10.1042/bj1750501; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; BEC G, 1989, J BIOL CHEM, V264, P21131; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BillautMulot O, 1997, GENE, V198, P259, DOI 10.1016/S0378-1119(97)00323-5; BILLAUTMULOT O, 1993, NUCLEIC ACIDS RES, V21, P3901, DOI 10.1093/nar/21.16.3901; BLACK S, 1993, BIOCHEM BIOPH RES CO, V191, P95, DOI 10.1006/bbrc.1993.1189; BLACK S, 1986, SCIENCE, V234, P1111, DOI 10.1126/science.3535073; BLACK S, 1983, J BIOL CHEM, V258, P2112; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DATTA J, 1992, MOL CELL BIOCHEM, V118, P31, DOI 10.1007/BF00249692; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb AH, 2003, TRENDS PARASITOL, V19, P488, DOI 10.1016/j.pt.2003.09.002; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Foley V, 1998, BIOCHEM J, V333, P839, DOI 10.1042/bj3330839; GABRIEL A, 1987, J BIOL CHEM, V262, P16192; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Habig W H, 1981, Methods Enzymol, V77, P398; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; Jeppesen MG, 2003, J BIOL CHEM, V278, P47190, DOI 10.1074/jbc.M306630200; Kamiie K, 2002, BIOSCI BIOTECH BIOCH, V66, P558, DOI 10.1271/bbb.66.558; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; KOSOWER NS, 1971, BIOCHEM BIOPH RES CO, V45, P816, DOI 10.1016/0006-291X(71)90490-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legare D, 1997, EXP PARASITOL, V87, P275, DOI 10.1006/expr.1997.4222; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MASAI E, 1993, FEBS LETT, V323, P135, DOI 10.1016/0014-5793(93)81465-C; MOUTIEZ M, 1995, BBA-GEN SUBJECTS, V1245, P161, DOI 10.1016/0304-4165(95)00085-P; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; NAVAL J, 1982, COMP BIOCHEM PHYS B, V71, P403, DOI 10.1016/0305-0491(82)90401-1; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PLUMASMARTY B, 1993, RES IMMUNOL, V144, P553, DOI 10.1016/S0923-2494(05)80002-1; PLUMASMARTY B, 1994, PARASITOL RES, V80, P626, DOI 10.1007/BF00933014; PLUMASMARTY B, 1992, PARASITOLOGY, V104, P87, DOI 10.1017/S0031182000060832; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANG LJ, 2002, BIOCHEM BIOPH RES CO, V291, P158; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; Sies H, 1988, GLUTATHIONE CONJUGAT; SMALL DAP, 1982, EUR J BIOCHEM, V128, P119; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VICKERS TJ, 2003, THESIS U DUNDEE; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; WARHOLM M, 1986, BIOCHEMISTRY-US, V25, P4119, DOI 10.1021/bi00362a020; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5; YAWETZ A, 1981, COMP BIOCHEM PHYS B, V68, P237, DOI 10.1016/0305-0491(81)90093-6; Zilberstein D, 2002, WORLD CL PARASITES, V4, P115	65	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27246	27256		10.1074/jbc.M311039200	http://dx.doi.org/10.1074/jbc.M311039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073172	hybrid, Green Accepted			2022-12-27	WOS:000222120400053
J	Chen, CB; Wallis, R				Chen, CB; Wallis, R			Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE DOMAIN; SUBSTRATE SPECIFICITIES; LECTIN; ACTIVATION; COMPLEXES; SEQUENCE	Serum mannose-binding protein (MBP) neutralizes invading microorganisms by binding to cell surface carbohydrates and activating MBP-associated serine proteases-1, -2, and -3 (MASPs). MASP-2 subsequently cleaves complement components C2 and C4 to activate the complement cascade. To analyze the mechanisms of activation and substrate recognition by MASP-2, zymogen and activated forms have been produced, and MBP . MASP-2 complexes have been created. These preparations have been used to show that MBP modulates MASP-2 activity in two ways. First, MBP stimulates MASP-2 autoactivation by increasing the rate of autocatalysis when MBP . MASP-2 complexes bind to a glycan-coated surface. Second, MBP occludes accessory C4-binding sites on MASP-2 until activation occurs. Once these sites become exposed, MASP-2 binds to C4 while separate structural changes create a functional catalytic site able to cleave C4. Only activated MASP-2 binds to C2, suggesting that this substrate interacts only near the catalytic site and not at accessory sites. MASP-1 cleaves C2 almost as efficiently as MASP-2 does, but it does not cleave C4. Thus MASP-1 probably enhances complement activation triggered by MBP . MASP-2 complexes, but it cannot initiate activation itself.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	rwallis@glycob.ox.ac.uk		Wallis, Russell/0000-0002-8705-5295				Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; BELT KT, 1984, CELL, V36, P907; BENTLEY DR, 1984, P NATL ACAD SCI-BIOL, V81, P1212, DOI 10.1073/pnas.81.4.1212; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Khan AR, 1998, PROTEIN SCI, V7, P815; Kolble K, 1993, Int Rev Immunol, V10, P17, DOI 10.3109/08830189309051169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Minton AP, 1997, PROG COLL POL SCI S, V107, P11; OGATA RT, 1995, J IMMUNOL, V154, P2351; PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SIM RB, 1983, ANN NY ACAD SCI, V421, P259, DOI 10.1111/j.1749-6632.1983.tb18114.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	32	94	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26058	26065		10.1074/jbc.M401318200	http://dx.doi.org/10.1074/jbc.M401318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060079	hybrid			2022-12-27	WOS:000222003000018
J	Freiberg, C; Brunner, NA; Schiffer, G; Lampe, T; Pohlmann, J; Brands, M; Raabe, M; Habich, D; Ziegelbauer, K				Freiberg, C; Brunner, NA; Schiffer, G; Lampe, T; Pohlmann, J; Brands, M; Raabe, M; Habich, D; Ziegelbauer, K			Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ACYL CARRIER PROTEIN; COENZYME-A CARBOXYLASE; CARBOXYLTRANSFERASE COMPONENT; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TARGET; FABI; PURIFICATION; MUTATIONS	The multisubunit acetyl-CoA carboxylase, which catalyzes the first committed step in fatty acid biosynthesis, is broadly conserved among bacteria. Its rate-limiting role in formation of fatty acids makes this enzyme an attractive target for the design of novel broad-spectrum antibacterials. However, no potent inhibitors have been discovered so far. This report describes the identification and characterization of highly potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity for the first time. We demonstrate that pseudopeptide pyrrolidine dione antibiotics such as moiramide B inhibit the Escherichia coli enzyme at nanomolar concentrations. Moiramide B targets the carboxyltransferase reaction of this enzyme with a competitive inhibition pattern versus malonyl-CoA (K-i value = 5 nM). Inhibition at nanomolar concentrations of the pyrrolidine diones is also demonstrated using recombinantly expressed carboxyltransferases from other bacterial species ( Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa). We isolated pyrrolidine dione-resistant strains of E. coli, S. aureus, and Bacillus subtilis, which contain mutations within the carboxyltransferase subunits AccA or AccD. We demonstrate that such mutations confer resistance to pyrrolidine diones. Inhibition values (IC50) of > 100 muM regarding an eukaryotic acetyl-CoA carboxylase from rat liver indicate high selectivity of pyrrolidine diones for the bacterial multisubunit enzyme. The natural product moiramide B and synthetic analogues show broad-spectrum antibacterial activity. The knowledge of the target and the availability of facile assays using carboxyltransferases from different pathogens will enable evaluation of the antibacterial potential of the pyrrolidine diones as a promising antibacterial compound class acting via a novel mode of action.	Bayer HealthCare, Pharma Res, Inst Antiinfect Res, D-42096 Wuppertal, Germany; Bayer HealthCare, Pharma Res, Inst Chem Res, D-42096 Wuppertal, Germany; Bayer HealthCare, Pharma Res, Inst Cardiovasc Res, D-42096 Wuppertal, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Freiberg, C (corresponding author), Bayer HealthCare, Pharma Res, Inst Antiinfect Res, D-42096 Wuppertal, Germany.	christoph.freiberg@bayerhealthcare.com						Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Blanchard CZ, 1999, BIOCHEM BIOPH RES CO, V266, P466, DOI 10.1006/bbrc.1999.1844; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chirala SS, 1997, P NATL ACAD SCI USA, V94, P5588, DOI 10.1073/pnas.94.11.5588; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Daines RA, 2003, J MED CHEM, V46, P5, DOI 10.1021/jm025571b; DAVIES SG, 1998, J CHEM SOC P1, V17, P2635; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Davis MS, 2001, J BACTERIOL, V183, P1499, DOI 10.1128/JB.183.4.1499-1503.2001; FALL RR, 1976, BIOCHIM BIOPHYS ACTA, V450, P475, DOI 10.1016/0005-2760(76)90022-9; FREDENHAGEN A, 1987, J AM CHEM SOC, V109, P4409, DOI 10.1021/ja00248a055; Guchhait R B, 1975, Methods Enzymol, V35, P32, DOI 10.1016/0076-6879(75)35135-5; Haas M, 2001, MICROBIOL-SGM, V147, P1783, DOI 10.1099/00221287-147-7-1783; HARWOOD JL, 1990, METHODS PLANT BIOCH, P96; He X, 2002, ANTIMICROB AGENTS CH, V46, P1310, DOI 10.1128/AAC.46.5.1310-1318.2002; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HOSOKAWA Y, 1986, ANAL BIOCHEM, V153, P45, DOI 10.1016/0003-2697(86)90058-8; Khandekar SS, 2001, J BIOL CHEM, V276, P30024, DOI 10.1074/jbc.M101769200; Levert KL, 2002, BIOCHEM BIOPH RES CO, V291, P1213, DOI 10.1006/bbrc.2002.6576; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MCWORTHER W, 1989, J CHEM SOC CHEM COMM, V5, P299; Miller WH, 2002, J MED CHEM, V45, P3246, DOI 10.1021/jm020050+; NEEDHAM J, 1994, J ORG CHEM, V59, P2058, DOI 10.1021/jo00087a020; OCLARIT JM, 1994, MICROBIOS, V78, P7; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P3118, DOI 10.1128/AAC.46.10.3118-3124.2002; Payne DJ, 2001, DRUG DISCOV TODAY, V6, P537, DOI 10.1016/S1359-6446(01)01774-3; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAO AVR, 1991, TETRAHEDRON LETT, V32, P4393, DOI 10.1016/S0040-4039(00)92179-8; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Sambrook J., 2001, MOL CLONING LAB MANU; Schujman GE, 2003, DEV CELL, V4, P663, DOI 10.1016/S1534-5807(03)00123-0; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; Schweizer HP, 1998, ANTIMICROB AGENTS CH, V42, P394; Seefeld MA, 2003, J MED CHEM, V46, P1627, DOI 10.1021/jm0204035; Singh MP, 1997, J ANTIBIOT, V50, P270, DOI 10.7164/antibiotics.50.270; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3	47	158	194	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26066	26073		10.1074/jbc.M402989200	http://dx.doi.org/10.1074/jbc.M402989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066985	hybrid			2022-12-27	WOS:000222003000019
J	Merot, Y; Metivier, R; Penot, G; Manu, D; Saligaut, C; Gannon, F; Pakdel, F; Kah, O; Flouriot, G				Merot, Y; Metivier, R; Penot, G; Manu, D; Saligaut, C; Gannon, F; Pakdel, F; Kah, O; Flouriot, G			The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION 1; BREAST-CANCER; ER-ALPHA; PROSTATE-CANCER; HISTONE ACETYLTRANSFERASE; STEROID-RECEPTORS; PROMOTER-CONTEXT; HER-ALPHA; COACTIVATOR; GENE	The activity of the transactivation functions (activation function (AF)-1 and AF-2) of the estrogen receptor alpha (ERalpha) is cell-specific. This study aimed to decipher the yet unclear mechanisms involved in this differential cell sensitivity, with particular attention to the specific influence that cell differentiation may have on these processes. Hence, we comparatively evaluated the permissiveness of cells to either ERalpha AFs in two different cases: (i) a series of cell lines originating from a common tissue, but with distinct differentiation phenotypes; and (ii) cell lines that undergo differentiation processes in culture. These experiments demonstrate that the respective contribution that AF-1 and AF-2 make toward ERalpha activity varies in a cell differentiation stage-dependent manner. Specifically, whereas AF-1 is the dominant AF involved in ERalpha transcriptional activity in differentiated cells, the more a cell is de-differentiated the more this cell mediates ERalpha signaling through AF-2. For instance, AF-2 is the only active AF in cells that have achieved their epithelial-mesenchymal transition. Moreover, the stable expression of a functional ERalpha in strictly AF-2 permissive cells restores an AF-1-sensitive cell context. These results, together with data obtained in different ERalpha-positive cell lines tested strongly suggest that the transcriptional activity of ERalpha relies on its AF-1 in most estrogen target cell types.	Univ Rennes 1, CNRS, UMR 6026, F-35042 Rennes, France; EMBL, D-69117 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; European Molecular Biology Laboratory (EMBL)	Flouriot, G (corresponding author), Univ Rennes 1, CNRS, UMR 6026, F-35042 Rennes, France.	gilles.flouriot@univ-rennes1.fr	Gannon, Frank/G-1194-2015; Flouriot, Gilles/K-1833-2015; Pakdel, Farzad/K-1700-2015; saligaut, christian/K-3360-2015; kah, olivier/K-7624-2012	Flouriot, Gilles/0000-0001-6250-4173; Pakdel, Farzad/0000-0002-3067-3156; 				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chlenski A, 2001, PROSTATE, V47, P66; Coradini D, 1997, TUMOR BIOL, V18, P22, DOI 10.1159/000218012; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; Griffin C, 1999, MOL ENDOCRINOL, V13, P1571, DOI 10.1210/me.13.9.1571; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jarrard DF, 1998, CANCER RES, V58, P5310; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MCGUIRE WL, 1986, CANCER SURV, V5, P527; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2002, EMBO J, V21, P3443, DOI 10.1093/emboj/cdf344; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	54	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26184	26191		10.1074/jbc.M402148200	http://dx.doi.org/10.1074/jbc.M402148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078875	hybrid			2022-12-27	WOS:000222003000033
J	Quesada, C; Sanchez, LM; Alvarez, J; Lopez-Otin, C				Quesada, C; Sanchez, LM; Alvarez, J; Lopez-Otin, C			Identification and characterization of human and mouse ovastacin - A novel metalloproteinase similar to hatching enzymes from arthropods, birds, amphibians, and fish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 CONSTITUENT PROTEASES; ASTACIN-LIKE PROTEASES; ZONA-PELLUCIDA; MATRIX METALLOPROTEINASES; PLASMINOGEN-ACTIVATOR; SERINE PROTEASES; AF4-RELATED GENE; ORYZIAS-LATIPES; IN-VITRO; EXPRESSION	We have cloned and characterized human and mouse ovary cDNAs encoding a new protein of the astacin family of metalloproteinases, called ovastacin because of its predominant expression in ovarian tissues. Human and mouse ovastacins exhibit the same domain organization as other astacins, including signal sequence, propeptide, and metalloproteinase domain. However, ovastacins show an additional C-terminal domain of about 150 amino acids with no similarity to other ancillary domains present in the equivalent region of most astacins. Northern blot analysis of human tissues and cell lines revealed that ovastacin is only detected at significant levels in leukemia and lymphoma cells of different origin. In addition, RT-PCR analysis demonstrated that ovastacin is expressed in human and mouse ovary, in unfertilized mouse oocytes, and in 1.5-day-postcoitum preimplantation embryos. Further studies showed that superovulation caused a dramatic increase in the expression of mouse ovastacin, indicating that the production of this enzyme is under hormonal regulation. Human ovastacin was expressed in Escherichia coli and the purified recombinant protein hydrolyzed synthetic substrates used for assaying metalloproteinases. These activities were abolished by inhibitors of metalloproteinases, but not by inhibitors of other classes of proteases. On the basis of these results, we suggest that ovastacin could play in mammals a physiological function similar to that performed by hatching proteases in evolutionary distant species from arthropods to fish.	Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Morfol & Biol Celular, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	CLO@uniovi.es	Quesada, Cecilio/A-1563-2009					Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertrand P, 2000, MACROMOL RAPID COMM, V21, P319, DOI 10.1002/(SICI)1521-3927(20000401)21:7<319::AID-MARC319>3.0.CO;2-7; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Bruch J, 2003, GENE CHROMOSOME CANC, V37, P106, DOI 10.1002/gcc.10187; Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Curry TE, 2003, ENDOCR REV, V24, P428, DOI 10.1210/er.2002-0005; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELAROUSSI MA, 1994, BBA-GENE STRUCT EXPR, V1217, P1, DOI 10.1016/0167-4781(94)90116-3; EPPIG JJ, 1993, METHOD ENZYMOL, V225, P77; Fan TJ, 2001, EUR J BIOCHEM, V268, P4892, DOI 10.1046/j.0014-2956.2001.02420.x; Fata JE, 2000, CELL MOL LIFE SCI, V57, P77, DOI 10.1007/s000180050500; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Geier G, 1998, EUR J BIOCHEM, V253, P796, DOI 10.1046/j.1432-1327.1998.2530796.x; Ghiglione C, 1997, EUR J BIOCHEM, V250, P502, DOI 10.1111/j.1432-1033.1997.0502y.x; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Gonzales DS, 2001, BIOL REPROD, V64, P222, DOI 10.1095/biolreprod64.1.222; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; INOHAYA K, 1995, DEV BIOL, V171, P374, DOI 10.1006/dbio.1995.1289; Inohaya K, 1997, DEV GROWTH DIFFER, V39, P191; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; Katagiri C, 1997, INT J DEV BIOL, V41, P19; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kiefer SM, 2002, BIOL REPROD, V66, P407, DOI 10.1095/biolreprod66.2.407; Kruse MN, 2004, BIOCHEM J, V378, P383, DOI 10.1042/BJ20031163; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; Litscher ES, 1999, BIOCHEMISTRY-US, V38, P12280, DOI 10.1021/bi991154y; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lottaz D, 1999, CANCER RES, V59, P1127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Montag M, 2000, BIOL REPROD, V62, P1738, DOI 10.1095/biolreprod62.6.1738; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Nomura K, 1997, BIOCHEMISTRY-US, V36, P7225, DOI 10.1021/bi9629790; Norman LP, 2003, CURR TOP DEV BIOL, V54, P145, DOI 10.1016/S0070-2153(03)54008-X; Northrop DB, 1999, ADV ENZYMOL RAMB, V73, P25, DOI 10.1002/9780470123195.ch2; Ny T, 2002, MOL CELL ENDOCRINOL, V187, P29, DOI 10.1016/S0303-7207(01)00711-0; O'Sullivan CM, 2001, REPRODUCTION, V122, P235, DOI 10.1530/rep.0.1220235; O'Sullivan CM, 2001, REPRODUCTION, V122, P61, DOI 10.1530/rep.0.1220061; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rankin T, 2000, MOL CELL ENDOCRINOL, V163, P21, DOI 10.1016/S0303-7207(99)00236-1; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Salamonsen Lois A, 2002, Rev Endocr Metab Disord, V3, P133, DOI 10.1023/A:1015407012559; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; Talbot P, 2003, BIOL REPROD, V68, P1, DOI 10.1095/biolreprod.102.007856; Uria JA, 2000, CANCER RES, V60, P4745; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; von Bergh ARM, 2002, GENE CHROMOSOME CANC, V35, P92, DOI 10.1002/gcc.10091; Vu TKH, 1997, J BIOL CHEM, V272, P31315, DOI 10.1074/jbc.272.50.31315; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; YASUMASU S, 1992, DEV BIOL, V149, P349, DOI 10.1016/0012-1606(92)90290-W; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3; Yasumasu S, 1996, EUR J BIOCHEM, V237, P752, DOI 10.1111/j.1432-1033.1996.0752p.x	65	67	77	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26627	26634		10.1074/jbc.M401588200	http://dx.doi.org/10.1074/jbc.M401588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087446	hybrid			2022-12-27	WOS:000222003000089
J	Torpey, N; Maher, SE; Bothwell, ALM; Pober, JS				Torpey, N; Maher, SE; Bothwell, ALM; Pober, JS			Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; IFN-GAMMA; MCP-1 DEFICIENCY; DENDRITIC CELLS; IL-12 RESPONSES; EXPRESSION; TRANSCRIPTION	STAT4 signaling, activated by either interleukin 12 (IL12) or interferon alpha (IFNalpha), promotes T(H)1 responses in CD4(+) T cells. Vascular endothelial cells (EC) may also become polarized in response to various cytokines, favoring recruitment and activation of T(H)1 or T(H)2 effector cells. Here we have investigated the role of the STAT4 pathway in EC. Cultured human umbilical vein EC ( HUVEC) express low levels of STAT4, which may be tyrosine-phosphorylated by treatment with IFNalpha but not IL12. This is because HUVEC lack both subunits of the IL12 receptor (IL12Rbeta1 and IL12Rbeta2), even following treatment with various cytokines. IL12 phosphorylation of STAT4 can be observed in HUVEC that have been transduced to express the IL12R. To identify STAT4-induced genes we pursued three approaches: analysis by DNA microarray and quantitative RT-PCR (Q-PCR) of the IL12 responses in IL12R-transduced EC; analysis by Q-PCR of IFNalpha responses in STAT4-overexpressing EC; and analysis of IFNalpha responses in U3A neuroblastoma cell lines that express either STAT1 or STAT4, but not both. In all three instances we observe STAT4-mediated induction of the chemokine monocyte chemoattractant protein 1 (MCP1) and suppressor of cytokine signaling 3 (SOCS3) mRNA, and we confirm the production of each protein in both IL12R-transduced EC and STAT4-transduced U3A cells. These observations reveal that there is a STAT4 response of EC, activated by IFNalpha but not IL12, and that it may modulate the proinflammatory behavior of EC.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England	Yale University; Yale University; Yale University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol, 333 Cedar St, New Haven, CT 06510 USA.	Jordan.pober@yale.edu			NHLBI NIH HHS [P01 HL70295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Briscoe DM, 1997, J IMMUNOL, V159, P3247; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Cho SS, 1996, J IMMUNOL, V157, P4781; Cuvelier SL, 2001, J EXP MED, V194, P1699, DOI 10.1084/jem.194.12.1699; da Silva AJ, 2002, J INTERF CYTOK RES, V22, P173, DOI 10.1089/107999002753536149; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Frucht DM, 2000, J IMMUNOL, V164, P4659, DOI 10.4049/jimmunol.164.9.4659; Fukao T, 2001, J IMMUNOL, V166, P4446, DOI 10.4049/jimmunol.166.7.4446; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Jaruga B, 2003, J IMMUNOL, V171, P3233, DOI 10.4049/jimmunol.171.6.3233; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kim WJH, 2003, BIOCHEM BIOPH RES CO, V310, P936, DOI 10.1016/j.bbrc.2003.09.088; Kluger MS, 1997, J IMMUNOL, V158, P887; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Luscinskas FW, 2002, SEMIN IMMUNOL, V14, P105, DOI 10.1006/smim.2001.0347; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Mahboubi K, 2003, J BIOL CHEM, V278, P25014, DOI 10.1074/jbc.M211867200; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Monaco C, 2002, J LEUKOCYTE BIOL, V71, P659; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Niculescu F, 1999, IMMUNOPHARMACOLOGY, V42, P187, DOI 10.1016/S0162-3109(99)00014-4; Pober JS, 1999, IMMUNOL RES, V19, P225, DOI 10.1007/BF02786490; Raju R, 2003, TRANSPLANTATION, V75, P1072, DOI 10.1097/01.TP.0000058349.08707.E6; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Shinkai A, 1999, J IMMUNOL, V163, P1602; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stamm LM, 1999, EUR J IMMUNOL, V29, P2524, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2524::AID-IMMU2524&gt;3.0.CO;2-H; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; THORNHILL MH, 1991, J IMMUNOL, V146, P592; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V310, P1188, DOI 10.1016/j.bbrc.2003.09.140; Yamamoto K, 2002, BIOCHEM BIOPH RES CO, V297, P1245, DOI 10.1016/S0006-291X(02)02378-1; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	56	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26789	26796		10.1074/jbc.M401517200	http://dx.doi.org/10.1074/jbc.M401517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087447	hybrid			2022-12-27	WOS:000222003000106
J	Moeschel, K; Beck, A; Weigert, C; Lammers, R; Kalbacher, H; Voelter, W; Schleicher, ED; Haring, HU; Lehmann, R				Moeschel, K; Beck, A; Weigert, C; Lammers, R; Kalbacher, H; Voelter, W; Schleicher, ED; Haring, HU; Lehmann, R			Protein kinase C-zeta-induced phosphorylation of Ser(318) in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SERINE/THREONINE PHOSPHORYLATION; RESISTANCE; SER(307); ALPHA; CELLS; IDENTIFICATION; MODULATION; MECHANISM; ABILITY	Insulin receptor substrate-1 (IRS-1) was recently identified as a novel upstream substrate for the insulin-activated protein kinase C (PKC)-zeta. This interaction down-regulates insulin signal transduction under hyper-insulinemic conditions. To clarify the molecular mechanism of this feedback loop, we sought to identify the PKC-zeta phosphorylation sites of IRS-1 and to investigate their biological significance. Upon incubation of recombinant IRS-1 fragments with PKC-zeta, we identified Ser(318) of rat IRS-1 (Ser(323) in human IRS-1) as the major in vitro phosphorylation site ( confirmed by mutation of Ser(318) to alanine). To monitor phosphorylation of Ser(318) in cellular extracts, we prepared a polyclonal phosphosite-specific antibody. The biological significance was studied in baby hamster kidney cells stably expressing the insulin receptor (BHKIR). Using the phospho-Ser(318)-specific antibody we observed that insulin stimulates phosphorylation of Ser(318) in IRS-1, which is mediated, at least partially, by PKC-zeta. Moreover, we found that the previously described insulin-stimulated, PKC-zeta-mediated inhibition of the interaction of IRS-1 with the insulin receptor and the reduced tyrosine phosphorylation of IRS-1 was abrogated by mutation of IRS-1 Ser(318) to alanine. These results, generated in BHKIR cells, suggest that phosphorylation of Ser(318) by PKC-zeta might contribute to the inhibitory effect of prolonged hyperinsulinemia on IRS-1 function.	Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, D-72076 Tubingen, Germany; Univ Tubingen, Inst Physiol Chem, Dept Phys Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Lehmann, R (corresponding author), Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rainer.lehmann@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANTI JF, 1994, J BIOL CHEM, V269, P6051; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	25	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25157	25163		10.1074/jbc.M402477200	http://dx.doi.org/10.1074/jbc.M402477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069075	hybrid			2022-12-27	WOS:000221827900031
J	Pitsi, D; Octave, JN				Pitsi, D; Octave, JN			Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-APP; NICASTRIN; COMPLEX; CELLS; TRAFFICKING; INHIBITORS; CLEAVAGE; DISTINCT; SITES	The cleavage of the transmembrane amyloid precursor protein (APP) by beta-secretase leaves the C-terminal fragment of APP, C99, anchored in the plasma membrane. C99 is subsequently processed by gamma-secretase, an unusual aspartyl protease activity largely dependent on presenilin ( PS), generating the amyloid beta-peptide (Abeta) that accumulates in the brain of patients with Alzheimer's disease. It has been suggested that PS proteins are the catalytic core of this proteolytic activity, but a number of other proteins mandatory for gamma-secretase cleavage have also been discovered. The exact role of PS in the gamma-secretase activity remains a matter of debate, because cells devoid of PS still produce some forms of Abeta. Here, we used insect cells expressing C99 to demonstrate that the expression of presenilin 1 (PS1), which binds C99, not only increases the production of Abeta by these cells but also increases the intracellular levels of C99 to the same extent. Using pulse-chase experiments, we established that this results from an increased half-life of C99 in cells expressing PS1. In Chinese hamster ovary cells producing C99 from full-length human APP, similar results were observed. Finally, we show that a functional inhibitor of gamma-secretase does not alter the ability of PS1 to increase the intracellular levels of C99. This finding suggests that the binding of PS1 to C99 does not necessarily lead to its immediate cleavage by gamma-secretase, which could be a spatio-temporally regulated or an induced event, and provides biochemical evidence for the existence of a substrate-docking site on PS1.	Univ Catholique Louvain, Lab Pharmacol Expt, B-1200 Brussels, Belgium	Universite Catholique Louvain	Octave, JN (corresponding author), Univ Catholique Louvain, Lab Pharmacol Expt, UCL 54-10,54 Ave Hippocrate, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be						Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Berezovska O, 2003, J NEUROSCI, V23, P4560; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hattori C, 2002, BIOCHEM BIOPH RES CO, V293, P1228, DOI 10.1016/S0006-291X(02)00351-0; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Meredith JE, 2002, BIOCHEM BIOPH RES CO, V299, P744, DOI 10.1016/S0006-291X(02)02747-X; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; Pitsi D, 2002, J NEUROCHEM, V83, P390, DOI 10.1046/j.1471-4159.2002.01138.x; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	36	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25333	25338		10.1074/jbc.M312710200	http://dx.doi.org/10.1074/jbc.M312710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087467	hybrid			2022-12-27	WOS:000221827900054
J	Solski, PA; Wilder, RS; Rossman, KL; Sondek, J; Cox, AD; Campbell, SL; Der, CJ				Solski, PA; Wilder, RS; Rossman, KL; Sondek, J; Cox, AD; Campbell, SL; Der, CJ			Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CYSTEINE-RICH DOMAINS; RHO-GTPASES; DBL FAMILY; EXPRESSION CLONING; DISTINCT ROLES; CELL-CYCLE; PH DOMAINS; ACTIVATION; CDC42	Ect2 was identified originally as a transforming protein and a member of the Dbl family of Rho guanine nucleotide exchange factors (GEFs). Like all Dbl family proteins, Ect2 contains a tandem Dbl homology (DH) and pleckstrin homology (PH) domain structure. Previous studies demonstrated that N-terminal deletion of sequences upstream of the DH domain created a constitutively activated, transforming variant of Ect2 (designated DeltaN-Ect2DH/PH/C), indicating that the N terminus served as a negative regulator of DH domain function in vivo. The role of sequences C-terminal to the DH domain has not been established. Therefore, we assessed the consequences of mutation of C-terminal sequences on Ect2-transforming activity. Surprisingly, in contrast to observations with other Dbl family proteins, we found that mutation of the invariant tryptophan residue in the PH domain did not impair DeltaN-Ect2DH/PH/C transforming activity. Furthermore, although the sequences C-terminal to the PH domain lack any known functional domains or motifs, deletion of these sequences (DeltaN-Ect2 DH/PH) resulted in a dramatic reduction in transforming activity. Whereas DeltaN-Ect2 caused formation of lamellipodia, DeltaN-Ect2 DH/PH enhanced actin stress fiber formation, suggesting that C-terminal sequences influenced Ect2 Rho GTPase specificity. Consistent with this possibility, we determined that DeltaN-Ect2 DH/PH activated RhoA, but not Rac1 or Cdc42, whereas DeltaN-Ect2 DH/PH/C activated all three Rho GTPases in vivo. Taken together, these observations suggest that regions of Ect2 C-terminal to the DH domain alter the profile of Rho GTPases activated in vivo and consequently may contribute to the enhanced transforming activity of DeltaN-Ect2 DH/PH/C.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Sondek, John/0000-0002-1127-8310; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA092240, R01CA063071, S15CA062299, U19CA067771, R01CA089614] Funding Source: NIH RePORTER; NCI NIH HHS [CA62299, CA63071, CA67771, CA89614, CA92240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; COX AD, 1995, METHOD ENZYMOL, V255, P195; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; MICHIELS F, 1997, J CELL BIOL, V137, P1; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Solski PA, 2000, METHOD ENZYMOL, V325, P425; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	40	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25226	25233		10.1074/jbc.M313792200	http://dx.doi.org/10.1074/jbc.M313792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073184	Green Published, hybrid			2022-12-27	WOS:000221827900040
J	Kittur, FS; Manithody, C; Rezaie, AR				Kittur, FS; Manithody, C; Rezaie, AR			Role of the N-terminal epidermal growth factor-like domain of factor X/Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; FACTOR-FACTOR-VIIA; SOLUBLE TISSUE FACTOR; FACTOR-VA BINDING; FACTOR-X; FACTOR-IX; PROTHROMBINASE COMPLEX; PROTEIN-C; ACTIVE-SITE; SUBSTRATE RECOGNITION	The functional importance of the N-terminal epidermal growth factor-like domain (EGF-N) of factor X/Xa (FX/Xa) was investigated by constructing an FX mutant in which the exon coding for EGF-N was deleted from FX cDNA. Following expression and purification to homogeneity, the mutant was characterized with respect to its ability to function as a zymogen for either the factor VIIa-tissue factor complex or the factor IXa-factor VIIIa complex and then to function as an enzyme in the prothrombinase complex to catalyze the conversion of prothrombin to thrombin. It was discovered that EGF-N is essential for the recognition and efficient activation of FX by both activators in the presence of the cofactors. On the other hand, the FXa mutant interacted with factor Va with a normal apparent dissociation constant and activated prothrombin with similar to3-fold lower catalytic efficiency in the prothrombinase complex. Surprisingly, the mutant activated prothrombin with similar to12-fold better catalytic efficiency than wild-type FXa in the absence of factor Va. The mutant was inactive in both prothrombin time and activated partial thromboplastin time assays; however, it exhibited a similar specific activity in a one-stage FXa clotting assay. These results suggest that EGF-N of FX is required for the cofactor-dependent zymogen activation by both physiological activators, but it plays no apparent role in FXa recognition of the cofactor in the prothrombinase complex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Kittur, Farooqahmed S/G-3832-2012	Kittur, Farooqahmed/0000-0002-2272-3387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL062565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68571, HL62565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Furie B.C., 1976, Methods Enzymol, V45, P191; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; ROSING J, 1980, J BIOL CHEM, V255, P274; RUF W, 1992, J BIOL CHEM, V267, P6375; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; Thiec F, 2003, J BIOL CHEM, V278, P10393, DOI 10.1074/jbc.M212144200; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	42	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24189	24196		10.1074/jbc.M402302200	http://dx.doi.org/10.1074/jbc.M402302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069066	hybrid			2022-12-27	WOS:000221702500042
J	He, B; Bai, SX; Hnat, AT; Kalman, RI; Minges, JT; Patterson, C; Wilson, EM				He, B; Bai, SX; Hnat, AT; Kalman, RI; Minges, JT; Patterson, C; Wilson, EM			An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; E3 UBIQUITIN LIGASE; HUMAN GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR TFIIF; RECURRENT PROSTATE-CANCER; HUMAN ESTROGEN-RECEPTOR; ACTIVATION FUNCTION 2; NUCLEAR-RECEPTOR; BINDING DOMAIN; PHOSPHORYLATION SITES	The NH2-terminal sequence of steroid receptors is highly variable between different receptors and in the same receptor from different species. In this study, a primary sequence homology comparison identified a 14-amino acid NH2-terminal motif of the human androgen receptor (AR) that is common to AR from all species reported, including the lower vertebrates. The evolutionarily conserved motif is unique to AR, with the exception of a partial sequence in the glucocorticoid receptor of higher species. The presence of the conserved motif in AR and the glucocorticoid receptor and its absence in other steroid receptors suggests convergent evolution. The function of the AR NH2-terminal conserved motif was suggested from a yeast two-hybrid screen that identified the COOH terminus of the Hsp70-interacting protein (CHIP) as a binding partner. We found that CHIP functions as a negative regulator of AR transcriptional activity by promoting AR degradation. In support of this, two mutations in the AR NH2-terminal conserved motif previously identified in the transgenic adenocarcinoma of mouse prostate model reduced the interaction between CHIP and AR. Our results suggest that the AR NH2-terminal domain contains an evolutionarily conserved motif that functions to limit AR transcriptional activity. Moreover, we demonstrate that the combination of comparative sequence alignment and yeast two-hybrid screening using short conserved peptides as bait provides an effective strategy to probe the structure-function relationships of steroid receptor NH2-terminal domains and other intrinsically unstructured transcriptional regulatory proteins.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Med Biomol Res Bldg,Rm 3340,103 Mason Far, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			FIC NIH HHS [R30TW001234] Funding Source: Medline; NCI NIH HHS [P01-CA77739] Funding Source: Medline; NICHD NIH HHS [HD16910, U54-HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, U54HD035041, R37HD016910] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW001234] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Betney R, 2003, J MOL ENDOCRINOL, V31, P427, DOI 10.1677/jme.0.0310427; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHOU ZX, 1993, STEROID HORMONE RECE, P407	72	101	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30643	30653		10.1074/jbc.M403117200	http://dx.doi.org/10.1074/jbc.M403117200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15107424	hybrid, Green Published			2022-12-27	WOS:000222531900094
J	Leal, S; Acosta-Serrano, A; Morris, J; Cross, GAM				Leal, S; Acosta-Serrano, A; Morris, J; Cross, GAM			Transposon mutagenesis of Trypanosoma brucei identifies glycosylation mutants resistant to concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; DROSOPHILA ELEMENT MARINER; SURFACE GLYCOPROTEIN; IN-VITRO; AFRICAN TRYPANOSOMES; STRUCTURAL-CHARACTERIZATION; DEVELOPMENTAL VARIATION; CONGENITAL DISORDERS; PROCYCLIC STAGE; TSETSE-FLY	We have engineered Trypanosoma brucei with a novel mariner transposition system that allows large populations of mutant cells to be generated and screened. As a proof of principle, we isolated and characterized two independent clones that were resistant to the cytotoxic action of concanavalin A. In both clones, the transposon had integrated into the locus encoding a homologue of human ALG12, which encodes a dolichyl-P-Man: Man(7)GlcNAc(2)-PP-dolichyl-alpha6-mannosyltransferase. Conventional knock-out of ALG12 in a wild-type background gave an identical phenotype to the mariner mutants, and biochemical analysis confirmed that they have the same defect in the N-linked oligosaccharide synthesis pathway. To our surprise, both mariner mutants were homozygous; the second allele appeared to have undergone gene conversion by the mariner-targeted allele. Subsequent experiments showed that the frequency of gene conversion at the ALG12 locus, in the absence of selection, was 0.25%. As we approach the completion of the trypanosome genome project, transposon mutagenesis provides an important addition to the repertoire of genetic tools for T. brucei.	Rockefeller Univ, Mol Parasitol Lab, New York, NY 10021 USA; Univ Dundee, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Rockefeller University; University of Dundee; Johns Hopkins University	Cross, GAM (corresponding author), Rockefeller Univ, Mol Parasitol Lab, 1230 York Ave, New York, NY 10021 USA.	george.cross@rockefeller.edu	Cross, George A M/B-7444-2011; Acosta-Serrano, Alvaro/L-5503-2015	Cross, George A M/0000-0003-1374-6955; Acosta-Serrano, Alvaro/0000-0002-2576-7959; Morris, James/0000-0003-2515-5714	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021729, R01AI021334, R01AI021729] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21334, AI21729] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acosta-Serrano A, 2000, J MOL BIOL, V304, P633, DOI 10.1006/jmbi.2000.4246; Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Acosta-Serrano A, 1999, J BIOL CHEM, V274, P29763, DOI 10.1074/jbc.274.42.29763; Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Bessereau JL, 2001, NATURE, V413, P70, DOI 10.1038/35092567; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clayton CE, 1999, PARASITOL TODAY, V15, P372, DOI 10.1016/S0169-4758(99)01498-2; Cross GAM, 2001, INT J PARASITOL, V31, P427, DOI 10.1016/S0020-7519(01)00141-2; Dawson A, 2003, MOL CELL, V11, P225, DOI 10.1016/S1097-2765(02)00798-0; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; Hartl DL, 2001, GENETICS, V157, P471; Hwa KY, 1999, GLYCOBIOLOGY, V9, P181, DOI 10.1093/glycob/9.2.181; Hwa KY, 2000, MOL BIOCHEM PARASIT, V111, P173, DOI 10.1016/S0166-6851(00)00310-8; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lozovsky ER, 2002, GENETICS, V160, P527; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDHORA M, 1991, GENETICS, V128, P311; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; Pearson TW, 2000, MOL BIOCHEM PARASIT, V111, P333, DOI 10.1016/S0166-6851(00)00327-3; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; Shi HF, 2002, MOL BIOCHEM PARASIT, V121, P141, DOI 10.1016/S0166-6851(02)00020-8; Tait A, 2002, PHILOS T ROY SOC B, V357, P89, DOI 10.1098/rstb.2001.1050; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Valdes J, 1996, NUCLEIC ACIDS RES, V24, P1809, DOI 10.1093/nar/24.10.1809; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Welburn SC, 1996, CELL DEATH DIFFER, V3, P229; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28979	28988		10.1074/jbc.M403479200	http://dx.doi.org/10.1074/jbc.M403479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123607	Green Submitted, hybrid			2022-12-27	WOS:000222445300020
J	Lim, YM; Han, I; Jeon, J; Park, H; Bahk, YY; Oh, ES				Lim, YM; Han, I; Jeon, J; Park, H; Bahk, YY; Oh, ES			Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for ras transformation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; IN-VIVO; V-SRC; BINDING; CRK; PATHWAY; FIBRONECTIN; ASSOCIATION; INVASION; DOMAIN	Although elevated expression and increased tyrosine phosphorylation of focal adhesion kinase (FAK) are crucial for tumor progression, the mechanism by which FAK promotes oncogenic transformation is unclear. We have therefore determined the role of FAK phosphorylation at tyrosine 861 in the oncogenic transformation of NIH3T3 fibroblasts. FAK phosphorylation at tyrosine 861 was increased in both constitutively H-Ras-transformed and H-Ras-inducible NIH3T3 cells, in parallel with cell transformation. However, H-Ras-inducible cells transfected with the nonphosphorylatable mutant FAK Y861F showed decreased migration/invasion, focus forming activity and anchorage-independent growth, compared with either wild-type or kinase-defective FAK. In contrast to unaltered FAK/Src activity, the association of FAK and p130(CAS) was decreased in FAK Y861F-transfected cells, and FAK phosphorylation at tyrosine 861 enhanced this association in vitro. Consistently, FAK Y861F-transfected cells were defective in activation of c-Jun NH2-terminal kinase and in expression of matrix metalloproteinase-9 during transformation. Taken together, these results strongly suggest that FAK phosphorylation at tyrosine 861 is crucial for H-Ras-induced transformation through regulation of the association of FAK with p130CAS.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Natl Canc Ctr, Res Inst, Gyeonggi Goyang 411764, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea	Ewha Womans University; Ewha Womans University; National Cancer Center - Korea (NCC); Yonsei University	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Daehyun Dong, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr						Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Burnham MR, 1996, ONCOGENE, V12, P2467; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2001, CANCER RES, V61, P7079; Hecker TP, 2002, CANCER RES, V62, P2699; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Nievers MG, 1997, J CELL SCI, V110, P389; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shibata K, 1998, CANCER RES, V58, P900; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wang DY, 2000, J CELL SCI, V113, P4221; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999	34	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29060	29065		10.1074/jbc.M401183200	http://dx.doi.org/10.1074/jbc.M401183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123632	hybrid			2022-12-27	WOS:000222445300029
J	Becker, KP; Hannun, YA				Becker, KP; Hannun, YA			Isoenzyme-specific translocation of protein kinase C (PKC) beta II and not PKC beta I to a juxtanuclear subset of recycling endosomes - Involvement of phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE HYDROLYSIS; ALPHA-THROMBIN; GROWTH-FACTOR; ACTIVATION; ISOZYMES; DIACYLGLYCEROL; FIBROBLASTS; OVEREXPRESSION; PROLIFERATION; LOCALIZATION	Elucidation of isoenzyme-specific functions of individual protein kinase C (PKC) isoenzymes has emerged as an important goal in the study of this family of kinases, but this task has been complicated by modest substrate specificity and high homology among the individual members of each PKC subfamily. The classical PKCbetaI and PKCbetaII isoenzymes provide a unique opportunity because they are the alternatively spliced products of the beta gene and are 100% identical except for the last 50 of 52 amino acids. In this study, it is shown that green fluorescent protein-tagged PKCbetaII and not PKCbetaI translocates to a recently described juxtanuclear site of localization for PKCalpha and PKCbetaII isoenzymes that arises with sustained stimulation of PKC. Mechanistically, translocation of PKCbetaII to the juxtanuclear region required kinase activity. PKCbetaII, but not PKCbetaI, was found to activate phospholipase D within this time frame. Inhibitors of phospholipase D (1-butanol and a dominant negative construct) prevented the translocation of PKCbetaII to the juxtanuclear region but not to the plasma membrane, thus demonstrating a role for phospholipase D in the juxtanuclear translocation of PKCbetaII. Taken together, these results define specific biochemical and cellular actions of PKCbetaII when compared with PKCbetaI.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HA KS, 1993, J BIOL CHEM, V268, P10534; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Hurley JH, 1997, PROTEIN SCI, V6, P477; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Yamamoto M, 1998, EXP CELL RES, V240, P349, DOI 10.1006/excr.1998.3999; Yamamoto M, 2000, AM J PHYSIOL-CELL PH, V279, pC587, DOI 10.1152/ajpcell.2000.279.3.C587; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	31	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28251	28256		10.1074/jbc.M400770200	http://dx.doi.org/10.1074/jbc.M400770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15067001	hybrid			2022-12-27	WOS:000222265400055
J	Starcevic, M; Dell'Angelica, EC				Starcevic, M; Dell'Angelica, EC			Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; MOUSE; GENE; DYSBINDIN; MODEL; YEAST; HPS1; MUTATIONS; PALLIDIN; HOMOLOG	Biogenesis of lysosome-related organelles complex-1 (BLOC-1) is a ubiquitously expressed multisubunit protein complex required for the normal biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules. The complex is known to contain the coiled-coil-forming proteins, Pallidin, Muted, Cappuccino, and Dysbindin. The genes encoding these proteins are defective in inbred mouse strains that serve as models of Hermansky-Pudlak syndrome (HPS), a genetic disorder characterized by hypopigmentation and platelet storage pool deficiency. In addition, mutation of human Dysbindin causes HPS type 7. Here, we report the identification of another four subunits of the complex. One is Snapin, a coiled-coil-forming protein previously characterized as a binding partner of synaptosomal-associated proteins 25 and 23 and implicated in the regulation of membrane fusion events. The other three are previously uncharacterized proteins, which we named BLOC subunits 1, 2, and 3 (BLOS1, -2, and -3). Using specific antibodies to detect endogenous proteins from human and mouse cells, we found that Snapin, BLOS1, BLOS2, and BLOS3 co-immunoprecipitate, and co-fractionate upon size exclusion chromatography, with previously known BLOC-1 subunits. Furthermore, steady-state levels of the four proteins are significantly reduced in cells from pallid mice, which carry a mutation in Pallidin and display secondary loss of other BLOC-1 subunits. Yeast two-hybrid analyses suggest a network of binary interactions involving all of the previously known and newly identified subunits. Interestingly, the HPS mouse model strain, reduced pigmentation, carries a nonsense mutation in the gene encoding BLOS3. As judged from size exclusion chromatographic analyses, the reduced pigmentation mutation affects BLOC-1 assembly less severely than the pallid mutation. Mutations in the human genes encoding Snapin and the BLOS proteins could underlie novel forms of HPS.	Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Dell'Angelica, EC (corresponding author), Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA.	Edellangelica@mednet.ucla.edu			NHLBI NIH HHS [HL 68117] Funding Source: Medline; NIGMS NIH HHS [GM 07104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068117] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURTON P, 2003, BIOCHEM J, V375, P433; Chiang PW, 2003, J BIOL CHEM, V278, P20332, DOI 10.1074/jbc.M300090200; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Di Pietro SM, 2004, TRAFFIC, V5, P276, DOI 10.1111/j.1600-0854.2004.0171.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Gautam R, 2004, J BIOL CHEM, V279, P12935, DOI 10.1074/jbc.M311311200; GIBB S, 1981, GENET RES, V37, P95, DOI 10.1017/S0016672300020048; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue M, 1996, CYTOGENET CELL GENET, V73, P134; King SM, 2002, SEMIN CELL DEV BIOL, V13, P293, DOI 10.1016/S1084952102000599; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; LUNDIN LG, 1980, MOUSE NEWS LETT, V62, P77; Lyerla TA, 2003, AM J PHYSIOL-LUNG C, V285, pL643, DOI 10.1152/ajplung.00024.2003; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Martina JA, 2003, J BIOL CHEM, V278, P29376, DOI 10.1074/jbc.M301294200; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nakatani Y, 2000, VIRCHOWS ARCH, V437, P304, DOI 10.1007/s004280000241; Nazarian R, 2003, P NATL ACAD SCI USA, V100, P8770, DOI 10.1073/pnas.1532040100; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Richardson SCW, 2004, MOL BIOL CELL, V15, P1197, DOI 10.1091/mbc.E03-06-0358; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Spritz RA, 2003, CURR OPIN GENET DEV, V13, P284, DOI 10.1016/S0959-437X(03)00059-5; Starcevic M, 2002, SEMIN CELL DEV BIOL, V13, P271, DOI 10.1016/S1084952102000563; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Vites O, 2004, J BIOL CHEM, V279, P26251, DOI 10.1074/jbc.M404079200; Watanabe T K, 1995, DNA Res, V2, P235, DOI 10.1093/dnares/2.5.235; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; Zhu YX, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r16	48	189	200	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28393	28401		10.1074/jbc.M402513200	http://dx.doi.org/10.1074/jbc.M402513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15102850	hybrid			2022-12-27	WOS:000222265400072
J	Xie, MT; Smith, JL; Ding, ZW; Zhang, DQ; Cornell, RB				Xie, MT; Smith, JL; Ding, ZW; Zhang, DQ; Cornell, RB			Membrane binding modulates the quaternary structure of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; ENDOPLASMIC-RETICULUM; DOMAIN; PHOSPHATIDYLCHOLINE; IDENTIFICATION; PROTEINS; LOCALIZATION; ACTIVATION; ENZYME; ALPHA	CTP:phosphocholine cytidylyltransferase (CCT), a key enzyme that controls phosphatidylcholine synthesis, is regulated by reversible interactions with membranes containing anionic lipids. Previous work demonstrated that CCT is a homodimer. In this work we show that the structure of the dimer interface is altered upon encountering membranes that activate CCT. Chemical cross-linking reactions were established which captured intradimeric interactions but not random CCT dimer collisions. The efficiency of capturing covalent cross-links with four different reagents was diminished markedly upon presentation of activating anionic lipid vesicles but not zwitterionic vesicles. Experiments were conducted to show that the anionic vesicles did not interfere with the chemistry of the cross-linking reactions and did not sequester available cysteine sites on CCT for reaction with the cysteine-directed cross-linking reagent. Thus, the loss of cross-linking efficiency suggested that contact sites at the dimer interface had increased distance or reduced flexibility upon binding of CCT to membranes. The regions of the enzyme involved in dimerization were mapped using three approaches: 1) limited proteolysis followed by cross-linking of fragments, 2) yeast two-hybrid analysis of interactions between select domains, and 3) disulfide bonding potential of CCTs with individual cysteine to serine substitutions for the seven native cysteines. We found that the N-terminal domain (amino acids 1-72) is an important participant in forming the dimer interface, in addition to the catalytic domain (amino acids 73-236). We mapped the intersubunit disulfide bond to the cystine 37 pair in domain N and showed that this disulfide is sensitive to anionic vesicles, implicating this specific region in the membrane-sensitive dimer interface.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University; Simon Fraser University	Cornell, RB (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	cornell@sfu.ca		Xie, Mingtang/0000-0002-2797-0598				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Drobnies AE, 1999, BIOCHEMISTRY-US, V38, P15606, DOI 10.1021/bi991573v; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; HABEEB AFS, 1968, ARCH BIOCHEM BIOPHYS, V126, P16, DOI 10.1016/0003-9861(68)90554-7; JAMIL H, 1990, J BIOL CHEM, V265, P4332; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; Taneva S, 2003, BIOCHEMISTRY-US, V42, P11768, DOI 10.1021/bi035234k; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9	28	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28817	28825		10.1074/jbc.M403311200	http://dx.doi.org/10.1074/jbc.M403311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15069071	hybrid			2022-12-27	WOS:000222265400120
J	Fernandes, R; Girao, H; Pereira, P				Fernandes, R; Girao, H; Pereira, P			High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PIGMENT EPITHELIAL-CELLS; GAP JUNCTIONAL COMMUNICATION; DIABETIC-RATS; PHORBOL-ESTER; PHOSPHORYLATION; EXPRESSION; BETA; COMPLICATIONS; INHIBITION	Intercellular communication through gap junctions (GJIC) is most likely relevant to maintaining the integrity of the blood-retinal barrier. In this study, we investigated the mechanism whereby high glucose enhances degradation of connexin 43 (Cx43), thus contributing to a decrease in GJIC. The levels of Cx43 in bovine retinal endothelial cells exposed to high glucose (25 mM) decreased about 50% as compared with controls (5.5 mM glucose). Consistently, the half-life of the protein decreased from 2.3 to 1.9 h. The proteasome inhibitors MG132 and lactacystin prevented the loss of Cx43 induced by high glucose and extended Cx43 half-life. The amount of phosphorylated Cx43 increased in high glucose and after proteasome inhibition. Scrape-loading dye transfer experiments show that high glucose is associated to a decrease of 40% in GJIC. Significantly, this reduction can be reversed by proteasome inhibitors. The decrease in GJIC in cells exposed to high glucose is associated with a loss of Cx43 from the plasma membrane, as demonstrated by immunofluorescence and biotinylation of cell-surface proteins. Results indicate that increased phosphorylation of Cx43 under high glucose is the mechanism targeting Cx43 for degradation by a proteasome-dependent mechanism. Increased degradation of Cx43 and reduction of GJIC in high glucose may be of physiological importance by contributing to endothelial cell dysfunction associated with the breakdown of the blood-retinal barrier in diabetic retinopathy.	Univ Coimbra, Fac Med, Ctr Ophthalmol, Biomed Inst Res Light & Image, P-3000354 Coimbra, Portugal	Universidade de Coimbra	Pereira, P (corresponding author), Univ Coimbra, Fac Med, Ctr Ophthalmol, Biomed Inst Res Light & Image, P-3000354 Coimbra, Portugal.	ppereira@ibili.uc.pt	Pereira, Paulo/AAD-8375-2022; Girao, H/I-7591-2012; Fernandes, Rosa/P-1102-2014	Pereira, Paulo/0000-0002-9908-2290; Girao, H/0000-0002-5786-8447; Fernandes, Rosa/0000-0001-7828-2296				Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Girao H, 2003, MOL VIS, V9, P24; Himpens B, 1999, FASEB J, V13, pS63; Husoy T, 2001, CARCINOGENESIS, V22, P221, DOI 10.1093/carcin/22.2.221; INOGUCHI T, 1995, BIOCHEM BIOPH RES CO, V208, P492, DOI 10.1006/bbrc.1995.1365; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Inoguchi Toyoshi, 2001, Medical Electron Microscopy, V34, P86, DOI 10.1007/s007950170002; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; King GL, 1996, DIABETES, V45, pS105, DOI 10.2337/diab.45.3.S105; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Kuroki T, 1998, DIABETES, V47, P931, DOI 10.2337/diabetes.47.6.931; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Larson DM, 1997, AM J PHYSIOL-CELL PH, V272, pC405, DOI 10.1152/ajpcell.1997.272.2.C405; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LITTLE TL, 1995, AM J PHYSIOL, V268, P729; Malfait M, 2001, J MEMBRANE BIOL, V181, P31, DOI 10.1007/s0023200100082; MATESIC DF, 1994, MOL CARCINOGEN, V10, P226, DOI 10.1002/mc.2940100407; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Sato T, 2002, DIABETES, V51, P1565, DOI 10.2337/diabetes.51.5.1565; Schulz R, 2003, FASEB J, V17, P1355, DOI 10.1096/fj.02-0975fje; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P1598; TenBroek EM, 1997, DEV BIOL, V191, P88, DOI 10.1006/dbio.1997.8703; Ward Walter F, 2002, Prog Mol Subcell Biol, V29, P35; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; Yeh HI, 1998, CIRC RES, V83, P1248, DOI 10.1161/01.RES.83.12.1248	41	72	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27219	27224		10.1074/jbc.M400446200	http://dx.doi.org/10.1074/jbc.M400446200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123628	Green Published, hybrid			2022-12-27	WOS:000222120400049
J	Izard, T; Vonrhein, C				Izard, T; Vonrhein, C			Structural basis for amplifying vinculin activation by talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITES; INTRAMOLECULAR ASSOCIATION; CYTOPLASMIC DOMAIN; FOCAL ADHESIONS; HEAD DOMAIN; KINASE; ACTIN; CONTAINS; DISRUPTION; REGION	Talin interactions with vinculin are essential for focal adhesions. Curiously, talin contains three noncontiguous vinculin binding sites (VBS) that can bind individually to the vinculin head (Vh) domain. Here we report the crystal structure of the human Vh . VBS1 complex, a validated model of the Vh . VBS2 structure, and biochemical studies that demonstrate that all of talin VBSs activate vinculin by provoking helical bundle conversion of the Vh domain, which displaces the vinculin tail (Vt) domain. Thus, helical bundle conversion is a structurally conserved response in talin-vinculin interactions. Furthermore, talin VBSs bind to Vh in a mutually exclusive manner but do differ in their affinity for Vh and in their ability to displace Vt, suggesting that the strengths of these interactions could lead to differences in signaling outcome. These findings support a model in which talin binds to and activates multiple vinculin molecules to provoke rapid reorganization of the actin cytoskeleton.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Global Phasing Ltd, Cambridge CB3 0AX, England	St Jude Children's Research Hospital; Global Phasing Limited	Izard, T (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tina.izard@stjude.org			NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailly M, 2003, TRENDS CELL BIOL, V13, P163, DOI 10.1016/S0962-8924(03)00030-8; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; EIMER W, 1993, J MOL BIOL, V229, P146, DOI 10.1006/jmbi.1993.1014; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Hemmings L, 1996, J CELL SCI, V109, P2715; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lesay A, 2001, NEUROREPORT, V12, P2111, DOI 10.1097/00001756-200107200-00014; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; MOLONY L, 1987, J BIOL CHEM, V262, P7790; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rush CL, 2004, ACTA CRYSTALLOGR D, V60, P945, DOI 10.1107/S0907444904006547; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; STEENBERGEN C, 1987, CIRC RES, V60, P478, DOI 10.1161/01.RES.60.4.478; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; Xu WM, 1998, DEVELOPMENT, V125, P327	51	80	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27667	27678		10.1074/jbc.M403076200	http://dx.doi.org/10.1074/jbc.M403076200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15070891	hybrid			2022-12-27	WOS:000222120400101
J	Jiang, C; Ito, M; Piening, V; Bruck, K; Roeder, RG; Xiao, H				Jiang, C; Ito, M; Piening, V; Bruck, K; Roeder, RG; Xiao, H			TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR RECEPTOR; IN-VITRO; COMPLEXES; TUMORIGENESIS; RECRUITMENT; EXPRESSION; MECHANISMS; ELONGATION; MOUSE	Deregulation of c-myc expression is implicated in the pathogenesis of many neoplasias. Estrogen receptor alpha (ERalpha) can increase the rate of c-myc transcription through the recruitment of a variety of cofactors to the promoter, yet the precise roles of these cofactors in transcription and tumorigenesis are largely unknown. We show here that a putative tumor suppressor TIP30, also called CC3 or Htatip2, interacts with an ERalpha-interacting coactivator CIA. Using chromatin immunoprecipitation assays, we demonstrate that TIP30 and CIA are distinct cofactors that are dynamically associated with the promoter and downstream regions of the c-myc gene in response to estrogen. Both TIP30 and CIA are recruited to the c-myc gene promoter by liganded ERalpha in the second transcription cycle. TIP30 overexpression represses ERalpha-mediated c-myc transcription, whereas TIP30 deficiency enhances c-myc transcription in both the absence and presence of estrogen. Ectopic CIA cooperates with TIP30 to repress ERalpha-mediated c-myc transcription. Moreover, virgin TIP30 knockout mice exhibit increased c-myc expression in mammary glands. Together, these results reveal an important role for TIP30 in the regulation of ERalpha-mediated c-myc transcription and suggest a mechanism for tumorigenesis promoted by TIP30 deficiency.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Kobe Univ, Sch Med, Dept Med, Div Hematol Oncol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Kobe University; Rockefeller University	Xiao, H (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	hxiao@unmc.edu						BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 1999, ANN ENDOCRINOL-PARIS, V60, P143; Cunha GR, 2000, ADV EXP MED BIOL, V480, P93; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBIK D, 1992, ONCOGENE, V7, P1587; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; FREEDMAN LP, 1999, ANNU REV BIOCHEM, V70, P475; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ito M, 2003, CANCER RES, V63, P8763; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; NicAmhlaoibh R, 2001, ONCOGENE, V20, P270, DOI 10.1038/sj.onc.1204075; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; Sauve FD, 2001, MOL CELL BIOL, V21, P343, DOI 10.1128/MCB.21.1.343-353.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; SPENCER CA, 1990, ANN NY ACAD SCI, V599, P12; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1999, J BIOL CHEM, V274, P3937, DOI 10.1074/jbc.274.7.3937; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	43	61	66	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27781	27789		10.1074/jbc.M401809200	http://dx.doi.org/10.1074/jbc.M401809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073177	hybrid			2022-12-27	WOS:000222120400113
J	Tinsley, CR; Voulhoux, R; Beretti, JL; Tommassen, J; Nassif, X				Tinsley, CR; Voulhoux, R; Beretti, JL; Tommassen, J; Nassif, X			Three homologues, including two membrane-bound proteins, of the disulfide oxidoreductase DsbA in Neisseria meningitidis - Effects on bacterial growth and biogenesis of functional type IV pili	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; BOND FORMATION; MENINGOCOCCAL PILIN; GONORRHOEAE; TRANSFORMATION; PATHWAY; IDENTIFICATION; ISOMERIZATION	Many proteins, especially membrane and exported proteins, are stabilized by intramolecular disulfide bridges between cysteine residues without which they fail to attain their native functional conformation. The formation of these bonds is catalyzed in Gram-negative bacteria by enzymes of the Dsb system. Thus, the activity of DsbA has been shown to be necessary for many phenotypes dependent on exported proteins, including adhesion, invasion, and intracellular survival of various pathogens. The Dsb system in Neisseria meningitidis, the causative agent of cerebrospinal meningitis, has not, however, been studied. In a previous work where genes specific to N. meningitidis and not present in the other pathogenic Neisseria were isolated, a meningococcus-specific dsbA gene was brought to light (Tinsley, C. R., and Nassif, X. ( 1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11109 - 11114). Inactivation of this gene, however, did not result in deficits in the phenotypes commonly associated with DsbA. A search of available genome data revealed that the meningococcus contains three dsbA genes encoding proteins with different predicted subcellular locations, i.e. a soluble periplasmic enzyme and two membrane-bound lipoproteins. Cell fractionation experiments confirmed the localization in the inner membrane of the latter two, which include the previously identified meningococcus-specific enzyme. Mutational analysis demonstrated that the deletion of any single enzyme was compensated by the action of the remaining two on bacterial growth, whereas the triple mutant was unable to grow at 37 C. Remarkably, however, the combined absence of the two membrane-bound enzymes led to a phenotype of sensitivity to reducing agents and loss of functionality of the pili. Although in many species a single periplasmic DsbA is sufficient for the correct folding of various proteins, in the meningococcus a membrane-associated DsbA is required for a wild type DsbA+ phenotype even in the presence of a functional periplasmic DsbA.	Fac Med Necker Enfants Malad, INSERM, U570, F-75730 Paris 15, France; Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Utrecht University	Nassif, X (corresponding author), Fac Med Necker Enfants Malad, INSERM, U570, 156 Rue Vaugirard, F-75730 Paris 15, France.	nassif@necker.fr	Voulhoux, Rome/AAT-5333-2021; Tommassen, Jan/I-1690-2016	Tommassen, Jan/0000-0001-7633-4945; Nassif, Xavier/0000-0003-2855-3240				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASUBEL FM, 1989, CURRENT PROTOCOLS MO, V2; ASUBEL FM, 1989, CURRENT PROTOCOLS MO, V1; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bouwman CW, 2003, J BACTERIOL, V185, P991, DOI 10.1128/JB.185.3.991-1000.2003; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Donnenberg MS, 1997, GENE, V192, P33, DOI 10.1016/S0378-1119(96)00826-8; Forest KT, 1999, MOL MICROBIOL, V31, P743, DOI 10.1046/j.1365-2958.1999.01184.x; GOODMAN SD, 1991, J BACTERIOL, V173, P5921, DOI 10.1128/jb.173.18.5921-5923.1991; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Gunn JS, 1996, MOL GEN GENET, V251, P509, DOI 10.1007/BF02173639; HECKELS JE, 1989, CLIN MICROBIOL REV, V2, pS66, DOI 10.1128/CMR.2.Suppl.S66-S73.1989; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Jackson MW, 1999, J BACTERIOL, V181, P5126, DOI 10.1128/JB.181.16.5126-5130.1999; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Klee SR, 2000, INFECT IMMUN, V68, P2082, DOI 10.1128/IAI.68.4.2082-2095.2000; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; NASSIF X, 1991, J BACTERIOL, V173, P2147, DOI 10.1128/JB.173.7.2147-2154.1991; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PARGE HE, 1990, J BIOL CHEM, V265, P2278; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Tinsley C, 2001, METH MOLEC MED, V67, P635, DOI 10.1385/1-59259-149-3:635; Tinsley CR, 1996, P NATL ACAD SCI USA, V93, P11109, DOI 10.1073/pnas.93.20.11109; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; WATRAI M, 1995, P NATL ACAD SCI USA, V92, P4927; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, MOL MICROBIOL, V29, P321, DOI 10.1046/j.1365-2958.1998.00935.x; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x	42	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27078	27087		10.1074/jbc.M313404200	http://dx.doi.org/10.1074/jbc.M313404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15105427	Green Published, hybrid			2022-12-27	WOS:000222120400034
J	Alric, J; Tsukatani, Y; Yoshida, M; Matsuura, K; Shimada, K; Hienerwadel, R; Schoepp-Cothenet, B; Nitschke, W; Nagashima, KVP; Vermeglio, A				Alric, J; Tsukatani, Y; Yoshida, M; Matsuura, K; Shimada, K; Hienerwadel, R; Schoepp-Cothenet, B; Nitschke, W; Nagashima, KVP; Vermeglio, A			Structural and functional characterization of the unusual triheme cytochrome bound to the reaction center of Rhodovulum sulfidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; ELECTRON-PARAMAGNETIC-RESONANCE; IRON-SULFUR PROTEIN; BLODGETT MONOLAYER FILMS; REACTION-CENTER COMPLEX; TETRAHEME CYTOCHROME; RHODOPSEUDOMONAS-VIRIDIS; PURPLE BACTERIUM; INTERACTION SITE; SUBUNIT	The cytochrome bound to the photosynthetic reaction center of Rhodovulum sulfidophilum presents two unusual characteristics with respect to the well characterized tetraheme cytochromes. This cytochrome contains only three hemes because it lacks the peptide motif CXXCH, which binds the most distal fourth heme. In addition, we show that the sixth axial ligand of the third heme is a cysteine (Cys-148) instead of the usual methionine ligand. This ligand exchange results in a very low midpoint potential ( - 160 +/- 10 mV). The influence of the unusual cysteine ligand on the midpoint potential of this distal heme was further investigated by site-directed mutagenesis. The midpoint potential of this heme is upshifted to + 310 mV when cysteine 148 is replaced by methionine, in agreement with the typical redox properties of a His/Met coordinated heme. Because of the large increase in the midpoint potential of the distal heme in the mutant, both the native and modified high potential hemes are photooxidized at a redox poise where only the former is photooxidizable in the wild type. The relative orientation of the three hemes, determined by EPR measurements, is shown different from tetraheme cytochromes. The evolutionary basis of the concomitant loss of the fourth heme and the down-conversion of the third heme is discussed in light of phylogenetic relationships of the Rhodovulum species triheme cytochromes to other reaction center-associated tetraheme cytochromes.	CEA Cadarache, DSV DEVM Lab Bioenerget Cellulaire, UMR CNRS CEA CNRS Aix Marseille 2 6191, F-13108 St Paul Les Durance, France; Lab Genet & Biophys Plantes, UMR CNRS CEA CNRS Aix Marseille 2 6191, Marseille, France; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan; Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, CNRS, UPR 9036, F-13402 Marseille 20, France	CEA; CEA; UDICE-French Research Universities; Aix-Marseille Universite; Tokyo Metropolitan University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Vermeglio, A (corresponding author), CEA Cadarache, DSV DEVM Lab Bioenerget Cellulaire, UMR CNRS CEA CNRS Aix Marseille 2 6191, F-13108 St Paul Les Durance, France.	avermeglio@cea.fr	Schoepp-Cothenet, Barbara/AAH-8911-2021; Alric, Jean/E-3538-2013; Nitschke, Wolfgang/C-4812-2012; Nagashima, Kenji V. P./M-2208-2017; Tsukatani, Yusuke/A-6448-2014	Schoepp-Cothenet, Barbara/0000-0002-6820-4478; Alric, Jean/0000-0003-3574-2234; Nagashima, Kenji V. P./0000-0002-4526-6625; Tsukatani, Yusuke/0000-0003-2831-8996; Nitschke, Wolfgang/0000-0003-2084-3032				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; Baymann F, 1998, BIOCHEMISTRY-US, V37, P15320, DOI 10.1021/bi980963z; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; MAILER C, 1972, CAN J BIOCHEM CELL B, V50, P1048, DOI 10.1139/o72-145; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; Masuda S, 2002, BIOCHEMISTRY-US, V41, P11211, DOI 10.1021/bi0258492; McDevitt CA, 2002, MOL MICROBIOL, V44, P1575, DOI 10.1046/j.1365-2958.2002.02978.x; Montoya G, 1999, EUR J BIOCHEM, V259, P709, DOI 10.1046/j.1432-1327.1999.00094.x; NITSCHKE W, 1993, BIOCHEMISTRY-US, V32, P8871, DOI 10.1021/bi00085a019; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; ORTEGA JM, 1993, BIOCHEMISTRY-US, V32, P1141, DOI 10.1021/bi00055a020; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; SCHEIDT WR, 1986, J AM CHEM SOC, V108, P1163, DOI 10.1021/ja00266a008; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TIEDE DM, 1978, BIOCHIM BIOPHYS ACTA, V503, P524, DOI 10.1016/0005-2728(78)90151-2; Tsukatani Y, 2004, PHOTOSYNTH RES, V79, P83, DOI 10.1023/B:PRES.0000011922.56394.92; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Yoshida MT, 2001, BBA-BIOENERGETICS, V1506, P23, DOI 10.1016/S0005-2728(01)00177-3	36	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26090	26097		10.1074/jbc.M400361200	http://dx.doi.org/10.1074/jbc.M400361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069076	hybrid			2022-12-27	WOS:000222003000022
J	Carter, WJ; Myles, T; Gibbs, CS; Leung, LL; Huntington, JA				Carter, WJ; Myles, T; Gibbs, CS; Leung, LL; Huntington, JA			Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ BINDING-SITE; POTENT ANTICOAGULANT; ACTIVE-SITE; SLOW; PROCOAGULANT; SPECIFICITY; ACTIVATION; MECHANISMS	Thrombin is the ultimate protease of the blood clotting cascade and plays a major role in its own regulation. The ability of thrombin to exhibit both pro- and anti-coagulant properties has spawned efforts to turn thrombin into an anticoagulant for therapeutic purposes. This quest culminated in the identification of the E217K variant through scanning and saturation mutagenesis. The antithrombotic properties of E217K thrombin are derived from its inability to convert fibrinogen to a fibrin clot while maintaining its thrombo-modul-independent ability to activate the anticoagulant protein C pathway. Here we describe the 2.5-Angstrom crystal structure of human E217K thrombin, which displays a dramatic restructuring of the geometry of the active site. Of particular interest is the repositioning of Glu-192, which hydrogen bonds to the catalytic Ser-195 and which results in the complete occlusion of the active site and the destruction of the oxyanion hole. Substrate binding pockets are further blocked by residues previously implicated in thrombin allostery. We have concluded that the E217K mutation causes the allosteric inactivation of thrombin by destabilizing the Na+ binding site and that the structure thus may represent the Na+-free, catalytically inert "slow" form.	Univ Cambridge, Dept Haematol, Div Struct Med, Thrombosis Res Unit,Cambridge Inst Med Res, Cambridge CB2 2XY, England; Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA; Gilead Sci Inc, Foster City, CA 94404 USA	University of Cambridge; Stanford University; Gilead Sciences	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Div Struct Med, Thrombosis Res Unit,Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL68629, R01 HL57530] Funding Source: Medline; MRC [G117/444] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530, R01HL068629] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Edwards PD, 2000, BIOORG MED CHEM LETT, V10, P2291, DOI 10.1016/S0960-894X(00)00460-1; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; GUILLIN MC, 1995, THROMB HAEMOSTASIS, V74, P129; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; Hall SW, 1997, CELL MOL LIFE SCI, V53, P731, DOI 10.1007/s000180050092; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2003, TRENDS PHARMACOL SCI, V24, P589, DOI 10.1016/j.tips.2003.09.002; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PARRY MAA, 1993, BIOCHEM J, V290, P665, DOI 10.1042/bj2900665; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	37	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26387	26394		10.1074/jbc.M402364200	http://dx.doi.org/10.1074/jbc.M402364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075325	hybrid			2022-12-27	WOS:000222003000059
J	Geddie, ML; Matsumura, I				Geddie, ML; Matsumura, I			Rapid evolution of beta-glucuronidase specificity by saturation mutagenesis of an active site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PCR-MEDIATED RECOMBINATION; IN-VITRO RECOMBINATION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; THERMOANAEROBACTERIUM-SACCHAROLYTICUM; GLYCOSIDE HYDROLASES; MOLECULAR EVOLUTION; METABOLIC PATHWAYS; INVERSE PCR; AMPLIFICATION	Protein engineers have widely adopted directed evolution as a design algorithm, but practitioners have not come to a consensus about the best method to evolve protein molecular recognition. We previously used DNA shuffling to direct the evolution of Escherichia coli beta-glucuronidase (GUS) variants with increased beta-galactosidase activity. Epistatic ( synergistic) mutations in amino acids 557, 566, and 568, which are part of an active site loop, were identified in that experiment (Matsumura, I., and Ellington, A. D. (2001) J. Mol. Biol. 305, 331-339). Here we show that site saturation mutagenesis of these residues, overexpression of the resulting library in E. coli, and high throughput screening led to the rapid evolution of clones exhibiting increased activity in reactions with p-nitrophenyl-beta-D-xylopyranoside (pNP-xyl). The xylosidase activities of the 14 fittest clones were 30-fold higher on average than that of the wild-type GUS. The 14 corresponding plasmids were pooled, amplified by long PCR, self-ligated with T4 DNA ligase, and transformed into E. coli. Thirteen clones exhibiting an average of 80-fold improvement in xylosidase activity were isolated in a second round of screening. One of the evolved proteins exhibited a similar to200-fold improvement over the wild type in reactivity (k(cat)/K-m) with pNP-xyl, with a 290,000-fold inversion of specificity. Sequence analysis of the 13 round 2 isolates suggested that all were products of intermolecular recombination events that occurred during whole plasmid PCR. Further rounds of evolution using DNA shuffling and staggered extension process (StEP) resulted in modest improvement. These results underscore the importance of epistatic interactions and demonstrate that they can be optimized through variations of the facile whole plasmid PCR technique.	Emory Univ, Sch Med, Rollins Res Ctr, Ctr Fundamental & Mol Evolut,Dept Biochem, Atlanta, GA 30322 USA	Emory University	Matsumura, I (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Ctr Fundamental & Mol Evolut,Dept Biochem, 1510 Clifton Rd,Rm 4119, Atlanta, GA 30322 USA.	imatsum@emory.edu	Matsumura, Ichiro/E-1985-2011					Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Coco WM, 2002, NAT BIOTECHNOL, V20, P1246, DOI 10.1038/nbt757; DeSantis G, 2003, J AM CHEM SOC, V125, P11476, DOI 10.1021/ja035742h; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Eisinger DP, 1997, BIOTECHNIQUES, V22, P250, DOI 10.2144/97222bm11; ElHawrani AS, 1996, J MOL BIOL, V264, P97, DOI 10.1006/jmbi.1996.0626; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; Geddie ML, 2004, METHOD ENZYMOL, V388, P134; GRAHAM LD, 1993, BIOCHEMISTRY-US, V32, P6250, DOI 10.1021/bi00075a019; Harris JL, 1998, CURR OPIN CHEM BIOL, V2, P127, DOI 10.1016/S1367-5931(98)80044-6; Hayes RJ, 2002, P NATL ACAD SCI USA, V99, P15926, DOI 10.1073/pnas.212627499; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, P NATL ACAD SCI USA, V93, P5674; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Judo MSB, 1998, NUCLEIC ACIDS RES, V26, P1819, DOI 10.1093/nar/26.7.1819; Juers DH, 2001, BIOCHEMISTRY-US, V40, P14781, DOI 10.1021/bi011727i; KACSER H, 1984, J MOL EVOL, V20, P38, DOI 10.1007/BF02101984; Lazcano A, 1995, Adv Space Res, V15, P345, DOI 10.1016/S0273-1177(99)80106-9; Lingen B, 2002, PROTEIN ENG, V15, P585, DOI 10.1093/protein/15.7.585; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Matsumura I, 1999, NAT BIOTECHNOL, V17, P696, DOI 10.1038/10910; MATSUMURA I, 2001, IN VITRO MUTAGENESIS, V182, P259; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Ness JE, 2002, NAT BIOTECHNOL, V20, P1251, DOI 10.1038/nbt754; Northrop DB, 1998, J CHEM EDUC, V75, P1153, DOI 10.1021/ed075p1153; Parikh A, 1998, BIOTECHNIQUES, V24, P428, DOI 10.2144/98243st01; Powell KA, 2001, ANGEW CHEM INT EDIT, V40, P3948, DOI 10.1002/1521-3773(20011105)40:21<3948::AID-ANIE3948>3.0.CO;2-N; Rowe LA, 2003, J MOL BIOL, V332, P851, DOI 10.1016/S0022-2836(03)00972-0; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Shafikhani S, 2002, ENVIRON MICROBIOL, V4, P482, DOI 10.1046/j.1462-2920.2002.00326.x; Sio CF, 2002, EUR J BIOCHEM, V269, P4495, DOI 10.1046/j.1432-1033.2002.03143.x; STEMMER WPC, 1993, GENE, V123, P1, DOI 10.1016/0378-1119(93)90531-7; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEWART ACM, 1995, GENOME RES, V5, P79, DOI 10.1101/gr.5.1.79; Temesgen B, 1996, BIOTECHNIQUES, V21, P828; THOMAS MR, 1994, BIOTECHNIQUES, V16, P988; Vocadlo DJ, 2002, BIOCHEMISTRY-US, V41, P9727, DOI 10.1021/bi020077v; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; WALEY SG, 1969, COMP BIOCHEM PHYSIOL, V30, P1, DOI 10.1016/0010-406X(69)91293-6; Whitehead TR, 1997, CURR MICROBIOL, V35, P282, DOI 10.1007/s002849900255; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Yang JK, 2004, J MOL BIOL, V335, P155, DOI 10.1016/j.jmb.2003.10.026; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; Zhao HM, 2002, CURR OPIN BIOTECH, V13, P104, DOI 10.1016/S0958-1669(02)00291-4; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	49	57	67	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26462	26468		10.1074/jbc.M401447200	http://dx.doi.org/10.1074/jbc.M401447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069062	hybrid			2022-12-27	WOS:000222003000068
J	Nittis, T; Gitlin, JD				Nittis, T; Gitlin, JD			Role of copper in the proteosome-mediated degradation of the multicopper oxidase hephaestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; HUMAN CERULOPLASMIN; IRON-DEFICIENCY; DISEASE PROTEIN; EXPRESSION; YEAST; MECHANISMS; PATHWAY; ACERULOPLASMINEMIA	To elucidate the mechanisms of cuproprotein biosynthesis in the secretory pathway, a polyclonal antiserum was generated against hephaestin, a multicopper oxidase essential for enteric iron absorption. Immunoblot analysis and pulse-chase metabolic labeling revealed that hephaestin is synthesized as a single-chain polypeptide modified by N-linked glycosylation to a mature 161-kDa species. Cell surface biotinylation and immunofluorescent studies of polarized, differentiated colon carcinoma cells detected hephaestin on the basolateral surface under steady-state conditions. However, a decrease in the intracellular copper concentration resulted in a marked diminution in the abundance of this protein. Metabolic studies revealed no effect of decreased intracellular copper on the rate of hephaestin synthesis but a dramatic, specific, and reproducible increase in the turnover of the mature 161-kDa protein. Surprisingly, inhibitor studies revealed that this turnover occurs exclusively in the proteasome, and consistent with this finding, in vitro studies identified polyubiquitinated hephaestin under conditions abrogating copper incorporation into this protein. Taken together, these studies demonstrate the presence of a quality control system for posttranslational protein modification occurring beyond the endoplasmic reticulum that, in the case of hephaestin, directly links the rate of enteric iron uptake to nutritional copper status.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061763] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07873] Funding Source: Medline; NIDDK NIH HHS [DK61763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347; Culotta VC, 2001, MOL METABOLIC BASIS, VII, P3105, DOI DOI 10.1036/OMMBID.155; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Frazer DM, 2001, AM J PHYSIOL-GASTR L, V281, pG931, DOI 10.1152/ajpgi.2001.281.4.G931; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Lencer WI, 2003, TRENDS BIOCHEM SCI, V28, P639, DOI 10.1016/j.tibs.2003.10.002; Li LT, 2003, BIOCHEM J, V375, P793, DOI 10.1042/BJ20030866; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Nittis T, 2002, SEMIN HEMATOL, V39, P282, DOI 10.1053/shem.2002.35633; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; SATO M, 1991, J BIOL CHEM, V266, P5128; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; Syed BA, 2002, PROTEIN ENG, V15, P205, DOI 10.1093/protein/15.3.205; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Zoller H, 2003, GASTROENTEROLOGY, V125, P746, DOI 10.1016/S0016-5085(03)01063-1	37	57	57	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25696	25702		10.1074/jbc.M401151200	http://dx.doi.org/10.1074/jbc.M401151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087449	hybrid			2022-12-27	WOS:000221827900099
J	Penzo, D; Petronilli, V; Angelin, A; Cusan, C; Colonna, R; Scorrano, L; Pagano, F; Prato, M; Di Lisa, F; Bernardi, P				Penzo, D; Petronilli, V; Angelin, A; Cusan, C; Colonna, R; Scorrano, L; Pagano, F; Prato, M; Di Lisa, F; Bernardi, P			Arachidonic acid released by phospholipase A(2) activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PERMEABILITY TRANSITION PORE; CELL-DEATH; FACTOR-ALPHA; ARISTOLOCHIC ACID; GD3 GANGLIOSIDE; CYTOCHROME-C; CALCIUM IONOPHORE; HUMAN-NEUTROPHILS; CORTICAL-NEURONS	We studied the effects of the divalent cation ionophore A23187 on apoptotic signaling in MH1C1 cells. Addition of A23187 caused a fast rise of cytosolic Ca2+ ([Ca2+](c)), which returned close to the resting level within about 40 s. The [Ca2+](c) rise was immediately followed by phospholipid hydrolysis, which could be inhibited by aristolochic acid or by pretreatment with thapsigargin in Ca2+-free medium, indicating that the Ca2+-dependent cytosolic phospholipase A(2) (cPLA(2)) was involved. These early events were followed by opening of the mitochondrial permeability transition pore (PTP) and by apoptosis in about 30% of the cell population. In keeping with a cause-effect relationship between addition of A23187, activation of cPLA2, PTP opening, and cell death, all events but the [Ca2+](c) rise were prevented by aristolochic acid. The number of cells killed by A23187 was doubled by treatment with 0.5 muM MK886 and 5 muM indomethacin, which inhibit arachidonic acid metabolism through the 5-lipoxygenase and cyclooxygenase pathway, respectively. Consistent with the key role of free arachidonic acid, its levels increased within minutes of treatment with A23187; the increase being more pronounced in the presence of MK886 plus indomethacin. Cell death was preceded by cytochrome c release and cleavage of caspase 9 and 3, but not of caspase 8. All these events were prevented by aristolochic acid and by the PTP inhibitor cyclosporin A. Thus, A23187 triggers the apoptotic cascade through the release of arachidonic acid by cPLA2 in a process that is amplified when transformation of arachidonic acid into prostaglandins and leukotrienes is inhibited. These findings identify arachidonic acid as the causal link between A23187-dependent perturbation of Ca2+ homeostasis and the effector mechanisms of cell death.	Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biol Chem, I-35121 Padua, Italy; Univ Trieste, Dept Pharmaceut Sci, I-34127 Trieste, Italy; Venetian Inst Mol Med, Dulbecco Telethon Inst, I-35129 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Trieste; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine	Bernardi, P (corresponding author), Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015; Scorrano, Luca/K-3967-2019; Prato, Maurizio/G-7067-2012; Scorrano, Luca/A-6652-2008	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Prato, Maurizio/0000-0002-8869-8612; Scorrano, Luca/0000-0002-8515-8928; Di Lisa, Fabio/0000-0001-9757-8818	Telethon [TCP02016] Funding Source: Medline	Telethon(Fondazione Telethon)		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; BABCOCK DF, 1976, J BIOL CHEM, V251, P3881; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chandra V, 2002, BIOCHEMISTRY-US, V41, P10914, DOI 10.1021/bi0258593; DE MR, 1997, SCIENCE, V277, P1652; DORDICK RS, 1980, J BIOL CHEM, V255, P299; Fleckenstein A, 1974, Recent Adv Stud Cardiac Struct Metab, V4, P563; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Grewal S, 2003, J CELL SCI, V116, P2303, DOI 10.1242/jcs.00446; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LUKAS W, 1994, NEUROSCIENCE, V61, P307, DOI 10.1016/0306-4522(94)90233-X; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Penzo D, 2002, BBA-BIOENERGETICS, V1555, P160, DOI 10.1016/S0005-2728(02)00272-4; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; PFEIFFER DR, 1976, BIOCHEMISTRY-US, V15, P935, DOI 10.1021/bi00650a001; PICKETT WC, 1976, BIOCHIM BIOPHYS ACTA, V486, P209; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; REED PW, 1972, J BIOL CHEM, V247, P6970; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHEN AC, 1972, AM J PATHOL, V67, P417; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317	52	138	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25219	25225		10.1074/jbc.M310381200	http://dx.doi.org/10.1074/jbc.M310381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070903	hybrid			2022-12-27	WOS:000221827900039
J	Standaert, ML; Sajan, MP; Miura, A; Kanoh, Y; Chen, HC; Farese, RV; Farese, RV				Standaert, ML; Sajan, MP; Miura, A; Kanoh, Y; Chen, HC; Farese, RV; Farese, RV			Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver - Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; TRANSCRIPTION FACTOR FKHR; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; PROMOTER ACTIVITY; SKELETAL-MUSCLE; POTENTIAL ROLE; KAKIZAKI RATS	Insulin resistance in type 2 diabetes is characterized by defects in muscle glucose uptake and hepatic overproduction of both glucose and lipids. These hepatic defects are perplexing because insulin normally suppresses glucose production and increases lipid synthesis in the liver. To understand the mechanisms for these seemingly paradoxical defects, we examined the activation of atypical protein kinase C (aPKC) and protein kinase B (PKB), two key signaling factors that operate downstream of phosphatidylinositol 3-kinase and regulate various insulin-sensitive metabolic processes. Livers and muscles of three insulin-resistant rodent models were studied. In livers of type 2 diabetic non-obese Goto-Kakazaki rats and ob/ob-diabetic mice, the activation of PKB was impaired, whereas activation of aPKC was surprisingly maintained. In livers of non-diabetic high fat-fed mice, the activation of both aPKC and PKB was maintained. In contrast to the maintenance of aPKC activation in the liver, insulin activation of aPKC was impaired in muscles of Goto-Kakazaki-diabetic rats and ob/ob-diabetic and non-diabetic high fat-fed mice. These findings suggest that, at least in these rodent models, (a) defects in aPKC activation contribute importantly to skeletal muscle insulin resistance observed in both high fat feeding and type 2 diabetes; (b) insulin signaling defects in muscle are not necessarily accompanied by similar defects in liver; (c) defects in hepatic PKB activation occur in association with, and probably contribute importantly to, the development of overt diabetes; and (d) maintenance of hepatic aPKC activation may explain the continued effectiveness of insulin for stimulating certain metabolic actions in the liver.	James A Haley Vet Adm Med Ctr, Res Serv, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Farese, RV (corresponding author), James A Haley Vet Hosp, ACOS 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@hsc.usf.edu	Farese, Robert/B-3605-2015	Chen, Hubert/0000-0002-7599-7218	NIDDK NIH HHS [R01 DK056084, R01 DK065969, 2R01-DK-38079, K08-DK-61363, R01-DK-56804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R01DK056804, K08DK061363, R01DK065969, R01DK038079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beeson M, 2003, DIABETES, V52, P1926, DOI 10.2337/diabetes.52.8.1926; Begum N, 1998, METABOLISM, V47, P54, DOI 10.1016/S0026-0495(98)90193-7; Bergman RN, 2000, DIABETOLOGIA, V43, P946, DOI 10.1007/s001250051474; BISBIS S, 1993, AM J PHYSIOL, V265, P807; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; FARESE RV, 1994, P NATL ACAD SCI USA, V91, P11040, DOI 10.1073/pnas.91.23.11040; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kanoh Y, 2000, J BIOL CHEM, V275, P16690, DOI 10.1074/jbc.M000287200; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; KROOK A, 1997, DIABETES, V46, P211; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Peak M, 1998, DIABETOLOGIA, V41, P16, DOI 10.1007/s001250050861; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Standaert ML, 2002, DIABETES, V51, P2936, DOI 10.2337/diabetes.51.10.2936; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Valverde AM, 2003, DIABETES, V52, P2239, DOI 10.2337/diabetes.52.9.2239; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Wang QH, 1999, MOL CELL BIOL, V19, P4008; YAMOUCHI T, 1996, MOL CELL BIOL, V16, P3074	35	72	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24929	24934		10.1074/jbc.M402440200	http://dx.doi.org/10.1074/jbc.M402440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069067	hybrid			2022-12-27	WOS:000221827900006
J	Devroe, E; Erdjument-Bromage, H; Tempst, P; Silver, PA				Devroe, E; Erdjument-Bromage, H; Tempst, P; Silver, PA			Human mob proteins regulate the NDR1 and NDR2 serine-threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRANSCRIPTION FACTOR; PHOSPHORYLATION; LOCALIZATION; CYTOKINESIS; INTERACTS; INTEGRASE; COMPLEXES; YEAST	Human NDR1 (nuclear Dbf2-related) is a widely expressed nuclear serine-threonine kinase that has been implicated in cell proliferation and/or tumor progression. Here we present molecular characterization of the human NDR2 serine-threonine kinase, which shares similar to87% sequence identity with NDR1. NDR2 is expressed in most human tissues with the highest expression in the thymus. In contrast to NDR1, NDR2 is excluded from the nucleus and exhibits a punctate cytoplasmic distribution. The differential localization of NDR1 and NDR2 suggests that each kinase may serve distinct functions. Thus, to identify proteins that interact with NDR1 or NDR2, epitope-tagged kinases were immunoprecipitated from Jurkat T-cells. Two uncharacterized proteins that are homologous to the Saccharomyces cerevisiae kinase regulators Mob1 and Mob2 were identified. We demonstrate that NDR1 and NDR2 partially colocalize with human Mob2 in HeLa cells and confirm the NDR-Mob interactions in cell extracts. Interestingly, NDR1 and NDR2 form stable complexes with Mob2, and this association dramatically stimulates NDR1 and NDR2 catalytic activity. In summary, this work identifies a unique class of human kinase-activating subunits that may be functionally analagous to cyclins.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Cell Biol, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Silver, PA (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	pamela_silver@dfci.harvard.edu		Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hauschild A, 1999, ONCOLOGY-BASEL, V56, P338, DOI 10.1159/000011989; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0	23	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24444	24451		10.1074/jbc.M401999200	http://dx.doi.org/10.1074/jbc.M401999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067004	hybrid			2022-12-27	WOS:000221702500071
J	Schneider, R; Bannister, AJ; Weise, C; Kouzarides, T				Schneider, R; Bannister, AJ; Weise, C; Kouzarides, T			Direct binding of INHAT to H3 tails disrupted by modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; PROTEIN SET; LYSINE 9; TRANSCRIPTION; METHYLATION; NUCLEOSOME; ACETYLATION; INHIBITOR	The N-terminal tails of histones are central to the regulation of chromatin structure. They form a binding platform for multiple protein complexes, which in turn regulate DNA processes such as transcription. Using peptide mass fingerprinting we identified INHAT ( inhibitor of acetyltransferases) as a specific histone H3 N-terminal tail-binding complex. INHAT comprises two essential subunits, SET and pp32. We demonstrate that both SET and pp32 bind directly to the N terminus of H3. The binding is differentially affected by various modifications within the H3 N terminus. In particular, single phosphorylations within the H3 tail abrogates binding of INHAT, as does the simultaneous acetylation of multiple lysine residues. The histone modifications that affect INHAT binding are therefore compatible with its known role in transcriptional repression. We suggest that the charge of the histone tail is a major determinant in allowing INHAT to bind chromatin and coordinate the activity of multiple histone acetyltransferases.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	University of Cambridge; University of Cambridge; Free University of Berlin	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk106@mole.bio.cam.ac.uk		Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	24	67	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23859	23862		10.1074/jbc.C400151200	http://dx.doi.org/10.1074/jbc.C400151200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15100215	hybrid			2022-12-27	WOS:000221702500004
J	Bai, R; Covell, DG; Taylor, GF; Kepler, JA; Copeland, TD; Nguyen, NY; Pettit, GR; Hamel, E				Bai, R; Covell, DG; Taylor, GF; Kepler, JA; Copeland, TD; Nguyen, NY; Pettit, GR; Hamel, E			Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; ANTINEOPLASTIC AGENTS; VINCA DOMAIN; ACID-SEQUENCE; ALPHA-TUBULIN; CROSS-LINKING; IDENTIFICATION; MAYTANSINE; NUCLEOTIDE; INHIBITOR	Tubulin with bound [5-H-3] dolastatin 10 was exposed to ultraviolet light, and 8-10% of the bound drug crosslinked to the protein, most of it specifically. The primary cross-link was to the peptide spanning amino acid residues 2-31 of beta-tubulin, but the specific amino acid could not be identified. Indirect studies indicated that cross-link formation occurred between cysteine 12 and the thiazole moiety of dolastatin 10. An equipotent analog of dolastatin 10, lacking the thiazole ring, did not form an ultraviolet light-induced cross-link to beta-tubulin. Preillumination of tubulin with ultraviolet light, known to induce cross-link formation between cysteine 12 and exchangeable site nucleotide, inhibited the binding of [5-H-3] dolastatin 10 and cross-link formation more potently than it inhibited the binding of colchicine or vinblastine to tubulin. Conversely, binding of dolastatin 10 to tubulin inhibited formation of the cross-link between cysteine 12 and the exchangeable site nucleotide. Dithiothreitol inhibited formation of the beta-tubulin/dolastatin 10 cross-link but not the beta-tubulin/exchangeable site nucleotide cross-link. Modeling studies revealed a highly favored binding site for dolastatin 10 at the + end of beta-tubulin in proximity to the exchangeable site GDP. Computational docking of an energy-minimized dolastatin 10 conformation at this site placed the thiazole ring of dolastatin 10 8-9 Angstrom from the sulfur atom of cysteine 12. Dolastatin 15 and cryptophycin 1 could also be docked into positions that overlapped more extensively with the docked dolastatin 10 than with each other. This result was consistent with the observed binding properties of these peptides.	NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21702 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA; US FDA, Facil Biotechnol Resources, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Canc Res Inst, Tempe, AZ 85287 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Hamel, E (corresponding author), NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Bldg 469,Rm 104,POB B, Frederick, MD 21702 USA.	hamele@mail.nih.gov						BAI R, 1993, BIOCHEM PHARMACOL, V45, P1503, DOI 10.1016/0006-2952(93)90051-W; BAI R, 1990, BIOCHEM PHARMACOL, V40, P1859, DOI 10.1016/0006-2952(90)90367-T; BAI R, 1991, J BIOL CHEM, V266, P15882; BAI R, 1990, J BIOL CHEM, V265, P17141; Bai RL, 1999, BIOCHEMISTRY-US, V38, P14302, DOI 10.1021/bi991323e; Bai RL, 1999, J BIOL CHEM, V274, P12710, DOI 10.1074/jbc.274.18.12710; Bai RL, 1998, J BIOL CHEM, V273, P9894, DOI 10.1074/jbc.273.16.9894; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BAI RL, 1995, MOL PHARMACOL, V47, P965; Bai RL, 2000, J BIOL CHEM, V275, P40443, DOI 10.1074/jbc.M005299200; Bai RL, 1996, CANCER RES, V56, P4398; BAI RL, 1995, BIOCHEMISTRY-US, V34, P9714, DOI 10.1021/bi00030a009; Barbier P, 2001, BIOCHEMISTRY-US, V40, P13510, DOI 10.1021/bi010926z; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; COVELL DG, 1994, PROTEIN SCI, V3, P2064, DOI 10.1002/pro.5560031119; Cruz-Monserrate Z, 2003, EUR J BIOCHEM, V270, P3822, DOI 10.1046/j.1432-1033.2003.03776.x; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; Gamble WR, 1999, BIOORGAN MED CHEM, V7, P1611, DOI 10.1016/S0968-0896(99)00089-9; GROVER S, 1994, EUR J BIOCHEM, V222, P163, DOI 10.1111/j.1432-1033.1994.tb18854.x; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HUANG AB, 1985, BIOCHEM BIOPH RES CO, V128, P1239, DOI 10.1016/0006-291X(85)91073-3; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landon, 1977, Methods Enzymol, V47, P145; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MANDELBAUMSHAVIT F, 1976, BIOCHEM BIOPH RES CO, V72, P47, DOI 10.1016/0006-291X(76)90958-X; MIYAZAKI K, 1995, CHEM PHARM BULL, V43, P1706; Miyazawa S, 1999, PROTEINS, V36, P357, DOI 10.1002/(SICI)1097-0134(19990815)36:3<357::AID-PROT10>3.3.CO;2-L; NASIOULAS G, 1990, EUR J BIOCHEM, V192, P69, DOI 10.1111/j.1432-1033.1990.tb19196.x; Natsume T, 2000, JPN J CANCER RES, V91, P737, DOI 10.1111/j.1349-7006.2000.tb01007.x; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Panda D, 2000, BIOCHEMISTRY-US, V39, P14121, DOI 10.1021/bi0010827; Pettit GR, 1995, ANTI-CANCER DRUG DES, V10, P529; PETTIT GR, 1989, J AM CHEM SOC, V111, P5463, DOI 10.1021/ja00196a061; Pettit GR, 1998, ANTI-CANCER DRUG DES, V13, P243; PETTIT GR, 1990, J MED CHEM, V33, P3132, DOI 10.1021/jm00174a006; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; Rai SS, 1996, J BIOL CHEM, V271, P14707, DOI 10.1074/jbc.271.25.14707; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROACH MC, 1984, J BIOL CHEM, V259, P2063; SAFA AR, 1987, BIOCHEMISTRY-US, V26, P97, DOI 10.1021/bi00375a014; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SAWADA T, 1993, BIOCONJUGATE CHEM, V4, P284, DOI 10.1021/bc00022a006; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; WALLQVIST A, 1995, PROTEIN SCI, V4, P1881, DOI 10.1002/pro.5560040923; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; YOUNG L, 1994, PROTEIN SCI, V3, P717	54	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30731	30740		10.1074/jbc.M402110200	http://dx.doi.org/10.1074/jbc.M402110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123603	hybrid			2022-12-27	WOS:000222531900104
J	Boutahar, N; Guignandon, A; Vico, L; Lafage-Proust, MH				Boutahar, N; Guignandon, A; Vico, L; Lafage-Proust, MH			Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SMOOTH-MUSCLE-CELLS; SRC FAMILY KINASES; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GROWTH-FACTOR; SHEAR-STRESS; FLUID-FLOW; MC3T3-E1 OSTEOBLASTS	The mechanisms involved in the mechanical loading-induced increase in bone formation remain unclear. In this study, we showed that cyclic strain (CS) (10 min, 1% stretch at 0.25 Hz) stimulated the proliferation of overnight serum-starved ROS 17/2.8 osteoblast-like cells plated on type I collagen-coated silicone membranes. This increase was blocked by MEK inhibitor PD-98059. Signaling events were then assessed 0 min, 30 min, and 4 h after one CS period with Western blotting and co-immunoprecipitation. CS rapidly and time-dependently promoted phosphorylation of both ERK2 at Tyr-187 and focal adhesion kinase (FAK) at Tyr-397 and Tyr-925, leading to the activation of the Ras/Raf/MEK pathway. Cell transfection with FAK mutated at Tyr-397 completely blocked ERK2 Tyr-187 phosphorylation. Quantitative immunofluorescence analysis of phosphotyrosine residues showed an increase in focal adhesion plaque number and size in strained cells. CS also induced both Src-Tyr-418 phosphorylation and Src to FAK association. Treatment with the selective Src family kinase inhibitor pyrazolopyrimidine 2 did not prevent CS-induced FAK-Tyr-397 phosphorylation suggesting a Src-independent activation of FAK. CS also activated proline-rich tyrosine kinase 2 (PYK2), a tyrosine kinase highly homologous to FAK, at the 402 phosphorylation site and promoted its association to FAK in a time-dependent manner. Mutation of PYK2 at the Tyr-402 site prevented the ERK2 phosphorylation only at 4 h. Intra and extracellular calcium chelators prevented PYK2 activation only at 4 h. In summary, our data showed that osteoblast response to mitogenic CS was mediated by MEK pathway activation. The latter was induced by ERK2 phosphorylation under the control of FAK and PYK2 phosphorylation orchestrated in a time-dependent manner.	INSERM, E366, Lab Biol Tissu Osseux, F-42023 St Etienne 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lafage-Proust, MH (corresponding author), INSERM, E366, Lab Biol Tissu Osseux, 15 Rue Ambroise Pare, F-42023 St Etienne 02, France.	lafagemh@univ-st-etienne.fr	Boutahar, Nadia/O-5196-2017; Vico, Laurence/ABG-7239-2020; Vico, Laurence/O-1927-2018	Boutahar, Nadia/0000-0003-2630-5366; Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; Lafage-Proust, Marie-Helene/0000-0002-2091-3961; GUIGNANDON, Alain/0000-0002-0745-5417				Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; Alahari SK, 2002, INT REV CYTOL, V220, P145; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; BANES AJ, 1995, CYTOMECHANICS BIOCH, V73, P349; Barani AE, 2003, EXP CELL RES, V283, P196, DOI 10.1016/S0014-4827(02)00030-7; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756-3282(01)00678-0; BENES AJ, 1985, J CELL SCI, V75, P35; BOURRIN S, 1995, J BONE MINER RES, V10, P820; Boutonnat J, 1998, ANTICANCER RES, V18, P4243; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Freitas F, 2002, BONE, V30, P99, DOI 10.1016/S8756-3282(01)00625-1; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Guignandon A, 2003, CELL COMMUN ADHES, V10, P69, DOI 10.1080/cac.10.2.69.83; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; HUNG CT, 1995, CLIN ORTHOP RELAT R, P256; IKEDA M, 1999, AM J PHYSIOL, V276, P14; Ingram AJ, 2000, J BIOL CHEM, V275, P40301, DOI 10.1074/jbc.M007018200; Ingram AJ, 1999, KIDNEY INT, V56, P1721, DOI 10.1046/j.1523-1755.1999.00743.x; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Iwasaki H, 2003, ENDOCRINOLOGY, V144, P2304, DOI 10.1210/en.2002-220939; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; KASSEM M, 1993, J BONE MINER RES, V8, P1453; Kawakami K, 2001, J CELL SCI, V114, P3125; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Matsuda K, 1998, BIOPHARM DRUG DISPOS, V19, P465, DOI 10.1002/(SICI)1099-081X(199810)19:7<465::AID-BDD126>3.0.CO;2-E; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Milgrom C, 2000, J BONE JOINT SURG BR, V82B, P591, DOI 10.1302/0301-620X.82B4.9677; Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335; Numaguchi K, 1999, CIRC RES, V85, P5; Ogata T, 2000, J CELL BIOCHEM, V76, P529, DOI 10.1002/(SICI)1097-4644(20000315)76:4<529::AID-JCB1>3.3.CO;2-X; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Oxlund H, 1998, ENDOCRINOLOGY, V139, P1899, DOI 10.1210/en.139.4.1899; Peake MA, 2000, J APPL PHYSIOL, V89, P2498, DOI 10.1152/jappl.2000.89.6.2498; Pommerenke H, 2002, J BONE MINER RES, V17, P603, DOI 10.1359/jbmr.2002.17.4.603; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Usson Y, 1997, CYTOMETRY, V28, P298, DOI 10.1002/(SICI)1097-0320(19970801)28:4<298::AID-CYTO4>3.0.CO;2-8; Valk P, 2000, Hematol J, V1, P254, DOI 10.1038/sj.thj.6200036; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAMOTO H, 1995, MOKUZAI GAKKAISHI, V41, P1; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang JH, 2003, FASEB J, V17, P926, DOI 10.1096/fj.02-0663fje; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	82	145	155	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30588	30599		10.1074/jbc.M313244200	http://dx.doi.org/10.1074/jbc.M313244200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15096502	Green Submitted, hybrid			2022-12-27	WOS:000222531900089
J	Hoflich, J; Berninsone, P; Gobel, C; Gravato-Nobre, MJ; Libby, BJ; Darby, C; Politz, SM; Hodgkin, J; Hirschberg, CB; Baumeister, R				Hoflich, J; Berninsone, P; Gobel, C; Gravato-Nobre, MJ; Libby, BJ; Darby, C; Politz, SM; Hodgkin, J; Hirschberg, CB; Baumeister, R			Loss of srf-3-encoded nucleotide sugar transporter activity in Caenorhabditis elegans alters surface antigenicity and prevents bacterial adherence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; ADHESION DEFICIENCY-II; UDP-GLUCURONIC ACID; GOLGI-APPARATUS; C-ELEGANS; INNATE IMMUNITY; ENDOPLASMIC-RETICULUM; KLUYVEROMYCES-LACTIS; BIOCHEMICAL-ANALYSIS; PARASITIC NEMATODES	During the establishment of a bacterial infection, the surface molecules of the host organism are of particular importance, since they mediate the first contact with the pathogen. In Caenorhabditis elegans, mutations in the srf-3 locus confer resistance to infection by Microbacterium nematophilum, and they also prevent biofilm formation by Yersinia pseudotuberculosis, a close relative of the bubonic plague agent Yersinia pestis. We cloned srf-3 and found that it encodes a multitransmembrane hydrophobic protein resembling nucleotide sugar transporters of the Golgi apparatus membrane. srf-3 is exclusively expressed in secretory cells, consistent with its proposed function in cuticle/surface modification. We demonstrate that SRF-3 can function as a nucleotide sugar transporter in heterologous in vitro and in vivo systems. UDP-galactose and UDP-N-acetylglucosamine are substrates for SRF-3. We propose that the inability of Yersinia biofilms and M. nematophilum to adhere to the nematode cuticle is due to an altered glycoconjugate surface composition of the srf-3 mutant.	Univ Munich, ABI Mol Neuogenet, D-80336 Munich, Germany; Inst Biol 3, D-79104 Freiburg, Germany; Boston Univ, Dept Mol & Cell Biol, Sch Dent Med, Boston, MA 02118 USA; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Worcester Polytech Inst, Dept Biol & Biotechnol, Worcester, MA 01609 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Munich; Boston University; University of Oxford; Worcester Polytechnic Institute; University of Alabama System; University of Alabama Birmingham	Baumeister, R (corresponding author), Bio Bioinformat & Mol Genet 3, Schaenzlestr 1, D-79104 Freiburg, Germany.	baumeister@celegans.de		Hirschberg, Carlos/0000-0003-2299-7721; Gravato-Nobre, Maria Joao/0000-0002-8032-2565	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI 37768] Funding Source: Medline; NIGMS NIH HHS [R01 GM 30365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; Alegado RA, 2003, CELL MICROBIOL, V5, P435, DOI 10.1046/j.1462-5822.2003.00287.x; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BLAXTER ML, 1993, J BIOL CHEM, V268, P6600; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; CLARK DV, 1988, GENETICS, V119, P345; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Darby C, 2002, NATURE, V417, P243, DOI 10.1038/417243a; de Gives PM, 1999, PARASITOLOGY, V119, P95, DOI 10.1017/S0031182099004424; Dell A, 1999, BBA-MOL BASIS DIS, V1455, P353, DOI 10.1016/S0925-4439(99)00064-2; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; EDWARDS MK, 1983, DEV BIOL, V97, P375, DOI 10.1016/0012-1606(83)90094-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GERARDYSCHAHN R, 2000, OLIGOSACCHARIDES CHE, V2, P19; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hinnebusch BJ, 1996, SCIENCE, V273, P367, DOI 10.1126/science.273.5273.367; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hodgkin J, 2000, CURR BIOL, V10, P1615, DOI 10.1016/S0960-9822(00)00867-8; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Joshua GWP, 2003, MICROBIOL-SGM, V149, P3221, DOI 10.1099/mic.0.26475-0; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; LIBBY BJ, 1998, THESIS WORCESTER POL; LINK CD, 1992, GENETICS, V131, P867; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; MADURO M, 1995, GENETICS, V141, P977; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; MOUNSEY A, 1999, C ELEGANS PRACTICAL, P181; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; POLITZ SM, 1990, P NATL ACAD SCI USA, V87, P2901, DOI 10.1073/pnas.87.8.2901; POLITZ SM, 1992, PARASITOL TODAY, V8, P6, DOI 10.1016/0169-4758(92)90302-I; POLITZ SM, 1987, GENETICS, V117, P467; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Silverman MA, 1997, J NEMATOL, V29, P296; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SMITH WL, 1975, J BIOL CHEM, V250, P3426; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Thein MC, 2003, DEV DYNAM, V226, P523, DOI 10.1002/dvdy.10259; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wood WB, 1988, NEMATODE CAENORHABDI	60	68	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30440	30448		10.1074/jbc.M402429200	http://dx.doi.org/10.1074/jbc.M402429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123614	hybrid			2022-12-27	WOS:000222531900071
J	Reynolds, M; Peterson, E; Quievryn, G; Zhitkovich, A				Reynolds, M; Peterson, E; Quievryn, G; Zhitkovich, A			Human nucleotide excision repair efficiently removes chromium-DNA phosphate adducts and protects cells against chromate toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; GROUP-A PROTEIN; MAMMALIAN-CELLS; CROSS-LINKS; IN-VITRO; NUCLEAR-MATRIX; AMINO-ACIDS; TRANSCRIPTION; MUTAGENESIS; RECOGNITION	Intracellular reduction of carcinogenic Cr(VI) leads to the extensive formation of Cr(III)-DNA phosphate adducts. Repair mechanisms for chromium and other DNA phosphate-based adducts are currently unknown in human cells. We found that nucleotide excision repair (NER)-proficient human cells rapidly removed chromium-DNA adducts, with an average t(1/2) of 7.1 h, whereas NER-deficient XP-A, XP-C, and XP-F cells were severely compromised in their ability to repair chromium-DNA lesions. Activation of NER in Cr(VI)-treated human fibroblasts or lung epithelial H460 cells was manifested by XPC-dependent binding of the XPA protein to the nuclear matrix, which was also observed in UV light-treated (but not oxidant-stressed) cells. Intracellular replication of chromium-modified plasmids demonstrated increased mutagenicity of binary Cr(III)-DNA and ternary cysteine-Cr(III)-DNA adducts in cells with inactive NER. NER deficiency created by the loss of XPA in fibroblasts or by knockdown of this protein by stable expression of small interfering RNA in H460 cells increased apoptosis and clonogenic death by Cr(VI), providing genetic evidence for the role of monofunctional chromium-DNA adducts in the toxic effects of this metal. The rate of NER of chromium-DNA adducts under saturating conditions was calculated to be similar to50,000 lesions/min/cell. Because chromium-DNA adducts cause only small changes in the DNA helix, rapid repair of these modifications in human cells indicates that the presence of major structural distortions in DNA is not required for the efficient detection of the damaged sites by NER proteins in vivo.	Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Brown University	Zhitkovich, A (corresponding author), Brown Univ, Dept Pathol & Lab Med, 69 Brown St,POB G-B511, Providence, RI 02912 USA.	Anatoly_Zhitkovich@brown.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272, R01ES008786] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR015578] Funding Source: Medline; NIEHS NIH HHS [2R01 ES008786, 5T32 ES007272, R01 ES008786] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Araujo SJ, 2000, GENE DEV, V14, P349; Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Blankert SA, 2003, CHEM RES TOXICOL, V16, P847, DOI 10.1021/tx034007g; BODELL WJ, 1979, NUCLEIC ACIDS RES, V6, P2819, DOI 10.1093/nar/6.8.2819; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; BRIDGEWATER LC, 1994, CARCINOGENESIS, V15, P2421, DOI 10.1093/carcin/15.11.2421; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; MACCUBBIN AE, 1991, CANCER RES, V51, P886; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; O'Brien T, 2002, BIOCHEMISTRY-US, V41, P12529, DOI 10.1021/bi020452j; Otrin VR, 1997, J CELL SCI, V110, P1159; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Quievryn G, 2002, BIOCHEMISTRY-US, V41, P3156, DOI 10.1021/bi011942z; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; Quievryn G, 2003, BIOCHEMISTRY-US, V42, P1062, DOI 10.1021/bi0271547; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; SINGER B, 1985, ENVIRON HEALTH PERSP, V62, P41, DOI 10.2307/3430091; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tomky LA, 1998, NUCLEIC ACIDS RES, V26, P2298, DOI 10.1093/nar/26.10.2298; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; Voitkun V, 1998, NUCLEIC ACIDS RES, V26, P2024, DOI 10.1093/nar/26.8.2024; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; You JS, 2003, J BIOL CHEM, V278, P7476, DOI 10.1074/jbc.M210603200; Zhitkovich A, 1996, BIOCHEMISTRY-US, V35, P7275, DOI 10.1021/bi960147w; ZHITKOVICH A, 1995, CARCINOGENESIS, V16, P907, DOI 10.1093/carcin/16.4.907; Zhitkovich A, 2001, BIOCHEMISTRY-US, V40, P549, DOI 10.1021/bi0015459; Zhitkovich A., 2002, BIOMARKERS ENV ASS D, P267, DOI [10.1039/c3ja50198a, DOI 10.1039/C3JA50198A]	42	89	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30419	30424		10.1074/jbc.M402486200	http://dx.doi.org/10.1074/jbc.M402486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15087443	hybrid			2022-12-27	WOS:000222531900068
J	Rummel, A; Karnath, T; Henke, T; Bigalke, H; Binz, T				Rummel, A; Karnath, T; Henke, T; Bigalke, H; Binz, T			Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-CC-DOMAIN; TETANUS TOXIN; B NEUROTOXIN; CLOSTRIDIAL NEUROTOXINS; PROTEIN-RECEPTOR; BINDING-SITES; NEURONS; INTERNALIZATION; GANGLIOSIDES; ENDOCYTOSIS	Botulinum neurotoxins (BoNTs) induce muscle paralysis by selectively entering cholinergic motoneurons and subsequent specific cleavage of core components of the vesicular fusion machinery. Complex gangliosides are requisite for efficient binding to neuronal cells, but protein receptors are critical for internalization. Recent work evidenced that synaptotagmins I and II can function as protein receptors for BoNT/B (Dong, M., Richards, D. A., Goodnough, M. C., Tepp, W. H., Johnson, E. A., and Chapman, E. R. ( 003) J. Cell Biol. 162, 1293-1303). Here, we report the protein receptor for a second BoNT serotype. Like BoNT/B, BoNT/G employs synaptotagmins I and II to enter phrenic nerve cells. Using pull-down assays we show that only BoNT/G, but neither the five remaining BoNTs nor tetanus neurotoxin, interacts with synaptotagmins I and II. In contrast to BoNT/B, interactions with both isoforms are independent of the presence of gangliosides. Peptides derived from the luminal domain of synaptotagmin I and II are capable of blocking the neurotoxicity of BoNT/G in phrenic nerve preparations. Pull-down and neutralization assays further established the membrane-juxtaposed 10 luminal amino acids of synaptotagmins I and II as the critical segment for neurotoxin binding. In addition, we show that the carboxyl-terminal domain of the cell binding fragment of BoNT/B and BoNT/G mediates the interaction with their protein receptor.	Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Binz, T (corresponding author), Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany.	Binz.Thomas@mh-hannover.de	Rummel, Andreas/I-7449-2013; Taylor, Graham/A-4027-2012	Rummel, Andreas/0000-0002-0645-1641				Bigalke H, 2000, HANDB EXP PHARM, V145, P407; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Eswaramoorthy S, 2001, ACTA CRYSTALLOGR D, V57, P1743, DOI 10.1107/S0907444901013531; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HABERMANN E, 1980, N-S ARCH PHARMACOL, V311, P33, DOI 10.1007/BF00500299; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Li L, 1998, J NAT TOXINS, V7, P215; Matteoli M, 1996, P NATL ACAD SCI USA, V93, P13310, DOI 10.1073/pnas.93.23.13310; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Nishiki T, 1996, NEUROSCI LETT, V208, P105, DOI 10.1016/0304-3940(96)12557-X; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rummel A, 2004, MOL MICROBIOL, V51, P631, DOI 10.1046/j.1365-2958.2003.03872.x; Rummel A, 2003, J MOL BIOL, V326, P835, DOI 10.1016/S0022-2836(02)01403-1; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sutton JM, 2001, FEBS LETT, V493, P45, DOI 10.1016/S0014-5793(01)02273-6; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526	27	191	213	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30865	30870		10.1074/jbc.M403945200	http://dx.doi.org/10.1074/jbc.M403945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123599	hybrid			2022-12-27	WOS:000222531900120
J	Tsuchida, A; Yamauchi, T; Ito, Y; Hada, Y; Maki, T; Takekawa, S; Kamon, J; Kobayashi, M; Suzuki, R; Hara, K; Kubota, N; Terauchi, Y; Froguel, P; Nakae, J; Kasuga, M; Accili, D; Tobe, K; Ueki, K; Nagai, R; Kadowaki, T				Tsuchida, A; Yamauchi, T; Ito, Y; Hada, Y; Maki, T; Takekawa, S; Kamon, J; Kobayashi, M; Suzuki, R; Hara, K; Kubota, N; Terauchi, Y; Froguel, P; Nakae, J; Kasuga, M; Accili, D; Tobe, K; Ueki, K; Nagai, R; Kadowaki, T			Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; MOLECULAR-MECHANISMS; RESISTANCE; MICE; PHOSPHORYLATION; FKHR; INHIBITION; CLONING	Adiponectin/Acrp30 is a hormone secreted by adipocytes, which acts as an antidiabetic and antiatherogenic adipokine. We reported previously that AdipoR1 and -R2 serve as receptors for adiponectin and mediate increased fatty acid oxidation and glucose uptake by adiponectin. In the present study, we examined the expression levels and roles of AdipoR1/R2 in several physiological and pathophysiological states such as fasting/refeeding, obesity, and insulin resistance. Here we show that the expression of AdipoR1/R2 in insulin target organs, such as skeletal muscle and liver, is significantly increased in fasted mice and decreased in refed mice. Insulin deficiency induced by streptozotocin increased and insulin replenishment reduced the expression of AdipoR1/R2 in vivo. Thus, the expression of AdipoR1/R2 appears to be inversely correlated with plasma insulin levels in vivo. Interestingly, the incubation of hepatocytes or myocytes with insulin reduced the expression of AdipoR1/R2 via the phosphoinositide 3-kinase/Foxo1-dependent pathway in vitro. Moreover, the expressions of AdipoR1/R2 in ob/ob mice were significantly decreased in skeletal muscle and adipose tissue, which was correlated with decreased adiponectin binding to membrane fractions of skeletal muscle and decreased AMP kinase activation by adiponectin. This adiponectin resistance in turn may play a role in worsening insulin resistance in ob/ob mice. In conclusion, the expression of AdipoR1/R2 appears to be inversely regulated by insulin in physiological and pathophysiological states such as fasting/refeeding, insulin deficiency, and hyperinsulinemia models via the insulin/phosphoinositide 3-kinase/Foxo1 pathway and is correlated with adiponectin sensitivity.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan; Inst Pasteur, CNRS 8090, Inst Biol, F-59000 Lille, France; Kobe Univ, Grad Sch Med, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Natl Inst Hlth & Nutr, Tokyo 1628636, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Kobe University; Columbia University; National Institute of Health & Nutrition - Japan	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Nakae, Jun/Q-6141-2019; Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; FROGUEL, Philippe/O-6799-2017; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; FROGUEL, Philippe/0000-0003-2972-0784; 	MRC [G0000477] Funding Source: UKRI; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; LEVINE BS, 1980, DRUG CHEM TOXICOL, V3, P201, DOI 10.3109/01480548009108283; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; RAKIETEN N, 1963, CANCER CHEMOTH REP, P91; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	32	426	462	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30817	30822		10.1074/jbc.M402367200	http://dx.doi.org/10.1074/jbc.M402367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123605	hybrid			2022-12-27	WOS:000222531900113
J	West, AB; Kapatos, G; O'Farrell, C; Gonzalez-de-Chavez, F; Chiu, K; Farrer, MJ; Maidment, NT				West, AB; Kapatos, G; O'Farrell, C; Gonzalez-de-Chavez, F; Chiu, K; Farrer, MJ; Maidment, NT			N-myc regulates parkin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-CONJUGATING ENZYME; NEUROBLASTOMA-CELLS; SENSORY NEUROPATHY; GENE; IDENTIFICATION; MUTATIONS; DISEASE; PROGRESSION; PGP9.5	Mutations in the parkin gene are common in early-onset and familial Parkinson's disease (PD), and the parkin protein interacts in the ubiquitin-proteasome system as an E3 ligase. However, the regulatory pathways that govern parkin expression are unknown. In this study, we showed that a phylogenetically conserved N-myc binding site in the bi-directional parkin promoter interacted with myc-family transcription factors in reporter assays, and N-myc bound to the parkin promoter in chromatin immunoprecipitation assays and repressed transcription activity. Parkin expression was inversely correlated with N-myc levels in the developing mouse and human brain, in human neuroblastoma cell lines with various levels of n-myc amplification, and in an inducible N-myc cell line. Although parkin and N-myc expression were dramatically altered upon retinoic acid-induced differentiation of a human neuroblastoma cell line, modulation of parkin expression did not significantly affect either rates of cellular proliferation or levels of cyclin E. Analysis of additional genes associated with familial PD revealed a shared basis of transcription regulation mediated by N-myc and the cell cycle. Our results, in combination with functional knowledge of the proteins encoded by these genes, suggest a common pathway linking together PD, the ubiquitin-proteasome system, and cell cycle control.	Univ Calif Los Angeles, Inst Neuropsychiat, Morris K Udall Ctr Parkinsons Dis Res, Los Angeles, CA 90024 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Mayo Clin Jacksonville, Labs Neurogenet, Morris K Udall Ctr Parkinsons Dis Res, Jacksonville, FL 32224 USA	University of California System; University of California Los Angeles; Wayne State University; Mayo Clinic	West, AB (corresponding author), 760 Westwood Plaza,Box 77, Los Angeles, CA 90024 USA.	abwest7@yahoo.com		Farrer, Matthew/0000-0003-1159-5321; West, Andrew/0000-0002-3034-4061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026081] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26081] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Harris RG, 2002, J BIOL CHEM, V277, P34815, DOI 10.1074/jbc.M109609200; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Khan NL, 2003, BRAIN, V126, P1279, DOI 10.1093/brain/awg142; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee SS, 2003, NEUROBIOL AGING, V24, P687, DOI 10.1016/S0197-4580(02)00196-3; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Lutz W, 1996, ONCOGENE, V13, P803; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Okuma Y, 2003, PARKINSONISM RELAT D, V9, P313, DOI 10.1016/S1353-8020(02)00114-1; Peverali FA, 1996, ONCOGENE, V12, P457; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Wang M, 2001, J NEUROCHEM, V77, P1561, DOI 10.1046/j.1471-4159.2001.00372.x; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; West AB, 2003, NEUROSCI LETT, V341, P139, DOI 10.1016/S0304-3940(03)00188-5; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28896	28902		10.1074/jbc.M400126200	http://dx.doi.org/10.1074/jbc.M400126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15078880	hybrid			2022-12-27	WOS:000222445300010
J	Martik, D; Baitinger, C; Modrich, P				Martik, D; Baitinger, C; Modrich, P			Differential specificities and simultaneous occupancy of human MutS alpha nucleotide binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; MISPAIR-BINDING; ENERGY-TRANSFER; ATPASE ACTIVITY; SLIDING CLAMP; PROTEIN MUTS; HUMAN-CELLS	We have examined the permissible nucleotide occupancy states of human MutSalpha. The MSH2.MSH6 heterodimer binds 1 mol of ADP and 1 mol of adenosine 5'-O-(thiotriphosphate) (ATPgammaS), with a K-d for each nucleotide of about 1 muM. Anisotropy measurements using BODIPY TR and BODIPY FL fluorescent derivatives of ADP and 5'-adenylyl-beta, gamma-imidodiphosphate (AMPPNP) also indicate an interaction stoichiometry of 1 mol of ADP and 1 mol of triphosphate analogue per MutSalpha heterodimer. Di- and triphosphate sites can be simultaneously occupied as judged by sequential filling of the two binding site classes with differentially radiolabeled ADP and ATPgammaS and by fluorescence resonance energy transfer between BODIPY TR- and BODIPY FL-labeled ADP and AMPPNP. ATP hydrolysis by MutSalpha is accompanied by a pre-steady-state burst of ADP formation, and analysis of MutSalpha-bound nucleotide during the first turnover has demonstrated the presence of both ADP and ATP. Simultaneous presence of ADP and a nonhydrolyzable ATP analogue modulates MutSalpha.heteroduplex interaction in a manner that is distinct from that observed in the presence of ADP or nonhydrolyzable triphosphate alone, and it is unlikely that this effect is due to the presence of a mixed population of binary complexes between MutSalpha and ADP or a triphosphate analogue. These findings imply that MutSalpha has two nucleotide binding sites with differential specificities for ADP and ATP and suggest that the ADP.MutSalpha.ATP ternary complex has an important role in mismatch repair.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM 45190] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HABER LT, 1988, J BACTERIOL, V170, P197, DOI 10.1128/jb.170.1.197-202.1988; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; MESELSON M, 1988, RECOMBINATION GENETI, P91; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Umar A, 1998, GENETICS, V148, P1637; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; Worth L, 1998, J BIOL CHEM, V273, P23176, DOI 10.1074/jbc.273.36.23176	57	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28402	28410		10.1074/jbc.M312108200	http://dx.doi.org/10.1074/jbc.M312108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15105434	hybrid			2022-12-27	WOS:000222265400073
J	Delpierre, G; Vertommen, D; Communi, D; Rider, MH; Van Schaftingen, E				Delpierre, G; Vertommen, D; Communi, D; Rider, MH; Van Schaftingen, E			Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTES; EXCISION-REPAIR; GLYCOSYLATION; EXPRESSION; PROTEINS; PATHWAY; CLONING; SITES	Fructosamine-3-kinase (FN3K) phosphorylates fructosamine residues, leading to their destabilization and their shedding from protein. Support for the occurrence of this deglycation mechanism in intact cells has been obtained by showing that hemoglobin is significantly more glycated when human erythrocytes are incubated with an elevated glucose concentration in the presence of 1-deoxy-1-morpholinofructose (DMF), a cell-permeable inhibitor of FN3K, than in its absence. The aim of this work was to identify the fructosamine residues on hemoglobin that are removed as a result of the action of FN3K in intact erythrocytes. Highly glycated hemoglobin derived from intact human erythrocytes incubated for 48 h with 200 mM glucose and DMF was incubated in vitro with FN3K and [gamma-P-32]ATP. After reduction of fructosamine 3-phosphates with borohydride, the protein was digested with trypsin. Peptides were separated by reversed-phase high-performance liquid chromatography, and the radioactive peaks were analyzed by mass spectrometry. Nine different modified residues were identified. These were Lys-alpha-16, Lys-alpha-61, Lys-alpha-139, Valbeta-1, Lys-beta-17, Lys-beta-59, Lys-beta-66, Lys-beta-132, and Lys-beta-144. Some (e.g. Lys-alpha-139) were readily phosphorylated to a maximal extent by FN3K in vitro whereas others (e.g. Val-beta-1) were slowly and only very partially phosphorylated. The radiolabeled peptides containing reduced fructosamine 3-phosphates bound to Lys-alpha-16, Lys-alpha-139, and Lys-beta-17 were much less abundant if the hemoglobin substrate used for the in vitro phosphorylation with FN3K and [gamma-P-32]ATP came from erythrocytes incubated with an elevated glucose concentration in the absence of DMF, indicating that these lysine residues had been substantially deglycated in intact cells when FN3K action was unrefrained. Other residues (e.g. Val-beta-1, Lys-alpha-61) seemed to be insignificantly deglycated in intact cells.	ICP, Physiol Chem Lab, B-1200 Brussels, Belgium; ICP, Hormones & Metab Unit, B-1200 Brussels, Belgium; Univ Catholique Louvain, B-1200 Brussels, Belgium; Free Univ Brussels, Inst Rech Interdisciplinaire & Biol Humaine & Mol, B-1070 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Van Schaftingen, E (corresponding author), ICP, Physiol Chem Lab, Ave Hippocrate 75, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020	Vertommen, Didier/0000-0001-7648-8282; Van Schaftingen, Emile/0000-0002-6199-7647				BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627; Delpierre G, 2002, BIOCHEM J, V365, P801, DOI 10.1042/BJ20020325; Dumoulin A, 1997, J BIOL CHEM, V272, P31326, DOI 10.1074/jbc.272.50.31326; FOLK JE, 1956, ARCH BIOCHEM BIOPHYS, V64, P6, DOI 10.1016/0003-9861(56)90236-3; Fortini P, 2003, BIOCHIMIE, V85, P1053, DOI 10.1016/j.biochi.2003.11.003; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; MOSSINE VV, 1994, CARBOHYD RES, V262, P257, DOI 10.1016/0008-6215(94)84183-7; NADOLNY C, 1993, BIOL CHEM H-S, V374, P403; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PARK JT, 1949, J BIOL CHEM, V181, P149; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139; UENO H, 1989, J BIOL CHEM, V264, P12344; VLASSARA H, 1994, LAB INVEST, V70, P138; Zhang XY, 2001, J CHROMATOGR B, V759, P1, DOI 10.1016/S0378-4347(01)00196-7	21	68	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27613	27620		10.1074/jbc.M402091200	http://dx.doi.org/10.1074/jbc.M402091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102834	hybrid			2022-12-27	WOS:000222120400096
J	Elsasser, S; Chandler-Militello, D; Muller, B; Hanna, J; Finley, D				Elsasser, S; Chandler-Militello, D; Muller, B; Hanna, J; Finley, D			Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; REPAIR PROTEIN HHR23A; 26 S PROTEASOME; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; REGULATORY PARTICLE; ATPASE SUBUNIT; DOMAINS; DEGRADATION; GENE	The selective recognition of ubiquitin conjugates by proteasomes is a key step in protein degradation. The receptors that mediate this step have yet to be clearly defined although specific candidates exist. Here we show that the proteasome directly recognizes ubiquitin chains through a specific subunit, Rpn10, and also recognizes chains indirectly through Rad23, a reversibly bound proteasome cofactor. Both binding events can be observed in purified biochemical systems. A block substitution in the chain-binding ubiquitin interacting motif of RPN10 when combined with a null mutation in RAD23 results in a synthetic defect in protein degradation consistent with the view that the direct and indirect recognition modes function to some extent redundantly in vivo. Rad23 and the deubiquitinating enzyme Ubp6 both bind proteasome subunit Rpn1 through N-terminal ubiquitin-like domains. Surprisingly, Rad23 and Ubp6 do not compete with each other for proteasome binding. Thus, Rpn1 may act as a scaffold to assemble on the proteasome multiple proteins that act to either bind or hydrolyze multiubiquitin chains.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Bldg C1,Rm 404,240 Longwood Ave, Boston, MA 02115 USA.	daniel_finley@hms.harvard.edu			NIGMS NIH HHS [GM43601] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043601, R01GM043601] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; HOUGH R, 1986, J BIOL CHEM, V261, P2400; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seeger M, 2003, J BIOL CHEM, V278, P16791, DOI 10.1074/jbc.M208281200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Walters KJ, 2003, P NATL ACAD SCI USA, V100, P12694, DOI 10.1073/pnas.1634989100; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	48	245	251	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26817	26822		10.1074/jbc.M404020200	http://dx.doi.org/10.1074/jbc.M404020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15117949	hybrid, Green Published			2022-12-27	WOS:000222120400004
J	Gong, XQ; Nedialkov, YA; Burton, ZF				Gong, XQ; Nedialkov, YA; Burton, ZF			alpha-amanitin blocks translocation by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; TRANSCRIPT CLEAVAGE; MICROCIN J25; ELONGATION; INHIBITION; COMPLEXES; ROLES	Our laboratory has developed methods for transient state kinetic analysis of human RNA polymerase II elongation. In these studies, multiple conformations of the RNA polymerase II elongation complex were revealed by their distinct elongation potential and differing dependence on nucleoside triphosphate substrate. Among these are conformations that appear to correspond to different translocation states of the DNA template and RNA-DNA hybrid. Using alpha-amanitin as a dynamic probe of the RNA polymerase II mechanism, we show that the most highly poised conformation of the elongation complex, which we interpreted previously as the posttranslocated state, is selectively resistant to inhibition with alpha-amanitin. Because initially resistant elongation complexes form only a single phosphodiester bond before being rendered inactive in the following bond addition cycle, alpha-amanitin inhibits elongation at each translocation step.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	burton@msu.edu	gong, xue/GYQ-8649-2022		NIGMS NIH HHS [GM57461] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2003, SCIENCE, V302, P650, DOI 10.1126/science.1087526; Bayro MJ, 2003, J AM CHEM SOC, V125, P12382, DOI 10.1021/ja036677e; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; Funk JD, 2002, J BIOL CHEM, V277, P46998, DOI 10.1074/jbc.M206249200; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Nedialkov YA, 2003, METHOD ENZYMOL, V371, P252; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Rosengren KJ, 2003, J AM CHEM SOC, V125, P12464, DOI 10.1021/JA0367703; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; Taylor JM, 2003, TRENDS MICROBIOL, V11, P185, DOI 10.1016/S0966-842X(03)00045-3; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WIELAND T, 1981, EUR J BIOCHEM, V117, P161, DOI 10.1111/j.1432-1033.1981.tb06315.x; WIELAND T, 1968, SCIENCE, V159, P946, DOI 10.1126/science.159.3818.946; Wilson KA, 2003, J AM CHEM SOC, V125, P12475, DOI 10.1021/JA036756q; Yamaguchi Y, 2001, SCIENCE, V293, P124, DOI 10.1126/science.1057925; Yuzenkova J, 2002, J BIOL CHEM, V277, P50867, DOI 10.1074/jbc.M209425200; Zhang CF, 2003, J BIOL CHEM, V278, P50101, DOI 10.1074/jbc.M307590200	30	55	60	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27422	27427		10.1074/jbc.M402163200	http://dx.doi.org/10.1074/jbc.M402163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15096519	hybrid			2022-12-27	WOS:000222120400073
J	Koeck, T; Fu, XM; Hazen, SL; Crabb, JW; Stuehr, DJ; Aulak, KS				Koeck, T; Fu, XM; Hazen, SL; Crabb, JW; Stuehr, DJ; Aulak, KS			Rapid and selective oxygen-regulated protein tyrosine denitration and nitration in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; OXIDATIVE STRESS; IN-VIVO; PEROXYNITRITE; GENERATION; HYPOXIA; DEGRADATION; SUPEROXIDE; ISCHEMIA; HEART	Growing evidence connects a cumulative formation of 3-nitrotyrosyl adducts in proteins as a marker for oxidative damage with the pathogenesis of various diseases and pathological conditions associated with oxidative stress. A physiological signaling role for protein nitration has also been suggested. Controlled "denitration" would be essential for such a contribution of protein nitration to cellular regulatory processes. Thus, we further characterized such a potentially controlled, reversible tyrosine nitration that occurs in respiring mitochondria during oxygen deprivation followed by reoxygenation, which we recently discovered. Mitochondria constitute cellular centers of protein nitration and are leading candidates for a "nitrative" regulation. Mitochondria are capable of completely eliminating 3-nitrotyrosyl adducts during 20 min of hypoxia-anoxia and undergoing a selective partial reduction after only 5 min. This denitration is independent of protein degradation but depends on the oxygen tension. Reoxygenation re-establishes protein tyrosine nitration patterns that are almost identical to the pattern that occurs before hypoxia- anoxia, with nitration levels that depend on the duration of hypoxia- anoxia. The identified mitochondrial targets of this process are critical for energy and antioxidant homeostasis and, therefore, cell and tissue viability. This cycle of protein nitration and denitration shows analogies to protein phosphorylation, and we demonstrate that the cycle meets most of the criteria for a cellular signaling mechanism. Taken together, our data reveal that protein tyrosine nitration in mitochondria can be controlled, is target-selective and rapid, and is dynamic enough to serve as a nitrative regulatory signaling process that likely affects cellular energy, redox homeostasis, and pathological conditions when these features become disturbed.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cole Eye Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Koeck, T (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	koeckt@ccf.org	Hazen, Stanley L/ABD-5845-2021					Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Balabanli B, 1999, P NATL ACAD SCI USA, V96, P13136, DOI 10.1073/pnas.96.23.13136; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Cruthirds DL, 2003, ARCH BIOCHEM BIOPHYS, V412, P27, DOI 10.1016/S0003-9861(03)00039-0; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Dunlop RA, 2002, FREE RADICAL BIO MED, V33, P894, DOI 10.1016/S0891-5849(02)00958-9; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Fleischer S, 1974, Methods Enzymol, V31, P6; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Ghafourifari P, 2003, ANTIOXID REDOX SIGN, V5, P349, DOI 10.1089/152308603322110913; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Gonzalez-Hernandez JC, 2003, AMINO ACIDS, V24, P163, DOI 10.1007/s00726-002-0317-5; GU G, 1998, FREE RADIC BIOL MED, V25, P1066; Guerra F C, 1974, Methods Enzymol, V31, P299; HOLCOMBE RF, 1993, CLIN IMMUNOL IMMUNOP, V67, P31, DOI 10.1006/clin.1993.1042; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Kuo WN, 1999, MOL CELL BIOCHEM, V201, P11, DOI 10.1023/A:1007024126947; Kuo Wu-Nan, 2002, J Biochem Mol Biol Biophys, V6, P143, DOI 10.1080/10258140290027298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Manevich Y, 2001, AM J PHYSIOL-HEART C, V280, pH2126, DOI 10.1152/ajpheart.2001.280.5.H2126; Manzo-Avalos S, 2002, AMINO ACIDS, V22, P381, DOI 10.1007/s007260200022; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Paddenberg R, 2003, AM J PHYSIOL-LUNG C, V284, pL710, DOI 10.1152/ajplung.00149.2002; Parker A, 2000, BIOCHEM J, V345, P429, DOI 10.1042/0264-6021:3450429; Potoka DA, 2003, AM J PHYSIOL-GASTR L, V285, pG861, DOI 10.1152/ajpgi.00412.2002; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Schild L, 2003, FASEB J, V17, P2194, DOI 10.1096/fj.02-1170com; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Turko IV, 2003, J BIOL CHEM, V278, P33972, DOI 10.1074/jbc.M303734200; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Turko IV, 2001, AM J PHYSIOL-HEART C, V281, pH2289, DOI 10.1152/ajpheart.2001.281.6.H2289; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Warnholtz A, 2002, ARTERIOSCL THROM VAS, V22, P525, DOI 10.1161/01.ATV.0000014220.78856.97; ZLATANOVA JS, 1990, MOL CELL BIOCHEM, V92, P1; Zou MH, 1999, J EXP MED, V190, P135, DOI 10.1084/jem.190.1.135	51	149	150	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27257	27262		10.1074/jbc.M401586200	http://dx.doi.org/10.1074/jbc.M401586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084586	hybrid			2022-12-27	WOS:000222120400054
J	Lan, CG; Lee, HC; Tang, S; Zhang, L				Lan, CG; Lee, HC; Tang, S; Zhang, L			A novel mode of chaperone action - Heme activation of Hap1 by enhanced association of Hsp90 with the repressed Hsp70-Hap1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; NITRIC-OXIDE SYNTHASE; MOLECULAR CHAPERONE; BINDING PROTEINS; YEAST; RECEPTOR; MECHANISM; ABSENCE; SEQUENCE; MUTANTS	Molecular chaperones Hsp90 and Hsp70 control many signal transducers, including cyclin-dependent kinases and steroid receptors. The yeast heme-responsive transcriptional activator Hap1 is a native substrate of both Hsp90 and Hsp70. Hsp90 and Hsp70 are critical for the precise regulation of Hap1 activity by heme. Here, to decipher the molecular events underlying the actions of Hsp90 and Hsp70 in heme regulation, we purified various multichaperone-Hap1 complexes and characterized the complexes linked to Hap1 repression and activation by two-dimensional electrophoresis analysis. Notably, we found that in vitro Hap1 is associated continuously with Ssa and its co-chaperones, and this association is not weakened by heme. Heme enhances the interaction between Hap1 and Hsp90. In vivo, defective Ssa, Ydj1, or Sro9 function causes Hap1 derepression in the absence of heme, whereas defective Hsp90 function causes reduced Hap1 activity at high heme concentrations. These results show that continuous association of Hap1 with Ssa, Ydj1, and Sro9 confers Hap1 repression, whereas enhanced association of Hsp90 with the repressed Hap1-Ssa-Ydj1-Sro9 complex by heme causes Hap1 activation. This novel mechanism of chaperone action may operate to control the activity of other important signal transducers.	Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University	Zhang, L (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.	lz2115@columbia.edu	Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062246] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62246] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker J, 1996, MOL CELL BIOL, V16, P4378; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Hach A, 1999, MOL CELL BIOL, V19, P4324; HALDI ML, 1995, MOL GEN GENET, V248, P229, DOI 10.1007/BF02190805; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hen T, 2000, BIOCHEM BIOPH RES CO, V273, P584, DOI 10.1006/bbrc.2000.2995; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Hon T, 1999, J BIOL CHEM, V274, P22770, DOI 10.1074/jbc.274.32.22770; Johnson JL, 2000, MOL CELL BIOL, V20, P3027, DOI 10.1128/MCB.20.9.3027-3036.2000; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; Lee HC, 2002, J BIOL CHEM, V277, P7430, DOI 10.1074/jbc.M106951200; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Picard Didier, 1998, P1; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; Reddy SV, 1998, BLOOD, V91, P1793, DOI 10.1182/blood.V91.5.1793.1793_1793_1801; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	48	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27607	27612		10.1074/jbc.M402777200	http://dx.doi.org/10.1074/jbc.M402777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15102838	hybrid			2022-12-27	WOS:000222120400095
J	Larkin, D; Murphy, D; Reilly, DF; Cahill, M; Sattler, E; Harriott, P; Cahill, DJ; Moran, N				Larkin, D; Murphy, D; Reilly, DF; Cahill, M; Sattler, E; Harriott, P; Cahill, DJ; Moran, N			ICln, a novel integrin alpha(IIb)beta(3)-associated protein, functionally regulates platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; CYTOPLASMIC TAIL; CELL-ADHESION; I-CLN; MEMBRANE; BINDING; EXPRESSION; DOMAIN; POTASSIUM; SEQUENCE	A critical role for the conserved alpha-integrin cytoplasmic motif, KVGFFKR, is recognized in the regulation of activation of the platelet integrin alpha(IIb)beta(3). To understand the molecular mechanisms of this regulation, we sought to determine the nature of the protein interactions with this cytoplasmic motif. We used a tagged synthetic peptide, biotin-KVGFFKR, to probe a high density protein expression array ( 37,200 recombinant human proteins) for high affinity interactions. A number of potential integrin-binding proteins were identified. One such protein, a chloride channel regulatory protein, ICln, was characterized further because its affinity for the integrin peptide was highest as was its expression in platelets. We verified the presence of ICln in human platelets by PCR, Western blots, immunohistochemistry, and its co-association with alpha(IIb)beta(3) by surface plasmon resonance. The affinity of this interaction was 82.2 +/- 24.4 nM in a cell free assay. ICln co-immunoprecipitates with alpha(IIb)beta(3) in platelet lysates demonstrating that this interaction is physiologically relevant. Furthermore, immobilized KVGFFKR peptides, but not control KAAAAAR peptides, specifically extract ICln from platelet lysates. Acyclovir ( 100 muM to 5 mM), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation. In parallel, a cell-permeable peptide corresponding to the potential integrin-recognition domain on ICln (AKFEEE, 10 - 100 muM) also inhibits platelet function. Thus, we have identified, verified, and characterized a novel functional interaction between the platelet integrin and ICln, in the platelet membrane.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Ctr Human Proteom, Dublin 2, Ireland; Queens Univ Belfast, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; Queens University Belfast	Moran, N (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, St Stephens Green, Dublin 2, Ireland.	nmoran@rcsi.ie	Murphy, Derek/F-6138-2011; Moran, Niamh/F-4188-2012	Moran, Niamh/0000-0002-8614-3242; Murphy, Derek/0000-0002-6905-0167				Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Artym VV, 2002, J GEN PHYSIOL, V120, P29, DOI 10.1085/jgp.20028607; Browe DM, 2003, J GEN PHYSIOL, V122, P689, DOI 10.1085/jgp.200308899; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; Colden-Stanfield M, 2002, AM J PHYSIOL-CELL PH, V283, pC990, DOI 10.1152/ajpcell.00481.2001; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; de Tassigny AD, 2003, FUND CLIN PHARMACOL, V17, P539, DOI 10.1046/j.1472-8206.2003.00197.x; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; Emma F, 1998, AM J PHYSIOL-CELL PH, V274, pC1545, DOI 10.1152/ajpcell.1998.274.6.C1545; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Gschwentner M, 1996, J ALLERGY CLIN IMMUN, V98, pS98, DOI 10.1016/S0091-6749(96)80135-7; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Israels SJ, 2001, THROMB HAEMOSTASIS, V85, P134; Kato A, 2002, J BIOL CHEM, V277, P28934, DOI 10.1074/jbc.M204340200; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; Laich A, 1997, KIDNEY INT, V51, P477, DOI 10.1038/ki.1997.65; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Lueking Angelika, 2003, Methods Mol Biol, V205, P31; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; McRedmond JP, 2004, MOL CELL PROTEOMICS, V3, P133, DOI 10.1074/mcp.M300063-MCP200; Menegazzi R, 1999, J IMMUNOL, V162, P423; Menegazzi R, 2000, J IMMUNOL, V165, P4606, DOI 10.4049/jimmunol.165.8.4606; MORAN N, 2004, IN PRESS J THROMBOSI; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Quinn M, 1999, CIRCULATION, V99, P2231, DOI 10.1161/01.CIR.99.17.2231; Ritter M, 2003, J BIOL CHEM, V278, P50163, DOI 10.1074/jbc.M300374200; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Shakibael M, 2003, HISTOL HISTOPATHOL, V18, P343, DOI 10.14670/HH-18.343; SheikhHamad D, 1997, AM J PHYSIOL-CELL PH, V273, pC902, DOI 10.1152/ajpcell.1997.273.3.C902; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Sullivan R, 1996, BLOOD, V87, P648, DOI 10.1182/blood.V87.2.648.bloodjournal872648; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Thiel M, 2001, J LEUKOCYTE BIOL, V70, P261; Vasilyev DV, 2003, J PHYSIOL-LONDON, V547, P859, DOI 10.1113/jphysiol.2002.036889; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Wang ZY, 2003, BLOOD, V102, P1307, DOI 10.1182/blood-2002-09-2753; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799	57	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27286	27293		10.1074/jbc.M402159200	http://dx.doi.org/10.1074/jbc.M402159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075326	hybrid			2022-12-27	WOS:000222120400058
J	Hashida, S; Yuzawa, S; Suzuki, NN; Fujioka, Y; Takikawa, T; Sumimoto, H; Inagaki, F; Fujii, H				Hashida, S; Yuzawa, S; Suzuki, NN; Fujioka, Y; Takikawa, T; Sumimoto, H; Inagaki, F; Fujii, H			Binding of FAD to cytochrome b(558) is facilitated during activation of the phagocyte NADPH oxidase, leading to superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; ELECTRON-SPIN-RESONANCE; SRC HOMOLOGY-3 DOMAINS; FLAVOCYTOCHROME B(558); HUMAN-NEUTROPHILS; HEME IRON; FLAVIN; P67(PHOX); P40(PHOX)	The superoxide-producing phagocyte NADPH oxidase can be reconstituted in a cell-free system. The activity of NADPH oxidase is dependent on FAD, but the physiological status of FAD in the oxidase is not fully elucidated. To clarify the role of FAD in NADPH oxidase, FAD-free full-length recombinant p47(phox), p67(phox), p40(phox), and Rac were prepared, and the activity was reconstituted with these proteins and purified cytochrome b(558) (cyt b(558)) with different amounts of FAD. A remarkably high activity, over 100 mumol/s/mumol heme, was obtained in the oxidase with purified cyt b558, ternary complex (p47-p67-p40(phox)), and Rac. From titration with FAD of the activity of NADPH oxidase reconstituted with purified FAD-devoid cyt b(558), the dissociation constant K-d of FAD in cyt b(558) of reconstituted oxidase was estimated as nearly 1 nM. We also examined addition of FAD on the assembly process in reconstituted oxidase. The activity was remarkably enhanced when FAD was present during assembly process, and the efficacy of incorporating FAD into the vacant FAD site in purified cyt b(558) increased, compared when FAD was added after assembly processes. The absorption spectra of reconstituted oxidase under anaerobiosis showed that incorporation of FAD into cyt b(558) recovered electron flow from NADPH to heme. From both K-d values of FAD and the amount of incorporated FAD in cyt b(558) of reconstituted oxidase, in combination with spectra, we propose the model in which the K-d values of FAD in cyt b(558) is changeable after activation and FAD binding works as a switch to regulate electron transfer in NADPH oxidase.	Sapporo Med Univ, Sch Hlth Sci, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Sapporo Medical University; Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Fujii, H (corresponding author), Sapporo Med Univ, Sch Hlth Sci, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	hfujii@sapmed.ac.jp	Noda, Nobuo/P-1397-2015	Noda, Nobuo/0000-0002-6940-8069; Yuzawa, Satoru/0000-0002-1031-5781; Fujioka, Yuko/0000-0002-6905-0669				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FOROOZAN R, 1992, J BIOL CHEM, V267, P24400; Fujii H, 1999, J BIOCHEM-TOKYO, V126, P708, DOI 10.1093/oxfordjournals.jbchem.a022507; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; GABIG TG, 1982, J BIOL CHEM, V257, P4114; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; KAKINUMA K, 1974, BIOCHIM BIOPHYS ACTA, V348, P76; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MIKI T, 1992, J BIOL CHEM, V267, P18695; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; TAMURA M, 1992, J BIOL CHEM, V267, P7529; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yoshida LS, 1998, J BIOL CHEM, V273, P27879, DOI 10.1074/jbc.273.43.27879; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	38	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26378	26386		10.1074/jbc.M309724200	http://dx.doi.org/10.1074/jbc.M309724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15102859	hybrid			2022-12-27	WOS:000222003000058
J	Lesley, J; Gal, I; Mahoney, DJ; Cordell, MR; Rugg, MS; Hyman, R; Day, AJ; Mikecz, K				Lesley, J; Gal, I; Mahoney, DJ; Cordell, MR; Rugg, MS; Hyman, R; Day, AJ; Mikecz, K			TSG-6 modulates the interaction between hyaluronan and cell surface CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; SMOOTH-MUSCLE-CELLS; LINK MODULE; PROTEIN TSG-6; PRIMARY ADHESION; UP-REGULATION; BINDING-SITE; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX	Interactions between CD44 and hyaluronan are implicated in the primary adhesion of lymphocytes to endothelium at inflammatory locations. Here we show that preincubation of hyaluronan with full-length recombinant TSG-6 or its Link module domain (Link_TSG6) enhances or induces the binding of hyaluronan to cell surface CD44 on constitutive and inducible cell backgrounds, respectively. These effects are blocked by CD44-specific antibodies and are absent in CD44-negative cells. Enhancement of CD44-mediated interactions of lymphoid cells with hyaluronan by TSG-6 proteins was seen under conditions of flow at shear forces that occur in post-capillary venules. Increases in the number of rolling cells were observed on substrates comprising TSG-6-hyaluronan complexes as compared with a substrate containing hyaluronan alone. In ligand competition experiments, cell surface-bound TSG-6-hyaluronan complexes were more potent than hyaluronan alone in inhibiting cell adhesion to immobilized hyaluronan. Link_TSG6 mutants with impaired hyaluronan binding function had a reduced ability to modulate ligand binding by cell surface CD44. However, some mutants that exhibited close to wild-type hyaluronan binding were found to have either reduced or increased activity, suggesting that some amino acid residues outside of the hyaluronan binding site might be involved in protein self-association, potentially leading to the formation of cross-linked hyaluronan fibers. In turn, cross-linked hyaluronan could increase the binding avidity of CD44 by inducing receptor clustering. The ability of TSG-6 to modulate the interaction of hyaluronan with CD44 has important implications for CD44-mediated cell activity at sites of inflammation, where TSG-6 is expressed.	Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Salk Inst, Mol & Cell Biol Lab, San Diego, CA 92186 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	Rush University; Rush University; Salk Institute; University of Oxford	Day, AJ (corresponding author), Rush Univ, Med Ctr, Dept Orthoped Surg, 1735 W Harrison St,712 Cohn, Chicago, IL 60612 USA.	tony.day@bioch.ox.ac.uk; Katalin_Mikecz@rsh.net	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31613] Funding Source: Medline; NIAMS NIH HHS [AR45652] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Bandman O, 2002, ANN NY ACAD SCI, V975, P77, DOI 10.1111/j.1749-6632.2002.tb05943.x; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; HATHCOCK KS, 1993, J IMMUNOL, V151, P6712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HYMAN R, 1991, IMMUNOGENETICS, V33, P392, DOI 10.1007/BF00216699; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2000, J BIOL CHEM, V275, P26967; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 2002, HYALURONAN, V1, P341; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Oertli B, 1998, J IMMUNOL, V161, P3431; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PITSILLIDES AA, 1994, BRIT J RHEUMATOL, V33, P5; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Stoop R, 2002, EUR J IMMUNOL, V32, P2532, DOI 10.1002/1521-4141(200209)32:9<2532::AID-IMMU2532>3.0.CO;2-A; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; WISNIEWSKI HG, 1996, PFLUEGERS ARCH EUR J, V431, P225; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	55	134	145	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25745	25754		10.1074/jbc.M313319200	http://dx.doi.org/10.1074/jbc.M313319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060082	hybrid			2022-12-27	WOS:000221827900104
J	Ju, DH; Xie, YM				Ju, DH; Xie, YM			Proteasomal degradation of RPN4 via two distinct mechanisms, ubiquitin-dependent and -independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST MUTANT; SYSTEM; PROTEIN; TURNOVER; PATHWAY; SIGNAL	Substrates of the ubiquitin system are degraded by the 26 S proteasome, a complex protease consisting of at least 32 different subunits. Recent studies showed that RPN4 (also named SON1 and UFD5) is a transcriptional activator required for normal expression of the Saccharomyces cerevisiae proteasome genes. Interestingly, RPN4 is extremely short-lived and degraded by the 26 S proteasome, establishing a feedback circuit that controls the homeostatic abundance of the 26 S proteasome. The mechanism underlying the degradation of RPN4, however, remains unclear. Here we demonstrate that the proteasomal degradation of RPN4 is mediated by two independent degradation signals (degron). One degron leads to ubiquitylation on internal lysine(s), whereas the other is independent of ubiquitylation. Stabilization of RPN4 requires inhibition of internal ubiquitylation and inactivation of the ubiquitin-independent degron. RPN4 represents the first proteasomal substrate in S. cerevisiae that can be degraded through ubiquitylation or without prior ubiquitylation. This finding makes it possible to use both yeast genetics and biochemical analysis to investigate the mechanism of ubiquitin-independent proteolysis.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Xie, YM (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.	xiey@karmanos.org						Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; James P, 1996, GENETICS, V144, P1425; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sasaki T, 2000, MOL GEN GENET, V262, P940, DOI 10.1007/PL00008662; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Wang GL, 1999, MOL CELL BIOL, V19, P342; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298	24	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23851	23854		10.1074/jbc.C400111200	http://dx.doi.org/10.1074/jbc.C400111200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15090546	hybrid			2022-12-27	WOS:000221702500002
